<SEC-DOCUMENT>0001628280-20-004221.txt : 20200327
<SEC-HEADER>0001628280-20-004221.hdr.sgml : 20200327
<ACCEPTANCE-DATETIME>20200327160320
ACCESSION NUMBER:		0001628280-20-004221
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		99
CONFORMED PERIOD OF REPORT:	20191231
FILED AS OF DATE:		20200327
DATE AS OF CHANGE:		20200327

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ocugen, Inc.
		CENTRAL INDEX KEY:			0001372299
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36751
		FILM NUMBER:		20751761

	BUSINESS ADDRESS:	
		STREET 1:		5 GREAT VALLEY PARKWAY
		STREET 2:		SUITE 160
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355
		BUSINESS PHONE:		484-328-4698

	MAIL ADDRESS:	
		STREET 1:		5 GREAT VALLEY PARKWAY
		STREET 2:		SUITE 160
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HISTOGENICS CORP
		DATE OF NAME CHANGE:	20060810
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ocgn-20191231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:cc72798c-c24e-4d47-845f-93333954ce8b,g:e003b04e-ddd7-4b29-b911-f80dc6cd6725,d:9e9cab2d4c4f4a33b2d90ea1e0c3f979--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ocgn="http://www.deitaxonomy.com/20191231" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ocgn-20191231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80L2ZyYWc6ZDUwZWYzMWZlYzcxNGJiMGE1ODJkNTgxMzI4ODllNmQvdGFibGU6YTMzNDhlZmZmMjMzNDNiZTg2MmU1ZmM0YmI4YjIxYzQvdGFibGVyYW5nZTphMzM0OGVmZmYyMzM0M2JlODYyZTVmYzRiYjhiMjFjNF81LTEtMS0xLTA_d44ab409-dbcc-442c-9939-93df7dce7591">0001372299</ix:nonNumeric><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80L2ZyYWc6ZDUwZWYzMWZlYzcxNGJiMGE1ODJkNTgxMzI4ODllNmQvdGFibGU6YTMzNDhlZmZmMjMzNDNiZTg2MmU1ZmM0YmI4YjIxYzQvdGFibGVyYW5nZTphMzM0OGVmZmYyMzM0M2JlODYyZTVmYzRiYjhiMjFjNF8xNS0xLTEtMS0w_7c0b480e-fae2-49d1-9977-b4411546cdc2">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80L2ZyYWc6ZDUwZWYzMWZlYzcxNGJiMGE1ODJkNTgxMzI4ODllNmQvdGFibGU6YTMzNDhlZmZmMjMzNDNiZTg2MmU1ZmM0YmI4YjIxYzQvdGFibGVyYW5nZTphMzM0OGVmZmYyMzM0M2JlODYyZTVmYzRiYjhiMjFjNF8xNi0xLTEtMS0w_8638226a-b521-4f84-8c2c-ad3d27484756">2019</ix:nonNumeric><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80L2ZyYWc6ZDUwZWYzMWZlYzcxNGJiMGE1ODJkNTgxMzI4ODllNmQvdGFibGU6YTMzNDhlZmZmMjMzNDNiZTg2MmU1ZmM0YmI4YjIxYzQvdGFibGVyYW5nZTphMzM0OGVmZmYyMzM0M2JlODYyZTVmYzRiYjhiMjFjNF8xNy0xLTEtMS0w_8eb31726-29cf-4ff8-b79d-133fbb3e8946">FY</ix:nonNumeric><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80L2ZyYWc6ZDUwZWYzMWZlYzcxNGJiMGE1ODJkNTgxMzI4ODllNmQvdGFibGU6YTMzNDhlZmZmMjMzNDNiZTg2MmU1ZmM0YmI4YjIxYzQvdGFibGVyYW5nZTphMzM0OGVmZmYyMzM0M2JlODYyZTVmYzRiYjhiMjFjNF8xOC0xLTEtMS0w_0b12ffb3-befe-4739-a471-1688e1cc0ad0">false</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="id83e33e57cad4f08967d8d41dfb42b28_D20190927-20190927" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80My9mcmFnOmQ5NzZkOTk4N2Q5NTQ5MzE4M2YxYjhmYmI0ZWFiMTkyL3RhYmxlOmY0ZThhYTY4MGM3NTQzMmI4Y2Y2MTFhZjhmNWMyZDIwL3RhYmxlcmFuZ2U6ZjRlOGFhNjgwYzc1NDMyYjhjZjYxMWFmOGY1YzJkMjBfMy0xLTEtMS0w_1577efe5-faaf-48d7-a448-344f340c2658">0.0167</ix:nonFraction><ix:nonNumeric contextRef="i7c306b6118f54e09b3f5ed1b41de8514_D20190101-20191231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfNzY5NjU4MTQxODYxNA_853dc9b7-c919-4df5-9190-d9436288daac">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i4c492065ff8d4ceb931653d3b6553ee6_D20190101-20191231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfODI0NjMzNzIzNzU5OQ_e571c6b5-bef2-4cd7-bc49-832c32f02b1a">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i98c6625973004b8697d9716a871ffa88_D20191004-20191004" name="ocgn:ConvertedAdditionalSharesThresholdReleaseTriggerPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfMTcwNDI0MzAyNDIzMTA_2a410e8c-05ba-4258-a80a-5a97f417ce2a">P3D</ix:nonNumeric><ix:nonNumeric contextRef="i885e5bb590844f6ebf88b1399519a254_I20191231" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RleHRyZWdpb246ZGM3YmMyNzE5ZTYwNGMyNjlkMWNiNjIxY2JhMTE0NDNfMTA5OTUxMTYyODYwOTQ_ca47572a-04ad-41bc-8ba1-21a7e15ee217">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="ie65f10daf6f84ce6802f5816662b4903_D20191105-20191231" name="ocgn:ClassOfWarrantOrRightExercisePriceDeterminationNumberOfTradingDaysConsidered" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTUzOTMxNjI4MzE0NTk_881a6831-237f-403e-b78d-48afce88aefa">P5D</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="ocgn-20191231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i73ff1de059af438fb2052b13e4f9d5b6_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i23c3ffb42fab4881887c19daef4a2535_I20200320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a1130e123594196bfc468092b84ac38_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86c3619320b043b3904853387d86d815_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1552d11edcd422ca262d2377a832c30_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8690510eb5349f08d66e9e06bb9e045_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b0b2789ee4e45ff8aa700de563ddc85_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6917ffcbaf80423da21d5e3906eb2fae_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedb883ebf37143d7b4c47a6d6946772b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e6a4645ddbc44dda8055b4048fed606_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a89501e1b134d4ebd569351917a9ccd_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3cbd854bf6742df83c09dc1b641443b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e3c1c69245740dca3e6b721cc45d9e0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98a2e8ccbfdb402682e11b7e0f8e3856_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i056a173f43694aaa8e9aeeb3b1af2dde_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bf0aa30ad2449048bb635d1a966c756_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1515189b9f7e45499b0325f53fa93549_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5b3357b82d34850aa8982528bb2f47d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6631f4c18a1a40ecbac6c62f92de5799_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17a96552b13e459d9ccd8b8026f03612_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32d7d0f983d5402d8056f502420bed85_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37ed1379a0e741cb891c3d578b500f9c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8cfe8fdf29a4818b64dd927a3441caf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f93f033b2964acd9d3cd23521742d13_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="id83e33e57cad4f08967d8d41dfb42b28_D20190927-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ocgn:HistogenicsCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-27</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c8bec4b6fb74710acd1aebcd65c0caf_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7530f5259ea4fb287abfd56f7c74a7f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i280158470c9b4af886ce65d165852eaa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ocgn:EquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad6c551567dc41aba66ce356fc5db8a9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ocgn:EquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c306b6118f54e09b3f5ed1b41de8514_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c492065ff8d4ceb931653d3b6553ee6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6258e5af615841ca8ed08b5fc6e64f13_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>ocgn:segment</xbrli:measure></xbrli:unit><xbrli:context id="i7860a6ea500e471894ae9e509085cdf6_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5010aa0712c74ac685012c6d136ca792_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfbc6400eef840d6b17bcf600923cbfa_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if83d8a8656604b6494f17eff209a905f_I20191004"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-10-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98c6625973004b8697d9716a871ffa88_D20191004-20191004"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-04</xbrli:startDate><xbrli:endDate>2019-10-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a90ecac0c074f6aa909c9426321c8d8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i342cd331097f4691b9092a11b982313e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08a49a87c9214a5188152f75514c346b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ocgn:SeriesAWarrantsAndSeriesCWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6de30431b0884e779b449c2552d931fc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ocgn:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cc6e7cd4ebb41879dbbbd27370e6258_I20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ocgn:EquityHoldersOfOcugenIncPerMergerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">ocgn:HistogenicsCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib33a77518a874faaa0e86a954580e035_I20190926"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ocgn:EquityHoldersOfHistogenicsCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">ocgn:HistogenicsCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c96e6e4a1ec48b79500273ba5fd55e8_D20190927-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocgn:HistogenicsCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-27</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i233f75f6ffd24f2fbc2db0b32db4d667_I20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocgn:HistogenicsCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1089f8a8a43a48879ed876ae4de5115b_D20190508-20190508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocgn:HistogenicsCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-08</xbrli:startDate><xbrli:endDate>2019-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22aaf4b1361c4ec7884cdd1e535ac03e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocgn:HistogenicsCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id02b04cce6a9413aae504f8cfc956e2b_D20191004-20191004"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocgn:HistogenicsCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-04</xbrli:startDate><xbrli:endDate>2019-10-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c31e84a90244ee78a2df7e88dca555a_D20191231-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-31</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4141b56122e4357bea6334ad7cbb7eb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocgn:NeocartMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i452b3f0c99ee4054a9b7492fcd19fe2a_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ocgn:HistogenicsCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib18c97e1d3e1439fa0756a1747c56510_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i702dd84e91b44b20bc3d8cb7ca9e4a59_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i477a58364a2b4532b86d564fdf1686e8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dedc44510f14e77b6d2358d6ebef9a1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36f2d441406443dcaba60c36eab4f7b7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ocgn:SeriesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd5bb0da90474df78f52019d31b3061f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ocgn:SeriesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91c2dd8a64e34278b820002768b4bdae_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ocgn:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e0464bba65447d099bca6eb5c866819_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ocgn:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32196db366ca47dfb065bbc67d9993d9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ocgn:SeriesCWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a1acd90bf1a4186b62635f3f1291ee8_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ocgn:SeriesCWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d16882d4b4e40b5817ec2c99e0a487e_D20190927-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocgn:CollaborationAgreementWithCansinoBiologicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-27</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ef76329772147dd8a1a1be7785f5e5d_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocgn:SchepensEyeResearchInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if76acb9aa16d490a90c7132533737b13_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocgn:SchepensEyeResearchInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i827132cd7da14ed8ad14eae7babe9d17_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocgn:SchepensEyeResearchInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb5f12c395364ac0968b482475cd5720_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocgn:CollaborationAgreementWithUniversityOfIllinoisChicagoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe9866f13f484211a602b7658ac319c6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocgn:CollaborationAgreementWithUniversityOfIllinoisChicagoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie00ff0e528c242f698fe9a5810b936e6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocgn:CollaborationAgreementWithUniversityOfIllinoisChicagoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97535139e9054d88803d1577aa998142_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocgn:CollaborationAgreementWithUniversityOfIllinoisChicagoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84c4c1d32cc746778f6f4ffed31a2f12_D20140101-20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocgn:CollaborationAgreementWithUniversityOfColoradoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fdb2024e3e04b00afbe628fe94fc6a1_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocgn:CollaborationAgreementWithUniversityOfColoradoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41512e91ea66459091142a09d64979ee_I20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:EB5ProgramBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie26010e163a44d8f8901034a2237a150_D20160901-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:EB5ProgramBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f4493de5f9a420f8e7d280ce9393d02_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:EB5ProgramBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49703b2d634a40219c09a4116c60351e_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:EB5ProgramBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa216e92d8ad45f695cf881fb2ec681d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:EB5ProgramBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10a74d4f5772493bb775e01c0458d587_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:EB5ProgramBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dd588e3e2fd4d56ba9f7ed7bf627e44_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:ConvertibleNotesBoardOfDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie107e1047f9e4c3fa462f46cf3e5e3e4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:ConvertibleNotesBoardOfDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i328baa90b6ca4ecf9cdc9e0a79ee26ad_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65b540d692bb45958ed8ced1fb3911da_I20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:ConvertibleDebtJanuary2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cc3532217ff4a829773c63ec209eebb_I20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:ConvertibleDebtJanuary2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ocgn:ConvertibleDebtConversionFeatureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i161b6716805149329fb75cb8d891a7d3_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:ConvertibleDebtJune2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0c9d3000afb440eb2ae0e4453fc13cd_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:ConvertibleDebtJune2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ocgn:ConvertibleDebtConversionFeatureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i514af234321c45249033c2c6004c3681_I20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:ConvertibleDebtNovember2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94d7513be73b4b42b644afe0f55eda9e_I20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:ConvertibleDebtNovember2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ocgn:ConvertibleDebtConversionFeatureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i932ae52afffe48a19dbc8e83e080b098_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:ConvertibleDebtDecember2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf9bc486110443f69af07574bf14d5f7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:ConvertibleDebtDecember2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ocgn:ConvertibleDebtConversionFeatureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf78c78261294ef3881f6cf13befd9a5_I20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:ConvertibleDebtJanuary2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if379bb8b26134244bc1ef93807f107a8_I20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:ConvertibleDebtJanuary2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ocgn:ConvertibleDebtConversionFeatureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4183d88399e94dd0af0b9cb7d63d5f7d_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:ConvertibleDebtFebruary2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74fd32d2c80748aeb83fa8309f3b484c_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:ConvertibleDebtFebruary2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ocgn:ConvertibleDebtConversionFeatureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17e3a21a882c45e6a5d43855f575a703_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1432fdaf1af748b9aa5b711d2c461c89_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ocgn:ConvertibleDebtConversionFeatureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30518d590b384689bc953bae8c788989_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:November2018AndDecember2018NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie03c47b9f9564d4ea485d3ffdd995bb6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ef067fabc2048d49a715adf223a6aaf_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie32a5c52109846399c80873ec089ffbb_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic10bc878b71a4eec829c618f097ab1f3_I20190405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-04-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf15ac65c13f41efa5b2c278c90ef1ad_I20190405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i408357dbb20b4db79414a01968187418_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:January2019AndFebruary2019NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d316476da1f4704bd006d963c24c9f3_I20190405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c77d97bd72b4690ab70a469f8712825_D20190405-20190405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-05</xbrli:startDate><xbrli:endDate>2019-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i016d0b71e20d44c6b6f177338d083e24_D20190405-20190405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-05</xbrli:startDate><xbrli:endDate>2019-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3af9928ff5934a50a728ddecb0030b9f_I20190404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:ConvertiblePromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9825c374339d495092fda175dbb9ecc6_D20190516-20190516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-16</xbrli:startDate><xbrli:endDate>2019-05-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff635dcebab24f36911b7b91f40c1759_I20190521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:SeniorSecuredConvertibleNotesMay2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58aa2dbee17a4346b99dfe95c91e455d_I20190628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:SeniorSecuredConvertibleNotesJune2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc8f3b70120644bcb0ea07e4c4e58532_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9169a31e29f845df9d4dcc1d4c8e89af_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dd31fe358a94242921f371e4a12056c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee4f88bad8cb4836b9a7cc7122e34867_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb06df9a8042478fbcacfde1e1ec008c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81f536df668b463db04d83beaea9fca4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21b036a7018e49f1ba389957307f069f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dd0fe8be9d9438c8e720727830deb3e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ocgn:A2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i901327021f4f4d8a9e7429629a2fe235_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocgn:A2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4c25c1678fc46f2a94db1f11c7a25d1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocgn:A2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf4d04bf884e47208ec21854eaf3c6fa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81f1955a085348c7b2651edceb71e43f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8f44ff16f6a48a5b00b8d8fb4955d6f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac0f32c415484121ac10d938108c47c4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebb192fe177843a59dda713200213ad2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f30ba30167e413fa31d614ef91c6c25_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d9bff3d3ae843c7b1af7507aeb3bcc2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78c531e0c2834d2c9ce23d519b06d67b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ocgn:A2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i765c6c431bab4e9ca9750ef3e6d5c0a4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ocgn:A2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f2a660290394b9288e546c9be4bde7a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ocgn:A2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i885e5bb590844f6ebf88b1399519a254_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67871994f7b24db59223486582b30e7a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if38d3cddf7364a18958c9f6b986c7132_D20190927-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-27</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6745b0e5cb764520ba29b0c6f1b86602_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieef5bdfd701441fea03e6621fed01d9d_D20191105-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-05</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77f0ebf13e6e4a578b9b6ffd815a024e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice482ddff55b45b4a75e3de02537f56b_D20191105-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-05</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cf5412727aa4f75918abdb76b03caf7_D20191120-20191121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-20</xbrli:startDate><xbrli:endDate>2019-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a4dec58cf3a474a90c3320d94bff77c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i914cfde7eb234db2ac6c9112d30eadfb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesCWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3301d78826140fb96af8db1fc68d531_I20191104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesCWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1153f084349d4b7ea469d4f40aff5141_I20191105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesCWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibca9608a3ab44021be1d03353a57553c_I20191104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesCWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3da044ce503648edbe7ad9e78f55ca78_D20191105-20191105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesCWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-05</xbrli:startDate><xbrli:endDate>2019-11-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie65f10daf6f84ce6802f5816662b4903_D20191105-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesCWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-05</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if254d19519344254a9f50cfcfe386457_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesCWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27857d6d3d5a42bd93969147f2520cad_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71ce16f5e5214d2780d7f39624f8b29d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d0d3793e46440a899ad41a111b2431f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesCWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b2b631bda3048ee8c734721295f429a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7980383d2e44bc2b50a1d2faf810a91_D20190927-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-27</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="measurementinput"><xbrli:measure>ocgn:measurementInput</xbrli:measure></xbrli:unit><xbrli:context id="i8c7e388caf954f629bf3e170e216d890_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2c38d1a38a84e6a82c73b5a98cb3e80_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:FormerOcugenWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86aee3af2c3f4b798c30aaca8de9b337_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:FormerOcugenWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cbe8832ab0843b598d967b9b9032b0d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d8219b4b2bc4150b6b1c651c7d324a5_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45e1ee8f0a174a99b058fcc427e9def5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10ef3ad5f41f48c39073eca93c89a51d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e36ccdb3dcd46a4ba0bf2a92174d054_D20200326-20200326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:EB5ProgramBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-26</xbrli:startDate><xbrli:endDate>2020-03-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie83135b281cb4e26b25b62e6bb7f951f_I20200326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:EB5ProgramBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-26</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1"></div><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;">Washington, D.C. 20549</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">___________________________________________________________</span></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%;">FORM <ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xMTU0NDg3MjEwMzI0NQ_46b765da-251f-4ed0-a400-1b331fee70cc">10-K</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">___________________________________________________________</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Mark One)</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:1.947%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:94.053%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGFibGU6OWMxMjc2YTYwNTFhNGRjNDhkYmI2NTllOWQ3ZmY1YzMvdGFibGVyYW5nZTo5YzEyNzZhNjA1MWE0ZGM0OGRiYjY1OWU5ZDdmZjVjM18wLTAtMS0xLTEwNzEx_5023c2f1-d6d3-4304-ae4e-669f52285578">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the fiscal year ended <ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xNTM5MzE2MjgwMTc5Mw_5eba6fa2-6d52-452e-b79e-f18967f1915e">December 31, 2019</ix:nonNumeric> </span></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OR</span></div><div style="text-align:center;margin-top:3pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:1.947%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:94.053%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGFibGU6OWFjYTc2MWFmMGYyNDI0MTk4YmNkZjVkNjRlNzc4ZjYvdGFibGVyYW5nZTo5YWNhNzYxYWYwZjI0MjQxOThiY2RmNWQ2NGU3NzhmNl8wLTAtMS0xLTEwNzE4_67cada99-8529-4590-87d0-9e091a0c314b">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Commission File Number <ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xMjA5NDYyNzkxNzEzOQ_d0ffa8ac-8eb2-477e-b62e-48f0c674cb26">001-36751</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">___________________________________________________________</span></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xMjA5NDYyNzkxNzE1MA_33fda10e-7510-4d82-8839-46d4ca917040">OCUGEN, INC.</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">___________________________________________________________</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGFibGU6NmIwYWYwZmJiMTI2NGQ0ZTk0MTFkYzM3ZjUyNjk5YjcvdGFibGVyYW5nZTo2YjBhZjBmYmIxMjY0ZDRlOTQxMWRjMzdmNTI2OTliN18wLTAtMS0xLTEwNzMx_03e024e0-7c65-4c2d-8ee5-23be233e527b">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGFibGU6NmIwYWYwZmJiMTI2NGQ0ZTk0MTFkYzM3ZjUyNjk5YjcvdGFibGVyYW5nZTo2YjBhZjBmYmIxMjY0ZDRlOTQxMWRjMzdmNTI2OTliN18wLTEtMS0xLTEwNzM1_5f4263ee-c90f-40b8-8eb6-a40fc8f57f6a">04-3522315</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xMjA5NDYyNzkxNzE2NA_485d313e-89b1-4dd2-95d3-05fbb04cb513">5 Great Valley Parkway, Suite 160</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xMjA5NDYyNzkxNzE5OQ_f2b6eba5-2f32-4b53-a1a5-9a462ebbf15e">Malvern,</ix:nonNumeric> <ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xMjA5NDYyNzkxNzIwOQ_03320bc4-1bce-4187-ba75-09fac2d9827a">Pennsylvania</ix:nonNumeric> <ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xMjA5NDYyNzkxNzIyMw_f962d102-8075-44fe-a926-7b408e7f3236">19355</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;">(<ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xMjA5NDYyNzkxNzIzMA_1b0f1012-a3fe-4c5d-a526-8301a1b87387">484</ix:nonNumeric>) <ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xMjA5NDYyNzkxNzIzNQ_3c667236-2448-4448-bd38-4988dbbd9211">328-4701</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">___________________________________________________________</span></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:30.844%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:30.844%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:30.846%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title of each class</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trading<br/>symbol(s)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name of each exchange<br/>on which registered</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGFibGU6NjM2YmFkMjRkN2UzNGFiMDg3NzEwNDI1OGYxMzM2MzUvdGFibGVyYW5nZTo2MzZiYWQyNGQ3ZTM0YWIwODc3MTA0MjU4ZjEzMzYzNV8xLTAtMS0xLTEwNzc2_1510e640-3c1d-4ab4-ba5e-a016f2fa5c22">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGFibGU6NjM2YmFkMjRkN2UzNGFiMDg3NzEwNDI1OGYxMzM2MzUvdGFibGVyYW5nZTo2MzZiYWQyNGQ3ZTM0YWIwODc3MTA0MjU4ZjEzMzYzNV8xLTItMS0xLTEwNzgy_f5b1653f-a612-4cf4-b4db-e28cfbe68de5">OCGN</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGFibGU6NjM2YmFkMjRkN2UzNGFiMDg3NzEwNDI1OGYxMzM2MzUvdGFibGVyYW5nZTo2MzZiYWQyNGQ3ZTM0YWIwODc3MTA0MjU4ZjEzMzYzNV8xLTQtMS0xLTEwNzg0_6a014719-8b71-4cfd-88c6-3cc4cfa95ddf">The Nasdaq Stock Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">Yes  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">o</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;"> <ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xMjA5NDYyNzkxNzI0NQ_fe38a38f-8d78-4e48-ba4a-bdc6cad05425">No</ix:nonNumeric>  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">x</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">   </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">Yes  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">o</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;"> <ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xMjA5NDYyNzkxNzI0OQ_28e731a3-1756-400d-a644-7f9194afb5b0">No</ix:nonNumeric>  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">x</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">  </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xMjA5NDYyNzkxNzI1Mw_f75b74c1-c3e0-486f-b084-d2cdb0772501">Yes</ix:nonNumeric>&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%;">x</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%;">&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%;">o</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xMjA5NDYyNzkxNzI1OA_16809b5d-aad2-4780-ad29-16038ada6935">Yes</ix:nonNumeric>&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%;">x</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%;">o</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:16.859%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.058%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.350%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:23.733%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">o</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accelerated&#160;filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">o</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGFibGU6ZmVmZjI3NmRjZGRlNDY5YmJhODdhOWJkNWU1OTVmYTQvdGFibGVyYW5nZTpmZWZmMjc2ZGNkZGU0NjliYmE4N2E5YmQ1ZTU5NWZhNF8xLTAtMS0xLTEwODQx_1b4b6800-42d2-4a35-a96a-21656a8799cd">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">x</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGFibGU6ZmVmZjI3NmRjZGRlNDY5YmJhODdhOWJkNWU1OTVmYTQvdGFibGVyYW5nZTpmZWZmMjc2ZGNkZGU0NjliYmE4N2E5YmQ1ZTU5NWZhNF8xLTMtMS0xLTEwODY0_18f380c9-aaf9-4f7b-ac21-68228d08a5de">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Emerging&#160;growth&#160;company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGFibGU6ZmVmZjI3NmRjZGRlNDY5YmJhODdhOWJkNWU1OTVmYTQvdGFibGVyYW5nZTpmZWZmMjc2ZGNkZGU0NjliYmE4N2E5YmQ1ZTU5NWZhNF8yLTMtMS0xLTEwODY3_cb912a47-8f80-487f-8bc3-6357b7aa67a9">&#9744;</ix:nonNumeric></span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B)&#160;of the Securities Act.&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%;">o</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%;"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xMjA5NDYyNzkxNzI2OA_a0fba168-72dd-41cf-a3f5-4921bc981fb5">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%;">&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%;">x</span></div><div style="margin-top:2pt;"><span><br/></span></div><div style="margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">As of June 30, 2019, the last day of the registrant's most recently completed second fiscal quarter, the aggregate market value of the common stock held by non-affiliates of the registrant was approximately $<ix:nonFraction unitRef="usd" contextRef="i73ff1de059af438fb2052b13e4f9d5b6_I20190630" decimals="-5" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl81NDk3NTU4MTQxNjQ5_aee0e9eb-7f06-4306-a0b8-d33382439717">18.1</ix:nonFraction>&#160;million, based upon the closing price of the registrant's common stock on June 30, 2019.</span></div><div style="margin-top:2pt;"><span><br/></span></div><div style="margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">As of March&#160;20, 2020, there were <ix:nonFraction unitRef="shares" contextRef="i23c3ffb42fab4881887c19daef4a2535_I20200320" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl81NDk3NTU4MTQxNjIw_c8a4b9dc-e943-4159-90f0-ae1e755b40b8">52,625,228</ix:nonFraction> outstanding shares of the registrant&#8217;s common stock, $0.01 par value per share.</span></div><div style="margin-top:2pt;"><span><br/></span></div><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xMTU0NDg3MjEwNDIzNw_226c5aa1-1b4f-4c71-9154-006459dc20e2" escape="true"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:115%;">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;">Part III of this Annual Report on Form 10-K incorporates certain information by reference from the registrant&#8217;s proxy statement for the 2020 annual meeting of stockholders to be filed no later than 120 days after the end of the registrant&#8217;s fiscal year ended December 31, 2019.</span></div></ix:nonNumeric><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907"></div><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.321%;"><tr><td style="width:1.0%;"></td><td style="width:7.815%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:35.116%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:43.245%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.824%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TABLE OF CONTENTS</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Page</span></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_10">FORWARD LOOKING STATEMENTS</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1595">Part I</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_154">Item 1.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_154">Business</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_154">1</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_133">Item 1A.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_133">Risk Factors</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_133">34</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1614">Item 1B.</a></span></div></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1614">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1614">82</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1620">Item 2.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1620">Properties</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1620">82</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_130">Item 3.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_130">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_130">83</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1627">Item 4.</a></span></div></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1627">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1627">83</a></span></div></td></tr><tr><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1606">Part II</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1636">Item 5.</a></span></div></td><td colspan="6" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1636">Market for Registrant's Common Equity</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1636">,</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1636"> Related Stockholder Matters and Issuer Purchases of Equity Securities </a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1636">84</a></span></div></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_13">Item 6.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_13">Selected Financial Data</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_13">84</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_94">Item 7.</a></span></div></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_94">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_94">85</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_121">Item 7A</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">.</span></div></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_121">Quantitative and Qualitative Disclosure About Market Risk</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_121">92</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_16">Item 8.</a></span></div></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_16">Financial Statements and Supplementary Data </a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_16">92</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1657">Item 9.</a></span></div></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1657">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1657">92</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_124">Item 9A.</a></span></div></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_124">Controls and Procedures</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_124">92</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_145">Item 9B.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_145">Other Information</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_145">93</a></span></div></td></tr><tr><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_127">Part III</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1674">Item 10.</a></span></div></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1674">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1674">95</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1680">Item 11.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1680">Executive Compensation </a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1680">95</a></span></div></td></tr><tr><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1687">Item 12.</a></span></div></td><td colspan="6" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1687">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1687">95</a></span></div></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1692">Item 13.</a></span></div></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1692">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1692">95</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1698">Item 14.</a></span></div></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1698">Principle Accountant Fees and Services</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1698">95</a></span></div></td></tr><tr><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1710">Part IV</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1704">Item 15.</a></span></div></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1704">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1704">96</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1828">Item 16.</a></span></div></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1828">Form 10-</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1828">K</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1828"> Summary </a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1828">101</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_151">Signatures</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> </span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1802">Consolidated Financial Statements</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1802">F-</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1802">1</a></span></div></td></tr></table></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">As previously announced, on September 27, 2019, Ocugen, Inc. (formerly known as Histogenics Corporation) (referred to herein as "Ocugen" or the "Company", completed its reverse merger with Ocugen Opco, Inc. (formerly known as Ocugen, Inc.) (&#8220;Former Ocugen&#8221;), in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of April 5, 2019 by and among Ocugen, Former Ocugen and a wholly owned subsidiary of Ocugen (&#8220;Merger Sub&#8221;), as amended (the &#8220;Merger Agreement&#8221;), pursuant to which Merger Sub merged with and into Former Ocugen, with Former Ocugen surviving as a wholly owned subsidiary of Ocugen (the &#8220;Merger&#8221;).</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">For accounting purposes, the Merger is treated as a &#8220;reverse asset acquisition&#8221; under generally acceptable accounting principles in the United States (&#8220;U.S. GAAP&#8221;) and Former Ocugen is considered the accounting acquirer. Accordingly, Former Ocugen&#8217;s historical results of operations will replace the Company&#8217;s historical results of operations for all periods prior to the Merger and, for all periods following the Merger, the results of operations of the combined company will be included in the Company&#8217;s financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">i</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">This Annual Report on Form 10-K relates to the Company&#8217;s fiscal year ended December 31, 2019, which includes the date of the completion of the Merger and is therefore the Company&#8217;s first annual report that includes results of operations for the combined company, including Former Ocugen.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Unless the context otherwise requires, references to the &#8220;Company,&#8221; the &#8220;combined company&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221; in this report refer to Ocugen, Inc. (formerly known as Histogenics Corporation) and its subsidiaries, references to &#8220;Ocugen&#8221; refer to the Company following the completion of the Merger, references to &#8220;Histogenics&#8221; refer to the Company prior to the completion of the Merger and references to &#8220;OpCo&#8221; refer to Ocugen OpCo, Inc., the Company&#8217;s wholly owned subsidiary following the Merger.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_10"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ii</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This Annual Report on Form 10-K and the documents incorporated by reference herein contain forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts contained in this Annual Report on Form 10-K or the documents incorporated by reference herein regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of such terms and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are based on assumptions and expectations that may not be realized and are inherently subject to risks, uncertainties and other factors, many of which cannot be predicted with accuracy and some of which might not even be anticipated.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The forward-looking statements in this Annual Report on Form 10-K and the documents incorporated herein by reference include, among other things, statements about: </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt;">our estimates regarding expenses, future revenue, capital requirements and timing and availability of and the need for additional financing; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt;">our ability to obtain sufficient additional capital to continue to advance these product candidates and its preclinical programs; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt;">our ability to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market and the risk that products will not achieve broad market acceptance; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt;">uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt;">our ability to comply with regulatory schemes applicable to our business and other regulatory developments in the United States and foreign countries; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt;">our ability to operate under increased leverage and associated lending covenants; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt;">the uncertainties associated with the clinical development and regulatory approval of product candidates, including potential delays in the commencement, enrollment and completion of clinical trials; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt;">the performance of third-parties upon which we depend, including third-party contract research organizations (&#8220;CROs&#8221;), and third-party suppliers, manufacturers, group purchasing organizations, distributors and logistics providers; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt;">our ability to obtain and maintain patent protection and defend our intellectual property rights against third-parties; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt;">our ability to maintain our relationships, profitability and contracts with our key commercial partners; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt;">our ability to recruit or retain key scientific, technical, commercial, and management personnel or to retain our executive officers; and</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt;">our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including Good Manufacturing Practice (&#8220;cGMP&#8221;) compliance and U.S. Drug Enforcement Agency compliance and other relevant regulatory authorities.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Annual Report on Form 10-K, particularly under &#8220;Risk Factors,&#8221; that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, collaborations or investments we may make. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">iii</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">You should read this Annual Report on Form 10-K and the documents that we incorporate by reference herein and have filed as exhibits to this Form 10-K, completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Form 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Solely for convenience, tradenames referred to in this Annual Report on Form 10-K appear without the &#174; symbol, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these tradenames. All trademarks, service marks and tradenames included or incorporated by reference in this Annual Report on Form 10-K are the property of their respective owners.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1595"></div><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">iv</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART I</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_154"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 1.&#160;Business</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_157"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OVERVIEW</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat the whole eye. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are focused on three waves of technological innovations that target the back and front of the eye:</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Potential therapies that target the back of the eye:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">Modifier Gene Therapy Platform</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;Based on nuclear hormone receptors, we believe our gene therapy platform has the potential to address many retinal diseases including retinitis pigmentosa ("RP") with one product.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">Novel Biologic Therapies for Retinal Diseases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;We are developing OCU200, which is being developed to treat diabetic macular edema (&#8220;DME&#8221;), diabetic retinopathy (&#8220;DR&#8221;) and wet age-related macular degeneration (&#8220;AMD&#8221;).</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Potential therapy that targets the front of the eye:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">Small Molecule Phase 3 Rare Disease Asset</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;Our OCU300 product candidate is in Phase 3 clinical development for the treatment of symptoms associated with ocular graft-versus-host disease (&#8220;oGVHD&#8221;).</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Modifier Gene Therapy Platform</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are developing a modifier gene therapy platform to generate therapies designed to fulfill unmet medical needs in the area of retinal diseases, including inherited retinal diseases (&#8220;IRDs&#8221;). Our modifier gene therapy platform is based on nuclear hormone receptors (&#8220;NHRs&#8221;), which have the potential to restore homeostasis, the basic biological processes in the retina. Unlike single-gene replacement therapies, which only target one genetic mutation, we believe that our gene therapy platform, through its use of NHRs, represents a novel approach in that it may address multiple retinal diseases with one product. IRDs such as RP affect over 1.5 million people worldwide. Over 150 gene mutations have been associated with RP and this number represents only 60% of the RP population. The remaining 40% of RP patients cannot be genetically diagnosed, making it difficult to develop individual treatments. OCU400 has the potential to eliminate the need for developing more than 150 individual products and provide one treatment option for all RP patients. Our first gene therapy candidate, OCU400, received two orphan drug designations ("ODDs") from the U.S. Food and Drug Administration ("FDA"), one for the treatment of nuclear receptor subfamily 2 group E member 3 ("</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NR2E3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">") mutation-associated retinal diseases and the other for the treatment of centrosomal protein 290 ("</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">CEP290")</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> mutation-associated retinal diseases. We are planning to initiate a Phase 1/2a clinical trial for OCU400 in 2021. Our second gene therapy candidate, OCU410, is being developed to utilize the nuclear receptor genes RAR-related orphan receptor A (&#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">RORA</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) for the treatment of dry AMD. This candidate is currently in preclinical development.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Novel Biologic Therapies for Retinal Diseases</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are in preclinical development for a novel biologic product candidate, OCU200. OCU200 is a novel fusion protein designed to treat DME, DR and wet AMD. We expect to initiate a Phase 1/2 clinical trial for OCU200 within the next two years. We plan to expand the therapeutic applications of OCU200 beyond DME, DR and wet AMD to potentially include macular edema following retinal vein occlusion (&#8220;RVO&#8221;) and myopic choroidal neovascularization (&#8220;mCNV&#8221;).</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Small Molecule Phase 3 Rare Disease Asset</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are also developing OCU300, which is a small molecule therapeutic currently in Phase 3 clinical development for patients with oGVHD. OCU300 is a brimonidine tartrate eye drop formulated as a topical nanoemulsion. As of March&#160;20, 2020, we had completed over 95% of planned enrollment of our Phase 3 clinical trial for OCU300. OCU300 has received ODD from the FDA, and it is the first and only product candidate to receive that designation for the treatment of symptoms associated with oGVHD. oGVHD, a severe chronic autoimmune disease that occurs in up to 60% of patients receiving hematopoietic stem cell transplantation (&#8220;HSCT&#8221;) from donors, referred to as allogeneic HSCT, can result in light sensitivity, excessive ocular redness, severe ocular pain and, ultimately, vision impairment. We estimate the current prevalence of patients suffering from oGVHD in the United States to be approximately 63,000. OCU300 is formulated using our proprietary nanoemulsion technology, OcuNanoE&#8212;Ocugen&#8217;s ONE Platform&#8482; (&#8220;OcuNanoE&#8482;&#8221;), which we believe represents an effective drug delivery mechanism </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">to treat ocular surface disorders. We believe that OcuNanoE&#8482; provides additional protection to the ocular surface and the potential for enhanced efficacy compared to traditional formulations. OcuNanoE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> nanoemulsion was developed to decrease the drainage rate, prolong precorneal residence time and increase the drug concentration in the lacrimal gland, which is critical for tear film production. We are the first and only company to use nanoemulsion technology in the ophthalmology space.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are headquartered in Malvern, Pennsylvania, and our common stock trades on The NASDAQ Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;OCGN.&#8221; On September 27, 2019, we completed our reverse merger with Ocugen OpCo Inc. (formerly known as Ocugen, Inc. (&#8220;Former Ocugen&#8221;)) in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of April 5, 2019, by and among Histogenics, Former Ocugen and Restore Merger Sub, Inc., a wholly owned subsidiary of Histogenics (&#8220;Merger Sub&#8221;), as amended (the &#8220;Merger Agreement&#8221;), pursuant to which Merger Sub merged with and into Former Ocugen, with Former Ocugen surviving as a wholly owned subsidiary of Histogenics (the &#8220;Merger&#8221;). Immediately after completion of the Merger, Histogenics changed its name to Ocugen, Inc. and the business conducted by Ocugen, Inc. became the business conducted by Former Ocugen.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_160"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OUR STRATEGY</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our product candidates have the potential to address unmet medical needs in both retinal and ocular surface diseases. We are committed to developing these product candidates and bringing them to market to serve patients. Key elements of the strategy we employ to accomplish this objective include:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt;">Establishing our modifier gene therapy platform and advancing OCU400 and OCU410 into clinical development. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We intend to advance OCU400 and OCU410 into and through clinical development for the treatment of multiple IRDs and for the treatment of dry AMD, respectively. In addition to OCU400 and OCU410, we will also explore additional NHR-based product candidates for multiple eye disease indications.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt;">Advancing the development of OCU300 to approval.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> We have initiated Phase&#160;3 registration trials using OCU300 as a first-in-class treatment for ocular redness and discomfort in patients with oGVHD. While the clinical trials are progressing and successful completion of such trials is a prerequisite for the submission of a New Drug Application (&#8220;NDA&#8221;) to the FDA, we have concurrently begun development of chemistry, manufacturing and controls (&#8220;CMC&#8221;) for OCU300, including process validation and stability studies of registration batches. OCU300 has been granted ODD, and accordingly it may be eligible for seven-year market exclusivity.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt;">Exploring potential partnerships with leading pharmaceutical and biotechnology companies to maximize patient access, global reach and the value of its product candidates.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> We currently plan to explore licensing the commercialization rights to our product candidates or other forms of collaboration with qualified potential partners in certain key markets outside of the United States, including Europe, Japan and emerging markets, including potentially partnering commercialization rights for OCU300. During 2019, we entered into a co-development commercialization agreement with CanSino Biologics Inc. ("CanSinoBIO") with respect to the development and commercialization of our initial gene therapy product candidate, OCU400.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt;">Advancing preclinical biological programs into clinical development.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Within the next two years, we intend to advance OCU200, our product candidate targeting DME, DR and wet AMD into clinical development. This candidate is currently in preclinical development.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_172"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">COMPETITIVE STRENGTHS</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our key competitive strengths include:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt;">Gene Therapy Manufacturing. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have established a strategic partnership with CanSinoBIO for CMC development and manufacturing of clinical supplies for our gene therapy candidate, OCU400. The partnership secures hard-to-find manufacturing capacity and expertise for gene therapy product development. This will help with the development timeline and significant reduction in associated costs.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt;">Intellectual Property Portfolio.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> We hold the worldwide commercial rights for our current product candidates. Our intellectual property portfolio contains patents and pending patent applications related to composition of matter, pharmaceutical compositions and methods of use for our product candidates, which have been licensed from leading institutions. We strive to protect the proprietary technology that we believe is important to our business, including seeking and maintaining patents for our product candidates and OcuNanoE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> platform. We have patent protection for OCU300 in the United States through at least 2036.</span></div><div style="padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We seek to protect our proprietary and intellectual property positions by filing U.S. and foreign applications for our clinical program, OCU300, preclinical development programs, OCU400, and OCU200, as well as technology </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">platforms critical to the development and implementation of our business strategy. We have built a strong global patent portfolio with 34 U.S. or foreign issued patents and 30 patent applications, including patents licensed from The Schepens Eye Research Institute ("SERI"), the University of Colorado ("CU"), and the University of Illinois at Chicago ("UIC"). As of March 2020, we had exclusive rights or owned rights to: (i)&#160;three issued patents and 11&#160;pending U.S. and foreign patent applications related to OCU300; (ii)&#160;one issued patent and four pending applications related to OCU400; and (iii)&#160;25&#160;issued U.S. and foreign patents and three pending patent applications related to OCU200.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt;">Licensing Arrangements with Leading Institutions.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> We have three licensing agreements with leading academic and medical institutions that cover our four product candidates. In December 2017, we entered into an exclusive worldwide license agreement with SERI, an affiliate of Harvard Medical School, pursuant to which we acquired patent rights for NHRs, including those used in our OCU400 and OCU410 programs. In March 2014, we entered into an exclusive worldwide license agreement with the CU pursuant to which we acquired rights to the transferrin-tumstatin fusion protein technology used in OCU200 as well as other technology. In February 2016, we entered into an exclusive worldwide license agreement with UIC pursuant to which we acquired rights develop brimonidine tartrate for the treatment of ocular surface diseases, which is the compound used in our OCU300 program. </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt;">Experienced Management Team.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Our management team has a combined experience of over 200&#160;years with a proven track record of success in developing, launching and managing the life cycle of many biopharmaceuticals at leading pharmaceutical companies (including Pfizer and Merck) and biotechnology companies. We believe that the experience of our management team and our broad network of relationships with leaders within the industry and the medical community provides us with insight into product development and identification of product opportunities to address underserved eye diseases.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_163"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OUR PRODUCT CANDIDATE PIPELINE</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our current product pipeline candidates are summarized in the following chart:</span></div><div style="text-align:center;margin-top:12pt;"><img src="ocgn-20191231_g1.jpg" alt="ocgn-20191231_g1.jpg" style="height:302px;width:684px;"/></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_181"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PRODUCT CANDIDATE FOR THE TREATMENT OF OCULAR SURFACE DISEASES</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">OCU300 for the Treatment of Ocular Redness and Discomfort in Patients with oGVHD</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">OCU300 is a late-stage product candidate for which we have initiated a randomized, double-masked, placebo-controlled, Phase 3 trial for the treatment of ocular redness and discomfort in patients with oGVHD. There currently are no FDA-approved products for oGVHD. oGVHD is a severe chronic autoimmune disease that occurs in up to 60% of allogeneic HSCT recipients and represents a critical unmet medical need. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">OCU300 is a twice-daily eye drop of brimonidine tartrate (0.18%) OcuNanoE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> nanoemulsion. OCU300 is sterile-filtered, preservative-free, and steroid-free, and it has been designed as such to avoid certain side effects. In addition to the existing ODD for oGVHD, we are eligible to utilize the streamlined Section 505(b)(2) regulatory pathway for the approval of OCU300 in the United States. We believe that the Section 505(b)(2) regulatory pathway provides us with a potential path to market by allowing us to rely on certain information from studies conducted by third parties. As of March 20, 2020, we have enrolled over 95% of the planned sample size into the first pivotal, Phase 3 trial of OCU300.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">oGVHD is a disease driven by the invasion of HSCT-derived leukocytes onto the ocular surface, resulting in fibrosis and excessive production of extracellular matrix (&#8220;ECM&#8221;) proteins. The donor leukocytes subsequently launch an autoimmune assault on the tear-producing glands, cornea, conjunctiva and eyelid of the recipient. oGVHD can cause irreparable damage to these ocular tissues, thereby decreasing the secretion and stability of tear film. Prolonged inflammation can result in ocular pain and discomfort, corneal ulceration, cicatricial conjunctivitis, blepharitis, and vision loss.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In order to treat oGVHD, a viable product must have the ability to interrupt the pathological process of the disease, which can involve the local infiltration of inflammatory cells, the activation of leukocytes, fibrosis, the production of ECM proteins and the disruption of tear production. Brimonidine tartrate, which is approved for other ophthalmic indications, is an imidazoline compound that acts as a specific &#945;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">2</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">-adrenergic agonist. It has 1,000 times higher selectivity for &#945;2-adrenergic receptors than &#945;-1 adrenergic receptors. We believe brimonidine tartrate can treat oGVHD in the following ways:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Reducing ocular surface blood flow,</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Disrupting leukocyte extravasation to the ocular tissue, </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Suppressing leukocyte activation,</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Providing analgesic properties, and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Reducing fibrosis and suppressing excessive ECM protein formation. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">By potentially attenuating autoimmune activity and inflammation, brimonidine tartrate may allow the ocular surface and tear film producing glands to avoid further atrophy and to heal from damage sustained during the HSCT pre-conditioning regimen. In addition, brimonidine tartrate may alleviate heightened ocular pain through its antinociceptive and anti-inflammatory properties, which in turn, may potentially make the drug more tolerable and more effective. Brimonidine tartrate is approved for other indications by the FDA and has demonstrated a favorable safety profile via topical ocular delivery.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Overview of Ocular Graft-versus-Host Disease</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">oGVHD, which occurs exclusively in allogeneic HSCT recipients, is recognized by the National Institutes of Health ("NIH") and clinical experts as a distinct organ manifestation of chronic graft-versus-host disease. oGVHD is driven by an autoimmune mechanism and initiates immediately after bone marrow transplant completion with the encroachment of autoimmune cells onto the ocular surface. HSCT-derived leukocytes (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">i.e.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">,&#160;T lymphocytes and neutrophils) invade the ocular surface of allogeneic HSCT recipients, resulting in excessive production of ECM proteins, and fibrosis. The donor leukocytes subsequently launch an autoimmune assault on the recipient eye&#8217;s tear producing glands, cornea, conjunctiva, and eyelid. The disease typically affects all major ocular surface tear film glands (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">i.e</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">., the lacrimal gland, conjunctiva, and meibomian gland), as well as the cornea.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If left untreated, oGVHD can cause irreparable ocular surface damage and significant vision loss, leading to an overall decrease in their quality of life. The disease is most commonly associated with severe dry eye signs and symptoms, including visual hazing, reduction in visual acuity, light sensitivity (referred to as photophobia), excessive ocular redness, foreign body sensation and heightened ocular pain. Of the clinical symptoms reported with oGVHD, ocular pain is the one that most severely impacts the quality of life. In fact, the pain scores in oGVHD patients are comparable to those of patients suffering from ocular chemical burns. In severe cases, oGVHD can cause lens opacification, significant corneal epithelium degeneration and melting, including the development of corneal ulcers and corneal perforation, and may require multiple corneal grafts or surgeries to improve visual acuity. Furthermore, patients with oGVHD have difficulties in performing both near-vision activities and distance-vision activities, both centrally and peripherally, and suffer from cases of vision-related mental health decline. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The majority of patients with oGVHD become disabled and are unable to work and have reduced social functioning. As a result, the disease is associated with a significant economic impact on both patients and society. It has been estimated that the combined direct medical costs (e.g., prescription therapy, procedures, physician visits) and indirect costs (e.g., lost wages/productivity) resulting from oGVHD in the United States aggregate to approximately $18,000 per patient per year.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Absence of Approved Treatments for oGVHD Provides a Market Opportunity</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Up to 60% of patients that receive allogeneic HSCT in the United States are expected to develop oGVHD. We estimate the current prevalence of patients suffering from oGVHD in the United States to be approximately 63,000, which is anticipated to grow to approximately 140,000 patients by 2030. There are currently no FDA-approved drug products for the treatment of oGVHD.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Ongoing OCU300 Phase 3 Clinical Trials</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;20, 2020, we have enrolled over 95% of the planned sample size into the first registration trial for OCU300. We plan to conduct two identical trials. These studies will test OCU300 brimonidine tartrate (0.18%) OcuNanoE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Ophthalmic Solution against placebo (ophthalmic buffered saline) for safety and efficacy in patients with oGVHD after 84 days of treatment. The study has two primary endpoints, ocular redness and ocular discomfort.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The pivotal trials have a planned sample size of approximately 60 patients in each study, randomized 2:1 (active: placebo). Subjects will be permitted to continue their existing ocular treatments. The trials are designed to measure the efficacy of OCU300 compared to placebo, dosed twice daily for approximately three months. After a baseline visit, patients will be observed during three additional visits, at Day 28, Day 56, and Day 84.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The co-primary endpoints of the Phase 3 trials are:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Ocular redness based on a 100-point Validated Bulbar Redness scale measuring change in appearance from baseline to Day 84; and</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Ocular discomfort based on a 10-point Visual Analog Scale measuring change in intensity from baseline to Day 84. This scale is designed to capture the type of severe discomfort or pain often seen with oGVHD patients and has been validated as an assessment of pain intensity in multiple populations. Moreover, it has been recommended as the primary endpoint for use in clinical trials for chronic pain.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Severe ocular inflammation is a key factor in the pathogenesis oGVHD. Ocular inflammation, in turn, contributes to ocular redness and discomfort. As a result, ocular redness and discomfort are markers of inflammation in patients with oGVHD. By choosing ocular redness and ocular discomfort as co-primary endpoints, we are indirectly assessing brimonidine tartrate&#8217;s anti-inflammatory properties. In addition to its potential overall anti-inflammatory properties, brimonidine tartrate may have a direct effect on both ocular redness and discomfort. First, as an &#945;2-adrenergic agonist, brimonidine tartrate may cause significant vasoconstriction leading to the reduction of blood flow to the ocular surface and thereby reducing redness. Second, brimonidine tartrate may act as an ocular analgesic by interrupting pain pathways. Brimonidine tartrate has been shown to significantly suppress the stimulation of pain receptors in the murine cerebral cortex by antagonizing the effects of norepinephrine and phenylephrine. Nociceptive neuron activation in ocular surface tissue is linked to elevated ocular pain, photophobia and ocular discomfort. Accordingly, we believe that a treatment that can reduce ocular redness (and hence inflammation) while relieving ocular discomfort would significantly enhance the quality of life for patients suffering from oGVHD.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We expect to have top-line data available from the first trial in the second half of 2020. We will meet with the FDA to discuss top-line results and finalize our regulatory strategy for approval. We will conduct a pharmacokinetics study on OCU300 before submitting an NDA to the FDA for product candidate approval.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Our Proprietary OcuNanoE&#8212;Ocugen&#8217;s ONE Platform&#8482;</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have core capabilities in ophthalmic drug delivery and plan to leverage our proprietary OcuNanoE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> nanoemulsion formulation to deliver drugs more efficiently to relevant ocular tissues. We believe that our proprietary drug delivery system is suitable for the delivery of drugs to the target tissues of the anterior segment of the eye for the treatment of ocular surface diseases such as oGVHD and dry eye disease ("DED"). OcuNanoE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> is also designed to provide protection to the ocular surface. Our proprietary OcuNanoE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> nanoemulsion formulation has shown positive results in preclinical studies and enhanced lacrimal gland drug distribution. It is manufactured as a sterile-filtered, preservative-free and steroid-free product, which is designed to avoid the side effects related to the use of steroids and preservatives.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have applied this technology to create a nanoemulsion formulation of brimonidine tartrate, resulting in the development of OCU300. Data from a preclinical study suggests that brimonidine formulated with OcuNanoE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> may enhance drug distribution and penetration into the lacrimal gland, which is critical for tear film production. We believe this is significant given that approximately 90% of topical drugs applied to the anterior segment of the eye, such as eye drops, are lost into systemic </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">circulation. We also believe our technology may be leveraged to formulate additional active molecules and to treat additional ocular surface disorders.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that our proprietary OcuNanoE&#8482; formulation has the following attributes:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Oil in water nanoemulsion;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Capable of formulating water-soluble drug molecules in the aqueous portion of the nanoemulsion;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Capable of formulating water insoluble (lipiphilic) drug molecules in the oil portion of the nanoemulsion;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Capable of delivering drug molecules to ocular tissues based upon a preclinical study;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Defined narrow range globules with average diameter of less than 100 nanometers;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Capable of filter sterilization without having to use non-scalable processes and/or preservatives; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Suitable for commercial scale manufacturing.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As illustrated in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Figure 1</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below, tear film is composed of the inner mucin layer, the middle aqueous component and the outer lipid layer. The mucin layer is derived from goblet cells from the conjunctiva and lacrimal glands; the aqueous layer is derived from the lacrimal glands; and the lipid layer is derived from the meibomian glands. Since 90% of topical drugs applied to the anterior segment of the eye is lost into systemic circulation, the rest of the drug must reach a minimum threshold concentration in the target tissues, such as the lacrimal glands, conjunctiva and cornea, in order to exert the functional characteristics of the therapeutic. Therefore, treatment of diseases associated with the front of the eye, such as oGVHD, requires the stabilization of tear film and targeting the drug molecule at sufficient concentrations to the lacrimal functional unit which is primarily responsible for the tear film production and stability.</span></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Figure 1 Tear film in Human Eye</span></div><div style="text-align:center;margin-top:12pt;"><img src="ocgn-20191231_g2.jpg" alt="ocgn-20191231_g2.jpg" style="height:173px;width:275px;"/></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Given the structure of tear film and the human eye, we believe that our formulation has several novel properties, which may enable it to improve drug distribution and penetration:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">it contains lipid components that may act as the lipid layer of the tear film both in its functional characteristics and its charge distribution;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">it may mimic the charge characteristics of mucin and glycocalyx components present in the inner mucin layer, thus, potentially allowing the drug molecules to be carried to the site of action without binding to the mucin layer; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">it is a reproducible nanosized (less than 100 nanometers) emulsion which may enable the drug molecules to be transported through the interstitial cells to reach the specific target tissues.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In a DED mouse model study, we demonstrated that our nanoemulsion technology significantly reduced corneal epitheliopathy using brimonidine tartrate formulated with OcuNanoE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> as compared to brimonidine formulated without OcuNanoE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. While a significant portion of conventionally formulated ophthalmic drugs are rapidly eliminated via the tear film, we believe that our nanoemulsion technology is capable of achieving higher concentration on the surface of the eye, thereby potentially enabling the active drug substance to reach cells in the underlying ocular tissue at higher therapeutic levels. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As shown in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Figure 2</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below, the protective effect of OCU300 against corneal epithelial damage in comparison to brimonidine tartrate 0.2% is demonstrated in a mouse DED model. OCU300 showed statistically significant protection against corneal </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">epithelial cell damage in comparison to a commercial brimonidine tartrate solution (p&lt;0.01). These results indicate that OCU300 may provide significantly better protection for corneal epithelial damage than placebo (vehicle) and a commercial brimonidine tartrate. The difference between OCU300 and brimonidine tartrate 0.2% provides support for the potential importance of its nanoemulsion formulation in contributing to the treatment of oGVHD. In addition, OCU300 significantly reduced the lacrimal gland pathology compared to the untreated control group (p&lt;0.01). Goblet cell data, though not statistically significantly, showed a numerical improvement trend compared to the untreated control group.</span></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Figure 2 Effect of OCU300 OcuNanoE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> against corneal epithelial damage in comparison to a commercial brimonidine tartrate using a mouse DED model. **P&lt;0.01</span></div><div style="text-align:center;margin-top:12pt;"><img src="ocgn-20191231_g3.jpg" alt="ocgn-20191231_g3.jpg" style="height:266px;width:250px;"/></div><div style="margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2018, we completed a preclinical ocular distribution study in dutch-belted rabbits that analyzed the distribution of brimonidine tartrate after the topical treatment with OCU300 in comparison to a brimonidine tartrate 0.2% solution.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Figure 3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> indicates brimonidine tartrate concentration in the lacrimal gland following a single dose with OCU300 versus brimonidine tartrate 0.2% solution. Dutch-belted rabbits were dosed with either OCU300 or a brimonidine tartrate 0.2% solution and the lacrimal glands were removed at various intervals of time and analyzed for the content of brimonidine tartrate. Results are represented as ng/g in the Y-axis. The preclinical study showed that, after a single dose, brimonidine tartrate levels in the dutch-belted rabbits were numerically higher for up to six hours in the group treated with OCU300 compared to brimonidine tartrate levels in the group treated with brimonidine tartrate 0.2% solution, which provides support for the relative increased distribution of OCU300 in the lacrimal gland.</span></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Figure 3 Brimonidine tartrate content (ng/g) in the lacrimal gland after a single dose</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">administration of OCU300 versus brimonidine tartrate 0.2%</span></div><div style="text-align:center;margin-top:3pt;"><img src="ocgn-20191231_g4.jpg" alt="ocgn-20191231_g4.jpg" style="height:218px;width:300px;"/></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In summary, our data reported in the preclinical study supports the thesis that OCU300 distributes brimonidine tartrate to the lacrimal gland to a greater extent than a formulation without OcuNanoE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OCU310 for Dry Eye Disease</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We were developing OCU310 for patients with DED, which is also formulated using OcuNanoE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. We completed a Phase 3 clinical trial for OCU310 in 2019. Although the trial showed that OCU310 is safe and well-tolerated, it did not meet its co-primary endpoints for symptom and sign.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">However, a pre-specified exploratory efficacy endpoint of reduction in redness (sign) from the baseline visit, measured by Validated Bulbar Redness score, was statistically significantly better for OCU310 relative to placebo at both Day 14 and Day 28. This is consistent with the mechanism of action of brimonidine tartrate as an &#945;2-agonist with anti-inflammatory properties. We are no longer pursuing the development of this product candidate.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_184"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OUR MODIFIER GENE THERAPY PLATFORM AND GENE THERAPY PRODUCT CANDIDATES</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are developing OCU400, which has received ODD for both the treatment of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NR2E3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> mutation-associated retinal diseases and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">CEP290</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> mutation-associated retinal diseases. We plan to initiate a Phase 1/2a clinical trial of OCU400 for the treatment of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NR2E3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> mutation-associated retinal degenerative disease in 2021. OCU400 is the first product candidate being developed by us with our modifier gene therapy platform utilizing NHRs. We are also utilizing our modifier gene therapy platform for the development of OCU410, a product candidate designed to treat dry AMD.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Breakthrough Platform Therapy Based on Nuclear Hormone Receptors</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">NHRs have long been known to play a critical role in modulating cellular homeostasis by regulating basic biological processes including development, metabolism, circadian cycle, and energy homeostasis. Our modifier gene therapy platform is being designed to target NHRs, which have the potential to restore homeostasis to the retina and accordingly to provide therapeutic benefit to patients suffering from IRDs. Moreover, unlike single-gene replacement therapies, which only target one genetic mutation, we believe that our NHR-based approach represents a breakthrough modifier gene therapy platform that has the potential to restore retinal integrity and function across a range of genetically diverse IRDs and other degenerative retinal diseases, leading to multiple potential product opportunities. This approach has shown potential to rescue many genetic defects and may lead to vision-sparing therapies for rare IRDs including a broad spectrum of RP, as well as other forms of retinal and macular degeneration, providing us with significant potential long-term value.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">NHR-based gene therapy platform encompasses the targeted delivery and expression of certain NHRs that are expressed naturally in retinal tissue. Preclinical studies conducted by Dr. Neena Haider and others have shown that </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NR2E3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, a member of the NHR family, is a dual activator/repressor and that, with other transcription factors, modulates cell fate and differentiation of rod and cone photoreceptor cells in the eye (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Figure 4</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">). The delivery of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Nr2e3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in a mouse, lacking a functional </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Nr2e3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene, restored the retina structure and function. We believe that </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NR2E3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> may partially or fully rescue photoreceptors, which are responsible for light detection in the retina, from degeneration in patients with IRDs and improve patients' vision. </span></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Figure 4 Schematic representation of the potential mechanism</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">impacting</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">NR2E3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">retinal degeneration.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:center;margin-top:12pt;"><img src="ocgn-20191231_g5.jpg" alt="ocgn-20191231_g5.jpg" style="height:178px;width:500px;"/></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">coR/coA&#8212;corepressor or coactivator; ESCS&#8212;Enhanced S-cone syndrome; GFS&#8212;Goldman Favre syndrome; adRP&#8212;autosomal dominant </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">retinitis</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> pigmentosa; rod photoreceptors in grey and cone photoreceptors are in blue, green, and red.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Dr. Haider&#8217;s lab at SERI, an affiliate of Harvard Medical School, and others have shown the preclinical phenotypic outcome results from a mutational load on a biological system that includes the primary mutation and other factors such as modifier alleles impacting the normal homeostatic state. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The use of genetic modifiers represents a broadened means of potentially treating a variety of retinal degenerative diseases, as compared to single-gene replacement therapy. While single-gene </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">replacement therapies have shown tremendous promise in rare retinal diseases, they are highly specific and cannot improve a multitude of disease-causing genetic defects. On the other hand, NHRs play a vital role in regulating retinal cell development, maturation, metabolism, visual cycle function and survival (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Figure 5</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">).</span></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Figure 5 Interacting</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">NR2E3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">and</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">RORA </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Associated Gene Networks.</span></div><div style="text-align:center;margin-top:12pt;"><img src="ocgn-20191231_g6.jpg" alt="ocgn-20191231_g6.jpg" style="height:178px;width:400px;"/></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(a) IPA analysis of E18 targets identified nine gene networks with seven biological classifications. (b) IPA analysis of P30 targets identified nine gene networks with six biological classifications. Venn Diagrams show unique and overlapping gene targets of NR2E3 and RORA at E18 and P30. Comparisons of RORA E18/P30 or NR2E3 E18/P30 show less overlap than RORA/NR2E3 at E18 or RORA/NR2E3 at P30.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Disease outcome is a result of a primary mutation as well as modifier alleles. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NR2E3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> is a master regulator of several key pathways in retinal development and function. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NR2E3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> potentially prevents and reduces disease by resetting the homeostatic state of key gene networks in the presence of a primary mutation (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Figure 6</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">).</span></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Figure 6 Schematic representation of potential</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">NR2E3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">mediated therapy.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:center;margin-top:12pt;"><img src="ocgn-20191231_g7.jpg" alt="ocgn-20191231_g7.jpg" style="height:218px;width:300px;"/></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NR2E3 potentially resets key gene networks that contribute to retinal degeneration in RP. RP&#8212;retinitis pigmentosa; PR&#8212;photoreceptor cells; Gene networks: M&#8212;Metabolism; I&#8212;Inflammation; O&#8212;oxidative stress; P&#8212;photoreceptor genes; S&#8212;cell survival.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In summary, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NR2E3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> regulates multiple transcriptional networks, such as cell survival, metabolism, inflammation and phototransduction, that impact retinal diseases, such as RP. It was also demonstrated preclinically that </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">RORA</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> offers a protective allele in AMD where loss of photoreceptor cells leads to blindness. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NR2E3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> regulates the expression of both </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NR1D1</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">RORA</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Thus, the nuclear receptors work in overlapping networks to modulate normal retinal development and function. These receptors impact gene expression of hundreds of genes and numerous networks and, as such, may be potent modifiers of retinal disease and degeneration.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">NR2E3 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Modifier Gene Therapy Demonstrated Efficacy in many IRD models</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Efficacy of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Nr2e3 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">was evaluated in </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">five RP models: FVB-</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Pde6&#223;</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><sup style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;vertical-align:top;">rd1</sup><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">/NJ (</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">rd1</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">), Rhodopsin null allele (</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rho</span><sup style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8722;/&#8722;</sup><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">), B6.129S6(Cg)-</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rho</span><sup style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;vertical-align:top;">tm1.1Kpal</sup><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">/J (</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rho</span><sup style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;vertical-align:top;">P23H</sup><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">), BXD24/TyJ-</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cep290</span><sup style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;vertical-align:top;">rd16</sup><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">/J (</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">rd16</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) and </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Nr2e3</span><sup style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;vertical-align:top;">rd7</sup><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">/J (</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">rd7</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) following subretinal delivery. These models represent a heterogeneous group of RP diseases in humans and are relevant in establishing the modifier role of</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> NR2E3</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The effect of </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Nr2e3</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene therapy was evaluated at both early and late disease states in these animal models. </span></div><div style="margin-top:12pt;"><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These animals were dosed with AAV8-</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Nr2e3 </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">in</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">subretinal space</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">at post-natal day 0 (P0) and evaluated at P30 (B6 and rd1) or P90-P120 (</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rho</span><sup style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8722;/&#8722;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">, Rho</span><sup style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;vertical-align:top;">P23H</sup><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">, rd16</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, and </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">rd7</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> ) using fundus imaging, electroretinogram ("ERG"), histology, and immunostaining of retinal layers. Considerable improvement was observed in the clinical phenotype for </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rho</span><sup style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;vertical-align:top;">P23H</sup><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">rd16</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, and </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">rd7</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> mice in fundus imaging, though not all models have a contrasting clinical phenotype (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Figure 7</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">). Further histological analyses of retinal sections demonstrated improvement in the integrity of the retinal layers, and overall anatomy and morphology of the retina in all of these models (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Figure 8</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">). Immunohistochemistry analyses of retina showed that </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Nr2e3</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> delivery enhanced the expression of opsin proteins (blue and green) in treated mice in all the models except</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> rd7</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. In the </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">rd7</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> model, the disease phenotype starts with a higher number of S-cone and a higher expression of opsin proteins. In this model, </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Nr2e3</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> treatments restored the physiological level of opsin proteins in photoreceptors (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Figure 9</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) needed for normal vision. Similarly, treated animals showed improvement in retinal ERG signal, both in photopic (light-adapted) and scotopic (dark-adapted) conditions (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Figure 10</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">). </span></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Figure 7:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AAV8-</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Nr2e3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> rescues clinical phenotype in multiple mouse models of RP.</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Fundus of P0 injected AAV8</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">-Nr2e3</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> treated and untreated animals evaluated at P30 (B6 and </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">rd1</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) or P90-P120 (</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rho</span><sup style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8722;/&#8722;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">, Rho</span><sup style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;vertical-align:top;">P23H</sup><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">, rd16</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, and </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">rd7</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">). </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">N </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">= 7.</span></div><div style="text-align:center;margin-top:12pt;"><img src="ocgn-20191231_g8.jpg" alt="ocgn-20191231_g8.jpg" style="height:193px;width:500px;"/></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Figure 8</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">: AAV8-</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Nr2e3</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> treatment preserves retinal morphology and retinal integrity in RP models.</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> B6, </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">rd1, Rho</span><sup style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8722;/&#8722;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">, Rho</span><sup style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;vertical-align:top;">P23H</sup><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">, rd16</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, and </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">rd7</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> animals injected at P0, evaluated at P30 (B6 and </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">rd1</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) or P90-P120 (</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rho</span><sup style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8722;/&#8722;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">, Rho</span><sup style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;vertical-align:top;">P23H</sup><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">, rd16,</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">rd7</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">). (</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a)</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Hematoxylin/eosin staining of AAV8-</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Nr2e3</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> treated and untreated retinas with white boxes indicating location of cell count. (b) Rescued and un-rescued regions in retinas treated with AAV8</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">-Nr2e3</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. (</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">c)</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Cell layer numbers of outer nuclear layer ("ONL") from AAV8</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">-Nr2e3</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> treated and untreated animals in different RP models. Results are mean &#177; SEM. </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">N </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">= 7.</span></div><div style="text-align:center;margin-top:12pt;"><img src="ocgn-20191231_g9.jpg" alt="ocgn-20191231_g9.jpg" style="height:262px;width:450px;"/></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Figure 9</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">: AAV8-</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Nr2e3</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> preserves cone and rod opsin expression in multiple mouse models of RP. </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Immunohistochemistry of P0 injected AAV8-</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Nr2e3</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> treated and untreated retinas labeled with green opsin, blue opsin and rhodopsin evaluated at P30 (</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">rd1</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) or P90-P120 (</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rho</span><sup style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8722;/&#8722;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">, RhoP23H, rd16</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, and </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">rd7</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) and B6 control (Left panel). Semiquantitative analysis of cell counts of blue and green opsin-positive photoreceptor cells per 100 &#956;m (Right panels). Results are mean SEM. </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">N </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">= 7.</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span></div><div style="text-align:center;margin-top:12pt;"><img src="ocgn-20191231_g10.jpg" alt="ocgn-20191231_g10.jpg" style="height:234px;width:500px;"/></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Figure 10: </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Improved ERG responses in AAV8-</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Nr2e3</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> treated RP retinas.</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a) Scotopic and photopic ERG B-wave amplitudes were evaluated at P30 (</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">rd1</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) or P90-P120 (</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rho</span><sup style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8722;/&#8722;</sup><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rho</span><sup style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">P23H</sup><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, and </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">rd16</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) AAV8-</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Nr2e3</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> treated and untreated animals; B6 control ERGs shown. (b) Percent increase in ERG B-wave responses in the treated RP models. Results are mean &#177; SEM. </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">N </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">= 7.</span></div><div style="text-align:center;margin-top:12pt;"><img src="ocgn-20191231_g11.jpg" alt="ocgn-20191231_g11.jpg" style="height:278px;width:500px;"/></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The efficacy of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Nr2e3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> was also evaluated in these animal models at a late disease stage.</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> AAV8-</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Nr2e3</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> was injected subretinally at P21 and evaluated 2&#8211;3 months post injection in </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rho</span><sup style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;vertical-align:top;">&#8722;/&#8722;</sup><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rho</span><sup style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;vertical-align:top;">P23H</sup><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">rd16</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, and </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">rd7</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> mice. Fundus imaging and histological analyses indicated a reduction in retinal degeneration in these models (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Figure 11</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">). The improvement in the rescue of retinal layers were between approximately 30% to 80% of the retina, depending on the delivery location and distribution of </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Nr2e3 </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">following dosing. Approximately 3-5 layers of ONL cells were preserved in </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Nr2e3</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> treated animals compared with 0-1 layer for untreated animals. These ONL photoreceptors induce phototransduction in the retina and thereby initiate the vision process. Immunohistochemistry labeling showed enhanced expression of blue and green cone opsins and rhodopsin in photoreceptors of treated groups compared to untreated groups (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Figure 12</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) suggesting preservation of photoreceptors with light absorbing opsins. </span></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Figure 11: </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AAV8</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">-Nr2e3</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> rescues RP degeneration after disease onset.</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Animals injected with AAV8</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">-Nr2e3</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> at P21 and evaluated at 2&#8211;3 months post injection. (</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a)</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Fundus of </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rho</span><sup style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8722;/&#8722;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">, Rho</span><sup style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;vertical-align:top;">P23H</sup><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">, rd16</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, and </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">rd7</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. (</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b)</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Hematoxylin/eosin staining shows partial preservation of photoreceptor cells in treated mutant animals. (</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">c)</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Cell layer numbers of ONL were compared between AAV8</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">-Nr2e3</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> treated and untreated animals in the four RP models and B6 control. Results are mean SEM. </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">N </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">= 7.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:12pt;"><img src="ocgn-20191231_g12.jpg" alt="ocgn-20191231_g12.jpg" style="height:385px;width:450px;"/></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Figure 12: AAV8-</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Nr2e3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;"> rescues rod and cone opsin expression after disease onset.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> Animals were injected with AAV8-Nr2e3 at P21 and evaluated at 2&#8211;3 months after injection. Immunohistochemistry of green opsin, blue opsin and rhodopsin of treated and untreated animals in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Rho</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;vertical-align:top;">&#8722;/&#8722;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">, Rho</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;vertical-align:top;">P23H</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">, rd16, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">and</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"> rd7 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(left panel). Semiquantitative analysis of cell counts of blue and green opsin-positive photoreceptor cells per 50 &#956;m of the retina (right panels)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Results are mean &#177; SEM. N = 7.</span></div><div style="text-align:center;margin-top:12pt;"><img src="ocgn-20191231_g13.jpg" alt="ocgn-20191231_g13.jpg" style="height:247px;width:450px;"/></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Safety of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">NR2E3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> in Rodent Model</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Safety of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Nr2e3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> was evaluated in healthy mice following subretinal administration. C57BL6/J (B6) mice were treated with AAV8-</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Nr2e3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">-GFP fusion construct at P0 and evaluated after seven days and one month for any toxic effect as well as expression of Nr2e3-GFP fusion protein in the retina. The expression of the Nr2e3 protein in a mouse retina did not show any detrimental effect on retinal cells, including photoreceptors (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Figure 13</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">). Also, there was no difference in retinal anatomy (as indicated by fundus), histology (cell layers), expression of opsin and rhodopsin proteins (immunohistochemistry) and retinal function (as indicated by ERG recording) between treated and untreated mice (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Figure 13</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">). Expression of EGFP-Nr2e3 fusion protein was observed at P30 in treated animals. These results confirm that overexpression of the Nr2e3 protein following subretinal injection of AAV8-</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Nr2e3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> was well-tolerated and safe to the retina.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Figure 13: Overexpression of AAV8-</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Nr2e3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> has no detrimental effects on the retina</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. B6 control AAV8-</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Nr2e3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> treated animals show no abnormalities in a. Fundus, hematoxylin/eosin histology staining, and blue, green, and rhodopsin labeling of photoreceptor cells; and b ERG response of control B6 treated and untreated. Animals injected at P0, tissue collected at P30. c GFP label of AAV8-</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Nr2e3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">-GFP injected at P0, GFP expression assessed at P7 and P30. N = 5.</span></div><div style="text-align:center;margin-top:12pt;"><img src="ocgn-20191231_g14.jpg" alt="ocgn-20191231_g14.jpg" style="height:282px;width:450px;"/></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Overview of Inherited Retinal Diseases and Current Treatment Options</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">IRDs are caused by genetic mutations that are passed down within families and lead to progressive disease, severe visual impairment and blindness. Treating these conditions has been a significant challenge due to the sheer volume of potential therapeutic gene targets. Gene replacement therapy is a promising approach to provide a sustained restoration effect of normal retinal function for a mutated gene, but such therapies can only address one gene at a time, limiting their effectiveness. Developing a custom gene therapy for genetic defects in each of the more than 150 known gene defects linked to RP would not only be expensive but also may not be possible due to size, class, or localization that will impact delivery of the gene. Not all genes and disease expressions are amenable to gene therapy, and for the approximately 40% of patients whose genetic mutations remain unknown, there are few or no therapeutic options. Modifier gene therapy to ameliorate multiple forms of RP without requiring knowledge of the mutated gene, may provide a robust and feasible treatment for RP.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">RP is a group of heterogeneous, pleiotropic IRDs that affect approximately one in every 4,000 individuals. It is associated with over 150 gene mutations that affect over 1.5 million individuals worldwide. Currently, there is no cure for RP and over 40% of RP cannot be genetically diagnosed. RP is heterogeneous and varies greatly in age of onset, rate of progression, and even genetic etiology, yet a common pathology of photoreceptor cell degeneration develops.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There is currently no approved treatment which slows or stops the progression of multiple forms of RP. Proposed treatments for RP include gene-replacement therapy, retinal implant devices, retinal transplantation, stem cells, vitamin therapy, and other pharmacological treatments. Gene-replacement therapies are promising but are limited to treating just a single mutation and therefore cannot address the multiple mutations implicated by RP. In addition, while gene therapies may provide a new functional gene, they do not necessarily eliminate the underlying genetic defect which may still cause stress and toxic effects. Therefore, the development of gene specific replacement therapy is highly challenging, especially when multiple and unknown genes are involved. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to RP, no effective treatments are available for a large number of other retinal degenerative diseases including treatments specifically for dry AMD. AMD is a degeneration of the macula of the retina that leads to impairment and loss of central vision. AMD is characterized by thickening and loss of normal architecture within Bruch&#8217;s membrane, lipofuscin accumulation in the retinal pigment epithelium ("RPE"), and drusen formation beneath the RPE in Bruch&#8217;s membrane. These deposits consist of complement components, other inflammatory molecules, lipids, lipoproteins B and E, and glycoproteins. Dry AMD involves the slow deterioration of the retina with submacular drusen, atrophy, loss of macular function and central vision impairment.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result, there remains a significant unmet medical need for a treatment with application across multiple genetic forms of RP as well as other ocular degenerative diseases, such as dry AMD.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OCU400 for the Treatment of Retinitis Pigmentosa</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">OCU400 is the first product candidate being developed with our gene therapy platform. OCU400 is comprised of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NR2E3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, an NHR gene expressed in adeno-associated viral vector that has the potential to be used as a gene therapeutic not only for the treatment of retinal diseases associated with mutation in genes such as </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NR2E3, RHO, CEP290, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> PDE6</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#223;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, but also</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">other gene mutations associated with IRDs, including RP. To date, OCU400 has received ODD from the FDA for both the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NR2E3 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">CEP290 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">mutation-associated retinal disease indications.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We completed the preclinical studies in multiple animal models of RP using mouse NHR. Currently, human NHRs are being evaluated in these animal models representing various forms of human RP diseases using an adeno-associated viral vectors for subretinal delivery. In parallel, we have initiated the cGMP for production of drug product to commence Investigational New Drug Application ("IND") enabling non-clinical studies and clinical supplies to initiate a Phase1/2a clinical trial.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We had a pre-IND meeting with the FDA in February 2019 and received guidance on IND-enabling preclinical studies to support the Phase 1/2a study. We plan to initiate a Phase 1/2a clinical trial targeting </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NR2E3 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">mutation-associated retinal disease in 2021.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OCU410 for the Treatment of Dry Age-Related Macular Degeneration</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are developing OCU410 for the treatment of dry AMD, which is the second product candidate being developed with our modifier gene therapy platform using NHRs. This candidate is currently in preclinical development.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">OCU410 utilizes an AAV vector for retinal delivery of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">RORA</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene. Various genes associated with AMD are regulated by </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">RORA</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The RORA protein plays an important role in lipid metabolism and demonstrates an anti-inflammatory role, which we believe could be a potential therapeutic candidate for dry AMD. Dry AMD affects approximately nine to ten million patients in the United States and there is currently no approved treatment for the disease. </span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1970"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOVEL BIOLOGIC PRODUCT CANDIDATE FOR RETINAL DISEASES</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have a biological preclinical program, OCU200 for the treatment of DME, DR and wet AMD. We have exclusively in-licensed a broad range of rights for this preclinical program. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OCU200 for the Treatment of Diabetic Macular Edema, Diabetic Retinopathy and Wet Age-Related Macular Degeneration</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">OCU200 is a biologic product candidate in preclinical development for treating severely sight-threatening diseases like DME, DR and wet AMD. Patients affected by these diseases share common symptoms, such as blurriness in vision and progressive vision loss. The formation of fragile and leaky new blood vessels leads to fluid accumulation in and around the retina, causing damage to vision. OCU200 is a novel fusion protein consisting of two human proteins, tumstatin and transferrin, that are already present normally in retinal tissues. OCU200 possesses unique features which enable it to (a) efficiently target leaky blood vessels, (b) regress the existing abnormal blood vessels, and (c) inhibit the growth of new blood vessels in the retina and choroid. Tumstatin, which acts as an anti-vascular endothelial growth factor ("VEGF"), anti-inflammatory and anti-oxidative agent, is the active component of OCU200. It binds to integrin receptors, which play a crucial role in disease pathogenesis. Transferrin facilitates the targeted delivery of tumstatin into the retina and choroid and potentially helps increase the interaction between tumstatin and integrin receptors. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">OCU200 demonstrated efficacy in an in-vitro cell culture model where it inhibited in new vessel formation. In an animal model for DME and DR (Oxygen-induced retinopathy in mice), OCU200 demonstrated comparable efficacy at a significantly lower dose (10 &#181;g/eye) compared to existing approved therapy (Evlea</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">,</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;"> </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">40 &#181;g/eye) in preventing disease manifestation and progression (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Figure 14</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">). In animal models for wet AMD (laser induced CNV in mice and rats), OCU200 demonstrated comparable or slightly better activity compared to anti-VEGF control groups in preventing the formation and growth of new leaky blood vessels and subsequent disease symptoms (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Figure 14</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">).</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Figure 14</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OCU200 Demonstrated Efficacy in Animal Models for DME, DR, and Wet-AMD.</span></div><div style="text-align:center;margin-top:12pt;"><img src="ocgn-20191231_g15.jpg" alt="ocgn-20191231_g15.jpg" style="height:228px;width:600px;"/></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">OCU200 is currently in preclinical development for the treatment of DME, DR, and wet AMD and we plan to initiate a Phase 1/2 clinical trial within the next two years.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Overview of Diabetic Macular Edema, Diabetic Retinopathy, and Wet Age-Related Macular Degeneration, and Current Treatment Options</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Diabetic macular edema and diabetic retinopathy are the most common vision threatening diseases occurring in diabetic patients. Excess blood sugar (glucose) in these patients causes damage to blood vessels in the retina and promotes the formation of leaky blood vessels. These leaky blood vessels secrete fluids in the retina and can cause retinal detachment, and vitreous hemorrhage leading to blindness. When this fluid accumulates in the macula region of the retina, the region primarily responsible for central and color vision, it can cause DME. Approximately 7.7 million people are affected with DR and approximately 0.7 million with DME in the United States. These numbers are expected to further increase as the number of diabetic patients increases, due to poor disease management and lifestyle-related changes.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Currently there are limited treatment options available for DR and DME patients and a significant unmet need for the development of safe and effective therapies. Current first-line treatments for DR and DME include laser photocoagulation, use of anti-VEGFs, and steroids which are sub-optimally active in these patients. Anti-VEGF therapy does not work effectively in approximately 50% of DME patients. Current therapies target only one pathway associated with DR and DME, either angiogenesis with anti-VEGF therapy or inflammation in case of steroid therapy. The development of a therapeutic which targets multiple causative pathways of DR and DME, such as angiogenesis, oxidation and inflammation, would offer the best treatment option for all of these patients. We believe that OCU200 possess unique characteristics to target these pathways and has the potential to offer better treatment options for all patients.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">OCU200 also has the potential to represent a superior treatment option for patients suffering from wet-AMD. AMD is a degeneration of the macula of the retina that leads to impairment and loss of central vision. Wet AMD involves the growth of abnormal blood vessels under the retina and macula, resulting in edema, tissue damage and rapid loss of central vision. If untreated, neovascularization in wet AMD patients typically results in significant vision loss and the formation of a scar under the macular region of the retina. Most cases begin as dry AMD and may progress to wet AMD.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Wet AMD is a leading cause of blindness in people over the age of 55 in the United States and the European Union. The incidence of wet AMD increases substantially with age, and we expect that the number of cases of wet AMD will increase with the growth of the elderly population in the United States. It has been estimated that approximately 11.0&#160;million patients in the United States have some form of AMD of which, approximately 1.1&#160;million, or 10&#160;percent, suffer from wet AMD. Approximately 200,000 new cases of wet AMD are diagnosed each year in the United States.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Current therapies for wet AMD focus on reducing new blood vessel formation (neovascularization) through the inhibition of a single key regulator, VEGF. Current FDA-approved therapeutics for wet AMD include intravitreal injection of either Lucentis</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> or Eylea</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which target VEGF. Bevacizumab (Avastin&#8482;), the parent antibody from which ranibizumab was derived, is also used as an off-label treatment. Though these products have been effective in mitigating the disease symptoms, they have substantial limitations as demonstrated in clinical studies. For example, a significant percentage of patients do not respond to </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">therapy and experience continuous deterioration of vision; long-term repeated dosing results in reduced effectiveness; and there remains a persistence of fluid in the subretinal space of 30-50% patients even after 1-2 years of treatment. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Given the above limitations of these existing treatments, we believe that a substantial unmet medical need still exists in these areas. OCU200 is designed to address the limitations of current therapies by targeting multiple mechanisms associated with ocular neovascularization and inflammation.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may expand the therapeutic applications of OCU200 beyond DME, DR, and wet AMD, potentially to include macular edema following RVO and mCNV. These patients suffer from retinal/choroidal complications in the back of the eye which may have a sudden and debilitating impact on visual acuity, eventually leading to blindness. Although anti-VEGF therapeutics have been recently approved for the treatment of these retinal disorders, we believe that, similar to its application to DME, DR, and wet AMD, OCU200 has the potential to fill a significant unmet need for the treatment of RVO and mCNV.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_187"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">COMPETITION</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The biopharmaceutical industry, including gene therapy, is characterized by rapidly advancing technologies, intense competition and a strong emphasis on intellectual property. We face competition from many different sources, including large and specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Competitors may include established, emerging, and growing companies. We are aware of several companies focusing on gene therapies for various indications, including Editas Medicine, Allergan, Inc., Adverum Biotechnologies, MeiraGTx, IVERIC bio, Inc., Applied Genetic Technologies Corporation and the Roche Group, which acquired Spark Therapeutics, Inc. Luxturna</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> (Spark Therapeutics) is currently the only gene therapy approved for an IRD in the United States addressing only one out of 150 known mutations of the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">RPE65 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">gene. Companies that may compete with our OCU200 product candidate include the Roche Group, Regeneron Pharmaceuticals, Inc., and Novartis AG, which have marketed anti-VEGF products. We are also aware of other companies that are working on therapies for the whole eye, including Santen, Inc. and Ocular Therapeutix.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Many of our competitors, either alone or with strategic partners, will have significantly greater financial resources to support research and development, manufacturing, preclinical testing, and clinical trials, as well as regulatory and marketing efforts. These organizations also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, patient registration for clinical trials, and in acquiring technologies necessary for our programs. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that the key competitive factors that will affect the development and commercial success of our product candidates are efficacy, safety and tolerability profile, convenience in dosing, product labeling, cost effectiveness, price, the level of generic competition and the availability of reimbursement from the government and other third-parties. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors may also obtain FDA or other regulatory approval for their products more rapidly than us. In addition, our ability to compete may be affected as insurers or other third-party payers seek to encourage the use of more cost-effective products.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_190"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">MANUFACTURING</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We utilize our in-house expertise and know-how to develop and scale up its manufacturing processes before these processes are transferred to third-party contract manufacturers and testing labs to understand and establish controls of critical process parameters and critical quality attributes. We also have personnel with deep product development experience who actively manage the third-party contract manufacturers producing OCU300, and other products that are in the development pipeline.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our OCU300 product candidate (using our proprietary OcuNanoE&#8482; nanoemulsion formulation) are currently manufactured at an established contract manufacturing facility located in the United States. The drug substance containing nanoemulsion is sterilized by 0.2-micron filtration and is filled into sterile single-use vials. The final process has been successfully scaled up to support commercial manufacturing. Labeling and packaging of vials also occurs at the same third-party manufacturer. Our third-party manufacturers and testing labs are subject to FDA inspections from time to time.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Commercial Supply Agreements for OCU300</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are currently working with third parties to finalize our commercial supply agreements and have negotiated an arrangement with a third-party manufacturer to supply brimonidine tartrate (drug substance). We intend to use the current third-party contract manufacturing organization to supply the commercial drug products, and to perform labeling and packaging activities for us. Similarly, we will continue to use current third-party testing labs for release and stability testing of our commercial products.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Clinical Supply Agreement for OCU400</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September 27, 2019, we entered into a co-development and commercialization agreement (the &#8220;CanSinoBIO Agreement&#8221;) with CanSinoBIO with respect to the development and commercialization of the gene therapy product candidate, OCU400, with respect to certain disease indications (the &#8220;Field&#8221;). </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The CanSinoBIO Agreement also grants CanSinoBIO an exclusive option (the &#8220;Option&#8221;) to obtain a non-exclusive license from us to manufacture Products (defined below) in the Field for commercial sale by us, subject to the terms of a supply agreement to be negotiated by us and CanSinoBIO upon CanSinoBIO&#8217;s exercise of the Option.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">CanSinoBIO will have an exclusive license under our intellectual property and intellectual property jointly developed by CanSinoBIO and us (the &#8220;Joint IP&#8221;) to develop, manufacture and commercialize products containing OCU400 (&#8220;Products&#8221;) in the Field in and for China, Hong Kong, Macau, and Taiwan (the &#8220;CanSinoBIO Territory&#8221;) and we will maintain exclusive development, manufacturing and commercialization rights under our intellectual property and have an exclusive license under the Joint IP with respect to Products in the Field in and for any global location outside the CanSinoBIO Territory (the &#8220;Ocugen Territory&#8221;).</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> CanSino will be responsible for all costs for chemistry, manufacturing and control development and manufacture of clinical supplies of OCU400 for all territories. CanSinoBIO will be solely responsible for all costs and expenses of its development activities in the CanSinoBIO Territory and we will be responsible for all costs and expenses of its development activities in the Ocugen Territory. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">CanSinoBIO will pay us an annual royalty between mid to high single digits based on net sales of Products in the CanSinoBIO Territory, and we will pay to CanSinoBIO an annual royalty between low to mid-single digits based on net sales of Products in the Ocugen Territory.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_193"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">LICENSE AGREEMENTS</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a party to license agreements under which we licenses patents, patent applications, technical information and other intellectual property for OCU400, OCU410, OCU300 and OCU200. Certain diligence and financial obligations are tied to these agreements. We consider the following agreements to be material to our business.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">License Agreement with University of Colorado</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2014, Former Ocugen entered into an exclusive license agreement with CU, which was amended in January 2017 and clarified by a letter of understanding in November 2017 (as so amended and clarified the &#8220;CU Agreement&#8221;). The CU Agreement gives us an exclusive, worldwide, sublicensable license to patents for OCU200 to make, have made, use, import, offer to sell, sell, have sold, and practice the licensed products in all therapeutic applications. Under the CU Agreement, we must use commercially reasonable efforts to develop, manufacture, sublicense, market and sell the licensed products.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the terms of the CU Agreement, we paid CU an initial fee of $26,179 and issued 0.1 million shares of common stock. Commencing in 2017, we pay CU an annual royalty payment. The CU Agreement also requires the payment of certain regulatory milestones, aggregating $1.5 million, and low single-digit percentage earned royalties on net sales and royalties in the mid-teens on sublicense income of OCU200.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The CU Agreement will expire on the later of the expiration date of the last to expire licensed patent or the end of any relevant statutory or regulatory exclusivity period. We may terminate the CU Agreement upon 60 days&#8217; prior written notice. CU may terminate the CU Agreement upon 60 days&#8217; notice if we fail to make payments within 60 days of such payment&#8217;s due date, breach and do not cure any diligence obligation, provide any materially false report or otherwise materially breach and do not cure any material provision of the CU Agreement.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">License Agreement with University of Illinois at Chicago</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2016, Former Ocugen entered into an exclusive license agreement (the &#8220;UIC Agreement&#8221;) with UIC. This agreement gives us an exclusive, worldwide, non-transferable, sublicensable license to patents and patent rights for OCU300 to make, have made, use, import, sell, and offer for sale products claimed by and/or incorporating or derived from the licensed patents. Under this agreement, we must use commercially reasonable efforts to develop and bring products to market. Pursuant to the terms of the UIC Agreement, we paid UIC a signing fee of $15,000. Commencing in 2019, we also pay UIC an annual </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">minimum payment and reimburses UIC for reasonable documented patent costs and expenses. The UIC Agreement also requires the payment of certain regulatory and commercial milestones, aggregating $1.3 million and low single digits to low teens percentage royalties on annual net sales and sublicense revenues from products that fall under the licensed patent rights.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The UIC Agreement will expire on the later of the expiration date of the last to expire licensed patents, when we provide notice to UIC that use of the technical information has ceased or the end of any relevant statutory or regulatory exclusivity period. We may terminate the license upon 90&#160;days&#8217; prior written notice. UIC may terminate the UIC Agreement if we fail to make payments within thirty days of receiving a written notice of missed payment, breach any provision of the UIC Agreement and do not cure such breach within 30 days, breach any obligation under any other agreement between us and UIC and do not cure such breach within 45 days, make any materially false report, become bankrupt or insolvent, or take any action that causes a lien or encumbrance to be placed on the licensed patent rights or technical information.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">License Agreement with The Schepens Eye Research Institute, Inc.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2017, Former Ocugen entered into an exclusive license agreement (the &#8220;SERI Agreement&#8221;) with SERI. The SERI Agreement gives us an exclusive, worldwide, sublicensable license to patent rights, biological materials and technical information for nuclear hormone receptor genes </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NR1D1</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NR2E3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (OCU400), </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">RORA </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(OCU410), </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NUPR1</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NR2C1</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Under the SERI Agreement, we may make, have made, use, offer to sell, sell and import licensed products.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under this agreement, we must use commercially reasonable efforts to bring one or more licensed products to market as soon as reasonably practicable.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the terms of the SERI Agreement, we paid SERI an upfront fee of $39,681 to reimburse SERI for patent expenses prior to the effective date of the SERI Agreement and an initial license fee of $0.1 million. The SERI Agreement requires us to pay an annual license maintenance fee. The SERI Agreement also requires the payment of certain regulatory and commercial milestones, aggregating $16.1 million and low single-digit percentage royalties on annual net sales of products that fall under the licensed patent rights.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">SERI maintains control of patent preparation, filing, prosecution and maintenance. After the first anniversary of the execution date of the SERI Agreement, we have the right, but not the obligation, to assume responsibility for and control of the prosecution and maintenance of the licensed patent rights, at our sole cost and expense. If we do not exercise this option, we must pay SERI&#8217;s out-of-pocket expenses related to the filing, prosecution and maintenance of the licensed patent rights. In the event that SERI decides to discontinue the prosecution or maintenance of the licensed patent rights, we have the right, but not the obligation, to file for, or continue to prosecute, maintain or enforce such licensed patent rights.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The SERI Agreement will expire on the&#160;expiration date of the last to expire licensed patents right. We may terminate the license upon 180 days&#8217; prior written notice. SERI may immediately terminate the SERI Agreement if we cease to carry on our business with respect to the licensed patent rights, fail to make payments within thirty days of receiving a written notice of missed payment, fail to comply with our diligence obligations, default on our obligation to procure and maintain insurance, one of our officers is convicted of felony related to the licensed products, we breach any material obligation of the agreement and do not cure such breach within 90 days or if we become bankrupt or insolvent.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_196"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">INTELLECTUAL PROPERTY</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have obtained patent protection for all of our product candidates. We intend to maintain and defend our patent rights to protect our technology, inventions, processes and improvements that are commercially important to the development of our business. We cannot be sure that any of our existing patents or patents that we obtain in the future will be commercially useful in protecting our technology, or that patents will be issued for any pending patent applications or patent applications that we file in the future. Our commercial success also depends in part on our non-infringement of the patents and proprietary rights of third parties.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March 2020, our patent portfolio included 34 U.S. or foreign issued patents and 30 patent applications, including those licensed from CU, UIC and SERI. Our intellectual property consists of issued patents and pending patent applications for compositions of matter and methods of use, as well as for product candidates and other proprietary technology, including our OcuNanoE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> technology. As of March 2020, we had exclusive rights or owned rights to: (i) three issued patents and 11 pending U.S. and foreign patent applications related to OCU300; (ii) one issued patent and four pending applications related to OCU400; and (iii) 25 issued U.S. and foreign patents and three pending patent applications related to OCU200.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to patents, we may rely, in some circumstances, on trade secrets to protect our technology. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, and obtain and maintain ownership of certain technologies, in part, by confidentiality and invention assignment agreements with its employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1953"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">HISTORICAL HISTOGENICS ASSETS (NEOCART</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">)</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Histogenics historically focused on the development of restorative cell therapies (&#8220;RCTs&#8221;), which term referred to a new class of products designed to offer patients rapid-onset pain relief and restored function through the repair of damaged or worn tissue. Histogenics&#8217; product, NeoCart</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, is an innovative cell therapy that utilizes various aspects of its RCT platform to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. In December 2018, after receiving feedback from the FDA regarding the need for an additional clinical trial prior to submission of a Biologic License Application (&#8220;BLA&#8221;), Histogenics discontinued the development of NeoCart</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">License and Commercialization Agreement with MEDINET Co., Ltd.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2017, Histogenics entered into the License and Commercialization Agreement with MEDINET Co., Ltd. (&#8220;MEDINET&#8221;) to grant MEDINET a license under certain patents, patent applications, know-how, and technology to develop and commercialize certain therapeutic products related to the NeoCart</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> program. As consideration for the granting of the license, MEDINET agreed to pay Histogenics a non-refundable upfront cash payment of $10.0 million which was received in January 2018. Based on the results of the NeoCart</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> research, Histogenics suspended the NeoCart</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> program. Subsequently, since MEDINET relied on the NeoCart</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> product to supply clinical trial patients, MEDINET suspended the development of its clinical trial. As of December 31, 2019, the contract with MEDINET was wholly unperformed. As a result of the expected sale of the NeoCart</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> asset, we do not expect to retain any future obligations related to the MEDINET agreement.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Medavate Asset Purchase Agreement</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the Merger, on May 8, 2019, Histogenics entered into an asset purchase agreement (the &#8220;Asset Purchase Agreement&#8221;) with Medavate Corp., a Colorado corporation (&#8220;Medavate&#8221;), pursuant to which Histogenics agreed to sell substantially all of its assets relating to its NeoCart</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> program, including, without limitation, intellectual property, business and license agreements and clinical trial data in return for a cash payment of $6.5 million. On September 26, 2019, the parties entered into an amendment to the Asset Purchase Agreement whereby the closing date was amended to October 4, 2019. On October 4, 2019, the parties entered into a second amendment (the &#8220;Second Amendment&#8221;) to the Asset Purchase Agreement whereby the purchase price was increased to $7.0 million under the Asset Purchase Agreement and the closing date of the Asset Purchase Agreement was revised from October 4, 2019 to two business days after Medavate obtains financing in an amount no less than the purchase price (the &#8220;Closing Date&#8221;). The Second Amendment further provides that if the Closing Date does not occur on or prior to October 31, 2019, we may choose to terminate the Asset Purchase Agreement without recourse and, if we do not terminate the Asset Purchase Agreement, the purchase price shall increase 10% per month (or any portion thereof) between October 31, 2019 and the Closing Date. The Closing Date did not occur as of October 31, 2019 and we did not terminate the agreement. As of March 1, 2020, the purchase price has increased to $11.3 million.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NeoCart</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> Intellectual Property</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March 2020, our intellectual property portfolio related to NeoCart</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> was composed of 18 issued patents and six patent applications in the United States that we own, and eight issued patents and one patent application in the United States that we license from academic institutions and business entities. We also have approximately 70 counterpart patent and patent applications owned or licensed in certain foreign jurisdictions.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_199"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">GOVERNMENT REGULATION AND PRODUCT APPROVAL</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Government authorities in the United States, at the federal, state, and local level, and in other countries, extensively regulate, among other things, the research, development, testing, approval, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, sales, import, and export of biopharmaceutical and drug products such as those we are developing. In addition, labelers of biopharmaceutical and drug products (the entity owning the National Drug Code listed for a product) participating in Medicaid and Medicare are required to comply with mandatory price reporting, discount, rebate and other requirements. The processes for obtaining regulatory approvals in the United States and in foreign countries, along with compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">FDA Regulation</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the United States, the FDA regulates drug products under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and its implementing regulations. In addition to the FDCA and its implementing regulations, biologic products are regulated under the Public Health Service Act (&#8220;PHSA&#8221;) and its implementing regulations. The process required by the FDA before product candidates may be marketed in the United States generally involves the following:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">completion of preclinical laboratory tests, animal studies, and formulation studies in compliance with the FDA&#8217;s Good Laboratory Practice (&#8220;GLP&#8221;) regulations;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">submission to the FDA of an IND, which must become effective before human clinical trials may begin at United States clinical trial sites;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">approval by an Institutional Review Board (&#8220;IRB&#8221;) for each clinical site, or centrally, before each trial may be initiated;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">adequate and well-controlled human clinical trials to establish the safety and efficacy, in the case of a drug product candidate, or safety, purity, and potency, in the case of a biologic product candidate for its intended use, performed in accordance with Good Clinical Practices (&#8220;GCPs&#8221;);</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">development of manufacturing processes to ensure the product candidate&#8217;s identity, strength, quality, purity, and potency;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">submission to the FDA of a NDA, in the case of a drug product candidate, or BLA, in the case of a biologic product candidate;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">satisfactory completion of an FDA advisory committee review, if applicable;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the products are produced to assess compliance with cGMPs, and to assure that the facilities, methods, and controls are adequate to preserve the therapeutics&#8217; identity, strength, quality, purity, and potency as well as satisfactory completion of an FDA inspection of selected clinical sites, selected clinical investigators to determine GCP compliance; and payment of user fees and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">FDA review and approval of the NDA or BLA to permit commercial marketing for particular indications for use.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Preclinical Studies and IND Submission</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The testing and approval process of product candidates requires substantial time, effort, and financial resources. Satisfaction of FDA pre-market approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product or disease. Preclinical studies include laboratory evaluation of chemistry, pharmacology, toxicity, and product formulation, as well as animal studies to assess potential safety and efficacy. Such studies must generally be conducted in accordance with the FDA&#8217;s GLPs. Prior to commencing the first clinical trial at a United States investigational site with a product candidate, an IND sponsor must submit the results of the preclinical tests and preclinical literature, together with manufacturing information, analytical data, any available clinical data or literature, and proposed clinical study protocols among other things, to the FDA as part of an IND. In the case of drug product candidates for which the sponsor will seek marketing approval via a 505(b)(2) NDA application, some of the above information may be abbreviated or omitted.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">An IND automatically becomes effective 30&#160;days after receipt by the FDA, unless the FDA, within the 30-day time period, notifies the applicant of safety concerns or questions related to one or more proposed clinical trials and places the trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in FDA authorization to commence a clinical trial. A separate submission to an existing IND must also be made for each successive clinical trial conducted during product development.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Clinical Trials</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with federal regulations and GCP requirements, which include the requirements that all research subjects provide their informed consent in writing for their participation in any clinical trial, as well as review and approval of the study by an IRB. Investigators must also provide certain information to the clinical trial sponsors to allow the sponsors to make certain financial disclosures to the FDA. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the trial procedures, the parameters to be used in monitoring safety, the effectiveness criteria to be </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">evaluated, and a statistical analysis plan. A protocol for each clinical trial, and any subsequent protocol amendments, must be submitted to the FDA as part of the IND. If a product candidate is being investigated for multiple intended indications, separate INDs may also be required. In addition, an IRB at each study site participating in the clinical trial and/or a central IRB must review and approve the plan for any clinical trial, informed consent forms, and communications to study subjects before a study commences at that site. An IRB considers, among other things, whether the risks to individuals participating in the trials are minimized and are reasonable in relation to anticipated benefits, and whether the planned human subject protections are adequate. The IRB must continue to oversee the clinical trial while it is being conducted. Progress reports detailing the results of the clinical trials must also be submitted at least annually to the FDA and the IRB and more frequently if serious adverse events or other significant safety information is found.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#8217;s requirements or if the trial poses an unexpected serious harm to subjects. The FDA or an IRB may also impose conditions on the conduct of a clinical trial. Clinical trial sponsors may also choose to discontinue clinical trials as a result of risks to subjects, a lack of favorable results, or changing business priorities.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Information about certain clinical trials, including a description of the study and study results, must be submitted within specific timeframes to the NIH for public dissemination on their </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">clinicaltrials.gov</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> website. Sponsors or distributors of investigational products for the diagnosis, monitoring, or treatment of one or more serious diseases or conditions must also have a publicly available policy on evaluating and responding to requests for expanded access requests.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The manufacture of investigational drugs and biologics for the conduct of human clinical trials is subject to cGMP requirements. Investigational drugs and biologics and active ingredients and therapeutic substances imported into the United States are also subject to regulation by the FDA. Further, the export of investigational products outside of the United States is subject to regulatory requirements of the receiving country, as well as U.S. export requirements under the FDCA.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In general, for purposes of NDA and BLA approval, human clinical trials are typically conducted in three sequential phases, which may overlap or be combined.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Phase&#160;1</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;Studies are initially conducted in healthy human volunteers or subjects with the target disease or condition to test the product candidate for safety, dosage tolerance, structure-activity relationships, mechanism of action, absorption, metabolism, distribution, and excretion. If possible, Phase&#160;1 trials may also be used to gain an initial indication of product effectiveness.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Phase&#160;2</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;Controlled studies are conducted in limited subject populations with a specified disease or condition to evaluate preliminary efficacy, identify optimal dosages, dosage tolerance and schedule, possible adverse effects and safety risks, and expanded evidence of safety.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Phase&#160;3&#8212;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These adequate and well-controlled clinical trials are undertaken in expanded subject populations, generally at geographically dispersed clinical trial sites, to generate enough data to provide statistically significant evidence of clinical efficacy and safety of the product candidate for approval, to establish the overall risk-benefit profile of the product candidate, and to provide adequate information for the labeling of the product candidate. Typically, two Phase&#160;3 trials are required by the FDA for product approval. Under some limited circumstances, however, the FDA may approve an NDA or BLA based upon a single Phase&#160;3 clinical study.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Moreover, in the case of 505(b)(2) NDAs, the above studies may be abbreviated. Additional kinds of data may also help to support a BLA or NDA, such as patient experience data and real world evidence. Real world evidence may also be used to assist in clinical trial design or to support an NDA for already approved products. For genetically targeted products and variant protein targeted products intended to address an unmet medical need in one or more patient subgroups with a serious or life threatening rare disease or condition, the FDA may allow a sponsor to rely upon data and information previously developed by the sponsor or for which the sponsor has a right of reference, that was previously submitted to support an approved application for a product that incorporates or utilizes the same or similar genetically targeted technology or a product that is the same or utilizes the same variant protein targeted drug as the product that is the subject of the application.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA may also require, or companies may conduct, additional clinical trials for the same indication after a product is approved. These so-called Phase&#160;4 studies may be made a condition to be satisfied after approval. The results of Phase&#160;4 studies can confirm or refute the effectiveness of a product candidate, and can provide important safety information.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, manufacturers must develop methods for testing the identity, strength, quality, potency, and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There are also various laws and regulations regarding laboratory practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances in connection with our research. In each of these areas, the FDA and other regulatory authorities have broad regulatory and enforcement powers, including the ability to levy fines and civil penalties, suspend or delay issuance of approvals, seize or recall products, and withdraw approvals.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Marketing Application Submission, Review by the FDA, and Marketing Approval</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Assuming successful completion of the required clinical and preclinical testing, the results of product development, including chemistry, manufacture, and controls, non-clinical studies, and clinical trial results, including negative or ambiguous results, as well as positive findings, are all submitted to the FDA, along with the proposed labeling, as part of an NDA, in the case of a drug, or BLA, in the case of a biologic, requesting approval to market the product for one or more indications. In most cases, the submission of a marketing application is subject to a substantial application user fee. These user fees must be paid at the time of the first submission of the application, even if the application is being submitted on a rolling basis. Fee waivers or reductions are available in certain circumstances. One basis for a waiver of the application user fee is if the applicant employs fewer than 500 employees, including employees of affiliates, the applicant does not have an approved marketing application for a product that has been introduced or delivered for introduction into interstate commerce, and the applicant, including its affiliates, is submitting its first marketing application. Product candidates that are designated as orphan products, which are further described below, are also not subject to application user fees unless the application includes an indication other than the orphan indication.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, under the Pediatric Research Equity Act ("PREA"), a BLA or NDA or supplement to a BLA or NDA for a new active ingredient, indication, dosage form, dosage regimen, or route of administration, must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Orphan products are also exempt from the PREA requirements.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA also may require submission of a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) to ensure that the benefits of the product candidate outweigh the risks. The REMS plan could include medication guides, physician communication plans, and elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools. An assessment of the REMS must also be conducted at set intervals. Following product approval, a REMS may also be required by the FDA if new safety information is discovered and the FDA determines that a REMS is necessary to ensure that the benefits of the product continue to outweigh the risks.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Once the FDA receives an application, it has 60&#160;days to review the NDA or BLA to determine if it is substantially complete to permit a substantive review, before it accepts the application for filing. The FDA may request additional information. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;), the FDA has set the review goal of completing its review of 90% of all applications for new molecular entities within ten months of the 60-day filing date. The FDA also has the review goal of completing its review of 90% of non-new molecular entity marketing applications within ten months of the agency&#8217;s receipt of the application. These review goals are referred to as the PDUFA date. The PDUFA date is only a goal, thus, the FDA does not always meet its PDUFA dates. The review process and the PDUFA date may also be extended if the FDA requests or the sponsor otherwise provides substantial additional information or clarification regarding the submission.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA may also refer certain applications to an advisory committee. Before approving a product candidate for which no active ingredient (including any ester or salt of an active ingredients) has previously been approved by the FDA, the FDA must either refer that product candidate to an external advisory committee or provide in an action letter, a summary of the reasons </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">why the FDA did not refer the product candidate to an advisory committee. The FDA may also refer other product candidates to an advisory committee if FDA believes that the advisory committee&#8217;s expertise would be beneficial. An advisory committee is typically a panel that includes clinicians and other experts, which review, evaluate, and make a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA reviews applications to determine, among other things, whether a product candidate meets the agency&#8217;s approval standards and whether the manufacturing methods and controls are adequate to assure and preserve the product&#8217;s identity, strength, quality, potency, and purity. Before approving a marketing application, the FDA typically will inspect the facility or facilities where the product is manufactured, referred to as a Pre-Approval Inspection. The FDA will not approve an application unless it determines that the manufacturing processes and facilities, including contract manufacturers and subcontractors, are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a marketing application the FDA will inspect one or more clinical trial sites to assure compliance with GCPs.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">After evaluating the marketing application and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a Complete Response Letter (&#8220;CRL&#8221;). A CRL indicates that the review cycle for the application is complete and the application is not ready for approval. It also describes all of the specific deficiencies that the FDA identified. A CRL generally contains a statement of specific conditions that must be met in order to secure final approval of the marketing application, and may require additional clinical or preclinical testing in order for the FDA to reconsider the application. The deficiencies identified may be minor, for example, requiring labeling changes; or major, for example, requiring additional clinical trials. If a CRL is issued, the applicant may either: resubmit the marketing application, addressing all of the deficiencies identified in the letter; withdraw the application; or request an opportunity for a hearing. The FDA has the goal of reviewing 90% of application resubmissions following a CRL in either two or six months of the resubmission date, depending on the kind of resubmission. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA may issue an approval letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if the FDA approves a product, it may limit the approved indications or populations for use of the product, require that contraindications, warnings, or precautions be included in the product labeling, including a boxed warning, require that post-approval studies, including Phase&#160;4 clinical trials, be conducted to further assess a product&#8217;s safety and efficacy after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms under a REMS which can materially affect the potential market and profitability of the product. The FDA may also not approve label statements that are necessary for successful commercialization and marketing.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval. The FDA may also withdraw the product approval if compliance with the pre- and post-marketing regulatory standards are not maintained or if problems occur after the product reaches the marketplace. Further, should new safety information arise, additional testing, product labeling changes, or FDA notification may be required.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">505(b)(2) New Drug Applications and the Hatch-Waxman Act</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Section&#160;505 of the FDCA describes three types of marketing applications that may be submitted to the FDA to request marketing authorization for a new drug. A Section&#160;505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy. A 505(b)(2) NDA is an application that contains full reports of investigations of safety and efficacy but where at least some of the information required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use. This regulatory pathway enables the applicant to rely, in part, on the FDA&#8217;s prior findings of safety and efficacy for an existing product, or published literature, in support of its application. Section&#160;505(j) establishes an abbreviated approval process for a generic version of approved drug products through the submission of an Abbreviated New Drug Application (&#8220;ANDA&#8221;). An ANDA provides for marketing of a generic drug product that has the same active ingredients, dosage form, strength, route of administration, labeling, performance characteristics and intended use to a previously approved product. ANDAs are termed &#8220;abbreviated&#8221; because they are generally not required to include preclinical (animal) and clinical (human) data to establish safety and efficacy. Instead, generic applicants must scientifically demonstrate that their product is bioequivalent to, or performs in the same manner as, the innovator drug through in vitro, in vivo, or other testing. The generic version must deliver the same amount of active ingredients to the site of </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">action in the same amount of time as the innovator drug and can often be substituted by pharmacists under prescriptions written for the reference listed drug.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent with claims that cover the applicant&#8217;s drug or a method of using the drug, as reflected in the NDA. Upon approval of a drug, each of the patents listed in the application for the drug is published in the FDA&#8217;s list of Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential competitors in support of approval of an ANDA or 505(b)(2) NDA.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon submission of an ANDA or a 505(b)(2) NDA, an applicant must certify to the FDA that (1)&#160;no patent information has been submitted to the FDA; (2)&#160;such patent has expired; (3)&#160;the date on which such patent expires; or (4)&#160;such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. Generally, the ANDA or 505(b)(2) NDA cannot be approved until all listed patents have expired, except where the ANDA or 505(b)(2) NDA applicant challenges a listed patent through the last type of certification, also known as a paragraph&#160;IV certification. If the applicant does not challenge the listed patents or does not indicate that it is not seeking approval of a patented method of use, the ANDA or 505(b)(2) NDA application approval will not be made effective until all of the listed patents claiming the referenced product have expired.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If the ANDA or 505(b)(2) NDA applicant has provided a paragraph&#160;IV certification to the FDA, the applicant must send notice of the certification to the NDA and patent holders. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the paragraph&#160;IV certification, in which case the FDA may not make an approval effective until the earlier of 30&#160;months from the patent or application owner&#8217;s receipt of the notice of the paragraph&#160;IV certification, the expiration of the patent, when the infringement case concerning each such patent is favorably decided in the applicant&#8217;s favor or settled, or such shorter or longer period as may be ordered by a court. This prohibition is generally referred to as the 30-month stay. In instances where an ANDA or 505(b)(2) NDA applicant files&#160;a paragraph&#160;IV certification, the NDA holder or patent owner(s) regularly take action to trigger the 30-month stay. Thus, approval of an ANDA or 505(b)(2) NDA could be delayed for a significant period of time depending on the patent certification the applicant makes and the reference drug sponsor&#8217;s decision to initiate patent litigation.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Hatch-Waxman Act establishes periods of regulatory exclusivity for certain approved drug products, during which the FDA cannot accept an ANDA or 505(b)(2) application that relies on the branded reference drug or make an approval of such a product effective. For example, the holder of an NDA, including a 505(b)(2) NDA, may obtain five years of exclusivity upon approval of a new drug containing new chemical entities that have not been previously approved by the FDA. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion, excluding appended portions that cause the drug to be an ester, salt, or other noncovalent derivative, responsible for the therapeutic activity of the drug substance. During the exclusivity period, the FDA may not accept for review an ANDA or a 505(b)(2) NDA submitted by another company that contains the previously approved active moiety. However, an ANDA or 505(b)(2) NDA may be submitted after four years if it contains a certification of patent invalidity or non-infringement.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Hatch-Waxman Act also provides three years of marketing exclusivity to the holder of an NDA (including a 505(b)(2) NDA) for a particular condition of approval, or change to a marketed product, such as a new indication or formulation for a previously approved product, if one or more new clinical studies (other than bioavailability or bioequivalence studies) was essential to the approval of the application and was conducted/sponsored by the applicant. This three-year exclusivity period protects against the FDA making an ANDA and 505(b)(2) NDA approval effective for the condition of the new drug&#8217;s approval. As a general matter, the three-year exclusivity does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for generic or modified versions of the original, unmodified drug product. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA; however, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and efficacy.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Biosimilars and Exclusivity</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Biologics Price Competition and Innovation Act of 2009 creates an abbreviated approval pathway for biological products shown to be highly similar to or interchangeable with an FDA-licensed reference biological product. Biosimilarity sufficient to reference a prior FDA-approved product requires a high similarity to the reference product notwithstanding minor differences in clinically inactive components, and no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency. Biosimilarity must be shown through analytical studies, animal studies, and at least one clinical trial, absent a waiver by the FDA. There must be no difference between the reference product and a biosimilar </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">in mechanism of action, conditions of use, route of administration, dosage form, and strength. A biosimilar product may be deemed interchangeable with a prior approved product if it meets the higher hurdle of demonstrating that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reference biologic is granted 12&#160;years of exclusivity from the time of first licensure, and no application for a biosimilar can be submitted for four years from the date of licensure. However, certain changes and supplements to an approved BLA, and subsequent applications filed by the same sponsor, manufacturer, licensor, predecessor in interest, or other related entity do not qualify for the twelve-year exclusivity period. The PHSA also includes provisions to protect reference products that have patent protection. The biosimilar product sponsor and reference product sponsor may exchange certain patent and product information for the purpose of determining whether there should be a legal patent challenge. Based on the outcome of negotiations surrounding the exchanged information, the reference product sponsor may bring a patent infringement suit and injunction proceedings against the biosimilar product sponsor. The biosimilar applicant may also be able to bring an action for declaratory judgment concerning the patent.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Pediatric Exclusivity</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity for both drugs and biologics, and also Orange Book listed patents in the case of drugs. Conditions for exclusivity include the FDA's determination that information relating to the use of a new drug in the pediatric population may produce health benefits in that population, the FDA making a written request for pediatric studies, and the applicant agreeing to perform and reporting on the requested studies within the statutory timeframe.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Orphan Products</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Orphan Drug Act provides incentives for the development of products for rare diseases or conditions. Specifically, sponsors may apply for and receive ODD if a product candidate is intended to treat rare diseases or conditions, which generally are diseases or conditions affecting less than 200,000 individuals in the United States, or affecting more than 200,000 in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States will be recovered from United States sales. ODD must be requested before submitting an NDA. Additionally, sponsors must present a plausible hypothesis for clinical superiority to obtain ODD if there is a product already approved by the FDA that that is considered by the FDA to be the same as the already approved product and is intended for the same indication. This hypothesis must be demonstrated to obtain orphan exclusivity. If granted, prior to product approval, ODD entitles a party to financial incentives such as opportunities for grant funding towards clinical study costs, tax advantages, and certain user-fee waivers. The tax advantages, however, were limited in the 2017 Tax Cuts and Jobs Act. In addition, if a product candidate receives FDA approval for the indication for which it has ODD, the product is generally entitled to orphan exclusivity, which means the FDA may not approve any other application to market the same product for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity. After the FDA grants ODD, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. ODD does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The first NDA applicant to receive FDA approval for a particular active moiety to treat a particular disease with FDA Orphan Drug designation is entitled to a seven-year exclusive marketing period in the U.S. for that product, for that indication. During the seven-year exclusivity period, the FDA may not approve any other applications to market the same drug for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with Orphan Drug exclusivity by means of greater effectiveness, greater safety, or providing a major contribution to patient care. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. Among the other benefits of ODD are tax credits for certain research and a waiver of the NDA application user fee. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Patent Term Restoration</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If approved, drug and biologic products may also be eligible for periods of U.S. patent term restoration. If granted, patent term restoration extends the patent life of a single unexpired patent, that has not previously been extended, for a maximum of five years. The total patent life of the product with the extension also cannot exceed fourteen years from the product&#8217; approval date. Subject to the prior limitations, the period of the extension is calculated by adding half of the time from the effective date of an IND to the initial submission of a marketing application, and all of the time between the submission of the marketing application and its approval. This period may also be reduced by any time that the applicant did not act with due diligence.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Special FDA Expedited Review and Approval Programs</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA has various programs that are intended to expedite or simplify the process for the development and FDA review of certain products that are intended for the treatment of serious or life threatening diseases or conditions, and demonstrate the potential to address unmet medical needs or present a significant improvement over existing therapy. The purpose of these programs is to provide important new therapeutics to patients earlier than under standard FDA review procedures.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To be eligible for a Fast Track designation, the FDA must determine, based on the request of a sponsor, that a product candidate is intended to treat a serious or life threatening disease or condition and demonstrates the potential to address an unmet medical need. If Fast Track designation is obtained, sponsors may be eligible for more frequent development meetings and correspondence with the FDA. In addition, the FDA may initiate review of sections of an application before the application is complete. This &#8220;rolling review&#8221; is available if the applicant provides and the FDA approves a schedule for the remaining information. Whether FDA is able to commence its review of portions of an application, however, before receipt of the complete submission, depends on a number of factors. In some cases, a Fast Track product may be eligible for accelerated approval or priority review.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA may give a priority review designation to product candidates that are intended to treat serious conditions and, if approved, would provide significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of the serious condition. A priority review means that the goal for the FDA is to review an application within six months, rather than the standard review of ten months under current PDUFA guidelines.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Drug or biological products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval, which means the FDA may approve the product based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. A drug or biologic candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase&#160;4 or post-approval clinical trials to confirm the effect of the product. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, will allow the FDA to withdraw the drug or biologic from the market on an expedited basis. All promotional materials for drug or biologic candidates approved under accelerated regulations are subject to prior review by the FDA.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the provisions of the Food and Drug Administration Safety and Innovation Act, enacted in 2012, a sponsor can request designation of a product candidate as a &#8220;breakthrough therapy.&#8221; A breakthrough therapy is defined as a product that is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Products designated as breakthrough therapies are eligible for intensive guidance on an efficient development program beginning as early as Phase&#160;1 trials, a commitment from the FDA to involve senior managers and experienced review staff in a proactive collaborative and cross-disciplinary review, rolling review, and the facilitation of cross-disciplinary review.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Post-approval Requirements</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements related to manufacturing, recordkeeping, and reporting, including adverse experience reporting, deviation reporting, shortage reporting, and periodic reporting, product sampling and distribution, advertising, marketing, promotion, certain electronic records and signatures, and post-approval obligations imposed as a condition of approval, such as Phase&#160;4 clinical trials, REMS, and surveillance to assess safety and effectiveness after commercialization.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also are continuing annual program user fee requirements for approved products, excluding orphan products. In addition, manufacturers and other entities involved in the manufacture and distribution of approved therapeutics are required to register their establishments with the FDA and certain state agencies, list their products, and are subject to periodic announced and unannounced inspections by the FDA and these state agencies for compliance with cGMP and other requirements. Manufacturers must continue to expend time, money, and effort in the areas of production and </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">quality-control to maintain compliance with cGMPs. Regulatory authorities may undertake regulatory enforcement action, withdraw product approvals, require label modifications, or request product recalls, among other actions, if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Changes to the manufacturing process are strictly regulated and often require prior FDA approval or notification before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and specifications, and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA also strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. A company can make only those claims relating to a product that are approved by the FDA. Physicians, in their independent professional medical judgment, may prescribe legally available products for unapproved indications that are not described in the product&#8217;s labeling and that differ from those tested and approved by the FDA. Biopharmaceutical companies, however, are required to promote their products only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability, including, but not limited to, criminal and civil penalties under the FDCA and False Claims Act ("FCA"), exclusion from participation in federal healthcare programs, mandatory compliance programs under corporate integrity agreements, suspension and debarment from government contracts, and refusal of orders under existing government contracts.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the distribution of prescription biopharmaceutical samples is subject to the Prescription Drug Marketing Act, (&#8220;PDMA&#8221;), which regulates the distribution of samples at the federal level. Both the PDMA and state laws limit the distribution of prescription biopharmaceutical product samples and impose requirements to ensure accountability in distribution. Free trial or starter prescriptions provided through pharmacies are also subject to regulations under the Medicaid Drug Rebate Program and potential liability under anti-kickback and false claims laws.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Moreover, the enacted Drug Quality and Security Act imposes obligations on sponsors of biopharmaceutical products related to product tracking and tracing. Among the requirements of this legislation, sponsors are required to provide certain information regarding the products to individuals and entities to which product ownership is transferred, are required to label products with a product identifier, and are required to keep certain records regarding the product. The transfer of information to subsequent product owners by sponsors is also required to be done electronically. Sponsors must also verify that purchasers of the sponsors&#8217; products are appropriately licensed. Further, under this legislation, manufactures have product investigation, quarantine, disposition, and notification responsibilities related to counterfeit, diverted, stolen, and intentionally adulterated products that would result in serious adverse health consequences or death to humans, as well as products that are the subject of fraudulent transactions or which are otherwise unfit for distribution such that they would be reasonably likely to result in serious health consequences or death. Similar requirements additionally are and will be imposed through this legislation on other companies within the biopharmaceutical product supply chain, such as distributors and dispensers, as well as certain sponsor licensees and affiliates.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in significant regulatory actions. Such actions may include refusal to approve pending applications, license or approval suspension or revocation, imposition of a clinical hold or termination of clinical trials, warning letters, untitled letters, cyber letters, modification of promotional materials or labeling, provision of corrective information, imposition of post-market requirements including the need for additional testing, imposition of distribution or other restrictions under a REMS, product recalls, product seizures or detentions, refusal to allow imports or exports, total or partial suspension of production or distribution, FDA debarment, injunctions, fines, consent decrees, corporate integrity agreements, suspension and debarment from government contracts, and refusal of orders under existing government contracts, exclusion from participation in federal and state healthcare programs, restitution, disgorgement, or civil or criminal penalties, including fines and imprisonment, and adverse publicity, among other adverse consequences.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Additional controls for biologics</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To help reduce the increased risk of the introduction of adventitious agents, the PHSA emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend licenses in situations where there exists a danger to public health, to prepare or procure products </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">in the event of shortages and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases in the United States and between states.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">After a BLA is approved, the product may also be subject to official lot release as a condition of approval. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products before releasing the lots for distribution by the manufacturer.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Gene therapy products are also subject to the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, which require, among other things, that trials involving recombinant or synthetic nucleic acid molecules be reviewed by an Institutional Biosafety Committee (&#8220;IBC&#8221;). The IBC reviews, approves, and supervises research involving recombinant or synthetic nucleic acid molecules.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to the regulations discussed above, there are a number of additional standards that apply to clinical trials involving the use of gene therapy. The FDA has issued various guidance documents regarding gene therapies, which outline additional factors that the FDA will consider during product development. By example, the FDA recommends that sponsors observe subjects for potential gene therapy-related delayed adverse events for a prolonged period of time.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fraud and Abuse, Data Privacy and Security, and Transparency Laws and Regulations</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our business activities, including but not limited to, research, marketing, sales, promotion, distribution, medical education, and other activities following product approval will be subject to regulation by numerous federal and state regulatory and law enforcement authorities in the United States in addition to the FDA, including potentially the Department of Justice, the Department of Health and Human Services and its various divisions, including the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) and the Health Resources and Services Administration, the Department of Veterans Affairs, the Department of Defense, and state and local governments. Our business activities must comply with numerous healthcare laws, including but not limited to, anti-kickback and false claims laws and regulations as well as data privacy and security laws and regulations, which are described below, as well as state and federal consumer protection and unfair competition laws. Moreover, to the extent that we license the right to sell its product candidates, if approved, to another entity under that entity&#8217;s labeler code, the licensee would have regulatory responsibilities, including healthcare, reimbursement, pricing, and reporting regulatory responsibilities.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The federal Anti-Kickback Statute, which regulates, among other things, marketing practices, educational programs, pricing policies, and relationships with healthcare providers or other entities, prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting, or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or order, or the referral to another for the furnishing or arranging for the furnishing of any item or service reimbursable under Medicare, Medicaid, or other federal healthcare programs, in whole or in part. The term &#8220;remuneration&#8221; has been interpreted broadly to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between biopharmaceutical industry members on one hand and prescribers, purchasers, formulary managers, and beneficiaries on the other. There are certain statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly, and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases, or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, including purchases of products paid by federal healthcare programs, the statute has been violated. The Patient Protection and Affordable Care Act of 2010, as amended (the &#8220;ACA&#8221;), modified the intent requirement under the Anti-Kickback Statute to a stricter standard, such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the ACA also provided that a violation of the federal Anti-Kickback Statute is grounds for the government or a whistleblower to assert that a claim for payment of items or services resulting from such violation constitutes a false or fraudulent claim for purposes of the federal civil FCA.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The federal civil FCA prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to, or approval by, the federal government, knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government, or avoiding, decreasing, or concealing an obligation to pay money to the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. The civil FCA has been used to assert liability on the basis of kickbacks and other improper referrals, improperly reported government pricing metrics such as Best Price or Average Manufacturer Price, improper use of Medicare provider or supplier numbers when detailing a provider of services, improper promotion of off-label uses not expressly approved by the FDA in a product&#8217;s label, and allegations as to misrepresentations with respect to products, contract requirements, and services rendered. In addition, private payers have been filing follow-on lawsuits alleging fraudulent misrepresentation, although establishing liability and damages in these cases is more difficult than under the FCA. Intent to deceive is not required to establish liability under the civil FCA. Civil FCA actions may be brought by the government or may be brought by private individuals on behalf of the government, called &#8220;qui tam&#8221; actions. If the government decides to intervene in a qui tam action and prevails in the lawsuit, the individual will share in the proceeds from any fines or settlement funds. If the government declines to intervene, the individual may pursue the case alone. The civil FCA provides for treble damages and a civil penalty for each false claim, such as an invoice or pharmacy claim for reimbursement, which can aggregate into millions of dollars. For these reasons, since 2004, FCA lawsuits against biopharmaceutical companies have increased significantly in volume and breadth, leading to several substantial civil and criminal settlements, as much as $3.0&#160;billion, regarding certain sales practices and promoting off label uses. Civil FCA liability may further be imposed for known Medicare or Medicaid overpayments, for example, overpayments caused by understated rebate amounts, that are not refunded within 60&#160;days of discovering the overpayment, even if the overpayment was not caused by a false or fraudulent act. In addition, conviction or civil judgment for violating the FCA may result in exclusion from federal health care programs, and suspension and debarment from government contracts, and refusal of orders under existing government contracts.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The government may further prosecute conduct constituting a false claim under the criminal FCA. The criminal FCA prohibits the making or presenting of a claim to the government knowing such claim to be false, fictitious, or fraudulent and, unlike the civil FCA, requires proof of intent to submit a false claim.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The civil monetary penalties statute is another potential statute under which biopharmaceutical companies may be subject to enforcement. Among other things, the civil monetary penalties statue imposes fines against any person who is determined to have knowingly presented, or caused to be presented, claims to a federal healthcare program that the person knows, or should know, is for an item or service that was not provided as claimed or is false or fraudulent.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payment or reimbursement of prescription therapeutics by Medicaid or Medicare requires the product&#8217;s labeler to submit certified pricing information to CMS. The Medicaid Drug Rebate statute requires labelers, as a condition of payment by Medicaid, to calculate and report price points, which are used to determine Medicaid rebate payments shared between the states and the federal government and Medicaid payment rates for certain therapeutics, to pay quarterly rebates on prescriptions paid by Medicaid, and to provide a discount based on the Medicaid rebate percentage to certain hospitals and clinics under the 340B program. For most therapeutics paid under Medicare Part&#160;B, labelers must also calculate and report their Average Sales Price ("ASP"), which is used to determine the Medicare Part&#160;B payment rate. In addition, therapeutics covered by Medicaid are subject to an additional inflation penalty which can substantially increase rebate payments. For products approved under a BLA (including biosimilars) or an NDA, the Veterans Health Care Act (&#8220;VHCA&#8221;) requires labelers, as a condition of payment by Medicaid, to calculate and report to the Veterans Administration (&#8220;VA&#8221;) a different price called the Non-Federal Average Manufacturing Price, which is used to determine the maximum price that can be charged to certain federal agencies, referred to as the Federal Ceiling Price ("FCP"). Like the Medicaid rebate amount, the FCP includes an inflation penalty. A Department of Defense statute and regulation requires labelers to provide this discount on therapeutics dispensed by retail pharmacies when paid by the TRICARE Program. All of these price reporting requirements create risk of submitting false information to the government, and potential FCA liability.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The VHCA also requires labelers of covered therapeutics participating in the Medicaid program to enter into Federal Supply Schedule contracts with the VA through which their covered therapeutics must be sold to certain federal agencies at FCP. This necessitates compliance with applicable federal procurement laws and regulations, including submission of commercial sales and pricing information, and subjects us to contractual remedies as well as administrative, civil, and criminal sanctions. In addition, the VHCA requires labelers participating in Medicaid to agree to provide different mandatory discounts to certain Public Health Service grantees and other safety net hospitals and clinics under the 340B program based on the labelers&#8217;s reported Medicaid pricing information. The 340B&#160;program has its own regulatory authority to impose sanctions for non-compliance and adjudicate overcharge claims against labelers by the purchasing entities.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) also created federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">29</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, a healthcare benefit program, regardless of whether the payor is public or private, in connection with the delivery or payment for health care benefits, knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a health care offense and knowingly and willfully falsifying, concealing, or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items, or services relating to healthcare matters. Additionally, the ACA amended the intent requirement of certain of these criminal statutes under HIPAA so that a person or entity no longer needs to have actual knowledge of the statute, or the specific intent to violate it, to have committed a violation.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The ACA further created new federal requirements for reporting, by applicable drug manufacturers of covered therapeutics, payments and other transfers of value to physicians and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members, including the Physician Payments Sunshine Act.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Further, we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;) and its respective implementing regulations imposes certain requirements on covered entities relating to the privacy, security, and transmission of certain individually identifiable health information, known as protected health information. Among other things, HITECH, through its implementing regulations, makes HIPAA&#8217;s security standards and certain privacy standards directly applicable to business associates, defined as a person or organization, other than a member of a covered entity&#8217;s workforce, that creates, receives, maintains, or transmits protected health information on behalf of a covered entity for a function or activity regulated by HIPAA. HITECH also strengthened the civil and criminal penalties that may be imposed against covered entities, business associates, and individuals, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, other federal and state laws may govern the privacy and security of health and other information in certain circumstances, many of which differ from each other in significant ways and may not be preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many states have also adopted laws similar to each of the above federal laws, which may be broader in scope and apply to items or services reimbursed by any third-party payor, including commercial insurers. Certain state laws also regulate sponsors&#8217; use of prescriber-identifiable data. Certain states also require implementation of commercial compliance programs and compliance with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government, or otherwise restrict payments or the provision of other items of value that may be made to healthcare providers and other potential referral sources; impose restrictions on marketing practices; or require drug companies to track and report information related to payments, gifts, and other items of value to physicians and other healthcare providers.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Recently, states have enacted or are considering legislation intended to make drug prices more transparent and deter significant price increases, typically as consumer protection laws. These laws may affect its future sales, marketing, and other promotional activities by imposing administrative and compliance burdens.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If our operations are found to be in violation of any of the laws or regulations described above or any other applicable laws, we may be subject to penalties or other enforcement actions, including criminal and significant civil monetary penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, corporate integrity agreements, suspension and debarment from government contracts, and refusal of orders under existing government contracts, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of its operations, any of which could adversely affect our ability to operate our business and our results of operations. Enforcement actions can be brought by federal or state governments, or as &#8220;qui tam&#8221; actions brought by individual whistleblowers in the name of the government under the civil FCA if the violations are alleged to have caused the government to pay a false or fraudulent claim.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Coverage and Reimbursement</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The commercial success of our product candidates and our ability to commercialize any approved product candidates successfully will depend in part on the extent to which governmental payor programs at the federal and state levels, including Medicare and Medicaid, private health insurers, and other third-party payors provide coverage for and establish adequate </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">30</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">reimbursement levels for our product candidates. Government authorities, private health insurers, and other organizations generally decide which therapeutics they will pay for and establish reimbursement levels for healthcare. Medicare is a federally funded program managed by CMS through local fiscal intermediaries and carriers that administer coverage and reimbursement for certain healthcare items and services furnished to the elderly and disabled. Medicaid is an insurance program for certain categories of patients whose income and assets fall below state defined levels and who are otherwise uninsured that is both federally and state funded and managed by each state. The federal government sets general guidelines for Medicaid and each state creates specific regulations that govern its individual program, including supplemental rebate programs that restrict coverage to therapeutics on the state Preferred Drug List. Similarly, government laws and regulations establish the parameters for coverage of prescription therapeutics by health plans participating in state exchanges and Tricare, the health care program for military personnel, retirees, and related beneficiaries. Some states have also created pharmacy assistance programs for individuals who do not qualify for federal programs. In the United States, private health insurers and other third-party payors often provide reimbursement for products and services based on the level at which the government provides reimbursement through the Medicare or Medicaid programs for such products and services.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the United States, the European Union, and other potentially significant markets for our product candidates, government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which often has resulted in average selling prices lower than they would otherwise be and sometimes at or below the provider&#8217;s acquisition cost. In the United States, it is also common for government and private health plans to use coverage determinations to leverage rebates from labelers in order to reduce the plans&#8217; net costs. These restrictions and limitations influence the purchase of healthcare services and products and lower the realization on labelers&#8217; sales of prescription therapeutics. Third-party payors are developing increasingly sophisticated methods of controlling healthcare costs. Third-party payors may limit coverage to specific therapeutic products on an approved list, or formulary, which might not include all of the FDA-approved products for a particular indication or might impose high copayment amounts to influence patient choice. Third-party payors also control costs by requiring prior authorization or imposing other dispensing restrictions before covering certain products and by broadening therapeutic classes to increase competition. Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. Absent clinical differentiators, third-party payors may treat products as therapeutically equivalent and base formulary decisions on net cost. To lower the prescription cost, labelers frequently rebate a portion of the prescription price to the third-party payors. Recently, purchasers and third-party payors have begun to focus on value of new therapeutics and sought agreements in which price is based on achievement of performance metrics.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Federal programs also impose price controls through mandatory ceiling prices on purchases by federal agencies and federally funded hospitals and clinics and mandatory rebates on retail pharmacy prescriptions paid by Medicaid and Tricare. These restrictions and limitations influence the purchase of healthcare services and products. Legislative proposals to reform healthcare or reduce costs under government programs may result in lower reimbursement for its product candidates or exclusion of its product candidates from coverage. In addition, government programs like Medicaid include substantial penalties for increasing commercial prices over the rate of inflation which can affect realization and return on investment.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Private payors often rely on the lead of the governmental payors in rendering coverage and reimbursement determinations. Therefore, achieving favorable CMS coverage and reimbursement is usually a significant gating issue for successful introduction of a new product. In addition, many government programs as a condition of participation mandate fixed discounts or rebates from labelers regardless of formulary position or utilization, and then rely on competition in the market to attain further price reductions, which can greatly reduce realization on the sale.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Further, the increased emphasis on managed healthcare in the United States and on country and regional pricing and reimbursement controls in the European Union will put additional pressure on product pricing, reimbursement, and utilization, which may adversely affect its future product sales and results of operations. These pressures can arise from rules and practices of managed care groups, competition within therapeutic classes, judicial decisions and governmental laws and regulations related to Medicare, Medicaid, and healthcare reform, biopharmaceutical coverage and reimbursement policies, and pricing in general. Patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Sales of our product candidates will therefore depend substantially, both domestically and abroad, on the extent to which the costs of our products will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, such as Medicare and Medicaid, private health insurers, and other third-party payors.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of the above, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain the FDA approvals. Our product </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">31</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">candidates may not be considered medically necessary or cost-effective, or the rebate percentages required to secure coverage may not yield an adequate margin over cost. Additionally, companies are increasingly finding it necessary to establish bridge programs to assist patients access new therapies during protracted initial coverage determination periods.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Moreover, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved or that significant price concessions will not be required to avoid restrictive conditions. High health plan co-payment requirements may result in patients refusing prescriptions or seeking alternative therapies. Additionally, where a new indication has been approved for a drug previously approved under a different NDA, health plans may cover off-label use of the original drug, even if it cannot be marketed for the new indication. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in therapeutic development. Legislative proposals to reform healthcare or reduce costs under government insurance programs may result in lower reimbursement for our products and product candidates or exclusion of our products and product candidates from coverage. The cost containment measures that healthcare payors and providers are instituting and any healthcare reform could significantly reduce our revenues from the sale of any approved product candidates. We cannot provide any assurances that we will be able to obtain and maintain third-party coverage or adequate reimbursement for our product candidates in whole or in part.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Healthcare Reform Measures</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals designed to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality, and expanding access. In the United States, the biopharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For example, the ACA created hybrid payment methodology for biosimilars under Medicare Part&#160;B, which covers products administered by physicians in an outpatient setting, intended to neutralize the incentive to purchase higher priced biologics reimbursed at ASP plus 6% of ASP by paying providers ASP of a biosimilar but adding the margin based on ASP of the reference biologic. More recently, the Bipartisan Budget Act extended labeler responsibility for prescription costs in the Medicare Part&#160;D coverage gap to biosimilars, which had previously been exempt.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Similarly, the American Recovery and Reinvestment Act of 2009 established funding for the federal government to compare the effectiveness of different treatments for the same illness. The Agency for Healthcare Research and Quality among other things, conducts patient-centered outcome research, develops evidence-based tools and resources on medication therapies, maintains databases of health care related data and standards, and issues periodic reports on specific studies. Although the results of the comparative effectiveness studies are not intended to mandate coverage policies for public or private payors, it is not clear what effect, if any, the organization&#8217;s research has had or will have on the sales of any product, if any such product or the condition that it is intended to treat is the subject of a study. It is also possible that comparative effectiveness research demonstrating benefits in a competitor&#8217;s product could adversely affect the sales of our product candidates. If third-party payors do not consider our product candidates to be cost-effective compared to other available therapies, they may not cover our product candidates or may severely restrict access, once approved, as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable basis.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Moreover, the ACA broadened access to health insurance, attempts to reduce or constrain the growth of healthcare spending, enhanced remedies against fraud and abuse, added new transparency requirements for healthcare and health insurance industries, imposed new taxes and fees on the health care industry, and imposed additional health policy reforms. The law expanded the eligibility criteria and mandatory eligibility categories for Medicaid programs, thereby potentially increasing both the volume of sales and labelers&#8217; Medicaid rebate liability. The law also expanded the 340B discount program that mandates discounts to certain hospitals, community centers, and other qualifying providers, by expanding the categories of entities eligible to purchase under the program, although, with the exception of children&#8217;s hospitals, these newly eligible entities are ineligible to receive discounted 340B pricing on orphan therapeutics used to treat an orphan disease or condition. The ACA revised the definition of &#8220;average manufacturer price ("AMP")&#8221; for reporting purposes, which generally increased the amount of Medicaid rebates to states and created a separate AMP for certain categories of therapeutics provided in non-retail outpatient settings. The law additionally extended labeler&#8217;s Medicaid rebate liability to covered therapeutics dispensed to patients enrolled in Medicaid managed care organizations and increased the statutory minimum rebates a labeler must pay under the Medicaid Drug Rebate program. The revisions to the AMP definition and Medicaid rebate formula can have the further effect of increasing the required 340B discounts. Further, the ACA requires labelers of therapeutics, to pay 50% of the pharmacy charge to Medicare Part&#160;D patients while they are in the coverage gap, and this percentage was increased to 70% by the Bipartisan Budget Act of 2018. Finally, the ACA imposes a significant annual fee on companies that manufacture or import branded </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">32</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">prescription therapeutic products. Substantial new provisions affecting compliance have also been enacted through the ACA and otherwise, including the reporting of therapeutic sample distribution, which may require us to modify our business practices with healthcare practitioners. Although the ACA was recently amended to repeal the individual insurance mandate, and efforts to repeal and replace portions of the law may continue, it is likely that pressure on biopharmaceutical pricing, especially under the Medicare program, will continue, and may also increase our regulatory burdens and operating costs. Moreover, in the coming years, additional changes could be made to governmental healthcare programs that could significantly impact the success of our product candidates.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The cost of biopharmaceuticals continues to generate substantial governmental and third-party payor interest. We expect that the biopharmaceutical industry will experience pricing pressures due to the trend toward managed healthcare, the increasing influence of managed care organizations and additional legislative proposals. Our results of operations could be adversely affected by current and future healthcare reforms.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Some third-party payors also require pre-approval of coverage for new or innovative devices or therapies before they will reimburse healthcare providers that use such therapies. While we cannot predict whether any proposed cost-containment measures will be adopted or otherwise implemented in the future, the announcement or adoption of these proposals could have a material adverse effect on our ability to obtain adequate prices for our product candidates and operate profitably.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, other legislative and regulatory changes have been proposed and adopted since the ACA was enacted. The Budget Control Act of 2011, as amended, created the Joint Select Committee on Deficit Reduction to recommend proposals in spending reductions to Congress. The Joint Select Committee on Deficit Reduction did not achieve its targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, triggering the legislation&#8217;s automatic reductions to several government programs. These reductions include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year. The Bipartisan Budget Act of 2018 retained the federal budget &#8220;sequestration&#8221; Medicare payment reductions of 2%, and extended it through 2027 unless congressional action is taken, and also increased labeler responsibility for prescription costs in the Medicare Part&#160;D coverage gap. The American Taxpayer Relief Act of 2012, further reduced Medicare payments to several categories of healthcare providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These and other healthcare reform initiatives may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our financial operations. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could further limit the prices we are able to charge, or the amounts of reimbursement available, for our product candidates once they are approved.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2016, CMS issued a final rule regarding the Medicaid drug rebate program. The final rule, effective April&#160;1, 2016, among other things, extended labeler rebate obligations to U.S. territories, revised the manner in which the AMP is calculated by labelers participating in the program, and implements certain amendments to the Medicaid rebate statute created under the ACA. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. The full impact of these laws, as well as other new laws and reform measures that may be proposed and adopted in the future remains uncertain, but may result in additional reductions in Medicare and other health care funding, or higher production costs which could have a material adverse effect on our customers and, accordingly, our financial operations.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been several recent U.S. Congressional inquiries and proposed and adopted federal and state legislation designed to, among other things, bring more transparency to drug pricing and deter price increases, review the relationship between pricing and sponsor patient programs, and reform government program reimbursement methodologies for drugs. Further, the current U.S. Presidential administration&#8217;s budget proposal for fiscal year 2020 contained proposed policy changes and further drug price control measures that could be enacted in future legislation. While any proposed measures will require authorization through additional legislation to become effective, Congress and the current U.S. Presidential administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The Foreign Corrupt Practices Act</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party, or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">33</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. Activities that violate the FCPA, even if they occur wholly outside the United States, can result in criminal and civil fines, imprisonment, disgorgement, oversight, and suspension and debarment from government contracts, and refusal of orders under existing government contracts.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_202"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EMPLOYEES</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have 16 full-time employees as of March 1, 2020. </span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1775"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CORPORATE INFORMATION</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Histogenics was originally incorporated as a Massachusetts corporation in 2000. In 2006, Histogenics underwent a corporate reorganization pursuant to which it was incorporated as a Delaware corporation. September 27, 2019, Histogenics completed its reverse merger with Former Ocugen, in accordance with the terms of the Merger Agreement by and among Histogenics, Former Ocugen and Merger Sub, pursuant to which Merger Sub merged with and into Former Ocugen, with Former Ocugen surviving as a wholly owned subsidiary of Histogenics. Following completion of the Merger, Histogenics changed its name to Ocugen, Inc.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our principal offices are located at 5 Great Valley Parkway, Suite 160, Malvern, Pennsylvania 19355, and our telephone number is (484) 328-4701. Our website address is </span><span style="background-color:rgb(255,255,255, 0.0);color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">www.ocugen.com</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Our website and the information contained on, or that can be accessed through, our website shall not be deemed to be incorporated by reference in, and are not considered part of, this Annual Report. You should not rely on any such information in making your decision whether to purchase our common stock.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1785"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AVAILABLE INFORMATION</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We file annual, quarterly, and current reports, proxy statements, and other documents with the Securities and Exchange Commission ("SEC") under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The SEC maintains an internet website, www.sec.gov, that contains reports, proxy and information statements, and other information regarding issuers, including us, that file electronically with the SEC.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Copies of each of our filings with the SEC on Form 10-K, Form 10-Q and Form 8-K and all amendments to those reports, can be viewed and downloaded free of charge at our website, www.ocugen.com as soon as reasonably practicable after the reports and amendments are electronically filed with or furnished to the SEC.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our code of ethics, other corporate policies and procedures, and the charters of our Audit Committee, Compensation Committee and Nominating/Corporate Governance Committee are available through our website at www.ocugen.com.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_133"></div><div style="text-indent:-54pt;padding-left:54pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;1A.&#160;Risk Factors.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Financial Position and Capital Requirements</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have incurred significant losses from operations and negative cash flows from operations since our inception. We expect to incur losses over the next several years and may never achieve or maintain profitability.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since inception, we have incurred significant net losses and expects to continue to incur net losses for the foreseeable future. We have not generated any revenue to date and have funded our operations to date through the sale of common stock, warrants to purchase common stock, the issuance of convertible notes, and borrowings under credit facilities. We incurred net losses of approximately $20.2 million for the year ended December 31, 2019, and $18.2 million for the year ended December 31, 2018. As of December&#160;31, 2019, we had an accumulated deficit of $51.5 million and a cash, cash equivalents and restricted cash balance of $7.6 million.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To date, we have not commercialized any products or generated any revenues from the sale of products, and absent the realization of sufficient revenues from product sales, if any, of our current or future product candidates, if approved, we may never attain profitability in the future. To date, we have devoted substantially all of its financial resources and efforts to research and development, including preclinical studies and clinical trials. We expect that over the next several years we will continue to incur losses from operations as we increase our expenditures in research and development in connection with clinical trials and other development activities. Even if we obtain regulatory approval to market a product candidate, our future revenues will depend upon the size of any markets in which our product candidates have received approval, and our ability to </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">34</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">achieve sufficient market acceptance, reimbursement from third-party payors and adequate market share for our products in those markets.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We anticipate that our expenses will increase substantially as compared to prior periods as we complete our Phase&#160;3 trial with respect to OCU300, prepare to commence Phase&#160;1/2a trials with respect to OCU400 and OCU200, and otherwise develop and prepare for commercialization of our product candidates, as a result of increased headcount, including management personnel to support our clinical, manufacturing and commercialization activities, expanded infrastructure, increased legal, compliance, accounting and investor and public relations expenses associated with being a public company, and increased insurance premiums, among other factors.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Due to the inherently unpredictable nature of preclinical and clinical development and the numerous risks and uncertainties associated with such activities, we are unable to predict with any certainty the nature or amounts of the costs we will incur, the timelines we will require in our continued development efforts or the timing, or if, we will be able to achieve profitability. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, our expenses will also increase if, and, as we:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">continue to pursue the clinical development of OCU300, through Phase&#160;3 clinical development, particularly if we are required by the FDA, European Medicines Agency ("EMA") or other foreign regulatory agencies to perform trials or studies in addition to those currently expected;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">initiate preclinical studies and clinical trials for any additional product candidates that we may pursue in the future, particularly if there are any delays in enrollment of patients in or completing our clinical trials or the development of our product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">seek marketing approvals for product candidates that successfully complete clinical development;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">establish sales, marketing and distribution capabilities for our product candidates for which we obtain marketing approval;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">scale up our manufacturing processes and capabilities to support our clinical trials of our product candidates and commercialization of any of our product candidates for which we obtain marketing approval;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a public company;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">hire additional clinical, quality control, scientific and management personnel;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">in-license or acquire the rights to other products, product candidates or technologies;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">develop, maintain, expand and protect our intellectual property portfolio; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">increase our product liability insurance coverage as we expand our commercialization efforts.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our ability to become and remain profitable depends on our ability to generate revenue. We do not expect to generate revenue that is sufficient to achieve profitability unless and until we obtain marketing approval for and commercializes one of our product candidates. We do not expect to commercialize any of our product candidates before 2021, if ever. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become profitable or inability to remain profitable would decrease the value of the company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, continue or undertake commercialization efforts, diversify our product offerings or even continue our operations. A decline in the value of the company could also cause you to lose all or part of your investment.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our recurring operating losses have raised substantial doubt regarding our ability to continue as a going concern.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our recurring operating losses raise substantial doubt about our ability to continue as a going concern. For the year ended December 31, 2019, we had a net loss of $20.2 million and net cash used in operating activities of $16.9 million. We have no current source of revenue to sustain our present activities, and we do not expect to generate revenue until and unless we receive regulatory approval of and successfully commercialize our product candidates. These circumstances raise substantial doubt about our ability to continue as a going concern. As a result of this uncertainty and the substantial doubt about our ability to continue as a going concern as of December 31, 2019, the report of our independent registered public accounting firm in this Annual Report on Form 10-K for the years ended December 31, 2019 and 2018 includes a going concern explanatory paragraph. Our ability to continue as a going concern is dependent upon our ability to obtain additional equity or debt financing, attain further operating efficiencies, reduce expenditures and ultimately, to generate revenue by obtaining approval of our product candidates and successfully commercializing such product candidates. The perception of our ability to continue as a </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">35</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">going concern may make it more difficult for us to obtain financing for the continuation of our operations and could result in the loss of confidence by investors, suppliers and employees.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have a limited operating history and no history of commercializing pharmaceutical products, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a clinical-stage biopharmaceutical company with a limited operating history. Investment in biopharmaceutical product development is a highly speculative endeavor. Biopharmaceutical product development entails substantial upfront capital expenditures and there is significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, to gain any required regulatory approvals or to become commercially viable. To date, our operations have been limited to organizing and staffing the company, acquiring rights to intellectual property, business planning, raising capital and developing OCU300 and other product candidates. We have not yet demonstrated an ability to obtain marketing approvals, manufacture a commercial-scale product, or arrange for a third party to do so on its behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have encountered, and will continue to encounter, risks and difficulties frequently experienced by growing companies in a rapidly developing and changing industry, such as the biopharmaceutical industry, including challenges in forecasting accuracy, determining appropriate investments of our limited resources, gaining market acceptance of our products, if approved, including those created using our modifier gene therapy platform, managing a complex regulatory landscape and developing new product candidates. Our current operating model may require changes in order for us to scale our operations efficiently. We will need to transition from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition. You should consider our business and prospects in light of the risks and difficulties we face as an early-stage company focused on developing products in the fields of biopharmaceuticals and biotechnology.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect our financial condition and operating results to fluctuate significantly from quarter-to-quarter and year-to-year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect to devote substantial financial resources to our ongoing and planned product development activities, particularly as we conduct multiple clinical trials and, assuming positive results from these trials, seek marketing approval for OCU300 and continue the development of and potentially seek marketing approval for other clinical and preclinical product candidates, including OCU400, OCU410 and OCU200. As of December&#160;31, 2019, we had cash, cash equivalents and restricted cash of approximately $7.6 million. We believe that our cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements through mid-2020. However, we have based this estimate on assumptions that may prove to be wrong, and our operating plan may change as a result of many factors currently unknown to us. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete. We may never generate the necessary data or results required to obtain regulatory approval of products with the market potential sufficient to enable us to achieve profitability. We do not expect to generate revenue from sales of any product candidates until at least 2021, if at all. Accordingly, we may need to obtain substantial additional funding in connection with our continuing operations. Our future capital requirements will depend on many factors, including:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the progress, costs and results of our Phase&#160;3 clinical trial for OCU300, any clinical trials for our preclinical product candidates, and any clinical activities for regulatory review of OCU300 or our other product candidates outside of the United States;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the costs and timing of process development and manufacturing scale-up activities associated with OCU300 and its preclinical product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the costs, timing and outcome of regulatory review of OCU300 and our preclinical product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the costs of commercialization activities for OCU300 or our preclinical product candidates if we receive, or expect to receive, marketing approval, including the costs and timing of establishing product sales, marketing, distribution and outsourced manufacturing capabilities;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">36</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">subject to receipt of marketing approval, revenue received from commercial sales of OCU300 or our preclinical product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to establish and maintain strategic collaborations, licensing or other agreements and the financial terms of such agreements;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the scope, progress, results and costs of any product candidates that we may derive from its OcuNanoE&#8482;&#160;program or any other product candidates that we may develop;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the extent to which we in-license or acquire rights to other products, product candidates or technologies; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against any intellectual property-related claims.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. Moreover, adequate additional financing may not be available to us on acceptable terms, or at all. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities for one or more of our product candidates or delay, limit, reduce or terminate our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize our product candidates.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Raising additional capital may cause dilution to stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and marketing and distribution arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we raise additional funds through collaborations, strategic alliances, licensing arrangements or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. Such arrangements may require us to grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market on our own.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our existing and future indebtedness may limit cash flow available to invest in the ongoing needs of our business.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, we had $1.0 million of outstanding principal borrowings under a Loan Agreement (the "EB-5 Loan Agreement") with EB5 Life Sciences, L.P. (the "Lender"), which we are required to repay on the seventh anniversary of the date of the last disbursement under the EB-5 Loan Agreement (unless terminated earlier pursuant to the terms of the EB-5 Loan Agreement). On March&#160;26, 2020, we borrowed an additional $0.5&#160;million under the terms and conditions of the EB-5 Loan Agreement. We are also eligible to borrow an additional $9.0 million under the EB-5 Loan Agreement, limited by the amount of funds raised by the Lender and subject to availability under the program and certain job creation requirements by it. Our obligations under this agreement are secured by substantially all of our assets other than our intellectual property. We could in the future incur additional indebtedness beyond our borrowings under the EB-5 Loan Agreement.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our existing or future debt could have significant adverse consequences, including:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">requiring us to dedicate a substantial portion of cash flow from operations or cash on hand to the payment of interest on, and principal of, our debt, which will reduce the amounts available to fund working capital, capital expenditures, product development efforts and other general corporate purposes;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">increasing our vulnerability to adverse changes in general economic, industry and market conditions;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">subjecting us to restrictive covenants that may reduce our ability to take certain corporate actions or obtain further debt or equity financing (for instance, the EB-5 Loan Agreement includes restrictive covenants related to, among other things, the disposition of our property, the incurrence by us of any additional indebtedness and the creation by us of any liens or other encumbrances);</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">limiting our flexibility in planning for, or reacting to, changes in our business and our industry; and</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">37</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">placing us at a competitive disadvantage compared to our competitors that have less debt or better debt servicing options.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We intend to satisfy our current and future debt service obligations with our existing cash and funds from external sources. Nonetheless, we may not have sufficient funds or may be unable to arrange for additional financing to pay the amounts due under our existing debt. Funds from external sources may not be available on acceptable terms, if at all. In addition, a failure to comply with the covenants under the EB-5 Loan Agreement, including covenants to take or avoid specific actions as set forth above, could result in an event of default and acceleration of amounts due. If an event of default occurs and the Lender accelerates the amounts due under the EB-5 Loan Agreement, we may not be able to make accelerated payments, and the Lender could seek to enforce security interests in the collateral securing such indebtedness.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to use carryforward tax losses or benefit from favorable tax legislation to reduce our taxes, our business, results of operations and financial condition may be adversely affected.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have incurred significant net operating losses since our inception. As of December&#160;31, 2019, we had federal and U.S. state net operating loss carryforwards of approximately $113.6 million and $112.4 million, respectively. If we are unable to use carryforward tax losses to reduce our future taxable income and liabilities in our business, results of operations and financial condition may be adversely affected.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under Section 382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change,&#8221; which will occur if there is a cumulative change in ownership by &#8220;5-percent shareholders&#8221; that exceeds 50 percentage points over a rolling three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income may be limited. A corporation that experiences an ownership change will generally be subject to an annual limitation on the use of its pre-ownership change net operating losses equal to the value of the corporation immediately before the ownership change, multiplied by the long-term tax-exempt rate (subject to certain adjustments). The annual limitation for a taxable year generally is increased by the amount of any &#8220;recognized built-in gains&#8221; for such year and the amount of any unused annual limitation in a prior year. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent U.S. tax legislation may materially adversely affect our financial condition, results of operations and cash flows.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Recently-enacted U.S. tax legislation has significantly changed the U.S. federal income taxation of U.S. corporations, including by reducing the U.S. corporate income tax rate, limiting interest deductions, modifying or repealing many business deductions and credits (including reducing the business tax credit for certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions generally referred to as &#8220;orphan drugs&#8221;), adopting elements of a territorial tax system, imposing a one-time transition tax, or repatriation tax, on all undistributed earnings and profits of certain U.S.-owned foreign corporations, revising the rules governing net operating losses and the rules governing foreign tax credits, and introducing new anti-base erosion provisions. Many of these changes are effective immediately, without any transition periods or grandfathering for existing transactions. The legislation is unclear in many respects and could be subject to potential amendments and technical corrections, as well as interpretations and implementing regulations by the Treasury and Internal Revenue Service, any of which could lessen or increase certain adverse impacts of the legislation. In addition, it is unclear how these U.S. federal income tax changes will affect state and local taxation, which often uses federal taxable income as a starting point for computing state and local tax liabilities.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While some of the changes made by the tax legislation may adversely affect us in one or more reporting periods and prospectively, other changes may be beneficial on a going forward basis. We continue to work with our tax advisors and auditors to determine the full impact that the recent tax legislation as a whole will have on us. We urge our investors to consult with their legal and tax advisors with respect to such legislation.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Business and the Development of Our Product Candidates</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are substantially dependent on the success of our product candidates and, in particular, our lead product candidate, OCU300. We cannot guarantee that our product candidates will successfully complete development, receive regulatory approval, or be successfully commercialized.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have invested a significant portion of our efforts and financial resources in the development of our product candidates. Notwithstanding such investment, we currently have no products approved for commercial distribution and we generate no revenues from sales of any products. Our business and our ability to generate revenues in the near term depends entirely on the successful development and commercialization of our product candidates, which may never occur. Our product candidates are </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">38</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">susceptible to the risks of failure inherent at any stage of product development, including the appearance of unexpected or unacceptable adverse events or failure to demonstrate efficacy in clinical trials. Further, our product candidates may not receive regulatory approval even if they are successful in clinical trials, and our product candidates may not be successfully commercialized even if they receive regulatory approval.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently have limited experience with our product candidates. We have advanced only one product candidate, OCU300, a small molecule therapeutic currently in Phase 3 clinical development for patients with oGVHD, beyond the preclinical development stage. All of our other product candidates are in early stages of development. Accordingly, our ability to generate product revenues in the near term will depend almost entirely on our ability to successfully obtain marketing approval for and commercialize OCU300. As of March&#160;20, 2020, the ongoing Phase 3 trials for OCU300, in which we anticipate 60 patients will be randomized in a 2:1 ratio to receive either OCU300 (brimonidine 0.18% nanoemulsion) or a placebo, has completed over 95% of our planned enrollment. We cannot assure you that we will meet our timelines for the Phase 3 clinical trials for OCU300 or for any of our other anticipated clinical trials, which may be delayed or not completed for a number of reasons.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The success of our product candidates and our ability to generate revenues from our product candidates will depend on many factors including our ability to:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">complete and obtain favorable results from our clinical and preclinical trials with respect to our product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">apply for and receive marketing approval from the applicable regulatory authorities;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">receive regulatory approval for claims that are necessary or desirable for successful marketing;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">receive approval for our manufacturing processes and third-party manufacturing facilities from the applicable regulatory authorities;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">recruit and enroll qualified patients for clinical trials with respect to our product candidates in a timely manner;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">expand and maintain a workforce of experienced scientists and others with experience in the relevant technology to continue to develop our product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">hire, train, and deploy marketing and sales representatives or contract with a third-party for marketing and sales representatives to commercialize product candidates in the United States;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">launch and create market demand for our product candidates through marketing and sales activities, and any other arrangements to promote these product candidates that we may otherwise establish;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">achieve market acceptance of our product candidates by patients, the medical community and third-party payors;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">effectively compete with other therapies and establish a market share;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">maintain a continued acceptable safety and efficacy profile of our product candidates following commercial launch;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">achieve appropriate reimbursement, pricing, and payment coverage for our product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">manufacture product candidates in sufficient quantities and at acceptable quality and manufacturing cost to meet commercial demand at launch and thereafter;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">establish and maintain agreements with wholesalers, distributors, and group purchasing organizations on commercially reasonable terms;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">pursue partnerships with, or offer licenses to, qualified third parties to promote and sell product candidates in domestic and key foreign markets where we receive marketing approval;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">develop our product candidates for additional indications or for use in broader patient populations;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">maintain patent and trade secret protection and regulatory exclusivity for our product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">qualify for, identify, register, maintain, enforce and defend intellectual property rights and claims covering our products and intellectual property portfolio; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">not infringe on others&#8217; intellectual property rights.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To the extent we are not able to do any of the foregoing, our business may be materially harmed. If we do not receive FDA approval for, and successfully commercialize our product candidates, we will not be able to generate revenue from these product candidates in the United States in the foreseeable future or at all.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">39</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our product candidates as expected, and our ability to generate revenue will be materially impaired.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The research, testing, manufacturing, labeling, approval, selling, marketing and distribution of pharmaceutical products are subject to extensive regulation by the FDA and other regulatory authorities, which regulations differ from country to country. The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials. The outcome of the approval process is inherently uncertain and depends upon numerous factors, including the substantial discretion of the regulatory authorities. This is especially true for rare and/or complicated diseases. Failure can occur at any time during the clinical trial process. We cannot predict if or when we might receive regulatory approvals for any of our product candidates currently under development. Any delay in our obtaining or our failure to obtain required approvals could materially adversely affect our ability to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact our stock price.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy for that indication. We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities and clinical trial sites by the regulatory authorities. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. The number and types of preclinical studies and clinical trials that will be required for regulatory approval also varies depending on the product candidate, the disease or condition that the product candidate is designed to address, and the regulations applicable to any particular product candidate. The FDA or other similar regulatory authorities may determine that our product candidates are not effective or only moderately effective (e.g., studies may not produce the necessary result on all study endpoints), that our studies failed to reach the necessary level of statistical significance, or that our product candidates have undesirable or unintended side effects, toxicities or other characteristics that preclude us from obtaining marketing approval or prevent or limit commercial use.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our Phase 3 clinical program for OCU300 consists of two clinical trials evaluating OCU300. As of March&#160;20, 2020, we achieved over 95% of planned enrollment of 60 patients in the first trial. We expect that we will be required to demonstrate effectiveness of both of the co-primary endpoints for marketing approval of OCU300 for the indication of treatment of ocular redness and discomfort in patients with oGVHD. However, the timing of the completion of the Phase 3 clinical trials for OCU300 is dependent, in part, on our ability to locate and enroll a sufficient number of eligible patients on a timely basis, as well as a sample size re-estimation based on data from the first approximately 50% of the planned sample size of 60 patients. If, moreover, OCU300 does not achieve statistical significance in both primary endpoints in our Phase 3 clinical trials, the FDA may require us to conduct additional clinical trials to support the approval of our proposed indications.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. If such changes occur, we may be required to amend our clinical trial protocols, conduct additional studies that require regulatory or IRB approval, or such changes may otherwise cause delays in the approval of an application. If we are required to conduct additional clinical trials or other testing of our product candidates that we develop beyond those that we currently expect, we may be delayed in obtaining marketing approval for our product candidates, or not obtain marketing approval at all.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may also experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">regulators, including the FDA and the NIH, or IRBs or IBCs may not authorize us or our investigators to commence or continue a clinical trial, conduct a clinical trial at a prospective trial site, or amend trial protocols, or regulators,&#160;IRBs or IBCs may require that we modify or amend our clinical trial protocols;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites and our CROs;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or participants may drop out of these clinical trials or be lost to follow-up at a higher rate than we anticipate. By example, the Phase 1/2 clinical study of brimonidine tartrate in patients with oGVHD was discontinued early due to slow enrollment;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">40</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our third-party contractors may fail to comply with regulatory requirements or the clinical trial protocol, or meet their contractual obligations to us in a timely manner, or at all, or we may be required to engage in additional clinical trial site monitoring;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">us, the regulators,&#160;IRBs or IBCs may require the suspension or termination of clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks, undesirable side effects, or other unexpected characteristics (alone or in combination with other products) of the product candidate, or due to findings of undesirable effects caused by a chemically or mechanistically similar therapeutic or therapeutic candidate;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">changes in marketing approval policies during the development period rendering our data insufficient to obtain marketing approval;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">changes in or the enactment of additional statutes or regulations;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the cost of clinical trials of our product candidates may be greater than we anticipate or we may have insufficient funds for a clinical trial or to pay the substantial user fees required by the FDA upon the filing of a marketing application;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">we may fail to reach an agreement with regulators,&#160;IRBs or IBCs regarding the scope, design, or implementation of our clinical trials. For instance, the FDA or comparable foreign regulatory authorities may require changes to our study design that make further study impractical or not financially prudent;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">we may have delays in adding new investigators or clinical trial sites, or we may experience a withdrawal of clinical trial sites;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">patients that enroll in our studies may misrepresent their eligibility or may otherwise not comply with the clinical trial protocol, resulting in the need to drop the patients from the study, increase the needed enrollment size for the study or extend the study&#8217;s duration;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">there may be regulatory questions or disagreements regarding interpretations of data and results, or new information may emerge regarding our product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the FDA or comparable foreign regulatory authorities may disagree with our study design, including endpoints, or our interpretation of data from preclinical studies and clinical trials or find that a product candidate&#8217;s benefits do not outweigh its safety risks;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the FDA or comparable foreign regulatory authorities may not accept data from studies with clinical trial sites in foreign countries;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the FDA or comparable foreign regulatory authorities may disagree with our intended indications;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the FDA or comparable foreign regulatory authorities may fail to approve or subsequently find fault with the manufacturing processes or our contract manufacturer&#8217;s manufacturing facility for clinical and future commercial supplies;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a marketing application, or other comparable submissions in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the FDA or comparable foreign regulatory authorities may take longer than we anticipate to make a decision on its product candidates; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">we may not be able to demonstrate that a product candidate provides an advantage over current standards of care or current or future competitive therapies in development.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Significant delays relating to any preclinical or clinical trials also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do. This may prevent us from receiving marketing approvals and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. In addition, many of the factors that cause, or lead to, delays in clinical trials may ultimately lead to the denial of marketing approval of any of our product candidates. If any of this occurs, our business, financial condition, results of operations, and prospects will be materially harmed.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">41</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The failure to comply with FDA and comparable foreign regulatory requirements may, either before or after product approval, if any, subject us to administrative or judicially imposed sanctions, including:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials&#894;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">restrictions on our products, manufacturers or manufacturing process&#894;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">warning letters or untitled letters alleging violations&#894;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">civil and criminal penalties&#894;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">injunctions&#894;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">suspension or withdrawal of regulatory approvals&#894;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">product seizures, detentions or import bans&#894;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">voluntary or mandatory product recalls and publicity requirements&#894;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">total or partial suspension of production&#894;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">imposition of restrictions on operations, including costly new manufacturing requirements&#894; and</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">refusal to approve pending marketing applications or supplements to approved marketing applications.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if we were to obtain regulatory approval of a product candidate, the FDA or comparable foreign regulatory authorities may grant approval for fewer or more limited indications, populations, or uses than we request, may require significant safety warnings, including black box warnings, contraindications, and precautions, may grant approval contingent on the performance of costly post-marketing clinical trials, surveillance, restrictions on use or other requirements, including a REMS to monitor the safety or efficacy of the product, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of these scenarios could compromise the commercial prospects for our product candidates.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we experience delays in obtaining approval, our ability to generate revenues from that product candidate will be materially impaired. If we fail to obtain marketing approval for a product candidate, we will be prevented from commercializing the product candidate.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our business may be adversely affected by the Coronavirus pandemic.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, a novel strain of coronavirus, or COVID-19, was reported to have surfaced in Wuhan, China. As of March 2020, COVID-19 has spread to other countries, including the United States, and has been declared to be a pandemic by the World Health Organization. The United States has declared a National Emergency and efforts to contain the spread of COVID-19 have intensified, including severe travel restrictions imposed by the U.S. government related to China and Europe. The outbreak and any preventative or protective actions that we, our suppliers, our licensors and other collaborators or governments may take in respect of this coronavirus may disrupt our business. We are diligently working to ensure that we can operate with minimal disruption, and to mitigate the impact of the outbreak on our employees&#8217; health and safety. However, given the interconnectivity of the global economy and the possible rate of future global transmission, the full extent to which the coronavirus pandemic could affect the global economy is unknown and its impact may extend beyond the areas which are currently known to be impacted. Any resulting financial impact will depend on future developments and cannot be reasonably estimated at this time, but may materially affect our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">COVID-19 has and may continue to have an impact on ports and trade into and out of China and Hong Kong, as well as travel in the region and globally. We currently rely on CanSinoBIO, which is headquartered in Tianjin, China, for CMC development and manufacturing of clinical supplies for our gene therapy candidate, OCU400. Accordingly, there is a risk that supplies of OCU400 may be significantly delayed or may become unavailable as a result of COVID-19 and the resulting impact on CanSinoBIO&#8217;s labor force and operations and its ability to obtain the materials required for the manufacture of our clinical supplies, including impacts resulting from the Chinese government&#8217;s imposition of certain restrictions on business operations and the movement of people and goods in an effort to curtail the spread of the virus. There can be no assurance that we would be able to timely locate an alternative supplier or otherwise successfully implement any mitigation plans. Disruptions in our operations or supply chain, whether as a result of restricted travel, quarantine requirements or otherwise, could negatively impact our ability to proceed with our clinical trials, preclinical development and other activities and delay our ability to receive product approval and generate revenue. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">42</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, our ongoing clinical trials for OCU300 may be affected by the COVID-19 outbreak. Clinical site initiation, patient enrollment and recruitment of clinical site investigators and staff at hospitals and medical institutions may be delayed due to prioritization of healthcare resources, such as physicians and staff, toward the COVID-19 outbreak. As COVID-19 has become a worldwide pandemic, it may delay enrollment in our clinical trials, and some patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Moreover, limitations on global international travel may interrupt key trial activities, including necessary interactions with regulators, ethics committees and other important agencies and contractors. We may be faced with limitations in employee resources that would otherwise be focused on the conduct of clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people. Any of the above could delay our clinical trials for OCU300 or prevent us from completing these clinical trials at all, and harm our ability to obtain approval for OCU300.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the continued spread of COVID-19 has led to severe disruption and volatility in the global capital markets, which could increase our cost of capital and adversely affect our ability to access the capital markets. It is possible that the continued spread of COVID-19 could cause an economic slowdown or recession or cause other unpredictable events, each of which could adversely affect our business, results of operations or financial condition.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. The extent to which the coronavirus impacts our results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the coronavirus, the ultimate geographic spread of the coronavirus, the duration of the outbreak, travel restrictions imposed by the United States and other countries, business closures or business disruption in the United States and other countries, a reduction in time spent out of home and the actions taken throughout the world, including in our markets, to contain the coronavirus or treat its impact. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, our preclinical development efforts, healthcare systems or the global economy as a whole. However, these effects could have a material impact on our operations, and we will continue to monitor the COVID-19 situation closely.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Data from preclinical studies and early stage clinical trials may not be predictive of success in later clinical trials.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The results of preclinical studies, preliminary study results, and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials or the ultimately completed trial. Preliminary and final results from such studies may not be representative of study results that are found in larger, controlled, blinded, and more long-term studies. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. A number of companies have suffered significant setbacks in advanced clinical trials, notwithstanding promising results in earlier trials. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, from time to time, we may publish interim, &#8220;top-line,&#8221; initial, or preliminary data from our clinical studies. Interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data becomes available. Preliminary, initial, or &#8220;top-line&#8221; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data previously published. As a result, interim, &#8220;top-line&#8221;, initial, and preliminary data should be viewed with caution until the final data are available. Adverse changes between preliminary, initial, &#8220;top-line&#8221; or interim data and final data could significantly harm our business prospects.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">With respect to OCU300, we have not conducted any clinical studies specifically with our proprietary nanoemulsion technology in patients with oGVHD. The formulation used in previous clinical studies conducted in patients with oGVHD is different from our proposed OCU300 nanoemulsion. The different formulation may impact the final Phase 3 clinical study results for OCU300. We have evaluated results from an investigator-led retrospective analyses of the use of brimonidine tartrate 0.15% eye drops in patients with oGVHD and an investigator-led prospective Phase 1/2 clinical trial assessing the use of 0.15% and 0.075% brimonidine tartrate eye drops in patients with oGVHD. The formulations used in these studies are different than our proposed OCU300 formulation. These studies and results are not sufficient to establish the safety and efficacy of OCU300 and the results from these studies should be viewed with caution. Additionally, these clinical studies were not powered for statistical significance due to their small sample size and the Phase 1/2 clinical study was discontinued early due to slow enrollment. These studies may not be predictive of the results of later studies conducted with the OCU300 formulation for which we intend to seek marketing approval. Moreover, although a dose ranging study was recommended but not required by FDA, we do not intend to conduct such a study and have proceeded directly into Phase 3 clinical trials. We cannot provide any assurance that </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">43</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the results of our ongoing and future clinical trials will reflect favorable results obtained in prior preclinical studies or clinical trials.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The development and manufacture of biologics is a complex process and entails particular risks.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">OCU200, our product candidate currently in preclinical development, is a novel biologic designed to treat retinal diseases. The process of developing and manufacturing biologics is complex, highly regulated and subject to multiple risks, and we have no experience in successfully developing, manufacturing or commercializing a biologics product. The manufacturing of biologics is highly susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions and higher costs. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The raw materials required in our third-party vendors&#8217; manufacturing processes are derived from biological sources. We cannot assure you that our third-party vendors have, or will be able to obtain on commercially reasonable terms, or at all, sufficient rights to these materials derived from biological sources. Such raw materials are difficult to procure and may also be subject to contamination or recall. If microbial, viral or other contaminations are discovered at the facilities of our manufacturer, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials, result in higher costs of drug product and adversely harm our business. A material shortage, recall, or restriction on the use of biologically derived substances in the manufacture of our product candidates could adversely impact or disrupt the clinical and commercial manufacturing of our product candidates, which could materially and adversely affect our operating results and development timelines.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, our biologics product candidates may expose us to additional potential product liability claims. The development of biologics products entails a risk of additional product liability claims because of the risk of transmitting disease to human recipients, and substantial product liability claims may be asserted against us as a result.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not be successful in our efforts to develop product candidates based on our OcuNanoE</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">&#8482;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> nanoemulsion formulation or expand the use of our OcuNanoE</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">&#8482;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> nanoemulsion formulation for treating additional diseases and conditions.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are currently directing some of our development efforts towards developing product candidates, including our lead product candidate, OCU300, based on our proprietary OcuNanoE&#8482; nanoemulsion formulation. We are the first company to use nanoemulsion technology in the ophthalmology space. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect to apply its OcuNanoE&#8482; nanoemulsion formulation to support therapeutic interventions of other ocular diseases with the potential of improving the tear film stability and targeting of drug molecules to the specialized tissues. We have product candidates at various stages of development for treatment of eye diseases and are exploring the potential use of our OcuNanoE&#8482; nanoemulsion formulation in other diseases. Our existing product candidates and any other potential product candidates that we identify may not be suitable for continued preclinical or clinical development, including as a result of being shown to have harmful side effects, a lack of efficacy or other characteristics that indicate that such product candidates are unlikely to be products that will receive marketing approval and achieve market acceptance.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we do not successfully develop and commercialize our product candidates based upon our OcuNanoE&#8482; nanoemulsion formulation, we may not be able to obtain substantial product revenues in future periods.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our product candidates generated from our modifier gene therapy platform are based on a novel technology and face an uncertain regulatory environment, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We anticipate that some of our product research and development efforts will be centered around our modifier gene therapy platform. The regulatory approval and successful commercialization of product candidates such as OCU400, a gene therapy designed to treat </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">NR2E3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> mutation-associated retinal degenerative disease and other IRDs, depend on the successful development of this platform. There can be no assurance that any development problems we experience in the future related to our modifier gene therapy platform will not cause significant delays or unanticipated costs, or that such development problems can be solved. The clinical trial requirements of the FDA, the EMA and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of such product candidates. The regulatory approval process for novel product candidates </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">44</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">such as OCU400 can be more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Regulatory requirements governing gene and cell therapy products have changed frequently and may continue to change in the future. For example, the FDA established the Office of Tissues and Advanced Therapies within its Center for Biologics Evaluation and Research (&#8220;CBER&#8221;) to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. Gene therapy clinical trials conducted at institutions that receive funding for recombinant DNA research from the United States NIH, are also subject to review by the NIH Novel and Exceptional Technology and Research Advisory Committee (&#8220;NExTRAC&#8221;), formerly the Recombinant DNA Advisory Committee, which now focuses on emerging areas of research including, but not restricted to, technologies surrounding advances in recombinant or synthetic nucleic acid research. Although the FDA decides whether individual gene therapy protocols may proceed, it is possible the NExTRAC review process, which is still being implemented, could delay the initiation of a clinical trial, even if the FDA has reviewed the trial design and details and approved its initiation. Before a clinical trial can begin at a study site, that the institution&#8217;s IRB, and its IBC, have to review the proposed clinical trial to assess the safety of the trial. In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other regulatory bodies to change the requirements for approval of any of our product candidates.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These regulatory review committees and advisory groups and the new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As we advance our gene therapy product candidates, we will be required to consult with these regulatory and advisory groups, and comply with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of our gene therapy product candidates. These additional processes may result in a review and approval process that is longer than we otherwise would have expected for orphan ophthalmology product candidates. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue to maintain our business.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Existing data on the safety and efficacy of gene therapy is very limited and sometimes include historically poor clinical efficacy of previous non-replicating gene therapy products. In addition, there have been publicized safety issues associated with previous gene therapy products in third-party clinical trials, including patient deaths. The results of preclinical and clinical trials performed for our product candidates will not definitively predict safety or efficacy in humans. OCU400 uses an adeno-associated virus vector. Possible serious side effects of other viral vector-based gene therapies in general include uncontrolled viral infections and the development of cancer, particularly lymphoma or leukemia. The risk of insertional mutagenesis or oncogenesis remains a significant concern for gene therapy, and we cannot provide any assurance that it will not occur in any of our planned or future clinical trials with respect to our product candidates based on our modifier gene therapy platform. There is also the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biological activity of the genetic material or other components of products used to carry the genetic material. Potential procedure-related adverse reactions, including inflammation, can also occur. If any such adverse events occur during clinical trials, further advancement of such clinical trials could be halted or delayed, which would have a material adverse effect on our business and operations.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The FDA may determine that our product candidates have undesirable side effects that could delay or prevent their regulatory approval or commercialization. If such side effects are identified during the development of our product candidates, we may need to abandon our development of such product candidates.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Undesirable side effects caused by our product candidates could cause us,&#160;IRBs, and other reviewing entities or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. For example, if concerns are raised regarding the safety of one of our product candidates as a result of undesirable side effects identified during clinical or preclinical testing, the FDA may order us to cease further development or issue a letter requesting additional data or information prior to making a final decision regarding whether or not to approve the product candidate. FDA requests for additional data or information can result in substantial delays in the approval of a new product candidate.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Undesirable side effects caused by or any unexpected characteristics (alone or in combination with other products) for any of our product candidates could also result in denial of regulatory approval by the FDA or other comparable foreign authorities for any or all targeted indications or the inclusion of unfavorable information in our product labeling, such as limitations on the indicated uses or populations for which the products may be marketed or distributed, a label with significant safety warnings, including boxed warnings, contraindications, and precautions, a label without statements necessary or desirable for successful commercialization, or may result in requirements for costly post-marketing testing and surveillance, or other requirements, </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">45</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">including REMS, to monitor the safety or efficacy of the products. These could prevent us from commercializing and generating revenues from the sale of our product candidates.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many compounds that initially showed promise in clinical or earlier stage testing have later been found to cause side effects that prevented further development of the compound. In addition, adverse events which had initially been considered unrelated to the study treatment may later be found to be caused by the study treatment. Moreover, incorrect or improper use of our product candidates (including use more frequently than is prescribed) by patients could cause unexpected side effects or adverse events. There can be no assurance that our product candidates will be used correctly, and if used incorrectly, such misuse could prevent its receipt or maintenance of marketing authorization, resulting in label changes or regulatory authority safety communications or warnings, or hamper commercial adoption of our product candidate, if approved, at the rate we currently expect.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While there have been a few adverse events that have occurred in the investigator-led clinical studies of brimonidine tartrate for the treatment of ocular redness and discomfort in patients with oGVHD, overall brimonidine tartrate was well-tolerated. We do not have any studies exploring long term exposure in these patient populations to brimonidine tartrate or our product candidates. Our understanding of the relationship between our product candidates and any adverse effects may change as we gather more information, and unexpected adverse effects, including serious adverse effects, may occur. We also do not have any studies demonstrating the safety profile of our other planned product candidates, which are currently in preclinical development.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If any of our product candidates are associated with serious adverse events or undesirable side effects or have properties that are unexpected, we may need to abandon development or limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. The therapeutic-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. We may also be held liable for harm caused to patients and our reputation may suffer. Any of these occurrences may significantly harm our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we experiences delays or difficulties in the enrollment of patients in clinical trials, our completion of clinical trials and receipt of necessary regulatory approvals could be delayed or prevented.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timing of our clinical trials depends on the speed at which we can recruit patients to participate in testing our product candidates. Our Phase 1/2 clinical study examining the use of brimonidine tartrate eye drops in patients with oGVHD was discontinued early due to slow enrollment, and we may experience similar difficulties in the future. If patients are unwilling to participate in our clinical trials because of negative publicity from adverse events in the industry or in the trials for other third party product candidates, or for other reasons, including competitive clinical trials for similar patient populations, the timeline for recruiting patients, conducting studies and obtaining regulatory approval of potential products may be delayed. These delays could result in increased costs, delays in advancing our product development, delays in testing the effectiveness of our product candidates or termination of the clinical trials altogether.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We or our clinical trial sites may not be able to identify, recruit and enroll a sufficient number of patients, or those with the required or desired characteristics in a clinical trial, to complete our clinical trials in a timely manner. Patient enrollment is affected by other factors including:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the size and nature of the patient population (for instance, we are pursuing clinical trials for certain orphan indications, for which the size of the patient population is limited);</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the severity of the disease under investigation;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the existence of current treatments for the indications for which we are conducting clinical trials;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the eligibility criteria for and design of the clinical trial in question, including factors such as frequency of required assessments, length of the study and ongoing monitoring requirements;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the perceived risks and benefits of the product candidate, including the potential advantages or disadvantages of the product candidate being studied in relation to other available therapies (for instance, novel therapies such as those involving our modifier gene therapy platform may suffer from negative publicity due to adverse events or other reasons);</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">competition in recruiting and enrolling patients in clinical trials;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">efforts to facilitate timely enrollment in clinical trials;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">46</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">patient referral practices of physicians;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">effectiveness of publicity created by clinical trial sites regarding the trial;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">patients&#8217; ability to comply with the specific instructions related to the trial protocol, proper documentation, and use of the product candidate;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">an inability to obtain or maintain patient informed consents;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the risk that enrolled patients will drop out before completion or not return for post-treatment follow-up;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the ability to monitor patients adequately during and after treatment;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the ability to compensate patients for their time and effort; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the proximity and availability of clinical trial sites for prospective patients.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may not be able to initiate or continue conducting clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. In particular, there may be low or slow enrollment, and the studies may enroll subjects that do not meet the inclusion criteria, requiring the erroneously enrolled subjects to be excluded and the trial population to be increased. Moreover, patients in our clinical trials, especially patients in our control groups, may be at risk for dropping out of our studies if they are not experiencing relief of their disease. A significant number of withdrawn patients would compromise the quality of a study's data.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Enrollment difficulties or delays in our clinical trials may result in increased development costs for our product candidates, or the inability to complete development of our product candidates, which would cause our value to decline, limit our ability to obtain additional financing, and materially impair our ability to generate revenues.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our development and commercialization strategy for OCU300 depends, in part, on published scientific literature and the FDA&#8217;s prior findings regarding the safety and efficacy of approved products. If we are not able to pursue this strategy, we will need to conduct additional development activities beyond what we currently plan, our development costs will increase, and we may be delayed in receiving regulatory authority approval. The submission of 505(b)(2)&#160;New Drug Applications may also subject us to the risk of patent infringement lawsuits or regulatory actions that would delay or prevent our submission of a marketing application to the FDA, or the FDA&#8217;s review and approval of our marketing applications.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Hatch-Waxman Act added Section&#160;505(b)(2)&#160;to the FDCA. Section&#160;505(b)(2)&#160;permits the filing of an NDA, where at least some of the information required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. The FDA interprets Section&#160;505(b)(2)&#160;of the FDCA, for purposes of approving an NDA, to permit the applicant to rely, in part, upon published literature and/or the FDA&#8217;s previous findings of safety and efficacy for an approved product. The FDA also requires companies to perform additional clinical trials or measurements to support any deviation from the previously approved product and to support the reliance on the applicable published literature or referenced product, referred to as bridging. The FDA may then approve the new product candidate for all or some of the label indications for which the referenced product has been approved, as well as for any new indication sought by the Section&#160;505(b)(2)&#160;applicant, if such approval is supported by study data. The label, however, may require all or some of the limitations, contraindications, warnings or precautions or restrictions on use included in the reference product&#8217;s label, including a black box warning, or may require additional limitations, contraindications, warnings or precautions or restrictions on use.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently plan to pursue marketing approval for OCU300 in the United States through 505(b)(2)&#160;NDAs and will be completing bridging analyses prior to NDA submission. If the FDA disagrees with our conclusions regarding the appropriateness of our reliance on a reference listed drug or published literature or if we are not otherwise able to bridge to the reference listed drug or published literature to demonstrate that our reliance is scientifically appropriate, we could be required to conduct additional clinical trials or other studies to support our NDA, which could lead to unanticipated costs and delays or to the termination of our development program. If we are unable to obtain approval for our pharmaceutical formulations through the 505(b)(2)&#160;NDA process, we may be required to pursue the more expensive and time consuming 505(b)(1)&#160;approval process, which consists of full reports of investigations of safety and effectiveness conducted by or for the applicant.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There may also be circumstances under which the FDA would not allow us to pursue a 505(b)(2)&#160;application. For instance, should the FDA approve a pharmaceutically equivalent product to our product candidates, we would no longer be able to use the 505(b)(2)&#160;regulatory pathway. In that case, it is the FDA&#8217;s policy that the appropriate submission would be an ANDA, for a </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">47</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">generic version of the approved product. We may, however, not be able to immediately submit an ANDA or have an ANDA approval made effective, as we could be blocked by others&#8217; periods of patent and regulatory exclusivity protection.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Notwithstanding the approval of a number of products by the FDA under Section&#160;505(b)(2), pharmaceutical companies and others have objected to the FDA&#8217;s interpretation of Section&#160;505(b)(2). If the FDA&#8217;s interpretation of Section&#160;505(b)(2)&#160;is successfully challenged, the FDA may change our policies and practices with respect to Section&#160;505(b)(2)&#160;regulatory approvals, which could delay or even prevent the FDA from approving any NDA that we submit pursuant to the 505(b)(2)&#160;process. It is also not uncommon for a sponsor of an approved product to file&#160;a citizen petition with the FDA seeking to delay approval of, or impose additional approval requirements for, pending competing products. If successful, such petitions can significantly delay, or even prevent, the approval of the new product. However, even if the FDA ultimately denies such a petition, the FDA may substantially delay approval while it considers and responds to the petition.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we cannot seek approval for OCU300 through the 505(b)(2)&#160;regulatory pathway, we may need to conduct additional clinical trials, provide additional data and information and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required to obtain FDA approval for OCU300, and the complications and risks associated with approval of OCU300, would likely substantially increase. Even if we are allowed to pursue the 505(b)(2)&#160;regulatory pathway to FDA approval, we cannot assure you that OCU300 will receive the requisite approvals for commercialization. Moreover, our inability to pursue a 505(b)(2)&#160;application could result in new competitive products reaching the market more quickly than our product candidates, which could hurt our competitive position and our business prospects.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our use of the 505(b)(2)&#160;regulatory pathway may also subject us to the risk of patent infringement lawsuits or other regulatory actions that could prevent our submission of a marketing application for OCU300, or prevent the FDA making the approval of a marketing application effective. Applicants submitting NDAs under Section&#160;505(b)(2)&#160;of the FDCA must provide a patent certification for the patents listed in the FDA&#8217;s list of Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the Orange Book, for all reference listed drugs and for all brand name products identified in published literature upon which the 505(b)(2)&#160;application relies. The possible certifications are that (1)&#160;no patent information has been submitted to the FDA; (2)&#160;such patent has expired; (3)&#160;the date on which such patent expires; or (4)&#160;such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. If there are any listed patents for the reference listed or brand name products that we rely upon for our 505(b)(2)&#160;applications, the FDA may not approve our 505(b)(2)&#160;product candidates until all listed patents have expired, unless we challenge the listed patents through the last type of certification, also known as a paragraph&#160;IV certification, or otherwise indicates that we are not seeking approval of a patented method of use.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we do challenge a listed patent through a paragraph&#160;IV certification, under the Hatch Waxman Act, the holder of the patents or NDAs that the 505(b)(2)&#160;application references may file&#160;a patent infringement lawsuit after receiving notice of the paragraph&#160;IV certification. Filing of a patent infringement lawsuit against the filer of the 505(b)(2)&#160;application within 45&#160;days of the patent or NDA owner&#8217;s receipt of notice triggers a one time, automatic, 30-month stay of the FDA&#8217;s ability to make the 505(b)(2)&#160;NDA approval effective. In such a case, the FDA may not make the 505(b)(2)&#160;NDA approval effective until the earlier of 30&#160;months from the receipt of the notice of the paragraph&#160;IV certification, the expiration of the patent, when the infringement case concerning each such patent was favorably decided in the applicant&#8217;s favor or settled, or such shorter or longer period as may be ordered by a court. Accordingly, we may invest a significant amount of time and expense in the development of one or more product candidates only to be subject to significant delay and patent litigation before such product candidates may be commercialized, if at all. In addition, a 505(b)(2)&#160;application approval may, in some cases, not be submitted, or may, in other cases, not be made effective until any existing non-patent regulatory exclusivities have expired or, if possible, are carved out from the label.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Companies that produce branded reference listed drugs routinely bring litigation against applicants that seek regulatory approval to manufacture and market new forms of their branded products. These companies often allege patent infringement or other violations of intellectual property rights as the basis for filing suit. Likewise, patent holders may bring patent infringement suits against companies that are currently marketing and selling such products. Litigation to enforce or defend intellectual property rights is often complex and often involves significant expense and can delay or prevent introduction or sale of our product candidates. If patents are held to be valid and infringed by our product candidates in a particular jurisdiction, we may be required to cease selling, relinquish or destroy existing stock, or pay monetary damages in that jurisdiction unless we can obtain a license from the patent holder. There may also be situations where we use our business judgment and decide to market and sell its approved products, notwithstanding the fact that allegations of patent infringement(s)&#160;have not been finally resolved by the courts, which is known as an &#8220;at risk launch.&#8221; The risk involved in doing so can be substantial because the remedies available to the owner of a patent for infringement may include, among other things, damages measured by the profits lost by the patent owner which may be greater than the profits earned by the infringer. In the case of willful infringement, such </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">48</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">damages may be increased up to three times. An adverse decision in patent litigation could have a material adverse effect on our business, financial position, and results of operations and could cause the market value of our common stock to decline.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Changes in product candidate manufacturing or formulation may result in additional costs or delay.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As product candidates are developed through preclinical studies to late-stage clinical trials toward approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, manufacturing sites, and formulation, are altered along the way in an effort to optimize processes and results. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. Such changes may also require additional testing, FDA notification, or FDA approval. For instance, the FDA may require that we conduct a comparability study that evaluates the potential differences in the product candidate resulting from the change. Delays in designing and completing such a study to the satisfaction of the FDA could delay or preclude our development and commercialization plans, and the regulatory approval of our product candidates. We may also require the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commence product sales and generate revenue. Any of the foregoing could limit our future revenues and growth. Any changes would also require that we devote time and resources to manufacturing development and would also likely require additional testing and regulatory actions on its part, which may delay the development of our product candidates.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which we would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may in the future conduct clinical trials for product candidates at sites outside the United States, and the FDA may not accept data from trials conducted in such locations.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may in the future choose to conduct one or more of our clinical trials outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of these data is subject to conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and be performed by qualified investigators in accordance with ethical principles, such as IRB or ethics committee approval and informed consent. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to the applicable local laws (and therefore failure to comply with such laws could result in regulatory enforcement action), acceptance of the data by the FDA will be dependent upon its determination that the trials were conducted consistent with all applicable U.S. laws and regulations. If the FDA does not accept the data from any trial that we conduct outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and could delay or permanently halt our development of the applicable product candidates.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Failure to obtain marketing approval in international jurisdictions would prevent our product candidates from being marketed abroad.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In order to market and sell our products in jurisdictions outside the United States, we must obtain separate marketing approvals in international jurisdictions and comply with numerous and varying regulatory requirements. The approval procedures vary among countries and the time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. Our clinical trials of our product candidates may not be sufficient to support an application for marketing approval outside the United States. Seeking foreign regulatory approval could result in difficulties and costs for us and require additional preclinical studies or clinical trials which could be costly and time consuming.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">49</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets. We, or any eventual collaborators, may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. However, the failure to obtain approval in one jurisdiction may compromise our ability to obtain approval elsewhere. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any market.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, on June&#160;23, 2016, the electorate in the United Kingdom voted in favor of leaving the European Union, commonly referred to as Brexit. On March&#160;29, 2017, the United Kingdom formally notified the European Union of its intention to withdraw pursuant to Article&#160;50 of the Lisbon Treaty. In October 2019, the United Kingdom and European Union agreed upon the terms of the U.K.'s withdrawal from the E.U. in the form of a Withdrawal Agreement. The Withdrawal Agreement was ratified by the U.K Parliament, and the European Parliament in Brussels, in late January 2020, with the consequence that Brexit formally occurred on January 31, 2020. An 11-month transition period will end on December 31, 2020. Since a significant proportion of the regulatory framework in the United Kingdom is derived from European Union directives and regulations, the withdrawal could materially impact the regulatory regime with respect to the approval of our product candidates in the United Kingdom or the European Union. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the United Kingdom and/or the European Union and restrict its ability to generate revenue and achieve and sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom and/or European Union for our product candidates, which could significantly and materially harm our business.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be subject to fines, penalties, injunctions, or other enforcement actions if we are determined to be promoting the use of our products for unapproved or &#8220;off-label&#8221; uses, resulting in damage to our reputation and business.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We must comply with requirements concerning advertising and promotion for any product candidates for which we obtain marketing approval. Promotional communications with respect to therapeutics are subject to a variety of legal and regulatory restrictions and continuing review by the FDA, Department of Justice, Department of Health and Human Services&#8217; Office of Inspector General, state attorneys general, members of Congress, and the public. When the FDA or comparable foreign regulatory authorities issue regulatory approval for a product candidate, the regulatory approval is limited to those specific uses and indications for which a product is approved. We may not market or promote them for other indications and uses, referred to as off-label uses. We further must be able to sufficiently substantiate any claims that we make for our products including claims comparing our products to other companies&#8217; products and must abide by the FDA&#8217;s strict requirements regarding the content of promotion and advertising. While physicians may choose to prescribe products for uses that are not described in the product&#8217;s labeling and for uses that differ from those tested in clinical studies and approved by the regulatory authorities, we are prohibited from marketing and promoting the products for indications and uses that are not specifically approved by the FDA.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we are found to have impermissibly promoted any of our product candidates, we may become subject to significant liability and government fines. The FDA and other agencies actively enforce the laws and regulations regarding product promotion, particularly those prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted a product may be subject to significant sanctions. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees of permanent injunctions under which specified promotional conduct is changed or curtailed.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the United States, engaging in the impermissible promotion of our products, following approval, for off-label uses can also subject us to false claims and other litigation under federal and state statutes, including fraud and abuse and consumer protection laws. Such litigation can lead to civil and criminal penalties and fines, agreements with governmental authorities that materially restrict the manner in which we promote or distribute therapeutic products and do business through, for example, corporate integrity agreements, suspension or exclusion from participation in federal and state healthcare programs, suspension and debarment from government contracts, and refusal of orders under existing government contracts. These false claims statutes include the federal civil FCA, which allows any individual to bring a lawsuit against a company on behalf of the federal government ("qui tam" action) alleging submission of false or fraudulent claims, or causing others to present such false or fraudulent claims, for payment by a federal program such as Medicare or Medicaid. If the government decides to intervene and prevails in the lawsuit, the individual will share in the proceeds from any fines or settlement funds. If the government declines to intervene, the individual may pursue the case alone. These FCA lawsuits against sponsors of drugs and biologics have increased significantly in volume and breadth, leading to several substantial civil and criminal settlements, up to $3.0&#160;billion, pertaining to certain sales practices and promoting off-label uses. In addition, FCA lawsuits may expose sponsors to follow-on claims by private payers based on fraudulent marketing practices. This growth in litigation has increased the risk that companies </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">50</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">will have to defend a false claim action, and pay settlements fines or restitution, as well as criminal and civil penalties, agree to comply with burdensome reporting and compliance obligations, and be excluded from Medicare, Medicaid, or other federal and state healthcare programs. If we do not lawfully promote our approved products, if any, we may become subject to such litigation and, if we do not successfully defend against such actions, those actions may have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the United States, the distribution of product samples to physicians must further comply with the requirements of the U.S. Prescription Drug Marketing Act, and the promotion of biologic and pharmaceutical products are subject to additional FDA requirements and restrictions on promotional statements. If the FDA determines that our promotional activities violate our regulations and policies pertaining to product promotion, it could request that we modify our promotional materials or subject us to regulatory or other enforcement actions, including issuance of warning letters or untitled letters, suspension or withdrawal of an approved product from the market, requests for recalls, payment of civil fines, disgorgement of money, imposition of operating restrictions, injunctions or criminal prosecution, and other enforcement actions. These regulatory and enforcement actions could significantly harm our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Even if our product candidates receive regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any product candidate for which we obtain marketing approval will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities, including requirements related to the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, advertising, marketing, and promotional activities for such product. These requirements further include submissions of safety and other post-marketing information, including manufacturing deviations and reports, registration and listing requirements, the payment of annual fees, continued compliance with cGMPs or cGMP-requirements relating to manufacturing, quality control, quality assurance, and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and GCPs, for any clinical trials that we conduct post-approval.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses and populations for which the product may be marketed or to the conditions of approval, including significant safety warnings, such as boxed warnings, contraindications, and precautions that are not desirable for successful commercialization. Any approved products may also be subject to a REMS that render the approved product not commercially viable or other post-market requirements, such as Phase&#160;4 studies, or restrictions. If the FDA or comparable foreign regulatory authorities become aware of new safety information after approval of any of our product candidates, they may, among other actions, withdraw approval, require labeling changes or establishment of a REMS or similar strategy, impose significant restrictions on a product&#8217;s indicated uses or marketing, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We and any of our collaborators, including our contract manufacturer, could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMPs and other FDA regulatory requirements. Application holders must further notify the FDA, and depending on the nature of the change, obtain FDA pre-approval for product and manufacturing changes.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, later discovery of previously unknown adverse events or that the product is less effective than previously thought or other problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements both before and after approval, may yield various results, including:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">restrictions on manufacturing, distribution, or marketing of such products;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">restrictions on the labeling, including restrictions on the indication or approved patient population, and required additional warnings, such as black box warnings, contraindications, and precautions;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">modifications to promotional pieces;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">issuance of corrective information;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">requirements to conduct post-marketing studies or other clinical trials;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">clinical holds or termination of clinical trials;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">requirements to establish or modify a REMS or a comparable foreign authority may require that we establish or modify a similar strategy;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">liability for harm caused to patients or subjects;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">51</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">reputational harm;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">warning, untitled, or cyber letters;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">suspension of marketing, withdrawal or recall of the products from the market;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">regulatory authority issuance of safety alerts, Dear Healthcare Provider letters, press releases, or other communications containing warnings or other safety information about the product;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">refusal to approve pending applications or supplements to approved applications that we submit;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">fines, restitution or disgorgement of profits or revenues;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">suspension or withdrawal of marketing approvals;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">refusal to permit the import or export of our products;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">product seizure or detention;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">FDA debarment, suspension and debarment from government contracts, and refusal of orders under existing government contracts, exclusion from federal healthcare programs, consent decrees, or corporate integrity agreements; or</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">injunctions or the imposition of civil or criminal penalties, including imprisonment.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, or could substantially increase the costs and expenses of developing and commercializing such product, which in turn could delay or prevent us from generating significant revenues from its sale. Any of these events could further have other material and adverse effects on our operations and business and could adversely impact our stock price and could significantly harm our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA&#8217;s policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates, that could limit the marketability of our product candidates, or that could impose additional regulatory obligations on us. Changes in medical practice and standard of care may also impact the marketability of our product candidates.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We will need to obtain FDA approval of any proposed product names, and any failure or delay associated with such approval may adversely affect its business.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any name we intend to use for our product candidates will require approval from the FDA regardless of whether we have secured a formal trademark registration from the U.S. Patent and Trademark Office (the &#8220;USPTO&#8221;). The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. The FDA may also object to a product name if it believes the name inappropriately implies medical claims or contributes to an overstatement of efficacy. If the FDA objects to any of our proposed product names, we may be required to adopt alternative names for our product candidates. If we adopt alternative names, we would lose the benefit of any existing trademark applications for such product candidate and may be required to expend significant additional resources in an effort to identify a suitable product name that would qualify under applicable trademark laws, not infringe the existing rights of third-parties, and be acceptable to the FDA. We may be unable to build a successful brand identity for a new trademark in a timely manner or at all, which would limit our ability to commercialize our product candidates.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">In the future we may seek FDA designations to facilitate product candidate development, such as fast track or breakthrough designation. We may not receive any such designations or if we receive such designations they may not lead to faster development or regulatory review or approval and it does not increase the likelihood that our product candidates will receive marketing approval.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the future, we may seek product designations, such as fast track or breakthrough designation, which are intended to facilitate the development or regulatory review or approval process for product candidates. Receipt of such a designation is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for a designation, the FDA may disagree. In any event, the receipt of such a designation for a product candidate may not result in a faster development process, review, or approval compared to product candidates considered for approval under conventional FDA procedures and does not assure ultimate marketing approval by the FDA. In addition, the FDA may later decide that the product candidates no longer meet the designation conditions, in which case any granted designations may be revoked.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">52</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">OCU300 and OCU400 have received ODD from the FDA. However, there is no guarantee that we will be able to maintain this designation, receive this designation for any of our other product candidates, or receive or maintain any corresponding benefits, including periods of exclusivity.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have obtained from the FDA Office of Orphan Products ODD for OCU300 for oGVHD and OCU400 for </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NR2E3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> mutation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">-</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">associated retinal diseases and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">CEP290</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> mutation-associated retinal diseases. We were the first company to receive ODD for oGVHD from the FDA. We may also seek ODD for its other product candidates, as appropriate. While ODD does provide us with certain advantages, it neither shortens the development time or regulatory review time of a product candidate nor gives the product candidate any advantage in the regulatory review or approval process.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Generally, if a product candidate with ODD subsequently receives marketing approval before another product considered by the FDA to be the same, for the same orphan indication, the product is entitled to a period of marketing exclusivity, which precludes the EMA or the FDA from approving another marketing application for the same drug or biologic for the same indication for a specified time period. The applicable period is seven years in the United States and 10 years in Europe. The European exclusivity period can be reduced to six years if a product no longer meets the criteria for ODD or if the product is sufficiently profitable so that market exclusivity is no longer justified.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may not be able to obtain any future ODDs that we apply for, ODDs do not guarantee that we will be able to successfully develop our product candidates, and there is no guarantee that we will be able to maintain any ODDs that we receive. For instance, ODDs may be revoked if the FDA finds that the request for designation contained an untrue statement of material fact or omitted material information, or if the FDA finds that the product candidate was not eligible for designation at the time of the submission of the request.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Moreover, even if we are able to receive and maintain ODDs, we may ultimately not receive any period of regulatory exclusivity if our product candidates are approved. For instance, we may not receive orphan product regulatory exclusivity if the indication for which we receive FDA approval is broader than the ODD. Orphan exclusivity may also be lost for the same reasons that ODD may be lost. Orphan exclusivity may further be lost if we are unable to assure a sufficient quantity of the product to meet the needs of patients with the rare disease or condition.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if we obtain orphan exclusivity for any of our current or future product candidates, that exclusivity may not effectively protect the product from competition as different products can be approved for the same condition or products that are the same as ours can be approved for different conditions. Even after an orphan product is approved, the FDA can also subsequently approve a product containing the same principal molecular features for the same condition if the FDA concludes that the later product is clinically superior by means of greater effectiveness, greater safety, or providing a major contribution to patient care. The FDA may further grant ODD to multiple sponsors for the same compound or active molecule and for the same indication. If another sponsor receives FDA approval for such product before we do, we would be prevented from launching our product in the United States for the orphan indication for a period of at least seven&#160;years unless we can demonstrate clinical superiority. Moreover, third-party payors may reimburse for products off-label even if not indicated for the orphan condition.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to the Commercialization of Our Product Candidates</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have no prior experience in the marketing, sale, and distribution of biologic and pharmaceutical products and there can be no assurance that our products, if approved, will be successfully commercialized.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have no prior experience in the marketing, sale, and distribution of biologic and pharmaceutical products, and there are significant risks involved in the building and managing of a commercial infrastructure. The establishment and development of commercial capabilities, including compliance plans, to market any products we may develop will be expensive and time consuming and could delay any product launch, and we may not be able to successfully develop this capability. We will have to compete with other biologic, pharmaceutical and biotechnology companies to recruit, hire, train, manage, and retain marketing and sales personnel. Factors that may inhibit our efforts to commercialize our product candidates include:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the inability to recruit, train, manage, and retain adequate numbers of effective sales and marketing personnel;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe our product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our inability to effectively oversee a geographically dispersed sales and marketing team;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the costs associated with training sales and marketing personnel on legal and regulatory compliance matters and monitoring their actions;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">53</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">an inability to secure adequate coverage and reimbursement by government and private health plans;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">reduced realization on government sales from mandatory discounts, rebates and fees, and from price concessions to private health plans and pharmacy benefit managers necessitated by competition for access to managed formularies;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the clinical indications for which the products are approved and the claims that we may make for the products;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">limitations or warnings, including distribution or use restrictions, contained in the products&#8217; approved labeling;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">any distribution and use restrictions imposed by the FDA or to which we agree as part of a mandatory REMS or voluntary risk management plan;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">liability for sales or marketing personnel who fail to comply with the applicable legal and regulatory requirements;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">unforeseen costs and expenses associated with creating an independent sales and marketing organization or engaging a contract sales organization.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Should any of the foregoing occur, we may not be successful in commercializing any product candidates for which we receive marketing approval.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We face significant competition from other biologic, pharmaceutical and biotechnology companies, academic institutions, government agencies, and other research organizations. Our operating results will suffer if we fail to compete effectively.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The development and commercialization of new therapeutic products is highly competitive. We face competition with respect to our current product candidates and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major biologic and pharmaceutical companies, specialty biologic and pharmaceutical companies, and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are aware of several companies focusing on gene therapies for various indications, including Editas Medicine, Allergan, Inc., Adverum Biotechnologies, MeiraGTx, IVERIC bio, Inc., Applied Genetic Technologies Corporation and Roche Group, which acquired Spark Therapeutics, Inc. Luxturna&#8482; (Spark Therapeutics) is currently the only gene therapy approved for an IRD in the United States, addressing only one out of 150 known mutations of the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">RPE65</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene. Companies that may compete with our OCU200 product candidate include the Roche Group, Regeneron Pharmaceuticals, Inc., and Novartis AG, which have marketed anti-VEGF products. We are also aware of other companies that are working on therapies for the whole eye, including Santen, Inc. and Ocular Therapeutix.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our product candidates will target markets that are already served by a variety of competing products. Many of these existing products have achieved widespread acceptance among clinicians, patients and payors.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our ability to compete may further be affected in many cases by insurers or other third-party payors, particularly Medicare, seeking to encourage the use of generic or biosimilar products. Many of the products that will compete with our product candidates, if approved, are available on a generic basis, and our product candidates may not demonstrate sufficient additional clinical benefits to clinicians, patients or payors to justify a higher price compared to generic products. Additional competing products are expected to become available on a generic basis over the coming years. In many cases, insurers or other third-party payors, particularly Medicare, seek to encourage the use of generic products.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for our products, which could result in our competitors establishing a strong market position before we are able to enter the market. They may obtain patent protection or other intellectual property rights that allow them to develop and commercialize their products before us and could limit our ability to develop or commercialize our product candidates. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors coverage decisions.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">54</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the biologic, pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to establish effective marketing and sales, capabilities or enter into agreements with third parties to market and sell our product candidates, if they are approved, we may be unable to generate product revenues.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently do not have a commercial infrastructure for the marketing, sale, and distribution of biologic and pharmaceutical products. If approved, in order to commercialize its products, we must build our marketing, sales, and distribution capabilities or make arrangements with third parties to perform these services. If we do not establish sales, marketing and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing any product candidates for which we receive marketing approval.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to FDA approval of any of its product candidates, we may build a commercial team of specialty sales and marketing representatives in support of OCU300 and possibly other preclinical product candidates that we develop in the United States, if and when they are approved, as well as distribution capabilities. There are risks involved with us establishing our own sales, marketing and distribution capabilities. Recruiting and training a sales force is expensive and time-consuming, particularly to the extent that we seek to commercialize any product for an indication, such as wet AMD, that has a patient population significantly larger than those addressed by its current lead product candidate, and could delay any product launch. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations to recruit, hire, train and retain marketing and sales personnel. Further, we may underestimate the size of the sales force required for a successful product launch and may need to expand its sales force earlier and at a higher cost than it anticipated. If the commercial launch of our product candidates for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if it cannot retain or reposition our sales and marketing personnel.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may also or alternatively decide to collaborate with a third-party or contract sales organization to commercialize any approved product candidates, in which event, our ability to generate product revenues may be limited. By example, we may retain commercialization rights to OCU300 or utilize a variety of collaboration, distribution and other marketing arrangements with one or more third parties to commercialize OCU300. Our product revenues and our profitability, if any, under any such third-party collaboration, distribution or other marketing arrangements are likely to be lower than if we were to market, sell and distribute OCU300 entirely ourselves. We may not be successful in entering into arrangements with third parties to sell, market and distribute its product candidates or may be unable to do so on terms that are favorable to us. In addition, we would have less control over the sales efforts of any other third parties involved in our commercialization efforts and any of them may fail to devote the necessary resources and attention to sell and market our product candidates effectively. We could also be held liable if they failed to comply with applicable legal or regulatory requirements.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the event we are unable to develop a team of marketing and sales representatives or to establish an effective third-party contractual relationship for such services, we may not be able to commercialize our product candidates, which would limit our ability to generate product revenues. Even if we are able to effectively hire a sales force and develop a marketing and sales infrastructure, our sales force and marketing teams may not be successful in commercializing our product candidates.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If our product candidates do not achieve broad market acceptance, the revenues that we generate from their sales will be limited.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if our product candidates are approved by the appropriate regulatory authorities for marketing and sale, they may not gain acceptance among physicians, patients, third-party payors, and others in the medical community. Physicians are often reluctant to switch their patients and patients may be reluctant to switch from existing therapies even when new and potentially more effective or safer treatments enter the market. We have never commercialized a product candidate for any indication, and efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. Market acceptance of our product candidates by the medical community, patients, and third-party payors will depend on a number of factors, some of which are beyond our control. If any product candidates for which we obtain regulatory approval does not gain an adequate level of market acceptance, it may not generate significant product revenues or become profitable.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">55</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We can provide no assurance that our lead product candidate, OCU300 for the treatment of oGVHD, will achieve market acceptance. While there are no drugs currently approved in the United States for treatment of oGVHD, there are several product candidates in clinical development for treatment of oGVHD in the United States. It is possible that doctors may rely on these treatments rather than OCU300, if and when it is approved for marketing by the FDA.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">It is also possible that physicians may prescribe other less expensive brimonidine tartrate products off label rather that prescribe OCU300. As a result, clinicians, patients and third-party payors may choose to rely on products other than our product candidates for the treatment of ocular redness and discomfort in patients with oGVHD.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The degree of market acceptance of any of our product candidates will depend on a number of factors, including:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the efficacy of our product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the prevalence and severity of adverse events associated with such product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">interactions of our products with other medicines patients are taking and any restrictions on the use of our products together with other medications;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the clinical indications for which the products are approved and the approved claims that we may make for the products;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">limitations or warnings contained in the product&#8217;s FDA-approved labeling, including potential limitations or warnings for such product candidates that may be more restrictive than other competitive products;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">changes in the standard of care for the targeted indications for such product candidates, which could reduce the marketing impact of any claims that we could make following FDA approval, if obtained;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the relative convenience and ease of administration of such product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">cost of treatment versus economic and clinical benefit in relation to alternative treatments or therapies;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the availability of third-party formulary coverage and adequate coverage or reimbursement by third parties, such as insurance companies and other healthcare payors, and by government healthcare programs, including Medicaid and particularly by Medicare in light of the prevalence of DED in persons over age 55;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the price concessions required by third party payors to obtain coverage;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the extent and strength of our marketing and distribution of such product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the safety, efficacy, and other potential advantages over, and availability of, alternative treatments already used or that may later be approved;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">distribution and use restrictions imposed by the FDA with respect to such product candidates or to which we agree as part of a REMS or voluntary risk management plan;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the timing of market introduction of such product candidates, as well as competitive products;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">its ability to offer such product candidates for sale at competitive prices;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the extent of availability of generic or biosimilar versions of any products that compete with any of our product candidates and the extent to which they are offered at a substantially lower price than we expect to offer for our product candidates, if approved;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the extent and strength of our third-party manufacturer and supplier support;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the approval of other new products;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">adverse publicity about the product or favorable publicity about competitive products; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">potential product liability claims.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">With respect to our product candidates being developed based on our modifier gene therapy platform, market acceptance may also be constrained by ethical, social and legal concerns about gene therapy and genetic research, which could result in additional regulations restricting or prohibiting the products and processes we may use. The novelty of the technology and any negative publicity surrounding adverse events associated with gene therapy may also prevent the medical community, patients, and third-party payors from accepting gene therapy products in general, and our product candidates in particular, as medically useful, cost-effective and safe.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">56</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If the market opportunities for our product candidates are smaller than we believe, our revenue may be adversely affected, and our business may suffer.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The potential market opportunities for our product candidates are difficult to precisely estimate. Our estimates of the potential market opportunities are predicated on many assumptions, which may include industry knowledge and publications, third-party research reports, and other surveys, some of which we may have commissioned. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe these industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data. In addition, while we believe that our internal assumptions are reasonable, these assumptions involve the exercise of significant judgment on the part of our management, are inherently uncertain, and the reasonableness of these assumptions has not been assessed by an independent source. If any of the assumptions proves to be inaccurate, the actual markets for our product candidates could be smaller than our estimates of the potential market opportunities, and as a result our product revenue may be limited, and it may be more difficult for us to achieve or maintain profitability.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If third-party payors do not reimburse patients for OCU300 or our other products candidates, if approved, or if reimbursement levels are set too low for us to sell our product candidates at a profit, our ability to successfully commercialize our product candidates, if approved, and our results of operations will be harmed. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our ability to successfully commercialize OCU300 and our other product candidates, if approved, will depend in part on the extent to which coverage and adequate reimbursement for our product candidates will be available in a timely manner from third-party payors, including governmental healthcare programs such as Medicare and Medicaid, commercial health insurers and managed care organizations. This is particularly true with respect to our product candidates designed to treat DED, which is most prevalent in persons over age 55. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, determine which medications they will cover and establish reimbursement levels. Reimbursement decisions by particular third-party payors depend upon a number of factors, including each third-party payor&#8217;s determination that use of a product is:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">a covered benefit under its health plan;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">appropriate and medically necessary for the specific condition or disease; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">cost effective; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">neither experimental nor investigational.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Obtaining coverage and reimbursement approval for our product candidates from government authorities or other third-party payors may be a time consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data, including expensive pharmacoeconomic studies beyond the data required to obtain marketing approval, for the use of each product candidate to each government authority or other third-party payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Third-party payors may deny reimbursement for covered products if they determine that a medical product was not used in accordance with cost-effective diagnosis methods, as determined by the third-party payor, or was used for an unapproved indication. Third-party payors also may refuse to reimburse for procedures and devices deemed to be experimental. Third-party payors may also limit coverage to specific products on an approved list, or formulary, which might not include all of the approved products for a particular indication. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Increasingly, third-party payors are also requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. These third-party payors could also impose price controls and other conditions that must be met by patients prior to providing coverage for use of our product candidates, if approved. For example, insurers may establish a &#8220;step-edit&#8221; system that requires a patient to first use a lower price alternative product prior to becoming eligible for reimbursement of a higher price product. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Third-party payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement for medical products and services. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Levels of reimbursement may also decrease in the future, and future legislation, regulation or reimbursement policies of third-party payors may adversely affect the demand for and reimbursement available for our product candidates, which in turn, could negatively impact pricing. If patients are not adequately reimbursed for our product candidates, </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">57</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">if approved, they may reduce or discontinue purchases of it, which would result in a significant shortfall in achieving revenue expectations and negatively impact our business, prospects and financial condition.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our product candidates may face competition sooner than anticipated.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Both our drug and biologic product candidates, if approved, may face competition from other products that are the same as or similar to our product candidates. If the FDA or comparable foreign regulatory authorities approve generic or similar versions of any of our product candidates that receive marketing approval, or such authorities do not grant our products appropriate periods of regulatory exclusivity before approving generic or similar versions of our products, the sales of our products could be adversely affected.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the case of our drug product candidates, once an NDA is approved, the product will become a &#8220;reference listed drug&#8221; in the FDA&#8217;s Orange Book. Other applicants may then seek approval of generic versions of our products through submission of ANDAs in the United States. In support of an ANDA, a generic applicant would not need to conduct full clinical studies. Rather, the applicant generally must show that its product has the same active ingredient(s), dosage form, strength, route of administration, conditions of use and labeling, among other commonalities, as the reference listed drug and that the generic version is bioequivalent to the reference listed drug, meaning it is available at the site of action at the same rate and to the same extent as the reference listed drug. Generic products may be significantly less costly to bring to market than the reference listed drug and companies that produce generic products are generally able to offer them at lower prices and are generally preferred by third party payors. As a result, the FDA, the administration and Congress have recently taken steps to encourage increased generic drug competition in the market in an effort to bring down drug costs. Following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference listed drug is typically lost to the generic product. Moreover, in addition to generic competition, we could face competition from other companies seeking approval of drug products that are similar to its products using the 505(b)(2)&#160;regulatory pathway. Such applicants may be able to rely on our product candidates, if approved, or other approved drug products or published literature to develop drug products that are similar to ours. The introduction of a drug product similar to our product candidates could expose us to increased competition.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any ANDA or 505(b)(2)&#160;applicants seeking to rely upon any of our product candidates, if such product candidates are approved, would need to submit patent certification statements with their applications for any of our patents that are listed in the FDA&#8217;s Orange Book. There are detailed rules&#160;and requirements regarding the patents that may be submitted to the FDA for listing in the Orange Book. We may be unable to obtain patents covering our product candidates that contain one or more claims that satisfy the requirements for listing in the Orange Book. If one of our product candidates is approved and a patent covering that product candidate is not listed in the Orange Book, an ANDA or 505(b)(2)&#160;applicant would not have to submit a patent certification with regard to such patent to the FDA, in which case, we would not receive the protections provided by the Hatch Waxman Act.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Moreover, if an ANDA or 505(b)(2)&#160;applicant files&#160;a paragraph&#160;IV challenge to any patents that we may list in the FDA&#8217;s Orange Book and if we do not file&#160;a patent infringement lawsuit within 45&#160;days of receiving notice of a paragraph&#160;IV certification, the ANDA or 505(b)(2)&#160;applicant would not be subject to a 30-month stay. If we did file such an action, the litigation or other proceedings to enforce or defend its intellectual property rights would likely be complex in nature, may be expensive and time consuming, may divert its management&#8217;s attention from its core business, and may result in unfavorable results that could adversely impact our ability to prevent third parties from competing with our products. Accordingly, upon approval of our product candidates We may be subject to generic competition or competition from similar products, or may need to commence patent infringement proceedings, which would divert our resources.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently anticipate that we may be eligible for three years of non-patent marketing exclusivity in the United States for OCU300 if it is approved. These three years, however, would only protect our modifications in formulation or approved uses in comparison to the reference listed drug, would not prevent other companies from submitting full NDAs, and would not prevent physicians from prescribing other products off-label or third-party payors from reimbursing for them.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If the FDA licenses OCU400, OCU410 or OCU200, we may face competition from biosimilar products. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The enactment of the Biologics Price Competition and Innovation Act of 2009 ("BPCIA"), as part of the ACA, created an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an existing brand product. As in the generic drug product space, the FDA and the administration are taking steps to encourage increased biosimilar competition in the market in an effort to bring down the cost of biologic products, including actions aimed at deterring anti-competitive business practices. If another company pursues approval of a product that is biosimilar to any biologic product for which we receive FDA approval, we may </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">58</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">need to pursue costly and time-consuming patent infringement actions, which may include certain statutorily specified regulatory steps before an infringement action may be brought. Biosimilar applicants may also be able to bring an action for declaratory judgment concerning our patents, requiring that we spend time and money defending the action.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12&#160;years after the original branded product was approved under a BLA. Certain changes, however, and supplements to an approved BLA, and certain subsequent applications filed by the same sponsor, manufacturer, licensor, predecessor in interest, or other related entity do not qualify for the 12-year exclusivity period. Moreover, there have been efforts to decrease this period of exclusivity to a shorter timeframe. Future proposed budgets, international trade agreements and other arrangements or proposals may affect periods of exclusivity. Our biologic product candidates may qualify for the BPCIA&#8217;s 12-year period of exclusivity, however, there is a risk that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Additionally, this period of regulatory exclusivity does not apply to companies pursuing regulatory approval via their own traditional BLA, rather than via the abbreviated pathway. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. It is also possible that payers will give reimbursement preference to biosimilars, even over reference biologics, absent a determination of interchangeability.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For certain of our drug and biologic product candidates, we may seek pediatric exclusivity, which is another type of non-patent marketing exclusivity in the United States. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application. We cannot provide any assurance that pediatric exclusivity will be obtained for any of our product candidates.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To the extent we do not receive any anticipated periods of regulatory exclusivity or to the extent FDA or foreign regulatory authorities approve any biosimilar, interchangeable, generic, similar, or other competing products, our business would be adversely impacted. Competition that our products may face from generic, biosimilar, interchangeable, similar, or other competing products could materially and adversely impact our future revenue, profitability, and cash flows and substantially limit our ability to obtain a return on the investments we have made in those product candidates.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we obtain approval to commercialize our product candidates outside of the United States, a variety of risks associated with international operations could materially adversely affect our business.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If any of our product candidates are approved for commercialization, we may enter into agreements with third parties to market them on a worldwide basis or in more limited geographical regions. We expect that we will be subject to additional risks related to conducting marketing and sales activities in international jurisdictions and entering into international business relationships, including:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">different regulatory requirements for approval of drugs and biologics in foreign countries&#894;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the potential for so-called parallel importing, which is what happens when a local seller, faced with high or higher local prices, opts to import goods from a foreign market (with low or lower prices) rather than buying them locally&#894;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States&#894;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the need to seek additional patent approvals, licenses to patents held by third parties and/or face claims of infringing third-party patent rights;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">unexpected changes in tariffs, trade barriers and regulatory requirements&#894;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">economic weakness, including inflation, or political instability in particular foreign economies and markets&#894;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad&#894;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country&#894;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">difficulties staffing and managing foreign operations&#894;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">workforce uncertainty in countries where labor unrest is more common than in the United States&#894;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">potential liability under the FCPA, the U.K. Bribery Act 2010 (the "Bribery Act") or other comparable foreign regulations&#894;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">59</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad&#894; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including pandemics or other outbreaks of infectious disease, earthquakes, typhoons, floods and fires.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These and other risks associated with international operations may materially adversely affect our ability to attain or maintain profitable operations.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for our product candidates and may have to limit our commercialization.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The use of our product candidates in clinical trials, and the sale of any of our product candidates for which we obtain regulatory approval, exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. For example, we may be sued if any product candidate we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourself against these claims, we will incur substantial liabilities or be required to limit development or commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">loss of revenue from decreased demand for our products and/or product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">impairment of our business reputation or financial stability;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">costs of related litigation;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">substantial monetary awards to patients or other claimants;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">exhaustion of any available insurance and our capital resources;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">diversion of management attention;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">withdrawal of clinical trial participants and potential termination of clinical trial sites or entire clinical programs;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the inability to commercialize our product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">significant negative media attention;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">decrease in our stock price; or</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">initiation of investigations, and enforcement actions by regulators; and product recalls, withdrawals, revocation of approvals, or labeling, marketing or promotional restrictions.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently hold $5.0 million in product liability insurance coverage in the aggregate, with a per incident limit of $5.0 million, which may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage as we expand our clinical trials. We will need to further increase our insurance coverage if we commence commercialization of any of our product candidates for which we obtain marketing approval. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. On occasion, large judgments have been awarded in class action lawsuits based on therapeutics that had unanticipated side effects. Our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. A successful product liability claim or series of claims brought against us could cause our stock price to fall and, if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business and our prospects.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We rely, and expect to continue to rely, on third parties to conduct, supervise, and monitor our preclinical studies and clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials or failing to comply with regulatory requirements.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely on third parties, study sites, and others to conduct, supervise, and monitor our preclinical and clinical trials for our product candidates and do not currently plan to independently conduct clinical or preclinical trials of any other potential product candidates. We expect to continue to rely on third parties, such as CROs, clinical data management organizations, medical and </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">60</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">scientific institutions, and clinical and preclinical investigators, to conduct our preclinical studies and clinical trials. For example, for the clinical studies completed to date concerning the use of brimonidine tartrate for the treatment of ocular discomfort and ocular redness in patients with oGVHD, we relied on an investigator to sponsor and conduct the studies. For the clinical study concerning the use of brimonidine tartrate for the treatment of the signs and symptoms of DED, while we sponsored the study, we relied on third-party vendors and investigators for the conduct of the study.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While we have agreements governing the activities of such third parties, we have limited influence and control over their actual performance and activities. Our third-party service providers are not our employees, and except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our ongoing clinical, non-clinical, and preclinical programs. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards and our reliance on third parties does not relieve us of our regulatory responsibilities. For example, we will remain responsible for ensuring that each of our trials is conducted in accordance with the general investigational plan and protocols for the trial. We must also ensure that our preclinical trials are conducted in accordance with GLP and under cGMP conditions, as appropriate. Moreover, the FDA and comparable foreign regulatory authorities require us to comply with GCPs for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity, and confidentiality of trial participants are protected. The FDA enforces these GCPs through periodic inspections of trial sponsors, principal investigators, clinical trial sites and institutional review boards.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our preclinical studies or clinical trials in accordance with regulatory requirements or our stated protocols, if they need to be replaced or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our protocols, regulatory requirements or for other reasons:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">we or our CROs or other third-party collaborators may be subject to regulatory enforcement or other legal actions;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the data generated in our trials may be deemed unreliable and our trials may need to be repeated, extended, delayed, or terminated;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates; or</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">we may not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with the applicable regulatory requirements. To the extent we are unable to successfully identify and manage the performance of third-party service providers in the future, our business may be materially and adversely affected. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our reliance on third parties in connection with our clinical trials will entail additional risks. Our third-party service providers may have relationships with other entities, some of which may be our competitors, for whom they may also be conducting trials or other therapeutic development activities that could harm our competitive position. In addition, we will be required to report certain financial interests of our third-party investigators if these relationships exceed certain financial thresholds or meet other criteria. The FDA or comparable foreign regulatory authorities may question the integrity of the data from those clinical trials conducted by investigators who may have conflicts of interest. Lastly, we are required to register certain clinical trials and post the results of certain completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in enforcement actions and adverse publicity.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Agreements with third parties conducting or otherwise assisting with our clinical or preclinical studies might terminate for a variety of reasons, including a failure to perform by the third parties. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative providers or to do so on commercially reasonable terms. Switching or adding additional third parties involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, if we need to enter into alternative arrangements, it could delay our product development activities and adversely affect our business. Though we carefully manage our relationships with its third parties, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects, and results of operations.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We also rely on other third parties to store and distribute our products for the clinical and preclinical trials that we conduct. Any performance failure on the part of its distributors could delay development, marketing approval, or commercialization of our product candidates, producing additional losses and depriving us of potential product revenue.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">61</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we encounter difficulties in negotiating commercial manufacturing and supply agreements with third-party manufacturers and suppliers of our product candidates or any product components, our ability to commercialize our product candidates, if approved, would be impaired.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not manufacture any of our product candidates or any product components, and we do not currently plan to develop any capacity to do so. We expect to rely on a qualified supplier to manufacture and supply to us a minimum amount of brimonidine tartrate (the drug substance used in the manufacture of OCU300) for use in process validation campaigns and future commercial needs. We expect to rely on our qualified supplier and other third parties to manufacture clinical supplies of other product candidates and commercial supplies of all of our products, if and when approved for marketing by applicable regulatory authorities, as well as for packaging, serialization, storage, distribution and other production logistics. We, however, may not succeed in our efforts to establish manufacturing relationships or other alternative arrangements for any of our product candidates, components and programs, or may be unable to do so on commercially favorable terms. If we are unable to enter into such agreements on commercially favorable terms, our future profit margins would be adversely affected and our ability to commercialize any products that receive marketing approval on a timely and competitive basis would be impaired. As a result, our business, financial condition and results of operations would be materially adversely affected.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If the manufacturers upon whom we rely fail to produce our product candidates or components pursuant to the terms of contractual arrangements with us or fail to comply with stringent regulations applicable to biologic and pharmaceutical manufacturers, we may face delays in the development and commercialization of, or be unable to meet demand for, our product candidates and may lose potential revenues.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As with the third parties on which we rely for our clinical trial activities, we have agreements governing the activities of our manufacturers but have limited influence and control over their actual performance and activities. Our third-party manufacturers are not our employees, and except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to its manufacturing requirements. If these third-party manufacturers do not successfully carry out their contractual duties, meet expected deadlines or manufacture our product candidates in accordance with regulatory requirements, if there are disagreements between us and such parties, clinical development or marketing approval of our product candidates could be delayed.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The manufacture of biologic and pharmaceutical products requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of therapeutics often encounter difficulties in production, particularly in scaling up initial production. These problems include difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel, and compliance with strictly enforced federal, state, and foreign regulations. If our manufacturers were to encounter any of these difficulties and were unable to perform as agreed, our ability to provide product candidates to patients in our clinical trials and for commercial use, if approved, would be jeopardized.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, all manufacturers of our product candidates and therapeutic substances must comply with cGMP requirements enforced by the FDA that are applicable to both finished products and their active components used both for clinical and commercial supply. The FDA enforces these requirements through its facilities inspection program. Our manufacturers must be approved by the FDA pursuant to inspections that will be conducted after we submit our marketing applications to the agency. Our manufacturers will also be subject to continuing FDA and other regulatory authority inspections should we receive marketing approval. Further, we, in cooperation with our contract manufacturers, must supply all necessary chemistry, manufacturing, and control documentation to the FDA in support of a marketing application on a timely basis.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The cGMP requirements include quality control, quality assurance, and the maintenance of records and documentation. Manufacturers of our product candidates and the therapeutic substances and active pharmaceutical ingredients necessary to produce our product candidates may be unable to comply with its specifications, cGMP requirements and with other FDA, state, and foreign regulatory requirements. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of a product candidate that may not be detectable in final product testing. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or other regulatory authorities, they will not be able to secure or maintain regulatory approval for their manufacturing facilities. Any such deviations may also require remedial measures that may be costly and/or time-consuming for us or a third party to implement and that may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any resulting delays in obtaining products or product candidates that comply with the applicable regulatory requirements may result in delays to clinical trials, product approvals, and commercialization. It may also require that we conduct additional studies.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">62</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While we are ultimately responsible for the manufacture of our product candidates, other than through our contractual arrangements, we have little control over our manufacturers&#8217; compliance with these regulations and standards. A failure to comply with the applicable regulatory requirements may result in regulatory enforcement actions against our manufacturers or us, including fines and civil and criminal penalties, including imprisonment, suspension or restrictions of production, injunctions, delay, withdrawal or denial of product approval or supplements to approved products, clinical holds or termination of clinical studies, warning or untitled letters, regulatory authority communications warning the public about safety issues with the product, refusal to permit the import or export of the products, product seizure, detention, or recall, operating restrictions, suits under the civil FCA, corporate integrity agreements, or consent decrees. Depending on the severity of any potential regulatory action, our clinical or commercial supply could be interrupted or limited, which could have a material adverse effect on our business.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any problems or delays we experience in preparing for commercial-scale manufacturing of a product candidate or component, including manufacturing validation, may result in a delay in FDA approval or commercial launch of the product candidate or may impair our ability to manufacture commercial quantities or such quantities at an acceptable cost, which could result in the delay, prevention, or impairment of commercialization of our product candidates and could adversely affect our business. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We or our third-party manufacturers may also encounter shortages in the materials necessary to produce our product candidates in the quantities needed for our clinical trials or, if our product candidates are approved, in sufficient quantities for commercialization.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We or our third-party manufacturers may also encounter shortages in the raw materials, therapeutic substances, or active pharmaceutical ingredients necessary to produce our product candidates in the quantities needed for our clinical trials or, if our product candidates are approved, in sufficient quantities for commercialization or to meet an increase in demand. Such shortages may occur for a variety of reasons, including capacity constraints, delays or disruptions in the market, and shortages caused by the purchase of such materials by our competitors or others. We or our third-party manufacturers&#8217; failure to obtain the raw materials, therapeutic substances, or active pharmaceutical ingredients necessary to manufacture sufficient quantities of our product candidates may cause the manufacturers to fail to deliver the required commercial quantities of our product candidates on a timely basis and at commercially reasonable prices. If such failure occurs, we would likely be unable to meet the demand for our products and we would lose potential revenues.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The number of available, qualified third-party manufactures is limited, and if we are compelled to locate an alternative manufacturing partner our product development activities and commercialization could be delayed and additional expense would be incurred.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There are a limited number of manufacturers that operate under cGMP regulations and that are both capable of manufacturing for us and willing to do so, and therefore our product candidates may compete with other products and product candidates for access to manufacturing facilities. Moreover, because our product candidates must be manufactured under sterile conditions, the number of manufacturers who can meet this requirement are even more limited. If our existing third-party manufacturers, or the third parties that we engage in the future to manufacture a product or component for commercial sale or for our clinical trials should cease to continue to do so for any reason (including the termination of our agreements with such manufacturers, which can occur for a variety of reasons, or the bankruptcy of such manufacturers), it would be difficult to obtain a suitable alternative manufacturer. We would likely experience delays in obtaining sufficient quantities of our product candidates for us to meet commercial demand or to advance our clinical trials while we identify and qualify replacement suppliers. Any change in our manufacturers could be costly because the commercial terms of any new arrangement could be less favorable and because the expenses relating to the transfer of necessary technology and processes could be significant.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If the FDA or a comparable foreign regulatory authority does not approve the facilities for the manufacture of our product candidates or if the FDA withdraws any such approval in the future, we may need to find alternative manufacturing facilities. Any new manufacturers would need to either obtain or develop the necessary manufacturing know-how, and obtain the necessary equipment and materials, which may take substantial time and investment. We must also receive FDA approval for the use of any new manufacturers for commercial supply. Any such developments would significantly impact our ability to develop, obtain and maintain regulatory approval for or market our product candidates, if approved.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The number of available third-party facilities may also be further limited by natural disasters, such as pandemics, floods or fire, or such facilities could face manufacturing issues, such as contamination or regulatory findings following a regulatory inspection of such facility. In such instances, an appropriate replacement third-party relationship may not be readily available to us or on acceptable terms, which would cause additional delay and increased expense and may have a material adverse effect on our business.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">63</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may rely on third parties to perform many essential services for any products that we commercialize. If these third parties fail to perform as expected or to comply with legal and regulatory requirements, our ability to commercialize our product candidates will be significantly impacted and we may be subject to regulatory sanctions.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may retain third-party service providers to perform a variety of functions related to the sale and distribution of our product candidates, key aspects of which will be out of our direct control. These service providers may provide key services related to warehousing and inventory control, distribution, customer service, accounts receivable management, and cash collection. If these third-party service providers fail to comply with applicable laws and regulations, fail to meet expected deadlines, or otherwise do not carry out their contractual duties to us, or encounter physical or natural damage at their facilities, our ability to deliver product to meet commercial demand would be significantly impaired and we may be subject to regulatory enforcement action.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we may engage third parties to perform various other services for us relating to pharmacovigilance and adverse event reporting, safety database management, fulfillment of requests for medical information regarding our product candidates and related services. If the quality or accuracy of the data maintained by these service providers is insufficient, or these third parties otherwise fail to comply with regulatory requirements, we could be subject to regulatory sanctions.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may also contract with a third party to calculate and report pricing information mandated by various government programs. If a third party fails to timely report or adjust prices as required, or errors in calculating government pricing information from transactional data in our financial records, it could impact our discount and rebate liability, and potentially subject us to regulatory sanctions or FCA lawsuits.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may seek to collaborate with third parties for the development or commercialization of our product candidates. We may not be successful in establishing or maintaining collaborative relationships, which could adversely affect our ability to develop and commercialize our product candidates.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the future we may seek collaboration arrangements with biologic, pharmaceutical or biotechnology companies for the development or commercialization of our product candidates. We may utilize a variety of types of collaboration, distribution and other marketing arrangements with third parties to develop and commercialize our product candidates outside the United States. We may also enter into arrangements with third parties to perform these services in the United States if we do not establish our own sales, marketing and distribution capabilities in the United States or if we determines that such third-party arrangements are otherwise beneficial. We may also consider potential collaborative partnership opportunities for sales, marketing, distribution, development, or licensing or broader collaboration arrangements, including with large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. We are not currently party to any such arrangement.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The success of future collaboration arrangements that we may enter into will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to collaboration arrangements. Accordingly, if we do enter into any such arrangements with any third parties in the future, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities and efforts to successfully perform the functions assigned to them in these arrangements. Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the development process or commercializing the applicable product candidate and, in some cases, termination of the collaboration arrangement. These disagreements can be difficult to resolve if neither of the parties has final decision-making authority. Moreover, collaborations with biologic and pharmaceutical companies and other third parties are often terminated or allowed to expire. Any such termination or expiration would adversely affect us financially and could harm our business reputation.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may also license the right to market and sell our product candidates under our collaborators&#8217; labeler codes. Alternatively, we may enter into agreements with collaborators to market and sell our product candidates under our own labeler code, in which case errors and omissions by collaborators in capturing and transmitting transactional data may impact the accuracy of our government price reporting.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any future collaborations we might enter into may pose a number of additional risks, including the following:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">collaborators may not pursue development of product candidates and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">64</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">programs based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">collaborators could fail to make timely regulatory submissions for a product candidate;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">collaborators may not comply with all applicable regulatory requirements or may fail to report safety data in accordance with all applicable regulatory requirements, which could subject them or us to regulatory enforcement actions;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product candidate or product;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time consuming and expensive;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner, or at all. If any collaborations we might enter into in the future do not result in the successful development and commercialization of product candidates or if one of our collaborators subsequently terminates our agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under the agreements, our development of our product candidates could be delayed, and we may need additional resources to develop our product candidates and our product platform. All of the risks relating to product development, regulatory approval and commercialization described in this report also apply to the activities of our collaborators.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, if any future collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate development or commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our reputation in the business and financial communities could be adversely affected.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Should we desire to pursue a collaboration agreement but are not able to establish collaborations, we may have to alter our development and commercialization plans and our business could be adversely affected.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For some of our product candidates, we may decide to collaborate with pharmaceutical or biotechnology companies for the development and potential commercialization of those product candidates. We face significant competition in seeking appropriate collaborators and whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">65</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. We may also be restricted under future license agreements from entering into agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to negotiate and document. Should we desire to pursue a collaboration agreement but are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay our development program or one or more of its other development programs, delay our potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our product platform and our business may be materially and adversely affected.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Legal and Compliance Matters</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we fail to comply with federal and state healthcare laws, including fraud and abuse and health and other information privacy and security laws, we could face substantial penalties and our business, financial condition, results of operations, and prospects could be adversely affected.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a biologic and pharmaceutical company, we are subject to many federal and state healthcare laws, such as the federal Anti-Kickback Statute, the federal civil and criminal FCA, the civil monetary penalties statute, the Medicaid Drug Rebate statute and other price reporting requirements, the VHCA, the HIPAA, the FCPA, the ACA, and similar state laws. We may also be subject to laws regarding transparency and patient privacy. Even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, certain federal and state healthcare laws, and regulations pertaining to fraud and abuse, reimbursement programs, government procurement, and patients&#8217; rights are and will be applicable to our business.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If we or our operations are found to be in violation of any federal or state healthcare law, or any other governmental laws or regulations that applies to us, we may be subject to penalties, including civil, criminal, and administrative penalties, damages, fines, imprisonment, disgorgement, suspension and debarment from government contracts, and refusal of orders under existing government contracts, exclusion from participation in U.S. federal or state health care programs, corporate integrity agreements, and the curtailment or restructuring of our operations, any of which could materially adversely affect our ability to operate our business and our financial results. Although an effective compliance program can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Moreover, achieving and sustaining compliance with applicable federal and state privacy, security, reimbursement, and fraud laws may prove costly. Any action against us for violation of these laws, even if we successfully defends against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are subject to new legislation, regulatory proposals and healthcare payor initiatives that may increase our costs of compliance, and adversely affect our ability to market our products, obtain collaborators, and raise capital.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any products for which we obtain marketing approval. The biopharmaceutical industry has been a particular focus of these efforts and has been significantly affected by legislative initiatives. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we may receive for any approved products.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2010, the ACA, included provisions of importance to our business, including, without limitation, our ability to commercialize and the prices we may obtain for any of our product candidates that are approved for sale. These provisions include:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents, including products approved through the 505(b)(2)&#160;regulatory pathway;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">an increase in the statutory minimum rebates a sponsor must pay under the Medicaid Drug Rebate Program;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">66</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">a Medicare Part&#160;D coverage gap discount program, in which participating sponsors must agree to offer 50% point-of-sale discounts off negotiated drug prices of drugs and biologics approved under an NDA or BLA (including drugs approved pursuant to the 505(b)(2)&#160;regulatory pathway) during the coverage gap period as a condition for the sponsors&#8217; outpatient drugs to be covered under Medicare Part&#160;D;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">expansion of healthcare fraud and abuse laws, including the federal FCA and the federal Anti-Kickback Statute, and the addition of new government investigative powers, and enhanced penalties for noncompliance;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">extension of sponsor&#8217;s Medicaid rebate liability to managed Medicaid plans;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">expansion of eligibility criteria for Medicaid programs;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">expansion of the entities eligible for discounts under the PHSA pharmaceutical pricing program; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">creation of a special Medicare Part&#160;B payment methodology for biosimilars approved under PHSA Section&#160;351(k)&#160;in which providers are paid the ASP of the biosimilar plus the margin based on ASP of the reference biologic.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The ACA was recently amended to repeal the individual insurance mandate, and efforts to repeal and replace portions of the law may continue. It remains to be seen, however, whether new legislation will be enacted and, if so, precisely what any new legislation could provide and what impact it will have on the availability of healthcare and containing or lowering the cost of healthcare. For example, it is possible that any repeal and replacement initiatives, if enacted into law, could ultimately result in fewer individuals having health insurance coverage or in individuals having insurance coverage with less generous benefits. Accordingly, such reforms, if enacted, could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain marketing approval and may affect our overall financial condition and ability to develop or commercialize product candidates. The timing and scope of any potential future legislation to repeal and replace ACA provisions is highly uncertain in many respects.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since the ACA was enacted in 2010, other legislative and regulatory changes have been proposed and adopted. These changes include, among other things, aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went effective on April&#160;1, 2013 and will remain in effect through 2024 unless additional Congressional action is taken. More recently, the Bipartisan Budget Act increased sponsor responsibility for prescription costs in the Medicare Part&#160;D coverage gap, and also extended sponsor responsibility for prescription costs in the Medicare Part&#160;D coverage gap to biosimilars, which had previously been exempt. In addition, the American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. CMS promulgated regulations governing sponsors&#8217; obligations and reimbursement under the Medicaid Drug Rebate Program, and recently promulgated a regulation that limited Medicare Part&#160;B payment to certain hospitals for outpatient drugs purchased under the 340B program. To the extent that we license the right to sell a product to another entity under that entity&#8217;s labeler code, the licensee would further have healthcare reimbursement and pricing regulatory responsibilities.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect that current law and federal and state healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, increased regulatory burdens and operating costs, decreased net revenue from our biologic and pharmaceutical products, decreased potential returns from our development efforts, new payment methodologies and in additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement physicians receive for administering any approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which any products we may develop are prescribed or administered. Any reduction in reimbursement from Medicare or other government healthcare programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The pricing of prescription pharmaceuticals and biologics is also subject to governmental control outside the United States. In certain countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidates to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our ability to generate revenues and become profitable could be impaired.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, there have been a number of other legislative and regulatory proposals aimed at changing the biologic and pharmaceutical industry. For instance, the Drug Quality and Security Act (the &#8220;DQSA&#8221;), imposes obligations on sponsors of </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">67</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">biologic and pharmaceutical products related to product tracking and tracing. Among the requirements of this legislation, sponsors are required to provide certain information regarding the product to individuals and entities to which product ownership is transferred, will be required to label products with a product identifier, and are required keep certain records regarding the product. The transfer of information to subsequent product owners by manufacturers is also required to be done electronically. Sponsors are also required to verify that purchasers of the sponsors&#8217; products are appropriately licensed. Further, manufacturers have product investigation, quarantine, disposition, and FDA and trading partner notification responsibilities related to counterfeit, diverted, stolen, and intentionally adulterated products that would result in serious adverse health consequences of death to humans, as well as products that are the subject of fraudulent transactions or which are otherwise unfit for distribution such that they would be reasonably likely to result in serious health consequences or death. Future licensees or affiliates may also have responsibilities under DQSA.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Compliance with the federal track and trace requirements may increase our operational expenses and impose significant administrative burdens. As a result of these and other new proposals, we may determine to change its current manner of operation, provide additional benefits or change our contract arrangements, any of which could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our employees, independent contractors, consultants, commercial partners, principal investigators, or CROs may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees, independent contractors, consultants, commercial partners, manufacturers, investigators, or CROs could include intentional, reckless, negligent, or unintentional failures to (i) comply with FDA regulations, or other similar regulatory requirements, (ii) comply with manufacturing standards, including cGMP requirements, (iii) comply with applicable fraud and abuse laws, (iv) comply with federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the U.S. and abroad, (v) provide accurate information to the FDA, (vi) properly calculate pricing information required by federal programs, (vii) comply with federal procurement rules&#160;or contract terms, (viii) report financial information or data accurately or (ix) disclose unauthorized activities to us. This misconduct could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">It is not always possible to identify and deter this type of misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting it from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our business and operations would suffer in the event of system failures, and we face risks related to our collection and use of data, which could result in investigations, inquiries, litigation, fines, legislative and regulatory action and negative press about our privacy and data protection practices. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our internal computer systems and those of our CROs and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war, and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product candidate development and, if such product candidates are approved, commercialization programs.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, our business processes personal data, including some data related to health. When conducting clinical trials, we face risks associated with collecting trial participants&#8217; data, especially health data, in a manner consistent with applicable laws and regulations. We also face risks inherent in handling large volumes of data and in protecting the security of such data. We could be subject to attacks on our systems by outside parties or fraudulent or inappropriate behavior by our service providers or employees. Third parties may also gain access to the company&#8217;s systems using stolen or inferred credentials, computer malware, viruses, spamming, phishing attacks or other means, and may use such access to obtain personal data. Data breaches could subject us to individual or consumer class action litigation and governmental investigations and proceedings by federal, </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">68</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">state and local regulatory entities in the U.S. and by international regulatory entities, resulting in exposure to material civil and/or criminal liability. As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities, including various domestic and international privacy and security regulations. The legislative and regulatory landscape for privacy and data protection continues to evolve. In the United States, certain states may adopt privacy and security laws and regulations that may be more stringent than applicable federal law. For example, California enacted the California Consumer Privacy Act (the &#8220;CCPA&#8221;), which took effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal data. We may also in the future be subject to data protection laws and regulations of other jurisdictions, such as the EU's General Data Protection Regulation (&#8220;GDPR&#8221;), which provides data subjects with certain rights and requires organizations to adopt technical and organizational safeguards to protect personal data. In the event that we are subject to or affected by privacy and data protection laws, including the CCPA or GDPR and other domestic or international privacy and data protection laws, we may expend significant resources to comply with such laws, and any liability from failure to comply with the requirements of these laws could adversely affect our financial condition. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, be precluded from developing manufacturing and selling certain products outside the United States, which could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we expand our operations outside of the United States, we must dedicate additional resources to compliance with anti-corruption laws, including the Bribery Act, the FCPA, and other anti-corruption laws that apply in countries where we do business and may do business in the future. The Bribery Act, FCPA and these other laws generally prohibit us, our officers, and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Compliance with the FCPA, in particular, is expensive and difficult, particularly in countries in which corruption is a recognized problem. The FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may in the future operate in jurisdictions that pose a high risk of potential Bribery Act or FCPA violations, and we may participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the Bribery Act, FCPA or local anti-corruption laws. We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United Kingdom and the United States, and authorities in the European Union, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations, collectively referred to as the Trade Control laws. In addition, various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we are not in compliance with the Bribery Act, the FCPA and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. Any investigation of any potential violations of the Bribery Act, the FCPA, other anti-corruption laws or Trade Control laws by U.K., U.S. or other authorities could also have an adverse impact on our reputation, our business, results of operations and financial condition.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Intellectual Property</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be unable to obtain and maintain patent protection for our technology and product candidates, or the scope of the patent protection obtained may not be sufficiently broad or enforceable, such that our competitors could develop and </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">69</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and product candidates may be impaired.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our success depends in large part on its ability to obtain and maintain patent protection in the United States and other countries with respect to its proprietary technology and product candidates. We have sought to protect our proprietary position by filing in the United States and in certain foreign jurisdictions patent applications related to our novel technologies and product candidates.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The patent prosecution process is expensive and time-consuming, and we may not have filed, maintained or prosecuted and may not be able to file, maintain and prosecute all necessary or desirable patents or patent applications at a reasonable cost or in a timely manner. We may also fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The patent position of pharmaceutical and biotechnology companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may fail to result in issued patents in the United States or in other foreign countries which protect our technology or product candidates, or which effectively prevent others from commercializing competitive technologies and products. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States, and the standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, unlike patent law in the United States, European patent law precludes the patentability of methods of treatment of the human body and imposes substantial restrictions on the scope of claims it will grant of broader than specifically disclosed embodiments. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. Therefore, we cannot be certain whether we or our licensors were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions. Databases for patents and publications, and methods for searching them, are inherently limited so we may not know the full scope of all issued and pending patent applications. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. In particular, during prosecution of any patent application, the issuance of any patents based on the application may depend upon our ability to generate additional preclinical or clinical data that support the patentability of its proposed claims. We may not be able to generate sufficient additional data on a timely basis, or at all. Moreover, changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if our owned and licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection for our proprietary technology and product candidates, prevent competitors from competing with us, or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. In particular, a competitor may develop an approach to deliver drugs through the mucus layer to the underlying target tissue that uses a different approach than our OcuNanoE&#8482; nanoemulsion formulation, and therefore may not infringe on our patent rights.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The issuance of a patent is not conclusive as to our inventorship, ownership, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit its ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September&#160;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to United States patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. The USPTO developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">70</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Smith Act, and in particular, the first to file provisions, became effective on March&#160;16, 2013. The first to file provisions limit the rights of an inventor to patent an invention if not the first to file an application for patenting that invention, even if such invention was the first invention. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, which could have a material adverse effect on our business, financial condition, results of operations and prospects. For example, the Leahy-Smith Act created a new administrative tribunal known as the Patent Trial and Appeals Board, or PTAB, that provides a venue for companies to challenge the validity of competitor patents at a cost that is much lower than district court litigation and on timelines that are much faster. Although it is not clear what, if any, long term impact the PTAB proceedings will have on the operation of our business, the outcome of patent challenge proceedings before the PTAB since its inception in 2013 have resulted in the invalidation of many U.S. patent claims. The availability of the PTAB as a lower-cost, faster and potentially more potent tribunal for challenging patents could therefore increase the likelihood that our own patents will be challenged, thereby increasing the uncertainties and costs of maintaining, defending and enforcing them.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are not able to obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity for our product candidates, our business may be materially harmed.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, one of the U.S. patents covering each of such product candidates or the use thereof may be eligible for up to five years of patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act allows a maximum of one patent to be extended per FDA approved product to account for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension also may be available in certain foreign countries upon regulatory approval of our product candidates. Nevertheless, we may not be granted patent term extension either in the United States or in any foreign country because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product may be shortened and our competitors may obtain approval of competing products following our patent expiration sooner, and our revenue could be reduced, possibly materially.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">It is possible that we will not obtain patent term extension under the Hatch-Waxman Act for a U.S. patent covering one of our product candidates even where that patent is eligible for patent term extension, or if we obtain such an extension, it may be for a shorter period than we had sought. Further, for our licensed patents, we do not have the right to control prosecution, including filing with the USPTO, a petition for patent term extension under the Hatch-Waxman Act. Thus, if one of our licensed patents is eligible for patent term extension under the Hatch-Waxman Act, we may not be able to control whether a petition to obtain a patent term extension is filed, or obtained, from the USPTO.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Competitors and other third parties may infringe, misappropriate or otherwise violate its owned and licensed patents, trade secrets, or other intellectual property. As a result, to counter infringement, misappropriation or unauthorized use, we may be required to file infringement or misappropriation claims or other intellectual property related proceedings, which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke such parties to assert counterclaims against us alleging that we infringed their patents or that our asserted patents are invalid. In addition, in a patent infringement or other intellectual property related proceeding, a court may decide that a patent of our is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly, and could put any of our patent applications at risk of not yielding an issued patent. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information or trade secrets could be compromised by disclosure during this type of litigation.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may be subject to a third-party preissuance submission of prior art to the USPTO, or become involved in other contested proceedings such as opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings in </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">71</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the United States or elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the United States, the FDA does not prohibit clinicians from prescribing an approved product for uses that are not described in the product&#8217;s labeling. Although use of a product directed by off-label prescriptions may infringe our method-of-treatment patents, the practice is common across medical specialties, particularly in the United States, and such infringement is difficult to detect, prevent or prosecute.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our commercial success depends upon our ability to develop, manufacture, market and sell OCU300, and other product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and other proprietary rights of third parties. There is a considerable amount of intellectual property litigation in the biotechnology and pharmaceutical industries. We may become party to, or threatened with, infringement litigation claims regarding our products and technology, including claims from competitors or from non-practicing entities that have no relevant product revenue and against whom our own patent portfolio may have no deterrent effect. Moreover, we may become party to future adversarial proceedings or litigation regarding our patent portfolio or the patents of third parties. Such proceedings could also include contested post-grant proceedings such as oppositions, inter partes review, reexamination, interference or derivation proceedings before the USPTO or foreign patent offices.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The legal threshold for initiating litigation or contested proceedings is low, so even lawsuits or proceedings with a low probability of success might be initiated and require significant resources to defend. Litigation and contested proceedings can also be expensive and time-consuming, and our adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we do. The risks of being involved in such litigation and proceedings may increase as our product candidates near commercialization and as we gain the greater visibility associated with being a public company. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. We may not be aware of all such intellectual property rights potentially relating to our product candidates and their uses.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Thus, we do not know with certainty that OCU300 or any of our other product candidates, or our development and commercialization thereof, do not and will not infringe or otherwise violate any third party&#8217;s intellectual property.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we are found to infringe, misappropriate or otherwise violate a third party&#8217;s intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing its products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we are able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us and could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent, and could be forced to indemnify our customers or collaborators. A finding of infringement could also result in an injunction that prevents us from commercializing our product candidates or forces us to cease some of our business operations, which could materially harm our business. In addition, we may be forced to redesign our product candidates, seek new regulatory approvals and indemnify third parties pursuant to contractual agreements. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Periodic maintenance, renewal and annuity fees on any issued patent must be paid to the USPTO and foreign patent agencies in several stages or annually over the lifetime of our owned and licensed patents and patent applications. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, we rely on our licensing partners to pay these </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">72</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">fees to, or comply with the procedural and documentary rules of the relevant patent agency. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications covering our product candidates, it would have a material adverse effect on our business.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Certain aspects of OCU300 and our other product candidates, and certain aspects of our OcuNanoE</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">&#8482;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">&#160;nanoemulsion formulation, are protected by patents exclusively licensed from other companies or institutions. If these third parties terminate their agreements with us or fail to maintain or enforce the underlying patents, or we otherwise lose our rights to these patents, our competitive position and our market share in the markets for any of our approved products will be harmed.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A substantial portion of our patent portfolio is in-licensed. As such, we are a party to license agreements and certain aspects of its business depend on patents and/or patent applications owned by other companies or institutions. In particular, we hold exclusive licenses for patent families relating to OCU300, other of our product candidates, and some aspects of our OcuNanoE&#8482;&#160;nanoemulsion formulation.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the license arrangement with UIC, which relates to OCU300, we are responsible for and control patent prosecution of licensed patent families developed jointly pursuant to the license arrangement with UIC, while we and UIC are each responsible for and control patent prosecution of licensed patent families developed or held individually by us or UIC, respectively.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the license arrangement with CU, which primarily relates to OCU200, we are responsible for and control patent prosecution of all patent families licensed under the CU license arrangement.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the license arrangement with SERI, which relates to NHR genes </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NR1D1</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NR2E3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">RORA</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NUPR1</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NR2C1</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, from and after December&#160;19, 2017, we have the right to assume responsibility and control patent prosecution of licensed patent families relating to these NHR genes. Additionally, we are responsible for and control patent prosecution for any patent applications developed in connection with the SERI licensing arrangement filed after December&#160;19, 2017 that are owned jointly by us and SERI or solely by us.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our rights with respect to in-licensed patents and patent applications may be lost if the applicable license agreement expires or is terminated. We are likely to enter into additional license agreements to in-license patents and patent applications as part of the development of our business in the future, under which we may not retain control of the preparation, filing, prosecution, maintenance, enforcement and defense of such patents. If we are unable to maintain these patent rights for any reason, our ability to develop and commercialize our product candidates could be materially harmed.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our licensors may not successfully prosecute certain patent applications, the prosecution of which they control, under which we are licensed and on which our business depends. Even if patents issue from these applications, our licensors may fail to maintain these patents, may decide not to pursue litigation against third-party infringers, may fail to prove infringement, or may fail to defend against counterclaims of patent invalidity or unenforceability.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Risks with respect to parties from whom we have obtained intellectual property rights may also arise out of circumstances beyond our control. In spite of our best efforts, our licensors might conclude that we have materially breached our intellectual property agreements and might therefore terminate the intellectual property agreements, thereby removing our ability to market products covered by these intellectual property agreements. If our intellectual property agreements are terminated, or if the underlying patents fail to provide the intended market exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products similar or identical to ours. Moreover, if our intellectual property agreements are terminated, our former licensors and/or assignors may be able to prevent us from utilizing the technology covered by the licensed or assigned patents and patent applications. This could have a material adverse effect on our competitive business position and our business prospects.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Some intellectual property which we own or have licensed may have been discovered through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements, and a preference for U.S. industry. Compliance with such regulations may limit our exclusive rights, subject us to expenditure of resources with respect to reporting requirements, and limit our ability to contract with non-U.S. manufacturers.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">73</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Some of the intellectual property rights that we own or licenses have been generated through the use of United States government funding and may therefore be subject to certain federal regulations under the Bayh-Dole Act. To the best of our knowledge, our intellectual property for OCU400 for the treatment of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">NR2E3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> mutation-associated retinal degenerative disease and other retinal degenerative diseases is subject to the Bayh-Dole Act. As a result, the United States government may have certain rights to intellectual property embodied in these patents and patent applications. In general, the Bayh-Dole Act provides the U.S. government certain rights in inventions developed using a government funded program, such as U.S. government&#8217;s right to a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, under the Bayh-Dole Act the U.S. government has the right to require any invention developed using U.S. government funding to be granted exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i)&#160;adequate steps have not been taken to commercialize the invention; (ii)&#160;government action is necessary to meet public health or safety needs; or (iii)&#160;government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). Under the Bayh-Dole Act, the U.S. government also has the right to take title to inventions developed using a U.S. government funded program, if one fails to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. In addition, the U.S. government may acquire title to these inventions in any country in which a patent application is not filed within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements. In addition, the Bayh-Dole Act requires that any products subject to the Bayh-Dole Act be manufactured substantially in the United States. However, under the Bayh-Dole Act, this manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable efforts to manufacture the product substantially in the United States were unsuccessful or that under the circumstances domestic manufacture is not commercially feasible. Any exercise by the government of any of the foregoing rights under the Bayh-Dole Act may affect our competitive position, business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we fail to comply with our obligations in our intellectual property licenses and funding arrangements with third parties, we could lose rights that are important to our business.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our license agreements with CU, UIC, and SERI under which we license certain of our patent rights and a significant portion of the technology for OCU300 and other product candidates, impose royalty and other financial obligations on us and other substantial performance obligations. We may also enter into additional licensing and funding arrangements with third parties that may impose diligence, development and commercialization timelines and milestone payment, royalty, insurance and other obligations on us. If we fail to comply with our obligations under current or future license and collaboration agreements, our counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture or market any product that is covered by these agreements or may face other penalties under the agreements. Such an occurrence could diminish the value of our products and product candidates. Termination of these agreements or reduction or elimination of our rights under these agreements may result in us having to negotiate new or reinstated agreements with less favorable terms or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, it is possible that CU, UIC or SERI may conclude that we have materially breached the applicable license agreement and might therefore terminate the agreement, thereby removing our ability to market products covered by our license agreements with CU, UIC, or SERI, respectively. If any license agreement is terminated, or if the underlying patents fail to provide the intended market exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products similar or identical to ours. Moreover, if any of our license agreements is terminated, the counterparty and/or its assignors may be able to prevent us from utilizing the technology covered by the licensed or assigned patents and patent applications. This could have a material adverse effect on our competitive business position and our business prospects.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the agreements under which we currently licenses intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not be able to protect our intellectual property and proprietary rights throughout the world.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">74</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection or licenses, but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property or claiming ownership of what we regard as our own intellectual property.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many of our and our licensors&#8217; employees and contractors were previously employed at other biotechnology, medical device or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees and contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. Litigation may be necessary to defend against these claims.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Furthermore, we are unable to control whether its licensors have obtained similar assignment agreements from their own employees and contractors. Our and their assignment agreements may not be self-executing or may be breached, and we or our licensors may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we or our licensors fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel which could have a material adverse effect on our competitive business position and prospects. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products, which may not be available on commercially reasonable terms or at all. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Intellectual property litigation or other legal proceedings relating to intellectual property could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">75</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and may also have an advantage in such proceedings due to their more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have an adverse effect on our ability to compete in the marketplace.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to seeking patents for our technology and product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Detecting the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Employee Matters and Managing Growth</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are highly dependent on the research and development, clinical and business development expertise of Shankar Musunuri, Ph.D., MBA, our Chief Executive Officer, Chairman of the Board and Co-Founder, Daniel Jorgensen, M.D., M.P.H., MBA, our Chief Medical Officer, and Rasappa Arumugham, Ph.D., our Chief Scientific Officer, as well as the other principal members of our management, scientific and clinical teams. Although we have entered into employment agreements with our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Recruiting and retaining qualified scientific, clinical, manufacturing, legal and sales and marketing personnel will also be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We expect to expand our development, regulatory and manufacturing capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, clinical, regulatory affairs, manufacturing, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Our management may need to devote a significant amount of our attention to managing these growth activities. Due to our limited financial resources and our limited experience in managing such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. Our inability to manage the expansion of our operations effectively may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could also require significant capital expenditures and </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">76</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">may divert financial resources from other projects, such as the development of additional product candidates. If we are unable to effectively manage our expected growth, our expenses may increase more than expected, our ability to generate revenues could be reduced and we may not be able to implement our business strategy, including the successful commercialization of our product candidates.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Common Stock</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The trading price of the shares of the our Common Stock could be highly volatile, and purchasers of the Common Stock could incur substantial losses.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our stock price has been, and will likely continue to be volatile. The stock market in general and the market for stock of biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at or above their purchase price. The market price for our common stock may be influenced by those factors discussed in this &#8220;Risk Factors&#8221; section and many others, including:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to enroll subjects in its ongoing and planned clinical trials;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">results of our clinical trials and preclinical studies, and the results of trials of our competitors or those of other companies in our market sector;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">regulatory approval of our product candidates, or limitations to specific label indications or patient populations for our use, or changes or delays in the regulatory review process;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the level of expenses related to any of our product candidates or clinical development programs;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">regulatory developments in the United States and foreign countries;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">reports of adverse events in other of our products, competing biologics or gene therapy products;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">changes in the structure of healthcare payment systems, especially in light of current reforms to the U.S. healthcare system;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the success or failure of our efforts to acquire, license or develop additional product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">innovations or new products developed by us or our competitors;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">manufacturing, supply or distribution delays or shortages;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">any changes to our relationship with any manufacturers, suppliers, licensors, future collaborators or other strategic partners;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">achievement of expected product sales and profitability;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">variations in our financial results or those of companies that are perceived to be similar to ours;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">market conditions in the biopharmaceutical sector and issuance of securities analysts&#8217; reports or recommendations;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">trading volume of our common stock;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">an inability to obtain additional funding;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">sales of our stock by insiders and stockholders or the perception that such sales could occur;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to effectively manage its growth;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">ineffectiveness of our internal control over financial reporting;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">additions or departures of key personnel, including major changes in our board or management;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">intellectual property, product liability or other litigation against us; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">general economic, industry and market conditions other events or factors, many of which are beyond our control.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, in the past, stockholders have initiated class action lawsuits against biopharmaceutical companies following periods of volatility in the market prices of these companies&#8217; stock. Such litigation, if instituted against us, could cause us to incur </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">77</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">substantial costs and divert management&#8217;s attention and resources, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">An active trading market for our common stock may not be sustainable. If an active trading market is not sustained, our ability to raise capital in the future may be impaired.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following the consummation of our reverse merger, our shares of common stock continue to be listed and are trading on the Nasdaq. However, an active trading market for our shares of common stock may not be sustained. If an active market for our common stock is not sustained, it may be difficult for our stockholders to sell shares of our common stock without depressing the market price for the shares or at all. An inactive trading market may also impair our ability to raise capital to continue to fund operations by selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our failure to meet the continued listing requirements of the Nasdaq could result in a delisting of the Common Stock.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We must continue to satisfy Nasdaq continued listing requirements, including, among other things, certain corporate governance requirements and a minimum closing bid price requirement of $1.00 per share. If a company fails for 30 consecutive business days to meet the $1.00 minimum closing bid price requirement, Nasdaq will send a deficiency notice to the company, advising that it has been afforded a &#8220;compliance period&#8221; of 180 calendar days to regain compliance with the applicable requirements.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 27, 2019, we received a deficiency letter from the Nasdaq notifying us that, for the last 30 consecutive business days, the closing bid price for our common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to the minimum closing bid price requirement. The Nasdaq deficiency letter had no immediate effect on the listing of our common stock. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have been given 180 calendar days, or until June 24, 2020, to regain compliance with the minimum closing bid price requirement by causing its stock to close above $1.00 for a minimum of 10 consecutive trading days. If we do not regain compliance with the minimum closing bid price requirement by June 24, 2020, we may be afforded a second 180 calendar day period to regain compliance. To qualify, we would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq, except for the minimum bid price requirement. In addition, we would be required to notify Nasdaq of our intent to cure the deficiency during the second compliance period.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We can provide no assurance that we will be able to regain compliance with the minimum closing bid price requirement by June 24, 2020, or by any date, or that we will be able to remain in compliance with other Nasdaq continued listing requirements. A delisting of our common stock from Nasdaq could materially reduce the liquidity of our common stock, impairing your ability to sell or purchase shares of common Stock when you wish to do so, and could result in a corresponding material reduction in the price of our common stock. In addition, delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors and employees. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow the common stock to become listed again, stabilize the market price or improve the liquidity of the common stock, prevent the common stock from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq&#8217;s listing requirements.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If shares of our common stock cease to be listed on a national exchange they may become subject to the &#8220;penny stock&#8221; rules of the SEC and the trading market in our securities may become limited, which will make transactions in its stock cumbersome and may reduce the value of an investment in the stock.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If shares of our common stock cease to be listed on the Nasdaq or another national exchange, they may be subject to regulation as a &#8220;penny stock&#8221; under Rule 15g-9 under the Exchange Act. That rule establishes the definition of a &#8220;penny stock,&#8221; for the purposes relevant to us, as any equity security that is no longer trading on a national exchange and has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, the rules require: (a) that a broker or dealer approve a person&#8217;s account for transactions in penny stocks; and (b) the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In order to approve a person&#8217;s account for transactions in penny stocks, the broker or dealer must: (a) obtain financial information and investment experience objectives of the person and (b) make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks. The broker or dealer must also deliver, prior to any transaction </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">78</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">in a penny stock, a disclosure schedule prescribed by the SEC relating to the penny stock market, which, in highlight form: (x) sets forth the basis on which the broker or dealer made the suitability determination; and (y) confirms that the broker or dealer received a signed, written agreement from the investor prior to the transaction.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Disclosure also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker or dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Generally, brokers may be less willing to execute transactions in securities subject to the &#8220;penny stock&#8221; rules. This may make it more difficult for investors to dispose of our common stock and cause a decline in the market value of our common stock.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If shares of our common stock cease to be listed on a national exchange, our securities will not be eligible for federal preemption rights and be subject to state &#8220;blue sky&#8221; laws which may affect our capabilities of raising capital.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Each state has its own securities laws, often called &#8220;blue sky&#8221; laws, which (i) limit sales of securities to a state&#8217;s residents unless the securities are registered in that state or qualify for an exemption from registration, and (ii) govern the reporting requirements for broker-dealers doing business directly or indirectly in the state. Before a security is sold in a state, there must be a registration in place to cover the transaction, or the transaction must be exempt from registration. The applicable broker must be registered in that state. We do not know whether securities will be registered or exempt from registration under the laws of any state. If our securities cease to be listed on the national exchange, a determination regarding registration will be made by those broker-dealers, if any, who agree to serve as the market-makers for our common stock. Registering or qualifying shares with states can be time consuming. Compliance and regulatory costs may vary from state to state and may adversely affect future financings and our ability to raise capital.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If our common stock is delisted from a national exchange, some institutional investors may not be allowed to purchase our shares and may be required to liquidate their current positions in our stock which could negatively affect the price and volatility of our shares.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Institutional investors may be restricted by their investment policies from investing in shares of companies that are not listed on a national exchange and may be required to liquidate their positions if our securities are delisted from a national exchange. Liquidations, should they occur, may increase volatility and cause wide fluctuations and further declines in the prices of our securities.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation, if any, in the price of our common stock.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have never declared or paid any cash dividend on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and does not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, the terms of any future debt agreements may preclude us from paying dividends. Any return to stockholders will therefore be limited to the appreciation of their stock. There is no guarantee that the common stock will appreciate in value or even maintain the price at which stockholders have purchased their shares.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Sales of a substantial number of common stock by our stockholders in the public market could cause our stock price to fall.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of common stock in the public market, the market price of our common stock could decline. We had 52.6 million shares of common stock outstanding as of December&#160;31, 2019. Of these shares, 46.9&#160;million shares of common stock were freely tradable, without restriction, in the public market as of December&#160;31, 2019. Upon the expiration of lock-up agreements entered into by our directors, executive officers and certain other stockholders in connection with the reverse merger, which expiration occurred on March 25, 2020, approximately 5.7 million shares of our common stock became eligible for sale in the public market to the extent permitted by the provisions of Rule 144 and Rule 701 under the Securities Act.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline, we are unable to predict the effect that sales may have on the prevailing market price of our common stock.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">79</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We began operating as a public company as a result of the Merger. As a public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company prior to the reverse merger. We are subject to the reporting requirements of the Exchange Act, which require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, Sarbanes-Oxley, as well as rules&#160;subsequently adopted by the SEC and Nasdaq to implement provisions of Sarbanes-Oxley, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. During the period we were considered an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, we were able to take advantage of certain exemptions from various reporting requirements that are applicable to public companies that are not emerging growth companies. As of December 31, 2019, we are no longer an emerging growth company, and accordingly we will no longer be able to take advantage of exemptions available by virtue of having emerging growth company status. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules&#160;and regulations in these areas, such as mandatory &#8220;say on pay&#8221; voting requirements that are applicable to us following its ceasing to be an emerging growth company. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect the rules&#160;and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules&#160;and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our Board of Directors, our board committees or as executive officers.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If securities or industry analysts do not publish research or reports or publish unfavorable research or reports about our business, our stock price and trading volume could decline.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us, our business, our market or our competitors. We do not currently have and may never obtain research coverage by securities and industry analysts. If no securities or industry analysts commence coverage of us, the trading price for our stock would be negatively impacted. In the event we obtain securities or industry analyst coverage, if one or more of the analysts who covers us downgrades our stock, our stock price would likely decline. If one or more of these analysts ceases to cover us or fails to regularly publish reports on us, interest in our stock could decrease, which could cause our stock price or trading volume to decline.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to Section&#160;404 of Sarbanes-Oxley, our management is required to report upon the effectiveness of our internal control over financial reporting. Additionally, if we reach an accelerated filer threshold, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules&#160;governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we will need to upgrade our information technology systems; implement additional financial and management controls, reporting systems and procedures; and hire additional accounting and finance staff. If we or, if required, our auditors are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">80</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or, if applicable, if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could significantly reduce the value of our shares to a potential acquiror or delay or prevent changes in control or changes in our management without the consent of our Board of Directors. The provisions in our charter documents include the following:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">a classified Board of Directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our Board of Directors;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the exclusive right of our Board of Directors, unless the Board of Directors grants such right to the stockholders, to elect a director to fill a vacancy created by the expansion of the Board of Directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our Board of Directors;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the prohibition on removal of directors without cause due to the classified Board of Directors;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the ability of our Board of Directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the ability of our Board of Directors to alter our amended and restated bylaws without obtaining stockholder approval;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the required approval of at least&#160;66-2/3%&#160;of the shares entitled to vote to adopt, amend or repeal our amended and restated bylaws or repeal certain provisions of our amended and restated certificate of incorporation;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">an exclusive forum provision providing that the Court of Chancery of the State of Delaware will be the exclusive forum for certain actions and proceedings;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the requirement that a special meeting of stockholders may be called only by the chairman of the Board of Directors, the chief executive officer or the Board of Directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">advance notice procedures that stockholders must comply with in order to nominate candidates to our Board of Directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of us.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are also subject to the anti-takeover provisions contained in Section&#160;203 of the Delaware General Corporation Law. Under Section&#160;203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">81</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our sixth amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our sixth amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine. This exclusive forum provision would not apply to suits brought to enforce any liability or duty created by the Securities Act or the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. By agreeing to this provision, however, stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules&#160;and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Certain of the warrants issued in the Pre-Merger Financing contain price-based adjustment provisions which, if triggered, may cause substantial additional dilution to our stockholders.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our Series A Warrants to purchase common stock (the "Series A Warrants"), which were issued in connection with the June 2019 common stock and warrant financing entered into by Former Ocugen and Histogenics with certain accredited investors for an aggregate purchase price of $25.0 million (the "Pre-Merger Financing"), contain price-based adjustment provisions, pursuant to which the number of shares of our common stock that are issuable upon exercise of such Series A Warrants may be adjusted upward in the event of certain dilutive issuances by us. Even if our stock increases in value, the number of shares of our common stock issuable upon exercise of the Series A Warrants may still increase. The circumstances under which the number of shares of our common stock issuable upon exercise of the Series A Warrants may be adjusted upward are set forth in the Series A Warrants.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2019, the holders of our Series B Warrants and Series C Warrants, which were also issued in connection with the Pre-Merger Financing, had exercised such warrants for an aggregate issuance of 40.5 million shares of our common stock. If the Series A Warrants are exercised, additional shares of our common stock will be issued, which will result in dilution to our then-existing stockholders and increase the number of shares eligible for resale in the public market. Ignoring certain blocker provisions which prevent exercises of the Series A Warrants if the exercising holder would beneficially own in excess of 4.99% or 9.99%, as applicable, of the outstanding common stock (including the common stock issuable upon such exercise), following the issuance of the maximum number of shares issuable upon exercise of the Series A Warrants, the holders of such Series A Warrants would acquire in the aggregate an additional 8.8 million shares of our common stock, representing approximately 14.3% of our total outstanding common stock following such issuance. In the event that we enter into a transaction with holders of the Series A Warrants to restructure the terms thereof, the number of shares of common stock into which such warrants are exercisable could be increased, resulting in even greater dilution to then-existing stockholders. Sales of substantial numbers of such shares in the public market could depress the market price of the common stock.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1614"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;1B.&#160;Unresolved Staff Comments.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1620"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 2.&#160;Properties</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our headquarters are located in Malvern, Pennsylvania, and consist of an aggregate of approximately 8,038 square feet of leased office space under one lease that expires by February&#160;28, 2022. We currently sublease laboratory space from another company in Malvern, Pennsylvania, pursuant to an agreement that expires on June 30, 2020.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_130"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">82</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="text-indent:-54pt;padding-left:54pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;3.&#160;Legal Proceedings.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, we are subject to claims in legal proceedings arising in the normal course of its business. We do not believe that we are currently party to any pending legal actions that could reasonably be expected to have a material adverse effect on our business, financial condition, results of operations or cash flows.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1627"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;4.&#160;Mine Safety Disclosures.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1606"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">83</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART II</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1636"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;5.&#160;Market for Registrant's Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Market Information</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our common stock is traded on The NASDAQ Capital Market under the symbol &#8220;OCGN.&#8221;</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Stockholders</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March 20, 2020, we had 52.6 million shares of common stock outstanding held by approximately 38 stockholders of record. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in &#8220;street&#8221; name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Dividend Policy</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have not declared or paid any cash dividends on our capital stock. We currently anticipate that we will retain future earnings, if any, to finance our operations and do not anticipate declaring or paying any cash dividends in the foreseeable future. As a result, we anticipate that only appreciation of the price of our common stock, if any, will provide a return to investors for at least the foreseeable future.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the period covered by this Annual Report, there were no sales by us of unregistered securities that were not previously reported by us in a Quarterly Report on Form 10-Q or Current Report on Form 8-K.</span></div><div style="text-indent:1.35pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Information about our equity compensation plans is incorporated herein by reference to Part III, Item 12 of this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Share Repurchase</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On October 9, 2019, we announced that our Board of Directors unanimously approved a share repurchase program authorizing the repurchase of up to $2.0 million in value of the outstanding common stock.&#160;Pursuant to this repurchase program, we plan to repurchase the common stock provided that the timing, actual number and price per share of the common stock to be purchased will be subject to management discretion and board guidance, market conditions, applicable legal requirements, including Rule&#160;10b-18 of the Exchange Act and various other factors. In November and December 2019, we repurchased 26,500 and 95,000 shares of common stock, respectively, at an average price of $0.25 and $0.42 per share, respectively.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_13"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 6.&#160;Selected Financial Data</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not required for smaller reporting companies.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> </span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_94"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">84</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="text-indent:-54pt;padding-left:54pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;7.&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the financial statements and the notes thereto included elsewhere in this Annual Report on Form&#160;10-K. Some of the information contained in this discussion and analysis, including information with respect to our plans and strategy for our business and related financing, include forward-looking statements that involve risks, uncertainties and assumptions. These statements are based on our beliefs and expectations about future outcomes and are subject to risks and uncertainties that could cause our actual results to differ materially from anticipated results. We undertake no obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise. You should read the &#8220;Risk Factors&#8221; and &#8220;Special Note Regarding Forward-Looking Statements&#8221; sections of this Annual Report on Form&#160;10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">On September 27, 2019, Ocugen completed its reverse merger with Ocugen OpCo Inc. (formerly known as Ocugen, Inc. (&#8220;Former Ocugen&#8221;)) in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of April 5, 2019, by and among Histogenics, Former Ocugen and Restore Merger Sub, Inc., a wholly owned subsidiary of Histogenics (&#8220;Merger Sub&#8221;), as amended (the &#8220;Merger Agreement&#8221;), pursuant to which Merger Sub merged with and into Former Ocugen, with Former Ocugen surviving as a wholly owned subsidiary of Histogenics (the &#8220;Merger&#8221;). Immediately after completion of the Merger, Histogenics changed its name to Ocugen, Inc. For accounting purposes, the Merger is treated as a &#8220;reverse asset acquisition&#8221; under generally acceptable accounting principles in the United States (&#8220;U.S. GAAP&#8221;) and Former Ocugen is considered the accounting acquirer. Accordingly, Former Ocugen&#8217;s historical results of operations replaced the Company&#8217;s historical results of operations for all periods prior to the Merger and, for all periods following the Merger, the results of operations of the combined company will be included in the Company&#8217;s financial statements.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_97"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat the whole eye.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our lead product candidate, OCU300, is a small molecule therapeutic currently in Phase 3 clinical development for patients with ocular redness and discomfort stemming from ocular graft-versus-host disease (&#8220;oGVHD&#8221;). As of March&#160;20, 2020, we had completed over 95% of planned enrollment of our Phase 3 clinical trial for OCU300. OCU300 has received Orphan Drug Designation (&#8220;ODD&#8221;) from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;), and it is the first and only product candidate to receive that designation for the treatment of symptoms associated with oGVHD. oGVHD, a severe chronic autoimmune disease that occurs in up to 60% of allogeneic hematopoietic stem cell transplantation (&#8220;HSCT&#8221;) patients, can result in light sensitivity, excessive ocular redness, severe ocular pain and, ultimately, vision impairment. We estimate the current prevalence of patients suffering from oGVHD in the United States to be approximately 63,000. OCU300 is formulated using our proprietary nanoemulsion technology, OcuNanoE&#8212;Ocugen&#8217;s ONE Platform</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;OcuNanoE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), which we believe represents an effective drug delivery mechanism to treat ocular surface disorders. We believe that OcuNanoE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> provides additional protection to the ocular surface and the potential for enhanced efficacy compared to traditional formulations. We are the first company to use nanoemulsion technology in the ophthalmology space.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We were developing OCU310 for patients with dry eye disease, which is also formulated using OcuNanoE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. We have completed a Phase 3 clinical trial for OCU310 that was initiated in September 2018. Although the trial showed that OCU310 is safe and well-tolerated, it did not meet its co-primary endpoints for symptom and sign. We are no longer pursuing the development of this product candidate.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are also developing a modifier gene therapy platform to generate therapies designed to fulfill unmet medical needs in the area of retinal diseases, including inherited retinal diseases (&#8220;IRDs&#8221;). Our modifier gene therapy platform is being designed to target nuclear hormone receptors (&#8220;NHRs&#8221;), which have the potential to restore homeostasis to the retina. Unlike single-gene replacement therapies, which only target one genetic mutation, we believe that our gene therapy platform, through its use of NHRs, represents a novel approach in that it may address multiple retinal diseases with one product. Our first gene therapy candidate, OCU400, received two ODDs from the FDA, one for the treatment of nuclear receptor subfamily 2 group E member 3 ("</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NR2E3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">") mutation-associated retinal diseases and the other for the treatment of centrosomal protein 290 ("</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">CEP290</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">") mutation-associated retinal diseases. We are planning to initiate a Phase 1/2a clinical trial for OCU400 in the next two years. Our second gene therapy candidate, OCU410, is being developed to utilize the nuclear receptor genes RAR-related orphan receptor A (&#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">RORA</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) for the treatment of dry age-related macular degeneration (&#8220;AMD&#8221;). This candidate is currently in preclinical development.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">85</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, we are conducting preclinical development for a novel biologic product candidate. OCU200 is a novel fusion protein designed to treat diabetic macular edema (&#8220;DME&#8221;), diabetic retinopathy (&#8220;DR&#8221;) and wet age-related macular degeneration (&#8220;wet AMD&#8221;). We expect to initiate a Phase 1/2 clinical trial for OCU200 within the next two years. We plan to expand the therapeutic applications of OCU200 beyond DME, DR and wet AMD to potentially include macular edema following retinal vein occlusion (&#8220;RVO&#8221;) and myopic choroidal neovascularization (&#8220;mCNV&#8221;).</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have no products approved for commercial sale and have not generated any revenue from product sales. We have never been profitable and have incurred operating losses in each year since inception. We incurred net losses of approximately $20.2 million and $18.2 million for the fiscal years ended December&#160;31, 2019 and 2018, respectively. As of December&#160;31, 2019, we had an accumulated deficit of $51.5 million and a cash, cash equivalents and restricted cash balance of $7.6 million. Substantially all of our operating losses resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To date, we have viewed our operations and manage our business as one operating segment. As of December&#160;31, 2019, all of our assets were located in the United States. Our headquarters and operations are located in Malvern, Pennsylvania.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_100"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Financial Operations Overview</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and development expense</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development costs are expensed as incurred. These costs consist of internal and external expenses. Internal expenses include the cost of salaries, benefits and other related costs, including stock-based compensation, for personnel serving in our product development functions, as well as allocated rent and utilities expenses. External expenses include development, clinical trials, patent costs and regulatory compliance costs incurred with research organizations and other third-party vendors. License fees paid to acquire access to proprietary technology are expensed to research and development unless it is determined that the technology is expected to have an alternative future use. All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred to research and development expense due to the uncertainty about the recovery of the expenditure. We record costs for certain development activities, such as clinical trials, based on our evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development expense, as the case may be.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We plan to incur research and development expenses for the foreseeable future as we expect to continue development and eventual commercialization of one or more of our product candidates, if approved. We anticipate that our research and development expenses will increase substantially as compared to prior periods as we complete our Phase 3 trial with respect to OCU300 and prepare to commence Phase 1/2a trials with respect to OCU400, OCU410 and OCU200, and otherwise develop and prepare for commercialization of our product candidates. At this time, due to the inherently unpredictable nature of preclinical and clinical development, we are unable to estimate with any certainty the costs we will incur and the timelines we will require in our continued development efforts.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of the uncertainties discussed above, successful development and completion of clinical trials is uncertain and may not result in approved products. Completion dates and completion costs can vary significantly for each future product candidate and are difficult to predict. We will continue to make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to our ability to enter into collaborations with respect to each product candidate, the scientific and clinical success of each product candidate as well as ongoing assessments as to the commercial potential of each product candidates.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">General and administrative expense</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative expense consists primarily of personnel expenses, including salaries, benefits and stock-based compensation expense, for employees in executive, accounting and other administrative functions. General and administrative expense also includes corporate facility costs, including rent and utilities, as well as legal fees related to corporate matters and fees for accounting and other consulting services.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We anticipate that our general and administrative expense will increase as a result of an expanded infrastructure and an increased headcount. We anticipate higher corporate infrastructure costs including, but not limited to accounting, legal, human resources, consulting, and investor relations fees, as well as increased director and officer insurance premiums, associated with becoming a public company. Additionally, if and when we believe a regulatory approval of a product candidate appears likely, </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">86</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">we anticipate an increase in payroll and expense as a result of its preparation for commercial operations, especially as it relates to the sales and marketing of our product candidates.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Change in fair value of derivative liabilities</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Change in fair value of derivative liabilities includes the change in fair value each reporting period of (a) the conversion and change in control features embedded in certain convertible notes, which were required to be bifurcated and recognized at fair value, and (b) the change in the fair value of the Company's Series B Warrants that were issued in connection with a Securities Purchase Agreement entered into with certain accredited investors in June 2019. The change in fair value of derivative liabilities related to the Series&#160;B Warrants was recognized through the date the Series B Warrants were reclassified to equity. The reclassification to equity occurred once the Series B Warrants were reassessed and determined to meet the derivative scope exception related to equity indexation allowing for equity classification. See Note 10 in the notes to the consolidated financial statements included in this report for additional information. The change in fair value of derivative liabilities related to our convertible notes was recognized through the date that the notes were converted or otherwise settled. There were no derivative liabilities valued as of December&#160;31, 2019. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other income (expense)</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other income (expense) consists primarily of interest expense, including the amortization of debt issuance costs related to our debt and accretion of the discount created by the bifurcation of the embedded conversion features and embedded change in control features from certain of the convertible promissory notes, interest income earned on our cash and cash equivalents held with institutional banks, and foreign currency income (losses) due to exchange rate fluctuations on transactions denominated in a currency other than its functional currency.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_103"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The preparation of our financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reported period. We base our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions and conditions.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While our significant accounting policies are described in more detail in the notes to the consolidated financial statements appearing elsewhere in this report, we believe that the following accounting policies and estimates are those most critical to the preparation of our consolidated financial statements:</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-based compensation</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We account for our stock-based compensation awards in accordance with the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 718, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Compensation&#8212;Stock Compensation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments to employees, including grants of employee stock options and restricted stock units and modifications to existing agreements, to be recognized in the statements of operations based on their fair values. We use the Black-Scholes option-pricing model to determine the fair value of options granted.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our stock-based awards are subject to service-based vesting conditions. Compensation expense related to awards to employees and directors with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Estimating the fair value of options requires the input of subjective assumptions, including expected life of the option, stock price volatility, the risk-free interest rate and expected dividends. The assumptions used in our Black-Scholes option-pricing model represent our best estimates and involve a number of variables, uncertainties and assumptions and the application of management&#8217;s judgment, as they are inherently subjective. If any assumptions change, our stock-based compensation expense could be materially different in the future.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">87</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These assumptions used in our Black-Scholes option-pricing model are as follows:</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Term.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Due to the historical lack of a public market for the trading of our common stock and the lack of sufficient company-specific historical data, the expected term of employee options is determined using the &#8220;simplified&#8221; method, as prescribed in Securities and Exchange Commission's ("SEC") Staff Accounting Bulletin No. 107 (&#8220;SAB&#160;No.&#160;107&#8221;), whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option. The expected term of non-employee options is equal to the contractual term.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Volatility.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The expected volatility is based on historical volatilities of similar entities within our industry which were commensurate with the expected term assumption as described in SAB No.&#160;107.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk-Free Interest Rate.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Dividends.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The expected dividend yield is 0% because we have not historically paid, and do not expect for the foreseeable future to pay, a dividend on our common stock.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock-based compensation expense was $0.9 million and $1.1 million for the years ended December 31, 2019 and 2018, respectively. At December&#160;31, 2019, we had $0.9 million of unamortized stock-based compensation expense related to unvested service-based stock options, which is expected to be recognized over a remaining weighted-average vesting period of 1.7 years.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Derivative liabilities</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our convertible notes contained bifurcated conversion features classified as derivative liabilities as the conversion feature does not have a fixed conversion price and conversion will be settled in a variable number of shares. Our convertible notes also contain bifurcated change in control features that were determined to be redemption features and not clearly and closely related to the debt host. We estimated the fair value of the embedded conversion and change in control features at each issuance of convertible promissory notes and at the end of each reporting period using an income approach model. Inputs into this model include the expected time until conversion or change in control and our estimates of the probability of conversion or change in control occurring. There are no such derivatives valued as of December&#160;31, 2019, due to either the payment or conversion of the related notes.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We issued warrants to purchase common stock and we account for our warrants in accordance with FASB ASC Topic 815-40, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC 815-40&#8221;), which is the authoritative guidance on accounting for derivative financial instruments indexed to and potentially settled in a company&#8217;s own stock. To determine whether a contract is considered indexed to the issuer&#8217;s own equity, we perform the following two-step analysis: (1)&#160;evaluate whether the contract contains any exercise contingencies and, if so, whether they disqualify the contract from being classified as equity, and (2)&#160;assess whether the settlement terms are consistent with equity classification.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We entered into a Securities Purchase Agreement with certain accredited investors, pursuant to which we issued three series of warrants, Series&#160;A Warrants, Series&#160;B Warrants and Series&#160;C Warrants. The Series&#160;A Warrants and Series&#160;C Warrants were determined to meet the criteria for equity classification. Upon the closing of the Merger, the Series&#160;B Warrants were recognized as a derivative liability as they did not meet the criteria related to equity indexation. We classified the Series&#160;B Warrants on our consolidated balance sheet as a derivative liability which was recognized at fair value at each reporting period subsequent to the initial issuance until the warrants were reclassified as equity in November 2019 following a final mark to market upon the completion of a reset period pursuant to which the number of shares of common stock underlying the Series B Warrants was increased based on the trading price for the common stock (the "Reset Period"). Changes in the fair value of derivatives were recognized as other income (expense) in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We estimated the fair value of Series&#160;B Warrants using the Monte Carlo simulation model. Key fair value inputs included the starting stock price, expected stock price volatility during the Reset Period, and additional shares issued from escrow. Upon conclusion of the Reset Period, we estimated the fair value of the Series B Warrants using a Black-Scholes valuation model. The methodology for measuring fair value is sensitive to the expected stock volatility assumption input mentioned above. Inputs used in the valuation are unobservable and are therefore classified as Level 3 fair value inputs. The use of different valuation techniques or assumptions could result in materially different fair value estimates. See Note 10 in the notes to the consolidated financial statements included in this report for additional information.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_106"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">88</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Results of Operations</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comparison of the Years Ended December&#160;31, 2019 and 2018</span></div><div style="margin-top:12pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the results of our operations for the years ended December 31, 2019 and 2018 (in thousands):</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:57.590%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.740%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended<br/>December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,086&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,321&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,235)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,077&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,819&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">258&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,163&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,140&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,977)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14,163)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16,140)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,977&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of derivative liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,187)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,665&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,852)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss on debt conversion</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(341)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(341)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,768)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,751)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,983&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(785)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(773)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other income (expense)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,080)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,079)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,001)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,243)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,219)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,024)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and development expense</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expense decreased by $2.2 million for the year ended December 31, 2019 when compared to the year ended December 31, 2018 primarily as a result of a net decrease in program development and clinical trial activities of $1.8 million and a net decrease of $0.4 million in other costs.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Specifically, expenses related to OCU300 decreased in 2019 by $2.0 million primarily related to preclinical and manufacturing activities in 2018. This decrease was offset by (a)&#160;a $0.2 million increase in OCU400 preclinical activities and (b)&#160;a $0.1 million net increase in OCU200 preclinical and manufacturing activities.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The $0.4 million net decrease in other research and development costs is primarily related to (a) a $0.2 million decrease in employee-related expenses due to a decrease in headcount and (b) a $0.2 million decrease in license fees associated with a license milestone achieved during 2018. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">General and administrative expense</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative expenses increased by $0.3 million, for the year ended December 31, 2019 when compared to the year ended December 31, 2018. The increase was primarily due to a $0.7 million increase in professional and consulting fees and a $0.3 million increase in insurance costs, which was offset by a $0.6 million decrease in employee-related expenses due to a decrease in headcount.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Change in fair value of derivative liability</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The change in fair value of derivative liability was a loss of $3.2 million&#160;for the year ended December 31, 2019 compared to a gain of $1.7 million related to a change in fair value of the derivatives related to the debt instruments for the year ended December 31, 2018. The loss for the year ended December 31, 2019 primarily relates to the remeasurement of the Series&#160;B Warrant liability.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Loss on debt conversion</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The loss on debt conversion of $0.3 million primarily relates to 2019 conversions of all previously-issued convertible debt.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">89</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interest expense</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest expense was $1.8 million for the year ended December 31, 2019 and $3.8 million for the year ended December 31, 2018. The decrease in interest expense was primarily due to the 2019 conversions of all previously-issued convertible debt.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other expense</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other expense was $0.8 million the year ended December 31, 2019 compared to a de minimis amount for the year ended December 31, 2018. Other expense for the year ended December 31, 2019 primarily relates to equity issuance fees associated with the Series&#160;B Warrants, which were expensed as incurred.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_109"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have not generated any revenue to date and have primarily funded our operations to date through the sale and issuance of common stock and warrants to purchase common stock, proceeds from convertible notes payable, and debt. Specifically, since its inception and through December&#160;31, 2019, we have raised an aggregate of $51.1 million to fund its operations, of which $39.5 million was from the sale of our common stock and warrants, $10.3 million was from the issuance of convertible notes, $1.1 million was from borrowings under the EB-5 Program, and $0.2 million from grant proceeds. As of December&#160;31, 2019, we had $7.6 million in cash, cash equivalents and restricted cash.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since our inception, we have devoted substantial resources to research and development and have incurred significant net losses and expect to continue to incur net losses for the foreseeable future. We incurred net losses of approximately $20.2 million and $18.2 million for the year ended December 31, 2019 and 2018, respectively. As of December&#160;31, 2019, we had an accumulated deficit of $51.5 million. In addition, as of December 31, 2019, we had accounts payable and accrued expenses of $4.2&#160;million and indebtedness of $1.1&#160;million.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although it is difficult to predict future liquidity requirements, we believe that we have sufficient cash and cash equivalents to fund our operations into mid-2020, during which time, we expect to continue our development efforts with respect to our product candidates. We will need to raise additional capital in the future to further the development and commercialization of our other product candidates. Until such time, if ever, that we generate product revenue, we expect to obtain additional financing through the issuance of our common stock, issuance of warrants to purchase company stock, through other equity or debt financings, licensing or sale of assets, or through collaborations or partnerships with other companies. We may not be able to raise additional capital on terms acceptable to us, or at all, and any failure to raise capital as and when needed could compromise our ability to execute on our business plan and cause us to delay or curtail our operations until such funding is received.</span></div><div style="margin-top:12pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table shows a summary of our cash flows for the periods indicated (in thousands):</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.792%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended<br/>December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16,893)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,631)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,357)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(77)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,066&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,185&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,816&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,523)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Operating activities</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash used in operating activities was $16.9 million for the year ended December 31, 2019 compared with $11.6 million for the year ended December 31, 2018. The increase in cash used in operating activities relates to additional cash used for working capital purposes during 2019, including a significant decrease in accounts payable.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investing activities</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash used in investing activities was $2.4 million for the year ended December 31, 2019 compared with $0.1 million for the year ended December 31, 2018. The $2.3&#160;million increase in cash used is primarily related to costs associated with the Merger.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">90</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financing activities</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash provided by financing activities was $25.1 million for the year ended December 31, 2019 compared to $7.2 million for the year ended December 31, 2018. This $17.9&#160;million increase is primarily due to the $22.5 million of proceeds, which were issued in connection with the June 2019 common stock and warrant financing entered into by Former Ocugen and Histogenics with certain accredited investors for an aggregate purchase price of $25.0&#160;million (the "Pre-Merger Financing"), $1.0 million from issuance of the stock subscription agreement, and $0.2 million from issuance of common stock for warrant exercises. These increases were partially offset by a payment of $5.3 million to settle the convertible debt and a decrease in net proceeds of $0.5 million from the issuance of convertible debt.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Indebtedness</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In September 2016, pursuant to the U.S. Government&#8217;s Immigrant Investor Program, commonly known as the EB-5 program (the &#8220;EB-5 Program&#8221;), we entered into an arrangement to borrow up to $10.0 million from EB5 Life Sciences, L.P. (the &#8220;Lender&#8221;) in $0.5 million increments. Borrowings are at a fixed interest rate of 4.0% and are to be utilized in the clinical development, manufacturing, and commercialization of our products and for our general working capital needs. Outstanding borrowings pursuant to the EB-5 Program become due upon the seventh anniversary of the final disbursement. Amounts repaid cannot be re-borrowed. At December&#160;31, 2019, there was $1.0 million of principal outstanding under the EB-5 program. Subsequent to December 31, 2019, we borrowed an additional $0.5&#160;million under the arrangement.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Funding requirements</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect to continue to incur significant expenses in connection with our ongoing activities, particularly as we continue research and development, including clinical development activities of our product candidates, increase our headcount and add operational, financial and information systems to execute our business plan, maintain, expand and protect our patent portfolio, contract to manufacture our product candidates, and operate as a public company.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our future funding requirements, both near- and long-term, will depend on many factors, including, but not limited to:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt;">the initiation, progress, timing, costs and results of clinical trials for our product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt;">the outcome, timing and cost of the regulatory approval process for our product candidates by the FDA;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt;">future costs of manufacturing and commercialization;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt;">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt;">the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt;">the costs of expanding infrastructure and increasing headcount, as well as the higher corporate infrastructure costs associated with becoming a public company; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the extent to which we in-license or acquire other products, product candidates or technologies.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that the existing cash and cash equivalents will be sufficient to fund our operations into mid-2020, during which time we expect to continue our development efforts with respect to our product candidates. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. Substantial additional financing will be needed to fund our operations thereafter and to commercially develop any current or future product candidates. We currently do not have any commitments to obtain additional funds and may be unable to obtain sufficient funding in the future on acceptable terms, if at all. However, our management is currently evaluating different strategies to obtain the required funding for future operations. These strategies may include, but are not limited to: public and private placements of equity and/or debt, payments from potential strategic research and development, sale of assets, and licensing and/or collaboration arrangements with pharmaceutical companies or other institutions. There can be no assurance that these future funding efforts will be successful. If we cannot obtain the necessary funding, we will need to delay, scale back or eliminate some or all of our research and development programs&#894; consider other various strategic alternatives, including a merger or sale&#894; or cease operations. If we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial condition and results of operations could be materially adversely affected.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_112"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">91</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Off-Balance Sheet Arrangements</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We did not have off-balance sheet arrangements during the periods presented, and we do not currently have any off-balance sheet arrangements as defined in the rules&#160;and regulations of the SEC.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_115"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For a discussion of recent accounting pronouncements, see Note 2 to our consolidated financial statements included in this report.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_118"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Other Company Information</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">JOBS Act</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April&#160;5, 2012, the Jumpstart Our Business Startups Act (&#8220;JOBS Act&#8221;) was enacted. Section&#160;107 of the JOBS Act permits an &#8220;emerging growth company&#8221; or a &#8220;smaller reporting company&#8221; to delay the adoption of new or revised accounting standards until those standards would otherwise apply to private companies. We plan to avail ourselves of this exemption from new or revised accounting standards as a smaller reporting company and, therefore, we may not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies or smaller reporting companies.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For so long as we are a &#8220;smaller reporting company,&#8221; we intend to rely on exemptions relating to: (1)&#160;providing an auditor&#8217;s attestation report on our system of internal control over financial reporting pursuant to Section&#160;404(b)&#160;of the Sarbanes-Oxley Act and (2)&#160;complying with certain requirements that may be adopted by the Public Company Accounting Oversight Board.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although we remain a smaller reporting company, as of December&#160;31, 2019, we are no longer an emerging growth company.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_121"></div><div style="text-indent:-54pt;padding-left:54pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;7A.&#160;Quantitative and Qualitative Disclosures about Market Risk.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_16"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 8.&#160;Financial Statements and Supplementary Data</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The financial statements required by this item are set forth beginning at page F-1 of this report and are incorporated herein by reference.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1657"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;9.&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_124"></div><div style="text-indent:-54pt;padding-left:54pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;9A.&#160;Controls and Procedures.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934, as amended) (the &#8220;Exchange Act&#8221;), as of&#160;December&#160;31, 2019. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that (a)&#160;the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules&#160;and forms, and (b)&#160;such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">92</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) under the Exchange Act as a process designed by, or under the supervision of, our principal executive officer and principal financial officer and effected by our Board of Directors, management, and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external reporting purposes in conformity with generally accepted accounting principles and includes those policies and procedures that:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our consolidated financial statements.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the supervision of and with the participation of our Chief Executive Officer and Chief Financial Officer, our management assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2019 based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013). Based on this assessment, management concluded that our internal control over financial reporting was effective as of December&#160;31, 2019.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been no changes in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_145"></div><div style="text-indent:-54pt;padding-left:54pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;9B.&#160;Other Information.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our Board of Directors has established Thursday, June 4, 2020 as the date of our 2020 Annual Meeting of Stockholders (the &#8220;2020 Annual Meeting&#8221;).  </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2020 Annual Meeting will be held at the offices of Pepper Hamilton LLP, 400 Berwyn Park, 899 Cassatt Road, Berwyn, PA 19312, at 8:00 a.m., local time. Stockholders of record at the close of business on Tuesday, April 14, 2020 will be entitled to vote at the 2020 Annual Meeting.  </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Because the date of the 2020 Annual Meeting has been advanced by more than 30 calendar days from the date of the preceding year&#8217;s annual meeting, in accordance with Rule 14a-5(f) under the Exchange Act, we are informing stockholders of certain dates related to the 2020 Annual Meeting.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to Rule 14a-8 under the Exchange Act, a stockholder intending to present a proposal to be included in the proxy materials for the 2020 Annual Meeting must deliver a proposal in writing to our principal executive offices no later than a reasonable time before we begin printing and mailing the proxy materials for the 2020 Annual Meeting. According to our bylaws, a stockholder must provide notice to the our corporate secretary of proposals intended to be presented at, but not included in the proxy materials for, the 2020 Annual Meeting, including director nominations for election to our Board of Directors, in a timely manner. Under our bylaws, in order to be timely, in the event that the date of the annual meeting is advanced more than 30 days prior to or delayed more than 30 days after the anniversary of the preceding year&#8217;s annual meeting, notice by the stockholder must be delivered to us by the close of business on the later of (x) the 90</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">th</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> day prior to such annual meeting or (y) the 10</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">th</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> day following the day on which public announcement of the date of such meeting is first made.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As such, the new deadline for submission of proposals to be included in the proxy materials or otherwise to be considered at the 2020 Annual Meeting is the close of business on Monday, April 6, 2020, which we consider a reasonable time before we will begin printing and mailing proxy materials and is the 10</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">th</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> day following the date of filing of this Annual Report. Proposals </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">93</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">should be addressed to: Corporate Secretary, Ocugen, Inc., 5 Great Valley Parkway, Suite 160, Malvern, PA 19355. Any such proposal must (i) meet the requirements set forth in the rules and regulations of the SEC in order to be eligible for inclusion in the proxy materials for the 2020 Annual Meeting and (ii) contain the information specified in, and otherwise comply with, our bylaws. We may omit any proposal from the proxy materials that does not comply with the SEC&#8217;s rules.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Because of the uncertainties surrounding the impact of the COVID-19 pandemic, we are planning for the possibility that the 2020 Annual Meeting may be held solely by means of remote communication. If we take this step, we will announce the decision to do so in advance of the 2020 Annual Meeting, and details on how to participate in the webcast will be set forth in a press release issued by us and available at www.ocugen.com.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_127"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">94</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART&#160;III</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1674"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;10.&#160;Directors, Executive Officers, and Corporate Governance.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The information required by this Item is incorporated by reference from the discussion responsive thereto contained in the Proxy Statement for our 2020 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1680"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;11. &#160;Executive Compensation.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The information required by this Item is incorporated by reference from the discussion responsive thereto contained in the Proxy Statement for our 2020 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1687"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;12.&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The information required by this Item is incorporated by reference from the discussion responsive thereto contained in the Proxy Statement for our 2020 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1692"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;13.&#160;Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The information required by this Item is incorporated by reference from the discussion responsive thereto contained in the Proxy Statement for our 2020 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1698"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;14.&#160;Principle Accountant Fees and Services.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The information required by this Item is incorporated by reference from the discussion responsive thereto contained in the Proxy Statement for our 2020 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1710"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">95</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART&#160;IV</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1704"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 15.&#160;Exhibits, Financial Statements</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The financial statement schedules and exhibits filed as part of this Annual Report on Form 10-K are as follows:</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)(1) Financial Statements</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See &#8220;Index to Consolidated Financial Statements&#8221; beginning on page F-1 of this report.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)(2) Financial Statement Schedules</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial statement schedules have been omitted because the required information is not present, not present in amounts sufficient to require submission of the schedules, or because the required information is provided in the financial statements or notes thereto.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)(3) Exhibits</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The exhibits required to be filed as part of this report are listed in the Exhibit Index attached hereto and are incorporated herein by reference.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_148"></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">96</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:82.797%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EXHIBIT INDEX</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Exhibit</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Description</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312519099909/d694480dex21.htm">Agreement and Plan of Merger and Reorganization, dated April 5, 2019, by and among the Registrant, Ocugen, Inc. and Restore Merger Sub, Inc. (filed as Exhibit 2.1 to the Registrant&#8217;s Current Report on Form 8-K as filed on April 8, 2019, and incorporated herein by reference)</a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312519173071/d754323dex21.htm">Consent and Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated June 13, 2019, by and among the Registrant, Ocugen, Inc. and Restore Merger Sub, Inc. (filed as Exhibit 2.1 to the Registrant&#8217;s Current Report on Form 8-K as filed on June 14, 2019, and incorporated herein by reference)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312514436359/d834595dex31.htm">Sixth Amended and Restated Certificate of Incorporation (filed as Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K as filed on December 8, 2014, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000110465919052266/a19-19180_3ex3d1.htm">Amendment to Sixth Amended and Restated Certificate of Incorporation related to the Reverse Stock Split and the Authorized Share Increase (filed as Exhibit&#160;3.1 to the Registrant&#8217;s Current Report on Form&#160;8-K as filed October&#160;1, 2019, and incorporated herein by reference)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000110465919052266/a19-19180_3ex3d2.htm">Amendment to Sixth Amended and Restated Certificate of Incorporation related to the Name Change (filed as Exhibit&#160;3.2 to the Registrant&#8217;s Current Report on Form&#160;8-K as filed on October&#160;1, 2019, and incorporated herein by reference)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312516711655/d262403dex33.htm">Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock of Histogenics Corporation (filed as Exhibit 3.3 to the Registrant&#8217;s Current Report on Form 8-K as filed on September 16, 2016, and incorporated herein by reference)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.1*&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="ocgn-20191231x10kxex41.htm">Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312514427246/d817729dex41.htm">Specimen stock certificate evidencing the shares of common stock (filed as Exhibit 4.1 to Amendment No. 3 to the Registrant&#8217;s Registration Statement on Form S-1 (SEC File No. 333-199202), as filed on November 26, 2014, and incorporated herein by reference)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312514403509/d817729dex45.htm">Amended and Restated Royalty Agreement dated as of October 14, 2014 (filed as Exhibit 4.5 to Amendment No. 1 to the Registrant&#8217;s Registration Statement on Form S-1 (SEC File No. 333-199202), as filed on November 7, 2014, and incorporated herein by reference)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000110465919053247/a19-19180_4ex4d1.htm">Form of Series A Investor Warrant (filed as Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K as filed on October 7, 2019, and incorporated herein by reference)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000110465919053247/a19-19180_4ex4d2.htm">Form of Series B Investor Warrant (filed as Exhibit 4.2 to the Registrant&#8217;s Current Report on Form 8-K as filed on October 7, 2019, and incorporated herein by reference)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000110465919053247/a19-19180_4ex4d3.htm">Form of Series C Investor Warrant (filed as Exhibit 4.3 to the Registrant&#8217;s Current Report on Form 8-K as filed on October 7, 2019, and incorporated herein by reference)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000110465919060289/a19-19409_4ex4d1.htm">Form of Amendment to Warrants to Purchase Common Stock (filed as Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K as filed on November 6, 2019, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312519173071/d754323dex43.htm">Registration Rights Agreement, dated June 13, 2019, by and among the Registrant and certain investors named therein (filed as Exhibit 4.3 to the Registrant&#8217;s Current Report on Form 8-K as filed on June 14, 2019, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312514365761/d624561dex101.htm">Form of Indemnity Agreement for directors and officers (filed as Exhibit 10.1 to the Registrant&#8217;s Registration Statement on Form S-1 (SEC File No. 333-199202), as filed on October 7, 2014, and incorporated herein by reference)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312514365761/d624561dex1010.htm">License Agreement dated as of May 12, 2005 among the Registrant and Angiotech Pharmaceuticals (US), Inc. and Angiodevice International GmbH (filed as Exhibit 10.10 to the Registrant&#8217;s Registration Statement on Form S-1 (SEC File No. 333-199202), as filed on October 7, 2014, and incorporated herein by reference)</a></span></div></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">97</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:82.797%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Exhibit</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Description</span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312514365761/d624561dex1011.htm">Amendment to License Agreement dated as of August 31, 2007 among the Registrant and Angiotech Pharmaceuticals (US), Inc. and Angiodevice International GmbH (filed as Exhibit 10.11 to the Registrant&#8217;s Registration Statement on Form S-1 (SEC File No. 333-199202), as filed on October 7, 2014, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.4#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312514365761/d624561dex1012.htm">Second Amendment to License Agreement dated as of January 1, 2008 among the Registrant and Angiotech Pharmaceuticals (US), Inc. and Angiodevice International GmbH (filed as Exhibit 10.12 to the Registrant&#8217;s Registration Statement on Form S-1 (SEC File No. 333-199202), as filed on October 7, 2014, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.5#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312514365761/d624561dex1013.htm">Third Amendment to License Agreement dated as of April 15, 2008 among the Registrant and Angiotech Pharmaceuticals (US), Inc. and Angiodevice International GmbH (filed as Exhibit 10.13 to the Registrant&#8217;s Registration Statement on Form S-1 (SEC File No. 333-199202), as filed on October 7, 2014, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.6#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312514365761/d624561dex1014.htm">Fourth Amendment to License Agreement dated as of November 1, 2008 among the Registrant and Angiotech Pharmaceuticals (US), Inc. and Angiodevice International GmbH (filed as Exhibit 10.14 to the Registrant&#8217;s Registration Statement on Form S-1 (SEC File No. 333-199202), as filed on October 7, 2014, and incorporated herein by reference)</a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.7#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312514365761/d624561dex1015.htm">Fifth Amendment to License Agreement dated as of August 6, 2010 among the Registrant and Angiotech Pharmaceuticals (US), Inc. and Angiodevice International GmbH (filed as Exhibit 10.15 to the Registrant&#8217;s Registration Statement on Form S-1 (SEC File No. 333-199202), as filed on October 7, 2014, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.8#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312514365761/d624561dex1016.htm">Reinstatement Agreement and Sixth Amendment to License Agreement dated as of February 8, 2011 among the Registrant and Angiotech Pharmaceuticals (US), Inc. and Angiodevice International GmbH (filed as Exhibit 10.16 to the Registrant&#8217;s Registration Statement on Form S-1 (SEC File No. 333-199202), as filed on October 7, 2014, and incorporated herein by reference)</a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.9#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312514365761/d624561dex1017.htm">Seventh Amendment to License Agreement dated as of March 31, 2011 among the Registrant and Angiotech Pharmaceuticals (US), Inc. and Angiodevice International GmbH (filed as Exhibit 10.17 to the Registrant&#8217;s Registration Statement on Form S-1 (SEC File No. 333-199202), as filed on October 7, 2014, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.10#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312514365761/d624561dex1018.htm">Eighth Amendment to License Agreement dated as of June 29, 2012 among the Registrant and Angiotech Pharmaceuticals (US), Inc. and Angiodevice International GmbH (filed as Exhibit 10.18 to the Registrant&#8217;s Registration Statement on Form S-1 (SEC File No. 333-199202), as filed on October 7, 2014, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.11#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312514365761/d624561dex1019.htm">Paid-up License Agreement dated as of March 6, 2013 between the Registrant and Koken Co., Ltd. (filed as Exhibit 10.19 to the Registrant&#8217;s Registration Statement on Form S-1 (SEC File No. 333-199202), as filed on October 7, 2014, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.12#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312514365761/d624561dex1020.htm">Agreement dated as of June 22, 2012 between the Registrant and Purpose Co., Ltd. f/k/a Takagi Sangyo Co. Ltd. and f/k/a Takagi Industrial Co., Ltd. (filed as Exhibit 10.20 to the Registrant&#8217;s Registration Statement on Form S-1 (SEC File No. 333-199202), as filed on October 7, 2014, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.13#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312514365761/d624561dex1021.htm">Exclusive Agreement dated as of April 15, 2001 between the Registrant and The Board of Trustees of The Leland Stanford Junior University (filed as Exhibit 10.21 to the Registrant&#8217;s Registration Statement on Form S-1 (SEC File No. 333-199202), as filed on October 7, 2014, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.14&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312514365761/d624561dex1022.htm">First Amendment to Exclusive Agreement dated as of October 26, 2005 between the Registrant and The Board of Trustees of The Leland Stanford Junior University (filed as Exhibit 10.22 to the Registrant&#8217;s Registration Statement on Form S-1 (SEC File No. 333-199202), as filed on October 7, 2014, and incorporated herein by reference) </a></span></div></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">98</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:82.797%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Exhibit</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Description</span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.15#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312514365761/d624561dex1023.htm">Second Amendment to Exclusive Agreement dated as of January 15, 2006 between the Registrant and The Board of Trustees of The Leland Stanford Junior University (filed as Exhibit 10.23 to the Registrant&#8217;s Registration Statement on Form S-1 (SEC File No. 333-199202), as filed on October 7, 2014, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.16#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312514365761/d624561dex1024.htm">Amendment No. 3 to the License Agreement Effective 4/15/2001 dated as of May 1, 2009 between the Registrant and The Board of Trustees of The Leland Stanford Junior University (filed as Exhibit 10.24 to the Registrant&#8217;s Registration Statement on Form S-1 (SEC File No. 333-199202), as filed on October 7, 2014, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.17&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312514365761/d624561dex1025.htm">Amendment No. 4 to the License Agreement Effective 4/15/2001 dated as of April 29, 2010 between the Registrant and The Board of Trustees of The Leland Stanford Junior University (filed as Exhibit 10.25 to the Registrant&#8217;s Registration Statement on Form S-1 (SEC File No. 333-199202), as filed on October 7, 2014, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.18#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312514365761/d624561dex1031.htm">Collagen Technology Transfer Agreement dated as of April 15, 2014 between the Registrant and Advanced BioMatrix, Inc. (filed as Exhibit 10.31 to the Registrant&#8217;s Registration Statement on Form S-1 (SEC File No. 333-199202), as filed on October 7, 2014, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.19#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312516679283/d212966dex1033.htm">First Amendment to License Agreement, dated May 9, 2016, between the Registrant and Purpose Co., Ltd., f/k/a Takagi Sangyo Co. Ltd. (filed as Exhibit 10.33 to the Registrant&#8217;s Quarterly Report on Form 10-Q as filed on August 11, 2016, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.20#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000156459018005711/hsgx-ex1033_187.htm">License and Commercialization Agreement dated as of December 21, 2017 between the Registrant and MEDINET Co., Ltd. (filed as Exhibit 10.33 to the Registrant&#8217;s Annual Report on Form 10-K as filed on March 15, 2018, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.21&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312518356434/d676886dex102.htm">Consulting Agreement, effective December 21, 2018, between the Registrant and Danforth Advisors, LLC (filed as Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K as filed on December 21, 2018, and incorporated herein by reference)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.22&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312519147982/d938452dex101.htm">Separation Agreement dated January 23, 2019 between the Registrant and Donald Haut, Ph.D. (filed as Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q as filed on May 15, 2019, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.23&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312519147982/d938452dex103.htm">Separation Agreement dated March 18, 2019 between the Registrant and Adam Gridley (filed as Exhibit 10.3 to the Registrant&#8217;s Quarterly Report on Form 10-Q as filed on May 15, 2019, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.24&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312519147982/d938452dex104.htm">Separation Agreement dated March 19, 2019 between the Registrant and Stephen Kennedy (filed as Exhibit 10.4 to the Registrant&#8217;s Quarterly Report on Form 10-Q as filed on May 15, 2019, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.25+&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312519173827/d701045dex1030.htm">Ocugen, Inc. 2014 Stock Option Plan (filed as Exhibit 10.30 to the Registrant&#8217;s Registration Statement on Form S-4 (SEC File No. 333-232147), as filed on June 14, 2019, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.26+&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312519173827/d701045dex1031.htm">Form of Incentive Stock Option Agreement under Ocugen, Inc. 2014 Stock Option Plan (filed as Exhibit 10.31 to the Registrant&#8217;s Registration Statement on Form S-4 (SEC File No. 333-232147), as filed on June 14, 2019, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.27+&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312519173827/d701045dex1032.htm">Form of Nonstatutory Stock Option Agreement under Ocugen, Inc. 2014 Stock Option Plan (filed as Exhibit 10.32 to the Registrant&#8217;s Registration Statement on Form S-4 (SEC File No. 333-232147), as filed on June 14, 2019, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.28+&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;">Ocugen, Inc. 2019 Equity Incentive Plan (filed as Appendix A to the Registrant's Proxy Statement on Schedule 14A as filed on November 8, 2019, and incorporated herein by reference)</span></div></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.29*+&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="ocgn-20191231x10kxex10.htm">Form of In</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="ocgn-20191231x10kxex10.htm">c</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="ocgn-20191231x10kxex10.htm">entive Stock Option Agreement under Ocugen, Inc. 2019 Equity Incentive Plan</a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.30*+&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="ocgn-20191231x10kxex101.htm">Form of Nonstatutory Stock Option Agreement under Ocugen, Inc. 2019 Equity Incentive Plan</a></span></div></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">99</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:82.797%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Exhibit</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Description</span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.31#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312519173827/d701045dex1033.htm">Exclusive License Agreement, effective as of March 3, 2014, between The Regents of the University of Colorado and Ocugen Opco, Inc. (filed as Exhibit 10.33 to the Registrant&#8217;s Registration Statement on Form S-4 (SEC File No. 333-232147), as filed on June 14, 2019, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.32#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312519173827/d701045dex1034.htm">First Amendment to the Exclusive License Agreement, dated as of January </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312519173827/d701045dex1034.htm">2</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312519173827/d701045dex1034.htm">3, 2017, by and between The Regents of the University of Colorado and Ocugen Opco, Inc. (filed as Exhibit 10.34 to the Registrant&#8217;s Registration Statement on Form S-4 (SEC File No. 333-232147), as filed on June 14, 2019, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.33&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312519173827/d701045dex1035.htm">Letter of Understanding, dated November 8, 2017, between The Regents of the University of Colorado and Ocugen Opco, Inc. (filed as Exhibit 10.35 to the Registrant&#8217;s Registration Statement on Form S-4 (SEC File No. 333-232147), as filed on June 14, 2019, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.34#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312519173827/d701045dex1036.htm">Exclusive License Agreement, effective as of February 3, 2016, between The Board of Trustees of the University of Illinois and Ocugen Opco, Inc. (filed as Exhibit 10.36 to the Registrant&#8217;s Registration Statement on Form S-4 (SEC File No. 333-232147), as filed on June 14, 2019, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.35#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312519173827/d701045dex1037.htm">Exclusive License Agreement, effective as of December 19, 2017, between The Schepens Eye Research Institute, Inc and Ocugen Opco, Inc. (filed as Exhibit 10.37 to the Registrant&#8217;s Registration Statement on Form S-4 (SEC File No. 333-232147), as filed on June 14, 2019, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.36&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312519173827/d701045dex1038.htm">Lease Agreement, dated December 19, 2016, by and between Ocugen Opco, Inc. and WPT Land 2 LP (filed as Exhibit 10.38 to the Registrant&#8217;s Registration Statement on Form S-4 (SEC File No. 333-232147), as filed on June 14, 2019, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.37&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312519173827/d701045dex1038a.htm">First Amendment to Lease Agreement, dated November 27, 2017, by and between Ocugen Opco, Inc. and WPT Land 2 LP (filed as Exhibit 10.38A to the Registrant&#8217;s Registration Statement on Form S-4 (SEC File No. 333-232147), as filed on June 14, 2019, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.38&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312519173827/d701045dex1038b.htm">Second Amendment to Lease Agreement, dated November 16, 2018, by and between Ocugen Opco, Inc. and WPT Land 2 LP (filed as Exhibit 10.38B to the Registrant&#8217;s Registration Statement on Form S-4 (SEC File No. 333-232147), as filed on June 14, 2019, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.39&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312519199843/d701045dex1042.htm">Loan and Security Agreement, effective as of September 12, 2016, by and between EB5 Life Sciences, LP and Ocugen Opco, Inc. (filed as Exhibit 10.42 to the Registrant&#8217;s Registration Statement on Form S-4/A (SEC File No. 333-232147), as filed on July 23, 2019, and incorporated herein by reference)</a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.40&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312519144797/d693461dex101.htm">Asset Purchase Agreement dated May 8, 2019 by and between the Registrant and Medavate Corp. (filed as Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K as filed on May 13, 2019, and incorporated herein by reference) </a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.41&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312519173071/d754323dex101.htm">Securities Purchase Agreement, dated as of June 13, 2019, by and among Ocugen Opco, Inc., the Registrant and the investors party thereto (filed as Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K as filed on June 14, 2019, and incorporated herein by reference)</a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.42&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312519189253/d754846dex101.htm">Form of Amendment to Securities Purchase Agreement, dated as of June 28, 2019, by and among Ocugen Opco, Inc., the Registrant and the investor named therein (filed as Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K as filed on Ju</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312519189253/d754846dex101.htm">ly</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312519189253/d754846dex101.htm"> </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312519189253/d754846dex101.htm">3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000119312519189253/d754846dex101.htm">, 2019, and incorporated herein by reference)</a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.43&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000110465919052266/a19-19180_3ex10d1.htm">Amendment No. 1 to Asset Purchase Agreement, dated September 26, 2019, by and between the Registrant and Madavate Corp. (filed as Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K as filed on October 1, 2019, and incorporated herein by reference)</a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.44&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000110465919053247/a19-19180_4ex10d1.htm">Amendment No. 2 to Asset Purchase Agreement, dated October 4, 2019, by and between the Registrant and Medavate Corp. (filed as Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K as filed on October 7, 2019, and incorporated herein by reference)</a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#0000ff;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.45#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000110465919062626/a19-21452_1ex10d2.htm">Co-Development and Commercialization Agreement, dated as of September 27, 2019, by and among the Registrant and CanSino Biologics Inc. (filed as Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q as filed on November 12, 2019, and incorporated herein by reference)</a></span></div></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">100</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:82.797%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Exhibit</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Description</span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.46+&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000110465919062626/a19-21452_1ex10d3.htm">Employment Agreement, dated as of September 10, 2019, by and between the Registrant and Sanjay Subramanian (filed as Exhibit 10.3 to the Registrant&#8217;s Quarterly Report on Form 10-Q as filed on November 12, 2019, and incorporated herein by reference)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.47+&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000110465920000923/tm201204d1_ex10-1.htm">Amended and Restated Employment Agreement, dated as of January 1, 2020, by and between the Registrant and Shankar Musunuri (filed as Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K as filed on January 3, 2020, and incorporated herein by reference)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.48+&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000110465920000923/tm201204d1_ex10-2.htm">Amended and Restated Employment Agreement, dated as of January 1, 2020, by and between the Registrant and Daniel Jorgensen (filed as Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K as filed on January 3, 2020, and incorporated herein by reference)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.49+&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1372299/000110465920000923/tm201204d1_ex10-3.htm">Amended and Restated Employment Agreement, dated as of January 1, 2020, by and between the Registrant and Rasappa Arumugham (filed as Exhibit 10.3 to the Registrant&#8217;s Current Report on Form 8-K as filed on January 3, 2020, and incorporated herein by reference)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.1*&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="ocgn-20191231x10kxex211.htm">List of Subsidiaries</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23.1*&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="ocgn-20191231x10kxex231.htm">Consent of Ernst &amp; Young LLP, Independent Registered public Accounting Firm to the Registrant</a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.1*&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="ocgn-20191231x10kxex311.htm">Certification of the Chief Executive Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.2*&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="ocgn-20191231x10kxex312.htm">Certification of the Chief Financial Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.1*&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="ocgn-20191231x10kxex321.htm">Certifications of the Chief Executive Officer and Chief Financial Officer as required by 18 U.S.C. 1350</a></span></div></td></tr><tr><td colspan="2" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.INS*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Instance Document</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.SCH*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.CAL*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.DEF*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.LAB*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.PRE*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr></table></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">_______________________</span></div><div style="text-indent:-22.5pt;padding-left:22.5pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">*&#160;Filed herewith.</span></div><div style="text-indent:-22.5pt;padding-left:22.5pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">#&#160;Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv)&#160;of Regulations S-K.</span></div><div style="text-indent:-22.5pt;padding-left:22.5pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">+&#160;Indicates a management contract or compensatory plan or arrangement.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1828"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 16.&#160;10-K Summary</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not applicable. </span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_151"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">101</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ocugen, Inc.</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dated: March 27, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Shankar Musunuri, Ph.D., MBA</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Shankar Musunuri, Ph.D., MBA</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Chief Executive Officer&#160;&amp; Chairman</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">(Principal Executive Officer)</span></div></td></tr><tr><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dated: March 27, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Sanjay Subramanian</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Sanjay Subramanian</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Chief Financial Officer</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">(Principal Financial Officer and Accounting Officer)</span></div></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirement of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed by the following persons in the capacities held on the dates indicated.</span></div><div style="margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:31.333%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:39.081%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:23.002%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Signature</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Shankar Musunuri</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chairman, Chief Executive Officer and Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 27, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shankar Musunuri</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Executive Officer)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Sanjay Subramanian</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 27, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sanjay Subramanian</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Financial and Accounting Officer)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Ramesh Kumar</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 27, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ramesh Kumar</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Junge Zhang</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 27, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Junge Zhang</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Manish Potti</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 27, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Manish Potti</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Uday B. Kompella</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 27, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Uday B. Kompella</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Frank Leo</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 27, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Frank Leo</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Suha Taspolatoglu</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 27, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Suha Taspolatoglu</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span><br/></span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1802"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">102</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OCUGEN, INC.</span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:4.432%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:25.631%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:25.631%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:28.847%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.459%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Page</span></td></tr><tr><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1852">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1852">F-</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1852">2</a></span></div></td></tr><tr><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consolidated Financial Statements</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_19">Consolidated Balance Sheets at December 31, 2019 and 2018</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_19">F-</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_19">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_25">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2019 and 2018</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_25">F-</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_25">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_28">Consolidated Statements of Stockholders' Equity </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_28">(Deficit) </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_28">for the years ended December 31, 2019 and 2018</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_28">F-</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_28">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_34">Consolidated Statements of Cash Flows for the years </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_34">ended December 31, 2019 and 2018</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_34">F-</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_34">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_37">Notes to the Consolidated Financial Statements</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_37">F-</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_37">7</a></span></div></td></tr></table></div><div style="text-align:center;margin-top:6pt;"><span><br/></span></div><div style="margin-top:12pt;"><span><br/></span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1852"></div><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-1</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To the Stockholders and the Board of Directors of Ocugen, Inc.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Opinion on the Financial Statements</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have audited the accompanying consolidated balance sheets of Ocugen, Inc. (the Company) as of December&#160;31, 2019 and 2018, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity (deficit) and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2019 and 2018, and the results of its operations and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">The Company&#8217;s Ability to Continue as a Going Concern</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations and has stated that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management&#8217;s evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Basis for Opinion</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:12pt;"><span><br/></span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">/s/ Ernst &amp; Young LLP</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have served as the Company&#8217;s auditor since 2018.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Philadelphia, Pennsylvania</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">March 27, 2020</span></div><div style="margin-top:12pt;"><span><br/></span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_19"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OCUGEN,&#160;INC.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:68.321%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.476%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfNC0xLTEtMS0w_903061fc-8b6f-4adf-9487-8730e996e6a4">7,444,052</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfNC0zLTEtMS0w_076d2f5c-fd27-42ca-b3ae-6081e9c166f6">1,628,136</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfNS0xLTEtMS0w_f1dfab27-f9f3-4ddf-9d61-d98afac1ef02">1,322,167</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfNS0zLTEtMS0w_20e0fd68-33e3-4a4f-bdd7-67c9fe77164c">313,499</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset held for sale</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfNi0xLTEtMS0w_cb22902c-2131-4880-ad45-520302aa13a6">7,000,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfNy0xLTEtMS0w_5eaed1ab-bccb-4a3f-bf3c-36b1469dbfa4">15,766,219</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfNy0zLTEtMS0w_4dd024a2-5850-401b-a812-ed41b5fd03a0">1,941,635</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfOC0xLTEtMS0w_aeffc00e-0ce3-4c62-b73e-9589b4ebb2a6">222,464</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfOC0zLTEtMS0w_ab0d190c-0503-4874-897f-6117d7dbb8a3">245,788</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfOS0xLTEtMS0w_24562fee-5cf4-45bb-8e92-e62d61d5c288">151,016</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfOS0zLTEtMS0w_bc48ed1b-efe3-4c2a-8c7e-06b7b2740018">150,477</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMTAtMS0xLTEtMA_bb4ca9fc-1194-4feb-b38d-9532efa16f50">667,747</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMTAtMy0xLTEtMA_7cda0cbe-ef07-45db-bb7d-5be0f47fc4ad">116,333</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMTEtMS0xLTEtMA_bc3cc2ea-f761-49fe-8f5e-73588a811899">16,807,446</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMTEtMy0xLTEtMA_dc2c0657-a5b9-4e17-b085-9ef15f2aae95">2,454,233</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities and stockholders&#8217; equity (deficit)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMTQtMS0xLTEtMA_8bbad5cb-9b52-4a2f-8625-d226a2d68274">1,895,613</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMTQtMy0xLTEtMA_60b90590-0550-4285-aa57-0811a1f4e38a">3,277,525</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMTUtMS0xLTEtMA_57142ae5-cdcf-4f91-9bd3-aa4bf2e9a251">2,270,045</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMTUtMy0xLTEtMA_e29f499d-ddf9-426a-b9e9-4bef95a6be70">1,402,750</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term debt, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermBorrowings" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMTYtMy0xLTEtMA_5f796eb9-1fc1-4f61-9ec1-e583e137d6df">7,483,847</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Derivative liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMTctMy0xLTEtMA_3edbde81-d8ce-48ae-86bd-857dd58d7b60">1,741,222</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease obligation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMTgtMS0xLTEtMA_efa215e7-3b73-4e60-915e-207bc045b5ce">172,310</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMTktMS0xLTEtMA_16a48756-5ada-42ad-b165-b2997843b604">205,991</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMTktMy0xLTEtMA_1feb1ccd-517e-40b1-bc20-a71e4903d3b0">204,242</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMjItMS0xLTEtMA_8765eb94-47b4-4f80-9f5b-0ec39b2bce08">4,543,959</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMjItMy0xLTEtMA_d338d9f4-23c2-4088-8c24-d24bb031ac0b">14,109,586</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease obligation, less current portion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMjUtMS0xLTEtMA_e99db382-f758-40c6-b942-6c0a88614aad">163,198</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long term debt, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMjItMS0xLTEtMTM5NDA_bdb43919-e99c-458d-9892-7dd2c102712f">1,072,123</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMjItMy0xLTEtMTM5NDA_284e5e6a-fc74-49d1-a94e-e0a07f983f06">1,016,727</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other non-current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMjYtMS0xLTEtMA_d09f4192-bbe0-4e9a-8bb7-3fa21ee1355a">9,755</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMjYtMy0xLTEtMA_ee1e191d-3f9c-4d88-bc9b-64d6b9856df1">37,459</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total non-current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMjgtMS0xLTEtMA_32e2875a-9f1c-4044-9998-f27443390d02">1,245,076</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMjgtMy0xLTEtMA_116a63e7-7580-4709-b08a-cb7054a3182a">1,054,186</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMjktMS0xLTEtMA_ed07d068-a4eb-4996-bad3-3f88f035bd21">5,789,035</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMjktMy0xLTEtMA_0e9a27cb-fa45-4f9c-bd30-3e85a58cb8dc">15,163,772</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commitments and contingencies (Note 9)</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzAtMS0xLTEtMA_e026862d-26f7-42fe-9fd3-ed08f9c32f79"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzAtMy0xLTEtMA_7a24df2a-d165-42d7-8ef6-070239259aa7"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stockholders&#8217; equity (deficit)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Convertible preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzItMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmQ1ZGViZGU0Mzg1MzQ2OTRhZDg5YzYxNjEwMzY5ZDdlXzcxNDY4MjU1ODA3NjA_a7bd3820-6fc5-48ec-b9b5-f94bebb9b928"><ix:nonFraction unitRef="usdPerShare" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzItMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmQ1ZGViZGU0Mzg1MzQ2OTRhZDg5YzYxNjEwMzY5ZDdlXzcxNDY4MjU1ODA3NjA_b4fb1302-7c07-4de2-945a-5b20c9e98b23">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzItMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmQ1ZGViZGU0Mzg1MzQ2OTRhZDg5YzYxNjEwMzY5ZDdlXzcxNDY4MjU1ODA3NDA_a6ff5ee3-ca38-458e-88d8-3ac64f4a8b98"><ix:nonFraction unitRef="shares" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzItMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmQ1ZGViZGU0Mzg1MzQ2OTRhZDg5YzYxNjEwMzY5ZDdlXzcxNDY4MjU1ODA3NDA_cf26d81e-5e30-4c33-b9e8-a0e058f2b4f0">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzItMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmQ1ZGViZGU0Mzg1MzQ2OTRhZDg5YzYxNjEwMzY5ZDdlXzcxNDY4MjU1ODA3NDc_2e7f08da-5264-45b6-b2c6-1a74de52915e"><ix:nonFraction unitRef="shares" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzItMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmQ1ZGViZGU0Mzg1MzQ2OTRhZDg5YzYxNjEwMzY5ZDdlXzcxNDY4MjU1ODA3NDc_8eecae8d-7462-4471-8ac9-90efcb9d43d5">seven</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzItMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmQ1ZGViZGU0Mzg1MzQ2OTRhZDg5YzYxNjEwMzY5ZDdlXzcxNDY4MjU1ODA3NTM_7f3270a3-06b0-4fce-b161-e7de16ddb7c5"><ix:nonFraction unitRef="shares" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzItMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmQ1ZGViZGU0Mzg1MzQ2OTRhZDg5YzYxNjEwMzY5ZDdlXzcxNDY4MjU1ODA3NTM_948b68a3-77ab-430a-abb6-744bf5a52150">zero</ix:nonFraction></ix:nonFraction> issued and outstanding, respectively</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzItMS0xLTEtMA_561aeb95-b652-4d46-a9a1-992289e5c46d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzItMy0xLTEtMA_e920392d-614b-46cd-945d-041e1bd7e82a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzMtMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmVkZjFjYjg1MTdkMTQ2Yjc4MzZhNWYwZjc3MDA0YWYyXzcxNDY4MjU1ODA3MTk_576ef5dc-04f8-4433-9516-1c59774e928f"><ix:nonFraction unitRef="usdPerShare" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzMtMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmVkZjFjYjg1MTdkMTQ2Yjc4MzZhNWYwZjc3MDA0YWYyXzcxNDY4MjU1ODA3MTk_67d0dd7c-a415-4168-affd-ac61e4b897d4">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzMtMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmVkZjFjYjg1MTdkMTQ2Yjc4MzZhNWYwZjc3MDA0YWYyXzcxNDY4MjU1ODA3MzI_9632c692-1a97-4f3e-b211-c444e7080f2a"><ix:nonFraction unitRef="shares" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzMtMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmVkZjFjYjg1MTdkMTQ2Yjc4MzZhNWYwZjc3MDA0YWYyXzcxNDY4MjU1ODA3MzI_f37a3c3b-7965-4530-bebc-1ca520f4f87d">200,000,000</ix:nonFraction></ix:nonFraction> authorized, <ix:nonFraction unitRef="shares" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzMtMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmVkZjFjYjg1MTdkMTQ2Yjc4MzZhNWYwZjc3MDA0YWYyXzcxNDY4MjU1ODA3NDQ_f1c15db4-5a7d-44d1-855a-eb0fc64a7c4d">52,746,728</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzMtMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmVkZjFjYjg1MTdkMTQ2Yjc4MzZhNWYwZjc3MDA0YWYyXzcxNDY4MjU1ODA3NTU_bb16c0b2-b4ad-4565-b4b0-e3ff36d3a26c">4,960,552</ix:nonFraction> shares issued, respectively; <ix:nonFraction unitRef="shares" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzMtMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmVkZjFjYjg1MTdkMTQ2Yjc4MzZhNWYwZjc3MDA0YWYyXzcxNDY4MjU1ODA3Njc_7a6991b7-8587-4de0-b619-d025dcf6ddfa">52,625,228</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzMtMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmVkZjFjYjg1MTdkMTQ2Yjc4MzZhNWYwZjc3MDA0YWYyXzcxNDY4MjU1ODA3Nzg_c6cb53ee-0a7f-46c3-9fd2-e1c870270987">4,960,552</ix:nonFraction> shares outstanding, respectively</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzMtMS0xLTEtMA_c5a5f7f4-3318-4ef2-b860-853e5de46fa1">527,467</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzMtMy0xLTEtMA_3d87328c-5c5f-4be7-9704-24acd9903a09">49,606</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Treasury Stock, at cost <ix:nonFraction unitRef="shares" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzQtMC0xLTEtMjg4Ny90ZXh0cmVnaW9uOjNiOWMzZjkwY2YwMzQ0ZWE5MDI0NmEzMWZhOTQ5MDU1XzcxNDY4MjU1ODA2MTM_02360a26-4015-4ada-b007-331bd79781a8">121,500</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TreasuryStockCommonShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzQtMC0xLTEtMjg4Ny90ZXh0cmVnaW9uOjNiOWMzZjkwY2YwMzQ0ZWE5MDI0NmEzMWZhOTQ5MDU1XzcxNDY4MjU1ODA2MTY_281f289d-ca60-4060-98ce-a15aacac37fd">zero</ix:nonFraction> shares, respectively</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzQtMS0xLTEtMjg4Nw_87560b69-e4be-494f-85f7-73ff1c5e83f7">47,864</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated other comprehensive income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzQtMy0xLTEtMA_b1153435-89ee-4644-97e8-4baf5c54539e">451</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional paid-in capital</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzUtMS0xLTEtMA_c00c2480-a4ab-4394-8cbf-e41509417302">62,018,632</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzUtMy0xLTEtMA_93511351-00ac-418c-bdcf-4c6ffd659bb3">18,477,598</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzYtMS0xLTEtMA_4a0cad74-6739-4e4d-9d22-579d93083930">51,479,824</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzYtMy0xLTEtMA_81b4fa87-96b8-4ead-9601-f930df64088a">31,237,194</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders&#8217; equity (deficit)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzctMS0xLTEtMA_0d43282d-8297-4725-9eb1-66215600d302">11,018,411</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzctMy0xLTEtMA_17a1a562-66d4-4de5-adff-e1dbcd4f9824">12,709,539</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and stockholders&#8217; equity (deficit)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzgtMS0xLTEtMA_c67e264c-9f44-4698-8bc1-b4db008a13cd">16,807,446</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzgtMy0xLTEtMA_d26c46f7-2f58-4962-aee9-be9e9b1ed763">2,454,233</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying notes to consolidated financial statements.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_25"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-3</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OCUGEN,&#160;INC.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:68.175%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.622%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMy01LTEtMS0w_87f89c55-3347-46c4-b8d2-1cac93b913af">8,085,522</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMy03LTEtMS0w_7fdf56fc-4e07-4929-838e-f7a949e63304">10,321,397</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfNC01LTEtMS0w_b890d5c6-1100-4de6-8d16-b83659d3ca4f">6,077,097</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfNC03LTEtMS0w_9b9e3fec-2d7c-4808-8e18-d347b0ecff38">5,819,111</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfNS01LTEtMS0w_572c78f8-fc26-4fb6-a78e-a5096605084e">14,162,619</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfNS03LTEtMS0w_33d4e23c-c995-4608-9a51-670ba00d408a">16,140,508</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfNi01LTEtMS0w_37a410b2-4e0c-45e0-aaa5-eaf4286ddccd">14,162,619</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfNi03LTEtMS0w_705f1a0a-ce37-4c2a-b5df-49e0925591a2">16,140,508</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of derivative liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfOC01LTEtMS0w_397858a0-ac04-44c2-9fae-e41d16771211">3,187,380</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfOC03LTEtMS0w_73051c8b-b772-4b76-965b-d41dc1895926">1,664,689</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss on debt conversion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ocgn:GainsLossesOnConversionOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfOS01LTEtMS0w_cab62802-8fec-409d-a212-dfd3d81f710f">341,136</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTAtNS0xLTEtMA_45cd89a2-5549-445d-8433-244d5e0bc109">1,214</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTAtNy0xLTEtMA_555e5fe8-618d-42ea-ae02-5f69a1866d76">19,213</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTEtNS0xLTEtMA_c9b14f85-fd70-4b2c-a5b2-6034d085003b">1,767,836</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTEtNy0xLTEtMA_ce0fee6a-9d2b-4e9f-bd1c-0e9d8dff5654">3,750,630</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTItNS0xLTEtMA_acec6f49-b3d0-4f1e-b57b-f4b0f6d165ee">784,873</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTItNy0xLTEtMA_5f009fad-900e-4a40-91f1-42484fabac4b">12,428</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other income (expense)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTMtNS0xLTEtMA_f8fc2be3-a0aa-4ca3-b2da-72eb256bf9a4">6,080,011</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTMtNy0xLTEtMA_b7e3482e-9848-4e0f-8510-693f592adcef">2,079,156</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTQtNS0xLTEtMA_2c8727a0-9d58-44f4-8026-6806dab6ec51">20,242,630</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTQtNy0xLTEtMA_65e6139b-00af-4d06-af1b-f8f6b67c5351">18,219,664</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTYtNS0xLTEtMA_df22742c-9435-4fa0-9e8d-1971f9c52871">451</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTYtNy0xLTEtMA_5cf2277d-5119-4027-a038-2dcdf2739858">451</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTctNS0xLTEtMA_b944b5c7-6453-48d7-aa5d-16ca4c371801">20,243,081</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTctNy0xLTEtMA_3b9798ea-8f3e-42de-93aa-da8206bfbbd8">18,219,213</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share of common stock&#8212;basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMjAtMi0xLTEtNTUyNg_9dc8e515-3721-439e-ad50-fdf69ef9a352">1.46</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMjAtNC0xLTEtNTUzNQ_fac67634-7ae9-43f1-99d2-16fe2581bd06">3.67</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average common shares outstanding&#8212;basic and diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTktMi0xLTEtNDc1MQ_c7774195-d085-4900-ad4d-31d3d5df242a">13,893,819</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTktNC0xLTEtNDc1NA_7554aa2a-5442-40a4-8bbe-56b7b8258fe6">4,960,552</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying notes to consolidated financial statements.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_28"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-4</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OCUGEN,&#160;INC.</span></div><div style="text-align:center;margin-top:6pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:28.263%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="width:1.0%;"></td><td style="width:6.187%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.894%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.625%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.502%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.549%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.087%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.389%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common&#160;Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Treasury Stock</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2017</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3a1130e123594196bfc468092b84ac38_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMi01LTEtMS0w_8a3a0f8b-2b0c-469a-9f61-b68de2b8f91b">4,960,552</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a1130e123594196bfc468092b84ac38_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMi03LTEtMS0w_41bb9cb5-b65d-46f0-8e6c-b5cc667be0d5">49,606</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i86c3619320b043b3904853387d86d815_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMi05LTEtMS0w_5b837210-b0b0-425d-a9b7-9acad5d16af3">17,402,911</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1552d11edcd422ca262d2377a832c30_I20171231" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMi0xMS0xLTEtMA_8a3e7534-c690-477e-a5e0-5d7b60c50ff2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia8690510eb5349f08d66e9e06bb9e045_I20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMi0xMy0xLTEtMA_86dd7fac-7ca4-42f3-9650-20a64f42c7e4">13,017,530</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3b0b2789ee4e45ff8aa700de563ddc85_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMi0xNS0xLTEtMA_14d6ef9c-7a69-4095-9b99-3337ec2dd486">4,434,987</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:9pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation adjustment</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6917ffcbaf80423da21d5e3906eb2fae_D20180101-20181231" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNC0xMS0xLTEtMA_6c77c4e8-ac19-4aa3-8e9d-482609461cb1">451</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNC0xNS0xLTEtMA_53e3c1b4-373b-415a-87bb-9b84d8c7e5b4">451</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:9pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation expense</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iedb883ebf37143d7b4c47a6d6946772b_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNC05LTEtMS0zMTc0_cba548d6-3960-4cd5-8824-c89adf9eec55">1,074,687</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNC0xNS0xLTEtMzE3NA_16aa4885-8e66-42b8-848d-b9b9bc107ec8">1,074,687</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:9pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4e6a4645ddbc44dda8055b4048fed606_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNS0xMy0xLTEtMA_7a943fbe-3c34-449c-9ff5-2cf3f5af8a60">18,219,664</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNS0xNS0xLTEtMA_b51ed7a8-5816-4cba-b43f-d438bb7b89b9">18,219,664</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:3pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4a89501e1b134d4ebd569351917a9ccd_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNi01LTEtMS0w_fdeb5c97-439e-4183-8889-a881d1ffb83b">4,960,552</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4a89501e1b134d4ebd569351917a9ccd_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNi03LTEtMS0w_68e4c240-6b32-4f1c-bf40-b075f170fe17">49,606</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia3cbd854bf6742df83c09dc1b641443b_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNi05LTEtMS0w_54b42ad0-46f8-431f-bd7b-97f72c7efcd1">18,477,598</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2e3c1c69245740dca3e6b721cc45d9e0_I20181231" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNi0xMS0xLTEtMA_25be13b5-9baf-4209-9811-d5e59d1744ce">451</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i98a2e8ccbfdb402682e11b7e0f8e3856_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNi0xMy0xLTEtMA_f5b1f7d3-be71-4154-8731-347380b499ae">31,237,194</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNi0xNS0xLTEtMA_ace4c8e1-974d-45b1-8c8f-5a3d4c80afe8">12,709,539</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:9pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock for Subscription Agreement</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i056a173f43694aaa8e9aeeb3b1af2dde_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNy01LTEtMS0zMTI3_92e03fc2-a9ee-49a2-89d1-134172ee33fc">80,569</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i056a173f43694aaa8e9aeeb3b1af2dde_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNy03LTEtMS0zMTI3_d672c9a3-3639-486d-a0c8-1f62d194e4c6">806</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0bf0aa30ad2449048bb635d1a966c756_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNy05LTEtMS0zMTI3_f7a68062-9c16-44af-ab07-c75d2740acb4">999,194</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNy0xNS0xLTEtMzEyNw_b75eb009-84bc-4c28-9699-cd1eebf6e0ff">1,000,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:9pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Conversion of debt</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i056a173f43694aaa8e9aeeb3b1af2dde_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfOC01LTEtMS0zMTAw_d6078f76-05d7-48bb-bbb9-20b4a44099b7">1,125,673</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i056a173f43694aaa8e9aeeb3b1af2dde_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfOC03LTEtMS0zMTAw_2e24eec2-fc63-4d35-899b-1218494c522e">11,256</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0bf0aa30ad2449048bb635d1a966c756_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfOC05LTEtMS0zMTAw_463786b0-8e1f-4403-a7ff-175da555bbcc">13,968,532</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfOC0xNS0xLTEtMzEwMA_63cf7367-6cfc-44a5-be60-aa3c5874b21b">13,979,788</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:9pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock and warrants for Pre-Merger Financing</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i056a173f43694aaa8e9aeeb3b1af2dde_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="ocgn:StockIssuedDuringPeriodPreMergerShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfOS01LTEtMS0zMTQw_edab4b06-6bb4-40d5-a41b-deada51267c8">4,385,964</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i056a173f43694aaa8e9aeeb3b1af2dde_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="ocgn:StockIssuedDuringPeriodPreMergerValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfOS03LTEtMS0zMTQw_c4c89f5c-e130-47c1-987f-28f3f9942993">43,860</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0bf0aa30ad2449048bb635d1a966c756_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ocgn:StockIssuedDuringPeriodPreMergerValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfOS05LTEtMS0zMTQw_0142bb23-9422-4613-983f-e35395d29567">13,106,596</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ocgn:StockIssuedDuringPeriodPreMergerValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfOS0xNS0xLTEtMzE0MA_a4b2e687-9fff-4620-9e20-1adc7e49658a">13,150,456</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Issuance of stock for reverse asset acquisition, net of $<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="ocgn:CostsRelatedToIssuanceOfStockUnderReverseAssetAcquisition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTAtMC0xLTEtMzE0MC90ZXh0cmVnaW9uOjk3N2ZmNzdiZDBjMjQ5NDE5ZTIyNjBmNGJiY2VjYjFhXzgyNDYzMzcyMDg0MTM_166dbfda-5e9a-45e1-8a9d-31ab45a7e339">2.6</ix:nonFraction>&#160;million of costs</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i056a173f43694aaa8e9aeeb3b1af2dde_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="ocgn:StockIssuedDuringPeriodSharesReverseAssetAcquisition" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTAtNS0xLTEtMzE0MA_e509c255-33ee-4482-8fb5-53646a8a0077">1,651,748</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i056a173f43694aaa8e9aeeb3b1af2dde_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="ocgn:StockIssuedDuringPeriodValueReverseAssetAcquisition" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTAtNy0xLTEtMzE0MA_b465b7e7-ae0b-4c8e-aea4-b1bed683ccf8">16,517</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0bf0aa30ad2449048bb635d1a966c756_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ocgn:StockIssuedDuringPeriodValueReverseAssetAcquisition" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTAtOS0xLTEtMzE0MA_5a1dbfdb-f21d-4f76-a9e5-4bb44693706a">3,549,271</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ocgn:StockIssuedDuringPeriodValueReverseAssetAcquisition" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTAtMTUtMS0xLTMxNDA_72cf2b34-8daa-4788-ac64-f21d074dde01">3,565,788</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:9pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reclassification of Series B Warrants from liability to equity</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0bf0aa30ad2449048bb635d1a966c756_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ocgn:ReclassificationOfWarrantsFromLiabilityToEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTEtOS0xLTEtMzE1Mw_c960847f-d334-40ba-9b72-686b2aa8cddf">11,255,740</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ocgn:ReclassificationOfWarrantsFromLiabilityToEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTEtMTUtMS0xLTMxNTM_fb60adb6-4f0c-43af-981c-49194ff9d2ec">11,255,740</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:9pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock for warrant exercises, net</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1515189b9f7e45499b0325f53fa93549_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTItNS0xLTEtMzE1Mw_4048e0e1-2e58-4516-b8d1-97c13e80e455">40,542,222</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i056a173f43694aaa8e9aeeb3b1af2dde_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="ocgn:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTItNy0xLTEtMzE1Mw_bbb43b25-4cdf-491f-99a5-41ce8c1d5c45">405,422</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0bf0aa30ad2449048bb635d1a966c756_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ocgn:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTItOS0xLTEtMzE1Mw_4f6ef4d1-b87b-4032-86a7-f3752e13c559">222,388</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ocgn:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTItMTUtMS0xLTMxNTM_847b5113-2c95-45b2-a25e-91ff20c3fb0a">183,034</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:9pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of treasury stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if5b3357b82d34850aa8982528bb2f47d_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTMtOS0xLTEtMTI2OTg_423e0527-90dc-4281-8c3a-f36e66251984">47,864</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTMtMTUtMS0xLTMxNTM_042a73d7-1f50-471a-8dba-408f4136b5f3">47,864</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:9pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6631f4c18a1a40ecbac6c62f92de5799_D20190101-20191231" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTQtMTEtMS0xLTMxNTk_e1a01fc6-debe-4789-8985-e879c9727ba2">451</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTQtMTUtMS0xLTMxNTk_9f322abb-510e-4805-b3a4-93c5b3b57ac9">451</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:9pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation expense</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0bf0aa30ad2449048bb635d1a966c756_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTUtOS0xLTEtMzE1OQ_31489e3c-4c70-43a6-a1a5-a6d6c04396d2">884,089</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTUtMTUtMS0xLTMxNTk_925149cb-d4a0-4fa5-b350-8e3ad768de84">884,089</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:9pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i17a96552b13e459d9ccd8b8026f03612_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTYtMTMtMS0xLTMxNTk_d0ebf60b-64c8-4b0c-909b-6dac629c0b85">20,242,630</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTYtMTUtMS0xLTMxNTk_b86cd454-4ee5-46f2-87dc-0d7dcb225779">20,242,630</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:3pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i32d7d0f983d5402d8056f502420bed85_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTItNS0xLTEtMA_92bfce06-1cc0-47e6-b74b-f4f3c5ea177a">52,746,728</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i32d7d0f983d5402d8056f502420bed85_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTItNy0xLTEtMA_bef056fe-1f1c-4f49-abea-82b85258c3fc">527,467</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i37ed1379a0e741cb891c3d578b500f9c_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTctOS0xLTEtMTI2OTg_4df69da2-42ef-416a-943d-8a2222d2defd">47,864</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if8cfe8fdf29a4818b64dd927a3441caf_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTItOS0xLTEtMA_9a579d09-251d-4edc-a030-436f2a70def1">62,018,632</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8f93f033b2964acd9d3cd23521742d13_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTItMTMtMS0xLTA_8d2127f6-e6d7-4d76-9a87-e1e4c3063f76">51,479,824</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTItMTUtMS0xLTA_528a7a9d-af2f-4694-83a9-f10be46544c3">11,018,411</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying notes to consolidated financial statements.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_34"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-5</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OCUGEN,&#160;INC.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:68.175%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.622%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMy0xLTEtMS0w_06f647e7-6ff4-4696-9372-cd900b0543ab">20,242,630</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMy0zLTEtMS0w_04ea6d55-5540-434a-9e85-689b009e6d8e">18,219,664</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfNS0xLTEtMS0w_ce26887a-43c5-4e02-a9f3-dc22e9265661">60,608</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfNS0zLTEtMS0w_69cc14d2-b986-4e7f-b8b8-003735df4cb2">49,623</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ocgn:NonCashInterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfNi0xLTEtMS0zMjQz_18cad386-a1d1-40ff-82c0-f763265e5b96">1,733,521</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ocgn:NonCashInterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfNi0zLTEtMS0zMjQz_59113d2b-5542-4c0b-8e8c-057e20b8301e">3,750,630</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash lease expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ocgn:NoncashLeaseExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfOC0xLTEtMS0zMTgz_b6b4658f-619d-4fbe-93cd-96df32ebb814">250,361</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:zerodash" name="ocgn:NoncashLeaseExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfOS0zLTEtMS0zMjQz_483f423b-c40e-4807-9f17-c6b8f12298a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of derivative liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfNy0xLTEtMS0w_beb1e0dc-73c3-4aa5-8780-cc6847959f10">3,187,380</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfNy0zLTEtMS0w_94133c69-17e9-4ac4-b923-40a267b1fdb1">1,664,689</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfOC0xLTEtMS0w_dabc5b0c-4fe0-4200-bcb5-86cc1651ab65">884,089</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfOC0zLTEtMS0w_bdbf3bec-c657-4786-96f4-46cb0e35928f">1,074,687</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Conversion of convertible notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ocgn:GainsLossesOnConversionOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfOS0xLTEtMS0w_11e3f19b-9e1b-4cbe-a1c5-4acedc858b11">341,136</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:zerodash" name="ocgn:GainsLossesOnConversionOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfOS0zLTEtMS0w_09e66d2a-1334-4c58-9ec9-8cdf35106ce1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other non-cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTEtMS0xLTEtMTUyOTQ_f89f9b3b-b21f-439e-8723-2c9b857d3973">4,803</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:OtherNoncashExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTEtMy0xLTEtMTUyODU_e64d3344-c916-4702-b179-05532d615e1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTEtMS0xLTEtMA_0dd9f54e-2d23-4ac0-8281-1c80cf7aa69a">1,007,367</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTEtMy0xLTEtMA_08ab253b-f810-4888-97bc-11d1d1c8fc36">201,861</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable and accrued expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTQtMS0xLTEtMzI2Nw_462eb5dd-337f-4017-bdee-2e533de4f36e">1,628,621</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTQtMy0xLTEtMzI2Nw_997b59c7-01ca-430a-8c26-f9b5e6e4aba3">3,633,394</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred rent</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ocgn:IncreaseDecreaseInDeferredRent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTUtMS0xLTEtMzI3Mw_317e6f85-1f55-4c06-9206-674d24cb4ed6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ocgn:IncreaseDecreaseInDeferredRent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTUtMy0xLTEtMzI3Mw_13ca8261-a3ff-4255-9f6a-b4fcff52c637">1,540</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTItMS0xLTEtMA_889799b2-e8ba-46ab-91e9-eb3391edd1fc">227,172</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTItMy0xLTEtMA_64023fe3-4cd3-4877-9e7b-068df0866c22">54,203</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease obligations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ocgn:IncreaseDecreaseInLeaseObligations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTQtMS0xLTEtMA_9147e094-487a-4403-adaa-89016d2e9294">249,389</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:zerodash" name="ocgn:IncreaseDecreaseInLeaseObligations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTQtMy0xLTEtMA_bf19e1d2-04e9-4ed4-9209-345658f3997a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTUtMS0xLTEtMA_6162b334-b4bb-4c92-b808-29e6e366c99c">16,893,281</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTUtMy0xLTEtMA_5a7dcd0b-b734-4530-a05c-79be5dc0ad0a">11,630,543</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase of property, plant and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTctMS0xLTEtMA_2c93c084-5c56-4b8a-9615-2a73f375a0b7">29,446</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTctMy0xLTEtMA_189b1b56-2de4-4c7c-a721-085bbb4119f9">77,414</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payment of asset acquisition costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTgtMS0xLTEtMA_979ca511-70aa-456d-a860-d88b6d138514">2,327,273</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTgtMy0xLTEtMA_2e15d1d0-81c5-4121-9d3b-7d2312eafde7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTktMS0xLTEtMA_bde2c48a-d6ef-4f07-8b7e-27ed914f49bf">2,356,719</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTktMy0xLTEtMA_68a4295b-796f-4aa4-aa2c-19b3042b1c40">77,414</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from sale of common stock for pre-merger financing</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ocgn:ProceedsFromPreMergerFinancingFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjQtMS0xLTEtMzI5NQ_7ec0493d-d724-47c6-9167-bf949a8127fd">22,546,353</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:zerodash" name="ocgn:ProceedsFromPreMergerFinancingFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjQtMy0xLTEtMzI5NQ_509d54ed-b924-43ea-8ea2-ef9b02a3c950">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from stock subscription</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjUtMS0xLTEtMzMwMA_6e751c2a-546b-4936-8368-3f5449824509">1,000,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjUtMy0xLTEtMzMwMA_326e0912-f8b3-46ea-a509-f34e421d513b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of treasury stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjYtMS0xLTEtMzMwMA_97d13459-c5b6-4aa9-bcf5-f40b42111fba">47,864</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjYtMy0xLTEtMzMwMA_749d254a-9c73-4113-b486-bd917eee4df3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock for warrant exercises</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjctMS0xLTEtMzMwMA_0da7d09c-d014-45b1-ad3e-4778dd047295">183,034</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjctMy0xLTEtMzMwMA_c6868b93-3f58-4e52-90de-ba0d6dd4da4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repayments of debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjgtMS0xLTEtMzMwNQ_82e96869-7bb8-407f-bfd7-da802b0a4152">5,290,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:RepaymentsOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjgtMy0xLTEtMzMwNQ_35c83a70-ad9a-4e5f-bb44-9f8e70084a30">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from issuance of debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjktMS0xLTEtMzMxMA_88d3db0d-8aca-44c0-9941-42e0ccc0ceec">6,800,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjktMy0xLTEtMzMxMA_faa00029-9c1b-48da-8296-efe915905201">7,300,400</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payment of debt issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjItMS0xLTEtMA_05175e3e-e0fd-4460-a4a4-7ff4d78b65cb">99,202</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjItMy0xLTEtMA_2f6df952-8f04-484b-8016-d136e22c353a">103,925</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments on financing leases</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjYtMS0xLTEtMA_45bc96be-83a0-4131-8982-f2169911262b">25,866</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjYtMy0xLTEtMA_3dcef08f-db8c-48dd-9cbc-9b93ee9ba301">11,928</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjgtMS0xLTEtMA_26875070-2e1c-440d-9a56-845ff01da7ef">25,066,455</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjgtMy0xLTEtMA_04fede6a-51ab-49d9-a7e7-b0d0548043ac">7,184,547</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of changes in exchange rate on cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjktMS0xLTEtMA_2db82aa3-eddc-425b-972c-897d0f7f5f58">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjktMy0xLTEtMA_775fe3f2-c731-49e5-b67b-e524f6754972">451</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzAtMS0xLTEtMA_69e042dd-f9e7-4b7b-959c-b51b20986891">5,816,455</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzAtMy0xLTEtMA_6d639793-9937-4292-84d3-be82d36dd559">4,522,959</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzEtMS0xLTEtMA_9650f044-4f6b-4219-b405-84ab1236aedb">1,778,613</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3b0b2789ee4e45ff8aa700de563ddc85_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzEtMy0xLTEtMA_20a9f560-d1fb-4e28-8ee7-2d26513b4a41">6,301,572</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash at end of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzItMS0xLTEtMA_77328215-40de-4863-8767-32ec59eba86d">7,595,068</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzItMy0xLTEtMA_b6de538a-9c85-4557-ac05-539e0c44f4f2">1,778,613</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental disclosure of non-cash investing and financing transactions:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase of fixed assets by entering into capital lease (Note 9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzQtMS0xLTEtMA_2caebf2a-a83c-4bfe-869c-173110016803">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzQtMy0xLTEtMA_0dbdfbf3-9eb0-40ae-ab5f-60670dda963d">63,817</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Conversion of convertible notes (Note 7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzUtMS0xLTEtMA_1d738a9a-d442-4506-a8a5-ff4dddd2a991">13,979,788</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzUtMy0xLTEtMA_f737d747-e22d-49ca-900b-a5df4998ae2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity issuance costs (Note 3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ocgn:NoncashOrPartNoncashAmountOfDeferredTransactionCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzctMS0xLTEtMA_e4c79306-4a9c-4c7b-adbd-352704879f62">1,150,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:zerodash" name="ocgn:NoncashOrPartNoncashAmountOfDeferredTransactionCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzctMy0xLTEtMA_a9d64ed1-89ec-4ff5-ae53-8fa3967ff46e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use asset related to operating leases</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ocgn:NoncashOrPartNoncashOperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzgtMS0xLTEtMA_2218779f-d330-4f45-9039-41a70a4ca558">470,356</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:zerodash" name="ocgn:NoncashOrPartNoncashOperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzgtMy0xLTEtMA_93a3f752-8c0e-4b19-a4a8-8b1fa6d5bee5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reverse asset acquisition costs (Note 3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ocgn:DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzktMS0xLTEtMA_52811602-c844-4d1e-b42d-3e60a7083515">2,252,795</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:zerodash" name="ocgn:DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzktMy0xLTEtMA_a388713e-c5c2-4af8-86f0-bf16343bedeb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying notes to consolidated financial statements.</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_37"></div><div style="position:relative;width:100%;height:21.6pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-6</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OCUGEN, INC.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_40"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">1.&#160;<ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80MC9mcmFnOjM1NDhhMTZlNGUwODRiZDA5NjE2M2FkNWRhOTgzYzY2L3RleHRyZWdpb246MzU0OGExNmU0ZTA4NGJkMDk2MTYzYWQ1ZGE5ODNjNjZfMTA5OTUxMTYyODk4OTI_432575da-1f4b-4e53-a042-8221d2b26ed4" continuedAt="i28ec158de5674c74ba325d81b8a8e37f" escape="true">Nature of Business</ix:nonNumeric></span></div><ix:continuation id="i28ec158de5674c74ba325d81b8a8e37f" continuedAt="iabf204f915ad44cb8863d9cae57eff91"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ocugen, Inc. (formerly known as Histogenics Corporation), together with its wholly owned subsidiaries (&#8220;Ocugen&#8221; or the &#8220;Company&#8221;), is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat the whole eye. The Company is located in Malvern, Pennsylvania.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ocugen has a late-stage, Phase 3 program, OCU300, which has received Orphan Drug Designation ("ODD") from the U.S. Food and Drug Administration ("FDA"). OCU300 is a small molecule therapeutic currently in Phase 3 clinical development for patients with ocular redness and discomfort stemming from ocular graft-versus-host disease (&#8220;oGVHD&#8221;). Ocugen is the first and only company to receive ODD for the treatment of symptoms associated with oGVHD and is the only company conducting Phase 3 studies in this patient population. OCU300 is formulated using the Company&#8217;s proprietary nanoemulsion technology, OcuNanoE&#8212;Ocugen&#8217;s ONE Platform&#8482; (&#8220;OcuNanoE&#8482;&#8221;).</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ocugen is developing a modifier gene therapy platform for unmet medical needs in the area of retinal diseases, including inherited retinal diseases (&#8220;IRDs&#8221;). Ocugen&#8217;s modifier gene therapy platform is novel in that it targets nuclear hormone receptors (&#8220;NHRs&#8221;), which have the potential to restore homeostasis to the retina and may target multiple genes that are associated with a range of IRDs. Unlike single-gene replacement therapies, which only target one genetic mutation, the Company believes that its gene therapy platform, through its targeting of NHRs, may impact multiple genes that are associated with a range of genetically diverse diseases. Ocugen&#8217;s first gene therapy candidate, OCU400, has received ODD from the FDA, for the treatment of nuclear receptor subfamily 2 group E member 3 ("</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NR2E3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">")</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">mutation-associated retinal diseases and centrosomal protein 290 ("</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">CEP290</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">") mutation-associated retinal diseases. Ocugen&#8217;s second gene therapy product candidate, OCU410, is targeted for dry age-related macular degeneration (&#8220;AMD&#8221;) and is currently in preclinical development. Currently, there are no FDA-approved therapies to treat this disease.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ocugen is also developing OCU200, a novel fusion protein for the treatment of wet AMD, diabetic retinopathy (&#8220;DR&#8221;) and diabetic macular edema (&#8220;DME&#8221;), which is in preclinical development. Ocugen expects to initiate a Phase 1/2 clinical trial for OCU200 within the next two years. Ocugen plans to expand the therapeutic applications of OCU200 beyond DME, DR and wet AMD to potentially include macular edema following retinal vein occlusion (&#8220;RVO&#8221;) and myopic choroidal neovascularization (&#8220;mCNV&#8221;).</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Merger with Histogenics</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September 27, 2019, the Company completed its reverse merger with Ocugen, OpCo Inc. (formerly known as Ocugen,&#160;Inc. (&#8220;Former Ocugen&#8221;)) in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of April&#160;5, 2019, by and among Histogenics, Former Ocugen and Restore Merger Sub,&#160;Inc., a wholly owned subsidiary of Histogenics (&#8220;Merger Sub&#8221;), as amended (the &#8220;Merger Agreement&#8221;), pursuant to which Merger Sub merged with and into Former Ocugen, with Former Ocugen surviving as a wholly owned subsidiary of Histogenics (the &#8220;Merger&#8221;). Immediately after completion of the Merger, Histogenics changed its name to Ocugen,&#160;Inc. and the business conducted by Ocugen,&#160;Inc. became the business conducted by Former Ocugen. Former Ocugen is deemed to be the accounting acquirer. Accordingly, the historical financial statements of Former Ocugen became the Company&#8217;s historical financial statements, including the comparative prior periods. See Note 3 for additional information.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Reverse Stock Split</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with, and immediately prior to the completion of the Merger, Histogenics effected a reverse stock split of the common stock, at a ratio of 1-for-60 (the &#8216;&#8216;Reverse Stock Split&#8217;&#8217;). Under the terms of the Merger Agreement, the Company issued common stock to Former Ocugen&#8217;s stockholders at an exchange rate of <ix:nonFraction unitRef="number" contextRef="id83e33e57cad4f08967d8d41dfb42b28_D20190927-20190927" decimals="INF" name="ocgn:BusinessCombinationIssuedSharesExchangeRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80MC9mcmFnOjM1NDhhMTZlNGUwODRiZDA5NjE2M2FkNWRhOTgzYzY2L3RleHRyZWdpb246MzU0OGExNmU0ZTA4NGJkMDk2MTYzYWQ1ZGE5ODNjNjZfMzYyNg_572cdc8e-01ca-4e20-a545-02aacb60f931">0.4794</ix:nonFraction> shares of common stock, after taking into account the Reverse Stock Split, for each share of Former Ocugen&#8217;s common stock outstanding immediately prior to the Merger.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The capital structure, including the number of shares of common stock issued appearing in the consolidated balance sheets for the periods presented, reflects that of Ocugen. All references in the consolidated financial statements to the number of shares and per-share amounts of common stock have been retroactively restated to reflect the exchange rate.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><ix:continuation id="iabf204f915ad44cb8863d9cae57eff91"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Going Concern</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, warrants to purchase common stock, the issuance of convertible notes, and debt. The Company incurred net losses of approximately $<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80MC9mcmFnOjM1NDhhMTZlNGUwODRiZDA5NjE2M2FkNWRhOTgzYzY2L3RleHRyZWdpb246MzU0OGExNmU0ZTA4NGJkMDk2MTYzYWQ1ZGE5ODNjNjZfODI0NjMzNzIyMDM3Mw_b4ab48e6-0cf9-4f65-8b3b-64019947f751">20.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80MC9mcmFnOjM1NDhhMTZlNGUwODRiZDA5NjE2M2FkNWRhOTgzYzY2L3RleHRyZWdpb246MzU0OGExNmU0ZTA4NGJkMDk2MTYzYWQ1ZGE5ODNjNjZfNzE0NjgyNTU5MjY3OQ_9b83e1b0-7ae9-4089-9c2e-5317fc647ebd">18.2</ix:nonFraction> million for the year ended December 31, 2019 and 2018, respectively, and had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80MC9mcmFnOjM1NDhhMTZlNGUwODRiZDA5NjE2M2FkNWRhOTgzYzY2L3RleHRyZWdpb246MzU0OGExNmU0ZTA4NGJkMDk2MTYzYWQ1ZGE5ODNjNjZfNjA0NzMxMzk1OTI5OQ_0dc2f8b7-0598-44d2-8b6a-64e2014d72f4">51.5</ix:nonFraction> million as of December&#160;31, 2019. As of December&#160;31, 2019, the Company had cash, cash equivalents and restricted cash totaling $<ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80MC9mcmFnOjM1NDhhMTZlNGUwODRiZDA5NjE2M2FkNWRhOTgzYzY2L3RleHRyZWdpb246MzU0OGExNmU0ZTA4NGJkMDk2MTYzYWQ1ZGE5ODNjNjZfNjA0NzMxMzk1OTMxNA_ff22d169-20eb-40a5-8d90-f38ad3ca4e4e">7.6</ix:nonFraction> million.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has a limited operating history and its prospects are subject to risks, expenses and uncertainties frequently encountered by companies in its industry. The Company intends to continue its research and development efforts for its product candidates, which will require significant funding. If the Company is unable to obtain additional financing in the future or research and development efforts require higher than anticipated capital, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital by raising additional capital through public and private placements of equity and/or debt, payments from potential strategic research and development arrangements, sale of assets, and licensing and/or collaboration arrangements with pharmaceutical companies or other institutions. Such financing may not be available at all, or on terms that are favorable to the Company. While management of the Company believes that it has a plan to fund ongoing operations, its plan may not be successfully implemented. Failure to generate sufficient cash flows from operations, raise additional capital through one or more financings, or appropriately manage certain discretionary spending could have a material adverse effect on the Company&#8217;s ability to achieve its intended business objectives.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of these factors, together with the anticipated increase in spending that will be necessary to continue to develop the Company&#8217;s products, there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that these audited consolidated financial statements are issued. The audited consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties.</span></div></ix:continuation><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_46"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">2.&#160;<ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTcwNDI0MzAyNTQwMDI_f2b59224-17f7-492f-ac3d-0cc4f7d64c02" continuedAt="i50e93078278447a0959ed878a0a3c22a" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i50e93078278447a0959ed878a0a3c22a" continuedAt="iba25f70a2bf442c09785bcd0a3ee2603"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfNzQxMA_e85ace11-01a0-46b9-962c-8719d6715304" continuedAt="i1c3b24b594784a32b08d4e74c9daba51" escape="true">Basis of Presentation and Consolidation</ix:nonNumeric></span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i1c3b24b594784a32b08d4e74c9daba51">The accompanying consolidated financial statements included herein have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;).</ix:continuation> <ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfNzQxMQ_661f8538-7f26-4e04-a774-0a172303b21c" escape="true">The consolidated financial statements include the accounts of Ocugen, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Certain prior year amounts have been reclassified to conform with current year presentation.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfNzQxNQ_1b1ae2a0-8741-4e89-bc49-dc4fac2a4f36" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Foreign Currency Translation and Transactions</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The assets and liabilities of the Company&#8217;s foreign subsidiary are translated into U.S. dollars based on exchange rates in effect at the end of each period. Revenues and expenses are translated at average exchange rates during the periods. Currency transaction gains or losses are included in other expenses. Gains or losses from balance sheet translation are included in accumulated other comprehensive income.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfNzQxMg_95e4c0e4-512f-4b39-8c35-9aa50d193043" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In preparing consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include those used in the estimation of clinical trial accruals and the valuation of share-based payment arrangements, warrants, and embedded conversion features on the convertible notes.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="ocgn:AssetHeldForSalePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTcwNDI0MzAyNTQwMDM_c2d51332-f3f4-4139-812b-0a35b1a2436c" continuedAt="i6511f2288bf745a1b3815844fa3d1160" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Asset Held for Sale</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">An asset is considered to be held for sale when all of the following criteria are met: (i) management commits to a plan to sell the asset; (ii) it is unlikely that the disposal plan will be significantly modified or discontinued; (iii) the asset is available for immediate sale in its present condition; (iv)&#160;actions required to complete the sale of the asset have been initiated; (v) sale of the asset is probable and the completed sale is expected to occur within one year; and (vi)&#160;the asset is actively being marketed for sale at a price that is reasonable given its current market value.</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><ix:continuation id="iba25f70a2bf442c09785bcd0a3ee2603" continuedAt="i70b5cfa69c9549bd973a19bca427110b"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i6511f2288bf745a1b3815844fa3d1160">A long-lived asset classified as held for sale is measured at the lower of its carrying amount or fair value less cost to sell. If the long-lived asset is newly acquired, the carrying amount of the long-lived asset is established based on its fair value less cost to sell at the acquisition date. A long-lived asset is not depreciated or amortized while it is classified as held for sale, and an impairment loss would be recognized to the extent the carrying amount exceeds the asset's fair value less cost to sell.</ix:continuation></span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, Ocugen had an intangible asset held for sale acquired from Histogenics with a fair value less cost to sell of $<ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMzg2MQ_4a383b20-979b-49de-b135-11e57c35d70b">7.0</ix:nonFraction> million. See Note 3 for additional information.</span></div><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfNzQxNA_4445ebe9-c3ff-40b6-99fa-18003b44a3be" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value Measurements</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The company follows the provisions of the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 820, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC 820&#8221;), which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair measurements.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The estimated fair value of certain financial instruments, cash and cash equivalents, accounts payable, and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. As of December&#160;31, 2019 and 2018, the Company believes the fair value of the EB-5 note approximates its carrying value.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 1 &#8212; quoted prices in active markets for identical assets or liabilities</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 2 &#8212; quoted prices for similar assets and liabilities in active markets or inputs that are observable</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 3 &#8212; inputs that are unobservable (for example cash flow modeling inputs based on assumptions)</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The company had derivative instruments that were fair valued on a recurring basis using Level 3 inputs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="ocgn:DerivativeInstrumentsAndHedgingActivitiesDisclosurePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfNzQwNw_59f01780-5a9e-484e-80da-f6a3f9da26a5" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Financial Instruments Indexed to and Potentially Settled in Common Stock</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for warrants in accordance with ASC Topic 815-40, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC 815-40&#8221;), which is the authoritative guidance on accounting for derivative financial instruments indexed to and potentially settled in a company&#8217;s own stock. To determine whether a contract is considered indexed to the issuer&#8217;s own equity, the Company performs a two-step analysis:</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Step 1: Evaluate whether the contract contains any exercise contingencies and, if so, whether they disqualify the contract from being classified as equity, and</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Step 2: Assess whether the settlement terms are consistent with equity classification.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company classifies the liability-designated warrants on its consolidated balance sheets as a derivative liability which is recognized at fair value at each reporting period subsequent to the initial issuance. Changes in the fair value of derivatives are recognized as other income (expense) in the consolidated statements of operations and comprehensive loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTcwNDI0MzAyNTQwMDQ_63f1726d-3e0f-4760-b052-fbb9a2463b97" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposit, commercial paper and United States government and United States government agency obligations. The Company&#8217;s restricted cash balance consists of cash held to collateralize a corporate credit card account.</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><ix:continuation id="i70b5cfa69c9549bd973a19bca427110b" continuedAt="ia19db5810f364e6c88a053570269afed"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTcwNDI0MzAyNTQwMzA_26d9ff64-a8d3-4050-ae56-41a1fd30a02a" escape="true"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTcwNDI0MzAyNTQwMzA_aa84a401-10c8-49a8-bffa-0d361b661515" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash in the consolidated balance sheets to the total amount shown in the consolidated statements of cash flows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:68.175%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.622%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash reconciliation:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RhYmxlOmU0NjAzZmE0YmRjZTQwNmE4ODliYjVlNDllNDc1MzJhL3RhYmxlcmFuZ2U6ZTQ2MDNmYTRiZGNlNDA2YTg4OWJiNWU0OWU0NzUzMmFfMy0xLTEtMS0w_15abd57d-3dbb-4eac-85e4-ee96899bd1ba">7,444,052</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RhYmxlOmU0NjAzZmE0YmRjZTQwNmE4ODliYjVlNDllNDc1MzJhL3RhYmxlcmFuZ2U6ZTQ2MDNmYTRiZGNlNDA2YTg4OWJiNWU0OWU0NzUzMmFfMy0zLTEtMS0w_421fde7e-9519-45ad-ab58-a58563edb397">1,628,136</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RhYmxlOmU0NjAzZmE0YmRjZTQwNmE4ODliYjVlNDllNDc1MzJhL3RhYmxlcmFuZ2U6ZTQ2MDNmYTRiZGNlNDA2YTg4OWJiNWU0OWU0NzUzMmFfNC0xLTEtMS0w_90a27e5b-f124-4df5-a1ed-2f2f6594aeea">151,016</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RhYmxlOmU0NjAzZmE0YmRjZTQwNmE4ODliYjVlNDllNDc1MzJhL3RhYmxlcmFuZ2U6ZTQ2MDNmYTRiZGNlNDA2YTg4OWJiNWU0OWU0NzUzMmFfNC0zLTEtMS0w_af399d75-8351-4c7b-9ad3-0ebc8700df9d">150,477</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash, cash equivalents and restricted cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RhYmxlOmU0NjAzZmE0YmRjZTQwNmE4ODliYjVlNDllNDc1MzJhL3RhYmxlcmFuZ2U6ZTQ2MDNmYTRiZGNlNDA2YTg4OWJiNWU0OWU0NzUzMmFfNS0xLTEtMS0w_e1448e5a-939c-405f-9269-674e9861a152">7,595,068</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RhYmxlOmU0NjAzZmE0YmRjZTQwNmE4ODliYjVlNDllNDc1MzJhL3RhYmxlcmFuZ2U6ZTQ2MDNmYTRiZGNlNDA2YTg4OWJiNWU0OWU0NzUzMmFfNS0zLTEtMS0w_95078d0d-2130-45c5-9325-3272ae396b47">1,778,613</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div><span><br/></span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTcwNDI0MzAyNTQwMDU_9a6f05c3-9a97-42db-bb62-5de9b66e2688" continuedAt="ibf498d446cf4426db6a92f85c934f87f" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ibf498d446cf4426db6a92f85c934f87f">Property and equipment is recorded at cost. Significant additions or improvements are capitalized, and expenditures for repairs and maintenance are charged to expense as incurred. Gains and losses on disposal of assets are included in the consolidated statements of operations and comprehensive loss. Depreciation is calculated using the straight-line method and is recognized over an expected useful life of <ix:nonNumeric contextRef="i0c8bec4b6fb74710acd1aebcd65c0caf_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTcwNDI0MzAyNTQwMzE_d8fbcdf2-d9b0-4ced-8036-43ff6b8216cd">5</ix:nonNumeric> years for equipment and <ix:nonNumeric contextRef="if7530f5259ea4fb287abfd56f7c74a7f_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTcwNDI0MzAyNTQwNDQ_bbc1e69a-bdf7-4431-9dc0-e7c6ad80c8fd">7</ix:nonNumeric> years for furniture.</ix:continuation> The total accumulated depreciation and amortization for equipment and furniture as of December&#160;31, 2019 and 2018 was $<ix:nonFraction unitRef="usd" contextRef="i280158470c9b4af886ce65d165852eaa_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfNzY5NjU4MTQxODY3MA_e969034b-b65a-4809-a72c-b27f27257af1">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iad6c551567dc41aba66ce356fc5db8a9_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfNzY5NjU4MTQxODY3Mw_3561029e-4419-4041-b1de-fc07d141cc84">0.1</ix:nonFraction>&#160;million, respectively.</span></div><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTcwNDI0MzAyNTQwMDY_9aa593c6-e626-4fd4-a3ec-0dc82f142db1" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements which include lease and&#160;non-lease&#160;components, which the Company has elected to account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components are recognized when the obligation is probable.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating leases are included in other assets and lease obligations on the Company&#8217;s consolidated balance sheets. Operating lease right-of-use ("ROU") assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Operating lease payments are recognized as lease expense on a straight-line basis over the lease term. The Company primarily leases buildings (real estate) which are classified as operating leases. ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As an implicit interest rate is not readily determinable in the Company&#8217;s leases, the incremental borrowing rate is used based on the information available at commencement date in determining the present value of lease payments.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The lease term for all of the Company&#8217;s leases includes the&#160;non-cancellable&#160;period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and lease liability) for the majority of the Company&#8217;s leases as the reasonably certain threshold is not met.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lease payments included in the measurement of the lease liability are comprised of fixed payments, variable payments that depend on index or rate, and amounts probable to be payable under the exercise of the Company option to purchase the underlying asset if reasonably certain.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Variable lease payments not dependent on a rate or index associated with the Company&#8217;s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed as probable. Variable lease payments include the Company's proportionate share of utilities and other operating expenses and are presented as operating expenses in the Company&#8217;s income statement in the same line item as expense arising from fixed lease payments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTcwNDI0MzAyNTQwMjU_a1b2e725-5dca-460d-b8b6-93bb4e8973e8" continuedAt="i178c00cc789c4a59b435c7689d67bfa4" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-based compensation</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ocugen accounts for its stock-based compensation awards in accordance with ASC Topic 718, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Compensation&#8212;Stock Compensation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments to employees, including grants of employee stock options and restricted stock units and modifications to existing agreements, to be recognized in the statements of operations </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><ix:continuation id="ia19db5810f364e6c88a053570269afed" continuedAt="i8d925426039345618a3f9b9e45905358"><ix:continuation id="i178c00cc789c4a59b435c7689d67bfa4"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">based on their fair values. Ocugen uses the Black-Scholes option-pricing model to determine the fair value of options granted. Ocugen recognized forfeitures as they occur.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ocugen&#8217;s stock-based awards are subject to service-based vesting conditions. Compensation expense related to awards to employees and directors with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Stock-based awards generally vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfNzY5NjU4MTQxODYxNA_853dc9b7-c919-4df5-9190-d9436288daac">one</span> to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfODI0NjMzNzIzNzU5OQ_e571c6b5-bef2-4cd7-bc49-832c32f02b1a">three</span> year requisite service period and have a contractual term of <ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfNzY5NjU4MTQxODYyNQ_5fbeff23-7f34-42dc-8ad9-c85d77b9ca7b">10</ix:nonNumeric> years.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Estimating the fair value of options requires the input of subjective assumptions, including expected life of the option, stock price volatility, the risk-free interest rate and expected dividends. The assumptions used in Ocugen&#8217;s Black-Scholes option-pricing model represent management&#8217;s best estimates and involve a number of variables, uncertainties and assumptions and the application of management&#8217;s judgment, as they are inherently subjective. If any assumptions change, Ocugen&#8217;s stock-based compensation expense could be materially different in the future.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These assumptions used in Ocugen&#8217;s Black-Scholes option-pricing model are as follows:</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Term.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Due to the historical lack of a public market for the trading of Ocugen common stock and the lack of sufficient company-specific historical data, the expected term of employee options is determined using the &#8220;simplified&#8221; method, as prescribed in Securities and Exchange Commission&#8217;s Staff Accounting Bulletin No. 107 (&#8220;SAB&#160;No.&#160;107&#8221;), whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option. The expected term of non-employee options is equal to the contractual term.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Volatility.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The expected volatility is based on historical volatilities of Ocugen and similar entities within Ocugen&#8217;s industry for periods commensurate with the expected term assumption.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk-Free Interest Rate.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Dividends.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The expected dividend yield is <ix:nonFraction unitRef="number" contextRef="i6258e5af615841ca8ed08b5fc6e64f13_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfNDM5ODA0NjUyNjEzNg_876281f9-d8c9-4da8-bd3c-99625a9ed41c">0</ix:nonFraction>% because Ocugen has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.</span></div></ix:continuation><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTcwNDI0MzAyNTQwMjc_25e730c2-bef5-4777-a238-1528597aef23" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is a Delaware C-Corporation. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, is applied during the years in which temporary differences are expected to be settled and is reflected in the financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on the weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. The Company&#8217;s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. No interest or penalty expense was recognized during the periods presented.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has assessed and concluded that there are uncertain tax positions giving rise to the unrecognized tax benefits as of December&#160;31, 2019. The Company&#8217;s conclusions regarding uncertain tax positions may be subject to review and adjustment at a later date based upon ongoing analysis of tax laws, regulations and interpretations thereof, as well as other factors. Generally, federal, state, and local authorities may examine the Company&#8217;s tax returns for three years from the date of the filing and the current and prior three years remain subject to examination as of December&#160;31, 2019.</span></div></ix:nonNumeric><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTcwNDI0MzAyNTQwMjg_5f1c630e-63d8-42af-a3ee-3695bdcefb27" continuedAt="i41892e2fba2047a79c93d4045fa3bb59" escape="true">Segment Information</ix:nonNumeric></span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i41892e2fba2047a79c93d4045fa3bb59">The Company views its operations and manages its business as <ix:nonFraction unitRef="segment" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTcwNDI0MzAyNTQwNTg_88c2cdb5-b19f-4ba8-bf5f-44997693e60f">one</ix:nonFraction> operating segment, which is the development of innovative therapies to address the whole eye.</ix:continuation> As of December&#160;31, 2019, substantially all of the Company&#8217;s assets were located in the United States.</span></div><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTcwNDI0MzAyNTQwMjk_e081168c-3d22-4108-842f-715ec885a093" continuedAt="i479e8d99823448d88fe7eb5b7166f7f7" escape="true"><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Standards</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February&#160;2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;)&#160;No.&#160;2016-02,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases (Topic 842)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC 842&#8221;). In July&#160;2018, the FASB issued ASU&#160;No.&#160;2018-10,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Codification Improvements to Topic 842, Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASU&#160;2018-10&#8221;),&#160;which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU&#160;No.&#160;2018-11,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><ix:continuation id="i8d925426039345618a3f9b9e45905358" continuedAt="i1ab7955e8443455c8a6ffbabd9b386ff"><ix:continuation id="i479e8d99823448d88fe7eb5b7166f7f7" continuedAt="icff595b9aea642da804b325e029b857c"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(Topic 842)&#8212;Targeted Improvements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASU&#160;2018-11&#8221;),&#160;which addressed implementation issues related to the new lease standard. These and certain other lease-related ASUs have generally been codified in ASC 842. ASC 842 supersedes the lease accounting requirements in ASC Topic 840, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC 840&#8221;). ASC 842 establishes a&#160;right-of-use&#160;model that requires a lessee to record a&#160;right-of-use&#160;(&#8220;ROU&#8221;) asset and a lease liability on the balance sheet for all leases. Under ASC 842, leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The standard also requires disclosures to help investors and other financial statement users better understand the amount, timing and uncertainty of cash flows arising from leases. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company adopted ASC 842 on January&#160;1, 2019 using the effective date transition method. Prior period results continue to be presented under ASC 840 based on the accounting standards originally in effect for such periods. The Company has elected certain practical expedients permitted under the transition guidance within ASC 842 to leases that commenced before January&#160;1, 2019, including the package of practical expedients. The election of the package of practical expedients resulted in the Company not reassessing prior conclusions under ASC 840 related to lease identification, lease classification and initial direct costs for expired and existing leases prior to January&#160;1, 2019. The adoption of ASU&#160;2016-02&#160;did not have a significant impact on the Company&#8217;s consolidated results of operations or cash flows. Upon adoption, the Company recognized an ROU asset and lease liability of $<ix:nonFraction unitRef="usd" contextRef="i7860a6ea500e471894ae9e509085cdf6_I20190101" decimals="-5" format="ixt:numdotdecimal" name="ocgn:LeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTA5OTUxMTY0ODYwOA_4fa1f3f7-6a42-48f3-8816-792e4b9af969">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7860a6ea500e471894ae9e509085cdf6_I20190101" decimals="-5" format="ixt:numdotdecimal" name="ocgn:LeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTA5OTUxMTY0ODYxNQ_46d28164-38b8-48c6-9cdd-9b94fc3f3cff">0.4</ix:nonFraction> million, respectively. See Note 9 for additional information.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU No. 2018-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This standard modifies certain disclosure requirements on fair value measurements and was effective for the Company on January 1, 2020. The adoption of this standard will not have a material impact on the Company's disclosures.</span></div></ix:continuation></ix:continuation><div style="margin-top:12pt;"><ix:continuation id="i1ab7955e8443455c8a6ffbabd9b386ff" continuedAt="iba9ed171cbef4397b5e25792815a4161"><ix:continuation id="icff595b9aea642da804b325e029b857c" continuedAt="i2ba1eb60139940b0a29bc17d6187a8be"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span></ix:continuation></ix:continuation><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="iba9ed171cbef4397b5e25792815a4161"><ix:continuation id="i2ba1eb60139940b0a29bc17d6187a8be">. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2023. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The Company does not expect the adoption of these standards to have a material impact on its consolidated financial statements.</ix:continuation></ix:continuation> </span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_52"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">3.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfMTcwNDI0MzAyNDIzMDM_76fe7296-f7f5-4840-b58b-01e284cd9f27" continuedAt="i1356c65e0bcb4bb6a1c92bdf84ccb429" escape="true">Merger and Pre-Merger Financing</ix:nonNumeric></span></div><ix:continuation id="i1356c65e0bcb4bb6a1c92bdf84ccb429" continuedAt="i2a00071c95084519b28628a343121a46"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Pre-Merger Financing</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June&#160;2019, Former Ocugen and Histogenics entered into a Securities Purchase Agreement (as amended, the &#8220;Financing SPA&#8221;) with certain accredited investors (the &#8220;Investors&#8221;). Pursuant to the Financing SPA, among other things, (i)&#160;immediately prior to the Merger, Former Ocugen issued <ix:nonFraction unitRef="shares" contextRef="i5010aa0712c74ac685012c6d136ca792_I20190630" decimals="-5" format="ixt:numdotdecimal" name="ocgn:NumberOfSharesAgreedToIssuePriorToMergerToInvestors" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNjA0NzMxMzk1OTc5NA_a701df6b-93a4-4d1e-9711-3c0ed3d532c0">4.6</ix:nonFraction> million shares of common stock to the Investors (the &#8220;Initial Shares&#8221; and, as converted pursuant to the exchange rate in the Merger into the right to receive approximately <ix:nonFraction unitRef="shares" contextRef="idfbc6400eef840d6b17bcf600923cbfa_D20190601-20190630" decimals="-5" format="ixt:numdotdecimal" name="ocgn:NumberOfConvertedInitialSharesAgreedToIssuePriorToMergerToInvestors" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNjA0NzMxMzk1OTgyNQ_e0ee659d-1f82-4aea-a567-d517076855dd">2.2</ix:nonFraction> million shares the Company&#8217;s common stock, the &#8220;Converted Initial Shares&#8221;), (ii)&#160;immediately prior to the Merger, Former Ocugen issued and deposited <ix:nonFraction unitRef="shares" contextRef="i5010aa0712c74ac685012c6d136ca792_I20190630" decimals="-5" format="ixt:numdotdecimal" name="ocgn:NumberOfSharesAgreedToIssuePriorToMergerToInvestors" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNzE0NjgyNTU5NDc5OA_3097c9a1-75ce-4b2d-844d-9d6f46fd81a7">4.6</ix:nonFraction>&#160;million shares of common stock into escrow on behalf of the Investors (the &#8220;Additional Shares&#8221; and, as converted pursuant to the exchange rate in the Merger, into the right to receive approximately <ix:nonFraction unitRef="shares" contextRef="idfbc6400eef840d6b17bcf600923cbfa_D20190601-20190630" decimals="-5" format="ixt:numdotdecimal" name="ocgn:NumberOfConvertedAdditionalSharesAgreedToIssuePriorToMergerToInvestors" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNjA0NzMxMzk1OTgzMA_65bb7757-aa09-45fa-8508-925b0b9bd3df">2.2</ix:nonFraction> million shares of the Company&#8217;s common stock, the &#8220;Converted Additional Shares&#8221;) and (iii)&#160;the Company agreed to issue, on the fifth trading day following the consummation of the Merger, three series of warrants to purchase shares of the Company&#8217;s common stock (the &#8220;Series&#160;A Warrants,&#8221; the &#8220;Series&#160;B Warrants&#8221; and the &#8220;Series&#160;C Warrants&#8221; and collectively, the &#8220;Pre-Merger Financing Warrants&#8221;) in exchange for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="idfbc6400eef840d6b17bcf600923cbfa_D20190601-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNjA0NzMxMzk1OTg1OQ_bed313c5-5692-497b-b32c-c5ad4c02b7d1">25.0</ix:nonFraction> million (&#8220;Pre-Merger Financing&#8221;). See Note 10 for additional information on the Pre-Merger Financing Warrants.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On October 4, 2019, the Converted Additional Shares were released from escrow to the investors because, as determined at the close of business on October 2, 2019, <ix:nonFraction unitRef="number" contextRef="if83d8a8656604b6494f17eff209a905f_I20191004" decimals="INF" name="ocgn:ConvertedAdditionalSharesThresholdReleaseTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfMTcwNDI0MzAyNDIzMDY_a54ec2e7-4adc-4aa5-9d95-3e18b2eb04a8">80</ix:nonFraction>% of the volume-weighted average trading price of a share of Ocugen&#8217;s common stock as quoted on Nasdaq for the first <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfMTcwNDI0MzAyNDIzMTA_2a410e8c-05ba-4258-a80a-5a97f417ce2a">three</span> trading days immediately following the closing date of the Pre-Merger Financing was lower than the price paid by the Investors for the Initial Shares.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Approximately $<ix:nonFraction unitRef="usd" contextRef="idfbc6400eef840d6b17bcf600923cbfa_D20190601-20190630" decimals="-5" format="ixt:numdotdecimal" name="ocgn:MergerAcquisitionCostsIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfMTA5OTUxMTYzOTk2NA_b8d28659-d26c-446e-9842-b82f348cf313">2.5</ix:nonFraction> million of the $<ix:nonFraction unitRef="usd" contextRef="idfbc6400eef840d6b17bcf600923cbfa_D20190601-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfMTA5OTUxMTYzOTk3NA_bed313c5-5692-497b-b32c-c5ad4c02b7d1">25.0</ix:nonFraction> million Pre-Merger Financing was utilized to pay transaction costs related to the Merger and the Pre-Merger Financing in the form of equity. In addition, the Company utilized $<ix:nonFraction unitRef="usd" contextRef="i3a90ecac0c074f6aa909c9426321c8d8_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfSeniorDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNzY5NjU4MTQwODkyNw_1d5182a9-5781-42a7-91af-78ddc1e00cae">5.3</ix:nonFraction>&#160;million of the Pre-Merger </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><ix:continuation id="i2a00071c95084519b28628a343121a46" continuedAt="i00a889d1cf7b4da98b49b2dd9b10c064"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financing for the repayment of the Senior Secured Notes, as defined in Note 7. As a result, the Company received total net proceeds of $<ix:nonFraction unitRef="usd" contextRef="idfbc6400eef840d6b17bcf600923cbfa_D20190601-20190630" decimals="-5" format="ixt:numdotdecimal" name="ocgn:NetProceedsFromReverseMerger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfMTA5OTUxMTY0MDI5Ng_0a4cb066-10bf-43b7-92c8-168b6ee5e67a">17.2</ix:nonFraction> million from the Pre-Merger Financing. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company incurred $<ix:nonFraction unitRef="usd" contextRef="i342cd331097f4691b9092a11b982313e_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="ocgn:StockIssuanceCostsRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfMTcwOQ_5318218d-f0f8-4743-8a6f-347e7588841c">1.9</ix:nonFraction> million in equity issuance costs related to the Pre-Merger Financing, of which $<ix:nonFraction unitRef="usd" contextRef="i342cd331097f4691b9092a11b982313e_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfMTc4Mw_49f29947-b935-48b9-aab9-2f1e8c10de2f">0.7</ix:nonFraction> million was paid in cash and $<ix:nonFraction unitRef="usd" contextRef="i342cd331097f4691b9092a11b982313e_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfMTgwNw_707a14e6-dbd1-452b-a6ec-ad99b9b4f0ec">1.2</ix:nonFraction> million was paid with equity as of December&#160;31, 2019. Approximately $<ix:nonFraction unitRef="usd" contextRef="i08a49a87c9214a5188152f75514c346b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="ocgn:StockIssuanceCostsRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfMTg1NQ_ddda33bc-d51a-449e-9991-13f0b36cebaf">1.1</ix:nonFraction> million of equity issuance costs was allocated to the Series&#160;A Warrants and Series&#160;C Warrants and is included in additional paid-in capital. Approximately $<ix:nonFraction unitRef="usd" contextRef="i6de30431b0884e779b449c2552d931fc_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="ocgn:StockIssuanceCostsRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfMjAwNQ_abca7019-5411-4fbf-824f-49c7b668ebde">0.8</ix:nonFraction> million of issuance costs allocated to the Series&#160;B Warrant liability was expensed and is reflected in other income (expense) on the consolidated statements of operations and comprehensive loss for the year ended December 31, 2019.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Merger with Histogenics</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September&#160;27, 2019, the Company completed the Merger in accordance with the terms of the Merger Agreement. The Merger was structured as a stock-for-stock transaction whereby all of Former Ocugen&#8217;s outstanding shares of common stock and securities convertible into or exercisable for Former Ocugen&#8217;s common stock were converted into the right to receive Histogenics&#8217; common stock and securities convertible into or exercisable for Histogenics&#8217; common stock. Immediately following the Merger, the former equity holders of Former Ocugen owned <ix:nonFraction unitRef="number" contextRef="i1cc6e7cd4ebb41879dbbbd27370e6258_I20190927" decimals="4" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNjA0NzMxMzk2MDA0Mw_f2fdde73-63b3-4d2f-8800-21a383f453c4">84.25</ix:nonFraction>% of the outstanding capital stock of the Company, and the equity holders of the Company immediately before the Merger owned <ix:nonFraction unitRef="number" contextRef="ib33a77518a874faaa0e86a954580e035_I20190926" decimals="4" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNjA0NzMxMzk2MDA1MQ_d996c4c5-531a-49a7-9f9b-0ced6e3cd912">15.75</ix:nonFraction>% of the outstanding capital stock of the Company, including the Initial Shares but excluding the Additional Shares and the Pre-Merger Financing Warrants pursuant to the Financing SPA.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In accordance with ASC Topic 805, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Business Combinations</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC 805&#8221;)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the Company concluded that, while Histogenics is the legal acquirer, Former Ocugen is the accounting acquirer due to the fact that (i)&#160;Former Ocugen&#8217;s shareholders have the majority of the voting rights in Ocugen, (ii)&#160;Former Ocugen holds all of the board seats of the combined company and (iii)&#160;Former Ocugen management holds all key positions in the management of the combined company. The Company has further concluded that Histogenics does not meet the definition of a business under ASC 805 due to the fact that substantially all of the fair value of the gross assets disposed of is concentrated in a single identifiable asset or a group of similar identifiable assets. Therefore, the Merger was accounted for as a reverse asset acquisition. The Company incurred $<ix:nonFraction unitRef="usd" contextRef="i2c96e6e4a1ec48b79500273ba5fd55e8_D20190927-20190927" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfMzk1NA_40a04b48-dfce-49c2-8d40-d23462258fc4">4.9</ix:nonFraction> million in transaction costs related to the Merger, of which $<ix:nonFraction unitRef="usd" contextRef="i2c96e6e4a1ec48b79500273ba5fd55e8_D20190927-20190927" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForMergerRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNDAxMA_2aae2566-ed41-4eb5-a5d8-1e432c225c30">2.6</ix:nonFraction> million was paid in cash and $<ix:nonFraction unitRef="usd" contextRef="i2c96e6e4a1ec48b79500273ba5fd55e8_D20190927-20190927" decimals="-5" format="ixt:numdotdecimal" name="ocgn:AdjustmentsToAdditionalPaidInCapitalMergerRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNDAzNA_b0badecb-f9b2-4fb7-b79c-ddf9f79b7cb5">2.3</ix:nonFraction> million was paid with equity.</span></div><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfMTcwNDI0MzAyNDIzMDQ_1108e320-1c14-4dcd-ab83-454f5d0477b8" escape="true"><div style="margin-top:12pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Assets and liabilities of Histogenics on September&#160;27, 2019 were as follows (in thousands):</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:83.380%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.620%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">September 27,</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">2019</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i233f75f6ffd24f2fbc2db0b32db4d667_I20190927" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RhYmxlOmE3NDk3MTFlOTMxYzQ3MTI5MTY1YjRjMTk1NzRjYTk2L3RhYmxlcmFuZ2U6YTc0OTcxMWU5MzFjNDcxMjkxNjViNGMxOTU3NGNhOTZfMS0xLTEtMS0w_f8b44b66-2fa5-4e3c-a978-c8dc30bffbcf">302</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset held for sale</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i233f75f6ffd24f2fbc2db0b32db4d667_I20190927" decimals="-3" format="ixt:numdotdecimal" name="ocgn:AssetsHeldForSale" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RhYmxlOmE3NDk3MTFlOTMxYzQ3MTI5MTY1YjRjMTk1NzRjYTk2L3RhYmxlcmFuZ2U6YTc0OTcxMWU5MzFjNDcxMjkxNjViNGMxOTU3NGNhOTZfMi0xLTEtMS0w_518593d7-abc5-4c06-956b-0642eddf54bf">7,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i233f75f6ffd24f2fbc2db0b32db4d667_I20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RhYmxlOmE3NDk3MTFlOTMxYzQ3MTI5MTY1YjRjMTk1NzRjYTk2L3RhYmxlcmFuZ2U6YTc0OTcxMWU5MzFjNDcxMjkxNjViNGMxOTU3NGNhOTZfMy0xLTEtMS0w_f74c6172-f54e-4618-9818-b8566a6079c5">1,106</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i233f75f6ffd24f2fbc2db0b32db4d667_I20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RhYmxlOmE3NDk3MTFlOTMxYzQ3MTI5MTY1YjRjMTk1NzRjYTk2L3RhYmxlcmFuZ2U6YTc0OTcxMWU5MzFjNDcxMjkxNjViNGMxOTU3NGNhOTZfNC0xLTEtMS0w_9c618daa-bf7f-46f4-a223-70e2f63e4acd">6,196</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Asset Held for Sale</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the Merger, on May&#160;8, 2019, Histogenics entered into an asset purchase agreement (the &#8220;Asset Purchase Agreement&#8221;) with Medavate Corp., a Colorado corporation (&#8220;Medavate&#8221;), pursuant to which Histogenics agreed to sell substantially all of its assets relating to its NeoCart</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> program, including, without limitation, intellectual property, business and license agreements and clinical trial data (the &#8220;Assets&#8221;) in return for a cash payment of $<ix:nonFraction unitRef="usd" contextRef="i1089f8a8a43a48879ed876ae4de5115b_D20190508-20190508" decimals="-5" format="ixt:numdotdecimal" name="ocgn:AssetPurchaseAgreementCashConsideration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNjA0NzMxMzk2MDA5OA_082ed752-e033-437d-9ea2-bbc3c59863a2">6.5</ix:nonFraction> million. On September&#160;26, 2019, the parties entered into an amendment to the Asset Purchase Agreement whereby the closing date was amended to October&#160;4, 2019. On October&#160;4, 2019, the parties entered into a second amendment (the &#8220;Second Amendment&#8221;) to the Asset Purchase Agreement whereby the purchase price was increased to $<ix:nonFraction unitRef="usd" contextRef="i22aaf4b1361c4ec7884cdd1e535ac03e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNzE0NjgyNTU5NDc5MQ_b96ca3b7-54c7-470c-a0ee-d1503bbab778">7.0</ix:nonFraction>&#160;million under the Asset Purchase Agreement and the closing date of the Asset Purchase Agreement was revised from October&#160;4, 2019 to two business days after Medavate obtains financing in an amount no less than the purchase price (the &#8220;Closing Date&#8221;). The Second Amendment further provides that if the Closing Date does not occur on or prior to October&#160;31, 2019, Ocugen may choose to terminate the Asset Purchase Agreement without recourse and, if Ocugen does not terminate the Asset Purchase Agreement, the purchase price shall increase <ix:nonFraction unitRef="number" contextRef="id02b04cce6a9413aae504f8cfc956e2b_D20191004-20191004" decimals="INF" name="ocgn:PercentageOfIncreaseInPurchasePriceOfAssetPerMonth" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNjA0NzMxMzk2MDEwMQ_288e36b8-ebf2-4f2e-92a8-56d070dad531">10</ix:nonFraction>% per month (or any portion thereof) between October&#160;31, 2019 and the Closing Date. The Closing Date did not occur as of December&#160;31, 2019, Ocugen has not terminated the Asset Purchase Agreement and as of December&#160;31, 2019, the purchase price has increased to $<ix:nonFraction unitRef="usd" contextRef="i7c31e84a90244ee78a2df7e88dca555a_D20191231-20191231" decimals="-5" format="ixt:numdotdecimal" name="ocgn:AssetPurchaseAgreementCashConsideration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNTQ5NzU1ODE1MDU1Mg_35713bf3-60b4-4bdc-81fe-07c7eeada624">8.5</ix:nonFraction> million.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The NeoCart</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> asset qualified as held for sale as of the date of the reverse asset acquisition and is carried at its original fair value less cost to sell on the consolidated balance sheet as of December&#160;31, 2019. The NeoCart</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> asset held for sale was valued at the </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><ix:continuation id="i00a889d1cf7b4da98b49b2dd9b10c064"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">acquisition date based on a quoted price of $<ix:nonFraction unitRef="usd" contextRef="id4141b56122e4357bea6334ad7cbb7eb_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNDM5ODA0NjUyMDk1NQ_d065de0f-b6e9-4113-b729-0680798c027d">7.0</ix:nonFraction> million, which is an observable Level 2 fair value input. Subsequent increases in fair value are not recognized beyond the initial value at the time the asset was classified as held for sale. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">MEDINET Agreement</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December&#160;2017, Histogenics entered into the License and Commercialization Agreement (the &#8220;License Agreement&#8221;) with MEDINET Co.,&#160;Ltd. (&#8220;MEDINET&#8221;) to grant MEDINET a license under certain patents, patent applications, know-how, and technology to develop and commercialize certain therapeutic products related to the NeoCart</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> program. As consideration for the granting of the license, MEDINET agreed to pay Histogenics a non-refundable upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="i452b3f0c99ee4054a9b7492fcd19fe2a_D20180101-20180131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLicenseFeesReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNjA0NzMxMzk2MDEwNA_bbe3c919-1733-4c33-89de-6012fdf33cca">10.0</ix:nonFraction> million which was received in January&#160;2018. Based on the results of the NeoCart</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> research, Histogenics suspended the NeoCart</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> program. Subsequently, since MEDINET relied on the NeoCart</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> product to supply clinical trial patients, MEDINET suspended the development of its clinical trial. As of December&#160;31, 2019, the contract with MEDINET was wholly unperformed. As a result of the expected sale of the NeoCart</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> asset, the Company does not expect to retain any future obligations related to the MEDINET agreement.</span></div></ix:continuation><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_55"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">4.&#160;<ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RleHRyZWdpb246MjRhY2UyOTU0YzM2NDVjNTgyOTI1ZDVhODEwYzU5ZWVfMTcwNDI0MzAyMzI0MDE_8247c66c-e7d5-4d33-99c7-4e0f412afd07" continuedAt="ia921850f21c748c5b50daa5cb8e56712" escape="true">Net Loss Per Share of Common Stock</ix:nonNumeric></span></div><ix:continuation id="ia921850f21c748c5b50daa5cb8e56712"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RleHRyZWdpb246MjRhY2UyOTU0YzM2NDVjNTgyOTI1ZDVhODEwYzU5ZWVfMTcwNDI0MzAyMzI0MDI_0ddad3f3-904c-4bba-8552-030f390c576c" escape="true"><div style="margin-top:12pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the computation of basic and diluted earnings per share for the years ended December 31, 2019 and 2018:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:68.175%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.622%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss&#8212;basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjU5N2I1ZGUwNDRmOTQ5Yzg5ZjYwNDM5YmIzZjBjZTQ0L3RhYmxlcmFuZ2U6NTk3YjVkZTA0NGY5NDljODlmNjA0MzliYjNmMGNlNDRfMi01LTEtMS0w_8615bf1a-effe-4e5f-a5c0-d419a04a116a"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjU5N2I1ZGUwNDRmOTQ5Yzg5ZjYwNDM5YmIzZjBjZTQ0L3RhYmxlcmFuZ2U6NTk3YjVkZTA0NGY5NDljODlmNjA0MzliYjNmMGNlNDRfMi01LTEtMS0w_d4e61df8-8f24-4569-bd34-aa5958a43635">20,242,630</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjU5N2I1ZGUwNDRmOTQ5Yzg5ZjYwNDM5YmIzZjBjZTQ0L3RhYmxlcmFuZ2U6NTk3YjVkZTA0NGY5NDljODlmNjA0MzliYjNmMGNlNDRfMi03LTEtMS0w_299d6b7b-3874-4fe3-8b32-9b30f114356a"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjU5N2I1ZGUwNDRmOTQ5Yzg5ZjYwNDM5YmIzZjBjZTQ0L3RhYmxlcmFuZ2U6NTk3YjVkZTA0NGY5NDljODlmNjA0MzliYjNmMGNlNDRfMi03LTEtMS0w_8f432abb-fe2b-44f3-afb7-5b36bc1cca99">18,219,664</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used in calculating net loss per common share&#8212;basic and diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjU5N2I1ZGUwNDRmOTQ5Yzg5ZjYwNDM5YmIzZjBjZTQ0L3RhYmxlcmFuZ2U6NTk3YjVkZTA0NGY5NDljODlmNjA0MzliYjNmMGNlNDRfNy0yLTEtMS00MjM4_065ceb63-e58e-498e-91ec-fa767e69bea7">13,893,819</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjU5N2I1ZGUwNDRmOTQ5Yzg5ZjYwNDM5YmIzZjBjZTQ0L3RhYmxlcmFuZ2U6NTk3YjVkZTA0NGY5NDljODlmNjA0MzliYjNmMGNlNDRfNy00LTEtMS00MjM4_571f48f2-e517-430d-94b0-23c7647ec5a6">4,960,552</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per common share&#8212;basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjU5N2I1ZGUwNDRmOTQ5Yzg5ZjYwNDM5YmIzZjBjZTQ0L3RhYmxlcmFuZ2U6NTk3YjVkZTA0NGY5NDljODlmNjA0MzliYjNmMGNlNDRfMTItMi0xLTEtNDI0OA_1aea2845-9d33-44a8-937d-dab26398187f">1.46</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjU5N2I1ZGUwNDRmOTQ5Yzg5ZjYwNDM5YmIzZjBjZTQ0L3RhYmxlcmFuZ2U6NTk3YjVkZTA0NGY5NDljODlmNjA0MzliYjNmMGNlNDRfMTItNC0xLTEtNDI0OA_d103dbc5-ec34-4a07-8342-1cee5a51afaf">3.67</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RleHRyZWdpb246MjRhY2UyOTU0YzM2NDVjNTgyOTI1ZDVhODEwYzU5ZWVfMTcwNDI0MzAyMzI0MDM_dcf85a1f-46f5-4aa9-8531-8d1d3fbd6a02" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as their inclusion would have been antidilutive:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:68.175%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.622%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options to purchase common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib18c97e1d3e1439fa0756a1747c56510_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjgzZDViNzJhZmQyYTQ3NGE4ZjFjZWJiOTUzYjZhZDI1L3RhYmxlcmFuZ2U6ODNkNWI3MmFmZDJhNDc0YThmMWNlYmI5NTNiNmFkMjVfMi01LTEtMS0w_cd61c55d-8816-427e-9f3c-52fa0c7074dc">731,189</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i702dd84e91b44b20bc3d8cb7ca9e4a59_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjgzZDViNzJhZmQyYTQ3NGE4ZjFjZWJiOTUzYjZhZDI1L3RhYmxlcmFuZ2U6ODNkNWI3MmFmZDJhNDc0YThmMWNlYmI5NTNiNmFkMjVfMi03LTEtMS0w_4039ff08-5037-4083-a325-6ba2e6e6e457">632,752</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i477a58364a2b4532b86d564fdf1686e8_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjgzZDViNzJhZmQyYTQ3NGE4ZjFjZWJiOTUzYjZhZDI1L3RhYmxlcmFuZ2U6ODNkNWI3MmFmZDJhNDc0YThmMWNlYmI5NTNiNmFkMjVfMy01LTEtMS0w_196b6cb1-e74d-47bb-8e20-da6b643e34f4">870,020</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1dedc44510f14e77b6d2358d6ebef9a1_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjgzZDViNzJhZmQyYTQ3NGE4ZjFjZWJiOTUzYjZhZDI1L3RhYmxlcmFuZ2U6ODNkNWI3MmFmZDJhNDc0YThmMWNlYmI5NTNiNmFkMjVfMy03LTEtMS0w_dcefe95b-2611-45f3-9c5a-c268f08e14db">870,020</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series&#160;A Warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i36f2d441406443dcaba60c36eab4f7b7_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjgzZDViNzJhZmQyYTQ3NGE4ZjFjZWJiOTUzYjZhZDI1L3RhYmxlcmFuZ2U6ODNkNWI3MmFmZDJhNDc0YThmMWNlYmI5NTNiNmFkMjVfNC01LTEtMS0w_0ed551eb-13ca-4bd6-9136-5eedf8b7855f">8,771,928</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ifd5bb0da90474df78f52019d31b3061f_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjgzZDViNzJhZmQyYTQ3NGE4ZjFjZWJiOTUzYjZhZDI1L3RhYmxlcmFuZ2U6ODNkNWI3MmFmZDJhNDc0YThmMWNlYmI5NTNiNmFkMjVfNC03LTEtMS0w_d3471902-76e3-461f-a789-8fc4d84134f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series B Warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i91c2dd8a64e34278b820002768b4bdae_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjgzZDViNzJhZmQyYTQ3NGE4ZjFjZWJiOTUzYjZhZDI1L3RhYmxlcmFuZ2U6ODNkNWI3MmFmZDJhNDc0YThmMWNlYmI5NTNiNmFkMjVfNS0xLTEtMS0xODY5MA_9b84bce0-ca53-432a-9369-66b3caec3385">1,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8e0464bba65447d099bca6eb5c866819_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjgzZDViNzJhZmQyYTQ3NGE4ZjFjZWJiOTUzYjZhZDI1L3RhYmxlcmFuZ2U6ODNkNWI3MmFmZDJhNDc0YThmMWNlYmI5NTNiNmFkMjVfNS0zLTEtMS0xODY4Ng_2064d9fe-02e7-4434-9140-65e1db7675b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series&#160;C Warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i32196db366ca47dfb065bbc67d9993d9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjgzZDViNzJhZmQyYTQ3NGE4ZjFjZWJiOTUzYjZhZDI1L3RhYmxlcmFuZ2U6ODNkNWI3MmFmZDJhNDc0YThmMWNlYmI5NTNiNmFkMjVfNi01LTEtMS0w_2174275b-e88e-464c-91d6-fd61737784c9">1,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7a1acd90bf1a4186b62635f3f1291ee8_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjgzZDViNzJhZmQyYTQ3NGE4ZjFjZWJiOTUzYjZhZDI1L3RhYmxlcmFuZ2U6ODNkNWI3MmFmZDJhNDc0YThmMWNlYmI5NTNiNmFkMjVfNi03LTEtMS0w_05a4bb69-83dd-447d-8cd7-2df222ad0abf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjgzZDViNzJhZmQyYTQ3NGE4ZjFjZWJiOTUzYjZhZDI1L3RhYmxlcmFuZ2U6ODNkNWI3MmFmZDJhNDc0YThmMWNlYmI5NTNiNmFkMjVfNy01LTEtMS0w_1d09b1d8-4a91-4508-b67a-d4b918d5e191">10,375,137</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjgzZDViNzJhZmQyYTQ3NGE4ZjFjZWJiOTUzYjZhZDI1L3RhYmxlcmFuZ2U6ODNkNWI3MmFmZDJhNDc0YThmMWNlYmI5NTNiNmFkMjVfNy03LTEtMS0w_b08cd20c-91a0-4528-88c7-10924a0c02a8">1,502,772</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_61"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">5.&#160;<ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfMTcwNDI0MzAyNDk4MTc_d787e5a4-4588-4f7b-834f-745ae337e401" continuedAt="i7747d6ed016149e8b228133e52926cf4" escape="true">License and Collaboration Agreements</ix:nonNumeric></span></div><ix:continuation id="i7747d6ed016149e8b228133e52926cf4" continuedAt="idf544cee54b64d199a5269bc3808029e"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Co-Development and Commercialization Agreement with CanSino Biologics</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September 27, 2019, Ocugen entered into a co-development and commercialization agreement (the &#8220;CanSinoBIO Agreement&#8221;) with CanSino Biologics Inc. (&#8220;CanSinoBIO&#8221;) with respect to the development and commercialization of the gene therapy product candidate, OCU400.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">CanSinoBIO will be responsible for all the costs for chemistry, manufacturing and control development and manufacture of clinical supplies of OCU400 for all territories. CanSinoBIO will be solely responsible for all costs and expenses of its development activities in and for China, Hong Kong, Macau, and Taiwan (the "CanSinoBIO Territory") and Ocugen will be responsible for all costs and expenses of its development activities for any global location outside the CanSinoBIO Territory (the "Ocugen Territory"). CanSinoBIO will pay to Ocugen an annual royalty between mid to high-single digits based on net sales of products in the CanSinoBIO Territory, and Ocugen will pay to CanSinoBIO an annual royalty between low to mid-single digits based on net sales of products in the Ocugen Territory.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><ix:continuation id="idf544cee54b64d199a5269bc3808029e" continuedAt="ic75c6ab07e8249fb9fc5eb0d312e4d73"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless terminated earlier, the CanSinoBIO Agreement will continue in force on a country-by-country and product-by-product basis until the later of (a) the expiration of the last valid claim of patent rights of Ocugen covering such product and (b)&#160;the tenth (<ix:nonNumeric contextRef="i4d16882d4b4e40b5817ec2c99e0a487e_D20190927-20190927" format="ixt-sec:duryear" name="ocgn:CollaborationAgreementTerm" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfMTcwNDI0MzAyNDk4MTk_a947cbd3-1684-477c-bd26-f4fc2082c080">10</ix:nonNumeric></span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">th</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) anniversary of the first commercial sale of such product in such country. The CanSinoBIO Agreement will also terminate upon the termination of the Exclusive License Agreement, dated December&#160;19, 2017, between Ocugen and Schepens Eye Research Institute, Inc. The CanSinoBIO Agreement may be terminated by either party in its entirety upon (a)&#160;a material breach of the Agreement by the other party, (b) a challenge by the other party or any of its affiliates of any intellectual property controlled by the terminating party or (c) bankruptcy or insolvency of the other party. Within forty-five (<ix:nonNumeric contextRef="i4d16882d4b4e40b5817ec2c99e0a487e_D20190927-20190927" format="ixt-sec:durday" name="ocgn:CollaborationAgreementTerminationDevelopmentCostStatement" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfMjE3MA_98e10d49-7625-4536-9a3d-1d0fdf345e3c">45</ix:nonNumeric>) days after such termination, CanSinoBIO shall provide Ocugen with a statement of the CanSinoBIO development costs and, within one (<ix:nonNumeric contextRef="i4d16882d4b4e40b5817ec2c99e0a487e_D20190927-20190927" format="ixt-sec:duryear" name="ocgn:CollaborationAgreementTerminationDevelopmentCostPayment" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfMjMwNQ_972f599e-19b1-4a90-8c12-845d0c309f58">1</ix:nonNumeric>) year after receipt of such report, Ocugen shall reimburse CanSinoBIO all such CanSinoBIO development costs.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">License Agreement with the Schepens Eye Research Institute</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2017, the Company entered into a license agreement with The Schepens Eye Research Institute (&#8220;SERI&#8221;), which granted the Company an exclusive license to develop, commercialize, and continue to secure patents for OCU400 and OCU410. This agreement is accounted for as a collaborative arrangement. In connection with acquiring the license, the Company was required to pay a license fee of $<ix:nonFraction unitRef="usd" contextRef="i7ef76329772147dd8a1a1be7785f5e5d_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="ocgn:LicenseAgreementPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfNjA0NzMxMzk3MTM3NQ_e2a22ce5-7318-4467-814f-63740631951f">0.1</ix:nonFraction> million, which was recognized in 2017. The Company will also be required to reimburse SERI for all future patent costs related to this licensed technology.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is obligated to pay SERI up to $<ix:nonFraction unitRef="usd" contextRef="i7ef76329772147dd8a1a1be7785f5e5d_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="ocgn:LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfNjA0NzMxMzk3MTQwMw_1c70a498-ca50-4eca-837a-a35e78318409">6.0</ix:nonFraction> million upon the achievement of certain development and regulatory milestones. The Company is also obligated to pay SERI up to $<ix:nonFraction unitRef="usd" contextRef="i7ef76329772147dd8a1a1be7785f5e5d_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="ocgn:LicenseAgreementPotentialCommercialMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfNjA0NzMxMzk3MTQxOA_de092887-0af7-4119-a3fa-8862dd4b7b10">10.1</ix:nonFraction> million upon the achievement of certain commercial milestones. The Company will also pay SERI royalties in the low single digits based on net sales. <ix:nonFraction unitRef="usd" contextRef="if76acb9aa16d490a90c7132533737b13_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="ocgn:LicenseAgreementMilestonePayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfMTcwNDI0MzAyNDk4MjY_f3629a05-5af7-497f-b6d8-f1db8b9d9df1"><ix:nonFraction unitRef="usd" contextRef="if76acb9aa16d490a90c7132533737b13_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PaymentsForRoyalties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfMTcwNDI0MzAyNDk4MjY_ff897fc4-4c01-4a00-ae46-a7b7643d40bc">No</ix:nonFraction></ix:nonFraction> milestones or royalties were paid or incurred through December&#160;31, 2019, as the Company has not achieved any milestones, net sales or sublicensing under this agreement. The Company may cancel the license agreement at any time with <ix:nonNumeric contextRef="i7ef76329772147dd8a1a1be7785f5e5d_D20170101-20171231" format="ixt-sec:durday" name="ocgn:LicenseAgreementCancellationPeriodNotice" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfMTcwNDI0MzAyNDk4MzU_286aeba6-d15e-4815-bf4c-c576e0c94cc3">180</ix:nonNumeric> days&#8217; written notice.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2017, the Company also entered into a Sponsored Research Agreement with SERI under which the Company recognized approximately $<ix:nonFraction unitRef="usd" contextRef="if76acb9aa16d490a90c7132533737b13_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfNjA0NzMxMzk3MTQ0Mw_f819a7cc-4ad1-4fa1-80fa-1b57d6ffc4af">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i827132cd7da14ed8ad14eae7babe9d17_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfNjA0NzMxMzk3MTQ0OQ_b50c5ae2-a926-4472-a85b-ea7c3fa654e1">0.5</ix:nonFraction> million as research and development expense for the year ended December 31, 2019 and 2018, respectively, for work performed under this agreement.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">License Agreement with the University of Illinois</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2016, the Company entered into a license agreement with the University of Illinois at Chicago (&#8220;UIC&#8221;), which granted the Company an exclusive license to develop, commercialize and continue to secure patents for OCU300 and OCU310. In connection with acquiring the license for OCU300 and OCU310, the Company was required to pay a signing fee of $<ix:nonFraction unitRef="usd" contextRef="ieb5f12c395364ac0968b482475cd5720_D20160101-20161231" decimals="INF" format="ixt:numdotdecimal" name="ocgn:LicenseAgreementSigningFee" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfNjA0NzMxMzk3MTQ5NQ_1ea06576-b390-4610-9ae4-8267cb9185ac">15,000</ix:nonFraction>.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is required to pay royalties in the low single digits to low teens to UIC based on net sales and sublicense revenues generated by OCU300 and OCU310. The Company is also required to pay minimum annual royalties to UIC, beginning with an annual payment of $<ix:nonFraction unitRef="usd" contextRef="ibe9866f13f484211a602b7658ac319c6_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="ocgn:LicenseAgreementMinimumAnnualRoyaltyPayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfNjA0NzMxMzk3MTUwNg_52d78a3d-40b8-4b14-89de-0dc78bf0b8b9">20,000</ix:nonFraction> on the third anniversary of the effective date of the agreement, and increasing gradually to $<ix:nonFraction unitRef="usd" contextRef="ie00ff0e528c242f698fe9a5810b936e6_D20220101-20221231" decimals="INF" format="ixt:numdotdecimal" name="ocgn:LicenseAgreementMinimumAnnualRoyaltyPayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfNjA0NzMxMzk3MTUxNw_895fa2cb-a935-4842-8d6b-03070cd476aa">50,000</ix:nonFraction> by the sixth anniversary and continuing through the term of the agreement. The Company is also obligated to pay UIC up to $<ix:nonFraction unitRef="usd" contextRef="ieb5f12c395364ac0968b482475cd5720_D20160101-20161231" decimals="-5" format="ixt:numdotdecimal" name="ocgn:LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfNjA0NzMxMzk3MTUzNA_cdfd4dee-fe73-46d6-8303-38aa1e56d07a">1.3</ix:nonFraction> million upon the achievement of certain development and regulatory milestones.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During 2018, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="i97535139e9054d88803d1577aa998142_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="ocgn:LicenseAgreementMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfNjA0NzMxMzk3MTU0NQ_c48b21f9-7a98-4ce2-98ab-62ad4c3694f0">0.3</ix:nonFraction> million in milestone payments due to achieving a milestone associated with dosing the first patient in a Phase 3 clinical trial. The Company has not achieved any other milestones, net sales or sublicensing for OCU300 or OCU310. The Company may cancel the license agreement at any time with <ix:nonNumeric contextRef="i97535139e9054d88803d1577aa998142_D20180101-20181231" format="ixt-sec:durday" name="ocgn:LicenseAgreementCancellationPeriodNotice" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfMTcwNDI0MzAyNDk4NDg_3f178380-b01f-46b3-acb3-b240ce16c61f">90</ix:nonNumeric> days&#8217; written notice.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">License Agreement with the University of Colorado</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2014, the Company entered into a patent license agreement with the University of Colorado (&#8220;CU&#8221;), which granted the Company an exclusive license to develop and commercialize, and continue to secure patents for OCU200, including the ability to enforce any rights against infringement. Under the agreement, the Company assumed primary responsibility for preparing, filing and prosecuting broad patent claims for OCU200 for CU's benefit. Further, the Company assumed primary responsibility for all patent activities, including all costs associated with the perfection and maintenance of the patents for OCU200.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the terms of the agreement, in exchange for the licensed patents, the Company issued CU <ix:nonFraction unitRef="shares" contextRef="i84c4c1d32cc746778f6f4ffed31a2f12_D20140101-20141231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfNjA0NzMxMzk3MTU1Nw_8a4f0b78-1c53-4342-84ea-bf6c982f86d2">0.1</ix:nonFraction> million shares of the Company&#8217;s common stock. The agreement with CU, as amended in January 2017, obligates the Company to pay certain development and regulatory milestone fees of up to $<ix:nonFraction unitRef="usd" contextRef="i5fdb2024e3e04b00afbe628fe94fc6a1_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="ocgn:LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfNjA0NzMxMzk3MTU3Mw_5a623433-dfd4-4da7-a092-6c9bb9c92393">1.5</ix:nonFraction> million, royalties in the low single digits on net sales and royalties in the mid-teens on sublicense income of OCU200.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The agreement with CU calls for minimum annual royalty payments of $<ix:nonFraction unitRef="usd" contextRef="i5fdb2024e3e04b00afbe628fe94fc6a1_D20170101-20171231" decimals="INF" format="ixt:numdotdecimal" name="ocgn:LicenseAgreementMinimumAnnualRoyaltyPayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfNjA0NzMxMzk3MTU4Mg_62004db9-c9c4-4bd1-9023-3eda5a98aa40">20,000</ix:nonFraction>, starting on the third anniversary of the agreement and on each annual anniversary thereafter, and after sales commence, increasing to a percentage rate in the mid-</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ic75c6ab07e8249fb9fc5eb0d312e4d73">twenties of the previous year&#8217;s royalty payment paid to CU, through the term of the agreement. Future annual royalties will be recognized in the years they are earned, per the license agreement. The Company may cancel the license agreement at any time with <ix:nonNumeric contextRef="i84c4c1d32cc746778f6f4ffed31a2f12_D20140101-20141231" format="ixt-sec:durday" name="ocgn:LicenseAgreementCancellationPeriodNotice" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfMTcwNDI0MzAyNDk4NjA_c27ebc9c-bfc3-44f0-a6c4-03af3bc0cb6c">60</ix:nonNumeric> days&#8217; written notice.</ix:continuation></span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_67"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">6.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:700;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RleHRyZWdpb246NzViNTQxNmJhYjA2NDJiYWI4ZDAzYjNkYTljNTY0OWJfMTcwNDI0MzAyMzA2NTI_62288d30-7f2c-44f5-83d1-7d9f5084ab0a" continuedAt="ic3f715c1be774e20be6dee7a35b00dee" escape="true">Accrued Expenses</ix:nonNumeric></span></div><ix:continuation id="ic3f715c1be774e20be6dee7a35b00dee"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RleHRyZWdpb246NzViNTQxNmJhYjA2NDJiYWI4ZDAzYjNkYTljNTY0OWJfMTcwNDI0MzAyMzA2NTM_ac035f46-ced9-4199-b6ca-92009192c9d9" escape="true"><div style="margin-top:12pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued Expenses are as follows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:68.175%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.622%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research&#160;and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="ocgn:ResearchAndDevelopmentExpensesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RhYmxlOmQzY2YzNzNhZDQ3MDQ2NGNiODUzOWNhNWFjYzEwNWRhL3RhYmxlcmFuZ2U6ZDNjZjM3M2FkNDcwNDY0Y2I4NTM5Y2E1YWNjMTA1ZGFfMi0xLTEtMS0w_8c925162-c0c4-436a-a2da-8acfc7b910e2">271,322</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="ocgn:ResearchAndDevelopmentExpensesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RhYmxlOmQzY2YzNzNhZDQ3MDQ2NGNiODUzOWNhNWFjYzEwNWRhL3RhYmxlcmFuZ2U6ZDNjZjM3M2FkNDcwNDY0Y2I4NTM5Y2E1YWNjMTA1ZGFfMi0zLTEtMS0w_adab105f-18c6-4917-87db-b8649e20a688">705,436</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Clinical</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="ocgn:AccountsPayableClinical" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RhYmxlOmQzY2YzNzNhZDQ3MDQ2NGNiODUzOWNhNWFjYzEwNWRhL3RhYmxlcmFuZ2U6ZDNjZjM3M2FkNDcwNDY0Y2I4NTM5Y2E1YWNjMTA1ZGFfMy0xLTEtMS0w_49244e81-2183-4041-885d-f90ebcf43e24">421,788</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="ocgn:AccountsPayableClinical" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RhYmxlOmQzY2YzNzNhZDQ3MDQ2NGNiODUzOWNhNWFjYzEwNWRhL3RhYmxlcmFuZ2U6ZDNjZjM3M2FkNDcwNDY0Y2I4NTM5Y2E1YWNjMTA1ZGFfMy0zLTEtMS0w_753bd675-7316-4684-8f2b-3f44deb54d1a">469,473</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consulting</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="ocgn:AccountsPayableConsulting" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RhYmxlOmQzY2YzNzNhZDQ3MDQ2NGNiODUzOWNhNWFjYzEwNWRhL3RhYmxlcmFuZ2U6ZDNjZjM3M2FkNDcwNDY0Y2I4NTM5Y2E1YWNjMTA1ZGFfNC0xLTEtMS0w_e41d1249-a0fe-4a90-a5c7-8f2d93b6f24e">98,245</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="ocgn:AccountsPayableConsulting" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RhYmxlOmQzY2YzNzNhZDQ3MDQ2NGNiODUzOWNhNWFjYzEwNWRhL3RhYmxlcmFuZ2U6ZDNjZjM3M2FkNDcwNDY0Y2I4NTM5Y2E1YWNjMTA1ZGFfNC0zLTEtMS0w_a5b50b1c-67dc-4b68-ba01-85feab1ebdaf">86,619</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee-related</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RhYmxlOmQzY2YzNzNhZDQ3MDQ2NGNiODUzOWNhNWFjYzEwNWRhL3RhYmxlcmFuZ2U6ZDNjZjM3M2FkNDcwNDY0Y2I4NTM5Y2E1YWNjMTA1ZGFfNS0xLTEtMS0w_3ee10981-dc6e-4547-9a4a-5e08352c3d03">624,420</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RhYmxlOmQzY2YzNzNhZDQ3MDQ2NGNiODUzOWNhNWFjYzEwNWRhL3RhYmxlcmFuZ2U6ZDNjZjM3M2FkNDcwNDY0Y2I4NTM5Y2E1YWNjMTA1ZGFfNS0zLTEtMS0w_e3037479-40f2-4a42-8bfe-7651e91aaac9">123,372</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Legal</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RhYmxlOmQzY2YzNzNhZDQ3MDQ2NGNiODUzOWNhNWFjYzEwNWRhL3RhYmxlcmFuZ2U6ZDNjZjM3M2FkNDcwNDY0Y2I4NTM5Y2E1YWNjMTA1ZGFfNi0xLTEtMS0w_df6150f7-bd6d-423c-af34-bc6742b421af">819,323</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RhYmxlOmQzY2YzNzNhZDQ3MDQ2NGNiODUzOWNhNWFjYzEwNWRhL3RhYmxlcmFuZ2U6ZDNjZjM3M2FkNDcwNDY0Y2I4NTM5Y2E1YWNjMTA1ZGFfNi0zLTEtMS0w_efbaed48-423a-4389-bed5-dc3f8aec58d2">15,400</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RhYmxlOmQzY2YzNzNhZDQ3MDQ2NGNiODUzOWNhNWFjYzEwNWRhL3RhYmxlcmFuZ2U6ZDNjZjM3M2FkNDcwNDY0Y2I4NTM5Y2E1YWNjMTA1ZGFfNy0xLTEtMS00OTI4_0bf16330-e034-47ff-879a-0a0e79def435">34,947</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RhYmxlOmQzY2YzNzNhZDQ3MDQ2NGNiODUzOWNhNWFjYzEwNWRhL3RhYmxlcmFuZ2U6ZDNjZjM3M2FkNDcwNDY0Y2I4NTM5Y2E1YWNjMTA1ZGFfNy0zLTEtMS00OTI4_0a1dd32b-da1b-46e7-96f1-cab9c5b50e17">2,450</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total accrued expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RhYmxlOmQzY2YzNzNhZDQ3MDQ2NGNiODUzOWNhNWFjYzEwNWRhL3RhYmxlcmFuZ2U6ZDNjZjM3M2FkNDcwNDY0Y2I4NTM5Y2E1YWNjMTA1ZGFfOC0xLTEtMS00OTI4_a3536ff9-770c-4ca2-86eb-9c448431bd37">2,270,045</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RhYmxlOmQzY2YzNzNhZDQ3MDQ2NGNiODUzOWNhNWFjYzEwNWRhL3RhYmxlcmFuZ2U6ZDNjZjM3M2FkNDcwNDY0Y2I4NTM5Y2E1YWNjMTA1ZGFfOC0zLTEtMS00OTI4_bf761481-07ea-4f02-a179-849967397728">1,402,750</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_73"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">7.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:700;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMTUzOTMxNjI4MTc5MDA_a2102107-0b3e-4158-ae03-a3d1b50da847" continuedAt="ifead831048ce48029742905f8962b32b" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="ifead831048ce48029742905f8962b32b" continuedAt="i6ae15a197d464c50af152d2aedcbdb0f"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">EB-5 Loan</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In September&#160;2016, pursuant to the U.S. government&#8217;s Immigrant Investor Program, commonly known as the EB-5 program (the &#8220;EB-5 Program&#8221;), the Company entered into an arrangement (the &#8220;EB-5 Loan Agreement&#8221;) to borrow up to $<ix:nonFraction unitRef="usd" contextRef="i41512e91ea66459091142a09d64979ee_I20160930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NTM0OQ_71a74ad7-581f-49ed-b43f-6b0a45242462">10.0</ix:nonFraction> million from EB5 Life Sciences,&#160;L.P. (the &#8220;Lender&#8221;) in $<ix:nonFraction unitRef="usd" contextRef="ie26010e163a44d8f8901034a2237a150_D20160901-20161231" decimals="INF" format="ixt:numdotdecimal" name="ocgn:LineOfCreditBorrowingEachDraw" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NTM4MA_84983f5a-a014-41ea-b9db-194353e2f4e0">0.5</ix:nonFraction> million increments. Borrowing may be limited by the amount of funds raised by the Lender and are subject to certain job creation requirements by the Company. Borrowings are at a fixed interest rate of <ix:nonFraction unitRef="number" contextRef="i41512e91ea66459091142a09d64979ee_I20160930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NTM4Mw_6e93f818-e5f2-436d-a90c-4c8d5750142f">4.0</ix:nonFraction>% per annum and are to be utilized in the clinical development, manufacturing, and commercialization of the Company&#8217;s products and for the general working capital needs of the Company. Outstanding borrowings pursuant to the EB-5 Program, including accrued interest, become due upon the seventh anniversary of the final disbursement. Amounts repaid cannot be re-borrowed. The EB-5 note is secured by substantially all assets of the Company, except for any patents, patent applications, pending patents, patent license, patent sublicense, trademarks, and other intellectual property rights.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In 2016, $<ix:nonFraction unitRef="usd" contextRef="i5f4493de5f9a420f8e7d280ce9393d02_I20161231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NTM4Ng_d062af63-b5b6-4c92-8cf9-cc4f87d6e009">1.0</ix:nonFraction> million was borrowed by the Company. Issuance costs for these borrowings totaled $<ix:nonFraction unitRef="usd" contextRef="i49703b2d634a40219c09a4116c60351e_D20160101-20161231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NTM4OQ_2125b798-8ae3-4c38-95ac-9c17839a89fb">0.1</ix:nonFraction> million, which was recognized as a reduction to the loan balance and is amortized to interest expense over the term of the loan. See Note 12 for information regarding events subsequent to December 31, 2019.</span></div><div style="margin-top:12pt;"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMTcwNDI0MzAyNTIxMjU_943e98cd-64c7-4c5b-b4fc-5d2ae8cd1de5" escape="true"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:68.175%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.622%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Principal outstanding</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa216e92d8ad45f695cf881fb2ec681d_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjc5Mjc3MDdhNjRhMTRkM2FiZWUyODhjZmUzMzg1MDkyL3RhYmxlcmFuZ2U6NzkyNzcwN2E2NGExNGQzYWJlZTI4OGNmZTMzODUwOTJfMS0yLTEtMS01MTM5_e473840a-2395-4269-991a-294f72ae5c36">1,000,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i10a74d4f5772493bb775e01c0458d587_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjc5Mjc3MDdhNjRhMTRkM2FiZWUyODhjZmUzMzg1MDkyL3RhYmxlcmFuZ2U6NzkyNzcwN2E2NGExNGQzYWJlZTI4OGNmZTMzODUwOTJfMS00LTEtMS01MTQ2_0ced3bfd-12a3-4c50-b017-f98b502f9250">1,000,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Plus: accrued interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa216e92d8ad45f695cf881fb2ec681d_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjc5Mjc3MDdhNjRhMTRkM2FiZWUyODhjZmUzMzg1MDkyL3RhYmxlcmFuZ2U6NzkyNzcwN2E2NGExNGQzYWJlZTI4OGNmZTMzODUwOTJfMi0yLTEtMS01MTM5_2068fa95-1e38-4fd6-bee5-ea0ac1c7a56f">127,777</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i10a74d4f5772493bb775e01c0458d587_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjc5Mjc3MDdhNjRhMTRkM2FiZWUyODhjZmUzMzg1MDkyL3RhYmxlcmFuZ2U6NzkyNzcwN2E2NGExNGQzYWJlZTI4OGNmZTMzODUwOTJfMi00LTEtMS01MTQ2_9c9688a9-49b6-4658-b101-81c1d715103c">87,222</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: unamortized debt issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifa216e92d8ad45f695cf881fb2ec681d_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjc5Mjc3MDdhNjRhMTRkM2FiZWUyODhjZmUzMzg1MDkyL3RhYmxlcmFuZ2U6NzkyNzcwN2E2NGExNGQzYWJlZTI4OGNmZTMzODUwOTJfMy0yLTEtMS01MTM5_1565def6-0413-4b8c-9a26-74ab7d7c9b15">55,654</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i10a74d4f5772493bb775e01c0458d587_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjc5Mjc3MDdhNjRhMTRkM2FiZWUyODhjZmUzMzg1MDkyL3RhYmxlcmFuZ2U6NzkyNzcwN2E2NGExNGQzYWJlZTI4OGNmZTMzODUwOTJfMy00LTEtMS01MTQ2_a27f19a5-99da-44d8-bd4f-2182420bcd2e">70,495</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying value of debt</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa216e92d8ad45f695cf881fb2ec681d_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjc5Mjc3MDdhNjRhMTRkM2FiZWUyODhjZmUzMzg1MDkyL3RhYmxlcmFuZ2U6NzkyNzcwN2E2NGExNGQzYWJlZTI4OGNmZTMzODUwOTJfNC0yLTEtMS01MTMx_4622a595-8336-4fcf-8290-74f73550bdb0">1,072,123</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i10a74d4f5772493bb775e01c0458d587_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjc5Mjc3MDdhNjRhMTRkM2FiZWUyODhjZmUzMzg1MDkyL3RhYmxlcmFuZ2U6NzkyNzcwN2E2NGExNGQzYWJlZTI4OGNmZTMzODUwOTJfNC00LTEtMS01MTU1_95b84a82-7a51-491f-b997-479f722af4db">1,016,727</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:nonNumeric></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Convertible Notes</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the years ended December&#160;31, 2019 and 2018, the Company issued convertible notes (the &#8220;Notes&#8221;) to new and existing stockholders in the Company, including Notes in the aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i4dd588e3e2fd4d56ba9f7ed7bf627e44_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNzE0NjgyNTYwMTU4OA_1811c294-bab7-4749-90e6-e29bb0d4b97c"><ix:nonFraction unitRef="usd" contextRef="ie107e1047f9e4c3fa462f46cf3e5e3e4_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNzE0NjgyNTYwMTU4OA_5bd91d46-51b2-4aed-8608-8f659530f1f5">3.5</ix:nonFraction></ix:nonFraction> million to members of the Board of Directors. As of December&#160;31, 2019, all Notes had been converted and were <ix:nonFraction unitRef="usd" contextRef="i328baa90b6ca4ecf9cdc9e0a79ee26ad_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ConvertibleDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMTcwNDI0MzAyNTIxMjY_0fa51f98-4f5c-45d6-a944-901a0a1fd374">no</ix:nonFraction> longer outstanding.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><ix:continuation id="i6ae15a197d464c50af152d2aedcbdb0f" continuedAt="i3c43111ae2d847848a3b3b3e8cb4f3f9"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMTE3ODM_aa470aef-f4c5-4da0-8416-8b81c06f7071" escape="true"><div style="margin-top:12pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At issuance, the following amounts were recorded:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.052%;"><tr><td style="width:1.0%;"></td><td style="width:35.290%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.220%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.408%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.220%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.408%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.220%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.408%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.226%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Note&#160;Issuance&#160;Date</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Note<br/>Principal<br/>Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair&#160;Value&#160;of<br/>Embedded Derivatives</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Debt<br/>Issuance<br/>Costs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying Value upon Issuance</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i65b540d692bb45958ed8ced1fb3911da_I20180131" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfMS0yLTEtMS0w_00a62779-ded6-4804-afde-5b3562b718d3">5,000,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5cc3532217ff4a829773c63ec209eebb_I20180131" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfMS00LTEtMS0w_fe5a852c-507c-4c22-b521-ff632ed3b853">2,657,711</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i65b540d692bb45958ed8ced1fb3911da_I20180131" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfMS04LTEtMS0w_3140f0c5-23ca-4afc-9744-10e45743080f">35,969</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i65b540d692bb45958ed8ced1fb3911da_I20180131" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfMS0xMC0xLTEtMA_da44213a-2a8c-449d-abbc-542dd5800323">2,306,320</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i161b6716805149329fb75cb8d891a7d3_I20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfMi0yLTEtMS0w_f6891a60-721f-4315-bfb1-b9c4db96b542">1,000,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0c9d3000afb440eb2ae0e4453fc13cd_I20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfMi00LTEtMS0w_4b7c4b09-0263-41f1-9885-916fa997fe6d">724,216</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i161b6716805149329fb75cb8d891a7d3_I20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfMi04LTEtMS0w_7255e065-8b5c-40b0-a5c1-67ae24defc01">3,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i161b6716805149329fb75cb8d891a7d3_I20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfMi0xMC0xLTEtMA_af3e8f69-e686-4cb3-b3cd-e2ed2a16b371">272,784</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">November 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i514af234321c45249033c2c6004c3681_I20181130" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfMy0yLTEtMS0w_c9897230-b9de-4f00-a5cf-8de4dd37273d">1,150,400</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i94d7513be73b4b42b644afe0f55eda9e_I20181130" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfMy00LTEtMS0w_7e5fed21-9103-486d-86ec-75905742735d">21,127</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i514af234321c45249033c2c6004c3681_I20181130" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfMy04LTEtMS0w_1151e875-c89b-4e79-93d5-cafc69f81785">50,646</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i514af234321c45249033c2c6004c3681_I20181130" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfMy0xMC0xLTEtMA_5dc525a2-17c5-42de-9030-1f05a356916f">1,078,627</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i932ae52afffe48a19dbc8e83e080b098_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNC0yLTEtMS0w_7d474c97-4abb-4e44-8f2c-fc93e515346c">150,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibf9bc486110443f69af07574bf14d5f7_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNC00LTEtMS0w_c9a3211e-cc6f-418f-9f0c-137a9a104910">2,857</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i932ae52afffe48a19dbc8e83e080b098_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNC04LTEtMS0w_375cf1e1-3674-4fe6-8e2c-0614cb0eced7">14,310</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i932ae52afffe48a19dbc8e83e080b098_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNC0xMC0xLTEtMA_05221911-232f-4462-8af9-eff14ea5d590">132,833</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idf78c78261294ef3881f6cf13befd9a5_I20190131" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNS0yLTEtMS01NzI3_74e9f133-09e1-4e33-a940-3f798f01cbf9">450,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if379bb8b26134244bc1ef93807f107a8_I20190131" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNS00LTEtMS01NzMx_f02e755d-5b0b-4da4-8f2e-cfc8e0492b0e">182,882</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idf78c78261294ef3881f6cf13befd9a5_I20190131" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNS03LTEtMS01NzM1_e3fec30e-b4db-40e9-91dc-7bb049c77c11">29,358</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idf78c78261294ef3881f6cf13befd9a5_I20190131" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNS05LTEtMS01NzM5_0cf12626-596e-4386-bf5c-0a2e949b5ea2">237,760</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4183d88399e94dd0af0b9cb7d63d5f7d_I20190228" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNi0yLTEtMS01NzI3_7f179e04-de7a-4e1f-a20e-81d067a0d4df">1,000,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i74fd32d2c80748aeb83fa8309f3b484c_I20190228" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNi00LTEtMS01NzMx_d8e08b00-dd1d-4097-8511-a2bd2eb15c3c">302,379</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4183d88399e94dd0af0b9cb7d63d5f7d_I20190228" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNi03LTEtMS01NzM1_27a79014-1da3-4a13-a22d-704ddf8a7612">55,875</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4183d88399e94dd0af0b9cb7d63d5f7d_I20190228" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNi05LTEtMS01NzM5_4ea8ed8a-f7bd-46e7-802e-cd7785fa56a4">641,746</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i17e3a21a882c45e6a5d43855f575a703_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNS0yLTEtMS0w_b8318ab0-48d8-458c-8707-add4b67e0de1">8,750,400</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1432fdaf1af748b9aa5b711d2c461c89_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNS00LTEtMS0w_4fc7a39a-abc7-47a0-bc12-6fdbc618e93d">3,891,172</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i17e3a21a882c45e6a5d43855f575a703_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNS04LTEtMS0w_345134e9-3e4d-4624-ac2b-263bb36b7dbc">189,158</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i17e3a21a882c45e6a5d43855f575a703_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNS0xMC0xLTEtMA_a2e3dd3e-39f0-4404-a3c3-5908841af9e1">4,670,070</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;"><span><br/></span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All Notes accrued interest at a rate of <ix:nonFraction unitRef="number" contextRef="i328baa90b6ca4ecf9cdc9e0a79ee26ad_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMjUzNw_792d32e4-b27e-4bd3-94e0-4d7f4bea5d16">5</ix:nonFraction>% per annum and had scheduled maturity dates on the <ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMTUzOTMxNjI4MTc5MDI_e9ee6832-8a82-4f59-9f20-539b44f79623">eighteen month</ix:nonNumeric> anniversary of the date of the issuance of the Notes (the &#8220;Maturity Date&#8221;). If prior to the Maturity Date, there was a consummation of the sale of all or substantially all of the assets of the Company, change in control or event of default, the Notes would become due and payable at an amount equal to <ix:nonFraction unitRef="number" contextRef="i328baa90b6ca4ecf9cdc9e0a79ee26ad_I20191231" decimals="INF" name="ocgn:DebtRedemptionMultipleUponDefault" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMTcwNDI0MzAyNTIxOTk_f56e1682-0f19-4613-b5e5-c8702f7aa0a3">1.5</ix:nonFraction> times the principal amount of the Notes together with all accrued interest (the &#8220;Change in Control Feature&#8221;).</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If the Company received equity financing from the issuance of stock of the Company from an investor or group of investors in a transaction or series of related transactions above a certain amount of gross proceeds, the principal amount and all interest accrued but not paid through the closing date of the qualified equity financing was to automatically convert into the same class of equity securities as those issued in the qualified equity financing ("conversion feature"). The price per share varied among the Notes ranging from a <ix:nonFraction unitRef="number" contextRef="i30518d590b384689bc953bae8c788989_I20191231" decimals="INF" name="ocgn:ConvertibleDebtEquityFinancingTriggeredDiscount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMzI5ODUzNDg5NzgyMQ_8c617bd7-3694-43e4-bc8f-0d73d2042d4f">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ie03c47b9f9564d4ea485d3ffdd995bb6_I20191231" decimals="INF" name="ocgn:ConvertibleDebtEquityFinancingTriggeredDiscount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNTQ5NzU1ODE1OTUzMg_e0eb8606-30e9-45b7-b7fd-e4466b50bbbe">30</ix:nonFraction>% discount to the lowest price per share being paid by investors in the qualified equity financing.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company bifurcated the Conversion Feature for the January&#160;2018, June&#160;2018, January&#160;2019, and February&#160;2019 notes and classified it as a derivative liability because the Conversion Feature does not have a fixed conversion price and conversion will be settled in a variable number of shares of common stock. There was no bifurcated Conversion Feature for the November&#160;2018 and December 2018 notes as there is no discount to the lowest equity price triggering conversion. The Company also bifurcated the Change in Control Feature for all of the Notes because it was determined to be a redemption feature not clearly and closely related to the debt host. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of both of the embedded features was accounted for as a derivative liability and was recorded as a discount on the Notes. Inputs used in valuation were unobservable and therefore considered Level 3 in the fair value hierarchy. The debt discount is accreted into interest expense over the expected time until conversion of the Notes. The accretion amounted to $<ix:nonFraction unitRef="usd" contextRef="i7ef067fabc2048d49a715adf223a6aaf_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjI5Ng_87f5fdfd-75f6-4af4-bfe9-bb8e0fee7bad">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie32a5c52109846399c80873ec089ffbb_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjMwMw_a8b2fb8a-14b1-46c1-a31e-55cb930d5a5e">3.4</ix:nonFraction> million, for the year ended December 31, 2019 and 2018, respectively.</span></div><div style="margin-top:12pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the embedded features was classified as a liability in the Company&#8217;s consolidated balance sheets at issuance, with subsequent changes in fair value during the year ended December 31, 2019 and 2018 recorded on the Company&#8217;s consolidated statements of operations and comprehensive loss as a change in fair value of derivative liabilities.</span></div><div style="margin-top:12pt;"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="ocgn:ChangesInFairValueOfEmbeddedDerivativeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMTE3ODU_2cf71071-8315-4943-822c-e35a39cf90f6" escape="true"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:82.795%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.621%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Balance at January 1, 2018 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3b0b2789ee4e45ff8aa700de563ddc85_I20171231" decimals="0" format="ixt:zerodash" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjIyYjg5NDgyOThkMTRkYzI5ZDUyNGE3MTdhNTgwNzAyL3RhYmxlcmFuZ2U6MjJiODk0ODI5OGQxNGRjMjlkNTI0YTcxN2E1ODA3MDJfMS0zLTEtMS0w_d5dcda11-7262-4176-9d7c-e6540cad76b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Fair value of embedded derivatives at issuance </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ocgn:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiabilityAtIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjIyYjg5NDgyOThkMTRkYzI5ZDUyNGE3MTdhNTgwNzAyL3RhYmxlcmFuZ2U6MjJiODk0ODI5OGQxNGRjMjlkNTI0YTcxN2E1ODA3MDJfMi0zLTEtMS0xMDY2Ng_2755126c-3d8f-4377-9602-c63e885aca7a">3,405,911</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Change in fair value of embedded derivatives </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjIyYjg5NDgyOThkMTRkYzI5ZDUyNGE3MTdhNTgwNzAyL3RhYmxlcmFuZ2U6MjJiODk0ODI5OGQxNGRjMjlkNTI0YTcxN2E1ODA3MDJfMy0zLTEtMS0xMDY2Ng_b122fdab-58e4-4e03-8b5b-ace72e8088df">1,664,689</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Balance at December 31, 2018 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjIyYjg5NDgyOThkMTRkYzI5ZDUyNGE3MTdhNTgwNzAyL3RhYmxlcmFuZ2U6MjJiODk0ODI5OGQxNGRjMjlkNTI0YTcxN2E1ODA3MDJfNC0zLTEtMS0xMDY2Ng_a54854a5-5235-4c56-9450-505ec2261cd4">1,741,222</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Fair value of embedded derivatives at issuance </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ocgn:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiabilityAtIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjIyYjg5NDgyOThkMTRkYzI5ZDUyNGE3MTdhNTgwNzAyL3RhYmxlcmFuZ2U6MjJiODk0ODI5OGQxNGRjMjlkNTI0YTcxN2E1ODA3MDJfMi0zLTEtMS0w_3e711078-4759-48b1-84c8-1bd5356b21c8">567,661</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Change in fair value of embedded derivatives </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjIyYjg5NDgyOThkMTRkYzI5ZDUyNGE3MTdhNTgwNzAyL3RhYmxlcmFuZ2U6MjJiODk0ODI5OGQxNGRjMjlkNTI0YTcxN2E1ODA3MDJfMy0zLTEtMS0w_57099c74-b122-4e6b-8f76-ff977b44254d">1,319,400</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Conversion and extinguishment of debt </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ocgn:EmbeddedDerivativeConversionAndExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjIyYjg5NDgyOThkMTRkYzI5ZDUyNGE3MTdhNTgwNzAyL3RhYmxlcmFuZ2U6MjJiODk0ODI5OGQxNGRjMjlkNTI0YTcxN2E1ODA3MDJfNC0zLTEtMS0w_03116218-8f08-426a-8bfa-6e5d47f72fd0">3,628,283</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Balance at December 31, 2019 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjIyYjg5NDgyOThkMTRkYzI5ZDUyNGE3MTdhNTgwNzAyL3RhYmxlcmFuZ2U6MjJiODk0ODI5OGQxNGRjMjlkNTI0YTcxN2E1ODA3MDJfNS0zLTEtMS0w_8722accf-dc1a-4660-a367-d1de5f6db2b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><ix:continuation id="i3c43111ae2d847848a3b3b3e8cb4f3f9"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company considered several possible outcomes in the likelihood and timing of a qualified equity financing and/or a change in control occurring that would trigger conversion or redemption and believes the amounts disclosed above based on inputs utilized in the valuation were the best estimates at each valuation date.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 5, 2019, Former Ocugen entered into a Stock Subscription Agreement (&#8220;Subscription Agreement&#8221;) with existing investors for the sale of <ix:nonFraction unitRef="shares" contextRef="ic10bc878b71a4eec829c618f097ab1f3_I20190405" decimals="-5" format="ixt:numdotdecimal" name="ocgn:CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NjY3MA_43e16e69-d3a3-4801-b96c-9dbe9c96c31d">0.1</ix:nonFraction> million shares of common stock for $<ix:nonFraction unitRef="usd" contextRef="ic10bc878b71a4eec829c618f097ab1f3_I20190405" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesSubscriptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NjY3NA_50d00e13-b504-4f78-ab83-9f964732a2b0">1.0</ix:nonFraction> million, or $<ix:nonFraction unitRef="usdPerShare" contextRef="ic10bc878b71a4eec829c618f097ab1f3_I20190405" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NjY4MA_72e90f5d-7210-4dff-afb2-cdaa49d0b801">12.41</ix:nonFraction> per share including the sale of <ix:nonFraction unitRef="shares" contextRef="iaf15ac65c13f41efa5b2c278c90ef1ad_I20190405" decimals="INF" format="ixt:numdotdecimal" name="ocgn:CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNzE0NjgyNTYwMjEzOQ_6762e170-1a8b-4494-a68d-34ed3f7f93c4">40,286</ix:nonFraction> shares of common stock for $<ix:nonFraction unitRef="usd" contextRef="iaf15ac65c13f41efa5b2c278c90ef1ad_I20190405" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesSubscriptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNzE0NjgyNTYwMjEwMg_4d51ab13-aca4-478d-a1d7-8d6d7e03fb83">0.5</ix:nonFraction> million to a member of the Board of Directors. This capital raise triggered the conversion features on the convertible debt described above. The Notes were modified to change the discount percentage from the <ix:nonFraction unitRef="number" contextRef="i30518d590b384689bc953bae8c788989_I20191231" decimals="INF" name="ocgn:ConvertibleDebtEquityFinancingTriggeredDiscount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMzI5ODUzNDg5OTUyMQ_8c617bd7-3694-43e4-bc8f-0d73d2042d4f">0</ix:nonFraction>% discount per the terms of the November&#160;2018 and December 2018 Notes and the <ix:nonFraction unitRef="number" contextRef="i408357dbb20b4db79414a01968187418_I20191231" decimals="INF" name="ocgn:ConvertibleDebtEquityFinancingTriggeredDiscount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMzI5ODUzNDg5OTUyOA_aaa2fb2d-497a-483e-b744-0f437b017c09">15</ix:nonFraction>% discount per the terms of the January&#160;2019 and February&#160;2019 Notes to <ix:nonFraction unitRef="number" contextRef="ie03c47b9f9564d4ea485d3ffdd995bb6_I20191231" decimals="INF" name="ocgn:ConvertibleDebtEquityFinancingTriggeredDiscount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMzI5ODUzNDg5OTUzNA_e0eb8606-30e9-45b7-b7fd-e4466b50bbbe">30</ix:nonFraction>% at the time of conversion. The Company issued <ix:nonFraction unitRef="shares" contextRef="i5d316476da1f4704bd006d963c24c9f3_I20190405" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NTc2Nw_b9540b96-c1e3-4d4d-b8c1-8084838b575b">1.1</ix:nonFraction> million shares of common stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="i5d316476da1f4704bd006d963c24c9f3_I20190405" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NTc3Mw_37584a95-1fb9-4634-b584-129ec9d813ab">8.69</ix:nonFraction> per share on the date of conversion to extinguish the debt, which resulted in a loss of $<ix:nonFraction unitRef="usd" contextRef="i2c77d97bd72b4690ab70a469f8712825_D20190405-20190405" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NTc3OA_537b9841-8630-4d54-9bfd-1b06c63a089f">0.3</ix:nonFraction> million. This non-cash conversion also resulted in an increase of $<ix:nonFraction unitRef="usd" contextRef="i016d0b71e20d44c6b6f177338d083e24_D20190405-20190405" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NTc4MQ_2b9037a5-6013-45c8-8929-232da6c1e8fb">13.0</ix:nonFraction> million in additional paid-in capital, which was based on the principal balance outstanding and the unpaid interest upon conversion.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Convertible Promissory Notes</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 4, 2019, the Company issued the convertible promissory note (the &#8220;Promissory Note&#8221;) to an existing stockholder for $<ix:nonFraction unitRef="usd" contextRef="i3af9928ff5934a50a728ddecb0030b9f_I20190404" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NTc4NA_404d0365-0e6e-4dbf-96a3-f732d58418d3">0.9</ix:nonFraction> million at an interest rate of <ix:nonFraction unitRef="number" contextRef="i3af9928ff5934a50a728ddecb0030b9f_I20190404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNzE0NjgyNTYwMTgxNw_c928329a-8dfa-4f39-86e6-85f662ae25c2">5</ix:nonFraction>% per annum. On May&#160;16, 2019, the Promissory Note was converted into equity. Former Ocugen issued <ix:nonFraction unitRef="shares" contextRef="ic10bc878b71a4eec829c618f097ab1f3_I20190405" decimals="-5" format="ixt:numdotdecimal" name="ocgn:CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMzI5ODUzNDkwMDU0Ng_9ef427f5-3f74-40a9-8026-d7914c1b2f73">0.1</ix:nonFraction> million shares of common stock at the conversion date to extinguish the debt at $<ix:nonFraction unitRef="usdPerShare" contextRef="ic10bc878b71a4eec829c618f097ab1f3_I20190405" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMzI5ODUzNDkwMDYyMQ_72e90f5d-7210-4dff-afb2-cdaa49d0b801">12.41</ix:nonFraction> per share. This non-cash transaction resulted in an increase of $<ix:nonFraction unitRef="usd" contextRef="i9825c374339d495092fda175dbb9ecc6_D20190516-20190516" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMzI5ODUzNDkwMDY4OA_52886914-6a8d-47ed-b49d-4b779d04b730">0.9</ix:nonFraction> million in additional paid-in capital, which was based on the principal balance outstanding and the unpaid interest upon conversion.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Senior Secured Convertible Notes</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May 21, 2019, the Company issued senior secured convertible notes to certain investors for $<ix:nonFraction unitRef="usd" contextRef="iff635dcebab24f36911b7b91f40c1759_I20190521" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NTgxNA_8df613e4-00ed-42c4-869a-3ec1207096d7">2.4</ix:nonFraction> million at an original issue discount of $<ix:nonFraction unitRef="usd" contextRef="iff635dcebab24f36911b7b91f40c1759_I20190521" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NTgxNw_74be4947-36fb-4bb8-be00-14b1df557c39">0.5</ix:nonFraction> million, and on June&#160;28, 2019, the Company entered into an agreement to issue additional senior secured convertible notes to the investors for $<ix:nonFraction unitRef="usd" contextRef="i58aa2dbee17a4346b99dfe95c91e455d_I20190628" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NTgyMA_1d5f8ce3-d422-4fcd-8799-3c23bc2e150c">2.9</ix:nonFraction> million with an original issue discount of $<ix:nonFraction unitRef="usd" contextRef="i58aa2dbee17a4346b99dfe95c91e455d_I20190628" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NTgyMw_4e50c8ec-a1f0-4ddb-b6a9-ff617a6b09b4">0.4</ix:nonFraction> million (together &#8220;Senior Secured Notes&#8221;). Immediately prior to the Merger completed on September 27, 2019, the investors offset $<ix:nonFraction unitRef="usd" contextRef="icc8f3b70120644bcb0ea07e4c4e58532_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NTgzMA_e95e94d0-8ff5-4adb-8815-ae400aef24a1">5.3</ix:nonFraction> million from the amount to be received under the Pre-Merger Financing and the Senior Secured Notes were deemed to have been repaid and cancelled. The accretion of the original issue discount to interest expense amounted to $<ix:nonFraction unitRef="usd" contextRef="i9169a31e29f845df9d4dcc1d4c8e89af_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMzI5ODUzNDkwMjQ4Nw_51661c6c-b46f-439e-9c55-7bbd10b6b93e">0.8</ix:nonFraction> million during the year ended December 31, 2019.</span></div></ix:continuation><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1844"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">8.&#160;<ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGV4dHJlZ2lvbjo3YTM1NjhhMDc3YmU0ODIwYWM4NzY3ZDQzNTI3MjNhYl8xNTM5MzE2Mjc5OTE2Mw_5f13c459-d190-4262-a5fa-bc6d9d34ed20" continuedAt="i41b03254222f4a4c89fb85e20233548f" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i41b03254222f4a4c89fb85e20233548f" continuedAt="ic745184fd98443ebba4b1c910b9700a7"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGV4dHJlZ2lvbjo3YTM1NjhhMDc3YmU0ODIwYWM4NzY3ZDQzNTI3MjNhYl8xNTM5MzE2Mjc5OTE2NA_dcd0aab9-9c36-4fc6-9c2d-10d8b9ca6d01" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock-based compensation expense for options granted are reflected in the consolidated statements of operations and comprehensive loss as follows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:68.175%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.622%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended<br/>December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dd31fe358a94242921f371e4a12056c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6YmRhMjE4ZWQwM2U0NGUwOWJkYjEzMDM2NmI4ZjAyMDgvdGFibGVyYW5nZTpiZGEyMThlZDAzZTQ0ZTA5YmRiMTMwMzY2YjhmMDIwOF8yLTEtMS0xLTQ3NzI_c6215217-12a9-45e2-8bb1-04a16708e217">362,833</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iee4f88bad8cb4836b9a7cc7122e34867_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6YmRhMjE4ZWQwM2U0NGUwOWJkYjEzMDM2NmI4ZjAyMDgvdGFibGVyYW5nZTpiZGEyMThlZDAzZTQ0ZTA5YmRiMTMwMzY2YjhmMDIwOF8yLTMtMS0xLTQxMzE_ec42f7b5-84e5-43d9-b551-9ba567ab7133">515,160</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifb06df9a8042478fbcacfde1e1ec008c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6YmRhMjE4ZWQwM2U0NGUwOWJkYjEzMDM2NmI4ZjAyMDgvdGFibGVyYW5nZTpiZGEyMThlZDAzZTQ0ZTA5YmRiMTMwMzY2YjhmMDIwOF8zLTEtMS0xLTQ3NzI_c18f3957-604e-457d-9d3f-92ae5bd46d65">521,256</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i81f536df668b463db04d83beaea9fca4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6YmRhMjE4ZWQwM2U0NGUwOWJkYjEzMDM2NmI4ZjAyMDgvdGFibGVyYW5nZTpiZGEyMThlZDAzZTQ0ZTA5YmRiMTMwMzY2YjhmMDIwOF8zLTMtMS0xLTQxMzE_96f00e8b-983f-4a6e-ad60-549be2d8de3c">559,527</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6YmRhMjE4ZWQwM2U0NGUwOWJkYjEzMDM2NmI4ZjAyMDgvdGFibGVyYW5nZTpiZGEyMThlZDAzZTQ0ZTA5YmRiMTMwMzY2YjhmMDIwOF80LTEtMS0xLTI0OTE_6c9a7aeb-7fdc-4a3c-8cfb-a785eafd0a02">884,089</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6YmRhMjE4ZWQwM2U0NGUwOWJkYjEzMDM2NmI4ZjAyMDgvdGFibGVyYW5nZTpiZGEyMThlZDAzZTQ0ZTA5YmRiMTMwMzY2YjhmMDIwOF80LTMtMS0xLTI0OTQ_b163339d-245f-45bc-a8d5-b470415526e6">1,074,687</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, the Company had $<ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGV4dHJlZ2lvbjo3YTM1NjhhMDc3YmU0ODIwYWM4NzY3ZDQzNTI3MjNhYl82MDQ3MzEzOTU0MDgz_2b7b2047-9645-4f4e-871d-0c3249e5a010">0.9</ix:nonFraction> million of unrecognized compensation expense related to options outstanding under its equity plans. This expense is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i21b036a7018e49f1ba389957307f069f_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGV4dHJlZ2lvbjo3YTM1NjhhMDc3YmU0ODIwYWM4NzY3ZDQzNTI3MjNhYl82MDQ3MzEzOTU0MDg2_356a2837-6697-46c3-b9d0-e0ace15b682d">1.7</ix:nonNumeric> years as of December&#160;31, 2019</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Equity Plans</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company maintains <ix:nonFraction unitRef="segment" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="ocgn:NumberOfEquityCompensationPlans" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGV4dHJlZ2lvbjo3YTM1NjhhMDc3YmU0ODIwYWM4NzY3ZDQzNTI3MjNhYl8xNTM5MzE2Mjc5OTE4Nw_f3ba72ec-4f07-4c29-bfbb-d86b2acde359">two</ix:nonFraction> equity compensation plans, the 2014 Ocugen OpCo, Inc. Stock Option Plan (the &#8220;2014 Plan&#8221;) and the Ocugen, Inc. 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;, collectively with the 2014 Plan, the "Plans"), which replaced the Histogenics Corporation 2013 Equity Incentive Plan (the "2013 Plan"). </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 18, 2019, Ocugen&#8217;s stockholders approved the adoption of the 2019 Plan and the 2013 Plan was frozen. No additional awards have been or will be made under the 2013 Plan and any remaining authorized shares under the 2013 Plan will be recycled into the 2019 Plan. The 2019 Plan provides for the granting of up to <ix:nonFraction unitRef="shares" contextRef="i9dd0fe8be9d9438c8e720727830deb3e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGV4dHJlZ2lvbjo3YTM1NjhhMDc3YmU0ODIwYWM4NzY3ZDQzNTI3MjNhYl82MDQ3MzEzOTU5NTk3_01177549-80b5-4c0b-844a-9fa44d1bf003">2.1</ix:nonFraction>&#160;million equity awards in respect of </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><ix:continuation id="ic745184fd98443ebba4b1c910b9700a7"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ocugen&#8217;s common stock, inclusive of equity awards that were previously available for issuance under the 2013 Plan, as of December&#160;31, 2019. Additionally, on the first business day of each fiscal year commencing on January 1, 2020, pursuant to the "Evergreen" provision of the 2019 Plan, the aggregate number of shares that may be issued under the 2019 Plan shall automatically increase by a number equal to the lesser of <ix:nonFraction unitRef="number" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="INF" name="ocgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGV4dHJlZ2lvbjo3YTM1NjhhMDc3YmU0ODIwYWM4NzY3ZDQzNTI3MjNhYl82MDQ3MzEzOTU5NjI3_b63bc10b-5ec5-4929-893c-8c9c6aed4b6e">4.0</ix:nonFraction>% of the total number of shares of Company common stock outstanding on December 31</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">st</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of the prior year, or a number of shares of Company common stock determined by the Board.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, an aggregate of <ix:nonFraction unitRef="shares" contextRef="i901327021f4f4d8a9e7429629a2fe235_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGV4dHJlZ2lvbjo3YTM1NjhhMDc3YmU0ODIwYWM4NzY3ZDQzNTI3MjNhYl84MjQ2MzM3MjE5MTQz_0e93a90a-7545-4d15-a20b-97a34932ea23">0.6</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="shares" contextRef="ie4c25c1678fc46f2a94db1f11c7a25d1_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGV4dHJlZ2lvbjo3YTM1NjhhMDc3YmU0ODIwYWM4NzY3ZDQzNTI3MjNhYl84MjQ2MzM3MjE5MTUz_66960988-e2ec-4ada-9aaf-eec6d9d68583">0.1</ix:nonFraction>&#160;million shares of Company common stock were issuable upon the exercise of outstanding stock options under the 2014 Plan and 2019 Plan, respectively.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Options to Purchase Common Stock</span></div><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGV4dHJlZ2lvbjo3YTM1NjhhMDc3YmU0ODIwYWM4NzY3ZDQzNTI3MjNhYl8xNTM5MzE2Mjc5OTE2Ng_0d332500-ec01-4781-b7ae-4e28f3b61f58" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average assumptions utilized in the fair value calculation for options to purchase common stock as of December&#160;31, 2019 and 2018 are as follows: </span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:68.175%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.622%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended<br/>December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average common stock price</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="iaf4d04bf884e47208ec21854eaf3c6fa_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6ZThmNTE1YTRmZDI0NDBmNGI1MjRlNTU4YzY2YmE5YzMvdGFibGVyYW5nZTplOGY1MTVhNGZkMjQ0MGY0YjUyNGU1NThjNjZiYTljM18yLTEtMS0xLTQxNDI_00a99e68-a20f-4e4a-bbac-bb1131059e91">1.04</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="i81f1955a085348c7b2651edceb71e43f_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6ZThmNTE1YTRmZDI0NDBmNGI1MjRlNTU4YzY2YmE5YzMvdGFibGVyYW5nZTplOGY1MTVhNGZkMjQ0MGY0YjUyNGU1NThjNjZiYTljM18yLTMtMS0xLTQxNDI_7d4bcd53-8513-4a34-86ed-357aa4040976">9.72</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected option term (years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i6258e5af615841ca8ed08b5fc6e64f13_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6ZThmNTE1YTRmZDI0NDBmNGI1MjRlNTU4YzY2YmE5YzMvdGFibGVyYW5nZTplOGY1MTVhNGZkMjQ0MGY0YjUyNGU1NThjNjZiYTljM18yLTEtMS0xLTI2MTE_99fbea53-5aae-4dab-ae48-93571a145081">6.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="ie8f44ff16f6a48a5b00b8d8fb4955d6f_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6ZThmNTE1YTRmZDI0NDBmNGI1MjRlNTU4YzY2YmE5YzMvdGFibGVyYW5nZTplOGY1MTVhNGZkMjQ0MGY0YjUyNGU1NThjNjZiYTljM18yLTMtMS0xLTI2MDcvdGV4dHJlZ2lvbjo0YmM5ZDQyMmZjZjU0NTA0OGVmNWNhZDY4Mzg1Yjc5NF84MjQ2MzM3MjA4MzM3_865be958-27a5-4262-af4a-b094933c0941">6.0</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="iac0f32c415484121ac10d938108c47c4_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6ZThmNTE1YTRmZDI0NDBmNGI1MjRlNTU4YzY2YmE5YzMvdGFibGVyYW5nZTplOGY1MTVhNGZkMjQ0MGY0YjUyNGU1NThjNjZiYTljM18yLTMtMS0xLTI2MDcvdGV4dHJlZ2lvbjo0YmM5ZDQyMmZjZjU0NTA0OGVmNWNhZDY4Mzg1Yjc5NF84MjQ2MzM3MjA4MzQz_71a2d3bd-dfa8-46ab-ba58-6b866e432805">10.0</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average expected stock price volatility</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i6258e5af615841ca8ed08b5fc6e64f13_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6ZThmNTE1YTRmZDI0NDBmNGI1MjRlNTU4YzY2YmE5YzMvdGFibGVyYW5nZTplOGY1MTVhNGZkMjQ0MGY0YjUyNGU1NThjNjZiYTljM18zLTEtMS0xLTI2MTE_26492558-6d86-491b-ad67-fb8a5b19b7ae">109</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="iebb192fe177843a59dda713200213ad2_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6ZThmNTE1YTRmZDI0NDBmNGI1MjRlNTU4YzY2YmE5YzMvdGFibGVyYW5nZTplOGY1MTVhNGZkMjQ0MGY0YjUyNGU1NThjNjZiYTljM18zLTMtMS0xLTI2MDc_7a2604aa-4e67-4e06-a01a-eddd78f92e0e">85</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i8f30ba30167e413fa31d614ef91c6c25_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6ZThmNTE1YTRmZDI0NDBmNGI1MjRlNTU4YzY2YmE5YzMvdGFibGVyYW5nZTplOGY1MTVhNGZkMjQ0MGY0YjUyNGU1NThjNjZiYTljM180LTEtMS0xLTI2MTEvdGV4dHJlZ2lvbjoyNGQ4NDBmNTNmMmY0NmNmOGY3MGNjZWE4MjE3NGYwMF84MjQ2MzM3MjA4MzM5_a7d05f5f-4619-4e25-8696-83e260540fce">1.5</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="number" contextRef="i9d9bff3d3ae843c7b1af7507aeb3bcc2_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6ZThmNTE1YTRmZDI0NDBmNGI1MjRlNTU4YzY2YmE5YzMvdGFibGVyYW5nZTplOGY1MTVhNGZkMjQ0MGY0YjUyNGU1NThjNjZiYTljM180LTEtMS0xLTI2MTEvdGV4dHJlZ2lvbjoyNGQ4NDBmNTNmMmY0NmNmOGY3MGNjZWE4MjE3NGYwMF84MjQ2MzM3MjA4MzQ0_5a554cef-28a7-4f2b-b2fc-dc0937b02f85">2.4</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="ie8f44ff16f6a48a5b00b8d8fb4955d6f_D20180101-20181231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6ZThmNTE1YTRmZDI0NDBmNGI1MjRlNTU4YzY2YmE5YzMvdGFibGVyYW5nZTplOGY1MTVhNGZkMjQ0MGY0YjUyNGU1NThjNjZiYTljM180LTMtMS0xLTI2MDcvdGV4dHJlZ2lvbjowMzA0NDY5YzQzZjk0Y2ZhYjE0Y2Q5M2UwYjQwNTY4Y184MjQ2MzM3MjA4MzM5_1fb8830b-5221-4f83-a534-bf184fc8004d">2.3</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="number" contextRef="iac0f32c415484121ac10d938108c47c4_D20180101-20181231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6ZThmNTE1YTRmZDI0NDBmNGI1MjRlNTU4YzY2YmE5YzMvdGFibGVyYW5nZTplOGY1MTVhNGZkMjQ0MGY0YjUyNGU1NThjNjZiYTljM180LTMtMS0xLTI2MDcvdGV4dHJlZ2lvbjowMzA0NDY5YzQzZjk0Y2ZhYjE0Y2Q5M2UwYjQwNTY4Y184MjQ2MzM3MjA4MzQ1_d66d9c84-2ef4-4b52-97d7-97f22b9405ab">3.0</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i6258e5af615841ca8ed08b5fc6e64f13_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6ZThmNTE1YTRmZDI0NDBmNGI1MjRlNTU4YzY2YmE5YzMvdGFibGVyYW5nZTplOGY1MTVhNGZkMjQ0MGY0YjUyNGU1NThjNjZiYTljM181LTEtMS0xLTI2MDQ_876281f9-d8c9-4da8-bd3c-99625a9ed41c">&#8212;</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="iebb192fe177843a59dda713200213ad2_D20180101-20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6ZThmNTE1YTRmZDI0NDBmNGI1MjRlNTU4YzY2YmE5YzMvdGFibGVyYW5nZTplOGY1MTVhNGZkMjQ0MGY0YjUyNGU1NThjNjZiYTljM181LTMtMS0xLTI2MDc_5e2848c7-af49-40fb-b1f3-461b2ded63a5">&#8212;</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGV4dHJlZ2lvbjo3YTM1NjhhMDc3YmU0ODIwYWM4NzY3ZDQzNTI3MjNhYl8xNTM5MzE2Mjc5OTE2NQ_0fc84d4b-bceb-4572-add9-a3bccb762348" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the stock option activity under the Plans:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:37.766%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.625%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Exercise Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Remaining Contractual Life (Years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options outstanding at December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i78c531e0c2834d2c9ce23d519b06d67b_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF8xLTEtMS0xLTI2NjI_2cf69880-385b-4052-8996-5c6073d16066">632,752</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i78c531e0c2834d2c9ce23d519b06d67b_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF8xLTMtMS0xLTI2NjI_8800f59e-2736-4a44-80b7-02a59b6a458a">5.93</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i765c6c431bab4e9ca9750ef3e6d5c0a4_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF8xLTUtMS0xLTQxNTk_eec4a89f-7af0-4f4e-8216-07cd915c5dda">7.9</ix:nonNumeric></span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i78c531e0c2834d2c9ce23d519b06d67b_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF8xLTctMS0xLTQxNTk_68564df8-09d4-4e73-97f5-3b709506e76c">4,801,696</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4f2a660290394b9288e546c9be4bde7a_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF8yLTEtMS0xLTI2NjI_e5303511-bf96-414b-bbad-18f365d615ed">238,761</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i4f2a660290394b9288e546c9be4bde7a_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF8yLTMtMS0xLTI2NjI_39337d22-d8ad-4418-bc43-14a41923e485">1.04</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancelled</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i4f2a660290394b9288e546c9be4bde7a_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF80LTEtMS0xLTI2NjI_659f0ebb-caf0-4256-a600-e6134715b0b0">140,324</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i4f2a660290394b9288e546c9be4bde7a_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF80LTMtMS0xLTI2NjI_8ecb5e64-63e0-4ea4-9946-aaf0a1c02485">4.58</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options outstanding at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9dd0fe8be9d9438c8e720727830deb3e_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF81LTEtMS0xLTI2NjI_29e61e8a-10b6-42cd-bec9-7765d732224b">731,189</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i9dd0fe8be9d9438c8e720727830deb3e_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF81LTMtMS0xLTI2NjI_68fbb015-6eee-4a66-a0a6-e4cf9066d3fd">4.59</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i4f2a660290394b9288e546c9be4bde7a_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF81LTUtMS0xLTQxOTk_71055290-ca9e-45da-b8ea-bd57dd73c918">8.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9dd0fe8be9d9438c8e720727830deb3e_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF81LTctMS0xLTQxOTY_dc81fba7-e2ab-49a7-a462-9ca3f7728ce6">24,028</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercisable at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9dd0fe8be9d9438c8e720727830deb3e_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF82LTEtMS0xLTI2NjI_d4f83d89-5e76-48a3-8472-cc75b66855a8">385,841</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i9dd0fe8be9d9438c8e720727830deb3e_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF82LTMtMS0xLTI2NjI_fc8d5f3f-4406-4a20-a111-da2763797379">5.15</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i4f2a660290394b9288e546c9be4bde7a_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF82LTUtMS0xLTQxOTk_1bc9a409-9da1-4af2-ba7b-3e4b66b7755c">6.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9dd0fe8be9d9438c8e720727830deb3e_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF82LTctMS0xLTQxOTY_65fc3103-a7e0-493e-83a1-d26057d462ea">3,049</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The weighted average grant date fair value of stock options granted during the year ended December 31, 2019 and 2018 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGV4dHJlZ2lvbjo3YTM1NjhhMDc3YmU0ODIwYWM4NzY3ZDQzNTI3MjNhYl82MDQ3MzEzOTYxMTYy_e30c11cb-6564-4498-9458-c4ac322167ac">0.84</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGV4dHJlZ2lvbjo3YTM1NjhhMDc3YmU0ODIwYWM4NzY3ZDQzNTI3MjNhYl82MDQ3MzEzOTYxMTc0_54c6e936-82cc-485d-b5a2-4ed7a8e7a4a3">7.97</ix:nonFraction>, respectively</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The total fair value of stock options vested during the year ended December&#160;31, 2019 was $<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGV4dHJlZ2lvbjo3YTM1NjhhMDc3YmU0ODIwYWM4NzY3ZDQzNTI3MjNhYl84MjQ2MzM3MjE4NDE5_27b58b3b-e799-4ac8-8ba0-91394a32ce4a">1.0</ix:nonFraction>&#160;million.</span></div></ix:continuation><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_79"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">9.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:700;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RleHRyZWdpb246ZGM3YmMyNzE5ZTYwNGMyNjlkMWNiNjIxY2JhMTE0NDNfMTA5OTUxMTYyODYyNDc_1bdc082e-0f91-4600-822c-c303443f41d3" continuedAt="i8a832064823547dd8f917ad11eab556b" escape="true">Commitments</ix:nonNumeric></span></div><ix:continuation id="i8a832064823547dd8f917ad11eab556b" continuedAt="i823094551cc74a049e29f658bac073bf"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating Leases</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has commitments under operating leases for certain facilities used in its operations. The Company&#8217;s leases have initial lease terms ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RleHRyZWdpb246ZGM3YmMyNzE5ZTYwNGMyNjlkMWNiNjIxY2JhMTE0NDNfMTA5OTUxMTYyODYwOTQ_ca47572a-04ad-41bc-8ba1-21a7e15ee217">one</span> to <ix:nonNumeric contextRef="i67871994f7b24db59223486582b30e7a_I20191231" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RleHRyZWdpb246ZGM3YmMyNzE5ZTYwNGMyNjlkMWNiNjIxY2JhMTE0NDNfMTA5OTUxMTYyODYwOTU_f880dddf-9bbf-4dbe-a4f0-dc0ba2e62928">five years</ix:nonNumeric>. Certain lease agreements contain provisions for future rent increases.</span></div><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RleHRyZWdpb246ZGM3YmMyNzE5ZTYwNGMyNjlkMWNiNjIxY2JhMTE0NDNfMTA5OTUxMTYyODYwODk_1303189e-b5b9-44f0-9c3f-f98a2db785a5" continuedAt="i3439dd3aefd14c12bcbf3f631981ba37" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of lease expense were as follows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:83.380%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.620%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended<br/>December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOmM2NzAwZDZhNTJmZTRkN2VhYjM0ZTAzYWZjOWMxNDcwL3RhYmxlcmFuZ2U6YzY3MDBkNmE1MmZlNGQ3ZWFiMzRlMDNhZmM5YzE0NzBfMS0zLTEtMS0w_8f5c50bc-310d-4324-b275-f63bba0f1f7e">250,361</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Variable lease cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOmM2NzAwZDZhNTJmZTRkN2VhYjM0ZTAzYWZjOWMxNDcwL3RhYmxlcmFuZ2U6YzY3MDBkNmE1MmZlNGQ3ZWFiMzRlMDNhZmM5YzE0NzBfMi0zLTEtMS0w_2413952f-beb8-486c-9a12-7e62ffabde62">79,700</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOmM2NzAwZDZhNTJmZTRkN2VhYjM0ZTAzYWZjOWMxNDcwL3RhYmxlcmFuZ2U6YzY3MDBkNmE1MmZlNGQ3ZWFiMzRlMDNhZmM5YzE0NzBfMy0zLTEtMS0w_f8e97617-8c91-4637-bfd7-f1c4809894be">330,061</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><ix:continuation id="i823094551cc74a049e29f658bac073bf"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="ocgn:SupplementalBalanceSheetInformationLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RleHRyZWdpb246ZGM3YmMyNzE5ZTYwNGMyNjlkMWNiNjIxY2JhMTE0NDNfMTA5OTUxMTYyODYwOTA_27b23922-0181-4d15-98f2-5235772ff2e9" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Supplemental balance sheet information related to leases was as follows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:83.380%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.620%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use assets, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOjI0ZDQyYmFjNzA0NDQ2ODc4MWE0MWZkN2UxMWM3ZWQ1L3RhYmxlcmFuZ2U6MjRkNDJiYWM3MDQ0NDY4NzgxYTQxZmQ3ZTExYzdlZDVfMS0xLTEtMS0w_654657b4-31a2-4b4d-b7c7-446f92927d9f">344,574</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current lease obligations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOjI0ZDQyYmFjNzA0NDQ2ODc4MWE0MWZkN2UxMWM3ZWQ1L3RhYmxlcmFuZ2U6MjRkNDJiYWM3MDQ0NDY4NzgxYTQxZmQ3ZTExYzdlZDVfMi0xLTEtMS0w_a6a8e5f9-d872-452a-b78b-c002c95b37c6">172,310</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current lease obligations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOjI0ZDQyYmFjNzA0NDQ2ODc4MWE0MWZkN2UxMWM3ZWQ1L3RhYmxlcmFuZ2U6MjRkNDJiYWM3MDQ0NDY4NzgxYTQxZmQ3ZTExYzdlZDVfMy0xLTEtMS0w_afb592dd-c784-4ef2-b691-60c79b2ff803">163,198</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOjI0ZDQyYmFjNzA0NDQ2ODc4MWE0MWZkN2UxMWM3ZWQ1L3RhYmxlcmFuZ2U6MjRkNDJiYWM3MDQ0NDY4NzgxYTQxZmQ3ZTExYzdlZDVfNC0xLTEtMS0w_7aa7f327-95f8-4aa4-9963-35b399448c54">335,508</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><ix:continuation id="i3439dd3aefd14c12bcbf3f631981ba37"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Supplemental information related to leases was as follows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:83.380%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.620%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended<br/>December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average remaining lease terms&#8212;operating leases (years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOjIyZjU5ZGJmNTBmOTQ3YjI5NWNhY2I2MzQyNzI1ZTlmL3RhYmxlcmFuZ2U6MjJmNTlkYmY1MGY5NDdiMjk1Y2FjYjYzNDI3MjVlOWZfNC0xLTEtMS0w_bddcd83b-2275-49be-9e35-fa120f5b2299">2.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average discount rate&#8212;operating leases</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOjIyZjU5ZGJmNTBmOTQ3YjI5NWNhY2I2MzQyNzI1ZTlmL3RhYmxlcmFuZ2U6MjJmNTlkYmY1MGY5NDdiMjk1Y2FjYjYzNDI3MjVlOWZfNS0xLTEtMS0w_06f66d3a-fd48-4922-89d3-efb1ca919efa">7.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RleHRyZWdpb246ZGM3YmMyNzE5ZTYwNGMyNjlkMWNiNjIxY2JhMTE0NDNfMTA5OTUxMTYyODYwOTI_4f112bb5-044a-45cc-825f-387a85f16428" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future minimum operating minimum lease payments for all leases, exclusive of taxes and other carrying charges, are approximately as follows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:83.380%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.620%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Years Ending December 31,</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOjA4MmU1NDQxOTMzZTQxM2Q4MTJjOGM2MDNjODVlZTFhL3RhYmxlcmFuZ2U6MDgyZTU0NDE5MzNlNDEzZDgxMmM4YzYwM2M4NWVlMWFfMi0yLTEtMS0w_06a2cdb6-969f-4ba3-bb62-30403709f98b">191,890</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOjA4MmU1NDQxOTMzZTQxM2Q4MTJjOGM2MDNjODVlZTFhL3RhYmxlcmFuZ2U6MDgyZTU0NDE5MzNlNDEzZDgxMmM4YzYwM2M4NWVlMWFfMy0yLTEtMS0w_526364fc-eae0-4949-aff4-7575bdf054c2">160,909</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOjA4MmU1NDQxOTMzZTQxM2Q4MTJjOGM2MDNjODVlZTFhL3RhYmxlcmFuZ2U6MDgyZTU0NDE5MzNlNDEzZDgxMmM4YzYwM2M4NWVlMWFfNC0yLTEtMS0w_7bcb7e65-aa8c-491a-a212-beee2be70a62">11,354</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOjA4MmU1NDQxOTMzZTQxM2Q4MTJjOGM2MDNjODVlZTFhL3RhYmxlcmFuZ2U6MDgyZTU0NDE5MzNlNDEzZDgxMmM4YzYwM2M4NWVlMWFfNS0yLTEtMS0w_3c985ba2-59b3-4da3-a10a-5f940e1c22ff">364,153</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: present value adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOjA4MmU1NDQxOTMzZTQxM2Q4MTJjOGM2MDNjODVlZTFhL3RhYmxlcmFuZ2U6MDgyZTU0NDE5MzNlNDEzZDgxMmM4YzYwM2M4NWVlMWFfNi0yLTEtMS0w_cd716466-c562-43a7-b66c-643c50a85d41">28,645</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of minimum lease payments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOjA4MmU1NDQxOTMzZTQxM2Q4MTJjOGM2MDNjODVlZTFhL3RhYmxlcmFuZ2U6MDgyZTU0NDE5MzNlNDEzZDgxMmM4YzYwM2M4NWVlMWFfNy0yLTEtMS0w_c48d5bce-0455-46c4-af6f-2d181ff1b512">335,508</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company does not have any leases that have not yet commenced which are significant.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Financing Leases</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2018, the Company leased specialized research equipment under a lease classified as a financing lease. The leased equipment is included in property and equipment, net and is amortized on a straight-line basis over <ix:nonNumeric contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RleHRyZWdpb246ZGM3YmMyNzE5ZTYwNGMyNjlkMWNiNjIxY2JhMTE0NDNfMzc0Mw_89a4764b-b491-41ce-9d14-3fc912da2404">five years</ix:nonNumeric>. Financing lease liabilities are included in other liabilities on the Company's consolidated balance sheets. The interest rate related to the lease obligation is <ix:nonFraction unitRef="number" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="3" name="us-gaap:LesseeFinanceLeaseDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RleHRyZWdpb246ZGM3YmMyNzE5ZTYwNGMyNjlkMWNiNjIxY2JhMTE0NDNfNDEwMg_8059093a-fb06-4139-8fba-3e3a6c3ee1c9">7.6</ix:nonFraction>% and the maturity date is July 2021.</span></div><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RleHRyZWdpb246ZGM3YmMyNzE5ZTYwNGMyNjlkMWNiNjIxY2JhMTE0NDNfMTA5OTUxMTYyODYwOTM_060d8971-f5c2-4e43-8a90-2ea15a6a125a" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future minimum lease payments for all financing leases, exclusive of taxes and other carrying charges, are approximately as follows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:83.380%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.620%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Years Ending December 31,</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOmNmODY1NjUyY2I2ZTQ2YWFhNmJjZjJhY2E5MGRmNmJjL3RhYmxlcmFuZ2U6Y2Y4NjU2NTJjYjZlNDZhYWE2YmNmMmFjYTkwZGY2YmNfMi0yLTEtMS0w_6595f2cf-e26a-4b4b-b47c-06110656f9ea">23,856</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOmNmODY1NjUyY2I2ZTQ2YWFhNmJjZjJhY2E5MGRmNmJjL3RhYmxlcmFuZ2U6Y2Y4NjU2NTJjYjZlNDZhYWE2YmNmMmFjYTkwZGY2YmNfMy0yLTEtMS0w_c0cb250d-1eb6-41f3-b030-7d2cb4a46193">9,941</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOmNmODY1NjUyY2I2ZTQ2YWFhNmJjZjJhY2E5MGRmNmJjL3RhYmxlcmFuZ2U6Y2Y4NjU2NTJjYjZlNDZhYWE2YmNmMmFjYTkwZGY2YmNfNC0yLTEtMS0w_5fe49a1c-2c37-4e6a-9952-471dbfea0c9a">33,797</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: present value adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOmNmODY1NjUyY2I2ZTQ2YWFhNmJjZjJhY2E5MGRmNmJjL3RhYmxlcmFuZ2U6Y2Y4NjU2NTJjYjZlNDZhYWE2YmNmMmFjYTkwZGY2YmNfNS0yLTEtMS0w_4f843815-76b2-4714-a623-132cc9939909">1,851</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of minimum lease payments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOmNmODY1NjUyY2I2ZTQ2YWFhNmJjZjJhY2E5MGRmNmJjL3RhYmxlcmFuZ2U6Y2Y4NjU2NTJjYjZlNDZhYWE2YmNmMmFjYTkwZGY2YmNfNi0yLTEtMS0w_a1d1f970-5d78-4b25-85fc-9abe9ddc6353">31,946</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_85"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">10</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="ocgn:WarrantsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTUzOTMxNjI4Mjg3Mjc_eacb5352-3bc6-4882-aad1-9a5db090f94d" continuedAt="i35df7d17e1614b9fb38b938bb044eaa6" escape="true">Warrants</ix:nonNumeric></span></div><ix:continuation id="i35df7d17e1614b9fb38b938bb044eaa6" continuedAt="i7bd9e0b785654a0e820ebaca17d115ef"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Pre-Merger Financing Warrants</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September&#160;27, 2019, Ocugen completed the Merger with Former Ocugen. Immediately prior to the Merger, Ocugen and Former Ocugen completed a previously announced private placement transaction with certain Investors pursuant to the Financing SPA, whereby, among other things, (i)&#160;Former Ocugen issued to the Investors shares of Former Ocugen&#8217;s common stock, (ii)&#160;Former Ocugen issued and deposited additional shares of Former Ocugen&#8217;s common stock into escrow, and (iii)&#160;the </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><ix:continuation id="i7bd9e0b785654a0e820ebaca17d115ef" continuedAt="i622c6c86133e43969646ca5a465efe1d"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Company agreed to issue on the fifth trading day following the consummation of the Merger, Series&#160;A Warrants, Series&#160;B Warrants, and Series&#160;C Warrants.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Pre-Merger Financing Warrants are subject to blocker provisions which restrict the exercise of the Pre-Merger Financing Warrants if, as a result of such exercise, the holder, together with its affiliates would beneficially own in excess of <ix:nonFraction unitRef="number" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="INF" name="ocgn:PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionLowerPercentageOfCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTUzOTMxNjI4Mjg3MzI_88de9d62-945f-4801-a8ad-c551b7558f9f">4.99</ix:nonFraction>% or <ix:nonFraction unitRef="number" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="INF" name="ocgn:PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionHigherPercentageOfCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTUzOTMxNjI4Mjg3NDE_4bfb0dc5-6442-4df6-a61e-98de3144d24a">9.99</ix:nonFraction>% of the outstanding common stock, including the common shares issuable upon such exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Merger Financing Warrants.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If Ocugen fails to issue to a holder of the Pre-Merger Financing Warrants the number of shares of common stock to which such holder is entitled upon such holder&#8217;s exercise of the such warrants, then Ocugen shall be obligated to pay the holder on each day while such failure is continuing an amount equal to <ix:nonFraction unitRef="number" contextRef="if38d3cddf7364a18958c9f6b986c7132_D20190927-20191231" decimals="INF" name="ocgn:PercentageOfAmountOnMarketValueForFailureToIssueCommonStockOnPreMergerFinancingWarrants" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTA5OTUxMTYzMjAzMDg_129fe7f4-1adc-4b3c-9867-ba5d43c03df8">2.0</ix:nonFraction>% of the market value of the undelivered shares determined using any trading price of the common stock selected by the holder as in effect at any time during the period from delivery of the exercise notice until the applicable share delivery date, and if the holder purchases shares of common stock in connection with such failure, then Ocugen must, at the holder&#8217;s discretion, reimburse the holder for the cost of such shares or deliver the owed shares and reimburse the holder for the difference between the price such holder paid for such shares and the closing market price for shares of common stock on the date of exercise.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 5, 2019, the Company entered into an agreement with each Investor that amends the terms of each of the Pre-Merger Financing Warrants held by each such Investor (collectively, the &#8220;Warrant Amendments&#8221;). The terms of the Pre-Merger Financing Warrants and the Warrant Amendments are discussed below.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Series A Warrants</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Series&#160;A Warrants have an initial exercise price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i6745b0e5cb764520ba29b0c6f1b86602_I20191231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfNjA0NzMxMzk2MzYzOQ_47c63b9a-b137-4c7c-bb8e-896fb5166cf4">7.13</ix:nonFraction>, were exercisable upon issuance and have a term of <ix:nonNumeric contextRef="i6745b0e5cb764520ba29b0c6f1b86602_I20191231" format="ixt-sec:durmonth" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfNjA0NzMxMzk2MzY0NA_b2fefbb8-9bf7-4b36-ae83-7e672950aa83">60</ix:nonNumeric> months from the date of issuance. The Series&#160;A Warrants are exercisable for up to <ix:nonFraction unitRef="shares" contextRef="i6745b0e5cb764520ba29b0c6f1b86602_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfNjA0NzMxMzk5MTAyMA_56026b49-b0d2-433c-b414-77dba9b16bab">8.8</ix:nonFraction>&#160;million shares of Ocugen common stock.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Series&#160;A Warrants have an anti-dilution adjustment whereby if Ocugen issues or sells, enters into a definitive, binding agreement pursuant to which Ocugen is required to issue or sell or is deemed, pursuant to the provisions of the Series&#160;A Warrants, to have issued or sold, any common stock for a price per share lower than the exercise price then in effect (a &#8220;Dilutive Issuance&#8221;), subject to certain limited exceptions, then (i)&#160;the exercise price of the Series&#160;A Warrants shall be reduced to such lower price per share and (ii)&#160;the number of shares issuable upon exercise of the Series&#160;A Warrants shall be increased to the number of shares of common stock determined by multiplying (a)&#160;the exercise price in effect immediately prior to such Dilutive Issuance by (b)&#160;the number of shares of common stock issuable upon exercise of the Series&#160;A Warrants immediately prior to such Dilutive Issuance (without giving effect to any limitation on exercise contained therein), and dividing the product thereof by the exercise price resulting from such Dilutive Issuance.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Each Series&#160;A Warrant was amended pursuant to the Warrant Amendments such that an equity financing involving a research or non-profit foundation or organization qualified under Section&#160;501(c)&#160;of the Internal Revenue Code of 1986, as amended, in an amount of gross proceeds not to exceed $<ix:nonFraction unitRef="usd" contextRef="ieef5bdfd701441fea03e6621fed01d9d_D20191105-20191231" decimals="-5" format="ixt:numdotdecimal" name="ocgn:ProceedsFromWarrantExercisesMaximumAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTA5OTUxMTYzMjAzMTQ_87f131d6-d467-4587-97c6-a5e9093bd6af">10.0</ix:nonFraction>&#160;million and closing on or prior to May&#160;31, 2020, will be excluded from the anti-dilution adjustment, as set forth in the Series&#160;A Warrant.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Series B Warrants</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Series&#160;B Warrants have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i77f0ebf13e6e4a578b9b6ffd815a024e_I20191231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfNjA0NzMxMzk2MzY1NA_8d46bca6-2515-4d2a-9427-242da3745712">0.01</ix:nonFraction>, were exercisable after the completion of a <ix:nonNumeric contextRef="ice482ddff55b45b4a75e3de02537f56b_D20191105-20191231" format="ixt-sec:durday" name="ocgn:ClassOfWarrantOrRightExercisePriceDeterminationNumberOfTradingDaysConsidered" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTA5OTUxMTYzMjk2NjQ_e8127236-b094-4253-a188-8540344abba0">10</ix:nonNumeric> trading-day period following the effectiveness of a registration statement covering the resale of common stock into which such warrants were exercisable and will expire on the date on which the Series&#160;B Warrants have been exercised in full (without giving effect to any limitation on exercise contained therein) and no shares remain issuable thereunder. The Series&#160;B Warrants were initially exercisable by a holder for <ix:nonFraction unitRef="usd" contextRef="i77f0ebf13e6e4a578b9b6ffd815a024e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfNjA0NzMxMzk5MTA0MA_a9437042-4adf-4e45-bbd9-590f3f81ec37">8.0</ix:nonFraction> million shares of common stock.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, each Series B Warrant included a Reset Period pursuant to which the number of shares issuable upon exercise of the Series B Warrants shall be increased during certain Reset Periods (as defined in the Series B Warrants) pursuant to a formula based on the greater of (i) <ix:nonFraction unitRef="number" contextRef="i77f0ebf13e6e4a578b9b6ffd815a024e_I20191231" decimals="INF" name="ocgn:ConvertedAdditionalSharesThresholdReleaseTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTA5OTUxMTYzMjAzMjk_f06a155c-fb29-4aa2-8bd2-2c6edc0eb111">80</ix:nonFraction>% of the arithmetic average of the two lowest dollar volume-weighted average prices of a share of Ocugen common stock on Nasdaq during the applicable Reset Period immediately preceding the applicable Reset Date to date and (ii) $<ix:nonFraction unitRef="usdPerShare" contextRef="ice482ddff55b45b4a75e3de02537f56b_D20191105-20191231" decimals="INF" name="ocgn:ConvertedAdditionalSharesThresholdReleaseTriggerPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTA5OTUxMTYzMjAzMzQ_3068da9b-bd6f-43a3-90c0-c095b96b45f6">1.00</ix:nonFraction> (the &#8220;Reset Price&#8221;). Among other things, the Reset Period was triggered by the effectiveness of the registration statement covering the resale of the shares of common stock underlying the warrants (the "Registration Statement') which became effective on November 5, 2019. The Warrant Amendments provided that Series B Warrants would not be exercisable and the effectiveness of the Registration Statement would not trigger the Reset Period until the completion of a 10 trading-day period following the SEC&#8217;s declaring it effective. The Reset Period commenced on November 20, 2019. As the dollar volume-weighted average prices of Ocugen&#8217;s common stock on Nasdaq was under $<ix:nonFraction unitRef="usdPerShare" contextRef="i3cf5412727aa4f75918abdb76b03caf7_D20191120-20191121" decimals="INF" name="ocgn:ConvertedAdditionalSharesThresholdReleaseTriggerPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTA5OTUxMTYzMjAzNDI_c9258290-7fb3-480a-8dd5-93003af7597f">1.00</ix:nonFraction> for the first two trading days of </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><ix:continuation id="i622c6c86133e43969646ca5a465efe1d" continuedAt="ica11d04ee3b24e98bcb29a82b2ede79e"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the Reset Period, the Investors elected to advance the end of the Reset Period to November 21, 2019 and the number of shares issuable upon exercise of the Series B Warrants was increased based on a Reset Price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9a4dec58cf3a474a90c3320d94bff77c_D20190101-20191231" decimals="2" name="ocgn:ConvertedAdditionalSharesThresholdReleaseTriggerPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTA5OTUxMTYzMjAzNDk_6ced5bca-0073-42c0-98f6-6b072b124696">1.00</ix:nonFraction>. This reset resulted in an aggregate of <ix:nonFraction unitRef="shares" contextRef="i77f0ebf13e6e4a578b9b6ffd815a024e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="ocgn:CommonStockAdditionalSharesOfCommonStockIssuableUponExerciseOfWarrantsBasedOnResetPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfNjA0NzMxMzk5MTA4Mw_51fbf27c-f8fe-4d1a-bee8-c53203e3e8e5">12.6</ix:nonFraction> million additional shares of common stock becoming issuable upon exercise of the Series B Warrants.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Series C Warrants</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Series&#160;C Warrants were exercisable upon issuance for up to <ix:nonFraction unitRef="shares" contextRef="i914cfde7eb234db2ac6c9112d30eadfb_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfNjA0NzMxMzk2MzY5NA_46af1248-51f5-4b91-afb0-67e4121cb8a3">50.0</ix:nonFraction> million shares of common stock at an initial exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib3301d78826140fb96af8db1fc68d531_I20191104" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfNjA0NzMxMzk2MzY4OQ_9cc403a7-6aea-4035-8ae8-8b6b314e7b7a">7.13</ix:nonFraction> per share. Each of the Series&#160;C Warrants was amended pursuant to the Warrant Amendments to permit the Investors, in lieu of making any cash payment otherwise contemplated to be made to the Company upon the exercise of the Series&#160;C Warrant, to elect instead to receive upon such exercise up to <ix:nonFraction unitRef="shares" contextRef="i1153f084349d4b7ea469d4f40aff5141_I20191105" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfNDk0NzgwMjM0ODYxMQ_dd775a4e-c6b8-47d3-b9f7-7a0d81ef63e8">20.0</ix:nonFraction> million shares of common stock.&#160;Prior to the Warrant Amendments, the Series&#160;C Warrants had permitted the exercise without any cash payment of up to <ix:nonFraction unitRef="shares" contextRef="ibca9608a3ab44021be1d03353a57553c_I20191104" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfNDk0NzgwMjM0ODc1NA_dbe61b83-a573-473f-9f82-4e3384f06c77">50.0</ix:nonFraction> million shares of common stock in the event that the volume weighted-average price of the common stock on Nasdaq was less than or equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="i3da044ce503648edbe7ad9e78f55ca78_D20191105-20191105" decimals="2" name="ocgn:ConvertedAdditionalSharesThresholdReleaseTriggerPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfNDk0NzgwMjM0ODg4OA_8dade037-f6ce-44cd-b5cf-f96cc74025d6">1.20</ix:nonFraction> per share on any <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTUzOTMxNjI4MzE0NTk_881a6831-237f-403e-b78d-48afce88aefa">five</span> trading days following the issuance of the Series&#160;C Warrants. The Series C Warrants will expire upon the <ix:nonNumeric contextRef="if254d19519344254a9f50cfcfe386457_D20190101-20191231" format="ixt-sec:durday" name="ocgn:ClassOfWarrantOrRightConditionForExpirationTradingDay" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTUzOTMxNjI4MzE0NjE_140ad7d6-6e05-4c57-a58d-1a1b2b198ee0">45</ix:nonNumeric></span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">th</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;trading day immediately following the earlier to occur of (i)&#160;the date the holder can sell all shares issuable upon exercise of the Series&#160;C Warrants pursuant to Rule&#160;144 without restriction or limitation and without the requirement to be in compliance with Rule&#160;144(c)(1)&#160;and (ii)&#160;October&#160;4, 2020, provided that if such date falls on a day other than a business day or on which trading does not take place on Nasdaq (a &#8220;Holiday&#8221;), the next day that is not a Holiday.</span></div><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="ocgn:ScheduleOfPreMergerFinancingWarrantsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTA5OTUxMTYzMjk2MDk_058eef10-525f-465c-814d-d37794be469e" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the activity of the Pre-Merger Financing Warrants, including the effect of the Warrant Amendments:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:31.479%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.520%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.520%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.520%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.625%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series A Warrants</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series B Warrants</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series C Warrants</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at January 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i27857d6d3d5a42bd93969147f2520cad_I20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfMS0yLTEtMS0xNDcwOA_ad06cc15-9b10-4844-9d08-f4ea70dee04e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i71ce16f5e5214d2780d7f39624f8b29d_I20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfMS00LTEtMS0xNDcxMA_63a5c09f-b5cf-4034-b6ff-93131a552775">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1d0d3793e46440a899ad41a111b2431f_I20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfMS02LTEtMS0xNDcxMg_17644656-c170-4747-b7ed-cdfdcf2824e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfMS04LTEtMS0xNDcxNA_ee01fc4e-d649-4da5-a24e-589d05bf9197">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issued</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1b2b631bda3048ee8c734721295f429a_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="ocgn:ClassOfWarrantOrRightIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfMi0yLTEtMS0xNDcwOA_e1ee5e82-2ca0-4697-b687-fa263a75e86e">8,771,928</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9a4dec58cf3a474a90c3320d94bff77c_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="ocgn:ClassOfWarrantOrRightIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfMi00LTEtMS0xNDcxMA_51072fa5-2540-4344-b440-0bc0f0ab2f3c">20,614,036</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if254d19519344254a9f50cfcfe386457_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="ocgn:ClassOfWarrantOrRightIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfMi02LTEtMS0xNDcxMg_3e2f94dc-b7f7-4dec-9259-701df48705b2">20,000,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="ocgn:ClassOfWarrantOrRightIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfMi04LTEtMS0xNDcxNA_9dffe7ec-299e-46a8-917b-0b28aa814092">49,385,964</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1b2b631bda3048ee8c734721295f429a_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="ocgn:ClassOfWarrantOrRightExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfMy0yLTEtMS0xNDcwOA_19481ba5-a21d-4962-bb72-36aa41ef2e96">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i9a4dec58cf3a474a90c3320d94bff77c_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="ocgn:ClassOfWarrantOrRightExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfMy00LTEtMS0xNDcxMA_8be05a79-5bea-43f4-94f1-371d3c711fac">20,613,036</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="if254d19519344254a9f50cfcfe386457_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="ocgn:ClassOfWarrantOrRightExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfMy02LTEtMS0xNDcxMg_a410daa9-7fdf-439b-adca-f126878be06e">19,999,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="ocgn:ClassOfWarrantOrRightExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfMy04LTEtMS0xNDcxNA_1479a678-98d7-4995-bd96-d6c6cd16dada">40,612,036</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i6745b0e5cb764520ba29b0c6f1b86602_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfNC0yLTEtMS0xNDcwOA_4cf08e64-8a8a-4513-8193-20b37d3093fa">8,771,928</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i77f0ebf13e6e4a578b9b6ffd815a024e_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfNC00LTEtMS0xNDcxMA_c3dd10e7-259f-47b4-a3c0-268db7403dbc">1,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i914cfde7eb234db2ac6c9112d30eadfb_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfNC02LTEtMS0xNDcxMg_29a93a44-e45d-47a4-b816-4218019a7e58">1,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfNC04LTEtMS0xNDcxNA_438e8da4-374d-477f-a72f-afbad2f4f4e9">8,773,928</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i6745b0e5cb764520ba29b0c6f1b86602_I20191231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfNS0yLTEtMS0xNDcwOA_2a50829c-f74e-4ba0-95cd-a82c6f89a0f4">7.13</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i77f0ebf13e6e4a578b9b6ffd815a024e_I20191231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfNS00LTEtMS0xNDcxMA_fcc9e8c3-3a09-4921-ae74-bd040c494622">0.01</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$                      <ix:nonFraction unitRef="usdPerShare" contextRef="i914cfde7eb234db2ac6c9112d30eadfb_I20191231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfNS02LTEtMS0xNDcxMg_7740431e-7e26-4e2e-9a28-6ed27a8a41c7">0.00</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Accounting for the Pre-Merger Financing Warrants</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although the Pre-Merger Financing Warrants were issued on October&#160;4, 2019, the agreement for issuance of the Pre-Merger Financing Warrants was a firm commitment reached between Ocugen and the Investors as part of the Financing SPA upon the closing of the Merger. Therefore, for accounting purposes the issuance date was determined to be the date of the Merger. As of the date of the Merger, the Series&#160;A Warrants and Series C Warrants were classified as equity and the Series&#160;B Warrants were classified as a liability on the consolidated balance sheet.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Series B Warrants were classified as a liability as they did not meet the derivative scope exception related to equity indexation because the Reset Date was triggered on the effective date of a Registration Statement and the timing of when a Registration Statement for the underlying shares is available is not an input in an option pricing model. Series&#160;B Warrants were classified as a derivative liability in the consolidated balance sheet measured at fair value on September 27, 2019 and marked to market at September 30, 2019. Upon the completion of the Reset Period, the Series B Warrants were reassessed and determined to meet the derivative scope exception allowing for equity classification. The Series B Warrants were marked to market a final time as a change in the fair value of a derivative liability and the remaining liability balance was reclassified to equity. Subsequent to the Reset Period, almost all of the Series B Warrants were exercised for shares of common stock. </span></div><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTUzOTMxNjI4Mjg3Mjg_f9e7fe32-3dde-4a8a-9ce0-dc47f6c49865" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a roll-forward of the Series&#160;B Warrant liability:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:83.380%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.620%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at January 1, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i71ce16f5e5214d2780d7f39624f8b29d_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOjcwYzQzNDM0MTdmMDQyNWJiZmI1NjcxYWY3MmY2YTBlL3RhYmxlcmFuZ2U6NzBjNDM0MzQxN2YwNDI1YmJmYjU2NzFhZjcyZjZhMGVfMS0xLTEtMS0w_081bf7fc-e40a-49d1-96b4-227b34d93103">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value at issuance (September&#160;27, 2019)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9a4dec58cf3a474a90c3320d94bff77c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOjcwYzQzNDM0MTdmMDQyNWJiZmI1NjcxYWY3MmY2YTBlL3RhYmxlcmFuZ2U6NzBjNDM0MzQxN2YwNDI1YmJmYjU2NzFhZjcyZjZhMGVfMi0xLTEtMS0w_763e03c9-eebd-4233-829d-229791fc379b">9,387,760</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of embedded derivatives</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9a4dec58cf3a474a90c3320d94bff77c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOjcwYzQzNDM0MTdmMDQyNWJiZmI1NjcxYWY3MmY2YTBlL3RhYmxlcmFuZ2U6NzBjNDM0MzQxN2YwNDI1YmJmYjU2NzFhZjcyZjZhMGVfMy0xLTEtMS0w_43e69d25-b6e2-4037-8c0b-90509986e303">1,867,980</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount reclassified to equity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9a4dec58cf3a474a90c3320d94bff77c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ocgn:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationAmountReclassifiedToEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOjcwYzQzNDM0MTdmMDQyNWJiZmI1NjcxYWY3MmY2YTBlL3RhYmxlcmFuZ2U6NzBjNDM0MzQxN2YwNDI1YmJmYjU2NzFhZjcyZjZhMGVfNC0xLTEtMS00MTE3_3aa55b6e-ee9f-4e5e-9121-0d6d0878550b">11,255,740</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i77f0ebf13e6e4a578b9b6ffd815a024e_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOjcwYzQzNDM0MTdmMDQyNWJiZmI1NjcxYWY3MmY2YTBlL3RhYmxlcmFuZ2U6NzBjNDM0MzQxN2YwNDI1YmJmYjU2NzFhZjcyZjZhMGVfNC0xLTEtMS0w_84cbf107-c16b-4478-a07f-6ec0ede377b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><ix:continuation id="ica11d04ee3b24e98bcb29a82b2ede79e" continuedAt="i11c0bdaae5be4740a5495da8d4c2ba82"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the Series&#160;B Warrants upon issuance was calculated using a Monte Carlo simulation while estimating the stock price during the <ix:nonNumeric contextRef="ia7980383d2e44bc2b50a1d2faf810a91_D20190927-20191231" format="ixt-sec:durday" name="ocgn:ClassOfWarrantOrRightConditionForExpirationTradingDay" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTUzOTMxNjI4MzE0Njk_c363e06a-3de4-4375-8a1b-688a824496b3">45</ix:nonNumeric>-day Reset Period, based on the terms described within the Financing SPA. Key fair value inputs included the starting stock price, expected stock volatility during the <ix:nonNumeric contextRef="i9a4dec58cf3a474a90c3320d94bff77c_D20190101-20191231" format="ixt-sec:durday" name="ocgn:ClassOfWarrantOrRightConditionForExpirationTradingDay" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTUzOTMxNjI4MzE0NjU_28b48fa9-0db5-40f3-aa21-d59bb5ba324e">45</ix:nonNumeric>-day Reset Period, and additional shares issued from escrow. The methodology for measuring fair value was sensitive to the expected stock volatility assumption input mentioned above. The volatility used in the fair value estimate at issuance was <ix:nonFraction unitRef="measurementinput" contextRef="i8c7e388caf954f629bf3e170e216d890_I20191231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfNDk0NzgwMjM1NjA2OQ_2a23d5c8-280f-41ee-b88c-3cd017574995">96.0</ix:nonFraction>%. Inputs used in the valuation are unobservable and are therefore classified as Level 3 fair value inputs. The fair value of the Series B Warrants upon the end of the Reset Period was based on a Black-Scholes valuation model, which is classified as Level 3 in the fair value hierarchy. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Accounting for the Warrant Amendments</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounted for the Warrant Amendments as a modification by assessing whether the modification resulted in an incremental fair value of the warrants. An increase in fair value resulting from the modification may be recognized as expense in the consolidated statements of operations and comprehensive loss, whereas a decrease in fair value is not recognized. The Company determined that the modifications to the Series A Warrants and Series B Warrants were not substantive amendments that would result in an increase in fair value based on a qualitative assessment of the terms of the amendments. The Series C Warrants were determined to substantially modified. The Company estimated the fair value of the Series C Warrants immediately prior to and immediately after the modification and concluded that the fair value of the warrants decreased and therefore there was no incremental fair value to recognize resulting from the modification. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Former Ocugen Warrants</span></div></ix:continuation><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i11c0bdaae5be4740a5495da8d4c2ba82">Prior to 2018, Former Ocugen issued warrants to investors of the Company pursuant to a stockholders' agreement and to <ix:nonFraction unitRef="segment" contextRef="i3b0b2789ee4e45ff8aa700de563ddc85_I20171231" decimals="INF" format="ixt-sec:numwordsen" name="ocgn:NumberOfFormerEmployeesWithWarrants" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTA5OTUxMTYzMjk3NDU_9cc9a4bf-b31b-4a49-bf59-017342eff74c">two</ix:nonFraction> employees of the Company pursuant to their respective employment agreements. As of December 31, 2019 and 2018, <ix:nonFraction unitRef="shares" contextRef="ic2c38d1a38a84e6a82c73b5a98cb3e80_I20181231" decimals="-5" format="ixt:numdotdecimal" name="ocgn:ClassOfWarrantOrRightExercisable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfODc5NjA5MzA2NjQ2NQ_9dfe4d8a-0bca-4e94-85e0-ab4d750506ce"><ix:nonFraction unitRef="shares" contextRef="i86aee3af2c3f4b798c30aaca8de9b337_I20191231" decimals="-5" format="ixt:numdotdecimal" name="ocgn:ClassOfWarrantOrRightExercisable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfODc5NjA5MzA2NjQ2NQ_c5b73fd9-2144-494e-b04f-d0ea9d6055ae">0.9</ix:nonFraction></ix:nonFraction> million warrants to purchase common stock were outstanding and exercisable and had a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i86aee3af2c3f4b798c30aaca8de9b337_I20191231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTUzOTMxNjI4MzE0ODM_c9dc0565-35e5-4468-aff1-76ca2c579c36">5.67</ix:nonFraction> per share. The warrants expire between 2025 and 2027.</ix:continuation> </span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1886"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">11.&#160;<ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF8xNTM5MzE2Mjc5NzE4Mg_11de8e1b-5627-4d6c-9a10-a21321de2aa1" continuedAt="i65ff7f6943b54469ba4fec2ab910856e" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i65ff7f6943b54469ba4fec2ab910856e" continuedAt="ia911163820f14b58b6d237b808b7c7fe">For the years ended December 31, 2019 and 2018, the Company did not recognize any current or deferred income tax expense or benefit due to the current and historical losses incurred by the Company. Losses before income taxes were $<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF83MTQ2ODI1NjI0MzM4_81df8153-8238-4436-aa18-aac2d1b897a7">20.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF83MTQ2ODI1NjI0MzU3_c99ae0fd-ea38-4a97-871d-cdd7c6060399">18.2</ix:nonFraction> million for the years ended December&#160;31, 2019 and 2018, respectively, substantially all of which were incurred in the United States.</ix:continuation></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><ix:continuation id="ia911163820f14b58b6d237b808b7c7fe" continuedAt="i6d157a8b1d4740bbb5cbd1f938738ba3"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. <ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF8xNTM5MzE2Mjc5NzE4Mw_42cb9e06-13c3-4217-948c-08cc10e6e60d" continuedAt="i3fa15d8f64d8419d8b151f051f70c526" escape="true">The significant components of the Company&#8217;s deferred tax assets and liabilities are comprised of the following: </ix:nonNumeric></span></div><div style="margin-top:12pt;margin-bottom:12pt;"><ix:continuation id="i3fa15d8f64d8419d8b151f051f70c526"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:68.175%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.622%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating loss carryforwards</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV8zLTEtMS0xLTE1MzYx_06710877-ce26-491b-b6e3-93886b820e90">31,575,288</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV8zLTMtMS0xLTE1MzY1_e2961160-f1e8-4a89-a3da-ed6f7346fc99">6,864,360</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capital loss carryforwards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV80LTEtMS0xLTE1MzYx_8612719e-9fcf-4d29-ad70-867f743ce417">7,298,052</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV80LTMtMS0xLTE1MzY1_c4c0bab0-08a2-4add-9d61-1b4aceba2e05">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Start-up costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="ocgn:DeferredTaxAssetsStartUpCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV81LTEtMS0xLTE1MzYx_93a50580-6a9e-4ccb-bbf0-228259b65dce">11,234,751</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:zerodash" name="ocgn:DeferredTaxAssetsStartUpCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV81LTMtMS0xLTE1MzY1_068ecd49-5db4-4f35-abc8-5c4b5d731491">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accruals and reserves</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV82LTEtMS0xLTE1MzYx_b8175461-c84f-4515-ae8f-89b68cd8348b">166,611</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV82LTMtMS0xLTE1MzY1_a7036e05-6d37-4e5e-bd19-c7461e0ed537">35,645</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intellectual property amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV83LTEtMS0xLTE1MzYx_d73c1184-c8e9-4b77-9383-a27ca9a55c47">555,352</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV83LTMtMS0xLTE1MzY1_934435d1-b3cc-4593-9632-8f0471354406">121,694</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV84LTEtMS0xLTE1MzYx_2202ce86-4485-40a8-892f-29b3535ce1a2">1,123,100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV84LTMtMS0xLTE1MzY1_a15e6276-0122-499b-8695-fe4f63e99012">993,234</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Convertible debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:zerodash" name="ocgn:DeferredTaxAssetsConvertibleDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV8zLTItMS0xLTI5MjE_cc0a00ec-c706-4287-9e7e-d13857ee4cbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="ocgn:DeferredTaxAssetsConvertibleDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV8zLTQtMS0xLTI5MjQ_25e47d91-9242-4528-88b3-a2372dbe1933">498,236</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV8xMC0xLTEtMS0xNTM2MQ_14a9771f-ac1b-42e3-8084-20f015792960">1,926,677</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV8xMC0zLTEtMS0xNTM2NQ_1ebcb708-20ff-4f65-96fa-05bb19fae417">548,399</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="ocgn:DeferredTaxAssetsLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV80LTItMS0xLTI5MjE_dabca6e1-89a5-42f9-aab0-f9021e25a6d1">96,895</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:zerodash" name="ocgn:DeferredTaxAssetsLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV80LTQtMS0xLTI5MjQ_cad37882-a0ae-491c-8fa9-eedff93506af">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV85LTItMS0xLTI5MjE_68fb3417-f12b-44b6-9aa8-537fb8b65bed">53,976,726</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV85LTQtMS0xLTI5MjQ_0c97d569-e167-498a-81ec-e56d8b5582dc">9,061,568</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV8xMC0yLTEtMS0yOTIx_14d012a6-55d7-4dac-8289-ef8527b800aa">53,877,168</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV8xMC00LTEtMS0yOTI0_0fc44351-5d21-4c60-9794-e555f98b6c0d">9,061,568</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets, net of allowance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV8xMS0yLTEtMS0yOTIx_5ca4c2e1-7bac-4ae8-bab5-49ca3fe6f38c">99,558</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV8xMS00LTEtMS0yOTI0_3e6f9a37-e4f5-4bdc-9053-f9d2c0d980b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liabilities:</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease ROU asset</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV8xNy0xLTEtMS0xNTM5OQ_50ef0f5c-6608-467b-8e99-ac43f3f45327">99,558</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV8xNy0zLTEtMS0xNTQwMg_d37ecd79-f9e5-42de-9611-ef53e0ee9750">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV8xOC0xLTEtMS0xNTM5OQ_c325b337-2b31-40f7-ac69-de376b441172">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV8xOC0zLTEtMS0xNTQwMg_faaaa777-b9c4-4f7e-be15-698dc2be4ca1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As of December&#160;31, 2019 and 2018, the Company had U.S. federal net operating loss ("NOL") carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i3cbe8832ab0843b598d967b9b9032b0d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF81NDk3NTU4MTQzMDY0_0e5c92c5-c24d-4e03-a2cf-ed570af44f4b">113.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3d8219b4b2bc4150b6b1c651c7d324a5_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF83MTQ2ODI1NjI1Mzkw_03d9ee64-00ad-4750-8526-af12d8009d6d">23.7</ix:nonFraction>&#160;million, respectively, which may be available to offset future income tax liabilities. The Tax Cut and Jobs Act, which was enacted in December 2017, will generally allow federal losses generated after 2017 to be carried over indefinitely, but will generally limit the NOL deduction to the lesser of the NOL carryover or 80% of a corporation&#8217;s taxable income. In addition, there will be no carryback for losses generated after 2017. Losses generated prior to 2018 will generally be deductible to the extent of the lesser of a corporation&#8217;s NOL carryover or 100% of a corporation&#8217;s taxable income and be available for twenty years from the period the loss was generated. The Company has federal NOLs generated after 2017 of $<ix:nonFraction unitRef="usd" contextRef="i3cbe8832ab0843b598d967b9b9032b0d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF83MTQ2ODI1NjI1NDU2_e3cb3b89-0c06-4058-a6eb-a5ca4f28338f">61.2</ix:nonFraction> million, which do not expire. The federal NOLs generated prior to 2018 of $<ix:nonFraction unitRef="usd" contextRef="i3cbe8832ab0843b598d967b9b9032b0d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF83MTQ2ODI1NjI1NDM2_fc1ae006-29ad-4aeb-8e44-10705007bf81">52.4</ix:nonFraction> million will expire at various dates through 2037. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As of December&#160;31, 2019 and 2018, the Company also had U.S. state NOL carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i45e1ee8f0a174a99b058fcc427e9def5_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF81NDk3NTU4MTQzMTAx_24fb0c61-641a-4ebb-b78e-fde297c32a27">112.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i10ef3ad5f41f48c39073eca93c89a51d_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF83MTQ2ODI1NjI1NDEz_00c18825-1e19-4b48-9128-64d02ea18dba">23.7</ix:nonFraction>&#160;million, respectively, which may be available to offset future income tax liabilities and expire at various dates through 2039. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As of December&#160;31, 2019 and 2018, the Company has federal tax credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i3cbe8832ab0843b598d967b9b9032b0d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF83MTQ2ODI1NjMwMjEx_3e244846-a429-4016-9c5e-d1794ff8312a">1.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3d8219b4b2bc4150b6b1c651c7d324a5_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF83MTQ2ODI1NjMwMjY2_dc0c28f6-ac9f-4d4b-8c42-e1b1a7abe27f">0.8</ix:nonFraction> million, respectively, which are available to offset future federal tax liabilities which expire at various dates through 2039. As of December&#160;31, 2019 and 2018, the Company has state tax credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i45e1ee8f0a174a99b058fcc427e9def5_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF83MTQ2ODI1NjMwMTcz_a969b1ca-e526-45b2-9446-85877d58f893">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i10ef3ad5f41f48c39073eca93c89a51d_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF83MTQ2ODI1NjMwMTg3_f8d30dad-d3df-4ff5-b3d9-e1c650645e19">0.1</ix:nonFraction>&#160;million, respectively, which are available to reduce future tax liabilities which expire at various dates through 2034. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company has recorded a full valuation allowance against its net deferred tax assets as of December&#160;31, 2019 and 2018 because the Company has determined that is it more likely than not that these assets will not be fully realized due to the Company's history of operating losses and lack of available evidence supporting future taxable income. The Company experienced a net change in valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF81NDk3NTU4MTQzMTgw_9f39e4ec-cba4-474e-aa46-cd92361482e3">44.8</ix:nonFraction> million during the year ended December 31, 2019, primarily related to the increase in NOL carryforwards. The increase in the federal and state NOL carryforwards during the year ended December 31, 2019 was primarily due to the acquired NOL carryforwards as a result of the Merger. </span></div><div style="text-align:justify;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Under the provisions of the IRC, the NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Utilization of U.S. federal and state operating loss and tax credit carryforwards may be subject to a substantial annual limitation under Section 382 and Section 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of NOL and tax credit carryforwards that can be utilized annually to offset future taxable income and tax liabilities, respectively. The Company acquired a significant amount of federal and state NOL carryforwards and federal and state tax credit carryforwards as a result of the Merger. The Company </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9e9cab2d4c4f4a33b2d90ea1e0c3f979_1907">Table of Contents</a></span></div></div><ix:continuation id="i6d157a8b1d4740bbb5cbd1f938738ba3" continuedAt="if5e79279e33143708376e3cad0c33c66"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">has not yet conducted a comprehensive study to assess whether a change of ownership has occurred, or whether there have been multiple ownership changes since its formation. Any limitation may result in expiration of a portion of the NOL carryforward or tax credit carryforwards before utilization, which would be offset by a change in the Company's valuation allowance. Further, until a study is completed by the Company and any limitation is known, no amounts are being presented as an uncertain tax position. </span></div><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF8xMDk5NTExNjMzMTEyNQ_403b07f1-1882-4913-b828-1cbcc0c63b37" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The reconciliation of federal statutory income tax to the Company's provision for income taxes is as follows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:68.175%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.622%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected provision at statutory rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6ODI3MTYzZmI0NGRjNDVkMTk2NjAyYWNlMTNlYzIzMDYvdGFibGVyYW5nZTo4MjcxNjNmYjQ0ZGM0NWQxOTY2MDJhY2UxM2VjMjMwNl8yLTItMS0xLTMwNTc_bb2a505a-2223-4ee4-91da-bf1103fe818e">21.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6ODI3MTYzZmI0NGRjNDVkMTk2NjAyYWNlMTNlYzIzMDYvdGFibGVyYW5nZTo4MjcxNjNmYjQ0ZGM0NWQxOTY2MDJhY2UxM2VjMjMwNl8yLTQtMS0xLTMwNjA_69aecba2-0ee7-4c39-bda8-da76ae403773">21.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State tax - net of federal benefit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6ODI3MTYzZmI0NGRjNDVkMTk2NjAyYWNlMTNlYzIzMDYvdGFibGVyYW5nZTo4MjcxNjNmYjQ0ZGM0NWQxOTY2MDJhY2UxM2VjMjMwNl8zLTItMS0xLTMwNTc_0ba4c64d-a0a9-439b-ba2c-3670b530db3b">5.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6ODI3MTYzZmI0NGRjNDVkMTk2NjAyYWNlMTNlYzIzMDYvdGFibGVyYW5nZTo4MjcxNjNmYjQ0ZGM0NWQxOTY2MDJhY2UxM2VjMjMwNl8zLTQtMS0xLTMwNjA_bd927b7a-1525-4f8a-b3ac-bc18f4cc2f46">7.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6ODI3MTYzZmI0NGRjNDVkMTk2NjAyYWNlMTNlYzIzMDYvdGFibGVyYW5nZTo4MjcxNjNmYjQ0ZGM0NWQxOTY2MDJhY2UxM2VjMjMwNl80LTItMS0xLTMwNTc_3b6d7530-1d8c-4f3a-83f2-a4330426a20d">3.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6ODI3MTYzZmI0NGRjNDVkMTk2NjAyYWNlMTNlYzIzMDYvdGFibGVyYW5nZTo4MjcxNjNmYjQ0ZGM0NWQxOTY2MDJhY2UxM2VjMjMwNl80LTQtMS0xLTMwNjA_691d1c23-9020-4cc5-a485-93e0b8edda41">2.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Permanent differences</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="number" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="3" name="ocgn:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6ODI3MTYzZmI0NGRjNDVkMTk2NjAyYWNlMTNlYzIzMDYvdGFibGVyYW5nZTo4MjcxNjNmYjQ0ZGM0NWQxOTY2MDJhY2UxM2VjMjMwNl81LTEtMS0xLTE1NDM0_b7b4b2e2-96a1-4442-bd51-0200845bdedb">8.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="number" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="3" name="ocgn:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6ODI3MTYzZmI0NGRjNDVkMTk2NjAyYWNlMTNlYzIzMDYvdGFibGVyYW5nZTo4MjcxNjNmYjQ0ZGM0NWQxOTY2MDJhY2UxM2VjMjMwNl81LTMtMS0xLTE1NDM0_d7cbd02f-93ff-49d5-b50b-9f8333ae9d74">0.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6ODI3MTYzZmI0NGRjNDVkMTk2NjAyYWNlMTNlYzIzMDYvdGFibGVyYW5nZTo4MjcxNjNmYjQ0ZGM0NWQxOTY2MDJhY2UxM2VjMjMwNl82LTEtMS0xLTE1NDM0_273d796b-19df-4f0d-b7a4-f5701560b365">2.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6ODI3MTYzZmI0NGRjNDVkMTk2NjAyYWNlMTNlYzIzMDYvdGFibGVyYW5nZTo4MjcxNjNmYjQ0ZGM0NWQxOTY2MDJhY2UxM2VjMjMwNl82LTMtMS0xLTE1NDM0_e0381f35-ae93-40e4-aa80-4581d47a94f6">0.0</ix:nonFraction></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="number" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6ODI3MTYzZmI0NGRjNDVkMTk2NjAyYWNlMTNlYzIzMDYvdGFibGVyYW5nZTo4MjcxNjNmYjQ0ZGM0NWQxOTY2MDJhY2UxM2VjMjMwNl83LTEtMS0xLTE1NDM0_82129676-6104-4391-a696-da83ac080376">24.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="number" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6ODI3MTYzZmI0NGRjNDVkMTk2NjAyYWNlMTNlYzIzMDYvdGFibGVyYW5nZTo4MjcxNjNmYjQ0ZGM0NWQxOTY2MDJhY2UxM2VjMjMwNl83LTMtMS0xLTE1NDM0_7192528f-48cf-4522-849f-4fb2c60a51e0">29.9</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total provision for income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6ODI3MTYzZmI0NGRjNDVkMTk2NjAyYWNlMTNlYzIzMDYvdGFibGVyYW5nZTo4MjcxNjNmYjQ0ZGM0NWQxOTY2MDJhY2UxM2VjMjMwNl84LTEtMS0xLTE1NDM0_cde20721-62e5-4d0f-ab89-358704c47d76">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6ODI3MTYzZmI0NGRjNDVkMTk2NjAyYWNlMTNlYzIzMDYvdGFibGVyYW5nZTo4MjcxNjNmYjQ0ZGM0NWQxOTY2MDJhY2UxM2VjMjMwNl84LTMtMS0xLTE1NDM0_23d394df-46c1-44fc-a4c3-710cbba5d971">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF8xMDk5NTExNjMzMTEyNg_1a6af7b3-dcf7-4807-92b5-979bbd6b2aed" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:83.380%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.620%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross unrecognized tax benefits as of December 31, 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MGMzOTNjODlhMGM1NDZhOWE5Zjg2ODFkNTg0NTU2ZmMvdGFibGVyYW5nZTowYzM5M2M4OWEwYzU0NmE5YTlmODY4MWQ1ODQ1NTZmY18xLTEtMS0xLTE1NDc5_3bfa8071-13e9-48bb-a29e-92fb7a700838">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions for tax positions taken in a prior year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MGMzOTNjODlhMGM1NDZhOWE5Zjg2ODFkNTg0NTU2ZmMvdGFibGVyYW5nZTowYzM5M2M4OWEwYzU0NmE5YTlmODY4MWQ1ODQ1NTZmY18yLTEtMS0xLTE1NDc5_57d645f8-4996-4f4e-9af5-8309fafe11d5">303,050</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions for tax positions taken in the current year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MGMzOTNjODlhMGM1NDZhOWE5Zjg2ODFkNTg0NTU2ZmMvdGFibGVyYW5nZTowYzM5M2M4OWEwYzU0NmE5YTlmODY4MWQ1ODQ1NTZmY18zLTEtMS0xLTE1NDc5_032656a0-f025-4660-ae67-192cb8b0d3ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reductions for tax positions taken in the prior year due to settlement</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MGMzOTNjODlhMGM1NDZhOWE5Zjg2ODFkNTg0NTU2ZmMvdGFibGVyYW5nZTowYzM5M2M4OWEwYzU0NmE5YTlmODY4MWQ1ODQ1NTZmY180LTEtMS0xLTE1NDc5_9a0ae393-6ddb-49dc-9545-1684403621d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reductions for tax positions taken in the prior year due to statutes lapsing</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MGMzOTNjODlhMGM1NDZhOWE5Zjg2ODFkNTg0NTU2ZmMvdGFibGVyYW5nZTowYzM5M2M4OWEwYzU0NmE5YTlmODY4MWQ1ODQ1NTZmY181LTEtMS0xLTE1NDc5_cee3cd0a-7807-48ff-a1a8-3f18c101b479">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross unrecognized tax benefits as of December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MGMzOTNjODlhMGM1NDZhOWE5Zjg2ODFkNTg0NTU2ZmMvdGFibGVyYW5nZTowYzM5M2M4OWEwYzU0NmE5YTlmODY4MWQ1ODQ1NTZmY182LTEtMS0xLTE1NDc5_8675f73f-2bc3-4a97-9f61-97715192866a">303,050</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The uncertain tax positions giving rise to the unrecognized tax benefits of $<ix:nonFraction unitRef="usd" contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF83MTQ2ODI1NjMwMDQ2_4ed8090f-b587-4556-b199-b06442664eeb">0.3</ix:nonFraction>&#160;million at December&#160;31, 2019 relate to the timing of certain income and deductions for federal income tax purposes taken by Histogenics prior to the Merger. The reversal of unrecognized tax benefits would not have any impact on the effective tax rate in future periods and is not expected to create cash tax liability.</span></div></ix:continuation><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"><ix:continuation id="if5e79279e33143708376e3cad0c33c66">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In a normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The Company&#8217;s tax years are still open under status from 2016 to present.</ix:continuation> </span></div><div id="i9e9cab2d4c4f4a33b2d90ea1e0c3f979_91"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">12.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV85MS9mcmFnOmMxOGFlZTBiMGE5OTRhNzE5NjUzNjEzOGYxZGYwYWY3L3RleHRyZWdpb246YzE4YWVlMGIwYTk5NGE3MTk2NTM2MTM4ZjFkZjBhZjdfMTA5OTUxMTYzMDI2MDI_7c25f05d-7e14-4ec9-8e20-d8ff40d9018d" continuedAt="if1bd72a5f15b463db13b39472929197d" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="if1bd72a5f15b463db13b39472929197d">On March&#160;26, 2020, the Company borrowed an additional $<ix:nonFraction unitRef="usd" contextRef="i1e36ccdb3dcd46a4ba0bf2a92174d054_D20200326-20200326" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV85MS9mcmFnOmMxOGFlZTBiMGE5OTRhNzE5NjUzNjEzOGYxZGYwYWY3L3RleHRyZWdpb246YzE4YWVlMGIwYTk5NGE3MTk2NTM2MTM4ZjFkZjBhZjdfNzE0NjgyNTYwNTM2Mg_c22567c8-07d9-445f-9a49-7a80a743fc57">0.5</ix:nonFraction>&#160;million under the terms and conditions of the EB-5 Loan Agreement. Outstanding borrowings pursuant to the EB-5 Program, including accrued interest, become due upon the seventh anniversary of the final disbursement. Following this borrowing, total principal outstanding under the EB-5 Loan Agreement is $<ix:nonFraction unitRef="usd" contextRef="ie83135b281cb4e26b25b62e6bb7f951f_I20200326" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV85MS9mcmFnOmMxOGFlZTBiMGE5OTRhNzE5NjUzNjEzOGYxZGYwYWY3L3RleHRyZWdpb246YzE4YWVlMGIwYTk5NGE3MTk2NTM2MTM4ZjFkZjBhZjdfNzE0NjgyNTYwNTM0NA_84a79b7e-a636-417f-8dd6-3a0f7848e090">1.5</ix:nonFraction>&#160;million.</ix:continuation></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-25</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ocgn-20191231x10kxex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i97ca8b5dad20457aab2c11347344e360_21"></div><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 4.1</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">DESCRIPTION OF REGISTRANT&#8217;S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF</font></div><div style="text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="text-indent:45.35pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ocugen, Inc. (the &#8220;Company&#8221;) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended&#58; our common stock, par value $0.01 per share.  As used in this summary, the terms &#8220;Ocugen,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; refer to Ocugen, Inc.</font></div><div style="text-indent:45.35pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is a description of the material terms and provisions relating to our common stock.  The following description is a summary that is not complete and is subject to and qualified in its entirety by reference to our Sixth Amended and Restated Certificate of Incorporation (the &#8220;Certificate of Incorporation&#8221;) and our amended and restated bylaws (the &#8220;Bylaws&#8221;), and to provisions of the Delaware General Corporation Law (the &#8220;DGCL&#8221;).  Copies of our Certificate of Incorporation and our Bylaws, each of which may be amended from time to time, are included as exhibits to the Annual Report on Form 10-K to which this description is an exhibit.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">General</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our authorized capital stock consists of 210,000,000 shares, 200,000,000 of which are designated as common stock with a par value of $0.01 per share and 10,000,000 of which are designated as preferred stock with a par value of $0.01.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Common Stock</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Shares of our common stock have the following rights, preferences and privileges&#58;</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Voting Rights</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Each holder of common stock is entitled to one vote per share on all matters submitted to a vote of stockholders.  We have not provided for cumulative voting in the election of directors.  Accordingly, the holders of a majority of the shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election.  Except as otherwise required by law, holders of our common stock are not entitled to vote on any amendment to the Certificate of Incorporation that relates solely to the terms of an outstanding series of preferred stock if the holders of such series are entitled to vote thereon pursuant to the Certificate of Incorporation or any certificate of designation.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Dividends</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to preferences that may apply to shares of preferred stock outstanding at the time, the holders of outstanding shares of our common stock are entitled to receive dividends out of assets legally available at the times and in the amounts that our board of directors may determine from time to time.  The timing, declaration, amount and payment of future dividends will depend on our financial condition, earnings, capital requirements and debt service obligations, as well as legal requirements, regulatory constraints, industry practice and other factors that its board of directors deems relevant.  Our board of directors will make all decisions regarding our payment of dividends from time to time in accordance with applicable law.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Liquidation</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon our liquidation, dissolution or winding-up, the holders of common stock are entitled to share ratably in all assets remaining after payment of all liabilities and the liquidation preferences of any outstanding preferred stock. </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">No Preemptive or Similar Rights</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The holders of our common stock do not have any preemptive rights or preferential rights to subscribe for shares of our capital stock or any other securities.  Our common stock is not subject to any redemption or sinking fund provisions.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Transfer Agent and Registrar</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The transfer agent and registrar for our common stock is Broadridge Corporate Issuer Solutions, Inc.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Listing</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our common stock is listed on The NASDAQ Capital Market under the symbol &#8220;OCGN.&#8221;  </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Preferred Stock</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to our Certificate of Incorporation, our board of directors has the authority, without further approval by our stockholders, to designate and issue up to 10,000,000 shares of preferred stock in one or more series.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  Our board of directors has provided for the issuance of Series A Convertible Preferred Stock (&#8220;Series A Preferred&#8221;) pursuant to the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the &#8220;Certificate of Designation&#8221;).  Up to 30,000 shares are designated as Series A Preferred.  Holders of Series A Preferred are entitled to receive dividends on Series A Preferred equal (on an as-converted to common stock basis) to and in the same form as dividends actually paid on shares of common stock, when and if such dividends are paid.  Except as provided by law, the Series A Preferred has no voting rights.  Upon our liquidation or dissolution, holders of Series A Preferred will be entitled to receive the same amount that a holder of common stock would receive if the preferred stock were fully converted to common stock.  Shares of Series A Preferred are convertible to common stock at the option of the holder, on the terms and subject to the conditions set forth in the Certificate of Designation.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Anti-Takeover Effects of Provisions of Our Certificate of Incorporation, our Bylaws and Delaware Law</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Various provisions contained in the Certificate of Incorporation, the Bylaws and Delaware law could delay, deter or discourage some transactions involving an actual or potential change in control of Ocugen, including acquisition of us by means of a tender offer&#59; acquisition of us by means of a proxy contest or otherwise&#59; or removal of our incumbent officers and directors.  These provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids.  These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors.  We believe that the benefits of increased protection of its potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Certificate of Incorporation and Bylaws</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Preferred Stock</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Certificate of Incorporation authorizes our board of directors to establish one or more series of preferred stock and to determine, with respect to any series of preferred stock, the preferences, rights and other terms of such series.  Under this authority, our board of directors could create and issue a series of preferred stock with rights, preferences or restrictions that have the effect of discriminating against an existing or prospective holder of our capital stock as a result of such holder beneficially owning or commencing a tender or exchange offer for a substantial amount of common stock.  One of the effects of authorized but unissued and unreserved shares of preferred stock may be to render it more difficult for, or to discourage an attempt by, a potential acquiror to obtain control of us by means of a merger, tender or exchange offer, proxy contest or otherwise, and thereby protect the </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">continuity of the company&#8217;s management.  The issuance of shares of preferred stock may have the effect of delaying, deferring or preventing a change in control of us without any action by our stockholders.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Classified Board</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Certificate of Incorporation and the Bylaws provide that the directors, other than those who may be elected by the holders of any series of preferred stock under specified circumstances, shall be divided into three classes.  Such classes shall be as nearly equal in number of directors as reasonably possible.  The election of the classes is staggered, such that only approximately one third of our board of directors is up for election in any given year.  Each director shall serve for a term ending on the third annual meeting of stockholders following the annual meeting of stockholders at which such director was elected.  Each director shall serve until such director&#8217;s successor shall have become duly elected and qualified, or until such director&#8217;s prior death, resignation, retirement, disqualification or other removal.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Election of Directors</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Certificate of Incorporation does not provide for cumulative voting in the election of directors.  Accordingly, the holders of a majority of the shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election.  </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Board Vacancies&#59; Removal</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Certificate of Incorporation provides that any vacancy occurring on our board of directors will be filled by a majority of directors then in office, even if less than a quorum.  The Certificate of Incorporation also provides that our directors can only be removed for cause upon the vote of more than two-thirds of the votes entitled to be cast by holders of all the then-outstanding shares of capital stock, voting together as a single class.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Special Meetings of Stockholders&#59; Number of Directors and No Action by Written Consent of Stockholders</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Certificate of Incorporation and the Bylaws provide that only the board of directors, the chairman of the board of directors or the president may call a special meeting of our stockholders.  The Bylaws provide that the authorized number of directors be changed only by resolution of the board of directors.  The Bylaws provide that the stockholders may act only duly called annual or special meeting and no action may be effected by written consent.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Advance Notification of Shareholder Nominations and Proposals</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Bylaws establish advance notice procedures with respect to shareholder proposals and the nomination of persons for election as directors, other than nominations made by or at the direction of our board of directors.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Amendments to Certificate of Incorporation and Bylaws</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The amendment of any of the above provisions (except for the provision making it possible for the board of directors to issue undesignated preferred stock) and the exclusive form and indemnification provisions described below, would require approval by a stockholder vote by the holders of at least a two thirds of the voting power of the then outstanding voting stock.  </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Delaware Anti-Takeover Statute</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are subject to Section 203 of the DGCL which prohibits persons deemed &#8220;interested stockholders&#8221; from engaging in a &#8220;business combination&#8221; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies.  Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">corporation&#8217;s voting stock.  Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder.  The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by our board of directors, such as discouraging takeover attempts that might result in a premium over the market price of our common stock. </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Exclusive Jurisdiction for Certain Actions </font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Certificate of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall, to the fullest extent permitted by law, be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (iii) any action arising pursuant to any provision of the DGCL, or (iv) any action asserting a claim governed by the internal affairs doctrine.  This exclusive forum provision would not apply to suits brought to enforce any liability or duty created by the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, or any other claim for which the federal courts have exclusive jurisdiction.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The enforceability of similar federal court choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find this type of provision to be inapplicable or unenforceable.  If a court were to find either of the choice of forum provisions contained in the Certificate of Incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees and result in increased costs for investors to bring a claim.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Indemnification</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Certificate of Incorporation includes provisions that limit the liability of our directors for monetary damages for breach of their fiduciary duty as directors, except for liability that cannot be eliminated under the DGCL.  Accordingly, our directors will not be personally liable for monetary damages for breach of their fiduciary duty as directors, except for liabilities&#58;</font></div><div style="text-indent:-18pt;padding-left:63pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">for any breach of the director&#8217;s duty of loyalty to us or our stockholders&#59;  </font></div><div style="text-indent:-18pt;padding-left:63pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law&#59;</font></div><div style="text-indent:-18pt;padding-left:63pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">for unlawful payments of dividends or unlawful stock repurchases or redemptions, as provided under Section 174 of the DGCL&#59; or</font></div><div style="text-indent:-18pt;padding-left:63pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">for any transaction from which the director derived an improper personal benefit.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any amendment or repeal of these provisions will require the approval of the holders of shares representing at least two-thirds of the shares entitled to vote in the election of directors, voting as one class.  The Certificate of Incorporation and Bylaws provide that we will indemnify our directors and officers to the fullest extent permitted by Delaware law.  The Certificate of Incorporation and Bylaws also permit us to purchase insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions as its officer, director, employee or agent, regardless of whether Delaware law would permit indemnification.  We have entered into separate indemnification agreements with our directors and executive officers that require us, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors and to advance their expenses incurred as a result of any proceeding against them as to which they could be indemnified.  We believe that the limitation of liability provision in the Certificate of Incorporation and the indemnification </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">agreements facilitate our ability to continue to attract and retain qualified individuals to serve as directors and officers. </font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The limitation of liability and indemnification provisions in the Certificate of Incorporation and Bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties.  They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might benefit us and our stockholders.  A stockholder&#8217;s investment may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.29
<SEQUENCE>3
<FILENAME>ocgn-20191231x10kxex10.htm
<DESCRIPTION>EX-10.29
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i9881133d512e43beb6e36ab58d2a2cff_29"></div><div style="height:72pt;width:100%;"><div style="text-indent:72pt;"><font><br></font></div></div><div style="text-align:right;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.29</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OCUGEN, INC.</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">STOCK OPTION AGREEMENT</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">THIS STOCK OPTION AGREEMENT (&#8220;Agreement&#8221;) is made and entered into as of the ___ day of ____________, 20___ (the &#8220;Grant Date&#8221;), by and between Ocugen, Inc., a Delaware corporation (the &#8220;Company&#8221;), and ________________, an individual (the &#8220;Optionee&#8221;).</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">W I T N E S S E T H&#58;</font></div><div style="text-indent:36pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">WHEREAS,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> pursuant to the Ocugen, Inc. 2019 Equity Incentive Plan, as amended (the &#8220;Plan&#8221;), the Company desires to grant to Optionee, and Optionee desires to accept, an option to purchase shares of the common stock of the Company, par value $.01 per share (the &#8220;Common Stock&#8221;), upon the terms and conditions set forth in this Agreement and the Plan.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOW, THEREFORE,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the parties hereto agree as follows&#58;</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"> Definitions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Plan.  </font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Grant</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  Subject to the terms hereof, Optionee is hereby awarded an option (the &#8220;Option&#8221;) to purchase _____________________  shares of Common Stock (the &#8220;Option Shares&#8221;) at a price of _____ per share (the &#8220;Option Price&#8221;), which price has been determined by the Company&#8217;s Board of Directors (&#8220;Board&#8221;) to be the Fair Market Value of the Common Stock as of the Grant Date&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, that if the Optionee then owns, directly or by attribution under Section 424(b) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), shares in the Company and&#47;or its Affiliates that represents ten percent (10%) or more of the total combined voting power of all classes of stock of the Company and each Affiliate, then the Option Price shall be at least one hundred ten percent (110%) of the Fair Market Value per share on the Grant Date. The Option is intended to qualify as an incentive stock option (&#8220;ISO&#8221;) within the meaning of Section 422 of the Code.  The Option Price of the Option Shares shall be paid at the time of exercise, as provided in Section 3 hereof.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Exercise</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.</font></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)&#160;Except as specifically provided otherwise herein or in the Plan, the Option will become exercisable in accordance with the following schedule subject to Optionee&#8217;s continuous employment by the Company or provision of services to the Company and&#47;or its Affiliates following the Grant Date&#58; </font></div><div style="padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Option Shares shall vest in three equal annual installments on each anniversary of the Grant Date over the three (3) year period following the Grant Date.</font></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)&#160;The Option may be exercised in whole or in part in accordance with this Section 3 by delivering to the Secretary of the Company (1) a written notice specifying the number of shares to be purchased, and (2) payment in full of the Option Price, together with the amount, if any, deemed necessary by the Company to enable it to satisfy any income tax withholding obligations with respect to the exercise (unless other arrangements, acceptable to the Company, are made for the satisfaction of such withholding obligations).  The Option Price may be paid in cash, by check, or as otherwise provided in the Plan.  </font></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)&#160;The Option shall not be exercisable after ten (10) years from the Grant Date (or, five (5) years from the Grant Date if on such date the Optionee owns, directly or by attribution under Section 424(b) of the Code, shares in the Company and&#47;or its Affiliates that represents ten percent (10%) or more of the total combined voting power of all classes of stock of the Company and each Affiliate). </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-indent:72pt;"><font><br></font></div></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4. &#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  Unless sooner terminated, to the extent not sooner exercised, the Option will terminate ten (10) years from the Grant Date.  If Optionee ceases to be employed by the Company or ceases to provide services to the Company or any Affiliate for any reason other than death or total disability (within the meaning of the Plan), then, unless sooner terminated under the terms hereof, the Option will terminate three (3) months after the effective date of Optionee&#8217;s termination of employment or services&#59; provided, however, that if the Company or any of its Affiliates terminates the Optionee&#8217;s employment or services for cause, the Option will terminate immediately upon the effective date of Optionee&#8217;s termination of employment or services.  If Optionee&#8217;s employment or services are terminated by reason of Optionee&#8217;s death or total disability, then, unless sooner terminated under the terms hereof, the Option will terminate on the date one (1) year after the date of such termination of employment or services.  </font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Change in Control</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  In the event of a Change in Control, all Option Shares shall automatically vest.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Rights as Stockholder</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  No shares of Common Stock shall be sold or delivered hereunder until full payment for such shares has been made.  Optionee shall have no rights as a stockholder with respect to any Option Shares until a stock certificate (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent) for such shares is issued to him or her.  Except as otherwise provided herein, no adjustment shall be made for dividends or distributions of other rights for which the record date is prior to the date such stock certificate is issued.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Nontransferability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  The Option is not assignable or transferable except by will or the laws of descent and distribution.  During Optionee&#8217;s lifetime, the option may be exercised only by Optionee or, in the event of Optionee&#8217;s total disability, Optionee&#8217;s legal representative.  </font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Securities Restrictions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  If a registration statement is not in effect under the Securities Act of 1933 or any applicable state securities laws with respect to the Option Shares, the Board may require, as a condition of exercise of the Option that the Optionee represent, in writing, that that (a) such Option Shares are being purchased for investment and not for distribution or resale, (b) the Optionee has been advised and understands that (i) the Option Shares have not been registered under the Act and are &#8220;restricted securities&#8221; within the meaning of Rule 144 under the Act and are subject to restrictions on transfer and (ii) the Company is under no obligation to register the Option Shares under the Act or to take any action which would make available to the Optionee any exemption from such registration, (c) such Option Shares may not be transferred without compliance with all applicable federal and state securities laws, and (d) an appropriate legend referring to the foregoing restrictions may be endorsed on the certificates.  </font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">No Right to Continued Employment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  Nothing in this Agreement shall give Optionee any right to continued employment by the Company and&#47;or its Affiliates or interfere in any way with the right of the Company or any Affiliate thereof to terminate the employment of Optionee.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Provisions of Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  The provisions of the Plan shall govern if and to the extent that there are inconsistencies between those provisions and the provisions hereof.  Optionee acknowledges receipt of a copy of the Plan prior to the execution of this Agreement.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Administration</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  The Board or the committee appointed by the Board to administer the Plan, if any, will have full power and authority to interpret and apply the provisions of this Agreement and act on behalf of the Company in connection with this Agreement, and the decision of said Board or committee as to any matter arising under this Agreement shall be binding and conclusive as to all persons.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Certain Dispositions of Option Shares</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Optionee acknowledges that the tax rules described in Section 421(a) of the Code will not apply to any Option Shares issued to the Optionee pursuant to the exercise of this Option if such Option Shares are disposed of either (a) within two (2) years of the Grant Date, or (b) within one (1) year of the issuance of such Option Shares to the Optionee upon exercise (herein, a &#8220;Disqualifying Disposition&#8221;). </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-indent:72pt;"><font><br></font></div></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Optionee shall give prompt, written notice to the Company&#8217;s Board of Directors of any Disqualifying Disposition.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Miscellaneous</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.</font></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)&#160;This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective heirs, legal representatives, successors and permitted assigns.</font></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)&#160;This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without regard to its conflicts of laws principles.</font></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)&#160;This Agreement and the Plan constitute the entire agreement between the parties with respect to the subject matter hereof and may not be modified except by written instrument executed by the parties.</font></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)&#160;This Agreement may be executed in counterparts, each of which shall be deemed a complete original.</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#91;Execution page follows&#93;</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-indent:72pt;"><font><br></font></div></div><div style="text-indent:36pt;text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">IN WITNESS WHEREOF,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> this Agreement has been executed as of the date first above written.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">                                                                        COMPANY&#58;</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">                                                                        OCUGEN, INC.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">                                                                        _____________________________</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">                                                                       </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OPTIONEE&#58;</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">                                                                        _________________________________________</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">                                                                        Printed Name&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">                                                             </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.30
<SEQUENCE>4
<FILENAME>ocgn-20191231x10kxex101.htm
<DESCRIPTION>EX-10.30
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i9665d7fede06431fa5f9d862504b5f67_29"></div><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.30</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OCUGEN, INC.</font></div><div style="text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">STOCK OPTION AGREEMENT</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">THIS STOCK OPTION AGREEMENT (&#8220;Agreement&#8221;) is made and entered into as of _____________ (the &#8220;Grant Date&#8221;), by and between Ocugen, Inc., a Delaware corporation (the &#8220;Company&#8221;), and ________________, an individual (the &#8220;Optionee&#8221;).</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">W I T N E S S E T H&#58;</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">WHEREAS,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> pursuant to the Ocugen, Inc. 2019 Equity Incentive Plan (the &#8220;Plan&#8221;), the Company desires to grant to Optionee, and Optionee desires to accept, an option to purchase shares of the common stock of the Company, par value $.01 per share (the &#8220;Common Stock&#8221;), upon the terms and conditions set forth in this Agreement and the Plan.</font></div><div style="text-indent:36pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOW, THEREFORE,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the parties hereto agree as follows&#58;</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Definitions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Plan.  </font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Grant</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  Subject to the terms hereof, Optionee is hereby awarded an option (the &#8220;Option&#8221;) to purchase ________________  shares of Common Stock (the &#8220;Option Shares&#8221;) at a price of _____ per share (the &#8220;Option Price&#8221;), which price has been determined by the Company&#8217;s Board of Directors (&#8220;Board&#8221;) to be the Fair Market Value of the Common Stock as of the Grant Date. The Option is not intended to qualify as an incentive stock option within the meaning of Section 422 of the Internal Revenue Code.  The Option Price of the Option Shares shall be paid at the time of exercise, as provided in Section 3 hereof.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Exercise</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.</font></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)&#160;Except as specifically provided otherwise herein or in the Plan, the Option will become exercisable in accordance with the following schedule subject to Optionee&#8217;s continuous employment by the Company or provision of services to the Company and&#47;or its Affiliates following the Grant Date&#58; </font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Option Shares shall vest in full on the one-year anniversary of the Grant Date.</font></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)&#160;The Option may be exercised in whole or in part in accordance with this Section 3 by delivering to the Secretary of the Company (1) a written notice specifying the number of shares to be purchased, and (2) payment in full of the Option Price, together with the amount, if any, deemed necessary by the Company to enable it to satisfy any income tax withholding obligations with respect to the exercise (unless other arrangements, acceptable to the Company, are made for the satisfaction of such withholding obligations).  The Option Price may be paid in cash, by check, or as otherwise provided in the Plan.  </font></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)&#160;The Option shall not be exercisable after ten (10) years from the Grant Date. </font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  Unless sooner terminated, to the extent not sooner exercised, the Option will terminate ten (10) years from the Grant Date.  If Optionee ceases to be employed by the Company or ceases to provide services to the Company or any Affiliate for any reason other than death or total disability (within the meaning of the Plan), then, unless sooner terminated under the terms hereof, the Option will terminate three (3) months after the effective date of Optionee&#8217;s termination of employment or services&#59; provided, however, that if the Company or any of its Affiliates terminates the Optionee&#8217;s employment or services for cause, the Option will terminate immediately upon the effective date of Optionee&#8217;s termination of employment or services.  If Optionee&#8217;s employment or services are terminated by reason of Optionee&#8217;s death or total disability, then, unless sooner terminated under the terms hereof, the Option will terminate on the date one (1) year after the date of such termination of employment or services.  </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Change in Control</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  In the event of a Change in Control, all Option Shares shall automatically vest.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Rights as Stockholder</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  No shares of Common Stock shall be sold or delivered hereunder until full payment for such shares has been made.  Optionee shall have no rights as a stockholder with respect to any Option Shares until a stock certificate (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent) for such shares is issued to him or her.  Except as otherwise provided herein, no adjustment shall be made for dividends or distributions of other rights for which the record date is prior to the date such stock certificate is issued.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Nontransferability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  The Option is not assignable or transferable except by will or the laws of descent and distribution.  During Optionee&#8217;s lifetime, the option may be exercised only by Optionee or, in the event of Optionee&#8217;s total disability, Optionee&#8217;s legal representative.  </font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Securities Restrictions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  If a registration statement is not in effect under the Securities Act of 1933 or any applicable state securities laws with respect to the Option Shares, the Board may require, as a condition of exercise of the Option that the Optionee represent, in writing, that that (a) such Option Shares are being purchased for investment and not for distribution or resale, (b) the Optionee has been advised and understands that (i) the Option Shares have not been registered under the Act and are &#8220;restricted securities&#8221; within the meaning of Rule 144 under the Act and are subject to restrictions on transfer and (ii) the Company is under no obligation to register the Option Shares under the Act or to take any action which would make available to the Optionee any exemption from such registration, (c) such Option Shares may not be transferred without compliance with all applicable federal and state securities laws, and (d) an appropriate legend referring to the foregoing restrictions may be endorsed on the certificates.  </font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">No Right to Continued Employment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  Nothing in this Agreement shall give Optionee any right to continued employment by the Company and&#47;or its Affiliates or interfere in any way with the right of the Company or any Affiliate thereof to terminate the employment of Optionee.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Provisions of Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  The provisions of the Plan shall govern if and to the extent that there are inconsistencies between those provisions and the provisions hereof.  Optionee acknowledges receipt of a copy of the Plan prior to the execution of this Agreement.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Administration</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  The Board or the committee appointed by the Board to administer the Plan, if any, will have full power and authority to interpret and apply the provisions of this Agreement and act on behalf of the Company in connection with this Agreement, and the decision of said Board or committee as to any matter arising under this Agreement shall be binding and conclusive as to all persons.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Miscellaneous</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">.</font></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)&#160;This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective heirs, legal representatives, successors and permitted assigns.</font></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)&#160;This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without regard to its conflicts of laws principles.</font></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)&#160;This Agreement and the Plan constitute the entire agreement between the parties with respect to the subject matter hereof and may not be modified except by written instrument executed by the parties.</font></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)&#160;This Agreement may be executed in counterparts, each of which shall be deemed a complete original.</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#91;Execution page follows&#93;</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">IN WITNESS WHEREOF,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> this Agreement has been executed as of the date first above written.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">                                                                        COMPANY&#58;</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">                                                                        OCUGEN, INC.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">                                                                        _____________________________</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">                                                                        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OPTIONEE&#58;</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">                                                                        _________________________________________</font></div><div style="margin-top:12pt;"><font><br></font></div><div style="margin-top:12pt;"><font><br></font></div><div style="margin-top:12pt;"><font><br></font></div><div style="margin-top:12pt;"><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>ocgn-20191231x10kxex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="iee410898ecf2469f84c42a79957991a9_29"></div><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 21.1</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Ocugen, Inc.</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">List of Subsidiaries</font></div><div style="text-align:center;margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:66.025%;"><tr><td style="width:1.0%;"></td><td style="width:50.427%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.155%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:42.418%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name of Wholly-Owned Subsidiary</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ocugen Limited</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ireland</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ocugen OpCo, Inc.</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Delaware</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Histogenics Securities Corporation</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Massachusetts</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>ocgn-20191231x10kxex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="if90c7a07db084de6830b4b8177a9e74a_21"></div><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 23.1</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Consent of Independent Registered Public Accounting Firm</font></div><div style="text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We consent to the incorporation by reference in the Registration Statement (Form S-3 No. 333-234127) of Ocugen, Inc. and in the related Prospectus of our report dated March 27, 2020, with respect to the consolidated financial statements of Ocugen, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2019.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#47;s&#47; Ernst &#38; Young LLP</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Philadelphia, Pennsylvania</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">March 27, 2020</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>ocgn-20191231x10kxex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i84ab612f39d24a26bc43da91b9494ea7_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit&#160;31.1</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Shankar Musunuri, certify that&#58;</font></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">I have reviewed this Annual Report on Form&#160;10-K of Ocugen,&#160;Inc.&#59;</font></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The registrant&#8217;s other certifying officer(s)&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The registrant&#8217;s other certifying officer(s)&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:32.407%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:63.593%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; March 27, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Shankar Musunuri, Ph.D., MBA</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shankar Musunuri, Ph.D., MBA</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer &#38; Chairman</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>ocgn-20191231x10kxex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="if7982707c3af4f3d9bd8087b3de70b70_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit&#160;31.2</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Sanjay Subramanian, certify that&#58;</font></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">I have reviewed this Annual Report on Form&#160;10-K of Ocugen,&#160;Inc.&#59;</font></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The registrant&#8217;s other certifying officer(s)&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The registrant&#8217;s other certifying officer(s)&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:35.683%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:60.317%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; March 27, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Sanjay Subramanian</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sanjay Subramanian</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Chief Financial Officer</font></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Principal Financial Officer and Accounting Officer)</font></div></td></tr></table></div><div style="margin-top:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>ocgn-20191231x10kxex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i298ee960585046b1b6b38885e5b6467d_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit&#160;32.1</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Subsections (a)&#160;and (b)&#160;of Section&#160;1350, Chapter 63 of Title 18, United States Code)</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Ocugen,&#160;Inc. (the Company), does hereby certify, to the best of such officer&#8217;s knowledge, that&#58;</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Annual Report on Form&#160;10-K for the year ended December 31, 2019 (the Form&#160;10-K) of the Company fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934, and the information contained in the Form&#160;10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:48.219%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:47.781%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58;March 27, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Shankar Musunuri, Ph.D., MBA</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shankar Musunuri, Ph.D., MBA</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer &#38; Chairman</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Executive Officer)</font></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58;March 27, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Sanjay Subramanian</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sanjay Subramanian</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Financial Officer and Accounting Officer)</font></td></tr></table></div><div style="text-indent:18pt;margin-top:12pt;"><font><br></font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. This certification &#8220;accompanies&#8221; the Form&#160;10-K to which it relates, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form&#160;10-K), irrespective of any general incorporation language contained in such filing.</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>ocgn-20191231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:cc72798c-c24e-4d47-845f-93333954ce8b,g:e003b04e-ddd7-4b29-b911-f80dc6cd6725-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ocgn="http://www.deitaxonomy.com/20191231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.deitaxonomy.com/20191231">
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ocgn-20191231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ocgn-20191231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ocgn-20191231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ocgn-20191231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.deitaxonomy.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusiness" roleURI="http://www.deitaxonomy.com/role/NatureofBusiness">
        <link:definition>2101101 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessReverseStockSplitDetails" roleURI="http://www.deitaxonomy.com/role/NatureofBusinessReverseStockSplitDetails">
        <link:definition>2402401 - Disclosure - Nature of Business - Reverse Stock Split (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessGoingConcernDetails" roleURI="http://www.deitaxonomy.com/role/NatureofBusinessGoingConcernDetails">
        <link:definition>2403402 - Disclosure - Nature of Business - Going Concern (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2104102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2205201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2306301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesSummaryCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2408404 - Disclosure - Summary of Significant Accounting Policies (Summary Cash, Cash Equivalents and Restricted Cash) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerandPreMergerFinancing" roleURI="http://www.deitaxonomy.com/role/MergerandPreMergerFinancing">
        <link:definition>2109103 - Disclosure - Merger and Pre-Merger Financing</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerandPreMergerFinancingTables" roleURI="http://www.deitaxonomy.com/role/MergerandPreMergerFinancingTables">
        <link:definition>2310302 - Disclosure - Merger and Pre-Merger Financing (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerandFinancingPreMergerFinancingDetails" roleURI="http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails">
        <link:definition>2411405 - Disclosure - Merger and Financing - Pre-Merger Financing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerandFinancingMergerwithHistogenicsDetails" roleURI="http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails">
        <link:definition>2412406 - Disclosure - Merger and Financing - Merger with Histogenics (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareofCommonStock" roleURI="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStock">
        <link:definition>2113104 - Disclosure - Net Loss Per Share of Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareofCommonStockTables" roleURI="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockTables">
        <link:definition>2314303 - Disclosure - Net Loss Per Share of Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareofCommonStockDetails" roleURI="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockDetails">
        <link:definition>2415407 - Disclosure - Net Loss Per Share of Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreements" roleURI="http://www.deitaxonomy.com/role/LicenseandCollaborationAgreements">
        <link:definition>2116105 - Disclosure - License and Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsDetails" roleURI="http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails">
        <link:definition>2417408 - Disclosure - License and Collaboration Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://www.deitaxonomy.com/role/AccruedExpenses">
        <link:definition>2118106 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://www.deitaxonomy.com/role/AccruedExpensesTables">
        <link:definition>2319304 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://www.deitaxonomy.com/role/AccruedExpensesDetails">
        <link:definition>2420409 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.deitaxonomy.com/role/Debt">
        <link:definition>2121107 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.deitaxonomy.com/role/DebtTables">
        <link:definition>2322305 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtEB5LoanDetails" roleURI="http://www.deitaxonomy.com/role/DebtEB5LoanDetails">
        <link:definition>2423410 - Disclosure - Debt - EB-5 Loan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSummaryofEB5LoanDetails" roleURI="http://www.deitaxonomy.com/role/DebtSummaryofEB5LoanDetails">
        <link:definition>2424411 - Disclosure - Debt - Summary of EB-5 Loan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtConvertibleNotesDetails" roleURI="http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails">
        <link:definition>2425412 - Disclosure - Debt - Convertible Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofFairValueoftheEmbeddedFeaturesDetails" roleURI="http://www.deitaxonomy.com/role/DebtScheduleofFairValueoftheEmbeddedFeaturesDetails">
        <link:definition>2426413 - Disclosure - Debt - Schedule of Fair Value of the Embedded Features (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtConvertibleNotesOtherInformationDetails" roleURI="http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails">
        <link:definition>2427414 - Disclosure - Debt - Convertible Notes Other Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSeniorSecuredConvertibleNotesDetails" roleURI="http://www.deitaxonomy.com/role/DebtSeniorSecuredConvertibleNotesDetails">
        <link:definition>2428415 - Disclosure - Debt - Senior Secured Convertible Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.deitaxonomy.com/role/ShareBasedCompensation">
        <link:definition>2129108 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.deitaxonomy.com/role/ShareBasedCompensationTables">
        <link:definition>2330306 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails" roleURI="http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails">
        <link:definition>2431416 - Disclosure - Stock-Based Compensation - Schedule of Compensation Expense for Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharedBasedCompensationDetails" roleURI="http://www.deitaxonomy.com/role/SharedBasedCompensationDetails">
        <link:definition>2432417 - Disclosure - Shared-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofValuationAssumptionsDetails" roleURI="http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofValuationAssumptionsDetails">
        <link:definition>2433418 - Disclosure - Stock-Based Compensation - Schedule of Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails" roleURI="http://www.deitaxonomy.com/role/StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails">
        <link:definition>2434419 - Disclosure - Stock-Based Compensation - Schedule Options to Purchase Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Commitments" roleURI="http://www.deitaxonomy.com/role/Commitments">
        <link:definition>2135109 - Disclosure - Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsTables" roleURI="http://www.deitaxonomy.com/role/CommitmentsTables">
        <link:definition>2336307 - Disclosure - Commitments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsDetails" roleURI="http://www.deitaxonomy.com/role/CommitmentsDetails">
        <link:definition>2437420 - Disclosure - Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsOperatingleasescomponentsofleaseexpenseDetails" roleURI="http://www.deitaxonomy.com/role/CommitmentsOperatingleasescomponentsofleaseexpenseDetails">
        <link:definition>2438421 - Disclosure - Commitments - Operating leases, components of lease expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsOperatingleasessupplementalbalancesheetinformationDetails" roleURI="http://www.deitaxonomy.com/role/CommitmentsOperatingleasessupplementalbalancesheetinformationDetails">
        <link:definition>2439422 - Disclosure - Commitments - Operating leases, supplemental balance sheet information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsOperatingleasessupplementalinformationrelatedtoleasesDetails" roleURI="http://www.deitaxonomy.com/role/CommitmentsOperatingleasessupplementalinformationrelatedtoleasesDetails">
        <link:definition>2440423 - Disclosure - Commitments - Operating leases, supplemental information related to leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsOperatingleasesfutureminimumleasepaymentsDetails" roleURI="http://www.deitaxonomy.com/role/CommitmentsOperatingleasesfutureminimumleasepaymentsDetails">
        <link:definition>2441424 - Disclosure - Commitments - Operating leases, future minimum lease payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsFinanceleasesDetails" roleURI="http://www.deitaxonomy.com/role/CommitmentsFinanceleasesDetails">
        <link:definition>2442425 - Disclosure - Commitments - Finance leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsFinanceleasesfutureminimumleasepaymentsDetails" roleURI="http://www.deitaxonomy.com/role/CommitmentsFinanceleasesfutureminimumleasepaymentsDetails">
        <link:definition>2443426 - Disclosure - Commitments - Finance leases, future minimum lease payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsFinanceleasesfutureminimumleasepaymentsDetails_1" roleURI="http://www.deitaxonomy.com/role/CommitmentsFinanceleasesfutureminimumleasepaymentsDetails_1">
        <link:definition>2443426 - Disclosure - Commitments - Finance leases, future minimum lease payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Warrants" roleURI="http://www.deitaxonomy.com/role/Warrants">
        <link:definition>2144110 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsTables" roleURI="http://www.deitaxonomy.com/role/WarrantsTables">
        <link:definition>2345308 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsDetails" roleURI="http://www.deitaxonomy.com/role/WarrantsDetails">
        <link:definition>2446427 - Disclosure - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleofActivityofthePreMergerFinancingWarrantsDetails" roleURI="http://www.deitaxonomy.com/role/ScheduleofActivityofthePreMergerFinancingWarrantsDetails">
        <link:definition>2447428 - Disclosure - Schedule of Activity of the Pre-Merger Financing Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleofRollforwardofSeriesBWarrantLiabilityDetails" roleURI="http://www.deitaxonomy.com/role/ScheduleofRollforwardofSeriesBWarrantLiabilityDetails">
        <link:definition>2448429 - Disclosure - Schedule of Roll-forward of Series&#160;B Warrant Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.deitaxonomy.com/role/IncomeTaxes">
        <link:definition>2149111 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.deitaxonomy.com/role/IncomeTaxesTables">
        <link:definition>2350309 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleofDeferredTaxAssetsDetails" roleURI="http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails">
        <link:definition>2451430 - Disclosure - Schedule of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.deitaxonomy.com/role/IncomeTaxesDetails">
        <link:definition>2452431 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleofEffectiveIncomeTaxRateDetails" roleURI="http://www.deitaxonomy.com/role/ScheduleofEffectiveIncomeTaxRateDetails">
        <link:definition>2453432 - Disclosure - Schedule of Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleofUnrecognizedTaxBenefitsDetails" roleURI="http://www.deitaxonomy.com/role/ScheduleofUnrecognizedTaxBenefitsDetails">
        <link:definition>2454433 - Disclosure - Schedule of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.deitaxonomy.com/role/SubsequentEvents">
        <link:definition>2155112 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.deitaxonomy.com/role/SubsequentEventsDetails">
        <link:definition>2456434 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ocgn_ResearchAndDevelopmentExpensesCurrent" abstract="false" name="ResearchAndDevelopmentExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_SeniorSecuredConvertibleNotesJune2019Member" abstract="true" name="SeniorSecuredConvertibleNotesJune2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_NumberOfConvertedInitialSharesAgreedToIssuePriorToMergerToInvestors" abstract="false" name="NumberOfConvertedInitialSharesAgreedToIssuePriorToMergerToInvestors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ocgn_StockIssuedDuringPeriodSharesReverseAssetAcquisition" abstract="false" name="StockIssuedDuringPeriodSharesReverseAssetAcquisition" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ocgn_January2019AndFebruary2019NotesMember" abstract="true" name="January2019AndFebruary2019NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_NumberOfSharesAgreedToIssuePriorToMergerToInvestors" abstract="false" name="NumberOfSharesAgreedToIssuePriorToMergerToInvestors" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ocgn_LeaseLiability" abstract="false" name="LeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_SeriesCWarrantsMember" abstract="true" name="SeriesCWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_SeniorSecuredConvertibleNotesMay2019Member" abstract="true" name="SeniorSecuredConvertibleNotesMay2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_LicenseAgreementSigningFee" abstract="false" name="LicenseAgreementSigningFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_DebtRedemptionMultipleUponDefault" abstract="false" name="DebtRedemptionMultipleUponDefault" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ocgn_LicenseAgreementMinimumAnnualRoyaltyPayment" abstract="false" name="LicenseAgreementMinimumAnnualRoyaltyPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_A2014PlanMember" abstract="true" name="A2014PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionHigherPercentageOfCommonStock" abstract="false" name="PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionHigherPercentageOfCommonStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ocgn_EB5ProgramBorrowingsMember" abstract="true" name="EB5ProgramBorrowingsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_WarrantsTextBlock" abstract="false" name="WarrantsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ocgn_SeriesWarrantsMember" abstract="true" name="SeriesWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_ReverseMergerAndFinancingDisclosureLineItems" abstract="true" name="ReverseMergerAndFinancingDisclosureLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ocgn_PercentageOfIncreaseInPurchasePriceOfAssetPerMonth" abstract="false" name="PercentageOfIncreaseInPurchasePriceOfAssetPerMonth" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ocgn_EquityHoldersOfHistogenicsCorporationMember" abstract="true" name="EquityHoldersOfHistogenicsCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_ClassOfWarrantOrRightExercised" abstract="false" name="ClassOfWarrantOrRightExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ocgn_ConvertibleNotesBoardOfDirectorsMember" abstract="true" name="ConvertibleNotesBoardOfDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_EquityHoldersOfOcugenIncPerMergerMember" abstract="true" name="EquityHoldersOfOcugenIncPerMergerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_BusinessCombinationIssuedSharesExchangeRate" abstract="false" name="BusinessCombinationIssuedSharesExchangeRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount" abstract="false" name="ConvertibleDebtEquityFinancingTriggeredDiscount" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPeriod" abstract="false" name="ConvertedAdditionalSharesThresholdReleaseTriggerPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ocgn_HistogenicsCorporationMember" abstract="true" name="HistogenicsCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ocgn_SecuritiesPurchaseAgreementMember" abstract="true" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_CollaborationAgreementTerm" abstract="false" name="CollaborationAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ocgn_EquipmentAndFurnitureMember" abstract="true" name="EquipmentAndFurnitureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_ChangesInFairValueOfEmbeddedDerivativeTableTextBlock" abstract="false" name="ChangesInFairValueOfEmbeddedDerivativeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ocgn_ClassOfWarrantOrRightIssued" abstract="false" name="ClassOfWarrantOrRightIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ocgn_PercentageOfAmountOnMarketValueForFailureToIssueCommonStockOnPreMergerFinancingWarrants" abstract="false" name="PercentageOfAmountOnMarketValueForFailureToIssueCommonStockOnPreMergerFinancingWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ocgn_DeferredTaxAssetsLeaseLiability" abstract="false" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_NetProceedsFromReverseMerger" abstract="false" name="NetProceedsFromReverseMerger" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_ConvertibleDebtJanuary2018Member" abstract="true" name="ConvertibleDebtJanuary2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_SupplementalBalanceSheetInformationLeasesTableTextBlock" abstract="false" name="SupplementalBalanceSheetInformationLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ocgn_ConvertibleDebtNovember2018Member" abstract="true" name="ConvertibleDebtNovember2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_NumberOfEquityCompensationPlans" abstract="false" name="NumberOfEquityCompensationPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ocgn_LicenseAgreementPotentialCommercialMilestonePayment" abstract="false" name="LicenseAgreementPotentialCommercialMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiabilityAtIssuance" abstract="false" name="EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiabilityAtIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_AssetPurchaseAgreementCashConsideration" abstract="false" name="AssetPurchaseAgreementCashConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_ConvertibleDebtDecember2018Member" abstract="true" name="ConvertibleDebtDecember2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_LicenseAgreementPayment" abstract="false" name="LicenseAgreementPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement" abstract="false" name="CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ocgn_AssetHeldForSalePolicyTextBlock" abstract="false" name="AssetHeldForSalePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ocgn_AssetsHeldForSale" abstract="false" name="AssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_AdjustmentsToAdditionalPaidInCapitalMergerRelatedCosts" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalMergerRelatedCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_CostsRelatedToIssuanceOfStockUnderReverseAssetAcquisition" abstract="false" name="CostsRelatedToIssuanceOfStockUnderReverseAssetAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_NoncashLeaseExpense" abstract="false" name="NoncashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_MergerAcquisitionCostsIncurred" abstract="false" name="MergerAcquisitionCostsIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_November2018AndDecember2018NotesMember" abstract="true" name="November2018AndDecember2018NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_AccountsPayableClinical" abstract="false" name="AccountsPayableClinical" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_NumberOfFormerEmployeesWithWarrants" abstract="false" name="NumberOfFormerEmployeesWithWarrants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ocgn_ClassOfWarrantOrRightExercisable" abstract="false" name="ClassOfWarrantOrRightExercisable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPrice" abstract="false" name="ConvertedAdditionalSharesThresholdReleaseTriggerPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="ocgn_ScheduleOfPreMergerFinancingWarrantsTableTextBlock" abstract="false" name="ScheduleOfPreMergerFinancingWarrantsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ocgn_ConvertibleDebtFebruary2019Member" abstract="true" name="ConvertibleDebtFebruary2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_CollaborationAgreementWithUniversityOfColoradoMember" abstract="true" name="CollaborationAgreementWithUniversityOfColoradoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_CollaborationAgreementTerminationDevelopmentCostPayment" abstract="false" name="CollaborationAgreementTerminationDevelopmentCostPayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ocgn_ProceedsFromWarrantExercisesMaximumAmount" abstract="false" name="ProceedsFromWarrantExercisesMaximumAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_LineOfCreditBorrowingEachDraw" abstract="false" name="LineOfCreditBorrowingEachDraw" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_StockIssuedDuringPeriodValueReverseAssetAcquisition" abstract="false" name="StockIssuedDuringPeriodValueReverseAssetAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_SchepensEyeResearchInstituteMember" abstract="true" name="SchepensEyeResearchInstituteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_CollaborationAgreementTerminationDevelopmentCostStatement" abstract="false" name="CollaborationAgreementTerminationDevelopmentCostStatement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionLowerPercentageOfCommonStock" abstract="false" name="PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionLowerPercentageOfCommonStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ocgn_SeniorSecuredConvertibleNotesMember" abstract="true" name="SeniorSecuredConvertibleNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_SeriesBWarrantsMember" abstract="true" name="SeriesBWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_DeferredTaxAssetsStartUpCosts" abstract="false" name="DeferredTaxAssetsStartUpCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_StockIssuedDuringPeriodPreMergerValue" abstract="false" name="StockIssuedDuringPeriodPreMergerValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_NumberOfConvertedAdditionalSharesAgreedToIssuePriorToMergerToInvestors" abstract="false" name="NumberOfConvertedAdditionalSharesAgreedToIssuePriorToMergerToInvestors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ocgn_ReverseMergerAndFinancingDisclosureTable" abstract="true" name="ReverseMergerAndFinancingDisclosureTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ocgn_ConvertibleDebtJanuary2019Member" abstract="true" name="ConvertibleDebtJanuary2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_A2019PlanMember" abstract="true" name="A2019PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_ClassOfWarrantOrRightConditionForExpirationTradingDay" abstract="false" name="ClassOfWarrantOrRightConditionForExpirationTradingDay" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ocgn_LicenseAgreementMilestonePayment" abstract="false" name="LicenseAgreementMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_GainsLossesOnConversionOfDebt" abstract="false" name="GainsLossesOnConversionOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_ReclassificationOfWarrantsFromLiabilityToEquity" abstract="false" name="ReclassificationOfWarrantsFromLiabilityToEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_ConvertibleDebtJune2018Member" abstract="true" name="ConvertibleDebtJune2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_ClassOfWarrantOrRightExercisePriceDeterminationNumberOfTradingDaysConsidered" abstract="false" name="ClassOfWarrantOrRightExercisePriceDeterminationNumberOfTradingDaysConsidered" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger" abstract="false" name="ConvertedAdditionalSharesThresholdReleaseTrigger" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ocgn_StockIssuanceCostsRecognized" abstract="false" name="StockIssuanceCostsRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_CollaborationAgreementWithUniversityOfIllinoisChicagoMember" abstract="true" name="CollaborationAgreementWithUniversityOfIllinoisChicagoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment" abstract="false" name="LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_ConvertiblePromissoryNotesMember" abstract="true" name="ConvertiblePromissoryNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationAmountReclassifiedToEquity" abstract="false" name="FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationAmountReclassifiedToEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_LeaseRightOfUseAsset" abstract="false" name="LeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_DerivativeInstrumentsAndHedgingActivitiesDisclosurePolicyTextBlock" abstract="false" name="DerivativeInstrumentsAndHedgingActivitiesDisclosurePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ocgn_ProceedsFromPreMergerFinancingFinancingActivities" abstract="false" name="ProceedsFromPreMergerFinancingFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset" abstract="false" name="NoncashOrPartNoncashOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_StockIssuedDuringPeriodPreMergerShares" abstract="false" name="StockIssuedDuringPeriodPreMergerShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ocgn_ConvertibleDebtConversionFeatureMember" abstract="true" name="ConvertibleDebtConversionFeatureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_SeriesAWarrantsAndSeriesCWarrantsMember" abstract="true" name="SeriesAWarrantsAndSeriesCWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_CollaborationAgreementWithCansinoBiologicsMember" abstract="true" name="CollaborationAgreementWithCansinoBiologicsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_AccountsPayableConsulting" abstract="false" name="AccountsPayableConsulting" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_IncreaseDecreaseInLeaseObligations" abstract="false" name="IncreaseDecreaseInLeaseObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_CommonStockAdditionalSharesOfCommonStockIssuableUponExerciseOfWarrantsBasedOnResetPeriodShares" abstract="false" name="CommonStockAdditionalSharesOfCommonStockIssuableUponExerciseOfWarrantsBasedOnResetPeriodShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ocgn_LicenseAgreementCancellationPeriodNotice" abstract="false" name="LicenseAgreementCancellationPeriodNotice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ocgn_DeferredTaxAssetsConvertibleDebt" abstract="false" name="DeferredTaxAssetsConvertibleDebt" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_EmbeddedDerivativeConversionAndExtinguishmentOfDebt" abstract="false" name="EmbeddedDerivativeConversionAndExtinguishmentOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_NeocartMember" abstract="true" name="NeocartMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ocgn_NonCashInterestExpense" abstract="false" name="NonCashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction" abstract="false" name="DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost" abstract="false" name="NoncashOrPartNoncashAmountOfDeferredTransactionCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_StockIssuedDuringPeriodValueWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_IncreaseDecreaseInDeferredRent" abstract="false" name="IncreaseDecreaseInDeferredRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_FormerOcugenWarrantsMember" abstract="true" name="FormerOcugenWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>ocgn-20191231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:cc72798c-c24e-4d47-845f-93333954ce8b,g:e003b04e-ddd7-4b29-b911-f80dc6cd6725-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/Cover" xlink:type="simple" xlink:href="ocgn-20191231.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6b2522ef-135e-4137-ba60-84e06c1b7c23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_20227478-218a-49ed-940b-d0b17129e7f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6b2522ef-135e-4137-ba60-84e06c1b7c23" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_20227478-218a-49ed-940b-d0b17129e7f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ProceedsFromPreMergerFinancingFinancingActivities_25341fdf-0418-4974-b878-09c7b29d65fc" xlink:href="ocgn-20191231.xsd#ocgn_ProceedsFromPreMergerFinancingFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6b2522ef-135e-4137-ba60-84e06c1b7c23" xlink:to="loc_ocgn_ProceedsFromPreMergerFinancingFinancingActivities_25341fdf-0418-4974-b878-09c7b29d65fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_13959f52-3827-4c0f-abcf-0ec3f9f26cff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6b2522ef-135e-4137-ba60-84e06c1b7c23" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_13959f52-3827-4c0f-abcf-0ec3f9f26cff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_d519af54-1dc2-407e-83fd-0b4c200ac710" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6b2522ef-135e-4137-ba60-84e06c1b7c23" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_d519af54-1dc2-407e-83fd-0b4c200ac710" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_39a21980-5c52-4633-9f33-feb689ba864a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6b2522ef-135e-4137-ba60-84e06c1b7c23" xlink:to="loc_us-gaap_RepaymentsOfDebt_39a21980-5c52-4633-9f33-feb689ba864a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_a16bbcdf-70a0-4b31-83f6-4aa449e0b04c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6b2522ef-135e-4137-ba60-84e06c1b7c23" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_a16bbcdf-70a0-4b31-83f6-4aa449e0b04c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_9e6159a5-251e-4dcf-9e0f-8dd9beace88a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6b2522ef-135e-4137-ba60-84e06c1b7c23" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_9e6159a5-251e-4dcf-9e0f-8dd9beace88a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_46975f50-8295-4b8b-a70b-c8f102ae0e2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6b2522ef-135e-4137-ba60-84e06c1b7c23" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_46975f50-8295-4b8b-a70b-c8f102ae0e2d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_e6f72746-a2a3-430c-adbb-7e57aa385d5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_084a8c78-e78b-43af-b7ef-1de8698d59f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_e6f72746-a2a3-430c-adbb-7e57aa385d5a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_084a8c78-e78b-43af-b7ef-1de8698d59f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0084c321-46f6-499e-8888-f5b2d87a7b03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_e6f72746-a2a3-430c-adbb-7e57aa385d5a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0084c321-46f6-499e-8888-f5b2d87a7b03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_f4074062-cc88-4a44-aabb-62b3d06de368" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_e6f72746-a2a3-430c-adbb-7e57aa385d5a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_f4074062-cc88-4a44-aabb-62b3d06de368" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6a0922c2-89a1-4f30-9e5f-f5d381d1c1e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_3c750c1c-b1f1-4f70-9004-4ac665d459e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6a0922c2-89a1-4f30-9e5f-f5d381d1c1e4" xlink:to="loc_us-gaap_TreasuryStockValue_3c750c1c-b1f1-4f70-9004-4ac665d459e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2ceccaa6-8e4a-44e7-9d62-22f80f24f0d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6a0922c2-89a1-4f30-9e5f-f5d381d1c1e4" xlink:to="loc_us-gaap_PreferredStockValue_2ceccaa6-8e4a-44e7-9d62-22f80f24f0d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_558e6008-8e43-4c12-8b70-a27f7db71881" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6a0922c2-89a1-4f30-9e5f-f5d381d1c1e4" xlink:to="loc_us-gaap_AdditionalPaidInCapital_558e6008-8e43-4c12-8b70-a27f7db71881" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1dcd1f19-f4fa-4407-85da-45827c2e72ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6a0922c2-89a1-4f30-9e5f-f5d381d1c1e4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1dcd1f19-f4fa-4407-85da-45827c2e72ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_1607baa9-98bb-46a8-a45f-56b81c30681a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6a0922c2-89a1-4f30-9e5f-f5d381d1c1e4" xlink:to="loc_us-gaap_CommonStockValue_1607baa9-98bb-46a8-a45f-56b81c30681a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e6f9a4f1-a290-4cb9-a991-1ee5151ea39e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9472c7ab-27ba-45d5-b531-96a7eaefa270" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e6f9a4f1-a290-4cb9-a991-1ee5151ea39e" xlink:to="loc_us-gaap_AssetsCurrent_9472c7ab-27ba-45d5-b531-96a7eaefa270" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_afdbf1ce-a26d-4ac5-8895-e19b0bbc7e82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e6f9a4f1-a290-4cb9-a991-1ee5151ea39e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_afdbf1ce-a26d-4ac5-8895-e19b0bbc7e82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_e4c70e1d-979f-4f6b-80d8-ddfa7dc83a80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e6f9a4f1-a290-4cb9-a991-1ee5151ea39e" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_e4c70e1d-979f-4f6b-80d8-ddfa7dc83a80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3cf5c687-afb4-4a76-8ee2-268a316a43ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e6f9a4f1-a290-4cb9-a991-1ee5151ea39e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3cf5c687-afb4-4a76-8ee2-268a316a43ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5c6cc719-506d-42f0-b7a7-9498b8c8493a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_11d22414-9571-484a-ba0a-35566dfaf030" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5c6cc719-506d-42f0-b7a7-9498b8c8493a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_11d22414-9571-484a-ba0a-35566dfaf030" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d2be1522-9e42-4f40-b8b1-09064448ad00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5c6cc719-506d-42f0-b7a7-9498b8c8493a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d2be1522-9e42-4f40-b8b1-09064448ad00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_0ca16e23-458a-4c00-b6e6-ca0cd5e446a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5c6cc719-506d-42f0-b7a7-9498b8c8493a" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_0ca16e23-458a-4c00-b6e6-ca0cd5e446a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6b599138-0d0d-48c9-a46b-3322ac75b0d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_b7e33cc4-7989-4b35-ab18-d7b1a31d13ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6b599138-0d0d-48c9-a46b-3322ac75b0d8" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_b7e33cc4-7989-4b35-ab18-d7b1a31d13ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8c96e71b-04a1-4a10-bf6d-2f615dd42a44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6b599138-0d0d-48c9-a46b-3322ac75b0d8" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8c96e71b-04a1-4a10-bf6d-2f615dd42a44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0b4bc613-8dc8-4f11-bcb5-b9d4d58f1f47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6b599138-0d0d-48c9-a46b-3322ac75b0d8" xlink:to="loc_us-gaap_AccountsPayableCurrent_0b4bc613-8dc8-4f11-bcb5-b9d4d58f1f47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a3d12e85-1dc8-4f4a-b706-bc30af9669b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6b599138-0d0d-48c9-a46b-3322ac75b0d8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a3d12e85-1dc8-4f4a-b706-bc30af9669b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c5230792-6d19-4a16-8804-e2264c69569e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c2c99237-ed91-48c3-8c8d-f1b8541847c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c5230792-6d19-4a16-8804-e2264c69569e" xlink:to="loc_us-gaap_Liabilities_c2c99237-ed91-48c3-8c8d-f1b8541847c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_862eea19-448f-488e-b3a0-b7ad9be6052a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c5230792-6d19-4a16-8804-e2264c69569e" xlink:to="loc_us-gaap_StockholdersEquity_862eea19-448f-488e-b3a0-b7ad9be6052a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_06e72010-4d5b-4aa9-9229-546ae0d57f73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a3b80003-89a6-428a-9589-7057fee61f15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_06e72010-4d5b-4aa9-9229-546ae0d57f73" xlink:to="loc_us-gaap_LiabilitiesCurrent_a3b80003-89a6-428a-9589-7057fee61f15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_e9760dc6-611f-40e9-b81f-45b41f14644b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_06e72010-4d5b-4aa9-9229-546ae0d57f73" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_e9760dc6-611f-40e9-b81f-45b41f14644b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9f18f129-d8c6-4982-9a38-30d9974c4d87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_f4eca3a6-4fb9-49db-9bd3-75dcfbbff06b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9f18f129-d8c6-4982-9a38-30d9974c4d87" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_f4eca3a6-4fb9-49db-9bd3-75dcfbbff06b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_87613474-6076-4f73-91f3-7684fb39b29b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9f18f129-d8c6-4982-9a38-30d9974c4d87" xlink:to="loc_us-gaap_OperatingIncomeLoss_87613474-6076-4f73-91f3-7684fb39b29b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_84194ca6-78ba-407c-b988-1bdc9a7fa70a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cd7c1e43-3614-4259-a6ba-caead3839ba1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_84194ca6-78ba-407c-b988-1bdc9a7fa70a" xlink:to="loc_us-gaap_NetIncomeLoss_cd7c1e43-3614-4259-a6ba-caead3839ba1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f3cf636c-8247-40b4-9995-7157992789cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_84194ca6-78ba-407c-b988-1bdc9a7fa70a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f3cf636c-8247-40b4-9995-7157992789cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a8a09e51-c8cf-4f36-b1bb-177fcb30b366" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_841ad6e7-7038-4918-a888-95e15e5cb44f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a8a09e51-c8cf-4f36-b1bb-177fcb30b366" xlink:to="loc_us-gaap_OperatingExpenses_841ad6e7-7038-4918-a888-95e15e5cb44f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_f23db373-e7d1-4ffd-bbd1-c3a9bfd26eaa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_GainsLossesOnConversionOfDebt_349c9d66-22fc-4f79-a25d-fb13b2a1e6cf" xlink:href="ocgn-20191231.xsd#ocgn_GainsLossesOnConversionOfDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f23db373-e7d1-4ffd-bbd1-c3a9bfd26eaa" xlink:to="loc_ocgn_GainsLossesOnConversionOfDebt_349c9d66-22fc-4f79-a25d-fb13b2a1e6cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f63f8bea-8cd2-4b67-8229-64675842879b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f23db373-e7d1-4ffd-bbd1-c3a9bfd26eaa" xlink:to="loc_us-gaap_InterestExpense_f63f8bea-8cd2-4b67-8229-64675842879b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_98464998-805a-4e97-a2b9-1505de7bdf2e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f23db373-e7d1-4ffd-bbd1-c3a9bfd26eaa" xlink:to="loc_us-gaap_InvestmentIncomeInterest_98464998-805a-4e97-a2b9-1505de7bdf2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_5315ac1f-c36c-44f7-be42-ef33ae8b3fd3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f23db373-e7d1-4ffd-bbd1-c3a9bfd26eaa" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_5315ac1f-c36c-44f7-be42-ef33ae8b3fd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3067880f-473f-4e47-b333-2bb3e2ddc957" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f23db373-e7d1-4ffd-bbd1-c3a9bfd26eaa" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3067880f-473f-4e47-b333-2bb3e2ddc957" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_7e0e2394-1e56-4147-957f-1e553a817823" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7c637d25-fc02-4e55-9f7f-f2480ad68a5c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_7e0e2394-1e56-4147-957f-1e553a817823" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7c637d25-fc02-4e55-9f7f-f2480ad68a5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d81fe277-f758-49cb-a9e0-aa2a23047b2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_7e0e2394-1e56-4147-957f-1e553a817823" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d81fe277-f758-49cb-a9e0-aa2a23047b2a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cb6f8e64-6206-4446-b7d7-68c26c8a43ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0d1d3e1d-79d2-40ec-9673-02d28862e812" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cb6f8e64-6206-4446-b7d7-68c26c8a43ed" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0d1d3e1d-79d2-40ec-9673-02d28862e812" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_820aef58-d98e-465d-b5e1-5032f9c6f271" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cb6f8e64-6206-4446-b7d7-68c26c8a43ed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_820aef58-d98e-465d-b5e1-5032f9c6f271" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6cf0ccad-f749-491b-9fcf-9802fee117a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cb6f8e64-6206-4446-b7d7-68c26c8a43ed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6cf0ccad-f749-491b-9fcf-9802fee117a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc49367a-d1a5-48f1-ad74-6cdfce9427cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cb6f8e64-6206-4446-b7d7-68c26c8a43ed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc49367a-d1a5-48f1-ad74-6cdfce9427cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d5018ff-773a-47fc-b90f-ae381fa389d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NoncashLeaseExpense_09b25819-7f93-4d70-a668-faf8173a5c02" xlink:href="ocgn-20191231.xsd#ocgn_NoncashLeaseExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d5018ff-773a-47fc-b90f-ae381fa389d1" xlink:to="loc_ocgn_NoncashLeaseExpense_09b25819-7f93-4d70-a668-faf8173a5c02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f9e41620-5af9-4662-ae88-3090cc426ab1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d5018ff-773a-47fc-b90f-ae381fa389d1" xlink:to="loc_us-gaap_ProfitLoss_f9e41620-5af9-4662-ae88-3090cc426ab1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_88cb2a4c-110c-4044-9051-fc76dd9d7554" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d5018ff-773a-47fc-b90f-ae381fa389d1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_88cb2a4c-110c-4044-9051-fc76dd9d7554" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3b003766-b8f9-4edc-b1bb-a81956902d44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d5018ff-773a-47fc-b90f-ae381fa389d1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3b003766-b8f9-4edc-b1bb-a81956902d44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_IncreaseDecreaseInDeferredRent_bfd817b6-42a1-46d8-9056-cb7a2bc9cf65" xlink:href="ocgn-20191231.xsd#ocgn_IncreaseDecreaseInDeferredRent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d5018ff-773a-47fc-b90f-ae381fa389d1" xlink:to="loc_ocgn_IncreaseDecreaseInDeferredRent_bfd817b6-42a1-46d8-9056-cb7a2bc9cf65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NonCashInterestExpense_8ef2e7e0-d399-444f-a51c-e380eee60dd7" xlink:href="ocgn-20191231.xsd#ocgn_NonCashInterestExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d5018ff-773a-47fc-b90f-ae381fa389d1" xlink:to="loc_ocgn_NonCashInterestExpense_8ef2e7e0-d399-444f-a51c-e380eee60dd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_GainsLossesOnConversionOfDebt_7e13f123-ae4b-4bc2-b28d-d3672fa7f40f" xlink:href="ocgn-20191231.xsd#ocgn_GainsLossesOnConversionOfDebt"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d5018ff-773a-47fc-b90f-ae381fa389d1" xlink:to="loc_ocgn_GainsLossesOnConversionOfDebt_7e13f123-ae4b-4bc2-b28d-d3672fa7f40f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_IncreaseDecreaseInLeaseObligations_1f6d8805-bb4c-4cfa-a8d7-6e00f1d2b234" xlink:href="ocgn-20191231.xsd#ocgn_IncreaseDecreaseInLeaseObligations"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d5018ff-773a-47fc-b90f-ae381fa389d1" xlink:to="loc_ocgn_IncreaseDecreaseInLeaseObligations_1f6d8805-bb4c-4cfa-a8d7-6e00f1d2b234" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_693179c6-2e2d-420d-a8c2-3855a2b7869b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d5018ff-773a-47fc-b90f-ae381fa389d1" xlink:to="loc_us-gaap_Depreciation_693179c6-2e2d-420d-a8c2-3855a2b7869b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_35c67a4c-fb11-4822-935e-15a2b25a981b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d5018ff-773a-47fc-b90f-ae381fa389d1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_35c67a4c-fb11-4822-935e-15a2b25a981b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2221544a-4fea-478a-8a93-f2c35deb4e32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d5018ff-773a-47fc-b90f-ae381fa389d1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2221544a-4fea-478a-8a93-f2c35deb4e32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense_ffce30f6-970a-4643-8e6d-61e8c78a92e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashExpense"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d5018ff-773a-47fc-b90f-ae381fa389d1" xlink:to="loc_us-gaap_OtherNoncashExpense_ffce30f6-970a-4643-8e6d-61e8c78a92e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_931bb2a0-1239-41a1-bf20-af1c0fc96a3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d5018ff-773a-47fc-b90f-ae381fa389d1" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_931bb2a0-1239-41a1-bf20-af1c0fc96a3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8de71309-b2a3-4831-9a63-488f686af3e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_3353713f-27f7-4d12-a541-1fb6773564aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8de71309-b2a3-4831-9a63-488f686af3e9" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_3353713f-27f7-4d12-a541-1fb6773564aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_540fc2bf-3894-40c3-a2b8-ee619ff1fe4d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8de71309-b2a3-4831-9a63-488f686af3e9" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_540fc2bf-3894-40c3-a2b8-ee619ff1fe4d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/NatureofBusiness" xlink:type="simple" xlink:href="ocgn-20191231.xsd#NatureofBusiness"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/NatureofBusiness" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/NatureofBusinessReverseStockSplitDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#NatureofBusinessReverseStockSplitDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/NatureofBusinessReverseStockSplitDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/NatureofBusinessGoingConcernDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#NatureofBusinessGoingConcernDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/NatureofBusinessGoingConcernDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ocgn-20191231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ocgn-20191231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ocgn-20191231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesSummaryCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#SummaryofSignificantAccountingPoliciesSummaryCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesSummaryCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5deae344-c56c-4617-969b-59a4cc574931" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_eebea94d-69b1-4b62-b7d7-15be2ce596c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5deae344-c56c-4617-969b-59a4cc574931" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_eebea94d-69b1-4b62-b7d7-15be2ce596c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_a3aabbd2-221a-4478-8269-592d8fbaa485" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5deae344-c56c-4617-969b-59a4cc574931" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_a3aabbd2-221a-4478-8269-592d8fbaa485" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/MergerandPreMergerFinancing" xlink:type="simple" xlink:href="ocgn-20191231.xsd#MergerandPreMergerFinancing"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/MergerandPreMergerFinancing" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/MergerandPreMergerFinancingTables" xlink:type="simple" xlink:href="ocgn-20191231.xsd#MergerandPreMergerFinancingTables"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/MergerandPreMergerFinancingTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#MergerandFinancingPreMergerFinancingDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#MergerandFinancingMergerwithHistogenicsDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNet_3784d59d-faf5-460c-893a-53e96420a752" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_fc6b6657-574d-49d6-8f66-c766b5d9c6f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNet_3784d59d-faf5-460c-893a-53e96420a752" xlink:to="loc_us-gaap_AccountsPayableCurrent_fc6b6657-574d-49d6-8f66-c766b5d9c6f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bf7b9403-94c9-4232-9ed8-4e77c70a28e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNet_3784d59d-faf5-460c-893a-53e96420a752" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bf7b9403-94c9-4232-9ed8-4e77c70a28e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AssetsHeldForSale_7f10e0a6-0bec-4de9-adc2-d5e4a71a2830" xlink:href="ocgn-20191231.xsd#ocgn_AssetsHeldForSale"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNet_3784d59d-faf5-460c-893a-53e96420a752" xlink:to="loc_ocgn_AssetsHeldForSale_7f10e0a6-0bec-4de9-adc2-d5e4a71a2830" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStock" xlink:type="simple" xlink:href="ocgn-20191231.xsd#NetLossPerShareofCommonStock"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStock" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockTables" xlink:type="simple" xlink:href="ocgn-20191231.xsd#NetLossPerShareofCommonStockTables"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#NetLossPerShareofCommonStockDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/LicenseandCollaborationAgreements" xlink:type="simple" xlink:href="ocgn-20191231.xsd#LicenseandCollaborationAgreements"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/LicenseandCollaborationAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#LicenseandCollaborationAgreementsDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/AccruedExpenses" xlink:type="simple" xlink:href="ocgn-20191231.xsd#AccruedExpenses"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/AccruedExpenses" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="ocgn-20191231.xsd#AccruedExpensesTables"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/AccruedExpensesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#AccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1e769382-c2a5-4abc-9fb7-7fde01e530c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8b4c21a8-0e66-44b9-8267-1d917ba6d3d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1e769382-c2a5-4abc-9fb7-7fde01e530c4" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8b4c21a8-0e66-44b9-8267-1d917ba6d3d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ResearchAndDevelopmentExpensesCurrent_7b49d098-7ab7-4878-9594-2a0403b5bccc" xlink:href="ocgn-20191231.xsd#ocgn_ResearchAndDevelopmentExpensesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1e769382-c2a5-4abc-9fb7-7fde01e530c4" xlink:to="loc_ocgn_ResearchAndDevelopmentExpensesCurrent_7b49d098-7ab7-4878-9594-2a0403b5bccc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_2f505f02-d7b6-4a54-b131-e632c4078469" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1e769382-c2a5-4abc-9fb7-7fde01e530c4" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_2f505f02-d7b6-4a54-b131-e632c4078469" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AccountsPayableConsulting_8b5d257d-3aec-4eea-aff1-0acb9db411cd" xlink:href="ocgn-20191231.xsd#ocgn_AccountsPayableConsulting"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1e769382-c2a5-4abc-9fb7-7fde01e530c4" xlink:to="loc_ocgn_AccountsPayableConsulting_8b5d257d-3aec-4eea-aff1-0acb9db411cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AccountsPayableClinical_2e6fe78f-5713-40a5-8260-d0df0192f9ea" xlink:href="ocgn-20191231.xsd#ocgn_AccountsPayableClinical"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1e769382-c2a5-4abc-9fb7-7fde01e530c4" xlink:to="loc_ocgn_AccountsPayableClinical_2e6fe78f-5713-40a5-8260-d0df0192f9ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_19c0dab7-aa13-4820-bd1f-a8fbc93a4253" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1e769382-c2a5-4abc-9fb7-7fde01e530c4" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_19c0dab7-aa13-4820-bd1f-a8fbc93a4253" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/Debt" xlink:type="simple" xlink:href="ocgn-20191231.xsd#Debt"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/Debt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtTables" xlink:type="simple" xlink:href="ocgn-20191231.xsd#DebtTables"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/DebtTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtEB5LoanDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#DebtEB5LoanDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/DebtEB5LoanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtSummaryofEB5LoanDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#DebtSummaryofEB5LoanDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/DebtSummaryofEB5LoanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a59817cd-0710-4d3d-b52a-688aa98b88d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_cb62acd0-75ed-4c79-bf4b-a530ad0b2811" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a59817cd-0710-4d3d-b52a-688aa98b88d2" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_cb62acd0-75ed-4c79-bf4b-a530ad0b2811" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_b001ad5a-e54a-48b8-9a4c-0469833e711d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a59817cd-0710-4d3d-b52a-688aa98b88d2" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_b001ad5a-e54a-48b8-9a4c-0469833e711d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_e86582d4-61af-46ca-bce8-248969098aed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a59817cd-0710-4d3d-b52a-688aa98b88d2" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_e86582d4-61af-46ca-bce8-248969098aed" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#DebtConvertibleNotesDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0e53ae67-34ae-4a50-9ac9-972ed4f54532" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_bbacbd64-f5d3-4de2-96dd-ebe105f6c0e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_0e53ae67-34ae-4a50-9ac9-972ed4f54532" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_bbacbd64-f5d3-4de2-96dd-ebe105f6c0e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_f10cbf3f-0516-4b5e-a1e7-c4585f99ecb7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_0e53ae67-34ae-4a50-9ac9-972ed4f54532" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_f10cbf3f-0516-4b5e-a1e7-c4585f99ecb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_51ead967-66f4-45bc-8647-6fd7e596eb2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_0e53ae67-34ae-4a50-9ac9-972ed4f54532" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_51ead967-66f4-45bc-8647-6fd7e596eb2b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtScheduleofFairValueoftheEmbeddedFeaturesDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#DebtScheduleofFairValueoftheEmbeddedFeaturesDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/DebtScheduleofFairValueoftheEmbeddedFeaturesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#DebtConvertibleNotesOtherInformationDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtSeniorSecuredConvertibleNotesDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#DebtSeniorSecuredConvertibleNotesDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/DebtSeniorSecuredConvertibleNotesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="ocgn-20191231.xsd#ShareBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/ShareBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="ocgn-20191231.xsd#ShareBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/ShareBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#StockBasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SharedBasedCompensationDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#SharedBasedCompensationDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/SharedBasedCompensationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofValuationAssumptionsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#StockBasedCompensationScheduleofValuationAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofValuationAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/Commitments" xlink:type="simple" xlink:href="ocgn-20191231.xsd#Commitments"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/Commitments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CommitmentsTables" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CommitmentsTables"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/CommitmentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CommitmentsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CommitmentsDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/CommitmentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CommitmentsOperatingleasescomponentsofleaseexpenseDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CommitmentsOperatingleasescomponentsofleaseexpenseDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/CommitmentsOperatingleasescomponentsofleaseexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_859405eb-2a8f-4392-b61c-7a351f088a87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_e99928a9-349f-42d7-b49d-f44a3431563c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_859405eb-2a8f-4392-b61c-7a351f088a87" xlink:to="loc_us-gaap_OperatingLeaseCost_e99928a9-349f-42d7-b49d-f44a3431563c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_ac6deb3e-c246-4242-94e9-00581f13de53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_859405eb-2a8f-4392-b61c-7a351f088a87" xlink:to="loc_us-gaap_VariableLeaseCost_ac6deb3e-c246-4242-94e9-00581f13de53" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CommitmentsOperatingleasessupplementalbalancesheetinformationDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CommitmentsOperatingleasessupplementalbalancesheetinformationDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/CommitmentsOperatingleasessupplementalbalancesheetinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1e0ed9e4-f42a-4a2f-ab3b-5c1c50151bfd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c3dd1a7c-0736-4941-b19d-c042e32e3792" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_1e0ed9e4-f42a-4a2f-ab3b-5c1c50151bfd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c3dd1a7c-0736-4941-b19d-c042e32e3792" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_084a54db-d64f-4f0c-8e37-fd2ca48bf989" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_1e0ed9e4-f42a-4a2f-ab3b-5c1c50151bfd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_084a54db-d64f-4f0c-8e37-fd2ca48bf989" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CommitmentsOperatingleasessupplementalinformationrelatedtoleasesDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CommitmentsOperatingleasessupplementalinformationrelatedtoleasesDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/CommitmentsOperatingleasessupplementalinformationrelatedtoleasesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CommitmentsOperatingleasesfutureminimumleasepaymentsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CommitmentsOperatingleasesfutureminimumleasepaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/CommitmentsOperatingleasesfutureminimumleasepaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d22f988e-a2a4-45d2-a645-3d8970d13fde" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_42a0a9eb-abd8-4987-9957-d9fed798d613" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d22f988e-a2a4-45d2-a645-3d8970d13fde" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_42a0a9eb-abd8-4987-9957-d9fed798d613" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3192c3f0-8225-4a89-86c0-9ff43fdd6465" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d22f988e-a2a4-45d2-a645-3d8970d13fde" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3192c3f0-8225-4a89-86c0-9ff43fdd6465" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9dedf164-09b8-44b5-871c-e7ec7159c84f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d22f988e-a2a4-45d2-a645-3d8970d13fde" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9dedf164-09b8-44b5-871c-e7ec7159c84f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CommitmentsFinanceleasesDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CommitmentsFinanceleasesDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/CommitmentsFinanceleasesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CommitmentsFinanceleasesfutureminimumleasepaymentsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CommitmentsFinanceleasesfutureminimumleasepaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/CommitmentsFinanceleasesfutureminimumleasepaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_38a9be6e-3ca5-4a65-9535-e8ba0ce02d46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_58664372-9cff-4354-81bd-715d70875da0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_38a9be6e-3ca5-4a65-9535-e8ba0ce02d46" xlink:to="loc_us-gaap_FinanceLeaseLiability_58664372-9cff-4354-81bd-715d70875da0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_05b155ed-be28-4e5c-9e2d-d03a858a0a53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_38a9be6e-3ca5-4a65-9535-e8ba0ce02d46" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_05b155ed-be28-4e5c-9e2d-d03a858a0a53" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CommitmentsFinanceleasesfutureminimumleasepaymentsDetails_1" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CommitmentsFinanceleasesfutureminimumleasepaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/CommitmentsFinanceleasesfutureminimumleasepaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_789c4f78-d87d-4049-bc9f-f486aaf89c8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_d02cf41f-61eb-481e-b0e5-17aa172d78b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_789c4f78-d87d-4049-bc9f-f486aaf89c8f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_d02cf41f-61eb-481e-b0e5-17aa172d78b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_3243fe04-095b-4fa5-8daf-a86f99908b6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_789c4f78-d87d-4049-bc9f-f486aaf89c8f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_3243fe04-095b-4fa5-8daf-a86f99908b6a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/Warrants" xlink:type="simple" xlink:href="ocgn-20191231.xsd#Warrants"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/Warrants" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/WarrantsTables" xlink:type="simple" xlink:href="ocgn-20191231.xsd#WarrantsTables"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/WarrantsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/WarrantsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#WarrantsDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/WarrantsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/ScheduleofActivityofthePreMergerFinancingWarrantsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#ScheduleofActivityofthePreMergerFinancingWarrantsDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/ScheduleofActivityofthePreMergerFinancingWarrantsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/ScheduleofRollforwardofSeriesBWarrantLiabilityDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#ScheduleofRollforwardofSeriesBWarrantLiabilityDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/ScheduleofRollforwardofSeriesBWarrantLiabilityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ocgn-20191231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="ocgn-20191231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#ScheduleofDeferredTaxAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_61536484-a18b-415f-bbce-97b36a556ae1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_9eb5ede1-3c79-4114-a8b8-bb330c299ee2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_61536484-a18b-415f-bbce-97b36a556ae1" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_9eb5ede1-3c79-4114-a8b8-bb330c299ee2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_6911f10b-daff-4fa6-a028-4150619744a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_61536484-a18b-415f-bbce-97b36a556ae1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_6911f10b-daff-4fa6-a028-4150619744a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_65f4d07e-b30b-47bb-907e-4f81a150cd0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_95c30378-4bb5-4264-8fe4-ae64d8f6b343" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_65f4d07e-b30b-47bb-907e-4f81a150cd0d" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_95c30378-4bb5-4264-8fe4-ae64d8f6b343" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_e315b344-b89c-4e0b-b221-41cd29360bc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_65f4d07e-b30b-47bb-907e-4f81a150cd0d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_e315b344-b89c-4e0b-b221-41cd29360bc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_50aee281-9a2a-477a-b9bb-df6d3ae30303" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_65f4d07e-b30b-47bb-907e-4f81a150cd0d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_50aee281-9a2a-477a-b9bb-df6d3ae30303" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_DeferredTaxAssetsConvertibleDebt_ec6abadb-caee-4b88-82ac-a5cb16233f05" xlink:href="ocgn-20191231.xsd#ocgn_DeferredTaxAssetsConvertibleDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_65f4d07e-b30b-47bb-907e-4f81a150cd0d" xlink:to="loc_ocgn_DeferredTaxAssetsConvertibleDebt_ec6abadb-caee-4b88-82ac-a5cb16233f05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_0283ea2d-2224-41b4-a87a-fba2c63963a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_65f4d07e-b30b-47bb-907e-4f81a150cd0d" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_0283ea2d-2224-41b4-a87a-fba2c63963a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_DeferredTaxAssetsStartUpCosts_89271e1e-d18c-4ca9-bb0f-cd31069b1b53" xlink:href="ocgn-20191231.xsd#ocgn_DeferredTaxAssetsStartUpCosts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_65f4d07e-b30b-47bb-907e-4f81a150cd0d" xlink:to="loc_ocgn_DeferredTaxAssetsStartUpCosts_89271e1e-d18c-4ca9-bb0f-cd31069b1b53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_dc195e8c-329f-4bec-b570-a1b25138319c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_65f4d07e-b30b-47bb-907e-4f81a150cd0d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_dc195e8c-329f-4bec-b570-a1b25138319c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_DeferredTaxAssetsLeaseLiability_1236a68a-49ec-4b2e-8c6f-f73d57f26aa0" xlink:href="ocgn-20191231.xsd#ocgn_DeferredTaxAssetsLeaseLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_65f4d07e-b30b-47bb-907e-4f81a150cd0d" xlink:to="loc_ocgn_DeferredTaxAssetsLeaseLiability_1236a68a-49ec-4b2e-8c6f-f73d57f26aa0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_ce2b15cc-3cd6-41f5-814f-d030ddf1e076" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_65f4d07e-b30b-47bb-907e-4f81a150cd0d" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_ce2b15cc-3cd6-41f5-814f-d030ddf1e076" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#IncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/IncomeTaxesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/ScheduleofEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#ScheduleofEffectiveIncomeTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/ScheduleofEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c261aea2-28cc-409f-ba4a-4708536f0c93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_fa19c719-b791-4802-b920-ef4a5a2cda6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c261aea2-28cc-409f-ba4a-4708536f0c93" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_fa19c719-b791-4802-b920-ef4a5a2cda6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_062c25a9-54fb-4dc9-a9a4-35e8fcc7e1cc" xlink:href="ocgn-20191231.xsd#ocgn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c261aea2-28cc-409f-ba4a-4708536f0c93" xlink:to="loc_ocgn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_062c25a9-54fb-4dc9-a9a4-35e8fcc7e1cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_91825f1f-fe04-40a1-bf27-0a0e93398aef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c261aea2-28cc-409f-ba4a-4708536f0c93" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_91825f1f-fe04-40a1-bf27-0a0e93398aef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_4ec39e56-756e-4fd9-9dc5-e4b4342e1b19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c261aea2-28cc-409f-ba4a-4708536f0c93" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_4ec39e56-756e-4fd9-9dc5-e4b4342e1b19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_1ed84474-85ac-4f9b-a60a-e3e654f079e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c261aea2-28cc-409f-ba4a-4708536f0c93" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_1ed84474-85ac-4f9b-a60a-e3e654f079e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_ff3d32d1-6b17-450b-b6c7-49f4e1c7b36e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c261aea2-28cc-409f-ba4a-4708536f0c93" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_ff3d32d1-6b17-450b-b6c7-49f4e1c7b36e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/ScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#ScheduleofUnrecognizedTaxBenefitsDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/ScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SubsequentEvents" xlink:type="simple" xlink:href="ocgn-20191231.xsd#SubsequentEvents"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/SubsequentEvents" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#SubsequentEventsDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/SubsequentEventsDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>ocgn-20191231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:cc72798c-c24e-4d47-845f-93333954ce8b,g:e003b04e-ddd7-4b29-b911-f80dc6cd6725-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/Cover" xlink:type="simple" xlink:href="ocgn-20191231.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/Cover" xlink:type="extended" id="i8719a00774a14b448b9ab34c31f9b112_f09ea00d-ae91-4768-bb89-7e60efe206d1"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="i0535838e39f24db99457fecfc5737021_9d81ce20-5202-48c2-871a-e7cccd53074a"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="i96bd01ca65dc4b68be431509b50c3549_95cb7aa4-7ef6-4860-8d0d-637494510d29"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended" id="i326dff1e0746489884f806cb23db0254_3e5c8766-dc7d-4293-8a78-cb6370a77ad5"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended" id="i7a50d3e5d78749759722c89fa7b5edcb_a9e5ced4-26fc-4ad2-95af-c51fb1146e45">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1ce3e81a-2f6c-4bbd-b204-53b6c7f7986b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1ce3e81a-2f6c-4bbd-b204-53b6c7f7986b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e885e894-3e6c-4b24-ad40-a41c9d51726c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_us-gaap_SharesOutstanding_e885e894-3e6c-4b24-ad40-a41c9d51726c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8b4e8d49-03ae-43f6-946c-be6b38f51267" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_us-gaap_StockholdersEquity_8b4e8d49-03ae-43f6-946c-be6b38f51267" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e31977fa-91e7-4b89-a460-cbcf524c135b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e31977fa-91e7-4b89-a460-cbcf524c135b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_306dae05-c363-4b91-8bbd-6caf2f8fe684" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_306dae05-c363-4b91-8bbd-6caf2f8fe684" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5c288466-1759-4d39-b47f-9e69a1eeef9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_us-gaap_NetIncomeLoss_5c288466-1759-4d39-b47f-9e69a1eeef9f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5b200607-cac2-415f-a646-9f7d4de5dc68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5b200607-cac2-415f-a646-9f7d4de5dc68" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_95982991-07a8-428c-9c8c-d057879d9fbf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_95982991-07a8-428c-9c8c-d057879d9fbf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_6807958a-6b81-4794-811f-28441cfcc378" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_6807958a-6b81-4794-811f-28441cfcc378" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_425944cd-76ae-49d3-93ba-da92c99c8631" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_425944cd-76ae-49d3-93ba-da92c99c8631" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_StockIssuedDuringPeriodPreMergerShares_a17b24f0-46be-4f15-bb1a-39e9372de684" xlink:href="ocgn-20191231.xsd#ocgn_StockIssuedDuringPeriodPreMergerShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_ocgn_StockIssuedDuringPeriodPreMergerShares_a17b24f0-46be-4f15-bb1a-39e9372de684" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_StockIssuedDuringPeriodPreMergerValue_212f16e7-75b8-4e19-830e-70e91f99758b" xlink:href="ocgn-20191231.xsd#ocgn_StockIssuedDuringPeriodPreMergerValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_ocgn_StockIssuedDuringPeriodPreMergerValue_212f16e7-75b8-4e19-830e-70e91f99758b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_StockIssuedDuringPeriodSharesReverseAssetAcquisition_587d1959-c77f-4ec0-bf67-f9eeeeb37ec1" xlink:href="ocgn-20191231.xsd#ocgn_StockIssuedDuringPeriodSharesReverseAssetAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_ocgn_StockIssuedDuringPeriodSharesReverseAssetAcquisition_587d1959-c77f-4ec0-bf67-f9eeeeb37ec1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_StockIssuedDuringPeriodValueReverseAssetAcquisition_bd79e1b7-e436-4903-8d16-4315c1a8ce10" xlink:href="ocgn-20191231.xsd#ocgn_StockIssuedDuringPeriodValueReverseAssetAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_ocgn_StockIssuedDuringPeriodValueReverseAssetAcquisition_bd79e1b7-e436-4903-8d16-4315c1a8ce10" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ReclassificationOfWarrantsFromLiabilityToEquity_e617314a-9b90-4f4a-8b6f-80d657fb9fa6" xlink:href="ocgn-20191231.xsd#ocgn_ReclassificationOfWarrantsFromLiabilityToEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_ocgn_ReclassificationOfWarrantsFromLiabilityToEquity_e617314a-9b90-4f4a-8b6f-80d657fb9fa6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_StockIssuedDuringPeriodValueWarrantsExercised_fdd70957-2605-4fc7-9ab5-90d524c2b1dd" xlink:href="ocgn-20191231.xsd#ocgn_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_ocgn_StockIssuedDuringPeriodValueWarrantsExercised_fdd70957-2605-4fc7-9ab5-90d524c2b1dd" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_883915dd-0ea6-404a-83ce-1ec176289a82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_883915dd-0ea6-404a-83ce-1ec176289a82" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2e50bccf-f5cf-41b2-b478-96f4ceaf08ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e34a8fa3-64a1-419f-aa01-7dc0c84ca812" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4e28046b-06dd-45e9-a9ba-8052f5aef239" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1ce3e81a-2f6c-4bbd-b204-53b6c7f7986b" xlink:to="loc_us-gaap_StatementTable_4e28046b-06dd-45e9-a9ba-8052f5aef239" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3568bb1e-0c7c-41ed-8b73-2866241f7f60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4e28046b-06dd-45e9-a9ba-8052f5aef239" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3568bb1e-0c7c-41ed-8b73-2866241f7f60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3568bb1e-0c7c-41ed-8b73-2866241f7f60_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3568bb1e-0c7c-41ed-8b73-2866241f7f60" xlink:to="loc_us-gaap_EquityComponentDomain_3568bb1e-0c7c-41ed-8b73-2866241f7f60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_84d52f0a-1580-4676-9c84-20edcf73cb25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3568bb1e-0c7c-41ed-8b73-2866241f7f60" xlink:to="loc_us-gaap_EquityComponentDomain_84d52f0a-1580-4676-9c84-20edcf73cb25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_295cebc8-3aa4-4223-a845-f506577ff48a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_84d52f0a-1580-4676-9c84-20edcf73cb25" xlink:to="loc_us-gaap_CommonStockMember_295cebc8-3aa4-4223-a845-f506577ff48a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_ff9582b1-0020-47a2-b2e9-7613796d9bbc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_84d52f0a-1580-4676-9c84-20edcf73cb25" xlink:to="loc_us-gaap_TreasuryStockMember_ff9582b1-0020-47a2-b2e9-7613796d9bbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e4889cdf-b311-4086-bfd7-7fa6dde11efc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_84d52f0a-1580-4676-9c84-20edcf73cb25" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e4889cdf-b311-4086-bfd7-7fa6dde11efc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3a32c679-5e30-4608-bc99-f63720a8e0f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_84d52f0a-1580-4676-9c84-20edcf73cb25" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3a32c679-5e30-4608-bc99-f63720a8e0f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_90c94ca4-e76a-434b-9e7c-03cbce0aff49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_84d52f0a-1580-4676-9c84-20edcf73cb25" xlink:to="loc_us-gaap_RetainedEarningsMember_90c94ca4-e76a-434b-9e7c-03cbce0aff49" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_04b1ca20-cb99-43fa-b025-9c01f17de5f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4e28046b-06dd-45e9-a9ba-8052f5aef239" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_04b1ca20-cb99-43fa-b025-9c01f17de5f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_04b1ca20-cb99-43fa-b025-9c01f17de5f0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_04b1ca20-cb99-43fa-b025-9c01f17de5f0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_04b1ca20-cb99-43fa-b025-9c01f17de5f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_196c1073-fdf2-477e-b833-cdbd51387b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_04b1ca20-cb99-43fa-b025-9c01f17de5f0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_196c1073-fdf2-477e-b833-cdbd51387b1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_acc7c1e2-536e-4477-9b45-56edb44b9705" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_196c1073-fdf2-477e-b833-cdbd51387b1d" xlink:to="loc_us-gaap_WarrantMember_acc7c1e2-536e-4477-9b45-56edb44b9705" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended" id="i4564de83803d43fa84bd151a4afa39f7_888ac0a3-d7a2-423c-aac8-803327d6f12f"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="if900200430974b7bb0ee794106c8efd1_0e2ae238-70d0-48d6-9143-87dc8d4c3066"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/NatureofBusiness" xlink:type="simple" xlink:href="ocgn-20191231.xsd#NatureofBusiness"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/NatureofBusiness" xlink:type="extended" id="i5a51c3de39724bb6ae836a86ded45e81_ac60c1e4-d2b6-4916-8279-9c52bc406f73"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/NatureofBusinessReverseStockSplitDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#NatureofBusinessReverseStockSplitDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/NatureofBusinessReverseStockSplitDetails" xlink:type="extended" id="i0815cec1242a48819a04d11bbf237a25_de1f3d3c-6364-4902-a6fb-1c487786fa34">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_81cad3ab-b657-48ed-ac6e-052b16ece416" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_5bcdbfcb-b6d3-4177-874a-b348b9317bcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_81cad3ab-b657-48ed-ac6e-052b16ece416" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_5bcdbfcb-b6d3-4177-874a-b348b9317bcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_BusinessCombinationIssuedSharesExchangeRate_3db1da20-afc4-4d40-acb2-54f420080e5d" xlink:href="ocgn-20191231.xsd#ocgn_BusinessCombinationIssuedSharesExchangeRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_81cad3ab-b657-48ed-ac6e-052b16ece416" xlink:to="loc_ocgn_BusinessCombinationIssuedSharesExchangeRate_3db1da20-afc4-4d40-acb2-54f420080e5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_59c284d4-fbe0-41fe-871b-addceaba2614" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_81cad3ab-b657-48ed-ac6e-052b16ece416" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_59c284d4-fbe0-41fe-871b-addceaba2614" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_63cf38d4-8f3f-42af-8f11-6f7404399170" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_59c284d4-fbe0-41fe-871b-addceaba2614" xlink:to="loc_dei_LegalEntityAxis_63cf38d4-8f3f-42af-8f11-6f7404399170" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_63cf38d4-8f3f-42af-8f11-6f7404399170_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_63cf38d4-8f3f-42af-8f11-6f7404399170" xlink:to="loc_dei_EntityDomain_63cf38d4-8f3f-42af-8f11-6f7404399170_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_453b1ffc-980a-40ef-b8ec-81d047376196" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_63cf38d4-8f3f-42af-8f11-6f7404399170" xlink:to="loc_dei_EntityDomain_453b1ffc-980a-40ef-b8ec-81d047376196" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_HistogenicsCorporationMember_a47ff01b-9bd7-4524-b6c0-fb40a01b6ec7" xlink:href="ocgn-20191231.xsd#ocgn_HistogenicsCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_453b1ffc-980a-40ef-b8ec-81d047376196" xlink:to="loc_ocgn_HistogenicsCorporationMember_a47ff01b-9bd7-4524-b6c0-fb40a01b6ec7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/NatureofBusinessGoingConcernDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#NatureofBusinessGoingConcernDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/NatureofBusinessGoingConcernDetails" xlink:type="extended" id="ib035057c6ba946b780d0a6d2ee488149_638ec817-6125-4798-b4ac-03cb5de08da0"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ocgn-20191231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="iec0e0dc2f9fd4002bb6327ee98a55538_70c246ce-329d-4690-a7f8-274e6dd6112b"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ocgn-20191231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="ib02d26e859bf4362a14d05da8f869243_78870b71-b756-4b94-8eb9-4fead4b1009d"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ocgn-20191231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="i8adb63201e9c426f9e39ff4942457790_baf066ca-d61a-4edb-b42f-c58923b7e928"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i8a2eaa487c86412788620c591be5b5d2_610a10f2-6481-4607-9365-f2a4acc41626">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_438565da-3aa6-4168-a510-716667bc67de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_cad6a211-957b-4b72-a79d-2af4713dbed3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_438565da-3aa6-4168-a510-716667bc67de" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_cad6a211-957b-4b72-a79d-2af4713dbed3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_453673ea-4099-421f-8789-2ec81d25230d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_438565da-3aa6-4168-a510-716667bc67de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_453673ea-4099-421f-8789-2ec81d25230d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9ff33384-62f9-46fb-b09a-c90f3fcc3efd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_438565da-3aa6-4168-a510-716667bc67de" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9ff33384-62f9-46fb-b09a-c90f3fcc3efd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3f7a1c49-cf5f-475f-8c53-71b292cba617" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_438565da-3aa6-4168-a510-716667bc67de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3f7a1c49-cf5f-475f-8c53-71b292cba617" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_f6318bfc-3fc7-47a4-9fb7-0df0280c9743" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_438565da-3aa6-4168-a510-716667bc67de" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_f6318bfc-3fc7-47a4-9fb7-0df0280c9743" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_01a564f2-34bc-4109-831c-33c7e04409ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_438565da-3aa6-4168-a510-716667bc67de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_01a564f2-34bc-4109-831c-33c7e04409ee" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_23ea6729-f0b7-4d8a-aa26-23a873822574" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_438565da-3aa6-4168-a510-716667bc67de" xlink:to="loc_us-gaap_NumberOfOperatingSegments_23ea6729-f0b7-4d8a-aa26-23a873822574" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LeaseRightOfUseAsset_b21e3d21-7a7e-4e0f-bcf2-6a34234a340b" xlink:href="ocgn-20191231.xsd#ocgn_LeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_438565da-3aa6-4168-a510-716667bc67de" xlink:to="loc_ocgn_LeaseRightOfUseAsset_b21e3d21-7a7e-4e0f-bcf2-6a34234a340b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LeaseLiability_b711cdad-6663-402a-a089-0a61adcaee64" xlink:href="ocgn-20191231.xsd#ocgn_LeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_438565da-3aa6-4168-a510-716667bc67de" xlink:to="loc_ocgn_LeaseLiability_b711cdad-6663-402a-a089-0a61adcaee64" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_c09ab41a-c379-4586-840e-21ed2a4f0387" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_438565da-3aa6-4168-a510-716667bc67de" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_c09ab41a-c379-4586-840e-21ed2a4f0387" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_d050879b-422b-4131-858b-d04f3e8efdbb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_c09ab41a-c379-4586-840e-21ed2a4f0387" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_d050879b-422b-4131-858b-d04f3e8efdbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_d050879b-422b-4131-858b-d04f3e8efdbb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_d050879b-422b-4131-858b-d04f3e8efdbb" xlink:to="loc_us-gaap_TypeOfAdoptionMember_d050879b-422b-4131-858b-d04f3e8efdbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_c0de1e4f-6af2-4680-8bf8-8a6e5342ab0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_d050879b-422b-4131-858b-d04f3e8efdbb" xlink:to="loc_us-gaap_TypeOfAdoptionMember_c0de1e4f-6af2-4680-8bf8-8a6e5342ab0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_e07bdb60-c479-43c2-a3f8-01f753bdff29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_c0de1e4f-6af2-4680-8bf8-8a6e5342ab0b" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_e07bdb60-c479-43c2-a3f8-01f753bdff29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d0b17f94-31aa-410a-bb87-26d84d13ae68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_c09ab41a-c379-4586-840e-21ed2a4f0387" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d0b17f94-31aa-410a-bb87-26d84d13ae68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d0b17f94-31aa-410a-bb87-26d84d13ae68_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d0b17f94-31aa-410a-bb87-26d84d13ae68" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d0b17f94-31aa-410a-bb87-26d84d13ae68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ff324dc0-9ac7-4192-8882-2ce282e8fca0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d0b17f94-31aa-410a-bb87-26d84d13ae68" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ff324dc0-9ac7-4192-8882-2ce282e8fca0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_b3acb432-ea02-458c-82a0-cd67ebb84ff8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ff324dc0-9ac7-4192-8882-2ce282e8fca0" xlink:to="loc_us-gaap_EquipmentMember_b3acb432-ea02-458c-82a0-cd67ebb84ff8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_4b41f533-e9d4-429f-8e4e-c26af5599084" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ff324dc0-9ac7-4192-8882-2ce282e8fca0" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_4b41f533-e9d4-429f-8e4e-c26af5599084" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EquipmentAndFurnitureMember_b56bedaa-9c26-421e-8faf-c6355e8306ac" xlink:href="ocgn-20191231.xsd#ocgn_EquipmentAndFurnitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ff324dc0-9ac7-4192-8882-2ce282e8fca0" xlink:to="loc_ocgn_EquipmentAndFurnitureMember_b56bedaa-9c26-421e-8faf-c6355e8306ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_549d5383-c78c-4cfe-a5d9-024733d4ec89" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_c09ab41a-c379-4586-840e-21ed2a4f0387" xlink:to="loc_srt_RangeAxis_549d5383-c78c-4cfe-a5d9-024733d4ec89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_549d5383-c78c-4cfe-a5d9-024733d4ec89_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_549d5383-c78c-4cfe-a5d9-024733d4ec89" xlink:to="loc_srt_RangeMember_549d5383-c78c-4cfe-a5d9-024733d4ec89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_50a2a104-7079-41d1-8158-26bad3ea19e3" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_549d5383-c78c-4cfe-a5d9-024733d4ec89" xlink:to="loc_srt_RangeMember_50a2a104-7079-41d1-8158-26bad3ea19e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ac0d3daf-5140-4b30-bd1b-bc4aa1434b7e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_50a2a104-7079-41d1-8158-26bad3ea19e3" xlink:to="loc_srt_MinimumMember_ac0d3daf-5140-4b30-bd1b-bc4aa1434b7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_00c15e08-6103-470b-bda8-53021a6041ff" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_50a2a104-7079-41d1-8158-26bad3ea19e3" xlink:to="loc_srt_MaximumMember_00c15e08-6103-470b-bda8-53021a6041ff" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesSummaryCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#SummaryofSignificantAccountingPoliciesSummaryCashCashEquivalentsandRestrictedCashDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesSummaryCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended" id="i6e4825ca76c04f67947886b73bda2f4e_dc9f30c4-d73f-4c23-9e9b-04516e95a225"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/MergerandPreMergerFinancing" xlink:type="simple" xlink:href="ocgn-20191231.xsd#MergerandPreMergerFinancing"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/MergerandPreMergerFinancing" xlink:type="extended" id="i24dca051918f42ecae6b601c6c08433b_3644b26b-3250-430c-9240-cb7b37b2122d"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/MergerandPreMergerFinancingTables" xlink:type="simple" xlink:href="ocgn-20191231.xsd#MergerandPreMergerFinancingTables"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/MergerandPreMergerFinancingTables" xlink:type="extended" id="i104be09a086f4d76a528511b2dbc1b5b_aa2104ab-53b7-4905-9579-66387ebddbd8"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#MergerandFinancingPreMergerFinancingDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails" xlink:type="extended" id="iacf652e598944d13bbbcd696fc1292d9_a1b59a88-c944-4dda-bac9-d007cfee062e">
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ReverseMergerAndFinancingDisclosureLineItems_42bfdcca-c69f-4fc8-9008-0b2269eb3098" xlink:href="ocgn-20191231.xsd#ocgn_ReverseMergerAndFinancingDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfSharesAgreedToIssuePriorToMergerToInvestors_728acffb-a374-4696-9d4d-98e59f84fcb3" xlink:href="ocgn-20191231.xsd#ocgn_NumberOfSharesAgreedToIssuePriorToMergerToInvestors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureLineItems_42bfdcca-c69f-4fc8-9008-0b2269eb3098" xlink:to="loc_ocgn_NumberOfSharesAgreedToIssuePriorToMergerToInvestors_728acffb-a374-4696-9d4d-98e59f84fcb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfConvertedInitialSharesAgreedToIssuePriorToMergerToInvestors_f424d735-20e6-4cd8-b14b-b56fdba803ac" xlink:href="ocgn-20191231.xsd#ocgn_NumberOfConvertedInitialSharesAgreedToIssuePriorToMergerToInvestors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureLineItems_42bfdcca-c69f-4fc8-9008-0b2269eb3098" xlink:to="loc_ocgn_NumberOfConvertedInitialSharesAgreedToIssuePriorToMergerToInvestors_f424d735-20e6-4cd8-b14b-b56fdba803ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfConvertedAdditionalSharesAgreedToIssuePriorToMergerToInvestors_fab2f876-e716-4adb-a6fe-fe4c9bb043a4" xlink:href="ocgn-20191231.xsd#ocgn_NumberOfConvertedAdditionalSharesAgreedToIssuePriorToMergerToInvestors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureLineItems_42bfdcca-c69f-4fc8-9008-0b2269eb3098" xlink:to="loc_ocgn_NumberOfConvertedAdditionalSharesAgreedToIssuePriorToMergerToInvestors_fab2f876-e716-4adb-a6fe-fe4c9bb043a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_d2a6304c-2b38-4866-a7b0-ccc3aabca69c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureLineItems_42bfdcca-c69f-4fc8-9008-0b2269eb3098" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_d2a6304c-2b38-4866-a7b0-ccc3aabca69c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger_c540539d-a4b8-46f8-912c-8dcc25b69cde" xlink:href="ocgn-20191231.xsd#ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureLineItems_42bfdcca-c69f-4fc8-9008-0b2269eb3098" xlink:to="loc_ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger_c540539d-a4b8-46f8-912c-8dcc25b69cde" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPeriod_08c7fe91-3fc0-4cb4-80a5-acec8685edd6" xlink:href="ocgn-20191231.xsd#ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureLineItems_42bfdcca-c69f-4fc8-9008-0b2269eb3098" xlink:to="loc_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPeriod_08c7fe91-3fc0-4cb4-80a5-acec8685edd6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_MergerAcquisitionCostsIncurred_c0849ee6-b8ee-4a2b-a317-266fefbe1878" xlink:href="ocgn-20191231.xsd#ocgn_MergerAcquisitionCostsIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureLineItems_42bfdcca-c69f-4fc8-9008-0b2269eb3098" xlink:to="loc_ocgn_MergerAcquisitionCostsIncurred_c0849ee6-b8ee-4a2b-a317-266fefbe1878" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_1f96306b-841c-46df-99d3-f72e6342eaed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureLineItems_42bfdcca-c69f-4fc8-9008-0b2269eb3098" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_1f96306b-841c-46df-99d3-f72e6342eaed" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_StockIssuanceCostsRecognized_c34bc844-9322-45d6-82a6-8290e59a280c" xlink:href="ocgn-20191231.xsd#ocgn_StockIssuanceCostsRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureLineItems_42bfdcca-c69f-4fc8-9008-0b2269eb3098" xlink:to="loc_ocgn_StockIssuanceCostsRecognized_c34bc844-9322-45d6-82a6-8290e59a280c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_96766263-29ce-4466-bbc7-22e2e3dc812c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureLineItems_42bfdcca-c69f-4fc8-9008-0b2269eb3098" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_96766263-29ce-4466-bbc7-22e2e3dc812c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_02728bdc-ae2d-4969-95c6-5f8705067fc3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureLineItems_42bfdcca-c69f-4fc8-9008-0b2269eb3098" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_02728bdc-ae2d-4969-95c6-5f8705067fc3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NetProceedsFromReverseMerger_f4b3841b-d40f-40cc-9544-9abdace0f1ff" xlink:href="ocgn-20191231.xsd#ocgn_NetProceedsFromReverseMerger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureLineItems_42bfdcca-c69f-4fc8-9008-0b2269eb3098" xlink:to="loc_ocgn_NetProceedsFromReverseMerger_f4b3841b-d40f-40cc-9544-9abdace0f1ff" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ReverseMergerAndFinancingDisclosureTable_eec8600d-e313-408e-82c5-f5eb05bf8a6c" xlink:href="ocgn-20191231.xsd#ocgn_ReverseMergerAndFinancingDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureLineItems_42bfdcca-c69f-4fc8-9008-0b2269eb3098" xlink:to="loc_ocgn_ReverseMergerAndFinancingDisclosureTable_eec8600d-e313-408e-82c5-f5eb05bf8a6c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7ef20d1d-c191-46d3-97eb-dc1d638706d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureTable_eec8600d-e313-408e-82c5-f5eb05bf8a6c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7ef20d1d-c191-46d3-97eb-dc1d638706d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7ef20d1d-c191-46d3-97eb-dc1d638706d7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7ef20d1d-c191-46d3-97eb-dc1d638706d7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7ef20d1d-c191-46d3-97eb-dc1d638706d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d10ac1d9-d452-44f4-95f0-32bf271ecd2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7ef20d1d-c191-46d3-97eb-dc1d638706d7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d10ac1d9-d452-44f4-95f0-32bf271ecd2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SecuritiesPurchaseAgreementMember_a8ca2bd3-6acb-43ff-b04d-bc1862c62634" xlink:href="ocgn-20191231.xsd#ocgn_SecuritiesPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d10ac1d9-d452-44f4-95f0-32bf271ecd2a" xlink:to="loc_ocgn_SecuritiesPurchaseAgreementMember_a8ca2bd3-6acb-43ff-b04d-bc1862c62634" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_19ddbd6f-a5cd-4b59-9519-1298513782e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureTable_eec8600d-e313-408e-82c5-f5eb05bf8a6c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_19ddbd6f-a5cd-4b59-9519-1298513782e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_19ddbd6f-a5cd-4b59-9519-1298513782e5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_19ddbd6f-a5cd-4b59-9519-1298513782e5" xlink:to="loc_us-gaap_EquityComponentDomain_19ddbd6f-a5cd-4b59-9519-1298513782e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_475eafc7-bc43-4f6d-b292-1eab6050981f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_19ddbd6f-a5cd-4b59-9519-1298513782e5" xlink:to="loc_us-gaap_EquityComponentDomain_475eafc7-bc43-4f6d-b292-1eab6050981f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesAWarrantsAndSeriesCWarrantsMember_006dd1a5-a934-4615-92df-98180aa4c7f5" xlink:href="ocgn-20191231.xsd#ocgn_SeriesAWarrantsAndSeriesCWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_475eafc7-bc43-4f6d-b292-1eab6050981f" xlink:to="loc_ocgn_SeriesAWarrantsAndSeriesCWarrantsMember_006dd1a5-a934-4615-92df-98180aa4c7f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesBWarrantsMember_75163fcd-8a23-4fcc-b560-763d2feecc8e" xlink:href="ocgn-20191231.xsd#ocgn_SeriesBWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_475eafc7-bc43-4f6d-b292-1eab6050981f" xlink:to="loc_ocgn_SeriesBWarrantsMember_75163fcd-8a23-4fcc-b560-763d2feecc8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0ab65acb-9bf2-499b-9318-b896dacd18b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureTable_eec8600d-e313-408e-82c5-f5eb05bf8a6c" xlink:to="loc_us-gaap_DebtInstrumentAxis_0ab65acb-9bf2-499b-9318-b896dacd18b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0ab65acb-9bf2-499b-9318-b896dacd18b0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0ab65acb-9bf2-499b-9318-b896dacd18b0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0ab65acb-9bf2-499b-9318-b896dacd18b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_30853bb9-3e47-417c-9234-73f165d2522a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0ab65acb-9bf2-499b-9318-b896dacd18b0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_30853bb9-3e47-417c-9234-73f165d2522a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeniorSecuredConvertibleNotesMember_57d1e7e2-9f67-43dc-98d5-e588b7c2948e" xlink:href="ocgn-20191231.xsd#ocgn_SeniorSecuredConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30853bb9-3e47-417c-9234-73f165d2522a" xlink:to="loc_ocgn_SeniorSecuredConvertibleNotesMember_57d1e7e2-9f67-43dc-98d5-e588b7c2948e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#MergerandFinancingMergerwithHistogenicsDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails" xlink:type="extended" id="i468cd1754fd54f64932af0ad2092aeef_a169099a-9e3d-49d8-a8bd-0f438254e655">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f555f0ad-0ecb-4877-aa9e-ec3284baf58f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_26d56bde-f554-4d3b-822c-fe4f7c8fc6e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f555f0ad-0ecb-4877-aa9e-ec3284baf58f" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_26d56bde-f554-4d3b-822c-fe4f7c8fc6e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_1e9db7f6-217d-47e5-b0f8-de8276c29a4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f555f0ad-0ecb-4877-aa9e-ec3284baf58f" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_1e9db7f6-217d-47e5-b0f8-de8276c29a4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForMergerRelatedCosts_7409e706-9cd4-48f9-97c6-9c07bd243825" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForMergerRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f555f0ad-0ecb-4877-aa9e-ec3284baf58f" xlink:to="loc_us-gaap_PaymentsForMergerRelatedCosts_7409e706-9cd4-48f9-97c6-9c07bd243825" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AdjustmentsToAdditionalPaidInCapitalMergerRelatedCosts_d65cbfae-2e86-4f1c-800a-6ee6299213a2" xlink:href="ocgn-20191231.xsd#ocgn_AdjustmentsToAdditionalPaidInCapitalMergerRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f555f0ad-0ecb-4877-aa9e-ec3284baf58f" xlink:to="loc_ocgn_AdjustmentsToAdditionalPaidInCapitalMergerRelatedCosts_d65cbfae-2e86-4f1c-800a-6ee6299213a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_86ca139c-1e20-481e-9a54-5b558ff08408" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f555f0ad-0ecb-4877-aa9e-ec3284baf58f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_86ca139c-1e20-481e-9a54-5b558ff08408" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AssetsHeldForSale_bafc3133-56cb-4f64-b0d4-14654f9475d5" xlink:href="ocgn-20191231.xsd#ocgn_AssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f555f0ad-0ecb-4877-aa9e-ec3284baf58f" xlink:to="loc_ocgn_AssetsHeldForSale_bafc3133-56cb-4f64-b0d4-14654f9475d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4f73a10e-cfd7-4011-af56-74a0eaee36c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f555f0ad-0ecb-4877-aa9e-ec3284baf58f" xlink:to="loc_us-gaap_AccountsPayableCurrent_4f73a10e-cfd7-4011-af56-74a0eaee36c6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNet_77e1602c-cd78-4aba-96f1-e855666ab29d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f555f0ad-0ecb-4877-aa9e-ec3284baf58f" xlink:to="loc_us-gaap_AssetsNet_77e1602c-cd78-4aba-96f1-e855666ab29d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AssetPurchaseAgreementCashConsideration_521e14f6-eb07-42a7-94e4-4136c58fb291" xlink:href="ocgn-20191231.xsd#ocgn_AssetPurchaseAgreementCashConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f555f0ad-0ecb-4877-aa9e-ec3284baf58f" xlink:to="loc_ocgn_AssetPurchaseAgreementCashConsideration_521e14f6-eb07-42a7-94e4-4136c58fb291" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_PercentageOfIncreaseInPurchasePriceOfAssetPerMonth_de96bb4c-478a-4832-bed7-6d20e1716a5b" xlink:href="ocgn-20191231.xsd#ocgn_PercentageOfIncreaseInPurchasePriceOfAssetPerMonth"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f555f0ad-0ecb-4877-aa9e-ec3284baf58f" xlink:to="loc_ocgn_PercentageOfIncreaseInPurchasePriceOfAssetPerMonth_de96bb4c-478a-4832-bed7-6d20e1716a5b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_fd728220-f708-4384-bfef-a6f680c10529" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f555f0ad-0ecb-4877-aa9e-ec3284baf58f" xlink:to="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_fd728220-f708-4384-bfef-a6f680c10529" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_57ec5450-5307-4b64-9b9e-7a1a6ba87458" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f555f0ad-0ecb-4877-aa9e-ec3284baf58f" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_57ec5450-5307-4b64-9b9e-7a1a6ba87458" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bab71755-24c3-4f92-853a-9c678313566c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f555f0ad-0ecb-4877-aa9e-ec3284baf58f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bab71755-24c3-4f92-853a-9c678313566c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_0aee939e-61b2-4fca-bffe-6250c40c7f40" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bab71755-24c3-4f92-853a-9c678313566c" xlink:to="loc_dei_LegalEntityAxis_0aee939e-61b2-4fca-bffe-6250c40c7f40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0aee939e-61b2-4fca-bffe-6250c40c7f40_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_0aee939e-61b2-4fca-bffe-6250c40c7f40" xlink:to="loc_dei_EntityDomain_0aee939e-61b2-4fca-bffe-6250c40c7f40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9ba4f696-10cb-4be0-a54a-a359fd91daa3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_0aee939e-61b2-4fca-bffe-6250c40c7f40" xlink:to="loc_dei_EntityDomain_9ba4f696-10cb-4be0-a54a-a359fd91daa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EquityHoldersOfOcugenIncPerMergerMember_408d1de7-3e6c-48cb-b600-e4758162fec4" xlink:href="ocgn-20191231.xsd#ocgn_EquityHoldersOfOcugenIncPerMergerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9ba4f696-10cb-4be0-a54a-a359fd91daa3" xlink:to="loc_ocgn_EquityHoldersOfOcugenIncPerMergerMember_408d1de7-3e6c-48cb-b600-e4758162fec4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EquityHoldersOfHistogenicsCorporationMember_089441e1-d1c5-49d7-a593-797201e9eb4f" xlink:href="ocgn-20191231.xsd#ocgn_EquityHoldersOfHistogenicsCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9ba4f696-10cb-4be0-a54a-a359fd91daa3" xlink:to="loc_ocgn_EquityHoldersOfHistogenicsCorporationMember_089441e1-d1c5-49d7-a593-797201e9eb4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_HistogenicsCorporationMember_33dbf45c-d2f5-4d05-ada8-9737447d9bdd" xlink:href="ocgn-20191231.xsd#ocgn_HistogenicsCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9ba4f696-10cb-4be0-a54a-a359fd91daa3" xlink:to="loc_ocgn_HistogenicsCorporationMember_33dbf45c-d2f5-4d05-ada8-9737447d9bdd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a8a167cb-ae3e-4d60-aea7-fdcbad627c7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bab71755-24c3-4f92-853a-9c678313566c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a8a167cb-ae3e-4d60-aea7-fdcbad627c7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a8a167cb-ae3e-4d60-aea7-fdcbad627c7b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a8a167cb-ae3e-4d60-aea7-fdcbad627c7b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a8a167cb-ae3e-4d60-aea7-fdcbad627c7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c9d037d7-e804-48bb-8513-0245a606b5d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a8a167cb-ae3e-4d60-aea7-fdcbad627c7b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c9d037d7-e804-48bb-8513-0245a606b5d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_HistogenicsCorporationMember_69af2b9c-6917-4ef7-98d0-fb61cc050c03" xlink:href="ocgn-20191231.xsd#ocgn_HistogenicsCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c9d037d7-e804-48bb-8513-0245a606b5d7" xlink:to="loc_ocgn_HistogenicsCorporationMember_69af2b9c-6917-4ef7-98d0-fb61cc050c03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NeocartMember_82900093-e31c-4133-a45c-23b280941f42" xlink:href="ocgn-20191231.xsd#ocgn_NeocartMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c9d037d7-e804-48bb-8513-0245a606b5d7" xlink:to="loc_ocgn_NeocartMember_82900093-e31c-4133-a45c-23b280941f42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_286ac42c-49ff-4294-acef-490d769f89e4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bab71755-24c3-4f92-853a-9c678313566c" xlink:to="loc_srt_OwnershipAxis_286ac42c-49ff-4294-acef-490d769f89e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_286ac42c-49ff-4294-acef-490d769f89e4_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_286ac42c-49ff-4294-acef-490d769f89e4" xlink:to="loc_srt_OwnershipDomain_286ac42c-49ff-4294-acef-490d769f89e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_d036b66b-9870-489c-a438-d1d358e26952" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_286ac42c-49ff-4294-acef-490d769f89e4" xlink:to="loc_srt_OwnershipDomain_d036b66b-9870-489c-a438-d1d358e26952" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_HistogenicsCorporationMember_405440ae-2a61-4b73-a171-5d1d5b066d2d" xlink:href="ocgn-20191231.xsd#ocgn_HistogenicsCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_d036b66b-9870-489c-a438-d1d358e26952" xlink:to="loc_ocgn_HistogenicsCorporationMember_405440ae-2a61-4b73-a171-5d1d5b066d2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9abe2ec5-6b38-429d-8ba3-e9ff40f65c8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bab71755-24c3-4f92-853a-9c678313566c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9abe2ec5-6b38-429d-8ba3-e9ff40f65c8a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9abe2ec5-6b38-429d-8ba3-e9ff40f65c8a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9abe2ec5-6b38-429d-8ba3-e9ff40f65c8a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9abe2ec5-6b38-429d-8ba3-e9ff40f65c8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a81818e9-a0b6-433c-ae6a-5a9f0efe6de7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9abe2ec5-6b38-429d-8ba3-e9ff40f65c8a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a81818e9-a0b6-433c-ae6a-5a9f0efe6de7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_889c1c76-3ad7-4c15-bc01-c1ac86b1ada5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a81818e9-a0b6-433c-ae6a-5a9f0efe6de7" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_889c1c76-3ad7-4c15-bc01-c1ac86b1ada5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStock" xlink:type="simple" xlink:href="ocgn-20191231.xsd#NetLossPerShareofCommonStock"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStock" xlink:type="extended" id="i18a74535fe0c47f1a3e0ddc89b136a64_d2329417-85dc-4e62-be18-6458c5903cef"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockTables" xlink:type="simple" xlink:href="ocgn-20191231.xsd#NetLossPerShareofCommonStockTables"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockTables" xlink:type="extended" id="idbd30fe935f64720967d9136bcb3096d_4c12aae5-2e69-4eeb-9b5b-f3c67a3626e2"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#NetLossPerShareofCommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockDetails" xlink:type="extended" id="i2d7277508c9b49e7a3ec71a23dc559cc_af91f673-d125-482a-a9f0-28a2ec03c26a">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d9507fab-1c27-464d-8c11-99640dfc7e49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_acd8d005-52d0-4aa1-b97d-fd9b2315a717" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d9507fab-1c27-464d-8c11-99640dfc7e49" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_acd8d005-52d0-4aa1-b97d-fd9b2315a717" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6eec9029-c11d-4b1b-bcad-c23930d99de2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d9507fab-1c27-464d-8c11-99640dfc7e49" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6eec9029-c11d-4b1b-bcad-c23930d99de2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c1895cd9-9aa6-49e2-8b90-3e5fadc25327" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d9507fab-1c27-464d-8c11-99640dfc7e49" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c1895cd9-9aa6-49e2-8b90-3e5fadc25327" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_38a6a9d3-cedd-4b14-b928-843a5db029c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d9507fab-1c27-464d-8c11-99640dfc7e49" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_38a6a9d3-cedd-4b14-b928-843a5db029c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_5fb612d7-01f9-4bb9-bf16-dce905e4e34f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d9507fab-1c27-464d-8c11-99640dfc7e49" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_5fb612d7-01f9-4bb9-bf16-dce905e4e34f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f6c1b75e-0def-460d-93be-f6758a95b26f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_5fb612d7-01f9-4bb9-bf16-dce905e4e34f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f6c1b75e-0def-460d-93be-f6758a95b26f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_66ed097e-5c41-4e5d-ac8a-2bab2dd6097f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d9507fab-1c27-464d-8c11-99640dfc7e49" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_66ed097e-5c41-4e5d-ac8a-2bab2dd6097f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c9698c6c-95d1-4ba2-9bc7-744fe4547591" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_66ed097e-5c41-4e5d-ac8a-2bab2dd6097f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c9698c6c-95d1-4ba2-9bc7-744fe4547591" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c9698c6c-95d1-4ba2-9bc7-744fe4547591_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c9698c6c-95d1-4ba2-9bc7-744fe4547591" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c9698c6c-95d1-4ba2-9bc7-744fe4547591_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3fe6daa9-d2b4-4456-9569-925476ea2768" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c9698c6c-95d1-4ba2-9bc7-744fe4547591" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3fe6daa9-d2b4-4456-9569-925476ea2768" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_c8362cfb-99ee-4c87-a93b-feeb1a4ce1ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3fe6daa9-d2b4-4456-9569-925476ea2768" xlink:to="loc_us-gaap_StockOptionMember_c8362cfb-99ee-4c87-a93b-feeb1a4ce1ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_f0994b6d-8e5d-42b8-a4b0-b89aed261a02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3fe6daa9-d2b4-4456-9569-925476ea2768" xlink:to="loc_us-gaap_WarrantMember_f0994b6d-8e5d-42b8-a4b0-b89aed261a02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesWarrantsMember_4d4a0b3f-4d56-4514-a3d8-a56597676bf2" xlink:href="ocgn-20191231.xsd#ocgn_SeriesWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3fe6daa9-d2b4-4456-9569-925476ea2768" xlink:to="loc_ocgn_SeriesWarrantsMember_4d4a0b3f-4d56-4514-a3d8-a56597676bf2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesBWarrantsMember_c9170ef2-430c-402a-879f-9ef59dd82441" xlink:href="ocgn-20191231.xsd#ocgn_SeriesBWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3fe6daa9-d2b4-4456-9569-925476ea2768" xlink:to="loc_ocgn_SeriesBWarrantsMember_c9170ef2-430c-402a-879f-9ef59dd82441" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesCWarrantsMember_9c277d86-2943-4f6b-a12a-3a7ba3014137" xlink:href="ocgn-20191231.xsd#ocgn_SeriesCWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3fe6daa9-d2b4-4456-9569-925476ea2768" xlink:to="loc_ocgn_SeriesCWarrantsMember_9c277d86-2943-4f6b-a12a-3a7ba3014137" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/LicenseandCollaborationAgreements" xlink:type="simple" xlink:href="ocgn-20191231.xsd#LicenseandCollaborationAgreements"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/LicenseandCollaborationAgreements" xlink:type="extended" id="i1379d315c2f040869bc7568900f47af5_40543dee-7744-4085-bf2c-6620ccfdd6f3"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#LicenseandCollaborationAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails" xlink:type="extended" id="id8959611e3fd47258368882fade9ab4a_62c120cf-f21c-4023-a629-a672bb1193ea">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d45ee091-1f92-4e63-ae9a-8943f4f57e53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborationAgreementTerm_bc2cbf5d-d60d-434e-b542-9a392ac4a1da" xlink:href="ocgn-20191231.xsd#ocgn_CollaborationAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d45ee091-1f92-4e63-ae9a-8943f4f57e53" xlink:to="loc_ocgn_CollaborationAgreementTerm_bc2cbf5d-d60d-434e-b542-9a392ac4a1da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborationAgreementTerminationDevelopmentCostStatement_99e58e40-69c5-4a5e-84e7-5abdf30ed8d0" xlink:href="ocgn-20191231.xsd#ocgn_CollaborationAgreementTerminationDevelopmentCostStatement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d45ee091-1f92-4e63-ae9a-8943f4f57e53" xlink:to="loc_ocgn_CollaborationAgreementTerminationDevelopmentCostStatement_99e58e40-69c5-4a5e-84e7-5abdf30ed8d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborationAgreementTerminationDevelopmentCostPayment_8e933577-ed38-471d-bfe0-4f7ecd11d65f" xlink:href="ocgn-20191231.xsd#ocgn_CollaborationAgreementTerminationDevelopmentCostPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d45ee091-1f92-4e63-ae9a-8943f4f57e53" xlink:to="loc_ocgn_CollaborationAgreementTerminationDevelopmentCostPayment_8e933577-ed38-471d-bfe0-4f7ecd11d65f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LicenseAgreementPayment_f8cbf696-d4fd-4681-b3d8-836ad22f427c" xlink:href="ocgn-20191231.xsd#ocgn_LicenseAgreementPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d45ee091-1f92-4e63-ae9a-8943f4f57e53" xlink:to="loc_ocgn_LicenseAgreementPayment_f8cbf696-d4fd-4681-b3d8-836ad22f427c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment_b6229ba6-9699-41cc-be26-e4f787613ed9" xlink:href="ocgn-20191231.xsd#ocgn_LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d45ee091-1f92-4e63-ae9a-8943f4f57e53" xlink:to="loc_ocgn_LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment_b6229ba6-9699-41cc-be26-e4f787613ed9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LicenseAgreementPotentialCommercialMilestonePayment_447a7cd9-9390-463f-a0ea-bd3536ea7f85" xlink:href="ocgn-20191231.xsd#ocgn_LicenseAgreementPotentialCommercialMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d45ee091-1f92-4e63-ae9a-8943f4f57e53" xlink:to="loc_ocgn_LicenseAgreementPotentialCommercialMilestonePayment_447a7cd9-9390-463f-a0ea-bd3536ea7f85" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LicenseAgreementMilestonePayment_b77b2062-6175-4fcc-8aa5-ca3f3d830cae" xlink:href="ocgn-20191231.xsd#ocgn_LicenseAgreementMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d45ee091-1f92-4e63-ae9a-8943f4f57e53" xlink:to="loc_ocgn_LicenseAgreementMilestonePayment_b77b2062-6175-4fcc-8aa5-ca3f3d830cae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_ad4d8f23-bea7-494a-8176-01a8c168d372" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d45ee091-1f92-4e63-ae9a-8943f4f57e53" xlink:to="loc_us-gaap_PaymentsForRoyalties_ad4d8f23-bea7-494a-8176-01a8c168d372" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LicenseAgreementCancellationPeriodNotice_1a170b47-c095-4c59-8932-7e779dd42781" xlink:href="ocgn-20191231.xsd#ocgn_LicenseAgreementCancellationPeriodNotice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d45ee091-1f92-4e63-ae9a-8943f4f57e53" xlink:to="loc_ocgn_LicenseAgreementCancellationPeriodNotice_1a170b47-c095-4c59-8932-7e779dd42781" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_78aa7bbc-b595-4e3b-9bbd-0d53871a07f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d45ee091-1f92-4e63-ae9a-8943f4f57e53" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_78aa7bbc-b595-4e3b-9bbd-0d53871a07f9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LicenseAgreementSigningFee_9c2e7206-7f57-4ae9-bb00-2def3d49f1a0" xlink:href="ocgn-20191231.xsd#ocgn_LicenseAgreementSigningFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d45ee091-1f92-4e63-ae9a-8943f4f57e53" xlink:to="loc_ocgn_LicenseAgreementSigningFee_9c2e7206-7f57-4ae9-bb00-2def3d49f1a0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LicenseAgreementMinimumAnnualRoyaltyPayment_4ec91f0e-e075-4107-b2ab-6c2e0dc6769b" xlink:href="ocgn-20191231.xsd#ocgn_LicenseAgreementMinimumAnnualRoyaltyPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d45ee091-1f92-4e63-ae9a-8943f4f57e53" xlink:to="loc_ocgn_LicenseAgreementMinimumAnnualRoyaltyPayment_4ec91f0e-e075-4107-b2ab-6c2e0dc6769b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a699d216-c627-46cb-b9a3-27a6ab1ee560" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d45ee091-1f92-4e63-ae9a-8943f4f57e53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a699d216-c627-46cb-b9a3-27a6ab1ee560" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dfb93697-ca0b-4b25-a70d-f667d11cb704" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d45ee091-1f92-4e63-ae9a-8943f4f57e53" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dfb93697-ca0b-4b25-a70d-f667d11cb704" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0fd643f8-2e03-4dd6-bb9e-3564dd182dde" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dfb93697-ca0b-4b25-a70d-f667d11cb704" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0fd643f8-2e03-4dd6-bb9e-3564dd182dde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0fd643f8-2e03-4dd6-bb9e-3564dd182dde_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0fd643f8-2e03-4dd6-bb9e-3564dd182dde" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0fd643f8-2e03-4dd6-bb9e-3564dd182dde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d7d733bb-4368-4c1c-b11d-5cdb8324d1e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0fd643f8-2e03-4dd6-bb9e-3564dd182dde" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d7d733bb-4368-4c1c-b11d-5cdb8324d1e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborationAgreementWithCansinoBiologicsMember_bb3be37f-f974-4642-82f1-76c979097b66" xlink:href="ocgn-20191231.xsd#ocgn_CollaborationAgreementWithCansinoBiologicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d7d733bb-4368-4c1c-b11d-5cdb8324d1e7" xlink:to="loc_ocgn_CollaborationAgreementWithCansinoBiologicsMember_bb3be37f-f974-4642-82f1-76c979097b66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SchepensEyeResearchInstituteMember_17be16cc-3fc2-4a89-bcb8-e53bef85c9b8" xlink:href="ocgn-20191231.xsd#ocgn_SchepensEyeResearchInstituteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d7d733bb-4368-4c1c-b11d-5cdb8324d1e7" xlink:to="loc_ocgn_SchepensEyeResearchInstituteMember_17be16cc-3fc2-4a89-bcb8-e53bef85c9b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborationAgreementWithUniversityOfIllinoisChicagoMember_c28ad5f1-86b3-4d7f-92a9-ddac1bb4cf45" xlink:href="ocgn-20191231.xsd#ocgn_CollaborationAgreementWithUniversityOfIllinoisChicagoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d7d733bb-4368-4c1c-b11d-5cdb8324d1e7" xlink:to="loc_ocgn_CollaborationAgreementWithUniversityOfIllinoisChicagoMember_c28ad5f1-86b3-4d7f-92a9-ddac1bb4cf45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborationAgreementWithUniversityOfColoradoMember_bc39ebc8-4606-4ee8-a178-e5eadcfe3981" xlink:href="ocgn-20191231.xsd#ocgn_CollaborationAgreementWithUniversityOfColoradoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d7d733bb-4368-4c1c-b11d-5cdb8324d1e7" xlink:to="loc_ocgn_CollaborationAgreementWithUniversityOfColoradoMember_bc39ebc8-4606-4ee8-a178-e5eadcfe3981" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_8c414924-bd68-4319-b9bd-9987b1d92e26" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dfb93697-ca0b-4b25-a70d-f667d11cb704" xlink:to="loc_srt_StatementScenarioAxis_8c414924-bd68-4319-b9bd-9987b1d92e26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_8c414924-bd68-4319-b9bd-9987b1d92e26_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_8c414924-bd68-4319-b9bd-9987b1d92e26" xlink:to="loc_srt_ScenarioUnspecifiedDomain_8c414924-bd68-4319-b9bd-9987b1d92e26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_08982780-89c8-4d88-974a-eedd4c651583" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_8c414924-bd68-4319-b9bd-9987b1d92e26" xlink:to="loc_srt_ScenarioUnspecifiedDomain_08982780-89c8-4d88-974a-eedd4c651583" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_0fcdb2be-40f8-4a6e-8ed8-4764566752fb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_08982780-89c8-4d88-974a-eedd4c651583" xlink:to="loc_srt_ScenarioForecastMember_0fcdb2be-40f8-4a6e-8ed8-4764566752fb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/AccruedExpenses" xlink:type="simple" xlink:href="ocgn-20191231.xsd#AccruedExpenses"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/AccruedExpenses" xlink:type="extended" id="i58b75f0b179443b2a0fc61bdd416f9dc_7779378c-645e-439c-9fb8-222ae4c6c9c9"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="ocgn-20191231.xsd#AccruedExpensesTables"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/AccruedExpensesTables" xlink:type="extended" id="i36045f4a0f7449759c44471ea2a0e57f_df84af94-e990-4671-89b0-05517466fa5d"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#AccruedExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/AccruedExpensesDetails" xlink:type="extended" id="i1f24672e5fdf496bbab2fb572eb23e24_d25e83e2-3f63-4da5-a381-f34901e2e5ad"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/Debt" xlink:type="simple" xlink:href="ocgn-20191231.xsd#Debt"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/Debt" xlink:type="extended" id="i7242c98501a341ef98fe0deb4368004b_c4fbfb3d-e57a-4423-a4a0-19cc7c3e6a50"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtTables" xlink:type="simple" xlink:href="ocgn-20191231.xsd#DebtTables"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/DebtTables" xlink:type="extended" id="i8868f823ae8d4e90ad74fa5e702b9e70_bafd7eb2-42a1-4083-bda6-588c5fa580bc"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtEB5LoanDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#DebtEB5LoanDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/DebtEB5LoanDetails" xlink:type="extended" id="i89875a8a437645ae844016908bf799f1_b6395c4f-c08d-44c1-843d-f03fd5db6edf">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1c3a6721-57ed-4160-9f6f-f3e3a474341d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b59a488d-5b10-4df6-971e-422aab44276b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1c3a6721-57ed-4160-9f6f-f3e3a474341d" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b59a488d-5b10-4df6-971e-422aab44276b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LineOfCreditBorrowingEachDraw_acee9b8d-97ed-4a03-be60-be9a9bb368e6" xlink:href="ocgn-20191231.xsd#ocgn_LineOfCreditBorrowingEachDraw"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1c3a6721-57ed-4160-9f6f-f3e3a474341d" xlink:to="loc_ocgn_LineOfCreditBorrowingEachDraw_acee9b8d-97ed-4a03-be60-be9a9bb368e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b08c6fc5-2cd7-41fa-bf4b-19c3c6982039" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1c3a6721-57ed-4160-9f6f-f3e3a474341d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b08c6fc5-2cd7-41fa-bf4b-19c3c6982039" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_f80f11ae-6b8a-4fcd-9f01-b1b9c2310b00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1c3a6721-57ed-4160-9f6f-f3e3a474341d" xlink:to="loc_us-gaap_LineOfCredit_f80f11ae-6b8a-4fcd-9f01-b1b9c2310b00" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_9d6f097a-8311-4740-86bb-b58cbce0010c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1c3a6721-57ed-4160-9f6f-f3e3a474341d" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_9d6f097a-8311-4740-86bb-b58cbce0010c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_109a4113-ac8f-46ca-951d-93cb4854fc1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1c3a6721-57ed-4160-9f6f-f3e3a474341d" xlink:to="loc_us-gaap_DebtInstrumentTable_109a4113-ac8f-46ca-951d-93cb4854fc1e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9e431d24-806a-49ac-aed0-11d7f1cf76ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_109a4113-ac8f-46ca-951d-93cb4854fc1e" xlink:to="loc_us-gaap_DebtInstrumentAxis_9e431d24-806a-49ac-aed0-11d7f1cf76ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9e431d24-806a-49ac-aed0-11d7f1cf76ca_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9e431d24-806a-49ac-aed0-11d7f1cf76ca" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9e431d24-806a-49ac-aed0-11d7f1cf76ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_31f5cdb4-e80a-4d64-81f3-eb398f32a7df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9e431d24-806a-49ac-aed0-11d7f1cf76ca" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_31f5cdb4-e80a-4d64-81f3-eb398f32a7df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EB5ProgramBorrowingsMember_e604487c-75cc-4e44-8354-4e5e883ea462" xlink:href="ocgn-20191231.xsd#ocgn_EB5ProgramBorrowingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31f5cdb4-e80a-4d64-81f3-eb398f32a7df" xlink:to="loc_ocgn_EB5ProgramBorrowingsMember_e604487c-75cc-4e44-8354-4e5e883ea462" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f8cc6950-dc7b-415b-897e-2dafc6494aaf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_109a4113-ac8f-46ca-951d-93cb4854fc1e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f8cc6950-dc7b-415b-897e-2dafc6494aaf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f8cc6950-dc7b-415b-897e-2dafc6494aaf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f8cc6950-dc7b-415b-897e-2dafc6494aaf" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f8cc6950-dc7b-415b-897e-2dafc6494aaf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_eb55026d-8ac8-48b4-b89d-d88e25e57f79" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f8cc6950-dc7b-415b-897e-2dafc6494aaf" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_eb55026d-8ac8-48b4-b89d-d88e25e57f79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_ce85a867-4d47-41bc-8032-faa2b31ccc6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_eb55026d-8ac8-48b4-b89d-d88e25e57f79" xlink:to="loc_us-gaap_LoansPayableMember_ce85a867-4d47-41bc-8032-faa2b31ccc6e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtSummaryofEB5LoanDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#DebtSummaryofEB5LoanDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/DebtSummaryofEB5LoanDetails" xlink:type="extended" id="ife2f060d0bfa40e3a3de105de98ccbf9_fe03d7e5-7d2a-400f-8a01-3d4f9a8911d7">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ff00a014-0e35-4b92-b05b-aa691ecb6ee1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_342bf0be-e435-4cd6-b580-a8eeab7426bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff00a014-0e35-4b92-b05b-aa691ecb6ee1" xlink:to="loc_us-gaap_LineOfCredit_342bf0be-e435-4cd6-b580-a8eeab7426bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_e026904d-2beb-4aa6-8ac1-2694312160b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff00a014-0e35-4b92-b05b-aa691ecb6ee1" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_e026904d-2beb-4aa6-8ac1-2694312160b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_65bf94c8-52eb-42ff-b51c-b29eaa55207b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff00a014-0e35-4b92-b05b-aa691ecb6ee1" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_65bf94c8-52eb-42ff-b51c-b29eaa55207b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_2a5e84ec-3265-4e7d-968a-7f3a89b3f6c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff00a014-0e35-4b92-b05b-aa691ecb6ee1" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_2a5e84ec-3265-4e7d-968a-7f3a89b3f6c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_09ce5457-35c5-4b34-b310-557b844f7f6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff00a014-0e35-4b92-b05b-aa691ecb6ee1" xlink:to="loc_us-gaap_LongTermDebt_09ce5457-35c5-4b34-b310-557b844f7f6a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_77150c6b-ec3d-4e21-94e4-954091422287" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff00a014-0e35-4b92-b05b-aa691ecb6ee1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_77150c6b-ec3d-4e21-94e4-954091422287" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9b3cb147-1027-4f0d-b32f-0f53fcc85e41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff00a014-0e35-4b92-b05b-aa691ecb6ee1" xlink:to="loc_us-gaap_DebtInstrumentTable_9b3cb147-1027-4f0d-b32f-0f53fcc85e41" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f1e55b75-7df5-4707-85a0-e0da057cf6a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9b3cb147-1027-4f0d-b32f-0f53fcc85e41" xlink:to="loc_us-gaap_DebtInstrumentAxis_f1e55b75-7df5-4707-85a0-e0da057cf6a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f1e55b75-7df5-4707-85a0-e0da057cf6a5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f1e55b75-7df5-4707-85a0-e0da057cf6a5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f1e55b75-7df5-4707-85a0-e0da057cf6a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a846a97d-85bc-487e-abfa-dce31497c03b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f1e55b75-7df5-4707-85a0-e0da057cf6a5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a846a97d-85bc-487e-abfa-dce31497c03b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EB5ProgramBorrowingsMember_03eebab1-7a34-4e2e-862d-8d6b47be8e3d" xlink:href="ocgn-20191231.xsd#ocgn_EB5ProgramBorrowingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a846a97d-85bc-487e-abfa-dce31497c03b" xlink:to="loc_ocgn_EB5ProgramBorrowingsMember_03eebab1-7a34-4e2e-862d-8d6b47be8e3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4f86e2ce-86e4-4c87-86ae-c7fb6e7ca08b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9b3cb147-1027-4f0d-b32f-0f53fcc85e41" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4f86e2ce-86e4-4c87-86ae-c7fb6e7ca08b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4f86e2ce-86e4-4c87-86ae-c7fb6e7ca08b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4f86e2ce-86e4-4c87-86ae-c7fb6e7ca08b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4f86e2ce-86e4-4c87-86ae-c7fb6e7ca08b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ffd0ffb8-28ab-407e-9eef-d2a93d43c781" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4f86e2ce-86e4-4c87-86ae-c7fb6e7ca08b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ffd0ffb8-28ab-407e-9eef-d2a93d43c781" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_db9b9350-10da-4333-8508-20b7a34c989c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ffd0ffb8-28ab-407e-9eef-d2a93d43c781" xlink:to="loc_us-gaap_LoansPayableMember_db9b9350-10da-4333-8508-20b7a34c989c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#DebtConvertibleNotesDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails" xlink:type="extended" id="i8ee4e623f7ea43a9a8bca931c4d36cfb_c83f7fa8-aa50-4d1c-a060-23df3f756fb2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4c8d3028-f8b9-4b66-8de1-97487d369e70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_16e95447-1433-440a-86a5-c7170ab85a86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c8d3028-f8b9-4b66-8de1-97487d369e70" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_16e95447-1433-440a-86a5-c7170ab85a86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_58baae61-04ce-449f-9bb9-e4e0b9e897cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c8d3028-f8b9-4b66-8de1-97487d369e70" xlink:to="loc_us-gaap_ConvertibleDebt_58baae61-04ce-449f-9bb9-e4e0b9e897cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_3a374961-a462-427d-9a97-a299eeb41756" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c8d3028-f8b9-4b66-8de1-97487d369e70" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_3a374961-a462-427d-9a97-a299eeb41756" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_53a5b6cb-d8fc-4c49-a838-e5da1f4d4710" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c8d3028-f8b9-4b66-8de1-97487d369e70" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_53a5b6cb-d8fc-4c49-a838-e5da1f4d4710" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_fcf66a07-ce7f-4ff9-8e23-ee151b060eb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c8d3028-f8b9-4b66-8de1-97487d369e70" xlink:to="loc_us-gaap_LongTermDebt_fcf66a07-ce7f-4ff9-8e23-ee151b060eb0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8c63892b-b73e-4f8d-99f5-6c0d171546b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c8d3028-f8b9-4b66-8de1-97487d369e70" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8c63892b-b73e-4f8d-99f5-6c0d171546b0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_7be9bdf3-d623-41bc-8f8f-38be293ea47b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c8d3028-f8b9-4b66-8de1-97487d369e70" xlink:to="loc_us-gaap_DebtInstrumentTerm_7be9bdf3-d623-41bc-8f8f-38be293ea47b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_DebtRedemptionMultipleUponDefault_34c1bc44-33df-4660-bf2d-c3fdc3486ffb" xlink:href="ocgn-20191231.xsd#ocgn_DebtRedemptionMultipleUponDefault"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c8d3028-f8b9-4b66-8de1-97487d369e70" xlink:to="loc_ocgn_DebtRedemptionMultipleUponDefault_34c1bc44-33df-4660-bf2d-c3fdc3486ffb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount_ec9a20d7-1c6b-4ef7-9543-a1986bd70ad8" xlink:href="ocgn-20191231.xsd#ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c8d3028-f8b9-4b66-8de1-97487d369e70" xlink:to="loc_ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount_ec9a20d7-1c6b-4ef7-9543-a1986bd70ad8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_e74324d9-c34a-4e5b-836b-73a0005cbc55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c8d3028-f8b9-4b66-8de1-97487d369e70" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_e74324d9-c34a-4e5b-836b-73a0005cbc55" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4f0baf02-60c0-47f6-93cb-5f6700afc1dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c8d3028-f8b9-4b66-8de1-97487d369e70" xlink:to="loc_us-gaap_DebtInstrumentTable_4f0baf02-60c0-47f6-93cb-5f6700afc1dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5a7bf24b-605b-4106-95ad-8bc87ff20b48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4f0baf02-60c0-47f6-93cb-5f6700afc1dd" xlink:to="loc_us-gaap_DebtInstrumentAxis_5a7bf24b-605b-4106-95ad-8bc87ff20b48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5a7bf24b-605b-4106-95ad-8bc87ff20b48_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5a7bf24b-605b-4106-95ad-8bc87ff20b48" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5a7bf24b-605b-4106-95ad-8bc87ff20b48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_adc77bdf-6a69-4ec3-8ed2-e610e0df85d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5a7bf24b-605b-4106-95ad-8bc87ff20b48" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_adc77bdf-6a69-4ec3-8ed2-e610e0df85d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_37f9d5fa-95bf-495c-a7cb-d7a2b5f05a01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_adc77bdf-6a69-4ec3-8ed2-e610e0df85d8" xlink:to="loc_us-gaap_ConvertibleDebtMember_37f9d5fa-95bf-495c-a7cb-d7a2b5f05a01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertibleNotesBoardOfDirectorsMember_931cc4c8-422d-4472-b247-a00e3eb53448" xlink:href="ocgn-20191231.xsd#ocgn_ConvertibleNotesBoardOfDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConvertibleDebtMember_37f9d5fa-95bf-495c-a7cb-d7a2b5f05a01" xlink:to="loc_ocgn_ConvertibleNotesBoardOfDirectorsMember_931cc4c8-422d-4472-b247-a00e3eb53448" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertibleDebtJanuary2018Member_b49fad90-eaec-4e3e-8d47-0d196ec6edc9" xlink:href="ocgn-20191231.xsd#ocgn_ConvertibleDebtJanuary2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConvertibleDebtMember_37f9d5fa-95bf-495c-a7cb-d7a2b5f05a01" xlink:to="loc_ocgn_ConvertibleDebtJanuary2018Member_b49fad90-eaec-4e3e-8d47-0d196ec6edc9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertibleDebtJune2018Member_4113dbb6-a543-4b88-944a-9c2aefd18ecc" xlink:href="ocgn-20191231.xsd#ocgn_ConvertibleDebtJune2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConvertibleDebtMember_37f9d5fa-95bf-495c-a7cb-d7a2b5f05a01" xlink:to="loc_ocgn_ConvertibleDebtJune2018Member_4113dbb6-a543-4b88-944a-9c2aefd18ecc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertibleDebtNovember2018Member_145d34e2-3e9f-4d6a-bee0-0bdf8ee4900a" xlink:href="ocgn-20191231.xsd#ocgn_ConvertibleDebtNovember2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConvertibleDebtMember_37f9d5fa-95bf-495c-a7cb-d7a2b5f05a01" xlink:to="loc_ocgn_ConvertibleDebtNovember2018Member_145d34e2-3e9f-4d6a-bee0-0bdf8ee4900a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertibleDebtDecember2018Member_d706d3f5-fd22-47df-a932-d3a25e03b974" xlink:href="ocgn-20191231.xsd#ocgn_ConvertibleDebtDecember2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConvertibleDebtMember_37f9d5fa-95bf-495c-a7cb-d7a2b5f05a01" xlink:to="loc_ocgn_ConvertibleDebtDecember2018Member_d706d3f5-fd22-47df-a932-d3a25e03b974" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertibleDebtJanuary2019Member_852a9bc7-9d12-458f-ae03-b5bc2a004b00" xlink:href="ocgn-20191231.xsd#ocgn_ConvertibleDebtJanuary2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConvertibleDebtMember_37f9d5fa-95bf-495c-a7cb-d7a2b5f05a01" xlink:to="loc_ocgn_ConvertibleDebtJanuary2019Member_852a9bc7-9d12-458f-ae03-b5bc2a004b00" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertibleDebtFebruary2019Member_5cfedd14-3c86-4288-9262-fb45ae1758f7" xlink:href="ocgn-20191231.xsd#ocgn_ConvertibleDebtFebruary2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConvertibleDebtMember_37f9d5fa-95bf-495c-a7cb-d7a2b5f05a01" xlink:to="loc_ocgn_ConvertibleDebtFebruary2019Member_5cfedd14-3c86-4288-9262-fb45ae1758f7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_babca7c0-d063-428c-852a-f0e1975751b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4f0baf02-60c0-47f6-93cb-5f6700afc1dd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_babca7c0-d063-428c-852a-f0e1975751b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_babca7c0-d063-428c-852a-f0e1975751b2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_babca7c0-d063-428c-852a-f0e1975751b2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_babca7c0-d063-428c-852a-f0e1975751b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3a3ad0d1-5a30-4789-a807-1e5d26ba9276" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_babca7c0-d063-428c-852a-f0e1975751b2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3a3ad0d1-5a30-4789-a807-1e5d26ba9276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_26bb1707-7b0d-415e-811b-6c532bcefd87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3a3ad0d1-5a30-4789-a807-1e5d26ba9276" xlink:to="loc_us-gaap_ConvertibleDebtMember_26bb1707-7b0d-415e-811b-6c532bcefd87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_63c2949a-0740-48b7-947b-d93543f07c91" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4f0baf02-60c0-47f6-93cb-5f6700afc1dd" xlink:to="loc_srt_RangeAxis_63c2949a-0740-48b7-947b-d93543f07c91" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_63c2949a-0740-48b7-947b-d93543f07c91_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_63c2949a-0740-48b7-947b-d93543f07c91" xlink:to="loc_srt_RangeMember_63c2949a-0740-48b7-947b-d93543f07c91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a32ebd92-6186-48d5-9a66-d0db46001f3d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_63c2949a-0740-48b7-947b-d93543f07c91" xlink:to="loc_srt_RangeMember_a32ebd92-6186-48d5-9a66-d0db46001f3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_78a280d4-8d20-4a51-b08e-ce2af473f920" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a32ebd92-6186-48d5-9a66-d0db46001f3d" xlink:to="loc_srt_MinimumMember_78a280d4-8d20-4a51-b08e-ce2af473f920" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e041e87d-df6c-4c73-8385-117485a5ef59" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a32ebd92-6186-48d5-9a66-d0db46001f3d" xlink:to="loc_srt_MaximumMember_e041e87d-df6c-4c73-8385-117485a5ef59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_116fdd6d-f497-4c52-869a-de0d121be451" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4f0baf02-60c0-47f6-93cb-5f6700afc1dd" xlink:to="loc_srt_TitleOfIndividualAxis_116fdd6d-f497-4c52-869a-de0d121be451" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_116fdd6d-f497-4c52-869a-de0d121be451_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_116fdd6d-f497-4c52-869a-de0d121be451" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_116fdd6d-f497-4c52-869a-de0d121be451_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9fe404db-f672-42bb-8ffb-37e82fd1693f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_116fdd6d-f497-4c52-869a-de0d121be451" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9fe404db-f672-42bb-8ffb-37e82fd1693f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_3135ded0-e0d4-4cb0-95eb-2d47fcc2b9d8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9fe404db-f672-42bb-8ffb-37e82fd1693f" xlink:to="loc_srt_DirectorMember_3135ded0-e0d4-4cb0-95eb-2d47fcc2b9d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_45bfa972-274b-474c-9308-40acf74e1291" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4f0baf02-60c0-47f6-93cb-5f6700afc1dd" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_45bfa972-274b-474c-9308-40acf74e1291" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_45bfa972-274b-474c-9308-40acf74e1291_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_45bfa972-274b-474c-9308-40acf74e1291" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_45bfa972-274b-474c-9308-40acf74e1291_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_02cf6a93-8277-461e-a7d5-a69b2ece1e71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_45bfa972-274b-474c-9308-40acf74e1291" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_02cf6a93-8277-461e-a7d5-a69b2ece1e71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertibleDebtConversionFeatureMember_1a1ac16d-9379-4cde-b7d5-4125b91d3f4d" xlink:href="ocgn-20191231.xsd#ocgn_ConvertibleDebtConversionFeatureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_02cf6a93-8277-461e-a7d5-a69b2ece1e71" xlink:to="loc_ocgn_ConvertibleDebtConversionFeatureMember_1a1ac16d-9379-4cde-b7d5-4125b91d3f4d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtScheduleofFairValueoftheEmbeddedFeaturesDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#DebtScheduleofFairValueoftheEmbeddedFeaturesDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/DebtScheduleofFairValueoftheEmbeddedFeaturesDetails" xlink:type="extended" id="if60b22e650ec4a1f9c0535518399177e_bb1f00ae-fc73-432f-9b5c-f1e89e870961"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#DebtConvertibleNotesOtherInformationDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails" xlink:type="extended" id="icf18c9b04dbc4eb094161aee877797c5_4a55db09-0007-40b7-9f5a-87980f723c5e">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5f1ac0e9-a992-4e02-98e9-3ff495db252c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement_2a78dc9b-8845-49d7-8039-2b3a28b734a6" xlink:href="ocgn-20191231.xsd#ocgn_CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f1ac0e9-a992-4e02-98e9-3ff495db252c" xlink:to="loc_ocgn_CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement_2a78dc9b-8845-49d7-8039-2b3a28b734a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions_9322f098-74c5-4705-a969-9f9554a999b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesSubscriptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f1ac0e9-a992-4e02-98e9-3ff495db252c" xlink:to="loc_us-gaap_CommonStockSharesSubscriptions_9322f098-74c5-4705-a969-9f9554a999b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_23615498-dc91-4b22-93d6-0ac05555d09d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f1ac0e9-a992-4e02-98e9-3ff495db252c" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_23615498-dc91-4b22-93d6-0ac05555d09d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount_1e327ec3-5198-45e1-a8b3-78db35dfcb4a" xlink:href="ocgn-20191231.xsd#ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f1ac0e9-a992-4e02-98e9-3ff495db252c" xlink:to="loc_ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount_1e327ec3-5198-45e1-a8b3-78db35dfcb4a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f40b1f43-563b-446b-98cd-518b2cbeae80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f1ac0e9-a992-4e02-98e9-3ff495db252c" xlink:to="loc_us-gaap_CommonStockSharesIssued_f40b1f43-563b-446b-98cd-518b2cbeae80" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f6119591-2863-44f8-b05d-c1bb11159a66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f1ac0e9-a992-4e02-98e9-3ff495db252c" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f6119591-2863-44f8-b05d-c1bb11159a66" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_cafc87a7-fd3d-4e68-b5af-ac70b562756e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f1ac0e9-a992-4e02-98e9-3ff495db252c" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_cafc87a7-fd3d-4e68-b5af-ac70b562756e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_ccc5054c-6978-4ed4-ac3c-40cb9ccfeead" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f1ac0e9-a992-4e02-98e9-3ff495db252c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_ccc5054c-6978-4ed4-ac3c-40cb9ccfeead" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ecd808de-7344-4f1e-ac5a-c7e889e93f0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f1ac0e9-a992-4e02-98e9-3ff495db252c" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ecd808de-7344-4f1e-ac5a-c7e889e93f0f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6728af94-9ff7-490a-b112-f37098f352c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f1ac0e9-a992-4e02-98e9-3ff495db252c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6728af94-9ff7-490a-b112-f37098f352c4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_09b873d8-dbf0-4825-83c6-aa6afdf4b4d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f1ac0e9-a992-4e02-98e9-3ff495db252c" xlink:to="loc_us-gaap_DebtInstrumentTable_09b873d8-dbf0-4825-83c6-aa6afdf4b4d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_1849a530-af2a-48f2-bb20-1b9d2a9c9415" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_09b873d8-dbf0-4825-83c6-aa6afdf4b4d3" xlink:to="loc_srt_TitleOfIndividualAxis_1849a530-af2a-48f2-bb20-1b9d2a9c9415" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1849a530-af2a-48f2-bb20-1b9d2a9c9415_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_1849a530-af2a-48f2-bb20-1b9d2a9c9415" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1849a530-af2a-48f2-bb20-1b9d2a9c9415_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bfd556e3-4c44-44b5-8325-a96aa90a8a9b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_1849a530-af2a-48f2-bb20-1b9d2a9c9415" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bfd556e3-4c44-44b5-8325-a96aa90a8a9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_190bf06c-787d-492d-9772-bf2854f415ed" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bfd556e3-4c44-44b5-8325-a96aa90a8a9b" xlink:to="loc_srt_DirectorMember_190bf06c-787d-492d-9772-bf2854f415ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAxis_6aabfc5f-d174-4172-a85a-643c62d7aff6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_09b873d8-dbf0-4825-83c6-aa6afdf4b4d3" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAxis_6aabfc5f-d174-4172-a85a-643c62d7aff6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_6aabfc5f-d174-4172-a85a-643c62d7aff6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis_6aabfc5f-d174-4172-a85a-643c62d7aff6" xlink:to="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_6aabfc5f-d174-4172-a85a-643c62d7aff6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_b4aa036b-fc67-475f-8b93-1b664791dabc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis_6aabfc5f-d174-4172-a85a-643c62d7aff6" xlink:to="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_b4aa036b-fc67-475f-8b93-1b664791dabc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_e1e631ef-4eb6-4071-a9a1-627135aa0e46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_b4aa036b-fc67-475f-8b93-1b664791dabc" xlink:to="loc_us-gaap_ConvertibleDebtMember_e1e631ef-4eb6-4071-a9a1-627135aa0e46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9fda81ee-f759-42db-bdc0-09115921fbe5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_09b873d8-dbf0-4825-83c6-aa6afdf4b4d3" xlink:to="loc_us-gaap_DebtInstrumentAxis_9fda81ee-f759-42db-bdc0-09115921fbe5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9fda81ee-f759-42db-bdc0-09115921fbe5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9fda81ee-f759-42db-bdc0-09115921fbe5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9fda81ee-f759-42db-bdc0-09115921fbe5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8ef7b1a7-61f9-4692-9656-ae3e607c03e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9fda81ee-f759-42db-bdc0-09115921fbe5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8ef7b1a7-61f9-4692-9656-ae3e607c03e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertiblePromissoryNotesMember_b9192daa-bc07-4548-b323-f22af3763737" xlink:href="ocgn-20191231.xsd#ocgn_ConvertiblePromissoryNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8ef7b1a7-61f9-4692-9656-ae3e607c03e9" xlink:to="loc_ocgn_ConvertiblePromissoryNotesMember_b9192daa-bc07-4548-b323-f22af3763737" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_January2019AndFebruary2019NotesMember_f939990d-d155-4007-99b3-95825d105cc0" xlink:href="ocgn-20191231.xsd#ocgn_January2019AndFebruary2019NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8ef7b1a7-61f9-4692-9656-ae3e607c03e9" xlink:to="loc_ocgn_January2019AndFebruary2019NotesMember_f939990d-d155-4007-99b3-95825d105cc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_November2018AndDecember2018NotesMember_03b07922-5916-490f-bf7d-568577bfcb60" xlink:href="ocgn-20191231.xsd#ocgn_November2018AndDecember2018NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8ef7b1a7-61f9-4692-9656-ae3e607c03e9" xlink:to="loc_ocgn_November2018AndDecember2018NotesMember_03b07922-5916-490f-bf7d-568577bfcb60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_58693e94-817a-40c2-aa7a-428dd017ea19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_09b873d8-dbf0-4825-83c6-aa6afdf4b4d3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_58693e94-817a-40c2-aa7a-428dd017ea19" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_58693e94-817a-40c2-aa7a-428dd017ea19_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_58693e94-817a-40c2-aa7a-428dd017ea19" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_58693e94-817a-40c2-aa7a-428dd017ea19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_90bf7c9c-b68c-493b-892f-3df83cb52943" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_58693e94-817a-40c2-aa7a-428dd017ea19" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_90bf7c9c-b68c-493b-892f-3df83cb52943" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_526121c2-603b-4f5e-9233-d34d3f18c14b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_90bf7c9c-b68c-493b-892f-3df83cb52943" xlink:to="loc_us-gaap_ConvertibleDebtMember_526121c2-603b-4f5e-9233-d34d3f18c14b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_550a44d1-be19-41f4-a77c-0f10e658df0a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_09b873d8-dbf0-4825-83c6-aa6afdf4b4d3" xlink:to="loc_srt_RangeAxis_550a44d1-be19-41f4-a77c-0f10e658df0a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_550a44d1-be19-41f4-a77c-0f10e658df0a_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_550a44d1-be19-41f4-a77c-0f10e658df0a" xlink:to="loc_srt_RangeMember_550a44d1-be19-41f4-a77c-0f10e658df0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4a182972-f58b-40a5-bfe9-ac2c59021ccf" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_550a44d1-be19-41f4-a77c-0f10e658df0a" xlink:to="loc_srt_RangeMember_4a182972-f58b-40a5-bfe9-ac2c59021ccf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8eba4dbc-879e-4122-85a5-6c00c9126318" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4a182972-f58b-40a5-bfe9-ac2c59021ccf" xlink:to="loc_srt_MinimumMember_8eba4dbc-879e-4122-85a5-6c00c9126318" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtSeniorSecuredConvertibleNotesDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#DebtSeniorSecuredConvertibleNotesDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/DebtSeniorSecuredConvertibleNotesDetails" xlink:type="extended" id="ibd7b8bcbc86f4a01804f33ac001883d1_d0f25eb4-7205-4c87-a55b-43d45c3a224a">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2a101cbd-607b-442d-bd8b-0b484d879536" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_83faeccb-ea10-468e-920a-999d03f7d22c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a101cbd-607b-442d-bd8b-0b484d879536" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_83faeccb-ea10-468e-920a-999d03f7d22c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_17cb5038-eb12-4bd8-bc6f-d860c1e09ba5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a101cbd-607b-442d-bd8b-0b484d879536" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_17cb5038-eb12-4bd8-bc6f-d860c1e09ba5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6f431783-acc7-4af2-b7c0-37c1dfabe536" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a101cbd-607b-442d-bd8b-0b484d879536" xlink:to="loc_us-gaap_DebtInstrumentTable_6f431783-acc7-4af2-b7c0-37c1dfabe536" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_175e9ffd-4428-41b9-9dbb-5cb028e3705d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6f431783-acc7-4af2-b7c0-37c1dfabe536" xlink:to="loc_us-gaap_DebtInstrumentAxis_175e9ffd-4428-41b9-9dbb-5cb028e3705d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_175e9ffd-4428-41b9-9dbb-5cb028e3705d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_175e9ffd-4428-41b9-9dbb-5cb028e3705d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_175e9ffd-4428-41b9-9dbb-5cb028e3705d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e7c21db7-6138-433d-a84a-8793871509a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_175e9ffd-4428-41b9-9dbb-5cb028e3705d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e7c21db7-6138-433d-a84a-8793871509a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeniorSecuredConvertibleNotesMay2019Member_40f927da-d1e8-46f3-8f43-716c12c421d8" xlink:href="ocgn-20191231.xsd#ocgn_SeniorSecuredConvertibleNotesMay2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e7c21db7-6138-433d-a84a-8793871509a5" xlink:to="loc_ocgn_SeniorSecuredConvertibleNotesMay2019Member_40f927da-d1e8-46f3-8f43-716c12c421d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeniorSecuredConvertibleNotesMember_c06b7b98-69f1-43a2-a4dd-43eb56fab2cb" xlink:href="ocgn-20191231.xsd#ocgn_SeniorSecuredConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e7c21db7-6138-433d-a84a-8793871509a5" xlink:to="loc_ocgn_SeniorSecuredConvertibleNotesMember_c06b7b98-69f1-43a2-a4dd-43eb56fab2cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeniorSecuredConvertibleNotesJune2019Member_4369c16f-23da-4f26-83b4-9a260665346a" xlink:href="ocgn-20191231.xsd#ocgn_SeniorSecuredConvertibleNotesJune2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e7c21db7-6138-433d-a84a-8793871509a5" xlink:to="loc_ocgn_SeniorSecuredConvertibleNotesJune2019Member_4369c16f-23da-4f26-83b4-9a260665346a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="ocgn-20191231.xsd#ShareBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/ShareBasedCompensation" xlink:type="extended" id="i02bf874af5f14b0e9553a94729d5f31d_49a58f63-4142-4c77-b7d5-3bed3ecfed96"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="ocgn-20191231.xsd#ShareBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/ShareBasedCompensationTables" xlink:type="extended" id="iba01801ca700465c96a9b26293024581_4937c20c-76df-4d67-ac34-af376b40db4f"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#StockBasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails" xlink:type="extended" id="i236d166afeb142a8b0f24cfd0252f1cb_f55505fb-36f9-4524-94cd-5a4bd8d71dc4">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73c86e4f-74ce-4513-a98e-548e7bea70d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_109d71f0-465a-4538-be81-bc86f93ad5e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73c86e4f-74ce-4513-a98e-548e7bea70d8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_109d71f0-465a-4538-be81-bc86f93ad5e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0b0baa5b-f258-4406-a302-05c3d8c116c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73c86e4f-74ce-4513-a98e-548e7bea70d8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0b0baa5b-f258-4406-a302-05c3d8c116c7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6f661788-68c8-4df3-9beb-bd5ace8e2d0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0b0baa5b-f258-4406-a302-05c3d8c116c7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6f661788-68c8-4df3-9beb-bd5ace8e2d0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6f661788-68c8-4df3-9beb-bd5ace8e2d0e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6f661788-68c8-4df3-9beb-bd5ace8e2d0e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6f661788-68c8-4df3-9beb-bd5ace8e2d0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_05a7a531-a492-4010-bfc1-4bc80e92efe1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6f661788-68c8-4df3-9beb-bd5ace8e2d0e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_05a7a531-a492-4010-bfc1-4bc80e92efe1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_417a577e-3c6e-46c2-b558-ad8a9b8bc4df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_05a7a531-a492-4010-bfc1-4bc80e92efe1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_417a577e-3c6e-46c2-b558-ad8a9b8bc4df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7196e010-d011-4382-a452-22dd600c87cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_05a7a531-a492-4010-bfc1-4bc80e92efe1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7196e010-d011-4382-a452-22dd600c87cb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SharedBasedCompensationDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#SharedBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/SharedBasedCompensationDetails" xlink:type="extended" id="i0e24aa5c69764cf183820633466e8678_4f96ef33-3d2f-4e37-9e24-132554d525c1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b61859f3-043e-481c-a363-f5b964d09886" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_819d47fb-d8e4-4af7-8896-1448eff2824d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b61859f3-043e-481c-a363-f5b964d09886" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_819d47fb-d8e4-4af7-8896-1448eff2824d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_fd2c4416-56af-4e9a-a7d5-834882482f21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b61859f3-043e-481c-a363-f5b964d09886" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_fd2c4416-56af-4e9a-a7d5-834882482f21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfEquityCompensationPlans_0f38fa66-b872-49de-a786-caa89723f385" xlink:href="ocgn-20191231.xsd#ocgn_NumberOfEquityCompensationPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b61859f3-043e-481c-a363-f5b964d09886" xlink:to="loc_ocgn_NumberOfEquityCompensationPlans_0f38fa66-b872-49de-a786-caa89723f385" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e24b01fe-859a-4d2b-b3f7-028140edcb55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b61859f3-043e-481c-a363-f5b964d09886" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e24b01fe-859a-4d2b-b3f7-028140edcb55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage_525cf500-561f-4c34-ab2c-0209497b133f" xlink:href="ocgn-20191231.xsd#ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b61859f3-043e-481c-a363-f5b964d09886" xlink:to="loc_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage_525cf500-561f-4c34-ab2c-0209497b133f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f5dd6b38-6892-4329-85a5-66b9b71343a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b61859f3-043e-481c-a363-f5b964d09886" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f5dd6b38-6892-4329-85a5-66b9b71343a8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_e4aba028-a10a-4f02-89a3-480470ef9348" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b61859f3-043e-481c-a363-f5b964d09886" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_e4aba028-a10a-4f02-89a3-480470ef9348" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1d92c5a1-2ca1-4ff9-a55e-792c015ca284" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b61859f3-043e-481c-a363-f5b964d09886" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1d92c5a1-2ca1-4ff9-a55e-792c015ca284" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2998c414-518e-44ea-94e0-942005ea1210" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b61859f3-043e-481c-a363-f5b964d09886" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2998c414-518e-44ea-94e0-942005ea1210" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_28dcc881-bf52-4bbd-a570-a8a703d4873b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2998c414-518e-44ea-94e0-942005ea1210" xlink:to="loc_us-gaap_AwardTypeAxis_28dcc881-bf52-4bbd-a570-a8a703d4873b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_28dcc881-bf52-4bbd-a570-a8a703d4873b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_28dcc881-bf52-4bbd-a570-a8a703d4873b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_28dcc881-bf52-4bbd-a570-a8a703d4873b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2790be1-e765-4e58-a63d-d5517436a5b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_28dcc881-bf52-4bbd-a570-a8a703d4873b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2790be1-e765-4e58-a63d-d5517436a5b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_A2019PlanMember_227015a2-73c8-4867-a823-99b1fd8234c5" xlink:href="ocgn-20191231.xsd#ocgn_A2019PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2790be1-e765-4e58-a63d-d5517436a5b9" xlink:to="loc_ocgn_A2019PlanMember_227015a2-73c8-4867-a823-99b1fd8234c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_54ef4181-9ec4-45b7-83bc-7ee06864bfef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2790be1-e765-4e58-a63d-d5517436a5b9" xlink:to="loc_us-gaap_StockOptionMember_54ef4181-9ec4-45b7-83bc-7ee06864bfef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c026742c-5a03-4e76-9c4f-78f76029ae34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2790be1-e765-4e58-a63d-d5517436a5b9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c026742c-5a03-4e76-9c4f-78f76029ae34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a747c7bc-6947-4170-abd7-cbd45fed4c17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2998c414-518e-44ea-94e0-942005ea1210" xlink:to="loc_us-gaap_PlanNameAxis_a747c7bc-6947-4170-abd7-cbd45fed4c17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a747c7bc-6947-4170-abd7-cbd45fed4c17_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_a747c7bc-6947-4170-abd7-cbd45fed4c17" xlink:to="loc_us-gaap_PlanNameDomain_a747c7bc-6947-4170-abd7-cbd45fed4c17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ab4f08c6-6589-410d-af71-314b40ee1bb9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_a747c7bc-6947-4170-abd7-cbd45fed4c17" xlink:to="loc_us-gaap_PlanNameDomain_ab4f08c6-6589-410d-af71-314b40ee1bb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_A2014PlanMember_bc52b2e6-7c9f-4765-a049-ace0cf8eecb8" xlink:href="ocgn-20191231.xsd#ocgn_A2014PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ab4f08c6-6589-410d-af71-314b40ee1bb9" xlink:to="loc_ocgn_A2014PlanMember_bc52b2e6-7c9f-4765-a049-ace0cf8eecb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_A2019PlanMember_3e3682a0-ae71-4b37-97bf-964553df8cda" xlink:href="ocgn-20191231.xsd#ocgn_A2019PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ab4f08c6-6589-410d-af71-314b40ee1bb9" xlink:to="loc_ocgn_A2019PlanMember_3e3682a0-ae71-4b37-97bf-964553df8cda" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofValuationAssumptionsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#StockBasedCompensationScheduleofValuationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofValuationAssumptionsDetails" xlink:type="extended" id="i2bb24ebf240c415ca48efa7577637324_f3a362a3-e582-438f-b326-62e81b32ca8e">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9eb6b34f-9877-4eb9-9260-f7fb61e493da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c931755a-b2f5-4836-841a-bd35182a4d9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9eb6b34f-9877-4eb9-9260-f7fb61e493da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c931755a-b2f5-4836-841a-bd35182a4d9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0e28265d-16c9-490e-9c42-b21a80a52a30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9eb6b34f-9877-4eb9-9260-f7fb61e493da" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0e28265d-16c9-490e-9c42-b21a80a52a30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_d28fa0d7-89e6-45ef-a8a5-57f7ee875df6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9eb6b34f-9877-4eb9-9260-f7fb61e493da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_d28fa0d7-89e6-45ef-a8a5-57f7ee875df6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3b02b4bf-8160-4949-9603-a40ff9a98a41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9eb6b34f-9877-4eb9-9260-f7fb61e493da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3b02b4bf-8160-4949-9603-a40ff9a98a41" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_121e966f-20d3-4816-8f0a-2a92576447ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9eb6b34f-9877-4eb9-9260-f7fb61e493da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_121e966f-20d3-4816-8f0a-2a92576447ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57da3160-892f-4283-9b34-6f59c46bc78b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9eb6b34f-9877-4eb9-9260-f7fb61e493da" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57da3160-892f-4283-9b34-6f59c46bc78b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5aabf93b-b3d5-4975-94c7-b2961753e1a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57da3160-892f-4283-9b34-6f59c46bc78b" xlink:to="loc_us-gaap_AwardTypeAxis_5aabf93b-b3d5-4975-94c7-b2961753e1a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5aabf93b-b3d5-4975-94c7-b2961753e1a2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5aabf93b-b3d5-4975-94c7-b2961753e1a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5aabf93b-b3d5-4975-94c7-b2961753e1a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7407897-b9e1-45da-82f6-19f94fe8ef95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5aabf93b-b3d5-4975-94c7-b2961753e1a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7407897-b9e1-45da-82f6-19f94fe8ef95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b7760b72-4efa-4304-a68e-6ddde6ca4413" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7407897-b9e1-45da-82f6-19f94fe8ef95" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b7760b72-4efa-4304-a68e-6ddde6ca4413" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_157104d5-f81d-42df-ab67-53ffc0718e0c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57da3160-892f-4283-9b34-6f59c46bc78b" xlink:to="loc_srt_RangeAxis_157104d5-f81d-42df-ab67-53ffc0718e0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_157104d5-f81d-42df-ab67-53ffc0718e0c_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_157104d5-f81d-42df-ab67-53ffc0718e0c" xlink:to="loc_srt_RangeMember_157104d5-f81d-42df-ab67-53ffc0718e0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_945bd49a-5376-4ae3-8be5-389d4343b0b8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_157104d5-f81d-42df-ab67-53ffc0718e0c" xlink:to="loc_srt_RangeMember_945bd49a-5376-4ae3-8be5-389d4343b0b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_099c9159-828b-4958-a0c3-6861ed70fc8c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_945bd49a-5376-4ae3-8be5-389d4343b0b8" xlink:to="loc_srt_MinimumMember_099c9159-828b-4958-a0c3-6861ed70fc8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cbc88350-cbaa-400d-86dc-6a22d5373e6b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_945bd49a-5376-4ae3-8be5-389d4343b0b8" xlink:to="loc_srt_MaximumMember_cbc88350-cbaa-400d-86dc-6a22d5373e6b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails" xlink:type="extended" id="i82c94917791d4bcd97131eed013cb172_918c2a07-3921-4440-bbb1-ea31e097f530">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c6e29d8-8521-43f3-8bfc-777a86dc9172" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0025a191-d2ae-4273-8d86-5c726a9d7b47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c6e29d8-8521-43f3-8bfc-777a86dc9172" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0025a191-d2ae-4273-8d86-5c726a9d7b47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_273426fc-20a5-477f-9c4d-4fc072fe67e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0025a191-d2ae-4273-8d86-5c726a9d7b47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_273426fc-20a5-477f-9c4d-4fc072fe67e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d415e0d8-323a-4f9a-baa7-7c31af547fdc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0025a191-d2ae-4273-8d86-5c726a9d7b47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d415e0d8-323a-4f9a-baa7-7c31af547fdc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_636447eb-375f-44cc-a975-6553f3eed375" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0025a191-d2ae-4273-8d86-5c726a9d7b47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_636447eb-375f-44cc-a975-6553f3eed375" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_f631db5e-efaa-4b03-8c78-0f2183b54ed0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0025a191-d2ae-4273-8d86-5c726a9d7b47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_f631db5e-efaa-4b03-8c78-0f2183b54ed0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4b714328-5c92-4b7b-b957-ad60a979d2c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c6e29d8-8521-43f3-8bfc-777a86dc9172" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4b714328-5c92-4b7b-b957-ad60a979d2c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4697ea66-78e7-4511-afab-13b7b8c100c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4b714328-5c92-4b7b-b957-ad60a979d2c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4697ea66-78e7-4511-afab-13b7b8c100c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a528a301-36af-448a-85fd-093a115b90cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4b714328-5c92-4b7b-b957-ad60a979d2c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a528a301-36af-448a-85fd-093a115b90cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_87bd90b1-103d-450e-83f4-80238ef1f070" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4b714328-5c92-4b7b-b957-ad60a979d2c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_87bd90b1-103d-450e-83f4-80238ef1f070" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_48626813-c3c0-42fa-870c-ea1bfe12b28e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4b714328-5c92-4b7b-b957-ad60a979d2c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_48626813-c3c0-42fa-870c-ea1bfe12b28e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8327e517-5f58-4c23-8539-07eb4d097919" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c6e29d8-8521-43f3-8bfc-777a86dc9172" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8327e517-5f58-4c23-8539-07eb4d097919" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8b6e0603-d42d-4b68-98d4-64ca4a5f385d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8327e517-5f58-4c23-8539-07eb4d097919" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8b6e0603-d42d-4b68-98d4-64ca4a5f385d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_60fa902d-9524-4b25-858f-cad2c18849b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8327e517-5f58-4c23-8539-07eb4d097919" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_60fa902d-9524-4b25-858f-cad2c18849b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f3830bdd-8885-4913-8d65-96212a1f616c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8327e517-5f58-4c23-8539-07eb4d097919" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f3830bdd-8885-4913-8d65-96212a1f616c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4c44aca4-8ba3-4e9e-92aa-2c003a34fb59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8327e517-5f58-4c23-8539-07eb4d097919" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4c44aca4-8ba3-4e9e-92aa-2c003a34fb59" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d0611bd-bd77-42f0-a742-fe2ae8bda524" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c6e29d8-8521-43f3-8bfc-777a86dc9172" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d0611bd-bd77-42f0-a742-fe2ae8bda524" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cd55a136-025e-428d-b125-afe36b0f253f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d0611bd-bd77-42f0-a742-fe2ae8bda524" xlink:to="loc_us-gaap_AwardTypeAxis_cd55a136-025e-428d-b125-afe36b0f253f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd55a136-025e-428d-b125-afe36b0f253f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_cd55a136-025e-428d-b125-afe36b0f253f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd55a136-025e-428d-b125-afe36b0f253f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c33ac664-7f29-466a-a053-4ab0edf03cea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_cd55a136-025e-428d-b125-afe36b0f253f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c33ac664-7f29-466a-a053-4ab0edf03cea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_A2019PlanMember_2efccf8b-6a4b-4f9d-a9e0-abfd79c72fcc" xlink:href="ocgn-20191231.xsd#ocgn_A2019PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c33ac664-7f29-466a-a053-4ab0edf03cea" xlink:to="loc_ocgn_A2019PlanMember_2efccf8b-6a4b-4f9d-a9e0-abfd79c72fcc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/Commitments" xlink:type="simple" xlink:href="ocgn-20191231.xsd#Commitments"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/Commitments" xlink:type="extended" id="ieacb05b2007a44c6bdc9cd549cb98418_4d252119-73a7-48bb-9388-06b324013fa8"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CommitmentsTables" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CommitmentsTables"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/CommitmentsTables" xlink:type="extended" id="idd0d862f987e4360b966ed431ad6f7ca_94da27ab-96ac-4108-bce9-ef66bc1af703"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CommitmentsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CommitmentsDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/CommitmentsDetails" xlink:type="extended" id="iea628a12fb444cdca2db1d212b672382_58b475f0-8bee-439a-9027-630097a448b3">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_21f99b9e-ac7e-4477-a3c4-95ec41dec0e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_37b306bb-9085-45ec-bf18-da46b8a8682c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_21f99b9e-ac7e-4477-a3c4-95ec41dec0e5" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_37b306bb-9085-45ec-bf18-da46b8a8682c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_97609dc3-a94b-485f-aa55-c211b4832180" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_21f99b9e-ac7e-4477-a3c4-95ec41dec0e5" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_97609dc3-a94b-485f-aa55-c211b4832180" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_da4bdbfc-ee72-4fa0-b8f8-888c9a8a10ce" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_97609dc3-a94b-485f-aa55-c211b4832180" xlink:to="loc_srt_RangeAxis_da4bdbfc-ee72-4fa0-b8f8-888c9a8a10ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_da4bdbfc-ee72-4fa0-b8f8-888c9a8a10ce_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_da4bdbfc-ee72-4fa0-b8f8-888c9a8a10ce" xlink:to="loc_srt_RangeMember_da4bdbfc-ee72-4fa0-b8f8-888c9a8a10ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d0eb1a8b-ff9b-4542-895d-07e2e32d81ba" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_da4bdbfc-ee72-4fa0-b8f8-888c9a8a10ce" xlink:to="loc_srt_RangeMember_d0eb1a8b-ff9b-4542-895d-07e2e32d81ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_aa6e9969-ab89-4700-b69d-943e59feb564" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d0eb1a8b-ff9b-4542-895d-07e2e32d81ba" xlink:to="loc_srt_MinimumMember_aa6e9969-ab89-4700-b69d-943e59feb564" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_11a15f4e-9e6a-4501-8b8d-17baa217327b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d0eb1a8b-ff9b-4542-895d-07e2e32d81ba" xlink:to="loc_srt_MaximumMember_11a15f4e-9e6a-4501-8b8d-17baa217327b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CommitmentsOperatingleasescomponentsofleaseexpenseDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CommitmentsOperatingleasescomponentsofleaseexpenseDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/CommitmentsOperatingleasescomponentsofleaseexpenseDetails" xlink:type="extended" id="ie551310c5ae04de8b417b9b3d6492aaa_124493f8-913c-4ee2-8e29-65a56a6b0c1a"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CommitmentsOperatingleasessupplementalbalancesheetinformationDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CommitmentsOperatingleasessupplementalbalancesheetinformationDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/CommitmentsOperatingleasessupplementalbalancesheetinformationDetails" xlink:type="extended" id="i19c3ca64999c4ea8a52c19047c75d4cd_830378d6-add1-492a-a0cb-eca209eb8f70"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CommitmentsOperatingleasessupplementalinformationrelatedtoleasesDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CommitmentsOperatingleasessupplementalinformationrelatedtoleasesDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/CommitmentsOperatingleasessupplementalinformationrelatedtoleasesDetails" xlink:type="extended" id="i6563fe4593474dd5a3ddad40061f64cb_1b69a685-6caa-42c4-8c22-45868e391bcb"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CommitmentsOperatingleasesfutureminimumleasepaymentsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CommitmentsOperatingleasesfutureminimumleasepaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/CommitmentsOperatingleasesfutureminimumleasepaymentsDetails" xlink:type="extended" id="i6699fc202d7c473ab902a903cb27781a_ee3dd697-4dd0-45c3-9b6f-a028df46c736"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CommitmentsFinanceleasesDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CommitmentsFinanceleasesDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/CommitmentsFinanceleasesDetails" xlink:type="extended" id="i8bbd7353405d4092aa7cde97d4039b9e_030049c3-f039-4670-a014-5faf7895094f"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CommitmentsFinanceleasesfutureminimumleasepaymentsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CommitmentsFinanceleasesfutureminimumleasepaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/CommitmentsFinanceleasesfutureminimumleasepaymentsDetails" xlink:type="extended" id="i08fb0abf2167426185eba7b929163411_80bb9a3e-7616-4d78-9768-7545e24ca79d"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/Warrants" xlink:type="simple" xlink:href="ocgn-20191231.xsd#Warrants"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/Warrants" xlink:type="extended" id="i8d2da618348d46b3bf933a88eb1f1103_08425795-dbaa-4320-8236-5ac69955b78c"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/WarrantsTables" xlink:type="simple" xlink:href="ocgn-20191231.xsd#WarrantsTables"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/WarrantsTables" xlink:type="extended" id="if2178fc1569348018a865b5f1fe831d7_6610664c-24c3-4f15-b17f-bb05e7e9e201"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/WarrantsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#WarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/WarrantsDetails" xlink:type="extended" id="i9694f60a991043f2aaa7861933985460_2540dcb4-2126-40af-af82-7ed9e2fa7406">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionLowerPercentageOfCommonStock_4d7f39bd-1546-405c-980d-21c696e6bb9d" xlink:href="ocgn-20191231.xsd#ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionLowerPercentageOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionLowerPercentageOfCommonStock_4d7f39bd-1546-405c-980d-21c696e6bb9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionHigherPercentageOfCommonStock_8b37a856-64f5-4836-8e39-9f968f41ad59" xlink:href="ocgn-20191231.xsd#ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionHigherPercentageOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionHigherPercentageOfCommonStock_8b37a856-64f5-4836-8e39-9f968f41ad59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_PercentageOfAmountOnMarketValueForFailureToIssueCommonStockOnPreMergerFinancingWarrants_f832d9f5-918c-4933-8a63-004421fe5de4" xlink:href="ocgn-20191231.xsd#ocgn_PercentageOfAmountOnMarketValueForFailureToIssueCommonStockOnPreMergerFinancingWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_ocgn_PercentageOfAmountOnMarketValueForFailureToIssueCommonStockOnPreMergerFinancingWarrants_f832d9f5-918c-4933-8a63-004421fe5de4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0aa415be-2155-48b1-a9fa-6fb89e422391" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0aa415be-2155-48b1-a9fa-6fb89e422391" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_8f5eb30d-5855-4c46-829d-491b31af1457" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_8f5eb30d-5855-4c46-829d-491b31af1457" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_1f2910e5-6c24-4744-a976-7ed9097b6806" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_1f2910e5-6c24-4744-a976-7ed9097b6806" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ProceedsFromWarrantExercisesMaximumAmount_414791e7-559d-439f-ad40-0dcbf764453f" xlink:href="ocgn-20191231.xsd#ocgn_ProceedsFromWarrantExercisesMaximumAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_ocgn_ProceedsFromWarrantExercisesMaximumAmount_414791e7-559d-439f-ad40-0dcbf764453f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger_d5755b53-8e70-4f64-a8d8-36d9b2756ba5" xlink:href="ocgn-20191231.xsd#ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger_d5755b53-8e70-4f64-a8d8-36d9b2756ba5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPrice_0851222a-f769-47a6-9908-5a8548e3dade" xlink:href="ocgn-20191231.xsd#ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPrice_0851222a-f769-47a6-9908-5a8548e3dade" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CommonStockAdditionalSharesOfCommonStockIssuableUponExerciseOfWarrantsBasedOnResetPeriodShares_299f0537-e0ed-4e97-a0f9-549648c9e57f" xlink:href="ocgn-20191231.xsd#ocgn_CommonStockAdditionalSharesOfCommonStockIssuableUponExerciseOfWarrantsBasedOnResetPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_ocgn_CommonStockAdditionalSharesOfCommonStockIssuableUponExerciseOfWarrantsBasedOnResetPeriodShares_299f0537-e0ed-4e97-a0f9-549648c9e57f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f136d5e1-4298-43aa-acd1-39cf49408b49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f136d5e1-4298-43aa-acd1-39cf49408b49" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightExercisePriceDeterminationNumberOfTradingDaysConsidered_4915f060-d643-4610-ba23-f6047044433b" xlink:href="ocgn-20191231.xsd#ocgn_ClassOfWarrantOrRightExercisePriceDeterminationNumberOfTradingDaysConsidered"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_ocgn_ClassOfWarrantOrRightExercisePriceDeterminationNumberOfTradingDaysConsidered_4915f060-d643-4610-ba23-f6047044433b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightConditionForExpirationTradingDay_9d609244-880f-4c5a-b60f-152edb3e5bd6" xlink:href="ocgn-20191231.xsd#ocgn_ClassOfWarrantOrRightConditionForExpirationTradingDay"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_ocgn_ClassOfWarrantOrRightConditionForExpirationTradingDay_9d609244-880f-4c5a-b60f-152edb3e5bd6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_84373ecb-e349-4f4b-97be-2c51048ee654" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_84373ecb-e349-4f4b-97be-2c51048ee654" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfFormerEmployeesWithWarrants_9fa94e40-07b2-4995-acdd-09107576ae1a" xlink:href="ocgn-20191231.xsd#ocgn_NumberOfFormerEmployeesWithWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_ocgn_NumberOfFormerEmployeesWithWarrants_9fa94e40-07b2-4995-acdd-09107576ae1a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightExercisable_6c55cfc5-b7f5-4790-8d0a-a799c3177b2d" xlink:href="ocgn-20191231.xsd#ocgn_ClassOfWarrantOrRightExercisable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_ocgn_ClassOfWarrantOrRightExercisable_6c55cfc5-b7f5-4790-8d0a-a799c3177b2d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_26f3c4c2-26ed-47e9-8eb4-4bc5cbf2d52e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_26f3c4c2-26ed-47e9-8eb4-4bc5cbf2d52e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_3b740be4-3947-42c5-99c9-0747c97dca72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_26f3c4c2-26ed-47e9-8eb4-4bc5cbf2d52e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_3b740be4-3947-42c5-99c9-0747c97dca72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3b740be4-3947-42c5-99c9-0747c97dca72_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3b740be4-3947-42c5-99c9-0747c97dca72" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3b740be4-3947-42c5-99c9-0747c97dca72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_931e7ab8-ecbf-4762-a47f-90093226d492" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3b740be4-3947-42c5-99c9-0747c97dca72" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_931e7ab8-ecbf-4762-a47f-90093226d492" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesWarrantsMember_16008f93-14d3-4074-9c30-49a5e31a3465" xlink:href="ocgn-20191231.xsd#ocgn_SeriesWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_931e7ab8-ecbf-4762-a47f-90093226d492" xlink:to="loc_ocgn_SeriesWarrantsMember_16008f93-14d3-4074-9c30-49a5e31a3465" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesBWarrantsMember_c9ef52df-03a8-4346-89c1-bc31f2f11c25" xlink:href="ocgn-20191231.xsd#ocgn_SeriesBWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_931e7ab8-ecbf-4762-a47f-90093226d492" xlink:to="loc_ocgn_SeriesBWarrantsMember_c9ef52df-03a8-4346-89c1-bc31f2f11c25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesCWarrantsMember_06d19cc2-b2b5-403f-a6af-c1974d439dc6" xlink:href="ocgn-20191231.xsd#ocgn_SeriesCWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_931e7ab8-ecbf-4762-a47f-90093226d492" xlink:to="loc_ocgn_SeriesCWarrantsMember_06d19cc2-b2b5-403f-a6af-c1974d439dc6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_FormerOcugenWarrantsMember_9ab0152b-dd66-4cc0-bb86-532f51d6aa44" xlink:href="ocgn-20191231.xsd#ocgn_FormerOcugenWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_931e7ab8-ecbf-4762-a47f-90093226d492" xlink:to="loc_ocgn_FormerOcugenWarrantsMember_9ab0152b-dd66-4cc0-bb86-532f51d6aa44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_924b3ee6-e11c-4c2f-a278-5d52ac8ae7a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_26f3c4c2-26ed-47e9-8eb4-4bc5cbf2d52e" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_924b3ee6-e11c-4c2f-a278-5d52ac8ae7a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_924b3ee6-e11c-4c2f-a278-5d52ac8ae7a9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_924b3ee6-e11c-4c2f-a278-5d52ac8ae7a9" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_924b3ee6-e11c-4c2f-a278-5d52ac8ae7a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_9965dbc2-79a4-4111-9f74-2af2ccdece9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_924b3ee6-e11c-4c2f-a278-5d52ac8ae7a9" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_9965dbc2-79a4-4111-9f74-2af2ccdece9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_e969efb8-5098-4c0e-b9f7-b0edc8cdc03f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9965dbc2-79a4-4111-9f74-2af2ccdece9c" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_e969efb8-5098-4c0e-b9f7-b0edc8cdc03f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_853c733f-2304-4995-a929-4b5617ddefb0" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_26f3c4c2-26ed-47e9-8eb4-4bc5cbf2d52e" xlink:to="loc_srt_RangeAxis_853c733f-2304-4995-a929-4b5617ddefb0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_853c733f-2304-4995-a929-4b5617ddefb0_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_853c733f-2304-4995-a929-4b5617ddefb0" xlink:to="loc_srt_RangeMember_853c733f-2304-4995-a929-4b5617ddefb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8f27c150-8cc4-450a-bb07-77813d01d290" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_853c733f-2304-4995-a929-4b5617ddefb0" xlink:to="loc_srt_RangeMember_8f27c150-8cc4-450a-bb07-77813d01d290" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3338b5a8-5f07-4a12-a8d1-e278f2d00f2c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8f27c150-8cc4-450a-bb07-77813d01d290" xlink:to="loc_srt_MaximumMember_3338b5a8-5f07-4a12-a8d1-e278f2d00f2c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/ScheduleofActivityofthePreMergerFinancingWarrantsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#ScheduleofActivityofthePreMergerFinancingWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/ScheduleofActivityofthePreMergerFinancingWarrantsDetails" xlink:type="extended" id="i95d8b14f498e41769433437be6367743_703ffaf2-4c03-42f3-a6cf-3efac9a51373">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_1a193d18-c625-4b05-ac05-725fc663b86f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b64eaebc-94e8-43c6-a17e-e3fef8c30918" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_1a193d18-c625-4b05-ac05-725fc663b86f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b64eaebc-94e8-43c6-a17e-e3fef8c30918" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_895cb6a4-b9e3-47a8-a957-2b4176df249e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b64eaebc-94e8-43c6-a17e-e3fef8c30918" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_895cb6a4-b9e3-47a8-a957-2b4176df249e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightIssued_d81c34e1-135a-4769-8629-958314f3cada" xlink:href="ocgn-20191231.xsd#ocgn_ClassOfWarrantOrRightIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b64eaebc-94e8-43c6-a17e-e3fef8c30918" xlink:to="loc_ocgn_ClassOfWarrantOrRightIssued_d81c34e1-135a-4769-8629-958314f3cada" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightExercised_dffd5a8b-eaf9-477b-aad2-68e5059ea4ef" xlink:href="ocgn-20191231.xsd#ocgn_ClassOfWarrantOrRightExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b64eaebc-94e8-43c6-a17e-e3fef8c30918" xlink:to="loc_ocgn_ClassOfWarrantOrRightExercised_dffd5a8b-eaf9-477b-aad2-68e5059ea4ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_117db1e1-83f6-4c2b-aebb-d122e93119ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5ca1aba2-052b-4422-a7ac-1300e8a31898" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b64eaebc-94e8-43c6-a17e-e3fef8c30918" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5ca1aba2-052b-4422-a7ac-1300e8a31898" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_be0de269-e145-4ad3-a4a6-7c97a4cecfab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_1a193d18-c625-4b05-ac05-725fc663b86f" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_be0de269-e145-4ad3-a4a6-7c97a4cecfab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_adca05b9-1f6c-403c-8705-777cdb4d1c5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_be0de269-e145-4ad3-a4a6-7c97a4cecfab" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_adca05b9-1f6c-403c-8705-777cdb4d1c5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_adca05b9-1f6c-403c-8705-777cdb4d1c5f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_adca05b9-1f6c-403c-8705-777cdb4d1c5f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_adca05b9-1f6c-403c-8705-777cdb4d1c5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ecda0270-4b03-4804-8f3d-71aa18ae8d9a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_adca05b9-1f6c-403c-8705-777cdb4d1c5f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ecda0270-4b03-4804-8f3d-71aa18ae8d9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesWarrantsMember_569a1f9c-0359-4a01-8559-d045c92719cf" xlink:href="ocgn-20191231.xsd#ocgn_SeriesWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecda0270-4b03-4804-8f3d-71aa18ae8d9a" xlink:to="loc_ocgn_SeriesWarrantsMember_569a1f9c-0359-4a01-8559-d045c92719cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesBWarrantsMember_6914f35e-03a3-4d5b-b546-ed9c36cc0839" xlink:href="ocgn-20191231.xsd#ocgn_SeriesBWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecda0270-4b03-4804-8f3d-71aa18ae8d9a" xlink:to="loc_ocgn_SeriesBWarrantsMember_6914f35e-03a3-4d5b-b546-ed9c36cc0839" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesCWarrantsMember_a55fb359-d743-4f2e-bcc8-1dd9274b47e2" xlink:href="ocgn-20191231.xsd#ocgn_SeriesCWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecda0270-4b03-4804-8f3d-71aa18ae8d9a" xlink:to="loc_ocgn_SeriesCWarrantsMember_a55fb359-d743-4f2e-bcc8-1dd9274b47e2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/ScheduleofRollforwardofSeriesBWarrantLiabilityDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#ScheduleofRollforwardofSeriesBWarrantLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/ScheduleofRollforwardofSeriesBWarrantLiabilityDetails" xlink:type="extended" id="i51e1437856d845faae9b7f645e9b34af_d1a31d4d-a532-4a3c-931f-8501e83ebb78">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_bf7525bd-f637-425c-af79-90442b6ade84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_5667938d-6c45-4d7b-98dc-268dbd40164e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_bf7525bd-f637-425c-af79-90442b6ade84" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_5667938d-6c45-4d7b-98dc-268dbd40164e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_902fed7d-4331-4c1c-837a-401c77e39952" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_5667938d-6c45-4d7b-98dc-268dbd40164e" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_902fed7d-4331-4c1c-837a-401c77e39952" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_bcbe3bee-7bc8-401c-b4dc-9c57225c8762" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_5667938d-6c45-4d7b-98dc-268dbd40164e" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_bcbe3bee-7bc8-401c-b4dc-9c57225c8762" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_87a9c105-a03f-4bac-bf66-5fc4416810c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_5667938d-6c45-4d7b-98dc-268dbd40164e" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_87a9c105-a03f-4bac-bf66-5fc4416810c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationAmountReclassifiedToEquity_71601d54-604e-4c67-b3f2-ed9bf12e74bf" xlink:href="ocgn-20191231.xsd#ocgn_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationAmountReclassifiedToEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_5667938d-6c45-4d7b-98dc-268dbd40164e" xlink:to="loc_ocgn_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationAmountReclassifiedToEquity_71601d54-604e-4c67-b3f2-ed9bf12e74bf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_7a570da1-8680-4c1f-8b54-df8b5828ff1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_7556e093-9aa3-47cf-a30c-574df5359662" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_bf7525bd-f637-425c-af79-90442b6ade84" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_7556e093-9aa3-47cf-a30c-574df5359662" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_6d87d766-4971-41b8-9068-253e70b8e517" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_7556e093-9aa3-47cf-a30c-574df5359662" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_6d87d766-4971-41b8-9068-253e70b8e517" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6d87d766-4971-41b8-9068-253e70b8e517_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6d87d766-4971-41b8-9068-253e70b8e517" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6d87d766-4971-41b8-9068-253e70b8e517_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7c91752f-d313-4f42-b88e-1cbedae2a4e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6d87d766-4971-41b8-9068-253e70b8e517" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7c91752f-d313-4f42-b88e-1cbedae2a4e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesBWarrantsMember_a4364310-f1b8-4c74-9e78-aae44972a8a7" xlink:href="ocgn-20191231.xsd#ocgn_SeriesBWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7c91752f-d313-4f42-b88e-1cbedae2a4e6" xlink:to="loc_ocgn_SeriesBWarrantsMember_a4364310-f1b8-4c74-9e78-aae44972a8a7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ocgn-20191231.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/IncomeTaxes" xlink:type="extended" id="i733bc98573ab47a9a9fd81d4b9da6905_297d3917-293b-4d2c-9fcc-03fb5abbffd3"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="ocgn-20191231.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/IncomeTaxesTables" xlink:type="extended" id="i4ec082f10e464657b2521b1f9e8b6546_aa1c5c42-223f-4b3f-a807-13aa7731bfb7"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#ScheduleofDeferredTaxAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails" xlink:type="extended" id="i7f8bc16b074747a49412a496fc2e9b57_b108179f-4d39-40c9-a364-7ec682d21b3b"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/IncomeTaxesDetails" xlink:type="extended" id="i86efdf6492f344a78cee12b6b321d1d9_ab9721b4-3682-4df0-a3bd-6615b1ba57a4">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_f6aa7945-3889-4a6e-94b3-980536cb6c97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a8dbfab7-9307-49d7-b3b4-775ff290e36d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f6aa7945-3889-4a6e-94b3-980536cb6c97" xlink:to="loc_us-gaap_NetIncomeLoss_a8dbfab7-9307-49d7-b3b4-775ff290e36d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_91681608-60ad-4557-ab7f-9e29cf68c002" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f6aa7945-3889-4a6e-94b3-980536cb6c97" xlink:to="loc_us-gaap_OperatingLossCarryforwards_91681608-60ad-4557-ab7f-9e29cf68c002" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_a27fd098-4f04-4377-9bc4-8a0fb9b2670a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f6aa7945-3889-4a6e-94b3-980536cb6c97" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_a27fd098-4f04-4377-9bc4-8a0fb9b2670a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_a07cd82a-e81f-421c-8da8-675aa5e9991f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f6aa7945-3889-4a6e-94b3-980536cb6c97" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_a07cd82a-e81f-421c-8da8-675aa5e9991f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_7a628fcf-1172-4fab-9bd2-9b58c4ada562" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f6aa7945-3889-4a6e-94b3-980536cb6c97" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_7a628fcf-1172-4fab-9bd2-9b58c4ada562" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_88c9a998-2f76-4c31-a934-bab800ae781b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f6aa7945-3889-4a6e-94b3-980536cb6c97" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_88c9a998-2f76-4c31-a934-bab800ae781b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_4e4b4005-c922-46ae-a78c-1690425e0d8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f6aa7945-3889-4a6e-94b3-980536cb6c97" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_4e4b4005-c922-46ae-a78c-1690425e0d8c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_56f22e2d-8ada-474f-b2ca-0e27f959f3a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f6aa7945-3889-4a6e-94b3-980536cb6c97" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_56f22e2d-8ada-474f-b2ca-0e27f959f3a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_a07c1573-b3b1-434f-bdb0-232a77097b5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_56f22e2d-8ada-474f-b2ca-0e27f959f3a3" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_a07c1573-b3b1-434f-bdb0-232a77097b5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_a07c1573-b3b1-434f-bdb0-232a77097b5b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_a07c1573-b3b1-434f-bdb0-232a77097b5b" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_a07c1573-b3b1-434f-bdb0-232a77097b5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_be4cc3ec-fe2a-4d59-adfc-43b343d84b58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_a07c1573-b3b1-434f-bdb0-232a77097b5b" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_be4cc3ec-fe2a-4d59-adfc-43b343d84b58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_fca0a602-9836-492f-b9f1-9c9efa188b9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_be4cc3ec-fe2a-4d59-adfc-43b343d84b58" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_fca0a602-9836-492f-b9f1-9c9efa188b9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_c4b11d25-d741-4cb8-97ff-bd9af801e13b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_be4cc3ec-fe2a-4d59-adfc-43b343d84b58" xlink:to="loc_us-gaap_DomesticCountryMember_c4b11d25-d741-4cb8-97ff-bd9af801e13b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/ScheduleofEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#ScheduleofEffectiveIncomeTaxRateDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/ScheduleofEffectiveIncomeTaxRateDetails" xlink:type="extended" id="i95bcc8dc198a43e88dfddac7201e3028_dd6053e5-171c-46b7-b586-cdc8c1cbd8b7"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/ScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#ScheduleofUnrecognizedTaxBenefitsDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/ScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="extended" id="icdfc1eb1170047d1a8375e68cb77f13e_d42a9eaa-748c-4ea7-83e3-0bd7398086cf"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SubsequentEvents" xlink:type="simple" xlink:href="ocgn-20191231.xsd#SubsequentEvents"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/SubsequentEvents" xlink:type="extended" id="ibb81ce5250d446abaf926e7fc0b3250f_be3ad9e2-ebc7-45e0-922b-4955f2a345a9"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/SubsequentEventsDetails" xlink:type="extended" id="i51625fefc8244c4f831d8ccb164f8f79_c28f13c9-7d38-4c4b-afb9-1276b6a96c0f">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_66c046da-1606-42be-9f23-9744a0640280" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_3d7ea319-111f-4102-991c-5663d4b95c01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_66c046da-1606-42be-9f23-9744a0640280" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_3d7ea319-111f-4102-991c-5663d4b95c01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d4c64e5a-e7fe-40f6-beb0-f215cbe1bcc7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_66c046da-1606-42be-9f23-9744a0640280" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d4c64e5a-e7fe-40f6-beb0-f215cbe1bcc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_5d8e15a2-23d2-4e14-804d-6de20f4e793d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_66c046da-1606-42be-9f23-9744a0640280" xlink:to="loc_us-gaap_SubsequentEventTable_5d8e15a2-23d2-4e14-804d-6de20f4e793d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1220e13d-3e2e-420d-8bd6-27ecd5c023b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5d8e15a2-23d2-4e14-804d-6de20f4e793d" xlink:to="loc_us-gaap_DebtInstrumentAxis_1220e13d-3e2e-420d-8bd6-27ecd5c023b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1220e13d-3e2e-420d-8bd6-27ecd5c023b7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1220e13d-3e2e-420d-8bd6-27ecd5c023b7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1220e13d-3e2e-420d-8bd6-27ecd5c023b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cbf68f0f-8ff9-4752-aa64-50ed7c54635b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1220e13d-3e2e-420d-8bd6-27ecd5c023b7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cbf68f0f-8ff9-4752-aa64-50ed7c54635b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EB5ProgramBorrowingsMember_91151057-8001-40d3-8c01-e7340734f1b1" xlink:href="ocgn-20191231.xsd#ocgn_EB5ProgramBorrowingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cbf68f0f-8ff9-4752-aa64-50ed7c54635b" xlink:to="loc_ocgn_EB5ProgramBorrowingsMember_91151057-8001-40d3-8c01-e7340734f1b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_db6d625a-6606-4313-86d1-7cb9b8a89fd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5d8e15a2-23d2-4e14-804d-6de20f4e793d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_db6d625a-6606-4313-86d1-7cb9b8a89fd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_db6d625a-6606-4313-86d1-7cb9b8a89fd4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_db6d625a-6606-4313-86d1-7cb9b8a89fd4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_db6d625a-6606-4313-86d1-7cb9b8a89fd4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c771a359-a757-417b-90e7-0e23985941c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_db6d625a-6606-4313-86d1-7cb9b8a89fd4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c771a359-a757-417b-90e7-0e23985941c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_42c6f3a6-ceb3-4fc7-a0c1-167f60b9b33d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c771a359-a757-417b-90e7-0e23985941c9" xlink:to="loc_us-gaap_LoansPayableMember_42c6f3a6-ceb3-4fc7-a0c1-167f60b9b33d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_347c9106-9cd1-4b1f-8902-8e3f4572c81c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5d8e15a2-23d2-4e14-804d-6de20f4e793d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_347c9106-9cd1-4b1f-8902-8e3f4572c81c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_347c9106-9cd1-4b1f-8902-8e3f4572c81c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_347c9106-9cd1-4b1f-8902-8e3f4572c81c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_347c9106-9cd1-4b1f-8902-8e3f4572c81c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c7f586e4-4426-4c01-8a4e-d9b367671b51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_347c9106-9cd1-4b1f-8902-8e3f4572c81c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c7f586e4-4426-4c01-8a4e-d9b367671b51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c93ca967-763e-432d-9a68-2f4d4bbc846a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c7f586e4-4426-4c01-8a4e-d9b367671b51" xlink:to="loc_us-gaap_SubsequentEventMember_c93ca967-763e-432d-9a68-2f4d4bbc846a" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>ocgn-20191231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:cc72798c-c24e-4d47-845f-93333954ce8b,g:e003b04e-ddd7-4b29-b911-f80dc6cd6725-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_6dad01e5-54d1-447e-9027-da322bd977ab_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_30149739-3910-4b81-b2af-ef8a6a6b5849_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_AssetHeldForSalePolicyTextBlock_20f0af67-e969-4da8-bf5d-82e31fd4a0b7_terseLabel_en-US" xlink:label="lab_ocgn_AssetHeldForSalePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Held for Sale</link:label>
    <link:label id="lab_ocgn_AssetHeldForSalePolicyTextBlock_label_en-US" xlink:label="lab_ocgn_AssetHeldForSalePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Held For Sale [Policy Text Block]</link:label>
    <link:label id="lab_ocgn_AssetHeldForSalePolicyTextBlock_documentation_en-US" xlink:label="lab_ocgn_AssetHeldForSalePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents asset held for sale.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AssetHeldForSalePolicyTextBlock" xlink:href="ocgn-20191231.xsd#ocgn_AssetHeldForSalePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_AssetHeldForSalePolicyTextBlock" xlink:to="lab_ocgn_AssetHeldForSalePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_b887ae40-08f5-4afd-82bd-e90564ed028d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_0d1efc39-c458-48fb-b348-ee0e95819282_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_ed045b0a-8719-4686-b65f-c1eab60f530e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_6789d519-35b8-4b03-84f4-f8d858bbae77_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount borrowed</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_1bb8b2ed-966f-44f8-8191-58a5a5673e74_verboseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLicenseFeesReceived_2f2530d5-c6d3-4455-a515-e22926c4a98a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront cash payment received for license granted to MEDINET</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLicenseFeesReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from License Fees Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="lab_us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_a5cec27a-b41b-4071-8e5b-935176a7632b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_658e0cfe-3f71-442d-95de-901d38d6d1e8_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_63a5c750-e681-4b18-a171-e38bc95355a1_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation and Transactions</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_d7743f1e-8a39-4385-9c79-0948b911a79a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_10674814-f310-4cb7-96f0-97a598b39b60_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_f279e0d3-2f42-4d06-a9f5-e0b7a3764096_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_a1af4da7-f063-4bce-9370-ccbf483045fa_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Beginning Balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_2fe9c241-3351-42b5-9cb2-eff868d6cbb1_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Ending Balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_91a6864c-9d8b-4751-910e-3b1a28401821_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_03665260-d877-4d6a-bb82-dd7d7f5de259_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_69beee9e-c00b-4f16-896e-7fab43561cb3_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b2c1d626-40c8-47d4-9d1e-78a8aca6587b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Standards; Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_eba84847-c912-4e40-95e5-1b33b0b80fdc_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Business</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_433e74af-d272-44f3-bbdc-1305f7bd8759_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_f0d86963-e3ca-425e-8df1-cf651acda88d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock subscription</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_5bb779fc-ec19-4dea-baab-28d66b10adbf_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_829dfd7e-a810-423c-971d-3f6a48ad695c_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of senior secured notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_9a577da2-291f-4084-8978-48e421864a73_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_bd5190d2-f960-4d7b-a035-e309359f46d3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity issuance costs paid with equity</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d37bbe54-e657-4e4c-8e45-59ab04536a84_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_48b014f2-d0e5-402a-919f-069f0ebd3d3d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for Subscription Agreement</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_762fd3c5-3bea-47a6-a8d5-084a756b5769_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_6204e563-41c5-47e1-99f7-93d01a375f9a_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: present value adjustment</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_35b6f83b-0781-4d54-b019-04d716772194_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ConvertibleDebtNovember2018Member_f7d95e30-235c-43a3-8244-4b2e0b8fea6c_terseLabel_en-US" xlink:label="lab_ocgn_ConvertibleDebtNovember2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Note - November 2018</link:label>
    <link:label id="lab_ocgn_ConvertibleDebtNovember2018Member_label_en-US" xlink:label="lab_ocgn_ConvertibleDebtNovember2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt November2018 [Member]</link:label>
    <link:label id="lab_ocgn_ConvertibleDebtNovember2018Member_documentation_en-US" xlink:label="lab_ocgn_ConvertibleDebtNovember2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock, issued in November 2018.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertibleDebtNovember2018Member" xlink:href="ocgn-20191231.xsd#ocgn_ConvertibleDebtNovember2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ConvertibleDebtNovember2018Member" xlink:to="lab_ocgn_ConvertibleDebtNovember2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4ce3fbdc-c797-4d32-8e66-7d424c15a0f2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_e069e892-8708-4b94-ba97-cc4caf2e1b30_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_DeferredTaxAssetsLeaseLiability_f12532cb-a868-4861-b789-9886f055e9e3_terseLabel_en-US" xlink:label="lab_ocgn_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_ocgn_DeferredTaxAssetsLeaseLiability_label_en-US" xlink:label="lab_ocgn_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:label id="lab_ocgn_DeferredTaxAssetsLeaseLiability_documentation_en-US" xlink:label="lab_ocgn_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_DeferredTaxAssetsLeaseLiability" xlink:href="ocgn-20191231.xsd#ocgn_DeferredTaxAssetsLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_DeferredTaxAssetsLeaseLiability" xlink:to="lab_ocgn_DeferredTaxAssetsLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_68f0a24b-4c24-44cb-a5e1-6cf3845538b7_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_91dd102e-e47b-46c0-8f88-4c3045cf13b1_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_032d14df-bf08-49be-afdb-f4982c9540a4_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_8efb6b8a-5b2a-4379-bbd8-b36a88b4c436_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c79abf45-3fa8-446d-929e-96009f7bb0e0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_fdd5ccb2-43ef-4783-821b-74e390f94a87_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_StockIssuedDuringPeriodPreMergerValue_b953b5f7-065b-4364-b09e-83658e81d6d7_terseLabel_en-US" xlink:label="lab_ocgn_StockIssuedDuringPeriodPreMergerValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock and warrants for Pre-Merger Financing</link:label>
    <link:label id="lab_ocgn_StockIssuedDuringPeriodPreMergerValue_label_en-US" xlink:label="lab_ocgn_StockIssuedDuringPeriodPreMergerValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Pre Merger, Value</link:label>
    <link:label id="lab_ocgn_StockIssuedDuringPeriodPreMergerValue_documentation_en-US" xlink:label="lab_ocgn_StockIssuedDuringPeriodPreMergerValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity impact of the value of stock issued during the period pursuant to pre-merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_StockIssuedDuringPeriodPreMergerValue" xlink:href="ocgn-20191231.xsd#ocgn_StockIssuedDuringPeriodPreMergerValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_StockIssuedDuringPeriodPreMergerValue" xlink:to="lab_ocgn_StockIssuedDuringPeriodPreMergerValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_DeferredTaxAssetsConvertibleDebt_8321fca3-9406-47c0-ad1b-5d29d21209bb_terseLabel_en-US" xlink:label="lab_ocgn_DeferredTaxAssetsConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_ocgn_DeferredTaxAssetsConvertibleDebt_label_en-US" xlink:label="lab_ocgn_DeferredTaxAssetsConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Convertible Debt</link:label>
    <link:label id="lab_ocgn_DeferredTaxAssetsConvertibleDebt_documentation_en-US" xlink:label="lab_ocgn_DeferredTaxAssetsConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_DeferredTaxAssetsConvertibleDebt" xlink:href="ocgn-20191231.xsd#ocgn_DeferredTaxAssetsConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_DeferredTaxAssetsConvertibleDebt" xlink:to="lab_ocgn_DeferredTaxAssetsConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_7721e40d-2515-4549-8bdb-717232fa38f9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_AssetPurchaseAgreementCashConsideration_2c8f7ad9-80d2-4628-afc6-6f2d2bb0bb34_terseLabel_en-US" xlink:label="lab_ocgn_AssetPurchaseAgreementCashConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset purchase agreement, cash consideration</link:label>
    <link:label id="lab_ocgn_AssetPurchaseAgreementCashConsideration_label_en-US" xlink:label="lab_ocgn_AssetPurchaseAgreementCashConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement, Cash Consideration</link:label>
    <link:label id="lab_ocgn_AssetPurchaseAgreementCashConsideration_documentation_en-US" xlink:label="lab_ocgn_AssetPurchaseAgreementCashConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of cash consideration agreed under the asset purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AssetPurchaseAgreementCashConsideration" xlink:href="ocgn-20191231.xsd#ocgn_AssetPurchaseAgreementCashConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_AssetPurchaseAgreementCashConsideration" xlink:to="lab_ocgn_AssetPurchaseAgreementCashConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_LicenseAgreementPayment_d7773b1b-2444-48ce-8017-bd08d66e31d0_terseLabel_en-US" xlink:label="lab_ocgn_LicenseAgreementPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fee paid</link:label>
    <link:label id="lab_ocgn_LicenseAgreementPayment_label_en-US" xlink:label="lab_ocgn_LicenseAgreementPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Payment</link:label>
    <link:label id="lab_ocgn_LicenseAgreementPayment_documentation_en-US" xlink:label="lab_ocgn_LicenseAgreementPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LicenseAgreementPayment" xlink:href="ocgn-20191231.xsd#ocgn_LicenseAgreementPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_LicenseAgreementPayment" xlink:to="lab_ocgn_LicenseAgreementPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_223af345-5009-4e6f-bd27-617b0f930fbc_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_BusinessCombinationIssuedSharesExchangeRate_dee13d34-f6bd-4ee3-8c4b-4a919776c072_terseLabel_en-US" xlink:label="lab_ocgn_BusinessCombinationIssuedSharesExchangeRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued exchange rate to former Ocugen's stockholders (exchange rate)</link:label>
    <link:label id="lab_ocgn_BusinessCombinationIssuedSharesExchangeRate_label_en-US" xlink:label="lab_ocgn_BusinessCombinationIssuedSharesExchangeRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Issued Shares Exchange Rate</link:label>
    <link:label id="lab_ocgn_BusinessCombinationIssuedSharesExchangeRate_documentation_en-US" xlink:label="lab_ocgn_BusinessCombinationIssuedSharesExchangeRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The exchange rate of share issued to shares surrendered by stockholder of the acquired entity in a business combination.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_BusinessCombinationIssuedSharesExchangeRate" xlink:href="ocgn-20191231.xsd#ocgn_BusinessCombinationIssuedSharesExchangeRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_BusinessCombinationIssuedSharesExchangeRate" xlink:to="lab_ocgn_BusinessCombinationIssuedSharesExchangeRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_038179f4-d1c8-44a6-bca7-ce2ce0d7e3c2_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_74d28b27-62c9-48d4-b8d7-faf459aa6b46_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_f5c36083-333c-4c23-b9ce-f028fc22f665_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plus: accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_81e414b1-befc-45c7-888e-9e2c48f7dc52_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_dee6fbf5-32b1-4ab3-936f-a4b78d621a5f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_SupplementalBalanceSheetInformationLeasesTableTextBlock_f360dad2-9e5b-4c3a-818f-94d4713cd555_terseLabel_en-US" xlink:label="lab_ocgn_SupplementalBalanceSheetInformationLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of supplemental balance sheet information related to leases</link:label>
    <link:label id="lab_ocgn_SupplementalBalanceSheetInformationLeasesTableTextBlock_label_en-US" xlink:label="lab_ocgn_SupplementalBalanceSheetInformationLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental balance sheet information leases [table text block]</link:label>
    <link:label id="lab_ocgn_SupplementalBalanceSheetInformationLeasesTableTextBlock_documentation_en-US" xlink:label="lab_ocgn_SupplementalBalanceSheetInformationLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of balance sheet information related to leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SupplementalBalanceSheetInformationLeasesTableTextBlock" xlink:href="ocgn-20191231.xsd#ocgn_SupplementalBalanceSheetInformationLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_SupplementalBalanceSheetInformationLeasesTableTextBlock" xlink:to="lab_ocgn_SupplementalBalanceSheetInformationLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_c876b349-1a07-4532-954a-663da963c9fc_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Original Issue Discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_16593040-d21f-4d27-8c20-10bff744f4d5_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of changes in exchange rate on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_64da453f-962f-49c3-8ffc-aa22d8432466_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_d8559b02-eb07-437f-8d1b-310e5eb0b689_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_d81b89e3-8d34-4934-aa8f-868dcd02fbfc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_f5c911a0-87dd-4c9c-af0a-3ea298b8ce10_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 9)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_b0207857-c9b7-40cb-a517-392df15d3c4a_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d66656c4-2987-4852-9bfa-14f84b109934_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_82258d64-09ae-400e-9991-57a204cf0fbb_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d7d48952-dabe-4980-8a38-e76051532b88_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_48f09fe0-9256-4d5e-a86e-8f979c1b1d40_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_767a0285-5028-4495-97b9-00dbaa968b4c_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of debt loss</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_97b10863-d28d-497b-9338-dd7874bb687b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c872a1e5-bfb5-403f-a3d9-d379da1227b1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares of common stock outstanding - basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3952bbe0-0fd9-49ed-81d6-56496bca72e6_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in calculation net loss per common share - basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_faa0c26b-a149-47c8-a0dd-7bb71b9c35e2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial exercise price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_dbd0e170-0b68-42b8-8dfc-606558ce26a4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_SeniorSecuredConvertibleNotesMay2019Member_2fc071eb-de0c-40ab-a993-7f31e78d8558_terseLabel_en-US" xlink:label="lab_ocgn_SeniorSecuredConvertibleNotesMay2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Convertible Notes - May 2019</link:label>
    <link:label id="lab_ocgn_SeniorSecuredConvertibleNotesMay2019Member_label_en-US" xlink:label="lab_ocgn_SeniorSecuredConvertibleNotesMay2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Convertible Notes May2019 [Member]</link:label>
    <link:label id="lab_ocgn_SeniorSecuredConvertibleNotesMay2019Member_documentation_en-US" xlink:label="lab_ocgn_SeniorSecuredConvertibleNotesMay2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior secured borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock, issued in May 2019.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeniorSecuredConvertibleNotesMay2019Member" xlink:href="ocgn-20191231.xsd#ocgn_SeniorSecuredConvertibleNotesMay2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_SeniorSecuredConvertibleNotesMay2019Member" xlink:to="lab_ocgn_SeniorSecuredConvertibleNotesMay2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_eec57e1e-7348-4311-99a3-a899c377a411_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of fixed assets by entering into capital lease (Note 9)</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_a04f77a1-aaa1-4aff-8bb0-69606d85aaf0_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_38166fe2-644c-4412-9414-a9b8302e9ce3_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3ba43b30-ac16-4b6d-aeea-7a3ef2810248_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_9dd3cb1f-2f3b-4a5c-9393-5cb02f5dbb40_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNet_ffa5159b-d378-40d8-8583-9d5870923fcc_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets acquired</link:label>
    <link:label id="lab_us-gaap_AssetsNet_label_en-US" xlink:label="lab_us-gaap_AssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNet" xlink:to="lab_us-gaap_AssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_AssetsHeldForSale_b74ad6f1-4432-41de-8fff-acf9c8fae168_terseLabel_en-US" xlink:label="lab_ocgn_AssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset held for sale</link:label>
    <link:label id="lab_ocgn_AssetsHeldForSale_label_en-US" xlink:label="lab_ocgn_AssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held For Sale</link:label>
    <link:label id="lab_ocgn_AssetsHeldForSale_documentation_en-US" xlink:label="lab_ocgn_AssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The carrying value as of the balance sheet date of the assets held for sale.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AssetsHeldForSale" xlink:href="ocgn-20191231.xsd#ocgn_AssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_AssetsHeldForSale" xlink:to="lab_ocgn_AssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_GainsLossesOnConversionOfDebt_41b0b7d9-b1d4-4007-ba58-36b7793d6add_verboseLabel_en-US" xlink:label="lab_ocgn_GainsLossesOnConversionOfDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on debt conversion</link:label>
    <link:label id="lab_ocgn_GainsLossesOnConversionOfDebt_18ba7c77-be60-4ecf-883e-e4b178723567_negatedLabel_en-US" xlink:label="lab_ocgn_GainsLossesOnConversionOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible notes</link:label>
    <link:label id="lab_ocgn_GainsLossesOnConversionOfDebt_label_en-US" xlink:label="lab_ocgn_GainsLossesOnConversionOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (Losses) on Conversion of Debt</link:label>
    <link:label id="lab_ocgn_GainsLossesOnConversionOfDebt_documentation_en-US" xlink:label="lab_ocgn_GainsLossesOnConversionOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain (loss) on conversion of debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_GainsLossesOnConversionOfDebt" xlink:href="ocgn-20191231.xsd#ocgn_GainsLossesOnConversionOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_GainsLossesOnConversionOfDebt" xlink:to="lab_ocgn_GainsLossesOnConversionOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_6417785a-b7c4-4841-8c1d-cc0333a5a943_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebt_3458cd56-964f-4030-98b3-67f5f7b22bc0_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note principal outstanding</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_d2671285-2e0e-4688-b1c4-75c188e54046_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_LicenseAgreementSigningFee_f2f6a511-ffc5-4756-8d46-5cf1a8afdfa9_terseLabel_en-US" xlink:label="lab_ocgn_LicenseAgreementSigningFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Signing fee paid</link:label>
    <link:label id="lab_ocgn_LicenseAgreementSigningFee_label_en-US" xlink:label="lab_ocgn_LicenseAgreementSigningFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Signing Fee</link:label>
    <link:label id="lab_ocgn_LicenseAgreementSigningFee_documentation_en-US" xlink:label="lab_ocgn_LicenseAgreementSigningFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Signing Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LicenseAgreementSigningFee" xlink:href="ocgn-20191231.xsd#ocgn_LicenseAgreementSigningFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_LicenseAgreementSigningFee" xlink:to="lab_ocgn_LicenseAgreementSigningFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_ccfc7962-45d4-4e6a-a266-8d8ba5d71da4_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward, amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_fab9f4bf-f934-4a6e-94bc-8e5ed73fe7ed_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, at cost 121,500 and zero shares, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0b036e47-b5cf-47c7-adcf-24053bfa1805_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionHigherPercentageOfCommonStock_41ab00e4-cca3-4d46-b367-b8e744a5f8d0_terseLabel_en-US" xlink:label="lab_ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionHigherPercentageOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-merger financing warrants, block provisions, exercise restriction percentage of common stock (in percentage)</link:label>
    <link:label id="lab_ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionHigherPercentageOfCommonStock_label_en-US" xlink:label="lab_ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionHigherPercentageOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-merger Financing Warrants, Block Provisions, Exercise Restriction Higher Percentage Of Common Stock</link:label>
    <link:label id="lab_ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionHigherPercentageOfCommonStock_documentation_en-US" xlink:label="lab_ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionHigherPercentageOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-merger Financing Warrants, Block Provisions, Exercise Restriction Higher Percentage Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionHigherPercentageOfCommonStock" xlink:href="ocgn-20191231.xsd#ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionHigherPercentageOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionHigherPercentageOfCommonStock" xlink:to="lab_ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionHigherPercentageOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_31ffa04e-07fb-4e1a-b0e0-6cdbc5c80dc4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Assumptions Utilized in Fair Value Calculation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22ba9fca-be56-4a91-ada7-ec7d5903e47b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_04263397-a80a-417d-8c2f-95b5c085751d_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits Reconciliation</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_803b2aa7-8e9d-461d-a2ba-c8601862069f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_0d9e9ac0-623b-4c1e-a253-8c310de33b49_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_e934e3a3-e055-4305-a1dd-2326b0683cab_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_c6eaf051-2aa6-428f-90f6-e7212deac209_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ScheduleOfPreMergerFinancingWarrantsTableTextBlock_f8d8f306-2b9e-4b8b-8b98-c2e8a82a7205_terseLabel_en-US" xlink:label="lab_ocgn_ScheduleOfPreMergerFinancingWarrantsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Pre-merger Financing Warrants</link:label>
    <link:label id="lab_ocgn_ScheduleOfPreMergerFinancingWarrantsTableTextBlock_label_en-US" xlink:label="lab_ocgn_ScheduleOfPreMergerFinancingWarrantsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Pre-merger Financing Warrants [Table Text Block]</link:label>
    <link:label id="lab_ocgn_ScheduleOfPreMergerFinancingWarrantsTableTextBlock_documentation_en-US" xlink:label="lab_ocgn_ScheduleOfPreMergerFinancingWarrantsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Pre-merger Financing Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ScheduleOfPreMergerFinancingWarrantsTableTextBlock" xlink:href="ocgn-20191231.xsd#ocgn_ScheduleOfPreMergerFinancingWarrantsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ScheduleOfPreMergerFinancingWarrantsTableTextBlock" xlink:to="lab_ocgn_ScheduleOfPreMergerFinancingWarrantsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2f4565b8-0662-41b3-a7de-de67638b2af5_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_26e72fcc-5697-42ea-b12d-40205dc34450_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_StockIssuedDuringPeriodValueWarrantsExercised_ce3b4804-d003-46db-a587-2b30a3442a3f_terseLabel_en-US" xlink:label="lab_ocgn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for warrant exercises, net</link:label>
    <link:label id="lab_ocgn_StockIssuedDuringPeriodValueWarrantsExercised_label_en-US" xlink:label="lab_ocgn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:label id="lab_ocgn_StockIssuedDuringPeriodValueWarrantsExercised_documentation_en-US" xlink:label="lab_ocgn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:href="ocgn-20191231.xsd#ocgn_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="lab_ocgn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30ef2c01-6fb0-47ee-b53f-cb0097f1ad47_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_7fb8d6a8-2bd0-439b-81be-9e85445e198c_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_69af97b5-61b5-4698-8d4a-409e2781309e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_0cccb8ef-28aa-447e-8322-e6d377cafe12_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_bdf29c88-7583-45da-9b28-fadeb1844216_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_ab47e103-cca1-4370-9554-cc73ba0fd816_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_91cfda4f-ae95-4f14-b5d7-523f909e5e4f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9ff64568-05cb-454d-bf66-5097ac4b0b4a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_0274a62b-9391-4d6b-a885-869a71573609_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ReverseMergerAndFinancingDisclosureLineItems_21e5709c-a0e6-46fb-bd32-d7fde06e8be8_terseLabel_en-US" xlink:label="lab_ocgn_ReverseMergerAndFinancingDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Merger and Financing</link:label>
    <link:label id="lab_ocgn_ReverseMergerAndFinancingDisclosureLineItems_label_en-US" xlink:label="lab_ocgn_ReverseMergerAndFinancingDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Merger And Financing Disclosure [Line Items]</link:label>
    <link:label id="lab_ocgn_ReverseMergerAndFinancingDisclosureLineItems_documentation_en-US" xlink:label="lab_ocgn_ReverseMergerAndFinancingDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ReverseMergerAndFinancingDisclosureLineItems" xlink:href="ocgn-20191231.xsd#ocgn_ReverseMergerAndFinancingDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureLineItems" xlink:to="lab_ocgn_ReverseMergerAndFinancingDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_405ac2ee-a95e-4b06-a59e-e8e39b8878d8_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0238d86f-671c-4b1c-8207-f1070cdc7c11_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ConvertibleNotesBoardOfDirectorsMember_0c6856a2-0d4c-47a3-ba94-9f2f75f8b463_terseLabel_en-US" xlink:label="lab_ocgn_ConvertibleNotesBoardOfDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes - Board of Directors</link:label>
    <link:label id="lab_ocgn_ConvertibleNotesBoardOfDirectorsMember_label_en-US" xlink:label="lab_ocgn_ConvertibleNotesBoardOfDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes, Board Of Directors [Member]</link:label>
    <link:label id="lab_ocgn_ConvertibleNotesBoardOfDirectorsMember_documentation_en-US" xlink:label="lab_ocgn_ConvertibleNotesBoardOfDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes, Board Of Directors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertibleNotesBoardOfDirectorsMember" xlink:href="ocgn-20191231.xsd#ocgn_ConvertibleNotesBoardOfDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ConvertibleNotesBoardOfDirectorsMember" xlink:to="lab_ocgn_ConvertibleNotesBoardOfDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_240f7e7f-1f78-47ea-8f71-095c9a36f456_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b09a3881-9130-46ad-b612-e5d133fd1e62_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_496688da-2b44-48c0-b46b-482ef16c6367_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1f298a4a-b322-41f4-b5de-043613606d3e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment_580251c4-7669-4984-a62a-5df7e368dc38_terseLabel_en-US" xlink:label="lab_ocgn_LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and regulatory milestone payments</link:label>
    <link:label id="lab_ocgn_LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment_label_en-US" xlink:label="lab_ocgn_LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Potential Development And Regulatory Milestone Payment</link:label>
    <link:label id="lab_ocgn_LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment_documentation_en-US" xlink:label="lab_ocgn_LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Potential Development And Regulatory Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment" xlink:href="ocgn-20191231.xsd#ocgn_LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment" xlink:to="lab_ocgn_LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_ff6208c1-8eac-47cc-870f-ecadb0b07070_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board members</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_NonCashInterestExpense_4160957b-b0c3-41a4-b1eb-12a8ae106468_terseLabel_en-US" xlink:label="lab_ocgn_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_ocgn_NonCashInterestExpense_label_en-US" xlink:label="lab_ocgn_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Expense</link:label>
    <link:label id="lab_ocgn_NonCashInterestExpense_documentation_en-US" xlink:label="lab_ocgn_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of non-cash interest expense during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NonCashInterestExpense" xlink:href="ocgn-20191231.xsd#ocgn_NonCashInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_NonCashInterestExpense" xlink:to="lab_ocgn_NonCashInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_f1390747-c68a-439d-9659-4df69bbf5071_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_EmbeddedDerivativeConversionAndExtinguishmentOfDebt_4529a4a5-6f99-4cc3-80e6-2e7a0093abd9_negatedLabel_en-US" xlink:label="lab_ocgn_EmbeddedDerivativeConversionAndExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion and extinguishment of debt</link:label>
    <link:label id="lab_ocgn_EmbeddedDerivativeConversionAndExtinguishmentOfDebt_label_en-US" xlink:label="lab_ocgn_EmbeddedDerivativeConversionAndExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative, Conversion And Extinguishment Of Debt</link:label>
    <link:label id="lab_ocgn_EmbeddedDerivativeConversionAndExtinguishmentOfDebt_documentation_en-US" xlink:label="lab_ocgn_EmbeddedDerivativeConversionAndExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative, Conversion And Extinguishment Of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EmbeddedDerivativeConversionAndExtinguishmentOfDebt" xlink:href="ocgn-20191231.xsd#ocgn_EmbeddedDerivativeConversionAndExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_EmbeddedDerivativeConversionAndExtinguishmentOfDebt" xlink:to="lab_ocgn_EmbeddedDerivativeConversionAndExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_bf1aa985-587f-4bb9-9d78-0168203e52c3_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_29cf9bf1-d1e5-4db3-9bf0-9dbe5964c839_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_LicenseAgreementMilestonePayment_a1e87723-34a5-485c-acd6-b3967e55b2e6_terseLabel_en-US" xlink:label="lab_ocgn_LicenseAgreementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_ocgn_LicenseAgreementMilestonePayment_label_en-US" xlink:label="lab_ocgn_LicenseAgreementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Payment</link:label>
    <link:label id="lab_ocgn_LicenseAgreementMilestonePayment_documentation_en-US" xlink:label="lab_ocgn_LicenseAgreementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LicenseAgreementMilestonePayment" xlink:href="ocgn-20191231.xsd#ocgn_LicenseAgreementMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_LicenseAgreementMilestonePayment" xlink:to="lab_ocgn_LicenseAgreementMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_ae4051e2-195c-4e50-b5a4-a2e5f2db5c97_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (in percentage)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_386ad03a-086e-42c6-b20c-11cbe2d0ca43_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_NumberOfEquityCompensationPlans_433a7573-a829-4b73-86f8-a04ce695f03f_terseLabel_en-US" xlink:label="lab_ocgn_NumberOfEquityCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of equity compensation plans</link:label>
    <link:label id="lab_ocgn_NumberOfEquityCompensationPlans_label_en-US" xlink:label="lab_ocgn_NumberOfEquityCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Equity Compensation Plans</link:label>
    <link:label id="lab_ocgn_NumberOfEquityCompensationPlans_documentation_en-US" xlink:label="lab_ocgn_NumberOfEquityCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Equity Compensation Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfEquityCompensationPlans" xlink:href="ocgn-20191231.xsd#ocgn_NumberOfEquityCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_NumberOfEquityCompensationPlans" xlink:to="lab_ocgn_NumberOfEquityCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_404f4150-0d4a-4018-9aec-32343236e70e_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of embedded derivatives</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative, Gain (Loss) on Embedded Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:to="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f39b34e9-2024-44a6-89bb-0e82e396a6cb_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost_1942bff7-e5cf-42fc-af9c-bdeef5f89b41_terseLabel_en-US" xlink:label="lab_ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity issuance costs (Note 3)</link:label>
    <link:label id="lab_ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost_label_en-US" xlink:label="lab_ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Or Part Noncash Amount of Deferred Transaction Cost</link:label>
    <link:label id="lab_ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost_documentation_en-US" xlink:label="lab_ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of noncash or part noncash amount of deferred transaction cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost" xlink:href="ocgn-20191231.xsd#ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost" xlink:to="lab_ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_2fbebf4f-c742-44c2-b102-d745bfe2bd95_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_4522ed88-e27c-48f2-80d1-3d815d713efc_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a83cf1c5-3019-434c-88d5-701421bb1036_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-based Compensation Expense for Options Granted Reflected in the Consolidated Statement of Operations and Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_7ac12bad-8521-4ae0-a486-e2f727bdacf4_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ProceedsFromPreMergerFinancingFinancingActivities_bf852fad-89ee-4487-a1c5-5ce333ea5002_terseLabel_en-US" xlink:label="lab_ocgn_ProceedsFromPreMergerFinancingFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of common stock for pre-merger financing</link:label>
    <link:label id="lab_ocgn_ProceedsFromPreMergerFinancingFinancingActivities_label_en-US" xlink:label="lab_ocgn_ProceedsFromPreMergerFinancingFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Pre Merger Financing, Financing Activities</link:label>
    <link:label id="lab_ocgn_ProceedsFromPreMergerFinancingFinancingActivities_documentation_en-US" xlink:label="lab_ocgn_ProceedsFromPreMergerFinancingFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash inflow from the pre-merger financing during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ProceedsFromPreMergerFinancingFinancingActivities" xlink:href="ocgn-20191231.xsd#ocgn_ProceedsFromPreMergerFinancingFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ProceedsFromPreMergerFinancingFinancingActivities" xlink:to="lab_ocgn_ProceedsFromPreMergerFinancingFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_96c4bbb5-b556-4c82-a93f-61e84e6d5de1_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7d246da4-8bda-4478-9fd5-b54ba92c0238_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_adb04d23-510b-4322-b955-504225da8b10_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_DeferredTaxAssetsStartUpCosts_be5fe3c2-6f23-41e8-be99-c85ffc19bdb9_terseLabel_en-US" xlink:label="lab_ocgn_DeferredTaxAssetsStartUpCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Start-up costs</link:label>
    <link:label id="lab_ocgn_DeferredTaxAssetsStartUpCosts_label_en-US" xlink:label="lab_ocgn_DeferredTaxAssetsStartUpCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Start-up Costs</link:label>
    <link:label id="lab_ocgn_DeferredTaxAssetsStartUpCosts_documentation_en-US" xlink:label="lab_ocgn_DeferredTaxAssetsStartUpCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Start-up Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_DeferredTaxAssetsStartUpCosts" xlink:href="ocgn-20191231.xsd#ocgn_DeferredTaxAssetsStartUpCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_DeferredTaxAssetsStartUpCosts" xlink:to="lab_ocgn_DeferredTaxAssetsStartUpCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_NumberOfConvertedInitialSharesAgreedToIssuePriorToMergerToInvestors_7cf1acc4-62e6-459f-af27-4af2d60e0c49_terseLabel_en-US" xlink:label="lab_ocgn_NumberOfConvertedInitialSharesAgreedToIssuePriorToMergerToInvestors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of converted initial shares, agreed to be issued (in shares)</link:label>
    <link:label id="lab_ocgn_NumberOfConvertedInitialSharesAgreedToIssuePriorToMergerToInvestors_label_en-US" xlink:label="lab_ocgn_NumberOfConvertedInitialSharesAgreedToIssuePriorToMergerToInvestors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Converted Initial Shares Agreed To Issue Prior To Merger To Investors</link:label>
    <link:label id="lab_ocgn_NumberOfConvertedInitialSharesAgreedToIssuePriorToMergerToInvestors_documentation_en-US" xlink:label="lab_ocgn_NumberOfConvertedInitialSharesAgreedToIssuePriorToMergerToInvestors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of converted common shares, which the investors have right to receive pursuant to the exchange rate in the Merger, as agreed to be issued by the accounting acquirer to the investors immediately prior to the Merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfConvertedInitialSharesAgreedToIssuePriorToMergerToInvestors" xlink:href="ocgn-20191231.xsd#ocgn_NumberOfConvertedInitialSharesAgreedToIssuePriorToMergerToInvestors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_NumberOfConvertedInitialSharesAgreedToIssuePriorToMergerToInvestors" xlink:to="lab_ocgn_NumberOfConvertedInitialSharesAgreedToIssuePriorToMergerToInvestors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_1d44e245-2d92-4db5-bc85-fe4c68e85128_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_4b0bedf3-8462-4c15-868f-3ec1af22a178_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_790e2cf9-d192-4099-9fd3-c36909f60236_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightConditionForExpirationTradingDay_0373ea19-b7ea-4eb7-9bf6-ee770b4c75c2_terseLabel_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightConditionForExpirationTradingDay" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants expiration, trading day</link:label>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightConditionForExpirationTradingDay_label_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightConditionForExpirationTradingDay" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Condition For Expiration, Trading Day</link:label>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightConditionForExpirationTradingDay_documentation_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightConditionForExpirationTradingDay" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The trading day after which the warrants will expire.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightConditionForExpirationTradingDay" xlink:href="ocgn-20191231.xsd#ocgn_ClassOfWarrantOrRightConditionForExpirationTradingDay"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ClassOfWarrantOrRightConditionForExpirationTradingDay" xlink:to="lab_ocgn_ClassOfWarrantOrRightConditionForExpirationTradingDay" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_2cd88375-f607-4dca-9ef2-4061ec89f97a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_d9f7bf99-8c6a-4f1c-aebb-b2978027e38d_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_7faf330e-a29f-47d2-86d5-e1392daf865c_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_df23f373-a688-47d3-8485-aeb0c81816c8_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_736f7f2e-de5f-47f0-8e78-c511276f6ffa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_a202040d-51b4-430b-b380-8f3ef6bf52af_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_98e3f9c4-d999-48b4-8fbd-c42bd06f3a9c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8589a192-3a91-4fc1-931c-43ff1970ebea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_809bbd8c-d0fa-4790-bfe5-aee8a35b9fbd_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_b241b974-d57c-48c2-8baf-a7da2d517856_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f4b01b47-8a11-41f0-85ab-2c1c695a80db_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Merger Financing Warrants</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_6ac9767c-1cb2-4b19-a743-5f359170b2a7_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount_c45e70b6-9e02-44a2-aa16-8d606f8ce6d2_terseLabel_en-US" xlink:label="lab_ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price discount per original agreement (as a percent)</link:label>
    <link:label id="lab_ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount_label_en-US" xlink:label="lab_ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Equity Financing Triggered, Discount</link:label>
    <link:label id="lab_ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount_documentation_en-US" xlink:label="lab_ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of discount of the convertible debt that automatically convert the same class of equity as those issued to the lowest price per share being paid by investors in the equity financing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount" xlink:href="ocgn-20191231.xsd#ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount" xlink:to="lab_ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_1fdf8b94-93e0-48e7-ad5d-1bdf9ae9bc65_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_59e55a5f-1ffa-4983-b6a8-fab79a30382b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_ea6e572c-b008-4970-9161-60e60e6351de_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_9eefe896-88b8-4a3e-bb65-087b92f02b00_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_907da3cf-1dd2-42cc-9d97-c2affce4b590_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_4d3b6934-d901-44eb-8437-9b0bcc18c633_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_95c6b4e8-9c8f-470a-b3b1-e327070c3cab_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of asset acquisition costs</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_824536cf-0412-4240-887f-3848c0aef593_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_be13f408-b4e2-4a53-af8f-d9b582193a60_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_0924f268-f5f5-4dd3-9a63-97f5a066b472_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_06e7c0f6-d3ca-4390-b34f-306117422490_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f69305db-5388-4b36-9b30-4ffc44619340_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of debt (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_99477f3f-3de1-4dfe-b207-73161502892b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_7a0ebad2-5e66-49bc-b93a-d55a5ea2b1fd_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_b5b9559f-b153-472e-a23c-2e2c4c61271e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease ROU asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForMergerRelatedCosts_217cfbce-1a82-4a75-98ff-5f4e30edca41_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForMergerRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition cost paid in cash</link:label>
    <link:label id="lab_us-gaap_PaymentsForMergerRelatedCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsForMergerRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Merger Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForMergerRelatedCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForMergerRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForMergerRelatedCosts" xlink:to="lab_us-gaap_PaymentsForMergerRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ConvertibleDebtFebruary2019Member_3775c053-711e-4883-81c4-def832864039_terseLabel_en-US" xlink:label="lab_ocgn_ConvertibleDebtFebruary2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Note - February 2019</link:label>
    <link:label id="lab_ocgn_ConvertibleDebtFebruary2019Member_label_en-US" xlink:label="lab_ocgn_ConvertibleDebtFebruary2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt February2019 [Member]</link:label>
    <link:label id="lab_ocgn_ConvertibleDebtFebruary2019Member_documentation_en-US" xlink:label="lab_ocgn_ConvertibleDebtFebruary2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock, issued in February 2019.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertibleDebtFebruary2019Member" xlink:href="ocgn-20191231.xsd#ocgn_ConvertibleDebtFebruary2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ConvertibleDebtFebruary2019Member" xlink:to="lab_ocgn_ConvertibleDebtFebruary2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_24a7f86b-4d0a-4c58-9a2e-57cf0c26052a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease obligation, less current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_ffef3b6b-4f25-40f6-913a-f00a35a0b2e6_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current lease obligations</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermBorrowings_3e657be8-5d00-49ec-a94c-23459fcafbc6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt, net</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_2bee8f5f-9cf8-4ba9-9ced-a263b9e316ba_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_151d36e0-2f05-483b-ad9d-28e1a21aa01c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_fb3b431f-a1cb-461f-ba19-612bb1b14512_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_25046283-e973-4139-aa6b-5bca41ada1d6_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_f7a4a02c-242b-4e8c-9c8f-b2e309a5ed48_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_e2ec0138-836e-48ff-9b12-016fe97f4a33_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_IncreaseDecreaseInDeferredRent_c37dec34-b912-468e-8b24-0ea71e34f6fa_terseLabel_en-US" xlink:label="lab_ocgn_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_ocgn_IncreaseDecreaseInDeferredRent_label_en-US" xlink:label="lab_ocgn_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Rent</link:label>
    <link:label id="lab_ocgn_IncreaseDecreaseInDeferredRent_documentation_en-US" xlink:label="lab_ocgn_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change during the period in carrying value for all deferred rent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_IncreaseDecreaseInDeferredRent" xlink:href="ocgn-20191231.xsd#ocgn_IncreaseDecreaseInDeferredRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_IncreaseDecreaseInDeferredRent" xlink:to="lab_ocgn_IncreaseDecreaseInDeferredRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_ca862353-010e-469f-b471-52c517f09c7f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals and reserves</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3276c537-b576-4a26-9460-73b592eda79b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_713f6452-23f0-46c2-8bce-5d2441fb394b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_f26e698a-73a2-4178-ac8d-439e80ae43cd_negatedLabel_en-US" xlink:label="lab_ocgn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Permanent Differences, Percent</link:label>
    <link:label id="lab_ocgn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_label_en-US" xlink:label="lab_ocgn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Permanent Differences, Percent</link:label>
    <link:label id="lab_ocgn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_documentation_en-US" xlink:label="lab_ocgn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Permanent Differences, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:href="ocgn-20191231.xsd#ocgn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:to="lab_ocgn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d9ca0442-1309-4cc7-bb73-a1363f18952a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal income tax benefit at statutory rate (in percentage)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset_f76b303c-bfb2-461e-99c7-79674226273e_terseLabel_en-US" xlink:label="lab_ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset related to operating leases</link:label>
    <link:label id="lab_ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash, Operating Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of noncash lessee's right-to-use underlying asset under operating lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset" xlink:href="ocgn-20191231.xsd#ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset" xlink:to="lab_ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_831f1013-cd33-4653-adfe-408066b4affb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted price of assets held for sale of NeoCart</link:label>
    <link:label id="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held-for-sale, Long Lived, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:to="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_cd0d1f6c-bb01-4002-9db2-7e1e0e1493d4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common shares in to which the warrants are exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_41bd53d7-6092-4184-84e1-d1107919dd64_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d55a3b63-92ed-4803-8785-1983dd40916f_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreements:</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_e2b237de-ba22-437c-8964-47efedc1c6d0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of potentially dilutive securities excluded from computation of diluted weighted average shares</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_fa4b50f0-b1d7-4272-940c-641fe68c637e_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_NumberOfConvertedAdditionalSharesAgreedToIssuePriorToMergerToInvestors_cbce3e6b-5a56-4af9-90c2-add8b4d7cce4_terseLabel_en-US" xlink:label="lab_ocgn_NumberOfConvertedAdditionalSharesAgreedToIssuePriorToMergerToInvestors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of converted additional shares in the form of escrow agreed to issue immediately prior to the merger (in shares)</link:label>
    <link:label id="lab_ocgn_NumberOfConvertedAdditionalSharesAgreedToIssuePriorToMergerToInvestors_label_en-US" xlink:label="lab_ocgn_NumberOfConvertedAdditionalSharesAgreedToIssuePriorToMergerToInvestors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Converted Additional Shares Agreed To Issue Prior To Merger To Investors</link:label>
    <link:label id="lab_ocgn_NumberOfConvertedAdditionalSharesAgreedToIssuePriorToMergerToInvestors_documentation_en-US" xlink:label="lab_ocgn_NumberOfConvertedAdditionalSharesAgreedToIssuePriorToMergerToInvestors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of converted common shares, which the investors have right to receive pursuant to the exchange rate in the Merger, as agreed to be deposited in escrow by the accounting acquirer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfConvertedAdditionalSharesAgreedToIssuePriorToMergerToInvestors" xlink:href="ocgn-20191231.xsd#ocgn_NumberOfConvertedAdditionalSharesAgreedToIssuePriorToMergerToInvestors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_NumberOfConvertedAdditionalSharesAgreedToIssuePriorToMergerToInvestors" xlink:to="lab_ocgn_NumberOfConvertedAdditionalSharesAgreedToIssuePriorToMergerToInvestors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_8b12a2bd-b77b-4091-a5e1-82d8aae2fe8e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_b6443eba-f5b4-4955-9f8b-f574023fcab5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_7e27ee1f-b08f-4c62-ac59-ed5c9d5f55ea_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_A2014PlanMember_b4624bba-bc71-40db-9853-68cb7faca71f_terseLabel_en-US" xlink:label="lab_ocgn_A2014PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Plan</link:label>
    <link:label id="lab_ocgn_A2014PlanMember_label_en-US" xlink:label="lab_ocgn_A2014PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Plan [Member]</link:label>
    <link:label id="lab_ocgn_A2014PlanMember_documentation_en-US" xlink:label="lab_ocgn_A2014PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_A2014PlanMember" xlink:href="ocgn-20191231.xsd#ocgn_A2014PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_A2014PlanMember" xlink:to="lab_ocgn_A2014PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4fdf16d5-36ce-41a5-a181-903c1079078b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_507f271f-5e0c-4795-bf72-221b2e15e9e1_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_c46c9e98-c58a-4210-b7d4-3c1bd0e0c06a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_75bd2637-b21f-491e-88ef-dc15cce0ca00_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_457a0a17-53a7-4088-8f4a-125fa600a97c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_DerivativeInstrumentsAndHedgingActivitiesDisclosurePolicyTextBlock_eebc5ed9-f3d3-433f-b2ea-086bead8a5fc_terseLabel_en-US" xlink:label="lab_ocgn_DerivativeInstrumentsAndHedgingActivitiesDisclosurePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Indexed to and Potentially Settled in Common Stock</link:label>
    <link:label id="lab_ocgn_DerivativeInstrumentsAndHedgingActivitiesDisclosurePolicyTextBlock_label_en-US" xlink:label="lab_ocgn_DerivativeInstrumentsAndHedgingActivitiesDisclosurePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Policy Text Block]</link:label>
    <link:label id="lab_ocgn_DerivativeInstrumentsAndHedgingActivitiesDisclosurePolicyTextBlock_documentation_en-US" xlink:label="lab_ocgn_DerivativeInstrumentsAndHedgingActivitiesDisclosurePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for financial instruments indexed to and potentially settled in common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_DerivativeInstrumentsAndHedgingActivitiesDisclosurePolicyTextBlock" xlink:href="ocgn-20191231.xsd#ocgn_DerivativeInstrumentsAndHedgingActivitiesDisclosurePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_DerivativeInstrumentsAndHedgingActivitiesDisclosurePolicyTextBlock" xlink:to="lab_ocgn_DerivativeInstrumentsAndHedgingActivitiesDisclosurePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_7d39d05c-dd41-49e8-839a-9c13ac9bde95_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_StockIssuedDuringPeriodSharesReverseAssetAcquisition_0f2bba66-8706-496f-816e-5dd96d65b3b9_terseLabel_en-US" xlink:label="lab_ocgn_StockIssuedDuringPeriodSharesReverseAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock for reverse asset acquisition, net of $2.6 million of costs (in shares)</link:label>
    <link:label id="lab_ocgn_StockIssuedDuringPeriodSharesReverseAssetAcquisition_label_en-US" xlink:label="lab_ocgn_StockIssuedDuringPeriodSharesReverseAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Asset Acquisition</link:label>
    <link:label id="lab_ocgn_StockIssuedDuringPeriodSharesReverseAssetAcquisition_documentation_en-US" xlink:label="lab_ocgn_StockIssuedDuringPeriodSharesReverseAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued during the period pursuant to reverse asset acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_StockIssuedDuringPeriodSharesReverseAssetAcquisition" xlink:href="ocgn-20191231.xsd#ocgn_StockIssuedDuringPeriodSharesReverseAssetAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_StockIssuedDuringPeriodSharesReverseAssetAcquisition" xlink:to="lab_ocgn_StockIssuedDuringPeriodSharesReverseAssetAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationAmountReclassifiedToEquity_435fe4eb-4ca8-492f-a7db-9b6c285f45d6_terseLabel_en-US" xlink:label="lab_ocgn_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationAmountReclassifiedToEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount reclassified to equity</link:label>
    <link:label id="lab_ocgn_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationAmountReclassifiedToEquity_label_en-US" xlink:label="lab_ocgn_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationAmountReclassifiedToEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Amount Reclassified To Equity</link:label>
    <link:label id="lab_ocgn_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationAmountReclassifiedToEquity_documentation_en-US" xlink:label="lab_ocgn_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationAmountReclassifiedToEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Amount Reclassified To Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationAmountReclassifiedToEquity" xlink:href="ocgn-20191231.xsd#ocgn_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationAmountReclassifiedToEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationAmountReclassifiedToEquity" xlink:to="lab_ocgn_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationAmountReclassifiedToEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_99ceeaad-c64d-48b6-84db-57f811913beb_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_fa666993-aecb-4094-80fc-d833f40e42b4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_7db984f2-b11d-44e0-97a0-0f73f776f8e6_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_78edfe9d-8bca-4124-a97b-994e4150a072_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_20b34658-97de-4a62-b60f-3d154e20d9b5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_SeriesWarrantsMember_4b2d1944-3111-49e4-8d33-0612c7cb7b38_terseLabel_en-US" xlink:label="lab_ocgn_SeriesWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Warrants</link:label>
    <link:label id="lab_ocgn_SeriesWarrantsMember_label_en-US" xlink:label="lab_ocgn_SeriesWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series Warrants [Member]</link:label>
    <link:label id="lab_ocgn_SeriesWarrantsMember_documentation_en-US" xlink:label="lab_ocgn_SeriesWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This member stands for Series A Warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesWarrantsMember" xlink:href="ocgn-20191231.xsd#ocgn_SeriesWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_SeriesWarrantsMember" xlink:to="lab_ocgn_SeriesWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ffb626cf-bd74-45b7-ae82-ca9e55c75124_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_96e7874d-6346-43a5-beb7-42b1ebde30ee_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_55d45eef-fec7-4576-a2b8-38a586cdd778_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_3d08f304-0ee3-4aab-b144-4d20efc9f22f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local tax, net of federal benefit (in percentage)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_b821e1d8-0ec0-4b5f-b524-5546d05e4d51_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5fa07f7a-0c61-487e-a861-73fb89d149de_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_CollaborationAgreementTerminationDevelopmentCostStatement_6cf0a495-5d49-4097-8c4f-d2ac48fdf98f_terseLabel_en-US" xlink:label="lab_ocgn_CollaborationAgreementTerminationDevelopmentCostStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period within with Cansino to provide development cost statement</link:label>
    <link:label id="lab_ocgn_CollaborationAgreementTerminationDevelopmentCostStatement_label_en-US" xlink:label="lab_ocgn_CollaborationAgreementTerminationDevelopmentCostStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Termination, Development Cost Statement</link:label>
    <link:label id="lab_ocgn_CollaborationAgreementTerminationDevelopmentCostStatement_documentation_en-US" xlink:label="lab_ocgn_CollaborationAgreementTerminationDevelopmentCostStatement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period within which a party to collaboration agreement is to provide the entity statement of development costs after termination of agreement, , in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborationAgreementTerminationDevelopmentCostStatement" xlink:href="ocgn-20191231.xsd#ocgn_CollaborationAgreementTerminationDevelopmentCostStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_CollaborationAgreementTerminationDevelopmentCostStatement" xlink:to="lab_ocgn_CollaborationAgreementTerminationDevelopmentCostStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_NoncashLeaseExpense_8b716d42-6d20-4125-be4b-4aac89a36658_terseLabel_en-US" xlink:label="lab_ocgn_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_ocgn_NoncashLeaseExpense_label_en-US" xlink:label="lab_ocgn_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:label id="lab_ocgn_NoncashLeaseExpense_documentation_en-US" xlink:label="lab_ocgn_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NoncashLeaseExpense" xlink:href="ocgn-20191231.xsd#ocgn_NoncashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_NoncashLeaseExpense" xlink:to="lab_ocgn_NoncashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_54451af4-71c1-464d-bf69-1fddb35a1121_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss- basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_80a7c778-3d59-4362-a7d1-75ccade6a58e_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_70f2ea7a-76be-4691-8d05-4be5e84139aa_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_570ba810-1006-4157-a5b3-e81db5e5d44c_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_CollaborationAgreementWithUniversityOfIllinoisChicagoMember_58761f07-048b-43c6-bbd7-3298aa0ef94f_terseLabel_en-US" xlink:label="lab_ocgn_CollaborationAgreementWithUniversityOfIllinoisChicagoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement with University of Illinois, Chicago</link:label>
    <link:label id="lab_ocgn_CollaborationAgreementWithUniversityOfIllinoisChicagoMember_label_en-US" xlink:label="lab_ocgn_CollaborationAgreementWithUniversityOfIllinoisChicagoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement With University Of Illinois, Chicago [Member]</link:label>
    <link:label id="lab_ocgn_CollaborationAgreementWithUniversityOfIllinoisChicagoMember_documentation_en-US" xlink:label="lab_ocgn_CollaborationAgreementWithUniversityOfIllinoisChicagoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement With University Of Illinois, Chicago</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborationAgreementWithUniversityOfIllinoisChicagoMember" xlink:href="ocgn-20191231.xsd#ocgn_CollaborationAgreementWithUniversityOfIllinoisChicagoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_CollaborationAgreementWithUniversityOfIllinoisChicagoMember" xlink:to="lab_ocgn_CollaborationAgreementWithUniversityOfIllinoisChicagoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_9fc97a96-594f-4e6b-8914-43e36caff37f_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_e27cd7b0-3159-4034-922c-e4c40c771052_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Contingencies</link:label>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_ed325be8-0df6-4548-ba2c-92992150f061_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_5fb04481-7a87-43c3-994d-e38ae6d897d9_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued, price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_ee826694-0a10-40bb-b1e2-1efd29fd7663_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_9c55779e-f7cc-4025-a638-1a6c1aeebb5c_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_48cab343-e9b2-4d20-a06f-d7b4959c6527_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f16da9e5-028a-4c2e-8ba8-05104a5f8bbe_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_0a513bb0-5203-492a-bcb5-ec00f2a636f9_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_a8083698-ab01-4376-9c5d-56617f390355_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note Principal Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_f22b0207-6ecc-4106-9f53-eb56a5bf4979_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Note Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_3c2bd281-cab8-48df-bb33-6ed10f2d6235_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for tax positions taken in the prior year due to settlement</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ec545e15-38b9-4971-8af9-61d5afb5b709_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_72493fc6-5eb9-451a-8255-cfeac169fc55_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_c35e6a29-762a-4522-8c62-dcacd1ea1809_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_WarrantsTextBlock_6e089d4b-b6e4-4d99-90d6-e3757fde992f_terseLabel_en-US" xlink:label="lab_ocgn_WarrantsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_ocgn_WarrantsTextBlock_label_en-US" xlink:label="lab_ocgn_WarrantsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants [Text Block]</link:label>
    <link:label id="lab_ocgn_WarrantsTextBlock_documentation_en-US" xlink:label="lab_ocgn_WarrantsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_WarrantsTextBlock" xlink:href="ocgn-20191231.xsd#ocgn_WarrantsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_WarrantsTextBlock" xlink:to="lab_ocgn_WarrantsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d7ec1336-f32c-447e-a4d4-b69ca05deae4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_459408d6-917d-4150-a20e-fdb78a347619_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity term (in months)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_338fe4f8-04b1-4878-8cbc-134d5c7d9814_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_445277ee-1179-4308-aa50-2d327902f3fd_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_d1a7a4cb-7710-49d8-a14d-ddf3fcdaebb7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of embedded derivatives</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_9ae29d77-81bd-42fc-9256-5712a105dbee_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fe849c02-2b0d-4c29-9c78-619727fd00c6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_SeniorSecuredConvertibleNotesJune2019Member_d03f588b-c85d-4f0f-8f79-bf9bb5f54089_terseLabel_en-US" xlink:label="lab_ocgn_SeniorSecuredConvertibleNotesJune2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Convertible Notes - June 2019</link:label>
    <link:label id="lab_ocgn_SeniorSecuredConvertibleNotesJune2019Member_label_en-US" xlink:label="lab_ocgn_SeniorSecuredConvertibleNotesJune2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Convertible Notes June2019 [Member]</link:label>
    <link:label id="lab_ocgn_SeniorSecuredConvertibleNotesJune2019Member_documentation_en-US" xlink:label="lab_ocgn_SeniorSecuredConvertibleNotesJune2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior secured borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock, issued in June 2019.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeniorSecuredConvertibleNotesJune2019Member" xlink:href="ocgn-20191231.xsd#ocgn_SeniorSecuredConvertibleNotesJune2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_SeniorSecuredConvertibleNotesJune2019Member" xlink:to="lab_ocgn_SeniorSecuredConvertibleNotesJune2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_22b9137d-b59a-42bd-8f96-2941f6c1ed84_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_60e823b1-558e-41c1-9605-3bc2b0b669a7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_NetProceedsFromReverseMerger_83d09b48-221b-404d-b3ce-5aa59f6f48b2_terseLabel_en-US" xlink:label="lab_ocgn_NetProceedsFromReverseMerger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from pre-merger financing</link:label>
    <link:label id="lab_ocgn_NetProceedsFromReverseMerger_label_en-US" xlink:label="lab_ocgn_NetProceedsFromReverseMerger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Proceeds from Reverse Merger</link:label>
    <link:label id="lab_ocgn_NetProceedsFromReverseMerger_documentation_en-US" xlink:label="lab_ocgn_NetProceedsFromReverseMerger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of net proceeds received from reverse merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NetProceedsFromReverseMerger" xlink:href="ocgn-20191231.xsd#ocgn_NetProceedsFromReverseMerger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_NetProceedsFromReverseMerger" xlink:to="lab_ocgn_NetProceedsFromReverseMerger" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_LeaseRightOfUseAsset_273baca7-35d2-430a-8c63-28c18eca328f_terseLabel_en-US" xlink:label="lab_ocgn_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label id="lab_ocgn_LeaseRightOfUseAsset_label_en-US" xlink:label="lab_ocgn_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_ocgn_LeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_ocgn_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LeaseRightOfUseAsset" xlink:href="ocgn-20191231.xsd#ocgn_LeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_LeaseRightOfUseAsset" xlink:to="lab_ocgn_LeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ResearchAndDevelopmentExpensesCurrent_740d7974-3dd1-4e5a-95d2-76d71a8d0f23_terseLabel_en-US" xlink:label="lab_ocgn_ResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research&#160;and development</link:label>
    <link:label id="lab_ocgn_ResearchAndDevelopmentExpensesCurrent_label_en-US" xlink:label="lab_ocgn_ResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expenses Current</link:label>
    <link:label id="lab_ocgn_ResearchAndDevelopmentExpensesCurrent_documentation_en-US" xlink:label="lab_ocgn_ResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ResearchAndDevelopmentExpensesCurrent" xlink:href="ocgn-20191231.xsd#ocgn_ResearchAndDevelopmentExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ResearchAndDevelopmentExpensesCurrent" xlink:to="lab_ocgn_ResearchAndDevelopmentExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_52ecf366-2c4d-498d-8353-c8e91b831554_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_AdjustmentsToAdditionalPaidInCapitalMergerRelatedCosts_16693558-99f1-4b7c-ae50-464e9e5d72ba_terseLabel_en-US" xlink:label="lab_ocgn_AdjustmentsToAdditionalPaidInCapitalMergerRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition cost paid with equity</link:label>
    <link:label id="lab_ocgn_AdjustmentsToAdditionalPaidInCapitalMergerRelatedCosts_label_en-US" xlink:label="lab_ocgn_AdjustmentsToAdditionalPaidInCapitalMergerRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Merger Related Costs</link:label>
    <link:label id="lab_ocgn_AdjustmentsToAdditionalPaidInCapitalMergerRelatedCosts_documentation_en-US" xlink:label="lab_ocgn_AdjustmentsToAdditionalPaidInCapitalMergerRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AdjustmentsToAdditionalPaidInCapitalMergerRelatedCosts" xlink:href="ocgn-20191231.xsd#ocgn_AdjustmentsToAdditionalPaidInCapitalMergerRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_AdjustmentsToAdditionalPaidInCapitalMergerRelatedCosts" xlink:to="lab_ocgn_AdjustmentsToAdditionalPaidInCapitalMergerRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_09b6f8a9-f9b3-4b10-a6ff-34e94f403815_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_96e60b95-9789-4f69-96a0-d87bb6ec4ac2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend rate (in percentage)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_0ff322bc-2464-4246-a66e-7e8f3e974800_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_StockIssuedDuringPeriodPreMergerShares_aff9472d-1227-4476-ab95-3be8baea45b3_terseLabel_en-US" xlink:label="lab_ocgn_StockIssuedDuringPeriodPreMergerShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock and warrants for pre-Merger Financing (in shares)</link:label>
    <link:label id="lab_ocgn_StockIssuedDuringPeriodPreMergerShares_label_en-US" xlink:label="lab_ocgn_StockIssuedDuringPeriodPreMergerShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Pre Merger, Shares</link:label>
    <link:label id="lab_ocgn_StockIssuedDuringPeriodPreMergerShares_documentation_en-US" xlink:label="lab_ocgn_StockIssuedDuringPeriodPreMergerShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of stock issued during the period, pursuant to pre-merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_StockIssuedDuringPeriodPreMergerShares" xlink:href="ocgn-20191231.xsd#ocgn_StockIssuedDuringPeriodPreMergerShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_StockIssuedDuringPeriodPreMergerShares" xlink:to="lab_ocgn_StockIssuedDuringPeriodPreMergerShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5bdfd462-817f-4ac8-946c-6fd2d8327e76_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9c291741-0971-4ebc-a737-e42577e89b28_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_1a2f5032-7f5f-4e30-a280-f21054e51217_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_SchepensEyeResearchInstituteMember_f3da80b7-84bb-4592-9f0f-29751d218f77_terseLabel_en-US" xlink:label="lab_ocgn_SchepensEyeResearchInstituteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schepens Eye Research Institute</link:label>
    <link:label id="lab_ocgn_SchepensEyeResearchInstituteMember_label_en-US" xlink:label="lab_ocgn_SchepensEyeResearchInstituteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schepens Eye Research Institute [Member]</link:label>
    <link:label id="lab_ocgn_SchepensEyeResearchInstituteMember_documentation_en-US" xlink:label="lab_ocgn_SchepensEyeResearchInstituteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schepens Eye Research Institute</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SchepensEyeResearchInstituteMember" xlink:href="ocgn-20191231.xsd#ocgn_SchepensEyeResearchInstituteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_SchepensEyeResearchInstituteMember" xlink:to="lab_ocgn_SchepensEyeResearchInstituteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ConvertiblePromissoryNotesMember_4d7894bf-d743-4f64-9fe5-933c90c7b323_terseLabel_en-US" xlink:label="lab_ocgn_ConvertiblePromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible promissory notes</link:label>
    <link:label id="lab_ocgn_ConvertiblePromissoryNotesMember_label_en-US" xlink:label="lab_ocgn_ConvertiblePromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Promissory Notes [Member]</link:label>
    <link:label id="lab_ocgn_ConvertiblePromissoryNotesMember_documentation_en-US" xlink:label="lab_ocgn_ConvertiblePromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory notes which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertiblePromissoryNotesMember" xlink:href="ocgn-20191231.xsd#ocgn_ConvertiblePromissoryNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ConvertiblePromissoryNotesMember" xlink:to="lab_ocgn_ConvertiblePromissoryNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_dd19f6f3-1386-4efe-99e7-019d459f2a25_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_e38fcf0f-e3aa-4668-9b94-b8378c18fd18_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_42c45be6-63e4-4b32-a42c-dd684beac6be_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_HistogenicsCorporationMember_34017ebb-3ad1-486b-ad12-4cc93be7901e_terseLabel_en-US" xlink:label="lab_ocgn_HistogenicsCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Histogenics</link:label>
    <link:label id="lab_ocgn_HistogenicsCorporationMember_label_en-US" xlink:label="lab_ocgn_HistogenicsCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Histogenics Corporation [Member]</link:label>
    <link:label id="lab_ocgn_HistogenicsCorporationMember_documentation_en-US" xlink:label="lab_ocgn_HistogenicsCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents Histogenics Corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_HistogenicsCorporationMember" xlink:href="ocgn-20191231.xsd#ocgn_HistogenicsCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_HistogenicsCorporationMember" xlink:to="lab_ocgn_HistogenicsCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4daaf8a6-60d6-48c7-82f2-aa63ca5aac91_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2f5469b8-6cac-48dc-b881-c73674dcc0df_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_7a6edd04-952a-4b68-a998-7cbafa0aa337_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_258f4c1e-eb0c-4461-bb83-89c91c324120_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_AccountsPayableClinical_e2f062a4-51e7-494f-a607-ded5ecc9d875_terseLabel_en-US" xlink:label="lab_ocgn_AccountsPayableClinical" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical</link:label>
    <link:label id="lab_ocgn_AccountsPayableClinical_label_en-US" xlink:label="lab_ocgn_AccountsPayableClinical" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable Clinical</link:label>
    <link:label id="lab_ocgn_AccountsPayableClinical_documentation_en-US" xlink:label="lab_ocgn_AccountsPayableClinical" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of obligations incurred classified as Clinical.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AccountsPayableClinical" xlink:href="ocgn-20191231.xsd#ocgn_AccountsPayableClinical"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_AccountsPayableClinical" xlink:to="lab_ocgn_AccountsPayableClinical" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_7f8d4d85-c25f-476b-8be3-879daa1c8119_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants fair value estimate volatility (in percentage)</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bf439952-1f34-4eca-aafa-d2be5366967a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate (in percentage)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_a1fa3bfc-b020-40ac-8b12-066d90dec9cd_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_b3c7e411-7155-4839-8c2b-bf7603265270_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_SeniorSecuredConvertibleNotesMember_f028e24b-e42d-4b84-b58d-8789232efaa2_terseLabel_en-US" xlink:label="lab_ocgn_SeniorSecuredConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Convertible Notes</link:label>
    <link:label id="lab_ocgn_SeniorSecuredConvertibleNotesMember_label_en-US" xlink:label="lab_ocgn_SeniorSecuredConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Convertible Notes [Member]</link:label>
    <link:label id="lab_ocgn_SeniorSecuredConvertibleNotesMember_documentation_en-US" xlink:label="lab_ocgn_SeniorSecuredConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior secured borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeniorSecuredConvertibleNotesMember" xlink:href="ocgn-20191231.xsd#ocgn_SeniorSecuredConvertibleNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_SeniorSecuredConvertibleNotesMember" xlink:to="lab_ocgn_SeniorSecuredConvertibleNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2c512352-5258-43d4-938b-b1ffe89f00a2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_5d98ce31-8587-4764-9627-0ed1203975c2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_SecuritiesPurchaseAgreementMember_5626985c-a5ba-44b5-a016-2d5f64d59f49_terseLabel_en-US" xlink:label="lab_ocgn_SecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing SPA</link:label>
    <link:label id="lab_ocgn_SecuritiesPurchaseAgreementMember_label_en-US" xlink:label="lab_ocgn_SecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
    <link:label id="lab_ocgn_SecuritiesPurchaseAgreementMember_documentation_en-US" xlink:label="lab_ocgn_SecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to Securities Purchase Agreement entered with several investors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SecuritiesPurchaseAgreementMember" xlink:href="ocgn-20191231.xsd#ocgn_SecuritiesPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_SecuritiesPurchaseAgreementMember" xlink:to="lab_ocgn_SecuritiesPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_dfbd2835-5844-479d-990e-117924dad09f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of maturities of operating leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_3fb316ea-7314-44bc-a176-1451ea558496_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_PercentageOfIncreaseInPurchasePriceOfAssetPerMonth_a4b69c77-00f7-4f20-84c8-4714aaf8d5fb_terseLabel_en-US" xlink:label="lab_ocgn_PercentageOfIncreaseInPurchasePriceOfAssetPerMonth" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of purchase price increase per month</link:label>
    <link:label id="lab_ocgn_PercentageOfIncreaseInPurchasePriceOfAssetPerMonth_label_en-US" xlink:label="lab_ocgn_PercentageOfIncreaseInPurchasePriceOfAssetPerMonth" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Increase In Purchase Price Of Asset Per Month</link:label>
    <link:label id="lab_ocgn_PercentageOfIncreaseInPurchasePriceOfAssetPerMonth_documentation_en-US" xlink:label="lab_ocgn_PercentageOfIncreaseInPurchasePriceOfAssetPerMonth" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of asset purchase agreement that the purchase price increases per month between October 31, 2019 and the closing date if agreement is not terminated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_PercentageOfIncreaseInPurchasePriceOfAssetPerMonth" xlink:href="ocgn-20191231.xsd#ocgn_PercentageOfIncreaseInPurchasePriceOfAssetPerMonth"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_PercentageOfIncreaseInPurchasePriceOfAssetPerMonth" xlink:to="lab_ocgn_PercentageOfIncreaseInPurchasePriceOfAssetPerMonth" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_a4590130-1aaf-40ec-8999-4e478ca9f626_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_dfcf4c4c-7e4a-472c-998e-8074c2654714_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_CostsRelatedToIssuanceOfStockUnderReverseAssetAcquisition_3deb62a7-d3e3-4c9b-aad0-5992f17b2735_terseLabel_en-US" xlink:label="lab_ocgn_CostsRelatedToIssuanceOfStockUnderReverseAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs under reverse asset acquisition</link:label>
    <link:label id="lab_ocgn_CostsRelatedToIssuanceOfStockUnderReverseAssetAcquisition_label_en-US" xlink:label="lab_ocgn_CostsRelatedToIssuanceOfStockUnderReverseAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Related to Issuance of Stock Under Reverse Asset Acquisition</link:label>
    <link:label id="lab_ocgn_CostsRelatedToIssuanceOfStockUnderReverseAssetAcquisition_documentation_en-US" xlink:label="lab_ocgn_CostsRelatedToIssuanceOfStockUnderReverseAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of costs related to issuance of stock under reverse asset acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CostsRelatedToIssuanceOfStockUnderReverseAssetAcquisition" xlink:href="ocgn-20191231.xsd#ocgn_CostsRelatedToIssuanceOfStockUnderReverseAssetAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_CostsRelatedToIssuanceOfStockUnderReverseAssetAcquisition" xlink:to="lab_ocgn_CostsRelatedToIssuanceOfStockUnderReverseAssetAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_5fab1662-86c7-45b1-bc92-6424c5642bfc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_517ab357-4a77-4653-8d69-4466787d5562_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_aa32aef9-7caf-4f01-916f-f7965a486b20_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_a00aed2b-f6ac-4d0e-8ae9-f1f4ce6aed2e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_e99148e5-e971-40bf-8418-201e42c306a1_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a9ade44d-e20e-4c15-9bc0-84dacf816ddc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease terms&#8212;operating leases (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_63810fae-40d6-4dc1-81fd-2b57b13f9f36_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ConvertibleDebtJune2018Member_62dd31e9-d3f7-47ee-bb8e-a4d1b0aa2d4e_terseLabel_en-US" xlink:label="lab_ocgn_ConvertibleDebtJune2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Note - June 2018</link:label>
    <link:label id="lab_ocgn_ConvertibleDebtJune2018Member_label_en-US" xlink:label="lab_ocgn_ConvertibleDebtJune2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt June2018 [Member]</link:label>
    <link:label id="lab_ocgn_ConvertibleDebtJune2018Member_documentation_en-US" xlink:label="lab_ocgn_ConvertibleDebtJune2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock, issued in June 2018.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertibleDebtJune2018Member" xlink:href="ocgn-20191231.xsd#ocgn_ConvertibleDebtJune2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ConvertibleDebtJune2018Member" xlink:to="lab_ocgn_ConvertibleDebtJune2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_d1e8372d-9fb6-4a91-8513-0455ac0c9478_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse stock split ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ProceedsFromWarrantExercisesMaximumAmount_72442307-0c6b-4bea-a018-388557fad844_terseLabel_en-US" xlink:label="lab_ocgn_ProceedsFromWarrantExercisesMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Warrant Exercises, Maximum Amount</link:label>
    <link:label id="lab_ocgn_ProceedsFromWarrantExercisesMaximumAmount_label_en-US" xlink:label="lab_ocgn_ProceedsFromWarrantExercisesMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Warrant Exercises, Maximum Amount</link:label>
    <link:label id="lab_ocgn_ProceedsFromWarrantExercisesMaximumAmount_documentation_en-US" xlink:label="lab_ocgn_ProceedsFromWarrantExercisesMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Warrant Exercises, Maximum Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ProceedsFromWarrantExercisesMaximumAmount" xlink:href="ocgn-20191231.xsd#ocgn_ProceedsFromWarrantExercisesMaximumAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ProceedsFromWarrantExercisesMaximumAmount" xlink:to="lab_ocgn_ProceedsFromWarrantExercisesMaximumAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_42f5987e-733e-453b-befe-a01ecaebf739_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reconciliation of Series B Warrant liability measured at fair value using Level 3 significant unobservable inputs</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_149b24fb-6660-4172-b9be-feea10c91720_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_fa84f05b-9aec-4ff4-85c8-aecfb1b18b1e_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_c6e73d2d-7e4c-4ec6-b935-fca84b73adf8_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_02810aac-8ad2-4af4-8841-67c82220f33c_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_LicenseAgreementPotentialCommercialMilestonePayment_d81323bb-1698-4c07-a218-048f4d0e6acf_terseLabel_en-US" xlink:label="lab_ocgn_LicenseAgreementPotentialCommercialMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential commercial milestone payment</link:label>
    <link:label id="lab_ocgn_LicenseAgreementPotentialCommercialMilestonePayment_label_en-US" xlink:label="lab_ocgn_LicenseAgreementPotentialCommercialMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Potential Commercial Milestone Payment</link:label>
    <link:label id="lab_ocgn_LicenseAgreementPotentialCommercialMilestonePayment_documentation_en-US" xlink:label="lab_ocgn_LicenseAgreementPotentialCommercialMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Potential Commercial Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LicenseAgreementPotentialCommercialMilestonePayment" xlink:href="ocgn-20191231.xsd#ocgn_LicenseAgreementPotentialCommercialMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_LicenseAgreementPotentialCommercialMilestonePayment" xlink:to="lab_ocgn_LicenseAgreementPotentialCommercialMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_877f110f-68e4-45ea-9cf9-9af78d2830f6_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtTypeDomain_e7d42cd3-d1d4-43bc-ba86-acdac6dc419d_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="lab_us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_57b89b3d-6666-447d-a8bc-0a73c942e01f_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_fd370fa6-8ad8-4c2e-9269-5e11231b0afa_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_c7d9fe8b-e058-4e29-bff3-a4c0864292c5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of common stock - basic and diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_9248f991-6644-4ea6-a6de-40ee578d4bfd_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_PercentageOfAmountOnMarketValueForFailureToIssueCommonStockOnPreMergerFinancingWarrants_454d4cde-c094-4ae4-b8d0-7a1c25435325_terseLabel_en-US" xlink:label="lab_ocgn_PercentageOfAmountOnMarketValueForFailureToIssueCommonStockOnPreMergerFinancingWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of amount on market value for failure to issue common stock on pre-merger financing warrants (in percentage)</link:label>
    <link:label id="lab_ocgn_PercentageOfAmountOnMarketValueForFailureToIssueCommonStockOnPreMergerFinancingWarrants_label_en-US" xlink:label="lab_ocgn_PercentageOfAmountOnMarketValueForFailureToIssueCommonStockOnPreMergerFinancingWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Amount On Market value For Failure To Issue Common Stock On Pre-Merger Financing Warrants</link:label>
    <link:label id="lab_ocgn_PercentageOfAmountOnMarketValueForFailureToIssueCommonStockOnPreMergerFinancingWarrants_documentation_en-US" xlink:label="lab_ocgn_PercentageOfAmountOnMarketValueForFailureToIssueCommonStockOnPreMergerFinancingWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">If company fails to issue to a holder of the Pre-Merger Financing Warrants the number of shares of common stock to which such holder is entitled upon such holder's exercise of the such warrants, then company shall be obligated to pay the holder on each day while such failure is continuing an amount equal to percentage of the market value of the undelivered shares determined using any trading price of the common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_PercentageOfAmountOnMarketValueForFailureToIssueCommonStockOnPreMergerFinancingWarrants" xlink:href="ocgn-20191231.xsd#ocgn_PercentageOfAmountOnMarketValueForFailureToIssueCommonStockOnPreMergerFinancingWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_PercentageOfAmountOnMarketValueForFailureToIssueCommonStockOnPreMergerFinancingWarrants" xlink:to="lab_ocgn_PercentageOfAmountOnMarketValueForFailureToIssueCommonStockOnPreMergerFinancingWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_f2de2ea9-38bd-4ea5-8365-6422d0c06c84_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_67b34fa2-1f46-4718-8485-da7699263057_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger_a6356c9e-adbd-4832-8cd8-c7c1584c9e91_terseLabel_en-US" xlink:label="lab_ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of volume-weighted average trading price of a share of common stock that triggered release of converted additional shares (in percentage)</link:label>
    <link:label id="lab_ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger_label_en-US" xlink:label="lab_ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Converted Additional Shares, Threshold Release Trigger</link:label>
    <link:label id="lab_ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger_documentation_en-US" xlink:label="lab_ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of the volume-weighted average trading price of a share of common stock as quoted on the Nasdaq Capital Market for the first three trading days immediately following the closing date of the Pre-Merger Financing as threshold to release converted additional shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger" xlink:href="ocgn-20191231.xsd#ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger" xlink:to="lab_ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_5e22f505-8069-46bf-9d7c-221436f4ea55_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_8b87102d-d5d6-427a-9229-a89f4d57be95_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_92dcb57f-c4ac-4fab-a8e6-642ef8ebbcd7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_fdf80613-b41c-4953-a9a7-3cc12a32cbdc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards, not subject to expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_f583bf70-e18f-4485-b90f-5abf23a7db5d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_8e690724-d298-40bb-9185-992ceecb3afc_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseDiscountRate_47b3ab34-a01b-446e-9eaa-cf98db2f3662_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseDiscountRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeFinanceLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_567603b4-2d82-44cd-a128-f40a3519dcbc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate&#8212;operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_877bdb00-c3ec-4e0e-a238-4381abb46c47_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage_4833f91f-af9f-43e6-b085-8945ca489026_terseLabel_en-US" xlink:label="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Automatic increase in shares to be issue (in percentage)</link:label>
    <link:label id="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage_label_en-US" xlink:label="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Automatic Increase In Shares To Be Issue, Percentage</link:label>
    <link:label id="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage_documentation_en-US" xlink:label="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Automatic Increase In Shares To Be Issue, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage" xlink:href="ocgn-20191231.xsd#ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage" xlink:to="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_63ff33f7-6c01-46d2-a5e9-886000a821f7_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_499fb03c-efc6-4caa-8ce1-760edc31f5e8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Merger Financing Warrants Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_83e9f7c1-fc69-43a7-989b-f86402548dc9_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_547df0df-1800-4709-b6f1-a32a8604c1e2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_cbb23fdb-2e56-4b19-861f-bba52df7445b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_57306fd4-2f0a-4fad-93cf-aa63fc688cbc_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_03a3c3b5-d12b-4521-bedd-0c99eb7d84b8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_November2018AndDecember2018NotesMember_aebabe41-cd5e-4bd7-ba50-eec7628ed936_terseLabel_en-US" xlink:label="lab_ocgn_November2018AndDecember2018NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">November&#160;2018 and December 2018 notes</link:label>
    <link:label id="lab_ocgn_November2018AndDecember2018NotesMember_label_en-US" xlink:label="lab_ocgn_November2018AndDecember2018NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">November&#160;2018 And December 2018 Notes [Member]</link:label>
    <link:label id="lab_ocgn_November2018AndDecember2018NotesMember_documentation_en-US" xlink:label="lab_ocgn_November2018AndDecember2018NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">November&#160;2018 And December 2018 Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_November2018AndDecember2018NotesMember" xlink:href="ocgn-20191231.xsd#ocgn_November2018AndDecember2018NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_November2018AndDecember2018NotesMember" xlink:to="lab_ocgn_November2018AndDecember2018NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_NumberOfSharesAgreedToIssuePriorToMergerToInvestors_0d7606e5-9bbc-4308-913c-532875d91dfc_terseLabel_en-US" xlink:label="lab_ocgn_NumberOfSharesAgreedToIssuePriorToMergerToInvestors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares agreed to issue immediately prior to the merger (in shares)</link:label>
    <link:label id="lab_ocgn_NumberOfSharesAgreedToIssuePriorToMergerToInvestors_label_en-US" xlink:label="lab_ocgn_NumberOfSharesAgreedToIssuePriorToMergerToInvestors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares Agreed to Issue Prior to Merger to Investors</link:label>
    <link:label id="lab_ocgn_NumberOfSharesAgreedToIssuePriorToMergerToInvestors_documentation_en-US" xlink:label="lab_ocgn_NumberOfSharesAgreedToIssuePriorToMergerToInvestors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares agreed to issue prior to the merger to investors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfSharesAgreedToIssuePriorToMergerToInvestors" xlink:href="ocgn-20191231.xsd#ocgn_NumberOfSharesAgreedToIssuePriorToMergerToInvestors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_NumberOfSharesAgreedToIssuePriorToMergerToInvestors" xlink:to="lab_ocgn_NumberOfSharesAgreedToIssuePriorToMergerToInvestors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_0e76ae65-c358-4135-b992-9982d9450e3d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_eb918ac0-656d-476b-bb37-7e3a7f8656cb_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_b0de2008-bf3c-4ddf-aec3-0b8966febed7_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_label_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2b550aad-03f8-42e1-9bd5-0c10101d9609_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_NumberOfFormerEmployeesWithWarrants_ee6e7539-517a-4b29-9536-d645553d4cc5_terseLabel_en-US" xlink:label="lab_ocgn_NumberOfFormerEmployeesWithWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of former employees with warrants</link:label>
    <link:label id="lab_ocgn_NumberOfFormerEmployeesWithWarrants_label_en-US" xlink:label="lab_ocgn_NumberOfFormerEmployeesWithWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Former Employees With Warrants</link:label>
    <link:label id="lab_ocgn_NumberOfFormerEmployeesWithWarrants_documentation_en-US" xlink:label="lab_ocgn_NumberOfFormerEmployeesWithWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Former Employees With Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfFormerEmployeesWithWarrants" xlink:href="ocgn-20191231.xsd#ocgn_NumberOfFormerEmployeesWithWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_NumberOfFormerEmployeesWithWarrants" xlink:to="lab_ocgn_NumberOfFormerEmployeesWithWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3eacef4c-b900-4080-9c02-6005015be92c_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions taken in the current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0e2c3791-de0c-414c-9c08-f1f16cdaf710_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_0e053625-05dc-4d10-8c76-0769394342ad_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease obligation</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_6c35909b-7694-4990-922c-5ce78d0e5d43_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current lease obligations</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_e1ee783d-b194-4f11-bdff-e23a9a99475c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from lines of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_60c9dfd8-e076-48eb-9775-e1d5e01146aa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of basic and diluted earnings per share of common stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_eb74a50f-664b-4598-8522-a26b6d38b640_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_3ed58fc0-9e72-4657-9d16-41a6d0bd9ac7_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_aad50e2a-3fcb-421e-b34b-3370f669c224_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity issuance costs paid in cash</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_ea58ebfc-d3e2-4bae-8bb9-5ec740de0a8a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_d64da34f-7695-4229-a405-e516c16d32cb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_4b7fe670-226c-4432-833f-a3164e999b37_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_StockIssuanceCostsRecognized_1980ea83-52c0-4538-934a-f3b94a68e703_terseLabel_en-US" xlink:label="lab_ocgn_StockIssuanceCostsRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity issuance cost</link:label>
    <link:label id="lab_ocgn_StockIssuanceCostsRecognized_label_en-US" xlink:label="lab_ocgn_StockIssuanceCostsRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs Recognized</link:label>
    <link:label id="lab_ocgn_StockIssuanceCostsRecognized_documentation_en-US" xlink:label="lab_ocgn_StockIssuanceCostsRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of stock issuance costs recognized during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_StockIssuanceCostsRecognized" xlink:href="ocgn-20191231.xsd#ocgn_StockIssuanceCostsRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_StockIssuanceCostsRecognized" xlink:to="lab_ocgn_StockIssuanceCostsRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_7fe5e36c-ff37-4253-b16c-ae111eecfaee_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credit (in percentage)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_2c368fbc-0d9e-4ca7-8e22-8a03991ce019_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_62391c10-291d-418b-b2a8-36db8826695e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases, term of contract (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashExpense_92f33602-e4ac-4244-a582-ab201aee7504_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash</link:label>
    <link:label id="lab_us-gaap_OtherNoncashExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashExpense" xlink:to="lab_us-gaap_OtherNoncashExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ReclassificationOfWarrantsFromLiabilityToEquity_9705fb2a-3b77-4a89-87db-98970f87ed4c_terseLabel_en-US" xlink:label="lab_ocgn_ReclassificationOfWarrantsFromLiabilityToEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of Series B Warrants from liability to equity</link:label>
    <link:label id="lab_ocgn_ReclassificationOfWarrantsFromLiabilityToEquity_label_en-US" xlink:label="lab_ocgn_ReclassificationOfWarrantsFromLiabilityToEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Of Warrants From Liability To Equity</link:label>
    <link:label id="lab_ocgn_ReclassificationOfWarrantsFromLiabilityToEquity_documentation_en-US" xlink:label="lab_ocgn_ReclassificationOfWarrantsFromLiabilityToEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Of Warrants From Liability To Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ReclassificationOfWarrantsFromLiabilityToEquity" xlink:href="ocgn-20191231.xsd#ocgn_ReclassificationOfWarrantsFromLiabilityToEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ReclassificationOfWarrantsFromLiabilityToEquity" xlink:to="lab_ocgn_ReclassificationOfWarrantsFromLiabilityToEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_CollaborationAgreementWithUniversityOfColoradoMember_086ca188-1b09-48e7-9056-89bc6aef8ccb_terseLabel_en-US" xlink:label="lab_ocgn_CollaborationAgreementWithUniversityOfColoradoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement with University of Colorado</link:label>
    <link:label id="lab_ocgn_CollaborationAgreementWithUniversityOfColoradoMember_label_en-US" xlink:label="lab_ocgn_CollaborationAgreementWithUniversityOfColoradoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement With University Of Colorado [Member]</link:label>
    <link:label id="lab_ocgn_CollaborationAgreementWithUniversityOfColoradoMember_documentation_en-US" xlink:label="lab_ocgn_CollaborationAgreementWithUniversityOfColoradoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement With University Of Colorado</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborationAgreementWithUniversityOfColoradoMember" xlink:href="ocgn-20191231.xsd#ocgn_CollaborationAgreementWithUniversityOfColoradoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_CollaborationAgreementWithUniversityOfColoradoMember" xlink:to="lab_ocgn_CollaborationAgreementWithUniversityOfColoradoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_d33d56bf-e395-428b-a8ea-322d3975dc71_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held-for-sale, Not Part of Disposal Group, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:to="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_eaabe117-e8cd-42a0-a571-b07777f72677_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of maturities of finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_24b2440e-d5ad-4e09-973e-76a3d79194c6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_CollaborationAgreementTerminationDevelopmentCostPayment_364c7096-e74b-4618-937e-47b2a13067cc_terseLabel_en-US" xlink:label="lab_ocgn_CollaborationAgreementTerminationDevelopmentCostPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period within which to reimburse Cansino of development costs</link:label>
    <link:label id="lab_ocgn_CollaborationAgreementTerminationDevelopmentCostPayment_label_en-US" xlink:label="lab_ocgn_CollaborationAgreementTerminationDevelopmentCostPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Termination, Development Cost Payment</link:label>
    <link:label id="lab_ocgn_CollaborationAgreementTerminationDevelopmentCostPayment_documentation_en-US" xlink:label="lab_ocgn_CollaborationAgreementTerminationDevelopmentCostPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period within which the entity is to reimburse a party to collaboration agreement of development costs after a statement of such is provided upon termination of the agreement, , in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborationAgreementTerminationDevelopmentCostPayment" xlink:href="ocgn-20191231.xsd#ocgn_CollaborationAgreementTerminationDevelopmentCostPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_CollaborationAgreementTerminationDevelopmentCostPayment" xlink:to="lab_ocgn_CollaborationAgreementTerminationDevelopmentCostPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_95a60b7f-9ecf-4300-bb76-2cc839250579_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership (as a percent)</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ReverseMergerAndFinancingDisclosureTable_769a4f42-5659-44f8-8317-e4c2157dfab7_terseLabel_en-US" xlink:label="lab_ocgn_ReverseMergerAndFinancingDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Merger And Financing Disclosure [Table]</link:label>
    <link:label id="lab_ocgn_ReverseMergerAndFinancingDisclosureTable_label_en-US" xlink:label="lab_ocgn_ReverseMergerAndFinancingDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Merger And Financing Disclosure [Table]</link:label>
    <link:label id="lab_ocgn_ReverseMergerAndFinancingDisclosureTable_documentation_en-US" xlink:label="lab_ocgn_ReverseMergerAndFinancingDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of information about reverse merger and financing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ReverseMergerAndFinancingDisclosureTable" xlink:href="ocgn-20191231.xsd#ocgn_ReverseMergerAndFinancingDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureTable" xlink:to="lab_ocgn_ReverseMergerAndFinancingDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_2131da70-e653-43fb-8e9c-95dbd0bde845_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_1f9057d7-c74b-4522-9c86-f8551b7e7a09_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_77a2bdb2-253c-4006-860c-78a1e1ff17f0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_cd980281-3df6-4761-bd8f-c2423dc1f6a6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Series B Warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_36f1892a-20a4-45eb-bb43-98e53fa6d91e_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_94910647-a2db-42fb-9a62-2184725225a5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAxis_724ac14b-dda1-470e-b148-fbbe29f634d6_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt [Axis]</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAxis_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_93fd21b4-bf89-4354-971e-345f9d048caa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d61d4bba-831d-4399-939e-96fa9123ec3f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_a0bea9f0-97df-46b7-93fc-3f4399d38227_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_9cbe42ed-60cc-4e80-87bb-2b16dfcfb284_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bfb323de-ecc4-4ea1-9f82-58d98c59153a_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c2d855e5-7c45-4427-9bd0-781f049c8c18_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_DebtRedemptionMultipleUponDefault_05861cc8-87a9-4de7-ac3b-6b9049eec87e_terseLabel_en-US" xlink:label="lab_ocgn_DebtRedemptionMultipleUponDefault" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption multiple upon default</link:label>
    <link:label id="lab_ocgn_DebtRedemptionMultipleUponDefault_label_en-US" xlink:label="lab_ocgn_DebtRedemptionMultipleUponDefault" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Redemption Multiple Upon Default</link:label>
    <link:label id="lab_ocgn_DebtRedemptionMultipleUponDefault_documentation_en-US" xlink:label="lab_ocgn_DebtRedemptionMultipleUponDefault" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption multiple of debt's principal and unpaid interest upon default.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_DebtRedemptionMultipleUponDefault" xlink:href="ocgn-20191231.xsd#ocgn_DebtRedemptionMultipleUponDefault"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_DebtRedemptionMultipleUponDefault" xlink:to="lab_ocgn_DebtRedemptionMultipleUponDefault" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPrice_ff7563d2-3a03-490f-802b-4cbcf1fe1d38_terseLabel_en-US" xlink:label="lab_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price over which trading price of common stock as quoted on the Nasdaq Capital Market was considered for the release of converted additional shares (in USD per share)</link:label>
    <link:label id="lab_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPrice_label_en-US" xlink:label="lab_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Converted Additional Shares, Threshold Release Trigger Price</link:label>
    <link:label id="lab_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPrice_documentation_en-US" xlink:label="lab_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The price over which the volume-weighted average trading price of a share of common stock as quoted on the Nasdaq Capital Market to release converted additional shares is determined.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPrice" xlink:href="ocgn-20191231.xsd#ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPrice" xlink:to="lab_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_b37f85f4-156d-456c-8048-bf472e029164_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_389ba351-4ed8-46a3-8cff-dc56fe81f5f9_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_abd974f9-1282-48f1-8934-e5598e47769d_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_603126b3-ba85-4758-bd78-9a3f0d465ac5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_92f4b51e-98fa-4bc1-9ca5-fb532a8766f5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_b274b746-fa82-4379-b279-89504c723ab1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards, subject to expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightExercisePriceDeterminationNumberOfTradingDaysConsidered_0a0f278a-8722-4f53-81b1-5b5dd7068719_terseLabel_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightExercisePriceDeterminationNumberOfTradingDaysConsidered" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, exercise price determination, number of trading days</link:label>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightExercisePriceDeterminationNumberOfTradingDaysConsidered_label_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightExercisePriceDeterminationNumberOfTradingDaysConsidered" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Determination, Number Of Trading Days Considered</link:label>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightExercisePriceDeterminationNumberOfTradingDaysConsidered_documentation_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightExercisePriceDeterminationNumberOfTradingDaysConsidered" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of trading days considered for determination of exercise price of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightExercisePriceDeterminationNumberOfTradingDaysConsidered" xlink:href="ocgn-20191231.xsd#ocgn_ClassOfWarrantOrRightExercisePriceDeterminationNumberOfTradingDaysConsidered"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ClassOfWarrantOrRightExercisePriceDeterminationNumberOfTradingDaysConsidered" xlink:to="lab_ocgn_ClassOfWarrantOrRightExercisePriceDeterminationNumberOfTradingDaysConsidered" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_ecf8ab90-7773-4fb5-a382-cb63a714a94d_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of assets and liabilities to be sold pursuant to Asset Purchase Agreement</link:label>
    <link:label id="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Long Lived Assets Held-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:to="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesSubscriptions_11841b12-0e2a-456e-8f6d-63ffc990f1ca_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesSubscriptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, value, subscriptions</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesSubscriptions_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesSubscriptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Subscriptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesSubscriptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesSubscriptions" xlink:to="lab_us-gaap_CommonStockSharesSubscriptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_2b143f34-7779-4995-832b-58fbbb7dbe56_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_a4414e21-e7d0-4a2e-ac75-a0d1a195f553_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_4203bc54-efd4-4b9a-9fe8-88255a81bf1d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_79ee1dd7-449e-4a59-89fc-a7b7f85b0e88_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense related to options outstanding, weighted average period for expense to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_d4dca529-b6e8-476f-9ae2-c6dc8990839e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_9cfa29a3-c702-4e86-b9ba-c5a994ec769d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_6833deb1-8ca2-4493-ba0e-1144fa27b781_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_8847eab8-273b-4531-8361-a371f81849b1_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_d557f7d7-9d99-4e0b-b0ac-47da79030bf5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_86c707cf-a614-428d-9911-8aaea5c16b6a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_SeriesBWarrantsMember_76a3c43a-8ed5-4576-95ec-4cf22b9f7553_terseLabel_en-US" xlink:label="lab_ocgn_SeriesBWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Warrants</link:label>
    <link:label id="lab_ocgn_SeriesBWarrantsMember_label_en-US" xlink:label="lab_ocgn_SeriesBWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Warrants [Member]</link:label>
    <link:label id="lab_ocgn_SeriesBWarrantsMember_documentation_en-US" xlink:label="lab_ocgn_SeriesBWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This member stands for Series B Warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesBWarrantsMember" xlink:href="ocgn-20191231.xsd#ocgn_SeriesBWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_SeriesBWarrantsMember" xlink:to="lab_ocgn_SeriesBWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_32a5bdaf-5b97-4f61-bfa1-f696d77d2df1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual property amortization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_15d56407-6332-44df-8135-44b3c6723a8f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_3dd74e64-5c41-4d49-81b9-0ead1f8dd6a4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a498df31-0163-4d93-b421-feac9bda314b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_7f5a6ecb-2c3b-4fc2-bee4-581aaa81a381_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_LineOfCreditBorrowingEachDraw_ab6cbdcd-39f4-4a84-94db-f2c3de7c5a62_terseLabel_en-US" xlink:label="lab_ocgn_LineOfCreditBorrowingEachDraw" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing increments</link:label>
    <link:label id="lab_ocgn_LineOfCreditBorrowingEachDraw_label_en-US" xlink:label="lab_ocgn_LineOfCreditBorrowingEachDraw" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Borrowing Each Draw</link:label>
    <link:label id="lab_ocgn_LineOfCreditBorrowingEachDraw_documentation_en-US" xlink:label="lab_ocgn_LineOfCreditBorrowingEachDraw" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of borrowing that can be borrowed each draw from a line of credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LineOfCreditBorrowingEachDraw" xlink:href="ocgn-20191231.xsd#ocgn_LineOfCreditBorrowingEachDraw"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_LineOfCreditBorrowingEachDraw" xlink:to="lab_ocgn_LineOfCreditBorrowingEachDraw" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_84beb718-ed17-43f7-aa9e-70ac62edfe6e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_a811b8b2-4f56-470f-9bc3-45d5d76ffe4b_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d32e7c09-1770-4840-8602-046b202ac198_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_0f380d65-ad28-49c0-9582-d8e9c336a8c8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_88a68906-09bd-432d-ac76-cfa70034ba50_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_12d7778f-6c78-4776-acbd-d0050acac23d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Capital Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_a2fcb15c-b84a-4261-b607-bbd968de5ede_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, common, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ec474375-7d59-4010-a474-bb2029c604dd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_e4ffa39b-3f69-4246-9773-98eb483ea277_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_926c64d5-c554-4e6f-a6ac-3118d9a06027_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans payable</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_b844b02a-a52d-4364-a575-ed167c982bcd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_bf63eddc-6705-48cc-ac82-7899efac237e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightIssued_3bf106a3-ffb1-4da4-97df-ad624ac0bca2_terseLabel_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued (in shares)</link:label>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightIssued_label_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Issued</link:label>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightIssued_documentation_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightIssued" xlink:href="ocgn-20191231.xsd#ocgn_ClassOfWarrantOrRightIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ClassOfWarrantOrRightIssued" xlink:to="lab_ocgn_ClassOfWarrantOrRightIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_909acaf2-1dc8-4fdd-8e99-fa434c648765_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_9e4af918-6054-4934-9fd1-d4f119603ffe_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger and Financing</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_7e1af49d-d593-435a-ac6b-6427aecae55f_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_7652f97d-f23d-43a0-abce-7b1ae3753a44_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_8bf81cbe-c3a2-401f-9e54-0ac9a2027549_negatedLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_LicenseAgreementCancellationPeriodNotice_9543619b-bb04-4c8a-a5eb-77efe77936dd_terseLabel_en-US" xlink:label="lab_ocgn_LicenseAgreementCancellationPeriodNotice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation period, written notice</link:label>
    <link:label id="lab_ocgn_LicenseAgreementCancellationPeriodNotice_label_en-US" xlink:label="lab_ocgn_LicenseAgreementCancellationPeriodNotice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Cancellation Period Notice</link:label>
    <link:label id="lab_ocgn_LicenseAgreementCancellationPeriodNotice_documentation_en-US" xlink:label="lab_ocgn_LicenseAgreementCancellationPeriodNotice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Cancellation Period Notice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LicenseAgreementCancellationPeriodNotice" xlink:href="ocgn-20191231.xsd#ocgn_LicenseAgreementCancellationPeriodNotice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_LicenseAgreementCancellationPeriodNotice" xlink:to="lab_ocgn_LicenseAgreementCancellationPeriodNotice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_ea7e902f-a851-497c-ad2c-e30ecfc1b187_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_e0058538-6271-4cca-a62a-fb20d0fe05c1_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightExercisable_1dd7a62c-d5fe-4987-a7ed-48a1276aed2b_terseLabel_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercisable (in shares)</link:label>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightExercisable_label_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercisable</link:label>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightExercisable_documentation_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightExercisable" xlink:href="ocgn-20191231.xsd#ocgn_ClassOfWarrantOrRightExercisable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ClassOfWarrantOrRightExercisable" xlink:to="lab_ocgn_ClassOfWarrantOrRightExercisable" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_A2019PlanMember_eb36c91d-d95e-487d-ae74-f41d88da06aa_terseLabel_en-US" xlink:label="lab_ocgn_A2019PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Plan</link:label>
    <link:label id="lab_ocgn_A2019PlanMember_label_en-US" xlink:label="lab_ocgn_A2019PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Plan [Member]</link:label>
    <link:label id="lab_ocgn_A2019PlanMember_documentation_en-US" xlink:label="lab_ocgn_A2019PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_A2019PlanMember" xlink:href="ocgn-20191231.xsd#ocgn_A2019PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_A2019PlanMember" xlink:to="lab_ocgn_A2019PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_FormerOcugenWarrantsMember_7c0cf62e-1ef7-45a2-98e2-92b3e5d5b795_terseLabel_en-US" xlink:label="lab_ocgn_FormerOcugenWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Ocugen warrants</link:label>
    <link:label id="lab_ocgn_FormerOcugenWarrantsMember_label_en-US" xlink:label="lab_ocgn_FormerOcugenWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Ocugen Warrants [Member]</link:label>
    <link:label id="lab_ocgn_FormerOcugenWarrantsMember_documentation_en-US" xlink:label="lab_ocgn_FormerOcugenWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Ocugen Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_FormerOcugenWarrantsMember" xlink:href="ocgn-20191231.xsd#ocgn_FormerOcugenWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_FormerOcugenWarrantsMember" xlink:to="lab_ocgn_FormerOcugenWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_cfe05972-0614-4d70-9df1-adf1c535796f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_efcfc1e9-d5dc-4bca-9a5d-3b5d46321e62_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_df38b9e1-f82c-479c-a6da-ff3470706f7b_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e4ab553a-2ae6-4e38-ae11-d5c12d9d2f50_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_5eefc89b-1f9d-4fba-945e-987c68d94843_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_59e02ac4-b493-42b6-b98d-d7539a4727e5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_45e8e16b-efda-4cf5-a32a-c4471d49b849_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for tax positions taken in the prior year due to statutes lapsing</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_987716d9-3020-4a06-a32f-eca0adb3ca10_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d7adf982-0e24-46b9-bdae-528c3182a038_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction_01dc5955-6f64-4061-942e-3692fe4150ca_verboseLabel_en-US" xlink:label="lab_ocgn_DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse asset acquisition costs (Note 3)</link:label>
    <link:label id="lab_ocgn_DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction_label_en-US" xlink:label="lab_ocgn_DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Equity Issuance Cost Incurred During Noncash Or Partial Noncash Transaction</link:label>
    <link:label id="lab_ocgn_DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction_documentation_en-US" xlink:label="lab_ocgn_DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of deferred equity issuance cost that were incurred during a noncash or partial noncash transaction.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction" xlink:href="ocgn-20191231.xsd#ocgn_DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="lab_ocgn_DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_LeaseLiability_632adc96-058e-453c-bc34-e274dfff8ada_terseLabel_en-US" xlink:label="lab_ocgn_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_ocgn_LeaseLiability_label_en-US" xlink:label="lab_ocgn_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:label id="lab_ocgn_LeaseLiability_documentation_en-US" xlink:label="lab_ocgn_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LeaseLiability" xlink:href="ocgn-20191231.xsd#ocgn_LeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_LeaseLiability" xlink:to="lab_ocgn_LeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_842e775a-7335-494b-9664-ca28da30f11b_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement_c048ab0b-21ae-418e-a1e5-48b267045982_terseLabel_en-US" xlink:label="lab_ocgn_CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares agreed to be sold, stock subscription agreement (in shares)</link:label>
    <link:label id="lab_ocgn_CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement_label_en-US" xlink:label="lab_ocgn_CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Agreed To Be Sold, Stock Subscription Agreement</link:label>
    <link:label id="lab_ocgn_CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement_documentation_en-US" xlink:label="lab_ocgn_CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Agreed To Be Sold, Stock Subscription Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement" xlink:href="ocgn-20191231.xsd#ocgn_CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement" xlink:to="lab_ocgn_CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ChangesInFairValueOfEmbeddedDerivativeTableTextBlock_486e064a-25ad-4619-9f20-7f06cdcb095a_terseLabel_en-US" xlink:label="lab_ocgn_ChangesInFairValueOfEmbeddedDerivativeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes of Embedded Derivative of Convertible Notes</link:label>
    <link:label id="lab_ocgn_ChangesInFairValueOfEmbeddedDerivativeTableTextBlock_label_en-US" xlink:label="lab_ocgn_ChangesInFairValueOfEmbeddedDerivativeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In Fair Value Of Embedded Derivative [Table Text Block]</link:label>
    <link:label id="lab_ocgn_ChangesInFairValueOfEmbeddedDerivativeTableTextBlock_documentation_en-US" xlink:label="lab_ocgn_ChangesInFairValueOfEmbeddedDerivativeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The tabular disclosure of the change of the embedded derivative during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ChangesInFairValueOfEmbeddedDerivativeTableTextBlock" xlink:href="ocgn-20191231.xsd#ocgn_ChangesInFairValueOfEmbeddedDerivativeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ChangesInFairValueOfEmbeddedDerivativeTableTextBlock" xlink:to="lab_ocgn_ChangesInFairValueOfEmbeddedDerivativeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueAdjustment_d07c81e2-93fa-47ca-9056-75f2e135896a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueAdjustment_b83d58cc-f9e4-4f41-90f0-cfb3a079a0e7_negatedLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueAdjustment_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueAdjustment" xlink:to="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_ed5e80a2-d91b-4e21-9531-207d3bba306f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share of Common Stock</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_99b477b0-7e49-410c-b143-4ef5deced24e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c8a32af3-6771-43f5-83e0-d563db4f5a33_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13538602-fb1d-4603-84d4-0175fa76658f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_CollaborationAgreementTerm_3e7b5118-5e9b-4237-b077-7639c9ce662b_terseLabel_en-US" xlink:label="lab_ocgn_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term (in years)</link:label>
    <link:label id="lab_ocgn_CollaborationAgreementTerm_label_en-US" xlink:label="lab_ocgn_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement term</link:label>
    <link:label id="lab_ocgn_CollaborationAgreementTerm_documentation_en-US" xlink:label="lab_ocgn_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the term of agreement or milestone.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborationAgreementTerm" xlink:href="ocgn-20191231.xsd#ocgn_CollaborationAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_CollaborationAgreementTerm" xlink:to="lab_ocgn_CollaborationAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1f82c858-b672-43ca-8885-6fada600d859_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_12e521fc-a448-4bb8-b5cc-d2c71d8633fd_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_de9d9fe7-7406-4930-9fee-aa15b07556c8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common stock price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_3a020544-bc67-4c78-b27a-a730aeaad372_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of minimum lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_422687ad-ab8a-45c5-8163-6f91e99a9ec2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_January2019AndFebruary2019NotesMember_a8f98722-96aa-4fd1-a622-9dd37aab4b94_terseLabel_en-US" xlink:label="lab_ocgn_January2019AndFebruary2019NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January&#160;2019 and February&#160;2019 notes</link:label>
    <link:label id="lab_ocgn_January2019AndFebruary2019NotesMember_label_en-US" xlink:label="lab_ocgn_January2019AndFebruary2019NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January&#160;2019 And February&#160;2019 Notes [Member]</link:label>
    <link:label id="lab_ocgn_January2019AndFebruary2019NotesMember_documentation_en-US" xlink:label="lab_ocgn_January2019AndFebruary2019NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January&#160;2019 And February&#160;2019 Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_January2019AndFebruary2019NotesMember" xlink:href="ocgn-20191231.xsd#ocgn_January2019AndFebruary2019NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_January2019AndFebruary2019NotesMember" xlink:to="lab_ocgn_January2019AndFebruary2019NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0817e37d-37fd-49b3-a225-bd686e13ce5d_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4029379d-98b8-4a8f-be15-bb3c84d05eb7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_3799e9f0-66cd-4f54-a160-669bc9a01f14_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in additional paid-in capital from conversion</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_c4af3dce-714f-4988-8c21-266ff5ed8d07_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_AccountsPayableConsulting_fb470fd6-4fb5-4a60-898f-252f9dba1807_terseLabel_en-US" xlink:label="lab_ocgn_AccountsPayableConsulting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting</link:label>
    <link:label id="lab_ocgn_AccountsPayableConsulting_label_en-US" xlink:label="lab_ocgn_AccountsPayableConsulting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable Consulting</link:label>
    <link:label id="lab_ocgn_AccountsPayableConsulting_documentation_en-US" xlink:label="lab_ocgn_AccountsPayableConsulting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of obligations incurred classified as Consulting.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AccountsPayableConsulting" xlink:href="ocgn-20191231.xsd#ocgn_AccountsPayableConsulting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_AccountsPayableConsulting" xlink:to="lab_ocgn_AccountsPayableConsulting" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_3f120c19-25ac-4812-b108-489ad2c123f9_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_LicenseAgreementMinimumAnnualRoyaltyPayment_b799bf18-8efd-4a47-b1c3-4aa8b0593794_terseLabel_en-US" xlink:label="lab_ocgn_LicenseAgreementMinimumAnnualRoyaltyPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum annual royalty payment</link:label>
    <link:label id="lab_ocgn_LicenseAgreementMinimumAnnualRoyaltyPayment_label_en-US" xlink:label="lab_ocgn_LicenseAgreementMinimumAnnualRoyaltyPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Minimum Annual Royalty Payment</link:label>
    <link:label id="lab_ocgn_LicenseAgreementMinimumAnnualRoyaltyPayment_documentation_en-US" xlink:label="lab_ocgn_LicenseAgreementMinimumAnnualRoyaltyPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Minimum Annual Royalty Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LicenseAgreementMinimumAnnualRoyaltyPayment" xlink:href="ocgn-20191231.xsd#ocgn_LicenseAgreementMinimumAnnualRoyaltyPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_LicenseAgreementMinimumAnnualRoyaltyPayment" xlink:to="lab_ocgn_LicenseAgreementMinimumAnnualRoyaltyPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_SeriesCWarrantsMember_335ba072-dc3c-4611-bab0-51771e3c43f1_terseLabel_en-US" xlink:label="lab_ocgn_SeriesCWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Warrants</link:label>
    <link:label id="lab_ocgn_SeriesCWarrantsMember_label_en-US" xlink:label="lab_ocgn_SeriesCWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Warrants [Member]</link:label>
    <link:label id="lab_ocgn_SeriesCWarrantsMember_documentation_en-US" xlink:label="lab_ocgn_SeriesCWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This member stands for Series C Warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesCWarrantsMember" xlink:href="ocgn-20191231.xsd#ocgn_SeriesCWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_SeriesCWarrantsMember" xlink:to="lab_ocgn_SeriesCWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_NeocartMember_502672cb-b962-49a7-be00-04c8101c5f58_terseLabel_en-US" xlink:label="lab_ocgn_NeocartMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neocart</link:label>
    <link:label id="lab_ocgn_NeocartMember_label_en-US" xlink:label="lab_ocgn_NeocartMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neocart [Member]</link:label>
    <link:label id="lab_ocgn_NeocartMember_documentation_en-US" xlink:label="lab_ocgn_NeocartMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NeoCart</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NeocartMember" xlink:href="ocgn-20191231.xsd#ocgn_NeocartMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_NeocartMember" xlink:to="lab_ocgn_NeocartMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_ab0ae3dd-de5a-4ad8-b1b9-68ab82e735ba_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_25bb2332-83a9-4e72-9f4c-a99ad43c4349_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_StockIssuedDuringPeriodValueReverseAssetAcquisition_54d03d8f-8d14-47fb-9c34-0463c9e975bf_terseLabel_en-US" xlink:label="lab_ocgn_StockIssuedDuringPeriodValueReverseAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock for reverse asset acquisition, net of $2.6&#160;million of costs</link:label>
    <link:label id="lab_ocgn_StockIssuedDuringPeriodValueReverseAssetAcquisition_label_en-US" xlink:label="lab_ocgn_StockIssuedDuringPeriodValueReverseAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Reverse Asset Acquisition</link:label>
    <link:label id="lab_ocgn_StockIssuedDuringPeriodValueReverseAssetAcquisition_documentation_en-US" xlink:label="lab_ocgn_StockIssuedDuringPeriodValueReverseAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity impact of the value of stock issued during the period pursuant to reverse asset acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_StockIssuedDuringPeriodValueReverseAssetAcquisition" xlink:href="ocgn-20191231.xsd#ocgn_StockIssuedDuringPeriodValueReverseAssetAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_StockIssuedDuringPeriodValueReverseAssetAcquisition" xlink:to="lab_ocgn_StockIssuedDuringPeriodValueReverseAssetAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4d11b5ee-a46b-4f60-9ac9-95c75ece682d_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total provision for income taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_MergerAcquisitionCostsIncurred_b238b8c7-0eb7-4f4e-ad09-2d0fd2f2a6fe_terseLabel_en-US" xlink:label="lab_ocgn_MergerAcquisitionCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition cost incurred</link:label>
    <link:label id="lab_ocgn_MergerAcquisitionCostsIncurred_label_en-US" xlink:label="lab_ocgn_MergerAcquisitionCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Acquisition Costs Incurred</link:label>
    <link:label id="lab_ocgn_MergerAcquisitionCostsIncurred_documentation_en-US" xlink:label="lab_ocgn_MergerAcquisitionCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of acquisition costs incurred during the period related to merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_MergerAcquisitionCostsIncurred" xlink:href="ocgn-20191231.xsd#ocgn_MergerAcquisitionCostsIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_MergerAcquisitionCostsIncurred" xlink:to="lab_ocgn_MergerAcquisitionCostsIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_IncreaseDecreaseInLeaseObligations_397b5f2d-271f-4f1f-9263-eb9217e4e93c_terseLabel_en-US" xlink:label="lab_ocgn_IncreaseDecreaseInLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease obligations</link:label>
    <link:label id="lab_ocgn_IncreaseDecreaseInLeaseObligations_label_en-US" xlink:label="lab_ocgn_IncreaseDecreaseInLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Lease Obligations</link:label>
    <link:label id="lab_ocgn_IncreaseDecreaseInLeaseObligations_documentation_en-US" xlink:label="lab_ocgn_IncreaseDecreaseInLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Lease Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_IncreaseDecreaseInLeaseObligations" xlink:href="ocgn-20191231.xsd#ocgn_IncreaseDecreaseInLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_IncreaseDecreaseInLeaseObligations" xlink:to="lab_ocgn_IncreaseDecreaseInLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_EB5ProgramBorrowingsMember_f2e3f37d-6ccb-48a5-8c35-09273559128c_terseLabel_en-US" xlink:label="lab_ocgn_EB5ProgramBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EB-5 Loan</link:label>
    <link:label id="lab_ocgn_EB5ProgramBorrowingsMember_label_en-US" xlink:label="lab_ocgn_EB5ProgramBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E B5 Program Borrowings [Member]</link:label>
    <link:label id="lab_ocgn_EB5ProgramBorrowingsMember_documentation_en-US" xlink:label="lab_ocgn_EB5ProgramBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents borrowings from the U.S. government's Immigrant Investor Program, commonly known as the EB 5 program (the "EB 5 Program").</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EB5ProgramBorrowingsMember" xlink:href="ocgn-20191231.xsd#ocgn_EB5ProgramBorrowingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_EB5ProgramBorrowingsMember" xlink:to="lab_ocgn_EB5ProgramBorrowingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionOriginalDebtAmount1_14f82e95-c4f7-48c9-b3cc-1a9a0356c0cb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible notes (Note 7)</link:label>
    <link:label id="lab_us-gaap_DebtConversionOriginalDebtAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Original Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="lab_us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_313a08ea-98d9-40e6-9b86-28c349979bbc_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0c8aa672-9b4d-46c6-b0f5-a62c33856f62_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_0c9a3240-8188-4ebb-a634-414e1ae09966_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value, 200,000,000 authorized, 52,746,728 and 4,960,552 shares issued, respectively; 52,625,228 and 4,960,552 shares outstanding, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_f6cb1603-03f5-4c89-a019-6658a8809a2e_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash reconciliation:</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_3fe5affa-1f98-419c-affb-bf1c5de9d63d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_9b1b2f1b-91c6-473e-acd5-a3260f2f4b91_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_57c02b97-0c41-4ab1-9cfe-d4f0ac106ad2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_2648e29c-9938-42a2-8cdc-2f9ebe15661b_terseLabel_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger and Pre-Merger Financing</link:label>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e16cde67-85f8-4b4f-bd8e-94c827cd19d3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_4a5c503e-6939-47a0-82e4-32ca88ab632c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_fe01bf94-5fdb-4237-b5c2-251f8167e619_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average expected stock price volatility (in percentage)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0af1689c-6f63-4a38-986c-53919e9adc49_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_a3f223f2-127e-4ac1-ba05-241934f3132c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_75e1254b-9b59-4a1f-9d70-199a27dade8f_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_bd36593e-b2b6-49f7-b668-fde76de0a0e8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_30b9dd5f-6bbe-4746-aa9e-162eafd5a239_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_SeriesAWarrantsAndSeriesCWarrantsMember_0049803b-0571-4413-95f2-72589a950ad9_terseLabel_en-US" xlink:label="lab_ocgn_SeriesAWarrantsAndSeriesCWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A and Series C warrants</link:label>
    <link:label id="lab_ocgn_SeriesAWarrantsAndSeriesCWarrantsMember_label_en-US" xlink:label="lab_ocgn_SeriesAWarrantsAndSeriesCWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Warrants And Series C Warrants [Member]</link:label>
    <link:label id="lab_ocgn_SeriesAWarrantsAndSeriesCWarrantsMember_documentation_en-US" xlink:label="lab_ocgn_SeriesAWarrantsAndSeriesCWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information pertaining to series A and C warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesAWarrantsAndSeriesCWarrantsMember" xlink:href="ocgn-20191231.xsd#ocgn_SeriesAWarrantsAndSeriesCWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_SeriesAWarrantsAndSeriesCWarrantsMember" xlink:to="lab_ocgn_SeriesAWarrantsAndSeriesCWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_14998eb7-6436-4893-b88d-daee0243276b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ConvertibleDebtDecember2018Member_381e4af1-2845-4fc7-af10-fca82240d5df_terseLabel_en-US" xlink:label="lab_ocgn_ConvertibleDebtDecember2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Note - December 2018</link:label>
    <link:label id="lab_ocgn_ConvertibleDebtDecember2018Member_label_en-US" xlink:label="lab_ocgn_ConvertibleDebtDecember2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt December2018 [Member]</link:label>
    <link:label id="lab_ocgn_ConvertibleDebtDecember2018Member_documentation_en-US" xlink:label="lab_ocgn_ConvertibleDebtDecember2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock, issued in December 2018.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertibleDebtDecember2018Member" xlink:href="ocgn-20191231.xsd#ocgn_ConvertibleDebtDecember2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ConvertibleDebtDecember2018Member" xlink:to="lab_ocgn_ConvertibleDebtDecember2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_b888c2ca-7bf2-4999-a63e-512521562653_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RECENT ACCOUNTING PRONOUNCEMENTS</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_b1ace8cb-4dc4-49ef-bb9c-4ad55bc37e17_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionLowerPercentageOfCommonStock_142aa7d0-de6a-42c7-87bb-a0a2d9c81e59_terseLabel_en-US" xlink:label="lab_ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionLowerPercentageOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-merger financing warrants, block provisions, exercise restriction percentage of common stock (in percentage)</link:label>
    <link:label id="lab_ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionLowerPercentageOfCommonStock_label_en-US" xlink:label="lab_ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionLowerPercentageOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-merger Financing Warrants, Block Provisions, Exercise Restriction Lower Percentage Of Common Stock</link:label>
    <link:label id="lab_ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionLowerPercentageOfCommonStock_documentation_en-US" xlink:label="lab_ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionLowerPercentageOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-merger Financing Warrants, Block Provisions, Exercise Restriction Lower Percentage Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionLowerPercentageOfCommonStock" xlink:href="ocgn-20191231.xsd#ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionLowerPercentageOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionLowerPercentageOfCommonStock" xlink:to="lab_ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionLowerPercentageOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_54da64f9-8ec3-4fc1-88b2-eee92828e515_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition cost incurred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_250c2e38-b69b-411a-aa37-c0e0a15f1034_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Principal, Embedded Derivatives and Carrying Value of Debts</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_568fa7b6-c232-495e-808b-206f8df46d64_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ecea96f4-97b0-495e-89c1-ce54e5d6806e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_07276d15-6c0a-48c3-8540-fc215bea3622_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_acb2e1f4-6658-45a8-aae3-0720e2a460c5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_210a867a-a0f3-4ca1-a4aa-2559727f47d3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value at issuance</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_feffa8fb-1ab7-4eaa-9152-5e0a30e2a77c_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing transactions:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ConvertibleDebtConversionFeatureMember_35907990-2b5b-4ff8-b29c-a1fdd2afb164_terseLabel_en-US" xlink:label="lab_ocgn_ConvertibleDebtConversionFeatureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt, conversion feature</link:label>
    <link:label id="lab_ocgn_ConvertibleDebtConversionFeatureMember_label_en-US" xlink:label="lab_ocgn_ConvertibleDebtConversionFeatureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Conversion Feature [Member]</link:label>
    <link:label id="lab_ocgn_ConvertibleDebtConversionFeatureMember_documentation_en-US" xlink:label="lab_ocgn_ConvertibleDebtConversionFeatureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion feature of the convertible debt that is considered as an embedded derivative of the debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertibleDebtConversionFeatureMember" xlink:href="ocgn-20191231.xsd#ocgn_ConvertibleDebtConversionFeatureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ConvertibleDebtConversionFeatureMember" xlink:to="lab_ocgn_ConvertibleDebtConversionFeatureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_d11507d5-b070-44f9-974c-aaf9392ea84a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_CommonStockAdditionalSharesOfCommonStockIssuableUponExerciseOfWarrantsBasedOnResetPeriodShares_8c11dd17-3407-4d38-a017-2be303781fd3_terseLabel_en-US" xlink:label="lab_ocgn_CommonStockAdditionalSharesOfCommonStockIssuableUponExerciseOfWarrantsBasedOnResetPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issuable upon exercise of warrant (in shares)</link:label>
    <link:label id="lab_ocgn_CommonStockAdditionalSharesOfCommonStockIssuableUponExerciseOfWarrantsBasedOnResetPeriodShares_label_en-US" xlink:label="lab_ocgn_CommonStockAdditionalSharesOfCommonStockIssuableUponExerciseOfWarrantsBasedOnResetPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Additional Shares Of Common Stock Issuable Upon Exercise Of Warrants Based on Reset Period, Shares</link:label>
    <link:label id="lab_ocgn_CommonStockAdditionalSharesOfCommonStockIssuableUponExerciseOfWarrantsBasedOnResetPeriodShares_documentation_en-US" xlink:label="lab_ocgn_CommonStockAdditionalSharesOfCommonStockIssuableUponExerciseOfWarrantsBasedOnResetPeriodShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Additional Shares Of Common Stock Issuable Upon Exercise Of Warrants Based on Reset Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CommonStockAdditionalSharesOfCommonStockIssuableUponExerciseOfWarrantsBasedOnResetPeriodShares" xlink:href="ocgn-20191231.xsd#ocgn_CommonStockAdditionalSharesOfCommonStockIssuableUponExerciseOfWarrantsBasedOnResetPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_CommonStockAdditionalSharesOfCommonStockIssuableUponExerciseOfWarrantsBasedOnResetPeriodShares" xlink:to="lab_ocgn_CommonStockAdditionalSharesOfCommonStockIssuableUponExerciseOfWarrantsBasedOnResetPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_c0fecc96-a8f5-49e7-856c-45a0ee881bf0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net of allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c0550996-0edc-45b4-87bc-0e7a1c700e8b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested in period, fair value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_42305013-079e-4cda-a9a3-3905bc5f7693_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPeriod_92675e5c-4761-4af7-8371-c754cfe61136_terseLabel_en-US" xlink:label="lab_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period over which trading price of common stock as quoted on the Nasdaq Capital Market was considered for the release of converted additional shares</link:label>
    <link:label id="lab_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPeriod_label_en-US" xlink:label="lab_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Converted Additional Shares, Threshold Release Trigger Period</link:label>
    <link:label id="lab_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPeriod_documentation_en-US" xlink:label="lab_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The period over which the percentage of the volume-weighted average trading price of a share of common stock as quoted on the Nasdaq Capital Market to release converted additional shares is determined, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPeriod" xlink:href="ocgn-20191231.xsd#ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPeriod" xlink:to="lab_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_67703924-4311-43f7-903a-80bed747398e_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of lease expense</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_bb2ed4d8-772b-4dd0-9ea4-6185b480fd99_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_5ddf9ec9-a2e8-46dd-afe3-9a66f0af4b8c_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate purchase price</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_9c5f6e95-21dc-4e65-a9e5-572615b6578d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of debt</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ConvertibleDebtJanuary2018Member_c79f33e0-78cc-4f9b-a452-d78409bfdfed_terseLabel_en-US" xlink:label="lab_ocgn_ConvertibleDebtJanuary2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Note - January 2018</link:label>
    <link:label id="lab_ocgn_ConvertibleDebtJanuary2018Member_label_en-US" xlink:label="lab_ocgn_ConvertibleDebtJanuary2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt January2018 [Member]</link:label>
    <link:label id="lab_ocgn_ConvertibleDebtJanuary2018Member_documentation_en-US" xlink:label="lab_ocgn_ConvertibleDebtJanuary2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock, issued in January 2018.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertibleDebtJanuary2018Member" xlink:href="ocgn-20191231.xsd#ocgn_ConvertibleDebtJanuary2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ConvertibleDebtJanuary2018Member" xlink:to="lab_ocgn_ConvertibleDebtJanuary2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_5863ca3e-bf93-45b0-a0b6-03c1d78880cb_negatedLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair&#160;Value&#160;of Embedded Derivatives</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_724f9aa2-8f74-48e3-9cec-6a1b447d809f_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of embedded derivative</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative, Fair Value of Embedded Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:to="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_ee929be8-2bd6-458a-9d0e-251883b6519e_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_4a62c1bf-735e-4209-bc20-ceb529d491bb_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, $0.01 par value, 10,000,000 shares authorized, seven and zero issued and outstanding, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_EquityHoldersOfOcugenIncPerMergerMember_cec92ace-f7a9-4403-9fb4-93755daaf69a_terseLabel_en-US" xlink:label="lab_ocgn_EquityHoldersOfOcugenIncPerMergerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Ocugen equity holders</link:label>
    <link:label id="lab_ocgn_EquityHoldersOfOcugenIncPerMergerMember_label_en-US" xlink:label="lab_ocgn_EquityHoldersOfOcugenIncPerMergerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Holders Of Ocugen Inc Per Merger [Member]</link:label>
    <link:label id="lab_ocgn_EquityHoldersOfOcugenIncPerMergerMember_documentation_en-US" xlink:label="lab_ocgn_EquityHoldersOfOcugenIncPerMergerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity holders of Ocugen, Inc. immediately before the merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EquityHoldersOfOcugenIncPerMergerMember" xlink:href="ocgn-20191231.xsd#ocgn_EquityHoldersOfOcugenIncPerMergerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_EquityHoldersOfOcugenIncPerMergerMember" xlink:to="lab_ocgn_EquityHoldersOfOcugenIncPerMergerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_b934875f-b663-431d-9060-6742330fd723_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_48c44918-77ad-4b4b-8f13-67b0f7fb2007_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_12dd5324-afe0-4756-b7ff-6564665e8548_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive securities outstanding excluded from the computation of diluted weighted average shares outstanding</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_EquipmentAndFurnitureMember_f6c574c8-c071-48d4-96da-f6fa90822399_terseLabel_en-US" xlink:label="lab_ocgn_EquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment and Furniture</link:label>
    <link:label id="lab_ocgn_EquipmentAndFurnitureMember_label_en-US" xlink:label="lab_ocgn_EquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment and Furniture [Member]</link:label>
    <link:label id="lab_ocgn_EquipmentAndFurnitureMember_documentation_en-US" xlink:label="lab_ocgn_EquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment and Furniture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EquipmentAndFurnitureMember" xlink:href="ocgn-20191231.xsd#ocgn_EquipmentAndFurnitureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_EquipmentAndFurnitureMember" xlink:to="lab_ocgn_EquipmentAndFurnitureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_EquityHoldersOfHistogenicsCorporationMember_e68960d6-6bc2-481b-9a90-19e3cbbc126f_terseLabel_en-US" xlink:label="lab_ocgn_EquityHoldersOfHistogenicsCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders of Histogenics immediately before the Merger</link:label>
    <link:label id="lab_ocgn_EquityHoldersOfHistogenicsCorporationMember_label_en-US" xlink:label="lab_ocgn_EquityHoldersOfHistogenicsCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Holders Of Histogenics Corporation [Member]</link:label>
    <link:label id="lab_ocgn_EquityHoldersOfHistogenicsCorporationMember_documentation_en-US" xlink:label="lab_ocgn_EquityHoldersOfHistogenicsCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity holders of Histogenics Corporation immediately before the merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EquityHoldersOfHistogenicsCorporationMember" xlink:href="ocgn-20191231.xsd#ocgn_EquityHoldersOfHistogenicsCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_EquityHoldersOfHistogenicsCorporationMember" xlink:to="lab_ocgn_EquityHoldersOfHistogenicsCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_a3102539-a181-4e6e-8f45-58dcce572115_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_56a7f604-29c4-4c42-aceb-4c66f9df5a8d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_ab482c0b-2cf7-4d65-8da5-e2049fe5076e_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions taken in a prior year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_164a3ee9-a19a-4d52-99e0-dbe111e994ae_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_33e4d152-dfad-4e00-822a-fca0c96302da_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_bc2c4f42-fb27-4a3a-b252-a4c14bf0b852_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5a39f6a0-7282-4c8a-b8c8-0978a23398c2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected option term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_0bf8ce15-13d6-4504-908c-738745b61b76_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_3ccd3813-f178-4829-b54d-1ab4fa39d589_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_6775dbe7-cc5c-460a-9c3e-da9d763f8a63_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_c0b25b00-f43a-4558-8bea-011cde6e186a_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_f696d3e3-06b4-4436-adca-7591d940fef6_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_3e65c00c-c262-4bea-bf0b-8b5765e7e0d5_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on financing leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_c0f27ed5-bdce-4781-bc69-1e6488d77bbb_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_fcf76244-bbf3-44fc-a840-e7e7a3e257b3_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss-diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ConvertibleDebtJanuary2019Member_2b5d8891-d887-4685-80a9-3d025d5c54b3_terseLabel_en-US" xlink:label="lab_ocgn_ConvertibleDebtJanuary2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Note - January 2019</link:label>
    <link:label id="lab_ocgn_ConvertibleDebtJanuary2019Member_label_en-US" xlink:label="lab_ocgn_ConvertibleDebtJanuary2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt January2019 [Member]</link:label>
    <link:label id="lab_ocgn_ConvertibleDebtJanuary2019Member_documentation_en-US" xlink:label="lab_ocgn_ConvertibleDebtJanuary2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock, issued in January 2019.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertibleDebtJanuary2019Member" xlink:href="ocgn-20191231.xsd#ocgn_ConvertibleDebtJanuary2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ConvertibleDebtJanuary2019Member" xlink:to="lab_ocgn_ConvertibleDebtJanuary2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_CollaborationAgreementWithCansinoBiologicsMember_428378c3-aa01-4965-b1ae-78c4524871d5_terseLabel_en-US" xlink:label="lab_ocgn_CollaborationAgreementWithCansinoBiologicsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement with CanSino Biologics</link:label>
    <link:label id="lab_ocgn_CollaborationAgreementWithCansinoBiologicsMember_label_en-US" xlink:label="lab_ocgn_CollaborationAgreementWithCansinoBiologicsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement With Cansino Biologics [Member]</link:label>
    <link:label id="lab_ocgn_CollaborationAgreementWithCansinoBiologicsMember_documentation_en-US" xlink:label="lab_ocgn_CollaborationAgreementWithCansinoBiologicsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents co-development and commercialization agreement (the "Agreement") with CanSino Biologics Inc. ("CanSino") with respect to the development and commercialization of the gene therapy product candidate, OCU400, for the treatment of NR2E3 Mutation-Associated Retinal Degeneration, Leber Congenital Amaurosis, Bardet-Biedl Syndrome and Rhodopsin Mutation-Associated Retinal Degeneration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborationAgreementWithCansinoBiologicsMember" xlink:href="ocgn-20191231.xsd#ocgn_CollaborationAgreementWithCansinoBiologicsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_CollaborationAgreementWithCansinoBiologicsMember" xlink:to="lab_ocgn_CollaborationAgreementWithCansinoBiologicsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_b883a8f0-c9e5-494c-b727-2ac7b63a6576_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for warrant exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightExercised_f88da36b-09ea-468f-a7b1-9e1e1d9f2ede_negatedLabel_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercised</link:label>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightExercised_label_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercised</link:label>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightExercised_documentation_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightExercised" xlink:href="ocgn-20191231.xsd#ocgn_ClassOfWarrantOrRightExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ClassOfWarrantOrRightExercised" xlink:to="lab_ocgn_ClassOfWarrantOrRightExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiabilityAtIssuance_7e30b0ee-f5fe-4c66-b153-9192dc170642_terseLabel_en-US" xlink:label="lab_ocgn_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiabilityAtIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of embedded derivatives at issuance</link:label>
    <link:label id="lab_ocgn_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiabilityAtIssuance_label_en-US" xlink:label="lab_ocgn_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiabilityAtIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative, Fair Value of Embedded Derivative Liability At Issuance</link:label>
    <link:label id="lab_ocgn_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiabilityAtIssuance_documentation_en-US" xlink:label="lab_ocgn_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiabilityAtIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative, Fair Value of Embedded Derivative Liability At Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiabilityAtIssuance" xlink:href="ocgn-20191231.xsd#ocgn_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiabilityAtIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiabilityAtIssuance" xlink:to="lab_ocgn_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiabilityAtIssuance" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>ocgn-20191231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:cc72798c-c24e-4d47-845f-93333954ce8b,g:e003b04e-ddd7-4b29-b911-f80dc6cd6725-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/Cover" xlink:type="simple" xlink:href="ocgn-20191231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_3f5de511-15ef-4700-9747-a682b71feaa4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_DocumentType_3f5de511-15ef-4700-9747-a682b71feaa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_0faff09e-40d6-4f3b-8aa3-2574bb9c2243" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_DocumentAnnualReport_0faff09e-40d6-4f3b-8aa3-2574bb9c2243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_57c16096-ad16-48c8-87f4-fa9c19e0f181" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_DocumentPeriodEndDate_57c16096-ad16-48c8-87f4-fa9c19e0f181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_00d04ce1-c311-403e-bb48-41521b34a42b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_DocumentTransitionReport_00d04ce1-c311-403e-bb48-41521b34a42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_de8e2280-aacc-43fb-be34-01f3b9b88a82" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_EntityFileNumber_de8e2280-aacc-43fb-be34-01f3b9b88a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_26125de6-d2bf-4f31-9ec0-67c556b77000" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_EntityRegistrantName_26125de6-d2bf-4f31-9ec0-67c556b77000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5315fe7d-398b-4ebf-8317-a88e9977744a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_EntityCentralIndexKey_5315fe7d-398b-4ebf-8317-a88e9977744a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9967deef-29d0-457c-99bd-9ed54a5e217c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_CurrentFiscalYearEndDate_9967deef-29d0-457c-99bd-9ed54a5e217c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_d0a53b57-62c8-442f-bf6a-52fc2680e416" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_DocumentFiscalYearFocus_d0a53b57-62c8-442f-bf6a-52fc2680e416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_03b83de7-65a2-46ed-8ab6-117466c75f6c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_DocumentFiscalPeriodFocus_03b83de7-65a2-46ed-8ab6-117466c75f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_64de0bfe-cb71-4568-b05b-a04b156cd96f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_AmendmentFlag_64de0bfe-cb71-4568-b05b-a04b156cd96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2c4b09e6-6f05-4c91-8d45-bb8f719f5e69" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2c4b09e6-6f05-4c91-8d45-bb8f719f5e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3208b615-56eb-49ab-b8af-673f0b6fc9d8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_EntityTaxIdentificationNumber_3208b615-56eb-49ab-b8af-673f0b6fc9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f369566b-e4a6-4e14-93c4-52419c4aed02" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_EntityAddressAddressLine1_f369566b-e4a6-4e14-93c4-52419c4aed02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_3b9c0cb6-25d5-46ae-a1e5-aeb2c2fe8929" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_EntityAddressCityOrTown_3b9c0cb6-25d5-46ae-a1e5-aeb2c2fe8929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_debefce9-921e-4f2a-9db1-bc33ef36627b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_EntityAddressStateOrProvince_debefce9-921e-4f2a-9db1-bc33ef36627b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a87a0be7-567d-40f0-a5ea-01d508315df5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_EntityAddressPostalZipCode_a87a0be7-567d-40f0-a5ea-01d508315df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_05affa4c-6213-4807-872a-8e6b8f231ca1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_CityAreaCode_05affa4c-6213-4807-872a-8e6b8f231ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_6e4c1bce-0d89-4290-a564-1b45265cb3f6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_LocalPhoneNumber_6e4c1bce-0d89-4290-a564-1b45265cb3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a0727d57-ab07-4584-a73b-e530a67dfb78" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_Security12bTitle_a0727d57-ab07-4584-a73b-e530a67dfb78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e812ef2e-7c1e-4efc-aaaa-62a18056895d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_TradingSymbol_e812ef2e-7c1e-4efc-aaaa-62a18056895d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_f37eaa95-2887-487f-8a25-b6e1e46d4f88" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_SecurityExchangeName_f37eaa95-2887-487f-8a25-b6e1e46d4f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_e4d88659-ffd6-4ff1-a5d4-35d7c61240bf" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_e4d88659-ffd6-4ff1-a5d4-35d7c61240bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_b85e472a-4217-470f-a8ef-f6d1dc200907" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_EntityVoluntaryFilers_b85e472a-4217-470f-a8ef-f6d1dc200907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_1861de0b-960f-4354-b7e0-cd9e3aa2c4eb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_EntityCurrentReportingStatus_1861de0b-960f-4354-b7e0-cd9e3aa2c4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_6d5dd25f-17cc-4058-bdec-a36f3b7df66d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_EntityInteractiveDataCurrent_6d5dd25f-17cc-4058-bdec-a36f3b7df66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_d9b3aabe-3960-4039-a519-0e2c9d4b8d2f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_EntityFilerCategory_d9b3aabe-3960-4039-a519-0e2c9d4b8d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_1549756e-f37b-44d7-a05e-e2b0226a8f59" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_EntitySmallBusiness_1549756e-f37b-44d7-a05e-e2b0226a8f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_97b9338e-01e1-44ad-bd37-9a435217e76e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_EntityEmergingGrowthCompany_97b9338e-01e1-44ad-bd37-9a435217e76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_ab9537e4-9eae-49ef-8be2-487ab55f75e0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_EntityShellCompany_ab9537e4-9eae-49ef-8be2-487ab55f75e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_ef106ca1-5b29-478c-9ff6-83bc60bc19f5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_EntityPublicFloat_ef106ca1-5b29-478c-9ff6-83bc60bc19f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_1fc07cad-5a26-404e-b1be-c6573404f838" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_1fc07cad-5a26-404e-b1be-c6573404f838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_85d44189-0b9c-47cf-ad50-0ddceee3f6da" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1184b082-332d-4ca1-8684-3c4df866ff32" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_85d44189-0b9c-47cf-ad50-0ddceee3f6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_eb0d4eb6-adab-4edb-a20d-c0e949626c73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_264cb345-971f-4da7-b9c5-71db5d8270a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_eb0d4eb6-adab-4edb-a20d-c0e949626c73" xlink:to="loc_us-gaap_AssetsAbstract_264cb345-971f-4da7-b9c5-71db5d8270a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_908d4322-4ecd-4c46-a696-ee186cc6ae0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_264cb345-971f-4da7-b9c5-71db5d8270a9" xlink:to="loc_us-gaap_AssetsCurrentAbstract_908d4322-4ecd-4c46-a696-ee186cc6ae0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ddef48b0-d211-4cc3-acec-e3d95abaa7a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_908d4322-4ecd-4c46-a696-ee186cc6ae0d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ddef48b0-d211-4cc3-acec-e3d95abaa7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c4645f7c-ff89-4077-ab31-6d8b4812f875" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_908d4322-4ecd-4c46-a696-ee186cc6ae0d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c4645f7c-ff89-4077-ab31-6d8b4812f875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_360cafba-6026-4a40-8c90-78afd57bf3bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_908d4322-4ecd-4c46-a696-ee186cc6ae0d" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_360cafba-6026-4a40-8c90-78afd57bf3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3a91baa3-701c-4a8d-91a3-891740e98242" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_908d4322-4ecd-4c46-a696-ee186cc6ae0d" xlink:to="loc_us-gaap_AssetsCurrent_3a91baa3-701c-4a8d-91a3-891740e98242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_444cfc4c-62e0-4322-85bc-9c2a4eaa46b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_264cb345-971f-4da7-b9c5-71db5d8270a9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_444cfc4c-62e0-4322-85bc-9c2a4eaa46b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_ffd947aa-9a19-4dc9-b8fe-26109bb2fd61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_264cb345-971f-4da7-b9c5-71db5d8270a9" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_ffd947aa-9a19-4dc9-b8fe-26109bb2fd61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_85038b12-99d1-45e0-b0a1-cc677697000e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_264cb345-971f-4da7-b9c5-71db5d8270a9" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_85038b12-99d1-45e0-b0a1-cc677697000e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3dcc626c-1858-44eb-a863-eb6ba76c5aa9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_264cb345-971f-4da7-b9c5-71db5d8270a9" xlink:to="loc_us-gaap_Assets_3dcc626c-1858-44eb-a863-eb6ba76c5aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f87d63b5-5887-4b4e-b8bb-1c6862bdd9c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_eb0d4eb6-adab-4edb-a20d-c0e949626c73" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f87d63b5-5887-4b4e-b8bb-1c6862bdd9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5019a81c-5ccd-463f-accb-8fe7850da72a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f87d63b5-5887-4b4e-b8bb-1c6862bdd9c3" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_5019a81c-5ccd-463f-accb-8fe7850da72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_46c99cf1-e524-49e9-9746-b229c6176610" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5019a81c-5ccd-463f-accb-8fe7850da72a" xlink:to="loc_us-gaap_AccountsPayableCurrent_46c99cf1-e524-49e9-9746-b229c6176610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_846d6670-35f1-4538-8475-717c40661d9a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5019a81c-5ccd-463f-accb-8fe7850da72a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_846d6670-35f1-4538-8475-717c40661d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_59b3c54c-db02-47af-91b9-dc05f33d0926" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5019a81c-5ccd-463f-accb-8fe7850da72a" xlink:to="loc_us-gaap_ShortTermBorrowings_59b3c54c-db02-47af-91b9-dc05f33d0926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_ea150572-9cd5-4c79-abfe-1a1eb418227f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5019a81c-5ccd-463f-accb-8fe7850da72a" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_ea150572-9cd5-4c79-abfe-1a1eb418227f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_efc712d3-5173-4b0a-987a-995dd7df3ea2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5019a81c-5ccd-463f-accb-8fe7850da72a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_efc712d3-5173-4b0a-987a-995dd7df3ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_c7968826-04b6-46d5-9bb9-9f73288175c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5019a81c-5ccd-463f-accb-8fe7850da72a" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_c7968826-04b6-46d5-9bb9-9f73288175c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b0cddea4-f674-4c80-b16b-76cc19f5c8b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5019a81c-5ccd-463f-accb-8fe7850da72a" xlink:to="loc_us-gaap_LiabilitiesCurrent_b0cddea4-f674-4c80-b16b-76cc19f5c8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_f4cda154-bbf8-4e98-9557-d1d52c4d404a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f87d63b5-5887-4b4e-b8bb-1c6862bdd9c3" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_f4cda154-bbf8-4e98-9557-d1d52c4d404a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a6bb2610-545e-4c9e-8009-ae4a3025bc80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_f4cda154-bbf8-4e98-9557-d1d52c4d404a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a6bb2610-545e-4c9e-8009-ae4a3025bc80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_9404efe2-6513-41c3-a4f7-e673844e0f2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_f4cda154-bbf8-4e98-9557-d1d52c4d404a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_9404efe2-6513-41c3-a4f7-e673844e0f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2ade95cc-4366-4bd6-acc3-e1fbf3cd0e69" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_f4cda154-bbf8-4e98-9557-d1d52c4d404a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2ade95cc-4366-4bd6-acc3-e1fbf3cd0e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_af6bb337-fbd1-49b0-bfca-9b6f137af464" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_f4cda154-bbf8-4e98-9557-d1d52c4d404a" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_af6bb337-fbd1-49b0-bfca-9b6f137af464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4b07ef70-bdb4-4e3f-8e8a-f162aaae1fef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f87d63b5-5887-4b4e-b8bb-1c6862bdd9c3" xlink:to="loc_us-gaap_Liabilities_4b07ef70-bdb4-4e3f-8e8a-f162aaae1fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3d3f35d1-a1f8-4c86-a9ba-404be209df08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f87d63b5-5887-4b4e-b8bb-1c6862bdd9c3" xlink:to="loc_us-gaap_CommitmentsAndContingencies_3d3f35d1-a1f8-4c86-a9ba-404be209df08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_5fafc18f-bea6-4760-97d3-50b5b671b895" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f87d63b5-5887-4b4e-b8bb-1c6862bdd9c3" xlink:to="loc_us-gaap_StockholdersEquityAbstract_5fafc18f-bea6-4760-97d3-50b5b671b895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8c0b2d25-76b7-42ce-99f2-99b7899afde8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5fafc18f-bea6-4760-97d3-50b5b671b895" xlink:to="loc_us-gaap_PreferredStockValue_8c0b2d25-76b7-42ce-99f2-99b7899afde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f4715565-b322-4d4c-973c-9cf39be8975f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5fafc18f-bea6-4760-97d3-50b5b671b895" xlink:to="loc_us-gaap_CommonStockValue_f4715565-b322-4d4c-973c-9cf39be8975f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_d447dde7-61e7-4e05-830f-71d772b2f2e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5fafc18f-bea6-4760-97d3-50b5b671b895" xlink:to="loc_us-gaap_TreasuryStockValue_d447dde7-61e7-4e05-830f-71d772b2f2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_333669db-7e7e-4921-877c-75813c8df4c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5fafc18f-bea6-4760-97d3-50b5b671b895" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_333669db-7e7e-4921-877c-75813c8df4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_a06554a0-e565-4048-addc-647380b0916f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5fafc18f-bea6-4760-97d3-50b5b671b895" xlink:to="loc_us-gaap_AdditionalPaidInCapital_a06554a0-e565-4048-addc-647380b0916f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_06b51488-6444-4bab-86d3-7dafdb6d4c5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5fafc18f-bea6-4760-97d3-50b5b671b895" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_06b51488-6444-4bab-86d3-7dafdb6d4c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_04a7fee8-a97b-4852-8811-8ff39baa10d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5fafc18f-bea6-4760-97d3-50b5b671b895" xlink:to="loc_us-gaap_StockholdersEquity_04a7fee8-a97b-4852-8811-8ff39baa10d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8948a717-940f-4caf-846f-e892f87469c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5fafc18f-bea6-4760-97d3-50b5b671b895" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_8948a717-940f-4caf-846f-e892f87469c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_bd098b7d-24d2-4a2a-8e77-4197b81f39e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_eb0d4eb6-adab-4edb-a20d-c0e949626c73" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_bd098b7d-24d2-4a2a-8e77-4197b81f39e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_e35479e5-d3ff-4079-aa6c-29f792aa0f49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_eb0d4eb6-adab-4edb-a20d-c0e949626c73" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_e35479e5-d3ff-4079-aa6c-29f792aa0f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_716a59ca-1172-410d-9574-741d2e5fe8c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_eb0d4eb6-adab-4edb-a20d-c0e949626c73" xlink:to="loc_us-gaap_PreferredStockSharesIssued_716a59ca-1172-410d-9574-741d2e5fe8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_31a268ce-bab9-43b2-8d64-b41d98dfe39a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_eb0d4eb6-adab-4edb-a20d-c0e949626c73" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_31a268ce-bab9-43b2-8d64-b41d98dfe39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f8fec673-b234-45da-b71a-dc6248962d02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_eb0d4eb6-adab-4edb-a20d-c0e949626c73" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f8fec673-b234-45da-b71a-dc6248962d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f456eb07-ae90-4501-b49c-0cc3604a0991" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_eb0d4eb6-adab-4edb-a20d-c0e949626c73" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f456eb07-ae90-4501-b49c-0cc3604a0991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f04f92dc-d381-47be-ae19-b03812d347ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_eb0d4eb6-adab-4edb-a20d-c0e949626c73" xlink:to="loc_us-gaap_CommonStockSharesIssued_f04f92dc-d381-47be-ae19-b03812d347ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8a0428de-b07c-4697-875d-4d0883bb1e52" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_eb0d4eb6-adab-4edb-a20d-c0e949626c73" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8a0428de-b07c-4697-875d-4d0883bb1e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_498631a1-24e3-429b-b997-126b97383d18" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_eb0d4eb6-adab-4edb-a20d-c0e949626c73" xlink:to="loc_us-gaap_TreasuryStockCommonShares_498631a1-24e3-429b-b997-126b97383d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b7e9219d-2ecd-4d3b-a0ce-6ba91d50a3f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_de536bc0-acd8-40d6-9e56-167813fafd8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b7e9219d-2ecd-4d3b-a0ce-6ba91d50a3f3" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_de536bc0-acd8-40d6-9e56-167813fafd8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_547e8154-3505-43cc-bf22-e27077036012" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b7e9219d-2ecd-4d3b-a0ce-6ba91d50a3f3" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_547e8154-3505-43cc-bf22-e27077036012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_774d4553-abfc-4bec-93b0-d28cdb6c1da1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b7e9219d-2ecd-4d3b-a0ce-6ba91d50a3f3" xlink:to="loc_us-gaap_PreferredStockSharesIssued_774d4553-abfc-4bec-93b0-d28cdb6c1da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_9ae8a0a8-3d7c-4dbf-a465-62e25480c369" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b7e9219d-2ecd-4d3b-a0ce-6ba91d50a3f3" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_9ae8a0a8-3d7c-4dbf-a465-62e25480c369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4063416b-f189-418a-9730-ffcc7ce19a62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b7e9219d-2ecd-4d3b-a0ce-6ba91d50a3f3" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_4063416b-f189-418a-9730-ffcc7ce19a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7c85285e-cb37-47ef-8c83-947ccac8ceb6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b7e9219d-2ecd-4d3b-a0ce-6ba91d50a3f3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7c85285e-cb37-47ef-8c83-947ccac8ceb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_40de024e-a189-49ad-9a3d-560dc5454487" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b7e9219d-2ecd-4d3b-a0ce-6ba91d50a3f3" xlink:to="loc_us-gaap_CommonStockSharesIssued_40de024e-a189-49ad-9a3d-560dc5454487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_55044107-4b64-41b3-b070-488d58c6670b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b7e9219d-2ecd-4d3b-a0ce-6ba91d50a3f3" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_55044107-4b64-41b3-b070-488d58c6670b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f2cb26da-6050-4615-bb2b-497a13a781b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_ee30938b-7f89-42f2-8250-86580655b8da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f2cb26da-6050-4615-bb2b-497a13a781b0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_ee30938b-7f89-42f2-8250-86580655b8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f32465fb-163c-4dd0-8ea4-a479203993f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ee30938b-7f89-42f2-8250-86580655b8da" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f32465fb-163c-4dd0-8ea4-a479203993f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_afa9c536-d2c1-4bd0-8081-1e260a936b28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ee30938b-7f89-42f2-8250-86580655b8da" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_afa9c536-d2c1-4bd0-8081-1e260a936b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8d0151db-c747-4cfd-8034-536ee0290e41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ee30938b-7f89-42f2-8250-86580655b8da" xlink:to="loc_us-gaap_OperatingExpenses_8d0151db-c747-4cfd-8034-536ee0290e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6391657b-ce4f-4602-99d5-fbee52b5a2a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f2cb26da-6050-4615-bb2b-497a13a781b0" xlink:to="loc_us-gaap_OperatingIncomeLoss_6391657b-ce4f-4602-99d5-fbee52b5a2a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e7bcd958-3797-4e34-b55d-b9da0367bd3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f2cb26da-6050-4615-bb2b-497a13a781b0" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e7bcd958-3797-4e34-b55d-b9da0367bd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_dfc385ef-4f86-42d0-a15f-fffce61e178d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e7bcd958-3797-4e34-b55d-b9da0367bd3c" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_dfc385ef-4f86-42d0-a15f-fffce61e178d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_GainsLossesOnConversionOfDebt_64e8b315-8b72-45bb-9883-29dd3ab5631e" xlink:href="ocgn-20191231.xsd#ocgn_GainsLossesOnConversionOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e7bcd958-3797-4e34-b55d-b9da0367bd3c" xlink:to="loc_ocgn_GainsLossesOnConversionOfDebt_64e8b315-8b72-45bb-9883-29dd3ab5631e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_9c22fc36-d573-434c-9136-76c37e7f2419" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e7bcd958-3797-4e34-b55d-b9da0367bd3c" xlink:to="loc_us-gaap_InvestmentIncomeInterest_9c22fc36-d573-434c-9136-76c37e7f2419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_2ac9c249-9f4b-48d4-9372-dd9af5221000" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e7bcd958-3797-4e34-b55d-b9da0367bd3c" xlink:to="loc_us-gaap_InterestExpense_2ac9c249-9f4b-48d4-9372-dd9af5221000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9ef75014-23fb-49f3-a9b3-f25f6dee5732" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e7bcd958-3797-4e34-b55d-b9da0367bd3c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9ef75014-23fb-49f3-a9b3-f25f6dee5732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_34761e52-c4e3-41ee-9f44-b4c429809859" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e7bcd958-3797-4e34-b55d-b9da0367bd3c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_34761e52-c4e3-41ee-9f44-b4c429809859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ed1dce24-1674-44d4-9fb6-7495b3336f2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f2cb26da-6050-4615-bb2b-497a13a781b0" xlink:to="loc_us-gaap_NetIncomeLoss_ed1dce24-1674-44d4-9fb6-7495b3336f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_f462d194-76e9-411a-96e5-85f7ba2d7e34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f2cb26da-6050-4615-bb2b-497a13a781b0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_f462d194-76e9-411a-96e5-85f7ba2d7e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_97b0baac-0130-4561-8840-a6e79b4a7add" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_f462d194-76e9-411a-96e5-85f7ba2d7e34" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_97b0baac-0130-4561-8840-a6e79b4a7add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_30500465-e7c1-4af8-9901-9ecd94cdddf8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f2cb26da-6050-4615-bb2b-497a13a781b0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_30500465-e7c1-4af8-9901-9ecd94cdddf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_f120c77f-e615-435b-95b5-9f8bce032c76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f2cb26da-6050-4615-bb2b-497a13a781b0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_f120c77f-e615-435b-95b5-9f8bce032c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_e3674e96-6a2d-4df0-bf86-0ad5ee70ec59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f2cb26da-6050-4615-bb2b-497a13a781b0" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_e3674e96-6a2d-4df0-bf86-0ad5ee70ec59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_abb096b5-89bd-4a8e-8cfe-3e5c1eade380" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4e28046b-06dd-45e9-a9ba-8052f5aef239" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_abb096b5-89bd-4a8e-8cfe-3e5c1eade380" xlink:to="loc_us-gaap_StatementTable_4e28046b-06dd-45e9-a9ba-8052f5aef239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3568bb1e-0c7c-41ed-8b73-2866241f7f60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4e28046b-06dd-45e9-a9ba-8052f5aef239" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3568bb1e-0c7c-41ed-8b73-2866241f7f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_84d52f0a-1580-4676-9c84-20edcf73cb25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3568bb1e-0c7c-41ed-8b73-2866241f7f60" xlink:to="loc_us-gaap_EquityComponentDomain_84d52f0a-1580-4676-9c84-20edcf73cb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_295cebc8-3aa4-4223-a845-f506577ff48a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_84d52f0a-1580-4676-9c84-20edcf73cb25" xlink:to="loc_us-gaap_CommonStockMember_295cebc8-3aa4-4223-a845-f506577ff48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_ff9582b1-0020-47a2-b2e9-7613796d9bbc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_84d52f0a-1580-4676-9c84-20edcf73cb25" xlink:to="loc_us-gaap_TreasuryStockMember_ff9582b1-0020-47a2-b2e9-7613796d9bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e4889cdf-b311-4086-bfd7-7fa6dde11efc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_84d52f0a-1580-4676-9c84-20edcf73cb25" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e4889cdf-b311-4086-bfd7-7fa6dde11efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3a32c679-5e30-4608-bc99-f63720a8e0f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_84d52f0a-1580-4676-9c84-20edcf73cb25" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3a32c679-5e30-4608-bc99-f63720a8e0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_90c94ca4-e76a-434b-9e7c-03cbce0aff49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_84d52f0a-1580-4676-9c84-20edcf73cb25" xlink:to="loc_us-gaap_RetainedEarningsMember_90c94ca4-e76a-434b-9e7c-03cbce0aff49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_04b1ca20-cb99-43fa-b025-9c01f17de5f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4e28046b-06dd-45e9-a9ba-8052f5aef239" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_04b1ca20-cb99-43fa-b025-9c01f17de5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_196c1073-fdf2-477e-b833-cdbd51387b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_04b1ca20-cb99-43fa-b025-9c01f17de5f0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_196c1073-fdf2-477e-b833-cdbd51387b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_acc7c1e2-536e-4477-9b45-56edb44b9705" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_196c1073-fdf2-477e-b833-cdbd51387b1d" xlink:to="loc_us-gaap_WarrantMember_acc7c1e2-536e-4477-9b45-56edb44b9705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1ce3e81a-2f6c-4bbd-b204-53b6c7f7986b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4e28046b-06dd-45e9-a9ba-8052f5aef239" xlink:to="loc_us-gaap_StatementLineItems_1ce3e81a-2f6c-4bbd-b204-53b6c7f7986b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1ce3e81a-2f6c-4bbd-b204-53b6c7f7986b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e885e894-3e6c-4b24-ad40-a41c9d51726c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_us-gaap_SharesOutstanding_e885e894-3e6c-4b24-ad40-a41c9d51726c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8b4e8d49-03ae-43f6-946c-be6b38f51267" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_us-gaap_StockholdersEquity_8b4e8d49-03ae-43f6-946c-be6b38f51267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e31977fa-91e7-4b89-a460-cbcf524c135b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e31977fa-91e7-4b89-a460-cbcf524c135b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_306dae05-c363-4b91-8bbd-6caf2f8fe684" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_306dae05-c363-4b91-8bbd-6caf2f8fe684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5c288466-1759-4d39-b47f-9e69a1eeef9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_us-gaap_NetIncomeLoss_5c288466-1759-4d39-b47f-9e69a1eeef9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5b200607-cac2-415f-a646-9f7d4de5dc68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5b200607-cac2-415f-a646-9f7d4de5dc68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_95982991-07a8-428c-9c8c-d057879d9fbf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_95982991-07a8-428c-9c8c-d057879d9fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_6807958a-6b81-4794-811f-28441cfcc378" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_6807958a-6b81-4794-811f-28441cfcc378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_425944cd-76ae-49d3-93ba-da92c99c8631" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_425944cd-76ae-49d3-93ba-da92c99c8631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_StockIssuedDuringPeriodPreMergerShares_a17b24f0-46be-4f15-bb1a-39e9372de684" xlink:href="ocgn-20191231.xsd#ocgn_StockIssuedDuringPeriodPreMergerShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_ocgn_StockIssuedDuringPeriodPreMergerShares_a17b24f0-46be-4f15-bb1a-39e9372de684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_StockIssuedDuringPeriodPreMergerValue_212f16e7-75b8-4e19-830e-70e91f99758b" xlink:href="ocgn-20191231.xsd#ocgn_StockIssuedDuringPeriodPreMergerValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_ocgn_StockIssuedDuringPeriodPreMergerValue_212f16e7-75b8-4e19-830e-70e91f99758b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_StockIssuedDuringPeriodSharesReverseAssetAcquisition_587d1959-c77f-4ec0-bf67-f9eeeeb37ec1" xlink:href="ocgn-20191231.xsd#ocgn_StockIssuedDuringPeriodSharesReverseAssetAcquisition"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_ocgn_StockIssuedDuringPeriodSharesReverseAssetAcquisition_587d1959-c77f-4ec0-bf67-f9eeeeb37ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_StockIssuedDuringPeriodValueReverseAssetAcquisition_bd79e1b7-e436-4903-8d16-4315c1a8ce10" xlink:href="ocgn-20191231.xsd#ocgn_StockIssuedDuringPeriodValueReverseAssetAcquisition"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_ocgn_StockIssuedDuringPeriodValueReverseAssetAcquisition_bd79e1b7-e436-4903-8d16-4315c1a8ce10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ReclassificationOfWarrantsFromLiabilityToEquity_e617314a-9b90-4f4a-8b6f-80d657fb9fa6" xlink:href="ocgn-20191231.xsd#ocgn_ReclassificationOfWarrantsFromLiabilityToEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_ocgn_ReclassificationOfWarrantsFromLiabilityToEquity_e617314a-9b90-4f4a-8b6f-80d657fb9fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_StockIssuedDuringPeriodValueWarrantsExercised_fdd70957-2605-4fc7-9ab5-90d524c2b1dd" xlink:href="ocgn-20191231.xsd#ocgn_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_ocgn_StockIssuedDuringPeriodValueWarrantsExercised_fdd70957-2605-4fc7-9ab5-90d524c2b1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_883915dd-0ea6-404a-83ce-1ec176289a82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_883915dd-0ea6-404a-83ce-1ec176289a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2e50bccf-f5cf-41b2-b478-96f4ceaf08ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_us-gaap_StockholdersEquity_2e50bccf-f5cf-41b2-b478-96f4ceaf08ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e34a8fa3-64a1-419f-aa01-7dc0c84ca812" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f5ed082-1a81-4dde-975f-d55e15f9a47c" xlink:to="loc_us-gaap_SharesOutstanding_e34a8fa3-64a1-419f-aa01-7dc0c84ca812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_4f4f1c4f-ff4c-46a0-9bed-85de7966038c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CostsRelatedToIssuanceOfStockUnderReverseAssetAcquisition_7a7b4fef-1b2b-4ce1-ba51-34d2ce8a0992" xlink:href="ocgn-20191231.xsd#ocgn_CostsRelatedToIssuanceOfStockUnderReverseAssetAcquisition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_4f4f1c4f-ff4c-46a0-9bed-85de7966038c" xlink:to="loc_ocgn_CostsRelatedToIssuanceOfStockUnderReverseAssetAcquisition_7a7b4fef-1b2b-4ce1-ba51-34d2ce8a0992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_ee0e5a26-456f-40d9-adb1-b1a6a49b1634" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76de8a25-3ad9-486e-8292-60a7b65f3bca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ee0e5a26-456f-40d9-adb1-b1a6a49b1634" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76de8a25-3ad9-486e-8292-60a7b65f3bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e683959b-2570-444a-9943-bc366086eadc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76de8a25-3ad9-486e-8292-60a7b65f3bca" xlink:to="loc_us-gaap_ProfitLoss_e683959b-2570-444a-9943-bc366086eadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_29508def-9fc2-4cee-8b70-1f3e077482df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76de8a25-3ad9-486e-8292-60a7b65f3bca" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_29508def-9fc2-4cee-8b70-1f3e077482df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_ce49d084-7b4d-4a60-a8e1-d3c3c8a99647" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_29508def-9fc2-4cee-8b70-1f3e077482df" xlink:to="loc_us-gaap_Depreciation_ce49d084-7b4d-4a60-a8e1-d3c3c8a99647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NonCashInterestExpense_3742a502-2bfe-4e84-a23b-56ba3150dc6b" xlink:href="ocgn-20191231.xsd#ocgn_NonCashInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_29508def-9fc2-4cee-8b70-1f3e077482df" xlink:to="loc_ocgn_NonCashInterestExpense_3742a502-2bfe-4e84-a23b-56ba3150dc6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NoncashLeaseExpense_8f87ad75-fffa-4223-8cf5-f707bb517f55" xlink:href="ocgn-20191231.xsd#ocgn_NoncashLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_29508def-9fc2-4cee-8b70-1f3e077482df" xlink:to="loc_ocgn_NoncashLeaseExpense_8f87ad75-fffa-4223-8cf5-f707bb517f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_5eb29c3d-5654-4233-a80a-d86e8c73e8ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_29508def-9fc2-4cee-8b70-1f3e077482df" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_5eb29c3d-5654-4233-a80a-d86e8c73e8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f7ca97cd-31b1-455e-bdaa-0c60eef90480" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_29508def-9fc2-4cee-8b70-1f3e077482df" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f7ca97cd-31b1-455e-bdaa-0c60eef90480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_GainsLossesOnConversionOfDebt_9498fd87-733d-4ea3-9007-06fb10afb11a" xlink:href="ocgn-20191231.xsd#ocgn_GainsLossesOnConversionOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_29508def-9fc2-4cee-8b70-1f3e077482df" xlink:to="loc_ocgn_GainsLossesOnConversionOfDebt_9498fd87-733d-4ea3-9007-06fb10afb11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense_12c13bda-b3c6-4540-b45c-82df93f6c26a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_29508def-9fc2-4cee-8b70-1f3e077482df" xlink:to="loc_us-gaap_OtherNoncashExpense_12c13bda-b3c6-4540-b45c-82df93f6c26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_247f6eb6-3aa2-46bd-a29b-75af89841314" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76de8a25-3ad9-486e-8292-60a7b65f3bca" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_247f6eb6-3aa2-46bd-a29b-75af89841314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fedf9a18-1b8c-44e3-b09d-6d7ee5066bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_247f6eb6-3aa2-46bd-a29b-75af89841314" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fedf9a18-1b8c-44e3-b09d-6d7ee5066bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e11ab9c4-1d77-4503-9afe-4feb7e032506" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_247f6eb6-3aa2-46bd-a29b-75af89841314" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e11ab9c4-1d77-4503-9afe-4feb7e032506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_IncreaseDecreaseInDeferredRent_76e61bac-83e5-4ecf-a3a9-c4adeb8ca295" xlink:href="ocgn-20191231.xsd#ocgn_IncreaseDecreaseInDeferredRent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_247f6eb6-3aa2-46bd-a29b-75af89841314" xlink:to="loc_ocgn_IncreaseDecreaseInDeferredRent_76e61bac-83e5-4ecf-a3a9-c4adeb8ca295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5215e407-9e7e-4133-bc50-baae1c054004" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_247f6eb6-3aa2-46bd-a29b-75af89841314" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5215e407-9e7e-4133-bc50-baae1c054004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_IncreaseDecreaseInLeaseObligations_6d2c4533-983b-4a69-9ba0-87557ee6e53c" xlink:href="ocgn-20191231.xsd#ocgn_IncreaseDecreaseInLeaseObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_247f6eb6-3aa2-46bd-a29b-75af89841314" xlink:to="loc_ocgn_IncreaseDecreaseInLeaseObligations_6d2c4533-983b-4a69-9ba0-87557ee6e53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a8c4021c-9456-46e3-978a-20987ae8ae1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76de8a25-3ad9-486e-8292-60a7b65f3bca" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a8c4021c-9456-46e3-978a-20987ae8ae1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f242c0fa-d515-4942-9312-c8fa73b5da0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ee0e5a26-456f-40d9-adb1-b1a6a49b1634" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f242c0fa-d515-4942-9312-c8fa73b5da0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7100bb05-a8a0-42f3-86c0-aaf97f2fce3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f242c0fa-d515-4942-9312-c8fa73b5da0f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7100bb05-a8a0-42f3-86c0-aaf97f2fce3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_0b1339b8-9701-42be-87cb-9c47ac964649" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f242c0fa-d515-4942-9312-c8fa73b5da0f" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_0b1339b8-9701-42be-87cb-9c47ac964649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6276dbf4-c966-46d0-9fdd-61367ffce067" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ee0e5a26-456f-40d9-adb1-b1a6a49b1634" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6276dbf4-c966-46d0-9fdd-61367ffce067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c4ada351-2ef0-47a6-973e-f6e48c2f634c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ee0e5a26-456f-40d9-adb1-b1a6a49b1634" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c4ada351-2ef0-47a6-973e-f6e48c2f634c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ProceedsFromPreMergerFinancingFinancingActivities_0cb88e79-f49f-47d6-a1bf-64a5bca57818" xlink:href="ocgn-20191231.xsd#ocgn_ProceedsFromPreMergerFinancingFinancingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c4ada351-2ef0-47a6-973e-f6e48c2f634c" xlink:to="loc_ocgn_ProceedsFromPreMergerFinancingFinancingActivities_0cb88e79-f49f-47d6-a1bf-64a5bca57818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dd7214ad-8595-4028-b762-d6b8eb45e3a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c4ada351-2ef0-47a6-973e-f6e48c2f634c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dd7214ad-8595-4028-b762-d6b8eb45e3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_31c4e4b6-3644-4814-834c-13d165330ce8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c4ada351-2ef0-47a6-973e-f6e48c2f634c" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_31c4e4b6-3644-4814-834c-13d165330ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_04c9339d-3578-489d-8a19-83c94dedddc0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c4ada351-2ef0-47a6-973e-f6e48c2f634c" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_04c9339d-3578-489d-8a19-83c94dedddc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_a64feb0e-ef80-4553-a630-04f38808ae1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c4ada351-2ef0-47a6-973e-f6e48c2f634c" xlink:to="loc_us-gaap_RepaymentsOfDebt_a64feb0e-ef80-4553-a630-04f38808ae1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_ad352a61-6d69-4d36-9c8a-50cd50ee4857" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c4ada351-2ef0-47a6-973e-f6e48c2f634c" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_ad352a61-6d69-4d36-9c8a-50cd50ee4857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_8583bc28-c927-450a-94b0-363e32d6fd8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c4ada351-2ef0-47a6-973e-f6e48c2f634c" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_8583bc28-c927-450a-94b0-363e32d6fd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_4fab73c7-658a-4406-b1f6-ca419b766a1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c4ada351-2ef0-47a6-973e-f6e48c2f634c" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_4fab73c7-658a-4406-b1f6-ca419b766a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5029ab76-fd6e-4c16-ad2a-0006dfab7dac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ee0e5a26-456f-40d9-adb1-b1a6a49b1634" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5029ab76-fd6e-4c16-ad2a-0006dfab7dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c4fa6fcf-66aa-4a71-aeb8-c2292b3522e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ee0e5a26-456f-40d9-adb1-b1a6a49b1634" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c4fa6fcf-66aa-4a71-aeb8-c2292b3522e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8e086535-cd79-4a52-8596-ad08f0d401cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ee0e5a26-456f-40d9-adb1-b1a6a49b1634" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8e086535-cd79-4a52-8596-ad08f0d401cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c57b90c6-99fd-4b74-887c-91248c487ae9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ee0e5a26-456f-40d9-adb1-b1a6a49b1634" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c57b90c6-99fd-4b74-887c-91248c487ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0ca5f315-fb82-4a8f-a81c-7e42c7896103" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ee0e5a26-456f-40d9-adb1-b1a6a49b1634" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0ca5f315-fb82-4a8f-a81c-7e42c7896103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_0493c040-f346-455a-a0fc-9b36c8eb380b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ee0e5a26-456f-40d9-adb1-b1a6a49b1634" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_0493c040-f346-455a-a0fc-9b36c8eb380b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_9ebb3772-b87f-4fb1-a27b-16450342e8e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_0493c040-f346-455a-a0fc-9b36c8eb380b" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_9ebb3772-b87f-4fb1-a27b-16450342e8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_31ae7bef-7bf8-4798-9c4e-70bb4d2f4d2e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_0493c040-f346-455a-a0fc-9b36c8eb380b" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_31ae7bef-7bf8-4798-9c4e-70bb4d2f4d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost_bcc709c3-74d0-43a9-9322-439a20b2cd15" xlink:href="ocgn-20191231.xsd#ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_0493c040-f346-455a-a0fc-9b36c8eb380b" xlink:to="loc_ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost_bcc709c3-74d0-43a9-9322-439a20b2cd15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset_e1964d26-4598-4513-bc51-84f24d0f4b8c" xlink:href="ocgn-20191231.xsd#ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_0493c040-f346-455a-a0fc-9b36c8eb380b" xlink:to="loc_ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset_e1964d26-4598-4513-bc51-84f24d0f4b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction_e6ebd3b3-9118-40a6-a7b7-f358e9e37394" xlink:href="ocgn-20191231.xsd#ocgn_DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_0493c040-f346-455a-a0fc-9b36c8eb380b" xlink:to="loc_ocgn_DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction_e6ebd3b3-9118-40a6-a7b7-f358e9e37394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/NatureofBusiness" xlink:type="simple" xlink:href="ocgn-20191231.xsd#NatureofBusiness"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/NatureofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e937dba3-478e-4ac6-a336-c2712120ec7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_da667e37-00d5-4740-a2bd-5eb16380ea96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e937dba3-478e-4ac6-a336-c2712120ec7f" xlink:to="loc_us-gaap_NatureOfOperations_da667e37-00d5-4740-a2bd-5eb16380ea96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/NatureofBusinessReverseStockSplitDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#NatureofBusinessReverseStockSplitDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/NatureofBusinessReverseStockSplitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4b6d25a8-4b3c-4ce7-87ba-73a8dcbb7300" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_59c284d4-fbe0-41fe-871b-addceaba2614" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4b6d25a8-4b3c-4ce7-87ba-73a8dcbb7300" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_59c284d4-fbe0-41fe-871b-addceaba2614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_63cf38d4-8f3f-42af-8f11-6f7404399170" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_59c284d4-fbe0-41fe-871b-addceaba2614" xlink:to="loc_dei_LegalEntityAxis_63cf38d4-8f3f-42af-8f11-6f7404399170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_453b1ffc-980a-40ef-b8ec-81d047376196" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_63cf38d4-8f3f-42af-8f11-6f7404399170" xlink:to="loc_dei_EntityDomain_453b1ffc-980a-40ef-b8ec-81d047376196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_HistogenicsCorporationMember_a47ff01b-9bd7-4524-b6c0-fb40a01b6ec7" xlink:href="ocgn-20191231.xsd#ocgn_HistogenicsCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_453b1ffc-980a-40ef-b8ec-81d047376196" xlink:to="loc_ocgn_HistogenicsCorporationMember_a47ff01b-9bd7-4524-b6c0-fb40a01b6ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_81cad3ab-b657-48ed-ac6e-052b16ece416" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_59c284d4-fbe0-41fe-871b-addceaba2614" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_81cad3ab-b657-48ed-ac6e-052b16ece416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_5bcdbfcb-b6d3-4177-874a-b348b9317bcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_81cad3ab-b657-48ed-ac6e-052b16ece416" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_5bcdbfcb-b6d3-4177-874a-b348b9317bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_BusinessCombinationIssuedSharesExchangeRate_3db1da20-afc4-4d40-acb2-54f420080e5d" xlink:href="ocgn-20191231.xsd#ocgn_BusinessCombinationIssuedSharesExchangeRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_81cad3ab-b657-48ed-ac6e-052b16ece416" xlink:to="loc_ocgn_BusinessCombinationIssuedSharesExchangeRate_3db1da20-afc4-4d40-acb2-54f420080e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/NatureofBusinessGoingConcernDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#NatureofBusinessGoingConcernDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/NatureofBusinessGoingConcernDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8ddbe7c-2f71-4d8e-ba1e-7211a2c3cc1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3462158f-28fc-44c7-a6b2-27c16f118a77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8ddbe7c-2f71-4d8e-ba1e-7211a2c3cc1d" xlink:to="loc_us-gaap_NetIncomeLoss_3462158f-28fc-44c7-a6b2-27c16f118a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c759f055-8024-434e-a369-6bd12652c8d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8ddbe7c-2f71-4d8e-ba1e-7211a2c3cc1d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c759f055-8024-434e-a369-6bd12652c8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_30f646d2-7be9-4a36-a929-331cf855b3f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8ddbe7c-2f71-4d8e-ba1e-7211a2c3cc1d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_30f646d2-7be9-4a36-a929-331cf855b3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ocgn-20191231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_577fa748-4091-4543-b7c3-9a616647082e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_e818c2d1-902f-4e88-81bb-757b31187a48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_577fa748-4091-4543-b7c3-9a616647082e" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_e818c2d1-902f-4e88-81bb-757b31187a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ocgn-20191231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fce3b524-f1ab-43d0-9720-5a3e1b2981e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_71eaf1fd-e94b-4610-857c-2d824aad6c3f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fce3b524-f1ab-43d0-9720-5a3e1b2981e7" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_71eaf1fd-e94b-4610-857c-2d824aad6c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_defc3557-9c44-42f8-8301-5dd8da4f255c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fce3b524-f1ab-43d0-9720-5a3e1b2981e7" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_defc3557-9c44-42f8-8301-5dd8da4f255c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_f5da5e52-8ac3-48c8-877c-f86511f9cb90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fce3b524-f1ab-43d0-9720-5a3e1b2981e7" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_f5da5e52-8ac3-48c8-877c-f86511f9cb90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_b193afda-7283-4829-951d-fc6cd5ac4552" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fce3b524-f1ab-43d0-9720-5a3e1b2981e7" xlink:to="loc_us-gaap_UseOfEstimates_b193afda-7283-4829-951d-fc6cd5ac4552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AssetHeldForSalePolicyTextBlock_0bc73af1-34d7-4e40-b5fe-3e1f4351c2ae" xlink:href="ocgn-20191231.xsd#ocgn_AssetHeldForSalePolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fce3b524-f1ab-43d0-9720-5a3e1b2981e7" xlink:to="loc_ocgn_AssetHeldForSalePolicyTextBlock_0bc73af1-34d7-4e40-b5fe-3e1f4351c2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8cc27621-30d6-4a5d-8336-c5d68a8419a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fce3b524-f1ab-43d0-9720-5a3e1b2981e7" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8cc27621-30d6-4a5d-8336-c5d68a8419a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_DerivativeInstrumentsAndHedgingActivitiesDisclosurePolicyTextBlock_4fc108fe-5de3-4ee3-8eb4-66c5c9c4f27d" xlink:href="ocgn-20191231.xsd#ocgn_DerivativeInstrumentsAndHedgingActivitiesDisclosurePolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fce3b524-f1ab-43d0-9720-5a3e1b2981e7" xlink:to="loc_ocgn_DerivativeInstrumentsAndHedgingActivitiesDisclosurePolicyTextBlock_4fc108fe-5de3-4ee3-8eb4-66c5c9c4f27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_bb684cf6-2e90-4e88-b124-3ef1a58ed70e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fce3b524-f1ab-43d0-9720-5a3e1b2981e7" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_bb684cf6-2e90-4e88-b124-3ef1a58ed70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3594025b-a5bc-4dce-918a-8eb7c0745bac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fce3b524-f1ab-43d0-9720-5a3e1b2981e7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3594025b-a5bc-4dce-918a-8eb7c0745bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_a411a234-664e-49dc-b6f8-79e16b0893a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fce3b524-f1ab-43d0-9720-5a3e1b2981e7" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_a411a234-664e-49dc-b6f8-79e16b0893a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2b2c8598-9a81-473b-92cd-e58e7ba897e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fce3b524-f1ab-43d0-9720-5a3e1b2981e7" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2b2c8598-9a81-473b-92cd-e58e7ba897e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_a0f4b8d0-2f58-4baf-ab2e-2759651ed2cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fce3b524-f1ab-43d0-9720-5a3e1b2981e7" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_a0f4b8d0-2f58-4baf-ab2e-2759651ed2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_0a008cf2-9b7b-4187-8b6b-8c03d8b30f98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fce3b524-f1ab-43d0-9720-5a3e1b2981e7" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_0a008cf2-9b7b-4187-8b6b-8c03d8b30f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_74a162cc-9541-4d4e-8afd-fab695a62927" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fce3b524-f1ab-43d0-9720-5a3e1b2981e7" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_74a162cc-9541-4d4e-8afd-fab695a62927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ocgn-20191231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ef6a1bca-2690-4ecb-ab93-25b3e4d0a293" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_6e2ca0c0-84c9-46c0-bbd6-12753f4f7705" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ef6a1bca-2690-4ecb-ab93-25b3e4d0a293" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_6e2ca0c0-84c9-46c0-bbd6-12753f4f7705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_d064c4b5-aa94-4029-a811-1876400f97b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ef6a1bca-2690-4ecb-ab93-25b3e4d0a293" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_d064c4b5-aa94-4029-a811-1876400f97b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2be43d59-0a4a-4b25-b83a-a22124051b57" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_c09ab41a-c379-4586-840e-21ed2a4f0387" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2be43d59-0a4a-4b25-b83a-a22124051b57" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_c09ab41a-c379-4586-840e-21ed2a4f0387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_d050879b-422b-4131-858b-d04f3e8efdbb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_c09ab41a-c379-4586-840e-21ed2a4f0387" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_d050879b-422b-4131-858b-d04f3e8efdbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_c0de1e4f-6af2-4680-8bf8-8a6e5342ab0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_d050879b-422b-4131-858b-d04f3e8efdbb" xlink:to="loc_us-gaap_TypeOfAdoptionMember_c0de1e4f-6af2-4680-8bf8-8a6e5342ab0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_e07bdb60-c479-43c2-a3f8-01f753bdff29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_c0de1e4f-6af2-4680-8bf8-8a6e5342ab0b" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_e07bdb60-c479-43c2-a3f8-01f753bdff29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d0b17f94-31aa-410a-bb87-26d84d13ae68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_c09ab41a-c379-4586-840e-21ed2a4f0387" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d0b17f94-31aa-410a-bb87-26d84d13ae68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ff324dc0-9ac7-4192-8882-2ce282e8fca0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d0b17f94-31aa-410a-bb87-26d84d13ae68" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ff324dc0-9ac7-4192-8882-2ce282e8fca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_b3acb432-ea02-458c-82a0-cd67ebb84ff8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ff324dc0-9ac7-4192-8882-2ce282e8fca0" xlink:to="loc_us-gaap_EquipmentMember_b3acb432-ea02-458c-82a0-cd67ebb84ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_4b41f533-e9d4-429f-8e4e-c26af5599084" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ff324dc0-9ac7-4192-8882-2ce282e8fca0" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_4b41f533-e9d4-429f-8e4e-c26af5599084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EquipmentAndFurnitureMember_b56bedaa-9c26-421e-8faf-c6355e8306ac" xlink:href="ocgn-20191231.xsd#ocgn_EquipmentAndFurnitureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ff324dc0-9ac7-4192-8882-2ce282e8fca0" xlink:to="loc_ocgn_EquipmentAndFurnitureMember_b56bedaa-9c26-421e-8faf-c6355e8306ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_549d5383-c78c-4cfe-a5d9-024733d4ec89" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_c09ab41a-c379-4586-840e-21ed2a4f0387" xlink:to="loc_srt_RangeAxis_549d5383-c78c-4cfe-a5d9-024733d4ec89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_50a2a104-7079-41d1-8158-26bad3ea19e3" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_549d5383-c78c-4cfe-a5d9-024733d4ec89" xlink:to="loc_srt_RangeMember_50a2a104-7079-41d1-8158-26bad3ea19e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ac0d3daf-5140-4b30-bd1b-bc4aa1434b7e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_50a2a104-7079-41d1-8158-26bad3ea19e3" xlink:to="loc_srt_MinimumMember_ac0d3daf-5140-4b30-bd1b-bc4aa1434b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_00c15e08-6103-470b-bda8-53021a6041ff" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_50a2a104-7079-41d1-8158-26bad3ea19e3" xlink:to="loc_srt_MaximumMember_00c15e08-6103-470b-bda8-53021a6041ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_438565da-3aa6-4168-a510-716667bc67de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_c09ab41a-c379-4586-840e-21ed2a4f0387" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_438565da-3aa6-4168-a510-716667bc67de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_cad6a211-957b-4b72-a79d-2af4713dbed3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_438565da-3aa6-4168-a510-716667bc67de" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_cad6a211-957b-4b72-a79d-2af4713dbed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_453673ea-4099-421f-8789-2ec81d25230d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_438565da-3aa6-4168-a510-716667bc67de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_453673ea-4099-421f-8789-2ec81d25230d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9ff33384-62f9-46fb-b09a-c90f3fcc3efd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_438565da-3aa6-4168-a510-716667bc67de" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9ff33384-62f9-46fb-b09a-c90f3fcc3efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3f7a1c49-cf5f-475f-8c53-71b292cba617" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_438565da-3aa6-4168-a510-716667bc67de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3f7a1c49-cf5f-475f-8c53-71b292cba617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_f6318bfc-3fc7-47a4-9fb7-0df0280c9743" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_438565da-3aa6-4168-a510-716667bc67de" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_f6318bfc-3fc7-47a4-9fb7-0df0280c9743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_01a564f2-34bc-4109-831c-33c7e04409ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_438565da-3aa6-4168-a510-716667bc67de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_01a564f2-34bc-4109-831c-33c7e04409ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_23ea6729-f0b7-4d8a-aa26-23a873822574" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_438565da-3aa6-4168-a510-716667bc67de" xlink:to="loc_us-gaap_NumberOfOperatingSegments_23ea6729-f0b7-4d8a-aa26-23a873822574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LeaseRightOfUseAsset_b21e3d21-7a7e-4e0f-bcf2-6a34234a340b" xlink:href="ocgn-20191231.xsd#ocgn_LeaseRightOfUseAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_438565da-3aa6-4168-a510-716667bc67de" xlink:to="loc_ocgn_LeaseRightOfUseAsset_b21e3d21-7a7e-4e0f-bcf2-6a34234a340b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LeaseLiability_b711cdad-6663-402a-a089-0a61adcaee64" xlink:href="ocgn-20191231.xsd#ocgn_LeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_438565da-3aa6-4168-a510-716667bc67de" xlink:to="loc_ocgn_LeaseLiability_b711cdad-6663-402a-a089-0a61adcaee64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesSummaryCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#SummaryofSignificantAccountingPoliciesSummaryCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesSummaryCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_dcdd0c70-16c9-4875-97f5-d56a76bfb9c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_baa166f2-b58d-4192-ad1b-5106c2c05f4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dcdd0c70-16c9-4875-97f5-d56a76bfb9c5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_baa166f2-b58d-4192-ad1b-5106c2c05f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6cb7d70a-e513-4b70-be55-be7511ab02fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_baa166f2-b58d-4192-ad1b-5106c2c05f4a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6cb7d70a-e513-4b70-be55-be7511ab02fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_b9ccdcc6-624f-4886-9fbc-215d4d2ae9ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_baa166f2-b58d-4192-ad1b-5106c2c05f4a" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_b9ccdcc6-624f-4886-9fbc-215d4d2ae9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_db47bbc3-3b59-4a03-9015-832dfcf9ba6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_baa166f2-b58d-4192-ad1b-5106c2c05f4a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_db47bbc3-3b59-4a03-9015-832dfcf9ba6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/MergerandPreMergerFinancing" xlink:type="simple" xlink:href="ocgn-20191231.xsd#MergerandPreMergerFinancing"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/MergerandPreMergerFinancing" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_804303cd-a5e6-46ae-ac69-04f871d57f2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_29573ffe-a7f1-4e15-8c41-241aa589d158" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_804303cd-a5e6-46ae-ac69-04f871d57f2b" xlink:to="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_29573ffe-a7f1-4e15-8c41-241aa589d158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/MergerandPreMergerFinancingTables" xlink:type="simple" xlink:href="ocgn-20191231.xsd#MergerandPreMergerFinancingTables"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/MergerandPreMergerFinancingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_b5140d11-0cf8-4bcc-b7d4-72fe5cb3bfff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_25335cf9-8ef2-4253-8326-1947eaf9f8c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_b5140d11-0cf8-4bcc-b7d4-72fe5cb3bfff" xlink:to="loc_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_25335cf9-8ef2-4253-8326-1947eaf9f8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#MergerandFinancingPreMergerFinancingDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_3c76b7f4-26a9-4da7-a248-c47f936790bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ReverseMergerAndFinancingDisclosureTable_eec8600d-e313-408e-82c5-f5eb05bf8a6c" xlink:href="ocgn-20191231.xsd#ocgn_ReverseMergerAndFinancingDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3c76b7f4-26a9-4da7-a248-c47f936790bd" xlink:to="loc_ocgn_ReverseMergerAndFinancingDisclosureTable_eec8600d-e313-408e-82c5-f5eb05bf8a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7ef20d1d-c191-46d3-97eb-dc1d638706d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureTable_eec8600d-e313-408e-82c5-f5eb05bf8a6c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7ef20d1d-c191-46d3-97eb-dc1d638706d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d10ac1d9-d452-44f4-95f0-32bf271ecd2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7ef20d1d-c191-46d3-97eb-dc1d638706d7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d10ac1d9-d452-44f4-95f0-32bf271ecd2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SecuritiesPurchaseAgreementMember_a8ca2bd3-6acb-43ff-b04d-bc1862c62634" xlink:href="ocgn-20191231.xsd#ocgn_SecuritiesPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d10ac1d9-d452-44f4-95f0-32bf271ecd2a" xlink:to="loc_ocgn_SecuritiesPurchaseAgreementMember_a8ca2bd3-6acb-43ff-b04d-bc1862c62634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_19ddbd6f-a5cd-4b59-9519-1298513782e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureTable_eec8600d-e313-408e-82c5-f5eb05bf8a6c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_19ddbd6f-a5cd-4b59-9519-1298513782e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_475eafc7-bc43-4f6d-b292-1eab6050981f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_19ddbd6f-a5cd-4b59-9519-1298513782e5" xlink:to="loc_us-gaap_EquityComponentDomain_475eafc7-bc43-4f6d-b292-1eab6050981f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesAWarrantsAndSeriesCWarrantsMember_006dd1a5-a934-4615-92df-98180aa4c7f5" xlink:href="ocgn-20191231.xsd#ocgn_SeriesAWarrantsAndSeriesCWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_475eafc7-bc43-4f6d-b292-1eab6050981f" xlink:to="loc_ocgn_SeriesAWarrantsAndSeriesCWarrantsMember_006dd1a5-a934-4615-92df-98180aa4c7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesBWarrantsMember_75163fcd-8a23-4fcc-b560-763d2feecc8e" xlink:href="ocgn-20191231.xsd#ocgn_SeriesBWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_475eafc7-bc43-4f6d-b292-1eab6050981f" xlink:to="loc_ocgn_SeriesBWarrantsMember_75163fcd-8a23-4fcc-b560-763d2feecc8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0ab65acb-9bf2-499b-9318-b896dacd18b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureTable_eec8600d-e313-408e-82c5-f5eb05bf8a6c" xlink:to="loc_us-gaap_DebtInstrumentAxis_0ab65acb-9bf2-499b-9318-b896dacd18b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_30853bb9-3e47-417c-9234-73f165d2522a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_0ab65acb-9bf2-499b-9318-b896dacd18b0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_30853bb9-3e47-417c-9234-73f165d2522a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeniorSecuredConvertibleNotesMember_57d1e7e2-9f67-43dc-98d5-e588b7c2948e" xlink:href="ocgn-20191231.xsd#ocgn_SeniorSecuredConvertibleNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30853bb9-3e47-417c-9234-73f165d2522a" xlink:to="loc_ocgn_SeniorSecuredConvertibleNotesMember_57d1e7e2-9f67-43dc-98d5-e588b7c2948e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ReverseMergerAndFinancingDisclosureLineItems_42bfdcca-c69f-4fc8-9008-0b2269eb3098" xlink:href="ocgn-20191231.xsd#ocgn_ReverseMergerAndFinancingDisclosureLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureTable_eec8600d-e313-408e-82c5-f5eb05bf8a6c" xlink:to="loc_ocgn_ReverseMergerAndFinancingDisclosureLineItems_42bfdcca-c69f-4fc8-9008-0b2269eb3098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfSharesAgreedToIssuePriorToMergerToInvestors_728acffb-a374-4696-9d4d-98e59f84fcb3" xlink:href="ocgn-20191231.xsd#ocgn_NumberOfSharesAgreedToIssuePriorToMergerToInvestors"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureLineItems_42bfdcca-c69f-4fc8-9008-0b2269eb3098" xlink:to="loc_ocgn_NumberOfSharesAgreedToIssuePriorToMergerToInvestors_728acffb-a374-4696-9d4d-98e59f84fcb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfConvertedInitialSharesAgreedToIssuePriorToMergerToInvestors_f424d735-20e6-4cd8-b14b-b56fdba803ac" xlink:href="ocgn-20191231.xsd#ocgn_NumberOfConvertedInitialSharesAgreedToIssuePriorToMergerToInvestors"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureLineItems_42bfdcca-c69f-4fc8-9008-0b2269eb3098" xlink:to="loc_ocgn_NumberOfConvertedInitialSharesAgreedToIssuePriorToMergerToInvestors_f424d735-20e6-4cd8-b14b-b56fdba803ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfConvertedAdditionalSharesAgreedToIssuePriorToMergerToInvestors_fab2f876-e716-4adb-a6fe-fe4c9bb043a4" xlink:href="ocgn-20191231.xsd#ocgn_NumberOfConvertedAdditionalSharesAgreedToIssuePriorToMergerToInvestors"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureLineItems_42bfdcca-c69f-4fc8-9008-0b2269eb3098" xlink:to="loc_ocgn_NumberOfConvertedAdditionalSharesAgreedToIssuePriorToMergerToInvestors_fab2f876-e716-4adb-a6fe-fe4c9bb043a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_d2a6304c-2b38-4866-a7b0-ccc3aabca69c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureLineItems_42bfdcca-c69f-4fc8-9008-0b2269eb3098" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_d2a6304c-2b38-4866-a7b0-ccc3aabca69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger_c540539d-a4b8-46f8-912c-8dcc25b69cde" xlink:href="ocgn-20191231.xsd#ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureLineItems_42bfdcca-c69f-4fc8-9008-0b2269eb3098" xlink:to="loc_ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger_c540539d-a4b8-46f8-912c-8dcc25b69cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPeriod_08c7fe91-3fc0-4cb4-80a5-acec8685edd6" xlink:href="ocgn-20191231.xsd#ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureLineItems_42bfdcca-c69f-4fc8-9008-0b2269eb3098" xlink:to="loc_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPeriod_08c7fe91-3fc0-4cb4-80a5-acec8685edd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_MergerAcquisitionCostsIncurred_c0849ee6-b8ee-4a2b-a317-266fefbe1878" xlink:href="ocgn-20191231.xsd#ocgn_MergerAcquisitionCostsIncurred"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureLineItems_42bfdcca-c69f-4fc8-9008-0b2269eb3098" xlink:to="loc_ocgn_MergerAcquisitionCostsIncurred_c0849ee6-b8ee-4a2b-a317-266fefbe1878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_1f96306b-841c-46df-99d3-f72e6342eaed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureLineItems_42bfdcca-c69f-4fc8-9008-0b2269eb3098" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_1f96306b-841c-46df-99d3-f72e6342eaed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_StockIssuanceCostsRecognized_c34bc844-9322-45d6-82a6-8290e59a280c" xlink:href="ocgn-20191231.xsd#ocgn_StockIssuanceCostsRecognized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureLineItems_42bfdcca-c69f-4fc8-9008-0b2269eb3098" xlink:to="loc_ocgn_StockIssuanceCostsRecognized_c34bc844-9322-45d6-82a6-8290e59a280c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_96766263-29ce-4466-bbc7-22e2e3dc812c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureLineItems_42bfdcca-c69f-4fc8-9008-0b2269eb3098" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_96766263-29ce-4466-bbc7-22e2e3dc812c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_02728bdc-ae2d-4969-95c6-5f8705067fc3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureLineItems_42bfdcca-c69f-4fc8-9008-0b2269eb3098" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_02728bdc-ae2d-4969-95c6-5f8705067fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NetProceedsFromReverseMerger_f4b3841b-d40f-40cc-9544-9abdace0f1ff" xlink:href="ocgn-20191231.xsd#ocgn_NetProceedsFromReverseMerger"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ocgn_ReverseMergerAndFinancingDisclosureLineItems_42bfdcca-c69f-4fc8-9008-0b2269eb3098" xlink:to="loc_ocgn_NetProceedsFromReverseMerger_f4b3841b-d40f-40cc-9544-9abdace0f1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#MergerandFinancingMergerwithHistogenicsDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_9f686b31-ee76-4b8a-814c-fee20e7ce3b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bab71755-24c3-4f92-853a-9c678313566c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_9f686b31-ee76-4b8a-814c-fee20e7ce3b6" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bab71755-24c3-4f92-853a-9c678313566c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_0aee939e-61b2-4fca-bffe-6250c40c7f40" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bab71755-24c3-4f92-853a-9c678313566c" xlink:to="loc_dei_LegalEntityAxis_0aee939e-61b2-4fca-bffe-6250c40c7f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9ba4f696-10cb-4be0-a54a-a359fd91daa3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_0aee939e-61b2-4fca-bffe-6250c40c7f40" xlink:to="loc_dei_EntityDomain_9ba4f696-10cb-4be0-a54a-a359fd91daa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EquityHoldersOfOcugenIncPerMergerMember_408d1de7-3e6c-48cb-b600-e4758162fec4" xlink:href="ocgn-20191231.xsd#ocgn_EquityHoldersOfOcugenIncPerMergerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9ba4f696-10cb-4be0-a54a-a359fd91daa3" xlink:to="loc_ocgn_EquityHoldersOfOcugenIncPerMergerMember_408d1de7-3e6c-48cb-b600-e4758162fec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EquityHoldersOfHistogenicsCorporationMember_089441e1-d1c5-49d7-a593-797201e9eb4f" xlink:href="ocgn-20191231.xsd#ocgn_EquityHoldersOfHistogenicsCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9ba4f696-10cb-4be0-a54a-a359fd91daa3" xlink:to="loc_ocgn_EquityHoldersOfHistogenicsCorporationMember_089441e1-d1c5-49d7-a593-797201e9eb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_HistogenicsCorporationMember_33dbf45c-d2f5-4d05-ada8-9737447d9bdd" xlink:href="ocgn-20191231.xsd#ocgn_HistogenicsCorporationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9ba4f696-10cb-4be0-a54a-a359fd91daa3" xlink:to="loc_ocgn_HistogenicsCorporationMember_33dbf45c-d2f5-4d05-ada8-9737447d9bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a8a167cb-ae3e-4d60-aea7-fdcbad627c7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bab71755-24c3-4f92-853a-9c678313566c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a8a167cb-ae3e-4d60-aea7-fdcbad627c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c9d037d7-e804-48bb-8513-0245a606b5d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a8a167cb-ae3e-4d60-aea7-fdcbad627c7b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c9d037d7-e804-48bb-8513-0245a606b5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_HistogenicsCorporationMember_69af2b9c-6917-4ef7-98d0-fb61cc050c03" xlink:href="ocgn-20191231.xsd#ocgn_HistogenicsCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c9d037d7-e804-48bb-8513-0245a606b5d7" xlink:to="loc_ocgn_HistogenicsCorporationMember_69af2b9c-6917-4ef7-98d0-fb61cc050c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NeocartMember_82900093-e31c-4133-a45c-23b280941f42" xlink:href="ocgn-20191231.xsd#ocgn_NeocartMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c9d037d7-e804-48bb-8513-0245a606b5d7" xlink:to="loc_ocgn_NeocartMember_82900093-e31c-4133-a45c-23b280941f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_286ac42c-49ff-4294-acef-490d769f89e4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bab71755-24c3-4f92-853a-9c678313566c" xlink:to="loc_srt_OwnershipAxis_286ac42c-49ff-4294-acef-490d769f89e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_d036b66b-9870-489c-a438-d1d358e26952" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_286ac42c-49ff-4294-acef-490d769f89e4" xlink:to="loc_srt_OwnershipDomain_d036b66b-9870-489c-a438-d1d358e26952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_HistogenicsCorporationMember_405440ae-2a61-4b73-a171-5d1d5b066d2d" xlink:href="ocgn-20191231.xsd#ocgn_HistogenicsCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_d036b66b-9870-489c-a438-d1d358e26952" xlink:to="loc_ocgn_HistogenicsCorporationMember_405440ae-2a61-4b73-a171-5d1d5b066d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9abe2ec5-6b38-429d-8ba3-e9ff40f65c8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bab71755-24c3-4f92-853a-9c678313566c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9abe2ec5-6b38-429d-8ba3-e9ff40f65c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a81818e9-a0b6-433c-ae6a-5a9f0efe6de7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9abe2ec5-6b38-429d-8ba3-e9ff40f65c8a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a81818e9-a0b6-433c-ae6a-5a9f0efe6de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_889c1c76-3ad7-4c15-bc01-c1ac86b1ada5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a81818e9-a0b6-433c-ae6a-5a9f0efe6de7" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_889c1c76-3ad7-4c15-bc01-c1ac86b1ada5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f555f0ad-0ecb-4877-aa9e-ec3284baf58f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bab71755-24c3-4f92-853a-9c678313566c" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_f555f0ad-0ecb-4877-aa9e-ec3284baf58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_26d56bde-f554-4d3b-822c-fe4f7c8fc6e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f555f0ad-0ecb-4877-aa9e-ec3284baf58f" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_26d56bde-f554-4d3b-822c-fe4f7c8fc6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_1e9db7f6-217d-47e5-b0f8-de8276c29a4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f555f0ad-0ecb-4877-aa9e-ec3284baf58f" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_1e9db7f6-217d-47e5-b0f8-de8276c29a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForMergerRelatedCosts_7409e706-9cd4-48f9-97c6-9c07bd243825" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForMergerRelatedCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f555f0ad-0ecb-4877-aa9e-ec3284baf58f" xlink:to="loc_us-gaap_PaymentsForMergerRelatedCosts_7409e706-9cd4-48f9-97c6-9c07bd243825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AdjustmentsToAdditionalPaidInCapitalMergerRelatedCosts_d65cbfae-2e86-4f1c-800a-6ee6299213a2" xlink:href="ocgn-20191231.xsd#ocgn_AdjustmentsToAdditionalPaidInCapitalMergerRelatedCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f555f0ad-0ecb-4877-aa9e-ec3284baf58f" xlink:to="loc_ocgn_AdjustmentsToAdditionalPaidInCapitalMergerRelatedCosts_d65cbfae-2e86-4f1c-800a-6ee6299213a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_86ca139c-1e20-481e-9a54-5b558ff08408" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f555f0ad-0ecb-4877-aa9e-ec3284baf58f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_86ca139c-1e20-481e-9a54-5b558ff08408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AssetsHeldForSale_bafc3133-56cb-4f64-b0d4-14654f9475d5" xlink:href="ocgn-20191231.xsd#ocgn_AssetsHeldForSale"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f555f0ad-0ecb-4877-aa9e-ec3284baf58f" xlink:to="loc_ocgn_AssetsHeldForSale_bafc3133-56cb-4f64-b0d4-14654f9475d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4f73a10e-cfd7-4011-af56-74a0eaee36c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f555f0ad-0ecb-4877-aa9e-ec3284baf58f" xlink:to="loc_us-gaap_AccountsPayableCurrent_4f73a10e-cfd7-4011-af56-74a0eaee36c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNet_77e1602c-cd78-4aba-96f1-e855666ab29d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f555f0ad-0ecb-4877-aa9e-ec3284baf58f" xlink:to="loc_us-gaap_AssetsNet_77e1602c-cd78-4aba-96f1-e855666ab29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AssetPurchaseAgreementCashConsideration_521e14f6-eb07-42a7-94e4-4136c58fb291" xlink:href="ocgn-20191231.xsd#ocgn_AssetPurchaseAgreementCashConsideration"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f555f0ad-0ecb-4877-aa9e-ec3284baf58f" xlink:to="loc_ocgn_AssetPurchaseAgreementCashConsideration_521e14f6-eb07-42a7-94e4-4136c58fb291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_PercentageOfIncreaseInPurchasePriceOfAssetPerMonth_de96bb4c-478a-4832-bed7-6d20e1716a5b" xlink:href="ocgn-20191231.xsd#ocgn_PercentageOfIncreaseInPurchasePriceOfAssetPerMonth"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f555f0ad-0ecb-4877-aa9e-ec3284baf58f" xlink:to="loc_ocgn_PercentageOfIncreaseInPurchasePriceOfAssetPerMonth_de96bb4c-478a-4832-bed7-6d20e1716a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_fd728220-f708-4384-bfef-a6f680c10529" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f555f0ad-0ecb-4877-aa9e-ec3284baf58f" xlink:to="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_fd728220-f708-4384-bfef-a6f680c10529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_57ec5450-5307-4b64-9b9e-7a1a6ba87458" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f555f0ad-0ecb-4877-aa9e-ec3284baf58f" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_57ec5450-5307-4b64-9b9e-7a1a6ba87458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStock" xlink:type="simple" xlink:href="ocgn-20191231.xsd#NetLossPerShareofCommonStock"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_712c4b48-0cd4-44b8-b2c6-599c3dc785b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_0cdda319-e431-4495-9ab7-2ec73e227518" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_712c4b48-0cd4-44b8-b2c6-599c3dc785b6" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_0cdda319-e431-4495-9ab7-2ec73e227518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockTables" xlink:type="simple" xlink:href="ocgn-20191231.xsd#NetLossPerShareofCommonStockTables"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_846815d2-b104-40d8-9822-19fe2c53a835" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8a838890-6fcb-4319-b15b-2b99cfa24979" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_846815d2-b104-40d8-9822-19fe2c53a835" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8a838890-6fcb-4319-b15b-2b99cfa24979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_578d7a09-8a7f-4918-b93d-e3dc089dc080" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_846815d2-b104-40d8-9822-19fe2c53a835" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_578d7a09-8a7f-4918-b93d-e3dc089dc080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#NetLossPerShareofCommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9884bc01-9ceb-4b94-a1db-36a8cb158656" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_66ed097e-5c41-4e5d-ac8a-2bab2dd6097f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9884bc01-9ceb-4b94-a1db-36a8cb158656" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_66ed097e-5c41-4e5d-ac8a-2bab2dd6097f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c9698c6c-95d1-4ba2-9bc7-744fe4547591" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_66ed097e-5c41-4e5d-ac8a-2bab2dd6097f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c9698c6c-95d1-4ba2-9bc7-744fe4547591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3fe6daa9-d2b4-4456-9569-925476ea2768" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c9698c6c-95d1-4ba2-9bc7-744fe4547591" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3fe6daa9-d2b4-4456-9569-925476ea2768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_c8362cfb-99ee-4c87-a93b-feeb1a4ce1ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3fe6daa9-d2b4-4456-9569-925476ea2768" xlink:to="loc_us-gaap_StockOptionMember_c8362cfb-99ee-4c87-a93b-feeb1a4ce1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_f0994b6d-8e5d-42b8-a4b0-b89aed261a02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3fe6daa9-d2b4-4456-9569-925476ea2768" xlink:to="loc_us-gaap_WarrantMember_f0994b6d-8e5d-42b8-a4b0-b89aed261a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesWarrantsMember_4d4a0b3f-4d56-4514-a3d8-a56597676bf2" xlink:href="ocgn-20191231.xsd#ocgn_SeriesWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3fe6daa9-d2b4-4456-9569-925476ea2768" xlink:to="loc_ocgn_SeriesWarrantsMember_4d4a0b3f-4d56-4514-a3d8-a56597676bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesBWarrantsMember_c9170ef2-430c-402a-879f-9ef59dd82441" xlink:href="ocgn-20191231.xsd#ocgn_SeriesBWarrantsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3fe6daa9-d2b4-4456-9569-925476ea2768" xlink:to="loc_ocgn_SeriesBWarrantsMember_c9170ef2-430c-402a-879f-9ef59dd82441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesCWarrantsMember_9c277d86-2943-4f6b-a12a-3a7ba3014137" xlink:href="ocgn-20191231.xsd#ocgn_SeriesCWarrantsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3fe6daa9-d2b4-4456-9569-925476ea2768" xlink:to="loc_ocgn_SeriesCWarrantsMember_9c277d86-2943-4f6b-a12a-3a7ba3014137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d9507fab-1c27-464d-8c11-99640dfc7e49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_66ed097e-5c41-4e5d-ac8a-2bab2dd6097f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d9507fab-1c27-464d-8c11-99640dfc7e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_acd8d005-52d0-4aa1-b97d-fd9b2315a717" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d9507fab-1c27-464d-8c11-99640dfc7e49" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_acd8d005-52d0-4aa1-b97d-fd9b2315a717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6eec9029-c11d-4b1b-bcad-c23930d99de2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d9507fab-1c27-464d-8c11-99640dfc7e49" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6eec9029-c11d-4b1b-bcad-c23930d99de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c1895cd9-9aa6-49e2-8b90-3e5fadc25327" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d9507fab-1c27-464d-8c11-99640dfc7e49" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c1895cd9-9aa6-49e2-8b90-3e5fadc25327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_38a6a9d3-cedd-4b14-b928-843a5db029c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d9507fab-1c27-464d-8c11-99640dfc7e49" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_38a6a9d3-cedd-4b14-b928-843a5db029c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_5fb612d7-01f9-4bb9-bf16-dce905e4e34f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d9507fab-1c27-464d-8c11-99640dfc7e49" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_5fb612d7-01f9-4bb9-bf16-dce905e4e34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f6c1b75e-0def-460d-93be-f6758a95b26f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_5fb612d7-01f9-4bb9-bf16-dce905e4e34f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f6c1b75e-0def-460d-93be-f6758a95b26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/LicenseandCollaborationAgreements" xlink:type="simple" xlink:href="ocgn-20191231.xsd#LicenseandCollaborationAgreements"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/LicenseandCollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bced566e-f3e6-4c36-886d-b1aa60f98db6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_3150d9a1-5f48-4a7d-9b82-08bb21064c49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bced566e-f3e6-4c36-886d-b1aa60f98db6" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_3150d9a1-5f48-4a7d-9b82-08bb21064c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#LicenseandCollaborationAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e6a5909e-211c-4a9b-a88b-78e3cd38b8c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dfb93697-ca0b-4b25-a70d-f667d11cb704" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e6a5909e-211c-4a9b-a88b-78e3cd38b8c9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dfb93697-ca0b-4b25-a70d-f667d11cb704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0fd643f8-2e03-4dd6-bb9e-3564dd182dde" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dfb93697-ca0b-4b25-a70d-f667d11cb704" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0fd643f8-2e03-4dd6-bb9e-3564dd182dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d7d733bb-4368-4c1c-b11d-5cdb8324d1e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0fd643f8-2e03-4dd6-bb9e-3564dd182dde" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d7d733bb-4368-4c1c-b11d-5cdb8324d1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborationAgreementWithCansinoBiologicsMember_bb3be37f-f974-4642-82f1-76c979097b66" xlink:href="ocgn-20191231.xsd#ocgn_CollaborationAgreementWithCansinoBiologicsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d7d733bb-4368-4c1c-b11d-5cdb8324d1e7" xlink:to="loc_ocgn_CollaborationAgreementWithCansinoBiologicsMember_bb3be37f-f974-4642-82f1-76c979097b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SchepensEyeResearchInstituteMember_17be16cc-3fc2-4a89-bcb8-e53bef85c9b8" xlink:href="ocgn-20191231.xsd#ocgn_SchepensEyeResearchInstituteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d7d733bb-4368-4c1c-b11d-5cdb8324d1e7" xlink:to="loc_ocgn_SchepensEyeResearchInstituteMember_17be16cc-3fc2-4a89-bcb8-e53bef85c9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborationAgreementWithUniversityOfIllinoisChicagoMember_c28ad5f1-86b3-4d7f-92a9-ddac1bb4cf45" xlink:href="ocgn-20191231.xsd#ocgn_CollaborationAgreementWithUniversityOfIllinoisChicagoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d7d733bb-4368-4c1c-b11d-5cdb8324d1e7" xlink:to="loc_ocgn_CollaborationAgreementWithUniversityOfIllinoisChicagoMember_c28ad5f1-86b3-4d7f-92a9-ddac1bb4cf45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborationAgreementWithUniversityOfColoradoMember_bc39ebc8-4606-4ee8-a178-e5eadcfe3981" xlink:href="ocgn-20191231.xsd#ocgn_CollaborationAgreementWithUniversityOfColoradoMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d7d733bb-4368-4c1c-b11d-5cdb8324d1e7" xlink:to="loc_ocgn_CollaborationAgreementWithUniversityOfColoradoMember_bc39ebc8-4606-4ee8-a178-e5eadcfe3981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_8c414924-bd68-4319-b9bd-9987b1d92e26" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dfb93697-ca0b-4b25-a70d-f667d11cb704" xlink:to="loc_srt_StatementScenarioAxis_8c414924-bd68-4319-b9bd-9987b1d92e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_08982780-89c8-4d88-974a-eedd4c651583" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_8c414924-bd68-4319-b9bd-9987b1d92e26" xlink:to="loc_srt_ScenarioUnspecifiedDomain_08982780-89c8-4d88-974a-eedd4c651583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_0fcdb2be-40f8-4a6e-8ed8-4764566752fb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_08982780-89c8-4d88-974a-eedd4c651583" xlink:to="loc_srt_ScenarioForecastMember_0fcdb2be-40f8-4a6e-8ed8-4764566752fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d45ee091-1f92-4e63-ae9a-8943f4f57e53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dfb93697-ca0b-4b25-a70d-f667d11cb704" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d45ee091-1f92-4e63-ae9a-8943f4f57e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborationAgreementTerm_bc2cbf5d-d60d-434e-b542-9a392ac4a1da" xlink:href="ocgn-20191231.xsd#ocgn_CollaborationAgreementTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d45ee091-1f92-4e63-ae9a-8943f4f57e53" xlink:to="loc_ocgn_CollaborationAgreementTerm_bc2cbf5d-d60d-434e-b542-9a392ac4a1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborationAgreementTerminationDevelopmentCostStatement_99e58e40-69c5-4a5e-84e7-5abdf30ed8d0" xlink:href="ocgn-20191231.xsd#ocgn_CollaborationAgreementTerminationDevelopmentCostStatement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d45ee091-1f92-4e63-ae9a-8943f4f57e53" xlink:to="loc_ocgn_CollaborationAgreementTerminationDevelopmentCostStatement_99e58e40-69c5-4a5e-84e7-5abdf30ed8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborationAgreementTerminationDevelopmentCostPayment_8e933577-ed38-471d-bfe0-4f7ecd11d65f" xlink:href="ocgn-20191231.xsd#ocgn_CollaborationAgreementTerminationDevelopmentCostPayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d45ee091-1f92-4e63-ae9a-8943f4f57e53" xlink:to="loc_ocgn_CollaborationAgreementTerminationDevelopmentCostPayment_8e933577-ed38-471d-bfe0-4f7ecd11d65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LicenseAgreementPayment_f8cbf696-d4fd-4681-b3d8-836ad22f427c" xlink:href="ocgn-20191231.xsd#ocgn_LicenseAgreementPayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d45ee091-1f92-4e63-ae9a-8943f4f57e53" xlink:to="loc_ocgn_LicenseAgreementPayment_f8cbf696-d4fd-4681-b3d8-836ad22f427c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment_b6229ba6-9699-41cc-be26-e4f787613ed9" xlink:href="ocgn-20191231.xsd#ocgn_LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d45ee091-1f92-4e63-ae9a-8943f4f57e53" xlink:to="loc_ocgn_LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment_b6229ba6-9699-41cc-be26-e4f787613ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LicenseAgreementPotentialCommercialMilestonePayment_447a7cd9-9390-463f-a0ea-bd3536ea7f85" xlink:href="ocgn-20191231.xsd#ocgn_LicenseAgreementPotentialCommercialMilestonePayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d45ee091-1f92-4e63-ae9a-8943f4f57e53" xlink:to="loc_ocgn_LicenseAgreementPotentialCommercialMilestonePayment_447a7cd9-9390-463f-a0ea-bd3536ea7f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LicenseAgreementMilestonePayment_b77b2062-6175-4fcc-8aa5-ca3f3d830cae" xlink:href="ocgn-20191231.xsd#ocgn_LicenseAgreementMilestonePayment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d45ee091-1f92-4e63-ae9a-8943f4f57e53" xlink:to="loc_ocgn_LicenseAgreementMilestonePayment_b77b2062-6175-4fcc-8aa5-ca3f3d830cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_ad4d8f23-bea7-494a-8176-01a8c168d372" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d45ee091-1f92-4e63-ae9a-8943f4f57e53" xlink:to="loc_us-gaap_PaymentsForRoyalties_ad4d8f23-bea7-494a-8176-01a8c168d372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LicenseAgreementCancellationPeriodNotice_1a170b47-c095-4c59-8932-7e779dd42781" xlink:href="ocgn-20191231.xsd#ocgn_LicenseAgreementCancellationPeriodNotice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d45ee091-1f92-4e63-ae9a-8943f4f57e53" xlink:to="loc_ocgn_LicenseAgreementCancellationPeriodNotice_1a170b47-c095-4c59-8932-7e779dd42781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_78aa7bbc-b595-4e3b-9bbd-0d53871a07f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d45ee091-1f92-4e63-ae9a-8943f4f57e53" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_78aa7bbc-b595-4e3b-9bbd-0d53871a07f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LicenseAgreementSigningFee_9c2e7206-7f57-4ae9-bb00-2def3d49f1a0" xlink:href="ocgn-20191231.xsd#ocgn_LicenseAgreementSigningFee"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d45ee091-1f92-4e63-ae9a-8943f4f57e53" xlink:to="loc_ocgn_LicenseAgreementSigningFee_9c2e7206-7f57-4ae9-bb00-2def3d49f1a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LicenseAgreementMinimumAnnualRoyaltyPayment_4ec91f0e-e075-4107-b2ab-6c2e0dc6769b" xlink:href="ocgn-20191231.xsd#ocgn_LicenseAgreementMinimumAnnualRoyaltyPayment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d45ee091-1f92-4e63-ae9a-8943f4f57e53" xlink:to="loc_ocgn_LicenseAgreementMinimumAnnualRoyaltyPayment_4ec91f0e-e075-4107-b2ab-6c2e0dc6769b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a699d216-c627-46cb-b9a3-27a6ab1ee560" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d45ee091-1f92-4e63-ae9a-8943f4f57e53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a699d216-c627-46cb-b9a3-27a6ab1ee560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/AccruedExpenses" xlink:type="simple" xlink:href="ocgn-20191231.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_802c619b-c509-493c-9c5e-3978f7adbb8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_3dce2e05-4493-412b-b066-ff31c65508e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_802c619b-c509-493c-9c5e-3978f7adbb8b" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_3dce2e05-4493-412b-b066-ff31c65508e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="ocgn-20191231.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_10e5a4ad-ab00-4177-a010-5cbf01024545" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_b07ccb00-ed1a-4ea3-8b85-e1dc3377df41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_10e5a4ad-ab00-4177-a010-5cbf01024545" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_b07ccb00-ed1a-4ea3-8b85-e1dc3377df41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#AccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_92c6bca7-f9bd-4041-88b7-0fe3dfd22e33" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ResearchAndDevelopmentExpensesCurrent_811948b5-1ecf-4c6a-affb-9cb68b938c1d" xlink:href="ocgn-20191231.xsd#ocgn_ResearchAndDevelopmentExpensesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_92c6bca7-f9bd-4041-88b7-0fe3dfd22e33" xlink:to="loc_ocgn_ResearchAndDevelopmentExpensesCurrent_811948b5-1ecf-4c6a-affb-9cb68b938c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AccountsPayableClinical_e7b7892f-49b7-480c-a642-59218cb4ad5d" xlink:href="ocgn-20191231.xsd#ocgn_AccountsPayableClinical"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_92c6bca7-f9bd-4041-88b7-0fe3dfd22e33" xlink:to="loc_ocgn_AccountsPayableClinical_e7b7892f-49b7-480c-a642-59218cb4ad5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AccountsPayableConsulting_ad67dc51-4467-46cd-af8d-541f42ca0ff7" xlink:href="ocgn-20191231.xsd#ocgn_AccountsPayableConsulting"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_92c6bca7-f9bd-4041-88b7-0fe3dfd22e33" xlink:to="loc_ocgn_AccountsPayableConsulting_ad67dc51-4467-46cd-af8d-541f42ca0ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9b4c2686-3fb4-4feb-a16e-0fe5a150dd54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_92c6bca7-f9bd-4041-88b7-0fe3dfd22e33" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9b4c2686-3fb4-4feb-a16e-0fe5a150dd54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_6d2914e2-ea20-4dd3-b481-3416c6d6d337" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_92c6bca7-f9bd-4041-88b7-0fe3dfd22e33" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_6d2914e2-ea20-4dd3-b481-3416c6d6d337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0735be31-6cb8-4a5a-96f0-e23bd5f43d5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_92c6bca7-f9bd-4041-88b7-0fe3dfd22e33" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0735be31-6cb8-4a5a-96f0-e23bd5f43d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_14319d69-dff5-4582-932b-a291e200cb90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_92c6bca7-f9bd-4041-88b7-0fe3dfd22e33" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_14319d69-dff5-4582-932b-a291e200cb90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/Debt" xlink:type="simple" xlink:href="ocgn-20191231.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_01bbe686-d291-4ee6-9709-bc1f159e3069" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_bddbfbc3-0b22-4a3f-bfe5-aa4fa04bb680" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_01bbe686-d291-4ee6-9709-bc1f159e3069" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_bddbfbc3-0b22-4a3f-bfe5-aa4fa04bb680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtTables" xlink:type="simple" xlink:href="ocgn-20191231.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_22b3aa78-2354-467a-94f6-ea1480859ada" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_f96f53bf-a0b9-4d65-993d-787feda9f799" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_22b3aa78-2354-467a-94f6-ea1480859ada" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_f96f53bf-a0b9-4d65-993d-787feda9f799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_2dc6c493-6a92-4a91-8e84-2bcb66796254" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_22b3aa78-2354-467a-94f6-ea1480859ada" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_2dc6c493-6a92-4a91-8e84-2bcb66796254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ChangesInFairValueOfEmbeddedDerivativeTableTextBlock_c702f335-77c2-4006-9fe3-d5e7b08893ac" xlink:href="ocgn-20191231.xsd#ocgn_ChangesInFairValueOfEmbeddedDerivativeTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_22b3aa78-2354-467a-94f6-ea1480859ada" xlink:to="loc_ocgn_ChangesInFairValueOfEmbeddedDerivativeTableTextBlock_c702f335-77c2-4006-9fe3-d5e7b08893ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtEB5LoanDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#DebtEB5LoanDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/DebtEB5LoanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2a5b6072-98e5-453a-99cb-b8a20cd766d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_109a4113-ac8f-46ca-951d-93cb4854fc1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2a5b6072-98e5-453a-99cb-b8a20cd766d8" xlink:to="loc_us-gaap_DebtInstrumentTable_109a4113-ac8f-46ca-951d-93cb4854fc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9e431d24-806a-49ac-aed0-11d7f1cf76ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_109a4113-ac8f-46ca-951d-93cb4854fc1e" xlink:to="loc_us-gaap_DebtInstrumentAxis_9e431d24-806a-49ac-aed0-11d7f1cf76ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_31f5cdb4-e80a-4d64-81f3-eb398f32a7df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9e431d24-806a-49ac-aed0-11d7f1cf76ca" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_31f5cdb4-e80a-4d64-81f3-eb398f32a7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EB5ProgramBorrowingsMember_e604487c-75cc-4e44-8354-4e5e883ea462" xlink:href="ocgn-20191231.xsd#ocgn_EB5ProgramBorrowingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31f5cdb4-e80a-4d64-81f3-eb398f32a7df" xlink:to="loc_ocgn_EB5ProgramBorrowingsMember_e604487c-75cc-4e44-8354-4e5e883ea462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f8cc6950-dc7b-415b-897e-2dafc6494aaf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_109a4113-ac8f-46ca-951d-93cb4854fc1e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f8cc6950-dc7b-415b-897e-2dafc6494aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_eb55026d-8ac8-48b4-b89d-d88e25e57f79" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f8cc6950-dc7b-415b-897e-2dafc6494aaf" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_eb55026d-8ac8-48b4-b89d-d88e25e57f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_ce85a867-4d47-41bc-8032-faa2b31ccc6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_eb55026d-8ac8-48b4-b89d-d88e25e57f79" xlink:to="loc_us-gaap_LoansPayableMember_ce85a867-4d47-41bc-8032-faa2b31ccc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1c3a6721-57ed-4160-9f6f-f3e3a474341d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_109a4113-ac8f-46ca-951d-93cb4854fc1e" xlink:to="loc_us-gaap_DebtInstrumentLineItems_1c3a6721-57ed-4160-9f6f-f3e3a474341d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b59a488d-5b10-4df6-971e-422aab44276b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1c3a6721-57ed-4160-9f6f-f3e3a474341d" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b59a488d-5b10-4df6-971e-422aab44276b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LineOfCreditBorrowingEachDraw_acee9b8d-97ed-4a03-be60-be9a9bb368e6" xlink:href="ocgn-20191231.xsd#ocgn_LineOfCreditBorrowingEachDraw"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1c3a6721-57ed-4160-9f6f-f3e3a474341d" xlink:to="loc_ocgn_LineOfCreditBorrowingEachDraw_acee9b8d-97ed-4a03-be60-be9a9bb368e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b08c6fc5-2cd7-41fa-bf4b-19c3c6982039" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1c3a6721-57ed-4160-9f6f-f3e3a474341d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b08c6fc5-2cd7-41fa-bf4b-19c3c6982039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_f80f11ae-6b8a-4fcd-9f01-b1b9c2310b00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1c3a6721-57ed-4160-9f6f-f3e3a474341d" xlink:to="loc_us-gaap_LineOfCredit_f80f11ae-6b8a-4fcd-9f01-b1b9c2310b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_9d6f097a-8311-4740-86bb-b58cbce0010c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1c3a6721-57ed-4160-9f6f-f3e3a474341d" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_9d6f097a-8311-4740-86bb-b58cbce0010c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtSummaryofEB5LoanDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#DebtSummaryofEB5LoanDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/DebtSummaryofEB5LoanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f61656ff-5ae0-4748-b4be-ed3a9d89ee58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9b3cb147-1027-4f0d-b32f-0f53fcc85e41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f61656ff-5ae0-4748-b4be-ed3a9d89ee58" xlink:to="loc_us-gaap_DebtInstrumentTable_9b3cb147-1027-4f0d-b32f-0f53fcc85e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f1e55b75-7df5-4707-85a0-e0da057cf6a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9b3cb147-1027-4f0d-b32f-0f53fcc85e41" xlink:to="loc_us-gaap_DebtInstrumentAxis_f1e55b75-7df5-4707-85a0-e0da057cf6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a846a97d-85bc-487e-abfa-dce31497c03b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f1e55b75-7df5-4707-85a0-e0da057cf6a5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a846a97d-85bc-487e-abfa-dce31497c03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EB5ProgramBorrowingsMember_03eebab1-7a34-4e2e-862d-8d6b47be8e3d" xlink:href="ocgn-20191231.xsd#ocgn_EB5ProgramBorrowingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a846a97d-85bc-487e-abfa-dce31497c03b" xlink:to="loc_ocgn_EB5ProgramBorrowingsMember_03eebab1-7a34-4e2e-862d-8d6b47be8e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4f86e2ce-86e4-4c87-86ae-c7fb6e7ca08b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9b3cb147-1027-4f0d-b32f-0f53fcc85e41" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4f86e2ce-86e4-4c87-86ae-c7fb6e7ca08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ffd0ffb8-28ab-407e-9eef-d2a93d43c781" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4f86e2ce-86e4-4c87-86ae-c7fb6e7ca08b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ffd0ffb8-28ab-407e-9eef-d2a93d43c781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_db9b9350-10da-4333-8508-20b7a34c989c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ffd0ffb8-28ab-407e-9eef-d2a93d43c781" xlink:to="loc_us-gaap_LoansPayableMember_db9b9350-10da-4333-8508-20b7a34c989c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ff00a014-0e35-4b92-b05b-aa691ecb6ee1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9b3cb147-1027-4f0d-b32f-0f53fcc85e41" xlink:to="loc_us-gaap_DebtInstrumentLineItems_ff00a014-0e35-4b92-b05b-aa691ecb6ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_342bf0be-e435-4cd6-b580-a8eeab7426bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff00a014-0e35-4b92-b05b-aa691ecb6ee1" xlink:to="loc_us-gaap_LineOfCredit_342bf0be-e435-4cd6-b580-a8eeab7426bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_e026904d-2beb-4aa6-8ac1-2694312160b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff00a014-0e35-4b92-b05b-aa691ecb6ee1" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_e026904d-2beb-4aa6-8ac1-2694312160b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_65bf94c8-52eb-42ff-b51c-b29eaa55207b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff00a014-0e35-4b92-b05b-aa691ecb6ee1" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_65bf94c8-52eb-42ff-b51c-b29eaa55207b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_2a5e84ec-3265-4e7d-968a-7f3a89b3f6c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff00a014-0e35-4b92-b05b-aa691ecb6ee1" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_2a5e84ec-3265-4e7d-968a-7f3a89b3f6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_09ce5457-35c5-4b34-b310-557b844f7f6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff00a014-0e35-4b92-b05b-aa691ecb6ee1" xlink:to="loc_us-gaap_LongTermDebt_09ce5457-35c5-4b34-b310-557b844f7f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_77150c6b-ec3d-4e21-94e4-954091422287" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff00a014-0e35-4b92-b05b-aa691ecb6ee1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_77150c6b-ec3d-4e21-94e4-954091422287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#DebtConvertibleNotesDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4dc71e36-effa-4fe6-a56d-6c3095984acd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4f0baf02-60c0-47f6-93cb-5f6700afc1dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4dc71e36-effa-4fe6-a56d-6c3095984acd" xlink:to="loc_us-gaap_DebtInstrumentTable_4f0baf02-60c0-47f6-93cb-5f6700afc1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5a7bf24b-605b-4106-95ad-8bc87ff20b48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4f0baf02-60c0-47f6-93cb-5f6700afc1dd" xlink:to="loc_us-gaap_DebtInstrumentAxis_5a7bf24b-605b-4106-95ad-8bc87ff20b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_adc77bdf-6a69-4ec3-8ed2-e610e0df85d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_5a7bf24b-605b-4106-95ad-8bc87ff20b48" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_adc77bdf-6a69-4ec3-8ed2-e610e0df85d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_37f9d5fa-95bf-495c-a7cb-d7a2b5f05a01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_adc77bdf-6a69-4ec3-8ed2-e610e0df85d8" xlink:to="loc_us-gaap_ConvertibleDebtMember_37f9d5fa-95bf-495c-a7cb-d7a2b5f05a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertibleNotesBoardOfDirectorsMember_931cc4c8-422d-4472-b247-a00e3eb53448" xlink:href="ocgn-20191231.xsd#ocgn_ConvertibleNotesBoardOfDirectorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConvertibleDebtMember_37f9d5fa-95bf-495c-a7cb-d7a2b5f05a01" xlink:to="loc_ocgn_ConvertibleNotesBoardOfDirectorsMember_931cc4c8-422d-4472-b247-a00e3eb53448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertibleDebtJanuary2018Member_b49fad90-eaec-4e3e-8d47-0d196ec6edc9" xlink:href="ocgn-20191231.xsd#ocgn_ConvertibleDebtJanuary2018Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConvertibleDebtMember_37f9d5fa-95bf-495c-a7cb-d7a2b5f05a01" xlink:to="loc_ocgn_ConvertibleDebtJanuary2018Member_b49fad90-eaec-4e3e-8d47-0d196ec6edc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertibleDebtJune2018Member_4113dbb6-a543-4b88-944a-9c2aefd18ecc" xlink:href="ocgn-20191231.xsd#ocgn_ConvertibleDebtJune2018Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConvertibleDebtMember_37f9d5fa-95bf-495c-a7cb-d7a2b5f05a01" xlink:to="loc_ocgn_ConvertibleDebtJune2018Member_4113dbb6-a543-4b88-944a-9c2aefd18ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertibleDebtNovember2018Member_145d34e2-3e9f-4d6a-bee0-0bdf8ee4900a" xlink:href="ocgn-20191231.xsd#ocgn_ConvertibleDebtNovember2018Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConvertibleDebtMember_37f9d5fa-95bf-495c-a7cb-d7a2b5f05a01" xlink:to="loc_ocgn_ConvertibleDebtNovember2018Member_145d34e2-3e9f-4d6a-bee0-0bdf8ee4900a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertibleDebtDecember2018Member_d706d3f5-fd22-47df-a932-d3a25e03b974" xlink:href="ocgn-20191231.xsd#ocgn_ConvertibleDebtDecember2018Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConvertibleDebtMember_37f9d5fa-95bf-495c-a7cb-d7a2b5f05a01" xlink:to="loc_ocgn_ConvertibleDebtDecember2018Member_d706d3f5-fd22-47df-a932-d3a25e03b974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertibleDebtJanuary2019Member_852a9bc7-9d12-458f-ae03-b5bc2a004b00" xlink:href="ocgn-20191231.xsd#ocgn_ConvertibleDebtJanuary2019Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConvertibleDebtMember_37f9d5fa-95bf-495c-a7cb-d7a2b5f05a01" xlink:to="loc_ocgn_ConvertibleDebtJanuary2019Member_852a9bc7-9d12-458f-ae03-b5bc2a004b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertibleDebtFebruary2019Member_5cfedd14-3c86-4288-9262-fb45ae1758f7" xlink:href="ocgn-20191231.xsd#ocgn_ConvertibleDebtFebruary2019Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConvertibleDebtMember_37f9d5fa-95bf-495c-a7cb-d7a2b5f05a01" xlink:to="loc_ocgn_ConvertibleDebtFebruary2019Member_5cfedd14-3c86-4288-9262-fb45ae1758f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_babca7c0-d063-428c-852a-f0e1975751b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4f0baf02-60c0-47f6-93cb-5f6700afc1dd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_babca7c0-d063-428c-852a-f0e1975751b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3a3ad0d1-5a30-4789-a807-1e5d26ba9276" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_babca7c0-d063-428c-852a-f0e1975751b2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3a3ad0d1-5a30-4789-a807-1e5d26ba9276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_26bb1707-7b0d-415e-811b-6c532bcefd87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3a3ad0d1-5a30-4789-a807-1e5d26ba9276" xlink:to="loc_us-gaap_ConvertibleDebtMember_26bb1707-7b0d-415e-811b-6c532bcefd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_63c2949a-0740-48b7-947b-d93543f07c91" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4f0baf02-60c0-47f6-93cb-5f6700afc1dd" xlink:to="loc_srt_RangeAxis_63c2949a-0740-48b7-947b-d93543f07c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a32ebd92-6186-48d5-9a66-d0db46001f3d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_63c2949a-0740-48b7-947b-d93543f07c91" xlink:to="loc_srt_RangeMember_a32ebd92-6186-48d5-9a66-d0db46001f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_78a280d4-8d20-4a51-b08e-ce2af473f920" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a32ebd92-6186-48d5-9a66-d0db46001f3d" xlink:to="loc_srt_MinimumMember_78a280d4-8d20-4a51-b08e-ce2af473f920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e041e87d-df6c-4c73-8385-117485a5ef59" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a32ebd92-6186-48d5-9a66-d0db46001f3d" xlink:to="loc_srt_MaximumMember_e041e87d-df6c-4c73-8385-117485a5ef59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_116fdd6d-f497-4c52-869a-de0d121be451" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4f0baf02-60c0-47f6-93cb-5f6700afc1dd" xlink:to="loc_srt_TitleOfIndividualAxis_116fdd6d-f497-4c52-869a-de0d121be451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9fe404db-f672-42bb-8ffb-37e82fd1693f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_116fdd6d-f497-4c52-869a-de0d121be451" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9fe404db-f672-42bb-8ffb-37e82fd1693f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_3135ded0-e0d4-4cb0-95eb-2d47fcc2b9d8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9fe404db-f672-42bb-8ffb-37e82fd1693f" xlink:to="loc_srt_DirectorMember_3135ded0-e0d4-4cb0-95eb-2d47fcc2b9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_45bfa972-274b-474c-9308-40acf74e1291" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4f0baf02-60c0-47f6-93cb-5f6700afc1dd" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_45bfa972-274b-474c-9308-40acf74e1291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_02cf6a93-8277-461e-a7d5-a69b2ece1e71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_45bfa972-274b-474c-9308-40acf74e1291" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_02cf6a93-8277-461e-a7d5-a69b2ece1e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertibleDebtConversionFeatureMember_1a1ac16d-9379-4cde-b7d5-4125b91d3f4d" xlink:href="ocgn-20191231.xsd#ocgn_ConvertibleDebtConversionFeatureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_02cf6a93-8277-461e-a7d5-a69b2ece1e71" xlink:to="loc_ocgn_ConvertibleDebtConversionFeatureMember_1a1ac16d-9379-4cde-b7d5-4125b91d3f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4c8d3028-f8b9-4b66-8de1-97487d369e70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4f0baf02-60c0-47f6-93cb-5f6700afc1dd" xlink:to="loc_us-gaap_DebtInstrumentLineItems_4c8d3028-f8b9-4b66-8de1-97487d369e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_16e95447-1433-440a-86a5-c7170ab85a86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c8d3028-f8b9-4b66-8de1-97487d369e70" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_16e95447-1433-440a-86a5-c7170ab85a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_58baae61-04ce-449f-9bb9-e4e0b9e897cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c8d3028-f8b9-4b66-8de1-97487d369e70" xlink:to="loc_us-gaap_ConvertibleDebt_58baae61-04ce-449f-9bb9-e4e0b9e897cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_3a374961-a462-427d-9a97-a299eeb41756" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c8d3028-f8b9-4b66-8de1-97487d369e70" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_3a374961-a462-427d-9a97-a299eeb41756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_53a5b6cb-d8fc-4c49-a838-e5da1f4d4710" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c8d3028-f8b9-4b66-8de1-97487d369e70" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_53a5b6cb-d8fc-4c49-a838-e5da1f4d4710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_fcf66a07-ce7f-4ff9-8e23-ee151b060eb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c8d3028-f8b9-4b66-8de1-97487d369e70" xlink:to="loc_us-gaap_LongTermDebt_fcf66a07-ce7f-4ff9-8e23-ee151b060eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8c63892b-b73e-4f8d-99f5-6c0d171546b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c8d3028-f8b9-4b66-8de1-97487d369e70" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8c63892b-b73e-4f8d-99f5-6c0d171546b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_7be9bdf3-d623-41bc-8f8f-38be293ea47b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c8d3028-f8b9-4b66-8de1-97487d369e70" xlink:to="loc_us-gaap_DebtInstrumentTerm_7be9bdf3-d623-41bc-8f8f-38be293ea47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_DebtRedemptionMultipleUponDefault_34c1bc44-33df-4660-bf2d-c3fdc3486ffb" xlink:href="ocgn-20191231.xsd#ocgn_DebtRedemptionMultipleUponDefault"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c8d3028-f8b9-4b66-8de1-97487d369e70" xlink:to="loc_ocgn_DebtRedemptionMultipleUponDefault_34c1bc44-33df-4660-bf2d-c3fdc3486ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount_ec9a20d7-1c6b-4ef7-9543-a1986bd70ad8" xlink:href="ocgn-20191231.xsd#ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c8d3028-f8b9-4b66-8de1-97487d369e70" xlink:to="loc_ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount_ec9a20d7-1c6b-4ef7-9543-a1986bd70ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_e74324d9-c34a-4e5b-836b-73a0005cbc55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c8d3028-f8b9-4b66-8de1-97487d369e70" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_e74324d9-c34a-4e5b-836b-73a0005cbc55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtScheduleofFairValueoftheEmbeddedFeaturesDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#DebtScheduleofFairValueoftheEmbeddedFeaturesDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/DebtScheduleofFairValueoftheEmbeddedFeaturesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_559b0114-731c-497c-828e-28aa052c4a48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_a7baef94-edcc-4e82-87ee-697a8eb0da08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_559b0114-731c-497c-828e-28aa052c4a48" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_a7baef94-edcc-4e82-87ee-697a8eb0da08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiabilityAtIssuance_d8af11f1-7e45-4967-818c-1db5350c58a9" xlink:href="ocgn-20191231.xsd#ocgn_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiabilityAtIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_559b0114-731c-497c-828e-28aa052c4a48" xlink:to="loc_ocgn_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiabilityAtIssuance_d8af11f1-7e45-4967-818c-1db5350c58a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_ee959296-2dd3-4670-9c6f-a1f39453ad86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_559b0114-731c-497c-828e-28aa052c4a48" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_ee959296-2dd3-4670-9c6f-a1f39453ad86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EmbeddedDerivativeConversionAndExtinguishmentOfDebt_2793edee-e01e-4e0d-9e2e-9a114eb2ca62" xlink:href="ocgn-20191231.xsd#ocgn_EmbeddedDerivativeConversionAndExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_559b0114-731c-497c-828e-28aa052c4a48" xlink:to="loc_ocgn_EmbeddedDerivativeConversionAndExtinguishmentOfDebt_2793edee-e01e-4e0d-9e2e-9a114eb2ca62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#DebtConvertibleNotesOtherInformationDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9420ea1b-b2ac-460d-8992-0fbabb5b02aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_09b873d8-dbf0-4825-83c6-aa6afdf4b4d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9420ea1b-b2ac-460d-8992-0fbabb5b02aa" xlink:to="loc_us-gaap_DebtInstrumentTable_09b873d8-dbf0-4825-83c6-aa6afdf4b4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_1849a530-af2a-48f2-bb20-1b9d2a9c9415" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_09b873d8-dbf0-4825-83c6-aa6afdf4b4d3" xlink:to="loc_srt_TitleOfIndividualAxis_1849a530-af2a-48f2-bb20-1b9d2a9c9415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bfd556e3-4c44-44b5-8325-a96aa90a8a9b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_1849a530-af2a-48f2-bb20-1b9d2a9c9415" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bfd556e3-4c44-44b5-8325-a96aa90a8a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_190bf06c-787d-492d-9772-bf2854f415ed" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bfd556e3-4c44-44b5-8325-a96aa90a8a9b" xlink:to="loc_srt_DirectorMember_190bf06c-787d-492d-9772-bf2854f415ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAxis_6aabfc5f-d174-4172-a85a-643c62d7aff6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_09b873d8-dbf0-4825-83c6-aa6afdf4b4d3" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAxis_6aabfc5f-d174-4172-a85a-643c62d7aff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_b4aa036b-fc67-475f-8b93-1b664791dabc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis_6aabfc5f-d174-4172-a85a-643c62d7aff6" xlink:to="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_b4aa036b-fc67-475f-8b93-1b664791dabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_e1e631ef-4eb6-4071-a9a1-627135aa0e46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_b4aa036b-fc67-475f-8b93-1b664791dabc" xlink:to="loc_us-gaap_ConvertibleDebtMember_e1e631ef-4eb6-4071-a9a1-627135aa0e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9fda81ee-f759-42db-bdc0-09115921fbe5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_09b873d8-dbf0-4825-83c6-aa6afdf4b4d3" xlink:to="loc_us-gaap_DebtInstrumentAxis_9fda81ee-f759-42db-bdc0-09115921fbe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8ef7b1a7-61f9-4692-9656-ae3e607c03e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9fda81ee-f759-42db-bdc0-09115921fbe5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8ef7b1a7-61f9-4692-9656-ae3e607c03e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertiblePromissoryNotesMember_b9192daa-bc07-4548-b323-f22af3763737" xlink:href="ocgn-20191231.xsd#ocgn_ConvertiblePromissoryNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8ef7b1a7-61f9-4692-9656-ae3e607c03e9" xlink:to="loc_ocgn_ConvertiblePromissoryNotesMember_b9192daa-bc07-4548-b323-f22af3763737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_January2019AndFebruary2019NotesMember_f939990d-d155-4007-99b3-95825d105cc0" xlink:href="ocgn-20191231.xsd#ocgn_January2019AndFebruary2019NotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8ef7b1a7-61f9-4692-9656-ae3e607c03e9" xlink:to="loc_ocgn_January2019AndFebruary2019NotesMember_f939990d-d155-4007-99b3-95825d105cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_November2018AndDecember2018NotesMember_03b07922-5916-490f-bf7d-568577bfcb60" xlink:href="ocgn-20191231.xsd#ocgn_November2018AndDecember2018NotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8ef7b1a7-61f9-4692-9656-ae3e607c03e9" xlink:to="loc_ocgn_November2018AndDecember2018NotesMember_03b07922-5916-490f-bf7d-568577bfcb60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_58693e94-817a-40c2-aa7a-428dd017ea19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_09b873d8-dbf0-4825-83c6-aa6afdf4b4d3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_58693e94-817a-40c2-aa7a-428dd017ea19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_90bf7c9c-b68c-493b-892f-3df83cb52943" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_58693e94-817a-40c2-aa7a-428dd017ea19" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_90bf7c9c-b68c-493b-892f-3df83cb52943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_526121c2-603b-4f5e-9233-d34d3f18c14b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_90bf7c9c-b68c-493b-892f-3df83cb52943" xlink:to="loc_us-gaap_ConvertibleDebtMember_526121c2-603b-4f5e-9233-d34d3f18c14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_550a44d1-be19-41f4-a77c-0f10e658df0a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_09b873d8-dbf0-4825-83c6-aa6afdf4b4d3" xlink:to="loc_srt_RangeAxis_550a44d1-be19-41f4-a77c-0f10e658df0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4a182972-f58b-40a5-bfe9-ac2c59021ccf" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_550a44d1-be19-41f4-a77c-0f10e658df0a" xlink:to="loc_srt_RangeMember_4a182972-f58b-40a5-bfe9-ac2c59021ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8eba4dbc-879e-4122-85a5-6c00c9126318" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4a182972-f58b-40a5-bfe9-ac2c59021ccf" xlink:to="loc_srt_MinimumMember_8eba4dbc-879e-4122-85a5-6c00c9126318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5f1ac0e9-a992-4e02-98e9-3ff495db252c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_09b873d8-dbf0-4825-83c6-aa6afdf4b4d3" xlink:to="loc_us-gaap_DebtInstrumentLineItems_5f1ac0e9-a992-4e02-98e9-3ff495db252c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement_2a78dc9b-8845-49d7-8039-2b3a28b734a6" xlink:href="ocgn-20191231.xsd#ocgn_CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f1ac0e9-a992-4e02-98e9-3ff495db252c" xlink:to="loc_ocgn_CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement_2a78dc9b-8845-49d7-8039-2b3a28b734a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions_9322f098-74c5-4705-a969-9f9554a999b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesSubscriptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f1ac0e9-a992-4e02-98e9-3ff495db252c" xlink:to="loc_us-gaap_CommonStockSharesSubscriptions_9322f098-74c5-4705-a969-9f9554a999b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_23615498-dc91-4b22-93d6-0ac05555d09d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f1ac0e9-a992-4e02-98e9-3ff495db252c" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_23615498-dc91-4b22-93d6-0ac05555d09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount_1e327ec3-5198-45e1-a8b3-78db35dfcb4a" xlink:href="ocgn-20191231.xsd#ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f1ac0e9-a992-4e02-98e9-3ff495db252c" xlink:to="loc_ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount_1e327ec3-5198-45e1-a8b3-78db35dfcb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f40b1f43-563b-446b-98cd-518b2cbeae80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f1ac0e9-a992-4e02-98e9-3ff495db252c" xlink:to="loc_us-gaap_CommonStockSharesIssued_f40b1f43-563b-446b-98cd-518b2cbeae80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f6119591-2863-44f8-b05d-c1bb11159a66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f1ac0e9-a992-4e02-98e9-3ff495db252c" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f6119591-2863-44f8-b05d-c1bb11159a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_cafc87a7-fd3d-4e68-b5af-ac70b562756e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f1ac0e9-a992-4e02-98e9-3ff495db252c" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_cafc87a7-fd3d-4e68-b5af-ac70b562756e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_ccc5054c-6978-4ed4-ac3c-40cb9ccfeead" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f1ac0e9-a992-4e02-98e9-3ff495db252c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_ccc5054c-6978-4ed4-ac3c-40cb9ccfeead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ecd808de-7344-4f1e-ac5a-c7e889e93f0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f1ac0e9-a992-4e02-98e9-3ff495db252c" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ecd808de-7344-4f1e-ac5a-c7e889e93f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6728af94-9ff7-490a-b112-f37098f352c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f1ac0e9-a992-4e02-98e9-3ff495db252c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6728af94-9ff7-490a-b112-f37098f352c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtSeniorSecuredConvertibleNotesDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#DebtSeniorSecuredConvertibleNotesDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/DebtSeniorSecuredConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0c8c1c42-9293-4b69-8dde-33251cb55e73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6f431783-acc7-4af2-b7c0-37c1dfabe536" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0c8c1c42-9293-4b69-8dde-33251cb55e73" xlink:to="loc_us-gaap_DebtInstrumentTable_6f431783-acc7-4af2-b7c0-37c1dfabe536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_175e9ffd-4428-41b9-9dbb-5cb028e3705d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6f431783-acc7-4af2-b7c0-37c1dfabe536" xlink:to="loc_us-gaap_DebtInstrumentAxis_175e9ffd-4428-41b9-9dbb-5cb028e3705d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e7c21db7-6138-433d-a84a-8793871509a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_175e9ffd-4428-41b9-9dbb-5cb028e3705d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e7c21db7-6138-433d-a84a-8793871509a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeniorSecuredConvertibleNotesMay2019Member_40f927da-d1e8-46f3-8f43-716c12c421d8" xlink:href="ocgn-20191231.xsd#ocgn_SeniorSecuredConvertibleNotesMay2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e7c21db7-6138-433d-a84a-8793871509a5" xlink:to="loc_ocgn_SeniorSecuredConvertibleNotesMay2019Member_40f927da-d1e8-46f3-8f43-716c12c421d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeniorSecuredConvertibleNotesMember_c06b7b98-69f1-43a2-a4dd-43eb56fab2cb" xlink:href="ocgn-20191231.xsd#ocgn_SeniorSecuredConvertibleNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e7c21db7-6138-433d-a84a-8793871509a5" xlink:to="loc_ocgn_SeniorSecuredConvertibleNotesMember_c06b7b98-69f1-43a2-a4dd-43eb56fab2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeniorSecuredConvertibleNotesJune2019Member_4369c16f-23da-4f26-83b4-9a260665346a" xlink:href="ocgn-20191231.xsd#ocgn_SeniorSecuredConvertibleNotesJune2019Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e7c21db7-6138-433d-a84a-8793871509a5" xlink:to="loc_ocgn_SeniorSecuredConvertibleNotesJune2019Member_4369c16f-23da-4f26-83b4-9a260665346a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2a101cbd-607b-442d-bd8b-0b484d879536" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6f431783-acc7-4af2-b7c0-37c1dfabe536" xlink:to="loc_us-gaap_DebtInstrumentLineItems_2a101cbd-607b-442d-bd8b-0b484d879536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_83faeccb-ea10-468e-920a-999d03f7d22c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a101cbd-607b-442d-bd8b-0b484d879536" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_83faeccb-ea10-468e-920a-999d03f7d22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_17cb5038-eb12-4bd8-bc6f-d860c1e09ba5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a101cbd-607b-442d-bd8b-0b484d879536" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_17cb5038-eb12-4bd8-bc6f-d860c1e09ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="ocgn-20191231.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bf45ca61-b3f0-4597-bc20-61a2f6550234" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3e734055-c387-4480-a4c7-2b7c27026614" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bf45ca61-b3f0-4597-bc20-61a2f6550234" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3e734055-c387-4480-a4c7-2b7c27026614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="ocgn-20191231.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7d9ac299-23a6-46cf-bd80-a609bae77faa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b183cd8e-7519-4e0e-93f1-1ab5edee6474" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7d9ac299-23a6-46cf-bd80-a609bae77faa" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b183cd8e-7519-4e0e-93f1-1ab5edee6474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ea84bcb5-ea30-419f-9f11-57d5c9beb401" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7d9ac299-23a6-46cf-bd80-a609bae77faa" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ea84bcb5-ea30-419f-9f11-57d5c9beb401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_584ed89a-603f-460a-8b72-c56a13a50426" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7d9ac299-23a6-46cf-bd80-a609bae77faa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_584ed89a-603f-460a-8b72-c56a13a50426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#StockBasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f449293-c4ca-4637-9f69-03bafec19bc5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0b0baa5b-f258-4406-a302-05c3d8c116c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f449293-c4ca-4637-9f69-03bafec19bc5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0b0baa5b-f258-4406-a302-05c3d8c116c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6f661788-68c8-4df3-9beb-bd5ace8e2d0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0b0baa5b-f258-4406-a302-05c3d8c116c7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6f661788-68c8-4df3-9beb-bd5ace8e2d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_05a7a531-a492-4010-bfc1-4bc80e92efe1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6f661788-68c8-4df3-9beb-bd5ace8e2d0e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_05a7a531-a492-4010-bfc1-4bc80e92efe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_417a577e-3c6e-46c2-b558-ad8a9b8bc4df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_05a7a531-a492-4010-bfc1-4bc80e92efe1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_417a577e-3c6e-46c2-b558-ad8a9b8bc4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7196e010-d011-4382-a452-22dd600c87cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_05a7a531-a492-4010-bfc1-4bc80e92efe1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7196e010-d011-4382-a452-22dd600c87cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73c86e4f-74ce-4513-a98e-548e7bea70d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0b0baa5b-f258-4406-a302-05c3d8c116c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73c86e4f-74ce-4513-a98e-548e7bea70d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_109d71f0-465a-4538-be81-bc86f93ad5e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73c86e4f-74ce-4513-a98e-548e7bea70d8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_109d71f0-465a-4538-be81-bc86f93ad5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SharedBasedCompensationDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#SharedBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/SharedBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c6c37188-6e14-4227-97c8-948b0e476b19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2998c414-518e-44ea-94e0-942005ea1210" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c6c37188-6e14-4227-97c8-948b0e476b19" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2998c414-518e-44ea-94e0-942005ea1210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_28dcc881-bf52-4bbd-a570-a8a703d4873b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2998c414-518e-44ea-94e0-942005ea1210" xlink:to="loc_us-gaap_AwardTypeAxis_28dcc881-bf52-4bbd-a570-a8a703d4873b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2790be1-e765-4e58-a63d-d5517436a5b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_28dcc881-bf52-4bbd-a570-a8a703d4873b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2790be1-e765-4e58-a63d-d5517436a5b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_A2019PlanMember_227015a2-73c8-4867-a823-99b1fd8234c5" xlink:href="ocgn-20191231.xsd#ocgn_A2019PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2790be1-e765-4e58-a63d-d5517436a5b9" xlink:to="loc_ocgn_A2019PlanMember_227015a2-73c8-4867-a823-99b1fd8234c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_54ef4181-9ec4-45b7-83bc-7ee06864bfef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2790be1-e765-4e58-a63d-d5517436a5b9" xlink:to="loc_us-gaap_StockOptionMember_54ef4181-9ec4-45b7-83bc-7ee06864bfef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c026742c-5a03-4e76-9c4f-78f76029ae34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2790be1-e765-4e58-a63d-d5517436a5b9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c026742c-5a03-4e76-9c4f-78f76029ae34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a747c7bc-6947-4170-abd7-cbd45fed4c17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2998c414-518e-44ea-94e0-942005ea1210" xlink:to="loc_us-gaap_PlanNameAxis_a747c7bc-6947-4170-abd7-cbd45fed4c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ab4f08c6-6589-410d-af71-314b40ee1bb9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_a747c7bc-6947-4170-abd7-cbd45fed4c17" xlink:to="loc_us-gaap_PlanNameDomain_ab4f08c6-6589-410d-af71-314b40ee1bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_A2014PlanMember_bc52b2e6-7c9f-4765-a049-ace0cf8eecb8" xlink:href="ocgn-20191231.xsd#ocgn_A2014PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ab4f08c6-6589-410d-af71-314b40ee1bb9" xlink:to="loc_ocgn_A2014PlanMember_bc52b2e6-7c9f-4765-a049-ace0cf8eecb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_A2019PlanMember_3e3682a0-ae71-4b37-97bf-964553df8cda" xlink:href="ocgn-20191231.xsd#ocgn_A2019PlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ab4f08c6-6589-410d-af71-314b40ee1bb9" xlink:to="loc_ocgn_A2019PlanMember_3e3682a0-ae71-4b37-97bf-964553df8cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b61859f3-043e-481c-a363-f5b964d09886" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2998c414-518e-44ea-94e0-942005ea1210" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b61859f3-043e-481c-a363-f5b964d09886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_819d47fb-d8e4-4af7-8896-1448eff2824d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b61859f3-043e-481c-a363-f5b964d09886" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_819d47fb-d8e4-4af7-8896-1448eff2824d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_fd2c4416-56af-4e9a-a7d5-834882482f21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b61859f3-043e-481c-a363-f5b964d09886" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_fd2c4416-56af-4e9a-a7d5-834882482f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfEquityCompensationPlans_0f38fa66-b872-49de-a786-caa89723f385" xlink:href="ocgn-20191231.xsd#ocgn_NumberOfEquityCompensationPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b61859f3-043e-481c-a363-f5b964d09886" xlink:to="loc_ocgn_NumberOfEquityCompensationPlans_0f38fa66-b872-49de-a786-caa89723f385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e24b01fe-859a-4d2b-b3f7-028140edcb55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b61859f3-043e-481c-a363-f5b964d09886" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e24b01fe-859a-4d2b-b3f7-028140edcb55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage_525cf500-561f-4c34-ab2c-0209497b133f" xlink:href="ocgn-20191231.xsd#ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b61859f3-043e-481c-a363-f5b964d09886" xlink:to="loc_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage_525cf500-561f-4c34-ab2c-0209497b133f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f5dd6b38-6892-4329-85a5-66b9b71343a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b61859f3-043e-481c-a363-f5b964d09886" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f5dd6b38-6892-4329-85a5-66b9b71343a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_e4aba028-a10a-4f02-89a3-480470ef9348" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b61859f3-043e-481c-a363-f5b964d09886" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_e4aba028-a10a-4f02-89a3-480470ef9348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1d92c5a1-2ca1-4ff9-a55e-792c015ca284" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b61859f3-043e-481c-a363-f5b964d09886" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1d92c5a1-2ca1-4ff9-a55e-792c015ca284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofValuationAssumptionsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#StockBasedCompensationScheduleofValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bbfba8d5-c051-47c6-a741-91cd5107eb0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57da3160-892f-4283-9b34-6f59c46bc78b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bbfba8d5-c051-47c6-a741-91cd5107eb0a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57da3160-892f-4283-9b34-6f59c46bc78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5aabf93b-b3d5-4975-94c7-b2961753e1a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57da3160-892f-4283-9b34-6f59c46bc78b" xlink:to="loc_us-gaap_AwardTypeAxis_5aabf93b-b3d5-4975-94c7-b2961753e1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7407897-b9e1-45da-82f6-19f94fe8ef95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5aabf93b-b3d5-4975-94c7-b2961753e1a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7407897-b9e1-45da-82f6-19f94fe8ef95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b7760b72-4efa-4304-a68e-6ddde6ca4413" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7407897-b9e1-45da-82f6-19f94fe8ef95" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b7760b72-4efa-4304-a68e-6ddde6ca4413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_157104d5-f81d-42df-ab67-53ffc0718e0c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57da3160-892f-4283-9b34-6f59c46bc78b" xlink:to="loc_srt_RangeAxis_157104d5-f81d-42df-ab67-53ffc0718e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_945bd49a-5376-4ae3-8be5-389d4343b0b8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_157104d5-f81d-42df-ab67-53ffc0718e0c" xlink:to="loc_srt_RangeMember_945bd49a-5376-4ae3-8be5-389d4343b0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_099c9159-828b-4958-a0c3-6861ed70fc8c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_945bd49a-5376-4ae3-8be5-389d4343b0b8" xlink:to="loc_srt_MinimumMember_099c9159-828b-4958-a0c3-6861ed70fc8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cbc88350-cbaa-400d-86dc-6a22d5373e6b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_945bd49a-5376-4ae3-8be5-389d4343b0b8" xlink:to="loc_srt_MaximumMember_cbc88350-cbaa-400d-86dc-6a22d5373e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9eb6b34f-9877-4eb9-9260-f7fb61e493da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57da3160-892f-4283-9b34-6f59c46bc78b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9eb6b34f-9877-4eb9-9260-f7fb61e493da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c931755a-b2f5-4836-841a-bd35182a4d9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9eb6b34f-9877-4eb9-9260-f7fb61e493da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c931755a-b2f5-4836-841a-bd35182a4d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0e28265d-16c9-490e-9c42-b21a80a52a30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9eb6b34f-9877-4eb9-9260-f7fb61e493da" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0e28265d-16c9-490e-9c42-b21a80a52a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_d28fa0d7-89e6-45ef-a8a5-57f7ee875df6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9eb6b34f-9877-4eb9-9260-f7fb61e493da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_d28fa0d7-89e6-45ef-a8a5-57f7ee875df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3b02b4bf-8160-4949-9603-a40ff9a98a41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9eb6b34f-9877-4eb9-9260-f7fb61e493da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3b02b4bf-8160-4949-9603-a40ff9a98a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_121e966f-20d3-4816-8f0a-2a92576447ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9eb6b34f-9877-4eb9-9260-f7fb61e493da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_121e966f-20d3-4816-8f0a-2a92576447ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee73c992-675f-4001-8c44-2f3f5442517f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d0611bd-bd77-42f0-a742-fe2ae8bda524" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee73c992-675f-4001-8c44-2f3f5442517f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d0611bd-bd77-42f0-a742-fe2ae8bda524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cd55a136-025e-428d-b125-afe36b0f253f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d0611bd-bd77-42f0-a742-fe2ae8bda524" xlink:to="loc_us-gaap_AwardTypeAxis_cd55a136-025e-428d-b125-afe36b0f253f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c33ac664-7f29-466a-a053-4ab0edf03cea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_cd55a136-025e-428d-b125-afe36b0f253f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c33ac664-7f29-466a-a053-4ab0edf03cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_A2019PlanMember_2efccf8b-6a4b-4f9d-a9e0-abfd79c72fcc" xlink:href="ocgn-20191231.xsd#ocgn_A2019PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c33ac664-7f29-466a-a053-4ab0edf03cea" xlink:to="loc_ocgn_A2019PlanMember_2efccf8b-6a4b-4f9d-a9e0-abfd79c72fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c6e29d8-8521-43f3-8bfc-777a86dc9172" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d0611bd-bd77-42f0-a742-fe2ae8bda524" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c6e29d8-8521-43f3-8bfc-777a86dc9172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0025a191-d2ae-4273-8d86-5c726a9d7b47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c6e29d8-8521-43f3-8bfc-777a86dc9172" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0025a191-d2ae-4273-8d86-5c726a9d7b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_273426fc-20a5-477f-9c4d-4fc072fe67e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0025a191-d2ae-4273-8d86-5c726a9d7b47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_273426fc-20a5-477f-9c4d-4fc072fe67e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d415e0d8-323a-4f9a-baa7-7c31af547fdc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0025a191-d2ae-4273-8d86-5c726a9d7b47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d415e0d8-323a-4f9a-baa7-7c31af547fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_636447eb-375f-44cc-a975-6553f3eed375" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0025a191-d2ae-4273-8d86-5c726a9d7b47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_636447eb-375f-44cc-a975-6553f3eed375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_f631db5e-efaa-4b03-8c78-0f2183b54ed0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0025a191-d2ae-4273-8d86-5c726a9d7b47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_f631db5e-efaa-4b03-8c78-0f2183b54ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4b714328-5c92-4b7b-b957-ad60a979d2c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c6e29d8-8521-43f3-8bfc-777a86dc9172" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4b714328-5c92-4b7b-b957-ad60a979d2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4697ea66-78e7-4511-afab-13b7b8c100c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4b714328-5c92-4b7b-b957-ad60a979d2c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4697ea66-78e7-4511-afab-13b7b8c100c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a528a301-36af-448a-85fd-093a115b90cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4b714328-5c92-4b7b-b957-ad60a979d2c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a528a301-36af-448a-85fd-093a115b90cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_87bd90b1-103d-450e-83f4-80238ef1f070" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4b714328-5c92-4b7b-b957-ad60a979d2c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_87bd90b1-103d-450e-83f4-80238ef1f070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_48626813-c3c0-42fa-870c-ea1bfe12b28e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4b714328-5c92-4b7b-b957-ad60a979d2c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_48626813-c3c0-42fa-870c-ea1bfe12b28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8327e517-5f58-4c23-8539-07eb4d097919" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c6e29d8-8521-43f3-8bfc-777a86dc9172" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8327e517-5f58-4c23-8539-07eb4d097919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8b6e0603-d42d-4b68-98d4-64ca4a5f385d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8327e517-5f58-4c23-8539-07eb4d097919" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8b6e0603-d42d-4b68-98d4-64ca4a5f385d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_60fa902d-9524-4b25-858f-cad2c18849b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8327e517-5f58-4c23-8539-07eb4d097919" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_60fa902d-9524-4b25-858f-cad2c18849b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f3830bdd-8885-4913-8d65-96212a1f616c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8327e517-5f58-4c23-8539-07eb4d097919" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f3830bdd-8885-4913-8d65-96212a1f616c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4c44aca4-8ba3-4e9e-92aa-2c003a34fb59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8327e517-5f58-4c23-8539-07eb4d097919" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4c44aca4-8ba3-4e9e-92aa-2c003a34fb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/Commitments" xlink:type="simple" xlink:href="ocgn-20191231.xsd#Commitments"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/Commitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4b08ed55-0b8d-489c-9619-99fe3aac6308" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4c4a93d8-deea-4949-984f-c9862d763a83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4b08ed55-0b8d-489c-9619-99fe3aac6308" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4c4a93d8-deea-4949-984f-c9862d763a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CommitmentsTables" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CommitmentsTables"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/CommitmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a80daa4d-4506-4e22-a0b7-61e25b522d90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_c1417a81-4966-47b1-bf96-0dd3e21a1082" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a80daa4d-4506-4e22-a0b7-61e25b522d90" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_c1417a81-4966-47b1-bf96-0dd3e21a1082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SupplementalBalanceSheetInformationLeasesTableTextBlock_f2d93694-244d-4d71-a953-d816574249e7" xlink:href="ocgn-20191231.xsd#ocgn_SupplementalBalanceSheetInformationLeasesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a80daa4d-4506-4e22-a0b7-61e25b522d90" xlink:to="loc_ocgn_SupplementalBalanceSheetInformationLeasesTableTextBlock_f2d93694-244d-4d71-a953-d816574249e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ba34e877-b534-41ee-9d1e-4aceb0c81f16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a80daa4d-4506-4e22-a0b7-61e25b522d90" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ba34e877-b534-41ee-9d1e-4aceb0c81f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_029348ce-6156-4c96-a2d2-4f4c9680007b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a80daa4d-4506-4e22-a0b7-61e25b522d90" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_029348ce-6156-4c96-a2d2-4f4c9680007b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CommitmentsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/CommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a92ce577-276a-4a98-8aa5-3d942c77d21c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_97609dc3-a94b-485f-aa55-c211b4832180" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a92ce577-276a-4a98-8aa5-3d942c77d21c" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_97609dc3-a94b-485f-aa55-c211b4832180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_da4bdbfc-ee72-4fa0-b8f8-888c9a8a10ce" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_97609dc3-a94b-485f-aa55-c211b4832180" xlink:to="loc_srt_RangeAxis_da4bdbfc-ee72-4fa0-b8f8-888c9a8a10ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d0eb1a8b-ff9b-4542-895d-07e2e32d81ba" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_da4bdbfc-ee72-4fa0-b8f8-888c9a8a10ce" xlink:to="loc_srt_RangeMember_d0eb1a8b-ff9b-4542-895d-07e2e32d81ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_aa6e9969-ab89-4700-b69d-943e59feb564" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d0eb1a8b-ff9b-4542-895d-07e2e32d81ba" xlink:to="loc_srt_MinimumMember_aa6e9969-ab89-4700-b69d-943e59feb564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_11a15f4e-9e6a-4501-8b8d-17baa217327b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d0eb1a8b-ff9b-4542-895d-07e2e32d81ba" xlink:to="loc_srt_MaximumMember_11a15f4e-9e6a-4501-8b8d-17baa217327b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_21f99b9e-ac7e-4477-a3c4-95ec41dec0e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_97609dc3-a94b-485f-aa55-c211b4832180" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_21f99b9e-ac7e-4477-a3c4-95ec41dec0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_37b306bb-9085-45ec-bf18-da46b8a8682c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_21f99b9e-ac7e-4477-a3c4-95ec41dec0e5" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_37b306bb-9085-45ec-bf18-da46b8a8682c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CommitmentsOperatingleasescomponentsofleaseexpenseDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CommitmentsOperatingleasescomponentsofleaseexpenseDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/CommitmentsOperatingleasescomponentsofleaseexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e4b8b616-b29c-4767-905a-975c487d07dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_dda5ffc9-0a95-4bae-8611-d3f6e6d98320" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e4b8b616-b29c-4767-905a-975c487d07dc" xlink:to="loc_us-gaap_OperatingLeaseCost_dda5ffc9-0a95-4bae-8611-d3f6e6d98320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_e1282e7d-2a57-4126-9d8d-62e063ec92a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e4b8b616-b29c-4767-905a-975c487d07dc" xlink:to="loc_us-gaap_VariableLeaseCost_e1282e7d-2a57-4126-9d8d-62e063ec92a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_2479581e-8d51-4446-8a4f-d4d5f15d251a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e4b8b616-b29c-4767-905a-975c487d07dc" xlink:to="loc_us-gaap_LeaseCost_2479581e-8d51-4446-8a4f-d4d5f15d251a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CommitmentsOperatingleasessupplementalbalancesheetinformationDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CommitmentsOperatingleasessupplementalbalancesheetinformationDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/CommitmentsOperatingleasessupplementalbalancesheetinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b52128fe-bfef-4406-9789-60519e3c2f93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7286faa8-1a52-4ce5-a3e1-f58bb9393beb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b52128fe-bfef-4406-9789-60519e3c2f93" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7286faa8-1a52-4ce5-a3e1-f58bb9393beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b5426111-6b1e-430f-8c3f-bbc453bbd984" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b52128fe-bfef-4406-9789-60519e3c2f93" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b5426111-6b1e-430f-8c3f-bbc453bbd984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_eb135748-40af-47f7-bc3e-7fad93599316" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b52128fe-bfef-4406-9789-60519e3c2f93" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_eb135748-40af-47f7-bc3e-7fad93599316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3785168d-5df5-4979-82a9-a946953428a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b52128fe-bfef-4406-9789-60519e3c2f93" xlink:to="loc_us-gaap_OperatingLeaseLiability_3785168d-5df5-4979-82a9-a946953428a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CommitmentsOperatingleasessupplementalinformationrelatedtoleasesDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CommitmentsOperatingleasessupplementalinformationrelatedtoleasesDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/CommitmentsOperatingleasessupplementalinformationrelatedtoleasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6e342ef8-a803-4d1a-b301-0b43a7cba3b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_463b0864-1c9a-428c-9817-5bfba39ce727" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6e342ef8-a803-4d1a-b301-0b43a7cba3b3" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_463b0864-1c9a-428c-9817-5bfba39ce727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_dfdb7b73-c124-497e-b2cc-cff49d1b1f35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6e342ef8-a803-4d1a-b301-0b43a7cba3b3" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_dfdb7b73-c124-497e-b2cc-cff49d1b1f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CommitmentsOperatingleasesfutureminimumleasepaymentsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CommitmentsOperatingleasesfutureminimumleasepaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/CommitmentsOperatingleasesfutureminimumleasepaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_da34765f-3f70-40da-ac3b-44c11b464752" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_90500d40-00d8-40d7-b3fd-9a14fa08e573" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_da34765f-3f70-40da-ac3b-44c11b464752" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_90500d40-00d8-40d7-b3fd-9a14fa08e573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ad7536f0-243b-4b57-885b-2f20645493cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_da34765f-3f70-40da-ac3b-44c11b464752" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ad7536f0-243b-4b57-885b-2f20645493cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_50be84ff-7ca5-4842-bbe0-f0940b6a6b60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_da34765f-3f70-40da-ac3b-44c11b464752" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_50be84ff-7ca5-4842-bbe0-f0940b6a6b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_20bbcb00-2e08-4347-90ba-695be91d38ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_da34765f-3f70-40da-ac3b-44c11b464752" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_20bbcb00-2e08-4347-90ba-695be91d38ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9c2b8e3b-150d-42ae-a544-41755340db7d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_da34765f-3f70-40da-ac3b-44c11b464752" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9c2b8e3b-150d-42ae-a544-41755340db7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e01f7a99-131c-4b52-80bf-e80910413ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_da34765f-3f70-40da-ac3b-44c11b464752" xlink:to="loc_us-gaap_OperatingLeaseLiability_e01f7a99-131c-4b52-80bf-e80910413ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CommitmentsFinanceleasesDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CommitmentsFinanceleasesDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/CommitmentsFinanceleasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3d318c4d-af5b-48b2-b094-2f216e6ef089" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_19ee4920-b4fb-48f9-a508-c23d7f8520b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3d318c4d-af5b-48b2-b094-2f216e6ef089" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_19ee4920-b4fb-48f9-a508-c23d7f8520b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseDiscountRate_5c29f59f-8aa8-412c-aece-452230bb3726" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeaseDiscountRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3d318c4d-af5b-48b2-b094-2f216e6ef089" xlink:to="loc_us-gaap_LesseeFinanceLeaseDiscountRate_5c29f59f-8aa8-412c-aece-452230bb3726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CommitmentsFinanceleasesfutureminimumleasepaymentsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#CommitmentsFinanceleasesfutureminimumleasepaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/CommitmentsFinanceleasesfutureminimumleasepaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5643ef2b-3db4-4976-b464-e8622b94049a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_817058de-de35-4f61-bf90-d6a2653f8bc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5643ef2b-3db4-4976-b464-e8622b94049a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_817058de-de35-4f61-bf90-d6a2653f8bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_5f39503d-69d3-4c4c-987b-f21489c614ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5643ef2b-3db4-4976-b464-e8622b94049a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_5f39503d-69d3-4c4c-987b-f21489c614ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_6d6ed9b8-65ce-4fbf-b97d-6a480c4dd853" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5643ef2b-3db4-4976-b464-e8622b94049a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_6d6ed9b8-65ce-4fbf-b97d-6a480c4dd853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_a22dd2a7-2107-4632-9405-b97d2701244a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5643ef2b-3db4-4976-b464-e8622b94049a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_a22dd2a7-2107-4632-9405-b97d2701244a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_cc41b5d2-267c-4f36-94b9-3aea579fc34a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5643ef2b-3db4-4976-b464-e8622b94049a" xlink:to="loc_us-gaap_FinanceLeaseLiability_cc41b5d2-267c-4f36-94b9-3aea579fc34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/Warrants" xlink:type="simple" xlink:href="ocgn-20191231.xsd#Warrants"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/Warrants" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_219ceb83-5b61-4996-99c8-26a7d54d563d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_WarrantsTextBlock_d0560a6e-848e-4b83-a4e5-320840c556ff" xlink:href="ocgn-20191231.xsd#ocgn_WarrantsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_219ceb83-5b61-4996-99c8-26a7d54d563d" xlink:to="loc_ocgn_WarrantsTextBlock_d0560a6e-848e-4b83-a4e5-320840c556ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/WarrantsTables" xlink:type="simple" xlink:href="ocgn-20191231.xsd#WarrantsTables"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/WarrantsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_771d6e60-927b-4b82-a621-90ed6a85bf4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ScheduleOfPreMergerFinancingWarrantsTableTextBlock_329cd78b-18b4-493b-a591-f3363735dd03" xlink:href="ocgn-20191231.xsd#ocgn_ScheduleOfPreMergerFinancingWarrantsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_771d6e60-927b-4b82-a621-90ed6a85bf4f" xlink:to="loc_ocgn_ScheduleOfPreMergerFinancingWarrantsTableTextBlock_329cd78b-18b4-493b-a591-f3363735dd03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_3038dd64-c3a1-4ab1-828e-24211abee5e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_771d6e60-927b-4b82-a621-90ed6a85bf4f" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_3038dd64-c3a1-4ab1-828e-24211abee5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/WarrantsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#WarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/WarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_395b2389-45d2-404c-be72-3ab979df471e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_26f3c4c2-26ed-47e9-8eb4-4bc5cbf2d52e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_395b2389-45d2-404c-be72-3ab979df471e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_26f3c4c2-26ed-47e9-8eb4-4bc5cbf2d52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_3b740be4-3947-42c5-99c9-0747c97dca72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_26f3c4c2-26ed-47e9-8eb4-4bc5cbf2d52e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_3b740be4-3947-42c5-99c9-0747c97dca72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_931e7ab8-ecbf-4762-a47f-90093226d492" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3b740be4-3947-42c5-99c9-0747c97dca72" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_931e7ab8-ecbf-4762-a47f-90093226d492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesWarrantsMember_16008f93-14d3-4074-9c30-49a5e31a3465" xlink:href="ocgn-20191231.xsd#ocgn_SeriesWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_931e7ab8-ecbf-4762-a47f-90093226d492" xlink:to="loc_ocgn_SeriesWarrantsMember_16008f93-14d3-4074-9c30-49a5e31a3465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesBWarrantsMember_c9ef52df-03a8-4346-89c1-bc31f2f11c25" xlink:href="ocgn-20191231.xsd#ocgn_SeriesBWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_931e7ab8-ecbf-4762-a47f-90093226d492" xlink:to="loc_ocgn_SeriesBWarrantsMember_c9ef52df-03a8-4346-89c1-bc31f2f11c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesCWarrantsMember_06d19cc2-b2b5-403f-a6af-c1974d439dc6" xlink:href="ocgn-20191231.xsd#ocgn_SeriesCWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_931e7ab8-ecbf-4762-a47f-90093226d492" xlink:to="loc_ocgn_SeriesCWarrantsMember_06d19cc2-b2b5-403f-a6af-c1974d439dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_FormerOcugenWarrantsMember_9ab0152b-dd66-4cc0-bb86-532f51d6aa44" xlink:href="ocgn-20191231.xsd#ocgn_FormerOcugenWarrantsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_931e7ab8-ecbf-4762-a47f-90093226d492" xlink:to="loc_ocgn_FormerOcugenWarrantsMember_9ab0152b-dd66-4cc0-bb86-532f51d6aa44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_924b3ee6-e11c-4c2f-a278-5d52ac8ae7a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_26f3c4c2-26ed-47e9-8eb4-4bc5cbf2d52e" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_924b3ee6-e11c-4c2f-a278-5d52ac8ae7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_9965dbc2-79a4-4111-9f74-2af2ccdece9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_924b3ee6-e11c-4c2f-a278-5d52ac8ae7a9" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_9965dbc2-79a4-4111-9f74-2af2ccdece9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_e969efb8-5098-4c0e-b9f7-b0edc8cdc03f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9965dbc2-79a4-4111-9f74-2af2ccdece9c" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_e969efb8-5098-4c0e-b9f7-b0edc8cdc03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_853c733f-2304-4995-a929-4b5617ddefb0" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_26f3c4c2-26ed-47e9-8eb4-4bc5cbf2d52e" xlink:to="loc_srt_RangeAxis_853c733f-2304-4995-a929-4b5617ddefb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8f27c150-8cc4-450a-bb07-77813d01d290" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_853c733f-2304-4995-a929-4b5617ddefb0" xlink:to="loc_srt_RangeMember_8f27c150-8cc4-450a-bb07-77813d01d290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3338b5a8-5f07-4a12-a8d1-e278f2d00f2c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8f27c150-8cc4-450a-bb07-77813d01d290" xlink:to="loc_srt_MaximumMember_3338b5a8-5f07-4a12-a8d1-e278f2d00f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_26f3c4c2-26ed-47e9-8eb4-4bc5cbf2d52e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionLowerPercentageOfCommonStock_4d7f39bd-1546-405c-980d-21c696e6bb9d" xlink:href="ocgn-20191231.xsd#ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionLowerPercentageOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionLowerPercentageOfCommonStock_4d7f39bd-1546-405c-980d-21c696e6bb9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionHigherPercentageOfCommonStock_8b37a856-64f5-4836-8e39-9f968f41ad59" xlink:href="ocgn-20191231.xsd#ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionHigherPercentageOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionHigherPercentageOfCommonStock_8b37a856-64f5-4836-8e39-9f968f41ad59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_PercentageOfAmountOnMarketValueForFailureToIssueCommonStockOnPreMergerFinancingWarrants_f832d9f5-918c-4933-8a63-004421fe5de4" xlink:href="ocgn-20191231.xsd#ocgn_PercentageOfAmountOnMarketValueForFailureToIssueCommonStockOnPreMergerFinancingWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_ocgn_PercentageOfAmountOnMarketValueForFailureToIssueCommonStockOnPreMergerFinancingWarrants_f832d9f5-918c-4933-8a63-004421fe5de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0aa415be-2155-48b1-a9fa-6fb89e422391" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0aa415be-2155-48b1-a9fa-6fb89e422391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_8f5eb30d-5855-4c46-829d-491b31af1457" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_8f5eb30d-5855-4c46-829d-491b31af1457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_1f2910e5-6c24-4744-a976-7ed9097b6806" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_1f2910e5-6c24-4744-a976-7ed9097b6806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ProceedsFromWarrantExercisesMaximumAmount_414791e7-559d-439f-ad40-0dcbf764453f" xlink:href="ocgn-20191231.xsd#ocgn_ProceedsFromWarrantExercisesMaximumAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_ocgn_ProceedsFromWarrantExercisesMaximumAmount_414791e7-559d-439f-ad40-0dcbf764453f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger_d5755b53-8e70-4f64-a8d8-36d9b2756ba5" xlink:href="ocgn-20191231.xsd#ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger_d5755b53-8e70-4f64-a8d8-36d9b2756ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPrice_0851222a-f769-47a6-9908-5a8548e3dade" xlink:href="ocgn-20191231.xsd#ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPrice_0851222a-f769-47a6-9908-5a8548e3dade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CommonStockAdditionalSharesOfCommonStockIssuableUponExerciseOfWarrantsBasedOnResetPeriodShares_299f0537-e0ed-4e97-a0f9-549648c9e57f" xlink:href="ocgn-20191231.xsd#ocgn_CommonStockAdditionalSharesOfCommonStockIssuableUponExerciseOfWarrantsBasedOnResetPeriodShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_ocgn_CommonStockAdditionalSharesOfCommonStockIssuableUponExerciseOfWarrantsBasedOnResetPeriodShares_299f0537-e0ed-4e97-a0f9-549648c9e57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f136d5e1-4298-43aa-acd1-39cf49408b49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f136d5e1-4298-43aa-acd1-39cf49408b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightExercisePriceDeterminationNumberOfTradingDaysConsidered_4915f060-d643-4610-ba23-f6047044433b" xlink:href="ocgn-20191231.xsd#ocgn_ClassOfWarrantOrRightExercisePriceDeterminationNumberOfTradingDaysConsidered"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_ocgn_ClassOfWarrantOrRightExercisePriceDeterminationNumberOfTradingDaysConsidered_4915f060-d643-4610-ba23-f6047044433b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightConditionForExpirationTradingDay_9d609244-880f-4c5a-b60f-152edb3e5bd6" xlink:href="ocgn-20191231.xsd#ocgn_ClassOfWarrantOrRightConditionForExpirationTradingDay"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_ocgn_ClassOfWarrantOrRightConditionForExpirationTradingDay_9d609244-880f-4c5a-b60f-152edb3e5bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_84373ecb-e349-4f4b-97be-2c51048ee654" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_84373ecb-e349-4f4b-97be-2c51048ee654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfFormerEmployeesWithWarrants_9fa94e40-07b2-4995-acdd-09107576ae1a" xlink:href="ocgn-20191231.xsd#ocgn_NumberOfFormerEmployeesWithWarrants"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_ocgn_NumberOfFormerEmployeesWithWarrants_9fa94e40-07b2-4995-acdd-09107576ae1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightExercisable_6c55cfc5-b7f5-4790-8d0a-a799c3177b2d" xlink:href="ocgn-20191231.xsd#ocgn_ClassOfWarrantOrRightExercisable"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ec5b1a4d-b872-4e35-b042-b0f496b2bffc" xlink:to="loc_ocgn_ClassOfWarrantOrRightExercisable_6c55cfc5-b7f5-4790-8d0a-a799c3177b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/ScheduleofActivityofthePreMergerFinancingWarrantsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#ScheduleofActivityofthePreMergerFinancingWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/ScheduleofActivityofthePreMergerFinancingWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_076b3576-85db-4353-b51c-a56fff1804bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_be0de269-e145-4ad3-a4a6-7c97a4cecfab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_076b3576-85db-4353-b51c-a56fff1804bc" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_be0de269-e145-4ad3-a4a6-7c97a4cecfab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_adca05b9-1f6c-403c-8705-777cdb4d1c5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_be0de269-e145-4ad3-a4a6-7c97a4cecfab" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_adca05b9-1f6c-403c-8705-777cdb4d1c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ecda0270-4b03-4804-8f3d-71aa18ae8d9a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_adca05b9-1f6c-403c-8705-777cdb4d1c5f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ecda0270-4b03-4804-8f3d-71aa18ae8d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesWarrantsMember_569a1f9c-0359-4a01-8559-d045c92719cf" xlink:href="ocgn-20191231.xsd#ocgn_SeriesWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecda0270-4b03-4804-8f3d-71aa18ae8d9a" xlink:to="loc_ocgn_SeriesWarrantsMember_569a1f9c-0359-4a01-8559-d045c92719cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesBWarrantsMember_6914f35e-03a3-4d5b-b546-ed9c36cc0839" xlink:href="ocgn-20191231.xsd#ocgn_SeriesBWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecda0270-4b03-4804-8f3d-71aa18ae8d9a" xlink:to="loc_ocgn_SeriesBWarrantsMember_6914f35e-03a3-4d5b-b546-ed9c36cc0839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesCWarrantsMember_a55fb359-d743-4f2e-bcc8-1dd9274b47e2" xlink:href="ocgn-20191231.xsd#ocgn_SeriesCWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecda0270-4b03-4804-8f3d-71aa18ae8d9a" xlink:to="loc_ocgn_SeriesCWarrantsMember_a55fb359-d743-4f2e-bcc8-1dd9274b47e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_1a193d18-c625-4b05-ac05-725fc663b86f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_be0de269-e145-4ad3-a4a6-7c97a4cecfab" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_1a193d18-c625-4b05-ac05-725fc663b86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b64eaebc-94e8-43c6-a17e-e3fef8c30918" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_1a193d18-c625-4b05-ac05-725fc663b86f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b64eaebc-94e8-43c6-a17e-e3fef8c30918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_895cb6a4-b9e3-47a8-a957-2b4176df249e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b64eaebc-94e8-43c6-a17e-e3fef8c30918" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_895cb6a4-b9e3-47a8-a957-2b4176df249e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightIssued_d81c34e1-135a-4769-8629-958314f3cada" xlink:href="ocgn-20191231.xsd#ocgn_ClassOfWarrantOrRightIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b64eaebc-94e8-43c6-a17e-e3fef8c30918" xlink:to="loc_ocgn_ClassOfWarrantOrRightIssued_d81c34e1-135a-4769-8629-958314f3cada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightExercised_dffd5a8b-eaf9-477b-aad2-68e5059ea4ef" xlink:href="ocgn-20191231.xsd#ocgn_ClassOfWarrantOrRightExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b64eaebc-94e8-43c6-a17e-e3fef8c30918" xlink:to="loc_ocgn_ClassOfWarrantOrRightExercised_dffd5a8b-eaf9-477b-aad2-68e5059ea4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_117db1e1-83f6-4c2b-aebb-d122e93119ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b64eaebc-94e8-43c6-a17e-e3fef8c30918" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_117db1e1-83f6-4c2b-aebb-d122e93119ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5ca1aba2-052b-4422-a7ac-1300e8a31898" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b64eaebc-94e8-43c6-a17e-e3fef8c30918" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5ca1aba2-052b-4422-a7ac-1300e8a31898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/ScheduleofRollforwardofSeriesBWarrantLiabilityDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#ScheduleofRollforwardofSeriesBWarrantLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/ScheduleofRollforwardofSeriesBWarrantLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_4a26f01b-3acc-4ff8-896a-5932c6d70ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_7556e093-9aa3-47cf-a30c-574df5359662" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_4a26f01b-3acc-4ff8-896a-5932c6d70ed2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_7556e093-9aa3-47cf-a30c-574df5359662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_6d87d766-4971-41b8-9068-253e70b8e517" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_7556e093-9aa3-47cf-a30c-574df5359662" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_6d87d766-4971-41b8-9068-253e70b8e517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7c91752f-d313-4f42-b88e-1cbedae2a4e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6d87d766-4971-41b8-9068-253e70b8e517" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7c91752f-d313-4f42-b88e-1cbedae2a4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesBWarrantsMember_a4364310-f1b8-4c74-9e78-aae44972a8a7" xlink:href="ocgn-20191231.xsd#ocgn_SeriesBWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7c91752f-d313-4f42-b88e-1cbedae2a4e6" xlink:to="loc_ocgn_SeriesBWarrantsMember_a4364310-f1b8-4c74-9e78-aae44972a8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_bf7525bd-f637-425c-af79-90442b6ade84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_7556e093-9aa3-47cf-a30c-574df5359662" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_bf7525bd-f637-425c-af79-90442b6ade84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_5667938d-6c45-4d7b-98dc-268dbd40164e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_bf7525bd-f637-425c-af79-90442b6ade84" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_5667938d-6c45-4d7b-98dc-268dbd40164e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_902fed7d-4331-4c1c-837a-401c77e39952" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_5667938d-6c45-4d7b-98dc-268dbd40164e" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_902fed7d-4331-4c1c-837a-401c77e39952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_bcbe3bee-7bc8-401c-b4dc-9c57225c8762" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_5667938d-6c45-4d7b-98dc-268dbd40164e" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_bcbe3bee-7bc8-401c-b4dc-9c57225c8762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_87a9c105-a03f-4bac-bf66-5fc4416810c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_5667938d-6c45-4d7b-98dc-268dbd40164e" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_87a9c105-a03f-4bac-bf66-5fc4416810c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationAmountReclassifiedToEquity_71601d54-604e-4c67-b3f2-ed9bf12e74bf" xlink:href="ocgn-20191231.xsd#ocgn_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationAmountReclassifiedToEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_5667938d-6c45-4d7b-98dc-268dbd40164e" xlink:to="loc_ocgn_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationAmountReclassifiedToEquity_71601d54-604e-4c67-b3f2-ed9bf12e74bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_7a570da1-8680-4c1f-8b54-df8b5828ff1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_5667938d-6c45-4d7b-98dc-268dbd40164e" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_7a570da1-8680-4c1f-8b54-df8b5828ff1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ocgn-20191231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_916811c7-ab2c-4184-aeee-f546da053c16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_4ee8b51c-986d-4175-961a-2700d436f66e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_916811c7-ab2c-4184-aeee-f546da053c16" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_4ee8b51c-986d-4175-961a-2700d436f66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="ocgn-20191231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a1e816d9-0212-4080-b46f-7a5f7eeb7955" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_a795ce79-1f11-49ff-a271-440ccd8c3eaa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a1e816d9-0212-4080-b46f-7a5f7eeb7955" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_a795ce79-1f11-49ff-a271-440ccd8c3eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_51f9fb36-06ab-470e-a4c0-162c7f4b99d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a1e816d9-0212-4080-b46f-7a5f7eeb7955" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_51f9fb36-06ab-470e-a4c0-162c7f4b99d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_ca5bd246-0c63-498a-b327-28f4ce475a91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a1e816d9-0212-4080-b46f-7a5f7eeb7955" xlink:to="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_ca5bd246-0c63-498a-b327-28f4ce475a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#ScheduleofDeferredTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_543cabb1-cc25-4fdd-91a2-405b6aa298aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_47e510f3-9337-4462-8734-63e03cfb172c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_543cabb1-cc25-4fdd-91a2-405b6aa298aa" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_47e510f3-9337-4462-8734-63e03cfb172c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_cb365c03-a460-42bd-898f-0dbd04c4e7bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_47e510f3-9337-4462-8734-63e03cfb172c" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_cb365c03-a460-42bd-898f-0dbd04c4e7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_fe4454e7-5567-4eb9-b124-e6ee4af573c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_47e510f3-9337-4462-8734-63e03cfb172c" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_fe4454e7-5567-4eb9-b124-e6ee4af573c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_DeferredTaxAssetsStartUpCosts_2326630d-8543-492f-b13f-8d0fa3a42436" xlink:href="ocgn-20191231.xsd#ocgn_DeferredTaxAssetsStartUpCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_47e510f3-9337-4462-8734-63e03cfb172c" xlink:to="loc_ocgn_DeferredTaxAssetsStartUpCosts_2326630d-8543-492f-b13f-8d0fa3a42436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_723f76ab-f6d6-4c34-ad7f-bd4585455e39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_47e510f3-9337-4462-8734-63e03cfb172c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_723f76ab-f6d6-4c34-ad7f-bd4585455e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_856d1f4e-87be-4810-ad24-67664ac7d68c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_47e510f3-9337-4462-8734-63e03cfb172c" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_856d1f4e-87be-4810-ad24-67664ac7d68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_177fa6db-44b0-40a6-a2fd-b6a617ae0cfd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_47e510f3-9337-4462-8734-63e03cfb172c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_177fa6db-44b0-40a6-a2fd-b6a617ae0cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_DeferredTaxAssetsConvertibleDebt_af92a23d-4c72-495e-9a20-384c32cb4574" xlink:href="ocgn-20191231.xsd#ocgn_DeferredTaxAssetsConvertibleDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_47e510f3-9337-4462-8734-63e03cfb172c" xlink:to="loc_ocgn_DeferredTaxAssetsConvertibleDebt_af92a23d-4c72-495e-9a20-384c32cb4574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_2fa29d30-5793-45ca-b4ba-152ba7b042f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_47e510f3-9337-4462-8734-63e03cfb172c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_2fa29d30-5793-45ca-b4ba-152ba7b042f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_DeferredTaxAssetsLeaseLiability_6ab599fd-38d0-4844-98a2-970b60042e7c" xlink:href="ocgn-20191231.xsd#ocgn_DeferredTaxAssetsLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_47e510f3-9337-4462-8734-63e03cfb172c" xlink:to="loc_ocgn_DeferredTaxAssetsLeaseLiability_6ab599fd-38d0-4844-98a2-970b60042e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_5bbeb611-f6fa-47ae-b0f4-0979b4e5065e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_543cabb1-cc25-4fdd-91a2-405b6aa298aa" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_5bbeb611-f6fa-47ae-b0f4-0979b4e5065e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_31be352a-43c3-4ead-98f3-53a06fbaa8c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_543cabb1-cc25-4fdd-91a2-405b6aa298aa" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_31be352a-43c3-4ead-98f3-53a06fbaa8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_332cb99d-38d3-404a-b37e-1c62b4012a43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_543cabb1-cc25-4fdd-91a2-405b6aa298aa" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_332cb99d-38d3-404a-b37e-1c62b4012a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_f49ee5c0-25d5-4425-b97c-2fd423409635" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_543cabb1-cc25-4fdd-91a2-405b6aa298aa" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_f49ee5c0-25d5-4425-b97c-2fd423409635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_8387f8a4-bcc8-48d6-a561-4d4e3c0c1944" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_f49ee5c0-25d5-4425-b97c-2fd423409635" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_8387f8a4-bcc8-48d6-a561-4d4e3c0c1944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c58548b6-7271-4f72-a3e1-a38489578997" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_543cabb1-cc25-4fdd-91a2-405b6aa298aa" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c58548b6-7271-4f72-a3e1-a38489578997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_186e4ba3-e628-48bb-b1ba-ccbaf6245927" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_56f22e2d-8ada-474f-b2ca-0e27f959f3a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_186e4ba3-e628-48bb-b1ba-ccbaf6245927" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_56f22e2d-8ada-474f-b2ca-0e27f959f3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_a07c1573-b3b1-434f-bdb0-232a77097b5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_56f22e2d-8ada-474f-b2ca-0e27f959f3a3" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_a07c1573-b3b1-434f-bdb0-232a77097b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_be4cc3ec-fe2a-4d59-adfc-43b343d84b58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_a07c1573-b3b1-434f-bdb0-232a77097b5b" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_be4cc3ec-fe2a-4d59-adfc-43b343d84b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_fca0a602-9836-492f-b9f1-9c9efa188b9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_be4cc3ec-fe2a-4d59-adfc-43b343d84b58" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_fca0a602-9836-492f-b9f1-9c9efa188b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_c4b11d25-d741-4cb8-97ff-bd9af801e13b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_be4cc3ec-fe2a-4d59-adfc-43b343d84b58" xlink:to="loc_us-gaap_DomesticCountryMember_c4b11d25-d741-4cb8-97ff-bd9af801e13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_f6aa7945-3889-4a6e-94b3-980536cb6c97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_56f22e2d-8ada-474f-b2ca-0e27f959f3a3" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_f6aa7945-3889-4a6e-94b3-980536cb6c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a8dbfab7-9307-49d7-b3b4-775ff290e36d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f6aa7945-3889-4a6e-94b3-980536cb6c97" xlink:to="loc_us-gaap_NetIncomeLoss_a8dbfab7-9307-49d7-b3b4-775ff290e36d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_91681608-60ad-4557-ab7f-9e29cf68c002" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f6aa7945-3889-4a6e-94b3-980536cb6c97" xlink:to="loc_us-gaap_OperatingLossCarryforwards_91681608-60ad-4557-ab7f-9e29cf68c002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_a27fd098-4f04-4377-9bc4-8a0fb9b2670a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f6aa7945-3889-4a6e-94b3-980536cb6c97" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_a27fd098-4f04-4377-9bc4-8a0fb9b2670a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_a07cd82a-e81f-421c-8da8-675aa5e9991f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f6aa7945-3889-4a6e-94b3-980536cb6c97" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_a07cd82a-e81f-421c-8da8-675aa5e9991f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_7a628fcf-1172-4fab-9bd2-9b58c4ada562" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f6aa7945-3889-4a6e-94b3-980536cb6c97" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_7a628fcf-1172-4fab-9bd2-9b58c4ada562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_88c9a998-2f76-4c31-a934-bab800ae781b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f6aa7945-3889-4a6e-94b3-980536cb6c97" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_88c9a998-2f76-4c31-a934-bab800ae781b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_4e4b4005-c922-46ae-a78c-1690425e0d8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f6aa7945-3889-4a6e-94b3-980536cb6c97" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_4e4b4005-c922-46ae-a78c-1690425e0d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/ScheduleofEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#ScheduleofEffectiveIncomeTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/ScheduleofEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_647bb123-1a76-434c-a90b-521e3898b98a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_46e315de-a1ba-44ab-8436-74537ca09370" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_647bb123-1a76-434c-a90b-521e3898b98a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_46e315de-a1ba-44ab-8436-74537ca09370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_167ec954-10ea-4023-807a-0ec65bdfa1f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_647bb123-1a76-434c-a90b-521e3898b98a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_167ec954-10ea-4023-807a-0ec65bdfa1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_2d6b7655-1f0b-427a-a6a4-5377532d9d3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_647bb123-1a76-434c-a90b-521e3898b98a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_2d6b7655-1f0b-427a-a6a4-5377532d9d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_c7d4c714-dfb0-4e1f-aa92-4a51594653a5" xlink:href="ocgn-20191231.xsd#ocgn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_647bb123-1a76-434c-a90b-521e3898b98a" xlink:to="loc_ocgn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_c7d4c714-dfb0-4e1f-aa92-4a51594653a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_d5567c40-76bd-45a4-9d2b-0d9802af7440" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_647bb123-1a76-434c-a90b-521e3898b98a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_d5567c40-76bd-45a4-9d2b-0d9802af7440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_8ccef8e0-101c-4f4d-980a-0754e03eba07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_647bb123-1a76-434c-a90b-521e3898b98a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_8ccef8e0-101c-4f4d-980a-0754e03eba07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8cc7a81e-5c8c-4dc4-aad1-33ec60953c4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_647bb123-1a76-434c-a90b-521e3898b98a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8cc7a81e-5c8c-4dc4-aad1-33ec60953c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/ScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#ScheduleofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/ScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1bc6de44-d55d-434c-b4a1-0eddc382cc3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f579ead0-a086-491a-ae28-55b1437028f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1bc6de44-d55d-434c-b4a1-0eddc382cc3b" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f579ead0-a086-491a-ae28-55b1437028f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_c3696234-4fda-40e7-b1c2-b98eeaf84500" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f579ead0-a086-491a-ae28-55b1437028f2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_c3696234-4fda-40e7-b1c2-b98eeaf84500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_a7934019-e3c0-4356-b70e-8932b9d18c64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f579ead0-a086-491a-ae28-55b1437028f2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_a7934019-e3c0-4356-b70e-8932b9d18c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_712fabcc-c3ee-4ca6-9024-7709cb157b35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f579ead0-a086-491a-ae28-55b1437028f2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_712fabcc-c3ee-4ca6-9024-7709cb157b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_8c75a117-064c-4a43-a1c8-b618df71d316" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f579ead0-a086-491a-ae28-55b1437028f2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_8c75a117-064c-4a43-a1c8-b618df71d316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_f285589b-d5ea-4c42-b6ac-331a2f9ae4b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f579ead0-a086-491a-ae28-55b1437028f2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_f285589b-d5ea-4c42-b6ac-331a2f9ae4b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_7cfc3773-ef72-4c1d-bea3-7c2b2c9837c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f579ead0-a086-491a-ae28-55b1437028f2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_7cfc3773-ef72-4c1d-bea3-7c2b2c9837c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SubsequentEvents" xlink:type="simple" xlink:href="ocgn-20191231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_244cb41f-843c-4457-83aa-810d5f5faa39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_6b319320-f4d6-4849-b31a-8c119d5b8489" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_244cb41f-843c-4457-83aa-810d5f5faa39" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_6b319320-f4d6-4849-b31a-8c119d5b8489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ocgn-20191231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_8c7f19e3-f20d-423a-b134-8ff7527e5fa8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_5d8e15a2-23d2-4e14-804d-6de20f4e793d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_8c7f19e3-f20d-423a-b134-8ff7527e5fa8" xlink:to="loc_us-gaap_SubsequentEventTable_5d8e15a2-23d2-4e14-804d-6de20f4e793d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1220e13d-3e2e-420d-8bd6-27ecd5c023b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5d8e15a2-23d2-4e14-804d-6de20f4e793d" xlink:to="loc_us-gaap_DebtInstrumentAxis_1220e13d-3e2e-420d-8bd6-27ecd5c023b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cbf68f0f-8ff9-4752-aa64-50ed7c54635b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1220e13d-3e2e-420d-8bd6-27ecd5c023b7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cbf68f0f-8ff9-4752-aa64-50ed7c54635b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EB5ProgramBorrowingsMember_91151057-8001-40d3-8c01-e7340734f1b1" xlink:href="ocgn-20191231.xsd#ocgn_EB5ProgramBorrowingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cbf68f0f-8ff9-4752-aa64-50ed7c54635b" xlink:to="loc_ocgn_EB5ProgramBorrowingsMember_91151057-8001-40d3-8c01-e7340734f1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_db6d625a-6606-4313-86d1-7cb9b8a89fd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5d8e15a2-23d2-4e14-804d-6de20f4e793d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_db6d625a-6606-4313-86d1-7cb9b8a89fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c771a359-a757-417b-90e7-0e23985941c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_db6d625a-6606-4313-86d1-7cb9b8a89fd4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c771a359-a757-417b-90e7-0e23985941c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_42c6f3a6-ceb3-4fc7-a0c1-167f60b9b33d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c771a359-a757-417b-90e7-0e23985941c9" xlink:to="loc_us-gaap_LoansPayableMember_42c6f3a6-ceb3-4fc7-a0c1-167f60b9b33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_347c9106-9cd1-4b1f-8902-8e3f4572c81c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5d8e15a2-23d2-4e14-804d-6de20f4e793d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_347c9106-9cd1-4b1f-8902-8e3f4572c81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c7f586e4-4426-4c01-8a4e-d9b367671b51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_347c9106-9cd1-4b1f-8902-8e3f4572c81c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c7f586e4-4426-4c01-8a4e-d9b367671b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c93ca967-763e-432d-9a68-2f4d4bbc846a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c7f586e4-4426-4c01-8a4e-d9b367671b51" xlink:to="loc_us-gaap_SubsequentEventMember_c93ca967-763e-432d-9a68-2f4d4bbc846a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_66c046da-1606-42be-9f23-9744a0640280" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5d8e15a2-23d2-4e14-804d-6de20f4e793d" xlink:to="loc_us-gaap_SubsequentEventLineItems_66c046da-1606-42be-9f23-9744a0640280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_3d7ea319-111f-4102-991c-5663d4b95c01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_66c046da-1606-42be-9f23-9744a0640280" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_3d7ea319-111f-4102-991c-5663d4b95c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d4c64e5a-e7fe-40f6-beb0-f215cbe1bcc7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_66c046da-1606-42be-9f23-9744a0640280" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d4c64e5a-e7fe-40f6-beb0-f215cbe1bcc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ocgn-20191231_g1.jpg
<TEXT>
begin 644 ocgn-20191231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M  50_:0'_-:/''_@4G_Q%>?_ +6'_)UOQ2_['+6?_2^>N!H ]]_X>H_M(?\
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M_LE77A_Q=IOPBU>[^+&@V=S!+KD?C">WTW69IMX\ZZLQ&0V _P!Q6"Y4'KR
M#E?B5\%_"_B3_@GCX'^*WAO2%T?6M)\47G@WQ3'%-)(EXQ0W-G=,')V/Y>8V
MQ@,0#@&N1_82_P"3W_@W_P!CMH__ *615Z'\6?C-H>D?\$Y/#/@BSUK2=5\8
M?$+QM>>/?$UOI[;ETA%1H+:VE'1)&+-)L'*KC->>?L)?\GO_  ;_ .QVT?\
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M3H?A3P]X)\-7/BWP#)XHU#6$U&X$,EI&X\R_U R B)U!4;(@P))QZ#I/$_\
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ML:!\+?AWYVK7&D> _ >@VXB(N)([.)(4&%CZA8X\# 4?,1QQT/Y%_P#!6O\
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M<_\ Q% ')T5UG_"@_'G_ $(_C+_P27/_ ,11_P *#\>?]"/XR_\ !)<__$4
M<G176?\ "@_'G_0C^,O_  27/_Q%'_"@_'G_ $(_C+_P27/_ ,10!R=%=9_P
MH/QY_P!"/XR_\$ES_P#$4?\ "@_'G_0C^,O_  27/_Q% ')T5UG_  H/QY_T
M(_C+_P $ES_\11_PH/QY_P!"/XR_\$ES_P#$4 <G176?\*#\>?\ 0C^,O_!)
M<_\ Q%'_  H/QY_T(_C+_P $ES_\10!R=%=9_P *#\>?]"/XR_\ !)<__$4?
M\*#\>?\ 0C^,O_!)<_\ Q% ')T5UG_"@_'G_ $(_C+_P27/_ ,11_P *#\>?
M]"/XR_\ !)<__$4 <G176?\ "@_'G_0C^,O_  27/_Q%'_"@_'G_ $(_C+_P
M27/_ ,10!R=%=9_PH/QY_P!"/XR_\$ES_P#$4?\ "@_'G_0C^,O_  27/_Q%
M ')T5UG_  H/QY_T(_C+_P $ES_\11_PH/QY_P!"/XR_\$ES_P#$4 <G176?
M\*#\>?\ 0C^,O_!)<_\ Q%'_  H/QY_T(_C+_P $ES_\10!R=%=9_P *#\>?
M]"/XR_\ !)<__$4?\*#\>?\ 0C^,O_!)<_\ Q% ')T5UG_"@_'G_ $(_C+_P
M27/_ ,11_P *#\>?]"/XR_\ !)<__$4 <G176?\ "@_'G_0C^,O_  27/_Q%
M'_"@_'G_ $(_C+_P27/_ ,10!R=?H5_P;5?\GV>)/^Q.N/\ TJMJ^(?^%!^/
M/^A'\9?^"2Y_^(K[Z_X-SOAAXF\&?MO>(KK6?#?B#2+5_",\:S7VG36\;-]I
MMSM#.H&< G'7B@#\]/B;_P E-\3?]AB\_P#2AZQ*]\^(/_!/7X\7_P 0O$-Q
M#\'_ (B30W&JW<L<BZ+,5D5IW*L#CH00:R?^'=7Q\_Z(W\1O_!)-_A0!XS17
MLW_#NKX^?]$;^(W_ ())O\*/^'=7Q\_Z(W\1O_!)-_A0!XS17LW_  [J^/G_
M $1OXC?^"2;_  H_X=U?'S_HC?Q&_P#!)-_A0!XS17LW_#NKX^?]$;^(W_@D
MF_PH_P"'=7Q\_P"B-_$;_P $DW^% 'C-%>S?\.ZOCY_T1OXC?^"2;_"C_AW5
M\?/^B-_$;_P23?X4 >,T5[-_P[J^/G_1&_B-_P""2;_"C_AW5\?/^B-_$;_P
M23?X4 >,T5[-_P .ZOCY_P!$;^(W_@DF_P */^'=7Q\_Z(W\1O\ P23?X4 >
M,UZK^PE_R>_\&_\ L=M'_P#2R*M'_AW5\?/^B-_$;_P23?X5Z1^QI^P7\;O"
M/[8'PIU;5/A/X^T_3-,\7Z7=7=U<:/*D-M$EW&SR.Q& JJ"23T H S_^"SG_
M "DZ^+/_ %_VO_I%;U\PU]@?\%@_@]XO\1_\%)_BI?:=X3\3ZA97%];&*XMM
M*GFAE LX =K*I!Y!'!ZBOFO_ (4'X\_Z$?QE_P""2Y_^(H Y.BNL_P"%!^//
M^A'\9?\ @DN?_B*/^%!^//\ H1_&7_@DN?\ XB@#DZ*ZS_A0?CS_ *$?QE_X
M)+G_ .(H_P"%!^//^A'\9?\ @DN?_B* .3HKK/\ A0?CS_H1_&7_ ()+G_XB
MC_A0?CS_ *$?QE_X)+G_ .(H Y.BNL_X4'X\_P"A'\9?^"2Y_P#B*/\ A0?C
MS_H1_&7_ ()+G_XB@#DZ*ZS_ (4'X\_Z$?QE_P""2Y_^(H_X4'X\_P"A'\9?
M^"2Y_P#B* .3HKK/^%!^//\ H1_&7_@DN?\ XBC_ (4'X\_Z$?QE_P""2Y_^
M(H Y.OO7_@W7_P"3WO%'_8B:A_Z/M:^-O^%!^//^A'\9?^"2Y_\ B*^YO^#?
MCX6>*/"'[:'B:ZU?PSXATFUD\$7\2S7NFS6\;.9[8A0SJ 6.#QUX- 'YYZG_
M ,A6\_Z^)/\ T,U#79:E\!/'C:I=$>!_&1!GD(/]B7//S'_8J'_A0?CS_H1_
M&7_@DN?_ (B@#DZ*ZS_A0?CS_H1_&7_@DN?_ (BC_A0?CS_H1_&7_@DN?_B*
M .3HKK/^%!^//^A'\9?^"2Y_^(H_X4'X\_Z$?QE_X)+G_P"(H Y.BNL_X4'X
M\_Z$?QE_X)+G_P"(H_X4'X\_Z$?QE_X)+G_XB@#DZ*ZS_A0?CS_H1_&7_@DN
M?_B*/^%!^//^A'\9?^"2Y_\ B* .3HKK/^%!^//^A'\9?^"2Y_\ B*/^%!^/
M/^A'\9?^"2Y_^(H Y.MSX6_\E4\*?]ARP_\ 2F.M#_A0?CS_ *$?QE_X)+G_
M .(K;^&7P(\=0?$_PO))X)\8)''K5BS,VBW(50+B,DD[. !WH ^K/^#C3_E(
MA%_V*MA_Z,GKX,K]$/\ @X2^%GBCQA^W_'>:/X9\1:M:?\(Q8Q^?9:;-<1;A
M)/E=R*1D9''O7PW_ ,*#\>?]"/XR_P#!)<__ !% ')T5UG_"@_'G_0C^,O\
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M9.^Z7('_ (+ ?M(#/_%U-2^7K_Q+K'C_ ,@T[_A[[^TC_P!%2U/_ ,%UC_\
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MNJ\TY37*W2=5*_-KHN5O2SMH>-#_ (+ ?M(%MO\ PM34MWI_9UC_ /&:0_\
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M&*DZ,;-7TI7[]H^3^Y]F$<!Q=.;A'$3NG;6M;73O/^]';NNZ/*?^'OO[2/\
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M9KYMHH_L++?^@>G_ . 1_P @_P!:,Y_Z"ZO_ (,E_F?27_#WW]I'_HJ6I_\
M@NL?_C-'_#WW]I'_ **EJ?\ X+K'_P",U\VT4?V%EO\ T#T__ (_Y!_K1G/_
M $%U?_!DO\SZ2_X>^_M(_P#14M3_ /!=8_\ QFC_ (>^_M(_]%2U/_P76/\
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M;13_ +#RW_H'A_X!'_(/]:,Y_P"@NK_X,E_F?27_  ][_:1_Z*EJG_@NL?\
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M_P#14M3_ /!=8_\ QFC_ (>^_M(_]%2U/_P76/\ \9KYMHI?V%EO_0/3_P#
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M?_C-?-M%']A9;_T#T_\ P"/^0?ZT9S_T%U?_  9+_,^DO^'OO[2/_14M3_\
M!=8__&:/^'OO[2/_ $5+4_\ P76/_P 9KYMHH_L++?\ H'I_^ 1_R#_6C.?^
M@NK_ .#)?YGTE_P]]_:1_P"BI:G_ ."ZQ_\ C-'_  ]]_:1_Z*EJ?_@NL?\
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MP]]_:1_Z*EJ?_@NL?_C-'_#WW]I'_HJ6I_\ @NL?_C-?-M%']A9;_P! ]/\
M\ C_ )!_K1G/_075_P#!DO\ ,^DO^'OO[2/_ $5+4_\ P76/_P 9H_X>^?M(
M_P#14M3_ /!=8_\ QFOFVBC^PLM_Z!Z?_@$?\@_UHSG_ *"ZO_@R7^9])?\
M#WW]I'_HJ6I_^"ZQ_P#C-'_#WW]I'_HJ6I_^"ZQ_^,U\VT4?V%EO_0/3_P#
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M,D\<W,NK6K7<NI7Z1E MP6;$D7)8J1DL<Y[5^G'_  [G_9H_Z)?J/_@_N?\
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MELL]G?)<[;@%E)B=5*D+DG..,YK],?\ AW/^S1_T2_4?_!_<_P#Q='_#N?\
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M?&G#SFZCP\KO?W8__)?UJ)>'?%JIJDL7#E6B]Z731?8Z+\EV/S&\&_ME^)_
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M8\0ZO.UUJNNWLVH7DI_Y:32N7<_FQK+K]E?^'<_[-'_1+]1_\']S_P#%T?\
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MC;X>ZUNC8J<:K<=0<?\ /:F_\.W/V5_^B>ZW_P"#6X_^/4_^(F97_)/[H_\
MR0O^(,9U_P _:7WR_P#D#\7**_:/_AVY^RO_ -$]UO\ \&MQ_P#'J/\ AVY^
MRO\ ]$]UO_P:W'_QZC_B)F5_R3^Z/_R0_P#B#&=?\_:7WR_^0/Q<HK]H_P#A
MVY^RO_T3W6__  :W'_QZC_AVY^RO_P!$]UO_ ,&MQ_\ 'J/^(F97_)/[H_\
MR0?\08SK_G[2^^7_ ,@?BY17[1_\.W/V5_\ HGNM_P#@UN/_ (]1_P .W/V5
M_P#HGNM_^#6X_P#CU'_$3,K_ ))_='_Y(/\ B#&=?\_:7WR_^0/Q<HK]H_\
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MZC_X/[G_ .+H_P"(F97_ "5/NC_\D'_$&<Z_Y^TOOE_\@?C517[*_P##N?\
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MX=S_ +-'_1+]1_\ !_<__%T?\.Y_V:/^B7ZC_P"#^Y_^+H_XB9E?\E3[H_\
MR0?\09SK_G[2^^7_ ,@?C517[*_\.Y_V:/\ HE^H_P#@_N?_ (NC_AW/^S1_
MT2_4?_!_<_\ Q='_ !$S*_Y*GW1_^2#_ (@SG7_/VE]\O_D#\:J*_97_ (=S
M_LT?]$OU'_P?W/\ \76_X*_X)6?LU^,[35)D^'-];_V9!YQ#:Y=-YG#' ^?C
M[OZTO^(F97_)/[H__)#_ .(,9U_S]I??+_Y _$NBOV4'_!.C]F@C_DE^H_\
M@_N?_BZ7_AW/^S1_T2_4?_!_<_\ Q=/_ (B9E?\ )/[H_P#R0O\ B#.=?\_:
M7WR_^0/QJHK]E?\ AW/^S1_T2_4?_!_<_P#Q='_#N?\ 9H_Z)?J/_@_N?_BZ
M/^(F97_)4^Z/_P D'_$&<Z_Y^TOOE_\ ('XU45^RO_#N?]FC_HE^H_\ @_N?
M_BZ/^'<_[-'_ $2_4?\ P?W/_P 71_Q$S*_Y*GW1_P#D@_X@SG7_ #]I??+_
M .0/QJHK]E?^'<_[-'_1+]1_\']S_P#%T?\ #N?]FC_HE^H_^#^Y_P#BZ/\
MB)F5_P E3[H__)!_Q!G.O^?M+[Y?_('XU45^RO\ P[G_ &:/^B7ZC_X/[G_X
MNC_AW/\ LT?]$OU'_P ']S_\71_Q$S*_Y*GW1_\ D@_X@SG7_/VE]\O_ ) _
M&JBOV5_X=S_LT?\ 1+]1_P#!_<__ !='_#N?]FC_ *)?J/\ X/[G_P"+H_XB
M9E?\E3[H_P#R0?\ $&<Z_P"?M+[Y?_('XU45^RO_  [G_9H_Z)?J/_@_N?\
MXNC_ (=S_LT?]$OU'_P?W/\ \71_Q$S*_P"2I]T?_D@_X@SG7_/VE]\O_D#\
M:J^PO^"37^O^('^[IO\ [=U]I_\ #N?]FC_HE^H_^#^Y_P#BZ[/X0_LS?!'X
M%-J)\,_#^_L/[5\H7.=8FE\SR]^S[S'&/,;IZUYF<>(&78K"3H4X3N[;I6T:
M?\Q[7#WA3FV S"GBJM2FXQO>SE?6+7\J[G13?ZY_]X_SIM.F_P!<_P#O'^=-
M4;F%?CQ_0( $T 9-?)?@O2/%'[9GQ3^,5Y=_$3QMX+T_P'K<OAW0M+T"\6T6
MU:&/<;NX&TF4R-R <#:#Z5QW@;]ICQY^TOX'^ /A&X\27WANZ^(5SJT7B#7=
M(58;R\CT[( A<@B,S8!9E&<YQQQ0,^Y=I]*,<5\P_&K0M:_9U\1? W0=/\;^
M--7M==^(BPW<VKZAY]Q/:O;N1:.X5=\09<@$=2:T'UC7O&?[<'Q>\'KXD\1Z
M;I</@;3Y[--.E'G:=.[/OFMU8%1,P&,XYXH$?1Q&T\T$8-?GS+^T/XN^#_@O
MXVOH_BCQ]:1Z;H>G-HVD>.LMXATRXGG6&6_"L@ @^?Y1D_,,D#&:T/C+\9/'
M?[)D_P 4/ NE^-_$'B!8_#>AZGIVKZU.+J^TJYO;I+6X:-\ ;2&+J"#M;%*X
M'WL1@T5\\_LMWVN?#C]IKXB?#"_\4>(/%VBZ+I.EZWIUWK5P+B]M7N%99HFD
MP-REE#*#TR:^AJ8';? G_D9-2_[!LO\ -:XD=*[;X$_\C)J7_8-E_FM<2.E
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MHN1_\^/_ ":?_P D'_$3N)O^@G_R2G_\B?4G_#X+XQ?\\_!?_@J?_P".4?\
M#X+XQ?\ //P7_P""I_\ XY7RW11_J+D?_/C_ ,FG_P#)!_Q$[B;_ *"?_)*?
M_P B?4G_  ^"^,7_ #S\%_\ @J?_ ..4?\/@OC%_SS\%_P#@J?\ ^.5\MT4?
MZBY'_P ^/_)I_P#R0?\ $3N)O^@G_P DI_\ R)]2?\/@OC%_SS\%_P#@J?\
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M_P#CE?+=%'^HN1_\^/\ R:?_ ,D'_$3N)O\ H)_\DI__ ")]2?\ #X+XQ?\
M//P7_P""I_\ XY1_P^"^,7_//P7_ ."I_P#XY7RW11_J+D?_ #X_\FG_ /)!
M_P 1.XF_Z"?_ "2G_P#(GU]=_P#!;SXW7O@^WT1XO OV.W8,I&DR;\@D_P#/
M7'<]JQ?^'P7QB_YY^"__  5/_P#'*^6Z*/\ 43(_^?'_ )-/_P"2#_B)W$W_
M $$_^24__D3ZD_X?!?&+_GGX+_\ !4__ ,<H_P"'P7QB_P">?@O_ ,%3_P#Q
MROENBC_47(_^?'_DT_\ Y(/^(G<3?]!/_DE/_P"1/J3_ (?!?&+_ )Y^"_\
MP5/_ /'*/^'P7QB_YY^"_P#P5/\ _'*^6Z*/]1<C_P"?'_DT_P#Y(/\ B)W$
MW_03_P"24_\ Y$^I/^'P7QB_YY^"_P#P5/\ _'*/^'P7QB_YY^"__!4__P <
MKY;HH_U%R/\ Y\?^33_^2#_B)W$W_03_ .24_P#Y$^I/^'P7QB_YY^"__!4_
M_P <H_X?!?&+_GGX+_\ !4__ ,<KY;HH_P!1<C_Y\?\ DT__ )(/^(G<3?\
M03_Y)3_^1/J3_A\%\8O^>?@O_P %3_\ QRC_ (?!?&+_ )Y^"_\ P5/_ /'*
M^6Z*/]1<C_Y\?^33_P#D@_XB=Q-_T$_^24__ )$^I/\ A\%\8O\ GGX+_P#!
M4_\ \<H_X?!?&+_GGX+_ /!4_P#\<KY;HH_U%R/_ )\?^33_ /D@_P"(G<3?
M]!/_ ))3_P#D3ZD_X?!?&+_GGX+_ /!4_P#\<K6\,_\ !;7XV>$[>^BM8O K
M+J$8BEWZ3)P.>F)?]HU\BT4?ZB9'_P ^/_)I_P#R0?\ $3N)O^@G_P DI_\
MR)]2#_@L%\8@/]7X+_\ !4__ ,<H_P"'P7QB_P">?@O_ ,%3_P#QROENBC_4
M7(_^?'_DT_\ Y(/^(G<3?]!/_DE/_P"1/J3_ (?!?&+_ )Y^"_\ P5/_ /'*
M/^'P7QB_YY^"_P#P4O\ _'*^6Z*/]1<C_P"?'_DT_P#Y(/\ B)W$W_03_P"2
M4_\ Y$^\/@A_P6F9&CL_B7X5**6Q_:WA\%U4>LELYW#W*,?I7V1\'OV@O!/[
M0&D_;/!OB;2]>C49DB@EQ<0?[\+8D3\5%?B/G%2:9>7&AZO#J&GW5UIVI6Y#
M17=I,T$\9'HZD&OE\V\,Z4KSRZIRO^66J^36J^:?J?;9#XSUH6IYO2YE_-#1
M_.+T?R<?0_>2BORU^!7_  5E^)WPJ^SV?B06GQ!T>/"G[8?LVI(H])U&UST_
MUBD^]?:W[-7_  43^&O[3VK0Z-I=_>:/XJD4G^Q-3A,=PV!EBC+E'4>H(/'2
MOS3-,AQ^72MBZ;BNCWB_1K3Y;^1^SY)Q/EF;QYL!54GNX[27K%V?SV\SW2BB
MBO(/>"BBB@ HHHH **** '3?ZY_]X_SIM.F_US_[Q_G3: /&OB9^P[X5^(OC
MK6O$5OK7C3PEJ'BB)(-=7P]JQLH=;55VCSDVL-VWC<NUB.]7?&/[%O@/Q5\-
MO"OABVL]0\.V_@9Q+X?O=&NVM;[27QAF27DDODEMP(8\FO6** /)M<_8X\-^
M+OA+#X3U[6O&6O&UU0:U:ZU>ZLS:O97B@!98I@ $V@<*%V\GCDTSP;^QGX;\
M%Z)XJCBUOQI>:_XRCBBU/Q+=:NS:TZQ$&)8YE4"-5(X"J ><@UZY10!XOX=_
M8/\ !-A:^+/[=O/%'C;4/&NFC1]4U'Q!J1N;I[,'<L,9546,*V&!50<@4WPS
M^P/X#T7P=XKT?4I/$7BK_A,K.'3]1O\ 6]1-S??9H/\ 411R +Y:Q$ K@9RH
M))->U44 >=_ 7]F70?V?;G6[S3[_ ,0:[K7B-H3J.K:Y??;+RY6%=D4>["@(
MBG  'US7HE%% ';? G_D9-2_[!LO\UKB1TKMO@3_ ,C)J7_8-E_FM<2.E !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3FG=T"EF*KT!/
M IM% #Y+B250&D=@O0%LXI#/(79M[;F&"<\FFT4 /2XDC(VR.NT8&#T%-9V=
MMS$LQZD]Z2B@ HHHH **** "BBB@ HHHH *\'U/_ )2CZ)_V2B]_].UO7O%>
M$_'/X,_%"7]I_1/B1\-[CX?R/9^%+CPS>67B=KM 1)=QW EC:W!Z;-I#>M '
MNU%>#^?^U'_SY_L]_P#@5J__ ,11Y_[4?_/G^SW_ .!6K_\ Q% '7?M@>+=8
M\!_LU^*]9T&\NM.U73;>*:*ZMA^\@43QAV'!X"%LG' S7F/Q$^,GB'Q;XW^*
M-OX-\;:9#I=A;:#'IERVHP0VD<LHD>ZAM[APT<=S)&!@MD*=IP*WY6_:@GB:
M.2Q_9YDC<%65KG5V5@>""-G(/I68G@S]H:+1'TU?#/[,:Z;(_F/:!-3$#M_>
M*>7M)]\9KUL#F%&C3Y9TU)WO=V>C<'JFM;<C2UVD_GX6995B,16YZ=9QBU:R
MNM5&HKIIZ7]HF]'K"/R]4_9O\=V_Q*^"FAZQ:WFM:A%<))'Y^K"/[8[1R-&W
MF-$!&Y#*0'088 ,.M=Q7@=I'^T[I]K'!;Z=^SO;P0J$CBBGU9$C4=  $P!["
MI//_ &H_^?/]GO\ \"M7_P#B*\[$5(SJRG!63;:797VZ'KX6G.G1A3J.\DDF
M^[2U?7?U9[Q7SAI/_*8O7O\ LA]A_P"I#<UK^?\ M1_\^?[/?_@5J_\ \157
MX%_ 7XH0?MAZY\5OB1=?#^-KSP/;^#K2P\,M=N!Y6H27AFD:X Z^85POH#61
ML?05>L?LP_\ ,9^L7_LU>3UZQ^S#_P QGZQ?^S4I;#CN>6ZA_P A&X_Z[/\
M^A&H:FU#_D(W'_79_P#T(U#3$%%%% !1110 9I-B^9NVKO(P6Q\Q'IGTI:*
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M?I%J?_! #3].^&UGX@_X6UJ3&Z<)Y)\/1 +DL.OG^U<Q_P .1+'_ **C?_\
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MX<B6/_14;_\ \$,?_P >H_XB-D_>7_@/_!#_ (A#Q!_<_P# O^ ? E%???\
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M4W_#*GPY\<?&/PMX#\"?$#Q5KGB#7]?72K@:EX7;3H+2W&_SKA'9SYA782%
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MM5E\->'].EU;Q9KWB3P^^EPZ#;*0%*Q[F:9W^8*@P21]:OZ]FG2?6V\=UO\
M=?5]#3^T,XZ5%O;[&ZM>W>U]7LNNQ[1_P^LC_P"B.^'O_!Q/_P#$T?\ #ZR/
M_HCOA[_P<3__ !->#?&C]E#0-!^!=C\2/ASXVF\<^%Y-8_X1^^%YI3:9>6-X
MR[H\QEFW1N.A]QUSQZ-\2_\ @G!X3\*P?$+1]'^)MYJ'CKX9Z!'X@UC2[S1/
ML]F(F1',:W(<C?AP ,9R0,=<-8[-7>T]O\.M[O3OL]NP1S#.7>T]K/[&MTVK
M=]$]K['9_P##ZR/_ *([X>_\'$__ ,31_P /K(_^B.^'O_!Q/_\ $UY1I?\
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M_P _/P7^0?ZQYC_S\_!?Y'W3_P /K(_^B.^'O_!Q/_\ $T?\/K(_^B.^'O\
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M^(H_X?:+_P!$;\-_^#67_P"(KX3HH_MS'?\ /S\%_D'^L>8_\_?P7^1]V?\
M#[1?^B-^&_\ P:R__$4?\/M%_P"B-^&__!K+_P#$5\)T4?VYCO\ GY^"_P @
M_P!8\Q_Y^_@O\C[L_P"'VB_]$;\-_P#@UE_^(H_X?:+_ -$;\-_^#67_ .(K
MX3HH_MS'?\_/P7^0?ZQYC_S]_!?Y'W9_P^T7_HC?AO\ \&LO_P 15C3?^"XT
MVCW\=U:_"#P[#<0G<CKJLN5/3^Y[U\%T4?VYCO\ GY^"_P @_P!8\Q_Y^_@O
M\C[QU7_@N#)K>H2W5U\(?#\UQ,<NYU>;+'&/[GM5?_A]9'_T1WP]_P"#B?\
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M^W<=_P _/P7^0_\ 6/,?^?OX+_(^_/\ A^[>?]$?\+_^![?_ !NC_A^[>?\
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M#F_^-T?\/W;S_HC_ (7_ / ]O_C=? =%']NX_P#Y^?@O\@_UCS'_ )^_@O\
M(^_/^'[MY_T1_P +_P#@>W_QNC_A^[>?]$?\+_\ @>W_ ,;KX#HH_MW'_P#/
MS\%_D'^L>8_\_?P7^1]^?\/W;S_HC_A?_P #V_\ C='_  _=O/\ HC_A?_P/
M;_XW7P'11_;N/_Y^?@O\@_UCS'_G[^"_R/OS_A^[>?\ 1'_"_P#X'M_\;H_X
M?NWG_1'_  O_ .![?_&Z^ Z*/[=Q_P#S\_!?Y!_K'F/_ #]_!?Y'WY_P_=O/
M^B/^%_\ P/;_ .-T?\/W;S_HC_A?_P #V_\ C=? =%']NX__ )^?@O\ (/\
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M !8\/R:]I?AFZUCQQ;3:?=VNF?99/$.@A_+\NY>--TAB7$N9#N( '.,5J?\
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M5_PX/^(G_0_> _\ OFX_^)H_X<'_ !$_Z'[P'_WS<?\ Q-']BX[_ )]O\/\
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MG^'^9\/T5]P?\.*O&W_12OAS_P!]S_X4?\.*O&W_ $4KX<_]]S_X4?V+CO\
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MM%?<7_#BCQQ_T4CX<_\ ?<_^%'_#BCQQ_P!%(^'/_?<_^%']BX[_ )]O\/\
M,/\ 5_,?^?3_  _S/AVBON+_ (<4>./^BD?#G_ON?_"C_AQ1XX_Z*1\.?^^Y
M_P#"C^Q<=_S[?X?YA_J_F/\ SZ?X?YGP[17W%_PXH\<?]%(^'/\ WW/_ (4?
M\.*/''_12/AS_P!]S_X4?V+CO^?;_#_,/]7\Q_Y]/\/\SX=HK[B_X<4>./\
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MF/\ SZ?X?YGPK17W5_PX/^(G_0_> _\ OFX_^)H_X<'_ !$_Z'[P'_WS<?\
MQ-']BX[_ )]O\/\ ,/\ 5_,?^?3_  _S/A6BONK_ (<'_$3_ *'[P'_WS<?_
M !-'_#@_XB?]#]X#_P"^;C_XFC^Q<=_S[?X?YA_J_F/_ #Z?X?YGPK17W5_P
MX/\ B)_T/W@/_OFX_P#B:/\ AP?\1/\ H?O ?_?-Q_\ $T?V+CO^?;_#_,/]
M7\Q_Y]/\/\SX5HK[J_X<'_$3_H?O ?\ WS<?_$T?\.#_ (B?]#]X#_[YN/\
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M %?S'_GT_P /\SX=HK[B_P"'%'CC_HI'PY_[[G_PH_X<4>./^BD?#G_ON?\
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M'DGP5_Z&]O\ P47O_P :K\S]U&ZLO];H_P#/E_\ @?\ ]H<_^N&,_EC]S_\
MDC],/^'DGP5_Z&]O_!1>_P#QJC_AY)\%?^AO;_P47O\ \:K\S]U&ZC_6Z/\
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MGU4GD?A7G'_#:?P7_P"BQ?"?_P +#3O_ (]1_P -I_!?_HL7PG_\+#3O_CU
M&C^T@/#]I\$?$<GB2"]?1)HXA?"P"K<R S1A<$XY#;>2>F:I^-_V@O"_PTU/
M7+"\L;PS^%TL6*P6L;>=)>DI"D)R/G8@ABVT<\FN7^+G[1OP/^+OPVU?PW=?
M&KX6V<.JPB/SXO%^FL\+*P=6 ,V#AE'!ZBN,'Q.^%]Y_PE%]J7[0GP1U;7/%
M4=I:W;W6IZ7)IYMK=6"Q&V-UR6W$EMV0<8%<-?VRJ7I+=;Z=.;S75JWS//Q"
MKJHW1BM4M=.G-INNKC;YGT9X8N(/$>@6=Y)HLVEM)&0+2^M4CN+89Y1E&0.1
MG )!X-:*V,".&6"!65BX(C&0QZGIU/<]37B/P=_:.^#/PE^&^F^'S\<_A?JO
M]GJX^TS>+].!;<[-M4>>=J+NVJN3A5 S73_\-I_!?_HL7PG_ /"PT[_X]753
MNX)R6MM3LI<S@G-6=E?U/2Z^<-)_Y3%Z]_V0^P_]2&YKT3_AM/X+_P#18OA/
M_P"%AIW_ ,>KQWX4_%7PK\6O^"N_B2^\)^*/#?BJQM_@I8P37.C:G!J$,4@U
M^X8HSPLRJVUE.TG.&![BM#0^K:]&_9H_Y&[4/^O/_P!G6O.:]&_9H_Y&[4/^
MO/\ ]G6E+8#@=7_Y"UW_ -=W_P#0C5>K&K_\A:[_ .N[_P#H1JO3 **** "N
M>^)OPRT_XL^&O[+U*ZURRA659EFTG4YM.ND89'$L3!L$$@C.#70T4 >5ZE^Q
M1\-=3@\.PGP_);V_AF(6]M#;7TT,=U$)O/\ *N55O](3SOWN),Y?YJU/#/[+
MO@?PC\2]2\666CG^UM3\\ND]P\UG;M.P:X:&W8F.)I6 +E5&XCFO0** //=;
M_97\"^(?B;!XMNM&;^U(6BE,$=U)'I]Q+$I2&:6U4B*26-255V7(!Q61I'[#
M_P --#\,ZUI-OH=W]DUP0JY?4IWFL4@D,D$=K(6W6Z12$NBQD!6YKUFB@#!^
M&GPTT?X0^#+70=!MY+?3[5GD'FS-/--)(Q>2621R6>1V)9F8Y)-;U%% !111
M0 5K> O^1XT?_K]B_P#0Q636MX"_Y'C1_P#K]B_]#% 'YF?\%7?^4@?Q$_Z[
MVO\ Z20U\\5]J?\ !2+]C+XH_%#]MCQSKOA_PO#J&D7\UN;>X.J6\)D"VT2G
MY6;(Y!'->'_\.]/C5_T)<'_@ZM?_ (JOS[&9#CIUYSA#1MM>]'9OU/RG,,IQ
ML\54G&E)IR=M/,\;HKV3_AWI\:O^A+@_\'5K_P#%4?\ #O3XU?\ 0EP?^#JU
M_P#BJYO]7<P_Y]_^31_^2./^QL=_SZE]QXW17LG_  [T^-7_ $)<'_@ZM?\
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M )"UU_UV?_T(U7JQJW_(6NO^NS_^A&J] !13DA>4?*K-CK@9Q2*C.VU5+-Z
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M*X4L<CTI=*_:W\ ZMXW\7^'UUORK[P/ MUJK26\@ACB**Y97"D-MWJ"/O9/
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MW]OX:TZ/7;W08WFD:X662VF:)GS&AVJ=I8Y&$'4]Z0'T9_PKSPO_ -#E;_\
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MO% :'LG_  [X_9W_ .A4^$?_ (1.G?\ QJC_ (=\?L[_ /0J?"/_ ,(G3O\
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MKZ>\\36]A<3%6:!H=QC^4 <Y[XS6'_PKSPW_ -#C:_\ @/\ _7KYF_;_ /\
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MK?SIE=DS)B0N ,[06;/7C'.E>-/B9XU\(>=J7C*+3['Q->_V;KEWI4=OJ-M
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M_P"@MK'_ 'S_ /84 <'17>?V-\//^@MK'_?/_P!A1_8WP\_Z"VL?]\__ &%
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M[KGO4EWH5C?F8W%C93_:@@F\R!&\X(<H&R/FVGD9Z'I7HW]C?#S_ *"VL?\
M?/\ ]A1_8WP\_P"@MK'_ 'S_ /84 <'G-%=Y_8WP\_Z"VL?]\_\ V%']C?#S
M_H+:Q_WS_P#84 <'17>?V-\//^@MK'_?/_V%']C?#S_H+:Q_WS_]A0!P=?*?
M[1_[0?A7]F'_ (*'^&/$GC:YU;3-"O\ X;7NF07EKHE]J4;7/]IP2>4?LL,I
M5MBEOF &!7W1_8WP\_Z"VL?]\_\ V%2P67@&U!\O6]=CW==N5S_XY0!\6?\
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M -A77_!RP\+VFNW3:%>WUU<&#$BSCY0FX<CY1SG%2]@1XYJ__(6N_P#KN_\
MZ$:KUZ)?Z?\ #TW\_F7VL"3S&W@*<!LG/\/K4/\ 9WP[_P"?[6?^^3_\35!8
MX&BN^_L[X=_\_P!K/_?)_P#B:/[.^'?_ #_:S_WR?_B: L<#17??V=\._P#G
M^UG_ +Y/_P 31_9WP[_Y_M9_[Y/_ ,30%C@:*[[^SOAW_P _VL_]\G_XFC^S
MOAW_ ,_VL_\ ?)_^)H"QP-%=]_9WP[_Y_M9_[Y/_ ,31_9WP[_Y_M9_[Y/\
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M[&^'G_06UC_OG_["@#@Z*[S^QOAY_P!!;6/^^?\ ["C^QOAY_P!!;6/^^?\
M["@#@Z*[S^QOAY_T%M8_[Y_^PH_L;X>?]!;6/^^?_L* .#HKO/[&^'G_ $%M
M8_[Y_P#L*/[&^'G_ $%M8_[Y_P#L* .#HKO/[&^'G_06UC_OG_["C^QOAY_T
M%M8_[Y_^PH X.BN\_L;X>?\ 06UC_OG_ .PH_L;X>?\ 06UC_OG_ .PH XO5
MO^0M=?\ 79__ $(U7JQJW_(6NO\ KL__ *$:KT %%%% !1110 4444 %%%%
M'9?!+_D.ZI_V"YOZ5QHZ5V7P2_Y#NJ?]@N;^E<:.E+J 4444P"BBB@ HHHH
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MOA_P/:>#C&EKY/GM!,9#<9R<;LXV\XZY-,#.U/\ ;R\(Z/X4^*6JW%CK$?\
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M?"[Q3XIUSQ!X@TW7=3\41V$<GV'338PP"T@\E<*7<G<N"3GKGVHU$>G4444
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MT3_P?04?\.V_C3_T+>B?^#Z"C_5O,/Y%_P"!1_\ D@_L7'_\^I?<>(45[?\
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MS[^TYI?[0,^MV$>B^(O"OB+PVT/]I:+KEN(;RV29=\,ORDJR.HR"#QT->DT
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MWOVGX=?\^^M_F?\ XJC[3\.O^??6_P S_P#%5P5%%@.]^T_#K_GWUO\ ,_\
MQ5'VGX=?\^^M_F?_ (JN"HHL!WOVGX=?\^^M_F?_ (JC[3\.O^??6_S/_P 5
M7!446 [W[3\.O^??6_S/_P 51]I^'7_/OK?YG_XJN"HHL!WOVGX=?\^^M_F?
M_BJ/M/PZ_P"??6_S/_Q5<%118#O?M/PZ_P"??6_S/_Q5'VGX=?\ /OK?YG_X
MJN"HHL!WOVGX=?\ /OK?YG_XJC[3\.O^??6_S/\ \57!446 [W[3\.O^??6_
MS/\ \51]I^'7_/OK?YG_ .*K@J*+ =[]I^'7_/OK?YG_ .*H^T_#K_GWUO\
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M_P!"CXU_[XMO_CE'_#W?P1_T*/C7_OBV_P#CE'MJ'_/V'_@</_D@_P!8,O\
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M_P ^^M_F?_BJX"/_ %:_2G4[ =[]I^'7_/OK?YG_ .*H^T_#K_GWUO\ ,_\
MQ5<%118#O?M/PZ_Y]];_ #/_ ,51]I^'7_/OK?YG_P"*K@J*+ =[]I^'7_/O
MK?YG_P"*H^T_#K_GWUO\S_\ %5P5%%@.]^T_#K_GWUO\S_\ %4?:?AU_S[ZW
M^9_^*K@J*+ =[]I^'7_/OK?YG_XJC[3\.O\ GWUO\S_\57!446 [W[3\.O\
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M"BBB@ HHHH **** "BBB@ HHHH *[?X%?\AS5_\ L&2_S%<17;_ K_D.:O\
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M_P#Q-'_#<^B?]$SL_P#P<2__ !-'_$9N#O\ H,7_ (!4_P#D _U'SS_H'?\
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M_P#$UI>'/^"BUKX1GDDTWX>VMK),H5R-5=MP'/=#1_Q&;@[_ *#%_P" 5/\
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M .0#_4?//^@=_?'_ .2.ZHKA?^&]='_Z)CI?_@Q;_P"(H_X;UT?_ *)CI?\
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M<^B?]$SL_P#P<2__ !-'_#<^B?\ 1,[/_P '$O\ \31_Q&;@[_H,7_@%3_Y
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M!W_X%'_Y(] HKS__ (;GT3_HF=G_ .#B7_XFC_AN?1/^B9V?_@XE_P#B:/\
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M\_\ ^&Y]$_Z)G9_^#B7_ .)H_P"&Y]$_Z)G9_P#@XE_^)H_XC-P=_P!!B_\
M *G_ ,@'^H^>?] [_P# H_\ R1Z!17G_ /PW/HG_ $3.S_\ !Q+_ /$T?\-S
MZ)_T3.S_ /!Q+_\ $T?\1FX._P"@Q?\ @%3_ .0#_4?//^@=_P#@4?\ Y(]
MHKS_ /X;GT3_ *)G9_\ @XE_^)H_X;GT3_HF=G_X.)?_ (FC_B,W!W_08O\
MP"I_\@'^H^>?] [_ / H_P#R1Z!17G__  W/HG_1,[/_ ,'$O_Q-'_#<^B?]
M$SL__!Q+_P#$T?\ $9N#O^@Q?^ 5/_D _P!1\\_Z!W_X%'_Y(] HKS__ (;G
MT3_HF=G_ .#B7_XFC_AN?1/^B9V?_@XE_P#B:/\ B,W!W_08O_ *G_R ?ZCY
MY_T#O_P*/_R1Z!17G_\ PW/HG_1,[/\ \'$O_P 31_PW/HG_ $3.S_\ !Q+_
M /$T?\1FX._Z#%_X!4_^0#_4?//^@=_^!1_^2/0**\__ .&Y]$_Z)G9_^#B7
M_P")H_X;GT3_ *)G9_\ @XE_^)H_XC-P=_T&+_P"I_\ (!_J/GG_ $#O_P "
MC_\ )'SL^2IV_>[8]:^N?&7P-\,^#] U"UUKP'I^E^']-\+QW$GB83-'<RZB
M8U^2,;L,Q?C&.N>U?)VEWBZ=JEK<-&)EMYDE,9.!(%8-MSVSC'XUZ3XT_:=O
MO'MMX\MM0TU9+/QK+!<10M=,PTF6'&QH\CYN!@C"YK^0.#LVRG 8?$O'Q4JD
MK*"E%26D*CM*\96C*?)%\KC+6]TDS]RSO!XS$5:7U=M17Q--IZR@M+-:J/,U
M>ZZ6NT>A7OP^TWX7_L[^%-:E\#>"]<O+C23J.JSZI?F*Z^=\Q>7$&#/E2.@[
M?6L/P5K7A73/V9[WQ1J'PZ\,:A>Z?JD&CVTDK2[KQV0O)))\W88P%KF?BA\=
M_#OQ4TNU^V>"&AU;3],BTNSO4UJ39;I&N$/E; &QDG&>:YB_^)\EW\&=-\&Q
MV:PPV6IRZI+<B7+7+NFP KC@*/<Y]J]G'\2990Q,G@73E3C0<(?NT[U+1BF^
M>C%J6CF[N:NG[WO<IPX?*\74I+ZPI*4JEY>^U:-V[+EJ/3[.BCH]M+GKOPL^
M$'A_Q7I_PI^V:19?:/%VMZCJ%]@-Q8P;L0]>(N#[\=:9\5O@IX=^'_@CXC^)
M+>QM[K2-0?3SX6FP=MM'<$NY0D_P@,G.?NUR&C?M02:'=:'+#H4(_P"$?\,S
M^';8?:C]Z7.ZY^[][G[OZU4T_P#:,N#\*/"_@[5-+35-)\-:HNH%7N2AO(UW
M%;=OE.U06///'&.]=7]N<,O!/#.,?:<CY9^S>D_8TZ6JY;M.4JM6]G:48VUM
M?'ZAFOMU53?+S*\>9;>TE/37>RA#T;.U\4?L\Z7X,_8\GU:ZLPWC**2SU.YE
M*MNM+6X<I'#GI]T;F[@GZ5Q/QK\(:9X+^&GPUCM[&&WU?5-(DU/4)QGS+D22
MGRMWT4$#&*TO$'[87B;QEH?C+3-:9M0TWQ3 8;>U,NV'2/GW*8QM^;  &"1T
MS6;\6OCAHOQ7T2T6;PBUGK6GZ?;Z=;Z@FKR/''%%@#]QL"Y(R.O&?:N'/,=P
MU7PM2.624&J,*:4X23;A5<G*\8R7/.,8*[:OS--QU2Z,OP^:TZL7BTY+GE)V
MDFDI022LVGRQ;EI9VLK)Z,TO@MIV@^&O@=XP\8:WX<TWQ'-97UGIVGP7Y<1!
MWW-)]T@_=(/X"NN@^"/AGQ?\:?A3=6.D#3-'\;61U34=(:1GBMQ#EI I/(C<
M#@>F:\_\$?''1]!^$J^$=:\(+X@LX]4;5@_]J26FZ0H$"LJ*=R@9XSSGM4]I
M^U%JB_$VX\37&G6K31Z1+HVEVD$AA@TB)D*)Y8P<[03P>I/45>7YMD%+"86A
MBG"<8^R<DJ;YE)574J.4G!.2<'[)14I)K5I6)Q.#S&=:M4I*46^>SYU9IP48
M)1YM+2]]MI-;:W.^^'O@'PWK/PYG\0:#X*T/QUJ+ZC=R:OI4E\\-QI-HLA\I
M;:(')^3!W<GIU[)\,?AGI,/[/H\50^#?"^MW>I:O>.D>NZA]G^RV40^5(SN!
MD8$8XR>37$_#W]HS1_A=]AU+1? NGVOBJQT\V":K_:,OEN2FPS-;XVER.O.,
MU#<?'GP_KWPS\/>'-<\$MJG_  C<4RVURFM26^Z29M\DC(J8)+<XS[9KT,-G
MN01I0G.=+VD:4E94WR<[=-*7,\/*7,X^T<DXU(*5N224K1YZF7YBYR45/E<T
M[N7O<MI:651*R?+9IQDUNG;7M?V5?@OH?Q@U;6O$FN:+:VVDZK</I6BZ?$CF
MWCNWC:3(YSLC5>I/5JPOV9OAGI/B70/$C'2-'\5>,]/N$AL=$U*]-K%-",^;
M(HR/,?(P!GBJGA+]L+7?A_)X5M=!MVTO0?#D:K<:;%<975GW%I))7VY!<GL#
MCWJAX4^.GASP]K$>J7'@"SOM8M-4EU2TO!JDL!B9Y#(B.JKB14. .F<5S83-
M.&H+!KFCST_:>UE*FTINHH>]&T*B;A)R]FIT[+E5XJZ9I6P>:MUW9\LN7D2D
MM%%O1WE'XE;FY97=]^AZ!\(/A?H_BT_$;6AX&T>"YTFXM+&QT+6[XPVME.Q/
MG@RL0>,$@9Z8%4_A7X3\._$KQ/XN=?"?A%O%&DB*UTKPR-1:'3[PAF$TJON_
M>OTP V.A]ZY@?M.V/B+PKKFE^*O"2:\-?UMM=N9(-4>Q_>E0B( J-\JKP,FL
M?P;\6/"7A:19)OA[;7\UGJ1U#3YCJ\T4ELN04A<A?WBJ0.3@FMHYYD49X:-.
M=)PCSN?-3:;<I3:=HX>24HJ2Y;.=-.,5R)*Y+R_,'&JY1GS/E4;2NDDHW5W5
M3:;3O=1E9M\S;*/C'PVOB[XVQZ'I_AUO"-Q?7D&GOI9D:06D[%4?!;G:6)8#
MTQ7IOB#]GJQ^+_BB^GTK6M \+:%I.KIX0TB.:W;=J,\:#YBR#+/(V26;/7KP
M!7GNB_&)O$'[3.E^./$#)"IUN"_N_)0LL,:.O"CJ=JC'J<5L:9^T9#X*U/P]
M;V.EPZG8>$_$%[K,4S3M%_:C2EA&S*5RFU<$=3QVKR<KQ60-UYY@U*G4K/HX
MR<4THOEIV<5:<YM1M%N"CO9'9C*.8VIQPR:E&"ZW2;3OK.]W>,8IN[M)ONR#
MP9^RSJ&OEO[8U[1/#"S:G)HNGF]9F.I7<;;62,*/NAL#>>,GH:K6?[,>NWT.
MGQQS6YU&\\13>')[3!S931+O:1VZ;-@+9]!6EX7_ &IAH^AZ7#J7A?3];U#P
M[?W.HZ-=SW4B+9RSN7;?&!B7:W(R1@@5E^%/VE=8\+>!O%VEK#'<7_BRY:Z?
M4G?$UF\BE)B@QU="5SD8![UGR\'J%.+<G[K<FN?F348RY7=*/,Y*4(.-XJ+4
MIN^U7SN\FK;I)>[:UVKK6]DK2DGJVFHZ;[VB?L<:AX@T][B#Q%I"K>+<RZ.D
MD4H;5XH-VZ8$ B*-MIVESR,'C-8_[1FAVOA#0_A_HMK:VL=U#X;AO;N6.)5E
MN)KEC(!(0,L57:!G-79_VJKG5/@O:>$+_2KJ;^S[!].M[FWUB>UA9#PC2VZ_
M)*R<8R1G'-<O\5/BROQ3^(UKX@FTN.R6""U@DM8[@LL@@ 7AB/EW 8P <>]+
M.,3PU3RV5+*7:I45-2O[2Z5U*:]Y-)QE%).,GS1:6K3<C!4LTEBE/&?#%R:M
MR^D=G=W3>ZT:Z)I+U3]I'X 6K:5Y^A:AH"WW@CPY9G5]'@B,=YC:"]PY VLQ
M+#J<X[]!6-XQ_9O>75XX;RZ\,^$=)\-Z59+JNJLLHCEN)TWJK*26DG((R%P
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1"SS_GZO_ 8_Y'E.B_L%^(_$5VT%EXC\)W$RH9"JSR\*.I_U?O4/_##>M?\
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M%'_##6M?]#;X)_\  R3_ .(KURBC_B!/"'_/F?\ X,G_ )A_Q$///^?B_P#
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M $-O@G_P,D_^(KURBC_B!/"'_/F?_@R?^8?\1#SS_GXO_ 8_Y'D?_##6M?\
M0V^"?_ R3_XBC_AAK6O^AM\$_P#@9)_\17KE%'_$">$/^?,__!D_\P_XB'GG
M_/Q?^ Q_R/(_^&&M:_Z&WP3_ .!DG_Q%'_##6M?]#;X)_P# R3_XBO7**/\
MB!/"'_/F?_@R?^8?\1#SS_GXO_ 8_P"1Y'_PPUK7_0V^"?\ P,D_^(H_X8:U
MK_H;?!/_ (&2?_$5ZY11_P 0)X0_Y\S_ /!D_P#,/^(AYY_S\7_@,?\ (\C_
M .&&M:_Z&WP3_P"!DG_Q%'_##6M?]#;X)_\  R3_ .(KURBC_B!/"'_/F?\
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MX8:UK_H;?!/_ (&2?_$5ZY11_P 0)X0_Y\S_ /!D_P#,/^(AYY_S\7_@,?\
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MHH_X@3PA_P ^9_\ @R?^8?\ $0L\_P"?J_\  8_Y'CO_  Q3K'_0U>$/^_\
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M?\1"SS_GZO\ P&/^1X[_ ,,4ZQ_T-7A#_O\ S?\ QNC_ (8IUC_H:O"'_?\
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M_ 8_Y'DY_8-\1#1?[1_X2/PG]A,OD^=Y\VW?UV_ZNJO_  Q3K'_0U>$/^_\
M-_\ &Z^E7_Y("O\ V&/_ &2N,H_X@3PA_P ^9?\ @R?^8?\ $0L\_P"?J_\
M 8_Y'CO_  Q3K'_0U>$/^_\ -_\ &Z/^&*=8_P"AJ\(?]_YO_C=>Q44?\0)X
M0_Y\S_\ !D_\P_XB%GG_ #]7_@,?\CQW_ABG6/\ H:O"'_?^;_XW1_PQ3K'_
M $-7A#_O_-_\;KV*BC_B!/"'_/F?_@R?^8?\1"SS_GZO_ 8_Y'CO_#%.L?\
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M#8^(O"=S+&GF,JSR\+TS_J_>O5:[[]GC_D;=0_Z\'_\ 0EH?@3PA_P ^9?\
M@R?^8?\ $0L\_P"?J_\  8_Y'R^?V*-8!_Y&KPA_W_F_^-T?\,4ZQ_T-7A#_
M +_S?_&Z]DD_UK?[QIM'_$">$/\ GS/_ ,&3_P P_P"(A9Y_S]7_ (#'_(\=
M_P"&*=8_Z&KPA_W_ )O_ (W1_P ,4ZQ_T-7A#_O_ #?_ !NO8J*/^($\(?\
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M&R<X!J35_P!K+X@^(=9UPPZ+IWAS1;?X9-XJFM+JZ:#6+"Y/VA<QDQD%UDB
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MR\DO+?4&GFME=VN;<%8)LG^.,$A3V% CY9\-?MS^+OA3^R]I&H:Y_9?C;QS
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M#JZDL6D\#^&)&TNV2RLRU@A-M"C;TC3CA5;D>AZ5W#-N.3U-, HHHH ****
M"BBB@ HHHH **** "BBB@ KT#]G#_D>[C_KS;_T):\_KT#]G#_D>[C_KS;_T
M):4M@.%U#_D(W'_79_\ T(U#4VH?\A&X_P"NS_\ H1J&F 4444 %<?\ ':8:
M;\,=4U27Q5JW@ZST.%]2N]0T](7F$,2,S)B5'7!^F2< &NPK/\5^$=+\=^'[
MC2=:T^TU72[P 3VEU&)(9@"& 93P1D X/I0!\9?%#]LWQA\$/@-X(TW7O%#6
M7CK6H[;Q'JE[?Z?NDATZ:]18[% B>69_(8EVP-JQM@9917J_PV^*/C#3_P!K
M*XTCQ9>:LWA_Q=<:C/X0%O>V,VF36<*)(OF1HOVF*14.X&1L$M@@$5[SXB\-
MZ?XNT1]-U2RMM0T^1XY&MIT#Q,T;K)&=O3*NBL/0J*Y/5OV:O NJ'Q%*GAO3
M]/U#Q9;3VFIZC8QBWOIXY_\ 6XF'S*7R<D8)/- 'A'CO]J3QGX<^/&LW%KK%
MM-H^C^.(?!L?AC[-&?MEN^F-=F[W_P"M\SS,8(.S:",5Q?A_]K;XC3-X4T63
MQA!?/\2+#P_J4FM16-N/^$5.H7<D4T48QLV[% C\W+*>3FOKVR^"OA#3_%]C
MXAB\-:*NOZ;:I96VI&U5KJ*%$\M5$AYX3Y<]<<53M/V<_ %AH>L:7!X+\,PZ
M=XAD674[9+!%COF5BRF08Y*L21Z$DC% S(_9,^(6K?$KX.+>:Y=+J&H:?JVH
MZ0U^L2QC4$M;N2!)]J_*&94&=O&X'%>E50\+^%M-\$>'[32=&T^STO2[%/+M
MK2UB$<,"]<*HX'K^-7Z!!1110 5M?#?_ )*!HW_7VG\ZQ:VOAO\ \E T;_K[
M3^= 'RO^W?\ #?P_KO[67C"ZO-%TVZN99H=\LL 9FQ!&!DUY'_PJ'PK_ -"[
MH_\ X#+7NW[;7_)T?BS_ *ZP_P#HB.O*Z_SNXQSW,H9]C80Q%1)5JB24Y))*
M;T2OL?T[D>6X.678>4J46W"'V5_*O(YW_A4/A7_H7='_ / 9:/\ A4/A7_H7
M='_\!EKHJ*^<_P!8,U_Z":G_ ('+_,]7^R\%_P ^8?\ @*_R.=_X5#X5_P"A
M=T?_ ,!EH_X5#X5_Z%W1_P#P&6NBHH_U@S7_ *":G_@<O\P_LO!?\^8?^ K_
M ".:M/A_)X(UN/7/ NHR^"_$%NNP36B;K2\3.?*N;<_)*A_!AV(KW3X*?MNV
M?B#6;7PS\0+.#P;XKN"(K6?S=VD:TW_3O.WW'/\ SRDPP[%J\PK!^)NH>';#
MP=<#Q5]B;1[C$317*>8)V/W51.69R>@4;L]*_6?#GQBSS+*\,NQ,98RC)V4-
M954W_P ^Y:M_X'=/IRW;/B.*N!,OQ5.6+H-4)I7;V@[?S+1+_$K/O?8^YB"I
MP:*^=?V#_#OQ,T/3KP^(&O;+X?-&/^$?TS7F,VN6X]6?.4@Q]V.4M(..1TKZ
M*K^V:<N:$9M.-TG9Z-76TDFTFMFDW9]3\$ZM;V;5UL_-;:/IHM.@44450!11
M10 5Z!^S?_R/EQ_UY/\ ^AI7G]>@?LW_ /(^7'_7D_\ Z&E*6P'*^//^1XUC
M_K\E_P#0C636MX\_Y'C6/^OR7_T(UDTP"BBB@ HHHH **** "BBB@ HHHH *
M*** .S?_ )("O_88_P#9*XRNS?\ Y("O_88_]DKC*2 ****8!1110 4444 %
M%%% !1110 4444 %=]^SQ_R-NH?]>#_^A+7 UWW[/'_(VZA_UX/_ .A+2EL!
MP<G^M;_>--ITG^M;_>--I@%%%% !1110 4444 %%%% !1110 4444 %%%% %
MSQ!_R,%__P!?,G_H9JG5SQ!_R,%__P!?,G_H9JG0 4444 %%%% !1110 444
M4 =M\!O^1RN?^O";_P!EKB1TKN/V?D$GCF96^ZUE*#CZK4!LO BDC[=X@X/_
M #R7_"IZC..HKL/L?@3_ )_?$'_?I?\ "C['X$_Y_?$'_?I?\*H1Q]%=A]C\
M"?\ /[X@_P"_2_X4?8_ G_/[X@_[]+_A0!Q]%=A]C\"?\_OB#_OTO^%'V/P)
M_P _OB#_ +]+_A0!Q]%=A]C\"?\ /[X@_P"_2_X4?8_ G_/[X@_[]+_A0!Q]
M%=A]C\"?\_OB#_OTO^%'V/P)_P _OB#_ +]+_A0!Q]%=A]C\"?\ /[X@_P"_
M2_X4?8_ G_/[X@_[]+_A0!Q]%=A]C\"?\_OB#_OTO^%'V/P)_P _OB#_ +]+
M_A0!Q]%=A]C\"?\ /[X@_P"_2_X4?8_ G_/[X@_[]+_A0!Q]%=A]C\"?\_OB
M#_OTO^%'V/P)_P _OB#_ +]+_A0!Q]%=A]C\"?\ /[X@_P"_2_X4?8_ G_/[
MX@_[]+_A0!Q]%=A]C\"?\_OB#_OTO^%'V/P)_P _OB#_ +]+_A0!Q]%=A]C\
M"?\ /[X@_P"_2_X4?8_ G_/[X@_[]+_A0!Q]%=A]C\"?\_OB#_OTO^%'V/P)
M_P _OB#_ +]+_A0!Q]%=A]C\"?\ /[X@_P"_2_X4?8_ G_/[X@_[]+_A0!Q]
M%=A]C\"?\_OB#_OTO^%'V/P)_P _OB#_ +]+_A0!Q]%=A]C\"?\ /[X@_P"_
M2_X4?8_ G_/[X@_[]+_A0!Q]%=A]C\"?\_OB#_OTO^%'V/P)_P _OB#_ +]+
M_A0!Q]%=A]C\"?\ /[X@_P"_2_X4?8_ G_/[X@_[]+_A0!Q]%=A]C\"?\_OB
M#_OTO^%'V/P)_P _OB#_ +]+_A0!Q]%=A]C\"?\ /[X@_P"_2_X4?8_ G_/[
MX@_[]+_A0!Q]%=A]C\"?\_OB#_OTO^%'V/P)_P _OB#_ +]+_A0!Q]>@?LX?
M\CW<?]>;?^A+6?\ 8_ G_/[X@_[]+_A77_!>V\,Q^*IFT>XU2:Z%L=RW*!5V
M[E]NN<5+V&CR;4/^0C<?]=G_ /0C4-=]=CX>_;)M[:[O\QMV!QG)S4>/AW_>
MU[\JH1PM%=UCX=_WM>_*C'P[_O:]^5 '"T5W6/AW_>U[\J,?#O\ O:]^5 '"
MT5W6/AW_ 'M>_*C'P[_O:]^5 '"T5W6/AW_>U[\J,?#O^]KWY4 <+17=8^'?
M][7ORHQ\._[VO?E0!PM%=UCX=_WM>_*C'P[_ +VO?E0!PM;7PW_Y*!HW_7VG
M\ZZ#'P[_ +VO?E6AX3D\"P^*-/:S;6OMGVA!#Y@^7>3@9]J5QGQ/^W?\0-+T
M7]K'Q?;7$EXLT<T.X)87$B_ZB,\,J$'\#7D?_"U-$_YZZA_X*[K_ .-U^HGC
MZV\&OXOOCJ6I:M#?;AYJ1$[%.T8Q\I[8K'^R?#__ *"^N?F?_B*_#LT\!,AQ
M^-JXZK7K*564IM)PLG)MNUZ;=KO35GW^$\1LSPU"&'A"G:"45=2O9*VOOGYI
M_P#"U-$_YZZA_P""NZ_^-T?\+4T3_GKJ'_@KNO\ XW7Z6?9/A_\ ]!?7/S/_
M ,11]D^'_P#T%]<_,_\ Q%</_$N?#W_017_\"I__ "LZ/^(H9K_S[I_=+_Y,
M_-/_ (6IHG_/74/_  5W7_QNC_A:FB?\]=0_\%=U_P#&Z_2S[)\/_P#H+ZY^
M9_\ B*/LGP__ .@OKGYG_P"(H_XESX>_Z"*__@5/_P"5A_Q%#-?^?=/[I?\
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MW_?K_P"QH_L7P#_T&-6_[]?_ &- 6.'KOOV>/^1MU#_KP?\ ]"6H?[%\ _\
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M(RG<K@]"#T(/J*6OTH^7"BBB@ HHHH *] _9O_Y'RX_Z\G_]#2O/Z] _9O\
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M-% '??;/AU_SZZU^9_\ BJ/MGPZ_Y]=:_,__ !5<#10!WWVSX=?\^NM?F?\
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M[<\!_P#0%U3_ +_?_94?VYX#_P"@+JG_ '^_^RKB:*+ =M_;G@/_ * NJ?\
M?[_[*C^W/ ?_ $!=4_[_ '_V5<3118#MO[<\!_\ 0%U3_O\ ?_95H^$M4\%W
M?BG3H[32-2BNFN$\IWFRJMG()^;UKSBMKX;_ /)0-&_Z^T_G18#MOB-JGA.#
MQM?IJ&GZK->*R^:\4^U&.T8P,^F*P_[:\#_] O6O_ C_ .RKY_\ VW/CKX]\
M ?M*:YIN@6O@V73$CMY$;45NC<;FB4MGRV"XSTKRC_AJGXK?\^/PW_[XOO\
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M.SB_)I76JT/#QV!Q.#J^PQ=-PEO9K==T]FO1O73<]+_M;P+_ - G6?\ O_\
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M\1>(OV?_  9?^+8YHO$UYI$$NI+-%Y4GG%>2Z?PL1@D=B37:4$Y-%,04444
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MH?\ 7@__ *$M*6P'!R?ZUO\ >--ITG^M;_>--I@%%%% !1110 4444 %%%%
M!1110 4444 %%%% %OQ ?^*@O_\ KYE_]#-5-U?F#)_P<&?&.:1G?PC\)69B
M69CH4A+$]2?WU)_Q$$?&+_H3_A)_X(I/_CM3S%<I^G^ZC=7Y@?\ $01\8O\
MH3_A)_X(I/\ X[1_Q$$?&+_H3_A)_P""*3_X[1S!RGZ?[J-U?F!_Q$$?&+_H
M3_A)_P""*3_X[1_Q$$?&+_H3_A)_X(I/_CM','*?I_NHW5^8'_$01\8O^A/^
M$G_@BD_^.T?\1!'QB_Z$_P"$G_@BD_\ CM','*?I_NHW5^8'_$01\8O^A/\
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M,G_\D?:'A_\ 8,\)6WB:SU+Q%JGB#QLNGGS+6QUF6(V,4F<B1H8T59&';?N
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MTW_@X>^-FC7!FL_#/PLM)67:7AT:5&(],B;IP*.8.4_4SQX?^*XUC_K\E_\
M0C65NK\P[C_@X/\ C+=SO++X2^$\DLA+.[:'*68GJ2?.ZTS_ (B"/C%_T)_P
MD_\ !%)_\=HY@Y3]/]U&ZOS _P"(@CXQ?]"?\)/_  12?_':/^(@CXQ?]"?\
M)/\ P12?_':.8.4_3_=1NK\P/^(@CXQ?]"?\)/\ P12?_':/^(@CXQ?]"?\
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M'_$0G\9O^A3^$_\ X(Y/_CM','*?IUO'J*[[]G=L^+M0_P"O!_\ T):_(?\
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M]"G\)_\ P1R?_':/^(A/XS?]"G\)_P#P1R?_ !VCF#E/TZWCU%&\>HK\Q?\
MB(3^,W_0I_"?_P $<G_QVC_B(3^,W_0I_"?_ ,$<G_QVCF#E/TZWCU%&\>HK
M\Q?^(A/XS?\ 0I_"?_P1R?\ QVC_ (B$_C-_T*?PG_\ !')_\=HY@Y3X2HHH
MJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8/[1G_1$_B%_X+Q_\51_P[!_:,_Z(G\0O_!>/_BJ** #_AV#^T9_T1/XA?\
M@O'_ ,51_P .P?VC/^B)_$+_ ,%X_P#BJ** #_AV#^T9_P!$3^(7_@O'_P 5
M1_P[!_:,_P"B)_$+_P %X_\ BJ** #_AV#^T9_T1/XA?^"\?_%4?\.P?VC/^
MB)_$+_P7C_XJBB@ _P"'8/[1G_1$_B%_X+Q_\51_P[!_:,_Z(G\0O_!>/_BJ
M** #_AV#^T9_T1/XA?\ @O'_ ,51_P .P?VC/^B)_$+_ ,%X_P#BJ** #_AV
M#^T9_P!$3^(7_@O'_P 51_P[!_:,_P"B)_$+_P %X_\ BJ** #_AV#^T9_T1
M/XA?^"\?_%4?\.P?VC/^B)_$+_P7C_XJBB@ _P"'8/[1G_1$_B%_X+Q_\51_
MP[!_:,_Z(G\0O_!>/_BJ** #_AV#^T9_T1/XA?\ @O'_ ,51_P .P?VC/^B)
M_$+_ ,%X_P#BJ** #_AV#^T9_P!$3^(7_@O'_P 51_P[!_:,_P"B)_$+_P %
MX_\ BJ** #_AV#^T9_T1/XA?^"\?_%4?\.P?VC/^B)_$+_P7C_XJBB@ _P"'
M8/[1G_1$_B%_X+Q_\51_P[!_:,_Z(G\0O_!>/_BJ** #_AV#^T9_T1/XA?\
M@O'_ ,51_P .P?VC/^B)_$+_ ,%X_P#BJ** #_AV#^T9_P!$3^(7_@O'_P 5
M1_P[!_:,_P"B)_$+_P %X_\ BJ** #_AV#^T9_T1/XA?^"\?_%4?\.P?VC/^
MB)_$+_P7C_XJBB@ _P"'8/[1G_1$_B%_X+Q_\51_P[!_:,_Z(G\0O_!>/_BJ
M** #_AV#^T9_T1/XA?\ @O'_ ,51_P .P?VC/^B)_$+_ ,%X_P#BJ** #_AV
M#^T9_P!$3^(7_@O'_P 51_P[!_:,_P"B)_$+_P %X_\ BJ** #_AV#^T9_T1
M/XA?^"\?_%4?\.P?VC/^B)_$+_P7C_XJBB@ _P"'8/[1G_1$_B%_X+Q_\51_
MP[!_:,_Z(G\0O_!>/_BJ** #_AV#^T9_T1/XA?\ @O'_ ,51_P .P?VC/^B)
M_$+_ ,%X_P#BJ** #_AV#^T9_P!$3^(7_@O'_P 51_P[!_:,_P"B)_$+_P %
MX_\ BJ** #_AV#^T9_T1/XA?^"\?_%4?\.P?VC/^B)_$+_P7C_XJBB@ _P"'
M8/[1G_1$_B%_X+Q_\51_P[!_:,_Z(G\0O_!>/_BJ** #_AV#^T9_T1/XA?\
M@O'_ ,51_P .P?VC/^B)_$+_ ,%X_P#BJ** #_AV#^T9_P!$3^(7_@O'_P 5
M1_P[!_:,_P"B)_$+_P %X_\ BJ** #_AV#^T9_T1/XA?^"\?_%4?\.P?VC/^
MB)_$+_P7C_XJBB@ _P"'8/[1G_1$_B%_X+Q_\51_P[!_:,_Z(G\0O_!>/_BJ
M** #_AV#^T9_T1/XA?\ @O'_ ,51_P .P?VC/^B)_$+_ ,%X_P#BJ** #_AV
M#^T9_P!$3^(7_@O'_P 51_P[!_:,_P"B)_$+_P %X_\ BJ** #_AV#^T9_T1
M/XA?^"\?_%4?\.P?VC/^B)_$+_P7C_XJBB@ _P"'8/[1G_1$_B%_X+Q_\51_
MP[!_:,_Z(G\0O_!>/_BJ** #_AV#^T9_T1/XA?\ @O'_ ,51_P .P?VC/^B)
M_$+_ ,%X_P#BJ** #_AV#^T9_P!$3^(7_@O'_P 51_P[!_:,_P"B)_$+_P %
MX_\ BJ** #_AV#^T9_T1/XA?^"\?_%4?\.P?VC/^B)_$+_P7C_XJBB@ _P"'
M8/[1G_1$_B%_X+Q_\51_P[!_:,_Z(G\0O_!>/_BJ** #_AV#^T9_T1/XA?\
M@O'_ ,51_P .P?VC/^B)_$+_ ,%X_P#BJ** #_AV#^T9_P!$3^(7_@O'_P 5
M1_P[!_:,_P"B)_$+_P %X_\ BJ** #_AV#^T9_T1/XA?^"\?_%4?\.P?VC/^
MB)_$+_P7C_XJBB@ _P"'8/[1G_1$_B%_X+Q_\51_P[!_:,_Z(G\0O_!>/_BJ
M** #_AV#^T9_T1/XA?\ @O'_ ,51_P .P?VC/^B)_$+_ ,%X_P#BJ** #_AV
M#^T9_P!$3^(7_@O'_P 51_P[!_:,_P"B)_$+_P %X_\ BJ** #_AV#^T9_T1
M/XA?^"\?_%4?\.P?VC/^B)_$+_P7C_XJBB@ _P"'8/[1G_1$_B%_X+Q_\51_
MP[!_:,_Z(G\0O_!>/_BJ** #_AV#^T9_T1/XA?\ @O'_ ,51_P .P?VC/^B)
M_$+_ ,%X_P#BJ** #_AV#^T9_P!$3^(7_@O'_P 51_P[!_:,_P"B)_$+_P %
MX_\ BJ** #_AV#^T9_T1/XA?^"\?_%4?\.P?VC/^B)_$+_P7C_XJBB@ _P"'
M8/[1G_1$_B%_X+Q_\51_P[!_:,_Z(G\0O_!>/_BJ** #_AV#^T9_T1/XA?\
M@O'_ ,51_P .P?VC/^B)_$+_ ,%X_P#BJ** #_AV#^T9_P!$3^(7_@O'_P 5
M1_P[!_:,_P"B)_$+_P %X_\ BJ** #_AV#^T9_T1/XA?^"\?_%4?\.P?VC/^
MB)_$+_P7C_XJBB@ _P"'8/[1G_1$_B%_X+Q_\51_P[!_:,_Z(G\0O_!>/_BJ
M** #_AV#^T9_T1/XA?\ @O'_ ,51_P .P?VC/^B)_$+_ ,%X_P#BJ** #_AV
M#^T9_P!$3^(7_@O'_P 51_P[!_:,_P"B)_$+_P %X_\ BJ** #_AV#^T9_T1
M/XA?^"\?_%4?\.P?VC/^B)_$+_P7C_XJBB@ _P"'8/[1G_1$_B%_X+Q_\51_
MP[!_:,_Z(G\0O_!>/_BJ** #_AV#^T9_T1/XA?\ @O'_ ,51_P .P?VC/^B)
M_$+_ ,%X_P#BJ** #_AV#^T9_P!$3^(7_@O'_P 51_P[!_:,_P"B)_$+_P %
MX_\ BJ** #_AV#^T9_T1/XA?^"\?_%4?\.P?VC/^B)_$+_P7C_XJBB@ _P"'
C8/[1G_1$_B%_X+Q_\51_P[!_:,_Z(G\0O_!>/_BJ** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ocgn-20191231_g10.jpg
<TEXT>
begin 644 ocgn-20191231_g10.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *)!6D# 2(  A$! Q$!_\0
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MT13G)8*NXC P'7KFNDH **** "BBB@ HHHH **** "BBFNZQJS,P55&2S'
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN3G- SP+_@G9XHAUCP-\0=(71O#=C=:%XLN[*ZU3PC&8],U>7:A-S$F2%)&
M0OR\# %?6=8/@GP'X=^&OARVT#PKHECX?T6VR8K'3X%BB4DY)P!U)ZD\FMZ@
M04444 %%%% !1110 4444 %%%% !7Q)\6/"M_P#M)?MW2>!1XIU[0/"'@_P>
ML^KQZ#J#VLES/=2_+"67[N4VDD<X4@$9K[;JK#I=E;7UQ>PV<$5Y<!1-<)$H
MDE"\*&8#)QVS0!^.OQ0\56/Q%^%OBY-4\>:[%\:]=\:'P?9^$8]4G6*PTOSE
M@6V>TSM,1C&3(PRSXYSNS]*_M1?L\^"I?VBOV<= L]/>Z\2:CJEL)IIIWD%O
MI6E6X8Q11D[8U<[2Q R2.O:ONN7PKHLUZUY)I%A)=M(LS7#6R&0NOW6+8SD=
MCU%6I=+LY[^"^DM()+V!62*Y:)3)&IZA6QD ]\4#+5%%% @HHHH **** "BB
MB@ HHHH **** /SV_:"TOXA_&;]O:6V^&-]H=MK'PU\'^>IUZU-S;M<W9;,6
MWH'9'3#'IM->'+ID_B/]DWQAXGF\1G4OBE\:_%^F^$-8LUL$LTTNXAG(>V$2
M'!PBY+<95EXZD_K'IWA'0]'US4]:L='L+/6-3V?;K^WMD2>ZV#">8X&Y]HX&
M2<5F1_"GP5#=+=1^$M#2Y743JXE73X@PO2,&YSM_UN/X_O>] S\]O$GQ$\?_
M +/.H?M+P^"O&7B'Q5I7@7P[HUA#)KDPNDL]1G9%DGBC"A8EBB+'RU&T8&<@
M5U/P[-YJO[0OAKX:^$_C1XM^(OAOQ!X/GOO&>I0Z[]H.GSD*8)[:=!_HKN_R
M[%/W6''>OO"S\%^']-FUF6UT/3K:36G\S4WBM44WS;=NZ8@?O#MX^;/%0>$/
MAYX6^'UO<0>%_#>D^'(;A_,FCTFQBMED;U8(HR?K0!Y+X+_9730K6X74?&7B
M9KH>(_[:CO-/UF>*>ZACBBAMX;V0G-P!'"NX-P2S5[W110(**** "BBB@ HH
MHH **** "O&?VROB%_PJ[]ESXE>(4E$5Q#HTUO;L3C]],/)CQ[[I!^5>S5P_
MQC^#?AGX\>"W\*>+[>>\T.2YANI+>"X:'S&B<.@8J<E=P!QWQ0!^2_@7X ZM
MKWB+X0_">'X0Z5\*OB#Y-IXB;Q]>:VTEUJ%K"P>5X$C&WS#G)CR64*,XQFO5
M_%GQ:^(G@WQU^TM\>_!>I:+;V-EXDT_PE9PZE8/=S:DULR0-;1$.HB0F3>6P
MQ)&!C&:_0WQQ\$?"GQ \5>"O$>JV<JZSX.NFN]'NK6=H6A9E"NAV_>1E !4\
M&N1C_9 ^&L?@:P\(_P!FWCZ':>(_^$J$+WTA:;4/,,F^5LY==Q^Z>.!Z4#/$
M_'7[1GQ=\6^)?B^W@K4O#/@KP_\ "G3XY-2DUJQ:\?5+[[.9Y(0?,3R8AM*!
ML%B<'OQ@^$_@WXQ_;5U>\^)VOZM>?#WPEXL\':3IAT_3[>UN7U"V=9);R-9)
M59X%\Q]H8 ,0<\X%?0?Q&_8O^%/Q3\9W_B;7=%O#?:F(1JMO8ZG<6MKJ@BQY
M?VJ&-PDNW ^\.W->TZ?I]MI5C;65E;QVMG;1K##!"H5(T4 *J@<    #VH ^
M--%^&_C^7XO>)/%.I?"4MH_A>RGTWP9X:6^LHK.]@D\J&YN;F3>S/=30IA5D
M38%0*S9.:Y30/V2_B5K7B?P[>7T^M^#H+74/$/BEM6TW4+235EN;@106-M,[
M!XS(+='4E%V*NU0V<FOOZB@+GC?[(/PSUCX2_L[^$O#WB2)HO$RQS7FK!Y5E
M;[7/,\TNYU.UFW2<D<$BO9***!!1110 4444 %%%% !5;4I&ATV[D0[76)V5
MAV(4\U9ILD:S1LCJ&1@5*GH0>U 'YB^$?C1\7-!_81N?C+=_$O6=3\1ZWJ"Z
M%%)?QP/9:+;&_,+7801@M* "-[L0 PXXKLOACX'EN/V\_%WA*[^)FJ^-Q<_"
M_P"R?\)&L\*:A;++<+P)85"[QO+HV,@.O7 )^V]'^$/@K0/ ,O@>P\+Z9;^$
M)5D231/LZM:NLC%G!0Y!RQ)^IK+^'W[/7PU^%&J+J?@[P3HWAO4%M6LOM.G6
MJQ2&%G#E"1U!8 \^@H&? ?A/P,OPO\#_ +=OACP-%=P1:7###:JLSRW!3['(
M96+DEF<@R,3G))-6_P!@CQ%#H/QN^'.B3:;\/=:EUSP$;BSU;P= T=]I$494
MM;WK!L2.S#YF<;M_?'%?HCH?PZ\,^&=:\0ZOI>B6=EJ7B&59M6N8HP'O752J
MF3^]A21^-9/P^^!GP]^%&I:EJ'@[P9HOAJ^U(YN[C3;-(7EYS@D#[N>=HXSV
MH [FBBB@04444 %%%% !1110 4444 %%%% !3)94AC>21@D: LS,<  =2:?3
M659%964,K#!4C((]* /RUT5_&.H?LX_&+]IJR\4>);K6YM<U2Y\+Z9#?2?8;
M"V>86K77D\AV2,R%<_*GE@@=36O\#_#/@CQA^V?\*M.\">.M8\>Z!X7\-3>)
M]8NM0U::_M_[3D3R1*ID)"2-YBEE7 &T# (-?I59Z38Z?IXL+6RM[:Q"E1;0
MQ*D0!SD;0,8.3^=0:;X9T?1Y-]AI5C8OY?D[K:V2,^7G.S@#Y<DG'3F@9\O?
MLGRM\?OBY\0OCOJF;FPCOIO"O@V.0Y2UT^W;$\\8[-/+DEASA,=*^LZK:=IM
MGH]HEK86D%E;(25AMXUC09.3A0,<DDU9H$%%%% !1110 4444 %%%% !1110
M 4444 >4_M57WBS3/V<_B#=>!_M0\51:3*UDU@A>X4\;VB Y+A-Y7'.0,<U\
M ?"W7?'7C;XZ>#?'^FZOX]F2^\5V/AKPW:Z@LL=O=Z#9VP74KF\C(P"X97W'
MK(7ZD<?0?[>?Q&TCP1XP\+0:E\>?%GPB>>QD=+'P[HTE]'> 28\QV4?*PZ8]
M*\6^!?QJ\.:Y\9/!EA;?M:_$+Q9<7&J011Z'J'AJ6"WOB7'[F20C"JW0F@#]
M.Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZTU(XR2^1D'G^5"GW&JNMF?6W_#W[X_#K_PBV?\ L%-_\<H_X? ?'[_J5O\
MP5-_\=KXV>R65B(Q^(YJI-9M&V!\U:71JI'VI_P^ ^/W_4K?^"IO_CE)_P /
M@/C]_P!2M_X*F_\ CE?$^PKU%-P,>]4.Y]M?\/@/C]_U*W_@J;_XY1_P^ ^/
MW_4K?^"IO_CE?$O%)COB@+GVW_P^ ^/W_4K?^"IO_CE+_P /?_C]_P!2L/\
MN%-_\=KXD(Z<=LTG- 'VW_P^ ^/W_4K?^"IO_CE'_#X#X_?]2M_X*F_^.5\2
M?AS2XH"Y]M?\/@/C]Z^%O_!4W_QRC_A\!\?O^I6_\%3?_'*^),?E24!<^WO^
M'OOQ^QG/A;_P5-_\=K[@U_\ ;0\<^%_^"=OAWXX_8]'O_&%ZT2S0S0.MH=]X
M\)(17!'RJ/XNM?B#7ZB_$09_X(L^#1@']Y;=?^PE)0,\Y_X?._&;_H5?!O\
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M (]1_P /H?C)_P!"MX-_\!KG_P"/5\$M;A6Z\^PI$RK8*Y'TH'S'ZE?LM_\
M!4[XH?&[]H#P5X&UOP]X7M-*UN\:WN)K*"=9E41N^5+2D9RHZ@UT?[<7[?'Q
M7^ 7[0VJ>#?"4NAIHUO8VMQ&+_3S-+ODCW-EMXXS[5\,?\$_D5?VS/A25X_X
MFK9_[\2UZO\ \%4(A)^V-KW'/]E:?_Z*J9.RT(G)\MT:+?\ !5W]H+G;-X5(
M]]);_P".UGW'_!7#]H6U^^OA4CU72F(_]&U\C&%C@@D$4QED[MNK-3?4QC4E
MU/K5?^"P7Q\_B'A?_P %3?\ QRE7_@K]\?Y'(0>%B/3^RF_^.5\>75JTC94*
M?PJ*WT^:.7=L'N%K3F5C7G5C[&7_ (+ _'Y6^<>%\=_^)4W_ ,<K9T[_ (*V
M?'/4$W++X94YQ@Z4W_QROBP(A^62+\QFIK>&UA;<J+^&142EH9RFVM#[:;_@
MJQ\=^HD\,$?]@MO_ (Y5>;_@K%\=XU)\[PN /72V_P#CE?',:Q-G&<'T>JE_
MH\=TV4>1?4;LBLU)]691J.^K/KRX_P""OGQVCW!)/"[$?]0IO_CE56_X+!?'
M[L?"W_@J;_XY7QK<:'+"W#;Q^55_[,FW= ?<5T)KN=<9+N?:/_#X+X_^OA;_
M ,%3?_'*/^'P7Q__ .I6_P#!4W_QROB_^RY>,C%2KHKM_'1=#YT?9?\ P^"^
M/_\ U*W_ (*F_P#CE.7_ (+!?'T]_"W_ (*F_P#CM?&O]BXQND_2E_L=5_B)
MXHYD+G1^M7_!/']O?XH?M-_'#4?"GC(Z*=*@T6:_3^S[$PR>8LL2C+%SQASQ
MBO&/%_\ P6(^+OA_Q9KFEP>&?![V]C?W%K&TEO<[BJ2,H)Q-UP*Q/^".]B+7
M]J/5V#9SX9N1_P"1X*^(OB>Q'Q,\7#/_ #&+S_T<].]RD^9:'W+_ ,/G/C#Y
M.\>&/!OH1]GN<_\ HZF?\/H/C#N'_%+^#<?]>]S_ /'J_/;)]:*8['Z%O_P6
M<^,2J#_PB_@TC_KWN?\ X]4#_P#!:7XQ#IX6\&_^ US_ /'J_/O<>F:2@#]!
MD_X+2?&)O^96\&Y_Z][G_P"/4C?\%IOC$/\ F5?!P/\ U[W/_P >K\^P=I!H
M)S0,_0+_ (?3?&/_ *%;P;_X#7/_ ,?H_P"'TWQD_P"A6\&_^ US_P#'Z_/R
MB@#] _\ A]-\8_\ H5O!O_@-<_\ Q^I%_P""TGQB\MF/A;P<?3_1[G_X]7Y\
MU<@C"6[,Z[MX(44"9][?\/IOC'_T*W@W_P !KG_X_1_P^F^,G_0K>#?_  &N
M?_C]? 'DMM)QQ2+&S=!0,_0#_A]-\8_^A6\&_P#@-<__ !^E_P"'TGQDZ?\
M"*^#L_\ 7M<__'Z^ E4;@".E.9?FW#D4 ?KKH_\ P47^)GBC]B'QE\6UT_0-
M-\3Z/XEMM(MXX;61[<POY18LC2$EOWAYSZ<5\X+_ ,%?/CPW'_%,?^"MO_CE
M97@-P?\ @E7\4&4;1_PG-D<?A;5\:!CLSTI$L^X?^'OGQW_ZEG/_ &"F_P#C
ME*O_  5Z^/#?Q>&,_P#8*;_XY7PNS%CF@2%>]%@LS[F_X>]_'D'D^%SSVTIO
M_CE-;_@KY\>OX?\ A%_QTIO_ (Y7P]',<\XQ3O.% M3[>/\ P5[^/O;_ (1?
M/_8*;_XY2?\ #WOX_8R?^$7_ /!4W_QROB3SMR' J(R,>] ]3[@;_@K]\>ES
MSX7_ /!4W_QRF2_\%@/CVOW#X6/_ '"F_P#CE?#]+M.,XH ^X(_^"P'Q[93N
M_P"$7S[:4V/_ $94UO\ \%=OC[,6^;PL !G_ )!3?_'*^&=Q ([59M9O(!;O
MVS0Q.Y]K2_\ !7[X_P ;8/\ PBP_[A3?_':9_P /@OC]Z^%O_!4W_P =KXFF
MF,S$FHZ97J?;O_#X+X__ /4K?^"IO_CM2V7_  5\^/MQ>6\3_P#"+[9)50XT
MILX) _YZ5\0)$TG0<5/IRE=4M 1C$\?_ *$* /ZC;&9KBRMY7^])&K''J0#4
M]5=+_P"079_]<4_]!%6J!A1110 4444 %%%% 'EW[3GCB_\ A=\!_''C/1])
M@U?6M%TN6ZM(9X?,4.!]YAU*KG>1Z*:^&O@[^U%XPTOXA^%-&_X6OH'Q5NM2
M\;6>FSVMMI\$<EW876GPRO-;K&,Q1VTID!)QD@@]"*^K/CE\:O&%C^T#\-OA
M!X&T[2IKK7HI-9UV^UD,T46E12!98XU'61QO49!QQQR2/-?'&C:=^R;^U1\/
MM8T'X9>!K#P#XWO(_#CZAI>G+#J]EJ4QD(D# 8$3# *KV5NAQD ^U*\/_:Z_
M:"E_9_\ A;<7FBV@U;QOJHDM= TO&[S9EC:229QG_50QJTCGIA0,C<*]PKY]
M_:1_9#TWX_:Q_P )(GBOQ'X;\46>AW6C6#:5J @MMLP;<)5\MF*N2JOM(+*H
M% 'A6G_M4?&'XE>'?ACH7A#4M!TGQ9J'P_F\=ZUJNHZ<9XIMCF..VCB5E";W
M!RW.!C'3!^L/V<OBPWQT^!O@OQY+:)87&N:>EQ/;1DE(Y02L@4GG;O5L9YQB
MOEGP]^P9\2/ACX8\$W7@GQWI4OC/3_"]UX3U>3Q()[JS-K.P<?9"@5D$3Y*(
MPQSS[_67P+^%-I\#_A!X3\"65TU]!H5@EH;IUVF9QDN^.VYBQQVS0!W=%%%
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M'NR<C\J5B>6X_P#L]?E.1AJJW.GK;SA /,+=,=ZGW'&,\U8LIO*N!)(=VT8
MJKM%7:U,R2QCC0,VX'//M5)X0Q/EOO'L.:WKIH[@29.P_P /O6;]E,;;P/\
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M'DJ<<<=34;-MP,?E2CIG.:5@1@C)% 'O_P"P/@?MC_"G _YBC?\ HB6O1?\
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M ?%GPT^)'Q4^+7BKX,>$K7XG:MX6L]:^%C:_J5SIUK;-++<I<.H==\95&/R
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M:WXF!R<DYH[XQBE\WWSCKZ5L:3X8N-:TVZO(KFTBCME,CK<3B-MH&21GCD\
M9R3G -6Y**NS24E!7D[&1DKSU;IR*:N57.>]7-/LYM4O!;VVQI&!;,DBQJ
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MAK6W&(O,4DAB#U.2?IG%?HO_ ,.5FQC_ (6\^/3^P>/_ $HI/^'*?_57&_\
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M_B*.4.0Q+2"*Z5L3JK#H&/6H!) NX.^"*Z7_ (4)\23S_P *Y\7*?^P)<_\
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M_P"#";_XS18.4^(U HD0;>.37V]_PYU^.W_03\(_^#";_P",TH_X(Z_'8?\
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M?_'*YB.S++GC\34JZ>I_B&<]!S4\R%S'1_\ "ZOB+_T4#Q5_X.[K_P".4?\
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M-CZ+_P"'B'[1G_15=7_[]0?_ !NC_AXA^T9_T575_P#OU!_\;KYTHH ^B_\
MAXA^T9_T575_^_4'_P ;H_X>(?M&?]%5U?\ []0?_&Z^=** /HO_ (>(?M&?
M]%5U?_OU!_\ &Z/^'B'[1G_15=7_ ._4'_QNOG2B@#Z+_P"'B'[1G_15=7_[
M]0?_ !NC_AXA^T9_T575_P#OU!_\;KYTHH ^B_\ AXA^T9_T575_^_4'_P ;
MH_X>(?M&?]%5U?\ []0?_&Z^=** /HO_ (>(?M&?]%5U?_OU!_\ &Z/^'B'[
M1G_15=7_ ._4'_QNOG2B@#[<_9;_ &Y_COXX_:-^&WA_7/B1JFHZ/J6O6EK=
MVDD<(6:)Y0&4X0'!![&O>O\ @H+^WQ\9/V?_ -I35/!_@S7+&QT*"PM)XX9]
M-AG8/)'N8[F4GDU\'_L8_P#)V7PD_P"QFL?_ $<M>T?\%;O^3S]<_P"P5I__
M *)H$5O^'LG[1W_0T:7_ ."6V_\ B:/^'LG[1W_0T:7_ ."6V_\ B:^/**!'
MV'_P]D_:._Z&C2__  2VW_Q-'_#V3]H[_H:-+_\ !+;?_$U\>44 ?8?_  ]D
M_:._Z&C2_P#P2VW_ ,31_P /9/VCO^AGTO\ \$MM_P#$U\>44 ?8?_#V3]H[
M_H9],_\ !+;?_$TO_#V3]H[_ *&C2_\ P2VW_P 37QW10!]A_P##V3]H[_H:
M-+_\$MM_\31_P]D_:._Z&C2__!+;?_$U\>44 ?8?_#V3]H[_ *&C2_\ P2VW
M_P 31_P]D_:._P"AHTO_ ,$MM_\ $U\>44 ?8?\ P]D_:._Z&C2__!+;?_$T
M?\/9/VCO^AHTO_P2VW_Q-?'E% 'ZX_\ !-O]N/XM_M(?'C4?#'CG6K/4-'AT
M2:]2*WTZ&!A*LL2@[D4'&';BOFSQU_P5._:'T'QKX@TZT\3::EI9ZC<6\*MH
M]N2$25E49V\\ 5K_ /!&7_DZ?6?^Q9N?_1\%?&/Q2S_PLSQ=_P!AB\_]'O0!
M]-_\/9?VCO\ H:-+_P#!+;?_ !-'_#V7]H[_ *&C2_\ P2VW_P 37QWM(HP:
M"M#[$_X>R_M'?]#1I?\ X);;_P")H_X>R_M'?]#1I?\ X);;_P")KX\92O44
ME 'V)_P]E_:._P"AHTO_ ,$MM_\ $T?\/9?VCO\ H:-+_P#!+;?_ !-?'=%
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M10 4444 %%%% !1110!_-#^TU_R<9\4/^QFU'_TIDKS6O2OVFO\ DXSXH?\
M8S:C_P"E,E>:T ?T\?!O_DD/@C_L!V/_ *(2NPKC_@W_ ,DA\$?]@.Q_]$)7
M84 %%%% !1110!D>+O">E^._"^J^'=;MC>:/JEN]I=VXD>/S8G&&7<A##()'
M!'6L#5_@OX*UWX4_\*UO= MYO!'V*/3QH^YUC$$>W8H8$,,;5.<YR,YKMJ*
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MX[SX;>&='\5>'_!5GK?A"^T"+Q"NK:QXBMM+:>.0!A;VT+!Y)9PIR5P!V!-
M'T)8?"OPKIOCS7O&D&D1CQ-KEI#8ZA?/([F:"(82/:254#/\(&>^:X_P_P#L
MG_"CPKIGAS3M*\'V]G8^'M8?7],MTN)BEO?L,&;!?YC@  -D# P!7@*?M;>.
M?$'[4G@./2]-@@^%6J^ O^$KGM[B\2.5;9BC2W3XC+%X?F00AL-RV1FI?A+_
M ,%,O#GQ$\=:%I6HZ'9Z-HGB(71TJ\MM>@O;V+R59\7MH@W6YD5"5Y;G - '
MN7Q>_9!^$GQY\30^(/'?A&/Q!J\-LMI'<2WEQ'LB5F8*%215'+,>F>:/$G['
M_P '_%WA_P -Z+JG@BSGL/#MI]@TP1S31206W>'S$<.Z'J58D$DD]:^3OB1^
MUO\ $#XL1_ OQ#I'A75? ?@;Q'X_LX-/UBWUE6DU2T$CQM%<P( 8UDP6"DL"
M$.>V?IC]F_Q%K'C[XF?&[Q/=:I=76@1^)1X>T:S>9FMX$LH%CG>-,X!>9Y,D
M==@]* .@\;?LF?"+XB:?H%EKW@;3;NVT&V^Q:<D1D@,%O_SPS&REHSW1B5.3
MQR:]0T?1['P_I5IIFF6<.GZ=9Q+!;VMM&$CBC485%4<   # JY10(*\Z_:._
MY-\^)?\ V+6H_P#I-)7HM>=?M'<_L^_$L?\ 4MZC_P"DTE '\XL;'RD]<"GG
M/-.CC+1KW^6G+%\W_P!:N<XB//0<T;MO/7^E/\LL<=Z58R&ZC% $>YNQ-*&]
M!T[T_P D\<\]Z4QXZD<]* (RQ/;GK@4%CWZ]JE\G\*3RSGK0%R/)Z]:.6QBI
M/+SCO]32[!W//Y4 0CH/K1@\>O>I2$VG/;WI69>YSD>E 7(L'J*._P#(U(K(
MH]OI2DIZY- $6WJ!U[5^L/[(,#S?\$J_B%$H^=[+Q HW'')C?O7Y1+( V<D\
M5^K?[);;O^"4WQ&/_3AXA_\ 13U4=S6G>Y^0&J737=T[LB1]%VQXP, #C'TJ
MJ9790-QP!@"F45KL=*22L2V]R]O,LB$AU.<U8CU65&<'YHV;<5SUQVS5*BF'
M*F61?2K)E6*C/1>E:5GK@66,2F00JV6 (8FL2BDTF2X*1LZQKBWETS0*R0]E
M;&3QWQ4,.N74:,B2!0P^8L,[JS**7*K6#V<;6L7O[49E<,F=_P!\@D9IUOK-
MQ9J@B<H%XVCN/2L^BG9#Y4:;>(KYH]HF9>0?EXJNVJ7#3I*9&+IRI8YQ52BB
MR0*$5T+,VH3W"D22,WU-5J**9226PH8A2 >#UK[D_:"OI++]A_\ 92,6"TEK
MK2[6. 1]I6OAJOLS]J9BG["O[)Q'!^SZU_Z4+2DN96(G%25CYJA\026LCV[.
MR $!H@V1UR.._P!:L-<Q7$R--" [Y.W:,LO./UZUR$.I@.2ZDAQL<#KM[X)[
MU>&H1W*@V\#)*,*P)!5A].WX5BZ9R.C;H:%[I<,)>-&A:907"JI93]&_QJQJ
M'AF2;2[219(O,8C.",\]CWK,NY8+-5"\.^2_E !0,\@9[U:LM;AC4RSL)@I"
M(&^_QT)SQBE[UDT)J=DT26^CFSA$1D'FAOF=6X+=U^HIDVDS26?F@^=&KG*J
M1R1R3STJM=:\]W*K6^W<YSL(P0WK3CK$OER6MU=)$=F3(F7ZC[G'>G:6X[3W
M*\]O=6ZI)(S1[SRI()0#H?;^M1-;W26<ZJI:(N"0%ZY[U+'?&2Z8R(@.%VEV
MR0,8 !_QI3KLT;B5=X,>5#9RO/K5ZFGO$,%BOS>5,5?=M7*G!XZYJ7R;V.T:
MX7<J1$*4B8@<'O4-QK4\BQQDJG\0*J!G\NG2KS:S_P 2>/$TJ2>8<JH !&.N
M>>AI.X/FTT*B:6\BB2;B61B0 <]LCZ5='AN2WMC/,P)49\M)!DCN<>U5;;5)
M6L)HUD8,VU68L.<GD_6FRZI+:E[=U* J02AQUH]X3Y]D,FTW9;-,9/W8;;EA
MD\>N.G6J\,<*N4=E//++Z8JM+,[*!EBI[4[^T9O)\H$!,YP!5ZFW*SW+]CFY
MBC_:F^$\(0ACXGLL-G.1YPKV/_@JY=)#^V7KP;_H%:?_ .BJ\(_8TD,G[6/P
MD8GG_A)K'_T:M>V?\%9XVD_;/UW'_0*T_P#]$T<J#E5CY*^W1$XXI6N$/H*S
M?L[]2,#UI'!7N32Y41RHT/M"9ZU()E]161SVIPW4^4?*:K.F/O"F>8@[BLPN
M?I0N3TS1RARFKYB#N*9(\?4D5G^7(.<&G+"TG_UZ+"Y302:/;G<,4-<1CG(-
M9S0NIV]::T;=Z.4.5&F+B-NXJ12K=#6/Y;=<4JRNG0FCE#E-GRQZTHCQWK)^
MU2>M'VJ3=D&ERL7*S[\_X(^J%_:CU?'_ $+5S_Z/@KX?^*"J?B5XN/\ U&+S
M_P!'O7VE_P $;IGD_:FUG<?^99N?_1\%?%7Q0X^)GB[/_08O/_1[TTK&L59'
M-;132,44YOF&>PJBAE&VE]Z.?I0 -'@U+-;QQPQ.DFYF'S+CI46:-QZ4 "Q[
MV"C )]3@4-'M8C(.#C(/!HW8HH 3 I3'MZ\4E+GM0 *JDC)X[^U/F2/S#Y>=
MN>,TS:=N['&<9H_A- #U,84@Q[B?XLD8J>."TDL[J5YS#<(5\F#82) 3S\W;
M ]>M5^<9'/'-:>H:%<6NCVFHLJ_9KABJ.K=2/:I9$FE97W/J;PNAD_X)FZR"
M0<?$VWZGI_H#5\XI;]D;&>H!KZ,\+R"/_@F;K3$9'_"SK?\ ](#7SA]J3C&[
M-9RO<SJ7OH.-FNXC@^U*MG''@M\P_NM1]L0D]<^M.%U$S8&?7FHU,_>(WME7
M&!M-#6OFMT 'M3_.1UZ\TJRC=][;GBC4-1GV7'\.32>0(XR!'E_>K!E4+]\$
MTWS.!_.C45V4OLLC?P?-["E$,@XQ@9YXJ_YQ;D/@"HG<MR>13NQ\S*TD)"C
M#'K4"Q[MQ=/P"UI$_*/D&&Z<4L>_:0H51ZFCF'S%$6T04;D.,>E/MXX&8+Y1
M_*K*LS,Q(W 4F=K<#FBX7,^X4$NB1<@]<5'<1^79L2@!VGG\*T]W7*[JCN%7
M[.WR_P )/7VI\P^8_I8^&W_).O"W_8*M?_1*UT=<Y\-_^2=^%_\ L%6O_HE:
MZ.MSI"BBB@ HHHH **** /GK]IG]FWQ'\3O%/A/X@_#GQ<G@GXF>%TFM[.^N
MH//M+NVE^_;SI@_+G)!P<9/'0CAO!W[+WQC^(GQ4\)>,/CWX_P!%UO3_  A=
M?VAH_ASPQ9M#;-> 82>9F522O4#!^H&0??/V@OBHWP0^"OC'QVFGG59="T^2
M[CL]Q42N,!0Q'1=Q&3V -?)?P[_;!^*^B^*_#^G>.+KP;XCCU/QG9^';I/#[
M%3'#>V$-Q;O:\DRK&TC"1CGL!ZT ?>U?*7_!2?PCXB\2?LQ^+KS3O%]SX>T+
M2],N+K4M-LK=3)JI!3RHGE)RD0.XLJC+Y R!G/U;7._$3P!HGQ3\$ZQX2\1V
MS7FAZM ;:[MTE:,O&<$@,I!'3L: /@K]HKX3:U\:KKX"Z99:-X2\6Z9H/@63
M5)_#OB37FL#<,T$"AQ'"?.(41\,,)D_,1BOJ_P#8U\7>&_''[,W@/5_"7A]O
M"N@2V31V^C&9IA:%)71T61B6==ZMACR015CXE_LE_##XN:9X<LO$OA][G_A'
M[06&GW5M>SVUQ%;; AA,L;JS(5&"K$@\^IKTKPGX4T?P+X;TWP_H&G0:3HNF
MP+;VEE;+MCAC48"@?UZGJ: -:BBB@#Y[_P""@7_)F?Q7_P"P0?\ T8E?SMU_
M1)_P4"_Y,S^*_P#V"#_Z,2OYVZ /I[_@F?\ \GN?#3_KO=_^D<]?KQ_P3U_Y
M-@TC_L+ZQ_Z<KBOR'_X)G_\ )[GPT_Z[W?\ Z1SU^O'_  3U_P"38-(_["^L
M?^G*XH ^B-4_Y!EW_P!<7_\ 037@O_!/[_DSOX9?]>$G_I1+7O6J?\@R[_ZX
MO_Z":\%_X)_?\F=_#+_KPD_]*): /H2BBB@ HHHH ***KWVH6NF6[7%Y<PVD
M"D RSR!%&>!R>* +%%8\7C'0+B5(HM<TV21R%5%NXR6)Z #/)K8H **** "B
MBB@ KA?BY\;O!7P)T*SUCQQK2Z+87ETME;O]GEG:68JS!%2-68G:K'IVKNJ^
M;OVN?^1^_9R_[*';_P#I%=4 >+^.OC1^S3XD\4^']4T>6*:SBU*2\\0R'2+]
M"\#1N,D-$"^963A 3WQC->\?!_\ :N^!.O:QHGP_\#>(4BO+KS$T[3&TV\MU
M<JK2.JM+$HS@,V,UL^+/A+\0O%/B+3=3;QWID*Z3?27NG1?V)GRBRL@#GS?G
MPCD=N>:X#XU6FK6/QV_9:@US4(=5U1=>U;SKNWM_(20_V=+C"9..,#KVH ^I
MZ*** "BBB@ HHKG/B+\0M!^%/@G5O%OB>]_L[0=*B\Z[NO+:38NX*/E4%B26
M P!WH Z.BOBOQM^WI876I7$O@GQ%');,J?9]/U3PAJ<<A.!O+3LJQ@=6&<9Q
MCDFM_P  _M]>!()#;^,?%KSS75S#;VD]KX2U2RAC9V" 2/+&1RS* <@4 ?6M
M%%% !1110 4444 %%8/C2W\276CA/"U[I]AJ?FJ3+J<#S1>7SN&U64YZ<YKS
MCX0^)/B/XNUO4Y-9U/P^^D:1JMSI5U#:6,J33-$  Z,9" "S X(Z T >RT44
M4 %%%% '\T/[37_)QGQ0_P"QFU'_ -*9*\UKTK]IK_DXSXH?]C-J/_I3)7FM
M ']/'P;_ .20^"/^P'8_^B$KL*X_X-_\DA\$?]@.Q_\ 1"5V% !1110 4444
M %%>!?M:?'[Q#\'=/\&^'? VE6>L?$'QOJPT?18]2<K:0'&9)YL$$J@*\#U]
ML'B_A/\ %GXR^$_C</ WQ-U?P1XTT>YL)KEM7\,3I;7.F7,2EC;RVSR;WW*.
M-JY[G@' !]$_%'P.GQ,^&WBGPC)=M8)KNF7.FM=+'O,(EC9-X7(SC=G&1TKQ
MS5OV/;;5/AU\#O"A\431I\,-3L-2CNA9@G4#;1E C+O_ '>[.<@MCWJ+PU^W
MY\+/%'@C4O&%NOB*V\-6(2/^TKK19DBN;EI/+6TMR ?.G+8_=IG .3C!QOZ;
M^V5\,[KP'XI\4WU]J/A^+PQ/':ZOI.M:;-;:E:S2X\F,VS#>S29&S:#N_ X!
MG.?$_P#8YF\5?%K6?B!X/\<OX)U77[6"UUJ&30[35([CR>(Y8A< ^5(%^4L,
M@^E<U\7_ /@GW9_%+QSJ7B*+QU<:5_:WAZ+P]J$,FB6=TYCC38'MG=0+4M_$
M(E&<MC;GCMYOVY/AE9> ?%7BK43KNC)X6FM8=9T?5-)EMM2L_M#!87:W?!*-
MNR&&1@'Z5T?PB_:F\#_&GQAJWA;0_P"V+'7=.M(]0-GK>ES6+W%I(0$N(A(
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M?PI6B?Y/W97</EX/S>XICT&M(68'IZ8'%(Q9<J21ZBAHVCP6!7/3(H"D].:
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M#_R:O\)/^Q6T[_TG2O7: "BBB@#^:']IK_DXSXH?]C-J/_I3)7FM>E?M-?\
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M&OH3P_\  _Q)IG[9>H_$^8V7_",S^";?0$"S$W'VE+@2'Y-N-FWOG\*^@:*
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MN;8@QECW8G))[DFNDHH **** /GO_@H%_P F9_%?_L$'_P!&)7\[=?T2?\%
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M"_\ )L^H_P#8<T/_ -.EM7T/IO\ R#K7_KDO\A7SQ_P4%_Y-GU'_ +#FA_\
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MHHH **** "BBB@ KS_\ :$N'M?@-\1IHR!)'X=U!ER 1D6[D<'@_C7H%8'Q
M\)1>/O OB'PS/<26<&LZ?<:>]Q$ 7B66-D+ '@D!L\TMQ/56/YW+*X>/Q#I]
MMXDO5$<:I&\N1(((B-W5>N,]%Y]ZQM4U;;J,L-K=?:]/@E(@9X_+$J Y!9,G
M]23[U^G_ /PY;\(;0/\ A9_B+_P"M_\ "E_X<N>#_P#HI_B+_P  K?\ PKE5
M&SN>?'"<KNWT^7J?F?X;\>7_ (.U&+4]'E^Q:DNY0Z*I4*1CA2#@]>:6\^)F
MOWWVP3W[2_;"3<ED7,V3DACC)&:_2W_ARUX/_P"BG^(__ .W_P *3_AROX./
M7XG^(_\ P#MZ/J\+\S2N#P-*4N>44WW/R]U#Q)<ZJS2WI%Q+L6-&;CRU7H !
M@8Q3--\07&C^:]H5BG<;?.V@N@[A2>F0><5^HO\ PY7\'?\ 13_$?_@';T'_
M ((K^#FZ_$_Q'_X!V]7[)6L:?5H\O)96/S%N_&6J:E<64U[>R7C648B@$YW>
M6@Z!0>!BK\/Q$O=)F%QHV_2=0;=YNH0RM]HE#=07SP/8 5^E7_#E3P8>OQ/\
M2?\ @);T-_P15\%M_P U-\1_^ D%3["+TMH0\'3=DTK'Y:3:I+<7$MQ,YFGE
M.YY9"2Q8\DDGO5O3?%FHZ3=2W-I>/!>2*R-<*?WC*PP5W=<$=J_3YO\ @BCX
M*;K\3O$G_@)!2?\ #D_P1G)^)?B(_P#;I;U?LD]&:O#QDN62T/RZFU^YFWEY
M_P!Y(V]G& Q/UZU3.I%8BAF_=EMY4MP3Z_6OU2_X<H>".O\ PLKQ!_X!V])_
MPY0\$_\ 12O$ _[<K>FJ:&J"6Q^54VK(68F4*&'*J>,4^Z\22W[(T]W+<NJ[
M5,C%B!Z<U^J7_#D_P3_T4KQ!_P" -O0?^"*/@H_\U,\0C_=LK<4_9HKV,;W/
MRA;5(VZEB?I7ZP?LBS>=_P $HOB*X! -AXAZ_P#7)Z;_ ,.4/!?_ $4[Q%_X
M!V]?2_P__8_M?A5^RCXH^#&A>(9[]-6M-0ABU34H0#&]TC+EE3J%)[<U:C8U
MC!1=S^>*BOTM_P"'(/C+_HIVA?\ @OF_^*H_X<@^,O\ HIVA?^"^;_XJJ-3\
MTJ*_2W_AR#XR_P"BG:%_X+YO_BJ/^'(/C+_HIVA?^"^;_P"*H"Y^:5%?I;_P
MY!\9?]%.T+_P7S?_ !5'_#D'QE_T4[0O_!?-_P#%4!<_-*BOTM_X<@^,O^BG
M:%_X+YO_ (JC_AR#XR_Z*=H7_@OF_P#BJ N?FE17Z6_\.0?&7_13M"_\%\W_
M ,51_P .0?&7_13M"_\ !?-_\50%S\TJ*_2W_AR#XR_Z*=H7_@OF_P#BJ/\
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MRPQW*>7.L;D"1<YPWJ,U^F/_  Y6C_Z+9IO_ (*!_P#)%'_#E:/_ *+9IO\
MX*!_\D4N6*OH)4X*]EOK\S\PZ*_3S_ARK'_T6S3?_!0/_DBC_ARK'_T6S3?_
M  4#_P"2*HT/S#-*00 >QZ5^G?\ PY5C_P"BV:;_ ."@?_)%'_#E6/\ Z+9I
MO_@H'_R10!^8C2,V 6)"C R>E)7Z>?\ #E6/_HMFF_\ @H'_ ,D4?\.58_\
MHMFF_P#@H'_R10!^8=%?IY_PY6C_ .BV:;_X*!_\D4?\.58_^BV:;_X*!_\
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M=M'_ /!8O_R12?\ #F>Q_P"B[:/_ ."Q?_DBGRKL5[.%[V/S3-Y.S F5V*C
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M>$G_ *42U[UJG_(,N_\ KB__ *":\%_X)_?\F=_#+_KPD_\ 2B6@#Z$HHHH
M**** "OF[6_^4AOA;_LF]]_Z<8:^D:^;M;_Y2&^%O^R;WW_IQAH ^D:^;OV0
M?^1U_:*_[*-=_P#I+;5](U\W?L@_\CK^T5_V4:[_ /26VH ^D:*** "BBB@
MKYN_:Z_Y'[]G+_LH=O\ ^D5U7TC7S=^UU_R/W[.7_90[?_TBNJ /I&OFW]I+
M_DY+]F/_ +#^J_\ IMDKZ2KYM_:2_P"3DOV8_P#L/ZK_ .FV2@#Z2HHHH **
M** "OGG_ (*"_P#)G/Q+_P"O.#_TJAKZ&KYY_P""@O\ R9S\2_\ KS@_]*H:
M /?=-_Y!UK_UR7^0KYX_X*"_\FSZC_V'-#_].EM7T/IO_(.M?^N2_P A7SQ_
MP4%_Y-GU'_L.:'_Z=+:@#Z/I:2EH **** "BBB@#YP_8]_Y&7]H+_LI6H?\
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M -]BC^TK0]+F'_OL4 6:^;OVNO\ D?OV<O\ LH=O_P"D5U7T3_:%K_S\1?\
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ME6QGBH3$0<'@TB;C*2IOLKL0 ,U(EA(W7Y3Z&BX717&.YI*NKI;Y()Z<TO\
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M6U-$URZG)1W1DZ#=G@>WO4PM7;D_A[5H0:>B,7(&*E95Z8I<W8ES70R_[,W
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MQSUQVKJZ* .3U3X4^$M:OI;V]T.WGN93EY"6&3] <55_X4KX)_Z%ZV_[Z?\
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M+QS)I>EP6BS$%PH+9(Z=2:U?[/M?^?:+_O@58HH 9%#'"NV-%C'7"C%/HHH
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M-O8"EYZ$\FE0?A3&(.?8TC?>]>*?M'UYHZ<]O2D(BD7; X[X/\J_H U@ _\
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M7<M(-N#O]1TKU?X>^(M5\6>"])U?7/#MQX3U:[A\RXT6ZF2:6T;)&QG3Y6.
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MLD05<9YZTR@4%3R,C^5- VL?3M3E9?+&3\WI3&9-Q'3VH =^-*!V8\4SY/7
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M)=S*%*:ZVUN['9^'%M8XC#;VXU?5=0#00V:!B8@3RYQC+'L!D <GTJ>WM/\
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M<^+-=_L 2:5=Q2+83X!S, V1UZ=>* /9**** "BOF-?VK/B+XE\8>--*\#?
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M&W]I+4",>L/_ ,8I?^&1/V,O^CD=0_\ (/\ \8I<R)T/STHK]"_^&1/V,O\
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MJ*H3R)),3C(/I7W>/V=OV)1_S<9K7_@%_P#<U _9W_8E4Y'[1FM _P#7C_\
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MTMI,;PJTL=K ZF#!Z*6/&X'./Y5(VJ>'[:&2>VU*[6\AWB/[191DOC'EC[Y
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MG.2>]:<GQ6\0S:*-*EOO.M5D,B><@=D) !P2.,X'OQ7T1_P@?[&/_12OB?\
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M   "J  *]*H$%>,?MH?\FG?%K_L6[W_T4:]GKQC]M#_DT[XM?]BW>_\ HHT
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M\^!O'/AN.UNKK3$OUOH9;:Y0O#*DJJN3P59<<$=Z]PH **** "BBB@ HHHH
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M1Q^.:HNPY954  &DWJ?4,!VII7Y_4XI&4]1Q0,DW[>@S]:&D7C:N#W&:9&"
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1LL<FD+DKCM7[;_\*I_8#_YZ_#O_ ,'Y_P#CU'_"J?V _P#GK\.__!\?_CU
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M_P#"1C_QHLA<L3\IEUZ=<X; (QCM]:8NM3KT88],5^KG_#5O[!7_ $2^V_\
M"1C_ ,:/^&KOV"O^B7VO_A(Q_P"-%D'+$_*%M6EW;@WUY-,.J3[=JO\ +Z5^
ML7_#5G[!?_1+[7_PD8_\:3_AJS]@K_HF%K_X2,?^-&@[1/R?.I3,N#(<9S]Z
MH_M\P8'?TZ?-7ZR_\-6?L&?]$OMO_"13_&C_ (:L_8+_ .B7VP_[E&/_ !H#
M0_)@WTO(W$ ]>32?;91CGI[U^M'_  U9^P7_ -$PMO\ PD8_\:/^&JOV"_\
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M7[[_ *'PCH&CV>MW B>\M+$'K)<[]H_(&I_$7A*+16)74=*O(NS6USN8_P#
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M!T[2+^8IWG1(I!D7/U%?JW_P\8_8\_Z)E+_X25E_\71_P\7_ &/._P ,9?\
MPDK+_P"+I6#D/F[X\RJO_!,O]GANJ_V[J'3_ 'KJOC);]&(YZ#'-?M/\</BM
M^S]XN_8Y\,_$W6OAI-XC^',>HA=+T**!+*2"5Y9(6<1I(J#D/WYSGK7QS_PT
MI^Q=_P!&UZI_X%+_ /)%#2!Q1\,_; &SDY]2:#<(<@#)QZU]R_\ #2O[%O\
MT;7JG_@4O_R12_\ #2G[%R_\VUZH/^WI?_DBBR%RKN?":S3(P9"5QTI_VJ7K
M(QD./XC7W7_PTI^Q?T_X9LU3_P "E_\ DBE_X:0_8O/_ #;9JF?^OM?_ )(H
MT"R/A3[=E3C"-Z@4JWVT \?UK[J_X:._8OZ_\,UZI_X%K_\ )%(?VD/V+Q_S
M;7JG_@6O_P D46B'+$^%OMI8\?*M+YO."#^=?<Y_:1_8O'_-M>J?^!2__)%
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M=9\(:SX'T?6=-TO1M.TWQ!"(+V5K=&,TC1@G:H8A5)ZCFOJN@ HHHH ****
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M\2O^Q:U+_P!)9* /YF*^W?\ @CY_R>#%_P!@"^_G%7Q%7V[_ ,$??^3P8O\
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MFA0K]X%U) QWYXIOA_QIX?\ %EC->Z'KNFZS9PL5EN-/O(YXXR.2&9"0#]:
M/@WXC?L/^*[[XQ?$B>3P>OQ \(^.-8CU03'QO=:+%9JV/-BN;6,$3[2,HP!(
MP/H(/VI_V4_CW\6M4^(6@Z<QUCPA>VUFGAI%\3FQL[2*%5W0W%J(\W,I*G:\
MK[1G/L/JV;]I[PW<?';P?\-]&^S^(/\ A(M/O;Y=:TV_BFM[<VWWHF"YRQ^O
M%>E:=XX\.:QKEUHUAK^EWNL6G_'QI]O>1R7$/^_&&W+^(H ^/=8_9;^(FO\
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M:!Z4JJ6Z"@^@'2@8E%.[;<<TGW<@]: &T4N,4I4K@D4 -HI[*?O8XI-I;I0
MG6BI!&9,!14DUN$C&.M %<4=ZE2,,A!Z]JD6U'EG/7% %8\=**7[N012F,KR
M1Q0!^EOCKG_@B_X(QS_Q-X__ $OGK\YEA;RPP&3W%?I1X@LX;[_@C5X+CEF\
MDC4U9.,AF%].0OMGUK\Y1;LTR@#G/85FY:V,I25[%46^T@R$#I@#UIBQAN!T
M)QNQ5_[.2V>M'V=DP?P [4N8FYGM&%89&>O\Z1L\,1@&K?V91DD$G\Z:8OFW
MC\O>G<=RH/O YY!S4O'EYQNYXJQY(93\OU-*L(QC'%%PN5?+>1L8Z\YJZMO'
M&PW .P[9XJ6-57!)VGWYJ%6>ZF^5>6/('8=S4WN3>XZ28[A@X53]WH.:G2\3
MS%;"EU8$[D&/Q'I2W%BBQE\D@-CBJS8:5W(&3USWJ=&+22([R!_.)'3IQ4/E
MGY2H&0.36FRM)&N<[L<>M1+:D9/5134A\Q26 [1EOH*<MON1@PP<\&KRQKP"
M?J:&(&!&N\\CFGS!<_H+_8B7;^R-\)1Z>'K7_P! KV^O$_V)P!^R7\)P/^A>
MM?\ T"O;*U6QN@HHHIC"BBB@ HHHH AN[6*^M9K:9=\,R-&ZYQE2,$?E7S"W
M_!,C]FUF)/PXCSU_Y"=Y_P#'J^I*_-_]N'7O </[65IIWQ<\6^-[/P<OA:&;
M3;#P@T\:VUV9Y [3;%.XNH&"N3\N#CC(!]P?!CX#>!OV??#EWH/@+0UT'2KJ
MZ-Y-;K<2S;I2JJ6S(S'[J*,9QQ7H%?-O["<_PQN/A?K+?"K5/%&K:%_:SBXF
M\5-*UPMQY4>57S%!V;=G3C)-?25 '$?&OPK>>-OA;XBT6R\7W/@*2ZMB)/$5
MGM\VSB!#2,I8@+E PW9&T$G/%?!?A;3O%TGPI_:(OO@]=^*=5^&E_I5OI/A-
M]9U*62:_U GRKN]M))W#+%AF.[< Q&5Z8'WC\;OA#IGQV^&FK^!]9U'4M,TG
M552.ZETF98IWC5PQ3<RL-K8 (QR,BO(O"?[!'@?P]X,\2>$=4\3^-/&'AC6]
M.CTU]*\1:T;B"T2-P\;VZA5\IU*K@CI@#&* //OV$[&Q^'_Q*\8^ M9T'Q=X
M9^(5MI%E?7=IX@\3#6K:YM6) GA=0%C;>Q#+VR!DX-?;%>1?!']F3PQ\#=5U
MC6;'4]>\3>)-6BAMKK7/$VH&]O#;Q#$4"M@!8U'8#GOG KUV@ HHHH ****
M,#QIJ?B#2M)2;PWHL&O:@955K6XO!:J$P<MO*GD''&.]>>_#WXL^.?'.K2QM
MX&LK/3+/4I--O[L:RKM \9PY5/+&\ D=#S7G-C^T-\;?'WC'QY8^ /AGX7U7
M0_"_B"XT WFK>(Y+6::2$(6;RQ P (<=ZY_X7^,OV@;&'Q*/#GPV\(:FDNNW
M<M^UYXED@\B\+#S8DQ =Z*<8?@GT% 'V/17D?[,GQGU;XX?#_4-8U[0[;P]K
M.FZU?:)=V5G=&YA$MM,8V9'*J2"1Z5ZY0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M>??M#?\ ) OB5_V+6I?^DLE>@UY]^T-_R0+XE?\ 8M:E_P"DLE '\S%?;O\
MP1]_Y/!B_P"P!??SBKXBK[=_X(^_\G@Q?]@"^_G%0!^Y=%%% !1110 4444
M?GC\5/V5?$OQV_:Z^.UQI^M^+/ EQ_PCVEG0M<TN>:TLKNY$(!CE90!,@*X(
M5LKDFN%B^&]SXP_9Y^!/@B;X3:MH%YH/Q.MK?Q9I$EC<RQ3X$@FO6D<$R0R@
MC+EBHY7. ,_J110,_,GQ[\ _&+6?[5GASP/X.O[+P]<>)-!O[?0M-MFLX-5L
M4CW7D-J %1MW&0G7&WVJ/QA\(?$7Q9U/XL:Q\#/AYK7PU\)WGP_719M-O-,.
MC'5]16X23RXK<[<LL >,R8P2V,G.3^G5% 7/S'\#^!SXD_:!^'E_\,/A3X@^
M&(M_A_JNCW&J7^A/IT2:I]D9(]S8Y978?O6^^3P6Q4'P?^%FI37'[/GAOPW\
M)O$'@KXH>#M>%YXS\67VE&VB>U7?]J#7G2[%QE=JAF].!7Z?T4 ?C=X4\%P^
M//A/XR\-^%?AAJ]_\5M2^)MQ/HWC2TTPM#:1PWBEW:]'^H$:B3*$C.\$ ]1Z
M#\:OACKN@?M!>++[PU\/M=\8ZWJ'B2UU$:)XH\'B[L[^4% ;FTUF%PUM$H4D
M([ # !7J*_2'X9_"CPQ\']%O]*\*:>=-L;[4)]4GC,TDNZXF8-(^78D9(Z#@
M=A77T!<_,;]I#X9^+]<_X;--IX3UBZ;6Y?#!T\6UA+)]L\L1^;Y)"_O-F#DK
MG&.<5[5\(?@]'\,?V[1+X:\(/X<\(S?#2VAGFL;%H+*6\6Y48=@ K3;0,Y^8
M]37V?10 4444""O%?VU<G]DOXM =?^$<O/\ T6:]JKQ?]M#G]D_XK\X_XIZ[
MY_[9F@#^=)K215!8_A3?L<OI6PVWHO6H&97Z*1VQGK6?,S#F946TER/G"_C2
M-:R]-P(]C5W:<]-HZ8]*4QE3\I)/KQ1S!S&?]DFYP,D>](+6<]%S6FX9EVD#
M<?0T*#R#S] *.9AS,S?LLR\MP*=]E9L9/TK1VADVY_*FLH&W<<C/I1S,.9F>
M;$[@-U*UBZK\I)]L8J^OWBPQMQ^5)&7R6SE?<478<S*/V'Y<E_K3OL"\8<M^
M%7%4'=GCFGA%7H:.87,S/?3SC*MGZBF?87XR0#]:TYD,F/FPH]!3"QS\J[<>
MV<T<S&I,]L_8+M?)_;&^$Y+@G^V5X'_7-Z_<G]J+_DVWXI_]BQJ7_I-)7X?_
M +"15OVQ/A.?+PPUE?F/_7.2OW _:B_Y-L^*?_8L:E_Z325:-8NZ/YPHP/+4
M]\4M,3B-,]P*=4D"\=J7C\:3=VZ48- "_I0#UI#PN?PHSTH 5<=QFC"^M)2#
M)R>PH <<8&/QHZ=:-IXI"WK0 4=:2E/'M0 O% /Y4W!I=IQG'&<4 %?3G[0;
M!?V;OV7\_P#0N:G_ .G!J^9-ORDYYQG%?37[0S8_9N_9?!''_".:GG_P8-2E
ML*7PL^?A[4[:64X&:K^:%;Y1MI_F,K'#85N":Q.8-P)]1Z4*3G-,52V ,'FC
MY=N<_-FF,D_"G=%R!3H4S(1+@J!D<T)<!5V*3@$XXZTA7&^^.:D@M99H998X
MV:.(9=@.%STS4;S\8(QGOWH6X=0T<;$*_# '@TM1.XA< TB\GCO1_"P?(HCS
M]X/P.F13&/VM@G;C'6I%MVD4'("GOFHUO&60E@),C!S0Q8\'[IZ4A:D@AC+8
M\XYZ?=IWD+NV^8#SC-0;6.-H^9::&.XC&?6@+>9[[^P@C+^V+\+0PP/[5;'O
M^XEKU_\ X+.'_C)/PG_V*T7_ *57%>.?L%R;OVQ/A;DY_P")HP'_ 'XEKV+_
M (+._P#)R?A/_L5HO_2JXK>&QTT_A/@7BC I**LT'4F*2B@!VVC;3:* ';11
MM%-HH =M%&T4VB@!V!1@4VE/US0 8'K2\4VB@#ZQ_P""6N/^&V/!7_7KJ'_I
M))7S1\3OE^)7BP#HVL7G_H]Z^EO^"6O_ ">QX)_Z]=0_]))*^;?B5C_A9'BT
M'_H,7G_H]Z8T<NT8A^[R30T8C 8<FI57;UH4;6.:!D6T;=_\5,V^8I)X-6"H
M+>U1LOI0!%''YS')I>9&VG@"GX'84NWCWH&,VMNV9^6G[?+;:.]&*<OO0(4@
M18(ZT;O,8 TJ_+G=1MV$F@0K1@=*;YC?=Q3N>IZ4,I8[EZ4 (T"[<D5%CS&V
MG@"I23)]WC%(R[N!UH _2GQE(8/^",_@AE/_ #%XQ_Y/SU^>-OJ$]C-]H1V1
MDY21<@@_7UK]#?&G'_!&;P,.G_$XC_\ 2^>OSP#%EVG[BG*_XUE+<SFD]R8W
MA:W #9"X+,H]:2&X)7+OE0.@]:J"$QY4MD-UIBHZD_.57J1V_*ILB.5&CM1U
M.&!I!"-N0?D[55A)3._"KCY3CKZT]7W1[D8@CHH%*P6)O,BD^4*R =:2:90Y
M$0SV!/>H5<HVX-N'=L\FFR(9(]XR'4YX[T[!8),J"QY^E;VD^'KRXL[::*UD
M8W4K6RS ?NRV%(4'U^8?F*PK/-S,JA6  YS7T!\'_!=Y#IYUA3)%#'#,D/G@
MK&+HD*H /<+\V?85SXBK[*-SS\?BU@Z7M&SSBZM;/26O(TB ^SJ8(TD 9RY/
M+$C )Z\]A7(7D*K<,J%21VKUCQAX0CM])E#22&2Q4AY6'WI&^Z#Z=^OI7C\B
MLK%&.6R<FE1ES*Z8L%6C7ASQ=_Z_I_,EW,RE@0!GUI9&<@$G ]ABHC(S!#CE
M1@<4@_U8//3M]:Z#T;#E0*N?7]*6-PK!@<;3Q]::=^6)&0W<_P!*&4,#CA<?
MK3 _H1_8D.[]DCX3'U\/6O\ Z!7MU?GQ\'?VA?B%:_#7X&_!KX/Z#HNI>,[C
MP1;:YJ6J>)))%L-.M,[%RL?S.S,.QXR.#DXZ;5/VV/B/X'\"_&K0/&OAK0])
M^+7P^TF'6+=[%I)]*U.UE=%695+!P 7 *ENXZ8(K<Z3[AHKX>T7]OO6/&7PO
M^!WB#1[#3;?6O$_C*V\)>*=.NHG)L92I,OEC>"I8;74MGAAUQ7N'[.?QLU[X
ML^-?C-I&L06,-MX/\5RZ)I[6D;*SP*@8&0ECELGJ,#VH ]QHHHH **** (;R
M.::SGCMY?(G:-ECE*[MC$<-CO@U\3_%W3/B]X+BTRVU+]JGP_P"%M0TGPZ^H
MZNMYX:MY9+B..=@]YLZJG[R&,*!RR\9)-?;U?G7_ ,%"/A59S?%B#5==\?>#
MO"7A'QE9:=I6M2:]<.FIP6MG=-.ZV:*"723<FX<#<BY.* /I?]BWQ-J?C/X3
M3ZUJ/Q7L/B^ESJ$GV?6M/TL:<($"H# \( (8-EOF .'';%>^U\Y?L3>$5TOP
MAXR\61ZKX=U*V\9>(KC5K6/PI*)+"VMU1((8U(_CV0JS^C,0>17T;0 45R7Q
M6^*/A_X+_#_6?&?BBY>UT32HA).T49DD8E@JHBC[S,S*H'J>PYKR+P_^W1X
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M8 P?[4;_ -$2U[#_ ,%G?^3D_"?_ &*T7_I5<5X[^P;*I_;%^%84@@ZHP_\
M($M>R_\ !9J,R?M)^%,?]"M%_P"E5Q6T-CJI_"? -%.V4;#5EC:*7::-I]*8
M"44NTTNTT -HIVTT>6: &T4[8:-AH ;13O+/K1Y=(!M%/\OWI?+[4!<^K/\
M@EK_ ,GL>"O^O74/_222OF[XE*#\2/%I/_08O/\ T>]?2G_!+=-O[;'@D_\
M3KJ'_I))7S9\2O\ DI'BW_L,7G_H]Z!]#F^O6D^]3]W:DIB$]J;CTI]-&.]
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M_J7Q.^''B[7/#FK?L_ZOX+T#Q;XBN]9EO([V)=.T5&B&R&.$#./W:@D$99^
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M/H ^;?V$_P#DG_Q!_P"RA>(O_2UZ^DJ^;?V$_P#DG_Q!_P"RA>(O_2UZ^DJ
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M7V[_ ,$??^3P8O\ L 7W\XJ^(J^W?^"/O_)X,7_8 OOYQ4 ?N71110 4444
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MV'&0<<TW<,C(P,55:^;G"@9IKWI8CCFBP69>D5550#GC-?2W[0F/^&;_ -F
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M:;XT\6^%/$GB'XI/X\M=-L[J[T'XCW\5TB0MG%S:F,D!69MK G(PH/>OLR@
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M=%UVLXSGUSBO=?\ AI[X2?\ 1KG@W_P=7_\ \51_PT]\)/\ HUSP;_X.;_\
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M_*/SE_OK^=*+A!_&OYU^@7_#V[2?^C>/!_\ W]3_ .1Z7_A[=I/_ $;QX/\
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M<?\ @OM/_C5*UQ.*>YX+)X-\238W:!JW' S8R_\ Q-1CP1XD[:!JH_[<9?\
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M+_\ $U[_ /\ #RO]I#_HI-Q_X+[7_P"-4?\ #RO]I#_HI5Q_X+[7_P"-4 >
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MOCS_ -E.UC^4->J_'W_DA/Q'_P"Q;U+_ -)9* ,G]E?_ )-G^%/_ &*^F_\
MI-'7J5>6_LL?\FS_  J_[%?3?_2:.O4J "BBB@ HHHH ^5_V9/!6A>/(_CMI
MWB#3+?5K)/BGJ\RP7*Y4.$A ;ZX)_.NO^,OP/\!^$_@W\0M6T?PMI^GZC;^&
M]3,5S#&0Z9M)0<'/H2/QK+_8W_X__CS_ -E/UC_T&"O3/VAO^2!?$K_L6M2_
M])9* ,_]EK_DVOX6?]BQIW_I,E>HUY?^RW_R;7\+/^Q8T[_TFCKU"@ HHHH
M**** /G']C/_ (^OCK_V4W6/Y0UZ9^T1_P F_P#Q,_[%G4O_ $EDKS/]C/\
MX^OCK_V4W6/Y0UZ9^T1_R;_\3/\ L6=2_P#262@"I^S#_P FW_"W_L6--_\
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M+M*T =)\+_\ DIW@X?\ 4:L?_2A*_H-_:B_Y-L^*?_8L:E_Z325_/I\,%/\
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MVNK.:;]JGXN%(V;_ (JG4.@_Z;M7UI_P1I'_ !D5XN(Z?\(PX_\ )J"OE?\
M:XN)(_VH?BTBS;1_PE&H]_\ IN]/IH;)M1T/$I;66'(=&7ZBHV8XK674)A(I
MF7SXSQQ@X_&G+I]O<,=DH&XYVL""M._<?-;<Q32^];DVDV=JP\ZXVKC(&,DU
M#)<Z= ,1VS2_[4AQFCFOL'/?9&3@^F*.<UKKJ5B^ ]GL"_W#G^=1_:-/EX:W
M>/W4T7\A\S[%21AMR!M(Z =ZK\\]JVFL[>^9?LTVYL<JPP36?-92V[89,+FF
MF$9(J<48J5H2K\C%:&DZ6M[(7F<0VR??D;^5#=M1N22NRA%:R3*61&('7 S3
M7MY(_O*5^HQ71?VUY+&VT^%=BYPQ&2:NV=]_:EOY-Y:1O(AVJP&,?6H<FM;&
M3J26K6AQNPTNPKBNTD\/VC1LVT1JO\7K4*Z;8V=MOF0F)_XFI>T0O;)[(]_T
MG_E&'KG_ &4ZW_\ 2!J^5*^P-/BL[W_@FMK26X,,(^)MORW<_8&YKYA3PY&X
MR)(W/NYJN=+<T]HNISM'K70MX=/78/3Y33H_#Y[A2?KTI<Z#VD3G:3\>*ZP:
M#&R\B($?Q $?I2-HMDO#8)'<*0*7M$3[6)RGK3U*C[R[O>NE&BV2X.__ ,=-
M2'1;>3 5AG_<./YT>T0>TB<JV">,XHQD5U;:% -H(Y[E1BE_LF)5(4D#MFCV
MB%[6)R>QNI4_7%*H;L&)KJSI65!:16XR1Z40Z:F3^\.[_9H]HA^U1RRQR-_"
M:0PLK?,I KJFT:-&!QGCCM3_ .RX@N#\W/()I>T0O:HY1H3M!7)'O3EMY''W
M,#UQ74?V5&#SDKCIFI$TN'@\^H!/\Z/:(7M4?M__ ,$NEV?L4^!1U^>]_P#2
MJ6OJZOES_@F>@C_8W\%*HV@27O'_ &]2U]1UJG=7-T[JX4444QA1110 4444
M -DC6:-D=5=&!5E89!!Z@BOC67]@WQSX'OK_ $[X0_'K7OASX&O[F2Y;PX+"
M.\6S,C%G%M(S QKDG '(]2>:^O\ 6K.;4M'OK2WN&L[B>"2*.X7K$S*0''N"
M<_A7YS:;K?[8GP"\30V'B'7O ,V@6&B0Z=;ZOXPUN2'3KR19G(E\QW5VNV7&
M[/&T#O0!]M_L^? 7P_\ LY_#N'PIH$UU?;IY+V^U34'WW-_=2',D\K=V.!]
M />O2Z\L_9UU[XF>)/!$VH?$^+PJFIS7):QD\(7+SV<MJ44J^]B<L6W]#C&*
M]3H **** "BBB@ HHHH _FA_::_Y.,^*'_8S:E_Z4R58_96_Y.8^%7_8T:;_
M .E,=5_VFO\ DXSXH?\ 8S:E_P"E,E6/V5?^3F/A5_V-&F_^E,= '[C_ +'/
M_(9^/O\ V4W5?_1<%?1]?.'['/\ R&?C[_V4W5?_ $7!7T?0!\V_L)_\D_\
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M5]/C?_V4W6OYQ5Z?^T1_R;_\3?\ L6-3_P#226@"M^S+_P FY?"[_L6--_\
M26.O2Z\T_9E_Y-R^%W_8L:;_ .DL=>ET %%%% !14%\Q2RN&4[6$;$$=N*_%
M/PE\>?$^L?#FSFTKXQ_&.^^-]_J$T.C>'H"UQI%Y(MR55 7&''E\L-Q /!%
M'[#>./A3X7^(VJ>&-1\0Z6-0O/#6H+JNE2&:1/L]RHP),*P#<=FR/:C3?A3X
M6TCXD:UX]M-+$7BO6;.&POK_ ,Z0^=!%_JTV%M@QZ@ GO7Q[XC^._P 5_ /[
M6FKV-OH-]XUGM/AE9ZK?>&HM62ST^UNED)N9P7W*&^4HNU26R!P.:]*C_;B7
MQAHOPQA^'O@6\\6>,/'>ERZS;:'<7\5E'8VL3%)9)YV#  .K*N%.XCMQ0,]$
M\)_LB?"/P/XZ'B_0_!EMI^MK)+-&T=Q,8(7ER)&C@+F)"V3G:HK+T']A_P""
M?ACQ%I^NZ3X'@L-4T[45U6RFAO+D"UN Q;,2^9M123DHH"GC(.!7!/\ M^6>
MH>"] ;1/ NI7_P 1M7\23^$AX,N+R*!K;4( &G$EQ@J(E4JV\ Y##@<X\O\
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M4C)+8!55  8T ?<E%>2?LR_'Z/\ :*\ 7VNOH,WAG4],U:ZT74M+FG6?R+J
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MFB(/RL."?2E,+;@=F>,%@<@4DD@W?+AE3 '%(6Y$_P#JW"D-WP?3O5AD8]'
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MEBCRQ0%QE%2>6/>E,6WM0*Y%14FP>E'ET!<CHJ78/2E\O/\ #0%R&BIO*/\
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M/_(9^/O_ &4W5?\ T7!7T?0!\V_L)_\ )/\ X@_]E"\1?^EKU])5\V_L)_\
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MO3/VB/\ DW_XF?\ 8LZE_P"DLE>9_L9_\?7QU_[*;K'\H:],_:(_Y(!\3/\
ML6=2_P#262@"I^S#_P FW_"W_L6--_\ 2:.O3:\R_9A_Y-O^%O\ V+&F_P#I
M-'7IM !7GW[0W_) OB5_V+6I?^DLE>@UY]^T-_R0/XE?]BUJ7_I+)0!_,Q7V
M[_P1\_Y/!B_[ %]_.*OB*OMW_@C[_P G@Q?]@"^_G%0!^G7[%?3XW_\ 93=:
M_G%7I_[1'_)O_P 3?^Q8U/\ ])):\P_8KZ?&_P#[*;K7\XJ]/_:(_P"3?_B;
M_P!BQJ?_ *22T 5OV9?^3<OA=_V+&F_^DL=>EUYI^S+_ ,FY?"[_ +%C3?\
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M?_OE?\*M0WUO<SW$,-Q%+-;L%FC1P6C) 8!@.A((//8BIZ ,[^S+G_H)3_\
M?*_X4?V9<_\ 02G_ .^5_P *T:XGQ5\;OAWX%U=]*\1^._#>@ZFBJ[6>I:K!
M;S*K#*DH[@@$=.* .)^-'QCM/A?8:HL/BW3Y/$%K%')%HET,2R;F4=0PXVDM
MT[5U_@'Q=IOCR&[?1_&5KKOV;8)O[/5?W18' ;D]<'\JMZAXT^'\GAVV\4WN
MM^''T.[=(8-8GNH#;S,QVHBS$[6)/  /6NIL]-M-/#?9+6&V#_>\F,)GZX%
M' :#\)KCP7>Z]+X9U.STB'6M2EU:]0V+RM-=2A?,E9C,!D[1T ''2K6N> _$
M'B;1-0TC4_$-E>:;J%O):75N^F.%EB=2KJ2)P<%21P>]=GJ^K6N@Z3>ZG?3+
M;V-G ]Q/,W1(T4LS'Z $UX?X7_;F^"_B[3=8O[+Q9)!;:58+JEP=0TR[M6>V
M+K&)(EDB4R@NZ* FXDNH[B@#U;POX)A\'^&]+T+2[F2STW3;6.TMK>)1LCC1
M0JJ-V3@ #J2?<UJ?V9<_]!*?_OE?\*\IU+]L'X4:3X-T_P 477B62+2[VXN+
M5%_LZY-S%);_ /'R)8!'YD0B'+EU 4$$D9%;NL?M&?#_ $/3_&M]=:\HLO!U
MO;7.LW$=O+(D"7$8DAVE5/F%D93A,GYAZT =S_9ES_T$I_\ OE?\*/[,N?\
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M_!D7A/P[I>B:9=26FG:;:QVEM;QJ-L<<:A549R<  #DD^YK2_LRY_P"@E/\
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MV?\ X'7?_P =H"Y^?G_!%/\ Y.*\8_\ 8LR?^E,%>%?M4:C!;_M,?%82,O\
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M_P#Q-9GBK]DGX*:5X8U>]MOA3X02XMK.::-CI$) 94)!QMYY%/4>I_.M+#)
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M"YX&*]<^#?[,/P\^ ]]J&H^$]'F35]0C6&YU34KV:]NWB7&V+S9F9@@P/E!
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MJ* !R2>!WH NT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6'XZ_
MY$CQ#_V#KC_T4U;E8OC:-YO!FOQQHSNVGW"JJC)),;8 'K0!^0G[!7[2WQM^
M$OP-FT3X?? R]^(F@MJUQ<-K%NTP43,D8:+Y$(R JGK_ !5]'?\ #<W[4O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /*_VGO![^/?@GK^@B#6[J&\-N+B'P['!)>O"L\;R+&D[!&RJD$$\@G
M)X/R+I/PB^*>D:[X'UB^\)3V%UID%C<:=J%I'!;0:+:6UW?2W<=Q%$X2.6XM
MY+;>D:E78D<;>/T.IKJLBLK*&5A@JPR"/2@9\):;XX_:&^-6E>'=MCXF\-Z3
M=0V=\=8TN&VM3/&VCSM*,Y8[7O5CQQPK(1@$5[=^RA9_%+3X]=B^)%WJ]]YV
MGZ/>6\NL>5N2\EM,W\2>6  B3#&W&!V)KWVWMXK6".""-(88U")'&H554#
M Z "I* "BBB@04444 %%%% !1110!1UZ:\M]#U&73HQ-J$=O(UO&W1I I*#\
M3BOAO]B+Q9\.=:_9I\4_\)W\3%;Q?XMN+X^,XM=UM;2[M)V+PO&JNP:)1&%
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MNV/0<59^$OQB\)?''PBGB3P9JRZMI9F>WD8QO%+!,F-\4D;@,CC(R& ZCUH
M[2BN6T/XG>&/$GCCQ#X0TO5H;WQ#X?C@DU2SB#$VGG F(.V,;B%)P#D#&>HK
MJ: "BBLOQ1XGTKP7X=U'7M<OX=+T?3H'N;N\N&Q'#&HRS$^@% &I165X5\3:
M=XT\-:5K^D3_ &K2M4MH[RTGV%?,BD4,C8(!&00<$9K5H **XCP7\9?"WQ \
M;^,O"6BWLMQK?A&>&WU:%[=T6%Y5+(%8C#Y /W<XKMZ "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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FO_7CX>_](37WE0 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ocgn-20191231_g11.jpg
<TEXT>
begin 644 ocgn-20191231_g11.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0 Z17AI9@  34T *@    @  U$0  $
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MN/A_=Z!_PL+6ECNO#%SX9\X:5!N1)_%A\2M*!N^\)3Y&.A4!OO<4 >U?%_\
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MU=46>YD>5[G[*\]GEV;]U.1G@"NCUK_@B+X;\4_M8VOC_6/'6N:QX/TZVO\
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MNT\RSO\ RXY?LS G_6;)HSM&?OXZ@@?"WQ"_X(I>+OVA]/U#4_B=XL^'NO\
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MX=U#P_#+8:/):ZQK!N=:?4Q>ZE.TC+/<@2&$L ,A%/ .U?MN@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBN'^"'[1/A7]HA/%C>%;V:]7P3XEO?"6K>9;O#Y&H6A03QC<!N4;UP
MRY4YX- '<4444 %%%% !1110 4444 %%('RQ7N.>E+0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\-_#'_@I%\9/
MVG_%.L7GP?\  7P)\7^&] O)[6[TJ;XK>7XH3RI3&?/MH;*6*SD)4_NY7.,C
M+"OM+P=K%[X@\)Z;?:EI-QH6H7EM'-<Z=/-'-)8RLH+1,\;,C%3D;D8J<9!Q
M7Y2_M#? RZ\+?\% _#?Q"_: \,_%3Q3>:#XKTI-%\2_#KPUHWACPGILEY<PP
MVR7M^;O^U[R-))8XY1*ZQ%@P$9!P?U(^,>LZQX=^$7BK4/#_ -A_M^QT>[N-
M-^V*[6WVE(7:+S @+E-X7<%!8C. 30!TE%?D7X@_X*F_M0:3\ /!.NZ3IKZQ
MK6H+K9TU'\+B8^.4M[Z. .?(_=P_9[1IKO,143?9QU4E3^A?_!/OXM^)/C=^
MRUHOB'Q1>_VQ?W%[J%O;:N=/_L_^W;*&]GAM;[[/@>5Y\"1R;0 /GR  0* /
M+O\ @A/$L'_!+GX=JBJJB^U_@?\ 8=U"O7/VX/VN=+_8>_9]U3XC:WI]YJ6C
MZ(5:\BM5+SB,YRR( 2Q!QP/Z5Y+_ ,$+!C_@EY\//^O[7_\ T^ZA7U'XO\#Z
M1X^TU+/6M/M]2M8Y!,L4R[E#@$ _7!/YT ?EYHO_  =F_ _Q!K-G86WA7Q]]
MHOITMX@^C3JN]V"C)V\#)'-?I-KFN>*O&/P-EU'P;_PC^G^+M2TP3Z9_;4<M
MQIT%PR@J)UA9)'C!/.QE)]JA/[-7@(C_ )%72/\ OU78:5I=OH>FV]G9PI;V
MMK&L4,2#"QH!@ >P% 'YU_LR_P#!:#QIIWPLLO$?QM\+:#=6VJ>%O$'CN6\\
M#6LL-KX=T31;HV=U)=+>7+23323F,1) IR).0-I:NRM/^"]/P]G\">$]<D\"
M^/(%\0:[_8=]:R?8DGTEFN;.VCGVM.#<PN]] 1);B10!(&*LFT_3GAS]C#X4
M^$K.WMM/\!>&[>UM=$O_  W'!]E#Q#3;ZX%S>6A1LJT4TP#NI!!-<G<_\$OO
MV?[[3?#]K<?"SPS<Q^%?,&E-,DDDMH'GCN"!(S%V430Q2*&)"O&I7! H ^=_
M@=_P7IT'Q%JGP_\ #OCSP!XET#Q9XUGNI+J+2?+U*ST2S_MB]TRSN)&1S(ZO
M)9R>844^6$9V 0K7:?LU?\%5]6_:*\4?$O4X?AIKNF^"_"_PUTGXB>&K:8P-
MK?B>VO6U-D=%CG>)5EBLHO+C<I(KNX?'&/;M"_8"^#7A?QGI'B+3?AYX>T_6
MM!OKK4K&[MXFC>">YG:XF/RL RM,[R!&!57=F4 L2=+X#?L8?"O]E[6]<U'X
M>^!?#_A&\\2)'%J4FG6_E_:HXWE>.,C. B--*510%7>0 !Q0!\EV_P#P7^^'
M_P 5H;NU^'NC^(+Z\L]5L8&O+JQCEM&L+C4=)LH[Q0MPA:*>74GAB<-@26DY
M92$VMSWPU_X+J^)I/'&CS>./A+=:3X/OM,>YOY])O8+RZT9F\6R^'H+B0M.H
MDMRPBW+&C2A_,8+Y8&?K[PO_ ,$\_@CX)T0Z;I'PQ\):;8FUT^Q\FWLQ&OD6
M%\VH6<?'\,-V[3*/[YSS@4RW_P""=OP1M#K'E_#7PR@UY_,OU$!VW!_M%=3Z
M9PH^W*+C"X'F<XY- 'A_[6G_  5KA_9L_P""E'PR^"Z1>%)O#FN?8;?Q9=W=
M\8]4TZYU:>:UTI;:/<%9?/@S/N!*QSQ,,9YX7PS_ ,%X=.A_:M^-WA?6=%T>
M^\$_#T7+Z%-HEV)M:N(=*OK>PUVXNXG<((X'N&N(]F&:WM9VPQ&*^RO%O[(7
MPR\>0>-H]8\%:%J2_$B>UN?$QG@W-K$EJD:6SRMG.8EABV$$;2@(P>:HP_L-
M_"&#PAX;T!?A[X:_L?PC'J$6CVIMLI9)?PS0WJKDY(N([B99-Q._S"3D\T ?
M(>I?\%N=2\2_M7_#_1_"WAK1U^$OB:XMXKO7=3\TS26]QJ&J64%\)XF,%G#-
M_9AEM4G5GO5DPGEE>6?M=_\ !>#3?@YXU^U?#^ST#QS\.+GX?W&L6GB2(RO$
MWB*YEO8=%T]MK+^YN9=.NHR=N[<8\,,\_7=G^PA\'-/\6>!M=@^&_A2'5OAK
MI\&E>&+E;)0VCVL"LMO%'VVQ!W\O<"8R[E=I8DZOCO\ 9'^&?Q/O]?NO$/@K
M0=8N/%,FERZJ]U;^8;UM,E::P+9_YX2,S)C&"S>IH ^2/C'_ ,%7/B0/V>IO
M$GP_\!Z#_;6F^*9_!ELOB*20KX_UBU>:VFLM"M+61IW\R\A9!/<&..&)996#
MK$PKJ=#_ ."N<'QVU#X@>%?AKX5O(?%WA>VO?[*U'7(S/HNKW-A?+8ZA#"EJ
MS7,LT4OF^3;E(WNQ$?+*KEU]E\>_\$W?@;\4-#\*Z;KWPU\/ZC8^![R]U#08
M7611I=Q>3_:+J6/:P(>64EV)SDD^IJ;Q!_P3L^"'BJV\60ZA\-?#-Q#XXO8M
M2UI# 56[NHY3,DX ($4HE9I-\>UB[LQ)+$D L_L"?M#ZM^UG^QE\.?B5KNGZ
M;I>J>--&BU2:VT^4R6RA\E&3<2R;DVL8V+-&6*$L5)/K]9_A+PEI?@'PMIVA
MZ'IUEI&C:1;1V=C8V<*PV]I"BA4CC10 JJH   P *T* "BBB@ HHHH ****
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M$+W/VG16EN"C*7D2+* JSAMOXH?M)_ML>%]-\&WWAVUO]3B\4^-?$UO-]O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7R?^V7\ ]2B^(-OXBM?VI+[X.V_B2Y6"'2=>T_0M7TV6X6(9%@NI0F2&1DC
MWLD<C*2I;8.37UA7Y%_\%U[?Q1\9_P!JGPWX?LOAMXMM]6\&>'=5UG2]<MM4
M\,WEGK.BQ?89=1D6TU.16@ECE\B(,/F=3(I5XV. #]/OV?\ X6W7PB^'$&F7
M_C;Q1\0KZ:5[RXUS7IX9+F[>3!.U8(XX8XA_!'&BJH]223VU>8?L63:'_P ,
M9?">3PVM^GAO_A#-(;2UO;@75TMI]BA,0EE48DD$>W<RC#') P:\GNO^"Q'P
M;T74;.SUEO&GAV[FU>32;N'5/#=S;2:,JQVLBW=X"O\ H]JXOK,+))CYKF-2
M%.0 #ZGKX_\ ^"0K;K?]IKG/_%_O%>?;FUKK/AU_P5<^$OQ-\1>#=)L9/%5O
MJ/C2^DT^&"\T2:!M+D#1K#]LS_J%N&FA$).=_FITYQR/_!( 8C_:?_[. \5_
M^VE 'V%7QI^UA_P0D_9__;8^,]_X]^(WAR;7_$5\BQ&XDN)(_+B4DK& C*,
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M0GU">UUN:UM_"NL7EXMY>-:JJDR13P>9IR[<>7$5.-N:^ZO^"?OP6U[]G_\
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MA?\ R@H _16BBB@#\9O^#T;_ ),?\ _]C W_ *"E<)_P9+?\D;^+W_84@_\
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MXLU\7O\ L*0?^BUKN_\ @]&_Y,?\ _\ 8P-_Z"E<)_P9+?\ )&_B]_V%(/\
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M%2X\$ZAX\>W\56MU)9OIW]@ZDTOF)*(7(*VY5D61E4R*2@+#YN10!]%4444
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M (BTWP_:75A=SSSV<-SX@AENA>H;QX[=?,EBO5%R)AMDDDR96D#$5]-?LV_
M+3_V:?A+9^%;#4]5UQH[FZU"]U34VC:\U.\NKB2XN+B7RT2,,\LKG"(J@8
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M+/\ :)^+]]X-L_A'\;/#EYH]S]BU:^U[0+>UL=(G-JEVD<\BW+D,\,L17:K
M^:G(SQ]$U\^?LA?\G/\ [3W_ &/&G?\ J.:30!VG[:/Q"U3X3_LL>.?$VBW'
MV;5-!TJ:^MI,<;XQN /L<8/L:_F,US_@ZM_: \3?$'P[XJO]!\#W&O\ A.*[
M@TJ[\JY4VJ72QK.-HEVMN$2?>!QMXQ7]*_\ P4;_ .3%_BG_ -B[=_\ HLU_
M#=0!_8I_P;_?MW^./^"BW[$Y^)'CV2S&L7FI3VH@M%*V\*12R1C:&);D*"<D
M\U]T5^5W_!H-_P HH;/_ +#=]_Z4S5^J- !7YF_\%VO$_C/PG^T#\'+[P'J_
M@G0?%-EI6K7.EW%WH^A:AXAO)Q<6"FVT[^UV6-',;R2 0L'=H54D#;7Z95^<
M/_!PC^SQXH_:$\.?"O3=/OSI_ANZU^WTB]_MO6?+\(W=Y>W=M;V4&HZ?#"]W
M>,\KXC,,D2QY<NV", 'W=^SQ-XEN/@#X'D\9JR^,)- L&UP&6.4B^-O']HRT
M0$;?O=_* *>W&*ZJZU""Q:,330PF9Q'&'<+O8] ,]3["L'X-^#)OAQ\(?"OA
MVXAT>WGT'1[33I(M)@>"PC:&%(RMO&[,R0@KA%9F(7 ))&:^??\ @H?^R#XM
M_:6^)_P;UWPC#I2WW@'6VO1J&HWJ?9](#RVQEG-F]O*+IS!#-'&5D@>*21'5
M\;L 'U!'J5O-(J)<0LTA<*H<$L4.&Q_NG@^AKY'_ ."0_P#QZ_M,?]E]\6?^
MAVU?/?[&O_!(7XN? O\ :A\"^+]8_P"$/L]'T._@G=;+6)IYM&%M936UY) K
M0J)'UF:1+FX&5V-$-QD;!KZ$_P""0PQ:_M,>_P ??%G_ *%;4 2_#<?\;Q_B
MO_V1WPS_ .G;6*3_ (([?\DQ^-W_ &7'QK_Z='H^&X_XWD?%;_LCOAG_ -.V
ML4?\$=_^29?&[_LN/C;_ -.DE 'UU7S]_P %5N?^"=/Q?_[%V?\ FM?0-?/O
M_!589_X)T_%__L79_P":T ?S\?\ !F[_ ,I)];_[%V;^3U_437\NO_!F]_RD
MFUO_ +%Z;^3U_450!\)^._\ @L]>>&OC/XZ\"Z?\,8[SQ%H?B,>&?#6GWOB$
MZ=>>*)5:3S;L)+;;8[-5AFQ,CS9944A=X->=_P#!2']N?X=_'B[_ &&]+T_6
MHK/Q=\0/BAX+\>Z=X>N%;[8-+E\\&9B%V81W"'YLY' Q7TS\4O\ @D_\*OC'
MXOU_Q!KUQXZNM<UB;SK"^_X2>[\_PN6F\^5=,8L?LBRR9+JG!!V@!>*\J_X*
MH_#/0?A3X0_8[\/Z!IEKI^E^&_CGX-TC3HD3+6UK"MPD<08Y;:%4#KSC)H ^
M[***^1?^"E5_\:OAK>>%O$GP]^,D?@W1_$'B?0/"4FC2>#[+5%B:_P!0CM9;
ML32L'+!900GW<H/4T ?75?SU_P#![+_R-'PA^MW_ .@1U^]GP9\*>)?!'PYT
M_3/%WBP^./$%OO\ M6M'3(M-^V9=BO[B(E$VJ57CKMSU-?@G_P 'LH_XJCX0
M_6[_ /0(Z /PQ^''_)0]!_["-O\ ^C5K^Z[]G7_DAGA7_L'1?RK^%'X<_P#)
M0M!_["-O_P"C%K^Z[]G3_DA?A7_L'1_RH [2BBO!/VS_ /@IQ\#_ /@G]'#%
M\5/'FE^&=4OM.GU/3M+D#->:K'%D%8% PS%AM ) +$<@<T >]U1\2ZT/#GAV
M_P!0:)IEL;>2X,:G#/L4M@?7%?FQ\,/^#L[]DWXD>/--T.XO/'7A>&_E\J35
M-;TB.#3[+Y2VZ61)G(7C&0IY(K[E\#_M&>!_VJ_V9K_QQ\._$FG^+/">J6-[
M'::G8L6AG:+S(Y "P!^5U93QU!H _-_]N/\ X."OV;?BYX=TWPDOC6VT?6?"
M?CG1=7OX[N"Y94&F:G#<7$(*0D%R(65>Q)'.*^NOV%O^"S?P>_X*)_$J\\,_
M#'4I-:NM,@^T7L@1XUM4(;82'1<[MC#C.,5_'K^U1_R<]\1O^QHU/_TKEK];
M/^#*[_D[CXF_]@BT_P#;F@#^E2BBB@ HKYS_ ."B'[4'Q2_9%^&-]XX\&>!_
M!GB_PQH-E]IU?^U?$4^FWB2-,D:)"B6TJN"'R2SKC&,&O6/@/K/C[7? OG_$
MC0?#/AWQ']ID7[)H6JRZE:&$8V/YLD,+;C\V5V8&!R<T =)XKU__ (17POJ6
MJ?8=0U+^S;66Z^R6,/G75UL4MY<29&Z1L85<C)(&:^=/@?\ \%0-'^._QFF\
M#:?\(_CSH^K:?=PV>K7&K^$Q:V>AO- )XC=2><?+5HRK @'[R^M;_P"W-_P4
M<^'/_!//1=*U3XE7[:/I.L2>1!>-_J_-Y(C. 3DA6/3'!KX4^#'_  <$?LP_
M#;]HWXS^,KSXC:3-IWQ$U#2KO3XHC*9H4M=,AM9/,&S )>,D $Y!'3I0!^L]
M%<A\"/C-IG[07PJTCQAHJR+I6N0BXM&<@F2(_=?Z,,$>QKKZ .(^-?[2GP__
M &;]-M;OQ]XT\+^#H=0\P69UG5(+'[8T8!=8O-9=[ $<#^\/6OC/PE_P<O\
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MO$5-KO)=;>4@JI V<D9&?HWQ%_P<$?LCW_AZ^@B^*EPTLUM(B#_A$]:^8E2
M/^/2@"P_[3^I?MI_\$-;CXJ:QIECHVJ>./ <^IW-E9NSV]L[*X*H6^8CCO7\
M;%?TD?LQ?\%<_P!GWP'_ ,$,O#WP7U;QQ>6?Q.TOX?MIEUH7_".:H\\-RWF!
M8RRVY3D]PVWWK^=?_A4OBK_H6?$'_@NF_P#B: /ZB_\ @T%_Y10V?_8<OO\
MTIFK]4:_"W_@VY_X*C? _P#88_X)YVO@GXJ^+=0\(^*(]5N[AK&?PUJD["-Y
MI'5MT-LZ'*L#P>]?K%^R-_P4=^#?[=>J:Y9_"WQ;+XFN?#D44VHH^CWUA]G6
M4L$.;F&,-DHW"YQCG'% 'N%?CG_P4N_:+^-3_MI>.O#+>)?VCM#\&V&M"WT^
MS\$_#AM2L+>RM_#Z7MA?VU\+*8_:GUPB*7:QQ$NW" ;A^QE% ' _LJ>)O$GC
M7]E[X;ZSXRAFM_%VK>%M,O=<BEMOLTD=]):1/<*T6!Y9$I<%,#:>.U=]110
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M6E^"_@IIGBJ?Q)+?^!O)DBBO;"*..1/WVTHGDNSEF&U>>:^+?^"^/B_XE?\
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M]N_#SPYX!T'Q!IECH^CV^B:=J.IVH\3PWHA1)KRXA@MO-CGE,A>.1E^:0$L
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M=Z1XV^'NH>"H9&T5EN]2T5M%OM7U-+ 1ZEOM_M$R3K%,B!;\!&NR[NVXJ&H
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M$7_[;,'@W1?''B:3XH:KXFU:PLO#:7&FMX7BLH_!TMU8Q3VXS<0W*ZEAIC(
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M1-=26MN)M.U71XX;6UU3S[C[1)I]TDA$EJT?DA8T41J%0@[F<#[HHH ****
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MAAGM<B+8(C,J8XE</Q]NT4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?%GPQ\-ZI>%6O-2TNVNIRJ[5,DD2LV!V&2>* -ZBBB@ HHHH **** "BBB@
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ML3/<B)E5HQ(Q+[&4%=V" 1BNZH \D_;]_P"3$?C7_P!B%KO_ *;YZ[#X#_\
M)#O!G_8"L?\ TG2N/_;]_P"3$?C7_P!B%KO_ *;YZ[#X$?\ )#_!O_8"LO\
MTG2@#JZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBO'_P!J_P#9'F_:
MGCT-8?BM\8/AC_8AF)/@778]+.H^9LXN-\,N_9L^7&,;VZYX /8**_+?]DS]
MC;QE\<_VM/VE/ NL?M3?M51Z-\(?$FE:1H;VOC.".XEANM(M[V0SL;4AV$LS
M $!<* ,$Y)_23X/_  Z;X2?#'1/#4GB#Q)XJ;1;5;8ZOK]V+O4]0Q_RTN)55
M0\A[D*/I0!TE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5^*?[>EE\-9_\ @M\\VH0_$C5-2C\4>%UGNTL=(ATGP_J!ET7<
M8KJXN%NMS1?V8FZ.(M$MU=B/=YCE?VLK\M?VF=#^,?Q@_P""Q9L_"?@WPWXR
M\-^#=?\ #]T;O^R-"N]/\,;4LY9;C4IIO^)A%?\ V6341"8\[4>T,?+2$ 'K
M_P#P7ITQM$_9X\&^,+?7OC)8:EX?\56L%EI7@3Q1#H*ZS/,&V)=S312QJHV$
M(2A)DD5 &,@QU/\ P0V^)FD_%W]A2'7M)E\172WGB/5?M=SK?B]?%=W=W G^
M>0WT<44+J>-J0H$0 +]X-4W_  6W\9^+O"7[$ZP>"/%A\(Z]XA\2Z9HL,L6I
MKI-SJ)N)2B6D%^\<D=G*\OED32!5PC)OC+JPZ_\ X)6>$_'_ (*_8]TNQ^(U
MUI<FNG4[^>"SLM0MM1_LBTDN'>*TDN;9$AFE0,<LB_Q!26*EB ?1M5=:_P"0
M-=_]<7_]!-?)W[4W[4/Q]^'7C3XI6?@/X=W7B+2_#MGHLWAZZ/AVXG^UW,[S
M"ZM@%F7[2ORV_P"]BP(!+*9/]6 V[\+/C5\?_B'<_&JPU#P)X=T>;PSJ$-MX
M3?6H[K3K#48F><3 W"><UPJP);R":*-5+W#1D QD@ [+_@FV?^-?_P &?^Q.
MTS_TF2O;*\1_X)JEC_P3Y^"WF;1)_P (9I>\*<J&^S1YQ[9KVZ@ HHHH ***
M* "BBB@ HHHH ***\,_:E_X)[^!_VO?&.G:YXHUCXF:;>:79_88H_#?CC5=!
MMWCWL^7BM)XT=\L1O8%L8&< 4 >YT5^8O[ G_!+KP'\?/"7Q,N_$OC7X]7DW
MAKXG>)O#5@4^+'B"+RK&ROWAMXSMN@&*QJ 6.6/4DFOTTT^R33+""WC,C1V\
M:QJ7<NQ"C RQY)XZGDT 34444 %%%% !1110 4444 %%%% !1110!^3?_!+S
MP[\6=$_X*E:Y;^(KKP'?:?!#XBN_$5OX9M?"]O;:%>3W4(,!:S!U!YG:.WE=
M9<$I) TK"1=E=1_P7\UWQ5\.?B/\.]>\+>//"_@:ZNM&U*V2-?[%@U[7I8YK
M65K=)M1MI@+=+<32;@4C1T7>V73')?\ !'3]G31?"_[;E]KVJ^&_CUX5\0:5
M)KZ:5H6O>!?L>@:.LMSY;R_VV+:)[\S01Q,GG$,=Q+!W0/7>_P#!;#X=_P#"
MR?VFOAI&GA'XJ:_9:;X8U>ZU>_\ ACXETS3/$%C!'<V3K%/%?RK$]DQ)9I%
M>-T3#@,00#[X_9MGU:Z_9V\ R^(+VWU+7I/#FGOJ5Y;W:WD-U<FVC,LB3* L
MJL^XAU # @@ &NTKB?V:X=!M_P!G3P#'X6T]])\,Q^'-.72+%YTG:SLQ;1^1
M$9$=U<I'M7<KL#C(9@<GMJ /)/V_?^3$?C9_V(6N_P#IOGKL/@/_ ,D.\&_]
M@*Q_])TKC_V_>?V$?C7_ -B%KO\ Z;YZ[#X$?\D.\&_]@*Q_])TH ZNBBB@
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MK_E'_P#!G_L3M,_])DKVRO$_^";7_*/_ .#/_8G:9_Z3)7ME !1110 4444
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M ZE_PK[4_+=)KV>T$'E_VED$& MNW<[@,<9K[1_9RT7XC>'_ (7V]M\5-?\
M"GB7Q@L\K3WWAW2IM,L'B+?NU6&6:9PP7@DN03V%>+Z1_P IJ/$'_9$],_\
M3[J%?45 !1110 4444 %%%% !1110!\J_P#!)S_DG_QJ_P"RV>-/_3K)7U57
MRK_P2<_Y)_\ &K_LMGC3_P!.LE?55 !1110 45\Z_M'_ +5WQB^"GB3Q$V@_
ML\:AXV\(Z#:F\&O0^-=+L!=1K")92+>8^:I0[EP?O%<C@BN3_9(_X*#_ !8_
M:V\+?#_Q=I_[-NK:1\/?']O:ZC!K]QXWTN1K2PN%#K</;*?-)"$$Q@;NW6@#
MZVHHHH **** "BB@G H **;#+YT*OM9=PSAAAA]13J /PY_X)\_&K3?V6_\
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M9\0M<^%W_!/C1-:\.ZM?:+JUIX@3R;FTF,<BYC8'D=<@D<U_->?^"@?QK/\
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M\E!T'_L(V_\ Z,6@#^ZS]F;_ )-P^'__ &+>G?\ I+'7;UQ'[,W_ ";A\/\
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M_*(O4_\ L8]+_P#1U?RFU_5E_P '?'_*(O4O^QDTO_T=7\IM !7W)_P;<?\
M*:?X'_\ 7_>?^F^YKX;K[D_X-N/^4T_P/_["%[_Z;[F@#^QBOYJ_^#UG_D\_
MX8_]BLW_ *4/7]*E?S5_\'K/_)Y_PR_[%9O_ $H>@#\5Z*** /U1_P"#0W_E
M*?9_]@JZ_P#2:>OZJZ_E4_X-#O\ E*?9_P#8*NO_ $FGK^JN@ HHHH ****
M"N9^,GP=\,_M!_"W7?!/C+2;?7O"WB:T>QU/3YV98[N%OO(2I##/J"#7344
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M0P&V,>&P>#C.#P:_CO'[0'CP?\SMXN_\'%Q_\70?V@O'I&/^$W\7?^#BX_\
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MAO4])71Y;BS^'UZ+M81#Y6Y2VIE=V.<[<9[=J /XZ:*_?#_B!RU+_HXRQ_\
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M)KWC_6;G[%X)DO/#LKZ7XO,.L6VF7\U@YDB6Y2V:<LQ:2)& #!]F7'!^)/\
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M^"?A;]HGX;:AX/\ &FCP:_X9U9H6O+"=W6.X\F9)XPVP@D"2-&QG!Q@@@D$
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ocgn-20191231_g12.jpg
<TEXT>
begin 644 ocgn-20191231_g12.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0 Z17AI9@  34T *@    @  U$0  $
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MD>SM[>6%O*,K+$[.H9@@ PSD@$'9GZ*45\*?!W_@M+K'B7X@>,OA[XX_9O\
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M--^ /P5\7>.M:$C:3X-T:\UN\6,@.\-M"\SA=Q W%4(&3C)% '545^<_AO\
MX.,O"7B?X,>%O&<'P2^-"P_$:6UTWP+I[:?;_;?'&I2LPFMK"/S<O%;A09+E
MPL66 4MD9Y#]GG_@KU\9/VIOVU_CI-X#^&_C;6O"WPC\*:1I*_"[4;2RT?5O
M^$JO+SRYOM%[+E8XH$CG+,)&C,:!U5B0"#L?J/17Y0_LV_\ !;3XH:#_ ,$O
MOVD_VH?B]8>')O\ A$/%USX<\&^&-)P-/CD@\BUCC%R!YDZ27<Q+RL22L;E
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MP^JOM9>.QJ/;&G]BQVNS]/OV$?CI\$?@3^TYX]^/GQL_:G\"?$?XR>/-,M]
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M%9O_ !%G?L4_]#UXI_\ "3O_ /XW7\M7[5__ "=+\2O^QJU3_P!*Y:YSX?\
M@>Y\?>(H[&!7$?WYI%7/E)W/U["@+']97AW_ (.H/V._%<KK8^,/%LPC'SL/
M"5_M7ZGRZZ+_ (B3?V4Q&C?\)5XIQ(,C_BE[[_XW7\U7@/X>1Z'IUO8VL?DP
MH0 N/F<^K'N37JNC^"UL=5C75X)EB\O<%48+#M656JH'I87+G55V?OI\3/\
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M^Z?>O)/'?@C2GTY_,,\E\<AE9<"/GIFOJ?XQ?#76?@]\?+BQD:QM]4+K+O@
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MV7VB2.3=) \BM(J^3NE4;@3R=V/P&:\CLOBQ-;:HLT<JFX9Q*2HVK&P^Z%]
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MY>[&[OZMKNB2\UV.VG(T[343=SYMTWGO]<D #\JYOQ#JUY>S_O;F1O<':H_
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M1OV=OA_Y&F?VA*O[^\P5SU6/M^?7\J^@?#^DJMO]W[M<;\/M*%C:QQQH52,
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M'BK4Y51K)+G[)Y5E;NI.69G#<;2,2?6@"_XS_P""QVC)^TU\ ?#'AK3])O\
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MTUA_V#?"'_HRTK\'_P!F?PS_ &?\"=)FV[6OI)[ACCK^\*#]$%?O!_P<*?\
M*M-8?]@WPA_Z,M*_%?\ 9VTD7O[-7A"9/F#6TBDXZ$3R BO7PWQ'-@8\TWY(
MTO#6B27-RJB/=N/I7LG@SX9-/&K>0R\>E97PC\-?:;Z,>4&Y%?4_@7P.OV)=
MT0 QZ=:JK@_:/4_2<DK1IQ3O<\.N_ ,EI'\J\_2N>U*.2P=UVXKWKX@^'ETQ
MCM],_2O'_%0W32%EKY_$X5TY'WU.M"K2O'1G$ZKJN^#_ &JS+>^(?+8QFMQ]
M)6Y?I4%UX<S+%''PLC8)J)58*/*<-/#5YOVO8S9$^VH%CXV]ZJZW;QS((8\K
MM3+,?[W7 KWK7/V>[*S^'CW-K\LUO:B=I"W!.,U\^W=Q\J-)\J[LMSVKQ8UE
M5=X=#ZS&9;5P"C3Q*5YJ]UM;3[MSE]7B-FT6_<7VEFS]>*Y?Q)<+=1S$E=V>
MF>M=!XMUU;W4IF7A>@^E<;JNYD?/2O4P]-Z.6Y^?9MC(<TJ5+6/]*_ZGF_Q;
MMQJ'AG4U8;BL)8?5><_I7[B_\&1'_)J'QN_[&VS_ /2.OP_^(Y$7AS42#C_1
MY,G\#7[@?\&1'_)J'QN_[&VS_P#2.O>I_"?DF;W]M=[GY#?\%)+43?\ !8G]
MHYS_ ,L_'>LX_&\<4O@K3#)"K=>>!FI?^"C1S_P6&_:27NWCS6"/PO7J[X#M
M6*1_,"/4=JRK[$X ZW3=-DC@5NK+W]!72>&YI1>!>&C(Y)[U!I>GR&)AE?NY
M)K5TC1<@.K?=.&!ZUYU26FI]5@XWDD>J?#?3_#5OX7O-1U+RV\DE2'YP,= .
MN<UX3\6=>THZ@5TF1I+6X!?&TJ8V_N\UT5V9X+*>W60FWN,Y ;&TUQ8\")?W
M<C&3<J\C!Z>U;4:D(:FF*P]2:M%:W,G0SLF56;8I.>G6MB]S>2,VW<O1<=,=
MJLVNBO;1QJRK(B\$@?-[\5JK8PQ6OFA5\G<0J8(+8KSZU9.9W4</)4K=#G#8
M1V\+-(?O*?E'4<9KSKQ5;9D(V\-WKTO6!YT;%5'E@<MGG=7%^(K3RX=LB_-L
MR/7/:NC"_%YGGYA%<NFQY9XFL&67A?UKZP_X->+;['_P7B\"QXQ_H&N'\]+N
M#_6OF?7K0FXVE=V*^I/^#95?+_X+[^"E_NZ?K:_EI4XKW>6U-7/A\3;G=C^K
MZBBBH.<**** "BBB@#RO]KW]JN']D'X:6OB:X\ _$[XB)=:A'IXTWP+H!UK4
M8BZ._FO"'7$0V8+YX+*,<UX+^Q%_P7 ^'?[>OBVWL_"7PX^.6BZ!*;J.7Q9X
MA\*+8^'+.:W&9(9;T3NB2[OD"GG>0O!K[.K\$?A?IER?^#2G]HVW:UN/.?Q9
MK!6(Q-O.=<M""%QGWH&?NU+XWT6#3I[R35]+2TM9?(FG:Z01PR=-C-G ;D<'
MGFK&K^(]/\/Z;]LO[ZSL;/C]_<3+''ST^9B!S7\^O[?W[#/@_P#8=?\ 9<LU
MT'0M+_9XUKP[=:[XINO&%GKNN>'KWQ;<6<*F[U2.PE%QYTD0C$/(1&#X4#?5
M'X@-X9^&O['7[*?@/XE1Z?\ %+P%J>H>(]0\+^.O%_A[Q:?#V@VS%4@TPZ+$
MR7=]<;MRVQN&"JACV,REB =C]S/VC_VVOAQ^RI=> ;?QEK\5G=?$S7[7PWX=
MAB7S6OKF<_*V1\J0JOS-*Q"J,<DD ^F'Q'IZZM#IYOK,7UQ'YT5MYR^=+'_?
M5<Y*\=0,5_-#X4^'/@V^_P""6W['_B7XQ>'+S5/"?PU^/.I>&?%DVI:7>2RZ
M#H+SR2RV,\"[YHH250^6<LIPH.3@N\7?#G5/&'[;?Q&TOQCXRT?X:?'R^^*T
M>H^ ?$%YX.\4:KXGCTD.C:5_9DED3:#33;X0QO'N52=W\.T"Q_15^TI^TGX8
M_95^#'BSQQXHGF;3?!^B7>OWEG9[)+Z>UMHS)*88F9=Y"J>X&>I%7/V=OCGH
MO[3GP&\'?$7PY'?Q:!XXT>UUS3DO8A%<K!<1++&)$#,%?:PR QP>YK\$?^"F
M_AWX;V/[1_[=4'[1'ASQKJWQKUS3X9O@E=066I7"-IRV+!/L#P PQQ(^#<!\
M+L64')\P']E/^"0L;1?\$L/V=UD5D=?AYH@964J0?L478\B@1]&5_*3_ ,')
MVI_V9_P7[\=%N%FTW1X3_P "TN#'ZXK^K:OY(_\ @ZHO9--_X+A_$2XCXD@L
M-#D4^XTVW(IK<<=SS_PDWFQ1_G7H&B%F*[1QWKRCX8>)(=8T:TO(W7R[B-9!
MD^O;^E>H>'[EKP_*NT?WS6M2B>UA:VFYU-B!%]_:#[U<:[D-OY<6YMW_ 'S5
M32O*A 9E\YN^>E;3;6@W,RKNZ*M<LJ.NQ[='%6CH<]=Z9MC;=Y?F'CY1TKIO
M!B32IMV^8%.U0>#FJ<6F+-(&:3"KRWRUMZ9:+8VBR+MV2').>M3+FBCT\+/F
MES'3PZVFG_*R1QRX +^_K^/Y53N]<^WRGS-K*!U'4>M8^JWJQ<K(S+(,MQV]
M*S]5UE0VZW.U-O"]/\FN6N[K0^AC6M\3T)O$MW']F,>[=MYSZ"O$_B0XA:1=
MS,&R>179:[XIS$V&;_:SW%>7^-_$"3!V60L,]_2L\-3DI'D9MB8.!X-^T-?K
M!H#1_P 5Q,JC\,D_RK^F7_@I)_RJR:E_V23PY_Z!I]?RX_M >(!J/B:*S0Y6
MS3<^/[[<_H,?G7]1W_!23_E5DU+_ +))X<_] T^O6GO8_,J\N:HV?SF_L>W@
MU7P!]G'+6=V\9'H&PP_F:^G/!]E]F>.OD?\ X)Z:Y#+\8)/#MU)M77(";?)Z
MS1@L!^*[_P A7W$OAF33+CR]OW17UF6X95\*IKIH_E_P#SIUO9U.5G;^"]66
M*W1&VA1Z]Z]+T:..\M .NX9W5Y+X=L655DKOO"&J2PPJO]WTZU-2DX.S1Z^%
MJ<RT9M2Z 3F18P%P>0,@FH]%TRXDNA&B^8J\,Q3.!6UI,UQ<2*N[:N<8'?\
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ML#_@5>A%\L'-]#Y+'-;(_2;_ (,BY6F_:J^.;M]YO"UDQ^IO#7C7_!W3J?\
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MXM5+B0KI>H$1W )XC/\ #)CV[^Q-?6N@WJR[6WKM8 C!R#W'YU\(U[%^S_\
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MCN1L#'=TSQD5T8?#SK2Y8(]#+\!+%3<(M*ROJ?8?_#,OPE_Z)[\.?_!%9_\
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M0<="<#''2N/\/_LV^&?#.L8TG0='ATR9&@O; QB:UE4Y(5(VX7YCN).3P!D
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M$B,Q(;&TK@\D8KC_  C^Q7\5-(\.:-?Z7K&EV.K+!"9+&>&&&XF4L?.0N#)
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M_@_X5']G3XC7OQ AL[KQ'<AX(8[P&0HC1G;,J8Q&2S$;L]NU?)OA3_@J=/\
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MSP"N.E[_ (1Z^\9> M!N] LYDTG39XM)DDD@@LE^UN"8723"N5DCC>5R-VS
M/&:(THPLHS26VVJOJD[N2\MEKK%J^I]8E->\F_R=M--$]M_+<^GOV1OCOK7P
M.\?3176AZIIMQXBO&O9(+%X8[.VM?.*^4D(YC"CS0S/M.Z/&T$5]N?''PWX=
M_:0\ 7$=Q;W$>BZE;M#*8TQY3L 4F4GG]YM,<@QP&S[U^3?PRM-/LM8CM-7L
M4LX;J&**:=;B6W^UG+O%(X8%[N.64JJJN(W52Q(QFOT>_8,^)NJ>+O X\/\
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M^":_POD\-0Z3<:#HMUI\#.RP-I-ML&[C@;..,#(ZU4L50A%.G>[ZV2:_"WZ
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MEM)(^^.W(F-NGIA-WYUQ3=*<>3EE&SNK6_S2^6W<[H9U1A4]K+%*3>C3Y_\
M(_+7XB^*?!MKH=Y/X>O/">H730^7F,3QKYPY,@5R.IZ8R/I7SGXD^(_B2XDN
M-0DU29=LNT8GS(K#G /WL>_3BOWDO/\ @CEX!UK5)&\1:'\/8[7;B-;*WN(I
M3@8&X,V" /0<<5XO\8_^"(7P+M]%UJZ@\2+IITN![Z^GMT>XCT^% 68OS\L>
M >3P ,YXKHHU)\SBW)[;V?RT?Z%8K,,-C9*>&FHOJHQFOT[]V?CU>?M(^-+#
M3VAA\3:JT"Q_=$S +WZ9Z]:^]?\ @H?XZU;0O$O[.'B9;BW7[/\ !CP]?3NP
M"M=S!972,LRLK9< A6& >:B'_!&CX7?%'1-<NO!/Q<M=<N-/FCLDM["&.<)<
MRPK+%!(2^X,RL6R 5PC9*FON7XA_L'7GQ?\ A3\)M/TO4O"&K+X9\":7HXNK
MRY:R^W?9PZK,L+H7V@CC=SECTQ7IT<1'"5>>OMJG=6W76Z[;&%/"576@\54Y
M8ZV;N]?S70_)?P8EQ=Z5?:<XN+J2003V\NF@RR27<;*6,<I53'&L<DCKL'+-
MP2*Z,>#?'M[8);VGAV.STV.ZDB@MY=.22'34G:-G,9(WM*"F3-(Q;"_*!FOT
MUTO_ ()>>*H[UE63P4>-T3C4#NV[0O0)V(XQQ]*Z2S_X)P>*YXHWDU+PW&P"
M-<1+>&1'"\'G:.HR-U=-3BK#7NK?-W[+\OU6S/8IX;*XK]YB/NT_S/RO@_9T
M^(/AO6-(U+1]+DU"2&\2:".ZF^T(TL9&V:3.W*+A&P0<D 8(%;FD?LB>.-;\
M/7=I?2K;V<-\]TCS.S27$LOEPL[1J0@7RT*I@9&[!ZU^JEC_ ,$Z/$$&CVN_
M5=+S#&T2H+GY(U/0JVWYN@X([<8S6Y;?\$^]2TU-D<UG>!T,?SW6Q$!P3A0G
MJ,YSQ7/+BR^JM?TU_'^OP-4LCC_R]O\ /3]#\Z?@]^QQ>V_BJQGO]3NM3U2S
M4Q0&4^:F^/ B5"VXQLBX1<-A<G ZU]L_#_X%CX4>'KZ:.6W^W?9TW1R+NWRK
MAE"D=) W QD'US7OOPN_9'CT'3V77'L[7!PMMI[@0LN<@N2N2V<X(YYZUZ%I
M?[/WA72WMV&E1RO:MYD3S2O(5/KR?R]*^=S#.*N*E9WM\O\ @?UL1B.)L!AU
M['#K3R5T_FW_ )GQ!\8O =YK>AZE:ZQ#/:WES;.]PMPI!MXV4L< ?-M;('/3
M/UK\[/CI^S?XP\ W\C:+=M=Z?J$7F2W-E*/.EA4*47SB-^U-O"J54#:.>:_H
M ^(WPDT?XI:0]OJ4;+(RE5N8L+-'GT;!X/H>*^8/%O\ P3<U:_U'4(;.31VL
MOLGV2RN&N&23;EL2/&5*^8%.,\CC(&:[\GSB6'TFM.W3_@6(I9YEV84%3Q;]
MG*/G^3Z^C/Q\\&_"+QB?"W]FV&G:A$U[$Z2"ZVE;!<LQ:(9&V9V*KO7G:SC.
M":T]._9>\?>#/%MCK.CZ-IUO<Z>K2*3&9!=S*=RN(RV$ )"I@C&W/U_6&+_@
MF;K2V(17TF&<1-EFNC(DC94J"-N0,@G(_O&I)/\ @G'XJEO)&&I:';PE6 6-
MV+MN^8J<@@ -TP.@%>U/BA7U2ZWT9O".1\MOK'X_\ _)?0OV=/'_ ((TW4I(
M-(TO[5H=@;BUFN[.)YXKB9P&D3 _>SA=J[Y"0GS%?6N&U'X4ZQKB0WEGH=UM
MO/.6X,=J\2S>1M9I660D+N<D?(5R1D>W[/7?_!.GQE)8QB+6-"^U)&(W\W+1
MS*&)4$8R, X/4' Z&O/_ (K?LFW'PO\ $-K)KWBOX=Z-:S,(;&"[U!HYII6*
MY3;M);."0%&<GWK7#\40<M+.3[7_ "ZZZ^6O4)8;**MH4J_ZO^NGW=CZG_X)
M;V\=S_P3J^%-O);QK"= 2%XFAVJP#.IRK$]>IR3G)]:](\*?LP?#3P'X7US0
M]#^'?@71=%\3!EUC3['0;6WM=6# JPN(TC"S9#$'>#D$^M5?V3/#8\'_ +./
MA'2Q/:W/V&R$1DMB?)9@S9VY .,YZ@5Z)7S%>HIU)375M_>?FF-BHXBI&+T4
MG^9R.M_ 'P'XEF:34O!/A'4)&T@^'RUSH]O*QTTD,;'+(?\ 1B0#Y/W,@<5!
M\)/V;/AU\ 9KZ3P'X!\%>"9-4""];0=#MM-:[";M@D,*+OV[FQNSC<<=37:T
M5D<H4444 %<C\:?C[X'_ &;_  </$7Q \7>&_!.@M<):#4-;U&*QMC,X)6,2
M2,J[B%8@9R0I]*ZZOQK_ ."]?QF\(_M(_P#!1CX:_ ?Q=X6^(GCCX=?#KPUJ
M7BOQ;I_@SPS<:_=+J=_:S6>E^;%#RGD!FG#' /F*.] '[$Z=KUCJ^A6^J6MY
M:W.FW4"W4-U%*K0RPLNY9%<'!4J00P."#FO-M _;G^"_BKX3:WX\TOXK?#[4
M?!/AJX%KJVO6VO6TNG:9*2@"33JY2-B9$P&(^^OK7Y!_"K_@JOKO@O\ X-A]
M>T&5=:C^,_A6]?X$VFFO:RQZM]NF/DVP%NP\T3)I[-A<%O,MF&,BN'_X)K>$
M?A[HW[7GQ*_9/L_"GQ(\%_"?]I[X36^FV4/C?PQ<:#/+XCTRP\BZN;>*?[YD
M7S+DNI_UFT8X% S]V/B%^T'X%^$OPYM?&'BCQCX9\/\ A2^, MM8U#4HK>QN
M#/CR0DK,$;S,C;@G=GC-9MO^UM\++OXV-\-8_B1X&D^(<:;V\,KKEL=648SS
M;;_,SCG&W..>E?B%^PC\2/$7_!2/QW^R+^R/XLM[J2Y_93UK5=<^*4$R.T+_
M -@W'V/1X6)&'5BZ1L">02>U>4:,=,B^+NE?% :+X5_X4I'^UR]U'XFC\I/B
MS-?M*2+:0_=.G&<[C&&\XQ\[0>: L?TK45X-\*OVVM5^)O[5GB+X8W'P1^-'
MABQT!KM8_&FL:-##X:U7R'5 ;>X69G<2[MR9C&54YQ7O- @KX=_;X^->K>&?
MVJ+/PKI]OX@M([[1(+F'48)3#8"Y:68+'(P(^8A??!V=B<?<5?#/_!2>UCU/
MXX6MO,MG'&^AHBW4I?-JYDE.?E/ .,9 SG'/IMA[<^I]%PO34\:HOL_,\9\2
M_MBZQ\/]?U2Q\527&DZ]:0KJ%KH&EZE<7]Y<6K@L'(5@I[%074LH8\!23'>_
MMG:Y_P *YOM5M8_&UU?65L99;25;JSEW2H"F_=N*B-OO(!P&!#$'-3Z?XQDN
M]5TBXEG6&;1[<6]EFU20A ,JC,P)9-QY#9X/?MVH_:&\::D;5IO$5T))EWSQ
MVD,4328&,*0,'(P2#W'M79[O8^YE@YQ?P1?WKTZ/IY[F'X+_ &GO$7C'PYI,
M4NI7F@ZSK3N##>:PZPP[7; C+'(5TPWS\KGDUD>-/VRKKPE::=/)X[U&S_MB
MXNHHXUDFFB"V[()'#X&5!?.X9XSZ9K5UCQ3#K5FLVJ1Z7K&HM<B827^GQW !
M&<D/P1NVC*]#GGIQBV6HZ=%8WEK;^'_#;:3(V_\ L_\ L])(("1C?&KDLIXY
M*L,"E[I<<''[--?/7\TOEZ>98\0_M=>)O#.FW]PVH:XUC82.MUJ<EY+]F6'R
MPXFC )=B-IZ#D!^!D5YAHO[>GC#3]'U#Q9KWB/4+SPKK&ZT\,"!;FV-]("Q$
M[.6R(U "D8W,V0" =P]GT#XJZYX0A6'3SH;V\FR(V::;&;?R@@18R"O*;3@#
MV.>I)FT/XLWED9K>33_"EX;QDN(XKS3 ZQRKE$" $*BA3C;P *I./8F>%>\:
M<;?C^2T/(_#O[8>K:3X<N/\ A+?'VGZSJ\-J-;FLM-BNK6Z2S;#&-(C+))(X
MR2I'\&TXP":[;Q%\4+KQ-H7A&X\.ZE-J4GBF20)*]U=20W%OP-X'_+,IAE?>
M,;@0,]1L:+XC;PUXKDURSTOPK9^((8S')J-MI%O#=QHBA!$CX/&WC:N,@#TJ
M&7XC76IZC->3ZY=0WUQ \/FMMC)&W[HQP!DGMD<XY.:/=OL:4Z-12NHQLNU_
MQT_KL>?_ /"U/&NN:WXPTNS^&=S>:KH3.L,+:U'<->0C@NBP9( !5AQD!QDY
M!4;GB/QQJ&E^&M#AU'PQKRZUK%E)NBM]*$DUI$<1I<OG"M(F,E3@,H!)%;FB
M^.4\,7\EUHK:?H=U+;IYUY9:;!!<2NH'!95&23G<3DMSSS6-XA^+D/Q,U&Y6
M?6+C59+,^7.[3AI89 ,;6QP!WP0#3TZ(UIT*[=I6MWUO_7SZ'+?$S5M0\*>!
M_"<%QXD\9^,/^)F56XT'2!YE^JDNL-X,#:HP/E4[I-K* <<?HA^P1:7$'PGN
MYKS3H]-O)K@>:BC#950!O[[\#D'D9%?%.D?%'4=&E$EIK6K1W"IM5UF_>>G'
M;&">HS[U];_\$V];DUOP%XJ,E[+>+_:BOB1BQC+0J2">Y)&3[UC7^$\/B7#U
M(X*3=K)KUW^2.6N_^"G7P[U'P]#)HOCZ36M9\\VSV.E:#)?R&4$@@HBY4=@>
MA->H:5^T?!XGTFSO-%O+K6+&>\-A<W<%CAM/G7&^*2,X;<I.#C@8(JC\+_V:
M/#WP1L-6C\*Z/INCC4F,DCP6_ENY//#?>QGGKZUL>&?#%OX1NX6A6"&-AEXX
ME&-_5GQZD\DGDUQ8BMA7=8=2M?3F:UOZ15K=-7YGQ]*BGK*S]$?,?CS_ (*I
M>/-$^(OB3PKX<^&6M>(-2T&8Q"21/)C= <><6QM5>F >N1S6Q\/?^"HT.N_#
M*\\0^+M$^('A*2WNFLDMH],%Q*TRKN;]V(P?+'&')P<U]%:EHZ3:NVH1*\EJ
MP87#/&-[D?-]X=5Z]<T:IHUCXTT-SJCV\RWP6"2W<*P52,8!/()!_6NF6.P4
MHJ/U>VUVIN_2^Z:U]-/GI'U5K6Z^X\E\ ?M@^)/BWHC::V@^(/#^N_:(U^TW
M"B"SGMW/$L$A7]X^""4P.^":ZCQK\6/B#\*]0TG0[;PZWCJ/4W;S+]KU[-[)
M=X ,KXV]#T'/%=(_@TZ?I%O9V=\L36I_<0R,2J[> !QP0*U$92D4=W"JM"JE
MFA'+OWX_+-<U3%4?:<T*:Y==+OY.^CMY)G1#"I0LW?Y69\R?&O4?CC!K/CJ\
M\)^"?#FI:;8;1IJZS=R3W6I$G;YENRR#8%SG#=<<\UB>&?B)^T!\(?$GP[F\
M?>%-$C\(QP-_PD&IVZ-//'*"2H;8Q6/.0 <;<#DBOK9-+_M_298YY)+5GW.&
M0 >8!ZXSQ[>M&OW""UCCC6:0QH@(5B=ZGC.WITKICFJ452E2@ULWK?X>7>^^
M[O9Z]-$3[!\UN9[_ "_KH?/_ (K_ &[=%^(OC30=-TGX7ZSXT\-W%PQDU?2=
M2A L@IQ*[0<2'9@$@\'L37;?'7X_:A/\$-8U?X.Z#'KVM:3>KI\^G3V4L#1$
M@DR+&I5B5ZX'7\*ZX?"^PTO7EU+0[&QLKKR9"TEQ:JRYD[L$ +8(4G!&>F16
MEH^FMYL?VR?3VNH55F\FW,,=Q,<\@9)Z>I./?%9SQ&&7(Z=/2-M')N^NMUYK
M^7E[V(^KMJW,[?D?$'PH_;K^/MS/I^GZMIUOINK+J2126EY(8[K5HBP\Q+:*
M8_-(@Z #'/)K[9\4_M,6_A+Q%INGM8^+KI]0C#/+!H1FBL/7SW5@$/KC(K)\
M2_!7P;XM\9PZ_JWA^RO?$&G*RVLQBW2VGS LR2$\-D#YAT!XZU'I7PU3X=_"
M2;0-!L]1FM[UY9+O[3>R-)-YK?-EMV<8.,KT ]:WQN.PV(<94Z?(^J6BUZW;
M>BMIIJW;1&4<&UI)WUZEK]FO]K.Q^.'Q.USP]'XA\.W>I:&I-SIMI%(+BW!/
MREV)*DXZA2<&O._V@_V\=)^&WQ&U+1;?0=2U+6M,U0V-U"1MA*E0R2!@"6^4
M@_*/E'4CI79_LN?LJ>$O@QXWAF\-:3_85OIL$VRVBF9EE:<C>SL23(?ER"Q)
M7/'7%:'QD_88\$?%_P"(7]MZA)?6<US*9M0CM91&VI<* KO]Y4 4<+C-;T)X
M#V[<E)PMY7O\NC]='U=KE4)0I5G[;33H8'@+]H6_\6>*=6L+CP[=Z'H=G8QM
M!J=U*$6\F90S>6,X*KG&1SD5Q_QR_P""@G@[]GR\T_2[JZOKK59&Q)#9[F<-
MGDR,3QQVYZ5Z-'^PS\,1X>70;C^T;K3UOQ?V]K+JDNVW8+@(F",+@=/49KC_
M !-_P3?^&,5MK3V]QJ%KJU]$(1<O<;VACP1L&02 V268<U=*6 ]IS55+E[)6
MOMJW=OS>GH>A#$X23LD]?)V]>[._\$?M&Q?$?P7;ZAX<NX]22Z7B28 /;G )
M#(/F) (/''O3-)O?B):?$!+R\\8Z%=>%[FV++9)I6VYAD[?/GE<C.<Y([#K7
M@=K_ ,$\+JP\$-:Z;\1M6M=4AN1<0OIRM:V[QKPEL&R"H!Y+-RWI6YX^^)GQ
M.\4?$V*U\/Z=#"GA6Q>":=SY4.HW!4!F&[Y<'H <GH1CK2EA:3DXX:::UOS*
MUETU:Z[75C:.#I3TIQ7G=?=O^GXGT9HWC#6=:UK[.DMN%V%N(-K+U[$GGBJN
MA?$+6[JPN'U*$Z/<1W!ABBF*%I0&/S#'!!4;NV.G6OENX^ /QD^,D=OXFUCQ
MQ;^'/$6BSK/I=MH<A2.ZA )\N0<?.&VC)Y(8Y&!7?6&F_'3QK\);J.WU+P6O
MBR:X9+6XO47SX86PLH=5S'O3E@1U!'':HG@8)*U6-[I/?3YVU7=]#&IA:<7M
M&W7:Z?\ P3U2U^/VGZCKEYI-OX@TN77;1!))I[742S(..HZ@X(//Y8K)\-?M
M"_\ "5VFH-8ZA!>W^EOY-W8VERMP]K)U )4<DC/3C-?,GQ _X)U>(/BK=ZGK
M%Q!H/@W5+6[5Y+V+4GN+K6VVJK2.%RL89MS  <;L5%JG[!7B+X;?!6Z70M2U
M"U\07NMK<3/;NR27:@XC;* _*&._!QD Y(S7;]1P7*DJOO.RVT3ZZIVM^/?J
M;4\/AKZ)-7^?H>T:G^W'X=UCPA?W"Z]<V=[#>1Z9!8")FNKNY<':%7!*K\I)
M;MC)QTKC_A!^UK:^,M<U+3?&4DWA?5])G:"(WTVW[:B?>F&[!P, =\CFM7XK
M_#3QUKWCGPO#X>E\,V6AW6F&RUR]>T7[3'<E=LDK+MW,'&=K(0034\?_  3Y
M\*ZCKWAS4-<NM0UI=!L9+7;GRX[QI PWN3\Q50V #SP.>QFG'!PIWJ7][56=
MVK=-DM;=;Z.^EC?FHTHODT^7X7_K7R/1M<_:+^'^A^&K#6F\9:(EFT*7+W4=
MV-OW_*W$8)^^"N,9!/(P*;+^T;?'X_KX<N-#FL?"/]F)J4OBB[<0Z?<(VW;L
M=AM(+,%R2,YX%>:>"/\ @FYX#\+Z/'ILVGO>:?;S"827DP>24C&%.!M$8QTQ
MR0#7MT/@FT\4> KKPKKFFPZIH=Q*O^C3R%E1 P9$7;R I4$'MC%<M982#M3O
M):J[TLM+-:ZM:Z/0\VI3IJ-[J7Z7_P CX>_X*M?"_P 3?$_]LZSOM:T_PDOA
M#08M'T_PWJKZ)#J&N6%]<WL+7/D2,I>)9((YD.2$^4G@G-<C^U+\:_C@GA'X
M8ZMX3\&Z=X?USQOK5S:#P%>::+S4-)M;=O*9;257V&9XCM:4!64H3&?O$_:G
M[5-G9W'Q;:3S(X;B.V@R\F0KMSMC;_9.<DX&,=:^>/&7P>\._ K1;J_T/P[-
M>WNJ:O+J#"2^,DWVFYD E6%Y&Q$NURZ+%@9W,2"2:]#"8J#5-2@O=Z624KJU
MV[KLFWU\M;_4Y31A]6IPBW>2Z]-.G;6VJUMIU,OQ9X*^-'PO^.OAFUT?Q%XN
M\5?"W2/#4EMXENM*U.WBN&U-(91YJRF1V%R)A!'Y97G=]TGFNA\<?MWV/[&7
MCCPIX?FF\0:CI'C2^U#5-2U[5[Q[J'1K&"#<\MP).5D5E?\ =0E5*JK8+, >
MD\+?"_3? GA"31]+M6TV'3Y)K@BVD>.'=)R9!][=PNW<,G.3U%8/QI^ =C\<
MM"UK1?$UU>>)O"][<6EUIFD02QV[0R6\2HT+L%_>Q3[G\T!LR$+@KL7)]9HU
M*D56C>%FG96;WM)I.UU>_1.UF%; PJQ<*C4GYVL[6UUOOONN]KV.I_:>_P""
MBC?"/]F/1OB)X=\3?#N[L?$H2'1+W5)I;?3M3N'7S8TWCYXVDA$K[6  :W<;
M@#ST[?MT70^%=CXPT2+PS\1-!O=!;6$OO#LTZV\DH:%1;+E7?S7\[Y%95)P,
MA<G'Q3\3/^"27@&?1_$$GA_2&\/ZWJ%S;WT>GSW_ )FCV8BVQ[8XG!?*0@J-
M[.P#, 2236CX/_X)P>'?@AXZ\&ZEIB^(8=.LO$LOB77K?2[Z2&RU2ZFCBMA'
M;Q9$BP"&,J"2QPQ!)  K5X7+_9KEJ:WEO'I:Z3L_E==6^AP4>'XOE4Z<6NMG
M9O=WOI>RM;:_WGVE!^WAI^J:)_:L)T6UT.2]6PAU<W#WVGO+E5>,S6X=0RN6
M7.,#:<X8%1YA>_\ !7G0M0^">N^/H[>T\(^&?#WQ'@^'KZQXC@G\G6':4Q23
M64<2^8ZCY7&X#**Y.,<>"VG[&FI?!J+Q%8_!'5)/A[X;U!9((-+U)%U2UDD:
M[6YO))C/O"K(S%%54SA2-PXKW1?%?A*#P?+J'CWP7=6.A^!TTS5+B.^@MKC0
MYKU4W&2W$F0K6I=2KHN\X"#G@\WU7#PM*#Y[M:;-;:-;-O;1M)WT+Q60X6%-
M2I4+2[7YETTW3ONM;IWO[MF7/B=^WS\1[KQ?\3/#W@'X=>(_&%YX,_LW^S;[
M2;56L]7:><V]TBS2[40P,#(02P(X+#!KGOCG^USXH\!^(?B18_$'5O&_P=\#
M^ [>&RM/B%JNGQW&E^++RY4*B6UM!&2X1V&3&['$<Q;R\@"M:?L^0>'/B#KV
MH>#[S6/#]GXKNXKK58X[T^5J!2-85;:1B.,(&;RQDB21LDX%;'C3X5Z#\6KN
M&R\3:)I/B;2W4SPZ;=0SS+%-&7VN8Y&VB54W!F&T.K(!D9JH_58N-HZ65VOB
MO97W?+NG;IKZ)=7]BPIZT5&.[5XQ;7:[[VUMWZ]3P3X"_M=_$#PG>Q+\4-%\
M-_%3P7I=W;>$-/\ $NF:NZ2?$36+BZ5Y+F"%RL8M[.T/S@QY4J#O);Y4_:=T
M3XJ_M6Z]XH^&\/B+PSX$T&Y\1V.D>%&\/6+&#5[:VTR=[VVU&XBPWD-(R[?,
M4Q[U=<$#=7TSK.D-KMWH\-Q9V[?88H&@6QCA*VQ*A'92458VPO+#!.=N6W5-
M8Z&VH:?JD=\MK=:>OFB.%XOW91XT!<DX9C\I^ZS E1@8)!VCCJ<*BJTX)26M
M[[.ZLTMOPMJTK65NB.7PY+U9MOU;LNBZ7_"]EKH?-'PT_P""?VE:#\"/%WA;
M4(;FRM?B=>:@OB<_VU;6$7AF-C8OYNGO;AB]LMO8R;5<;\W"Y&=X/TU\2/V<
MM,OOA3\*X]/\2:QINN>&?!^G6&B:SIR^8;.-.'E^;F595"!A(2,*" "346H:
M!I][J<WVF!;JZN(X4!G@+L5500B+PIX & HQM7)'4>R^.KV&/2?!Z*L%JUQH
M<(6''R)& 25Q_",$ $<UX^:8RLHNI%N[=^_KO?2VC6S6C,<50@I4H='?NNC>
MFOGY;7W/(;GX,^*+GX<W7AC0_C#XHLM6^TFX_M*^@MVO$@*AFME9$&R$G<R@
M=.AXK-U6Q^-HT;4M)L_B1IZ6^FI:_P!E7$6GI;2O&4.^.61$)4C:AR <L<$8
M.*]8T'6+*UO9S,C75Y=!I(59C'((P,##'ZXY_I6U?WL/BNRM;6U6\EMY&4Q(
MORJ7&-PW@9S\O4]3CFOFXYA4@[2A%J][N$=]+O;RMTZG+6PT.:SB[=V_7_/?
M3U/+?"'P[^(&BQ>&[OQ'XBEOM0M]MMKPT7;+;ZK:R/DF6!D!62-?XXQD[CQC
M%=!X[^(6E_LU>'=4CL;?Q]XFTFU6*;3Y[.VEU&6&?>Q\J5\JS0;BBG.2!QSB
MNECEM;];V5K=;6\BN!'(^_:L:]2 ,9Y SNSG)K7%Q:ZUK<,<TSM:QR<-+<@C
M)((R5YZ8P?QZ5,L9S23JQ5MVE:/6_GWT\M-B*E)VNV]O\M>MWI^9Y_IW[7'C
M#7_B3IG@MO!5GHUUXFTA[N"]>Z^TC1+C#8EN59=ICW;0$R')X[\+\;=6^*MG
MX%\/W'P\OM-C\16K+)JZW;O'!K#A,3",,62*,,-P Y&0!TP>YCTF&XUF:98;
M>\A5"BL2RO)&&.<,H!;DGJ,Y%26PL;:6Q@3>K0LTRL_*," @8@]^3QC'!YS0
ML73C.,Z5):;IW:;UWN[VM96^>YBL+2BWRI_TNO\ P49?P@^(?Q0\0>*;"V\8
M>&])T'18[/S'O;/7&N)[V?@!3$4^5&R2,'.5YQD"N@\6^*_%7@O0KC6--35O
M$K6#RM/H:/!]INXQG'D2LH =< [6/S#C(-)'<6CZA(3>;I)91''')(&9B,G@
MX 4 Y(&3C S5[4-.A6]F5KK;#(@4PB7+!\AL=,<\YQ^E<TL0O:<W(DNVMOQ;
M?7H_2QS2P\+V:W\OZ[_AN>>:7^V7K&I?"&P^(E]X8\6:'X:CG:+4=..E-)JD
M2[BH;8>JKPQ=!@C(XX);\%?VCO%GQU^*&HV<GA7X@^'?"5K*4M]1OH+>U-V_
M7;C D10I4C&2WKP:]"U_2+BUC2W6:Z"R("B$*^\;A\I!.3P"/\*HWFD:A)-]
MMCNU9D)2-3Y@50N<IM&2".06YXKI>)HN$E&&KO;5NRZ>KW5V]NET53HT7&Z4
M=K7M^/K_ )?(X3XE_'CXAZ/\3- TG1_A[XTU+2;J>>&^N6GMS#M1]J/]Y7(
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M/U"9_M2JX>:,11V;M#B2-VR?NHK#.%RPZYH]C%HZ?[6KQ:4Z:U>BZ^MKZGV
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M-+WG;S/7]0AN7O)H[>>:=8T$;H&VB'=TW'H1UYH%[<6\L:1W&?LZL&0$<G.
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MJQJ\D;*ADM;V>,1F25FV.D"YP5^7^(@JV0#SW!I]U-%:32?+(TC!@"5PMN5
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M;0G>I<+C8RC' R:_0,375'DKOWE)1BTFVV[[Q2U:6O5:<V[9\I2C.HW%>O\
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M-]XL\8ZA\8+S3;J\T;6],\4^'BMQX@MH=\=A?6D]H%#1B&*\NEBDE8V^U?\
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M"[I7.3A<.#G /X5Z/UA'Z-RY+L^777<T-1_X)^>&M0L'CD-U-/%=1S8$,/\
MI@#M*=S*HZC;$3_<C4=224U;]@+2;ZSE*:YK:ZE=VC:=YJ0Q0_8H#''$PB55
M"*2L6!@<"1@>HJ_H7_!4?X0ZO.L=M'XHC5MY,2Z80T87GYFSL SSD>M5)?\
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MC.0".HSUHEGV(=>$Z<I/ECH[IM:/35)6[IIO;WY+0PC*C&#C)Z/70_/76?\
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M3.9=G +,Q5.0P.,BN=5,/'WD]?R\EIMZ>E[)(T_LW&O1P=OS_'^M][G[4_\
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M'@RZ\.6UQ)J[^&[K4P+MIIQ) 6C<(=J*AVD9'F9]*_4RBJC*SN;X>M[*?/\
M\#]&?S*:QX[_ &YK'5[C6M+_ &>[CPE=7@9YOL/PV:X:3Y\@N)4DP5!(SCD>
M_-4+_P 4?MJ?$ZRFN_%WPU^.E[>;'-G-HG@VWL(58#Y28S8G)'(Y(.#P17]/
M5%:>V9ZW]N5>;F][_P "_P" ?RR_!N+]MOX+^);K6!\"_%WBI;N(Q3VFO> [
MBZ@;)!W%%5<'C&0>F>,5]%:3_P %$OVNO$WAZ;1;/]C/1])NIML O++P7J,8
MB &TD0E<2>PS@ 8YK^A"BCVS>Y']M5>92UT[N_Z'\POBO_@G7^T]^U)XB75O
MB'X=\;V.GLS+]ECT1]/6%3S_ *B)&)ZXYYXZTC_\$#O%D]J?)T_Q-;WF5,9;
MPW?2*N.N<\-GTP*_I[HJHUDMU^)V?V]AW_%PZD^[DVS^72?_ ((3?'GP_/'>
M^%[[7K6[C!P\.CZGITF#_"&CS].@I=*_8^_;]^'7AF/P]I-U\5K?2;%]L-O8
MS7<\"ESECDKO'WB=Q!QSC%?U%44O;+M^)SRSBA>].DX^DW^MS^8?X>_LP?M^
M7EW)YFI?&+30T+0/YT-RL!4?*!G*[C@D_=/OFNR'_!,[]I3Q-#J=WK'B#QY)
MK6I2-)/=)HTZSWTC ;O.E6/<R[0?EWX]N:_I&HIJO;I^)M1SZ%/>FY/SF_T/
MYBK[_@B1\<HM4^T6.N>,-+D>+:'CTK4XY-W/RGR^".3\V>_2OU5_X-O/V+/&
M?[%W[/WQ&TCQM=:A<:CKFOPWD:7-I<0)"HME0B/SL%ER,D@ 9SQ7Z045,ZBD
MK6.7&9G0KTW"%%1;Z\S?X/0^?_A'^PQ)X7@T&\\8>//%'C+7O#^H/J%I,9?L
MEG;D_*(DMU)7RU7C:21]*]6^)_PN'Q+\$7FAC6-6T-+XKYEWIDWD72*&!(1_
MX<XP2.<5U5%<OLH*7,EK^773MZ(\N6(J2:;>QBZ3X)AT:6&2&XO'>-=K--,T
MC2C:%^8D\] ?KGU-:H@.!ELXJ6BJ44MC.4F]R,6_RXS0MOMJ2BJ)(3;9/6G"
M'GYN:DHH ;Y0SFD:+?3Z* *]KID5DK+$BQJ[%V"K@%CR3^-/:WR?O?I4M% $
M*V*"X64A6D48#%1D#ZU^*_[?O_!#W]HS]H+]MCXE>.O"D/A4^'?$^LF]T\W&
MOF"8Q^5&GS)Y9VG*GC)K]KJ*Z,+B)8>3E2ZE1FT[H_"WX3_\$:/VX/@EK=OJ
M'A?Q%I.A75LY=&M/&4BKD]<IY>UL]PP(-?:G[-&G_MZ?#:[^R^/M(^&?Q TM
MAA7GUQ;2\MV[,)(H0''JK*2?45]_45IB,8ZZM6A&7RU^3W7R9M]8D]TCY1T;
MXF?M:PZ\$U+X.?"V\T7<P81>,Y$NF7/&"T!7IV(_&MW2O#7BWXB3W'_">?L[
M^!<19>U>#6[._P!Q(.0_F0(5SZC-?2-%<LE1:LJ45Y^]?_TH(8F<'>&GI=?D
MSYWN_P!@SX7_ !NT+_BKO@QX;T.Z\Q6:*"2+<VWIB2WVY7GH<5YS\0_^"%GP
M,\8AI-+TO6/"]X>DUC?M(OXI)D>W&.*^SJ*N-:I!_NY.*6J2;27RO^9M',L4
MOMM^KO\ G<^#[O\ X(CP>%=!\GP3\6O'OAZ[\@VY=[G?&ZGJ"J[?E/.0,$YZ
M\"N9UG_@EY^TSX5>R;PK^T+;7*V^2\6I6LBJ2,[>TF[@X.<=.]?HM15QQE=*
MW-?U2?XM-G4L\Q?VFG\K?E8_/;3/V7OVVO"=E=1V?Q ^&]](P5DGD\Y9F(/
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M^S5:>+1"VM>"9[.QDS' J;?-M^0OS<YV\< ]J$_8.L]8A:.;P[;VQA?]R[S
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MU];(JMP=-OXKKR"V=H?RV.W.#C/7!K<H **** "BBB@ HHHH **** "BBB@
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M^<D KN;)^8D'-?T?5_&9_P $ O\ E+/\(O\ L)-_Z+:O[,Z!,****!!1110
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MO[,Z D%%%%!(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDK*;73Y9I"6E:+#_ #<#Y\   5]"TB J@!.X@<GUI:!!1110 5\>_P#!1O\
MY/:_8G_[*7J?_J-:K7V%7Q[_ ,%&_P#D]K]B?_LI>I_^HUJM 'V%7X-?MK?\
MJ^7[0G_9</&/_I]NJ_>6OP:_;6_Y5\OVA/\ LN'C'_T^W5 ^A_/17]C7_!N9
M_P HA_A/_P!@]?\ T!*_CEK^QK_@W,_Y1#_"?_L'K_Z E Y'W%11102%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7QS_P $BO\
MD9OVLO\ LO\ XA_])=/K[&KXY_X)%?\ (S?M9?\ 9?\ Q#_Z2Z?0 O\ P6D_
MY([\%O\ LN?@;_T\0U_*Q_P5Z_Y28?&7_L8I?_0$K^J?_@M)_P D=^"W_9<_
M W_IXAK^5C_@KU_RDP^,O_8Q2_\ H"4%([G_ ((!?\I9_A%_V$F_]%M7]F=?
MQF?\$ O^4L_PB_["3?\ HMJ_LSH"04444$A1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMM'GN-.TM%NS;QJ=H:0@F0X7J^2<D]3F@#^GJBBB@ KXY_X)%?\ (S?M9?\
M9?\ Q#_Z2Z?7V-7QS_P2*_Y&;]K+_LO_ (A_])=/H 7_ (+2?\D=^"W_ &7/
MP-_Z>(:_E8_X*]?\I,/C+_V,4O\ Z E?U3_\%I/^2._!;_LN?@;_ -/$-?RL
M?\%>O^4F'QE_[&*7_P! 2@I'<_\ ! +_ )2S_"+_ +"3?^BVK^S.OXS/^" 7
M_*6?X1?]A)O_ $6U?V9T!(****"0HHHH **** "BBB@ HHHH **** "BBB@
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MJ_LSH"04444$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5EUWPY<S^1'-+L1/(N Q0M$=W$@Y&.?M@G H *^/?^"C?_)[7[$__92]3_\
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M1_X1?3?^@?9_]^5_PH_X1?3?^@?9_P#?E?\ "O!/^"M?[2%U^R1_P35^-/Q
MTV\?3M8T+PM=+I=RC['@OIU^SVSJ1R&$TL9&.<@5^3W[ GQB^)7CS]KKX$>'
M_AC\4/VPO$7C3PS)8:Q\<;+XJW_D>&M-T9[<-=&*TN0)MTLFX0, V!M.<D$
MS]X+?1+.TSY5K;Q[NNR,+FI#I\##!AC_ .^:_''_ ()V_P#!77XM^"D\'^*_
M'GA^;Q9\-/VFOBYXF70=;U+Q5++J6BZ5#YC1M:6'DE$TZVCMI-P\P,26(7!4
MM[=X!_X+F>/_ !3;?"/Q]??!/3--^"_[0'BIO!O@*\?Q3_Q45Q>2><ME<7EI
M]G\J&WN)(&&5E=HE(<AA@,"/T8/AC32?^0?9_P#?E?\ "C_A%]-_Z!]G_P!^
M5_PKXQTCXE?M'?%WXX:?XTF^#MO8R?#HKX=D\*/XX:UTZ:\O0);S5!=_90M\
MEK:BVAC3R0OFW5V V8LU]N4 4?\ A%]-_P"@?9_]^5_PH_X1?3?^@?9_]^5_
MPJ]7YG_\%>/^"FGB[X ?MZ_#?X->%?CE\./@'I>I>$+[Q3X@\2>+=&BU2 M]
MH6"TMD1W3#L8YS@,,@$\[<$ _2+_ (1?3?\ H'V?_?E?\*DM]&L[0$16MO&#
MU"(%S7XRZ)_P6X^/5O\ L2+J_P#:FF^,]>USXZ:?\./!7C+1/!TD/_"<:0P\
MVZN[33)"=[!4:-2ORDR* =REJ^S-,_X+M_"JZ^$FL:[=^%/B=IWBS2_'K_#*
M'P)+H\,OB34]?55<6EO%%,\+?(X8N90B=&()7<#L?:3:=;NI5H8V4\$%>M5_
M^$8TW_H'V?\ WY7_  K\O_VP_P#@J1XI_;(/P]^&'P/T;XQ>#_B>/B!=Z9XZ
M\)VMSIVA>*]-LK'2YKN2-;FY::RCCE:6U99=S*ZJ57YCBN7\.?M-?&;X3?M$
M_ OX6^-OC=K2?%GPK8'Q)\2M.N;JRN-&TKP\DUY<&VF$5N)M6UJ>R-O$JVP
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M\/UU*_-C:6$1N('A::-OM#74P4*23OP@Z\@['ZP2Z7;3(5>"%E/4,H(-0_\
M"+Z;_P! ^S_[\K_A7SG_ ,$E-9^/7C7]CG0_%G[1&M:;J'C;Q@1K%K86>CQZ
M:=$T^5$-O;S(A(,Y7]X_]PR>7SL+'Z:H$0V6FV^FJRV\$,"L<L(T"Y/X5-11
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !M\/]/^'OQYDT.?QG<^(?#K:AXKT2;3?+!ETF[!"JT_EAG,F,,[8S7ZL44
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M_P 2D\??$B_?2F7_ (3F,7\EZ]H$\S$8=S &9BW^H!QVK]&**  #:,"BBB@
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MJIVO>1,JKP"Z99> Y#<7\;O@S\5/CYJ'[8WA'P78ZYK7C[_A7?PA7Q#I%O\
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MO[3O[?7A/]F/XG?"WPG>03Z]JOQ0\9VW@J*/3KB%FT:YG@EF26Y0L&5"L1X
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ML?A/JGQ8\ >&]>\-^'X]/^(WQH\$I<>)X]4M&$4^FQ6\\B--IZVX<("0D+L
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I10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ocgn-20191231_g13.jpg
<TEXT>
begin 644 ocgn-20191231_g13.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0 Z17AI9@  34T *@    @  U$0  $
M   ! 0   %$1  0    !     %$2  0    !          #_VP!#  (! 0(!
M 0(" @(" @(" P4# P,# P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,
M# P,!PD.#PT,#@L,# S_VP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" %B
M H4# 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+
M_\0 M1   @$# P($ P4%! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T? D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"
M! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 5
M8G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F
M9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:W
MN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!
M  (1 Q$ /P#]_**** "BBB@ HHHH **^6?VN_P#@M/\ LU?L(_%YO ?Q4^(R
M^%_%2646H&R.B:A=X@EW;'WP0.G.UN-V1CD5Y=_Q$Z?L0_\ 1:%_\)?6?_D2
MIYD3S+N?>]<)^T5^TCX3_97^':^*/&5Y?VVFS7]KI5M%8:;<ZE>7UW<RK#!;
MP6UNDDTLCR, %1">IZ U\A?\1.O[$/\ T6E?_"7UG_Y$KP/]N7_@LA^PO^W3
M?_#/2?$GQ\CA\!>#_$3^(M;TF+PYXBM;S694LKB"S6*YMX(W@\F><3EE8$F)
M ,4<R#GCW/T ^'W_  4D^#?Q*U+PS8V/B[[#J7BN[U33[.QU;3[G2[J&ZTV2
M&.\M[B*YCC>WECDN($V3!&9I5"ALUZE>?%WPGI]W?V]QXG\.P7&E3PVM[')J
M,*O9S3'$,<@+91Y#]U6P6[9K\!8?CG^P_JW@'2/#NO?M)>"-2M_#^B6/AZPN
MC\-M=DN#'_PD0U35M2=I+=C_ &G?6L-I;O< [A(LLF<,%'>?LE?MH?L(_!3X
MMZYKGCSX]>!O'6CSZ=J6EVD$'PTUFWO]:^VZK_:37^L7$D#FZOHG"1PR)M$0
M#LNTOA3F0<\>Y^W7PH^+>A_&CPHNL:!>)=6ID:)U++YL##!"R("3&Q0HX5L-
MM=20,XKIJ_//PM_P<=_L#^!EO5T7XHZ3HXU*Y-[>?8O!NJV_VN<JJF63;9C?
M(5106;)(4#/ KM_A#_P<._L@_'CXJ^&_!/A7XM+JGB;Q;J5OI&E6?_".ZK#]
MJNIY%CBCWR6RHNYV RQ &>2*.9!S1[GVK17YW?'/_@Z#_96_9W^-/BSP#XDU
M+QU'X@\%ZQ=:'J:0>'7DB6YMI6AE"-N&Y=R'#8Y&#7*_\1<W['?_ $%OB#_X
M3+__ !=.Z'S(_3NO"O$G_!2#X2^$OV@9/AK?ZQK<7B&#6[+PU/<KX<U&31[7
M5+R*.:UL9=16 VD=Q*DL6V-I0Q,BC&3BOCG_ (BYOV._^@M\0?\ PF7_ /BZ
M^!K_ /X*9_LAK\7+SXG6?Q0\52_$W5/%GB/Q/>7FH^"[^YTEFOK>:'2GCLS=
M&..[TT"SV7 7>RQS+D;T*G,@YD?O5\)OVP?AE\;?A1)XX\.^--"N/"UO(\4]
M_<7*VJ6I69X1YHEVF,,Z'87 #@JRY# GE?B%_P %"? OP^^+^J>!S;ZYK&N:
M/:I<SKIL<$J9>SEO53YIE8#[/"SF5E$*;XP\BEP#^"%M^VM^QGX$DTNZ\(^.
M;=I/#Z:%;6FC>(OA/+>Z!K$6G:-=6#S:G;QW*&[NGN[^ZO4E<G:XB5MV-R_4
M?P4_X+:_\$[_ (6?L>V_P;U9_B#XNT:[TFSTSQ!?7GAR>&Z\1&WAMX0\KQS!
MT0K:P@1*P0*@3!&<G,@YD?I?)_P55^$VFBPFU:XU_P /Z?JEGIFHV=_JFG&W
MM;BUO[:YN89PQ;(C6.TN-Q8#F,[=PYKW?X;>/+/XI?#O0?$VG1W46G^(M/M]
M3M4N8_+F6*:-9$#KD[6VL,C/!XK\A[W_ (.!_P#@G5JFJ7E]>:7X]OKR^MI[
M.6>ZTB]GD$$]M);2Q(SSDHC0S3+M3 S+(PPS,Q^H_P!A[_@X3_9H_;<^/GAG
MX0_#6Z\7?\)%K,$Z:;;W6@M:VJ1VUM).P+[B% BA;'') '>BZ#F1]WT5^7'[
M2W_!V3\ ?V7/VA?&WPWUWP/\7+W6O FMW>A7T]C86#6TTUO*T3M&7NU8H64D
M%E!QV%<0/^#S_P#9M/\ S3WXV?\ @MTW_P"3:7,A<R/U^K+\;^-])^&W@W5_
M$.O:A;Z7HN@V4VHZA>3MMCM+>&-I)96/951&8GT4U^2-_P#\'GW[.JV$S6OP
MY^-$ET(V,22Z?IRHSX^4,1>$@9QD@'Z&OR<^*/\ P4J^$/B?X4^#]%L?!WBW
M4M8U'P]<VOC?5-3Q%/%KE[J<-W>:Q9-'.WGS?9S=VL2S>6(XY,#Y7D0G,@YD
M?U4?#K]J/X>?%SQW<>%_#/C#0]<\16>D6VNW.G6=P)+BSLKG_42S(.8O,'*J
M^&(YQCFN]K^?S]D[_@Y@_9C_ &;_ -I_XY>/K?X4_$+2+7XE7FDP:5::-H^F
MQ-!8V-GM+7'^DH#/)=3W<A(+_*8\L2,#Z%_XC/\ ]FW_ *)[\:O_  7:;_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXK/F9CS,A,)!IHAW']"?2K&[!Z'GWH!&/X?<YHYF/F9 8=O8U]$_\$AXL?\
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M_P""HTNO^!_A1\2/&.AGPGIEN-0T3PY>7]KYB&;<GF11LNX9&1G(R*_.8?\
M!+G]I8CC]G[XT?CX+U'_ .,UPU)>\]#S:DGS-6/GORYR,;/R-.7[5C@8XQDF
MOH+_ (=;_M+#K^S_ /&C_P (O4?_ (S3?^'7G[2F?^3?OC5_X16I?_&:CF;Z
M&?.WT/G]+::$@JV[U ;%#K<.Y^7[W8MG%?0)_P""7G[2A'_)OWQJ_P#")U+_
M .,TG_#KS]I0-_R;]\:OP\%:E_\ &:.9]@YI=CY\6SF_O*N>M?1__!'_ $]D
M_P""JW[.+&3I\2-!./\ M_AJD?\ @E]^TH/^;??C5_X1.I?_ !FO>_\ @EC_
M ,$[/V@/ '_!2CX":YKGP/\ BYH^C:1X_P!$O+Z_OO"5_;VUE E]"SRR2/$%
M1%4$EF(  )JXRE<TC*=T>-?\%<' _P""I?[17+?\E'U[_P!.$U?.Q<YXKZV_
MX*M?!KQIK/\ P4W_ &@[RS\!>+;RSN/B)KLD-Q#I%R\<ZF_FPZL$PRD<@C@C
MD5\^M\!_'S'_ ))WXR'_ '!;G_XBMM;['19WV.();/\ ]C1R.S5VH^ ?CW_H
MGOC+_P $US_\13Q\!/'F?^2=^-/_  3W7_Q%&O8->QPVX_W?UIV<_P /ZUW'
M_"AO'W_1//&G_@GN?_C=-_X4+X^)_P"2>>-O_!-<_P#QNC7L&O8XC./2OT%_
MX-<3G_@MI\)_^O76^W_4'O*^,3\ ?'Q_YIYXU_\ !+<__$5][?\ !LQ\)/%W
MA+_@LY\*K[5O!OBC2;&.VUD/=7>E3PPQ$Z1> ;G90HR< 9/)('4BB-[CC>Y\
M[?\ !7R2,?\ !4_]HC,C@_\ "P];XW'_ )_9:^=!-&/^6C_]]-7UM_P5F^$/
MC'6O^"GG[0%U9^ ?%E]:W'Q UIXKB'2+AXYU-[+AU8)@J>H(X(Y%?/8^!OCK
M_HG'C+_P2W/_ ,;K&2=]C"47?8XXS(/XV_,U%)./7/XFNW/P-\=?]$Y\8_\
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M_%5UX)\%:CJUEH>J>)+JQB\R/3-.\O[5>'(&R/S&1-W.?F8#CK0!^6'[,?\
MP3^\1?$+_@IOXF^(G@_XF?!7Q1X5TOQX-<UGQ!H_B"^N/&T$UI>:D9-,N[53
MY$;/'>BPD$C;!;6D12-7.1^M-?DCX&^!MQX[_P""HFF_%OXE?#OXL76H:=XZ
MFTGPUXD\-6/AGPSX5MHA>O!#]LN+>];4=3Y4*R3-EBI3R 24K],/VH?VBM%_
M9.^ OB+X@^(+/6-2TSP[#&[66E6XN+Z^EEE2&&"",LH:2262-%!8#+C) YH
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MAJ)/"J!F(\M5[9Y^E3]:AU)^O4SFZ*Z3_A$UD+?ZM?0'.:9)X45$' +9YQT
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M+;H'CA=#M\I2% +_ -]J_1JOG/\ X*=_\D,\$_\ 95O ?_J4:97T90 4444
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MFA?LD_\ 96?&?_J.7M?D-_P7=_Y3#?M$?]CE=_\ LM?KS_P;8?\ )H7[)/\
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M9H ^AJ^:O^"RG_*)O]I#_LG&N?\ I#+7TK7S5_P64_Y1-_M(?]DXUS_TAEH
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MOE2[TLY1N;+9&_C'05\1O^Q%_P $KY!\W[8WQ6(]/^$2N>/_ "G52_X/ O\
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MTC@;RY"GG$_NC*K#+;0?SB^$WPB^%+_\%/X[6_\ B\NLZGI7Q5;_ (134'\
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M<QP_VKN-N #WZBBB@#^+?_@N[_RF&_:(_P"QRN__ &6OUY_X-L/^30OV2?\
MLK/C/_U'+VOR&_X+N_\ *8;]HC_L<KO_ -EK]>?^#;#_ )-"_9)_[*SXS_\
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M']H@>9)_R4/6_P"#_I]EKYS$S?\ /23_ +XKZ8_X*\#/_!4O]H;_ +*%K?\
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MECM(TAA9CAMOSL.V>W0#CIUJO9ZM-97(DSO/&0XR#BM.:H]4C;FJO5)+R?\
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MT ?15?-7_!93_E$W^TA_V3C7/_2&6OI6OFK_ (+*?\HF_P!I#_LG&N?^D,M
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M!!!H _@AK^S#_@D:I34OBP&!!W>#^#_V)>AU]&?\,F_"S_HFO@'_ ,)^T_\
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M!^!?_AJ/#_\ \BTX?\%W/C=G_D _ O\ \-3X?_\ D6CE#E/C;;S_ (U]%_\
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MS3I=:S:K<W$T=JDL+;"=IS);NB/\P):)7R#7L0_X+N?&S_H _ K_ ,-/X?\
M_D6@?\%V_C9_T ?@7_X:?P__ /(M=F(X?P%9/FAJTE=-W23NK:Z6;NO,]#%<
M+9973YH6;2C=-W23;5M=+-W6F^NISW[0O_!2JQ^,OB70[JQ\%_V;I-D\0U+1
M;F\^TV&IQ *)!L*YCD(CB D0AAM!.2,GG+S]M_1O$'AOQUH>N^#_ .U+'Q!:
MQ6FCS+=)$=*%O(7MF:(1[&8#:C,FPE RC[V1Z)_P_<^-G_0!^!7_ (:?P_\
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M)"VY>O#JI/UQ@UP_[3OQ%UKX;^#='FT+>;W5-=L]-;R[9;B8QRL0WEH[HI?
MXW-CZUZ15/6?#UCXB%J+ZSM[P65PEW!YT8?R9D.4D7/1E['J* / OAK^U3XD
MN9M/OM:LK/4M'O=)T*6YFLY1#]AFOKN[M]RQE2[DE(=Z%AY95P-Q&#/XN_:X
MU+4/#&EMINF3:+<Z^-+U#3YD0:E++I]U>I;EC"H&V?:ZD)EQ\_4E6%>Q6/PJ
M\-:8DBV^A:7"LTT=PX2V50TD<[W$;=.JS2/(/1G)ZFH=)^#7A30I)6L_#VDV
M[37,=VQ2W4?O8Y#)&P]-CDLH& &)(P2: /.K7XD^/K4> H[U[./7-<OFAN]%
M.G8DDL$ED#WTC"0_9RL'D.4R5$KB/)+C;B2?M#^,_"/B^ZT?4;5M0G@U_3+:
M.W^P1P7UQ9W4-P6=5$QBVF6W<(Q?=\D@8<*6]CU[X1^&?$_BV'7K_1;&ZUB"
M%;=+QT_>B)7+K&3W4,2=IXR33-!^#7A7PO$JV'A_2[;R[F.\4K -PFC4I&^3
MSE5)"^@) QF@#/\ @1\1-0^)GAC5+[4K5K*:UUS4+".W= LD,4-P\:*^UF7?
MM49(8@UVU5=(T*ST"*9+&U@M4N9Y+J41(%$DLC%G<XZLS$DGN35J@#S7XI?M
M$K\,/&FH:;+HLUY8Z/X<E\27]ZERJF.)'9!$D>"7=F7J2J@9)/ !\_\ %'QE
M^($K>)8H;RQT'7K?Q+9>'M(TGR8]0AEDN+2UF^:4!&*(KSS-P"%1AV%>\7_@
M[2=5U&XN[K3;&XN;NS.GSR2PJ[36Q))A;(Y0DD[3QR:S?#?P<\*^#WM6TOP_
MI=C)9W#7<+Q6ZAHYFB\EI,]=YB^3<>=O&<<4 =(N0HSR>Y]:*** "O+O'7[2
M$W@WQAXFTU/#\EY;^&K;3F>Y^VK']IN+^9H;>%4VG W@;W8@*K9 8@BO4:Q]
M6^'VAZZNJB\TG3[K^W(4M]0\R!6^V1INV*_]X+N;&>F3B@#QOP9\;?'6K>+/
M#ZWIT>"POO&VJ>'=0M/*-Q-''#!<20K%,I10J^1DLR%FS@A<&MG]G;]H&\^*
MWB.1=5%YI\FKPW=YI5@UBJ0FVM[K[.S+,'9G<%H]X=4YD^4$#-=B/V?/!*'3
M=OAG28_['N&O++9#M^SSL26E7'_+1LG+=3DY)R:UO#OPU\/^$=<O=2TS1]/L
M;_4"3<3PPA7DRQ=N>V7)8@=6))R>: -RBBB@ HHHH **** "BBB@ HHHH _E
M6_X/ 49O^"O\V Q_XHS2>GUN*_+1HF0?,&7ZBOUN_P"#M>QAN?\ @KA-YG\7
M@W2R2.JX,]?F"FAV\RLV6*(>XR/7&>V:\^IC(QFXM'EU,PC";BUL<?M[T=#Q
M77W6CVMQ&9(VQ\V,$9"^W_UZK#0G,RB0PK$RY!Q@Y]/QHCC8L(YA!J[.;16;
M[O/T%.-M(I'RMS[5TP\,QQ*ICD0*1MD XY_.IXK6%(-K+YD:D;P/XJEXV/V2
M)9A'[.IR:VDI;[C<<G(Z5])_\$?;25?^"JO[.#,OR_\ "R= .<]/^)A#7C]M
MIMOO_P"/5U;! &[GZ_AZ5]$?\$CK'R/^"HW[.[")E5_B-H1PR97B_AP<_P!:
MB..O)*Q$<QYII)=CG?\ @LL__&V+]HS_ +*'K77_ *_):^:Q(!7TK_P66B_X
MVQ?M&?\ 90]:/_DY+7S4MNW]VNUV.^5@+Y]*-].%L[#[IIT=JQ]JFZ)NB/S?
MFYY^M-W5,UKSQFG)8,W\2_0FCF0N9(KDX%?HE_P:LG/_  6W^%O_ %X:W_Z:
M;NOSWDLU1<?G7Z'?\&K\2+_P6S^%Y4\_8-;_ /35=4XR394)IM'A/_!9,G_A
MZ]^T5_V4+6?_ $LDKYJ+;A7TY_P6/AB?_@J[^T5N9E;_ (6!K/;_ *?)*^;/
MLL03<)$/MS6#DKG/*2N0N% 4J>HY]J9MXW8]JE^R''WEZ^M2+IS8!+(H;IEJ
M.9"YX]RKTZ48YJ2XA^SIN.WKCK4T&ERRNG VMSG/"_6CF5KCYE:[*O>OU"_X
M-#_^4O5O_P!B=JW_ +0K\R+O27M[N6+/F>6<!U^ZX]17Z=_\&BEK);_\%>+8
M,N-O@[5<G_OQ5TY)M6+I3BY*S/RU\;G'C76/^OV;_P!&-67FNJ\;Z(Q\::Q^
M['_'Y.>3S]\UEC0C([;8V90,YZ5K]8@;_68&3DTN2*TQH9P^Z/;M'<]:%T?*
M?*OS9QC/:CVT0^L0,S=FEZUL0:%N'S*H7//%3IX?=(]R[<?EFLWB((SEC((P
MHXF;[JL?PK^@[_@QW@:'PA^TEN4KNO/#N,CK\FIU^"<5BKHS*1&RKMSCH>]?
MOY_P9*0M#X-_:*#2-)_I?A_KV^34J=/$<T^5!2Q7/-11^ZU%%%=9W!1110 4
M444 %%%% !1110 445YC^UI'XFO_ (1WNG^&[+5;C[=%,E_/IETEO?6MN(7;
M]R6=3O=PB94[E#L1\P% 'IU%?+7A;4?$VH>*_#[7,/BRU\4?VGH)MH)FF\E=
M(-C#]M\S!,)_>?:]Y8EO,$??97U+0 4444 %%%% !117X=_\'"?_  6Z_:>_
MX)]_M^0> ?A%+I:>$Y/"]CJ;"X\-+J#_ &B62X63]X0>,1IQVH _<2BO$_B5
M\9=5\'^*IEN-6ATVRG\ 7>J6PE6-%?4(V3YE+#)95<?)DC!Z5@G]I'QM8^&I
M86M='6ZMXAI*S7"R-=?V@- 74_.DB4*NWS T9C&#R#D8VT ?15%?.>G?M:>*
M+3PIJVH3VOAW5(=#T;1;B2XLS)_I5SJ+; ^W<52&+[S?,2P##*8S5V3]KK5K
M75_#&FW&GZ9#JFJW\5A>6IR3$L]U-;6]RK"0JJN8M_E9=\!E)0@$@'O]%?./
MPM_:N\7:^O@C3[JPT?6;[5M.L+[5+FT'V>-EN;EX&$8:3"O!Y;.ZG<6)50%)
M&=;X'?'76/BU\?8UN+K3[?2Y_#EU=1:5;3LTUFZ:@L(^TJ>DH52,C&,NN/ER
M0#WBBN5^.WB>\\%?!#QEK.FRK#J&DZ'>WMK(4#B.6.W=T;!X.&4'!X-?GU\*
M/VE;RTT?]G37=+_; U;XC^*?'FO>'[+Q#X0N-0\+W,3QWL!:[3R+2QCND\MS
M@$293'S9YH _2^BOD/3?VJO&G@[Q=%:ZQJ7]H6^J:WXEU'27:"*..YLM/AU%
M6T]V5<AH9;>W<-]YDEY)VMGOO$?QCUMW^'LW]NPV_BK6((-8OM#T]HVLETWE
MYV<2+YK,P80QD,I:7:0H DP >_45\W_\-"^*/BG\$M4U:/R/"M]]FCO=*FCU
M6ULQ/YEJ\AC?SA+DPL 6R$#@@X4!A78)\7]?N]>^#OV:_P!-CTOQGI\D^I&^
ML6AN+IQ;12J(UW@1.=SG8=V.G.#0![!17SCX'_; \6>))?"OVCP_H[?V]I]G
MK$R6TS;4MKFY:#:DDC*"\*HTCG:=VY$ !(8QZ+^U[KGCSQ;I5GI-QX=MM/DU
MZP@DOIX)!'>65W9W<T856<,C[K<89L%MZ?(O*D ^DJ*^=](_;'U_7$>3_A'[
M#3;/4-2CTZSO+Z;9%I[F[E@/VE0^\_+&"" @WMLST8^A?LG>+-0\<_ +0]5U
M2^34KZ[DNS)<I+YL<F+J95V-@;D"@!3_ '0* /1J*** "BBB@ HHHH ****
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MWHIJO#?K#UA7/&34CZRQ*[8T7/MUJ/9ZZ(ETM=(CSJ,\NW:N=R\*!TK]^O\
M@R-EDD\)?M'>9G'VOP\0/3Y-2K^?U]6FPNW]WW!4<BOW]_X,A)FF\)?M(%CG
M_3/#O?\ V-2K>A"TMCHPU.TT[(_>"BBBNX](**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH JZGHEEK8A^V6=K>?9Y!-%YT2R>4XZ,N1PP]1
MS4G]GV_F^9Y$/F;_ #=VP9W[=N[/KMXSZ<5-10!2M?#>GV-C):PV%E#;3)Y3
MQ) JQNG/RE0,$<GCIR:9%X4TN&2U9--T]6L5V6S+;H#;KG.$X^49[#%:%% %
M!/"NEQSPRKIM@LEM(\T+BW0-$[_?93CAF[D<GO4MGH=EIUW-<6]G:P3W+%YI
M(XE5Y6.,EB!DDX')]*M44 -FB6XB:.15DCD!5E89# ]017.:1\&?!^@:E#>6
M'A/PU8WENV^*>WTR".2(^JLJ@@_2NEHH JOHEG(JAK.U81EV4&)?E+Y#D<?Q
M9.?7)SUJ&[\(Z3?WUO=3Z7I\US:A1!+);(TD(4Y7:Q&5P>1CI6A10!ES>"=%
MN+9H9-(TN2&2<W+1M:H5:4]9",8W?[76O/\ X9?M$6/QM^(^L^'#X$\9:;-X
M1N_+NKW6+&U6TMKD112HJ,LSMO:*>-U(7&U^2#Q7GG_!8C]JCQ9^Q+_P37^*
MGQ2\#MIL?BKPA8VUQ8-?VWVBW#/>V\+;X\KN^21L<\'![8K\*?V>_P#@YB^/
MEY^T!X3L].\5?#?4;KXF>+-+C\46\?A2XB9I)7@LF:%F(556VB@7&2=X=AD&
M@#^F%_#VGR26CM8V;/I^?LK&%<VV>#LX^7.!TQ4<?A'28K:2%=+T]89)!,Z"
MV0*[@[@Q&,%@><]<\UH44 4)?"NESK>+)IM@ZZ@0;H-;H?M..F_CYL>^:MVU
MK'90+'#''#&OW410JCZ 5)10 4444 %%%% !1110 4444 %%%% !1110 444
M4 ?R[?\ !WII"V__  5!N-9&KZ;')'X;TBS_ +.\T_;F!6X?SPF,>4,;2V<[
MB!CG-?EA;7%Q)8/>1SH5CD$>TXW1YZ$CH ><?0U_29_P7=_X)O\ ['/Q\_;5
MM?&'[0'[2&I?"7QEJGARTCMM&CEME26SBDFC2=0\+M\SB5>3C*&OBY?^"07_
M  3'/'_#<&K?^!%G_P#(M<CP^K;=[OLMNQPRPMVVY7N[[+1=O^"?D+?07&F7
MLD4[VL;1-B4)(L@R>O*D@_@:]1\ ? JQ\2_#/_A+?$OB[1="T>\^TV>DV=NR
MW&I7M^B?NHV@X,4#M\OFL<#TY!K]*?\ AT'_ ,$Q\?\ )\&K?^!%E_\ (M+_
M ,.A/^"8[_\ -\&K=,?\?%GT_P# 6N/&8"M5IJ-*KR.^K44W;JE>Z3;ZN]EI
M;J<6.RVM6IJ-&K[-WU:BF[=4KW2;=M7>RTMU/R-U2PFT_:KR6,DRIB=(I [0
MN&*[7XZY&>,C!!S5S2_#FI:KX1U34K?3XKNPTGRQ=7895^S-(<(N&())(/"@
M]*_67_AT'_P3'#?\GP:M_P"!%G_\BTI_X)!_\$Q\_P#)\&K?+_T\6?'_ )*U
MO+"RY;*2O==.E]5NNFBUTZI[/>6"DXI*2O==.E]5HUTNEKII=.UG^2^G?##7
M-1\16>DPZ3?W&I7R+)#:0)YUPRL"P.Q<D?*,D'! ZXKWS_@E7H5QX0_X*Z?L
M[Z;J5I-:ZC;_ !*T&.6*7Y7C/V^#&1V/L:^]M)_X)3?\$UM!N?.L?V[_ !%9
M3;6426]]:1OM;AAE;8'![^M>K_L#?\$H?V ]$_;B^%NO?#G]K[6O&_Q T/Q-
M9ZSHVC-<6CG5KFUE%PL38MPQ#>4<X8'&<$&BG1K^UO.2Y;=$T[_>]+=-?4=+
M#UU5O4DN6W1-._WO2W37U/S:_P""U'PQO_#7_!3KXX:I>I%#9ZYX]UR:WDW!
MB=MY)D,HY&05(R.0P-?+S>'X4T"WU S0_OIV@>'(WQX (.W.<'/7&*^[?^"I
M'P6^ WC#_@I!\=M1US]H_5- UBZ\=ZP;W3!\.+R[&GS"\E#0B47($@0@J'
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MTK^2[]BG_D\GX2_]CGH__I=#0!_=?1110 4444 %%%% !1110 4444 %%%%
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M ">3\)?^QST?_P!+H:_K1_X.0?\ E"7\?/\ L$V7_IRM*_DN_8I_Y/)^$O\
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M^H_)GV_T2XK2G12DF:TJ"4T_,\__ ."MKG_AZ1^T3\I_Y*/KW_I?-7SSO/\
M=-?1'_!6Q<_\%1_VB.G_ "4;7N__ $_S5\\E3CM^==QZ/43)]*3<WI3MI]:7
M;[B@!@8YZ4_=["C;[C\Z3'NOYT!H.S_LU^@G_!KF?^-V7PG^7_EUUO\ ]-%Y
M7Y]#C^[^=?H+_P &N9_XW9?"?[O_ !ZZWT/_ %"+RB.X1W/)?^"O#[?^"I?[
M0W3_ )*%K?\ Z6RU\Y^;_N_G7T5_P5Z'_&TS]H;_ +*%K?\ Z6RU\YXK"6YS
M2W'>;_N_G1YO^[^=-Q1BD(=YO^[^='F_[OYTW%&* '>;_N_G7Z9?\&F;[O\
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ML$9?.<X/Q3^PQ=>')OVPOASI[:I^TQ<? JQ\2ZHWP<MO$GAG3+;P@NJ"WO\
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M2RL/'Y\.Z=I>G6R6+>3%!':R%Y)(Y9P)6;Y'VL0PXKVW]@RP\4?#C]H_XK>
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MG_@L!\?A_P S-X3_ /" \/?_ "#4?_!7)(S_ ,%1?VCL_P"L_P"%DZ]M]_\
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MT5W(D<89[<L0J@#+$DXY)->)Q?\ !P_^V25Y^-VK\>NC:9_\C5P/_!8B'?\
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M6_AC\(/!FEMX7O-6>\\+Z-)97DCPRVZJC,96!0^:21CJ!S7\W]?JY_P9P?\
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M4_M!?]BQX-_GK5-_X)]\:S^T!_V5S5__ $EL:=\#/^4E/[07_8L>#?\ W,T
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M4H?%7_"VO!6O:%XYM[BS2&"TU2\OCJ5G>Z<T422L+>\GNF!NWDD"N@5E VT
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M );DDGU3PW\,]%\&Z!9Z3H]FVDZ5IL*V]I965Q);V]K$HPL<<:,%10!@*H
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MF*,X=]AVH??_  KU[Q;^UO>>+M&FL6L]+T^&=_->/3[7[+&S8VYV(=H.WY>
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M7.,D=Z^H+;]GWX-_\(XMU<?'J)9(2$>P@T"Y>?>2P)7^$H< [O<<57T_X5?
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MZ9J*GE1/LUN?S-G_ (,KOVCC_P U(^"G_@=J?_R%3?\ B"N_:/\ ^BD?!/\
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MFJBGRFOM&?S*M_P94?M(L?\ DI7P3XZ?Z=J?_P A4+_P94?M)(<CXE?!,?\
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M*]>* /2**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M??A9H7@GP?IJZ/X8\,VB6.FV2RR2K;0K]U TC,[8]6)/O734 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!\#> ?^#<_P"!?PZ_X*&2?M+6.N?$
MJ3Q])XHO/%IM9M4M6TO[7=/*\B^6+82>6#,V%\S( ')[_54W[,UO-XBFF.M7
MG]COK%QX@CT_R4_=7TT+Q,_F]3&/,D<(1]YOO%0%KT^B@#RBR_98M](FT6XL
MM=OH;K0XM(BMY'@1U86$-Q"-R\9\R.YDS@C:0I'3!H7'[&.BS:#X9L6OI+I/
M#MG=::XO+=9H[ZUN)EED1XP57=N1<'D8SE6SQ[-10!XNO[(&WQ+JVL-XLU:X
MU*^>%[:>XA65K?R=1%_$'R?W@5U$>!L'EJ  "-QDM/V-='L+'7(8=0>-M1F:
MXL[H6RM=6$C7J7Q^=B0Z?:$1MF%!50#N.&KV2B@#E?A+\-&^&&BZC;R:E-JU
MUJNIW&JW-Q)"D699FW,JJO 4= .3CJ2>3SG[6O[.;?M1?"2+PW!XBO?"=]8Z
MYI7B&PU6UM8KI[2ZTZ_@OH"8I04=3) H*L,$$UZ;10!\U^%?V!]>N/&7C3Q#
MXY^*^L^-]8\8>&;7PJLYT.RTU=/M8+F>Y4JL"@.Q>=^6[8KMM"_8_P!'\-_%
M'4O$EGJFH1)J'B"W\0KI^U#!:S1V]S"\<?&0DCW4LI'9V., XKUZB@#QK7/V
M26\6:IK-YK'B674;G4M5AU6&9[$));&!C]GMRRN-UO&CR*$ 4DR,^[>23J1?
MLRVZ7_A=1J4-MI/A6>"[M;2STV*WD$T6\X$P^98G=RS1CKD@MAB#ZC10!YWX
MC_9^B\1>)=8OFUBZAM]8U32]9>V$*'RKFQ>%EVL>=CK!&I4C@Y(/.*YY?V/+
M+3WU9M-UJYT^6^NY+J"=(<SQ)+>"[GMY)-X,D$D@P4782N 2Q ->RT4 >*Z?
M^Q?I]AX#G\-_V]J$FFW6CVVES P(',EM=RW4$X(QC#S.&3!# #H<DKJ/[&MG
M<VCPV>M2:1'J$<<6K)9V,82_\N\-VC#>6*,79PS$L65NH(##VFB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ocgn-20191231_g14.jpg
<TEXT>
begin 644 ocgn-20191231_g14.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0 Z17AI9@  34T *@    @  U$0  $
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MV9],45\MZE_P6S_9/T>!I+KX\?#^&->26O3Q_P".UF?\/Y/V._\ HX;X;_\
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MH?A?XVU.+P]XW\0'Q=XGU1M#M_%6G>'=5^RQ7%NL"-&TMU;_ #90"/<CR#"
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M&%R6C0_*A.0 :]&/_!UW^Q&!_P E*U[_ ,)+4_\ XQ02?HY17S'^V-_P6 ^
M_P"P9\._ /BKXF>*-0T71?B9;-=^'YH-&NKQKJ-8HI266*-FC^2>,X8 _-CL
M:^?_ /B*[_8C_P"BE:[_ .$EJ?\ \8H _1ROQI_X*??ME_%[X9?MC?M(6_A_
MQM\8M!TGP)'X/L?#.I:+J.EVW@_P=?ZG;'$^NK<QO-]CDF"EY$5E5=P)4LIK
MWK_B*[_8C_Z*5KO_ (26I_\ QBN2UK_@X_\ ^"=GB23Q:VH:Y!?-X]M8[+Q*
M;CP#?2?V]!'&T4<5UNMSYR+&S*%?("L0.*!EG1_^"EWQD^ O[;?Q*TSQ!!H/
MC?X<Q_%GPE\/I2;^2&]TF;5=#M)&;3H%B*O +EGE(EDW,)MJXQFJ+?\ !POX
MH\,_"5O'FM?#GP?>:#XR\%:QXS\&6&C>)'GU+2H["^M[/R-=5H@MKO:ZC9I(
M]RQF.:,AF7-4]/\ ^#A#_@FQI4:K;WFG0K'J-EK"[?A[>C%[91)%9W.?LW^M
M@CC1(W^\BHH!  J'P_\ \' 7_!,_PGJ_BK4-+_L'3[[QU&\/B.>W^&EU')KL
M;Y+I=$6O[Y6))97R&)).230!:^'7_!47XW>#_P!ISXG>!]7N/AGX@\:>*/B)
MHG@WPV&\02_\(/X8)\,G4[EQ="$3MYOE-M@(WF>0J& 7FKJW_!PSX^UCPU<Z
MWX?^'OPWM;'PG\-[[Q_XBAUKQ1-"^H_V=K5WI=Y;Z3(D16Y67[-YEO*P4'>H
M898"LFR_X+?_ /!+2S^'>H>#[?2O",/A75I8)[W2$^%]PME=2PKMAD>+[+M9
MT4D*Q&0#P:Y+Q%_P5R_X)C>*/VF]/^(VM:\NKKH?A*S\(Z1X<O/AW<3:-HT-
MK>27<,]M"UH?*E5I"H*D*%  % CU_P 8_P#!<?Q5K7Q+^*OA'4/">C>#=#A\
M,>)9?!]X-3N#JNK76GZ.;\>5<PPRV:7&W<7MW9)K?8"P<_*9O"O_  6=^)N@
M:KIMNO@CPGJW@CPNWPTTO7M1OM<N#KMV_BJRMB)(E$/E.\,LVYF<H'7H 22.
M9N?^"^__  3+O/'^N>*Y1H,GB;Q-:36&KZJWPUNOMFIP3)Y<T<TOV7=(LD?R
M,&)W+P<CBK0_X.$?^":ZV]Q"+O3!%=2:;+,G_"O+W;*^FA1I[,/LW)M@B"(G
M_5A1MQB@9^K5%?G'_P 17?[$?_12M=_\)+4__C%?6G["_P"W_P#"_P#X*._"
M*\\=?";6KO7O#=CJ<FCS7%QI\]BRW,<<<C+LF56(VRH<XQS[&@1[11110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?S1?\'M'_
M "?Q\)_^Q '_ *<;NOQFT[3YM6OH[>!2\LK;5%?LS_P>T?\ )_'PG_[$ ?\
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M.V.@/48J.[\/:?JEJL-W8V]Q&B^61)$&8J#D+DC)4'G!XHY<(_\ EV_O_P"
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M<4 ?NA_P=B_\F%?L0_\ 8 G_ /3=IE?AFJ&3I7[F?\'8PQ^P5^Q%_P!@"?\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _FB_X/:/\ D_CX3_\
M8@#_ -.-W7YC?LF?$R/2]8;PY?2!(;Y]]F[GY4E[I_P+M[CWK]9O^#R7X!>/
M/BY^W1\+KSPIX)\7>)[.U\""&:?2='N+V*)_[0NSL9HT8!L$'!.<$>M?D%'^
MQ9\:(9%9?A+\3U93E6'A>^!!]1^ZK?#5W1J*HA2BI1L?5,=GY?\ O>E6[=F#
MXSCZ5C? /P9\6/$FGPZ3XE^%GQ*M-5B 2*\?PO?".\ '\1\KY7X[\-]>*]*;
M]F[XCKG_ (MWX^_\)Z\_^-U]#6HTJ\/:TGH_O7DPPN+E3?+,Q+-LD_,K[!@
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M<DJ<8V[M?K)?@V>Z?M0:OHNM_P#!M7^TE/H(OFL3=L/,N[62V>9_M>G[F"R
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MX<X?M9?]&Z?&,_7PM=__ !%:1A&*M$VI48TX\L%9'S2F=W%?IW_P0(O&T_\
M8P_X*!31_?M_@^[J?0A;L@CZ'FOEC_AS9^UA_P!&Y_&/_P ):[_^(K]!_P#@
MB[_P3F^/GP@_9#_;@T?Q5\'?B-X?U3QM\*I-,T"TU#0Y[>76+HK<@00*RCS)
M#N7Y5R>1ZU1I;N?FC\/OVW-0\$ZKH<TWA+PEK%GH=G);):W=GF.ZG=VD:ZF5
M2%DFW,0&93@!0,$ USOBC]I76O&&BWVGRV6CPVFH2I),4MPK?NV9U53_ ,LQ
MN;D(%!VJ#P!7IEI_P1K_ &KH;A6E_9Q^,C*O4+X7NP?_ $"I)/\ @C9^U1)T
M_9W^-:@G)!\*W3#/_?(K&.%I7YK:_P!/\SACE>%C4]JH*^G=[._YNYXU:_M!
M^(+?QA_PDB_85\0I=Q7J:DELD<\3QQ^6%4* @0KC*[>2 :U=>_:R\6>)M*TN
MVNCITD>@+&NGR?8X_-MMH922^W,C,';)DW'IC!%>HVO_  14_:TU)V^S_LY_
M%X*O_/3PW<1_^A**L+_P0_\ VN^_[.OQ8'_<!FQ_*J^KTVU[JOTT-)9?A9-.
M5-::+39=EY6T]&^YXMJ7[1/B:2PN;6,Z9I]O>R"9DL;*.W$9!4@1[1F,94'Y
M,9W-DD,<Y=]\9M;U33+JTNKJXN(;J];5-LD\G[N]; >Z&",RL% +'/'I7O:_
M\$1_VO+@9'[.OQ:QT^;0)OZBG/\ \$/OVN@WR_LZ_%@K[Z#*#_*J]G%;(TCA
M:$=%%=]CYYE^*6L2^&9=):[9K*YD\R=2,M,=Q<;FZM\Q+<GJ:?I/Q@\2:&^Z
MSU:^M6%O):JT4S(4BD7;(@QT5UX8#J*^@O\ AQ_^UY_T;I\6/_!#+_A0/^"(
M'[7@//[.GQ8_\$,W^%'LX[6+^KTK-.*UUV/F5]?N9$*^=,J -M1)"J)GJ HX
M /<"H9[SSEW%G,AX))_*OJ6W_P""(O[7$<ZLW[.'Q79/0Z#,?\*AE_X(D?M;
MO<2+'^SK\7&5>[>')US^F/RJ^AI9=#].O^#J;Q7J7A;]@[]B9M/NY;5IM F#
M[#C=C3=,QG\S7X=7WQ"US4S^_P!6OI.,?ZTCBOZ!O^#E_P#8B^,7[17[&/[(
M6B^ _ACXW\8:MX3T6:#6K32-)EO)M*D-CIR!)EC!*$M'(.>Z-Z5^/2_\$<OV
MLE3;_P ,X_&#'_8J7>?_ $"HY(WO;4S]G%OF:5SYR/B&_:+9]MNMN<X\TTT:
MW>+_ ,OEUQR/WK<?K7TL/^".G[5#RJ6_9N^,<>,9QX5N\'_QRD?_ ((X_M6#
M<?\ AF[XQ%9.>/"]WD?^.<4[(?*NQ\T3ZM=77^LNKB3_ 'I":B-S*1_K)/\
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M9E^IKK;CP0U[9PM'!V*EB.M<;JZGO4\KBX_"ON.U3_@JY^U)*[#_ (75XP
M_NVW_P :JM>_\%8/VI$B;'QN\8!U'9;;_P"-5R,O@5H+?YHVW+V(P:SM4\';
M$W!02PX&*S]L[FG]DQM\*^XN>+_^"MG[6QL9!;?'OQQ;O_"Z+:97_P @U\_^
M.?\ @N_^V[X"UAK6[^/WC)E;)BE$-KME7U'[GKZCM7HWB#PHD_F*%&[T["O%
M?CA\&H?%6@SV[JJS??ADQS$_8_3L?:NZC4YD?.YAESA[T46_^(AC]M#_ *.
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MLWQQ\'7&KS>#?&W@9X+R2S^P>*+&*SO)0@4^<J1RR Q-NPK;LG:>!0!^ ?\
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MJ &9S7]0W_!F+_RBQ\5?]E$U#_TBL*_E_P#LN/O&OZ@O^#,A=O\ P2R\5?\
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MFP/(3(X0,Y+,: /Q+_X/6G"?M5?L[,W0:+?Y_P# N"OSE\%IY87U[@U^A_\
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M3:-JB/Y%4=^!66/'FJ^8S?VA>9;@XE(II5[:M?B"CB6M6E]YU4?P8UK>T;6
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M +ZR/S>>/E<'&1BOKJBN@Z@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPSXA%YK?G2&T(D!\EO+'EO\ O&^;GM7W-10!^6__ !!__L>#_ES^)7_A3?\
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M10!^5/\ Q!U?LA_\]OBQ_P"%'%_\CT?\0=7[(?\ SV^+'_A1Q?\ R/7ZK44
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y7\//V/\ P/\
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M9K&[\.Z1\1H2GB"[U@($NK@&5GN3"0K?ZZ1\[DP<AP/U"HHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#XU^/_P#P2,F\5_M+>*/BU\'O
MC1X\^ 7C#XA6<5EXP_X1^TL[ZQ\1")2D5P\%RC"*Z525$R$,.2,$L6]D_8(_
M8:\'_P#!._\ 9PTWX;>"[C6M0L;6YGU"]U+5[K[3?ZM>SOOGN9GP!O=NR@
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ME[=7U[IPMV2+);SY[=9MZ@*GF;-Q"YY__@F[^Q)\=OAQ+\4;CX_77@.;Q/\
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M)%=IIFK6NMV:W%G=6]W;R#*RPR"1&^A'%*I1J0UG%KU0*2>Q8HHHK,H****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\U_\
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MTCXP_"7Q=9V^B643>%OAW\,[OP=IMF_GS'[?/]I0--.X/E#:Q 5!P.I_2:@
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M&V&PM7$M\FD5NV[)>KZ>75[)-FWX8^ OA[P[K4>J7$=_KVL0KLBO]9O)+^:
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M .3ZKV<>Y2IP6S1^3EY>O/83+(S,ZJPSG#?C^M?<W_!SFL4O_!2^PWR+&/\
MA7?AKJ?^G2O?KC_@HK_P2]2*1V_8M\9?=.[_ $P<_P#D_7V'_P %5/\ @K1^
MSW^RI^U58^#_ !9^R)X1^*FIMX3TG4X=<U,:>;A;6:)O)MCYUK*_[I5P/G(Y
MX][CRQ3;9I3<8)ML_FN>S5=Q6:+C_;%1RW,@B6/S_E4E@N[(!-?M]+_P<$_L
MIH^U?^"?GP\8]L#2/_D&G-_P<#?LH)%N;_@G_P##I3V7;I&?_2&G[:/<M8BG
MU?X'X:LQW9W*?QIT=Y)$?ED9?HV*_<Q_^"_/[*:G_E'[\.3D9'&D<_\ DC4<
M_P#P7^_9/C@W+_P3]^',C*V&79I''X_8:/;0[C^M4GU_,_#VWUZ[LY&:&ZFC
M9E*DA^H/!%0K>R(,+-(H]F(K]Q(_^#@/]E*16;_AWS\.L+U^72./_)"FG_@X
M'_91;[G_  3Y^';*,Y)72!_[84_:0#V]*^_X'X=O=22?>ED;ZN::2#7[F_\
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MHH **** "BBB@ HHHH *_.7_ (.JT:7_ ((X>,E5=Q.NZ+Q_V_1U^C5?G?\
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MSKH_[6_[.WBSX:>(=2UK2M!\:6)TS4;C2KA;>[-N[+YD:.RL%\Q08S\I^5V
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M;'YRX PR@'/4;4<1*G\/]-;->:Z,.7^O)[KT?4^KJ*\I_P"&M-._Z$GXK?\
MA'7W_P 11_PUIIW_ $)/Q6_\(Z^_^(K$#U:BO*?^&M-._P"A)^*W_A'7W_Q%
M'_#6FG?]"3\5O_".OO\ XB@#U:BO(-:_;,T7P[HUWJ%[X.^*T-G8PO<3R?\
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M_P"$=??_ !% CU:BO*?^&M-._P"A)^*W_A'7W_Q%'_#6FG?]"3\5O_".OO\
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M?0(]0;1](\.:3IVD06\*72&&-KC49+R1#CIN;#@;3P5K^T'J5K\6?V@OC?\
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M*T-+U.RCG;SI9(YO*VQ;5SO.> :)1\AU(*VQJI'<:?=*EQ)Y-Q!$WF^8PP<
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M,/\ L.:,/_)V.OT2K\[?^#I5=_\ P1\\8#_J.:-_Z6QU%3X695OX;]#^8>/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *H>*M$_X2;PO
MJ6F^8(?[0M9;;>5+;-Z%<X!&<9Z9'U%%% 'YPWW_  1H\4_L]>%M%\1>$?B5
MI.FZYX3\E=+CM-&FM8=)87,T<5M9S-<33P61BO[CSH2TC2N$^=%X'I^A_P#!
M+CXG/XZTOQ1KG[0'B34-<L;VSN97@^VPV]PEL^FG88?M9C^=+.Z#9!!-_(2#
0MY**!GV]1110(**** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ocgn-20191231_g15.jpg
<TEXT>
begin 644 ocgn-20191231_g15.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +M!Z\# 2(  A$! Q$!_\0
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M2;2=HMZI/\'H0_V?XZ_Z'S_RCP4?V?XZ_P"A\_\ */!72T5X_P!1A_S\J?\
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ML?\ P"'_ ,B<U_9_CK_H?/\ RCP4?V?XZ_Z'S_RCP5TM%'U&'_/RI_X-J_\
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ML?\ P"'_ ,B<U_9_CK_H?/\ RCP4?V?XZ_Z'S_RCP5TM%'U&'_/RI_X-J_\
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ML?\ P"'_ ,B<U_9_CK_H?/\ RCP4?V?XZ_Z'S_RCP5TM%'U&'_/RI_X-J_\
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ML?\ P"'_ ,B<U_9_CK_H?/\ RCP4?V?XZ_Z'S_RCP5TM%'U&'_/RI_X-J_\
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ML?\ P"'_ ,B<U_9_CK_H?/\ RCP4?V?XZ_Z'S_RCP5TM%'U&'_/RI_X-J_\
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ML?\ P"'_ ,B<U_9_CK_H?/\ RCP4?V?XZ_Z'S_RCP5TM%'U&'_/RI_X-J_\
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ML?\ P"'_ ,B<U_9_CK_H?/\ RCP4?V?XZ_Z'S_RCP5TM%'U&'_/RI_X-J_\
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ML?\ P"'_ ,B<U_9_CK_H?/\ RCP4?V?XZ_Z'S_RCP5TM%'U&'_/RI_X-J_\
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ML?\ P"'_ ,B<U_9_CK_H?/\ RCP4?V?XZ_Z'S_RCP5TM%'U&'_/RI_X-J_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/V_B7X@:_>0:;<(/[/TG276*,*.#*X(8;B03TS[@8 ]*_:8_Y(=XJ_ZXQ_\
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M(9_MVXR*W4KEF9E;;DJ0V#@Y%>@_L@WMM=?!2PB@*^;;W5Q'. >=Y<L,_P#
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M0K]37O\ \1-;L/#_ ('UN]U*ZCL[5;213)*<#<5(51ZDD@ #DUS/2CS=7?\
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M<<$1)"X!! SC( P #WKM?VE/"PM_V>[[3=,C(M]+CMBL:_\ /*-E!_(<_A7
M_"#]G?PM\0/AWHVM+XH\21S30[9X;2_C6.*5>&0*8R0!Z$]"*UTE*;2VLEZ6
M,]8QC=ZN[?KV+_@FZU?X$_'&R\ 3:M=:OX5UF'S+#[:VY[=CNV@'H/F0J0,
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M_P #C_F'U+%?\^I?<_\ ([*BN-_X7!X1_P"@M_Y+3?\ Q%'_  N#PC_T%O\
MR6F_^(H_M?+O^@F'_@<?\P^I8K_GU+[G_D=E17&_\+@\(_\ 06_\EIO_ (BC
M_A<'A'_H+?\ DM-_\11_:^7?]!,/_ X_YA]2Q7_/J7W/_([*BN-_X7!X1_Z"
MW_DM-_\ $4?\+@\(_P#06_\ ):;_ .(H_M?+O^@F'_@<?\P^I8K_ )]2^Y_Y
M'945QO\ PN#PC_T%O_):;_XBC_A<'A'_ *"W_DM-_P#$4?VOEW_03#_P./\
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M+?\ DM-_\11_:^7?]!,/_ X_YA]2Q7_/J7W/_([*BN-_X7!X1_Z"W_DM-_\
M$4?\+@\(_P#06_\ ):;_ .(H_M?+O^@F'_@<?\P^I8K_ )]2^Y_Y'945QO\
MPN#PC_T%O_):;_XBC_A<'A'_ *"W_DM-_P#$4?VOEW_03#_P./\ F'U+%?\
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M*BN-_P"%P>$?^@M_Y+3?_$4?\+@\(_\ 06_\EIO_ (BC^U\N_P"@F'_@<?\
M,/J6*_Y]2^Y_Y'945QO_  N#PC_T%O\ R6F_^(H_X7!X1_Z"W_DM-_\ $4?V
MOEW_ $$P_P# X_YA]2Q7_/J7W/\ R.RHKC?^%P>$?^@M_P"2TW_Q%'_"X/"/
M_06_\EIO_B*/[7R[_H)A_P"!Q_S#ZEBO^?4ON?\ D=E17&_\+@\(_P#06_\
M):;_ .(H_P"%P>$?^@M_Y+3?_$4?VOEW_03#_P #C_F'U+%?\^I?<_\ ([*B
MN-_X7!X1_P"@M_Y+3?\ Q%'_  N#PC_T%O\ R6F_^(H_M?+O^@F'_@<?\P^I
M8K_GU+[G_D=E17&_\+@\(_\ 06_\EIO_ (BC_A<'A'_H+?\ DM-_\11_:^7?
M]!,/_ X_YA]2Q7_/J7W/_([*BN-_X7!X1_Z"W_DM-_\ $4?\+@\(_P#06_\
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M  N#PC_T%O\ R6F_^(H_M?+O^@F'_@<?\P^I8K_GU+[G_D=E17&_\+@\(_\
M06_\EIO_ (BC_A<'A'_H+?\ DM-_\11_:^7?]!,/_ X_YA]2Q7_/J7W/_([*
MBN-_X7!X1_Z"W_DM-_\ $4?\+@\(_P#06_\ ):;_ .(H_M?+O^@F'_@<?\P^
MI8K_ )]2^Y_Y'945QO\ PN#PC_T%O_):;_XBC_A<'A'_ *"W_DM-_P#$4?VO
MEW_03#_P./\ F'U+%?\ /J7W/_([*BN-_P"%P>$?^@M_Y+3?_$4?\+@\(_\
M06_\EIO_ (BC^U\N_P"@F'_@<?\ ,/J6*_Y]2^Y_Y'945QO_  N#PC_T%O\
MR6F_^(H_X7!X1_Z"W_DM-_\ $4?VOEW_ $$P_P# X_YA]2Q7_/J7W/\ R.RH
MKC?^%P>$?^@M_P"2TW_Q%'_"X/"/_06_\EIO_B*/[7R[_H)A_P"!Q_S#ZEBO
M^?4ON?\ D=E17&_\+@\(_P#06_\ ):;_ .(H_P"%P>$?^@M_Y+3?_$4?VOEW
M_03#_P #C_F'U+%?\^I?<_\ ([*BN-_X7!X1_P"@M_Y+3?\ Q%'_  N#PC_T
M%O\ R6F_^(H_M?+O^@F'_@<?\P^I8K_GU+[G_D=E17&_\+@\(_\ 06_\EIO_
M (BC_A<'A'_H+?\ DM-_\11_:^7?]!,/_ X_YA]2Q7_/J7W/_([*BN-_X7!X
M1_Z"W_DM-_\ $4?\+@\(_P#06_\ ):;_ .(H_M?+O^@F'_@<?\P^I8K_ )]2
M^Y_Y'945QO\ PN#PC_T%O_):;_XBC_A<'A'_ *"W_DM-_P#$4?VOEW_03#_P
M./\ F'U+%?\ /J7W/_([*BN-_P"%P>$?^@M_Y+3?_$4?\+@\(_\ 06_\EIO_
M (BC^U\N_P"@F'_@<?\ ,/J6*_Y]2^Y_Y'945QO_  N#PC_T%O\ R6F_^(H_
MX7!X1_Z"W_DM-_\ $4?VOEW_ $$P_P# X_YA]2Q7_/J7W/\ R.RHKC?^%P>$
M?^@M_P"2TW_Q%'_"X/"/_06_\EIO_B*/[7R[_H)A_P"!Q_S#ZEBO^?4ON?\
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M^@F'_@<?\P^I8K_GU+[G_D=E17&_\+@\(_\ 06_\EIO_ (BC_A<'A'_H+?\
MDM-_\11_:^7?]!,/_ X_YA]2Q7_/J7W/_([*BN-_X7!X1_Z"W_DM-_\ $4?\
M+@\(_P#06_\ ):;_ .(H_M?+O^@F'_@<?\P^I8K_ )]2^Y_Y'945QO\ PN#P
MC_T%O_):;_XBC_A<'A'_ *"W_DM-_P#$4?VOEW_03#_P./\ F'U+%?\ /J7W
M/_([*BN-_P"%P>$?^@M_Y+3?_$4?\+@\(_\ 06_\EIO_ (BC^U\N_P"@F'_@
M<?\ ,/J6*_Y]2^Y_Y'945QO_  N#PC_T%O\ R6F_^(H_X7!X1_Z"W_DM-_\
M$4?VOEW_ $$P_P# X_YA]2Q7_/J7W/\ R.RHKC?^%P>$?^@M_P"2TW_Q%'_"
MX/"/_06_\EIO_B*/[7R[_H)A_P"!Q_S#ZEBO^?4ON?\ D=E17&_\+@\(_P#0
M6_\ ):;_ .(H_P"%P>$?^@M_Y+3?_$4?VOEW_03#_P #C_F'U+%?\^I?<_\
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MV_M%^%?@+'IG_"01W]W<:B7\FVTV)))-JXW.V]U &2!US[<&OEWX12?\*/\
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MX:U4S6]E912*<L\RNPVKTVA1U Y;BLZ/OQBWUC=OL^WS-JWN2DETE9>:_P"
M?8]%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME<@;5Z?PTWQS\>_'G@#Q3\'-8OM9$G@_Q)IUFVIV_P!C@ :8A?/??LW+Q(C
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M $3;BV!RRL?EZCDU]3+\5_"GAJ&WTSQ-XV\.6/B"WAC6^@N-4@A=9M@+$HS
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M'^Y<?^E$E>U5TU(J,VD<].3E!-A11161J%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !4-Y=)8V<]S(&,<,;2,%ZX R<?E4U9WB+_
M )%_5/\ KUE_] -9U).,)271&E.*E.,7U9QGP5^..@_';0;[5M M=0M+>SN?
MLLBZC$B.6VAL@([#&&'>O1*^%?V3O$FH>#_V5_BGK>DSBVU*PFFGMYBBOL=;
M="#M8$''H1BET/XM?M%^//A#/XWTG5-+T_1]%@D:XN)+:$W6I>629'"&)D 4
M<8 3[IQDUO4M"32Z)-_-&4+R2?=M+Y,^Z:X#XS?&C1_@;X;MM<URPU.^L9KE
M;7_B611R,C%68%M[H /E(Z]:Y?X'_M":;XR^#>C^*_&&J:3X=NIII+*:6[ND
MMH99D)^YO8<E<-MSZ]JL_&"U\/?'WX+^+=(\.ZSIGB"6.W,L3Z;=QW(CN$_>
M1J2A."2N/H365:]--KI^7_#%TK3:3Z_U^9Z;X<UZS\5>']-UG3W,ECJ%O'=0
M,<9*.H89]\&O'YOVLO#MY8_$*71-&U75)O!L3/<LR)'!<,)"F(Y S'!(8Y*#
MA2<5YE^SG\<%T7]D'Q!>SR_\3#PE'/:QJW4E^;?_ ,>?;_P&J?P*TO5?A'^Q
MWXL\<V4WV7Q)JL<NI173HLC*JG9&2&!!_C;D$?/5U;1E4:V2O]^WW+4FG>2@
MGNW;[M_\CZ,^!_Q4_P"%S?#NQ\4_V1)HGVJ21/LDDOFXV,5W!]J[@<=<"N^K
MX@\3?M ?%32_V<_AW\0[37UDEGO[BUUC-C;XN )G$61Y>$&V-E)7'4=Z]$_:
M:^/VOZ+H?P\LOAYJ"VNN>+98YX)1!',?(=5"+M=67YFD7G&?E-5)>]:*UORV
M\_\ @[D1>FKZ-_).Q]-T5\G^/OC5\3O&7Q>?X7?#&YL;/4-)MP=3UV^A0AI%
M5?,;!1E5=S!<!"23Q@4[X6_&_P")7@SXY6WPP^*DECJT^HQ[[/5+*-4Y*LR$
M;%0,AV,O*!@?:IBN9JW7;S]/T*E[J;?3?R]3ZAUK58=!T>_U*X5VM[.WDN)%
MC +%44L0 2.<#UKD/@W\9-%^.'A:;7M!MK^ULXKIK1H]0C1)-ZJK$X1V&,,.
M];/Q(_Y)WXH_[!5U_P"B6KP'_@GE_P D3U+_ +#4W_HJ*E#WI33Z)/\ &P3]
MU0:ZMK\+GU#17@/[1'B'XJ:7K]E!X3\1>%_!/ALVP>37/$%S#'OGW-NC D#\
M!0IX3^+KV'&?LS_M!>,O$7Q:UCP!XOUO1_%AAMGN+;6M&\MHG9=A(5XE564J
MQ_A!!&*4??O\_P !R]U7]/Q/K&BOA71/C]\9/BYXPUQ/#'BWPQX7DL;IH;;P
MOJ8BCN+H D!4,D3%VXP?G7![ 5ZK^T1^T%XM^'EGX,\*Z%:6<'CWQ%!&T\DY
M5H;-CM4[=QVGYRPRQ*@*3S1>\4^]K+U&U:3B^E[_ "/I6BOCKPW\<OBE\*?B
MMX8\._$;7M"\7:/XBE6W2\TGRLVSLP4<QQQ]&9<AE((/!XH\<?&KXO7_ .TE
MXG^'7@F]M)%>...R%Y;Q"/3QY<;R3EMA9L9;AMP^;A2<"GO:VM[_ (;BZ-OI
M;\=C[%KSOXU?'+0?@3H=AJNOVNH7=O>W/V6-=.BC=PVTMDAW48PI[TSPUX[A
M\ >%-&TWXH>-?#MKXP\AGNI)[Z"V$_[Q@KHK;/EP ,A1R#7@?_!0+6].\1?"
M/PAJ.DW]KJFGS:N3%=6<RS1/B*0':ZD@\@C@]J4M&K=TOQL732D]>S?X7/KV
MSNDOK."YC#".9%D4-UP1D9J:OE']I+XX>-OA/K7POLO"4L<J:E;?OM-D@C<7
MC@Q*B%F7<H);'RE3SUKG-9^,?QQ^"7Q)\()\0]0TG4]#\0SA#8V,,86W4NJN
MH<(K!TWJ>6=3ZFM+<T^5=6TO5&-VHW>]D_O5S[1KQWQ)^T,OA_\ :"T+X8?V
M"9SJ<"S_ -J?;-OE960X\K8<_P"KZ[AU]J\Z^-_QL^(NK?'"S^%?PPGM-+U)
M(5FN]1NHDDP2GF'.]7"HJ%2<*6).![^4Z3_PG,?[;/@BW^(7V&7Q!;1"'[5I
M^!%<Q"*8K*  ,$Y(^ZO3H*FE^\G#LW]^^WS-)^["?=*_IM^A]^T5\W?"+XP>
M+/%'[4GQ"\(:GJ@N?#NE1S-9V?V:)/**RQJ/G50S<,?O$]:A^'GQJ\4:I^U7
M\0/">K:NLGA31[*>XM[3[-$OD[&A^;>JASP[=2>M3%J2B^Z<ODA/1R79I?-G
MTO17QAX7^+'QX_:,U37=7^'6H:3X7\,Z=.8(8;V&-FG.,A2S12$OM()QM4;A
M73_&3]H3X@?#WPSX$\*QV5A;?$WQ!"/M<CE&@M3OV KR4RQYR257!ZT];+35
MVLNNH]+O717UZ:'U117QUX;^.7Q2^%/Q6\,>'?B-KVA>+M'\12K;I>:3Y6;9
MV8*.8XX^C,N0RD$'@\5I_$WXT_$_QU\>KKX9_"R[L=%;2XM]YJ-Y"D@8A5+E
MBZ/M0%U4!5))/7'1]K:WO^&_W"[WTM;\=CU)?VA%;]HP_"K^P3D6WVC^UOM?
M?R?-V^5L_#._\*]4UC5(=#TF]U&YW?9[.![B78,MM12QP/7 KX;^$\GB^3]N
M:V7QU':)XEBLI8KA[''DRJMH0DBX_O+@]!UZ#I7V;\2/^2=^*/\ L%77_HEJ
MRFW&@I];-_BRH+FJ\KVNOR1Y=\)_VQ? WQ@\80^&M*M=8T_4IXW>'^TH(D24
MJ-Q4%)7^; )Y Z&O2?B?\2]&^$?@V\\2Z\TPL+8JOEVZ!Y978X5$!(!)]R!P
M:_-WPKIMSX'^%_@3XK:8A^TZ/XEFM+HJ/O)MCD0'V.)5_P"!U]'_ +3&O1?'
M#XE?"WX;Z1/Y^F:BT>M7S1\CR64E2?I$)3_P(5M*-^6,=V[/\[_=^1G&5KRE
MLDW]SM^?YGMWP1_:&\-_'R'5I/#]IJ=G_9C1K,NI0QH3O#;2NR1\_=/7%>H5
M\5_L>^(+'P*WQRUFZ79I^E7/VATC'.R-K@[0/PP*=X5^('[1_P <]%U'QEX/
MU+1O#V@QRR):Z9)#$TEQLZJC21.2>Q+,@)SC%2Y+1KLF_*XTG=I]VE\C[2HK
MY'T#]JCQ+XR_9C\;^(D\G2/&GAQHH)+B"%6C.^10L@C<, 2-X(.1D9&,X'76
M_P 6O%4G[&!\>-J8/BK^SFF^W_9XOOBX*!O+V[/N]MN*4GR*3?V;?BKCC[SB
MN]U]UE^I]%45\<^)OVG?&_AG]EKP3XH2>&Z\2:]<S6L^L7%LGEP!9) &\M%"
M[B%&/EQ\IX-=_P#L^>)/BA=:A>WWC'Q=X;\;>#S8/.FKZ%)"WD3*5/EL$CC/
MW-Y(*G&WJ.E4U9R3^SO]UR5*ZBUU_P ['T/17Q%I?QU^,_QTU#7=8\#:]X?\
M'^'=/F,5M9ZDT ENL#(7,D;DN1C/W%&X#/>O=/V5?CC??&[P)=W.L6\-OKNE
MW/V.\^SC"2?*"L@&3C/((Z94XXXHBG)?*_R8Y/E=OD>K>)/$NE^#]#N]8UJ^
MAT[3+1/,FN9VPJC^I)X '))P*^?H_P#@H!\+9-:%B5UR.V+[?[2:R7[.!_>P
M'\S'_ ,^U<?_ ,%$M<NSI/@?PY%*T%GJ5Y--.W(5B@14SZX\QCCZ5],:+\+_
M  OH_@.W\(1Z-93:"D A>TDA5DEXP6;CEB>2W7/-1&\HN?2]EYVW*E9-1[JY
MPOQ:_:N\%_!^XT2/4X=3U2/6+07MK<:3%%+&82<!B7D7KUXS7=ZG\3-%TWX:
MS>.E::\T*/3_ .T@ULH,CQ;=WR@D#=CL2.:^6OVD/ ^DWG[1'PA\(K;^3HDN
MF_V8(0Q;9"6>, $DDD+W)SQ6?X+\17_A?X$_&7X1^()/^)OX5L;I[0M_RUM'
M!.5]@2&^DJT<UZ4Y+=<UO2+_ ."G]Y48OVD(RV]V_P _Z?X'MVO?M?>#_#G@
M#POXQNM*UYM&\0R316YBMH2\+1MM(E'FX&<$C:6R :]K@O(+FSCNXY5:VDC$
MJR9^4J1D'/IBOC.U\ ?\)_\ \$^=.CBC\R^TN*;4[? R<Q7$I<#ZQEQ6OX?^
M.WD_L*SZO]HQJ]G:-X>4Y^;SLB-"/<1,K?@:JI[GM4MXO3T>WXZ&5.\_9M[2
MO?U7_ U/=/@[\>/#_P ;_P"VW\/VFI0P:3.MO)<7T2)',QW8,95VR,+GG!^8
M4WXV_'SP[\!=-TR]\06NI7::A,T,*:;%&[ JH))WN@ Y'?O7._L>_#X_#_X$
MZ&DT?EWVK ZI<9&#^] * _2,)^M>8_\ !090UE\. 1D'59 0?I'55(N,E!;W
M2^=TF$)<T7-K2S?X-H^A/A'\7=!^-7A(>(/#_P!H2U$S6\D%XBI-%(N"58*S
M#H0>">#7&?&3]K/P5\$?$L.@ZS;ZMJ&HO MP\>F01N(E8G:&+R)R<9P,\5Y'
M^SK?)\$/VC?B+\.;V7[-H]YOU.P\SA551Y@Q_P!LG.?^N5>%^/(Y?BAX1^*O
MQ9O$)BN]8MM-TXN/NQ!P2!]$6$?B:SE*_+*.S2;_ "M]_P"1HHVYHRW3LO/K
M?[C])_#>O6WBGP]IFLV8D6TU"VCNH1* '".H89 )P<'UK2KY2\?_ !\U?X2_
M!?X5:%X5LXKWQ9XATNTAM/.7<L2^5&N=N0"Q9P!GCJ3Z5S/C'XH_M _LZ3:+
MKWCS4M'\4^';RX6">VM88U,1(+%-R11E7VAL'YEXYS6LTE-I:*]KF4&W"+>K
M:O8^TZ\?^(W[0B_#_P",G@[P$=!-^?$/E_\ $P^U^7]GWR,@_=[#N^[G[PKS
MGX\?M ^,[OXA>%/A[\+7M[76-:M8KUM0N8D<HLBEE #AE "*78E2<8Q[^0^)
M$^(MK^U;\+++XDRZ?>ZO;7-LEOJ&F@".ZA,['<0 N"&+#[B].G<Q%-U()Z)R
ML_.U[_B5-J-.36_+?[]C]!*BNIQ:VTTQ&X1H7('? S7R=\3/CU\0_&OQHU/X
M??#74](\,PZ,I^V:QJWE[6=<!AEU< !F"@*A8D$].FM\ ?CMXM\0^+/%WPY\
M?36&H:]I=G)<0ZII^P1W" *&'R *>'5@0!QD$9%9MN5-RCV;7RZFEDII/ND_
MF>B?LZ?'Y?C_ *'K&HC0CH7]GW8M?+-W]H\S*AMV=B8^F#]:]<KY$_X)R_\
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M#.6P[(A21=S'D2+P:^W:*.OE9+[M@_S;^\^'_P!I+X&^(G^+5I\09/ C^/\
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M(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?#_1?#T&FZ;I$=E$0;'1_,^RQ,S,[",R?,1N8G+<DDGC.*ZN@ HHHH ****
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M1I5MHFFO9V\:2O&\]Q('ED+2OY,8P"%4 X'- 'L=%%% !1110 4444 %%%%
M!7D/[67Q U;X8? ?Q!XCT75UT"_MIK*,:HT,<PM8Y+N&*239(K*<(['Y@17K
MU>>?'WX:W_Q<^%NJ>&=+U&WTK4;B:UN;>ZNX6FA1X+F*<!T5E)!,>."#S0!Y
M]\,?C9HFF3:+%-\4;[XK67B76?[$M-86RL8K?3KM;=YE@D-O''S*JD*2K?,
M.,U!XC^,A\8_&CX;6/A^XU.RTRS\8:MH&HDOY=OJ,EOIDKN%"L?,C27Y?F P
M\;8'&:K_ !V\-_$C4_V>_&[^*+C1]6\2:>MOJ?AD^"])NEGBU""59+<E))I"
MQ\T1CY< *7SQTWO!_P"SE/X=TCX,Q'4X_M/@N:YO]39XR[:A=75K,EPX;(P3
M-.[Y(/'% %O0?VKO"_B#Q!I%K%I.M0>']:U)](TKQ1/%"-/OKM2ZB- )3,H9
MHW5'>)48CAN1G5TC]H&SO/B%I7A+5?"?B/PQ<:RUQ'I-[JT5NL-Z\*&1U"QS
M/)&=@9P)43(4]^*\[^%/['\7PI\1:=':6'@&^T+3+R6ZL]4N/"JGQ BL[NB&
M[\S;O0OM$VS=A1QGFLWX:_L:ZMX)^(O@CQ%>ZUX;OCX7O;VX;4[?1'CUG6%N
M(9H]UY=M,Q=U,H. -IP>!P  ?5=%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5B>-_&.
MF?#WP?K7B?6I7@TC1[26^NY(XS(RQ1J68A1R3@'@5MUY'^UU_P FM_%C_L6-
M0_\ 1#T >*?\/:/V<O\ H9-6_P#!+<?_ !-'_#VC]G+_ *&35O\ P2W'_P 3
M7X1!:-M*YKR'[N_\/:/V<O\ H9-6_P#!+<?_ !-'_#VC]G+_ *&35O\ P2W'
M_P 37X1;:"/PI7#D/W=_X>T?LY?]#)JW_@EN/_B:/^'M'[.7_0R:M_X);C_X
MFOPCX]*?';22?=C9^_"DT7&J;D[(_=G_ (>T?LY?]#)JW_@EN/\ XFC_ (>T
M?LY?]#)JW_@EN/\ XFOPK73;AR,029/ &VEDTJZC<*;>12>FY:GGCW-?JU6U
M^5_<S]U/^'L_[.7_ $,FK?\ @EN?_B:/^'M'[.7_ $,FK?\ @EN/_B:_"1XV
MC^\K+]1BDP.XJKF?L[:,_=S_ (>S_LY?]#)JW_@EN?\ XFD_X>T?LY?]#)JW
M_@EN/_B:_"3'XTA7VHN+V9^[G_#VC]G+_H9-6_\ !+<?_$T?\/:/V<O^ADU;
M_P $MQ_\37X1XI-M%Q<A_0W=_M\?!RQ^#.G?%*?6[Z/P=J&IMH\%U_9DQD:Y
M568J8PNX#"-SC%<-_P /8OV<?^AIU/\ \$EU_P#$5^=GBU?^-4/@3_LH=Q_Z
M(GKXVVT-E0I\Q^[G_#V']G'_ *&G4_\ P277_P 11_P]B_9Q_P"AIU/_ ,$E
MU_\ $5^$>VEV_2ES%^Q/W;_X>Q?LX?\ 0U:G_P""2Z_^(H_X>P_LX_\ 0TZG
M_P""2Z_^(K\)-OTHV^]',/V)^[?_  ]A_9Q_Z&G4_P#P277_ ,11_P /8OV<
M?^AIU/\ \$EU_P#$5^$FVA5ZTN8/8'[M_P##V+]G#_H:M3_\$EU_\11_P]B_
M9Q_Z&G4__!)=?_$5^$>T9I2HI\P>P\S]V_\ A[%^SC_T-.I_^"2Z_P#B*/\
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MLYY*SL%%%%!(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2S7.[6\U;34QEG%6S7M'9KK=6TU_KN6F^/7Q2>X*1?$/QL863.Y=?O&*]/\
MIIU]<U1E^/WQ3N)&%G\2O&4X7B0#Q'>94CL2)< ^M5GT;4--L[BT6Y5,_O(?
MW6)9D1N2_/!+=CR0/>L VMTEO/J<=NUN;JYDC1F CC0]6?:?F)/3VK:ECJDM
M5/TU?]?\,=%',:LKN-1]E[SU]?ZZ=RY>?'#XW73$I\5/%Y40LX6U\0WBY.>
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3IZ5E9/K7H4VW!-GQV,C"GB)Q@K*^@O--YI>?6C)]:T.+0^SO%H_XU1> _\
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MR8"J6]@,UT'CJW838._ ]J15IS*RY##:?0TT$T!I?83;SQ2F.A6.ZG&0XZ4
MN6PV13L-?H+_ ,%9/^1?_9T_[%1O_0+:OSZD9MA]*_07_@K'_P B_P#LZ?\
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M%21Z?83:AI\K2*EX8<EYF'!ZE-V,#GCV JYK5O+X@BU630=0&G7>ERI)L\X
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M5B<G3P]:>EM':^KWNNRN]%\_+>\)ZA/H]O<6EI TTMB/+RTIBA9N 0Q;K@Y
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-<AU"QFNWOXK*UCVQR03(&\LG( >0C.X8'4]\5\95]K*/M6G%JVS?W;MZ_\
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M (MV D.6D95_K6JM*;5:*M]_]=>AM&TZC6(BN6_FW_P^_0]/^&5B?$'B:RO
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ:O_ !JB\"?]E#N/_1$]?(>E:6^IW*1KPF1N8]J^N_%F?^'47@3_ +*'<?\
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M;:/\0)])36;.-[FSCA\XB5L(H=E /8. ,\$L>N*\QL]->\L[I66.)T1=WG,
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M?0=6_L^\B69V%J6^8+V]ZZ_5+99K5+NWD$B,<JRGI7AUHNG5UV9^H9;6IXK
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M?>^M?4*:O<N>'J*DTFK-O9W9I:MY\.BWY8M\J'AJ\8\LKG(Q7MWC+%KX?NI
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM)_L"L\4$L02**8L[22<>8/WN-JS#@"OA_PKXCU/PW:W5]IFIW-EJ$D1MQ/
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MO4]6_P""C'_)['Q4_P"OZ#_TDAKYP1@L@)&X YP>AKZ/_P""C/\ R>M\5/\
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M34F]?3_(XIY+AJD6I-N_I_D?%5U^P)\>)KDW/_"'W4LS*8]\M];YP.F0)/\
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M_P"$-_;&_P"AI\+_ /?!H_X0W]L;_H:?"_\ WP: /R _X9/^-_\ T1OX@?\
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M0W]L;_H:?"__ 'P:CZK3Y^>VIG]3I<_M+:GYV1_\$T_VB5^]X#[YXU"VX_\
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M\&NN--15D=T::BK(_-C_ (=D?M'=/^$ ;'_81MO_ (Y2'_@F/^T=U'@!L_\
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M?_VJ/V*_ _[5RZ+>Z[=:GH'B71,_V=KVBRK'<1*6#;&# AE# ,.C*<[6&6R
M?(W[*^B:W\%_VZOB/\/?B-+;^/\ XF>)] :ZMO'4=S(TQB\I&^S/&_RHK+&O
M3&WRD495AMI_\$X=8L]#_P""<_Q\%_<+:O8WFMS7,<F0\2G2;< E>O)1P!C)
M*D=:^L?V8?V#_!'[,OB?5?%EKJNL^,/&>I1&"77-?G626.(D%E0 #&[:N68L
MWR@ @9!\Y^*G_!*'X9_$CQYKGB"R\2^)_"-AX@G^TZOH>BW$2VEQ)NW[E5T;
M;\Y+8(8 D[0.E %3_@FW_P )5HG_  3K6_\ "^GPZGXG*:U=:#8WC;8;JZ62
M58(W)= $:9-I^=1R?F'4>=?%+]K;]N7X+^!-3\9>,O@Y\/\ 1O#>F^5]KO?.
M$_E^9*D2?)%J;.<O(@X4XSD\ FOT,\!^!]$^&?@W1O"OANQ73="TBU2SL[56
M+;(U&!EB26)ZEB222222:^<_^"H__)B?Q-_[AG_ITM* /=?@CXVOOB5\%_ /
MB[4XK>#4M?\ #^GZK=16BLL*2SVT<KJ@9F(4,YP"2<8R3UKM:\J_9._Y-9^#
M?_8F:-_Z0PUZK0 4444 %%%% !1110 4444 %%%% !1110 4444 ?#/[<G[.
M?[1GC;XH:7\1O@KXZ-DVEZ:MC'X>MKYK"9CO=W.6/DS;R5R)2H&U1SC->*^"
M?^"JGQ2^!>M0>%?VB_AE?"XC)5M3LK7[#>NHQE_)?$,W7[T;1K@CZG]4*P?&
MG@/PW\1M#FT;Q3H.G>(M*F&'L]3MDGC/OA@<'T(Y':@#SCX(_M@?"+]H2.&/
MP9XTT^[U21-YT6[?[-?KC[P\B3#-CNR;EZ<\BO9:_/'XY?\ !''P'XHN'U?X
M6^(+WX?:NK>:EC<,UW8[@<C821+$<_Q;G P,**\@7XH?MJ_L'!H?%VEM\3O
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>8?M0:)J'B3
M]G+XF:5I-E/J6IWOAZ^M[:SM8S)+-(T+!411R6)(  KT^B@#^;K_ (8Y^.O_
M $1_QM_X(KG_ .(I?^&.?CK_ -$?\;?^"*Y_^(K^D2BE8KF/YN_^&.?CK_T1
M_P ;?^"*Y_\ B*/^&.?CK_T1_P ;?^"*Y_\ B*_I$HHL/F/YN_\ ACCXZ_\
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M\7?^"J3_  KK/A+^Q[\<M)^+'@F_OOA3XKM;*UURQGGGETR14CC6X1F9CC@
M DGVK^@FBCE0O:R:L?B3^W1^R3\9?B!^UE\1?$/AOX;Z_K6B7UY"]M?6EJ6B
MF46T2DJ<\\@C\*\'_P"&%_V@/^B2>)__  #/^-?T744R%)H_G2/["_[0'_1)
M/$__ (!__7H/["_[0'_1)/$__@'_ /7K^BVBBP^=G\Z7_#"_[0'_ $23Q/\
M^ ?_ ->C_AA?]H#_ *))XG_\ S_C7]%M%%@]HS^=+_AA?]H#/_))/$__ (!_
M_7H/["_[0'_1)/$__@&?\:_HMHHL'M&?SIC]ACX__P#1)/%'_@'_ /7H7]AC
MX_C_ )I)XG_\ _\ Z]?T644N4?M&?SI_\,,?M ;L_P#"I/$__@'_ /7H;]AG
MX_\ _1)/$_\ X!G_ !K^BRBCE'[5G\ZI_89^/^/^22>)_P#P#_\ KTB_L+_'
M\+_R27Q/_P" ?_UZ_HKHHY4/VLKW/RU_X)-_L[_$SX._&3QCJ7C;P3J_ABPN
MM"^SP7&HV_EI))]HC;:#ZX!/X5^I5%%48MW=PHHHH$%%%% !1110 4444 %%
M%% !1110 4444 ,EW>6^S[^#MSZ]J^.O''[+GQ8^-GB2_NO&GQ+F\.^'?.86
MNFZ*3&1'GC<W<U]D5\J?\% _&VJ^"_ WA.:TOI=+TN76X!J-]$2/*A!!))':
M@#S"[_X)T^#?"^J16UO\7O$.E:[=?-")-0P\C>N,\U[K^SW\+_BS\*?$,^E>
M)_%\7C#PEY7^C3S+BYC;L">]?G]\1)K?XV7WQ5^+S>(+W[+X:GMK+PW<03LD
M<L@QT'?-?JK\'=3U#6?A;X6O=44IJ$^GPO,&Z[B@SF@#L:*** "BBB@ HHHH
M **** "BBB@ KXP_:Z_Y.F^!/_7])_*OLJY1Y+>5(VV2,I"MZ''!K\V_BCX!
M^(7@_P#; ^%-QXS\71^([&[U*1K&W2+8;=?0^O% 'Z44M)2T %%%% !1110
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M372_L9_L[Z_\ =!\8R>(1X=TR\\3:O\ VF/#OA!)ETG2U$21!8?-PQ9@@+G
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MOWKZ%H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC[\=_$_B#6_"UK\3]?*66H^&X-VK2:3;S+96-K C_P#+64+)'DX&V0M\H&0
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MR/4+2.X"@8QN4'% '0T444 %%%% !1110 4444 %%%% !7QA^UU_R=-\"?\
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M110 4444 %?*O_!4?_DQ/XF_]PS_ -.EI7U57RK_ ,%1_P#DQ/XF_P#<,_\
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M?'W]KI\3/L%RFIZO;EKJ&[C.^ZEFV85A(Y9E50 @P*].U3]FKQ WQE\)>/\
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MRC>&#S_-EVCC@R+D\_,[C.5:@#[LHHHH **** "OE7_@J/\ \F)_$W_N&?\
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS['Y!X@9#EN1_5?[/I<G/SWUD[VY+?$WW>PM%%%?0'Y %%%% !1110 4444
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M )Y.37V%7G7Q]^"]A\?OAO<^#M2U&XTNUGN[2[-S:JK.&@G291AN,$Q@'V-
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M?_\ A!WW_P N:/\ A'/C?_T4/X?_ /A!WW_RYH_X:6\(_P#0(^('_AN/$/\
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M^-__ $4/X?\ _A!WW_RYH_X:6\(_] CX@?\ AN/$/_R#1_PTMX1_Z!'Q _\
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M "BBB@ HJE/K6GVMZEG->V\5U)]V%Y ';Z"KM !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9'B_\
MY%75_P#KUD_]!-:]9'B__D5=7_Z]9/\ T$T ?+G_  35_P"2.Z__ -AVZ_\
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M.:$$(7Q\Q4$D@9SC)J:BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX1TB?5-9OH=.L(1F2XN'"JOXFM2OD+_@I%87&I?#7PO!/YI\.2:U FKB+/\
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MA_V#F_G7[:T %%%% !1110 5'//';0O+*P2.-2S,W0 =34E8'C[_ )$?7O\
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MX:^"^IZ]K>O_ !<U#PK=3^#+V#3/"5OY2FXN1YK)>6Q=#NN0VV-5)VY"Y'-
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M_MK_ /)N/BK_ '(__0Q2>*]:T#P_^SGH%_XGT1]>T6&UM3/;K'OVC ^<CT%
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M+?1&(W5J^V2//=3ZU^=WCK]F^W^ O[4WP;,'B?6/$)O;U@?[4G,FS _ASTH
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M_P"":O\ R1W7_P#L.W7_ *&:^NJ "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *P_'.@Z%XI\&:[H_BB&WG\.7UE-;ZC'=/
MLB-NR$2;FR-HVY^;(QUR,5N5XY^V)X,\0?$+]E_XE>'?"R23:]?Z/-';6\/W
M[C&&:%?4N@9 /]J@#X6_9#/[)'PZ_:OM= ^'&H>-/'GBS61=:9IVJZA'"VFZ
M>@A=I/+DQ%(=T:/&) K_ "\ @,6/U7_P3SL?@C8_ YE^"-U<WNE_:V&JW&J\
M:D]T% S<C  .W;M"@)CISNKX@\#_ +7/P8\+0_LG6I>7PA/\.VOHO%EC)I$R
M2071L# \Y$:$2&:<,W&6&_+A>:^DO^"<+#X@_%;]H3XOZ#H,WAWX?^,=8M4T
M6*6'ROM;0>?YT^WIRTNXD9&^21<Y4T ?=U%%% !1110 5\J_\%1_^3$_B;_W
M#/\ TZ6E?55?*O\ P5'_ .3$_B;_ -PS_P!.EI0!ZK^R=_R:S\&_^Q,T;_TA
MAKU6O*OV3O\ DUGX-_\ 8F:-_P"D,->JT %%%% 'C?[7_P#R;KXM_P"W3_TK
MAK\U:_2K]K__ )-U\6_]NG_I7#7YJU^;\2?[W'_"OS9]EDW^[R]?T04445\H
M>\%%%% !1110!^KGP7_Y([X%_P"P#8?^DZ5V5<;\%_\ DCO@7_L V'_I.E=E
M7[9A_P"##T7Y'YI5_B2]6%%%%;F05\F?MY?\R-_V_?\ MO7UG7R9^WE_S(W_
M &_?^V]>5FG^YS^7YH^_X"_Y*/"_]O\ _IN1\F4445^?G]?!1110 4444 %?
MK+7Y-5^LM?59%_R]^7ZGX#XK?\P7_<3_ -L%HHHKZL_  HHHH _.7_@HW_R6
M[0_^Q=@_]*;FOE:OJG_@HW_R6[0_^Q=@_P#2FYKY6K^SN$/^1#A/\/\ F?/X
MC^+(****^O.<**** "NX^!?_ "6WX??]C#I__I3'7#UW'P+_ .2V_#[_ +&'
M3_\ TICK@S#_ '.M_AE^3+A\2/V+HHHK^$3Z4**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ KB/C)X2\&^*_AQXFB\<VEM+X>&DWB7UW-&#);6K0L)W1\%D(0$Y7
MD$ ]J[>N8^*.@Z/XJ^&?B[1/$5TMCX?U+2+RSU&Z>01K#;20NDKESPH",QSV
MQ0!\@?"WXO:IX@^)7P;T:X^!_AGPI\,_'D5Y'HMUJIBN-9EMK;3WN8IY(T79
M%Y@5/E)8X8\]"??/V;?BPWC8^,/"6K^#[?P%XS\'WZ6^K:'9O');F.93);74
M+H &CFC!/(!!5E/2OEB73_VBO#OB?X$W=O\ "O3OBEI?PWAODTWQ-X9\1VEK
M:^(+6>P:TM9"DIS;ML:-G;YT)R4XZ?3'[,?PO\;:#KGC_P"(WQ+CTVQ\<^.;
MJT>?2-(F:6VTRRM8C':V^\_?D DE+N."6XX H ]YKXC_ ."D]G\2;CX<W5];
MZ]8:'\.-/O\ 20]A9J[7^L7$M[$C).YPL<$896"KDNP^;  S]N5\Y_M_>%=:
M\9?LUZGI?A_1[_7-2?5])E6STVV>XF*)?P.[!$!.%4%B<< $F@"']LPZEXLD
M^%?PQLM7O="L/'7B=;+6+S3IFAN'T^"WEN9H$D4@H9/*521V)!R"0>&\#_#_
M $#]CG]JKPYX,\#2:AI_P_\ &GAG4KN3PS->S74%M?V+1R?:(3*S,I>.1U8;
M@#@$]% ]+_:Z\(^++FS^'OCWP3HDGB?7O ?B*/5Y-#A<+-?V3PR6]U'"6('F
M[)=RY_ND $D \3\-I_$G[37[2&E_$C5OAUXD^'O@GPGX>O=*L(?&%F++4KZ]
MO'C$S"#<Q2)(H\;L\E^,\@ 'A>G_ +/MMX\_9%UC]IS5=?UN'XZ2:1?>,K/Q
M/::G.OV!8?-GALHH=WE^0(HQ&593]YN0, ?H!\*?&7_"QOA;X.\6;%C_ +>T
M:SU38N<+Y\"2X&?]^OABWU3XN^!_V<M7_9<B^$'B?6_%4EE=^%]-\90VRCPY
M+IMPTD:7<MWN/E.L$AS%@G*CH3@?67BK]E?X>?$GX,^$/AGXWT3_ (2/PWX:
MALUM+?[5/:8DM[8VZ29@=&^X[C;G'S=.!@ \T_:(_P"3[/V1O^YN_P#37%7U
M57P!JG[+?PP_9K_;L_9A_P"%<>&?^$<_MK_A*/M_^GW5UYWDZ6/*_P!?*^W'
MFR?=QG=SG Q]_P! !1110!S/B#X8^#O%FH?;]<\):'K-]L$?VK4--AGEVCHN
MYU)P,GBOS:\;_M+?L]:=^V/HNH6_A73;KP'I>F3Z+?3V>BV[6<MT\H(N5C _
M>1H.-^-Q .T,,9_4B:%;B%XG&4=2K $C@C!Y%?C'XP_X)U>+=+_:8L?AAIVM
M:?/9ZK;2ZM9ZK<.04L4DVL9$"_ZT<#:O!)Z@=/V[PV_LO$U,9#.,5*FHTWRI
M2:7*T^=K?6*M9>;=G;3S<9SQ4?9QOK_PQ^M?A7X;?#VS?3_$'AOPIX:MI'C$
M]GJ>F:;;HQ1TX>.1%!PRMU!Y!]Z[2L+P'X1MOA_X'\.^%[*62>ST33K?38)9
ML;WCAB6-2V.Y"C-;M?CF*JNK6D^=S2NDWO:^G_#'H15EL%%%%<A04444 %%%
M% !1110 4444 %<%\<-=UW0?AOJC>&=-O=3URZ7[+;)8PM(\1<$&4[>1M7)!
M_O;:[VBL*]-UJ4J<9<K:M=;HYL32E7HSI1DXN2:NMU?JO,^0/V0-/\=?#_Q=
M>:-K?AC6;/0M50N9[BTD6."= 2K$G@!AE3ZG9Z5]?T45PY9@%EF&6&C-R2VO
MTOT/-R?+%E&$6$C4<XINU^E^GWW^\****]4]L**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "OE3_@H5\/O&7Q"^%^DVG@?39K[6[>_6XC>&8Q^5MY
MR?45]5U\Q_MY?$[Q/X#^'>B:7X2O?[+U?Q%J4>FIJ&/]0&/WJ /"M#^-'[8F
MEZ;9V<GP_P!+N/(C6,S.YW-@8R?>OO/P'?:MJ7@_2+K7K=+36)K=7NH(SE4D
M(Y K\F]8\#_'30=!\8:QJ'QAU%K?POJ$=O?P++AVB?!WK^!K]5/A)(DWPS\-
M21ZA)JJ/8Q,+R;[\N5!W'WH W/$/AW3O%6DSZ9JMI'>V,PQ)#*,JV#GFI?[%
ML?[)&F&UC:P$?D_9V4%-F,8QZ5=HH X?PI\$O W@?5Y=4T/PU8:=?R$DSPQ
M-SUQZ5>\<?"_PK\2K>*'Q+H=IJZ1',?VB,$K]#7544 9'AOPGH_A'1X]*T?3
MK?3]/C&%MX$"K^5<S8_ ?P!IOB8^(;;PKIT6KEM_VI81N#>H]Z[VB@# \8>
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M]+AM_P"S_M,KLEUN+AD0&) H0(O3/WATKZ%HH **** "BBB@ KY5_P""H_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^$-\9>'_ !;]AV?:_P"PM4@O?L^_=L\SRG;;NV/C.,[6QT- '5T444 %%%%
M!1110!\J_M$?\GV?LC?]S=_Z:XJ^JJ^5?VB/^3[/V1O^YN_]-<5?55 !1110
M 5\T>+?^4@_@'_L1[_\ ]*5KZ7KYH\6_\I!_ /\ V(]__P"E*U]5P[_%Q/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG_T$]1_\&#__ !55:*^.]OBO^?\ /[SX'ZQC/^@B?_@1:_X6!XS_ .@GJ/\
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M44 %%,FC,L+H':(LI =,;ESW&01FOS4U;QM\>=/^.3_#*/QQJ\NJG4!:12Y
M5HF^99R #A?+(<^@KZ3)LEEG+JJ%6,.1<SYK[=7HGMU]3W<KRJ6:.HHU(QY%
M=WOMU>BZ=?4_2ZBJVFVLECIUK;2W,E[+#$L;W,V-\K  %VP ,GJ< #FK-?./
M1V1X;W"BBBD(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY.+U#_L'-_.OVUH **** "BBB@ K \??\B/KW_7C-_Z :WZP/'W_ "(^O?\
M7C-_Z : /YS-6_Y#FJ?]?DW_ *&:K59U;_D.:I_U^3?^AFJU?Z5\+?\ (BP/
M_7J'_I*/CJ_\67J%%%%?4& V3_5M]*_:?_@E]_R:EHG_ %\3?^A5^+$G^K;Z
M5^T__!+[_DU+1/\ KXF_]"K^6O''^'@/6?Y1/<RS[?R/K:BBBOY1/<"BBB@
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M_P"AFOKJOD7_ ()J_P#)'=?_ .P[=?\ H9KZZH **** "BBB@ HHHH ****
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M#Z!HHHH **** "OE7_@J/_R8G\3?^X9_Z=+2OJJOE7_@J/\ \F)_$W_N&?\
MITM* /5?V3O^36?@W_V)FC?^D,->JUY5^R=_R:S\&_\ L3-&_P#2&&O5: "B
MBB@#QO\ :_\ ^3=?%O\ VZ?^E<-?FK7Z5?M?_P#)NOBW_MT_]*X:_-6OS?B3
M_>X_X5^;/LLF_P!WEZ_H@HHHKY0]X**** "BBB@#]7/@O_R1WP+_ -@&P_\
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M_A7_ /S-']E?\(+]N_Z!8\[S_M7_ &RV[/\ ;SVK[_H *^'?V O^3E/VN/\
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M&S"2)<G8,=/F"'\*\]_9_P#V;_$GP6\6W&H2>([*]TR[@,-S9Q1."Y'*,,G
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M-T.#X8ZUX+LO#&F3R1Q:GK+SC:T:D;BO/?%?H-X'\-V_@_P?H^B6I#06-K'
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M'0T 8>A^.KOX Z/\;/"-KJ=Q<V?ARV6ZTM[J0N\"RC:%R>P-9_B#]GJP\"_
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MPWS_ # '-?67P+_:D^&'[2G]M_\ "N/$W_"1_P!B^1]O_P! NK7R?.\SRO\
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M /A!XB\:WVO7>GZL+#4-1&L7_A>'5)4T2\O,@F>6T!V,Q*@D?=.,$$9%?1P
M4  8%+10!\J_M$?\GV?LC?\ <W?^FN*OJJOE7]HC_D^S]D;_ +F[_P!-<5?5
M5 !7P[^P%_R<I^UQ_P!C:O\ Z6:G7W%7P[^P%_R<I^UQ_P!C:O\ Z6:G7W^1
M?\B'.?\ !2_]/P.2K_%I_/\ (^X2P4$DX ZFOQD^)7QN^ &K_MB)XLC^'<VJ
M> XYG&HB*X,:ZA=>9G[:L!P-F1_JB5#CE@I)4_LS-"EQ$\4BAXW4JRL."#P1
M7Y$>-?\ @F_-:?M7:;\-]*\50Q:!K-E-K<%Y<Q,]Q;6B2[6B91P\@R #N4-C
M)V]*^Q\+L1E.'KXYYE7E3?LW;E<HKELW-^[KS15G'YM*YAC54:CR*^O_  Q^
MM7A_6-/\1:#INJZ3/'<Z5?6T5U:31#"20N@9& ]"I!_&OBW_ (*]?\FU^&O^
MQMMO_2.]K[+\(>%['P/X3T3PYI:NFF:/8P:?:K(VYA%%&L: GN=JCFOC3_@K
MU_R;7X:_[&VV_P#2.]KY3@;V?^MF"]E?E]II?>VMK^9MBK^PE?L?<5%%%?G1
MV!7+?$;X<Z9\4/#ZZ/JUQJ%M:K.MP'TVZ:VEW*" -Z\X^8\?2NIHJ91C.+C)
M73-Z%>KA:L:U"3C*.J:W3/S/_:NL/AO\,=4UOPEHZ^+G\:6J6S1ZA>:HTUJ%
M?9(006W']VQ'3J:];_9W^&/PC^/&FZU<^'!XWT>+39HXYDN=:=-Y=201L8_W
M3UKY\_;VCV?M->(SN5MUO9G"GE?]'C&#[\9_$5[_ /\ !,-,>%?';[EYO;4;
M<\C$;\_K^AKX#"N-3-94)07+=K;M>W_!/ZXSR%?"< T,VI8FHJW+3E?G>KJ<
MBE?R7V5LKNVY]G:1ID6BZ39:= TCP6D"6\;3.7<JBA068]3@<GO5NO(_&W[6
M'PJ^'?B:]\/>(/%7V#5[(JL]N-/NI=A90P^9(F4\,.AKK_AK\5_"OQ@T.?5_
M".J_VOIT%P;62;[/+#MD"JQ7;(JGHRG.,<U]Q#$4)2]E":<ETNKZ>1_+6)RC
M-*-!8[$X:I&G*SYY0DHOFU3YFK._374ZVO./VB/%VK>!?@[X@US0[O[#JEK]
MG\FX\M)-NZXB1OE<%3E68<CO7H]>0?M;?\F^>*_^W3_TKAKES2<J> KS@[-0
MDTUTT9\=G%2=++<34INTE";36C347JCR:ZU#X_6/PU3QQ<_$/0;?1GT^/40L
MEM$)=CH&1,?9=N\[E7&<9/7O6+\(O'GQR^-$.HOH?C[2+:6Q91-;W]G"DF&S
MAAMMF!'!'7C'N*]MM?A;:?%S]GWP'H=_J5[IUFNE:?/)]B909=MLH"MD'(R<
MX]0*/A3^S%HOPA\5?VYI.M:I-*T+V\EO.8_+E1L'#87/! /!'(%?'K+,?/$4
M94ZE1T6ES?O97NUNM>A\%')\SJ8K#SIU:CH.*YG[:5[M;K79::==3PSX96/Q
MDL_ >NZQH7C70]$T.QO;M[P75NA;S8^99!_HS\'''/X"H/A'\4OC9\9-4OM.
MT;Q[I=I>6D0G,6HV<"&1"V"R;;9LX)7.<?>'X>J?!WP#9_$SX*^)/#VH7E[9
M6-UXAO#*]@Z)(P656"Y96&,@9X[5T'P]_9/\*_#/Q99>(='UC7C>VNX".XN(
M6BD5E*E6 A!(P?4=JY</EF.J+#3H5)^R:7-^\DM^ROI;?S./"Y/F5582>&JS
M]BTN?][);_RJ^EEKY['.?!'QM\1O^%[^(? _CCQ!;:S_ &9I7VDBTMXDB\QF
MMV5@RQ(QPDQ&",9)] :^CJ^<? __ "?!\0O^P'%_Z!8U]'5];DKG[&I"<G+E
MJ32;;;LG9:L^XX><_J]:$YN7+4J13DVW92LM6%%%%?0'U!SNN_$3POX9N);;
M5/$6E6%Y&F]K6YOHHY<8R/E9@>>U?/Y_X**?"]6(-CXDSG'_ !Y1?_'J]O\
M$WP9\"^--6?5->\):1J^HR*J-=7EHDDA51@ DCL*^2=8_9:\,C]M73=#ALX(
M_"EQIO\ PD,FE*N(QM9HS"!_=,BJQ'3:Q6ON<CPV1XF-18WGYHP<M+)>[NEO
M>_2]CZW*:&4UXS6*Y[QBY=$M-TO7I<^P/#'Q/\*^,%L4TO7]-N+R[B$J6"WD
M37(RNXJT:L2& SD=L&NIKBO#?P4\!>#]8@U;0_"&CZ5J< 817=I:)'(FY2K8
M8#C()'XUVM?(XKZO[3_9>;E_O6O^%SYO$>PY_P#9[\OG:_X!1117(<P4444
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M8E)XP2 ?3%%%% !1110 4444 ?*O[1'_ "?9^R-_W-W_ *:XJ^JJ^5?VB/\
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M\^&WQ<T;2O#'B:]T73Y-#BNG@M2H#2M<7"ECD9SA%'X5D?LF_ME'1]4\0_\
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M^*?_  62_P"3BM*_[!:?S-?M97XI_P#!9+_DXK2O^P6G\S0!\!T444 %%%%
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MC_DFL?\ ]>Y'[H6?_'G!_N+_ "J:H;/_ (\X/]Q?Y5-7[ ?YR!1110 4444
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M** /U<^"_P#R1WP+_P!@&P_])TKLJXWX+_\ )'? O_8!L/\ TG2NRK]LP_\
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M/_)-](_[;?\ HYZ^4-:_U,'_ %V7^1KZO^#/_)-](_[;?^CGK[C@C_D:5O\
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M8"=#$:SC4FF]===];/5]>IZK7Y53?%/XB_#'X^?$/2/ NM2QZIK7B6XM9O\
M0K>:2\E6ZF6/AXR%):1N% 'S>PK] /\ AK'X(?\ 19/A_P#^%18__':^./@/
MX]^#EQ^T-\7/&6L_$;P=9:AIVM75QX<GU/7[6*SN6FENQYHRX\U0/+(*GC<#
MW!K]JX6QF&P-'&U<7!3CRQ]V233?-IH^E[-]M^A^S\/8JAA*6*J8B*E'E6CL
MTWS:;^=F_OZ'W!X3^%MK8WUEXEU_9JOCA]&CTK4=651&)P#N?"(%49;C( .T
M*.U?G7KG[.6N6O[44?PV@N;H075T)+>^9R6&GG,ADR<9*H&![%U(KOX?^"D7
MC>:ZCB_LKP;';O($^W27#K:!2<>89_/\L1]]^[;CG.*]3NOC_P##";]K+1O%
M#_$CP;)H47@]K"?6HM=M39)=&Y9O)\[S-H?:=P0G=@YQ7MX)YKPY4K2Q+B_:
M4I.*332Y?A:2V2OHMON/6PKS'(YU95VGSTY-6:=N79I+9*^BV/H;5/A#H5SJ
M>FZW8VZV/B71]*ETK2=5(\U[1'3:K;6R'*\XW9^^_P#>-?EQ\>/B5\1/&7B0
MZ%\1-4_M#4/#MQ<6R1_98(?*9F428,2+N!\M,$YX''6NP\:_M'>.-+^)&I:-
MH7QLMM6\.K?B"V\00ZQ;/8B)R-CR7"_NUVJPW\X4@YZ4G[;GBCX4/K/A'6O#
M7Q-\.^+=9O+%K36;NRUNTN#+);I"D<\@C<[7D#-G/!\L8'!S[/#M&&38R@L=
M5A4]M%NG+=P23>\DN523?75_,]3):4,KQ5)8NI&?M8W@^L4DWNUHFF_G\S]3
MHU*QJ"Q<@ %CC)]^*=7E/_#6/P0_Z+)\/_\ PJ+'_P".TO\ PUC\$/\ HLGP
M_P#_  J+'_X[7X6?D9#\3/B9XLT'XA:;X8\,:;I^HSWMD+E$NPP8L&EW -YB
M* %CSS[US7BCXJ_%7P?IPO=:\.:#96I<*K/(&+-V 47!)_ 5R7C;XZ>$]0^,
M6C^*_"'B#1?&MEIVG&"231-2ANHEF83@(SQ,P! D5B.N"/6J?QX^(7@+QEHN
MD:_<_$#0/#&K>68SH7B+6[>R9@"-S1"5UR06&2.",=",'\:Q^-Q=:KCJ6%Q-
M3ZQ3D^2G%I+DM'5)Q;DUKHG=H_6,%A,-2I8.IB,/#V$XKFJ--OFN]&U))7TU
M:M<?\5O'_CWQ!X4T]=<T^RL-%O6$T4^G$.DY'(#,)'Q@\[>#D>W'8Z=\3_BS
M'X;T_4)=#T8V,X2.*\U"18'F)X4D-.O+=?NC(Y'%<-J/BSP;IGP7@T3P]XLT
M[QO<:C<+<R76CWT=W90%&&Y5="5SD;<=3R3C@5D?M$?%SPUK%]I&H3^/M"L[
M::#?%H6H:G!:W5G@'>[1,X9E^5CYF,?+C( %>!.KB\+6Q%58BK*NH4[PC*+D
MGK=-\K34-[1C=<^NS9[<*>%Q%*A3]A3C1<YVG*,K-:6:5TTY]W*SY=-TCV34
MO'7QETC3KJ^N_">BQ6MK$T\TGF!MJ*"S' N,G !Z5Z+\*_%EWXX\!Z9K=_'#
M%=77F[TMU*H-LKH, DGHH[UX;_PN[1[#X+PZ39^)],\>WNI6DUL+S1KZ.ZM[
M6-E*;3-&65V4Y& >Q'0#.U\(_P!H+X7>!?AWH^C>)?B3X0\/:Q )C+I^JZ[:
MVUQ&&FD92T<D@89!!&1R"*^ZR7&2>;K"K$3G^Z<I1FXMPES1T]U)72;OVZV/
MC,WPL5E;Q+H0A^\2C*":4HVEKJV[-I6_"Y]"45Y5_P -8_!#_HLGP_\ _"HL
M?_CM:OA?]H7X6>.->M=$\.?$OP?X@UJZW?9].TO7K6YN)MJEVV1I(6;"JS'
MX"D]!7Z4?GYZ!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!/\ U_2?RH ^SJ6DI: "OQ3_ ."R7_)Q6E?]@M/YFOVLK\4_^"R7_)Q6E?\
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MP9A_N=;_  R_)EP^)'[%T445_")]*%%%% 'EW[1'_(D6G_7^G_HJ6OG#1?\
MD&P_\"_]"-?1_P"T1_R)%I_U_I_Z*EKYPT7_ )!L/_ O_0C7X-QA_P CG_MU
M?H?S+QY_R/\ _MQ?H7:***^0/A HHHH **** ,[6O]3!_P!=E_D:^K_@S_R3
M?2/^VW_HYZ^4-:_U,'_79?Y&OJ_X,_\ )-](_P"VW_HYZ^XX(_Y&E;_!^L3]
M'\.?^1U7_P"O?_MT3M:***_<#^C@HHHH **** "BBB@ HHHH **** "BBB@
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MO_U5ZQ16YY)Y8O[*?P52-8U^$/@5$4@@+X;LQT^D?_ZZ;)^RA\$II1))\'O
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MM]2TW0K6WN8MR%&VRI&&&59E//(8@]:]"HKUCS HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** (KH;K:4%=X*'Y1WXZ5^?">-
MF^%?CW7)]!_9DU74+MKQW;56C61ICG[RD]C7Z$S2"&)Y&^ZJEC^%?GI\6/\
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M)%6(@QJWH3BJ7B[XIZ_\?O!&A?#&S\#ZQ8:O+-;QZM->P;8+9(R"QW=\XXH
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MAB3P/>_$*_M6T_P[<*5FM[6!'"O(" V2)%7+*C,8W;: ZT ?9E%%% !1110
M5\J_\%1_^3$_B;_W#/\ TZ6E?55?*O\ P5'_ .3$_B;_ -PS_P!.EI0!ZK^R
M=_R:S\&_^Q,T;_TAAKU6O*OV3O\ DUGX-_\ 8F:-_P"D,->JT %%%% 'C?[7
M_P#R;KXM_P"W3_TKAK\U:_2K]K__ )-U\6_]NG_I7#7YJU^;\2?[W'_"OS9]
MEDW^[R]?T04445\H>\%%%% !1110!^KGP7_Y([X%_P"P#8?^DZ5V5<;\%_\
MDCO@7_L V'_I.E=E7[9A_P"##T7Y'YI5_B2]6%%%%;F05\F?MY?\R-_V_?\
MMO7UG7R9^WE_S(W_ &_?^V]>5FG^YS^7YH^_X"_Y*/"_]O\ _IN1\F4445^?
MG]?!1110 4444 %?K+7Y-5^LM?59%_R]^7ZGX#XK?\P7_<3_ -L%HHHKZL_
M HHHH _.7_@HW_R6[0_^Q=@_]*;FOE:OJG_@HW_R6[0_^Q=@_P#2FYKY6K^S
MN$/^1#A/\/\ F?/XC^+(****^O.<**** "NX^!?_ "6WX??]C#I__I3'7#UW
M'P+_ .2V_#[_ +&'3_\ TICK@S#_ '.M_AE^3+A\2/V+HHHK^$3Z4**** /+
MOVB/^1(M/^O]/_14M?.&B_\ (-A_X%_Z$:^C_P!HC_D2+3_K_3_T5+7SAHO_
M "#8?^!?^A&OP;C#_D<_]NK]#^9>//\ D?\ _;B_0NT445\@?"!1110 4444
M 9VM?ZF#_KLO\C7U?\&?^2;Z1_VV_P#1SU\H:U_J8/\ KLO\C7U?\&?^2;Z1
M_P!MO_1SU]QP1_R-*W^#]8GZ/X<_\CJO_P!>_P#VZ)VM%%%?N!_1P4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>;^.OC]X5^&/C
MC3O#OBU[SP];:E DEGXBOK<II$LS.Z_96NONQ3#8&VR;0PD7:6.0/2*\._:
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M03QY@N(F,4F'B8_=^8*>* /2Z*** "BBB@ HHHH ^5?VB/\ D^S]D;_N;O\
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M99-_N\O7]$%%%%?*'O!1110 4444 ?JY\%_^2.^!?^P#8?\ I.E=E7&_!?\
MY([X%_[ -A_Z3I795^V8?^##T7Y'YI5_B2]6%%%%;F05\F?MY?\ ,C?]OW_M
MO7UG7R9^WE_S(W_;]_[;UY6:?[G/Y?FC[_@+_DH\+_V__P"FY'R91117Y^?U
M\%%%% !1110 5^LM?DU7ZRU]5D7_ "]^7ZGX#XK?\P7_ '$_]L%HHHKZL_
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M10!G:U_J8/\ KLO\C7U?\&?^2;Z1_P!MO_1SU\H:U_J8/^NR_P C7U?\&?\
MDF^D?]MO_1SU]QP1_P C2M_@_6)^C^'/_(ZK_P#7O_VZ)VM%%%?N!_1P4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?/'QV^&/A7
MQQ\6M#FLOB?K'PK^*+:6;:UN='NDA?5+ 2L?):.93'<".1F;:OS1F4$\.N?H
M>N<\??#GPO\ %/PW<>'_ !?H&G^(]&GY>SU&!94W#HPR/E89X88([$4 <O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_,/]?>'/^@K_ ,DJ?_(GME%>9_\ "5?&_P#Z-H^('_@KOO\ Y$H_X2KXW_\
M1M'Q _\ !7??_(E']EXS^3\5_F'^OO#G_05_Y)4_^1/3*_66OQ._X2KXW_\
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MU_A*CAJJDFU^1^XM%? '_#Q[XW_]&7_$#_ON^_\ E;1_P\>^-_\ T9?\0/\
MON^_^5M?R:>X??\ 17P!_P /'OC?_P!&7_$#_ON^_P#E;1_P\>^-_P#T9?\
M$#_ON^_^5M 'U=^T1_R)%I_U_I_Z*EKYPT7_ )!L/_ O_0C7F_Q$_;F^-_C[
M0XM._P"&//B!8^7.)_,VWTF<*RXQ_9P_O>O:O.++]H7XWV=LD/\ PRG\0'VY
M^;[)?#OG_GQK\DXDR+,<?F7UC#4N:'+:]XK7YM,_#.+>&LUS/-_K6$H\T.5*
M_-%:Z=&TSZ<HKYI_X:.^-_\ T:A\0/\ P%OO_D&C_AH[XW_]&H?$#_P%OO\
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M_P#\KE?55% 'RK_QF]_U;_\ ^5RC_C-[_JW_ /\ *Y7U510!\J_\9O?]6_\
M_E<KS_\ X77^V%_POW_A47V7X'_\))_PC/\ PE?VKR]8^Q_9?M7V79NW[_-W
M\XV;=O\ %GBONJO*O^%%_P#&4W_"Y?[;_P"9,_X1'^Q?LG_3]]J^T>=O_P"
M;-GON[4 >5?\9O?]6_\ _E<H_P",WO\ JW__ ,KE?55% 'RK_P 9O?\ 5O\
M_P"5RC_C-[_JW_\ \KE?55% 'RK_ ,9O?]6__P#E<H_XS>_ZM_\ _*Y7U510
M!\*_'KXU_MA?L[?"?7?B%XDM?@?>Z+H_D>?!I<>L27#>;/' NQ7=%.&E4G+#
M@'J>#Z!_QF]_U;__ .5RO5?VI/@7_P -*? GQ-\./[;_ .$<_MK[+_Q,_LGV
MKR?)NHI_]5O3=GRMOWAC=GG&#ZK0!\J_\9O?]6__ /E<H_XS>_ZM_P#_ "N5
M]544 ?*O_&;W_5O_ /Y7*/\ C-[_ *M__P#*Y7U510!\J_\ &;W_ %;_ /\
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M+T6WG_91JOV9OLADSC'F=.M>^031W,*2Q,'CD4,K+T(/0T 25\8?M=?\G3?
MG_K^D_E7V?7QA^UU_P G3? G_K^D_E0!]G4M)2T %?BG_P %DO\ DXK2O^P6
MG\S7[65^*?\ P62_Y.*TK_L%I_,T ? =%%% !1110!]Y_P#!'G_DXO4/^P<W
M\Z_;6OQ*_P""//\ R<7J'_8.;^=?MK0 4444 %%%% !6!X^_Y$?7O^O&;_T
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M_:JOQ5_;,_Y.T\>?]LOY5Y&;?[G/Y?FCPL[_ -PJ?+\T>0T445^=GY2%%%%
M'V5_P2C_ .2L?$'_ *]H:_3ZOS!_X)1_\E8^(/\ U[0U^GU?IV"_W:GZ(_8\
MO_W.E_A7Y!61XO\ ^15U?_KUD_\ 036O61XO_P"15U?_ *]9/_037:>@?+G_
M  35_P"2.Z__ -AVZ_\ 0S7UU7R+_P $U?\ DCNO_P#8=NO_ $,U]=4 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_"OZ **\G&Y90QTE*K>Z['Z%PSQQFG"E&I0P"C:;N^97UM;NC^?_ /X2]_\
MH"ZK_P" C_X4?\)>_P#T!=5_\!'_ ,*_H HKSO\ 5W!^?WGV7_$8^).U/_P%
M_P"9_/\ _P#"7O\ ] 75?_ 1_P#"I]%\:?8?&/AG49=%U;[/8:C%<RD6CYVJ
MV3VK]^:*VHY'A</4C5A>Z\SS,S\4\^S;!5<#B%#DJ)IVB[V?S/D*W_X*5_#.
M."-#IVOY50/^0?)Z?2I/^'EWPS_Z!VO_ /@OD_PKZYHKZ$_'CY&_X>7?#/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\*#3])T[2]7\8-I$&CPO9QR%XK=0"S3,6<RL3T"K@+7VGHO['?PZT#X2^+_
M%K#JDECXN0C7=6N]0>XU._8J%WR7$FXD@# &,#)P.34?Q0_8U\ ?%+Q/:^)I
MI]?\,>)XK--/EUKPMJ\NG7-U;H %CF:/B0# Y(S@ 9P   9W[$7A;XA>!?A7
MJOAWX@6(TTZ?K=RNB6;:RNK26FG,$>.V>X^\YC=I%&[!"!!C %?0M<7\(_@_
MX5^!W@V/PQX0TYM/TQ9Y+J5IIWGFN)Y#NDFEE<EG=CU)/0 #   [2@ HHHH
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M"_8:^&WCSQIJGBVTF\1^"/$.KD-JE[X/UJ;33?L,_-,B$HQ.22=H))))))R
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M*D+^2\9"KF/@;@?FYZ5]%U%=6L%]:S6US#'<6TR-'+#*H9'4C!5@>""#@@T
M?)O[ .G_ !CA^$'P[G\3:MX/N/ATWA>V_LRSTVTN$U./,<?D^=([>6<)N#;1
MR<8KZWJMINFVFC:?;V.GVL-C96Z"*&VMHQ''$@& JJ   !V%6: "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHKPWQ];^.OAI'K%S\,;ZU\>>)+[5GUR\\)>+-:*2M9
MF'8;73GQBW'F*KKY@* LX) (P </\,=*U/\ ;3\+MXQ\=7'A_5O@WKWVM-(\
M#R:())_*29HH;N6]9]Z3$(S;8U7;O #9!IW['NC^);2\U5M&\8:W=?#?3K_4
M-&G\(>.(1=:OHM];S[1'!>H_[RW*$%0^_:NP!CDD>9?"56UCQ_KFD?"#XG:E
M\$/$U[<37NM?"7QYHBWJVMQ(Y>6YL(WE0B-F+-^Y=HSNSA1@#Z[^#/PHM/@[
MX+&B0ZE=ZY?W%W/J6IZS?A1<:A>SN9)IW"@*,DX"@8555>U '=4444 %%%%
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MGT][+Q% (&C_ +46+<MO)(G&RZMY5>(EAG8[J3\J8 /=:*** "BBB@ HHHH
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M:_G6TD7W=K8 6522.>!Q6[8^*/%'PH_9=\)7DWCYA>ZL+&/2S#H$=Q<6\+P
MK:0Q!@LSC'WY",\]\4W[M[]+?._]?GY7:UM;K?\ "W^?]:V^LJSM=\1:5X7L
M#?:SJ=GI%EO"?:;ZX2&/<>B[F(&3Z5\C>#_BEX_^(?@KXP^$M<UC4+74-)TD
M7=OJ&L:!%8WHB9"TL4MLK%5#H-JMDD!]V>@&)')XC\'_ +%NC:K=:U9:[:7=
MU9?V?I]_HMK+'I\?FN'3]XKB4D\[F&5[4)7?_@/_ ),[?H_N?E<_X/X)/]?Z
MZ?<BL&4$'(/((I:^:_$GBGXG>+/CYXD\#>%/%UGX:TVQT>WU!)9],BN7C8JH
M*H".=S.,EB< <#L>_P#V9/B3JOQ5^$.F:YKAC?5A+-:W$L*!%E:-RN_:. 2,
M9QQG. .E$?>3:Z?E=K\T3?1?+\5?\CU6BBBD4%<QX^^)GA?X7Z4FH^*=9M]'
MM9&V1F7<SR'N$106;'? .*Z>OF7X@-9R?MM^"(_$)B_LU="D;3%N\>5]J+R<
MKGC?P,=\A?:EJY1BNO\ DW^@]HRD^G^:7ZGL/PY^-_@;XLR7$?A3Q#;ZK/;K
MNDM_+DAE5<XW;)%5B,]P,<UE^+OVEOAGX%\0OH>M^+;6UU1&VR01Q2S>4WH[
M1HRH?9B,5Y5\0A%)^VIX(_X1H0MK$>D73:O]GQG9Y<@3S<=_NXSZIVQ3?V)/
M^$>F^%/B5]3^QMKC:G<G7C?!/,QD8\W=_!C/7C.[WIQ]Y<RTT;^Z5A2]UV?=
M?BKGOD/Q,\,W'C*U\*Q:JDNNW5B-2@MDB=EDMR>)!(%V8]MV?:EC^)GAF3Q;
MJ_AG^U8TUK2;07U]!)&Z+! 0#O,C*$QA@>&X[UX7=7>G6/[;GA>2&:V@TZ[\
M)>58-&RB&4;W*+&1P1@< =NE2>")K#5OVPOBM.[V]WI,.@V]M>2.5>%3B+>C
MD\=%<$'T.:6[C;JI?^2MV_)7&]+^7+^/+?\ -V/3?!_[2'PV\>>)AX?T+Q5;
M7VKMN"6_E2QB3;R0CN@5^ 3\I/ IWC']HSX<> /$HT#7O%5K8:M\NZW\J63R
M]W3S&1"J<$'YB.#GI7CWAW3(OVB/V@M%\9Z'9+8> O!2&UM-0$(C_M*<$_+$
M,?ZM21^7^UQR&@MI\GPP_:<;6S;_ -JG5;SSO.^_CYOL_7G&_.WWI.5H<SZ)
MNW=)I+TO>_7\2HQYI<OFE\VG?UM:W0^H?B!\:_!'PNLK&Z\3>(;;3H;X;K;:
MKSM,N =RK&K,5Y'S8QR.:WO"/C#1O'F@VVM:!J,.J:7< F.XA)P<'!!!P00>
MH(!%?)'P%\U?CMX!C\1A1(OP[@_L];C/&3SC=WV>9GVS7HO[$\>WPEXX-J%&
MC-XJO#8;,[3'A!\O^STQCWK9Q2E*/K^$N7_@F/-=)^GXQYO^ ?1=%%%9EA11
M10 5Q>F?&3P=K'Q!O?!%GK<<WBBS5FGL!#*-NT L Y782 PX#$]?0UN>,/$U
MKX+\*:OKUZ<6NFVLEU)SC(12<?4XQ^-?GSI'C*[\(VO@7X@7'A/Q59ZS!KT^
MK:SKUWI;Q:?=6UXP#+'/N.X; H7( .XX[9(>]4Y7M^K=E^MQRTAS+?\ R5W^
MB^9^CU%?+'Q,^+>H_!+XT>([^\UF[O/#7B#PR]_H]O/<M);Q7L2X"1*257=@
M$[>N\5Q>MWWC&W\*_#+PB-;\<:SXSU33)M8N;;2_$":=(ZR-O!DNIE<X105"
M8QP>123TO_5_>_\ D6&G?_AK+_Y)'VW6?KGB'2O#-C]MUC4[/2;/>L?VB^G2
M&/<QPJ[F(&2>@KX\\'^,OB3\0/V:7M=,UZZD\36WB1]/+?VK%%J%W:HF]H8;
MD\-*,YW#DA3C/0\[\4-1@\:?LOS7*^)O%EU-H7B1;2XM=?G7[3$S% 8KAUXF
MV'+(_P I!8C'%5;6R\ON?+_\E]_RNEM]_P"%_P#(^TO$'Q$\/>%_$&@Z)J>H
M?9M4UR1HM.@\F1_/90"PW*I5>H^\171U\V>+UU/X=_$3X$>&].\6:_J>GW5[
M?+=S:CJ+32WJ[495F88$@4L0H(X&*\FDN/&NL?#7XJ>-U^)/BBSG\+>(;J'3
MM/M[TB#:LJ$B3.2ZX<!4SM7;T.<5-URN3V7-?T32_4%>2C;K;\>;_P"1/NRB
ML3P1J\_B#P7H&J7./M-]I]O<R[1@;GC5CC\36W5RBXR<7T)C+FBI+J%%%%24
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7@W[77Q1\=_#7P_P##ZV^';Z)%XB\5>,+/PXLWB""2
M:UBCF@N7+D1LK9#0KZ\9XYR/>:^4?^"A'AJV\9:#\$M$O=2OM&M+_P")NF02
MW^FW7V:Y@4VE[EHY?X&_VNU &I9Z#^UZMY ;KQ7\)&M1(OFK%I6H!RF?F"DR
M8SC.*^@M%\7Z)XBU+5]/TS5;2_O]'G%MJ-M;RAI+24J'"2*.5)4AAGJ#FOG7
MP_\ L>^"/#NO:;JT7Q@^)%W+8W,5TEO>^.))8)2CA@DB'AD.,%3U!(KD_P!H
MKXB1_L?_ !VU[XEK'&-#\?>$KBVDCV?+-X@TZ-GL0S=,S0.\0&.3$HST! /6
MOC%^T&/#MQ\-_P#A#-1TK68-9^(EMX-UAP?/$ ,5RT\:E6&V9'A0'.<<@CT[
MKQ5\=OAQX%\3VWASQ'X]\-Z%K]R%,6F:CJL$%PP8X0[&8$;CP,CD],U\J>)O
MA?<_!_X,_LF>'-1)?7E^)6DWNL3.Q=I=0N+:_GNF+'EOWLCC/H!P.E>$?![X
M<^,?BAH'Q-OKZZ^!EQ?3>)-4C\3+\0-,EN-7MY4N)!B:7>/*15 \O9M"@<$,
M": /TZ\;_$;PK\,]%&K^+?$FD^&=+9Q&MYJU[';1,Q!(56<@%B >!SQ47@'X
MH>#_ (J:7-J/@WQ1H_BJQAD\F6XT>^CN4BDP#L<H3M;!!P<'!!KX0L9$T_P_
M\"OAN/#_ ( ^./Q&L?#-[>Z;XJ\2:H4T.#3EN?*C,"NKF>4HL2G:NX"$D':#
MMTOV#Y)X?VO_ (W6\R^ K:Y_LC3S>6?PS\P:/%.LLHVY8#=.H;]XP&-Y8<'(
MH _02BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ***J7&K6-G?VEC/>00WMYO^S6
M\D@62;8,OL4G+;0<G'04 >;?'"]^+N@_V7KGPPL-!\46]BLO]I^$]6D:TN-2
M4@;/LUYDI%(I!&)$VD,<D8%?)G[/GPT^$'[04?B>P\>V.J^%?VB)M<U#5=0F
MOKR73_$MENN'^RRV<F[/DQV_D*HCW1+MQ@@@MZ/^T9\3K_4OB+\0=&O_ (@:
M_P##CP=X \.V&JS0^%/(CU?7KR\DF6&.&66-\(K0I"$5<O).H+  "LW1OAW<
M?$F;X<?"+X_:2OBSQG/X5N/$\'C:WF2TU/3+R*\C!MXG@5&C,*SV_P"]!Q(T
M9++0![C\(?A+XM\-Z@S_ !(U[1/B1=:+*?\ A&/$T^CI;ZS;PR*ZRI.ZY3=M
M*INC"[P"6&37L-06-FFGV-O:QO+(D$:Q*\\K2R,%  +.Q+,W'))))Y-3T %%
M%% !4=Q EU;R0R F.12C;6*G!&#@CD?44LTR6\,DLK!(XU+,QZ  9)KXYOOC
M_P#'>\^&=Q\==%TOPI<_#")7U2#P>\$_]L7&B(23=&YW^6MP8U,HBV%0I"DL
MPY (-/\ V-?$G@CXB?#WP;:7-GXJ_9OT;6+OQ -"UIP;G1[CR)S! 6;_ (^K
M83S>8@<%U8?,Q"Y:71/%'PX^+_[8'PZ\1?!.>QU*\TFQU$>,]<T*T9+-M.D@
MV6UM<2A5229KD1O&F2RK"['@ 'ZL_P"$F_MSP3%K?AN2SO)=1L!=:2;V8Q07
M#R1;X [ ,P5LKDA20"< ]*;\/X]83P;I#^(M.TW2?$4UM'+J=II+%K:.Y*CS
M!&Q + 'C)].IZT =#1110 4444 %?+?[2WP%^(%GK7BOXI?!/51'X^U;07T7
M4M$U*4M!?PK&PA>V=F'V:XB9MRX(C8_> )9C]244 ?!W[0W@/X"_#C]G1/A9
M!IFB:;\5K#1X3X7TC1PK:^NLL@^RRQ/$/.+-<*I>3." Q8XK[>\,QZE#X;TF
M/69(Y=72TA6]DB^XTX0>81[%LU(V@Z8VK+JATZT.IJNP7I@7S@N,8WXW8P?6
MK] !1110 4444 >/_&7P;I?[27PYU#2?"GBNP@\0Z#K,-YI^K6<B7:Z9K%C.
M)$69 2,JZ%'1N0&;C.*\U7]L"P\(Z==>%_VDO!-U\/+QHFM[C4I;%]2\,ZNI
M+*3#<1JX <#<8IE5@'53DFL^^_8IU6Z^.'Q2^(WAWQ?J?PX\3:OJ-I>:'K.B
M7'G0S1BRCCFAOK)_W4T9N%DDVD G<I#CD#TGX4_%+XGV_C2#P'\4O +PZG)#
M+-:>-/"^9]"ODC SYFX^9:2G(Q&X8,0VUL"@# _8<LDL_ ?B]]"LM1T[X:7'
MB6YG\%6NJ0O#(NF-%$Q:..0"1(&N#<-&' ;:0< %:^D*** "BBJNJ6]Q=Z;=
MP6EU]ANI872&ZV!_)<J0K[3PV#@X/7% 'D7A/XNZ[\1OVC/$WAOP]':'X?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPO'S0V]N(K@'(R\T7! !/Z 5^5"?MZ?MMQM(R?LWJK2-N<KX%UL%C@#)_?\
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M7Y5_\-]?MO?]&Y?^6-KG_P ?H_X;Z_;>_P"C<O\ RQM<_P#C] 'ZJ45^5?\
MPWU^V]_T;E_Y8VN?_'Z/^&^OVWO^C<O_ "QM<_\ C] 'ZJ45^5?_  WU^V]_
MT;E_Y8VN?_'Z/^&^OVWO^C<O_+&US_X_0!]:>/\ ]J#Q5X5_;[^&OP/M-/T>
M3PGXE\/S:K>7DT,IOHY5CU!@L;B4(%S:1\&,GYFYY&/J"OR@^ .N?'WX]?\
M!0SX6?$KXI?"36/!UOI&F7NE/>0^&]0L;&.(6=^R-(]P7 9I+@KG< <J ,]?
MU?H 1E#J58!E(P01P:\^\ _L^_#SX6^,_$7BKPEX4T_P_K?B!(TU&:Q0QI*$
M9F!$8.U"2Y+;0-Q"DY(%>A44 %?)WQ^T_0/B!^U%X:\ _%2_OK'X>:EX=,OA
M^RAU6XTZUU761<D3QRRP/&S2QPB QQEMI\QR-S'"_17Q.TOQ#KGPY\3:?X2U
M4:'XHN=.GBTS46C5Q;W)0^6Y# C ;'45\-6?[2%SXR_9\LQ^U3\,XO$/P\U.
MW*S>,/#MM)/!:7<;O%)!>VR@3V5S'*C1^;'\A<@*5% 'K'BKX;_$#]D/3+[Q
MC\-_$NK>-_AUI<;WFL?#WQ-=M=SP6B#=))IMV^9%=%#,(9"RO\V#NVBOJ3P[
MKUGXH\/Z9K.GR&6PU&UBO+>1E*EHY$#J<'IP17R+\+?V>-2^+GP?T231_CAX
M^@^$OBC3UN)O"FIO8WUX+689:S&I!7E1 I,>T.2%^7(.:^P-+TVUT73;33[&
M!+6RM(4@@@C&%CC50JJ/8  ?A0!:HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M81GUX8CDM/%T,%Q+]U)+E3+:+\V,,T =5(ZYP"=W(!]=_ ?]H?6_B)XR\0^
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M!U.\Y/ITK?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+(J@F./Y2 [X4G"@Y(!3=E=CWT-^BO*M#^-5]?3>%KW4O#0TSPSXHF^SZ7J
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MQO<Q;<!MT8;<,9&<CO4=C\0?"VIW%Q!9^)=(NY[>!KJ:*"_B=HX5.&D8!LA
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MO\7+N']G^S\=W=M ^L76FQS0V=NC>7+=RX6*)5+%L-(RCKG!ZTNC:Z6_&_\
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MM<QXQG=$&W#&1U'>F!MT5SUI\1/"E_J]OI5MXGT:XU2X#&&QAOXFGE"E@VU
MVXX*/G XVMZ&LKPE\8_"?C;Q/K/A_2M8M)]4TN?R7@%S"S3X169XE5RS(I;:
M3@892.U):[ =M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%:.5YN?=W_4SM[JBNUOS_P SYIT'P+J%G\%=!@'AZY@U9?&\>H31BR99PO\
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M#C>2%*#'2N\^)UK;>*OBYX#\*ZM;I?Z!/;7^HW.GS@/!<R1")8A*A&'53(S
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MQ#;>"5NK&P%S=:A/9^(RJ2*EDL5TMF60%CMS-+&?G)^7/U&-XE\7Z]XY\=>
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M_P!G:SX@UO6'^W6U^;RYEA63=!(LD:!(XEB5<KSM0%L\G.""/3F_NW]/=O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5D:)X4TOP[?:O>
M:?;&&ZU:Y^UWLK2O(TLFU4!RQ. %4 *,*,<"M>B@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
K HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>ocgn-20191231_g2.jpg
<TEXT>
begin 644 ocgn-20191231_g2.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0 Z17AI9@  34T *@    @  U$0  $
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M[-"W&NW2-SR.L$;#"CHS MR M>?_ +&G@.WU'Q3=:A=1JRV:A$8C[F<EB/?
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M3+#./:N)\06/#<5VFAVJSZ;<2O>QZG?/)BZN8EQ"7''EQ]<(G0#).<ECN)K
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MQ(HPL?EZGJ)  ["OS+\-^.)/@Y^RGX\\9VM[#;ZEX:\"75S91&0+(\RV9='
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M+B'Q_P"'W'A_Q!(4U6T8(D4&Y\3H<#][C)Z#-?IA_P %B_\ DUC2?^QEMO\
MT3/7YT?#W_DHOAO_ +"]G_Z41U_H-]%/]YX?1E3]U>UJZ+5=.]W^)_.?C+4C
M'BBTHJ3Y(:Z^?9H_H+_X:NUG_HBGQB_\!-+_ /DZOG'_ (*G?M_?%+]F:/X&
MZYX$T]]%L]8O-5USQ?H&MZ?#-J%WHVEV@O+RW0H[K%-]G2=U9&;E%]Q7WA7!
M?'V^^&_@[P[!XJ^)$?A>&QT/S;>VOM8MXY#;FZ0P20P[@6+3HQB,: M(&VX;
M.*X3]T/@+]GS_@LMXS\0?M*^*M2\0+I6K_"7QOXA\)V/P]MTB33I=-TG5]3U
M;38]3FF92TPF_LP7*HVW"SHH(KM_AY_P7,/Q,\,^(/%&G_#S3T\)_#_P;=>-
M?%<\OB=/MQM5NM7@MH],A$.+UY/[(D=B7B5?/107(.?IWPA\%_@3^TK\'%_L
MOP3\/_$W@O5+&TT8VTF@P?9GMM/D8VUH\,D8*K;2%]D3*/*8G 4DUDR> ?V<
M= \)Z=\0!X0^'-KI7@&XN_#FFZK'X=A4:.[WTEG<6MOMBRJM=R2QE8QM+R/C
M.XD@'@GPW_X+6W5Y\3=-\&^-O &@^'=9O+N'S[O3_%\>H:5;6ESX;OM>MG^T
MM!$#,4L6A>,@ %TD5G1@#V?['/\ P52NOVI_C3X)\-ZEX(M_ NF_$+P%8>,_
M#UQ?ZG+/-XA,]G;W5S%9%+?[/*MI]H6.4/,DP.U_)V,&KV"Y_8B^ ?A7X;6W
MA&X^%?PKL?"<VMPZE!I,^@626,NIGY(I5B9-C3X.Q3@MCY1QQ6;XHC_9Y_9"
M^*NBZI?:7\/?!7C/6-/CTC3I[;2XHM0-C%Y<2HOE(7CMDQ"A8[8UQ&I(PHH
M^<?#/_!6;Q%X(_9$\1>+-6_X1;QEXZC^*?B?P?I&AM<RV4US:V%_J AC2*TM
MKF9Y%M;(DDQ@$*SNZ@'//ZI_P<3:/HO@N?4;CX5ZU_:=OX73X@OI<>K1M+_P
MB\NAPZA#J8?R]I#7DZ6!7HKJS[B!MKZL^)O[)/[-_@N6ZU;Q1\+_ (5VLWC;
M7+6.ZNKCPU:M)J^I2S$PF1A&6>1I'8[F_O.2<;C3OA7^RE\(?&_CR'XP>'M/
ML=6T_P 6?#VR\$Z;:_98ET9/#@DDN4@AMC&H$4IF!96RI1(P% !R >-_!/\
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MT_A46'@OQE-!KE[I>E:G<*UEY?A^]U&ZDMK:"0^?F?)BDE9K<2*L/ER<AP*
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MUDW@FST6?Q-%)HE@EEHNG")-0O\ 5KR2^FQY\TB0QPP66FW$LA=APR8)+*I
M/I&BOE>S_P""NOPU_P"%=P>)=1TOQ;HMI-I]KK+07=I$;F'3Y],GU+[6R1R-
MF-(+=U;:2?,:-!N+KG2^"W_!2C3_ ([:[X5TG1?ASX\_M+Q5>WJ1B1+06MI8
MV@LS/J+S^=L>W7[=%&/*+LTR2Q@$H30!]+45^:FE?\%6OC-=:7;2V_A?3M6M
MY(E:*^BT^01WBD B50&QAQ\PQV-% 'Z5T444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YO^T)^R
M/\/?VJ(+&+QYX?778K"VN[%$^V7%L)+:Z5%N;>3R73S89?*B+1ON1C&A(RHK
MTBB@#R[Q+^Q9\+?&-CJ-MJ?@[3;RWU9M3:[1Y)0)FU&)(;UN'X,D<:)D8*A0
M%VTS2?V)_AEHWP8\3?#^+PV9/"WC2ZDO]=MYM1NII]6N9!&))YKAI3.TC>3'
ME]^?D'->J44 >-M^P!\)Y_'&B^)+GPS<:AK7A][2:TN;[6;Z[8RVDLLMK-*)
M9F$\L+3S>7)*'9!(R@A< :'PW_8I^&OPEBTR/0_#TMO'HB7,6F+-J=W<KI<5
MQ$L,D-N)96$,7EHJ+''M5%&%"Y.?5** /-_#/[(?PW\'-I;:;X3T^U;1;FQO
M+(JTC?9Y;*Q-A:,,L?\ 56K&-0>!DMC=\U<[9?\ !._X-Z;XETC5K?P3:P76
M@P6\%@D=[=+;VQ@MI;2&40B3RS.EO-)$)BIDVMC=P,>U44 >=^-?V4_ ?CWX
M?>%_#-YHKV^E^!S WAUM/OKBPN]#:&$V\9MKB%TFB(A9HSM<;D8JV02*YZ7_
M ()^?"%_#5GI,?A".UMM/%F+:2UU&[M[J#[+)=R0E9TE$H;??7I9M^Z3[5+O
M+;C7LM% 'E?A3]B7X5>!]+TNQTGP5I5C9Z*=+^Q0QF3R[<:;&\=B "V-L*R/
MM!R,L203S4?PG_8@^&?P*\-^)-+\(^'FT>'Q5ID.CZA(;ZXNII+.".6*WMU>
M:1RD4,<TBQHN%16P!BO6** /)OA=^Q=X%^&VC^$PVEKJNN>$].TZP@U>=G6X
MF-C83V$$I56V!A!=7(  P#.Y'."+>B?L8_"_P[86=K9^#=+CM;"6RF@A8R21
MHUG9-86V0S$$1VS-& <CYBQ!8[J].HH \W^&W[)?@3X41^'5TC2[YO\ A$9)
MGT,ZAJ]YJ#:0)8!;-' ;B5_+C$"B-47"JN0 ,G-/XL_L3?#'XWZGJ%]XE\+I
M>WVJ745Y=W4-]<VL\[QVDMD 7AD1MAMIIHFC!V.LC!@<YKU2B@#P?1/^"=OP
MXM_&/BS4]4T>SU:U\1>%;+P'9Z<8/(M]&\/6J?)81%3N.96>1I2P?B%00(EK
MI]3_ &4=#@\*7UOH5_KFC^))]!NO#MKXFN-2N-4U:PMKF02R%)KJ21F;S K@
ML3@HG90M>HT4 8'@'X7Z#\,O NB^&]%TVVM='\/V$&FV,&P-Y,$,:QQKD\G"
MJ!D\\45OT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
544 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>ocgn-20191231_g3.jpg
<TEXT>
begin 644 ocgn-20191231_g3.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0 Z17AI9@  34T *@    @  U$0  $
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M':O:OVD/VK9/AI^P_JGQ=\+VEKJ&S1;;6-/@O@WER).8MHD",#PLG(!'(ZT
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M1N>5EW8S@=*^M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3?@9X?\ B]XE\):IKL-S=2^"]2_M?381,5@%T$*)(Z='*!B5ST)- '84444
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M(UX6_P#3MK-?8E?'?PO_ .4[OQ>_[(UX6_\ 3MK-?8E !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?*/@[_@EAIO@']HK
M_A-K#Q_XJNO#NBZIJGB?PIX'OH[>30_#>O:BLHN;]2J+/,"9YV2*20K&9Y2F
M"V1]75\ ?\%=/V@='^''[4?P7\*^/?CKXS^!WPQ\0:7K5[>WWA*[:RU"^U*
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MW4,LBQQNQ+J(SC <G K[JH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "OS?_P""M?Q.UK]E+PIX:T_3_BY^T5>^(+.TUKQ1J">%
M;G0;=H=&%_!YMU>R7=DZ^3:->6]M!'"OF.K#=N(9Z_2"OAG_ (*D_L_>%_VW
MOVG_ (2_!'5K'7--OO$V@Z_J>H>*-)U^32+NPT>'[&D]E&H1TO//N)+1FAD&
MU%@\P<J* /2?^"9.OWQ\._$OPOKOC+XK>+O%'@;Q?/HVJ#QXVFR7EGB"&6!K
M=["&*)[6>WDBG0L"X,SJV"N!U?[5_P"P?H/[5?BK0/$G_"7_ !$^'OBSP[:W
M&G0:YX-UHZ;>3V-P4::TERKI)&S1HP)7>C#<C*<FO-_^"1FE6G@/PC\7/!%Q
MI=]'XT\%^/[NR\5:[=Z_)KLWBV[DMK:>'4'NI%5][6DEM&T)5?),.P#:!GZZ
MH XCX-_LY^#?@/\ ![PWX#\.Z+;0^&_"MH+33X+@?:71>K.SR99Y'8EW=B2S
M,222:^<?^"%4:Q?L%3*JJBK\0O&H55&%4?\ "3:EP!VK[%KX[_X(7?\ )AT_
M_90_&O\ ZDVI4 ?8E%%% !1110!S_P 2OA1X7^,OA2\T'Q=X=T7Q-HNH0M!<
MV6IV4=U!-&V,JR.""#@'Z@'M7Q1^TY\!O _AK_@L!^Q3I.G^#?"]CIFE>&?'
M26=K!I4$<-LL%KI0@"*%P!&'?9C[N]L8R:^]Z^-/VN/^4T'['/\ V+?Q!_\
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M"0/+'=O_ +# E3C:1WS7Z'445Q5JTZL_:5'=OJRDK:(****R&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %?$'[=?_!1GX?\ A#Q=INF^
M'M+_ &>?BW>Z>UQ;:I'XC^)NB:)<:#,CJOE>7=+(Q)(;<!MVE,$5]OU^1.A?
MMN_![2_AUX%N/&<G[/%]X]\0?'?5O"?BQ=:TG25O[/1%U758UEE3:K1LL4%J
M/.D'(8$DELT ?67_  1QA_M3X<_%#Q-')\*M-L_&7C:?5[7PSX!URUUO3O"Z
M-:VT9AENK95C>XE>-KAPH"CSQCJ:^Q*\U_9A\2?"'Q-X/OIO@W=?#V[T&.\*
M7C>$#:&T%SL4D2?9OE\S9LZ\XQVQ7I5 !7QW_P $+O\ DPZ?_LH?C7_U)M2K
M[$KX[_X(7?\ )AT__90_&O\ ZDVI4 ?8E%%% !7Y*^%/^5B7]KK_ +$[PG_Z
M26]?K57Y*^%/^5B7]KK_ +$[PG_Z26]?B_TAO^3>YE_AI_\ IVF>UP[_ ,C&
MEZO\F?55%%%?Y1GZ\%?-_P#P5?\ ^3._^YV\)?\ J06%?2%?-_\ P5?_ .3.
M_P#N=O"7_J06%?<>&/\ R6&5?]A-#_T[$\_-O]RK?X9?DS]4****_P!C#\7"
MBBB@ HHHH ^._A?_ ,IW?B]_V1KPM_Z=M9K[$KX[^%__ "G=^+W_ &1KPM_Z
M=M9K[$H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KXS\>_ME?L':'XYUJR\2>+/V=8?$5K>36^J1WT.G&Z2X5RLJR[DW;
MPX(.><U]F5^<O_!9N3Q9HGQ+\)^'_!NN:A\.[/5_"/B7Q!:W?AW0;2XOO%.N
MV"6UQ#I;22P2;-]I]NE4#:7:/&20!0!]?_L??%;X)_%OP)J5]\#=2\ ZIX<M
M[XP7TGA-($M5NMB$A_) 7S-A3KS@BN0_X*>?M>>-/V+OV8=6\8>!O H\9:M9
MH999KNZ2VTS1H%9!)<7+;A(_#82*(%G;@E%!8><_\$7_ !/I/B?P!\4G\._$
M3Q)\7/#-OXN5=*\7:JD<2ZA"^G6<IMXDBBBC'V=Y'A<HN&=6)PVY1[M^W9^S
MUJ/[5_[(WCKX=Z3J%EI>I>*]/^QP7=VK-# WF(V6"@MC"GI0!ZM:2F>UCD/5
MT#'\17R!_P $,%*?L(7"L"K+\0_&P(/;_BIM2KU_]JK]@?X7_MMZ3X>L_B9H
M>J:W'X8,K6 LO$.I:1Y32B,2%C9SPF3/EI@/NQ@XQDY\/_X(!^&++P1_P3EL
M]%TV.2'3='\<>,+*TC>5YFCBC\1ZBB*7<EV(50-S$D]22>: /M2BBB@ K\8?
M''[1GP__ &=O^#A;]JRZ\?\ C;PKX)MM4\)>%8;.76]3BL4NG6RMV94,A&X@
M<D#H*_9ZOBG]M7_@W\_9I_;[_:6M/BM\0_"^M77BC?#_ &J++69[:VU^.&*.
M**.Y0'(54C5<PF)B,Y))S7R?'7"5'B?(L1D6(J.G"LHIRC9M<LHRTOIO&QUX
M'&2PM>->*NXGDO\ P\S_ &<?^B\?"/\ \*FT_P#BZ/\ AYG^SC_T7CX1_P#A
M4VG_ ,73Y?\ @TP_8UDL_%T:^$O%2-XFD#V4@\1W&[PT 2=MGS@@YQ_I F.
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M\LZ /L:BOCG_ (>H^//^C,_VIO\ P T+_P"6='_#U'QY_P!&9_M3?^ &A?\
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M=.L]'T71;6.RL+&TB$-O9P1J$CCC1>%55   X %:5%% !1110!Y_^T=^U/\
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ME=)<2L@C/VN]F@=-C-YN-_.,C]/_ (EHTOPX\0*J&1FTVY 4?Q'RFXH \.^
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M#6UF9]/2^6\9C*";54DC0L 7WN $(^:O4(K^">X:&.:%YD4,R*X+*#T)'H:
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MP]U,=2O%;SQ]JC!5UF8M(2RBO4OB=^S7\4_$W[0-QX@TGQ EOX;DOH)TMO\
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$4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>ocgn-20191231_g4.jpg
<TEXT>
begin 644 ocgn-20191231_g4.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0 Z17AI9@  34T *@    @  U$0  $
M   ! 0   %$1  0    !     %$2  0    !          #_VP!#  (! 0(!
M 0(" @(" @(" P4# P,# P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,
M# P,!PD.#PT,#@L,# S_VP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" $4
M 7P# 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+
M_\0 M1   @$# P($ P4%! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T? D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"
M! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 5
M8G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F
M9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:W
MN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!
M  (1 Q$ /P#]_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHJAXJUBX\/>%]2U"TTN^URZL;66XATZR:);F_=$++#$
M9GCB#N0%4R.B L-S*,D %^BOF'5?VB_BA>WTWF^+_P!FSP'<6DKQ2Z)J.M7&
MM72,K$;);A9+189.,,HAD",2 7VY;U7]G/XL>*OB?IVH?\)-X=\/Z?\ 8_+-
MIK'AWQ#'K6BZTK&0'R9"D4Z21^6/,22$*OFH$DEPY4 ])HHHH **** /S_\
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M_;S6,ZFST4ZOJ6L+K#3%"AMI[.>*))=^UYKH0Y\P.B@%S_@ZO_8L\1?MA_\
M!.;1?^$3F:?Q#X6\;:-]BTG=M_MJ;4KN/2(8%)(19//OH2&<A0HD&1G-?@#^
MPM_P3H^*T7[9'AW0/&7ASQA\+8-$\;^%]$U_4[ZS:PU'PU-J=YML95BF ;<X
MBE>-]I3,8).#S^^O_!7#]J/XV?"C]M?X+_#/Q!KG[/\ 8?!OXL?%7P7_ ,(I
MIOV+7Y?'>J_V=K^@7-Y^]2-M,B\NZ96_>NFZW.%W2\5X?_P<!Z?XS^$/[;GB
M;5O!>CZ3>6_CWX4Z?XJOIKR^>UDMKKPEKJ7QN+<+&XFE6VN$0QL4_=M(P?*A
M6^MX$Q4J&?X7E:7/+V;;2:M43INZ:::M)[HPQ4;TI??]VIZ7^QW\;O$?[-'_
M  3M\(_ME?&;X]?'CQYH=A'.VK>#;;^SKBSOFEO9M,A 1TA8[&>.;F=<-'GD
M?*?!/A1_P<P_ GP)_P %%OB]\7;SPG\6Y/#?C[PWH.CZ?;0Z7I[7T,UC]I\Y
MI4-Z$5#YR[2KL3@Y"\9\_P#&7Q*^.WCG_@V'M[9OASX#C^#@C!_X2"'Q/<2Z
MXJQ^(F^9K#[((POVE2A/G\1_/U^6OROM?V:/B1>VT<T/P_\ &TT,RAXY$T*Z
M974C(((3!!'>OZOX)X'R+/O[5Q&;>Z_;UL.E%QII4H3A.*2BDKJ7VG=VT9X6
M)Q56ER*GV3[ZM-']I'P4^*^F_'GX->$?'.BQWD.C^,]%L]=L([M%CN$@NH$G
MC$BJS .%<9 8@'.">M=-7YY_L40_ML?![]C;X2IINB_ 7Q]X;M/!.C+::/J$
MVJ>%_$-G$+&$);32,MQ;M+&H",Q6/+ D@=*]0C_X*1_%+X=2)'\3/V1_C5HN
MX<W7@R>P\:VJX[XM94N-OI^XW'^[7\K9AP?76*JT\!4IU8J4DDJL.:R;LN23
MC-NW:+/<CB%RIR37R?\ PQ]>4V:%;B%HY%5XY 592.&!ZBOE;PG_ ,%L?V:=
M=U6#3=8^(\/P_P!8F.UM/\;Z7>>&9H6[AFO8HH^,C)5RHSUKW"7]I?P/=?"/
MQ!XXT?Q+HOBGP[X:TZXU2\N-"OH=0'E0Q-*^TQN5+%4. 2,FO$Q?#^:8248X
MK#S@Y.RYH2C=O:S:5[]+&D:T)?"T?!'[4?\ P3'_ &>?"W_!3']E7PSIOP9^
M'-CX?\56_C%M8TZ'1(5M]3-MIUM) 94"X?RW9F7/0L:_1#X3_"/PO\"/A]IW
MA/P9H.E^&/#.D*ZV6F:;;K;VMJ'D:1PB+@+EW9CCJ6)K\3?CS_P<W? ;XH_M
MQ? 'XF:?X1^+L.@_"N'Q)'JT%QI>G+=W!U&S@@@\A5OBC;6B8OO=, C&X\#[
ML^%'_!P/\%?V@_AAI&I_#S0_B5XV\;:\9A9^ =(T-;SQ!$(Y&C\VZ\F5[6UA
M) ;S)IU&QMV."!^I\8<'\9SR_ 1QU&M*,:;4N9MI3]K7:<KMI-4VO>>BC:[2
M.'#XC#\\N5K?\++]3[HKQ;]J+_@H1\)?V0+FUT[QCXJA;Q1J6%TWPOI,$FJ>
M(-5<C*K!8VX>=MW0,5"#NP'->/'X2?M4?MJ#S/'GBZS_ &:/ MSG/ASP/=)J
M?B^YC/\ #<:NZ^1:MQD?9(V89_UOI[5^RW^P3\)_V-K:Y;P#X/L=.UC4<MJ6
MNW;O?ZUJKGEFN+V8O/)N;YL%]H).% XK\^_LW*\#KF%;VL_^?=%JR\I56G'_
M ,%QJ)_S)G7SSE\"MYO_ "_SL>*_\)U^U=^VMQX7T/3?V7/ -SC&K^)H(M;\
M;7L9YW0Z>K&TL21E2+AY74X.SM7H'[.G_!+SX5_L_>-5\:75GK'Q(^)C >=X
MW\<7S:WKA8=/*DE_=VRC) 6W2-0.,8KZ*HK#$<38ETI8;!1CAZ4M'&G=.2[3
MFVYS7E*3BGM%#C15[RU?G_EL@HHHKYPV/A_]F;_E/-^U)_V3_P %_P ]0K[?
M=1(I5@&5A@@CK7Q!^S-_RGF_:D_[)_X+_GJ%?<% 'QO\2/V#?&7[)GCO5/B5
M^RK-INDSZI.;WQ+\+-1G^S^%_%C_ ,<MH>FF7S 8$L8\ER%\Q ,L?6OV.OV]
M/!O[8EIJFFV,.I^$_B!X680^)_!.OQ?9=<\/2\#]Y$?]9"V04GCW1N",$'*C
MVZO!_P!L3]@+PM^UG=:7XDM]0U3P#\5/"H+>&O'?A]A#JVD-S^[<_=N;5LD/
M;3;HW5F'RD[J^LIYQALRBJ&<M\ZTC62O)=E47_+R*VO_ !(K9R24##V;AK3^
M[_+M^7YGO%%?'_PA_;^\4_L_?$C2_A7^U)I^E^$O$VJS?9/#/C[3P8_"?CAO
MX4#L?]!OF'6VF(#,#Y;,&13]@5X^:9/B<!-1K).,E>,HN\)KO&6S71K>+TDD
MTTM(5%+8****\LL**** "BBB@ HHHH **** "BBB@ HHHH **** "O#_ /@I
M#XM\3>"?V*O'%]X0DU^'7&BM;1)]#MIKC4[6">\@@N9K9(5:3SH[>25U9%9E
M90P!Q7N%>-_\%!_&7BGX?_L9?$#6/!MQJ5CKUGIP*7NGV_VB\TVW:5%N;N",
MHX>6"W::5%V/EHQ\K?=(!\=_M6M\"O!O[*/CW4O@SH?Q2T/XR:'X;O+[PAK>
MD>$O%,>N7FKV]N\EDD]U+;%KM99TB22.Z:2.5699 RDU^A4]OJ7C/X:>7%J%
MUX=UC4].&V]M8(WETZ9X_OI',KH2C'(616'&"#7YL_'+XZQ_$'X??%3QE\./
MB_XVU'1_ VCV/@KX"G0/%U]>Q^._%T-C/>3R;DF9=>$DDMI:R_://BB%C>,2
MC++(GZ>Z6]Q)IENUVD<=TT2F98SE5? W 'TSF@#\R;3]IO6OA!/XN\,:C^T5
M^TAXUNH==\62)J?A[X9Z=>PK'87K?;;:W>2SD:1['ST@81?)OB<1(%0HGZ$_
MLVZA8ZM^SMX!NM-U?7O$&FW7AS3I;35-;E674]2B:VC*7%TZ@!IY%(>1@ "[
M,17QKJ7A3X<ZYJOC;2O$7PI_:&\$:MI_Q U_5;*_\'Z=XAN+:X>Z:6WN+ZRN
M((0J17\+M+-"%,?GRR2(781W#?:GP,\+Z#X'^"7@[1?"NDW6@^%]'T.RLM'T
MRYMY;>;3K.*!$@@>.7]Y&T<:JI5_F4J0W(- '54444 %%%% 'R!_P5PUG[%I
M?P7L_P#A)/B!IGV[XJ^"_P#B4Z1X<^W:#K6SQ?H!_P")I??89OL/E??@_P!*
MM/.D)3_2,>6/SZ_X.QOVH=?^!O[1?P6M](M-(F0>$/%%E(US"[M/;ZO;?V;>
M0MA@"AAVNN "LD:MD@8K]!?^"N'P[\=^)-+^"_B#P_\ $7_A&O!/AKXJ^"_^
M$K\*?V!;WG_"9>?XOT".S_TQR);/[+,&E_= ^=NV-@"OB[_@ZR_X)Q_$']H_
MPSI?QJ\-OH<GA7X0^$[Z?7;>:Y=+XQK*)F>)-A5@(]Q.6!^4\=*_2O"2MDU+
MB>A4SYQ5"*DVY_"I*+<7Z\UK>9QX_P!HZ+5+?R/S_P#^"4/[<WC+]H?XP_LN
M_LM^*X-%U'X,^%_&#7C:+]G91K,SSW%Y&;Q@_P"^2*>5G2(@1DA=ZOM&/ZD*
M_FK_ .",?_!OWXZ_:6UOX1_&KQ+#X#UKX+:]<7%QJ>EWM[,;J]LT:XMI(FB6
M/!+.A &\#!!R*^W_ (!?\$=?V8O$W_!8O]H7P'?_  8\&W7@_P +^"_"NH:3
MI3PR?9[&XN3>^?(@WYW/Y:9R?X17U?CSFV1XW-J#R"I"=+DE*7)M[2<Y2DW_
M 'I:-O=JW1(Y\KIU8TW[5:^?:Q^NM%5M&T>U\/:/:Z?90I;V=C"EO!$GW8HT
M4*JCV  %6:_"CU#.\4^$-)\<:/)I^M:7IVL:?+]^VOK9+B%^W*."#U/;O7Q[
M^W)_P2%_9S\4?L_?$7Q!IWP8\)Z1XKLO#6IW=A=^&K1]&NFN5M96C/\ H1B\
MPEPN58,'/!#9Q7VG39(UFC96565AAE(R"/0U[&3Y]CLLK1K8.K.%FFU&4HWL
M]G9K<SJ4XS5I(_AG_L*^_P"?.Z_[\M_A7]0O_!K?X/A\-_\ !)CPW>+I4>GW
MFK:UJ4T\WV40RWNVX:-79L OC:5!.<;<#I4/[8'[%GP;T3_@K-^QOHME\)?A
MG9Z/KEKXY.I6,'A>QCMM0,.F6C0F:,1;9/+9B5W [221@FOT%\"^ ="^%_A6
MTT'PSHND^'=#T\,+73M,LX[2UM@S%V"11@(N69F. ,EB>IK]>\2/'#$<6Y4L
MKGA%12FIW4W*]DU:W*N]]^AY^#RU4*G.I7T[&M117G_Q]_:O^&/[*V@#5/B5
M\0/!W@2Q92\<FN:O!8F?':-9&#2'MA 23VK\)/4/0**^+F_X+1:'\7W%O^S_
M /!_XT?'Z2?Y;?5='\/MH?AIG]&U34S;P[?]J,2 CD9'-./A_P#;F_:2;=>:
M_P#!O]F70;@;UATFTD\=^)8!_<:6X%O8*WNL4H'7GI0!]EWE[#IUG-<7$L=O
M;VZ&2661@J1J!DLQ/  '))Z5^<O_  65_P""X7P[^ 7[&7Q.TKX+?%+POXH^
M.$>FK!I5CX==];DTO?/''<W,KVH>*W:"W::56G= 'C08)(4^HV'_  1!^&OC
M^ZCOOC=XR^+'[16HJXF$7CKQ1.^CP2 Y)BTRT\BS5<_PM$^..21FOIGX?_LX
M?#WX3_#FY\'^%_ G@[P[X3O('MKG1=,T:WM=/N8G4HZ20(@1U9200P.02#G-
M '\/?PU_:S^)OPF_:!@^*7AWQQXGL/B)'>F_.O+?R/?7,S'+F61B3*'Y#J^Y
M7!(8$$BO['O^">7_  5#^%O[=7P>\(RZ=X^\&2_$J\T6SG\1>%8;X6^I:3J#
M0(US!]DF(G"QRF1 VT@[>&/6N#^'/_!N[^QY\*_CM#\1-'^#>DKKMG>-J%K;
MW.H7EUIMK<$D[UM)96AP"251E*(<;57:NWW/]J#_ ()[_!+]M"VV_%#X8^$?
M%]TBA8M1NK%8]3M@.GE7D>VXBQQ]R1>@]* /8Z*^+/\ AV1\5OV>'\_]G[]I
MOX@>'[&([D\*?$:(>.-!*K]V"*6=DO[:/ME+EB!VI!^W-^TQ^S2/+^-G[-%U
MXSTF $S>*?@MJ?\ ;T3>YTBZ\F^0#J?+,W<#) R ?5_Q?^#GA7X_?#G5/"/C
M30-+\3>&M:A,%[IVH0":&=?H>C X(8892 000#7Q]_9/Q<_X)*,7TM/%'QT_
M9KMSEM/+&^\9_#F ?\\"3NU/3X_[C'[1$F,%U0Y]@_9L_P""K/[/W[5^NG0_
M"7Q,T./Q7&PBF\,ZV)-$UZ"3O&;&\6*<D$X)5&7)&"003]#5[F5YY4PD'AJL
M55H2=Y4Y;7_FB]X3724=>DN:+<7G.FI/F6C[G)? [X\>#OVEOACI?C+P'XBT
MOQ5X8UB/S+6_L)=\;^JL.&213PR. Z$$, 0176U\C_'/_@GSX@^%GQ/U+XN?
MLRZQIO@'X@:E)]I\1>%;U6_X1/Q^1U%W G_'M=G^&[A ;)(<.&8CN/V/_P#@
MH+X?_:;U_4O!.NZ/J7PU^,?AF(2:_P"!->*KJ%JO3[3;./DO+-C]VXARI!7<
M$+ 'IQV1TYT98_*I.I16LD_XE/\ QI;QOHJD?=>EU"3Y28U&GRST?X/T_P O
MS/H"BBBOFC8**** "BBB@ HHHH **** "BBB@ HHHH *QOB#X4G\<>#;_2K7
M6]8\-W5W&!#JFEM$MY8R AEDC\U)(V(('RR(Z,,JRLI(.S10!X3>?#[]I"P6
M2RTWXI?".ZM=ZB#4-5^'E[)?1QC /FI!JT4,TI 8[T6%,L/W6%PW;>!_@MJV
MF_#O7-'\5>//%7B[4?$32M<ZF'CTF2P5T"B*R%FL9MXTZH2SS9.6E<\U\9_!
MO]K_ ,5_$WPG<:EXX^,/QF^'_BA=2O;:]T#2O@S/)IVG>7<2+$MM--I,[W$1
MB$;";S6#Y)PARB_H-ITGFZ?;MYDDVZ-3YCIL9^.I7 P3Z8&/2@#\X_@3\ /[
M<TWXAZ7\/]&_:*\7>&-/\=>)-,N=3U'XS7.BM=WBZC.+U8H(Y]WDI<-+$DL@
M$DJQB0[MX=OOSX*>#K;X=_!KPCX?L])DT"ST+1;/3X-+>]:^;38X8$C6 SL2
MTQC"A?,))?;N).<U^:_Q!^-WP;LOVGOB3#%\'OAWH[74?C;6]1U?7?'MSH5U
MJ.K>'[FP@GDU&-(F2SANOMBO!.6E9H(TD\M595K]%/V7_&FG_$C]FCX=^(M)
MT/5/#.E:]X9TW4;+1]2!%[I4,UK%)';3@DD2QJP1LDG<IY- '=4444 %%%%
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M4N[TWPWJ_CR;X9_&/PO(+C0)-86?P7XY\)WAX'V47B1.YSPT:>;$^.0< C]
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MX[/S?-M8XX#:![&WMO*E,+P.98W:5_U?TL2+IEN)+A;J3REWSJH59C@98 9
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MY-U\.?\ 95?AQ_ZF^A5] 4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M67C>32+G^P?$=KH\]_-%'#+N98XTDO;YHYY(HEN1)F.295CQ]&4 ?G!\6/\
M@K!^V=\#OA9XF\;>*?\ @GS_ &7X9\'Z5=:WJ]Y_PO70Y_LEG;0O-/+Y<=NT
MC[8T9MJ*S'& "<"CX3_\%8/VSOCC\+/#/C;PM_P3Y_M3PSXPTJUUO2+S_A>N
MAP?:[.YA2:"7RY+=9$W1NK;756&<$ Y%?H_10!\ ?\/#_P!NS_I'5_YGOP__
M /&:X#XB?\%LOVL/A1\=OAS\,_$'[ _V#QM\6?[3_P"$4TW_ (7?H\O]J_V=
M;K<WG[U+5HHO+A96_>NF[.%W'BOT^HH ^ /^'A_[=G_2.K_S/?A__P",T?\
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MK+YAM_+;?)I]XNU6++Y.6"AD+?H_10!\ ?\ #P_]NS_I'5_YGOP__P#&:/\
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M/F-LGE:)46,_<E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM+K<,O\ RS\Z^O\ 4&502&A6W<X9BJ@'MM%%% !1110 4444 %%%% !1110
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MV$-O/X1TV6VN'RP+)(SJ,H=JG [@>@KR3Q-_P2XO-3^'/PXTO2?B5=>']?\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>ocgn-20191231_g5.jpg
<TEXT>
begin 644 ocgn-20191231_g5.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0 Z17AI9@  34T *@    @  U$0  $
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M% !1110 4444 %%%% !7BO[3O['UY^T=XU\.ZY:_$[QQX#N/#*NUDFAV&BW
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M (@^$GBB\F%LMEXFLMUK)*6"A%NH=Z#)./WHCYK]+T8GK6AS#J*** "BBB@
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MA3_@K_\ M??\$5/BXF@?M=>'9OB_\(==U-_L?CK1E#SV8=V8B*7"JX&<BVN
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MX.WG@7XF>';7Q!H=T&:!V 6[TR8C N+:7&Z*4>HX/1@P)!_+']EO]HSXG?\
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MZ_9/^!XD:.Q\?>,7NKP!R-Q$EK9Q<#T%W-^=?01DG'F/SF5&4:CI/=.QM_\
M!N=^P++\ OV7YOC3XT6;4OBQ\<LZU>:C>L9+JWTV5_-AC+-SOG8_:)#U8O&#
M]VOT8EMVNXI(5X:9&C!]"00/YU'INBVGAK3;;3;"&.VL=-A2TMH47:L,4:A$
M4 = %4#\*F5_+=6'53D5\_*LW4]HS](PN%C1H*G'L?QV_$RPU#2?BEJVA^9]
MCN+:]N5N'9,N&29E*@'OD53TJXGM=8N-/EN#=+'$LHD90K+DXVG''N*^K?\
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MH>)/&FJ#1M&:Z2S%P8GES*^2J[4!/.T\XQQ7Y%:O^UM\>OVP/C</#_PZ;6M
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MOL%0Z:<>3H?CL<1)5O;/5WN>Z*P==P8,K#(8'(8>M!YKXX_X(5_MZ6G[>_[
M'A>]N+Q9_&O@6"+PUXF@:3=-YT,86&Y8==L\2JV[IO60?PFNG^,G_!3O1/"7
MCJ^\-^ _">N?%'4=#1YM7ET<XM+!$^_^\"MO*X.2 %!&,FO ]C/F<4MC]$CC
MZ*HQJR>C.'_X+<?\$RKC_@H-^SW;:AX3BA7XG>!EEFT4,0G]JV[C,MD6/ 8D
M!XR> X(X#DC^:?Q9ID/PUU.XTC6M#U#3?$6CSO!-:ZC;-#<1SAL,'#="&Z@]
M*_IRU;_@KMH?B&UL_P#A7_P_\8>.KP60O]4B@B,*Z0F,NKL%?<R\_, %]">W
M)^'_ -C+]GW_ (* _%CQ-^TM\0H]+\::-?:/::79Z-K<2VMKX.%LFZZ-P8V7
MSIGD((DD)Q&0!D$8_<>"/&3,LBRR.4XNG&I3I\RI2G"-1TE.492Y8R:5^9*4
M'=-2WNK)?'YODN%Q^(]MA9VD[<W1.W6_DGK;\#\I?^"27[$_Q<^+WPP\=?%S
MX?VC77]@QIH$#6K 75_)+A[K[+GJT<8CS@@XFPN3Q6/=_&[6+6^OM0CM?B-?
MV>F736E[KEEI]Y<65K.K[&1[A<C<K?*<9P>.M?K9X/\ VZOA3\ =.\0:?\(?
M@KJ&E_"\W7EZYX@\.Z<NGV,<S((/M"PJFTL%"@%BC,%7VKX5T#]M'XW? ']@
M#3?@W\)?#_Q<TG4OA/?:C&GC_P )V=I-X;U^*XNI)+66]>ZB8PY\P,X^5]W?
MG%?G/B9GF-XVSMYOCIS@E&$(04W9*.C=]?>>[>[;ZVU_5?#SQ,?!.4RRW+<)
MAZDYR<IU9TE.<E;2#>EX::=M4FKGM'PN^.GC#X8OI?PS\8>#OBQXR^('D6VM
M36/A_P .OJO]C:==DI:S7\D;_NI&\N0X9<B,*22<@=1I7[6/AC7/VCU^%]G8
M^*KK7&UE_#0U"/19FT<ZND?F-IOVO&S[4$Y*8X]<UY]_P4-T.TU[7I/BAI?P
MA\<_\+-\11>%K[PI\<=(\222Z' UNL(NVN(A)&MK)&%GC-N(Y#-DD;<D5YA\
M OB3XL^!'[<NF>,DTCXN^%?#OBCXT7_BQ_%UY?3+X/U/PM<AGNK4V !C:\=B
MIWKN?(49 4$?3\/^(>:Y=@*6#=JBAIS3NY.UM&TU?1[O73J?RWXA>$?#W$>?
M8K/'%X:5=RFZ=%*-.#EJN6+3Y4FM(I\KONCZ_P#V5_\ @L'\-_AMX/OK[Q#X
M2^-FD^#[[Q!_9+^++GP9+_PC&GW"3&U;S+U'95!F^0D X( //3]&P,#^$]P0
M<@^XK^=;PYIWBOP3\(?!?B+Q%X<^-WB;X2S?$6_U'Q'X"U'5[FW\.>(+-M2D
MN(7L[5%0+-'E)RC.ZRL"< 9K]U/VE_VO?"W[,GPPL?$6I+=7T^N*@T728$\N
M\U)W4,JA#]P ,NXD?+D#!) KX?/,76S#$RQM:WM*CUMHMET_KSU/U7@W 87)
M<OCE6&;]C15H\SN]6VW?K?I^&ECU6BO'OV0?VO\ 3OVKM U@?V/>^&/$OAJZ
M^RZOHMX^Z:T)SM?.%)4X8<J"&4@]L^P]17@RBXNTMS[2E6A4CSP=T8/Q3\=6
MOPN^%_B;Q1>ND=GX;TF[U69G^Z$@A>4Y_P"^:\M_X-]O^"BOQ _X*;_L5ZE\
M0/'GA?PYX9^P^(Y]$TP:.)ECO88HH7>5A*[D$22LG!Q\A[YKY/\ ^#E3]M-O
M@U^Q[;?!KPLTE_\ $?X[7$>BVFGVOSW*Z>95$S!1S^^?9;J/XO,DQ]TU^B7_
M  2=_8L3_@GW_P $^?AC\+9%A&K:#I2S:T\7*RZE<,9[H@]P)9&4'^ZBUZV7
MT^6+F^I\?Q%BN>HJ*>BW]?\ ACZ*HHHKT#YL**** "BBB@ HHHH _!KQ^?\
MAU+_ ,'1NK2ZG(VE_#?]JJR\V*X<XMQ?7;*<L<X#+J,3 YZ+= \ U^K_ (I\
M.Q>*?#>HZ3=275O#J5M):2O;2F&:-74J2CCE6 /!'0UYQ_P69_X(]>'_ /@K
MI\)O"&DW'B&3P3XJ\$:U'J.E^(8+7[1-;6[E1=0!=RGYU5&4[AMDBC/3(/IN
MC^$+SX?Z'I^AZAJ-_K-YI-I%:2ZC?;?M.HLB!3/)M 4O)C<Q4 9)X%>9CH6:
MFCZSAW$<T)4)>J_4\B\!?L-^"_AM^S1K'PPTO^T[;2_$%O)#J>I13"/4;YF_
MY:/(!@X&%"XV[<C')S\X? Z\TO\ 82^+_CWX'^/M66+X=^(M/?7M U>[54.-
MGS@G&#(0F !_RTB&/OBOO2O/_CY^RWX%_:;LM-@\:Z#'JXTF4RVD@E>":+.-
MR;T(;8V!E>AP#UK'#XJ5.?-?K>_9K9GI8_*Z=:ER1BMFK/9Q:LT_)H_/_P (
M?M,^$_%=I>S274^CK96SWH&IH(&N8 ^T/%R1(Q_N+EN&P#@UWWBO0O$%O^RI
M=?%C0=/74-)MBETMK<*\-Q=66_;+<(N,A0.1GJN6Z#GZL^)G[$?PL^+[>'?[
M>\'Z?<1^%85MM-CA9K>..!>5@94(WQ@\[6SR3ZG/ISZ3:R:0VGM:V[6#0?9C
M:^4/),6W;Y>WIMV\8QC'%?I-;Q<SF5%4H.*?67+K^+:_ _"<']&SABGBI8BM
MSRCK:#E[MWZ)2LNBYF?FKJ_[07@W1K/3YFUZUNO[0TU-4*6D<EPUI&W&R8(I
M\N13P5;IP>XS'JGAR;]J[XGZ5\)_"6H6-Y;ZO;0ZGKNM6C?:+?2+/Y9,=@TO
MW 5R,,P7KG'V_P##+]B#X5_"#3?$5GH?@_3X;?Q5$]MJ:7#/<>? W6 %R2D?
M?:N.0/08U_@)^R_X&_9ET>\LO!>A1Z2NHR"6ZF:5YY[@C[H:1R6VKDX7H.O7
MFL,R\4LUQF#EA)<J4E9M*S?XV7R1T9#]'G(,MS*&8)SEROF492O&+6UK)-_-
M_>?%?PQC\-Z5^S9\8/V>?BQ-INAW7P[,^JZ;J0B5'N4)WQ3H.LD@=DP!EF2;
M;VKC_P!A3XK>%H+7Q1\9OBOKS>(O$GPOTZSL/#FE7K@LJ!"L#1*?O/N 0$ [
M,LYR<$?<'[0W[!GPW_:?\<Z3XB\5Z7>3:EI:+"SVET;<7T2G*Q3 #YE!)P1A
ML$C.*H_$3_@G1\)?B=\5M,\7ZEX<*7NF111?8[67R;"[6(!8A+"!AMJA5P"
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M+#]N\-7L4GD2:K"C>:;$R#[K[QYD+DX23(RHD9A^B2=:<1N%>X?GFVQ^)/\
MP2]_;M^'_P#P51\=^$_#?QWT^XT+]ICX0>=97&@:D6M;/Q(\1PUPML^%^TQL
MNZ2#"L&4D!D&U/L/]O#]@_2_VN-!DU:*\U2T\::'ITL6BM'=$6KR[A(BO&>
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M[,-KJ">"?#\.CMJCAKJ8RO//* <JF]R2$'91QGGD\USWQ#_8&^%_Q5^.EO\
M$36]!N+OQ% \4KJ+MEL[J2+ C>6(<,PVKW .T9!KES.C0S# 5LJQEY4*T7&<
M;M*2DK.]FMTVK[KU-HT<9"DE"=M=KOE6EEIL^^IY1\5?B'-X3_X*'?".;Q5I
MNGKX>\<^%#;M;W9$R:;?(9)BP+# 9"ZINP-P;U KP;XD?&/XH?&_]F#Q9\;%
M\4:E9Z5X3\>V\WA[2+1$CBM+>)BA=F50[$>=&O+8.9,YR,?<_P"T]^Q]X-_;
M T32[+Q;!J6[1)WN;6YL+CR)HMP =2V"-C #((Z@'BO&_P#AJG]E+X+>(O#'
M[+=OXN\+76I>-)WT"#P]:77V_=-/DD7DZ$I%+(^ -[!R[( !QCQLKX3R;!X/
M!X*AAHN&#35'F7.Z:;N^24KM-NUVG=V,\5&O)\M:I:"O:[ZNW3M>[^9E_ ']
MJN^^/G[6_CWQ[)XN/A_X+_#WP_#!<+<W2P:9-.Z;WFE+_*NP^:=V0<(@Z'%?
M#/Q]^+'CC_@YP_;(L?@;\'9M4T#]F?P'?1ZAXM\5R6[1KJ;*2!,0>K$;EMH&
MY)+2N !\G[">#/\ @F!\+=-_9F\0_"?4/#<=UX(\60S0ZII\\[32W9D 'F/,
M?F\Q-J%&&-A12.17HG['O[&OP[_82^!6E?#KX9^';7P[X;TH;MJ_/<7LQ WW
M%Q*?FEF? R[>@ PH 'UU&BK\[7H>#C,=)P]C&5[ZM^?9>1TWP)^"'AG]FOX/
M>&_ 7@W2X-%\+^$["+3=-LX1\L42# R?XF8Y9F/+,S$Y))KK***ZCR3XX_X+
M0_\ !(CPK_P5I_9H;0;N:'0_B#X9\R]\'^(2ISI]R0-T$NWEK:;:H<#)4A7
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M%I'7(SLR$!Y"BO>**Z%IL>?*4I.\G<,4444$A1110 4444 >2_MM?L3^ O\
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MC3A'X4>76Q=:K_$DV>+?L8_\$\_@U_P3]\$2Z#\)/ .C>$+>Z5%O;J%6FO\
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MR3_R,>@C_N(0_P#Q5?GK_P %=+K[;^U#IEK(T.V'0[?RPP&5W32Y_D*U(?\
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M?@']F:^\*VWCCQ!#H4WC;5$T715DAED^W7;D!8AL5MI.X<M@<]:^,A_P<S?
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M=1L=7M5MKRV9EW(Y17<;7 ;!SG*-P.X![M1110 4444 %%%% !1110 4444
M%-FC$L;*RAE88((X(IU>&_'7_@H_\&?V<OB)JW@WQ5XZTNR\9Z-X<N_%<V@(
M'DU"33[:VGNI9$0##-Y-M,X3<&81D@8YH _&W_@N;_P2\;]C'XO-X_\ !NGL
MOPO\;7;'RHD_=^'M0?+-;''W89/F:+L/F3^%<]5_P0*_X)=?\-(_$2'XQ>.M
M.\SP'X2N_P#B26=Q'F/7=1C.=Y!^]! P!/9I !R$85^GOP'_ &A_A)_P6;_9
M3\96<.@^(G\)7%[)X:UK2_$-A_9]]!.((+E64*[!6$<\,B2*V02#P17-:_\
M\%.OV:OV+_A9XA\)^&]<CU=/@M=6'A:_\*>%K,W>I:?<3W LX(!&=BLQG!5F
MW\.&W'<>:Y7>W47,K7/L 1KC[J_E1Y:_W5_*N"_9=_:2\-_M>? 'PM\2O"+7
MS>&_&%D+^Q%[;_9[E$W,I62,D[65E8$9(R.":[[<,5(S\3/^"X?CWXZ> O\
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MB3Q=<>"=26.V\:>&TU2XDL;1LJ([U8-VP0L0BR+C"MM?NV/UT9L+7R1\=O\
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M7\#Z/IOAZSM=/T*QLH8-/M;>/RX[>W5 (T5>P"XXIN+6K"YL"-?[J_E7A?\
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MNDJ/,]?.46UY'U?#'$F*S',IT:L7&*C-Z]U4LOP:/7_VP/CJO[-G[/\ KGC
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MCL:N?\%'M6U;0_V#OBQ<:+-86NH?\(W=1B>]N/(@MXW39*[/@XVQ,Y  RQ
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MWTK2+70M+M[&QMH+.RLXE@M[>",1Q01J JHBC 50   !@ 5N\5)N]M?^#?\
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M@O/#MSXF^-7A/PWJ<MLJ$W>GW=TT=Q;MN4_(ZX!Q@\<$5]>5Y)^UW^QYX?\
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MOT+9_P#!53X#7W@#Q)XD7X@01V7A'5K70M5M9]*OH=4@OKK'V2W6P>$74CW
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M-+TJ..X5;*2'4%B2X\Z,J2YQ$NW# #G(/:7?F371_H_PON4FK-,_(+XX?\%
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M]HN->U/683#J%YJ+LF9Y9%.05V!2!@8 %5&U[RV_X;_@B?\ 7X_\ \5\"?\
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MX_\ "?C[PK;_ !$T/XS>(OB?X>.IZ3/<:2]EK-K':7&G7:)*LA<1IN$T;##
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M6RS'(&<D^M;SZ3:S:4UB]K;M8O%]G-NT0,+1XV["N,;<<8QC'%9R3<'&^O\
MP+?\$=US7_K>_P#P#\;_ !)^W'\>OAS^R=^R'J>J?%3QEJO_  T5I-QX@\5^
M)S>>'-!DTJ6'3(9[;3;*ZOK=;"U21F>1S.'EF\AUC9=VT7/!_P#P43^+'Q?\
M9?LVZ3\2/VA+'X(Z3\1_A3X@US6]>TB+2TM=5O+34/+LKN*:[@>*%I;=1*P
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MN@^$SH%CX1\,V>A_:!=_V;!I4$=IYP8,)?*50F\,JL&QG(![57,D[V[?G?\
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M I"8R!CI2CH[O^MO^&]&#VMY?Y_YK[C1T^R:QLH86FEN&A14,LI!>7 QN;
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/ 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>ocgn-20191231_g6.jpg
<TEXT>
begin 644 ocgn-20191231_g6.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0 Z17AI9@  34T *@    @  U$0  $
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M(WG[E'V<K<_N6$VPK)\IP>*[CPS^T9X$\9Z_XVTK2?%6BZAJ/PWE6#Q1;P7
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M?#3]A_X=_!JR\5:?X5TNZT#P_P",?MC:CH-C>20Z0'NTB2>2&U4B.%V$0.4
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M#^(WPV\6?$S5V^U> /AC%XAM+CP_X"@9R$6&W\PK>7VY,/,0X$B$#<R*5 /
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MF2?"CX(_%VUT]AXRTO6-8L;2.T35#K,*ZE.J#"M(Z%&+>X KYO\ BS_P3_\
MB>OQ&NM5T34I-<LXYQ+:ZM)J;-<6T2\J?,9BV4 '0]JX!_V2OBSXMU"?SO"&
MLZU-"^)$>6+<2>"P,DD:\=?O#Z'I7>_!WQQ=? 34=6_M_P"%K6FM>&+,6]^L
M&JO9SW,5POE+*L:J\3,S-MRK</TQD&O5X8XJS#+)3Q&#7LY23B^:*>FCZK^N
MMS;PR\2<YPU*IF.%P\\+.5X.-6$6W'1W2:VOY+5-6:W^G/A?\6OB;X2LO/\
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M7!PHR9&;DN3DG..2>G2@""7XM:7#XOM]#:W\0"^NL;&_L*]-J,@D;K@1>2O
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M[BM2@ KS'XI_"N3QK\8/#6K?\)A)IC:-#*;'2'M(9X6N'5U^U /SYJJ2JGG
MW@8W,:].KG?%6FK=:]I,DFJ6MFR3'[+#(HWSS!'.%.X$_+N+* 3M4XV\FN;%
M9EF&!A[?+8J52ZBTU%^Y)VG\323Y6[/5WZ';E^85,'5=6G)1;3C=I/22Y6K2
M36M[=]=#SCXY_LV>&_B?X[TW5O$6MR1726<-F+=HHVCG\LSX=E8'&6N3[ A:
MYB+]@+P-X7U.UN+K5&,<#6;Q036T'E#[*]@[8&WC?]A0/Z^:_M7L'BC4--TS
MQG8K-XDTK2=5U"!+9;6X>/S;M!)D>4C,#N+$KG##GID"JL/P76&*5?[1D;S'
M=LF,DG=_>^;EO4C&>/2O.Q''W'&$<L/EE)2@M(^]"*C%6:^U>3>O2'+:UYK4
M]_+^-,RHTUAZ&+<5!*-E;3JEMI^;1X^_[!'A=)(?#S>+M4:WCLHX?L!MX&R_
MV6&U,I.W.&AMD&PG;D-Z@#JO!/[#_AWP'\9+'QA:ZA?--9S7,\=FT:+#&\LU
MW*HCP!L5!>2K@?> 7ISGTC6_"MC=ZU?"?4/L]YKMJ;6WB\W:WR(P9E3</,P'
MSTXQ51?A.9[S[1<:AYESYHF$B0[#&?-$AV_,=N1\OT]>E=F*\0N-_P!Y0E15
M2$G-*TX07)=I*2:;<I1M+33WK-Q:-JW'&;UZ4J,\6^5IQDK1UYEJG9+=/UZG
ME/B+]@GPC<RZMLUR_L+OQ%]JDO658V:Y>34UOHGP1E?+FVQG;@2(0'R0K+F>
M)/\ @G79V^C7J^'?$$EG<75C8Z<T,]O$+63R+BUD:610IWMMM\*I& 6VDE0
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M%=)0 5^?O@^#_A>O_!R5XROKH^=8_ CX/V.EV<6.+>_U>\:X>7V9K=-GTK]
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M<5\]1_LI_'BV^)$EJOQ U=--TC3+2_M=136]3E6TE.IW\\MA;Q/,4O3]F%M
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M3=O'X_\ VG-:30IV@^:32/#T++-JM\XYPBPKY?(PP=P,E2*^Y?AYX#TOX6>
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M:=7O/#EQ*S(B,-\DEJ99$C=BH>10[F/WZ]_X*,>*;3PVU]<>(/#^EQ^%=/\
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M_L^^,OCI\7O%G[8WQHTFXT?Q]\4[)-,\$^&KM<R>!/"JMOM[<@C*W%P<32\
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M#:K!9-$T2Y.0Q+G=QCL.A]: ,"Y^+]OXU;Q%H=C#K^B7UA']G:\O-/DM55I
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MJ",5QWCSQ?>?%Z]T:Q\0Q[[&UO[G5;V[&F+]MEN)B=T;J6/FL6(&"5  '!.
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M_-&X&VNZL/\ @W3^#?C._CO/B_XZ^.WQ^N(Y!*8O'?CN[N;0N#GB"W,*[?\
M9.17U[^S[^RG\,_V4/"O]B_#7P'X3\"Z80 \.BZ9%:>>1WD9%#2-_M.2?>@#
M\1_'GP%_;\U3X!>#=/\ VDM'^+'Q"_9MM9IV\0>$?!&N64OQ"N].!S;Q:M)$
MBM>H$ #I"^]ANWE&"E?TT_X)R?\ !1W]D7XB_#C1OA[\%O%7@_P4N@Q?8X/
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M?\%S+K]I/6[KPG^QS\*O$O[0'B!9#;R^*KF"31O!&C/G!:>^F"--MZ^7$ 7
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MM'\$ZU$WEW&E>,[>;P]=VC_W'^U(D>[_ '785]G5P_Q>_9H^'/[0%I]G\=^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3,!D*"Q"@D\9) YYQ6#8ZGXC\6^%6D73U\)ZA-N5%OGCO9+?#$!BD+E&R!D
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2Q&YCR>Y/K6SXITN[UKPY?6ECJ$NDWUQ"R07D<2RM;.1\K[6^5L''!ZCN.H
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M[5KV];6_"=EH]BDD@LVM]8^UW$Z"0JC21F*-8]R!7P'8KNVGD$USWQ/^.O\
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MC^+?P?\ "OQZ^'NI^$_&OAW1_%7AK6(C#>Z;JEJES;7"G^\C C(Z@]00"""
M: -S3]0M]7T^"ZM)X;FUNHUFAFA</',C#*LK#@J0001P0:\6_;>_X*+_  C_
M .">G@BWUCXF^*(=-NM3;RM(T6TC-YK.N2Y $5K:)F20EB%W8"*6&YESFORJ
M_:\^.OQ"_P"" OQNUGX7?LN^(KKXO>%-8\,WOB*;X8ZO;7>MS_!Z% &&I1W$
M676Q^8M]FE;.%W<[Q(?M;_@DC^P-\+9/"VC_ +25]XZ3]H[XN?$*S6^F^)>J
M*)1 &R#;:=;MQ811'='Y:JLBD,K;1^[4 YFS^+?[<_\ P497SO OAS0?V/\
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MNUKXL?%#Q/>?\)7I=CX1\83:-=ZE8_V0TNH+-ICF6$17'GA$1Y%B+9B+;58
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MBI\0$\_XQ?M$WY\>^+[J12)(?M.7L[$9)*QV]NR*$Z(SR #&!7VK0 5\/?\
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M+\-_''AMOL-U&=7S9M=W M\_,L:F2/RV;! D977G[I(KN-.T(Z)XAEDMX_\
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M4/''PM\,W6F^++2UA;1[;PK=VZ:/X4A6WN;R:,I).9(H7:T,<A$$99,G:0,
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M=6VET';9ZG(FFD7$!6)Y9K>SC5IEF++('$B_:84C_1.O@'_@O_X]O_B'\$/
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MM+]JA\F2*5HP0"JR@8^8 \CT[]#U&#0 WQ'X6TSQEI$FGZOI]CJEC,,26]W
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M (2;Q!X-OK'25.FK+)I=S<7S6\E[I]Y?1V[)-:V[^>L=JA;:K0A+E)#,%5B
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M.-"H(+'/4>F:IXMU#QEX4MSX;T:6.Z6Z"_8M66;2TDC!P[D>67V@-N7Y0KL
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M,8PPKYB[><ON)'7-<9_PSK/X<?5O&UOXT\7^/--U:W:T%]8W-_'KH<96")!
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MMK\4O!'B+6O@G\?-'CV:=X^\+XCN+@ #$.H0<1WT!P 4D^8J N[;E3Y#9?\
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MP9X$T/X<:%%I?A[1M*T'2X.(K/3K2.U@C^B( H_ 5K4 ?EI\*_\ @GY\>O\
M@AC?:W<?LRZ-H/QX^"6MWIU/5? FK>1I?C#3Y" &>TU)4"W@"CB.<%@/E126
M9S[_ /LW_P#!=_\ 9[^.GB7_ (17Q'XAU#X+_$:$B.[\(?$BS/AW4K:4_P
M:;$,F2#C9(2?09K[,KSO]H;]DCX7_M:>&?['^)G@#PEXZT]01''K6F1736^>
M\;LI:-O="#0!:\1_ OX?_%XG5-2\/Z#X@^WW=AJBW3HLXEGLF+VDZL,C=$68
MJR]-Q[$TZR_9M\"Z=K>DZE!X7TJ.]T*QM].L95CY@M[>.:*"/&<%8X[F=5R#
MA9G'\1S\=7__  ;H?!?P?>2W7PC\<?';X"S.YE6/P+X]O+6U5SSGR9S,N/\
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M_2[*.SM8!Z+'& J_@*VJ (=.TZWT?3X+2T@AM;6UC6&&&% D<** %55' 4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_&?@/2?B%IL-GK%
MH+RWMYTN40R.F)%SM/RD9QD\'BMBB@"AX?\ #UCX,\.VNF:9:QV>GZ="L%M;
MQ+\L4:C"JH]A7/>'[VU^+P^U:AH6I6=KI-W_ */;:O8>2[S*H(G56SE0'(4^
MN[VQV%% '!Z;9>))_BQ<1W6CVT/A5)'N89Q=*TKW 5%5BF>$/SG&,AL&MC6-
M"UJW\8Z;>:+=:;!ILLCC6;:YB=FG7:-DD)4@+*",'<"&4\\J*Z2B@!LLJP1M
M)(RHB LS,<!0.I)K#LO&NE^,-%FN-$OK#7+=93;R-9RI<1[APR%E;:".^3QW
MK<EB6>-HY%5T8;65AD,#U!K!U[X:Z7K?A8:,BW6DZ>K[A'I5S)IY'7(S"5.T
MY.1T- '"?#:Q\62_$&\OO$=QI]YI#6H_LJVL2[2)&DK?.Y< R?>4=3]U&YR3
M6W?^"M/F\<KJR^,->LV:;[6VEBYC6U=@H0;HFCW;<@'J"6QR>!72>(/"<VKS
MZ2UKJEYI9TN8.?)CBD-S&!@Q.9%8A6 &2N&X'-,\0_"OPUXM\5:;KFJ:#I&H
M:SHYS8WUQ:))<6GS;AL<C<OS '@]1GK0!R.M>%O$ES\3M/U=-8:S\*F-;?4K
M'[+'NU&1G^21LJ6C48"G##<&Y5=I+>@ZWH=KXATJ>SNX_,M[B-HF"L48!@0=
MK*0RG!ZJ01VQ4/BSPG8>./#EWI.J0M<:??)Y<\2RO&77(.-R$,.G8BK6F:;#
MHNF06ENK+;VL:Q1JSER% P!EB2>.Y)- %/P?X3A\%:''I]O=:G=0QLS"2_O9
M;R;DDX,DK,Q SP">!Q6;\4_AN?BAX>AL%UW7O#TEO<I=)=Z3.D,^5##:2R."
MI#'(QU ]*Z:B@"MI6F1Z18QV\>YA&H!=SEY"!C<Q[L>Y[FL#QUX/UKQ-KFCR
M:?K\6CZ?9S;[^!; 3S:A%WA65G B5L#)"%N."M=110!@:9X=MKE+Y%5HVCNR
M8Y4/[R,A$&0WX8QTQQC'%5-"U>30_%]QI-W#=.UXHN8KB*UD-NS'(?+@%4)V
MAMI/4G&<BKG@?PO?^&(K];[6)M8:\NFN4:2!8_LX;'[M=O\ "#TS6]0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
A110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>ocgn-20191231_g7.jpg
<TEXT>
begin 644 ocgn-20191231_g7.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0 Z17AI9@  34T *@    @  U$0  $
M   ! 0   %$1  0    !     %$2  0    !          #_VP!#  (! 0(!
M 0(" @(" @(" P4# P,# P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,
M# P,!PD.#PT,#@L,# S_VP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" %
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***:S[!0
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MW_(.^%O_ &$;W_T0M?'_ /P20_Y2*_#C_KI>?^DLE>34VJ_XX_\ MA^A9?\
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M8R"LD923)5@1\H/&,U]+>"?#$?A/0+>SBP$@18U &T* ,  =  .,"N5_:?\
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MP:#+@?2@!U%"MN%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%-EG2!&:1E15ZEC@"@!U%1F\B#*OF1@R?=!;[WT]:<
M'4]Z '44TRJ/XJ;%<QSQ>8DBNAZ,IR#^- $E%1Q7<<Z[DD1UZ94Y%.,BCO0
MZBH9]0@M #+-%$&Z%V"Y_.@ZC;BW\[SH?)/1]XVG\>E $U%0P:A!=!O*FCEV
M]=C!L?7%2"13WH =13=ZGO37O88F*M+&K!=Q!8 @>OT]Z 'L,U2U'0+74TVS
MP1R;NN5JY'/',BLC*RL,@J<@T$@T 8>C> --T&^:XMK:.)LY)45N>8 *\W_:
M=L_&6I_#F2'P1XB7PKK'F*_V]M.2^^09RFQC@9X^;DC'2O@[6OVQ?CW#XO\
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M(FW+^-.IL8VK2[A7LGYV+10#FB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9-KFDK6245\#D'$>88BI3IX[ 3ITZM&<T^:Z@D[.$D^LDDU>[]Y=CP/XW?\
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M%C[DY)]R:\S_ ."@?[*'_#9?[+VM>#;6XL=/UU)[;5M"O+N,O!:ZA:S+- 9
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M8R7$^Z-P5#33&WA1B/O,0.:A\8_\%:U_X<;Q_M,:-';OXJU;PM##I^G^5O\
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M?M>ZMXR^'>J7MC\-_'G@>Z\'^./">M7]]K4VN%V)AN4NKJ:1T**3&4.5VEL
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M8FHK8:LUHR^HE"[,?C4T_P#P<%_M_P =O:S-^Q#-!#?8^S23:5JRI<9Z;"2
MWX9JO937NV?W=?\ ,)8>JI-2B[WML]UNOEV/W&HK\QO^"0O_  <*Q_MH_&#Q
MA\(_CMX3TWX(_&+PQ(\D&F74\EK;ZA"@'FQ;;DAX[F+[Q1B=Z-N7A6Q^E/AS
MQ5IGC#35O-)U&QU2S9BHGM+A)XR1U&Y21FLS$T**** &RR^4N:^;M6_X*H_#
M'2-<N-+:W\8-J5I>-:R6S:)+%)L4X,ZB3;NCSP,?,>RU]$:W>VNG:7<7%[-#
M;6EO$TLTTKB..)%&69F/"J "23P *_'S_@H-_P %4/@'\3?B3X9TGP[KNJZQ
M;V^H[I;Q$ALH]9A?]V4T][J6(S@G^,!8V'*LW%>YD&#H8C$<N*A*4.KB[6W\
MGN]%MJ>5G53%4L+*KA&E)?S)M:][-62W?D?H!X<_X*B_#/7]1O(YO^$ATFUL
M;1KEKJ]T\K&[JV/(4(7;S"/FP0..N*Z+2_V_/A]>1LUY+KFCK]G%S&UYI4WE
MW )(VQ/&'21N,[5)/(K\V=<_:F^%'PQU#7-)TW5M=\(WFO:;:6FHZ1J.D36F
MI::TTS@W/V= PE'V<28E@,BGY<MQ5K5OVV_@;\*?#6JZ?X;^(]K_ ,(7XDM-
M/A>\L;2Z$=O$6D%Q/%%Y8=_W(5"\:MRPR<KQI5P>%YK*,HZ7LVKI*U[Z:.]_
MN.:AC,1*FI\\9>:6CNM+:O38^]_!O_!4CX<?$*ZV:+8^,+Z./+74B:0W^B)S
MM=EW;F!Q_ &P#DXP<1^$?^"I/@+QGXHN]/M=&\8+#IX5KNZ-@CI;9!.61)&?
M'')"G&><<U^>'Q+_ &Z?@_K_ .T?X7\(^'H?$UY;QVYL;C2&@M=+U/6$8J\*
MVUK=SPRO"2@^5PC-D *02:A\0_MP_"'Q7^UOI?A70]'\;22::KZ9J7AFZLK3
M3=<OIT(E14LKBXC:2$<''5R!M5E.X_$XW,HPG75+$48I*,XJ3;<8)I3E.TU=
M_$HM**7NWOJ<<<PQ;5XU82]Y)66C6EWN]%KJ?HII?_!6#X1:E!XA<ZAJD,F@
MS) MNUINNM29@23!$I+,JX(9FV@=ZW=%_P""E/PCUJ*V8>(+VU:X@DN&6?2;
MI3 L>-V_$9 Z\$$@^M?G]^UO^UE\ ?$G@_2SX'\6177BRSOT6_M$T2X34M$5
M&,4\,Z>7\LZ-P;?<7)&0",&N/^'_ .T+\)_^$HNO"-UXMU-]-UC5UFU/[3HN
MH->"U2VC813P^3YZQO-N))79B-\'DU^@1P.63R^GB_?O+7=<MDEJG;7FNVEU
M[VU*^O9BL:\/>#C9-;\S;OTOLM+O4_3/QO\ \%&_ACX#^ FI?$>ZO]6N/#]A
M&\T$%KILLNI:M&K*IDM;3'FRQAFP7VA5"L20JDUYU\(O^"TGPM^.=E8:GX:T
M#XB7GAO4@(8-9ET9+:U-YC+69$LJR+*!N^<IY3%&"2,<9^)?CAXA^"/P9^(^
MDW6E?$'P7:>!]0TU;Z?5+#4H]2C,A<B."U53(QN)-R@1*"PW$[1UKP/PQ\?/
M .M?MM?$+4/&-EXN'PK\(VUC>:?:3R64]Q_: MEBFOI;,W6^7RD;8BQ+(X:9
MLH' 4<N88++L/&G4I3E+G7-RM)-*[6KN^W1:^1V8'%8^M4J4ZL(Q4'92NWS.
MR>D;*UF[:L_7O1_^"I?@7_A ]2USQ!X>\?>$9-/U*6Q.EZIHQ^WM"A %X5C9
MT6W?.59G!/ID@'H5_P""BOPVGL[-K>XUNXO+Z5HX[#^RY8;L!>KE)0@"D8(Y
MW,", U^?NB_MC?"/Q+8Z;X+U7QU)%X-T-K[599YM-O9HD@$K"V2Y01,]ND:%
MGVS*H7<G3'&'HG[8OP)\5MX5T#Q%\1;&/PKI?GS6-S+:7-W:WDL\\JV<1*QN
M586_*(X#'S% ' J987!Q3NGIJ]5L[VZ;[?>:^VQ4G[K6NBT>ZM?KMO\ <?HO
MXJ_X*3_#'P;H-K?WTWB11<7!MI8/[#N5GLCNV@S*RC8&.-O)+9& :U%_X* ?
M#!?#T>H3:SJ%MYKB,6DFD7?VP2%MJQF(1E@['HO4Y%?G99?MF?"#QOI&F:#X
MR\>"U\,^"]*EN)[FYL+NYM/,::14-PZ1.(C' J*!-M(+D<$5VG[*/[;GPG\2
M_$'PIIWB#X@6MG:^%]-@M;.^O(YS8->7#%=\MUL,,,@3RXE\YT.6<9!.#-;"
MX2$7H[Q>OO+6][):??ZCIU\3)JS7O;:/I:]]?/\  _3CPOXB3Q5H%IJ$=O>6
MD=Y$LJPW<1AGB!&<.AY5O4'D5H56TZS6SLTCC/RJ.#GK[U++<K"A9B%50223
M@ >]>&]]#UE?9DE0W,"W(VNNY3P1BO#OA;_P4?\ A/\ %GQ!X\MK'Q1IECIO
M@"^BTZ[U;4+R&VLKV5D9F^SNS#S%0J5+8P3TR.:\!_:O_P""]OPN^$NGW5A\
M.UE^)'B+!6.6#=!I-N_0%YV ,@SVB!S_ 'AUJ?:1M=,^@_U6S55'2J490Y;.
M3G[L8II-<TI62NFG9N_2US@/^"\7P]\#>'_#G@&^N/)C\97'B6U_L:*(#SFB
M$J?:"W?R@"O_  ,KCO7Z2>&&+:-#GGY<9]:_!'X$#Q]_P4X_;RT?6O%E]/JT
MUO>0ZAJ<R+LM=,LX9 Z6\*<B-68!0O4Y9B2037[Y:#;M:Z7"C?>"C-8T5[\I
M>A]%Q76IT\FR_+8R<G3]K*[NKQFXV:3U4&XRY$[-J\[)225RBBBN@_/0HH)P
M*BFNTMT+2,JJO5F. * ):*CBN%G3=&RNOJIR*=YG&: '44 Y%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7QO_ ,%.?@OJGQLN[6W\
M.Z;X8U3Q1HU]X8O]'AU]96L6G&K3@B78PS&T9<,"&W*< !L,/LBOG#]IS]E3
MXG?&SXTZ=J/AWXGP^"?!T<>G2WT-II<,FK27%G>&=!%.Z,J1%6<,&#%B0/E7
M.0#S+]KO]EC5H_%W@3Q/ GPMT&^\/KK$UQ<Z;X5/VBZMSI=PTUL':;Y%?;D,
M!N5E1AT(/YFZM_P4Z^ >F?\ !37]K[QE)XVT?7O#/CKX?>'="\/75JHFBU"[
MAL88IMOF!1B)T;<W48XS7[,?MP^$_B'XN\+:';?#WPWHOB*\NGO]/O3J6H&S
MCTV&YT^XA%T"/]9M=E!C );?P5QN'RIX _X-<_V19OASHL?C/X2Z5/XL6TC7
M5;G1O$6LV]G<7.WYWB1[HE58\A3TSBML-65&K&JU>SO:[7XH[LLQBPF+IXIQ
MYN22=KM7L[[K5'Y$^+OVMO"]Y\-]/TNS^)/AEO#<K^9#X:@U_P [R+SR4C>Z
M:'[BF4J6X)QZ#-;?P8_:8\#MXR\-WGB;Q9X-\6>%M(:2"/P[?>,(;?:K AOE
ME=1 K2$/\O\ <S7ZQWO_  :H_L2WB?)\,=8M_>+Q7J?]9C6=/_P:9?L63?=\
M#^*X_P#=\5WW'YN:^Z_XB)CG2=-TXZWUU6Z:W3O?7>]S]QJ?2&SJ>&>&^K4M
M7*[2FG:2DMU)-2][X[\SLM;ZGXO_ /!4+4_#?_!7K]J#P'X9_9-^#&O:]KW@
M/PM_9WB6ZT5&NH]2\ME\L"7^.*W&Z);F0@R[U RJIGT/_@F#_P $8_\ @I%\
M*_$NOW_PNGU3]GFVO8!#=2^(=:6UM]1Y!"BV5)V9QC(D:(8!(#<D'^AG]A?_
M ()W_"/_ ()Q_"N;PA\)?"5OX;TV]G-U?7#RO<WVI2] \]Q(2[[1PJD[5&=H
M&3GVT+BO@ZE1SFYO=MO[_74_!\57E7K3K2WDVWN]W?=MM^K;?=GQM_P1X_9Q
M_:H_9U\$>-K;]J/XI:/\3M7U2^MIM!GT^[>X&GPK&XF1BUO!C<Q0@ -T/3O]
ME445F8&)\1_ 6F?%/P%K7AG6[?[7HOB*PGTS4( Y3SK>:-HY%R,$95B,@Y%?
MSV?M*_\ !&:QT3]MV[\-ZE=V>M-H%Y!9^'[C6]'>>ZN[ E?L@F,4\45QM4A-
MQC&2ASDYK^BQ^E>:_%7]FG1_BO\ &#P/XNOTC^U>"Y9I541@M=[E'EJS?W8Y
M!O ]?QKZSA/.\+@*M6&/I\]*<7IVG'6#MUU]WR4FT<.:4:U?!SH4)<LI6U[:
M[_=<_'[XK?\ !-KXS>-_&_QF\&GQ-X)\3WVB+8Z;J.M:Y;6\TUVHLDOK6"UA
M:Q=K2$+(L;PQ3!69I&RN\FL2+]GKXI_M8>"/B%XWT>/X9VUM.MEKM^;6)5N&
MO8M(L-3B73GFL9;BTC0M!&L2SE$>-]FU&Q7Z"?M'>-=)_97_ &Q/B;K'BB^B
MTO0_'7A"U\4Z?=7<JPP7-SI4,UM?6R$_>F$+64@4?,RL< [&QXC\*+B/]A/X
M4:YH_C1H]%DUSX5:/XQT^WNSY#7=W;Z0MCJ%FBMR]PDT5GE%RQ^TIQUKY>M4
ME5FYS=W+?YG11P].C1C0IJT8JR7DCY$T/_@FLOQT_;%\.^/)K_0]1^(/BJ?3
M=4M]:N/#3%S/-#%-'=-$MP+4R(&5@WE%<H#MK5TG_@DE>:Q_P4$^U:AXH&M?
M$M]=-LOBC5=%DFOX&7[MR%^T"V62*,#RR(=JA$PO2OV-_91_9RL_ 7P4^$\F
ML:<B^*?"O@W2](N&:(*T<L5I'&V?]I2&7VKT-OA-HK_$A?%36<7]KQP>0)=@
MSZ;C_M;>,^E?F=7@K%SJ2J2Q#NY6V5_8[NGMHGU6SLM#\CAP-Q#!I1Q_NJKH
MN5?[O_)Y-;+IMH?SI_M[?\$7[SPA^T=:_#F^U2/Q#H?@^&+^Q;^>^ETFXOK2
M;]X&N(XX98Y)@Y=6EB\LN5)(!X'>?&S]CCXR?%#]F^^^)5UKG@W^Q? ]M#X?
MTZQMWEM;R"ST[5DAE@29H)+J*1YHWW3BY!**. "R']L/VI/V1-+_ &DO$?@G
M4KB.WANO#>JI-=3E<2W%CAF>W!'7+B,\]/F(Y//Q-\>#'X&^'7QT^"TTEO:^
M+-4\;-#X:TSS,3:I:^(-1CN;26W0_,Z))-=HQ4$(;.3)&*_H#.N(,)B,%A98
M6/+6LO:WU3=.T8:-6::5VK>1^F+!SGFGURKK&,4H+LW\3_!(_*[X%_LO?$WP
MK^U.?$ECI7B^3PSI-S-</X&M(M/339Q&K>9;$K*RR)A3EA;M(P'3=S7VWX-_
M8,\3Z)XO^#OBGPGXP^'^M:AXSUZ\U3PEX6BT^\E\)>'K2\T^:>\DM9/M(,,<
M%L)'CG@@CF^T2KC:#M'Z,^"_V%+7P-^WCJ'CS3+5;3PS)9MJ<<2L-O\ :<S.
MDH4=54+F3TW28'%1_LQ?\$^KCX'?M6>.?&FH:IIM]X2:XNF\ :%;0-&OAB/4
M6CN-5WJ?EW2W*?N]F%2+<H WL*GC3,L!BJM/^SF^22YY)])RWBNRC;9:=DC'
M X&:Q^(QE5)<S48VT]U:W?1N[>MKV6]C\N?!/[/WQ>\!?!SX4?$K1[CX6Z!8
M"XL3X?N;FU2XN](:^@E@BN+Q[:RMY;QE\P(RRRE)'E#R+(1SD^&?V2_B=\%_
MA1\,?'4K?#-/"^J>'KO1+>%[=1J4%IJVE37;2->6EG;RQWF8$B2XW/M:8C85
M9L_77ARSLW^&OP_^ =](LOBSPY\4K#PG>:6S W36-A?MJ2W?E?>^SR:9%%()
M,;0) ,Y!%)X1TRU^)WPP^#GP)U2XCE\7:#XWC\)^(--5Q]JM;?1H;EY;AH^H
MADM4MG20_*5NXL$DXKXD]P^6_%GP%^,WP,^%OA/QJM]\+=%AU3P[J-EI3V>G
M0++96T^@W-[*DOV:QMEFFEM[9H$:;S(DFE63RF(&/0?@)_P3_P#'VC_$GX3^
M$?$FL>"O#_AOX@:+?>"X+O0["WFOK/3GTLW,T+[;2VCFFGM[9HA/<>=Y;9D6
M/>=P]<\*Z='^TW\*_@=\%M4N((_&5KJ%]X>\4Z>KJUQI+:3H]]974DD?)6-I
M)+7:Q&&6[B()W"NR_9M^(T?QM^)G[+NA-+'_ ,)=X7N]0N_%>FHP:ZT.?2])
MN--NEG3.8Q]MN(T!;&X2*5R#F@#]"O"OAJU\&^&=/T>QC:.QTJUBL[9'D:1E
MCC0(H+-DL< <DDGO7Q%_P73^*GQ.\%?LUQZ?X%B>#P_JC21>*M0M)#]OMK3
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M=J?PJSNK2<T[7ZGAO[$'["?AK]DSP1#8Z19>5(Q\V>:0[Y[F3'+R/U8_H!P
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M[5+BQBDO=/608=89F4O&&'!"D9[UN44  &!1110!A?\ "K_#?_"?_P#"6?\
M"/Z)_P )5]D_L_\ MG[#%_:'V;=N\CS]OF>7NYV;MN><4MM\,?#=EX[N/%4/
MA_18O%%Y:K8SZPEC$NH36ZD%86G"^8T8(!"EL CI6Y10!AZ?\,O#FE>-[[Q-
M:Z!HMOXDU2!+6\U:*QB2^NXDQMCDF"[W5<#"L2!@>E&C?#+PWX=\8:IXBT_P
M_HMCX@UU8UU/4[>QBBO-1$8Q&)I54/(%'"[B<#I6Y10 4444 %%%% !7AO\
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M1WQ1^QS\:O@3X,\*:'X9US_A9FM/8:M%J\,DAC@\^UB5HBCKM;,SGD$':.*
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MP#^!.I^%[73XO!_C3Q4VM76I:\ERSOJ$,;7-P8(UMSY1S)\Y(('&%^^/CQ\
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M+&5MTI*_*G9\BA)I.31H4445TGYZ%%%% !1110 4444 %%%% !1110 4444
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MOQ-U/2K9/$<^D0;;=[A5R41V^=HU9C@$D EL<5[<.*104444 %%%% !1110
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M)DF+2NTLN)')\N/)8[5VKBOJB::.VC9W98T0%F8\*H'4DU^>/_!:?XF?%/\
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M7B?PQ?"-8P]A?@+) H5<[.5)8D@G&-'L[=W_ .E7_+_(SVMZ?I;\^WJ?G?\
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M?KE.+44I.[/Z0HQE&"C-\S2U>UWWLMK]@HHHJC0**** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*LURWE.LDBPJQC4Y.3D"Q^T=_P %O/#/P0^)_C;2M ^&'Q(^)GA3X2VEG?\
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M8:#X\U2P^#5SX,M[KPUY.FJVE2:U A>*UEB^>=HWD_>><QRR8C.TUZ#\&_\
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M.>[M[J=3;W46Z5PCPPQQJ<YWNI; !VC]$**'KO\ UO\ YL(Z;?U:W^2/DO\
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944 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>ocgn-20191231_g8.jpg
<TEXT>
begin 644 ocgn-20191231_g8.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0 Z17AI9@  34T *@    @  U$0  $
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M251(D9MOLWF*QW'"5]>?\$M/VZ;_ /X*%?LJ0^/-6\)W'@_6+75KO1;VT*7
MM;J2W9<75J;B*&9K>5'1T\R-6&2I&5- 'T;1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO&?^%-?&/_HM5C_X15M_\>H_X4U\8_\ HM5C_P"$5;?_ !ZCZI2_Y_1^Z?\
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M\*:^,?\ T6JQ_P#"*MO_ (]1_P *:^,?_1:K'_PBK;_X]1]4I?\ /Z/W3_\
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M?\_H_=/_ .0#Z]7_ .@:?WT__EA[-17BUS\(?C%:VTDA^-5D1&I8C_A"K;G
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M77B;]A3_ ()[>/\ XI>#X=%G\1>&?[/%HNK6\EQ9K]HU"VMG:2.-T=ML<SL
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M/'GPS\/?#7Q0WAWX=FWCU/QM+>6J:69;FPM;ZUBCA+BX9Y(KDY 3$>P;C\X
MR--_X(Z_"GP.?![^!=0\=?#6X\'^&8?!PG\-:R+>36-*BF>=(+LRQR;V$LLS
M^<FR8&:3$@! 'LGP6_99\,? 7XE_$CQ7H3:HVJ?%35;;6-:%U<^;$)X+.&S3
MRAM!5?*@3()8ELG/.* /2**** "OCWXV?\GS)_V,O@S_ -$:]7V%7Q[\;/\
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MBB@"OJW_ ""KK_KD_P#(U_+O7]1&K?\ (*NO^N3_ ,C7\N]?K?A;MB?^W/\
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MT37%]*;9S:1P);",>6D[S$HVU-Y"W?C3_P %O]>^.'[*VM0_"3X;ZW!XTO\
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M#(Z001+%&&9N6(51DGD]:VJ /D'XZ_\ (!_:(_['OPK_ .BM"KZ^KY!^.O\
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MXDZ6OB>30KK7M,TW7%BL-<O=&,?V"]N4:)F>9%B1&PP1PJED+JKJ ?7%%%%
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MU-_R7.?_ +)+XJ_]'Z;7JW[-/_)N7P__ .Q;T[_TECKVL7_N%+^NLCYO _\
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MI:/[0K>7_@,?\A?V3ANS_P# I?\ R1X__P ,JZQ_T6CXP?\ @7IG_P @T?\
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MF?\ R#1_PRKK'_1:/C!_X%Z9_P#(->P44?VA6\O_  &/^0?V3ANS_P# I?\
MR1X;IW[">D^'6TNXT7QU\1-#U33;6[M)-1M+VT-QJ"7-[)?2F;S+9T+&>5V!
M15P#BM+_ (95UC_HM'Q@_P# O3/_ )!KV"BG+,L1)WD[^J3\^J)CDV$BK0BT
MO*4DM%;9/LCQ_P#X95UC_HM'Q@_\"],_^0:/^&5=8_Z+1\8/_ O3/_D&O8**
M7]H5O+_P&/\ D5_9.&[/_P "E_\ )'R?^U)XA\(?L8^'=%U/XC?M$?&'0[?Q
M)J(TK2XXH[2^N;^Y,;R^7'#;Z=)(Q"1NQ(7  Y/(KGOA)\>OA7\=/^$17PK^
MU%\4M5N/'&M7WAW2;0&SANI-0LK=KF[MI89-.62"2*%=["54P&3^\N<__@I)
M^Q3\2?VUOVW/@>GAOQ!XJ^'/A/X<Z+XBUMO&F@SVRW5AK5S##9V<*QRARX\I
M[EG&S!0LN]20:^+O#'_!)[XJ^*OAOH<GC#X1Z]?>)O"/P\\<^(-;-[XF2YD\
M=_$349(;&"Y>99U9HYK:V2=0VV.-61#RO)_:%;R_\!C_ )#_ +)PWG_X%+_Y
M(_5+_AE76/\ HM'Q@_\  O3/_D&OEW_ALSP#+K'C*QM_B]^TM>7'@V.]N&%K
MINGS+K$%E??8;N>S9;(B2&"<$/(Q15 +9P":^:?&/_!,O]HZ^U*U\,W6A>*/
M$OBZ'0/ >E?#WXER^+DCL_AA'IL%L=9DEA\\3/=27$<YRD<OVA944L%5E/V_
MK?\ P1@^$[_LXW'P[\/3:UX+_MJ^AO\ Q'XBT2*RBUOQ<T<[W!BU&9[=UN(9
M)G+O$R[7P%(VEE)_:%;R_P# 8_Y!_9.&\_\ P*7_ ,D<=+^U%\.8-?DL)/C[
M\<X,P:)=6EU<1Z=;6NHPZM<06UK)#))9*"@DN8@[-M"C>03Y;[?7/@EX&MOV
MA?!MQX@\+_'+XPW^CPZI?Z2EV+K2O*NI;.ZEM9GB861#Q^;"X5P<,!D<$5E^
M)/\ @DM\./B%\3+CQ-XPU3Q5XVENM3T^^DL-<FMKFPE@L6NI+>QDB$ $MLD]
MY+*JR;BA6-%98UV'V+]EK]F[P[^R'\ ?#?PX\)BZ_P"$?\+P/!:&X*&5@\KR
ML6V*JY+R,<*H SP*/[0K>7_@,?\ (/[)PW9_^!2_^2.?_P"&5=8_Z+1\8/\
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M:]@HH_M"MY?^ Q_R#^R<-V?_ (%+_P"2/'W_ &4M7D0JWQH^,&&&#_I>F?\
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M4/\ @MU^UA/(IM?VA/C!;J%PRMXHN)-QR><Y'L,>U?1O_!;/_E%E_P $[?\
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MJQMSN9/EQ]:P_$6A1_9W*_P]S7T]\2/B)I__  ALVFM965PKPAX9?+"-" ,
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MG<:BZC]R/*CR.A/4_EQ^->\:#;,#N7<0HRV!Q7F'P3T];;PE:GC=,6<CZG_
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MSTK['+8I:L^1S'%N1K?$+7DBM74?ZSU)QFORJ_;2^*R_%+XW7QMY?-T_1_\
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MV!_Y KXDTC36M<8FN#T&/.;C]:ZNQLVETM6,UQYF<#]ZW/ZUYE;--;N/X_\
M /LL+DN*E'2JO_ ?^"?5/_#A3X[&X\S_ (2#X8ALYW#69N?_ "!3)/\ @@C\
M=C_S'/A?USSK4_\ \8KYITRV:.>%6GN/G!!'FL3_ #J_?>$Y/M#1M-<+QQ^]
M;T^M8QSA1E\'X_\  -9</XJ4;^VZ_P O_P!L?0$G_! [X['+#7OA</0?VW-C
M_P!$5R7Q*_X($_M*MH<BZ#K_ ,&O[2F)5'O/$,ZQ0_[6!;G<?;IZUXIJG@'[
M5'( ]PK-TS*W/ZUX_P#'3]GV#Q5HLUK>)=20L,@B9U>-O[RG/!%>QA<ZJ2]U
M:'S>99'7I1NY7^5OU.F\0?\ !HU^U1XJUFXU'4?'/P4O+Z[<R332>)[@L['_
M +=?T[53_P"(/K]IK_H</@?_ .%+<?\ R+7YS_&_X;^(/@OXH:UN+Z_GL9R3
M:W/FL!(!U4\\,.X_&N)_X2/4/^?Z\_[_ #?XUI>^K/FN5K0_H9_X*._\&\_Q
MN_:G_8C_ &2/ /A_Q!\,+76/@OX3N]&UR6_UJ:&VN)I6MBIMG$#&1!Y39)"]
M1Q7QI_Q!\_M-_P#0W_ __P *6X_^1:P_^"UFJW5M_P $N/\ @G?)'=7,<DGP
M^U$NRRL"_P ]EUYYK\SO^$DU'_G_ +W_ +_M_C0)'ZX_#;_@U)_:L^&6K?:+
M3QA\#9K>0CSK=_$UQLD'K_QZ\-Z&OHCP9_P;M_M :+;1B;Q#\)-V 3LUZ9O_
M &WK\8?@;\)]0\211:MK%U?-:MAH+<SN/-']YN?N^@[_ $Z^_:/ILEJ%VW%R
M%P.!,_ _.N+$UH?"U<]/!8:J_?B['ZG?\."OCG+%L?Q!\+<8QQK<Q_\ :%5T
M_P"#?+XWI,)/^$D^%[E3QOUF8\?]^*_-NP@N)/NS77_?]_\ &M2ULIQ&S-<7
M3;5^4^<_7\ZX/:TX[1_'_@'JO+ZM3>7X?\$_16U_X-^OC< 5F\0_# QYR%&M
M3?\ QBH[K_@WX^-TL?'B#X7[APH_MN8 #_OQ7YX0VDLHR;BZ9R>,SO\ XTR^
MT>X@?RY)+P.>WG/_ (U4:U-O;\?^ 8RRZK&-U+\/^"?>>L?\&[/QZO5/E^(O
MA/\ \"UV?_XQ7CWQL_X-C_VJ/B+%)ING^+/@G8:6QQ*3XEN!-<^S?Z-\J^PZ
M]_2OE36O#4JJV+BZ]_W[\?K7C_QH^"]QXDM9;K3[JZM=5C&583N$N<?PMSP?
M1OSKTJ%2+5D>/BL/.#O(^N/^(/G]IO\ Z&_X'_\ A2W'_P BU]%?\$E_^#9G
MX^?L7?\ !1CX5?%#Q3XE^$M[X?\ !^J27=[#I>O33WCHUM-&!&C6ZACN<<%A
MQFOPMO-8U;3[N2WGO-0BFA8HZ-,P92."#S7V5_P;Q:W>W?\ P6B^ ,<MY=21
MMKTV5:5B#_H5QVS70<NI]8?MC_\ !L)\<?C;^UU\4O&6F?$+X#6NF^*O%NJZ
MO:0WGBR2*XBBGNY9461! =KA6 89."#S7F__ !":_'__ **1^SS_ .%A)_\
M(]?"?[=S8_;<^,B[1QXZUOG_ +?YZ\QT;1[C7M1CM;:/?+(?P4=R?84#BF]$
M?KMX+_X-J_VDO#%I';O\0?V>-0,./*9O&<JNH'8_Z-\U=5!_P;S_ +2D7_,U
M_LZG<,8_X32;GW_X]:_,GP!\-+/0[156-99FQYDSKRQ]O0>U=Q8>%81+'^YC
M;:1_#7E8BM23UC<^WRNCF"II0K./DDF?H)%_P;T_M'10+%_PDO[.YC5MY7_A
M-Y_F;U/^B]NU*/\ @WG_ &D"O_(R?L\]^1XVGR?_ "5KX83PW:"1O]'CSC'2
MK]IH%N\L<*Q1JF>/E'RUY\L926OL_P 6?24\IS%^[]:?;X(GV=J/_!NM^T=J
M,'EMXH_9YZYR?&TYQZ?\NM9$G_!M5^T6S,__  EG[/2EN ?^$TF_^1:^3[GP
M?!:ZI#,UO&RMA<;?;BLB^\*_:XXPT4<:R,P4 >O JZ>:02M&&GJ98CA7%S;E
M4KMR6GP+I;S\SZ^N/^#:C]HPV[!O&O[/*+ZGQG-Q_P"2U<7X@_X-5OVB/$M\
M;BX^)7[//HJ+XPD"H/0#[/7RAXI\$V]U&UO'#$T<)VN"H(8UX?\ $_X9_P#"
M-7$EU8JS68_UB=?)]_\ =/Z5Z>$Q<*G2S/DL\R;%897E+GBO*WY;I'Z(?\0F
MOQ__ .BD?L\_^%A)_P#(]?;G[./_  ;W?&C1?^")WQM^ </B7X6:IXQ\?>-M
M,US3KK3]<EN--BAMC:M(LLH@W+)B)L*$/4<C-?SOU^K'[)NNWWAG_@U%_:(O
M--O;S3[R/XKZ8%GMIFAD4$Z6#AE(/(XKO/E=31_X@S_VK_\ H/?![_P>W?\
M\B59TC_@SF_:VT._CN;7Q%\'XY8^A_MV[P1Z'_1.E?EM_P +R\;?]#AXI_\
M!K/_ /%UV_P6N_B#\6-9/_%8>+(--MV'GSC5)\L?[B_-]X_H.?3)>VI<*<IR
MY8ZL_6'PW_P:H_M16EO#]LU3X3QR+_K!#KMT5)]1_HO\ZWK?_@UR_::B*_\
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MN79P 0?^?2OWZ_X9-\4?\]M)_P"_S?\ Q-?QCZ+\;_&LFLVBGQAXJPTR _\
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M_"MHROHSQ\7A[+F0?\&WG_*;/X"_]A6]_P#3;=UX?_P4U_Y2.?'O_LH6O?\
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MQK$_X-^M&E\._P#!<3X&6$PQ+9^)+F%OJMG<BO<IRYE<^/K4^231\[_MW_\
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MS^;$$64NQD (4$$?LU7\-$E]Y/[4/CJW_P"?G6+_ ![E;ES_ "S7]R]?P?\
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M\I.,9[52UWQBEG;2R23+''&I=V9MJHH&22>P'4U]:2_\$/?C)@[?$GPU4?\
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M&9G%_P '[^Q_.?+*T\K.[%F<EF)ZDU^IG[-/_*IG^T5_V5?2_P#T+2Z^WO\
MB!\\!_\ 1?O%W_A-V_\ \>KZ LO^#9^V^'W_  28^(W[,/A;XLW%P?'WBJT\
M3_V]JNB+BR,+6N81#'*-P86WWMPP7Z8%=!XG,?RIJQ1@1P1R".U?2'P ^+L?
MB[3EM+J3&JVB8=2?]>H_C'OZC\>]?J7_ ,0.WB[_ *.'\.?^$E-_\E5/IO\
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6:_:/_AC>\_Z#UO\ ^ I_^*K(YKG_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>ocgn-20191231_g9.jpg
<TEXT>
begin 644 ocgn-20191231_g9.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0 Z17AI9@  34T *@    @  U$0  $
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M;>XYXKT;QG_P3I@%RUQX8\136K-@?9M1B\Z,@=MZ;6_,&O,_$O[%/Q,TN?\
M<V.GZA%&3L.G7L46[G/(D53CVY].E>M"6$GM;YJQ]91Q655-E!>J2_-?J.NO
MVR/B##$Q_MQ5\MPI;[' WWLD<;?PJM/^V7\1K2*+S-?4"178N;.#@*>OW<?Y
M]:P[_P#9O^(FF1_Z9X)U9CG<S6QCF0G'/"L?Y5@3_"[Q%;_NKSP_X@L<C:4.
MGRJ "><MM("@D\X/?BMU1P[VM^!Z%.GE[VA!_*+.RN?VU_B+!*JQ^(TDW9 !
ML(>H'<A< '('U%0W'[:_Q,6?8OB*)3&,,&L8.>JYX7UP<=>OM7G_ (BT$VLP
M-OHOB6%648\^!V"KG)&1$O0]QV'0UB7$YTX-)-#?6\TCD-YMM(A7/<G&&!SS
M@ X'2K6#I/[*^XZ(X7!-?PH_^ H]6U']N#XG0VL;1:]#ND5PN;&$[B,D<;>O
M08YZBJC_ +>GQ.#1O_;4/DS(2F+*$9(+X/*]P!U]:\KO[J(P+(+J.5X0%6,'
M;NR O&>O;G@9/)[U#/JD"7&V<0Q,V%=%DWB,<<G^$$$9X/8=<U?U&G_*ON*^
MIX-_\NH_^ K_ "/6+K]O[XCI&THUDQQJN?GLX ">?]CID'FJJ_\ !0+XEJ7W
M:]-M:-958:=;X53C_9['<OU%>;6SZ7,)H?[>TJU#JQ\N<L7G&X'8,*0A8X((
M)QCMQ6%?W^FI(WEW5I'\Q49+$@?B3COSGKQVX:P%-_97W!]5P=[>QC_X"O\
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MB)=6\#Z[I4<UJUO!>:7+,84E#*YE\N4$M'Y150I(^=@05RP'>_MM>'+7P?\
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MRVS5.*;OV[];M:?H3+VC5U(Y?5/V]/'2W%O>&]MHX5C0&!(?W$W*EMQZ@X8
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MGD.#A1NZ'DUG_K-&,74=.6G]UIN[[:]V]_F.7#^+C%-PDE_AE_E_F?5WB?\
M8Y\41^.I-%\3_%#X:GQ]->PZ=!;76L73S1R%4B4F3[-M$B*(XEV' !.XD'GS
MNZ_8U\3Z+\3+70?%DVC:>UY<ZA;3117<;,GV4YG>*/ !6-D)V\$Y''K7UO\
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M]4\7-;MXE:6^MM1\B#R(UFAO9X6 3) QY?\ #P>HX-?1%?G;^RS\&O$OQ?\
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MX+'/)KEJY]AFN:=.G/UBXO\ *2_&QPXKB>-6-IT:<[]>1QDOQ:_,_EE\-?\
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M$];7Y=;6WV^5OT/F7XJ_\$3O">AZ->W5I\1M8TW3S$ J:MI\5S'YF><F/8S
MC@(H))]>E8_[&G[&WC+]CGQ3\2]>U^Y74O ]KX"U<VJP6\]O=W1V1N2EK(?E
M)5",$[B<=!S7M/PL_P""-,GP.\;Z?K_A'XU>/M(N[.X2:6)XX[JVO54Y*2QR
MLRD-R,C##.00:^D?B/\ L]W7Q0T?Q-H.H>)KF'PIXJ\.WF@75A:V4:7*&YC,
M;7"W#%B'56;:NW;DY.<5CBLZDJ3HPK>T4EUC9K\-_._W'/B<[Q#7)[;VD6M;
MJS_KYL_$^/\ X*$_ 73+ZRAU33_&FAS3,JHVHZ%(J2E<AA\K%B<AAMR,;><Y
MY2[_ &^?V9]8B\Z3QCY<?$5NEQITT<A*?,W\)*Q[N QY.TY[5]=_ 7_@WA_9
MD\+?%*QUC4OB%\3OB,VA@1KI/B+7Q]E+*?E+^7%$Y"G)QO .><U]):Q_P1-_
M9LU7X1:AX0L? $&DZ=J$<OE7=I>S->632'<9()I&<H0V"!RO;!!(/!'.,5!^
M])_=^EU^9Z%3B"*?OP:]4_\ -?D?F?X9_:&_9W\9Z=;P0^-O#]U=7%Y#;Q6^
M_,X#D!682A%C1<C<<Y_E7;:M^P%X+\6VC6UK#I]Y'(79IK60*(RR%4VF(D*F
MT;MPX"K@>H]>U;_@TS^ VN:S]NNO'_Q<N+IE7>TM[I[>80NW)'V3'(KL/A[_
M ,&T/PE^&)4Z/\3OC?IYCP8_LGB"&WV$?=.$@ ..P((K>GQ)B8RT[[W_ $U)
MCGF#J75:/X7_ *^\\/\ &G[#WPO^*NL1>(/$WA7QUJ%\(+1;E;#Q(([,FWMH
MK572/[-\@*QK\N?3KVP?B[^Q#X?\=>%?#/A/1]'U+P[X>\&17+$7FI1WQN9;
MF1) S.(T(DR" JC.9&.01D?=FB_\$DH]"L+>&+XY?&6=K<DB:ZN=.N)&SG@E
M[0C^(]LCMBL]?^"86F^(=;O=+L_CQ\6+>^TWRI+B*U_LR-X6(.U\FSX9L$D@
M^_&>>BGQ'45FK^[MK=+IW^1SK$93NH/[G_F?-_P8_9PL_@[%#]B#/8>2CHUO
M(L<LH'#LV>,@!TYY^Z<UTGCGQ'<>(-!M5D@7R9)&>26"(PR;5^4^6RA@%VNW
M)X+L.>M>P6__  16M()49OC]\=)$C<.$:]TW!P<X)^Q[B/4$U;\4_P#!&^W\
M56<UN_QX^-5G#< !EM;G38R#N+;@?L9(.6(X[5A+.XSGSS3;_KS.J.=8!+KI
MY6_4^&_B)^SUI?C^*:W?37NV:+,4LX>(0(7 $DC+M.Y.OKGD'"G/ :Q_P3S\
M*G55FM5VK,JQP6T090Y7&U2"<!2^23@CY_QK[@\:?\&YW@OXAD_VU\>/VBM0
MYW?O?$5KP>_2V[]<=*Y__B%T^$4FK2:A)\6OC])J101QW7_"2PK)$.AY%OSD
M<<UUQXJJ0T@G;U,:F;9=-\TJ;;\TO^"?7'_!,SP);_#3]BGP;HMK'###9"Z
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MKG>#\Y.:]+"\,UIM2JOE76^EMW;OTMHGJ=-/ <SWOZ?UYGU!^WU_P5 ^(/Q
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MTO;[3[>PFB75IXYEO[&ZE@FM$A?>D7F98[2QR<+G .3TKH;WX>^&_@JK0?\
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MFN[^&?PU\8>'?"NK6.F_$_6-2T./0(;7P_"T,IO-,NU;Y]TC<'!,I1OXMR#
MQ7)1^)KJVGN([BSDMUM]LEE.DOS3%F7>NTCY0 !C/6MS0_B#)H/V>U69K;[4
MYQ-C[I!#Y)'7&WH/6O0K8BK-=.G1.]MGMO;2^]M#-\/T8/FI76O?[UZ%?PGI
M&O\ C;XI6-]\0-4O;?Q#X/C A\1:0DD5KXRM@ %$H0D-<QD,?,'/53TJ;X,?
MM5Z7I_B[XB:3\55O-/UBSG6]\-2Z*TXE:RGE"8="VQY%&PYSN.YQCI5*._\
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M5;;]DKX:_M=?L\^'--\=^&5\0:=ISW?V83SRVLRI*SQS1L\#HQCE3AXR2CC
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M.?,FMI6"X3+B1Y""ISNXR<A>XATJ">T@M[+RIW6180%9&C5BV1NW*#L&W&,
M90\L<5<TA9M*,<-O?>3-JJHGVEK?RS*0J8$PRV7A# C.0$R,<L*=.I*'PO\
MK?4SK8>#MS)?-'U=^VG86^H?%C3;B:>\^U?V!!%Y6]F2)&#EPH)VG=CD@Y&P
M-G@9\LM?!D,>HM?KM#&)U:7)+;'4)@.>BL"!D'NN2>,^@_M8^,;74_CMHOA^
M%[=;K_A$K&\C$MS"OV@/(R%1$6\W*@*Q)4+AAR3Q7$K+;V?B1=+\RQEU"3<J
M6<5U_I,I5$=T"'<7*KACW7OTKDPO,J,5Y?@<>#M["-CG?$WPDT+Q9?Z=)=:?
M97@TU;@VT]W81R26:W$:I<^4Y&[$@;:3P#LS@'FN)3]CGPW+=>%+A=+BC7PM
MJ%Q?6]K$FY6>:)('RF\C:R"(?,2,8]2:]9M[;S-":^VS0_(&G9XW7R@2>%&3
M@D,HW<?='KD00B.34XQCR<1E%C7.Y"3A@2!SE<YZ\$\=Z[*>(JQ5HR?]7_S-
MO9QZI?<>$Z=^PAX7M?@;?>#&M6&AZS?S7]Y%*95=+TF(V[P.6;$D;"0%<X=9
MY%R,@CTC0OV;O#6@WUX&TM6FU3P_;>$KWS_-87NFP95+=\G8R(2"KD!AM7!(
M&X=<91#I<EO;S36[Y9=LS2(^$&UH\'T/\7? SGFI-0LFU>WD!:;;(K2AT+M'
M$&R,JZKGDX.,\G QS55,56DK2D[7O^7]?(I4H7TBCE=)^ GAWP]IMO%#I5O!
M-X9@6P59(E(MK5B2%10NX*)&R2"3E\\8.;FI>!=+T6>-=0O;JV=3%/97EJ&\
MR*;=O#@MDC) (!SR/3&-:]BA@MS]H,MXLT6<2)^[1E5>/, ' ;T .!SS7<7?
MPIM/#UN5U3Q5IT?VA(;G$MG<R-;J\>]5W!2#M5QTP,@G@\UC+$23O)O^OO"5
M11T_)?Y'BMOX:\/Z#XFU;7K?3+6XU:9 ][>+&OVK48QM8-ELE-S'HI"ACG&#
M61X.\6S?'/X4M:ZMX>OM$76(#;7>B7)$DL ,SJK&10")/W:2HVW<"$/! SZQ
MXX\!2^#+RZCCF6\N(2OE74"ETF$BK(LB+PQ1@1PPQELY)7 \4\->"M?^#<=C
MX7TK2_$6L6^HW.R._P!7EFG>XN[B<R-;$J&,4<,2M([RA!LF4#D 'JISC4C=
MO72WI_5O3R)YXJTUM_PUCWW]CVSE/[3'A.6ZFFFD2651(5VF1Q#(,D9(&X9/
M!ZJ:XGQ-\=? OCGQGXLVZ@VDW&AZS?0WUKK ^RRJL=RZ-*%)YC)'#8Y&.AJW
M^S9^TCX7\-?\% /"'PO7SM4\:MJ-U#J45M$\D>B%+-I2)G;&TG(P0,'(Y' /
MRC^U=]LD^+_BK6M:TVS\<3:#K]U<Z?:DS3+-8M)+!'%?F,K,L<,RL 8\ERXR
M2G-:8/ +$8AJI>/NQ:\[M]'WZ:KOL<?UJ=/$.=/565_O9]+VWB#PKXY5K:PU
M/3]3DD51!]GO5,K$J)!Y8S\V5(;C^'%)<>$I-!9AY<<-KM5(H3"WVBVE&26)
MQM*$$#&,Y!ZBOA'4?%S6U@UKHV@V"Z5#LN!<0VWV^71EN4\L);75JPV&0<89
M695" \Y%>H_ []H[5/"?C&/$WBJ'1OL%Q]JL->CEOH]/O5B#;VE.V;;))N94
MV[AC;\W%>E6R&<(N5.5_)_\  Z_+YZJ_H4,W;?+*)]*WNB64\/">85)#AOW;
M>_0U1?2([<1M%#/#NRVYG/"@8 SU/UXKA?AM^T;K?C'1I/\ A(-'\/7%NI,L
MOB'1[QOL"B-B)("9 &^T[BJB(#YAC&<YJT?VLOAPE]OCTOQZURT0B6,:=*T!
M0. 63Y@K#YMS,H)"J:X'@<3&3ARMV[:G9',J+5VRY>_#Z"75([H7=P9 YDA5
M&#%-W!P0-W;U_"KDVCZMIM\!I^BW%S;A%>6[<)#'O.0I'_/3GJ./K7JOC[]I
MSP_)^T9XT\#PMX3_ .$?T7P_K&I7DD.GHM[8BVB7RI82D>]\.V20V[.3@X-?
M,VM_%#X7V/C#5H]4\6:WI%UKD)U"ZMKZ>X:RO4\LIO/EGRRJHF0. "P.,DX>
M'IUZB3G%[)K1O1_=_7J8T\SA+:RVZ]_EN6/BEXR\9>+=0D\'^&KC1K&XBLK6
M6^U2Z:>W$<F]VD6!DSN VQJR8+D,<<"N!U7X:^+[KXDR:U+#8ZYJD5]]EMM7
MUC9=VP147RYQITBE&B!W)'O*NH;YE) Q[9X.U[P!=:+-]C\3Z*MMILI2</NB
MD@?9N/RL<DX&21GIR<BID\5^$9HM1OH?%^C^5I*RI>LVI>5! 0@=MZ,?OA/F
M&,X /6NZGBIT?=IT[>J=];?GIIMZF-3#T*SO4J7\KZ>APNG_  \FL=5U_5M'
MO]0CU;79F29;NZ2[M(U:1I9HEM^% ,C$[B2R@%<GK6QK7Q%U+PKXC\*:/':6
M;-J$D@U&66"<>3 B*?W;QY579B0 _&,=LUTL.IZ++J?V6VUS1[FZDB6X\FTO
MH96:)P-LV% R&W+SU)8=S5#QEX:U.]T6XFTV.T;R$827>H.R+ N.6V(I=RO4
M*0,_W@#6/MG.:]JOOTZ67W'5&G34+4W9>6O]7/>_BM=MK'[)_P %[@,L236U
M^V#UQ]H!&.<MTXQG(YQ7DT#R><L=Q"J*J"-N-W0''7Z=/>H/VM]/OO#W[*'[
M-JWGBH-J-I9WBPO'I+1V=_NNXR'P"S0R)&!@\[MSY(R:\2^#_P"T;;^%HH%U
MJ\UY]-72YKY]-O+>*5Y"MR_F3V]QN$C!%P63RVP..@S7/A<JG4P[K4G?WI:6
M?\TMON_SL<N!SZG0_<58M>]+7UEU^\]EM]:_MB&^A^P7VGP6=P((FF</]N4!
M6\Q0I;"DL1@X.0>*+R[,-O9S+ND59]PW=>1@<C&/3ITKB/ O[2UCXJTB^6:Q
M7^V+-)':RLW+(0K#;M:0#YBI0^QX]JJZK\?=*\3:1>6UKI7B8,EL;QKB"%#<
M* (\I!'_ ,M6&X@D?=*G@BJ>7XCG<>2UOZ_K\#W*>;X3E3<]'_73M^AZ'JNJ
M--:1*ZK-N.P/$NWS,?=/?IC'O6<E^]W<JTGF;0H*L1MW8 QSVYQ61J?Q:\&3
M21Z<NK3+JD*7)DC>VD5H3;QB217Z8;:<CCG:WI7K_@BP^%^IZI\.],NFO;VX
M\;Z=I]R+X:ZEN0]XS"/;;F(DY(^7+?-BN:I2J4HWE!_<;/-,*HWC)/?9KIJ]
MVCS^_OEDT[:SS C]YY9? D&<GC@Y]Q_.L?29X;RS5I)67YP2)..<D''')X]?
MUK>US3)%OK:W^T(6D=EBC+[?M&,ME3W^Z3@=,5SL>G7R JS,I W(6).Q#CG'
M^]^IHA:QZ$>7EW.@CU"0:1,QO9BR@^2P)&X#J,=NM85U?2^8K2*Z[HR),>A/
M.>_KTK7N+Z:\N%L4MA%,;&.Y22-"(YH^0_S<C(*DGVYZ5RFO:SH-G=+IVIZY
MIMO)>6C$JTP1=CN8_FD!POS<<D$9!XZU=.#;T1#J4X:S:7J37,T9L&APTBOD
M' W 9].<8/7WKZ._X)*G/[2.I#:WRZ'/EB<9_>P]NO\ DU\B>&/%7@?P3H]I
MI]GXJL;73]-MOW:7%RY;R5<1H^YQEQYAV[N22,].:^KO^"2?C+1=>_:EU+^S
M+QKYFTJ\MGD2-_+1XI+=F4LP SAU(QU!/-9YE1G'#5/==K/5JQY6<8VA++ZD
M5-7<=D[GYO\ B/\ ;'\;67CO7+6&^CDC@N+JU+W$22>9(ES(3(%RISY95<9(
M) P,FLV?]N#QX^H#[1?0F&2"2%8X(_*9&"X9UVCJS$-C[OR#I6A\0?VG_#<W
MC+Q S:!:LUC>WL4-G#:K:F0K<,F]Y%//R-]P\YR<C%8_@3XJ_"N\M9DO]$GM
MVN(7D),;XMBK;0J,&)4;>>!@!>0<8K[JG3HJ-Y4/N29\'[2;M&.*7S;0[PY^
MVM\0/"6AVUC_ &JUS]AMG*^:$:XEE+ KYS'F7Y<@@8Y&>@J/1/VH/B,]Q9QQ
M^*+[[3=73QEFC1H9S,RB/@#"%6^7MQW%=AX$_:V\!?";PM;V_P#PC/AG6(5B
M6VAO/LTLMUI1#2X;!P2PC^;/.XN>G2LO3?'/PGM-.N]2CLYIH;FX.R";>'C=
M4D8B!%P5 ZJPX!V=ZF+I)N^'_!.YI&%1VMBE_P"!-6_S,O6_VL_B9;?$.ZMY
MM8O+)=/E-O=648C\H2*0NW:!A_G0@8R<,W)/-;&C_MT_$S6]'CTY-0LU>T2:
M4W$T:*[(6X&YLY()"J "2,<'K7I7AK]LW1?A'^S#HOBSP]X+\.O-J/BRYTF_
MO-3TBVO;F:UMK*T:)<S*YW*TI.5(^8$GK4W[:'COX+W?Q;M?.MX='W:-INLW
M.GZ98BVMI7NK.*X:,Q*NQ6D9@Q*8/S+VS6"J4G)0GAE;6S23^'1W7S[D4Y5)
M2:CBN^\K=NYX_)^U_P".M-\;ZMX@L;X1V^LPM";0@F.!8EV1R+'G"2)O!W #
M=@YJU#^VY\5)-,\^'6M/F421*\\5NL<UTK2E@X! !V8";<9VRK]:Z#X??&+X
M ZM:W!U7P[::3M9U0W N&>W<R%@X92>FPMMQ@!E!JWXDD_9_\!Z=I4IOK?6+
M'+W-M/!=O<,H<JA65%'R;N-V0#P,54JV&YN66&=_\*>B.B.$KN/-#%1MU]^V
M[,S6/^"AOC[61]GNI(62U!A"VUMY/FI%LD5ED4YRQ #)R"'Z\T>./^"A_C+4
M=9CA75KVRL[$10SO'8"&6\(D??(BL"4;8T;!6R,C;QGGH?$FC_!_QLVFZ@/%
MFE:1I=^T(LXDB3?!:0V[QF%=['RLL<Y92>,8)P1JWVE? WP9J%YJQU>&ZCTF
M2?\ <PZF9HF5H]Q,?ECYD$91!MSE8@.67-8^UP*M:@[]N7_@?(U^J8Y_\Q$;
M=^9;??\ ,^UO"_\ P4K\9?LZ_P#!,#X5^-M"\*Q^,];\4SZQ;06FJW9MY)C;
M_:Y( 7B4JID:)%Z84/[5[-^PY_P58L/VK?BQ?>&M?T_2_ MS=+=?V#IVIW9M
M]6U&2WU74;&:#R),%I8ELE9Q'NP6;^'!/7?\$E?$?ASX@_\ !/WP#J7AS1X]
M*T*X6[^R6AM_+$86[F4MM).-Q!;).3NR>M?1C:3:O=1SM:V[31DE)#&-R$]<
M'&1FOR#,[?7*ME9<TM.VKT/FJWQRN^;5Z]_/YEBBBBN$R/%?VY/A!XN^,7PY
M\.V?@OQ%XP\.ZE;>*=)>^F\/:PNFS/IC7L*:AO=@0P6T:=@!\VY5*Y8 'Y]F
M\4?MO^&XEC31/#NN6[>%7G+*EE'=0ZH]S*HC!:;:S0Q"!AN!253+EE?:!]V4
M4 ?GWX&\2_M\:?K%I->:'X3O&U1S>WL&I?8ULK"7^R;,+:1F&?S%M_M:WA+_
M #N)-@RT;9KZ._X)]VGQ8@^$WB";XQ2:LWB*^\2WES8+J(M$FBT]EB\E/+M9
M)(HU#"3"!V(').3BO=J* /YQ_P!N6W'C+Q]\8?$VH:E8PVVH^/=;\#W4MO#)
MMM+>W@74=.D:)LNQ::WN 6)RY8A 0.-B^^/]M\?O"/P[^)OQ#73_  Y_PA?@
MV?POX-MIE:2'^U)+U;>*_,KG,JVD4)GV.,23I(<<@'SS]L#Q-)H'QR^+7AGS
M[C4K+5_B1=ZC!#8 LL.HNY\QF8A0DT:QI$FTG:6FY)852_X3*^\;6GBGP7XQ
MT_5/&4.L27D7AW7GN9?^),\2&:"WLBQ&X237!\W?G<I!X8$G]<CA.:E&ZOM9
M[-*RO;SL_N6FI2PU2?PJ_P O,F^''P-O/$/P#\9ZII>EWUG<> ;72_$?]IWF
MI6VEW=Q9WVJ0J\DP9]D.1;M)&&W!)4W;<[0U'QU\-?$6C>&O%CZ])X@UO4/%
M37?BJZMH+:4G5_+-M=#SO-57$ZVMW=/*C+N1 LVPB5:Y_P &>&;/P_\ !?XE
MPWVJZQ._B.\L]"BM6A^SK%!:W$&H2O<*WWKAXXRL$2D;G67YN!GU#X%_'SXB
M:):>-/$^@R:IJ&M>/C<2W_B>]MLZ=X-MF,<=W*+>- @N[IH(+<DY"6Y!?<&)
M&E558R<HZJ]ET[?\._32YG[.2T95_;1^(/C7XP_LN_!GXFZSX6T?0? ^M0)X
M6N&T#2XFTP3V5T)$N+U5P["6W$!2,GYEA8!LG-;7[2TVB^"/@)XOTWP];R+X
M=\/_ !3CTJ\6*Y-U8:[<0>&UC$L>'S#:W(\R01*TFW'EL&);'F_[/^L>-OBK
M\+?B'#Y>[P?XHV:QXDO;]TM].@U"WN&EMI+*-BD?VP.5M_+CQQ.N5*@8]L\%
M:KI?C7]D:?3_ (BPW6JW[?$_4Q>3:SJNYO$>IQZ%;6J6L<D*Y<2/N5&.YHPZ
MG( 8GEG3=-I:6BWHNVC7JUJON?H1B]V9?_!1NP\4:;_PSYKGCJ;5+'Q#IOPQ
ML?$OB+48YWLEO'N+R<R6MM;VR^09O)<*[H!MB/[T]#6M^Q/\";CXC?M'_"7P
MEJZWRZ];S1P_$3P;J5Y-8(NEQ02:EI^JP^;(2XM3=@O#A#(\43A<,QK&_;LN
M=8_:LU;X<>/-4\17*W4OPNO;M;;[6ZI!Y&IWJ3:9&K8D>=DDMH5P 6-O(Q!"
MXKQCXF?M5_$:ZT#1I&UK6M-N]9\'PVT^KV</DW.OJE[(B/=72HIEDCMHU@+@
M@$0)&"#P<:>'G.@HQLG[WHFW*UOTZJRM;<GV;1Z/^T+I/AOX76%YH^ER:+-J
M'@_P_-I_BJQ^QAL7#ZW=VR:C%<,VZ2_:)7NS&=@590B )M Y+5/BEK7P=^)4
MVM>&[74/$NGJM[X'\&KK&G#%_;R11F>*[@7Y9Y/*N(8'69GP[(Q+'9CD_$-O
M;^-(O!.N:/)JNL7'PX,OA_Q%IK9C&H7<2_:X]1^9MX2X$@A=I"7 MLIT"C-\
M#?&+Q!\(O WB+^R;K4%\'S7\$<BWERUQ9R7$BDBUN$Z,!"F6?"'-O&<HX KO
MP]%^SM)WW6J6MW:_YV\G9CC'N?4W_!-[Q[8_'/\ X*-?#G4-0\*VNA>'_!^H
M:?I>BJHDN6TJ[+CRK(7$S//+)F*[+,SG;&BIM50 ?M[]ISXM^&=%_:"\;PK?
MVJW=CKK6>H6Z*QFWR/$(T(4K)\Q=22@8;77+#(S^</\ P3$\/7VG?M;?LX:E
M-;K#:77C6*QLIF7+:TD;3_:+INH:2*58XS+G<5EC4EADUZY_P4&U;5K_ /;%
M^.$C1>&+/Q%IWBF2/3IYK6Z.KII!A5+F9/WB1%6+01I(64H(IC%O8$5Y&.PM
M.6,4&[)0_P#;OQWU>_W'=A,0Z+YK;V.H\>_MHZ#X_N]&TKP[-JC:G8WHO=+U
M"YN/[)TZ?[.)HB+R7#2);BX1X9#AQER%0;@U8>I_MU>*-3\#PV6G^'?"%WKE
MU?):65HU](MU>PQHFTM"R+(LI98<^8$5$DWLW3'CFJ?'K5=<^!7@VTT!H]0N
M[BVEM8TU>YMI$T%_MZSQW<DIA1HK][>5K=YD9'AC="=S!W&%I7Q*UWQK::UX
M#MM)_P"$8U;X@P@ZE:W<YU#S7TRVC2&V2>3SIY))HX)#)&Y032 *22J"MHX.
M"3;AI?J^SU?]::=+F[QU7F;V_K3N>_:M\?O'!\+7G]DH?%UBUDU@$T[3XM.D
MT;46A:Y6.Y=KPC>L2R#81$)&B=U^Z<>?ZY^U[XV\+:1I[:SK=OJNHW-UJ?A^
M+2_":Q:C;Z7J%O:I-$S0Q%MT(#JVZ)F,I$XR0ASXQ'_PD7PV\9V^DK]AU*_T
MV];3;:\CLDU%)S;1B'[0NYA%OE0I$_G+(0KRJH3>0VCI'QUDTWQ5?>*O!-OH
M_A&UU&Y6>=["T>TO(%FNT2<Z=JGF)*JR[I D8^:.%WB9#@M6RPL8Z*":[_UL
M%7%5I2;BW;7K_5STC5?BEK?B&SN9-8\9>)-0U#3?$ZZ2VDV6J064EQ$X: W=
MM JD2L;YEA*,Z!59&*Y"X[?XK+-\-/V&?"NH^*HO&,/C/4O'5W'I'AY]7:YB
MU:2]MK*.6RN9 5=5C^^I@)"2*(]P9L#YN^&WCS4O#=MXHM=#;3TTNZL[BUU#
M5+I5M[Z_AF8L]H6ROF.I\Q_O('=MY*[5V^O^._&/_"J_V)_"^K77B+Q!H>IZ
M+XVU_1M*@BF\V.VACL=/@>*(.501--#'*SQJX'F2 9=@]56H\LHJ-M_3IMIW
MZ^3Z:"E4F[MOK^AZ5^TMXME^'7Q>\9^)-/\ %&I6JZ+9>&M,TG2=6@N=5MM1
MMY=+M0MJL$*_N[E2DA/FN6\GSI<%@N>>\%_M%?%+P[X4N?$7BJX\+ZQX;TN[
M>T6:WUBV:ZN;YX46&UA2.7%U),TUN/,A!5"1NV$;:Y3]LJ'1YOVAO&$=WJ&M
MZ;K']B:7="YCL_EL8%T2PB\N)$<2?:SYJ11-'M W.I<C KS@ZWJVK>(;<^'4
M\F[\"S"[O[C7=;6".&TE>-?LMO!@+ 7D**88HY3(9854DHI.=/#Q=*-[/1;K
MR6W]/5_?<,16II2BWH>M>&?C_JGP<?6M-U/0K7S;?57^W_V3J5O<V>F3-;R2
MW!NF1 89^&5H\,VU1R3P>D\._MX6_AJPFGU3P[J^G6LUG<H]\+F*ZTG3;M(!
M RV\P^6Y:$2@%U!QO/'RDU\S^.OC3??#C6UU/X::E=Z3>:3XCG&F7+QN4#0K
MY,<[6TT\T=O(T;(D:RJ'*O)DC<365\./%+:CXCU3Q5X@ABT_3;[3;RUBM=-L
M7@A@DF0,EM!"ID\CS!'*N]T;R482C).*KZC"HG.4>GG>_IT_I6-HYC6Y;/;T
M7<_0W_@LWXOLE_:06:\\(7DVE2>!-$6X\3:-JT=CJVEPS37+FVC:3='(CB+<
MV8V8*K'(7-?)?@S]I?PCI\WQ \2Z+X3TOX<ZE;^'K_[)XJ3Q#>7FN65_-%Y/
M[N-FV/)<-A!-&BA TA&T9KZ&_P""T_P8'C[]JOP;J=QK'ANWMX? >ES?V1JM
MVZ6TXB2X+/).N F V.3\Z[CP <_._P /OV3;C7/A%J6L:;<Z']EFGL9=/EF.
M(O$%S!$\CI%+-CS8 T@*;$)S&% .2:Z,MC1^H04WNDMVM'IWL_RTUZMUA\/.
MI35NW]??_70] \/?MG^+KGP3:WUE\>K3_B4FVL);#Q!X<DLK;5'#)/-'%=Q@
M^=LCC<'<JL3\JY+ UUWQ-_X*?7FF?#JZT?POX8'A6XM9+:32]4O]42[B_LG[
MR3*'"B6:2-0"A3<J2ID YKY#E^$^J:QI,7AK3K-2NI:/+Y5T)S"QEM(WS<[)
M4#VZO*ORQ+M<L3DX:J]S^SSXVU7QY=?9=-N_,N(HFMK= M]>(KK"K%4VG=)$
MJ@R[#F,*1G-=TL#A93O)+35;+[TK7U[I]5<TC*O%/5GV_P"(/V^-<\ >"]#D
ML?%GA'7->\8M)KL%EX@TRZT>UT_2;AFCM;".:%BBS!HI)&+G:%( 8_-4MI_P
M48\0?$67Q!>>$;?PWHFB>&4BO;Z\NVN);JRM 8AYZ0Y+7<,\W[M5CCW*) 'P
M#O'R;\5/AU\5H1JD+0ZI>-:W/_".:Y(BR2J\"SS7!:21U,CPDMN22,8 !''
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M'$6::MX5GO/#K>+=+O-9TG4)OL.EBU9K2/RY)EC0ZC*(T9/,>.3,.0X(S@#
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M?MX5^&GQ>\$^,/$BV[W8TRQO@;J2),;W1& +A<@G;G Y.!0![U1110 4444
M%%%% !1110 445\V_&W_ (*D_#WX&_&S7? %YHOCS6_$'A]]+M)_['T87-O-
M?ZF3]@T^.0R*&NI@"X0X"HI=V51NH ^DJ*^'?V?/^"M?BC]H;XP?"/0-/^$N
MHZ=H/Q:UWQ.MIKM_>+"EEI&CO<Q!W@YE-Y)+#'N3 BC$Z?O'8XK[BH ****
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M##_A]9K'_1FW[:'_ (0,/_R51_P^LUC_ *,V_;0_\(&'_P"2J^YJ^</VG?\
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M/?\ B3Q+8^,-0NQX**7$VK6444-K=K(M\&C:**&- $*KM!!!#-GW6X_X+F_
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M ]=)MZ_(OXF2II_Q?^#L,.DEK?4OBAX2/FSQ^9+83G58Y9D$A).6=R 2<[
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M@W5L4<[)^L3/DW]CG7K>W_X+B?MI3MY@CD\.^ 6'R\X^P7G7\Z^W%\;V3?\
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MDU.XT/PC9_9(+C4;DW-W=,69Y)97/5WD=V. %&["@  #T:BB@ HHHH ****
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MPV\2:?K'Q"LYKMM)LI-/6Q\0WMO]KU9WL[;5)68C"P26FG++%$VX+-J=T&P
M'/W)^S5X3\<^!_A9IND^/-7T76M4TZSM+6.XL([@N1':Q)(9YII&:>5IEE;S
M=L>X,N4!R3\>^'O^"<'Q^\)?'S5/%6A_%32_".FZUXO_ +3N]+T[5+N<:GIM
MML^Q_:7GA9YKIQ]H^U9.R7[2NQHUMXEKZ2_82_9XU3]F'X::UH>O7FAG5O$7
MB+4/$8T_2IY9;/2X9W0);0&4*[1QJJ OY:99B6!8L[@V<!_P71_Y0_?M$_\
M8E7W_H(K\9O@I\?=9\(:/'JVE:G=PZDNE6MKJ%]=M$\MY.P5@[94LD050J@$
MG(]#M'[-?\%SQG_@C_\ M$_]B3??^@5^>_Q9_P""7/B+X>_LWVGBK3[%=8T?
M5O"^EWUZNE2O'/:/'#$Y#1!295?(;?@E6!)P *^[X'QN$HU*M'%6]_E2OL]7
M??3K_3L>?C*567+4HRY91NT[VZ=//L>N?!CX]6?Q0MHU7;I^K0A1-ITD@=UW
M %'4$ LK#!'&0",@5T^B2VOA/XNOJD&BQKK,+?9;C4)+)I8P7'*X5AN4@<L5
M:-3P<$X/YR> OC+I?A?XB:/-?>$&L6TV\C:3[+>3'R(D\S,D9FWLTNYE;,C,
MH"G"J ,?5'P,_:WC7P%J5]XBNEDT'0$TRWCU"/\ >W4C3N\32W,:GY%#(-TB
MY7<ZH,GFOH\TX=JX=NIATW%I*W75VMHW?T?XGO9?Q11QD5A,RM%][:/_ .1?
MG^1Z')8?$#X#Z_K7B3PUXK%Q<:A>QW=O:W+?9)IBQ</;RX#6_D*@&UE7?G:H
M"@$U[3X!_P""G$\*2Z?XH\.W/B9K:WMI?[4\* 7$,$KE%>&12028G;#.JX&#
MD8YK@[;Q?9W1L/+F6]AU#>+<P?O(?NDG+ 87@'K@Y.,9JU;PZ?I_BG3?$4=K
M:+JNCAOLKW$/G&+<AC; R,C8S+M)*\].X^9KTZ-;_>:?O=&M/+6UNV_KH]CZ
M*OEZJTDE:K'^\]4NT9KWK=D^9:Z6/I[P9^UYX7^)?@WQ5JNAS+'?>$[?SKN#
M4A]G,9*G83@D[69=N1W[<BO _P#@K?\ &BS\7_\ !&SX_:D]G-;R77A.ZTZ>
M '+6L[JI&X'!"'JK8.X$'VKR2;]GNSUWQNM[<:EJBZ(TT<\>D:<\5BT2I*72
M**3<-L8D82%2K@E%' R3XU_P4:B\8ZI^Q'\>KB\DDTG3G\,WNXIYL[:A CEE
MBG3>5W;G#"<D;<$;.<GS:V3T(PE*E-.ROKITV\WOTMMJ>;+*<(DY.G..K?\
M,E;HVMT]^:R:VM9-O[4^%/[9FO/\-/!^C:+X?6:?1= TJ.:"Y7RX[M6LTV_O
M2P" [>F20<9KQ[]KK]HKP%\1/B1:W7BB/6O#M]%8R>=IPGD\Q)E3:KHZJ0@_
M>+]X=2IQS6?\*+WQ/!^S[H^H6]KJTVKR6.@7ZSWUU#J1G:UMMJ>1%(%BM=GF
M;LC);HIP,"[X:^$$=B@74K>WU*.\\PS?VO9)>?:9F:-][&3/E8,9($049;N>
M:]+!Y?A:3]K-[6TB]7I=]U:^WZ=.C#UZU&IRX+"J$G%KG;;M?N[J_P!S:=NA
ME_#GQWJ'P^U#2=<\%VI33_&=A'!<V>OD7BWT4<1#1O"6==KLLCJQEC8^6R@<
M9/::/\-?"&@^*I]2\/:);>'K6ZM0A@29Y$4_>RH<GR^21@;NW..NO,(VO+B2
M:-9KG8D4190PCC0?+&HQ\JKT 7  R.]9FHO-=ZA'-)<%;?RG#0[1L+$KAB>H
M(QC'3YO:M*F(Y_X:Y4UKJ]>U^]EHM#MP65RA+VV+E[2IWLM._F]WN_D:-W<[
MXW:-5"LV\,S?.YZ;A^ Z?C7C7[5_B>WMOAQJ&GM<744=U"+>5[9'7$Y>)HD+
MB,KEAN8 ,"2G7@UUWC+XJ6/@S5[&QDNK/[=J%Y#:+"SG>GF,4#A%!9CNPNQ<
M%BP Y-?/_P 4O$K/KG@7Q5KL=Q-K6K2:GI^J7?FS)I):Q8A)!&&:.*=5,2M$
MF6$D3D8:O2R;+Y2KQJS6G3S:3?W:/7O;0\KB[/X8?#2PE%^_):^2_P _R]3P
MWXQ#05_:)^%-UH5UKD-CJ_Q6\&7$%E<(J*K/J2N_F[&V[E(QRN2<D8%??W_!
M?:/16_;U_8X_M^VCN],8^,4>-V90&.GVNQ@5((*M@@^W>O@KXS>/=3\4?%_X
M&A=0\[3+SXP>$Y;JTAMUBL[*Z&H1G9%DE\X)8\("2Y"X(Q]9?\'4NJ76B_'O
M]DVZLYKBWN()_%+![?'FX^R6>0H/!)'&*\[B*G.>=T(7LVH*]]5K;>R=SY+A
M6%-\D:J;AS)-+=K2^AZ[X6^,]S>:G;_\(_XFTW0X(K"*P33[NP%W9PR#EKC.
M58R;55<EL<9[\>EO^U%:^'/'T.AW/BK4-+6<68T^=8)+B&]>5',D7'F)_ 2.
MA4J<G')_&3X>?MTZQX=O1%JUO,T<>X/+;867&.-R]#TYQCK7TM\#/V\H=07R
M=/US_5[/-5F\F3:3]W=UP0<=\<UUX_A^I3O[6%UW27EJW9_CKZ'Z'_JS@<Q7
M-DN(3E_)+25UTY7T_P -UYZ'Z;>$?VQK75OAW>>+ENM/UCPOI\#RM=QQ/%)(
M4+>;C.!\J@=N3FO0?@)^T-X5_:2\$6^N^%;YKFUN%^:&:)H9X#UPR-@X(((8
M<$$$'!K\_?@%\;?!&DZ[&5L[K3[YK:XMI9IM0N;Y;JVGF+S0NDCD,1R5<XVA
MB,'K7K_AF[U#X)V5O'X#M]3\>VNI3BZABTW;'J"+'&J)'M7:BJJ\%RWW>=C$
M5\SC,GHW<:-T[Z7LE;L^GG>Z]#Y;'9'B<'&2QU-PFNR;BUU_I'VPOW>S<YSZ
M?6FR3(@:9W5%4%B[G&!WR?ZU\S^(OVUM#\&ZK;Z+X@\;+X6UW48V)L[FQ:1K
M)E8*5$I3:X'()Y/](-:\773^.K/PRWB;Q9Y$TTD]W-KUM'?6>IPQDF2WAY4
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MMMM]7DT=-K$2WRX4D#@?(#R>GMFOU(U:VCC4Z3?6.K:M9S1GS9M0MQ=0L?\
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M[[73<K,=W)!)K[IHKGQ?%&88A<LI63WM_P %LTHX>-)\U)).]T[:KT>Y\U^
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M *+6OS<N/^/>3_=-?I'\._\ DG^A?]@^W_\ 1:U50DV****S **** "BBB@
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MJ$K^7O\ X/0O^4I'@_\ [)U8_P#I?J% 'Y.>!?\ D=]'_P"OZ#_T8M?V;?\
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MY.,UB_M:_M5^$?V+/@/K7Q$\;37D>AZ*(U:&R@^T7EY+(X2.&"+(WR,QZ9
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M "7[Q9_U_G_T%:NGN []F/\ Y. \)_\ 7[_[3>OOZO@']F/_ ). \)_]?O\
M[3>OOZG4 ****S **** "BBB@ HHHH Q?B!=>(;/PG=2>%;'1]1UQ=OV>WU6
M]DL[5_F&[?+'%*RX7)&$.2 .,Y'GO[&_QO\ &7[0_P +(/%GBCPWX;\-6>J
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M]Y/]TU^D?P[_ .2?Z%_V#[?_ -%K7YN7'_'O)_NFOTC^'?\ R3_0O^P?;_\
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MDZQ)83"*(6MW+S/9^6Y<$#A65LX*L"'&,^M>W'#Y=4CU@[>;_'MWT[V/JZW
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M?L_^/X[K4+C5+BYTJ?S)O-,:3.PWLP1@&/K@  #VZ_K]_P %CO\ E6\\5?\
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MI/WHV':OA/\ X/C/^29?LZ?]A37?_15A0!_/'7]>7[/?_*$?]F'_ +%+0?\
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M/P;U#J?^)M+U/_3.*O=J3T=@"BBBD!\3_MS?\G W7_7A;_R:O,?!O_(Y:/\
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MB8N&F[VU[]5ITU^77Z0NT6>W6.X7SAN\R.0\[I.2I)]1U_&O"?VG/!NDZ?\
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MQ',]J@;<8G^[G&.<<4#/P=K^O+]GO_E"/^S#_P!BEH/_ *;J_EB_X83^-_\
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MYFD'&W(4D\??OP6^!_AO]G_P5%H/ABQ:SL4;S)&DE:::YDP%+R.Q)9L*!Z
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MH&R_ PQ#;6 &17(?$?XJ^(?'4VGZ9J;)=;;/SI19NR"\B>9FW* !RT9CQW5
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M45^;GSX5A_$+X8^&_BWX=_LCQ5X?T7Q+I/GQW/V+5;*.\M_-C8/&^R0%=RL
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M\ ^&;'[-=1W>8M/B+2LGW59F4DKZCOBO4=-TJUT:T6WL[:WM8$^['#&(T7Z
M<58HJ:E6<]9MOU,ZF(JU%:I)OU=PHHHK,Q"D<;E(!VDCJ.U+10!XE_P4:_9/
MO?VX_P!A_P"(WPGT_7/^$=OO&VCOI\&H,NZ.%R0R^8 ,F,LHW!<$C(R*S/VD
MOV"]._:N_P""=]W^S_XEUZ^TRPU;P_I^B7NJZ7&GG+]E,#EXUD#+\S0 88'
M8]Z^@**+Z6 ^&=0_X(8^#OML,NF^-/$>GI;[5CA$,9CV \J0I7/KUQGG!Z5Y
MOXP_X-^9+W4F?3/&^FR0M,''VS3Y$,:!]VP+&^,$?+UR/4U^EU%>Q1S[,*3O
M"JSV*V>8JLK5N67K"'^1^6L?_!OSXHN7F^T>.O#*+Q#"%M;F15M\C,>TL-N
M"%*G(#').23U.A_\&_J,EO)>?$9--NK4;8FTS2I'*C.?O2W![DG  Z^YK](:
M*Z)<4YI)6]J_N7^1Q_7I*ZC""OVA'\&U=?(^(+#_ ((6?#N-+6.\\2>([J'Y
MC?B.*VA-V67G!\L[!NW$ 9QNX/ ->H?#G_@E5\%O!,,+W7A)M<N(0H3^U]0F
MOTBV<+M5BJ=,9^3VKZ/HKSZF;8RHK3JR^]FDLTQ35E-KTT_*Q\[_ !A_X)G?
M#?XL?%[X*^+(]-L=!_X4GJ-U?Z;I]EIMO]GU!9[5[?R9MR$[%WF08.=XS7T'
M96,.FVL<%O#%;PQC:D<:!50>@ X%2T5P2DV[LXI5)R^)MA1112("OGW]OC]M
MF;]BVX^#.S1]/U.U^*'Q*TOP+>SW=Z;5-)@NTG9[L':0Q3R1\K%0=W45]!5\
MJ_\ !5;_ ()]S_\ !1/PK\'_  W-#X=OO"_A+XE:7XH\4:=K#2"+5=*@BN([
MBV0(IW2.)EP&*J0#EA0!]!_\+L\&?]#=X8_\&D'_ ,57PU^UAXAU#]O3_@K'
M\)_@MHNL>%[/PM\%(M&^.\FKVY:^NM4N+>_N]/;3/DD$<2E)5D#G+ @?*0:\
MN^*W_!/?]G_X4^,]:MYO^"?NEZKX=T2\E635M.62<3V<<AS<QIM&XF(;PF[@
M\%L?-7=_\$T?V(O#_P (/^"FWBSXE?#7X+ZQ\$?AAJ7PR@\/1Z7J&D/82:EJ
M7]J&=[G:6;:?)6--IPWR XQ0,_2*BBB@04444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
-%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6775760672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Collaboration Agreements</a></td>
<td class="text">License and Collaboration Agreements<div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Co-Development and Commercialization Agreement with CanSino Biologics</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September 27, 2019, Ocugen entered into a co-development and commercialization agreement (the &#8220;CanSinoBIO Agreement&#8221;) with CanSino Biologics Inc. (&#8220;CanSinoBIO&#8221;) with respect to the development and commercialization of the gene therapy product candidate, OCU400.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">CanSinoBIO will be responsible for all the costs for chemistry, manufacturing and control development and manufacture of clinical supplies of OCU400 for all territories. CanSinoBIO will be solely responsible for all costs and expenses of its development activities in and for China, Hong Kong, Macau, and Taiwan (the "CanSinoBIO Territory") and Ocugen will be responsible for all costs and expenses of its development activities for any global location outside the CanSinoBIO Territory (the "Ocugen Territory"). CanSinoBIO will pay to Ocugen an annual royalty between mid to high-single digits based on net sales of products in the CanSinoBIO Territory, and Ocugen will pay to CanSinoBIO an annual royalty between low to mid-single digits based on net sales of products in the Ocugen Territory.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless terminated earlier, the CanSinoBIO Agreement will continue in force on a country-by-country and product-by-product basis until the later of (a) the expiration of the last valid claim of patent rights of Ocugen covering such product and (b)&#160;the tenth (10</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">th</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) anniversary of the first commercial sale of such product in such country. The CanSinoBIO Agreement will also terminate upon the termination of the Exclusive License Agreement, dated December&#160;19, 2017, between Ocugen and Schepens Eye Research Institute, Inc. The CanSinoBIO Agreement may be terminated by either party in its entirety upon (a)&#160;a material breach of the Agreement by the other party, (b) a challenge by the other party or any of its affiliates of any intellectual property controlled by the terminating party or (c) bankruptcy or insolvency of the other party. Within forty-five (45) days after such termination, CanSinoBIO shall provide Ocugen with a statement of the CanSinoBIO development costs and, within one (1) year after receipt of such report, Ocugen shall reimburse CanSinoBIO all such CanSinoBIO development costs.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">License Agreement with the Schepens Eye Research Institute</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2017, the Company entered into a license agreement with The Schepens Eye Research Institute (&#8220;SERI&#8221;), which granted the Company an exclusive license to develop, commercialize, and continue to secure patents for OCU400 and OCU410. This agreement is accounted for as a collaborative arrangement. In connection with acquiring the license, the Company was required to pay a license fee of $0.1 million, which was recognized in 2017. The Company will also be required to reimburse SERI for all future patent costs related to this licensed technology.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is obligated to pay SERI up to $6.0 million upon the achievement of certain development and regulatory milestones. The Company is also obligated to pay SERI up to $10.1 million upon the achievement of certain commercial milestones. The Company will also pay SERI royalties in the low single digits based on net sales. No milestones or royalties were paid or incurred through December&#160;31, 2019, as the Company has not achieved any milestones, net sales or sublicensing under this agreement. The Company may cancel the license agreement at any time with 180 days&#8217; written notice.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2017, the Company also entered into a Sponsored Research Agreement with SERI under which the Company recognized approximately $0.6 million and $0.5 million as research and development expense for the year ended December 31, 2019 and 2018, respectively, for work performed under this agreement.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">License Agreement with the University of Illinois</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2016, the Company entered into a license agreement with the University of Illinois at Chicago (&#8220;UIC&#8221;), which granted the Company an exclusive license to develop, commercialize and continue to secure patents for OCU300 and OCU310. In connection with acquiring the license for OCU300 and OCU310, the Company was required to pay a signing fee of $15,000.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is required to pay royalties in the low single digits to low teens to UIC based on net sales and sublicense revenues generated by OCU300 and OCU310. The Company is also required to pay minimum annual royalties to UIC, beginning with an annual payment of $20,000 on the third anniversary of the effective date of the agreement, and increasing gradually to $50,000 by the sixth anniversary and continuing through the term of the agreement. The Company is also obligated to pay UIC up to $1.3 million upon the achievement of certain development and regulatory milestones.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During 2018, the Company incurred $0.3 million in milestone payments due to achieving a milestone associated with dosing the first patient in a Phase 3 clinical trial. The Company has not achieved any other milestones, net sales or sublicensing for OCU300 or OCU310. The Company may cancel the license agreement at any time with 90 days&#8217; written notice.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">License Agreement with the University of Colorado</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2014, the Company entered into a patent license agreement with the University of Colorado (&#8220;CU&#8221;), which granted the Company an exclusive license to develop and commercialize, and continue to secure patents for OCU200, including the ability to enforce any rights against infringement. Under the agreement, the Company assumed primary responsibility for preparing, filing and prosecuting broad patent claims for OCU200 for CU's benefit. Further, the Company assumed primary responsibility for all patent activities, including all costs associated with the perfection and maintenance of the patents for OCU200.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the terms of the agreement, in exchange for the licensed patents, the Company issued CU 0.1 million shares of the Company&#8217;s common stock. The agreement with CU, as amended in January 2017, obligates the Company to pay certain development and regulatory milestone fees of up to $1.5 million, royalties in the low single digits on net sales and royalties in the mid-teens on sublicense income of OCU200.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The agreement with CU calls for minimum annual royalty payments of $20,000, starting on the third anniversary of the agreement and on each annual anniversary thereafter, and after sales commence, increasing to a percentage rate in the mid-</span></div>twenties of the previous year&#8217;s royalty payment paid to CU, through the term of the agreement. Future annual royalties will be recognized in the years they are earned, per the license agreement. The Company may cancel the license agreement at any time with 60 days&#8217; written notice.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6775740320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments</a></td>
<td class="text">Commitments<div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating Leases</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has commitments under operating leases for certain facilities used in its operations. The Company&#8217;s leases have initial lease terms ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RleHRyZWdpb246ZGM3YmMyNzE5ZTYwNGMyNjlkMWNiNjIxY2JhMTE0NDNfMTA5OTUxMTYyODYwOTQ_ca47572a-04ad-41bc-8ba1-21a7e15ee217">one</span> to five years. Certain lease agreements contain provisions for future rent increases.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of lease expense were as follows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.380%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.620%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended<br/>December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">250,361&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Variable lease cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79,700&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">330,061&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Supplemental balance sheet information related to leases was as follows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.380%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.620%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use assets, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">344,574&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current lease obligations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">172,310&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current lease obligations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">163,198&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">335,508&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Supplemental information related to leases was as follows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.380%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.620%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended<br/>December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average remaining lease terms&#8212;operating leases (years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average discount rate&#8212;operating leases</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future minimum operating minimum lease payments for all leases, exclusive of taxes and other carrying charges, are approximately as follows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.380%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.620%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Years Ending December 31,</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">191,890&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">160,909&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,354&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">364,153&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: present value adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(28,645)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of minimum lease payments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">335,508&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company does not have any leases that have not yet commenced which are significant.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Financing Leases</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2018, the Company leased specialized research equipment under a lease classified as a financing lease. The leased equipment is included in property and equipment, net and is amortized on a straight-line basis over five years. Financing lease liabilities are included in other liabilities on the Company's consolidated balance sheets. The interest rate related to the lease obligation is 7.6% and the maturity date is July 2021.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future minimum lease payments for all financing leases, exclusive of taxes and other carrying charges, are approximately as follows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.380%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.620%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Years Ending December 31,</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,856&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,941&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,797&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: present value adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,851)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of minimum lease payments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,946&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6790235376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger and Financing - Merger with Histogenics (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Oct. 04, 2019</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>May 08, 2019</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Sep. 26, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger and Financing</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 7,444,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,628,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="num">(1,895,613)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,277,525)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_AssetPurchaseAgreementCashConsideration', window );">Asset purchase agreement, cash consideration</a></td>
<td class="nump">8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ocgn_HistogenicsCorporationMember', window );">Histogenics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger and Financing</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition cost incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForMergerRelatedCosts', window );">Acquisition cost paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_AdjustmentsToAdditionalPaidInCapitalMergerRelatedCosts', window );">Acquisition cost paid with equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_AssetsHeldForSale', window );">Asset held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,106,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNet', window );">Net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,196,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_AssetPurchaseAgreementCashConsideration', window );">Asset purchase agreement, cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_PercentageOfIncreaseInPurchasePriceOfAssetPerMonth', window );">Percentage of purchase price increase per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ocgn_HistogenicsCorporationMember', window );">Histogenics | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger and Financing</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure', window );">Quoted price of assets held for sale of NeoCart</a></td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ocgn_NeocartMember', window );">Neocart | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger and Financing</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure', window );">Quoted price of assets held for sale of NeoCart</a></td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ocgn_EquityHoldersOfOcugenIncPerMergerMember', window );">Former Ocugen equity holders | Histogenics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger and Financing</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ocgn_EquityHoldersOfHistogenicsCorporationMember', window );">Stockholders of Histogenics immediately before the Merger | Histogenics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger and Financing</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ocgn_HistogenicsCorporationMember', window );">Histogenics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger and Financing</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Upfront cash payment received for license granted to MEDINET</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_AdjustmentsToAdditionalPaidInCapitalMergerRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_AdjustmentsToAdditionalPaidInCapitalMergerRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_AssetPurchaseAgreementCashConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash consideration agreed under the asset purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_AssetPurchaseAgreementCashConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_AssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the assets held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_AssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_PercentageOfIncreaseInPurchasePriceOfAssetPerMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of asset purchase agreement that the purchase price increases per month between October 31, 2019 and the closing date if agreement is not terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_PercentageOfIncreaseInPurchasePriceOfAssetPerMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of assets classified as held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net assets (liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77885760&amp;loc=SL35686385-199418<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 205<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118262037&amp;loc=d3e9915-115836<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637345&amp;loc=SL114874367-224272<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e604008-122996<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637345&amp;loc=SL114874367-224272<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=116868678&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForMergerRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the reporting period for charges associated with the mergers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForMergerRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ocgn_HistogenicsCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ocgn_HistogenicsCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ocgn_NeocartMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ocgn_NeocartMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ocgn_EquityHoldersOfOcugenIncPerMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ocgn_EquityHoldersOfOcugenIncPerMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ocgn_HistogenicsCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ocgn_HistogenicsCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ocgn_EquityHoldersOfHistogenicsCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ocgn_EquityHoldersOfHistogenicsCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ocgn_HistogenicsCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ocgn_HistogenicsCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6775821072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business - Going Concern (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (20,242,630)<span></span>
</td>
<td class="num">$ (18,219,664)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(51,479,824)<span></span>
</td>
<td class="num">(31,237,194)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 7,595,068<span></span>
</td>
<td class="nump">$ 1,778,613<span></span>
</td>
<td class="nump">$ 6,301,572<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6781029376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - EB-5 Loan (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,202<span></span>
</td>
<td class="nump">$ 103,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ocgn_EB5ProgramBorrowingsMember', window );">EB-5 Loan | Loans payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_LineOfCreditBorrowingEachDraw', window );">Borrowing increments</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount borrowed</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_LineOfCreditBorrowingEachDraw">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of borrowing that can be borrowed each draw from a line of credit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_LineOfCreditBorrowingEachDraw</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ocgn_EB5ProgramBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ocgn_EB5ProgramBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>35
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ocgn-20191231.htm": {
   "axisCustom": 0,
   "axisStandard": 24,
   "contextCount": 162,
   "dts": {
    "calculationLink": {
     "local": [
      "ocgn-20191231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ocgn-20191231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "ocgn-20191231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ocgn-20191231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ocgn-20191231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ocgn-20191231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 528,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 4,
    "http://www.deitaxonomy.com/20191231": 2,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 11
   },
   "keyCustom": 75,
   "keyStandard": 341,
   "memberCustom": 32,
   "memberStandard": 24,
   "nsprefix": "ocgn",
   "nsuri": "http://www.deitaxonomy.com/20191231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.deitaxonomy.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109103 - Disclosure - Merger and Pre-Merger Financing",
     "role": "http://www.deitaxonomy.com/role/MergerandPreMergerFinancing",
     "shortName": "Merger and Pre-Merger Financing",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113104 - Disclosure - Net Loss Per Share of Common Stock",
     "role": "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStock",
     "shortName": "Net Loss Per Share of Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116105 - Disclosure - License and Collaboration Agreements",
     "role": "http://www.deitaxonomy.com/role/LicenseandCollaborationAgreements",
     "shortName": "License and Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118106 - Disclosure - Accrued Expenses",
     "role": "http://www.deitaxonomy.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121107 - Disclosure - Debt",
     "role": "http://www.deitaxonomy.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129108 - Disclosure - Share-Based Compensation",
     "role": "http://www.deitaxonomy.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135109 - Disclosure - Commitments",
     "role": "http://www.deitaxonomy.com/role/Commitments",
     "shortName": "Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ocgn:WarrantsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144110 - Disclosure - Warrants",
     "role": "http://www.deitaxonomy.com/role/Warrants",
     "shortName": "Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ocgn:WarrantsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149111 - Disclosure - Income Taxes",
     "role": "http://www.deitaxonomy.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2155112 - Disclosure - Subsequent Events",
     "role": "http://www.deitaxonomy.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ia6368cd0825d4ed8bf32f05ae6035107_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ia6368cd0825d4ed8bf32f05ae6035107_I20191231",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2205201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - Merger and Pre-Merger Financing (Tables)",
     "role": "http://www.deitaxonomy.com/role/MergerandPreMergerFinancingTables",
     "shortName": "Merger and Pre-Merger Financing (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314303 - Disclosure - Net Loss Per Share of Common Stock (Tables)",
     "role": "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockTables",
     "shortName": "Net Loss Per Share of Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319304 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://www.deitaxonomy.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322305 - Disclosure - Debt (Tables)",
     "role": "http://www.deitaxonomy.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330306 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://www.deitaxonomy.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336307 - Disclosure - Commitments (Tables)",
     "role": "http://www.deitaxonomy.com/role/CommitmentsTables",
     "shortName": "Commitments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ocgn:ScheduleOfPreMergerFinancingWarrantsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2345308 - Disclosure - Warrants (Tables)",
     "role": "http://www.deitaxonomy.com/role/WarrantsTables",
     "shortName": "Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ocgn:ScheduleOfPreMergerFinancingWarrantsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2350309 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.deitaxonomy.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ia6368cd0825d4ed8bf32f05ae6035107_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "id83e33e57cad4f08967d8d41dfb42b28_D20190927-20190927",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ocgn:BusinessCombinationIssuedSharesExchangeRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Nature of Business - Reverse Stock Split (Details)",
     "role": "http://www.deitaxonomy.com/role/NatureofBusinessReverseStockSplitDetails",
     "shortName": "Nature of Business - Reverse Stock Split (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "id83e33e57cad4f08967d8d41dfb42b28_D20190927-20190927",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ocgn:BusinessCombinationIssuedSharesExchangeRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403402 - Disclosure - Nature of Business - Going Concern (Details)",
     "role": "http://www.deitaxonomy.com/role/NatureofBusinessGoingConcernDetails",
     "shortName": "Nature of Business - Going Concern (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ia6368cd0825d4ed8bf32f05ae6035107_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)",
     "role": "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ia6368cd0825d4ed8bf32f05ae6035107_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies (Summary Cash, Cash Equivalents and Restricted Cash) (Details)",
     "role": "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesSummaryCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies (Summary Cash, Cash Equivalents and Restricted Cash) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "if83d8a8656604b6494f17eff209a905f_I20191004",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ocgn:ConvertedAdditionalSharesThresholdReleaseTrigger",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Merger and Financing - Pre-Merger Financing (Details)",
     "role": "http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails",
     "shortName": "Merger and Financing - Pre-Merger Financing (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "i3a90ecac0c074f6aa909c9426321c8d8_D20190101-20191231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RepaymentsOfSeniorDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ia6368cd0825d4ed8bf32f05ae6035107_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Merger and Financing - Merger with Histogenics (Details)",
     "role": "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails",
     "shortName": "Merger and Financing - Merger with Histogenics (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "i7c31e84a90244ee78a2df7e88dca555a_D20191231-20191231",
      "decimals": "-5",
      "lang": null,
      "name": "ocgn:AssetPurchaseAgreementCashConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Net Loss Per Share of Common Stock (Details)",
     "role": "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockDetails",
     "shortName": "Net Loss Per Share of Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - License and Collaboration Agreements (Details)",
     "role": "http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails",
     "shortName": "License and Collaboration Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "i4d16882d4b4e40b5817ec2c99e0a487e_D20190927-20190927",
      "decimals": null,
      "lang": "en-US",
      "name": "ocgn:CollaborationAgreementTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ia6368cd0825d4ed8bf32f05ae6035107_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ocgn:ResearchAndDevelopmentExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420409 - Disclosure - Accrued Expenses (Details)",
     "role": "http://www.deitaxonomy.com/role/AccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ia6368cd0825d4ed8bf32f05ae6035107_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ocgn:ResearchAndDevelopmentExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfDebtIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423410 - Disclosure - Debt - EB-5 Loan (Details)",
     "role": "http://www.deitaxonomy.com/role/DebtEB5LoanDetails",
     "shortName": "Debt - EB-5 Loan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "i41512e91ea66459091142a09d64979ee_I20160930",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "i5f4493de5f9a420f8e7d280ce9393d02_I20161231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCredit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - Debt - Summary of EB-5 Loan (Details)",
     "role": "http://www.deitaxonomy.com/role/DebtSummaryofEB5LoanDetails",
     "shortName": "Debt - Summary of EB-5 Loan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ifa216e92d8ad45f695cf881fb2ec681d_I20191231",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ocgn:ChangesInFairValueOfEmbeddedDerivativeTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ia6368cd0825d4ed8bf32f05ae6035107_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Debt - Convertible Notes (Details)",
     "role": "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails",
     "shortName": "Debt - Convertible Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ocgn:ChangesInFairValueOfEmbeddedDerivativeTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ia6368cd0825d4ed8bf32f05ae6035107_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Debt - Schedule of Fair Value of the Embedded Features (Details)",
     "role": "http://www.deitaxonomy.com/role/DebtScheduleofFairValueoftheEmbeddedFeaturesDetails",
     "shortName": "Debt - Schedule of Fair Value of the Embedded Features (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ocgn:ChangesInFairValueOfEmbeddedDerivativeTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": "0",
      "lang": null,
      "name": "ocgn:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiabilityAtIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ic10bc878b71a4eec829c618f097ab1f3_I20190405",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ocgn:CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - Debt - Convertible Notes Other Information (Details)",
     "role": "http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails",
     "shortName": "Debt - Convertible Notes Other Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ic10bc878b71a4eec829c618f097ab1f3_I20190405",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ocgn:CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "iff635dcebab24f36911b7b91f40c1759_I20190521",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Debt - Senior Secured Convertible Notes (Details)",
     "role": "http://www.deitaxonomy.com/role/DebtSeniorSecuredConvertibleNotesDetails",
     "shortName": "Debt - Senior Secured Convertible Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "iff635dcebab24f36911b7b91f40c1759_I20190521",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Stock-Based Compensation - Schedule of Compensation Expense for Options Granted (Details)",
     "role": "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails",
     "shortName": "Stock-Based Compensation - Schedule of Compensation Expense for Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "i1dd31fe358a94242921f371e4a12056c_D20190101-20191231",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ia6368cd0825d4ed8bf32f05ae6035107_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Shared-Based Compensation (Details)",
     "role": "http://www.deitaxonomy.com/role/SharedBasedCompensationDetails",
     "shortName": "Shared-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ia6368cd0825d4ed8bf32f05ae6035107_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "iaf4d04bf884e47208ec21854eaf3c6fa_I20191231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Stock-Based Compensation - Schedule of Valuation Assumptions (Details)",
     "role": "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofValuationAssumptionsDetails",
     "shortName": "Stock-Based Compensation - Schedule of Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "iaf4d04bf884e47208ec21854eaf3c6fa_I20191231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "i9dd0fe8be9d9438c8e720727830deb3e_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Stock-Based Compensation - Schedule Options to Purchase Common Stock (Details)",
     "role": "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails",
     "shortName": "Stock-Based Compensation - Schedule Options to Purchase Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "i9dd0fe8be9d9438c8e720727830deb3e_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ia6368cd0825d4ed8bf32f05ae6035107_I20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Commitments (Details)",
     "role": "http://www.deitaxonomy.com/role/CommitmentsDetails",
     "shortName": "Commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "i67871994f7b24db59223486582b30e7a_I20191231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "i3a1130e123594196bfc468092b84ac38_I20171231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)",
     "role": "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "i3a1130e123594196bfc468092b84ac38_I20171231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - Commitments - Operating leases, components of lease expense (Details)",
     "role": "http://www.deitaxonomy.com/role/CommitmentsOperatingleasescomponentsofleaseexpenseDetails",
     "shortName": "Commitments - Operating leases, components of lease expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ocgn:SupplementalBalanceSheetInformationLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ia6368cd0825d4ed8bf32f05ae6035107_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439422 - Disclosure - Commitments - Operating leases, supplemental balance sheet information (Details)",
     "role": "http://www.deitaxonomy.com/role/CommitmentsOperatingleasessupplementalbalancesheetinformationDetails",
     "shortName": "Commitments - Operating leases, supplemental balance sheet information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ocgn:SupplementalBalanceSheetInformationLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ia6368cd0825d4ed8bf32f05ae6035107_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ia6368cd0825d4ed8bf32f05ae6035107_I20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440423 - Disclosure - Commitments - Operating leases, supplemental information related to leases (Details)",
     "role": "http://www.deitaxonomy.com/role/CommitmentsOperatingleasessupplementalinformationrelatedtoleasesDetails",
     "shortName": "Commitments - Operating leases, supplemental information related to leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ia6368cd0825d4ed8bf32f05ae6035107_I20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ia6368cd0825d4ed8bf32f05ae6035107_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441424 - Disclosure - Commitments - Operating leases, future minimum lease payments (Details)",
     "role": "http://www.deitaxonomy.com/role/CommitmentsOperatingleasesfutureminimumleasepaymentsDetails",
     "shortName": "Commitments - Operating leases, future minimum lease payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ia6368cd0825d4ed8bf32f05ae6035107_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ia6368cd0825d4ed8bf32f05ae6035107_I20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442425 - Disclosure - Commitments - Finance leases (Details)",
     "role": "http://www.deitaxonomy.com/role/CommitmentsFinanceleasesDetails",
     "shortName": "Commitments - Finance leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ia6368cd0825d4ed8bf32f05ae6035107_I20191231",
      "decimals": "3",
      "lang": null,
      "name": "us-gaap:LesseeFinanceLeaseDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ia6368cd0825d4ed8bf32f05ae6035107_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443426 - Disclosure - Commitments - Finance leases, future minimum lease payments (Details)",
     "role": "http://www.deitaxonomy.com/role/CommitmentsFinanceleasesfutureminimumleasepaymentsDetails",
     "shortName": "Commitments - Finance leases, future minimum lease payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ia6368cd0825d4ed8bf32f05ae6035107_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ia6368cd0825d4ed8bf32f05ae6035107_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ocgn:PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionLowerPercentageOfCommonStock",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446427 - Disclosure - Warrants (Details)",
     "role": "http://www.deitaxonomy.com/role/WarrantsDetails",
     "shortName": "Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "if38d3cddf7364a18958c9f6b986c7132_D20190927-20191231",
      "decimals": "INF",
      "lang": null,
      "name": "ocgn:PercentageOfAmountOnMarketValueForFailureToIssueCommonStockOnPreMergerFinancingWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ocgn:ScheduleOfPreMergerFinancingWarrantsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447428 - Disclosure - Schedule of Activity of the Pre-Merger Financing Warrants (Details)",
     "role": "http://www.deitaxonomy.com/role/ScheduleofActivityofthePreMergerFinancingWarrantsDetails",
     "shortName": "Schedule of Activity of the Pre-Merger Financing Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ocgn:ScheduleOfPreMergerFinancingWarrantsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "i71ce16f5e5214d2780d7f39624f8b29d_I20181231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448429 - Disclosure - Schedule of Roll-forward of Series\u00a0B Warrant Liability (Details)",
     "role": "http://www.deitaxonomy.com/role/ScheduleofRollforwardofSeriesBWarrantLiabilityDetails",
     "shortName": "Schedule of Roll-forward of Series\u00a0B Warrant Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "i71ce16f5e5214d2780d7f39624f8b29d_I20181231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ia6368cd0825d4ed8bf32f05ae6035107_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451430 - Disclosure - Schedule of Deferred Tax Assets (Details)",
     "role": "http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails",
     "shortName": "Schedule of Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ia6368cd0825d4ed8bf32f05ae6035107_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ocgn:CostsRelatedToIssuanceOfStockUnderReverseAssetAcquisition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "role": "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ocgn:CostsRelatedToIssuanceOfStockUnderReverseAssetAcquisition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452431 - Disclosure - Income Taxes (Details)",
     "role": "http://www.deitaxonomy.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453432 - Disclosure - Schedule of Effective Income Tax Rate (Details)",
     "role": "http://www.deitaxonomy.com/role/ScheduleofEffectiveIncomeTaxRateDetails",
     "shortName": "Schedule of Effective Income Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454433 - Disclosure - Schedule of Unrecognized Tax Benefits (Details)",
     "role": "http://www.deitaxonomy.com/role/ScheduleofUnrecognizedTaxBenefitsDetails",
     "shortName": "Schedule of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "i1e36ccdb3dcd46a4ba0bf2a92174d054_D20200326-20200326",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromLinesOfCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456434 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.deitaxonomy.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "i1e36ccdb3dcd46a4ba0bf2a92174d054_D20200326-20200326",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromLinesOfCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Nature of Business",
     "role": "http://www.deitaxonomy.com/role/NatureofBusiness",
     "shortName": "Nature of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20191231.htm",
      "contextRef": "ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 67,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails",
      "http://www.deitaxonomy.com/role/NatureofBusinessReverseStockSplitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails",
      "http://www.deitaxonomy.com/role/NatureofBusinessReverseStockSplitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ocgn_A2014PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2014 Plan",
        "label": "2014 Plan [Member]",
        "terseLabel": "2014 Plan"
       }
      }
     },
     "localname": "A2014PlanMember",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/SharedBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_A2019PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2019 Plan",
        "label": "2019 Plan [Member]",
        "terseLabel": "2019 Plan"
       }
      }
     },
     "localname": "A2019PlanMember",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/SharedBasedCompensationDetails",
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_AccountsPayableClinical": {
     "auth_ref": [],
     "calculation": {
      "http://www.deitaxonomy.com/role/AccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligations incurred classified as Clinical.",
        "label": "Accounts Payable Clinical",
        "terseLabel": "Clinical"
       }
      }
     },
     "localname": "AccountsPayableClinical",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_AccountsPayableConsulting": {
     "auth_ref": [],
     "calculation": {
      "http://www.deitaxonomy.com/role/AccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligations incurred classified as Consulting.",
        "label": "Accounts payable Consulting",
        "terseLabel": "Consulting"
       }
      }
     },
     "localname": "AccountsPayableConsulting",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_AdjustmentsToAdditionalPaidInCapitalMergerRelatedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with merger.",
        "label": "Adjustments to Additional Paid in Capital, Merger Related Costs",
        "terseLabel": "Acquisition cost paid with equity"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalMergerRelatedCosts",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_AssetHeldForSalePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents asset held for sale.",
        "label": "Asset Held For Sale [Policy Text Block]",
        "terseLabel": "Asset Held for Sale"
       }
      }
     },
     "localname": "AssetHeldForSalePolicyTextBlock",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ocgn_AssetPurchaseAgreementCashConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash consideration agreed under the asset purchase agreement.",
        "label": "Asset Purchase Agreement, Cash Consideration",
        "terseLabel": "Asset purchase agreement, cash consideration"
       }
      }
     },
     "localname": "AssetPurchaseAgreementCashConsideration",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_AssetsHeldForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the assets held for sale.",
        "label": "Assets Held For Sale",
        "terseLabel": "Asset held for sale"
       }
      }
     },
     "localname": "AssetsHeldForSale",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_BusinessCombinationIssuedSharesExchangeRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exchange rate of share issued to shares surrendered by stockholder of the acquired entity in a business combination.",
        "label": "Business Combination, Issued Shares Exchange Rate",
        "terseLabel": "Shares issued exchange rate to former Ocugen's stockholders (exchange rate)"
       }
      }
     },
     "localname": "BusinessCombinationIssuedSharesExchangeRate",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/NatureofBusinessReverseStockSplitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ocgn_ChangesInFairValueOfEmbeddedDerivativeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The tabular disclosure of the change of the embedded derivative during the period.",
        "label": "Changes In Fair Value Of Embedded Derivative [Table Text Block]",
        "terseLabel": "Schedule of Changes of Embedded Derivative of Convertible Notes"
       }
      }
     },
     "localname": "ChangesInFairValueOfEmbeddedDerivativeTableTextBlock",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ocgn_ClassOfWarrantOrRightConditionForExpirationTradingDay": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The trading day after which the warrants will expire.",
        "label": "Class Of Warrant Or Right, Condition For Expiration, Trading Day",
        "terseLabel": "Warrants expiration, trading day"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightConditionForExpirationTradingDay",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ocgn_ClassOfWarrantOrRightExercisable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercisable",
        "label": "Class of Warrant or Right, Exercisable",
        "terseLabel": "Warrants exercisable (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisable",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ocgn_ClassOfWarrantOrRightExercisePriceDeterminationNumberOfTradingDaysConsidered": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of trading days considered for determination of exercise price of warrants.",
        "label": "Class Of Warrant Or Right, Exercise Price Determination, Number Of Trading Days Considered",
        "terseLabel": "Warrants, exercise price determination, number of trading days"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceDeterminationNumberOfTradingDaysConsidered",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ocgn_ClassOfWarrantOrRightExercised": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercised",
        "label": "Class of Warrant or Right, Exercised",
        "negatedLabel": "Class of Warrant or Right, Exercised"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercised",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofActivityofthePreMergerFinancingWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ocgn_ClassOfWarrantOrRightIssued": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of Warrant or Right, Issued",
        "label": "Class of Warrant or Right, Issued",
        "terseLabel": "Issued (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssued",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofActivityofthePreMergerFinancingWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ocgn_CollaborationAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the term of agreement or milestone.",
        "label": "Collaboration agreement term",
        "terseLabel": "Term (in years)"
       }
      }
     },
     "localname": "CollaborationAgreementTerm",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ocgn_CollaborationAgreementTerminationDevelopmentCostPayment": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period within which the entity is to reimburse a party to collaboration agreement of development costs after a statement of such is provided upon termination of the agreement, , in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Collaboration Agreement, Termination, Development Cost Payment",
        "terseLabel": "Period within which to reimburse Cansino of development costs"
       }
      }
     },
     "localname": "CollaborationAgreementTerminationDevelopmentCostPayment",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ocgn_CollaborationAgreementTerminationDevelopmentCostStatement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period within which a party to collaboration agreement is to provide the entity statement of development costs after termination of agreement, , in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Collaboration Agreement, Termination, Development Cost Statement",
        "terseLabel": "Period within with Cansino to provide development cost statement"
       }
      }
     },
     "localname": "CollaborationAgreementTerminationDevelopmentCostStatement",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ocgn_CollaborationAgreementWithCansinoBiologicsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents co-development and commercialization agreement (the \"Agreement\") with CanSino Biologics Inc. (\"CanSino\") with respect to the development and commercialization of the gene therapy product candidate, OCU400, for the treatment of NR2E3 Mutation-Associated Retinal Degeneration, Leber Congenital Amaurosis, Bardet-Biedl Syndrome and Rhodopsin Mutation-Associated Retinal Degeneration.",
        "label": "Collaboration Agreement With Cansino Biologics [Member]",
        "terseLabel": "Collaboration Agreement with CanSino Biologics"
       }
      }
     },
     "localname": "CollaborationAgreementWithCansinoBiologicsMember",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_CollaborationAgreementWithUniversityOfColoradoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement With University Of Colorado",
        "label": "Collaboration Agreement With University Of Colorado [Member]",
        "terseLabel": "Collaboration agreement with University of Colorado"
       }
      }
     },
     "localname": "CollaborationAgreementWithUniversityOfColoradoMember",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_CollaborationAgreementWithUniversityOfIllinoisChicagoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement With University Of Illinois, Chicago",
        "label": "Collaboration Agreement With University Of Illinois, Chicago [Member]",
        "terseLabel": "Collaboration agreement with University of Illinois, Chicago"
       }
      }
     },
     "localname": "CollaborationAgreementWithUniversityOfIllinoisChicagoMember",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_CommonStockAdditionalSharesOfCommonStockIssuableUponExerciseOfWarrantsBasedOnResetPeriodShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock, Additional Shares Of Common Stock Issuable Upon Exercise Of Warrants Based on Reset Period, Shares",
        "label": "Common Stock, Additional Shares Of Common Stock Issuable Upon Exercise Of Warrants Based on Reset Period, Shares",
        "terseLabel": "Common stock, issuable upon exercise of warrant (in shares)"
       }
      }
     },
     "localname": "CommonStockAdditionalSharesOfCommonStockIssuableUponExerciseOfWarrantsBasedOnResetPeriodShares",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ocgn_CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock, Shares Agreed To Be Sold, Stock Subscription Agreement",
        "label": "Common Stock, Shares Agreed To Be Sold, Stock Subscription Agreement",
        "terseLabel": "Common stock, shares agreed to be sold, stock subscription agreement (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of the volume-weighted average trading price of a share of common stock as quoted on the Nasdaq Capital Market for the first three trading days immediately following the closing date of the Pre-Merger Financing as threshold to release converted additional shares.",
        "label": "Converted Additional Shares, Threshold Release Trigger",
        "terseLabel": "Percentage of volume-weighted average trading price of a share of common stock that triggered release of converted additional shares (in percentage)"
       }
      }
     },
     "localname": "ConvertedAdditionalSharesThresholdReleaseTrigger",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails",
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The period over which the percentage of the volume-weighted average trading price of a share of common stock as quoted on the Nasdaq Capital Market to release converted additional shares is determined, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Converted Additional Shares, Threshold Release Trigger Period",
        "terseLabel": "Period over which trading price of common stock as quoted on the Nasdaq Capital Market was considered for the release of converted additional shares"
       }
      }
     },
     "localname": "ConvertedAdditionalSharesThresholdReleaseTriggerPeriod",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The price over which the volume-weighted average trading price of a share of common stock as quoted on the Nasdaq Capital Market to release converted additional shares is determined.",
        "label": "Converted Additional Shares, Threshold Release Trigger Price",
        "terseLabel": "Price over which trading price of common stock as quoted on the Nasdaq Capital Market was considered for the release of converted additional shares (in USD per share)"
       }
      }
     },
     "localname": "ConvertedAdditionalSharesThresholdReleaseTriggerPrice",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ocgn_ConvertibleDebtConversionFeatureMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Conversion feature of the convertible debt that is considered as an embedded derivative of the debt.",
        "label": "Convertible Debt Conversion Feature [Member]",
        "terseLabel": "Convertible debt, conversion feature"
       }
      }
     },
     "localname": "ConvertibleDebtConversionFeatureMember",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_ConvertibleDebtDecember2018Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock, issued in December 2018.",
        "label": "Convertible Debt December2018 [Member]",
        "terseLabel": "Convertible Note - December 2018"
       }
      }
     },
     "localname": "ConvertibleDebtDecember2018Member",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of discount of the convertible debt that automatically convert the same class of equity as those issued to the lowest price per share being paid by investors in the equity financing.",
        "label": "Convertible Debt, Equity Financing Triggered, Discount",
        "terseLabel": "Conversion price discount per original agreement (as a percent)"
       }
      }
     },
     "localname": "ConvertibleDebtEquityFinancingTriggeredDiscount",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails",
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ocgn_ConvertibleDebtFebruary2019Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock, issued in February 2019.",
        "label": "Convertible Debt February2019 [Member]",
        "terseLabel": "Convertible Note - February 2019"
       }
      }
     },
     "localname": "ConvertibleDebtFebruary2019Member",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_ConvertibleDebtJanuary2018Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock, issued in January 2018.",
        "label": "Convertible Debt January2018 [Member]",
        "terseLabel": "Convertible Note - January 2018"
       }
      }
     },
     "localname": "ConvertibleDebtJanuary2018Member",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_ConvertibleDebtJanuary2019Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock, issued in January 2019.",
        "label": "Convertible Debt January2019 [Member]",
        "terseLabel": "Convertible Note - January 2019"
       }
      }
     },
     "localname": "ConvertibleDebtJanuary2019Member",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_ConvertibleDebtJune2018Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock, issued in June 2018.",
        "label": "Convertible Debt June2018 [Member]",
        "terseLabel": "Convertible Note - June 2018"
       }
      }
     },
     "localname": "ConvertibleDebtJune2018Member",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_ConvertibleDebtNovember2018Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock, issued in November 2018.",
        "label": "Convertible Debt November2018 [Member]",
        "terseLabel": "Convertible Note - November 2018"
       }
      }
     },
     "localname": "ConvertibleDebtNovember2018Member",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_ConvertibleNotesBoardOfDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Convertible Notes, Board Of Directors",
        "label": "Convertible Notes, Board Of Directors [Member]",
        "terseLabel": "Convertible Notes - Board of Directors"
       }
      }
     },
     "localname": "ConvertibleNotesBoardOfDirectorsMember",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_ConvertiblePromissoryNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Promissory notes which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Promissory Notes [Member]",
        "terseLabel": "Convertible promissory notes"
       }
      }
     },
     "localname": "ConvertiblePromissoryNotesMember",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_CostsRelatedToIssuanceOfStockUnderReverseAssetAcquisition": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of costs related to issuance of stock under reverse asset acquisition.",
        "label": "Costs Related to Issuance of Stock Under Reverse Asset Acquisition",
        "terseLabel": "Issuance costs under reverse asset acquisition"
       }
      }
     },
     "localname": "CostsRelatedToIssuanceOfStockUnderReverseAssetAcquisition",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_DebtRedemptionMultipleUponDefault": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Redemption multiple of debt's principal and unpaid interest upon default.",
        "label": "Debt, Redemption Multiple Upon Default",
        "terseLabel": "Redemption multiple upon default"
       }
      }
     },
     "localname": "DebtRedemptionMultipleUponDefault",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ocgn_DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of deferred equity issuance cost that were incurred during a noncash or partial noncash transaction.",
        "label": "Deferred Equity Issuance Cost Incurred During Noncash Or Partial Noncash Transaction",
        "verboseLabel": "Reverse asset acquisition costs (Note 3)"
       }
      }
     },
     "localname": "DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_DeferredTaxAssetsConvertibleDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Assets, Convertible Debt",
        "label": "Deferred Tax Assets, Convertible Debt",
        "terseLabel": "Convertible debt"
       }
      }
     },
     "localname": "DeferredTaxAssetsConvertibleDebt",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Assets, Lease Liability",
        "label": "Deferred Tax Assets, Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_DeferredTaxAssetsStartUpCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Assets, Start-up Costs",
        "label": "Deferred Tax Assets, Start-up Costs",
        "terseLabel": "Start-up costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsStartUpCosts",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_DerivativeInstrumentsAndHedgingActivitiesDisclosurePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for financial instruments indexed to and potentially settled in common stock.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Policy Text Block]",
        "terseLabel": "Financial Instruments Indexed to and Potentially Settled in Common Stock"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosurePolicyTextBlock",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ocgn_EB5ProgramBorrowingsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents borrowings from the U.S. government's Immigrant Investor Program, commonly known as the EB 5 program (the \"EB 5 Program\").",
        "label": "E B5 Program Borrowings [Member]",
        "terseLabel": "EB-5 Loan"
       }
      }
     },
     "localname": "EB5ProgramBorrowingsMember",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtEB5LoanDetails",
      "http://www.deitaxonomy.com/role/DebtSummaryofEB5LoanDetails",
      "http://www.deitaxonomy.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.deitaxonomy.com/role/ScheduleofEffectiveIncomeTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Permanent Differences, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Permanent Differences, Percent",
        "negatedLabel": "Effective Income Tax Rate Reconciliation, Permanent Differences, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ocgn_EmbeddedDerivativeConversionAndExtinguishmentOfDebt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Embedded Derivative, Conversion And Extinguishment Of Debt",
        "label": "Embedded Derivative, Conversion And Extinguishment Of Debt",
        "negatedLabel": "Conversion and extinguishment of debt"
       }
      }
     },
     "localname": "EmbeddedDerivativeConversionAndExtinguishmentOfDebt",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtScheduleofFairValueoftheEmbeddedFeaturesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiabilityAtIssuance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Embedded Derivative, Fair Value of Embedded Derivative Liability At Issuance",
        "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability At Issuance",
        "terseLabel": "Fair value of embedded derivatives at issuance"
       }
      }
     },
     "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiabilityAtIssuance",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtScheduleofFairValueoftheEmbeddedFeaturesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_EquipmentAndFurnitureMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment and Furniture",
        "label": "Equipment and Furniture [Member]",
        "terseLabel": "Equipment and Furniture"
       }
      }
     },
     "localname": "EquipmentAndFurnitureMember",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_EquityHoldersOfHistogenicsCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity holders of Histogenics Corporation immediately before the merger.",
        "label": "Equity Holders Of Histogenics Corporation [Member]",
        "terseLabel": "Stockholders of Histogenics immediately before the Merger"
       }
      }
     },
     "localname": "EquityHoldersOfHistogenicsCorporationMember",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_EquityHoldersOfOcugenIncPerMergerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity holders of Ocugen, Inc. immediately before the merger.",
        "label": "Equity Holders Of Ocugen Inc Per Merger [Member]",
        "terseLabel": "Former Ocugen equity holders"
       }
      }
     },
     "localname": "EquityHoldersOfOcugenIncPerMergerMember",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationAmountReclassifiedToEquity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Amount Reclassified To Equity",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Amount Reclassified To Equity",
        "terseLabel": "Amount reclassified to equity"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationAmountReclassifiedToEquity",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofRollforwardofSeriesBWarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_FormerOcugenWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Former Ocugen Warrants",
        "label": "Former Ocugen Warrants [Member]",
        "terseLabel": "Former Ocugen warrants"
       }
      }
     },
     "localname": "FormerOcugenWarrantsMember",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_GainsLossesOnConversionOfDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on conversion of debt.",
        "label": "Gains (Losses) on Conversion of Debt",
        "negatedLabel": "Conversion of convertible notes",
        "verboseLabel": "Loss on debt conversion"
       }
      }
     },
     "localname": "GainsLossesOnConversionOfDebt",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_HistogenicsCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents Histogenics Corporation.",
        "label": "Histogenics Corporation [Member]",
        "terseLabel": "Histogenics"
       }
      }
     },
     "localname": "HistogenicsCorporationMember",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails",
      "http://www.deitaxonomy.com/role/NatureofBusinessReverseStockSplitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_IncreaseDecreaseInDeferredRent": {
     "auth_ref": [],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Change during the period in carrying value for all deferred rent.",
        "label": "Increase (Decrease) in Deferred Rent",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRent",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_IncreaseDecreaseInLeaseObligations": {
     "auth_ref": [],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Lease Obligations",
        "label": "Increase (Decrease) In Lease Obligations",
        "terseLabel": "Lease obligations"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseObligations",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_January2019AndFebruary2019NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "January\u00a02019 And February\u00a02019 Notes",
        "label": "January\u00a02019 And February\u00a02019 Notes [Member]",
        "terseLabel": "January\u00a02019 and February\u00a02019 notes"
       }
      }
     },
     "localname": "January2019AndFebruary2019NotesMember",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_LeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease, Liability",
        "label": "Lease, Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "LeaseLiability",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_LeaseRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease, Right-Of-Use Asset",
        "label": "Lease, Right-Of-Use Asset",
        "terseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "LeaseRightOfUseAsset",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_LicenseAgreementCancellationPeriodNotice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Agreement, Cancellation Period Notice",
        "label": "License Agreement, Cancellation Period Notice",
        "terseLabel": "Cancellation period, written notice"
       }
      }
     },
     "localname": "LicenseAgreementCancellationPeriodNotice",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ocgn_LicenseAgreementMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Agreement, Milestone Payment",
        "label": "License Agreement, Milestone Payment",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "LicenseAgreementMilestonePayment",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_LicenseAgreementMinimumAnnualRoyaltyPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Agreement, Minimum Annual Royalty Payment",
        "label": "License Agreement, Minimum Annual Royalty Payment",
        "terseLabel": "Minimum annual royalty payment"
       }
      }
     },
     "localname": "LicenseAgreementMinimumAnnualRoyaltyPayment",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_LicenseAgreementPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Agreement, Payment",
        "label": "License Agreement, Payment",
        "terseLabel": "License fee paid"
       }
      }
     },
     "localname": "LicenseAgreementPayment",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_LicenseAgreementPotentialCommercialMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Agreement, Potential Commercial Milestone Payment",
        "label": "License Agreement, Potential Commercial Milestone Payment",
        "terseLabel": "Potential commercial milestone payment"
       }
      }
     },
     "localname": "LicenseAgreementPotentialCommercialMilestonePayment",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Agreement, Potential Development And Regulatory Milestone Payment",
        "label": "License Agreement, Potential Development And Regulatory Milestone Payment",
        "terseLabel": "Potential development and regulatory milestone payments"
       }
      }
     },
     "localname": "LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_LicenseAgreementSigningFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Agreement, Signing Fee",
        "label": "License Agreement, Signing Fee",
        "terseLabel": "Signing fee paid"
       }
      }
     },
     "localname": "LicenseAgreementSigningFee",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_LineOfCreditBorrowingEachDraw": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of borrowing that can be borrowed each draw from a line of credit",
        "label": "Line Of Credit Borrowing Each Draw",
        "terseLabel": "Borrowing increments"
       }
      }
     },
     "localname": "LineOfCreditBorrowingEachDraw",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtEB5LoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_MergerAcquisitionCostsIncurred": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of acquisition costs incurred during the period related to merger.",
        "label": "Merger Acquisition Costs Incurred",
        "terseLabel": "Acquisition cost incurred"
       }
      }
     },
     "localname": "MergerAcquisitionCostsIncurred",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_NeocartMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "NeoCart",
        "label": "Neocart [Member]",
        "terseLabel": "Neocart"
       }
      }
     },
     "localname": "NeocartMember",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_NetProceedsFromReverseMerger": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of net proceeds received from reverse merger.",
        "label": "Net Proceeds from Reverse Merger",
        "terseLabel": "Net proceeds from pre-merger financing"
       }
      }
     },
     "localname": "NetProceedsFromReverseMerger",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_NonCashInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of non-cash interest expense during the period.",
        "label": "Non-Cash Interest Expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "NonCashInterestExpense",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_NoncashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncash Lease Expense",
        "label": "Noncash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NoncashLeaseExpense",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash or part noncash amount of deferred transaction cost.",
        "label": "Noncash Or Part Noncash Amount of Deferred Transaction Cost",
        "terseLabel": "Equity issuance costs (Note 3)"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAmountOfDeferredTransactionCost",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash lessee's right-to-use underlying asset under operating lease.",
        "label": "Noncash or Part Noncash, Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset related to operating leases"
       }
      }
     },
     "localname": "NoncashOrPartNoncashOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_November2018AndDecember2018NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "November\u00a02018 And December 2018 Notes",
        "label": "November\u00a02018 And December 2018 Notes [Member]",
        "terseLabel": "November\u00a02018 and December 2018 notes"
       }
      }
     },
     "localname": "November2018AndDecember2018NotesMember",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_NumberOfConvertedAdditionalSharesAgreedToIssuePriorToMergerToInvestors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of converted common shares, which the investors have right to receive pursuant to the exchange rate in the Merger, as agreed to be deposited in escrow by the accounting acquirer.",
        "label": "Number Of Converted Additional Shares Agreed To Issue Prior To Merger To Investors",
        "terseLabel": "Number of converted additional shares in the form of escrow agreed to issue immediately prior to the merger (in shares)"
       }
      }
     },
     "localname": "NumberOfConvertedAdditionalSharesAgreedToIssuePriorToMergerToInvestors",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ocgn_NumberOfConvertedInitialSharesAgreedToIssuePriorToMergerToInvestors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of converted common shares, which the investors have right to receive pursuant to the exchange rate in the Merger, as agreed to be issued by the accounting acquirer to the investors immediately prior to the Merger.",
        "label": "Number Of Converted Initial Shares Agreed To Issue Prior To Merger To Investors",
        "terseLabel": "Number of converted initial shares, agreed to be issued (in shares)"
       }
      }
     },
     "localname": "NumberOfConvertedInitialSharesAgreedToIssuePriorToMergerToInvestors",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ocgn_NumberOfEquityCompensationPlans": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Equity Compensation Plans",
        "label": "Number Of Equity Compensation Plans",
        "terseLabel": "Number of equity compensation plans"
       }
      }
     },
     "localname": "NumberOfEquityCompensationPlans",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/SharedBasedCompensationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ocgn_NumberOfFormerEmployeesWithWarrants": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Former Employees With Warrants",
        "label": "Number Of Former Employees With Warrants",
        "terseLabel": "Number of former employees with warrants"
       }
      }
     },
     "localname": "NumberOfFormerEmployeesWithWarrants",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ocgn_NumberOfSharesAgreedToIssuePriorToMergerToInvestors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares agreed to issue prior to the merger to investors.",
        "label": "Number of Shares Agreed to Issue Prior to Merger to Investors",
        "terseLabel": "Number of shares agreed to issue immediately prior to the merger (in shares)"
       }
      }
     },
     "localname": "NumberOfSharesAgreedToIssuePriorToMergerToInvestors",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ocgn_PercentageOfAmountOnMarketValueForFailureToIssueCommonStockOnPreMergerFinancingWarrants": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "If company fails to issue to a holder of the Pre-Merger Financing Warrants the number of shares of common stock to which such holder is entitled upon such holder's exercise of the such warrants, then company shall be obligated to pay the holder on each day while such failure is continuing an amount equal to percentage of the market value of the undelivered shares determined using any trading price of the common stock.",
        "label": "Percentage Of Amount On Market value For Failure To Issue Common Stock On Pre-Merger Financing Warrants",
        "terseLabel": "Percentage of amount on market value for failure to issue common stock on pre-merger financing warrants (in percentage)"
       }
      }
     },
     "localname": "PercentageOfAmountOnMarketValueForFailureToIssueCommonStockOnPreMergerFinancingWarrants",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ocgn_PercentageOfIncreaseInPurchasePriceOfAssetPerMonth": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of asset purchase agreement that the purchase price increases per month between October 31, 2019 and the closing date if agreement is not terminated.",
        "label": "Percentage Of Increase In Purchase Price Of Asset Per Month",
        "terseLabel": "Percentage of purchase price increase per month"
       }
      }
     },
     "localname": "PercentageOfIncreaseInPurchasePriceOfAssetPerMonth",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionHigherPercentageOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pre-merger Financing Warrants, Block Provisions, Exercise Restriction Higher Percentage Of Common Stock",
        "label": "Pre-merger Financing Warrants, Block Provisions, Exercise Restriction Higher Percentage Of Common Stock",
        "terseLabel": "Pre-merger financing warrants, block provisions, exercise restriction percentage of common stock (in percentage)"
       }
      }
     },
     "localname": "PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionHigherPercentageOfCommonStock",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionLowerPercentageOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pre-merger Financing Warrants, Block Provisions, Exercise Restriction Lower Percentage Of Common Stock",
        "label": "Pre-merger Financing Warrants, Block Provisions, Exercise Restriction Lower Percentage Of Common Stock",
        "terseLabel": "Pre-merger financing warrants, block provisions, exercise restriction percentage of common stock (in percentage)"
       }
      }
     },
     "localname": "PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionLowerPercentageOfCommonStock",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ocgn_ProceedsFromPreMergerFinancingFinancingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.deitaxonomy.com/role/Cover": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the pre-merger financing during the period.",
        "label": "Proceeds from Pre Merger Financing, Financing Activities",
        "terseLabel": "Proceeds from sale of common stock for pre-merger financing"
       }
      }
     },
     "localname": "ProceedsFromPreMergerFinancingFinancingActivities",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_ProceedsFromWarrantExercisesMaximumAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds From Warrant Exercises, Maximum Amount",
        "label": "Proceeds From Warrant Exercises, Maximum Amount",
        "terseLabel": "Proceeds From Warrant Exercises, Maximum Amount"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercisesMaximumAmount",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_ReclassificationOfWarrantsFromLiabilityToEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reclassification Of Warrants From Liability To Equity",
        "label": "Reclassification Of Warrants From Liability To Equity",
        "terseLabel": "Reclassification of Series B Warrants from liability to equity"
       }
      }
     },
     "localname": "ReclassificationOfWarrantsFromLiabilityToEquity",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_ResearchAndDevelopmentExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.deitaxonomy.com/role/AccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Research And Development Expenses Current",
        "terseLabel": "Research\u00a0and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensesCurrent",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_ReverseMergerAndFinancingDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reverse Merger And Financing Disclosure [Line Items]",
        "terseLabel": "Reverse Merger and Financing"
       }
      }
     },
     "localname": "ReverseMergerAndFinancingDisclosureLineItems",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ocgn_ReverseMergerAndFinancingDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about reverse merger and financing.",
        "label": "Reverse Merger And Financing Disclosure [Table]",
        "terseLabel": "Reverse Merger And Financing Disclosure [Table]"
       }
      }
     },
     "localname": "ReverseMergerAndFinancingDisclosureTable",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ocgn_ScheduleOfPreMergerFinancingWarrantsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule Of Pre-merger Financing Warrants",
        "label": "Schedule Of Pre-merger Financing Warrants [Table Text Block]",
        "terseLabel": "Schedule of Pre-merger Financing Warrants"
       }
      }
     },
     "localname": "ScheduleOfPreMergerFinancingWarrantsTableTextBlock",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ocgn_SchepensEyeResearchInstituteMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schepens Eye Research Institute",
        "label": "Schepens Eye Research Institute [Member]",
        "terseLabel": "Schepens Eye Research Institute"
       }
      }
     },
     "localname": "SchepensEyeResearchInstituteMember",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_SecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the information pertaining to Securities Purchase Agreement entered with several investors.",
        "label": "Securities Purchase Agreement [Member]",
        "terseLabel": "Financing SPA"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementMember",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_SeniorSecuredConvertibleNotesJune2019Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior secured borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock, issued in June 2019.",
        "label": "Senior Secured Convertible Notes June2019 [Member]",
        "terseLabel": "Senior Secured Convertible Notes - June 2019"
       }
      }
     },
     "localname": "SeniorSecuredConvertibleNotesJune2019Member",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtSeniorSecuredConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_SeniorSecuredConvertibleNotesMay2019Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior secured borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock, issued in May 2019.",
        "label": "Senior Secured Convertible Notes May2019 [Member]",
        "terseLabel": "Senior Secured Convertible Notes - May 2019"
       }
      }
     },
     "localname": "SeniorSecuredConvertibleNotesMay2019Member",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtSeniorSecuredConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_SeniorSecuredConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior secured borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Senior Secured Convertible Notes [Member]",
        "terseLabel": "Senior Secured Convertible Notes"
       }
      }
     },
     "localname": "SeniorSecuredConvertibleNotesMember",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtSeniorSecuredConvertibleNotesDetails",
      "http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_SeriesAWarrantsAndSeriesCWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information pertaining to series A and C warrants.",
        "label": "Series A Warrants And Series C Warrants [Member]",
        "terseLabel": "Series A and Series C warrants"
       }
      }
     },
     "localname": "SeriesAWarrantsAndSeriesCWarrantsMember",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_SeriesBWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This member stands for Series B Warrants.",
        "label": "Series B Warrants [Member]",
        "terseLabel": "Series B Warrants"
       }
      }
     },
     "localname": "SeriesBWarrantsMember",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails",
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockDetails",
      "http://www.deitaxonomy.com/role/ScheduleofActivityofthePreMergerFinancingWarrantsDetails",
      "http://www.deitaxonomy.com/role/ScheduleofRollforwardofSeriesBWarrantLiabilityDetails",
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_SeriesCWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This member stands for Series C Warrants.",
        "label": "Series C Warrants [Member]",
        "terseLabel": "Series C Warrants"
       }
      }
     },
     "localname": "SeriesCWarrantsMember",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockDetails",
      "http://www.deitaxonomy.com/role/ScheduleofActivityofthePreMergerFinancingWarrantsDetails",
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_SeriesWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This member stands for Series A Warrants.",
        "label": "Series Warrants [Member]",
        "terseLabel": "Series A Warrants"
       }
      }
     },
     "localname": "SeriesWarrantsMember",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockDetails",
      "http://www.deitaxonomy.com/role/ScheduleofActivityofthePreMergerFinancingWarrantsDetails",
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Automatic Increase In Shares To Be Issue, Percentage",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Automatic Increase In Shares To Be Issue, Percentage",
        "terseLabel": "Automatic increase in shares to be issue (in percentage)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/SharedBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ocgn_StockIssuanceCostsRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of stock issuance costs recognized during the period.",
        "label": "Stock Issuance Costs Recognized",
        "terseLabel": "Equity issuance cost"
       }
      }
     },
     "localname": "StockIssuanceCostsRecognized",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_StockIssuedDuringPeriodPreMergerShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued during the period, pursuant to pre-merger.",
        "label": "Stock Issued During Period, Pre Merger, Shares",
        "terseLabel": "Issuance of common stock and warrants for pre-Merger Financing (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodPreMergerShares",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "ocgn_StockIssuedDuringPeriodPreMergerValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of stock issued during the period pursuant to pre-merger.",
        "label": "Stock Issued During Period, Pre Merger, Value",
        "terseLabel": "Issuance of common stock and warrants for Pre-Merger Financing"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodPreMergerValue",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_StockIssuedDuringPeriodSharesReverseAssetAcquisition": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period pursuant to reverse asset acquisition.",
        "label": "Stock Issued During Period, Shares, Reverse Asset Acquisition",
        "terseLabel": "Issuance of stock for reverse asset acquisition, net of $2.6 million of costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesReverseAssetAcquisition",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "ocgn_StockIssuedDuringPeriodValueReverseAssetAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of stock issued during the period pursuant to reverse asset acquisition.",
        "label": "Stock Issued During Period, Value, Reverse Asset Acquisition",
        "terseLabel": "Issuance of stock for reverse asset acquisition, net of $2.6\u00a0million of costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueReverseAssetAcquisition",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Warrants Exercised",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "terseLabel": "Issuance of common stock for warrant exercises, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_SupplementalBalanceSheetInformationLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of balance sheet information related to leases.",
        "label": "Supplemental balance sheet information leases [table text block]",
        "terseLabel": "Schedule of supplemental balance sheet information related to leases"
       }
      }
     },
     "localname": "SupplementalBalanceSheetInformationLeasesTableTextBlock",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/CommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ocgn_WarrantsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants",
        "label": "Warrants [Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsTextBlock",
     "nsuri": "http://www.deitaxonomy.com/20191231",
     "presentation": [
      "http://www.deitaxonomy.com/role/Warrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Board members"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails",
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CommitmentsDetails",
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails",
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofValuationAssumptionsDetails",
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CommitmentsDetails",
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails",
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails",
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofValuationAssumptionsDetails",
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CommitmentsDetails",
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails",
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails",
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofValuationAssumptionsDetails",
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CommitmentsDetails",
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails",
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails",
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofValuationAssumptionsDetails",
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r134",
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r123",
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails",
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails",
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "negatedLabel": "Accounts payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/AccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpensesDetails",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r39"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/AccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Legal"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r33",
      "r128"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r53",
      "r54",
      "r55"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r52",
      "r55",
      "r56",
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": {
     "auth_ref": [
      "r145",
      "r150",
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.",
        "label": "Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature",
        "terseLabel": "Increase in additional paid-in capital from conversion"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r158",
      "r160",
      "r188",
      "r189"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r145",
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Equity issuance costs paid with equity"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r160",
      "r183",
      "r187"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r69",
      "r85",
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "verboseLabel": "Accretion of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities outstanding excluded from the computation of diluted weighted average shares outstanding"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r121",
      "r290",
      "r300"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r49"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of assets classified as held for sale.",
        "label": "Assets Held-for-sale, Long Lived, Fair Value Disclosure",
        "terseLabel": "Quoted price of assets held for sale of NeoCart"
       }
      }
     },
     "localname": "AssetsHeldForSaleLongLivedFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.",
        "label": "Assets Held-for-sale, Not Part of Disposal Group, Current",
        "terseLabel": "Asset held for sale"
       }
      }
     },
     "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNet": {
     "auth_ref": [
      "r1",
      "r310",
      "r311",
      "r312",
      "r313"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of net assets (liabilities).",
        "label": "Net Assets",
        "totalLabel": "Net assets acquired"
       }
      }
     },
     "localname": "AssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r161",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SharedBasedCompensationDetails",
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails",
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r224",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Merger and Financing"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition cost incurred"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r31",
      "r87"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNet",
       "weight": 1.0
      },
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesSummaryCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails",
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesSummaryCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r13",
      "r88",
      "r92",
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r80",
      "r87",
      "r91"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesSummaryCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "terseLabel": "Cash, cash equivalents and restricted cash",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.deitaxonomy.com/role/NatureofBusinessGoingConcernDetails",
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesSummaryCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Cash, cash equivalents and restricted cash reconciliation:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesSummaryCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r80",
      "r258"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r99",
      "r154",
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.deitaxonomy.com/role/ScheduleofActivityofthePreMergerFinancingWarrantsDetails",
      "http://www.deitaxonomy.com/role/ScheduleofRollforwardofSeriesBWarrantLiabilityDetails",
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.deitaxonomy.com/role/ScheduleofActivityofthePreMergerFinancingWarrantsDetails",
      "http://www.deitaxonomy.com/role/ScheduleofRollforwardofSeriesBWarrantLiabilityDetails",
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Initial exercise price (in USD per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofActivityofthePreMergerFinancingWarrantsDetails",
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofRollforwardofSeriesBWarrantLiabilityDetails",
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of common shares in to which the warrants are exercisable (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Outstanding at the end of the period (in shares)",
        "periodStartLabel": "Outstanding at beginning of the period (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofActivityofthePreMergerFinancingWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r93",
      "r154",
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofRollforwardofSeriesBWarrantLiabilityDetails",
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r227",
      "r228",
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License and Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "License agreements:"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r44",
      "r133",
      "r295",
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r132",
      "r135"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Commitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r23",
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesSubscriptions": {
     "auth_ref": [
      "r23",
      "r144"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.",
        "label": "Common Stock, Value, Subscriptions",
        "terseLabel": "Common stock, value, subscriptions"
       }
      }
     },
     "localname": "CommonStockSharesSubscriptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value, 200,000,000 authorized, 52,746,728 and 4,960,552 shares issued, respectively; 52,625,228 and 4,960,552 shares outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r58",
      "r60",
      "r61"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]",
        "terseLabel": "Nature of Business"
       }
      }
     },
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NatureofBusinessReverseStockSplitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable": {
     "auth_ref": [
      "r236",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent which may have occurred during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary.",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]",
        "terseLabel": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]"
       }
      }
     },
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NatureofBusinessReverseStockSplitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r232",
      "r240",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r20",
      "r292",
      "r302"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "terseLabel": "Note principal outstanding"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails",
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "auth_ref": [
      "r89",
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Original Debt, Amount",
        "terseLabel": "Conversion of convertible notes (Note 7)"
       }
      }
     },
     "localname": "DebtConversionOriginalDebtAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r291",
      "r292",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails",
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails",
      "http://www.deitaxonomy.com/role/DebtEB5LoanDetails",
      "http://www.deitaxonomy.com/role/DebtSeniorSecuredConvertibleNotesDetails",
      "http://www.deitaxonomy.com/role/DebtSummaryofEB5LoanDetails",
      "http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails",
      "http://www.deitaxonomy.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r20",
      "r138",
      "r292",
      "r299"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/DebtSummaryofEB5LoanDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Principal outstanding"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtSummaryofEB5LoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r263",
      "r265"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Note Principal Amount",
        "verboseLabel": "Principal outstanding"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails",
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails",
      "http://www.deitaxonomy.com/role/DebtSeniorSecuredConvertibleNotesDetails",
      "http://www.deitaxonomy.com/role/DebtSummaryofEB5LoanDetails",
      "http://www.deitaxonomy.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails",
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails",
      "http://www.deitaxonomy.com/role/DebtEB5LoanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails",
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails",
      "http://www.deitaxonomy.com/role/DebtEB5LoanDetails",
      "http://www.deitaxonomy.com/role/DebtSeniorSecuredConvertibleNotesDetails",
      "http://www.deitaxonomy.com/role/DebtSummaryofEB5LoanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails",
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails",
      "http://www.deitaxonomy.com/role/DebtEB5LoanDetails",
      "http://www.deitaxonomy.com/role/DebtSeniorSecuredConvertibleNotesDetails",
      "http://www.deitaxonomy.com/role/DebtSummaryofEB5LoanDetails",
      "http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails",
      "http://www.deitaxonomy.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r42",
      "r94",
      "r146",
      "r147",
      "r148",
      "r149",
      "r262",
      "r263",
      "r265",
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails",
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails",
      "http://www.deitaxonomy.com/role/DebtEB5LoanDetails",
      "http://www.deitaxonomy.com/role/DebtSeniorSecuredConvertibleNotesDetails",
      "http://www.deitaxonomy.com/role/DebtSummaryofEB5LoanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Maturity term (in months)"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r262",
      "r265"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedLabel": "Original Issue Discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtSeniorSecuredConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r264"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "negatedLabel": "Debt Issuance Costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r34",
      "r264"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/DebtSummaryofEB5LoanDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedLabel": "Less: unamortized debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtSummaryofEB5LoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "auth_ref": [
      "r193",
      "r217",
      "r218"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.",
        "label": "Deferred Tax Assets, Capital Loss Carryforwards",
        "terseLabel": "Capital loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intellectual property amortization"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r210"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r211"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "terseLabel": "Deferred tax assets, net of allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r192",
      "r217",
      "r218"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "Operating loss carryforwards, not subject to expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Operating loss carryforwards, subject to expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r215",
      "r217",
      "r218"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r192",
      "r217",
      "r218"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r192",
      "r217",
      "r218"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accruals and reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r193",
      "r217",
      "r218"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "terseLabel": "Lease ROU asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r85",
      "r126"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r242",
      "r244",
      "r245",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Current",
        "terseLabel": "Derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss).",
        "label": "Disclosure of Long Lived Assets Held-for-sale [Table Text Block]",
        "terseLabel": "Summary of assets and liabilities to be sold pursuant to Asset Purchase Agreement"
       }
      }
     },
     "localname": "DisclosureOfLongLivedAssetsHeldForSaleTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandPreMergerFinancingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share of common stock - basic and diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share of Common Stock"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r258"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of changes in exchange rate on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r96",
      "r198",
      "r199"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/ScheduleofEffectiveIncomeTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total provision for income taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r198",
      "r199",
      "r220"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/ScheduleofEffectiveIncomeTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal income tax benefit at statutory rate (in percentage)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r198",
      "r199",
      "r220"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/ScheduleofEffectiveIncomeTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "negatedLabel": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r198",
      "r199",
      "r220"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/ScheduleofEffectiveIncomeTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other (in percentage)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r198",
      "r199",
      "r220"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/ScheduleofEffectiveIncomeTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State and local tax, net of federal benefit (in percentage)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r198",
      "r199",
      "r220"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/ScheduleofEffectiveIncomeTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research and development credit (in percentage)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.",
        "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability",
        "negatedLabel": "Fair\u00a0Value\u00a0of Embedded Derivatives",
        "terseLabel": "Fair value of embedded derivative"
       }
      }
     },
     "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails",
      "http://www.deitaxonomy.com/role/DebtScheduleofFairValueoftheEmbeddedFeaturesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": {
     "auth_ref": [
      "r247"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.",
        "label": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net",
        "terseLabel": "Change in fair value of embedded derivatives"
       }
      }
     },
     "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtScheduleofFairValueoftheEmbeddedFeaturesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/AccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee-related"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense related to options outstanding, weighted average period for expense to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SharedBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SharedBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SharedBasedCompensationDetails",
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAxis": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information pertaining to the debt extinguished including the amount of gain (loss), the income tax effect on the gain (loss), and the amount of gain (loss), net or the related income tax, by debt instrument.",
        "label": "Extinguishment of Debt [Axis]",
        "terseLabel": "Extinguishment of Debt [Axis]"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ExtinguishmentOfDebtTypeDomain": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of debt extinguished.",
        "label": "Extinguishment of Debt, Type [Domain]",
        "terseLabel": "Extinguishment of Debt, Type [Domain]"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Pre-Merger Financing Warrants"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofActivityofthePreMergerFinancingWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r248",
      "r255",
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofActivityofthePreMergerFinancingWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r249",
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r249",
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]",
        "terseLabel": "Reconciliation of Series B Warrant liability"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofRollforwardofSeriesBWarrantLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": {
     "auth_ref": [
      "r252",
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of Series B Warrant liability measured at fair value using Level 3 significant unobservable inputs"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues": {
     "auth_ref": [
      "r253",
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues",
        "terseLabel": "Fair value at issuance"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofRollforwardofSeriesBWarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease": {
     "auth_ref": [
      "r252",
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease)",
        "terseLabel": "Change in fair value of embedded derivatives"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofRollforwardofSeriesBWarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs": {
     "auth_ref": [
      "r248",
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofRollforwardofSeriesBWarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r268",
      "r281"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CommitmentsFinanceleasesfutureminimumleasepaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Present value of minimum lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CommitmentsFinanceleasesfutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of maturities of finance leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CommitmentsFinanceleasesfutureminimumleasepaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.deitaxonomy.com/role/CommitmentsFinanceleasesfutureminimumleasepaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CommitmentsFinanceleasesfutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CommitmentsFinanceleasesfutureminimumleasepaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.",
        "label": "Finance Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CommitmentsFinanceleasesfutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CommitmentsFinanceleasesfutureminimumleasepaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.",
        "label": "Finance Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CommitmentsFinanceleasesfutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CommitmentsFinanceleasesfutureminimumleasepaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: present value adjustment"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CommitmentsFinanceleasesfutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r269",
      "r276"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/Cover": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payments on financing leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r257",
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation and Transactions"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r85",
      "r140",
      "r141"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Extinguishment of debt loss"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r62",
      "r92",
      "r196",
      "r197",
      "r208",
      "r209",
      "r214",
      "r221",
      "r315"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r63",
      "r120",
      "r261",
      "r264",
      "r297"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r294",
      "r308"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/DebtSummaryofEB5LoanDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
        "label": "Interest Payable",
        "terseLabel": "Plus: accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtSummaryofEB5LoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r67",
      "r119"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r280",
      "r282"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CommitmentsOperatingleasescomponentsofleaseexpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CommitmentsOperatingleasescomponentsofleaseexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of components of lease expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeFinanceLeaseDiscountRate": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of finance lease payments.",
        "label": "Lessee, Finance Lease, Discount Rate",
        "terseLabel": "Interest rate (as a percent)"
       }
      }
     },
     "localname": "LesseeFinanceLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CommitmentsFinanceleasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of maturities of operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CommitmentsOperatingleasesfutureminimumleasepaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CommitmentsOperatingleasesfutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CommitmentsOperatingleasesfutureminimumleasepaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CommitmentsOperatingleasesfutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CommitmentsOperatingleasesfutureminimumleasepaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CommitmentsOperatingleasesfutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CommitmentsOperatingleasesfutureminimumleasepaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CommitmentsOperatingleasesfutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CommitmentsOperatingleasesfutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Leases, term of contract (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CommitmentsDetails",
      "http://www.deitaxonomy.com/role/CommitmentsFinanceleasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r28",
      "r293",
      "r305"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.",
        "label": "Liabilities, Fair Value Adjustment",
        "negatedLabel": "Change in fair value of derivative liability",
        "terseLabel": "Change in fair value of derivative liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r20",
      "r21"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r20",
      "r292",
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Amount borrowed",
        "verboseLabel": "Long-term Line of Credit"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtEB5LoanDetails",
      "http://www.deitaxonomy.com/role/DebtSummaryofEB5LoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtEB5LoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Loans payable"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtEB5LoanDetails",
      "http://www.deitaxonomy.com/role/DebtSummaryofEB5LoanDetails",
      "http://www.deitaxonomy.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r20",
      "r139",
      "r292",
      "r302"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.deitaxonomy.com/role/DebtSummaryofEB5LoanDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Carrying value of debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails",
      "http://www.deitaxonomy.com/role/DebtSummaryofEB5LoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long term debt, net"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails",
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails",
      "http://www.deitaxonomy.com/role/DebtEB5LoanDetails",
      "http://www.deitaxonomy.com/role/DebtSummaryofEB5LoanDetails",
      "http://www.deitaxonomy.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r42",
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails",
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails",
      "http://www.deitaxonomy.com/role/DebtEB5LoanDetails",
      "http://www.deitaxonomy.com/role/DebtSummaryofEB5LoanDetails",
      "http://www.deitaxonomy.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Price Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "auth_ref": [
      "r0",
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures.  This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "terseLabel": "Merger and Pre-Merger Financing"
       }
      }
     },
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandPreMergerFinancing"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "verboseLabel": "Ownership (as a percent)"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r110",
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NatureofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      },
      "http://www.deitaxonomy.com/role/Cover": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r80",
      "r83",
      "r86"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r57",
      "r59",
      "r64",
      "r86",
      "r108",
      "r296",
      "r309"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.deitaxonomy.com/role/IncomeTaxesDetails",
      "http://www.deitaxonomy.com/role/NatureofBusinessGoingConcernDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r102",
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss- basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r104",
      "r105"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net Loss-diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "RECENT ACCOUNTING PRONOUNCEMENTS"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r101",
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Standards; Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r274",
      "r282"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CommitmentsOperatingleasescomponentsofleaseexpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CommitmentsOperatingleasescomponentsofleaseexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r268"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CommitmentsOperatingleasessupplementalbalancesheetinformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CommitmentsOperatingleasesfutureminimumleasepaymentsDetails",
      "http://www.deitaxonomy.com/role/CommitmentsOperatingleasessupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r268"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.deitaxonomy.com/role/CommitmentsOperatingleasessupplementalbalancesheetinformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease obligation",
        "verboseLabel": "Current lease obligations"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.deitaxonomy.com/role/CommitmentsOperatingleasessupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r268"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://www.deitaxonomy.com/role/CommitmentsOperatingleasessupplementalbalancesheetinformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease obligation, less current portion",
        "verboseLabel": "Non-current lease obligations"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.deitaxonomy.com/role/CommitmentsOperatingleasessupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CommitmentsOperatingleasessupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r279",
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate\u2014operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CommitmentsOperatingleasessupplementalinformationrelatedtoleasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r278",
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease terms\u2014operating leases (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CommitmentsOperatingleasessupplementalinformationrelatedtoleasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r215"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r39"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/AccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r51",
      "r259"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r39"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashExpense": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.",
        "label": "Other Noncash Expense",
        "terseLabel": "Other non-cash"
       }
      }
     },
     "localname": "OtherNoncashExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForMergerRelatedCosts": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the reporting period for charges associated with the mergers.",
        "label": "Payments for Merger Related Costs",
        "terseLabel": "Acquisition cost paid in cash"
       }
      }
     },
     "localname": "PaymentsForMergerRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/Cover": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Purchases of treasury stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Payments for Royalties",
        "terseLabel": "Royalty payments"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/Cover": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payment of debt issuance costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.deitaxonomy.com/role/DebtEB5LoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Equity issuance costs paid in cash"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Payment of asset acquisition costs"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r161",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SharedBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SharedBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Convertible preferred stock, par value (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Convertible preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Convertible preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Convertible preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Convertible preferred stock, $0.01 par value, 10,000,000 shares authorized, seven and zero issued and outstanding, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r29",
      "r30"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/Cover": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/Cover": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from stock subscription"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received from licensees for license fees during the current period.",
        "label": "Proceeds from License Fees Received",
        "terseLabel": "Upfront cash payment received for license granted to MEDINET"
       }
      }
     },
     "localname": "ProceedsFromLicenseFeesReceived",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r74",
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from lines of credit"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/Cover": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Issuance of common stock for warrant exercises"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r57",
      "r59",
      "r79",
      "r121",
      "r122",
      "r231",
      "r233",
      "r234",
      "r237",
      "r238"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r33",
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r14",
      "r15",
      "r129",
      "r306"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r32",
      "r92",
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r14",
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Unrecognized Tax Benefits Reconciliation"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/Cover": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedLabel": "Repayments of Debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.",
        "label": "Repayments of Senior Debt",
        "terseLabel": "Repayment of senior secured notes"
       }
      }
     },
     "localname": "RepaymentsOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r191",
      "r316"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r5",
      "r16",
      "r91",
      "r314"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesSummaryCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesSummaryCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r25",
      "r150",
      "r304"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.deitaxonomy.com/role/NatureofBusinessGoingConcernDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r277",
      "r282"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Purchase of fixed assets by entering into capital lease (Note 9)"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "verboseLabel": "Aggregate purchase price"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price per share (in USD per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of potentially dilutive securities excluded from computation of diluted weighted average shares"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r224",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Principal, Embedded Derivatives and Carrying Value of Debts"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r42",
      "r94",
      "r146",
      "r147",
      "r148",
      "r149",
      "r262",
      "r263",
      "r265",
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of basic and diluted earnings per share of common stock"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r160",
      "r182",
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense for Options Granted Reflected in the Consolidated Statement of Operations and Comprehensive Loss"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r13",
      "r91",
      "r289",
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r161",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SharedBasedCompensationDetails",
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails",
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails",
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r167",
      "r172",
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Weighted Average Assumptions Utilized in Fair Value Calculation"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Weighted average common stock price (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofValuationAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "verboseLabel": "Expected dividend rate (in percentage)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofValuationAssumptionsDetails",
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate (in percentage)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Weighted average expected stock price volatility (in percentage)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SharedBasedCompensationDetails",
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails",
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails",
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SharedBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Additional disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SharedBasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r169",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Pre-Merger Financing Warrants Activity",
        "verboseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofActivityofthePreMergerFinancingWarrantsDetails",
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options Outstanding (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Shares issued in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SharedBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r159",
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SharedBasedCompensationDetails",
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails",
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r92",
      "r161",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r177",
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected option term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofValuationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable, intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, weighted average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding, weighted average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r166"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Options vested in period, fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SharedBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares issued, price per share (in USD per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r17",
      "r291",
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-term Debt",
        "verboseLabel": "Short-term debt, net"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and local"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r47",
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r46",
      "r145",
      "r146",
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "verboseLabel": "Conversion of debt (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r145",
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Shares issued (in shares)",
        "verboseLabel": "Issuance of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r47",
      "r145",
      "r150"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of debt"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r145",
      "r150"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock for Subscription Agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockDetails",
      "http://www.deitaxonomy.com/role/SharedBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r23",
      "r26",
      "r27",
      "r124"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NatureofBusinessReverseStockSplitDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent events"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r200",
      "r207",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Summary of Income Tax Contingencies"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing transactions:"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r215"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward, amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r48",
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Treasury stock, common, shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r45",
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r45",
      "r152",
      "r153"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury Stock, at cost 121,500 and zero shares, respectively"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r145",
      "r150",
      "r152"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedLabel": "Repurchase of treasury stock"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r194",
      "r202"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance",
        "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/IncomeTaxesDetails",
      "http://www.deitaxonomy.com/role/ScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "terseLabel": "Reductions for tax positions taken in the prior year due to settlement"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r204"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions for tax positions taken in the current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r203"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions for tax positions taken in a prior year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "terseLabel": "Reductions for tax positions taken in the prior year due to statutes lapsing"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/ScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r195"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "verboseLabel": "Net change in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r275",
      "r282"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CommitmentsOperatingleasescomponentsofleaseexpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CommitmentsOperatingleasescomponentsofleaseexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Warrants and Rights Note Disclosure [Abstract]"
       }
      }
     },
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrants outstanding (in shares)"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Warrants fair value estimate volatility (in percentage)"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants outstanding, term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]",
        "terseLabel": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average shares of common stock outstanding - basic and diluted (in shares)",
        "verboseLabel": "Shares used in calculation net loss per common share - basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=77885760&loc=SL35686385-199418"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=77912953&loc=d3e400-110220"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=7516071&loc=d3e13374-112631"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32123-109318"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "51",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117331294&loc=d3e34017-109320"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4M",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591554-111686"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "15",
   "Topic": "815",
   "URI": "http://asc.fasb.org/subtopic&trid=2229187"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13476-108611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b,c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262037&loc=d3e9915-115836"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=6488278&loc=d3e604008-122996"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=116637345&loc=SL114874367-224272"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=116637345&loc=SL114874367-224272"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r317": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r318": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r319": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r321": {
   "Name": "Forms 10-K, 20-F, 40-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-1"
  },
  "r322": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r323": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i)(4))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6775740320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Roll-forward of Series&#160;B Warrant Liability (Details) - Series B Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward', window );"><strong>Reconciliation of Series B Warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Balance at beginning of period</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues', window );">Fair value at issuance</a></td>
<td class="nump">9,387,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease', window );">Change in fair value of embedded derivatives</a></td>
<td class="nump">1,867,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationAmountReclassifiedToEquity', window );">Amount reclassified to equity</a></td>
<td class="nump">11,255,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Balance at end of period</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationAmountReclassifiedToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Amount Reclassified To Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationAmountReclassifiedToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ocgn_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ocgn_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6790272736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments - Operating leases, components of lease expense (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 250,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">79,700<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 330,061<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6789169616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments - Finance leases (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Leases, term of contract (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDiscountRate', window );">Interest rate (as a percent)</a></td>
<td class="nump">7.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of finance lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6789178416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Compensation Expense for Options Granted (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 884,089<span></span>
</td>
<td class="nump">$ 1,074,687<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">362,833<span></span>
</td>
<td class="nump">515,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 521,256<span></span>
</td>
<td class="nump">$ 559,527<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6793430048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Convertible Notes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair&#160;Value&#160;of Embedded Derivatives</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1,741,222)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Maturity term (in months)</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible notes | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount', window );">Conversion price discount per original agreement (as a percent)</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtMember', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Note Principal Amount</a></td>
<td class="nump">$ 8,750,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt Issuance Costs</a></td>
<td class="num">(189,158)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value of debt</a></td>
<td class="nump">4,670,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Accretion of debt discount</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtMember', window );">Convertible notes | Convertible debt, conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair&#160;Value&#160;of Embedded Derivatives</a></td>
<td class="num">(3,891,172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtMember', window );">Convertible notes | Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Note principal outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_DebtRedemptionMultipleUponDefault', window );">Redemption multiple upon default</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ocgn_ConvertibleNotesBoardOfDirectorsMember', window );">Convertible Notes - Board of Directors | Convertible notes | Board members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Note Principal Amount</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ocgn_ConvertibleDebtJanuary2018Member', window );">Convertible Note - January 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Note Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,969)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,306,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ocgn_ConvertibleDebtJanuary2018Member', window );">Convertible Note - January 2018 | Convertible debt, conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair&#160;Value&#160;of Embedded Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,657,711)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ocgn_ConvertibleDebtJune2018Member', window );">Convertible Note - June 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Note Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ocgn_ConvertibleDebtJune2018Member', window );">Convertible Note - June 2018 | Convertible debt, conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair&#160;Value&#160;of Embedded Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (724,216)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ocgn_ConvertibleDebtNovember2018Member', window );">Convertible Note - November 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Note Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,150,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,646)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,078,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ocgn_ConvertibleDebtNovember2018Member', window );">Convertible Note - November 2018 | Convertible debt, conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair&#160;Value&#160;of Embedded Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (21,127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ocgn_ConvertibleDebtDecember2018Member', window );">Convertible Note - December 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Note Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ocgn_ConvertibleDebtDecember2018Member', window );">Convertible Note - December 2018 | Convertible debt, conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair&#160;Value&#160;of Embedded Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,857)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ocgn_ConvertibleDebtJanuary2019Member', window );">Convertible Note - January 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Note Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,358)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ocgn_ConvertibleDebtJanuary2019Member', window );">Convertible Note - January 2019 | Convertible debt, conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair&#160;Value&#160;of Embedded Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (182,882)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ocgn_ConvertibleDebtFebruary2019Member', window );">Convertible Note - February 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Note Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,875)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">641,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ocgn_ConvertibleDebtFebruary2019Member', window );">Convertible Note - February 2019 | Convertible debt, conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair&#160;Value&#160;of Embedded Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (302,379)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of discount of the convertible debt that automatically convert the same class of equity as those issued to the lowest price per share being paid by investors in the equity financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_DebtRedemptionMultipleUponDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redemption multiple of debt's principal and unpaid interest upon default.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_DebtRedemptionMultipleUponDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=ocgn_ConvertibleDebtConversionFeatureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=ocgn_ConvertibleDebtConversionFeatureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ocgn_ConvertibleNotesBoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ocgn_ConvertibleNotesBoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ocgn_ConvertibleDebtJanuary2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ocgn_ConvertibleDebtJanuary2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ocgn_ConvertibleDebtJune2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ocgn_ConvertibleDebtJune2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ocgn_ConvertibleDebtNovember2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ocgn_ConvertibleDebtNovember2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ocgn_ConvertibleDebtDecember2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ocgn_ConvertibleDebtDecember2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ocgn_ConvertibleDebtJanuary2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ocgn_ConvertibleDebtJanuary2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ocgn_ConvertibleDebtFebruary2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ocgn_ConvertibleDebtFebruary2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6775804416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Leases, term of contract (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Leases, term of contract (in years)</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Leases, term of contract (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6956267696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Unrecognized Tax Benefits (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Unrecognized Tax Benefits Reconciliation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits, Beginning Balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions taken in a prior year</a></td>
<td class="nump">303,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions for tax positions taken in the current year</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Reductions for tax positions taken in the prior year due to settlement</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Reductions for tax positions taken in the prior year due to statutes lapsing</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits, Ending Balance</a></td>
<td class="nump">$ 303,050<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6775760960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation and Consolidation</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying consolidated financial statements included herein have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;). The consolidated financial statements include the accounts of Ocugen, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Certain prior year amounts have been reclassified to conform with current year presentation.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Foreign Currency Translation and Transactions</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The assets and liabilities of the Company&#8217;s foreign subsidiary are translated into U.S. dollars based on exchange rates in effect at the end of each period. Revenues and expenses are translated at average exchange rates during the periods. Currency transaction gains or losses are included in other expenses. Gains or losses from balance sheet translation are included in accumulated other comprehensive income.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In preparing consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include those used in the estimation of clinical trial accruals and the valuation of share-based payment arrangements, warrants, and embedded conversion features on the convertible notes.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Asset Held for Sale</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">An asset is considered to be held for sale when all of the following criteria are met: (i) management commits to a plan to sell the asset; (ii) it is unlikely that the disposal plan will be significantly modified or discontinued; (iii) the asset is available for immediate sale in its present condition; (iv)&#160;actions required to complete the sale of the asset have been initiated; (v) sale of the asset is probable and the completed sale is expected to occur within one year; and (vi)&#160;the asset is actively being marketed for sale at a price that is reasonable given its current market value.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A long-lived asset classified as held for sale is measured at the lower of its carrying amount or fair value less cost to sell. If the long-lived asset is newly acquired, the carrying amount of the long-lived asset is established based on its fair value less cost to sell at the acquisition date. A long-lived asset is not depreciated or amortized while it is classified as held for sale, and an impairment loss would be recognized to the extent the carrying amount exceeds the asset's fair value less cost to sell.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, Ocugen had an intangible asset held for sale acquired from Histogenics with a fair value less cost to sell of $7.0 million. See Note 3 for additional information.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value Measurements</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The company follows the provisions of the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 820, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC 820&#8221;), which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair measurements.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The estimated fair value of certain financial instruments, cash and cash equivalents, accounts payable, and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. As of December&#160;31, 2019 and 2018, the Company believes the fair value of the EB-5 note approximates its carrying value.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 1 &#8212; quoted prices in active markets for identical assets or liabilities</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 2 &#8212; quoted prices for similar assets and liabilities in active markets or inputs that are observable</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 3 &#8212; inputs that are unobservable (for example cash flow modeling inputs based on assumptions)</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The company had derivative instruments that were fair valued on a recurring basis using Level 3 inputs.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Financial Instruments Indexed to and Potentially Settled in Common Stock</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for warrants in accordance with ASC Topic 815-40, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC 815-40&#8221;), which is the authoritative guidance on accounting for derivative financial instruments indexed to and potentially settled in a company&#8217;s own stock. To determine whether a contract is considered indexed to the issuer&#8217;s own equity, the Company performs a two-step analysis:</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Step 1: Evaluate whether the contract contains any exercise contingencies and, if so, whether they disqualify the contract from being classified as equity, and</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Step 2: Assess whether the settlement terms are consistent with equity classification.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company classifies the liability-designated warrants on its consolidated balance sheets as a derivative liability which is recognized at fair value at each reporting period subsequent to the initial issuance. Changes in the fair value of derivatives are recognized as other income (expense) in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposit, commercial paper and United States government and United States government agency obligations. The Company&#8217;s restricted cash balance consists of cash held to collateralize a corporate credit card account.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash in the consolidated balance sheets to the total amount shown in the consolidated statements of cash flows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.175%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash reconciliation:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,444,052&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,628,136&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">151,016&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150,477&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash, cash equivalents and restricted cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,595,068&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,778,613&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and Equipment, Net</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment is recorded at cost. Significant additions or improvements are capitalized, and expenditures for repairs and maintenance are charged to expense as incurred. Gains and losses on disposal of assets are included in the consolidated statements of operations and comprehensive loss. Depreciation is calculated using the straight-line method and is recognized over an expected useful life of 5 years for equipment and 7 years for furniture. The total accumulated depreciation and amortization for equipment and furniture as of December&#160;31, 2019 and 2018 was $0.1&#160;million and $0.1&#160;million, respectively.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements which include lease and&#160;non-lease&#160;components, which the Company has elected to account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components are recognized when the obligation is probable.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating leases are included in other assets and lease obligations on the Company&#8217;s consolidated balance sheets. Operating lease right-of-use ("ROU") assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Operating lease payments are recognized as lease expense on a straight-line basis over the lease term. The Company primarily leases buildings (real estate) which are classified as operating leases. ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As an implicit interest rate is not readily determinable in the Company&#8217;s leases, the incremental borrowing rate is used based on the information available at commencement date in determining the present value of lease payments.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The lease term for all of the Company&#8217;s leases includes the&#160;non-cancellable&#160;period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and lease liability) for the majority of the Company&#8217;s leases as the reasonably certain threshold is not met.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lease payments included in the measurement of the lease liability are comprised of fixed payments, variable payments that depend on index or rate, and amounts probable to be payable under the exercise of the Company option to purchase the underlying asset if reasonably certain.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Variable lease payments not dependent on a rate or index associated with the Company&#8217;s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed as probable. Variable lease payments include the Company's proportionate share of utilities and other operating expenses and are presented as operating expenses in the Company&#8217;s income statement in the same line item as expense arising from fixed lease payments.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-based compensation</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ocugen accounts for its stock-based compensation awards in accordance with ASC Topic 718, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Compensation&#8212;Stock Compensation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments to employees, including grants of employee stock options and restricted stock units and modifications to existing agreements, to be recognized in the statements of operations </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">based on their fair values. Ocugen uses the Black-Scholes option-pricing model to determine the fair value of options granted. Ocugen recognized forfeitures as they occur.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ocugen&#8217;s stock-based awards are subject to service-based vesting conditions. Compensation expense related to awards to employees and directors with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Stock-based awards generally vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfNzY5NjU4MTQxODYxNA_853dc9b7-c919-4df5-9190-d9436288daac">one</span> to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfODI0NjMzNzIzNzU5OQ_e571c6b5-bef2-4cd7-bc49-832c32f02b1a">three</span> year requisite service period and have a contractual term of 10 years.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Estimating the fair value of options requires the input of subjective assumptions, including expected life of the option, stock price volatility, the risk-free interest rate and expected dividends. The assumptions used in Ocugen&#8217;s Black-Scholes option-pricing model represent management&#8217;s best estimates and involve a number of variables, uncertainties and assumptions and the application of management&#8217;s judgment, as they are inherently subjective. If any assumptions change, Ocugen&#8217;s stock-based compensation expense could be materially different in the future.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These assumptions used in Ocugen&#8217;s Black-Scholes option-pricing model are as follows:</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Term.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Due to the historical lack of a public market for the trading of Ocugen common stock and the lack of sufficient company-specific historical data, the expected term of employee options is determined using the &#8220;simplified&#8221; method, as prescribed in Securities and Exchange Commission&#8217;s Staff Accounting Bulletin No. 107 (&#8220;SAB&#160;No.&#160;107&#8221;), whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option. The expected term of non-employee options is equal to the contractual term.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Volatility.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The expected volatility is based on historical volatilities of Ocugen and similar entities within Ocugen&#8217;s industry for periods commensurate with the expected term assumption.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk-Free Interest Rate.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Dividends.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The expected dividend yield is 0% because Ocugen has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is a Delaware C-Corporation. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, is applied during the years in which temporary differences are expected to be settled and is reflected in the financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on the weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. The Company&#8217;s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. No interest or penalty expense was recognized during the periods presented.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has assessed and concluded that there are uncertain tax positions giving rise to the unrecognized tax benefits as of December&#160;31, 2019. The Company&#8217;s conclusions regarding uncertain tax positions may be subject to review and adjustment at a later date based upon ongoing analysis of tax laws, regulations and interpretations thereof, as well as other factors. Generally, federal, state, and local authorities may examine the Company&#8217;s tax returns for three years from the date of the filing and the current and prior three years remain subject to examination as of December&#160;31, 2019.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Segment Information</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company views its operations and manages its business as one operating segment, which is the development of innovative therapies to address the whole eye. As of December&#160;31, 2019, substantially all of the Company&#8217;s assets were located in the United States.</span></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Standards</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February&#160;2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;)&#160;No.&#160;2016-02,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases (Topic 842)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC 842&#8221;). In July&#160;2018, the FASB issued ASU&#160;No.&#160;2018-10,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Codification Improvements to Topic 842, Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASU&#160;2018-10&#8221;),&#160;which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU&#160;No.&#160;2018-11,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(Topic 842)&#8212;Targeted Improvements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASU&#160;2018-11&#8221;),&#160;which addressed implementation issues related to the new lease standard. These and certain other lease-related ASUs have generally been codified in ASC 842. ASC 842 supersedes the lease accounting requirements in ASC Topic 840, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC 840&#8221;). ASC 842 establishes a&#160;right-of-use&#160;model that requires a lessee to record a&#160;right-of-use&#160;(&#8220;ROU&#8221;) asset and a lease liability on the balance sheet for all leases. Under ASC 842, leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The standard also requires disclosures to help investors and other financial statement users better understand the amount, timing and uncertainty of cash flows arising from leases. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company adopted ASC 842 on January&#160;1, 2019 using the effective date transition method. Prior period results continue to be presented under ASC 840 based on the accounting standards originally in effect for such periods. The Company has elected certain practical expedients permitted under the transition guidance within ASC 842 to leases that commenced before January&#160;1, 2019, including the package of practical expedients. The election of the package of practical expedients resulted in the Company not reassessing prior conclusions under ASC 840 related to lease identification, lease classification and initial direct costs for expired and existing leases prior to January&#160;1, 2019. The adoption of ASU&#160;2016-02&#160;did not have a significant impact on the Company&#8217;s consolidated results of operations or cash flows. Upon adoption, the Company recognized an ROU asset and lease liability of $0.4 million and $0.4 million, respectively. See Note 9 for additional information.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU No. 2018-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This standard modifies certain disclosure requirements on fair value measurements and was effective for the Company on January 1, 2020. The adoption of this standard will not have a material impact on the Company's disclosures.</span></div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span>. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2023. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The Company does not expect the adoption of these standards to have a material impact on its consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6789103632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th">
<div>Common&#160;Stock </div>
<div>Warrants</div>
</th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,960,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="nump">$ 4,434,987<span></span>
</td>
<td class="nump">$ 49,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,402,911<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (13,017,530)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,074,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,074,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(18,219,664)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,219,664)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2018</a></td>
<td class="num">(12,709,539)<span></span>
</td>
<td class="nump">$ 49,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,477,598<span></span>
</td>
<td class="nump">451<span></span>
</td>
<td class="num">(31,237,194)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,960,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(451)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (451)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">884,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">884,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,242,630)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,242,630)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,569<span></span>
</td>
<td class="nump">40,542,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for Subscription Agreement</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">$ 806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">999,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of debt (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,125,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of debt</a></td>
<td class="nump">13,979,788<span></span>
</td>
<td class="nump">$ 11,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,968,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_StockIssuedDuringPeriodPreMergerShares', window );">Issuance of common stock and warrants for pre-Merger Financing (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,385,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_StockIssuedDuringPeriodPreMergerValue', window );">Issuance of common stock and warrants for Pre-Merger Financing</a></td>
<td class="nump">13,150,456<span></span>
</td>
<td class="nump">$ 43,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,106,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_StockIssuedDuringPeriodSharesReverseAssetAcquisition', window );">Issuance of stock for reverse asset acquisition, net of $2.6 million of costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,651,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_StockIssuedDuringPeriodValueReverseAssetAcquisition', window );">Issuance of stock for reverse asset acquisition, net of $2.6&#160;million of costs</a></td>
<td class="nump">3,565,788<span></span>
</td>
<td class="nump">$ 16,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,549,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ReclassificationOfWarrantsFromLiabilityToEquity', window );">Reclassification of Series B Warrants from liability to equity</a></td>
<td class="nump">11,255,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,255,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock for warrant exercises, net</a></td>
<td class="nump">183,034<span></span>
</td>
<td class="nump">405,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(222,388)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of treasury stock</a></td>
<td class="num">(47,864)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (47,864)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">$ 11,018,411<span></span>
</td>
<td class="nump">$ 527,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (47,864)<span></span>
</td>
<td class="nump">$ 62,018,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (51,479,824)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,746,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ReclassificationOfWarrantsFromLiabilityToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification Of Warrants From Liability To Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ReclassificationOfWarrantsFromLiabilityToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_StockIssuedDuringPeriodPreMergerShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period, pursuant to pre-merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_StockIssuedDuringPeriodPreMergerShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_StockIssuedDuringPeriodPreMergerValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock issued during the period pursuant to pre-merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_StockIssuedDuringPeriodPreMergerValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_StockIssuedDuringPeriodSharesReverseAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period pursuant to reverse asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_StockIssuedDuringPeriodSharesReverseAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_StockIssuedDuringPeriodValueReverseAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock issued during the period pursuant to reverse asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_StockIssuedDuringPeriodValueReverseAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6789310592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 20, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">OCUGEN, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001372299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3522315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5 Great Valley Parkway, Suite 160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Malvern,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">328-4701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OCGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,625,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:115%;">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;">Part III of this Annual Report on Form 10-K incorporates certain information by reference from the registrant&#8217;s proxy statement for the 2020 annual meeting of stockholders to be filed no later than 120 days after the end of the registrant&#8217;s fiscal year ended December 31, 2019.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 20-F, 40-F<br> -Number 240<br> -Section 15<br> -Subsection d-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6779172816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ScheduleOfPreMergerFinancingWarrantsTableTextBlock', window );">Schedule of Pre-merger Financing Warrants</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the activity of the Pre-Merger Financing Warrants, including the effect of the Warrant Amendments:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:31.479%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.520%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.520%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.520%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.625%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series A Warrants</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series B Warrants</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series C Warrants</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at January 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issued</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,771,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,614,036&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,000,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,385,964&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,613,036)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(19,999,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(40,612,036)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,771,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,773,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.13&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.01&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$                      0.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">Schedule of reconciliation of Series B Warrant liability measured at fair value using Level 3 significant unobservable inputs</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a roll-forward of the Series&#160;B Warrant liability:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.380%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.620%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at January 1, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value at issuance (September&#160;27, 2019)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,387,760&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of embedded derivatives</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,867,980&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount reclassified to equity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,255,740)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ScheduleOfPreMergerFinancingWarrantsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Pre-merger Financing Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ScheduleOfPreMergerFinancingWarrantsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6790064176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation and ConsolidationThe accompanying consolidated financial statements included herein have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">The consolidated financial statements include the accounts of Ocugen, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Certain prior year amounts have been reclassified to conform with current year presentation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation and Transactions</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Foreign Currency Translation and Transactions</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The assets and liabilities of the Company&#8217;s foreign subsidiary are translated into U.S. dollars based on exchange rates in effect at the end of each period. Revenues and expenses are translated at average exchange rates during the periods. Currency transaction gains or losses are included in other expenses. Gains or losses from balance sheet translation are included in accumulated other comprehensive income.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In preparing consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include those used in the estimation of clinical trial accruals and the valuation of share-based payment arrangements, warrants, and embedded conversion features on the convertible notes.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_AssetHeldForSalePolicyTextBlock', window );">Asset Held for Sale</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Asset Held for Sale</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">An asset is considered to be held for sale when all of the following criteria are met: (i) management commits to a plan to sell the asset; (ii) it is unlikely that the disposal plan will be significantly modified or discontinued; (iii) the asset is available for immediate sale in its present condition; (iv)&#160;actions required to complete the sale of the asset have been initiated; (v) sale of the asset is probable and the completed sale is expected to occur within one year; and (vi)&#160;the asset is actively being marketed for sale at a price that is reasonable given its current market value.</span></div>A long-lived asset classified as held for sale is measured at the lower of its carrying amount or fair value less cost to sell. If the long-lived asset is newly acquired, the carrying amount of the long-lived asset is established based on its fair value less cost to sell at the acquisition date. A long-lived asset is not depreciated or amortized while it is classified as held for sale, and an impairment loss would be recognized to the extent the carrying amount exceeds the asset's fair value less cost to sell.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value Measurements</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The company follows the provisions of the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 820, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC 820&#8221;), which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair measurements.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The estimated fair value of certain financial instruments, cash and cash equivalents, accounts payable, and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. As of December&#160;31, 2019 and 2018, the Company believes the fair value of the EB-5 note approximates its carrying value.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 1 &#8212; quoted prices in active markets for identical assets or liabilities</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 2 &#8212; quoted prices for similar assets and liabilities in active markets or inputs that are observable</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 3 &#8212; inputs that are unobservable (for example cash flow modeling inputs based on assumptions)</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The company had derivative instruments that were fair valued on a recurring basis using Level 3 inputs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_DerivativeInstrumentsAndHedgingActivitiesDisclosurePolicyTextBlock', window );">Financial Instruments Indexed to and Potentially Settled in Common Stock</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Financial Instruments Indexed to and Potentially Settled in Common Stock</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for warrants in accordance with ASC Topic 815-40, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC 815-40&#8221;), which is the authoritative guidance on accounting for derivative financial instruments indexed to and potentially settled in a company&#8217;s own stock. To determine whether a contract is considered indexed to the issuer&#8217;s own equity, the Company performs a two-step analysis:</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Step 1: Evaluate whether the contract contains any exercise contingencies and, if so, whether they disqualify the contract from being classified as equity, and</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Step 2: Assess whether the settlement terms are consistent with equity classification.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company classifies the liability-designated warrants on its consolidated balance sheets as a derivative liability which is recognized at fair value at each reporting period subsequent to the initial issuance. Changes in the fair value of derivatives are recognized as other income (expense) in the consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposit, commercial paper and United States government and United States government agency obligations. The Company&#8217;s restricted cash balance consists of cash held to collateralize a corporate credit card account.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, NetProperty and equipment is recorded at cost. Significant additions or improvements are capitalized, and expenditures for repairs and maintenance are charged to expense as incurred. Gains and losses on disposal of assets are included in the consolidated statements of operations and comprehensive loss. Depreciation is calculated using the straight-line method and is recognized over an expected useful life of 5 years for equipment and 7 years for furniture.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements which include lease and&#160;non-lease&#160;components, which the Company has elected to account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components are recognized when the obligation is probable.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating leases are included in other assets and lease obligations on the Company&#8217;s consolidated balance sheets. Operating lease right-of-use ("ROU") assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Operating lease payments are recognized as lease expense on a straight-line basis over the lease term. The Company primarily leases buildings (real estate) which are classified as operating leases. ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As an implicit interest rate is not readily determinable in the Company&#8217;s leases, the incremental borrowing rate is used based on the information available at commencement date in determining the present value of lease payments.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The lease term for all of the Company&#8217;s leases includes the&#160;non-cancellable&#160;period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and lease liability) for the majority of the Company&#8217;s leases as the reasonably certain threshold is not met.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lease payments included in the measurement of the lease liability are comprised of fixed payments, variable payments that depend on index or rate, and amounts probable to be payable under the exercise of the Company option to purchase the underlying asset if reasonably certain.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Variable lease payments not dependent on a rate or index associated with the Company&#8217;s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed as probable. Variable lease payments include the Company's proportionate share of utilities and other operating expenses and are presented as operating expenses in the Company&#8217;s income statement in the same line item as expense arising from fixed lease payments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-based compensation</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ocugen accounts for its stock-based compensation awards in accordance with ASC Topic 718, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Compensation&#8212;Stock Compensation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments to employees, including grants of employee stock options and restricted stock units and modifications to existing agreements, to be recognized in the statements of operations </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">based on their fair values. Ocugen uses the Black-Scholes option-pricing model to determine the fair value of options granted. Ocugen recognized forfeitures as they occur.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ocugen&#8217;s stock-based awards are subject to service-based vesting conditions. Compensation expense related to awards to employees and directors with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Stock-based awards generally vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfNzY5NjU4MTQxODYxNA_853dc9b7-c919-4df5-9190-d9436288daac">one</span> to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfODI0NjMzNzIzNzU5OQ_e571c6b5-bef2-4cd7-bc49-832c32f02b1a">three</span> year requisite service period and have a contractual term of 10 years.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Estimating the fair value of options requires the input of subjective assumptions, including expected life of the option, stock price volatility, the risk-free interest rate and expected dividends. The assumptions used in Ocugen&#8217;s Black-Scholes option-pricing model represent management&#8217;s best estimates and involve a number of variables, uncertainties and assumptions and the application of management&#8217;s judgment, as they are inherently subjective. If any assumptions change, Ocugen&#8217;s stock-based compensation expense could be materially different in the future.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These assumptions used in Ocugen&#8217;s Black-Scholes option-pricing model are as follows:</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Term.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Due to the historical lack of a public market for the trading of Ocugen common stock and the lack of sufficient company-specific historical data, the expected term of employee options is determined using the &#8220;simplified&#8221; method, as prescribed in Securities and Exchange Commission&#8217;s Staff Accounting Bulletin No. 107 (&#8220;SAB&#160;No.&#160;107&#8221;), whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option. The expected term of non-employee options is equal to the contractual term.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Volatility.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The expected volatility is based on historical volatilities of Ocugen and similar entities within Ocugen&#8217;s industry for periods commensurate with the expected term assumption.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk-Free Interest Rate.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Dividends.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The expected dividend yield is 0% because Ocugen has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is a Delaware C-Corporation. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, is applied during the years in which temporary differences are expected to be settled and is reflected in the financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on the weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. The Company&#8217;s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. No interest or penalty expense was recognized during the periods presented.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has assessed and concluded that there are uncertain tax positions giving rise to the unrecognized tax benefits as of December&#160;31, 2019. The Company&#8217;s conclusions regarding uncertain tax positions may be subject to review and adjustment at a later date based upon ongoing analysis of tax laws, regulations and interpretations thereof, as well as other factors. Generally, federal, state, and local authorities may examine the Company&#8217;s tax returns for three years from the date of the filing and the current and prior three years remain subject to examination as of December&#160;31, 2019.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">Segment InformationThe Company views its operations and manages its business as one operating segment, which is the development of innovative therapies to address the whole eye.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standards; Recent Accounting Pronouncements</a></td>
<td class="text"><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Standards</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February&#160;2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;)&#160;No.&#160;2016-02,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases (Topic 842)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC 842&#8221;). In July&#160;2018, the FASB issued ASU&#160;No.&#160;2018-10,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Codification Improvements to Topic 842, Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASU&#160;2018-10&#8221;),&#160;which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU&#160;No.&#160;2018-11,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(Topic 842)&#8212;Targeted Improvements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASU&#160;2018-11&#8221;),&#160;which addressed implementation issues related to the new lease standard. These and certain other lease-related ASUs have generally been codified in ASC 842. ASC 842 supersedes the lease accounting requirements in ASC Topic 840, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC 840&#8221;). ASC 842 establishes a&#160;right-of-use&#160;model that requires a lessee to record a&#160;right-of-use&#160;(&#8220;ROU&#8221;) asset and a lease liability on the balance sheet for all leases. Under ASC 842, leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The standard also requires disclosures to help investors and other financial statement users better understand the amount, timing and uncertainty of cash flows arising from leases. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company adopted ASC 842 on January&#160;1, 2019 using the effective date transition method. Prior period results continue to be presented under ASC 840 based on the accounting standards originally in effect for such periods. The Company has elected certain practical expedients permitted under the transition guidance within ASC 842 to leases that commenced before January&#160;1, 2019, including the package of practical expedients. The election of the package of practical expedients resulted in the Company not reassessing prior conclusions under ASC 840 related to lease identification, lease classification and initial direct costs for expired and existing leases prior to January&#160;1, 2019. The adoption of ASU&#160;2016-02&#160;did not have a significant impact on the Company&#8217;s consolidated results of operations or cash flows. Upon adoption, the Company recognized an ROU asset and lease liability of $0.4 million and $0.4 million, respectively. See Note 9 for additional information.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU No. 2018-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This standard modifies certain disclosure requirements on fair value measurements and was effective for the Company on January 1, 2020. The adoption of this standard will not have a material impact on the Company's disclosures.</span></div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span>. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2023. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The Company does not expect the adoption of these standards to have a material impact on its consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_AssetHeldForSalePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents asset held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_AssetHeldForSalePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_DerivativeInstrumentsAndHedgingActivitiesDisclosurePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for financial instruments indexed to and potentially settled in common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_DerivativeInstrumentsAndHedgingActivitiesDisclosurePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6779237504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:12pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued Expenses are as follows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.175%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research&#160;and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271,322&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">705,436&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Clinical</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">421,788&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">469,473&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consulting</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">98,245&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">86,619&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee-related</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">624,420&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">123,372&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Legal</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">819,323&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,947&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,450&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total accrued expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,270,045&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,402,750&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6777764032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule Options to Purchase Common Stock (Details) - 2019 Plan - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="nump">731,189<span></span>
</td>
<td class="nump">632,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">238,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</a></td>
<td class="num">(140,324)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">385,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding (in USD per share)</a></td>
<td class="nump">$ 4.59<span></span>
</td>
<td class="nump">$ 5.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="nump">1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled (in USD per share)</a></td>
<td class="nump">4.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in USD per share)</a></td>
<td class="nump">$ 5.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual term</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, weighted average remaining contractual term</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, intrinsic value</a></td>
<td class="nump">$ 24,028<span></span>
</td>
<td class="nump">$ 4,801,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, intrinsic value</a></td>
<td class="nump">$ 3,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ocgn_A2019PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ocgn_A2019PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6955384208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Senior Secured Convertible Notes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>May 21, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ocgn_SeniorSecuredConvertibleNotesMay2019Member', window );">Senior Secured Convertible Notes - May 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Note Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Original Issue Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ocgn_SeniorSecuredConvertibleNotesMember', window );">Senior Secured Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Note Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Original Issue Discount</a></td>
<td class="num">$ (0.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ocgn_SeniorSecuredConvertibleNotesJune2019Member', window );">Senior Secured Convertible Notes - June 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Note Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Original Issue Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ocgn_SeniorSecuredConvertibleNotesMay2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ocgn_SeniorSecuredConvertibleNotesMay2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ocgn_SeniorSecuredConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ocgn_SeniorSecuredConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ocgn_SeniorSecuredConvertibleNotesJune2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ocgn_SeniorSecuredConvertibleNotesJune2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6955058016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Summary of EB-5 Loan (Details) - EB-5 Loan - Loans payable - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal outstanding</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Plus: accrued interest</a></td>
<td class="nump">127,777<span></span>
</td>
<td class="nump">87,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Less: unamortized debt issuance costs</a></td>
<td class="num">(55,654)<span></span>
</td>
<td class="num">(70,495)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value of debt</a></td>
<td class="nump">$ 1,072,123<span></span>
</td>
<td class="nump">$ 1,016,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ocgn_EB5ProgramBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ocgn_EB5ProgramBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>ocgn-20191231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:ocgn="http://www.deitaxonomy.com/20191231"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ocgn-20191231.xsd" xlink:type="simple"/>
    <context id="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i73ff1de059af438fb2052b13e4f9d5b6_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i23c3ffb42fab4881887c19daef4a2535_I20200320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <instant>2020-03-20</instant>
        </period>
    </context>
    <context id="ia6368cd0825d4ed8bf32f05ae6035107_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3a1130e123594196bfc468092b84ac38_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i86c3619320b043b3904853387d86d815_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ib1552d11edcd422ca262d2377a832c30_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ia8690510eb5349f08d66e9e06bb9e045_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i3b0b2789ee4e45ff8aa700de563ddc85_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i6917ffcbaf80423da21d5e3906eb2fae_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iedb883ebf37143d7b4c47a6d6946772b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i4e6a4645ddbc44dda8055b4048fed606_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i4a89501e1b134d4ebd569351917a9ccd_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia3cbd854bf6742df83c09dc1b641443b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2e3c1c69245740dca3e6b721cc45d9e0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i98a2e8ccbfdb402682e11b7e0f8e3856_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i056a173f43694aaa8e9aeeb3b1af2dde_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0bf0aa30ad2449048bb635d1a966c756_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1515189b9f7e45499b0325f53fa93549_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if5b3357b82d34850aa8982528bb2f47d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6631f4c18a1a40ecbac6c62f92de5799_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i17a96552b13e459d9ccd8b8026f03612_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i32d7d0f983d5402d8056f502420bed85_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i37ed1379a0e741cb891c3d578b500f9c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if8cfe8fdf29a4818b64dd927a3441caf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8f93f033b2964acd9d3cd23521742d13_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id83e33e57cad4f08967d8d41dfb42b28_D20190927-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ocgn:HistogenicsCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-27</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i0c8bec4b6fb74710acd1aebcd65c0caf_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if7530f5259ea4fb287abfd56f7c74a7f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i280158470c9b4af886ce65d165852eaa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ocgn:EquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iad6c551567dc41aba66ce356fc5db8a9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ocgn:EquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7c306b6118f54e09b3f5ed1b41de8514_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4c492065ff8d4ceb931653d3b6553ee6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6258e5af615841ca8ed08b5fc6e64f13_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7860a6ea500e471894ae9e509085cdf6_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i5010aa0712c74ac685012c6d136ca792_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="idfbc6400eef840d6b17bcf600923cbfa_D20190601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="if83d8a8656604b6494f17eff209a905f_I20191004">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <instant>2019-10-04</instant>
        </period>
    </context>
    <context id="i98c6625973004b8697d9716a871ffa88_D20191004-20191004">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <startDate>2019-10-04</startDate>
            <endDate>2019-10-04</endDate>
        </period>
    </context>
    <context id="i3a90ecac0c074f6aa909c9426321c8d8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i342cd331097f4691b9092a11b982313e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i08a49a87c9214a5188152f75514c346b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ocgn:SeriesAWarrantsAndSeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6de30431b0884e779b449c2552d931fc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ocgn:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1cc6e7cd4ebb41879dbbbd27370e6258_I20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ocgn:HistogenicsCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ocgn:EquityHoldersOfOcugenIncPerMergerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="ib33a77518a874faaa0e86a954580e035_I20190926">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ocgn:HistogenicsCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ocgn:EquityHoldersOfHistogenicsCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-26</instant>
        </period>
    </context>
    <context id="i2c96e6e4a1ec48b79500273ba5fd55e8_D20190927-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocgn:HistogenicsCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-27</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i233f75f6ffd24f2fbc2db0b32db4d667_I20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocgn:HistogenicsCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="i1089f8a8a43a48879ed876ae4de5115b_D20190508-20190508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocgn:HistogenicsCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-08</startDate>
            <endDate>2019-05-08</endDate>
        </period>
    </context>
    <context id="i22aaf4b1361c4ec7884cdd1e535ac03e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocgn:HistogenicsCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id02b04cce6a9413aae504f8cfc956e2b_D20191004-20191004">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocgn:HistogenicsCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-04</startDate>
            <endDate>2019-10-04</endDate>
        </period>
    </context>
    <context id="i7c31e84a90244ee78a2df7e88dca555a_D20191231-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <startDate>2019-12-31</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id4141b56122e4357bea6334ad7cbb7eb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocgn:NeocartMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i452b3f0c99ee4054a9b7492fcd19fe2a_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ocgn:HistogenicsCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="ib18c97e1d3e1439fa0756a1747c56510_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i702dd84e91b44b20bc3d8cb7ca9e4a59_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i477a58364a2b4532b86d564fdf1686e8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1dedc44510f14e77b6d2358d6ebef9a1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i36f2d441406443dcaba60c36eab4f7b7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ocgn:SeriesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifd5bb0da90474df78f52019d31b3061f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ocgn:SeriesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i91c2dd8a64e34278b820002768b4bdae_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ocgn:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8e0464bba65447d099bca6eb5c866819_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ocgn:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i32196db366ca47dfb065bbc67d9993d9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ocgn:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7a1acd90bf1a4186b62635f3f1291ee8_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ocgn:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i4d16882d4b4e40b5817ec2c99e0a487e_D20190927-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocgn:CollaborationAgreementWithCansinoBiologicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-27</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i7ef76329772147dd8a1a1be7785f5e5d_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocgn:SchepensEyeResearchInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="if76acb9aa16d490a90c7132533737b13_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocgn:SchepensEyeResearchInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i827132cd7da14ed8ad14eae7babe9d17_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocgn:SchepensEyeResearchInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ieb5f12c395364ac0968b482475cd5720_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocgn:CollaborationAgreementWithUniversityOfIllinoisChicagoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="ibe9866f13f484211a602b7658ac319c6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocgn:CollaborationAgreementWithUniversityOfIllinoisChicagoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie00ff0e528c242f698fe9a5810b936e6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocgn:CollaborationAgreementWithUniversityOfIllinoisChicagoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i97535139e9054d88803d1577aa998142_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocgn:CollaborationAgreementWithUniversityOfIllinoisChicagoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i84c4c1d32cc746778f6f4ffed31a2f12_D20140101-20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocgn:CollaborationAgreementWithUniversityOfColoradoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="i5fdb2024e3e04b00afbe628fe94fc6a1_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocgn:CollaborationAgreementWithUniversityOfColoradoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i41512e91ea66459091142a09d64979ee_I20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:EB5ProgramBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="ie26010e163a44d8f8901034a2237a150_D20160901-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:EB5ProgramBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i5f4493de5f9a420f8e7d280ce9393d02_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:EB5ProgramBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i49703b2d634a40219c09a4116c60351e_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:EB5ProgramBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="ifa216e92d8ad45f695cf881fb2ec681d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:EB5ProgramBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i10a74d4f5772493bb775e01c0458d587_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:EB5ProgramBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4dd588e3e2fd4d56ba9f7ed7bf627e44_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:ConvertibleNotesBoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie107e1047f9e4c3fa462f46cf3e5e3e4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:ConvertibleNotesBoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i328baa90b6ca4ecf9cdc9e0a79ee26ad_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i65b540d692bb45958ed8ced1fb3911da_I20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:ConvertibleDebtJanuary2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-31</instant>
        </period>
    </context>
    <context id="i5cc3532217ff4a829773c63ec209eebb_I20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:ConvertibleDebtJanuary2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ocgn:ConvertibleDebtConversionFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-31</instant>
        </period>
    </context>
    <context id="i161b6716805149329fb75cb8d891a7d3_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:ConvertibleDebtJune2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="id0c9d3000afb440eb2ae0e4453fc13cd_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:ConvertibleDebtJune2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ocgn:ConvertibleDebtConversionFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i514af234321c45249033c2c6004c3681_I20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:ConvertibleDebtNovember2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="i94d7513be73b4b42b644afe0f55eda9e_I20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:ConvertibleDebtNovember2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ocgn:ConvertibleDebtConversionFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="i932ae52afffe48a19dbc8e83e080b098_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:ConvertibleDebtDecember2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibf9bc486110443f69af07574bf14d5f7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:ConvertibleDebtDecember2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ocgn:ConvertibleDebtConversionFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="idf78c78261294ef3881f6cf13befd9a5_I20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:ConvertibleDebtJanuary2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="if379bb8b26134244bc1ef93807f107a8_I20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:ConvertibleDebtJanuary2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ocgn:ConvertibleDebtConversionFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="i4183d88399e94dd0af0b9cb7d63d5f7d_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:ConvertibleDebtFebruary2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="i74fd32d2c80748aeb83fa8309f3b484c_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:ConvertibleDebtFebruary2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ocgn:ConvertibleDebtConversionFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="i17e3a21a882c45e6a5d43855f575a703_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1432fdaf1af748b9aa5b711d2c461c89_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ocgn:ConvertibleDebtConversionFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i30518d590b384689bc953bae8c788989_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:November2018AndDecember2018NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie03c47b9f9564d4ea485d3ffdd995bb6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7ef067fabc2048d49a715adf223a6aaf_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie32a5c52109846399c80873ec089ffbb_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic10bc878b71a4eec829c618f097ab1f3_I20190405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <instant>2019-04-05</instant>
        </period>
    </context>
    <context id="iaf15ac65c13f41efa5b2c278c90ef1ad_I20190405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-05</instant>
        </period>
    </context>
    <context id="i408357dbb20b4db79414a01968187418_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:January2019AndFebruary2019NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5d316476da1f4704bd006d963c24c9f3_I20190405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-05</instant>
        </period>
    </context>
    <context id="i2c77d97bd72b4690ab70a469f8712825_D20190405-20190405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-05</startDate>
            <endDate>2019-04-05</endDate>
        </period>
    </context>
    <context id="i016d0b71e20d44c6b6f177338d083e24_D20190405-20190405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <startDate>2019-04-05</startDate>
            <endDate>2019-04-05</endDate>
        </period>
    </context>
    <context id="i3af9928ff5934a50a728ddecb0030b9f_I20190404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-04</instant>
        </period>
    </context>
    <context id="i9825c374339d495092fda175dbb9ecc6_D20190516-20190516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <startDate>2019-05-16</startDate>
            <endDate>2019-05-16</endDate>
        </period>
    </context>
    <context id="iff635dcebab24f36911b7b91f40c1759_I20190521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:SeniorSecuredConvertibleNotesMay2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-21</instant>
        </period>
    </context>
    <context id="i58aa2dbee17a4346b99dfe95c91e455d_I20190628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:SeniorSecuredConvertibleNotesJune2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="icc8f3b70120644bcb0ea07e4c4e58532_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i9169a31e29f845df9d4dcc1d4c8e89af_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1dd31fe358a94242921f371e4a12056c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iee4f88bad8cb4836b9a7cc7122e34867_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifb06df9a8042478fbcacfde1e1ec008c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i81f536df668b463db04d83beaea9fca4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i21b036a7018e49f1ba389957307f069f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9dd0fe8be9d9438c8e720727830deb3e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ocgn:A2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i901327021f4f4d8a9e7429629a2fe235_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocgn:A2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie4c25c1678fc46f2a94db1f11c7a25d1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocgn:A2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaf4d04bf884e47208ec21854eaf3c6fa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i81f1955a085348c7b2651edceb71e43f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie8f44ff16f6a48a5b00b8d8fb4955d6f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iac0f32c415484121ac10d938108c47c4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iebb192fe177843a59dda713200213ad2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8f30ba30167e413fa31d614ef91c6c25_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9d9bff3d3ae843c7b1af7507aeb3bcc2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i78c531e0c2834d2c9ce23d519b06d67b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ocgn:A2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i765c6c431bab4e9ca9750ef3e6d5c0a4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ocgn:A2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i4f2a660290394b9288e546c9be4bde7a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ocgn:A2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i885e5bb590844f6ebf88b1399519a254_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i67871994f7b24db59223486582b30e7a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if38d3cddf7364a18958c9f6b986c7132_D20190927-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <startDate>2019-09-27</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6745b0e5cb764520ba29b0c6f1b86602_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ieef5bdfd701441fea03e6621fed01d9d_D20191105-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-05</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i77f0ebf13e6e4a578b9b6ffd815a024e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ice482ddff55b45b4a75e3de02537f56b_D20191105-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-05</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3cf5412727aa4f75918abdb76b03caf7_D20191120-20191121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-20</startDate>
            <endDate>2019-11-21</endDate>
        </period>
    </context>
    <context id="i9a4dec58cf3a474a90c3320d94bff77c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i914cfde7eb234db2ac6c9112d30eadfb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib3301d78826140fb96af8db1fc68d531_I20191104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-04</instant>
        </period>
    </context>
    <context id="i1153f084349d4b7ea469d4f40aff5141_I20191105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-05</instant>
        </period>
    </context>
    <context id="ibca9608a3ab44021be1d03353a57553c_I20191104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-04</instant>
        </period>
    </context>
    <context id="i3da044ce503648edbe7ad9e78f55ca78_D20191105-20191105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-05</startDate>
            <endDate>2019-11-05</endDate>
        </period>
    </context>
    <context id="ie65f10daf6f84ce6802f5816662b4903_D20191105-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-05</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if254d19519344254a9f50cfcfe386457_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i27857d6d3d5a42bd93969147f2520cad_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i71ce16f5e5214d2780d7f39624f8b29d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1d0d3793e46440a899ad41a111b2431f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1b2b631bda3048ee8c734721295f429a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia7980383d2e44bc2b50a1d2faf810a91_D20190927-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-27</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8c7e388caf954f629bf3e170e216d890_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic2c38d1a38a84e6a82c73b5a98cb3e80_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:FormerOcugenWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i86aee3af2c3f4b798c30aaca8de9b337_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:FormerOcugenWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3cbe8832ab0843b598d967b9b9032b0d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3d8219b4b2bc4150b6b1c651c7d324a5_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i45e1ee8f0a174a99b058fcc427e9def5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i10ef3ad5f41f48c39073eca93c89a51d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1e36ccdb3dcd46a4ba0bf2a92174d054_D20200326-20200326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:EB5ProgramBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-26</startDate>
            <endDate>2020-03-26</endDate>
        </period>
    </context>
    <context id="ie83135b281cb4e26b25b62e6bb7f951f_I20200326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:EB5ProgramBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-26</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>ocgn:segment</measure>
    </unit>
    <unit id="measurementinput">
        <measure>ocgn:measurementInput</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80L2ZyYWc6ZDUwZWYzMWZlYzcxNGJiMGE1ODJkNTgxMzI4ODllNmQvdGFibGU6YTMzNDhlZmZmMjMzNDNiZTg2MmU1ZmM0YmI4YjIxYzQvdGFibGVyYW5nZTphMzM0OGVmZmYyMzM0M2JlODYyZTVmYzRiYjhiMjFjNF81LTEtMS0xLTA_d44ab409-dbcc-442c-9939-93df7dce7591">0001372299</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80L2ZyYWc6ZDUwZWYzMWZlYzcxNGJiMGE1ODJkNTgxMzI4ODllNmQvdGFibGU6YTMzNDhlZmZmMjMzNDNiZTg2MmU1ZmM0YmI4YjIxYzQvdGFibGVyYW5nZTphMzM0OGVmZmYyMzM0M2JlODYyZTVmYzRiYjhiMjFjNF8xNS0xLTEtMS0w_7c0b480e-fae2-49d1-9977-b4411546cdc2">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80L2ZyYWc6ZDUwZWYzMWZlYzcxNGJiMGE1ODJkNTgxMzI4ODllNmQvdGFibGU6YTMzNDhlZmZmMjMzNDNiZTg2MmU1ZmM0YmI4YjIxYzQvdGFibGVyYW5nZTphMzM0OGVmZmYyMzM0M2JlODYyZTVmYzRiYjhiMjFjNF8xNi0xLTEtMS0w_8638226a-b521-4f84-8c2c-ad3d27484756">2019</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80L2ZyYWc6ZDUwZWYzMWZlYzcxNGJiMGE1ODJkNTgxMzI4ODllNmQvdGFibGU6YTMzNDhlZmZmMjMzNDNiZTg2MmU1ZmM0YmI4YjIxYzQvdGFibGVyYW5nZTphMzM0OGVmZmYyMzM0M2JlODYyZTVmYzRiYjhiMjFjNF8xNy0xLTEtMS0w_8eb31726-29cf-4ff8-b79d-133fbb3e8946">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80L2ZyYWc6ZDUwZWYzMWZlYzcxNGJiMGE1ODJkNTgxMzI4ODllNmQvdGFibGU6YTMzNDhlZmZmMjMzNDNiZTg2MmU1ZmM0YmI4YjIxYzQvdGFibGVyYW5nZTphMzM0OGVmZmYyMzM0M2JlODYyZTVmYzRiYjhiMjFjNF8xOC0xLTEtMS0w_0b12ffb3-befe-4739-a471-1688e1cc0ad0">false</dei:AmendmentFlag>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="id83e33e57cad4f08967d8d41dfb42b28_D20190927-20190927"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80My9mcmFnOmQ5NzZkOTk4N2Q5NTQ5MzE4M2YxYjhmYmI0ZWFiMTkyL3RhYmxlOmY0ZThhYTY4MGM3NTQzMmI4Y2Y2MTFhZjhmNWMyZDIwL3RhYmxlcmFuZ2U6ZjRlOGFhNjgwYzc1NDMyYjhjZjYxMWFmOGY1YzJkMjBfMy0xLTEtMS0w_1577efe5-faaf-48d7-a448-344f340c2658"
      unitRef="number">0.0167</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7c306b6118f54e09b3f5ed1b41de8514_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfNzY5NjU4MTQxODYxNA_853dc9b7-c919-4df5-9190-d9436288daac">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i4c492065ff8d4ceb931653d3b6553ee6_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfODI0NjMzNzIzNzU5OQ_e571c6b5-bef2-4cd7-bc49-832c32f02b1a">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ocgn:ConvertedAdditionalSharesThresholdReleaseTriggerPeriod
      contextRef="i98c6625973004b8697d9716a871ffa88_D20191004-20191004"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfMTcwNDI0MzAyNDIzMTA_2a410e8c-05ba-4258-a80a-5a97f417ce2a">P3D</ocgn:ConvertedAdditionalSharesThresholdReleaseTriggerPeriod>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i885e5bb590844f6ebf88b1399519a254_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RleHRyZWdpb246ZGM3YmMyNzE5ZTYwNGMyNjlkMWNiNjIxY2JhMTE0NDNfMTA5OTUxMTYyODYwOTQ_ca47572a-04ad-41bc-8ba1-21a7e15ee217">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <ocgn:ClassOfWarrantOrRightExercisePriceDeterminationNumberOfTradingDaysConsidered
      contextRef="ie65f10daf6f84ce6802f5816662b4903_D20191105-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTUzOTMxNjI4MzE0NTk_881a6831-237f-403e-b78d-48afce88aefa">P5D</ocgn:ClassOfWarrantOrRightExercisePriceDeterminationNumberOfTradingDaysConsidered>
    <dei:DocumentType
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xMTU0NDg3MjEwMzI0NQ_46b765da-251f-4ed0-a400-1b331fee70cc">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGFibGU6OWMxMjc2YTYwNTFhNGRjNDhkYmI2NTllOWQ3ZmY1YzMvdGFibGVyYW5nZTo5YzEyNzZhNjA1MWE0ZGM0OGRiYjY1OWU5ZDdmZjVjM18wLTAtMS0xLTEwNzEx_5023c2f1-d6d3-4304-ae4e-669f52285578">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xNTM5MzE2MjgwMTc5Mw_5eba6fa2-6d52-452e-b79e-f18967f1915e">2019-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGFibGU6OWFjYTc2MWFmMGYyNDI0MTk4YmNkZjVkNjRlNzc4ZjYvdGFibGVyYW5nZTo5YWNhNzYxYWYwZjI0MjQxOThiY2RmNWQ2NGU3NzhmNl8wLTAtMS0xLTEwNzE4_67cada99-8529-4590-87d0-9e091a0c314b">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xMjA5NDYyNzkxNzEzOQ_d0ffa8ac-8eb2-477e-b62e-48f0c674cb26">001-36751</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xMjA5NDYyNzkxNzE1MA_33fda10e-7510-4d82-8839-46d4ca917040">OCUGEN, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGFibGU6NmIwYWYwZmJiMTI2NGQ0ZTk0MTFkYzM3ZjUyNjk5YjcvdGFibGVyYW5nZTo2YjBhZjBmYmIxMjY0ZDRlOTQxMWRjMzdmNTI2OTliN18wLTAtMS0xLTEwNzMx_03e024e0-7c65-4c2d-8ee5-23be233e527b">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGFibGU6NmIwYWYwZmJiMTI2NGQ0ZTk0MTFkYzM3ZjUyNjk5YjcvdGFibGVyYW5nZTo2YjBhZjBmYmIxMjY0ZDRlOTQxMWRjMzdmNTI2OTliN18wLTEtMS0xLTEwNzM1_5f4263ee-c90f-40b8-8eb6-a40fc8f57f6a">04-3522315</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xMjA5NDYyNzkxNzE2NA_485d313e-89b1-4dd2-95d3-05fbb04cb513">5 Great Valley Parkway, Suite 160</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xMjA5NDYyNzkxNzE5OQ_f2b6eba5-2f32-4b53-a1a5-9a462ebbf15e">Malvern,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xMjA5NDYyNzkxNzIwOQ_03320bc4-1bce-4187-ba75-09fac2d9827a">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xMjA5NDYyNzkxNzIyMw_f962d102-8075-44fe-a926-7b408e7f3236">19355</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xMjA5NDYyNzkxNzIzMA_1b0f1012-a3fe-4c5d-a526-8301a1b87387">484</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xMjA5NDYyNzkxNzIzNQ_3c667236-2448-4448-bd38-4988dbbd9211">328-4701</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGFibGU6NjM2YmFkMjRkN2UzNGFiMDg3NzEwNDI1OGYxMzM2MzUvdGFibGVyYW5nZTo2MzZiYWQyNGQ3ZTM0YWIwODc3MTA0MjU4ZjEzMzYzNV8xLTAtMS0xLTEwNzc2_1510e640-3c1d-4ab4-ba5e-a016f2fa5c22">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGFibGU6NjM2YmFkMjRkN2UzNGFiMDg3NzEwNDI1OGYxMzM2MzUvdGFibGVyYW5nZTo2MzZiYWQyNGQ3ZTM0YWIwODc3MTA0MjU4ZjEzMzYzNV8xLTItMS0xLTEwNzgy_f5b1653f-a612-4cf4-b4db-e28cfbe68de5">OCGN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGFibGU6NjM2YmFkMjRkN2UzNGFiMDg3NzEwNDI1OGYxMzM2MzUvdGFibGVyYW5nZTo2MzZiYWQyNGQ3ZTM0YWIwODc3MTA0MjU4ZjEzMzYzNV8xLTQtMS0xLTEwNzg0_6a014719-8b71-4cfd-88c6-3cc4cfa95ddf">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xMjA5NDYyNzkxNzI0NQ_fe38a38f-8d78-4e48-ba4a-bdc6cad05425">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xMjA5NDYyNzkxNzI0OQ_28e731a3-1756-400d-a644-7f9194afb5b0">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xMjA5NDYyNzkxNzI1Mw_f75b74c1-c3e0-486f-b084-d2cdb0772501">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xMjA5NDYyNzkxNzI1OA_16809b5d-aad2-4780-ad29-16038ada6935">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGFibGU6ZmVmZjI3NmRjZGRlNDY5YmJhODdhOWJkNWU1OTVmYTQvdGFibGVyYW5nZTpmZWZmMjc2ZGNkZGU0NjliYmE4N2E5YmQ1ZTU5NWZhNF8xLTAtMS0xLTEwODQx_1b4b6800-42d2-4a35-a96a-21656a8799cd">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGFibGU6ZmVmZjI3NmRjZGRlNDY5YmJhODdhOWJkNWU1OTVmYTQvdGFibGVyYW5nZTpmZWZmMjc2ZGNkZGU0NjliYmE4N2E5YmQ1ZTU5NWZhNF8xLTMtMS0xLTEwODY0_18f380c9-aaf9-4f7b-ac21-68228d08a5de">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGFibGU6ZmVmZjI3NmRjZGRlNDY5YmJhODdhOWJkNWU1OTVmYTQvdGFibGVyYW5nZTpmZWZmMjc2ZGNkZGU0NjliYmE4N2E5YmQ1ZTU5NWZhNF8yLTMtMS0xLTEwODY3_cb912a47-8f80-487f-8bc3-6357b7aa67a9">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xMjA5NDYyNzkxNzI2OA_a0fba168-72dd-41cf-a3f5-4921bc981fb5">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i73ff1de059af438fb2052b13e4f9d5b6_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl81NDk3NTU4MTQxNjQ5_aee0e9eb-7f06-4306-a0b8-d33382439717"
      unitRef="usd">18100000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i23c3ffb42fab4881887c19daef4a2535_I20200320"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl81NDk3NTU4MTQxNjIw_c8a4b9dc-e943-4159-90f0-ae1e755b40b8"
      unitRef="shares">52625228</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xL2ZyYWc6MThhYzNlYzIyYTlhNDc3ZDhhNjczZGQ0YzM1MzBmNTYvdGV4dHJlZ2lvbjoxOGFjM2VjMjJhOWE0NzdkOGE2NzNkZDRjMzUzMGY1Nl8xMTU0NDg3MjEwNDIzNw_226c5aa1-1b4f-4c71-9154-006459dc20e2">&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:115%;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;"&gt;Part III of this Annual Report on Form 10-K incorporates certain information by reference from the registrant&#x2019;s proxy statement for the 2020 annual meeting of stockholders to be filed no later than 120 days after the end of the registrant&#x2019;s fiscal year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfNC0xLTEtMS0w_903061fc-8b6f-4adf-9487-8730e996e6a4"
      unitRef="usd">7444052</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfNC0zLTEtMS0w_076d2f5c-fd27-42ca-b3ae-6081e9c166f6"
      unitRef="usd">1628136</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfNS0xLTEtMS0w_f1dfab27-f9f3-4ddf-9d61-d98afac1ef02"
      unitRef="usd">1322167</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfNS0zLTEtMS0w_20e0fd68-33e3-4a4f-bdd7-67c9fe77164c"
      unitRef="usd">313499</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfNi0xLTEtMS0w_cb22902c-2131-4880-ad45-520302aa13a6"
      unitRef="usd">7000000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfNy0xLTEtMS0w_5eaed1ab-bccb-4a3f-bf3c-36b1469dbfa4"
      unitRef="usd">15766219</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfNy0zLTEtMS0w_4dd024a2-5850-401b-a812-ed41b5fd03a0"
      unitRef="usd">1941635</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfOC0xLTEtMS0w_aeffc00e-0ce3-4c62-b73e-9589b4ebb2a6"
      unitRef="usd">222464</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfOC0zLTEtMS0w_ab0d190c-0503-4874-897f-6117d7dbb8a3"
      unitRef="usd">245788</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfOS0xLTEtMS0w_24562fee-5cf4-45bb-8e92-e62d61d5c288"
      unitRef="usd">151016</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfOS0zLTEtMS0w_bc48ed1b-efe3-4c2a-8c7e-06b7b2740018"
      unitRef="usd">150477</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMTAtMS0xLTEtMA_bb4ca9fc-1194-4feb-b38d-9532efa16f50"
      unitRef="usd">667747</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMTAtMy0xLTEtMA_7cda0cbe-ef07-45db-bb7d-5be0f47fc4ad"
      unitRef="usd">116333</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMTEtMS0xLTEtMA_bc3cc2ea-f761-49fe-8f5e-73588a811899"
      unitRef="usd">16807446</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMTEtMy0xLTEtMA_dc2c0657-a5b9-4e17-b085-9ef15f2aae95"
      unitRef="usd">2454233</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMTQtMS0xLTEtMA_8bbad5cb-9b52-4a2f-8625-d226a2d68274"
      unitRef="usd">1895613</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMTQtMy0xLTEtMA_60b90590-0550-4285-aa57-0811a1f4e38a"
      unitRef="usd">3277525</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMTUtMS0xLTEtMA_57142ae5-cdcf-4f91-9bd3-aa4bf2e9a251"
      unitRef="usd">2270045</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMTUtMy0xLTEtMA_e29f499d-ddf9-426a-b9e9-4bef95a6be70"
      unitRef="usd">1402750</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ShortTermBorrowings
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMTYtMy0xLTEtMA_5f796eb9-1fc1-4f61-9ec1-e583e137d6df"
      unitRef="usd">7483847</us-gaap:ShortTermBorrowings>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMTctMy0xLTEtMA_3edbde81-d8ce-48ae-86bd-857dd58d7b60"
      unitRef="usd">1741222</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMTgtMS0xLTEtMA_efa215e7-3b73-4e60-915e-207bc045b5ce"
      unitRef="usd">172310</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMTktMS0xLTEtMA_16a48756-5ada-42ad-b165-b2997843b604"
      unitRef="usd">205991</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMTktMy0xLTEtMA_1feb1ccd-517e-40b1-bc20-a71e4903d3b0"
      unitRef="usd">204242</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMjItMS0xLTEtMA_8765eb94-47b4-4f80-9f5b-0ec39b2bce08"
      unitRef="usd">4543959</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMjItMy0xLTEtMA_d338d9f4-23c2-4088-8c24-d24bb031ac0b"
      unitRef="usd">14109586</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMjUtMS0xLTEtMA_e99db382-f758-40c6-b942-6c0a88614aad"
      unitRef="usd">163198</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMjItMS0xLTEtMTM5NDA_bdb43919-e99c-458d-9892-7dd2c102712f"
      unitRef="usd">1072123</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMjItMy0xLTEtMTM5NDA_284e5e6a-fc74-49d1-a94e-e0a07f983f06"
      unitRef="usd">1016727</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMjYtMS0xLTEtMA_d09f4192-bbe0-4e9a-8bb7-3fa21ee1355a"
      unitRef="usd">9755</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMjYtMy0xLTEtMA_ee1e191d-3f9c-4d88-bc9b-64d6b9856df1"
      unitRef="usd">37459</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMjgtMS0xLTEtMA_32e2875a-9f1c-4044-9998-f27443390d02"
      unitRef="usd">1245076</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMjgtMy0xLTEtMA_116a63e7-7580-4709-b08a-cb7054a3182a"
      unitRef="usd">1054186</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMjktMS0xLTEtMA_ed07d068-a4eb-4996-bad3-3f88f035bd21"
      unitRef="usd">5789035</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMjktMy0xLTEtMA_0e9a27cb-fa45-4f9c-bd30-3e85a58cb8dc"
      unitRef="usd">15163772</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzAtMS0xLTEtMA_e026862d-26f7-42fe-9fd3-ed08f9c32f79"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzAtMy0xLTEtMA_7a24df2a-d165-42d7-8ef6-070239259aa7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzItMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmQ1ZGViZGU0Mzg1MzQ2OTRhZDg5YzYxNjEwMzY5ZDdlXzcxNDY4MjU1ODA3NjA_a7bd3820-6fc5-48ec-b9b5-f94bebb9b928"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzItMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmQ1ZGViZGU0Mzg1MzQ2OTRhZDg5YzYxNjEwMzY5ZDdlXzcxNDY4MjU1ODA3NjA_b4fb1302-7c07-4de2-945a-5b20c9e98b23"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzItMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmQ1ZGViZGU0Mzg1MzQ2OTRhZDg5YzYxNjEwMzY5ZDdlXzcxNDY4MjU1ODA3NDA_a6ff5ee3-ca38-458e-88d8-3ac64f4a8b98"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzItMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmQ1ZGViZGU0Mzg1MzQ2OTRhZDg5YzYxNjEwMzY5ZDdlXzcxNDY4MjU1ODA3NDA_cf26d81e-5e30-4c33-b9e8-a0e058f2b4f0"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzItMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmQ1ZGViZGU0Mzg1MzQ2OTRhZDg5YzYxNjEwMzY5ZDdlXzcxNDY4MjU1ODA3NDc_2e7f08da-5264-45b6-b2c6-1a74de52915e"
      unitRef="shares">7</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzItMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmQ1ZGViZGU0Mzg1MzQ2OTRhZDg5YzYxNjEwMzY5ZDdlXzcxNDY4MjU1ODA3NDc_8eecae8d-7462-4471-8ac9-90efcb9d43d5"
      unitRef="shares">7</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzItMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmQ1ZGViZGU0Mzg1MzQ2OTRhZDg5YzYxNjEwMzY5ZDdlXzcxNDY4MjU1ODA3NTM_7f3270a3-06b0-4fce-b161-e7de16ddb7c5"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzItMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmQ1ZGViZGU0Mzg1MzQ2OTRhZDg5YzYxNjEwMzY5ZDdlXzcxNDY4MjU1ODA3NTM_948b68a3-77ab-430a-abb6-744bf5a52150"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzItMS0xLTEtMA_561aeb95-b652-4d46-a9a1-992289e5c46d"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzItMy0xLTEtMA_e920392d-614b-46cd-945d-041e1bd7e82a"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzMtMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmVkZjFjYjg1MTdkMTQ2Yjc4MzZhNWYwZjc3MDA0YWYyXzcxNDY4MjU1ODA3MTk_576ef5dc-04f8-4433-9516-1c59774e928f"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzMtMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmVkZjFjYjg1MTdkMTQ2Yjc4MzZhNWYwZjc3MDA0YWYyXzcxNDY4MjU1ODA3MTk_67d0dd7c-a415-4168-affd-ac61e4b897d4"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzMtMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmVkZjFjYjg1MTdkMTQ2Yjc4MzZhNWYwZjc3MDA0YWYyXzcxNDY4MjU1ODA3MzI_9632c692-1a97-4f3e-b211-c444e7080f2a"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzMtMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmVkZjFjYjg1MTdkMTQ2Yjc4MzZhNWYwZjc3MDA0YWYyXzcxNDY4MjU1ODA3MzI_f37a3c3b-7965-4530-bebc-1ca520f4f87d"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzMtMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmVkZjFjYjg1MTdkMTQ2Yjc4MzZhNWYwZjc3MDA0YWYyXzcxNDY4MjU1ODA3NDQ_f1c15db4-5a7d-44d1-855a-eb0fc64a7c4d"
      unitRef="shares">52746728</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzMtMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmVkZjFjYjg1MTdkMTQ2Yjc4MzZhNWYwZjc3MDA0YWYyXzcxNDY4MjU1ODA3NTU_bb16c0b2-b4ad-4565-b4b0-e3ff36d3a26c"
      unitRef="shares">4960552</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzMtMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmVkZjFjYjg1MTdkMTQ2Yjc4MzZhNWYwZjc3MDA0YWYyXzcxNDY4MjU1ODA3Njc_7a6991b7-8587-4de0-b619-d025dcf6ddfa"
      unitRef="shares">52625228</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzMtMC0xLTEtMTIxMC90ZXh0cmVnaW9uOmVkZjFjYjg1MTdkMTQ2Yjc4MzZhNWYwZjc3MDA0YWYyXzcxNDY4MjU1ODA3Nzg_c6cb53ee-0a7f-46c3-9fd2-e1c870270987"
      unitRef="shares">4960552</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzMtMS0xLTEtMA_c5a5f7f4-3318-4ef2-b860-853e5de46fa1"
      unitRef="usd">527467</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzMtMy0xLTEtMA_3d87328c-5c5f-4be7-9704-24acd9903a09"
      unitRef="usd">49606</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzQtMC0xLTEtMjg4Ny90ZXh0cmVnaW9uOjNiOWMzZjkwY2YwMzQ0ZWE5MDI0NmEzMWZhOTQ5MDU1XzcxNDY4MjU1ODA2MTM_02360a26-4015-4ada-b007-331bd79781a8"
      unitRef="shares">121500</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzQtMC0xLTEtMjg4Ny90ZXh0cmVnaW9uOjNiOWMzZjkwY2YwMzQ0ZWE5MDI0NmEzMWZhOTQ5MDU1XzcxNDY4MjU1ODA2MTY_281f289d-ca60-4060-98ce-a15aacac37fd"
      unitRef="shares">0</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzQtMS0xLTEtMjg4Nw_87560b69-e4be-494f-85f7-73ff1c5e83f7"
      unitRef="usd">47864</us-gaap:TreasuryStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzQtMy0xLTEtMA_b1153435-89ee-4644-97e8-4baf5c54539e"
      unitRef="usd">451</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzUtMS0xLTEtMA_c00c2480-a4ab-4394-8cbf-e41509417302"
      unitRef="usd">62018632</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzUtMy0xLTEtMA_93511351-00ac-418c-bdcf-4c6ffd659bb3"
      unitRef="usd">18477598</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzYtMS0xLTEtMA_4a0cad74-6739-4e4d-9d22-579d93083930"
      unitRef="usd">51479824</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzYtMy0xLTEtMA_81b4fa87-96b8-4ead-9601-f930df64088a"
      unitRef="usd">31237194</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzctMS0xLTEtMA_0d43282d-8297-4725-9eb1-66215600d302"
      unitRef="usd">11018411</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzctMy0xLTEtMA_17a1a562-66d4-4de5-adff-e1dbcd4f9824"
      unitRef="usd">-12709539</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzgtMS0xLTEtMA_c67e264c-9f44-4698-8bc1-b4db008a13cd"
      unitRef="usd">16807446</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xOS9mcmFnOjM2ZDIwMjJjMGY3MjRkOWRiMjFmYWQ4MDI1YTA3ZjUyL3RhYmxlOjQyMTRiMmIzNWZkODQ1ZDk5Zjg2NTcyYjcyNTVjZDg4L3RhYmxlcmFuZ2U6NDIxNGIyYjM1ZmQ4NDVkOTlmODY1NzJiNzI1NWNkODhfMzgtMy0xLTEtMA_d26c46f7-2f58-4962-aee9-be9e9b1ed763"
      unitRef="usd">2454233</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMy01LTEtMS0w_87f89c55-3347-46c4-b8d2-1cac93b913af"
      unitRef="usd">8085522</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMy03LTEtMS0w_7fdf56fc-4e07-4929-838e-f7a949e63304"
      unitRef="usd">10321397</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfNC01LTEtMS0w_b890d5c6-1100-4de6-8d16-b83659d3ca4f"
      unitRef="usd">6077097</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfNC03LTEtMS0w_9b9e3fec-2d7c-4808-8e18-d347b0ecff38"
      unitRef="usd">5819111</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfNS01LTEtMS0w_572c78f8-fc26-4fb6-a78e-a5096605084e"
      unitRef="usd">14162619</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfNS03LTEtMS0w_33d4e23c-c995-4608-9a51-670ba00d408a"
      unitRef="usd">16140508</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfNi01LTEtMS0w_37a410b2-4e0c-45e0-aaa5-eaf4286ddccd"
      unitRef="usd">-14162619</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfNi03LTEtMS0w_705f1a0a-ce37-4c2a-b5df-49e0925591a2"
      unitRef="usd">-16140508</us-gaap:OperatingIncomeLoss>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfOC01LTEtMS0w_397858a0-ac04-44c2-9fae-e41d16771211"
      unitRef="usd">-3187380</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfOC03LTEtMS0w_73051c8b-b772-4b76-965b-d41dc1895926"
      unitRef="usd">1664689</us-gaap:LiabilitiesFairValueAdjustment>
    <ocgn:GainsLossesOnConversionOfDebt
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfOS01LTEtMS0w_cab62802-8fec-409d-a212-dfd3d81f710f"
      unitRef="usd">-341136</ocgn:GainsLossesOnConversionOfDebt>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTAtNS0xLTEtMA_45cd89a2-5549-445d-8433-244d5e0bc109"
      unitRef="usd">1214</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTAtNy0xLTEtMA_555e5fe8-618d-42ea-ae02-5f69a1866d76"
      unitRef="usd">19213</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTEtNS0xLTEtMA_c9b14f85-fd70-4b2c-a5b2-6034d085003b"
      unitRef="usd">1767836</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTEtNy0xLTEtMA_ce0fee6a-9d2b-4e9f-bd1c-0e9d8dff5654"
      unitRef="usd">3750630</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTItNS0xLTEtMA_acec6f49-b3d0-4f1e-b57b-f4b0f6d165ee"
      unitRef="usd">-784873</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTItNy0xLTEtMA_5f009fad-900e-4a40-91f1-42484fabac4b"
      unitRef="usd">-12428</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTMtNS0xLTEtMA_f8fc2be3-a0aa-4ca3-b2da-72eb256bf9a4"
      unitRef="usd">-6080011</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTMtNy0xLTEtMA_b7e3482e-9848-4e0f-8510-693f592adcef"
      unitRef="usd">-2079156</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTQtNS0xLTEtMA_2c8727a0-9d58-44f4-8026-6806dab6ec51"
      unitRef="usd">-20242630</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTQtNy0xLTEtMA_65e6139b-00af-4d06-af1b-f8f6b67c5351"
      unitRef="usd">-18219664</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTYtNS0xLTEtMA_df22742c-9435-4fa0-9e8d-1971f9c52871"
      unitRef="usd">-451</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTYtNy0xLTEtMA_5cf2277d-5119-4027-a038-2dcdf2739858"
      unitRef="usd">451</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTctNS0xLTEtMA_b944b5c7-6453-48d7-aa5d-16ca4c371801"
      unitRef="usd">-20243081</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTctNy0xLTEtMA_3b9798ea-8f3e-42de-93aa-da8206bfbbd8"
      unitRef="usd">-18219213</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMjAtMi0xLTEtNTUyNg_9dc8e515-3721-439e-ad50-fdf69ef9a352"
      unitRef="usdPerShare">-1.46</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMjAtNC0xLTEtNTUzNQ_fac67634-7ae9-43f1-99d2-16fe2581bd06"
      unitRef="usdPerShare">-3.67</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTktMi0xLTEtNDc1MQ_c7774195-d085-4900-ad4d-31d3d5df242a"
      unitRef="shares">13893819</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yNS9mcmFnOjM5ZTg3NGM4MjJkYTRkZmM4MDU2NWUyOWRhNTIwNjJjL3RhYmxlOmU4ZjJkM2Y2OWE1MDRkNjJhM2QxYTAzMDM4OGM0OWE3L3RhYmxlcmFuZ2U6ZThmMmQzZjY5YTUwNGQ2MmEzZDFhMDMwMzg4YzQ5YTdfMTktNC0xLTEtNDc1NA_7554aa2a-5442-40a4-8bbe-56b7b8258fe6"
      unitRef="shares">4960552</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="i3a1130e123594196bfc468092b84ac38_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMi01LTEtMS0w_8a3a0f8b-2b0c-469a-9f61-b68de2b8f91b"
      unitRef="shares">4960552</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3a1130e123594196bfc468092b84ac38_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMi03LTEtMS0w_41bb9cb5-b65d-46f0-8e6c-b5cc667be0d5"
      unitRef="usd">49606</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i86c3619320b043b3904853387d86d815_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMi05LTEtMS0w_5b837210-b0b0-425d-a9b7-9acad5d16af3"
      unitRef="usd">17402911</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib1552d11edcd422ca262d2377a832c30_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMi0xMS0xLTEtMA_8a3e7534-c690-477e-a5e0-5d7b60c50ff2"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia8690510eb5349f08d66e9e06bb9e045_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMi0xMy0xLTEtMA_86dd7fac-7ca4-42f3-9650-20a64f42c7e4"
      unitRef="usd">-13017530</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3b0b2789ee4e45ff8aa700de563ddc85_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMi0xNS0xLTEtMA_14d6ef9c-7a69-4095-9b99-3337ec2dd486"
      unitRef="usd">4434987</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i6917ffcbaf80423da21d5e3906eb2fae_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNC0xMS0xLTEtMA_6c77c4e8-ac19-4aa3-8e9d-482609461cb1"
      unitRef="usd">451</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNC0xNS0xLTEtMA_53e3c1b4-373b-415a-87bb-9b84d8c7e5b4"
      unitRef="usd">451</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iedb883ebf37143d7b4c47a6d6946772b_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNC05LTEtMS0zMTc0_cba548d6-3960-4cd5-8824-c89adf9eec55"
      unitRef="usd">1074687</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNC0xNS0xLTEtMzE3NA_16aa4885-8e66-42b8-848d-b9b9bc107ec8"
      unitRef="usd">1074687</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i4e6a4645ddbc44dda8055b4048fed606_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNS0xMy0xLTEtMA_7a943fbe-3c34-449c-9ff5-2cf3f5af8a60"
      unitRef="usd">-18219664</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNS0xNS0xLTEtMA_b51ed7a8-5816-4cba-b43f-d438bb7b89b9"
      unitRef="usd">-18219664</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i4a89501e1b134d4ebd569351917a9ccd_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNi01LTEtMS0w_fdeb5c97-439e-4183-8889-a881d1ffb83b"
      unitRef="shares">4960552</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4a89501e1b134d4ebd569351917a9ccd_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNi03LTEtMS0w_68e4c240-6b32-4f1c-bf40-b075f170fe17"
      unitRef="usd">49606</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia3cbd854bf6742df83c09dc1b641443b_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNi05LTEtMS0w_54b42ad0-46f8-431f-bd7b-97f72c7efcd1"
      unitRef="usd">18477598</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2e3c1c69245740dca3e6b721cc45d9e0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNi0xMS0xLTEtMA_25be13b5-9baf-4209-9811-d5e59d1744ce"
      unitRef="usd">451</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i98a2e8ccbfdb402682e11b7e0f8e3856_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNi0xMy0xLTEtMA_f5b1f7d3-be71-4154-8731-347380b499ae"
      unitRef="usd">-31237194</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNi0xNS0xLTEtMA_ace4c8e1-974d-45b1-8c8f-5a3d4c80afe8"
      unitRef="usd">-12709539</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i056a173f43694aaa8e9aeeb3b1af2dde_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNy01LTEtMS0zMTI3_92e03fc2-a9ee-49a2-89d1-134172ee33fc"
      unitRef="shares">80569</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i056a173f43694aaa8e9aeeb3b1af2dde_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNy03LTEtMS0zMTI3_d672c9a3-3639-486d-a0c8-1f62d194e4c6"
      unitRef="usd">806</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0bf0aa30ad2449048bb635d1a966c756_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNy05LTEtMS0zMTI3_f7a68062-9c16-44af-ab07-c75d2740acb4"
      unitRef="usd">999194</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfNy0xNS0xLTEtMzEyNw_b75eb009-84bc-4c28-9699-cd1eebf6e0ff"
      unitRef="usd">1000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i056a173f43694aaa8e9aeeb3b1af2dde_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfOC01LTEtMS0zMTAw_d6078f76-05d7-48bb-bbb9-20b4a44099b7"
      unitRef="shares">1125673</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i056a173f43694aaa8e9aeeb3b1af2dde_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfOC03LTEtMS0zMTAw_2e24eec2-fc63-4d35-899b-1218494c522e"
      unitRef="usd">11256</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i0bf0aa30ad2449048bb635d1a966c756_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfOC05LTEtMS0zMTAw_463786b0-8e1f-4403-a7ff-175da555bbcc"
      unitRef="usd">13968532</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfOC0xNS0xLTEtMzEwMA_63cf7367-6cfc-44a5-be60-aa3c5874b21b"
      unitRef="usd">13979788</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <ocgn:StockIssuedDuringPeriodPreMergerShares
      contextRef="i056a173f43694aaa8e9aeeb3b1af2dde_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfOS01LTEtMS0zMTQw_edab4b06-6bb4-40d5-a41b-deada51267c8"
      unitRef="shares">4385964</ocgn:StockIssuedDuringPeriodPreMergerShares>
    <ocgn:StockIssuedDuringPeriodPreMergerValue
      contextRef="i056a173f43694aaa8e9aeeb3b1af2dde_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfOS03LTEtMS0zMTQw_c4c89f5c-e130-47c1-987f-28f3f9942993"
      unitRef="usd">43860</ocgn:StockIssuedDuringPeriodPreMergerValue>
    <ocgn:StockIssuedDuringPeriodPreMergerValue
      contextRef="i0bf0aa30ad2449048bb635d1a966c756_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfOS05LTEtMS0zMTQw_0142bb23-9422-4613-983f-e35395d29567"
      unitRef="usd">13106596</ocgn:StockIssuedDuringPeriodPreMergerValue>
    <ocgn:StockIssuedDuringPeriodPreMergerValue
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfOS0xNS0xLTEtMzE0MA_a4b2e687-9fff-4620-9e20-1adc7e49658a"
      unitRef="usd">13150456</ocgn:StockIssuedDuringPeriodPreMergerValue>
    <ocgn:CostsRelatedToIssuanceOfStockUnderReverseAssetAcquisition
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTAtMC0xLTEtMzE0MC90ZXh0cmVnaW9uOjk3N2ZmNzdiZDBjMjQ5NDE5ZTIyNjBmNGJiY2VjYjFhXzgyNDYzMzcyMDg0MTM_166dbfda-5e9a-45e1-8a9d-31ab45a7e339"
      unitRef="usd">2600000</ocgn:CostsRelatedToIssuanceOfStockUnderReverseAssetAcquisition>
    <ocgn:StockIssuedDuringPeriodSharesReverseAssetAcquisition
      contextRef="i056a173f43694aaa8e9aeeb3b1af2dde_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTAtNS0xLTEtMzE0MA_e509c255-33ee-4482-8fb5-53646a8a0077"
      unitRef="shares">1651748</ocgn:StockIssuedDuringPeriodSharesReverseAssetAcquisition>
    <ocgn:StockIssuedDuringPeriodValueReverseAssetAcquisition
      contextRef="i056a173f43694aaa8e9aeeb3b1af2dde_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTAtNy0xLTEtMzE0MA_b465b7e7-ae0b-4c8e-aea4-b1bed683ccf8"
      unitRef="usd">16517</ocgn:StockIssuedDuringPeriodValueReverseAssetAcquisition>
    <ocgn:StockIssuedDuringPeriodValueReverseAssetAcquisition
      contextRef="i0bf0aa30ad2449048bb635d1a966c756_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTAtOS0xLTEtMzE0MA_5a1dbfdb-f21d-4f76-a9e5-4bb44693706a"
      unitRef="usd">3549271</ocgn:StockIssuedDuringPeriodValueReverseAssetAcquisition>
    <ocgn:StockIssuedDuringPeriodValueReverseAssetAcquisition
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTAtMTUtMS0xLTMxNDA_72cf2b34-8daa-4788-ac64-f21d074dde01"
      unitRef="usd">3565788</ocgn:StockIssuedDuringPeriodValueReverseAssetAcquisition>
    <ocgn:ReclassificationOfWarrantsFromLiabilityToEquity
      contextRef="i0bf0aa30ad2449048bb635d1a966c756_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTEtOS0xLTEtMzE1Mw_c960847f-d334-40ba-9b72-686b2aa8cddf"
      unitRef="usd">11255740</ocgn:ReclassificationOfWarrantsFromLiabilityToEquity>
    <ocgn:ReclassificationOfWarrantsFromLiabilityToEquity
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTEtMTUtMS0xLTMxNTM_fb60adb6-4f0c-43af-981c-49194ff9d2ec"
      unitRef="usd">11255740</ocgn:ReclassificationOfWarrantsFromLiabilityToEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i1515189b9f7e45499b0325f53fa93549_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTItNS0xLTEtMzE1Mw_4048e0e1-2e58-4516-b8d1-97c13e80e455"
      unitRef="shares">40542222</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <ocgn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i056a173f43694aaa8e9aeeb3b1af2dde_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTItNy0xLTEtMzE1Mw_bbb43b25-4cdf-491f-99a5-41ce8c1d5c45"
      unitRef="usd">405422</ocgn:StockIssuedDuringPeriodValueWarrantsExercised>
    <ocgn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i0bf0aa30ad2449048bb635d1a966c756_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTItOS0xLTEtMzE1Mw_4f6ef4d1-b87b-4032-86a7-f3752e13c559"
      unitRef="usd">-222388</ocgn:StockIssuedDuringPeriodValueWarrantsExercised>
    <ocgn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTItMTUtMS0xLTMxNTM_847b5113-2c95-45b2-a25e-91ff20c3fb0a"
      unitRef="usd">183034</ocgn:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if5b3357b82d34850aa8982528bb2f47d_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTMtOS0xLTEtMTI2OTg_423e0527-90dc-4281-8c3a-f36e66251984"
      unitRef="usd">47864</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTMtMTUtMS0xLTMxNTM_042a73d7-1f50-471a-8dba-408f4136b5f3"
      unitRef="usd">47864</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i6631f4c18a1a40ecbac6c62f92de5799_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTQtMTEtMS0xLTMxNTk_e1a01fc6-debe-4789-8985-e879c9727ba2"
      unitRef="usd">-451</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTQtMTUtMS0xLTMxNTk_9f322abb-510e-4805-b3a4-93c5b3b57ac9"
      unitRef="usd">-451</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0bf0aa30ad2449048bb635d1a966c756_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTUtOS0xLTEtMzE1OQ_31489e3c-4c70-43a6-a1a5-a6d6c04396d2"
      unitRef="usd">884089</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTUtMTUtMS0xLTMxNTk_925149cb-d4a0-4fa5-b350-8e3ad768de84"
      unitRef="usd">884089</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i17a96552b13e459d9ccd8b8026f03612_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTYtMTMtMS0xLTMxNTk_d0ebf60b-64c8-4b0c-909b-6dac629c0b85"
      unitRef="usd">-20242630</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTYtMTUtMS0xLTMxNTk_b86cd454-4ee5-46f2-87dc-0d7dcb225779"
      unitRef="usd">-20242630</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i32d7d0f983d5402d8056f502420bed85_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTItNS0xLTEtMA_92bfce06-1cc0-47e6-b74b-f4f3c5ea177a"
      unitRef="shares">52746728</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i32d7d0f983d5402d8056f502420bed85_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTItNy0xLTEtMA_bef056fe-1f1c-4f49-abea-82b85258c3fc"
      unitRef="usd">527467</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i37ed1379a0e741cb891c3d578b500f9c_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTctOS0xLTEtMTI2OTg_4df69da2-42ef-416a-943d-8a2222d2defd"
      unitRef="usd">-47864</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if8cfe8fdf29a4818b64dd927a3441caf_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTItOS0xLTEtMA_9a579d09-251d-4edc-a030-436f2a70def1"
      unitRef="usd">62018632</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8f93f033b2964acd9d3cd23521742d13_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTItMTMtMS0xLTA_8d2127f6-e6d7-4d76-9a87-e1e4c3063f76"
      unitRef="usd">-51479824</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8yOC9mcmFnOjViYzdiMTNhYWVlOTRiMWY4ZWE2YWJjZTQ2ODc4Y2Y4L3RhYmxlOjc3MTA2YzBiYjZmMTQzZTU4NGFiMWUzZGZhZDM4ZjFmL3RhYmxlcmFuZ2U6NzcxMDZjMGJiNmYxNDNlNTg0YWIxZTNkZmFkMzhmMWZfMTItMTUtMS0xLTA_528a7a9d-af2f-4694-83a9-f10be46544c3"
      unitRef="usd">11018411</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMy0xLTEtMS0w_06f647e7-6ff4-4696-9372-cd900b0543ab"
      unitRef="usd">-20242630</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMy0zLTEtMS0w_04ea6d55-5540-434a-9e85-689b009e6d8e"
      unitRef="usd">-18219664</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfNS0xLTEtMS0w_ce26887a-43c5-4e02-a9f3-dc22e9265661"
      unitRef="usd">60608</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfNS0zLTEtMS0w_69cc14d2-b986-4e7f-b8b8-003735df4cb2"
      unitRef="usd">49623</us-gaap:Depreciation>
    <ocgn:NonCashInterestExpense
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfNi0xLTEtMS0zMjQz_18cad386-a1d1-40ff-82c0-f763265e5b96"
      unitRef="usd">1733521</ocgn:NonCashInterestExpense>
    <ocgn:NonCashInterestExpense
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfNi0zLTEtMS0zMjQz_59113d2b-5542-4c0b-8e8c-057e20b8301e"
      unitRef="usd">3750630</ocgn:NonCashInterestExpense>
    <ocgn:NoncashLeaseExpense
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfOC0xLTEtMS0zMTgz_b6b4658f-619d-4fbe-93cd-96df32ebb814"
      unitRef="usd">250361</ocgn:NoncashLeaseExpense>
    <ocgn:NoncashLeaseExpense
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfOS0zLTEtMS0zMjQz_483f423b-c40e-4807-9f17-c6b8f12298a0"
      unitRef="usd">0</ocgn:NoncashLeaseExpense>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfNy0xLTEtMS0w_beb1e0dc-73c3-4aa5-8780-cc6847959f10"
      unitRef="usd">-3187380</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfNy0zLTEtMS0w_94133c69-17e9-4ac4-b923-40a267b1fdb1"
      unitRef="usd">1664689</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfOC0xLTEtMS0w_dabc5b0c-4fe0-4200-bcb5-86cc1651ab65"
      unitRef="usd">884089</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfOC0zLTEtMS0w_bdbf3bec-c657-4786-96f4-46cb0e35928f"
      unitRef="usd">1074687</us-gaap:AllocatedShareBasedCompensationExpense>
    <ocgn:GainsLossesOnConversionOfDebt
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfOS0xLTEtMS0w_11e3f19b-9e1b-4cbe-a1c5-4acedc858b11"
      unitRef="usd">-341136</ocgn:GainsLossesOnConversionOfDebt>
    <ocgn:GainsLossesOnConversionOfDebt
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfOS0zLTEtMS0w_09e66d2a-1334-4c58-9ec9-8cdf35106ce1"
      unitRef="usd">0</ocgn:GainsLossesOnConversionOfDebt>
    <us-gaap:OtherNoncashExpense
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTEtMS0xLTEtMTUyOTQ_f89f9b3b-b21f-439e-8723-2c9b857d3973"
      unitRef="usd">4803</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTEtMy0xLTEtMTUyODU_e64d3344-c916-4702-b179-05532d615e1d"
      unitRef="usd">0</us-gaap:OtherNoncashExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTEtMS0xLTEtMA_0dd9f54e-2d23-4ac0-8281-1c80cf7aa69a"
      unitRef="usd">1007367</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTEtMy0xLTEtMA_08ab253b-f810-4888-97bc-11d1d1c8fc36"
      unitRef="usd">201861</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTQtMS0xLTEtMzI2Nw_462eb5dd-337f-4017-bdee-2e533de4f36e"
      unitRef="usd">-1628621</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTQtMy0xLTEtMzI2Nw_997b59c7-01ca-430a-8c26-f9b5e6e4aba3"
      unitRef="usd">3633394</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <ocgn:IncreaseDecreaseInDeferredRent
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTUtMS0xLTEtMzI3Mw_317e6f85-1f55-4c06-9206-674d24cb4ed6"
      unitRef="usd">0</ocgn:IncreaseDecreaseInDeferredRent>
    <ocgn:IncreaseDecreaseInDeferredRent
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTUtMy0xLTEtMzI3Mw_13ca8261-a3ff-4255-9f6a-b4fcff52c637"
      unitRef="usd">1540</ocgn:IncreaseDecreaseInDeferredRent>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTItMS0xLTEtMA_889799b2-e8ba-46ab-91e9-eb3391edd1fc"
      unitRef="usd">227172</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTItMy0xLTEtMA_64023fe3-4cd3-4877-9e7b-068df0866c22"
      unitRef="usd">54203</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <ocgn:IncreaseDecreaseInLeaseObligations
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTQtMS0xLTEtMA_9147e094-487a-4403-adaa-89016d2e9294"
      unitRef="usd">-249389</ocgn:IncreaseDecreaseInLeaseObligations>
    <ocgn:IncreaseDecreaseInLeaseObligations
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTQtMy0xLTEtMA_bf19e1d2-04e9-4ed4-9209-345658f3997a"
      unitRef="usd">0</ocgn:IncreaseDecreaseInLeaseObligations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTUtMS0xLTEtMA_6162b334-b4bb-4c92-b808-29e6e366c99c"
      unitRef="usd">-16893281</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTUtMy0xLTEtMA_5a7dcd0b-b734-4530-a05c-79be5dc0ad0a"
      unitRef="usd">-11630543</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTctMS0xLTEtMA_2c93c084-5c56-4b8a-9615-2a73f375a0b7"
      unitRef="usd">29446</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTctMy0xLTEtMA_189b1b56-2de4-4c7c-a721-085bbb4119f9"
      unitRef="usd">77414</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTgtMS0xLTEtMA_979ca511-70aa-456d-a860-d88b6d138514"
      unitRef="usd">2327273</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTgtMy0xLTEtMA_2e15d1d0-81c5-4121-9d3b-7d2312eafde7"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTktMS0xLTEtMA_bde2c48a-d6ef-4f07-8b7e-27ed914f49bf"
      unitRef="usd">-2356719</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMTktMy0xLTEtMA_68a4295b-796f-4aa4-aa2c-19b3042b1c40"
      unitRef="usd">-77414</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <ocgn:ProceedsFromPreMergerFinancingFinancingActivities
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjQtMS0xLTEtMzI5NQ_7ec0493d-d724-47c6-9167-bf949a8127fd"
      unitRef="usd">22546353</ocgn:ProceedsFromPreMergerFinancingFinancingActivities>
    <ocgn:ProceedsFromPreMergerFinancingFinancingActivities
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjQtMy0xLTEtMzI5NQ_509d54ed-b924-43ea-8ea2-ef9b02a3c950"
      unitRef="usd">0</ocgn:ProceedsFromPreMergerFinancingFinancingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjUtMS0xLTEtMzMwMA_6e751c2a-546b-4936-8368-3f5449824509"
      unitRef="usd">1000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjUtMy0xLTEtMzMwMA_326e0912-f8b3-46ea-a509-f34e421d513b"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjYtMS0xLTEtMzMwMA_97d13459-c5b6-4aa9-bcf5-f40b42111fba"
      unitRef="usd">47864</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjYtMy0xLTEtMzMwMA_749d254a-9c73-4113-b486-bd917eee4df3"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjctMS0xLTEtMzMwMA_0da7d09c-d014-45b1-ad3e-4778dd047295"
      unitRef="usd">183034</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjctMy0xLTEtMzMwMA_c6868b93-3f58-4e52-90de-ba0d6dd4da4f"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:RepaymentsOfDebt
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjgtMS0xLTEtMzMwNQ_82e96869-7bb8-407f-bfd7-da802b0a4152"
      unitRef="usd">5290000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjgtMy0xLTEtMzMwNQ_35c83a70-ad9a-4e5f-bb44-9f8e70084a30"
      unitRef="usd">0</us-gaap:RepaymentsOfDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjktMS0xLTEtMzMxMA_88d3db0d-8aca-44c0-9941-42e0ccc0ceec"
      unitRef="usd">6800000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjktMy0xLTEtMzMxMA_faa00029-9c1b-48da-8296-efe915905201"
      unitRef="usd">7300400</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjItMS0xLTEtMA_05175e3e-e0fd-4460-a4a4-7ff4d78b65cb"
      unitRef="usd">99202</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjItMy0xLTEtMA_2f6df952-8f04-484b-8016-d136e22c353a"
      unitRef="usd">103925</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjYtMS0xLTEtMA_45bc96be-83a0-4131-8982-f2169911262b"
      unitRef="usd">25866</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjYtMy0xLTEtMA_3dcef08f-db8c-48dd-9cbc-9b93ee9ba301"
      unitRef="usd">11928</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjgtMS0xLTEtMA_26875070-2e1c-440d-9a56-845ff01da7ef"
      unitRef="usd">25066455</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjgtMy0xLTEtMA_04fede6a-51ab-49d9-a7e7-b0d0548043ac"
      unitRef="usd">7184547</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjktMS0xLTEtMA_2db82aa3-eddc-425b-972c-897d0f7f5f58"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMjktMy0xLTEtMA_775fe3f2-c731-49e5-b67b-e524f6754972"
      unitRef="usd">451</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzAtMS0xLTEtMA_69e042dd-f9e7-4b7b-959c-b51b20986891"
      unitRef="usd">5816455</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzAtMy0xLTEtMA_6d639793-9937-4292-84d3-be82d36dd559"
      unitRef="usd">-4522959</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzEtMS0xLTEtMA_9650f044-4f6b-4219-b405-84ab1236aedb"
      unitRef="usd">1778613</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3b0b2789ee4e45ff8aa700de563ddc85_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzEtMy0xLTEtMA_20a9f560-d1fb-4e28-8ee7-2d26513b4a41"
      unitRef="usd">6301572</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzItMS0xLTEtMA_77328215-40de-4863-8767-32ec59eba86d"
      unitRef="usd">7595068</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzItMy0xLTEtMA_b6de538a-9c85-4557-ac05-539e0c44f4f2"
      unitRef="usd">1778613</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzQtMS0xLTEtMA_2caebf2a-a83c-4bfe-869c-173110016803"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzQtMy0xLTEtMA_0dbdfbf3-9eb0-40ae-ab5f-60670dda963d"
      unitRef="usd">63817</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzUtMS0xLTEtMA_1d738a9a-d442-4506-a8a5-ff4dddd2a991"
      unitRef="usd">13979788</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzUtMy0xLTEtMA_f737d747-e22d-49ca-900b-a5df4998ae2a"
      unitRef="usd">0</us-gaap:DebtConversionOriginalDebtAmount1>
    <ocgn:NoncashOrPartNoncashAmountOfDeferredTransactionCost
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzctMS0xLTEtMA_e4c79306-4a9c-4c7b-adbd-352704879f62"
      unitRef="usd">1150000</ocgn:NoncashOrPartNoncashAmountOfDeferredTransactionCost>
    <ocgn:NoncashOrPartNoncashAmountOfDeferredTransactionCost
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzctMy0xLTEtMA_a9d64ed1-89ec-4ff5-ae53-8fa3967ff46e"
      unitRef="usd">0</ocgn:NoncashOrPartNoncashAmountOfDeferredTransactionCost>
    <ocgn:NoncashOrPartNoncashOperatingLeaseRightOfUseAsset
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzgtMS0xLTEtMA_2218779f-d330-4f45-9039-41a70a4ca558"
      unitRef="usd">470356</ocgn:NoncashOrPartNoncashOperatingLeaseRightOfUseAsset>
    <ocgn:NoncashOrPartNoncashOperatingLeaseRightOfUseAsset
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzgtMy0xLTEtMA_93a3f752-8c0e-4b19-a4a8-8b1fa6d5bee5"
      unitRef="usd">0</ocgn:NoncashOrPartNoncashOperatingLeaseRightOfUseAsset>
    <ocgn:DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzktMS0xLTEtMA_52811602-c844-4d1e-b42d-3e60a7083515"
      unitRef="usd">2252795</ocgn:DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction>
    <ocgn:DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8zNC9mcmFnOjQxNTBmZDUxNzZhZjQ3MDE4ZjZjN2IyNDFlNTI2ODU2L3RhYmxlOjYzM2QzYmQ4YjFiMjQwMjdhZmRlZGVkZDE0MjAzNGI3L3RhYmxlcmFuZ2U6NjMzZDNiZDhiMWIyNDAyN2FmZGVkZWRkMTQyMDM0YjdfMzktMy0xLTEtMA_a388713e-c5c2-4af8-86f0-bf16343bedeb"
      unitRef="usd">0</ocgn:DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:NatureOfOperations
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80MC9mcmFnOjM1NDhhMTZlNGUwODRiZDA5NjE2M2FkNWRhOTgzYzY2L3RleHRyZWdpb246MzU0OGExNmU0ZTA4NGJkMDk2MTYzYWQ1ZGE5ODNjNjZfMTA5OTUxMTYyODk4OTI_432575da-1f4b-4e53-a042-8221d2b26ed4">Nature of Business&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Ocugen, Inc. (formerly known as Histogenics Corporation), together with its wholly owned subsidiaries (&#x201c;Ocugen&#x201d; or the &#x201c;Company&#x201d;), is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat the whole eye. The Company is located in Malvern, Pennsylvania.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Ocugen has a late-stage, Phase 3 program, OCU300, which has received Orphan Drug Designation ("ODD") from the U.S. Food and Drug Administration ("FDA"). OCU300 is a small molecule therapeutic currently in Phase 3 clinical development for patients with ocular redness and discomfort stemming from ocular graft-versus-host disease (&#x201c;oGVHD&#x201d;). Ocugen is the first and only company to receive ODD for the treatment of symptoms associated with oGVHD and is the only company conducting Phase 3 studies in this patient population. OCU300 is formulated using the Company&#x2019;s proprietary nanoemulsion technology, OcuNanoE&#x2014;Ocugen&#x2019;s ONE Platform&#x2122; (&#x201c;OcuNanoE&#x2122;&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Ocugen is developing a modifier gene therapy platform for unmet medical needs in the area of retinal diseases, including inherited retinal diseases (&#x201c;IRDs&#x201d;). Ocugen&#x2019;s modifier gene therapy platform is novel in that it targets nuclear hormone receptors (&#x201c;NHRs&#x201d;), which have the potential to restore homeostasis to the retina and may target multiple genes that are associated with a range of IRDs. Unlike single-gene replacement therapies, which only target one genetic mutation, the Company believes that its gene therapy platform, through its targeting of NHRs, may impact multiple genes that are associated with a range of genetically diverse diseases. Ocugen&#x2019;s first gene therapy candidate, OCU400, has received ODD from the FDA, for the treatment of nuclear receptor subfamily 2 group E member 3 ("&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;NR2E3&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;")&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;mutation-associated retinal diseases and centrosomal protein 290 ("&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;CEP290&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;") mutation-associated retinal diseases. Ocugen&#x2019;s second gene therapy product candidate, OCU410, is targeted for dry age-related macular degeneration (&#x201c;AMD&#x201d;) and is currently in preclinical development. Currently, there are no FDA-approved therapies to treat this disease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Ocugen is also developing OCU200, a novel fusion protein for the treatment of wet AMD, diabetic retinopathy (&#x201c;DR&#x201d;) and diabetic macular edema (&#x201c;DME&#x201d;), which is in preclinical development. Ocugen expects to initiate a Phase 1/2 clinical trial for OCU200 within the next two years. Ocugen plans to expand the therapeutic applications of OCU200 beyond DME, DR and wet AMD to potentially include macular edema following retinal vein occlusion (&#x201c;RVO&#x201d;) and myopic choroidal neovascularization (&#x201c;mCNV&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Merger with Histogenics&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On September 27, 2019, the Company completed its reverse merger with Ocugen, OpCo Inc. (formerly known as Ocugen,&#160;Inc. (&#x201c;Former Ocugen&#x201d;)) in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of April&#160;5, 2019, by and among Histogenics, Former Ocugen and Restore Merger Sub,&#160;Inc., a wholly owned subsidiary of Histogenics (&#x201c;Merger Sub&#x201d;), as amended (the &#x201c;Merger Agreement&#x201d;), pursuant to which Merger Sub merged with and into Former Ocugen, with Former Ocugen surviving as a wholly owned subsidiary of Histogenics (the &#x201c;Merger&#x201d;). Immediately after completion of the Merger, Histogenics changed its name to Ocugen,&#160;Inc. and the business conducted by Ocugen,&#160;Inc. became the business conducted by Former Ocugen. Former Ocugen is deemed to be the accounting acquirer. Accordingly, the historical financial statements of Former Ocugen became the Company&#x2019;s historical financial statements, including the comparative prior periods. See Note 3 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with, and immediately prior to the completion of the Merger, Histogenics effected a reverse stock split of the common stock, at a ratio of 1-for-60 (the &#x2018;&#x2018;Reverse Stock Split&#x2019;&#x2019;). Under the terms of the Merger Agreement, the Company issued common stock to Former Ocugen&#x2019;s stockholders at an exchange rate of 0.4794 shares of common stock, after taking into account the Reverse Stock Split, for each share of Former Ocugen&#x2019;s common stock outstanding immediately prior to the Merger.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The capital structure, including the number of shares of common stock issued appearing in the consolidated balance sheets for the periods presented, reflects that of Ocugen. All references in the consolidated financial statements to the number of shares and per-share amounts of common stock have been retroactively restated to reflect the exchange rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, warrants to purchase common stock, the issuance of convertible notes, and debt. The Company incurred net losses of approximately $20.2 million and $18.2 million for the year ended December 31, 2019 and 2018, respectively, and had an accumulated deficit of $51.5 million as of December&#160;31, 2019. As of December&#160;31, 2019, the Company had cash, cash equivalents and restricted cash totaling $7.6 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has a limited operating history and its prospects are subject to risks, expenses and uncertainties frequently encountered by companies in its industry. The Company intends to continue its research and development efforts for its product candidates, which will require significant funding. If the Company is unable to obtain additional financing in the future or research and development efforts require higher than anticipated capital, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital by raising additional capital through public and private placements of equity and/or debt, payments from potential strategic research and development arrangements, sale of assets, and licensing and/or collaboration arrangements with pharmaceutical companies or other institutions. Such financing may not be available at all, or on terms that are favorable to the Company. While management of the Company believes that it has a plan to fund ongoing operations, its plan may not be successfully implemented. Failure to generate sufficient cash flows from operations, raise additional capital through one or more financings, or appropriately manage certain discretionary spending could have a material adverse effect on the Company&#x2019;s ability to achieve its intended business objectives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As a result of these factors, together with the anticipated increase in spending that will be necessary to continue to develop the Company&#x2019;s products, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that these audited consolidated financial statements are issued. The audited consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <ocgn:BusinessCombinationIssuedSharesExchangeRate
      contextRef="id83e33e57cad4f08967d8d41dfb42b28_D20190927-20190927"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80MC9mcmFnOjM1NDhhMTZlNGUwODRiZDA5NjE2M2FkNWRhOTgzYzY2L3RleHRyZWdpb246MzU0OGExNmU0ZTA4NGJkMDk2MTYzYWQ1ZGE5ODNjNjZfMzYyNg_572cdc8e-01ca-4e20-a545-02aacb60f931"
      unitRef="number">0.4794</ocgn:BusinessCombinationIssuedSharesExchangeRate>
    <us-gaap:NetIncomeLoss
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80MC9mcmFnOjM1NDhhMTZlNGUwODRiZDA5NjE2M2FkNWRhOTgzYzY2L3RleHRyZWdpb246MzU0OGExNmU0ZTA4NGJkMDk2MTYzYWQ1ZGE5ODNjNjZfODI0NjMzNzIyMDM3Mw_b4ab48e6-0cf9-4f65-8b3b-64019947f751"
      unitRef="usd">-20200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80MC9mcmFnOjM1NDhhMTZlNGUwODRiZDA5NjE2M2FkNWRhOTgzYzY2L3RleHRyZWdpb246MzU0OGExNmU0ZTA4NGJkMDk2MTYzYWQ1ZGE5ODNjNjZfNzE0NjgyNTU5MjY3OQ_9b83e1b0-7ae9-4089-9c2e-5317fc647ebd"
      unitRef="usd">-18200000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80MC9mcmFnOjM1NDhhMTZlNGUwODRiZDA5NjE2M2FkNWRhOTgzYzY2L3RleHRyZWdpb246MzU0OGExNmU0ZTA4NGJkMDk2MTYzYWQ1ZGE5ODNjNjZfNjA0NzMxMzk1OTI5OQ_0dc2f8b7-0598-44d2-8b6a-64e2014d72f4"
      unitRef="usd">51500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80MC9mcmFnOjM1NDhhMTZlNGUwODRiZDA5NjE2M2FkNWRhOTgzYzY2L3RleHRyZWdpb246MzU0OGExNmU0ZTA4NGJkMDk2MTYzYWQ1ZGE5ODNjNjZfNjA0NzMxMzk1OTMxNA_ff22d169-20eb-40a5-8d90-f38ad3ca4e4e"
      unitRef="usd">7600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTcwNDI0MzAyNTQwMDI_f2b59224-17f7-492f-ac3d-0cc4f7d64c02">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying consolidated financial statements included herein have been prepared in conformity with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;). The consolidated financial statements include the accounts of Ocugen, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Certain prior year amounts have been reclassified to conform with current year presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Foreign Currency Translation and Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The assets and liabilities of the Company&#x2019;s foreign subsidiary are translated into U.S. dollars based on exchange rates in effect at the end of each period. Revenues and expenses are translated at average exchange rates during the periods. Currency transaction gains or losses are included in other expenses. Gains or losses from balance sheet translation are included in accumulated other comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In preparing consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include those used in the estimation of clinical trial accruals and the valuation of share-based payment arrangements, warrants, and embedded conversion features on the convertible notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Asset Held for Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;An asset is considered to be held for sale when all of the following criteria are met: (i) management commits to a plan to sell the asset; (ii) it is unlikely that the disposal plan will be significantly modified or discontinued; (iii) the asset is available for immediate sale in its present condition; (iv)&#160;actions required to complete the sale of the asset have been initiated; (v) sale of the asset is probable and the completed sale is expected to occur within one year; and (vi)&#160;the asset is actively being marketed for sale at a price that is reasonable given its current market value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A long-lived asset classified as held for sale is measured at the lower of its carrying amount or fair value less cost to sell. If the long-lived asset is newly acquired, the carrying amount of the long-lived asset is established based on its fair value less cost to sell at the acquisition date. A long-lived asset is not depreciated or amortized while it is classified as held for sale, and an impairment loss would be recognized to the extent the carrying amount exceeds the asset's fair value less cost to sell.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of December&#160;31, 2019, Ocugen had an intangible asset held for sale acquired from Histogenics with a fair value less cost to sell of $7.0 million. See Note 3 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The company follows the provisions of the Financial Accounting Standards Board&#x2019;s (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 820, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASC 820&#x201d;), which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The estimated fair value of certain financial instruments, cash and cash equivalents, accounts payable, and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. As of December&#160;31, 2019 and 2018, the Company believes the fair value of the EB-5 note approximates its carrying value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 1 &#x2014; quoted prices in active markets for identical assets or liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 2 &#x2014; quoted prices for similar assets and liabilities in active markets or inputs that are observable&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 3 &#x2014; inputs that are unobservable (for example cash flow modeling inputs based on assumptions)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The company had derivative instruments that were fair valued on a recurring basis using Level 3 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Financial Instruments Indexed to and Potentially Settled in Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for warrants in accordance with ASC Topic 815-40, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASC 815-40&#x201d;), which is the authoritative guidance on accounting for derivative financial instruments indexed to and potentially settled in a company&#x2019;s own stock. To determine whether a contract is considered indexed to the issuer&#x2019;s own equity, the Company performs a two-step analysis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Step 1: Evaluate whether the contract contains any exercise contingencies and, if so, whether they disqualify the contract from being classified as equity, and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Step 2: Assess whether the settlement terms are consistent with equity classification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company classifies the liability-designated warrants on its consolidated balance sheets as a derivative liability which is recognized at fair value at each reporting period subsequent to the initial issuance. Changes in the fair value of derivatives are recognized as other income (expense) in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposit, commercial paper and United States government and United States government agency obligations. The Company&#x2019;s restricted cash balance consists of cash held to collateralize a corporate credit card account.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash in the consolidated balance sheets to the total amount shown in the consolidated statements of cash flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.175%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash, cash equivalents and restricted cash reconciliation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,444,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,628,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;151,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;150,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,595,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,778,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Property and equipment is recorded at cost. Significant additions or improvements are capitalized, and expenditures for repairs and maintenance are charged to expense as incurred. Gains and losses on disposal of assets are included in the consolidated statements of operations and comprehensive loss. Depreciation is calculated using the straight-line method and is recognized over an expected useful life of 5 years for equipment and 7 years for furniture. The total accumulated depreciation and amortization for equipment and furniture as of December&#160;31, 2019 and 2018 was $0.1&#160;million and $0.1&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements which include lease and&#160;non-lease&#160;components, which the Company has elected to account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components are recognized when the obligation is probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating leases are included in other assets and lease obligations on the Company&#x2019;s consolidated balance sheets. Operating lease right-of-use ("ROU") assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Operating lease payments are recognized as lease expense on a straight-line basis over the lease term. The Company primarily leases buildings (real estate) which are classified as operating leases. ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As an implicit interest rate is not readily determinable in the Company&#x2019;s leases, the incremental borrowing rate is used based on the information available at commencement date in determining the present value of lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The lease term for all of the Company&#x2019;s leases includes the&#160;non-cancellable&#160;period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and lease liability) for the majority of the Company&#x2019;s leases as the reasonably certain threshold is not met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Lease payments included in the measurement of the lease liability are comprised of fixed payments, variable payments that depend on index or rate, and amounts probable to be payable under the exercise of the Company option to purchase the underlying asset if reasonably certain.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Variable lease payments not dependent on a rate or index associated with the Company&#x2019;s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed as probable. Variable lease payments include the Company's proportionate share of utilities and other operating expenses and are presented as operating expenses in the Company&#x2019;s income statement in the same line item as expense arising from fixed lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Ocugen accounts for its stock-based compensation awards in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Compensation&#x2014;Stock Compensation&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASC 718&#x201d;). ASC 718 requires all stock-based payments to employees, including grants of employee stock options and restricted stock units and modifications to existing agreements, to be recognized in the statements of operations &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;based on their fair values. Ocugen uses the Black-Scholes option-pricing model to determine the fair value of options granted. Ocugen recognized forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Ocugen&#x2019;s stock-based awards are subject to service-based vesting conditions. Compensation expense related to awards to employees and directors with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Stock-based awards generally vest over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfNzY5NjU4MTQxODYxNA_853dc9b7-c919-4df5-9190-d9436288daac"&gt;one&lt;/span&gt; to &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfODI0NjMzNzIzNzU5OQ_e571c6b5-bef2-4cd7-bc49-832c32f02b1a"&gt;three&lt;/span&gt; year requisite service period and have a contractual term of 10 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Estimating the fair value of options requires the input of subjective assumptions, including expected life of the option, stock price volatility, the risk-free interest rate and expected dividends. The assumptions used in Ocugen&#x2019;s Black-Scholes option-pricing model represent management&#x2019;s best estimates and involve a number of variables, uncertainties and assumptions and the application of management&#x2019;s judgment, as they are inherently subjective. If any assumptions change, Ocugen&#x2019;s stock-based compensation expense could be materially different in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;These assumptions used in Ocugen&#x2019;s Black-Scholes option-pricing model are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Expected Term.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Due to the historical lack of a public market for the trading of Ocugen common stock and the lack of sufficient company-specific historical data, the expected term of employee options is determined using the &#x201c;simplified&#x201d; method, as prescribed in Securities and Exchange Commission&#x2019;s Staff Accounting Bulletin No. 107 (&#x201c;SAB&#160;No.&#160;107&#x201d;), whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option. The expected term of non-employee options is equal to the contractual term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Expected Volatility.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; The expected volatility is based on historical volatilities of Ocugen and similar entities within Ocugen&#x2019;s industry for periods commensurate with the expected term assumption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Risk-Free Interest Rate.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Expected Dividends.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; The expected dividend yield is 0% because Ocugen has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is a Delaware C-Corporation. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, is applied during the years in which temporary differences are expected to be settled and is reflected in the financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on the weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. The Company&#x2019;s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. No interest or penalty expense was recognized during the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has assessed and concluded that there are uncertain tax positions giving rise to the unrecognized tax benefits as of December&#160;31, 2019. The Company&#x2019;s conclusions regarding uncertain tax positions may be subject to review and adjustment at a later date based upon ongoing analysis of tax laws, regulations and interpretations thereof, as well as other factors. Generally, federal, state, and local authorities may examine the Company&#x2019;s tax returns for three years from the date of the filing and the current and prior three years remain subject to examination as of December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company views its operations and manages its business as one operating segment, which is the development of innovative therapies to address the whole eye. As of December&#160;31, 2019, substantially all of the Company&#x2019;s assets were located in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In February&#160;2016, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;)&#160;No.&#160;2016-02,&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASC 842&#x201d;). In July&#160;2018, the FASB issued ASU&#160;No.&#160;2018-10,&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Codification Improvements to Topic 842, Leases&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASU&#160;2018-10&#x201d;),&#160;which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU&#160;No.&#160;2018-11,&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;(Topic 842)&#x2014;Targeted Improvements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASU&#160;2018-11&#x201d;),&#160;which addressed implementation issues related to the new lease standard. These and certain other lease-related ASUs have generally been codified in ASC 842. ASC 842 supersedes the lease accounting requirements in ASC Topic 840, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASC 840&#x201d;). ASC 842 establishes a&#160;right-of-use&#160;model that requires a lessee to record a&#160;right-of-use&#160;(&#x201c;ROU&#x201d;) asset and a lease liability on the balance sheet for all leases. Under ASC 842, leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The standard also requires disclosures to help investors and other financial statement users better understand the amount, timing and uncertainty of cash flows arising from leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company adopted ASC 842 on January&#160;1, 2019 using the effective date transition method. Prior period results continue to be presented under ASC 840 based on the accounting standards originally in effect for such periods. The Company has elected certain practical expedients permitted under the transition guidance within ASC 842 to leases that commenced before January&#160;1, 2019, including the package of practical expedients. The election of the package of practical expedients resulted in the Company not reassessing prior conclusions under ASC 840 related to lease identification, lease classification and initial direct costs for expired and existing leases prior to January&#160;1, 2019. The adoption of ASU&#160;2016-02&#160;did not have a significant impact on the Company&#x2019;s consolidated results of operations or cash flows. Upon adoption, the Company recognized an ROU asset and lease liability of $0.4 million and $0.4 million, respectively. See Note 9 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the FASB issued ASU No. 2018-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Fair Value Measurement (Topic 820): Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. This standard modifies certain disclosure requirements on fair value measurements and was effective for the Company on January 1, 2020. The adoption of this standard will not have a material impact on the Company's disclosures.&lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2023. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The Company does not expect the adoption of these standards to have a material impact on its consolidated financial statements.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfNzQxMA_e85ace11-01a0-46b9-962c-8719d6715304">Basis of Presentation and ConsolidationThe accompanying consolidated financial statements included herein have been prepared in conformity with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;).</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfNzQxMQ_661f8538-7f26-4e04-a774-0a172303b21c">The consolidated financial statements include the accounts of Ocugen, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Certain prior year amounts have been reclassified to conform with current year presentation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfNzQxNQ_1b1ae2a0-8741-4e89-bc49-dc4fac2a4f36">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Foreign Currency Translation and Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The assets and liabilities of the Company&#x2019;s foreign subsidiary are translated into U.S. dollars based on exchange rates in effect at the end of each period. Revenues and expenses are translated at average exchange rates during the periods. Currency transaction gains or losses are included in other expenses. Gains or losses from balance sheet translation are included in accumulated other comprehensive income.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfNzQxMg_95e4c0e4-512f-4b39-8c35-9aa50d193043">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In preparing consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include those used in the estimation of clinical trial accruals and the valuation of share-based payment arrangements, warrants, and embedded conversion features on the convertible notes.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <ocgn:AssetHeldForSalePolicyTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTcwNDI0MzAyNTQwMDM_c2d51332-f3f4-4139-812b-0a35b1a2436c">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Asset Held for Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;An asset is considered to be held for sale when all of the following criteria are met: (i) management commits to a plan to sell the asset; (ii) it is unlikely that the disposal plan will be significantly modified or discontinued; (iii) the asset is available for immediate sale in its present condition; (iv)&#160;actions required to complete the sale of the asset have been initiated; (v) sale of the asset is probable and the completed sale is expected to occur within one year; and (vi)&#160;the asset is actively being marketed for sale at a price that is reasonable given its current market value.&lt;/span&gt;&lt;/div&gt;A long-lived asset classified as held for sale is measured at the lower of its carrying amount or fair value less cost to sell. If the long-lived asset is newly acquired, the carrying amount of the long-lived asset is established based on its fair value less cost to sell at the acquisition date. A long-lived asset is not depreciated or amortized while it is classified as held for sale, and an impairment loss would be recognized to the extent the carrying amount exceeds the asset's fair value less cost to sell.</ocgn:AssetHeldForSalePolicyTextBlock>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMzg2MQ_4a383b20-979b-49de-b135-11e57c35d70b"
      unitRef="usd">7000000.0</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfNzQxNA_4445ebe9-c3ff-40b6-99fa-18003b44a3be">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The company follows the provisions of the Financial Accounting Standards Board&#x2019;s (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 820, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASC 820&#x201d;), which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The estimated fair value of certain financial instruments, cash and cash equivalents, accounts payable, and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. As of December&#160;31, 2019 and 2018, the Company believes the fair value of the EB-5 note approximates its carrying value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 1 &#x2014; quoted prices in active markets for identical assets or liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 2 &#x2014; quoted prices for similar assets and liabilities in active markets or inputs that are observable&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 3 &#x2014; inputs that are unobservable (for example cash flow modeling inputs based on assumptions)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The company had derivative instruments that were fair valued on a recurring basis using Level 3 inputs.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <ocgn:DerivativeInstrumentsAndHedgingActivitiesDisclosurePolicyTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfNzQwNw_59f01780-5a9e-484e-80da-f6a3f9da26a5">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Financial Instruments Indexed to and Potentially Settled in Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for warrants in accordance with ASC Topic 815-40, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASC 815-40&#x201d;), which is the authoritative guidance on accounting for derivative financial instruments indexed to and potentially settled in a company&#x2019;s own stock. To determine whether a contract is considered indexed to the issuer&#x2019;s own equity, the Company performs a two-step analysis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Step 1: Evaluate whether the contract contains any exercise contingencies and, if so, whether they disqualify the contract from being classified as equity, and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Step 2: Assess whether the settlement terms are consistent with equity classification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company classifies the liability-designated warrants on its consolidated balance sheets as a derivative liability which is recognized at fair value at each reporting period subsequent to the initial issuance. Changes in the fair value of derivatives are recognized as other income (expense) in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</ocgn:DerivativeInstrumentsAndHedgingActivitiesDisclosurePolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTcwNDI0MzAyNTQwMDQ_63f1726d-3e0f-4760-b052-fbb9a2463b97">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposit, commercial paper and United States government and United States government agency obligations. The Company&#x2019;s restricted cash balance consists of cash held to collateralize a corporate credit card account.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTcwNDI0MzAyNTQwMzA_26d9ff64-a8d3-4050-ae56-41a1fd30a02a">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash in the consolidated balance sheets to the total amount shown in the consolidated statements of cash flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.175%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash, cash equivalents and restricted cash reconciliation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,444,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,628,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;151,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;150,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,595,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,778,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTcwNDI0MzAyNTQwMzA_aa84a401-10c8-49a8-bffa-0d361b661515">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash in the consolidated balance sheets to the total amount shown in the consolidated statements of cash flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.175%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash, cash equivalents and restricted cash reconciliation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,444,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,628,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;151,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;150,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,595,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,778,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RhYmxlOmU0NjAzZmE0YmRjZTQwNmE4ODliYjVlNDllNDc1MzJhL3RhYmxlcmFuZ2U6ZTQ2MDNmYTRiZGNlNDA2YTg4OWJiNWU0OWU0NzUzMmFfMy0xLTEtMS0w_15abd57d-3dbb-4eac-85e4-ee96899bd1ba"
      unitRef="usd">7444052</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RhYmxlOmU0NjAzZmE0YmRjZTQwNmE4ODliYjVlNDllNDc1MzJhL3RhYmxlcmFuZ2U6ZTQ2MDNmYTRiZGNlNDA2YTg4OWJiNWU0OWU0NzUzMmFfMy0zLTEtMS0w_421fde7e-9519-45ad-ab58-a58563edb397"
      unitRef="usd">1628136</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RhYmxlOmU0NjAzZmE0YmRjZTQwNmE4ODliYjVlNDllNDc1MzJhL3RhYmxlcmFuZ2U6ZTQ2MDNmYTRiZGNlNDA2YTg4OWJiNWU0OWU0NzUzMmFfNC0xLTEtMS0w_90a27e5b-f124-4df5-a1ed-2f2f6594aeea"
      unitRef="usd">151016</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RhYmxlOmU0NjAzZmE0YmRjZTQwNmE4ODliYjVlNDllNDc1MzJhL3RhYmxlcmFuZ2U6ZTQ2MDNmYTRiZGNlNDA2YTg4OWJiNWU0OWU0NzUzMmFfNC0zLTEtMS0w_af399d75-8351-4c7b-9ad3-0ebc8700df9d"
      unitRef="usd">150477</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RhYmxlOmU0NjAzZmE0YmRjZTQwNmE4ODliYjVlNDllNDc1MzJhL3RhYmxlcmFuZ2U6ZTQ2MDNmYTRiZGNlNDA2YTg4OWJiNWU0OWU0NzUzMmFfNS0xLTEtMS0w_e1448e5a-939c-405f-9269-674e9861a152"
      unitRef="usd">7595068</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RhYmxlOmU0NjAzZmE0YmRjZTQwNmE4ODliYjVlNDllNDc1MzJhL3RhYmxlcmFuZ2U6ZTQ2MDNmYTRiZGNlNDA2YTg4OWJiNWU0OWU0NzUzMmFfNS0zLTEtMS0w_95078d0d-2130-45c5-9325-3272ae396b47"
      unitRef="usd">1778613</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTcwNDI0MzAyNTQwMDU_9a6f05c3-9a97-42db-bb62-5de9b66e2688">Property and Equipment, NetProperty and equipment is recorded at cost. Significant additions or improvements are capitalized, and expenditures for repairs and maintenance are charged to expense as incurred. Gains and losses on disposal of assets are included in the consolidated statements of operations and comprehensive loss. Depreciation is calculated using the straight-line method and is recognized over an expected useful life of 5 years for equipment and 7 years for furniture.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i0c8bec4b6fb74710acd1aebcd65c0caf_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTcwNDI0MzAyNTQwMzE_d8fbcdf2-d9b0-4ced-8036-43ff6b8216cd">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="if7530f5259ea4fb287abfd56f7c74a7f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTcwNDI0MzAyNTQwNDQ_bbc1e69a-bdf7-4431-9dc0-e7c6ad80c8fd">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i280158470c9b4af886ce65d165852eaa_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfNzY5NjU4MTQxODY3MA_e969034b-b65a-4809-a72c-b27f27257af1"
      unitRef="usd">100000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iad6c551567dc41aba66ce356fc5db8a9_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfNzY5NjU4MTQxODY3Mw_3561029e-4419-4041-b1de-fc07d141cc84"
      unitRef="usd">100000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTcwNDI0MzAyNTQwMDY_9aa593c6-e626-4fd4-a3ec-0dc82f142db1">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements which include lease and&#160;non-lease&#160;components, which the Company has elected to account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components are recognized when the obligation is probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating leases are included in other assets and lease obligations on the Company&#x2019;s consolidated balance sheets. Operating lease right-of-use ("ROU") assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Operating lease payments are recognized as lease expense on a straight-line basis over the lease term. The Company primarily leases buildings (real estate) which are classified as operating leases. ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As an implicit interest rate is not readily determinable in the Company&#x2019;s leases, the incremental borrowing rate is used based on the information available at commencement date in determining the present value of lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The lease term for all of the Company&#x2019;s leases includes the&#160;non-cancellable&#160;period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and lease liability) for the majority of the Company&#x2019;s leases as the reasonably certain threshold is not met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Lease payments included in the measurement of the lease liability are comprised of fixed payments, variable payments that depend on index or rate, and amounts probable to be payable under the exercise of the Company option to purchase the underlying asset if reasonably certain.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Variable lease payments not dependent on a rate or index associated with the Company&#x2019;s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed as probable. Variable lease payments include the Company's proportionate share of utilities and other operating expenses and are presented as operating expenses in the Company&#x2019;s income statement in the same line item as expense arising from fixed lease payments.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTcwNDI0MzAyNTQwMjU_a1b2e725-5dca-460d-b8b6-93bb4e8973e8">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Ocugen accounts for its stock-based compensation awards in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Compensation&#x2014;Stock Compensation&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASC 718&#x201d;). ASC 718 requires all stock-based payments to employees, including grants of employee stock options and restricted stock units and modifications to existing agreements, to be recognized in the statements of operations &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;based on their fair values. Ocugen uses the Black-Scholes option-pricing model to determine the fair value of options granted. Ocugen recognized forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Ocugen&#x2019;s stock-based awards are subject to service-based vesting conditions. Compensation expense related to awards to employees and directors with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Stock-based awards generally vest over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfNzY5NjU4MTQxODYxNA_853dc9b7-c919-4df5-9190-d9436288daac"&gt;one&lt;/span&gt; to &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfODI0NjMzNzIzNzU5OQ_e571c6b5-bef2-4cd7-bc49-832c32f02b1a"&gt;three&lt;/span&gt; year requisite service period and have a contractual term of 10 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Estimating the fair value of options requires the input of subjective assumptions, including expected life of the option, stock price volatility, the risk-free interest rate and expected dividends. The assumptions used in Ocugen&#x2019;s Black-Scholes option-pricing model represent management&#x2019;s best estimates and involve a number of variables, uncertainties and assumptions and the application of management&#x2019;s judgment, as they are inherently subjective. If any assumptions change, Ocugen&#x2019;s stock-based compensation expense could be materially different in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;These assumptions used in Ocugen&#x2019;s Black-Scholes option-pricing model are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Expected Term.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Due to the historical lack of a public market for the trading of Ocugen common stock and the lack of sufficient company-specific historical data, the expected term of employee options is determined using the &#x201c;simplified&#x201d; method, as prescribed in Securities and Exchange Commission&#x2019;s Staff Accounting Bulletin No. 107 (&#x201c;SAB&#160;No.&#160;107&#x201d;), whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option. The expected term of non-employee options is equal to the contractual term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Expected Volatility.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; The expected volatility is based on historical volatilities of Ocugen and similar entities within Ocugen&#x2019;s industry for periods commensurate with the expected term assumption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Risk-Free Interest Rate.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Expected Dividends.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; The expected dividend yield is 0% because Ocugen has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfNzY5NjU4MTQxODYyNQ_5fbeff23-7f34-42dc-8ad9-c85d77b9ca7b">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i6258e5af615841ca8ed08b5fc6e64f13_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfNDM5ODA0NjUyNjEzNg_876281f9-d8c9-4da8-bd3c-99625a9ed41c"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTcwNDI0MzAyNTQwMjc_25e730c2-bef5-4777-a238-1528597aef23">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is a Delaware C-Corporation. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, is applied during the years in which temporary differences are expected to be settled and is reflected in the financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on the weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. The Company&#x2019;s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. No interest or penalty expense was recognized during the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has assessed and concluded that there are uncertain tax positions giving rise to the unrecognized tax benefits as of December&#160;31, 2019. The Company&#x2019;s conclusions regarding uncertain tax positions may be subject to review and adjustment at a later date based upon ongoing analysis of tax laws, regulations and interpretations thereof, as well as other factors. Generally, federal, state, and local authorities may examine the Company&#x2019;s tax returns for three years from the date of the filing and the current and prior three years remain subject to examination as of December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTcwNDI0MzAyNTQwMjg_5f1c630e-63d8-42af-a3ee-3695bdcefb27">Segment InformationThe Company views its operations and manages its business as one operating segment, which is the development of innovative therapies to address the whole eye.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTcwNDI0MzAyNTQwNTg_88c2cdb5-b19f-4ba8-bf5f-44997693e60f"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTcwNDI0MzAyNTQwMjk_e081168c-3d22-4108-842f-715ec885a093">&lt;div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In February&#160;2016, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;)&#160;No.&#160;2016-02,&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASC 842&#x201d;). In July&#160;2018, the FASB issued ASU&#160;No.&#160;2018-10,&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Codification Improvements to Topic 842, Leases&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASU&#160;2018-10&#x201d;),&#160;which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU&#160;No.&#160;2018-11,&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;(Topic 842)&#x2014;Targeted Improvements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASU&#160;2018-11&#x201d;),&#160;which addressed implementation issues related to the new lease standard. These and certain other lease-related ASUs have generally been codified in ASC 842. ASC 842 supersedes the lease accounting requirements in ASC Topic 840, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASC 840&#x201d;). ASC 842 establishes a&#160;right-of-use&#160;model that requires a lessee to record a&#160;right-of-use&#160;(&#x201c;ROU&#x201d;) asset and a lease liability on the balance sheet for all leases. Under ASC 842, leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The standard also requires disclosures to help investors and other financial statement users better understand the amount, timing and uncertainty of cash flows arising from leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company adopted ASC 842 on January&#160;1, 2019 using the effective date transition method. Prior period results continue to be presented under ASC 840 based on the accounting standards originally in effect for such periods. The Company has elected certain practical expedients permitted under the transition guidance within ASC 842 to leases that commenced before January&#160;1, 2019, including the package of practical expedients. The election of the package of practical expedients resulted in the Company not reassessing prior conclusions under ASC 840 related to lease identification, lease classification and initial direct costs for expired and existing leases prior to January&#160;1, 2019. The adoption of ASU&#160;2016-02&#160;did not have a significant impact on the Company&#x2019;s consolidated results of operations or cash flows. Upon adoption, the Company recognized an ROU asset and lease liability of $0.4 million and $0.4 million, respectively. See Note 9 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the FASB issued ASU No. 2018-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Fair Value Measurement (Topic 820): Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. This standard modifies certain disclosure requirements on fair value measurements and was effective for the Company on January 1, 2020. The adoption of this standard will not have a material impact on the Company's disclosures.&lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2023. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The Company does not expect the adoption of these standards to have a material impact on its consolidated financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <ocgn:LeaseRightOfUseAsset
      contextRef="i7860a6ea500e471894ae9e509085cdf6_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTA5OTUxMTY0ODYwOA_4fa1f3f7-6a42-48f3-8816-792e4b9af969"
      unitRef="usd">400000</ocgn:LeaseRightOfUseAsset>
    <ocgn:LeaseLiability
      contextRef="i7860a6ea500e471894ae9e509085cdf6_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV80Ni9mcmFnOmFhNmNkY2NjMDhlYjQyNWFiYmJkYmI4MzQ4Y2NlNGU4L3RleHRyZWdpb246YWE2Y2RjY2MwOGViNDI1YWJiYmRiYjgzNDhjY2U0ZThfMTA5OTUxMTY0ODYxNQ_46d28164-38b8-48c6-9cdd-9b94fc3f3cff"
      unitRef="usd">400000</ocgn:LeaseLiability>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfMTcwNDI0MzAyNDIzMDM_76fe7296-f7f5-4840-b58b-01e284cd9f27">Merger and Pre-Merger Financing&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Pre-Merger Financing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June&#160;2019, Former Ocugen and Histogenics entered into a Securities Purchase Agreement (as amended, the &#x201c;Financing SPA&#x201d;) with certain accredited investors (the &#x201c;Investors&#x201d;). Pursuant to the Financing SPA, among other things, (i)&#160;immediately prior to the Merger, Former Ocugen issued 4.6 million shares of common stock to the Investors (the &#x201c;Initial Shares&#x201d; and, as converted pursuant to the exchange rate in the Merger into the right to receive approximately 2.2 million shares the Company&#x2019;s common stock, the &#x201c;Converted Initial Shares&#x201d;), (ii)&#160;immediately prior to the Merger, Former Ocugen issued and deposited 4.6&#160;million shares of common stock into escrow on behalf of the Investors (the &#x201c;Additional Shares&#x201d; and, as converted pursuant to the exchange rate in the Merger, into the right to receive approximately 2.2 million shares of the Company&#x2019;s common stock, the &#x201c;Converted Additional Shares&#x201d;) and (iii)&#160;the Company agreed to issue, on the fifth trading day following the consummation of the Merger, three series of warrants to purchase shares of the Company&#x2019;s common stock (the &#x201c;Series&#160;A Warrants,&#x201d; the &#x201c;Series&#160;B Warrants&#x201d; and the &#x201c;Series&#160;C Warrants&#x201d; and collectively, the &#x201c;Pre-Merger Financing Warrants&#x201d;) in exchange for an aggregate purchase price of $25.0 million (&#x201c;Pre-Merger Financing&#x201d;). See Note 10 for additional information on the Pre-Merger Financing Warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On October 4, 2019, the Converted Additional Shares were released from escrow to the investors because, as determined at the close of business on October 2, 2019, 80% of the volume-weighted average trading price of a share of Ocugen&#x2019;s common stock as quoted on Nasdaq for the first &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfMTcwNDI0MzAyNDIzMTA_2a410e8c-05ba-4258-a80a-5a97f417ce2a"&gt;three&lt;/span&gt; trading days immediately following the closing date of the Pre-Merger Financing was lower than the price paid by the Investors for the Initial Shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Approximately $2.5 million of the $25.0 million Pre-Merger Financing was utilized to pay transaction costs related to the Merger and the Pre-Merger Financing in the form of equity. In addition, the Company utilized $5.3&#160;million of the Pre-Merger &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Financing for the repayment of the Senior Secured Notes, as defined in Note 7. As a result, the Company received total net proceeds of $17.2 million from the Pre-Merger Financing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company incurred $1.9 million in equity issuance costs related to the Pre-Merger Financing, of which $0.7 million was paid in cash and $1.2 million was paid with equity as of December&#160;31, 2019. Approximately $1.1 million of equity issuance costs was allocated to the Series&#160;A Warrants and Series&#160;C Warrants and is included in additional paid-in capital. Approximately $0.8 million of issuance costs allocated to the Series&#160;B Warrant liability was expensed and is reflected in other income (expense) on the consolidated statements of operations and comprehensive loss for the year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Merger with Histogenics&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On September&#160;27, 2019, the Company completed the Merger in accordance with the terms of the Merger Agreement. The Merger was structured as a stock-for-stock transaction whereby all of Former Ocugen&#x2019;s outstanding shares of common stock and securities convertible into or exercisable for Former Ocugen&#x2019;s common stock were converted into the right to receive Histogenics&#x2019; common stock and securities convertible into or exercisable for Histogenics&#x2019; common stock. Immediately following the Merger, the former equity holders of Former Ocugen owned 84.25% of the outstanding capital stock of the Company, and the equity holders of the Company immediately before the Merger owned 15.75% of the outstanding capital stock of the Company, including the Initial Shares but excluding the Additional Shares and the Pre-Merger Financing Warrants pursuant to the Financing SPA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In accordance with ASC Topic 805, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Business Combinations&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASC 805&#x201d;)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; the Company concluded that, while Histogenics is the legal acquirer, Former Ocugen is the accounting acquirer due to the fact that (i)&#160;Former Ocugen&#x2019;s shareholders have the majority of the voting rights in Ocugen, (ii)&#160;Former Ocugen holds all of the board seats of the combined company and (iii)&#160;Former Ocugen management holds all key positions in the management of the combined company. The Company has further concluded that Histogenics does not meet the definition of a business under ASC 805 due to the fact that substantially all of the fair value of the gross assets disposed of is concentrated in a single identifiable asset or a group of similar identifiable assets. Therefore, the Merger was accounted for as a reverse asset acquisition. The Company incurred $4.9 million in transaction costs related to the Merger, of which $2.6 million was paid in cash and $2.3 million was paid with equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;margin-bottom:15pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Assets and liabilities of Histogenics on September&#160;27, 2019 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;September 27,&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,106)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Asset Held for Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the Merger, on May&#160;8, 2019, Histogenics entered into an asset purchase agreement (the &#x201c;Asset Purchase Agreement&#x201d;) with Medavate Corp., a Colorado corporation (&#x201c;Medavate&#x201d;), pursuant to which Histogenics agreed to sell substantially all of its assets relating to its NeoCart&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; program, including, without limitation, intellectual property, business and license agreements and clinical trial data (the &#x201c;Assets&#x201d;) in return for a cash payment of $6.5 million. On September&#160;26, 2019, the parties entered into an amendment to the Asset Purchase Agreement whereby the closing date was amended to October&#160;4, 2019. On October&#160;4, 2019, the parties entered into a second amendment (the &#x201c;Second Amendment&#x201d;) to the Asset Purchase Agreement whereby the purchase price was increased to $7.0&#160;million under the Asset Purchase Agreement and the closing date of the Asset Purchase Agreement was revised from October&#160;4, 2019 to two business days after Medavate obtains financing in an amount no less than the purchase price (the &#x201c;Closing Date&#x201d;). The Second Amendment further provides that if the Closing Date does not occur on or prior to October&#160;31, 2019, Ocugen may choose to terminate the Asset Purchase Agreement without recourse and, if Ocugen does not terminate the Asset Purchase Agreement, the purchase price shall increase 10% per month (or any portion thereof) between October&#160;31, 2019 and the Closing Date. The Closing Date did not occur as of December&#160;31, 2019, Ocugen has not terminated the Asset Purchase Agreement and as of December&#160;31, 2019, the purchase price has increased to $8.5 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The NeoCart&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; asset qualified as held for sale as of the date of the reverse asset acquisition and is carried at its original fair value less cost to sell on the consolidated balance sheet as of December&#160;31, 2019. The NeoCart&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; asset held for sale was valued at the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;acquisition date based on a quoted price of $7.0 million, which is an observable Level 2 fair value input. Subsequent increases in fair value are not recognized beyond the initial value at the time the asset was classified as held for sale. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;MEDINET Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December&#160;2017, Histogenics entered into the License and Commercialization Agreement (the &#x201c;License Agreement&#x201d;) with MEDINET Co.,&#160;Ltd. (&#x201c;MEDINET&#x201d;) to grant MEDINET a license under certain patents, patent applications, know-how, and technology to develop and commercialize certain therapeutic products related to the NeoCart&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; program. As consideration for the granting of the license, MEDINET agreed to pay Histogenics a non-refundable upfront cash payment of $10.0 million which was received in January&#160;2018. Based on the results of the NeoCart&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; research, Histogenics suspended the NeoCart&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; program. Subsequently, since MEDINET relied on the NeoCart&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; product to supply clinical trial patients, MEDINET suspended the development of its clinical trial. As of December&#160;31, 2019, the contract with MEDINET was wholly unperformed. As a result of the expected sale of the NeoCart&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; asset, the Company does not expect to retain any future obligations related to the MEDINET agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <ocgn:NumberOfSharesAgreedToIssuePriorToMergerToInvestors
      contextRef="i5010aa0712c74ac685012c6d136ca792_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNjA0NzMxMzk1OTc5NA_a701df6b-93a4-4d1e-9711-3c0ed3d532c0"
      unitRef="shares">4600000</ocgn:NumberOfSharesAgreedToIssuePriorToMergerToInvestors>
    <ocgn:NumberOfConvertedInitialSharesAgreedToIssuePriorToMergerToInvestors
      contextRef="idfbc6400eef840d6b17bcf600923cbfa_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNjA0NzMxMzk1OTgyNQ_e0ee659d-1f82-4aea-a567-d517076855dd"
      unitRef="shares">2200000</ocgn:NumberOfConvertedInitialSharesAgreedToIssuePriorToMergerToInvestors>
    <ocgn:NumberOfSharesAgreedToIssuePriorToMergerToInvestors
      contextRef="i5010aa0712c74ac685012c6d136ca792_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNzE0NjgyNTU5NDc5OA_3097c9a1-75ce-4b2d-844d-9d6f46fd81a7"
      unitRef="shares">4600000</ocgn:NumberOfSharesAgreedToIssuePriorToMergerToInvestors>
    <ocgn:NumberOfConvertedAdditionalSharesAgreedToIssuePriorToMergerToInvestors
      contextRef="idfbc6400eef840d6b17bcf600923cbfa_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNjA0NzMxMzk1OTgzMA_65bb7757-aa09-45fa-8508-925b0b9bd3df"
      unitRef="shares">2200000</ocgn:NumberOfConvertedAdditionalSharesAgreedToIssuePriorToMergerToInvestors>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="idfbc6400eef840d6b17bcf600923cbfa_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNjA0NzMxMzk1OTg1OQ_bed313c5-5692-497b-b32c-c5ad4c02b7d1"
      unitRef="usd">25000000.0</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <ocgn:ConvertedAdditionalSharesThresholdReleaseTrigger
      contextRef="if83d8a8656604b6494f17eff209a905f_I20191004"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfMTcwNDI0MzAyNDIzMDY_a54ec2e7-4adc-4aa5-9d95-3e18b2eb04a8"
      unitRef="number">0.80</ocgn:ConvertedAdditionalSharesThresholdReleaseTrigger>
    <ocgn:MergerAcquisitionCostsIncurred
      contextRef="idfbc6400eef840d6b17bcf600923cbfa_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfMTA5OTUxMTYzOTk2NA_b8d28659-d26c-446e-9842-b82f348cf313"
      unitRef="usd">2500000</ocgn:MergerAcquisitionCostsIncurred>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="idfbc6400eef840d6b17bcf600923cbfa_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfMTA5OTUxMTYzOTk3NA_bed313c5-5692-497b-b32c-c5ad4c02b7d1"
      unitRef="usd">25000000.0</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i3a90ecac0c074f6aa909c9426321c8d8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNzY5NjU4MTQwODkyNw_1d5182a9-5781-42a7-91af-78ddc1e00cae"
      unitRef="usd">5300000</us-gaap:RepaymentsOfSeniorDebt>
    <ocgn:NetProceedsFromReverseMerger
      contextRef="idfbc6400eef840d6b17bcf600923cbfa_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfMTA5OTUxMTY0MDI5Ng_0a4cb066-10bf-43b7-92c8-168b6ee5e67a"
      unitRef="usd">17200000</ocgn:NetProceedsFromReverseMerger>
    <ocgn:StockIssuanceCostsRecognized
      contextRef="i342cd331097f4691b9092a11b982313e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfMTcwOQ_5318218d-f0f8-4743-8a6f-347e7588841c"
      unitRef="usd">1900000</ocgn:StockIssuanceCostsRecognized>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i342cd331097f4691b9092a11b982313e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfMTc4Mw_49f29947-b935-48b9-aab9-2f1e8c10de2f"
      unitRef="usd">700000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i342cd331097f4691b9092a11b982313e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfMTgwNw_707a14e6-dbd1-452b-a6ec-ad99b9b4f0ec"
      unitRef="usd">1200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <ocgn:StockIssuanceCostsRecognized
      contextRef="i08a49a87c9214a5188152f75514c346b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfMTg1NQ_ddda33bc-d51a-449e-9991-13f0b36cebaf"
      unitRef="usd">1100000</ocgn:StockIssuanceCostsRecognized>
    <ocgn:StockIssuanceCostsRecognized
      contextRef="i6de30431b0884e779b449c2552d931fc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfMjAwNQ_abca7019-5411-4fbf-824f-49c7b668ebde"
      unitRef="usd">800000</ocgn:StockIssuanceCostsRecognized>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i1cc6e7cd4ebb41879dbbbd27370e6258_I20190927"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNjA0NzMxMzk2MDA0Mw_f2fdde73-63b3-4d2f-8800-21a383f453c4"
      unitRef="number">0.8425</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="ib33a77518a874faaa0e86a954580e035_I20190926"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNjA0NzMxMzk2MDA1MQ_d996c4c5-531a-49a7-9f9b-0ced6e3cd912"
      unitRef="number">0.1575</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i2c96e6e4a1ec48b79500273ba5fd55e8_D20190927-20190927"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfMzk1NA_40a04b48-dfce-49c2-8d40-d23462258fc4"
      unitRef="usd">4900000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:PaymentsForMergerRelatedCosts
      contextRef="i2c96e6e4a1ec48b79500273ba5fd55e8_D20190927-20190927"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNDAxMA_2aae2566-ed41-4eb5-a5d8-1e432c225c30"
      unitRef="usd">2600000</us-gaap:PaymentsForMergerRelatedCosts>
    <ocgn:AdjustmentsToAdditionalPaidInCapitalMergerRelatedCosts
      contextRef="i2c96e6e4a1ec48b79500273ba5fd55e8_D20190927-20190927"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNDAzNA_b0badecb-f9b2-4fb7-b79c-ddf9f79b7cb5"
      unitRef="usd">2300000</ocgn:AdjustmentsToAdditionalPaidInCapitalMergerRelatedCosts>
    <us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfMTcwNDI0MzAyNDIzMDQ_1108e320-1c14-4dcd-ab83-454f5d0477b8">&lt;div style="margin-top:12pt;margin-bottom:15pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Assets and liabilities of Histogenics on September&#160;27, 2019 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;September 27,&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,106)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i233f75f6ffd24f2fbc2db0b32db4d667_I20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RhYmxlOmE3NDk3MTFlOTMxYzQ3MTI5MTY1YjRjMTk1NzRjYTk2L3RhYmxlcmFuZ2U6YTc0OTcxMWU5MzFjNDcxMjkxNjViNGMxOTU3NGNhOTZfMS0xLTEtMS0w_f8b44b66-2fa5-4e3c-a978-c8dc30bffbcf"
      unitRef="usd">302000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <ocgn:AssetsHeldForSale
      contextRef="i233f75f6ffd24f2fbc2db0b32db4d667_I20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RhYmxlOmE3NDk3MTFlOTMxYzQ3MTI5MTY1YjRjMTk1NzRjYTk2L3RhYmxlcmFuZ2U6YTc0OTcxMWU5MzFjNDcxMjkxNjViNGMxOTU3NGNhOTZfMi0xLTEtMS0w_518593d7-abc5-4c06-956b-0642eddf54bf"
      unitRef="usd">7000000</ocgn:AssetsHeldForSale>
    <us-gaap:AccountsPayableCurrent
      contextRef="i233f75f6ffd24f2fbc2db0b32db4d667_I20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RhYmxlOmE3NDk3MTFlOTMxYzQ3MTI5MTY1YjRjMTk1NzRjYTk2L3RhYmxlcmFuZ2U6YTc0OTcxMWU5MzFjNDcxMjkxNjViNGMxOTU3NGNhOTZfMy0xLTEtMS0w_f74c6172-f54e-4618-9818-b8566a6079c5"
      unitRef="usd">1106000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AssetsNet
      contextRef="i233f75f6ffd24f2fbc2db0b32db4d667_I20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RhYmxlOmE3NDk3MTFlOTMxYzQ3MTI5MTY1YjRjMTk1NzRjYTk2L3RhYmxlcmFuZ2U6YTc0OTcxMWU5MzFjNDcxMjkxNjViNGMxOTU3NGNhOTZfNC0xLTEtMS0w_9c618daa-bf7f-46f4-a223-70e2f63e4acd"
      unitRef="usd">6196000</us-gaap:AssetsNet>
    <ocgn:AssetPurchaseAgreementCashConsideration
      contextRef="i1089f8a8a43a48879ed876ae4de5115b_D20190508-20190508"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNjA0NzMxMzk2MDA5OA_082ed752-e033-437d-9ea2-bbc3c59863a2"
      unitRef="usd">6500000</ocgn:AssetPurchaseAgreementCashConsideration>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure
      contextRef="i22aaf4b1361c4ec7884cdd1e535ac03e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNzE0NjgyNTU5NDc5MQ_b96ca3b7-54c7-470c-a0ee-d1503bbab778"
      unitRef="usd">7000000.0</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <ocgn:PercentageOfIncreaseInPurchasePriceOfAssetPerMonth
      contextRef="id02b04cce6a9413aae504f8cfc956e2b_D20191004-20191004"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNjA0NzMxMzk2MDEwMQ_288e36b8-ebf2-4f2e-92a8-56d070dad531"
      unitRef="number">0.10</ocgn:PercentageOfIncreaseInPurchasePriceOfAssetPerMonth>
    <ocgn:AssetPurchaseAgreementCashConsideration
      contextRef="i7c31e84a90244ee78a2df7e88dca555a_D20191231-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNTQ5NzU1ODE1MDU1Mg_35713bf3-60b4-4bdc-81fe-07c7eeada624"
      unitRef="usd">8500000</ocgn:AssetPurchaseAgreementCashConsideration>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure
      contextRef="id4141b56122e4357bea6334ad7cbb7eb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNDM5ODA0NjUyMDk1NQ_d065de0f-b6e9-4113-b729-0680798c027d"
      unitRef="usd">7000000.0</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="i452b3f0c99ee4054a9b7492fcd19fe2a_D20180101-20180131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfNjA0NzMxMzk2MDEwNA_bbe3c919-1733-4c33-89de-6012fdf33cca"
      unitRef="usd">10000000.0</us-gaap:ProceedsFromLicenseFeesReceived>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RleHRyZWdpb246MjRhY2UyOTU0YzM2NDVjNTgyOTI1ZDVhODEwYzU5ZWVfMTcwNDI0MzAyMzI0MDE_8247c66c-e7d5-4d33-99c7-4e0f412afd07">Net Loss Per Share of Common Stock&lt;div style="margin-top:12pt;margin-bottom:15pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table sets forth the computation of basic and diluted earnings per share for the years ended December 31, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.175%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&#x2014;basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20,242,630)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(18,219,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares used in calculating net loss per common share&#x2014;basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,893,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,960,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss per common share&#x2014;basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.46)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3.67)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as their inclusion would have been antidilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.175%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;731,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;632,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;870,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;870,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Series&#160;A Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,771,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Series B Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Series&#160;C Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,375,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,502,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RleHRyZWdpb246MjRhY2UyOTU0YzM2NDVjNTgyOTI1ZDVhODEwYzU5ZWVfMTcwNDI0MzAyMzI0MDI_0ddad3f3-904c-4bba-8552-030f390c576c">&lt;div style="margin-top:12pt;margin-bottom:15pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table sets forth the computation of basic and diluted earnings per share for the years ended December 31, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.175%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&#x2014;basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20,242,630)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(18,219,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares used in calculating net loss per common share&#x2014;basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,893,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,960,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss per common share&#x2014;basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.46)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3.67)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjU5N2I1ZGUwNDRmOTQ5Yzg5ZjYwNDM5YmIzZjBjZTQ0L3RhYmxlcmFuZ2U6NTk3YjVkZTA0NGY5NDljODlmNjA0MzliYjNmMGNlNDRfMi01LTEtMS0w_8615bf1a-effe-4e5f-a5c0-d419a04a116a"
      unitRef="usd">-20242630</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjU5N2I1ZGUwNDRmOTQ5Yzg5ZjYwNDM5YmIzZjBjZTQ0L3RhYmxlcmFuZ2U6NTk3YjVkZTA0NGY5NDljODlmNjA0MzliYjNmMGNlNDRfMi01LTEtMS0w_d4e61df8-8f24-4569-bd34-aa5958a43635"
      unitRef="usd">-20242630</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjU5N2I1ZGUwNDRmOTQ5Yzg5ZjYwNDM5YmIzZjBjZTQ0L3RhYmxlcmFuZ2U6NTk3YjVkZTA0NGY5NDljODlmNjA0MzliYjNmMGNlNDRfMi03LTEtMS0w_299d6b7b-3874-4fe3-8b32-9b30f114356a"
      unitRef="usd">-18219664</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjU5N2I1ZGUwNDRmOTQ5Yzg5ZjYwNDM5YmIzZjBjZTQ0L3RhYmxlcmFuZ2U6NTk3YjVkZTA0NGY5NDljODlmNjA0MzliYjNmMGNlNDRfMi03LTEtMS0w_8f432abb-fe2b-44f3-afb7-5b36bc1cca99"
      unitRef="usd">-18219664</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjU5N2I1ZGUwNDRmOTQ5Yzg5ZjYwNDM5YmIzZjBjZTQ0L3RhYmxlcmFuZ2U6NTk3YjVkZTA0NGY5NDljODlmNjA0MzliYjNmMGNlNDRfNy0yLTEtMS00MjM4_065ceb63-e58e-498e-91ec-fa767e69bea7"
      unitRef="shares">13893819</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjU5N2I1ZGUwNDRmOTQ5Yzg5ZjYwNDM5YmIzZjBjZTQ0L3RhYmxlcmFuZ2U6NTk3YjVkZTA0NGY5NDljODlmNjA0MzliYjNmMGNlNDRfNy00LTEtMS00MjM4_571f48f2-e517-430d-94b0-23c7647ec5a6"
      unitRef="shares">4960552</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjU5N2I1ZGUwNDRmOTQ5Yzg5ZjYwNDM5YmIzZjBjZTQ0L3RhYmxlcmFuZ2U6NTk3YjVkZTA0NGY5NDljODlmNjA0MzliYjNmMGNlNDRfMTItMi0xLTEtNDI0OA_1aea2845-9d33-44a8-937d-dab26398187f"
      unitRef="usdPerShare">-1.46</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjU5N2I1ZGUwNDRmOTQ5Yzg5ZjYwNDM5YmIzZjBjZTQ0L3RhYmxlcmFuZ2U6NTk3YjVkZTA0NGY5NDljODlmNjA0MzliYjNmMGNlNDRfMTItNC0xLTEtNDI0OA_d103dbc5-ec34-4a07-8342-1cee5a51afaf"
      unitRef="usdPerShare">-3.67</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RleHRyZWdpb246MjRhY2UyOTU0YzM2NDVjNTgyOTI1ZDVhODEwYzU5ZWVfMTcwNDI0MzAyMzI0MDM_dcf85a1f-46f5-4aa9-8531-8d1d3fbd6a02">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as their inclusion would have been antidilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.175%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;731,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;632,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;870,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;870,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Series&#160;A Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,771,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Series B Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Series&#160;C Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,375,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,502,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib18c97e1d3e1439fa0756a1747c56510_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjgzZDViNzJhZmQyYTQ3NGE4ZjFjZWJiOTUzYjZhZDI1L3RhYmxlcmFuZ2U6ODNkNWI3MmFmZDJhNDc0YThmMWNlYmI5NTNiNmFkMjVfMi01LTEtMS0w_cd61c55d-8816-427e-9f3c-52fa0c7074dc"
      unitRef="shares">731189</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i702dd84e91b44b20bc3d8cb7ca9e4a59_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjgzZDViNzJhZmQyYTQ3NGE4ZjFjZWJiOTUzYjZhZDI1L3RhYmxlcmFuZ2U6ODNkNWI3MmFmZDJhNDc0YThmMWNlYmI5NTNiNmFkMjVfMi03LTEtMS0w_4039ff08-5037-4083-a325-6ba2e6e6e457"
      unitRef="shares">632752</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i477a58364a2b4532b86d564fdf1686e8_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjgzZDViNzJhZmQyYTQ3NGE4ZjFjZWJiOTUzYjZhZDI1L3RhYmxlcmFuZ2U6ODNkNWI3MmFmZDJhNDc0YThmMWNlYmI5NTNiNmFkMjVfMy01LTEtMS0w_196b6cb1-e74d-47bb-8e20-da6b643e34f4"
      unitRef="shares">870020</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1dedc44510f14e77b6d2358d6ebef9a1_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjgzZDViNzJhZmQyYTQ3NGE4ZjFjZWJiOTUzYjZhZDI1L3RhYmxlcmFuZ2U6ODNkNWI3MmFmZDJhNDc0YThmMWNlYmI5NTNiNmFkMjVfMy03LTEtMS0w_dcefe95b-2611-45f3-9c5a-c268f08e14db"
      unitRef="shares">870020</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i36f2d441406443dcaba60c36eab4f7b7_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjgzZDViNzJhZmQyYTQ3NGE4ZjFjZWJiOTUzYjZhZDI1L3RhYmxlcmFuZ2U6ODNkNWI3MmFmZDJhNDc0YThmMWNlYmI5NTNiNmFkMjVfNC01LTEtMS0w_0ed551eb-13ca-4bd6-9136-5eedf8b7855f"
      unitRef="shares">8771928</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifd5bb0da90474df78f52019d31b3061f_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjgzZDViNzJhZmQyYTQ3NGE4ZjFjZWJiOTUzYjZhZDI1L3RhYmxlcmFuZ2U6ODNkNWI3MmFmZDJhNDc0YThmMWNlYmI5NTNiNmFkMjVfNC03LTEtMS0w_d3471902-76e3-461f-a789-8fc4d84134f9"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i91c2dd8a64e34278b820002768b4bdae_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjgzZDViNzJhZmQyYTQ3NGE4ZjFjZWJiOTUzYjZhZDI1L3RhYmxlcmFuZ2U6ODNkNWI3MmFmZDJhNDc0YThmMWNlYmI5NTNiNmFkMjVfNS0xLTEtMS0xODY5MA_9b84bce0-ca53-432a-9369-66b3caec3385"
      unitRef="shares">1000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8e0464bba65447d099bca6eb5c866819_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjgzZDViNzJhZmQyYTQ3NGE4ZjFjZWJiOTUzYjZhZDI1L3RhYmxlcmFuZ2U6ODNkNWI3MmFmZDJhNDc0YThmMWNlYmI5NTNiNmFkMjVfNS0zLTEtMS0xODY4Ng_2064d9fe-02e7-4434-9140-65e1db7675b4"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i32196db366ca47dfb065bbc67d9993d9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjgzZDViNzJhZmQyYTQ3NGE4ZjFjZWJiOTUzYjZhZDI1L3RhYmxlcmFuZ2U6ODNkNWI3MmFmZDJhNDc0YThmMWNlYmI5NTNiNmFkMjVfNi01LTEtMS0w_2174275b-e88e-464c-91d6-fd61737784c9"
      unitRef="shares">1000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7a1acd90bf1a4186b62635f3f1291ee8_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjgzZDViNzJhZmQyYTQ3NGE4ZjFjZWJiOTUzYjZhZDI1L3RhYmxlcmFuZ2U6ODNkNWI3MmFmZDJhNDc0YThmMWNlYmI5NTNiNmFkMjVfNi03LTEtMS0w_05a4bb69-83dd-447d-8cd7-2df222ad0abf"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjgzZDViNzJhZmQyYTQ3NGE4ZjFjZWJiOTUzYjZhZDI1L3RhYmxlcmFuZ2U6ODNkNWI3MmFmZDJhNDc0YThmMWNlYmI5NTNiNmFkMjVfNy01LTEtMS0w_1d09b1d8-4a91-4508-b67a-d4b918d5e191"
      unitRef="shares">10375137</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81NS9mcmFnOjI0YWNlMjk1NGMzNjQ1YzU4MjkyNWQ1YTgxMGM1OWVlL3RhYmxlOjgzZDViNzJhZmQyYTQ3NGE4ZjFjZWJiOTUzYjZhZDI1L3RhYmxlcmFuZ2U6ODNkNWI3MmFmZDJhNDc0YThmMWNlYmI5NTNiNmFkMjVfNy03LTEtMS0w_b08cd20c-91a0-4528-88c7-10924a0c02a8"
      unitRef="shares">1502772</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfMTcwNDI0MzAyNDk4MTc_d787e5a4-4588-4f7b-834f-745ae337e401">License and Collaboration Agreements&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Co-Development and Commercialization Agreement with CanSino Biologics&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On September 27, 2019, Ocugen entered into a co-development and commercialization agreement (the &#x201c;CanSinoBIO Agreement&#x201d;) with CanSino Biologics Inc. (&#x201c;CanSinoBIO&#x201d;) with respect to the development and commercialization of the gene therapy product candidate, OCU400.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;CanSinoBIO will be responsible for all the costs for chemistry, manufacturing and control development and manufacture of clinical supplies of OCU400 for all territories. CanSinoBIO will be solely responsible for all costs and expenses of its development activities in and for China, Hong Kong, Macau, and Taiwan (the "CanSinoBIO Territory") and Ocugen will be responsible for all costs and expenses of its development activities for any global location outside the CanSinoBIO Territory (the "Ocugen Territory"). CanSinoBIO will pay to Ocugen an annual royalty between mid to high-single digits based on net sales of products in the CanSinoBIO Territory, and Ocugen will pay to CanSinoBIO an annual royalty between low to mid-single digits based on net sales of products in the Ocugen Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Unless terminated earlier, the CanSinoBIO Agreement will continue in force on a country-by-country and product-by-product basis until the later of (a) the expiration of the last valid claim of patent rights of Ocugen covering such product and (b)&#160;the tenth (10&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;th&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;) anniversary of the first commercial sale of such product in such country. The CanSinoBIO Agreement will also terminate upon the termination of the Exclusive License Agreement, dated December&#160;19, 2017, between Ocugen and Schepens Eye Research Institute, Inc. The CanSinoBIO Agreement may be terminated by either party in its entirety upon (a)&#160;a material breach of the Agreement by the other party, (b) a challenge by the other party or any of its affiliates of any intellectual property controlled by the terminating party or (c) bankruptcy or insolvency of the other party. Within forty-five (45) days after such termination, CanSinoBIO shall provide Ocugen with a statement of the CanSinoBIO development costs and, within one (1) year after receipt of such report, Ocugen shall reimburse CanSinoBIO all such CanSinoBIO development costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;License Agreement with the Schepens Eye Research Institute&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In 2017, the Company entered into a license agreement with The Schepens Eye Research Institute (&#x201c;SERI&#x201d;), which granted the Company an exclusive license to develop, commercialize, and continue to secure patents for OCU400 and OCU410. This agreement is accounted for as a collaborative arrangement. In connection with acquiring the license, the Company was required to pay a license fee of $0.1 million, which was recognized in 2017. The Company will also be required to reimburse SERI for all future patent costs related to this licensed technology.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is obligated to pay SERI up to $6.0 million upon the achievement of certain development and regulatory milestones. The Company is also obligated to pay SERI up to $10.1 million upon the achievement of certain commercial milestones. The Company will also pay SERI royalties in the low single digits based on net sales. No milestones or royalties were paid or incurred through December&#160;31, 2019, as the Company has not achieved any milestones, net sales or sublicensing under this agreement. The Company may cancel the license agreement at any time with 180 days&#x2019; written notice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In 2017, the Company also entered into a Sponsored Research Agreement with SERI under which the Company recognized approximately $0.6 million and $0.5 million as research and development expense for the year ended December 31, 2019 and 2018, respectively, for work performed under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;License Agreement with the University of Illinois&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In 2016, the Company entered into a license agreement with the University of Illinois at Chicago (&#x201c;UIC&#x201d;), which granted the Company an exclusive license to develop, commercialize and continue to secure patents for OCU300 and OCU310. In connection with acquiring the license for OCU300 and OCU310, the Company was required to pay a signing fee of $15,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is required to pay royalties in the low single digits to low teens to UIC based on net sales and sublicense revenues generated by OCU300 and OCU310. The Company is also required to pay minimum annual royalties to UIC, beginning with an annual payment of $20,000 on the third anniversary of the effective date of the agreement, and increasing gradually to $50,000 by the sixth anniversary and continuing through the term of the agreement. The Company is also obligated to pay UIC up to $1.3 million upon the achievement of certain development and regulatory milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During 2018, the Company incurred $0.3 million in milestone payments due to achieving a milestone associated with dosing the first patient in a Phase 3 clinical trial. The Company has not achieved any other milestones, net sales or sublicensing for OCU300 or OCU310. The Company may cancel the license agreement at any time with 90 days&#x2019; written notice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;License Agreement with the University of Colorado&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In 2014, the Company entered into a patent license agreement with the University of Colorado (&#x201c;CU&#x201d;), which granted the Company an exclusive license to develop and commercialize, and continue to secure patents for OCU200, including the ability to enforce any rights against infringement. Under the agreement, the Company assumed primary responsibility for preparing, filing and prosecuting broad patent claims for OCU200 for CU's benefit. Further, the Company assumed primary responsibility for all patent activities, including all costs associated with the perfection and maintenance of the patents for OCU200.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pursuant to the terms of the agreement, in exchange for the licensed patents, the Company issued CU 0.1 million shares of the Company&#x2019;s common stock. The agreement with CU, as amended in January 2017, obligates the Company to pay certain development and regulatory milestone fees of up to $1.5 million, royalties in the low single digits on net sales and royalties in the mid-teens on sublicense income of OCU200.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The agreement with CU calls for minimum annual royalty payments of $20,000, starting on the third anniversary of the agreement and on each annual anniversary thereafter, and after sales commence, increasing to a percentage rate in the mid-&lt;/span&gt;&lt;/div&gt;twenties of the previous year&#x2019;s royalty payment paid to CU, through the term of the agreement. Future annual royalties will be recognized in the years they are earned, per the license agreement. The Company may cancel the license agreement at any time with 60 days&#x2019; written notice.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ocgn:CollaborationAgreementTerm
      contextRef="i4d16882d4b4e40b5817ec2c99e0a487e_D20190927-20190927"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfMTcwNDI0MzAyNDk4MTk_a947cbd3-1684-477c-bd26-f4fc2082c080">P10Y</ocgn:CollaborationAgreementTerm>
    <ocgn:CollaborationAgreementTerminationDevelopmentCostStatement
      contextRef="i4d16882d4b4e40b5817ec2c99e0a487e_D20190927-20190927"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfMjE3MA_98e10d49-7625-4536-9a3d-1d0fdf345e3c">P45D</ocgn:CollaborationAgreementTerminationDevelopmentCostStatement>
    <ocgn:CollaborationAgreementTerminationDevelopmentCostPayment
      contextRef="i4d16882d4b4e40b5817ec2c99e0a487e_D20190927-20190927"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfMjMwNQ_972f599e-19b1-4a90-8c12-845d0c309f58">P1Y</ocgn:CollaborationAgreementTerminationDevelopmentCostPayment>
    <ocgn:LicenseAgreementPayment
      contextRef="i7ef76329772147dd8a1a1be7785f5e5d_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfNjA0NzMxMzk3MTM3NQ_e2a22ce5-7318-4467-814f-63740631951f"
      unitRef="usd">100000</ocgn:LicenseAgreementPayment>
    <ocgn:LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment
      contextRef="i7ef76329772147dd8a1a1be7785f5e5d_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfNjA0NzMxMzk3MTQwMw_1c70a498-ca50-4eca-837a-a35e78318409"
      unitRef="usd">6000000.0</ocgn:LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment>
    <ocgn:LicenseAgreementPotentialCommercialMilestonePayment
      contextRef="i7ef76329772147dd8a1a1be7785f5e5d_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfNjA0NzMxMzk3MTQxOA_de092887-0af7-4119-a3fa-8862dd4b7b10"
      unitRef="usd">10100000</ocgn:LicenseAgreementPotentialCommercialMilestonePayment>
    <ocgn:LicenseAgreementMilestonePayment
      contextRef="if76acb9aa16d490a90c7132533737b13_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfMTcwNDI0MzAyNDk4MjY_f3629a05-5af7-497f-b6d8-f1db8b9d9df1"
      unitRef="usd">0</ocgn:LicenseAgreementMilestonePayment>
    <us-gaap:PaymentsForRoyalties
      contextRef="if76acb9aa16d490a90c7132533737b13_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfMTcwNDI0MzAyNDk4MjY_ff897fc4-4c01-4a00-ae46-a7b7643d40bc"
      unitRef="usd">0</us-gaap:PaymentsForRoyalties>
    <ocgn:LicenseAgreementCancellationPeriodNotice
      contextRef="i7ef76329772147dd8a1a1be7785f5e5d_D20170101-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfMTcwNDI0MzAyNDk4MzU_286aeba6-d15e-4815-bf4c-c576e0c94cc3">P180D</ocgn:LicenseAgreementCancellationPeriodNotice>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if76acb9aa16d490a90c7132533737b13_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfNjA0NzMxMzk3MTQ0Mw_f819a7cc-4ad1-4fa1-80fa-1b57d6ffc4af"
      unitRef="usd">600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i827132cd7da14ed8ad14eae7babe9d17_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfNjA0NzMxMzk3MTQ0OQ_b50c5ae2-a926-4472-a85b-ea7c3fa654e1"
      unitRef="usd">500000</us-gaap:ResearchAndDevelopmentExpense>
    <ocgn:LicenseAgreementSigningFee
      contextRef="ieb5f12c395364ac0968b482475cd5720_D20160101-20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfNjA0NzMxMzk3MTQ5NQ_1ea06576-b390-4610-9ae4-8267cb9185ac"
      unitRef="usd">15000</ocgn:LicenseAgreementSigningFee>
    <ocgn:LicenseAgreementMinimumAnnualRoyaltyPayment
      contextRef="ibe9866f13f484211a602b7658ac319c6_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfNjA0NzMxMzk3MTUwNg_52d78a3d-40b8-4b14-89de-0dc78bf0b8b9"
      unitRef="usd">20000</ocgn:LicenseAgreementMinimumAnnualRoyaltyPayment>
    <ocgn:LicenseAgreementMinimumAnnualRoyaltyPayment
      contextRef="ie00ff0e528c242f698fe9a5810b936e6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfNjA0NzMxMzk3MTUxNw_895fa2cb-a935-4842-8d6b-03070cd476aa"
      unitRef="usd">50000</ocgn:LicenseAgreementMinimumAnnualRoyaltyPayment>
    <ocgn:LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment
      contextRef="ieb5f12c395364ac0968b482475cd5720_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfNjA0NzMxMzk3MTUzNA_cdfd4dee-fe73-46d6-8303-38aa1e56d07a"
      unitRef="usd">1300000</ocgn:LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment>
    <ocgn:LicenseAgreementMilestonePayment
      contextRef="i97535139e9054d88803d1577aa998142_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfNjA0NzMxMzk3MTU0NQ_c48b21f9-7a98-4ce2-98ab-62ad4c3694f0"
      unitRef="usd">300000</ocgn:LicenseAgreementMilestonePayment>
    <ocgn:LicenseAgreementCancellationPeriodNotice
      contextRef="i97535139e9054d88803d1577aa998142_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfMTcwNDI0MzAyNDk4NDg_3f178380-b01f-46b3-acb3-b240ce16c61f">P90D</ocgn:LicenseAgreementCancellationPeriodNotice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i84c4c1d32cc746778f6f4ffed31a2f12_D20140101-20141231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfNjA0NzMxMzk3MTU1Nw_8a4f0b78-1c53-4342-84ea-bf6c982f86d2"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <ocgn:LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment
      contextRef="i5fdb2024e3e04b00afbe628fe94fc6a1_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfNjA0NzMxMzk3MTU3Mw_5a623433-dfd4-4da7-a092-6c9bb9c92393"
      unitRef="usd">1500000</ocgn:LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment>
    <ocgn:LicenseAgreementMinimumAnnualRoyaltyPayment
      contextRef="i5fdb2024e3e04b00afbe628fe94fc6a1_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfNjA0NzMxMzk3MTU4Mg_62004db9-c9c4-4bd1-9023-3eda5a98aa40"
      unitRef="usd">20000</ocgn:LicenseAgreementMinimumAnnualRoyaltyPayment>
    <ocgn:LicenseAgreementCancellationPeriodNotice
      contextRef="i84c4c1d32cc746778f6f4ffed31a2f12_D20140101-20141231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82MS9mcmFnOjA5MGU3MjBmMTYwZjRiNjViZjQ4MDIyODM0YmQ1YjYyL3RleHRyZWdpb246MDkwZTcyMGYxNjBmNGI2NWJmNDgwMjI4MzRiZDViNjJfMTcwNDI0MzAyNDk4NjA_c27ebc9c-bfc3-44f0-a6c4-03af3bc0cb6c">P60D</ocgn:LicenseAgreementCancellationPeriodNotice>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RleHRyZWdpb246NzViNTQxNmJhYjA2NDJiYWI4ZDAzYjNkYTljNTY0OWJfMTcwNDI0MzAyMzA2NTI_62288d30-7f2c-44f5-83d1-7d9f5084ab0a">Accrued Expenses&lt;div style="margin-top:12pt;margin-bottom:15pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accrued Expenses are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.175%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research&#160;and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;271,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;705,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;421,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;469,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Consulting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;98,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;86,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employee-related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;624,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;123,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Legal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;819,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,270,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,402,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RleHRyZWdpb246NzViNTQxNmJhYjA2NDJiYWI4ZDAzYjNkYTljNTY0OWJfMTcwNDI0MzAyMzA2NTM_ac035f46-ced9-4199-b6ca-92009192c9d9">&lt;div style="margin-top:12pt;margin-bottom:15pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accrued Expenses are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.175%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research&#160;and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;271,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;705,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;421,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;469,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Consulting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;98,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;86,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employee-related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;624,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;123,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Legal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;819,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,270,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,402,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <ocgn:ResearchAndDevelopmentExpensesCurrent
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RhYmxlOmQzY2YzNzNhZDQ3MDQ2NGNiODUzOWNhNWFjYzEwNWRhL3RhYmxlcmFuZ2U6ZDNjZjM3M2FkNDcwNDY0Y2I4NTM5Y2E1YWNjMTA1ZGFfMi0xLTEtMS0w_8c925162-c0c4-436a-a2da-8acfc7b910e2"
      unitRef="usd">271322</ocgn:ResearchAndDevelopmentExpensesCurrent>
    <ocgn:ResearchAndDevelopmentExpensesCurrent
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RhYmxlOmQzY2YzNzNhZDQ3MDQ2NGNiODUzOWNhNWFjYzEwNWRhL3RhYmxlcmFuZ2U6ZDNjZjM3M2FkNDcwNDY0Y2I4NTM5Y2E1YWNjMTA1ZGFfMi0zLTEtMS0w_adab105f-18c6-4917-87db-b8649e20a688"
      unitRef="usd">705436</ocgn:ResearchAndDevelopmentExpensesCurrent>
    <ocgn:AccountsPayableClinical
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RhYmxlOmQzY2YzNzNhZDQ3MDQ2NGNiODUzOWNhNWFjYzEwNWRhL3RhYmxlcmFuZ2U6ZDNjZjM3M2FkNDcwNDY0Y2I4NTM5Y2E1YWNjMTA1ZGFfMy0xLTEtMS0w_49244e81-2183-4041-885d-f90ebcf43e24"
      unitRef="usd">421788</ocgn:AccountsPayableClinical>
    <ocgn:AccountsPayableClinical
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RhYmxlOmQzY2YzNzNhZDQ3MDQ2NGNiODUzOWNhNWFjYzEwNWRhL3RhYmxlcmFuZ2U6ZDNjZjM3M2FkNDcwNDY0Y2I4NTM5Y2E1YWNjMTA1ZGFfMy0zLTEtMS0w_753bd675-7316-4684-8f2b-3f44deb54d1a"
      unitRef="usd">469473</ocgn:AccountsPayableClinical>
    <ocgn:AccountsPayableConsulting
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RhYmxlOmQzY2YzNzNhZDQ3MDQ2NGNiODUzOWNhNWFjYzEwNWRhL3RhYmxlcmFuZ2U6ZDNjZjM3M2FkNDcwNDY0Y2I4NTM5Y2E1YWNjMTA1ZGFfNC0xLTEtMS0w_e41d1249-a0fe-4a90-a5c7-8f2d93b6f24e"
      unitRef="usd">98245</ocgn:AccountsPayableConsulting>
    <ocgn:AccountsPayableConsulting
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RhYmxlOmQzY2YzNzNhZDQ3MDQ2NGNiODUzOWNhNWFjYzEwNWRhL3RhYmxlcmFuZ2U6ZDNjZjM3M2FkNDcwNDY0Y2I4NTM5Y2E1YWNjMTA1ZGFfNC0zLTEtMS0w_a5b50b1c-67dc-4b68-ba01-85feab1ebdaf"
      unitRef="usd">86619</ocgn:AccountsPayableConsulting>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RhYmxlOmQzY2YzNzNhZDQ3MDQ2NGNiODUzOWNhNWFjYzEwNWRhL3RhYmxlcmFuZ2U6ZDNjZjM3M2FkNDcwNDY0Y2I4NTM5Y2E1YWNjMTA1ZGFfNS0xLTEtMS0w_3ee10981-dc6e-4547-9a4a-5e08352c3d03"
      unitRef="usd">624420</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RhYmxlOmQzY2YzNzNhZDQ3MDQ2NGNiODUzOWNhNWFjYzEwNWRhL3RhYmxlcmFuZ2U6ZDNjZjM3M2FkNDcwNDY0Y2I4NTM5Y2E1YWNjMTA1ZGFfNS0zLTEtMS0w_e3037479-40f2-4a42-8bfe-7651e91aaac9"
      unitRef="usd">123372</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RhYmxlOmQzY2YzNzNhZDQ3MDQ2NGNiODUzOWNhNWFjYzEwNWRhL3RhYmxlcmFuZ2U6ZDNjZjM3M2FkNDcwNDY0Y2I4NTM5Y2E1YWNjMTA1ZGFfNi0xLTEtMS0w_df6150f7-bd6d-423c-af34-bc6742b421af"
      unitRef="usd">819323</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RhYmxlOmQzY2YzNzNhZDQ3MDQ2NGNiODUzOWNhNWFjYzEwNWRhL3RhYmxlcmFuZ2U6ZDNjZjM3M2FkNDcwNDY0Y2I4NTM5Y2E1YWNjMTA1ZGFfNi0zLTEtMS0w_efbaed48-423a-4389-bed5-dc3f8aec58d2"
      unitRef="usd">15400</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RhYmxlOmQzY2YzNzNhZDQ3MDQ2NGNiODUzOWNhNWFjYzEwNWRhL3RhYmxlcmFuZ2U6ZDNjZjM3M2FkNDcwNDY0Y2I4NTM5Y2E1YWNjMTA1ZGFfNy0xLTEtMS00OTI4_0bf16330-e034-47ff-879a-0a0e79def435"
      unitRef="usd">34947</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RhYmxlOmQzY2YzNzNhZDQ3MDQ2NGNiODUzOWNhNWFjYzEwNWRhL3RhYmxlcmFuZ2U6ZDNjZjM3M2FkNDcwNDY0Y2I4NTM5Y2E1YWNjMTA1ZGFfNy0zLTEtMS00OTI4_0a1dd32b-da1b-46e7-96f1-cab9c5b50e17"
      unitRef="usd">2450</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RhYmxlOmQzY2YzNzNhZDQ3MDQ2NGNiODUzOWNhNWFjYzEwNWRhL3RhYmxlcmFuZ2U6ZDNjZjM3M2FkNDcwNDY0Y2I4NTM5Y2E1YWNjMTA1ZGFfOC0xLTEtMS00OTI4_a3536ff9-770c-4ca2-86eb-9c448431bd37"
      unitRef="usd">2270045</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV82Ny9mcmFnOjc1YjU0MTZiYWIwNjQyYmFiOGQwM2IzZGE5YzU2NDliL3RhYmxlOmQzY2YzNzNhZDQ3MDQ2NGNiODUzOWNhNWFjYzEwNWRhL3RhYmxlcmFuZ2U6ZDNjZjM3M2FkNDcwNDY0Y2I4NTM5Y2E1YWNjMTA1ZGFfOC0zLTEtMS00OTI4_bf761481-07ea-4f02-a179-849967397728"
      unitRef="usd">1402750</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMTUzOTMxNjI4MTc5MDA_a2102107-0b3e-4158-ae03-a3d1b50da847">Debt&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;EB-5 Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In September&#160;2016, pursuant to the U.S. government&#x2019;s Immigrant Investor Program, commonly known as the EB-5 program (the &#x201c;EB-5 Program&#x201d;), the Company entered into an arrangement (the &#x201c;EB-5 Loan Agreement&#x201d;) to borrow up to $10.0 million from EB5 Life Sciences,&#160;L.P. (the &#x201c;Lender&#x201d;) in $0.5 million increments. Borrowing may be limited by the amount of funds raised by the Lender and are subject to certain job creation requirements by the Company. Borrowings are at a fixed interest rate of 4.0% per annum and are to be utilized in the clinical development, manufacturing, and commercialization of the Company&#x2019;s products and for the general working capital needs of the Company. Outstanding borrowings pursuant to the EB-5 Program, including accrued interest, become due upon the seventh anniversary of the final disbursement. Amounts repaid cannot be re-borrowed. The EB-5 note is secured by substantially all assets of the Company, except for any patents, patent applications, pending patents, patent license, patent sublicense, trademarks, and other intellectual property rights.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;In 2016, $1.0 million was borrowed by the Company. Issuance costs for these borrowings totaled $0.1 million, which was recognized as a reduction to the loan balance and is amortized to interest expense over the term of the loan. See Note 12 for information regarding events subsequent to December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.175%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Principal outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Plus: accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;127,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;87,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(55,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(70,495)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Carrying value of debt&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,072,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,016,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the years ended December&#160;31, 2019 and 2018, the Company issued convertible notes (the &#x201c;Notes&#x201d;) to new and existing stockholders in the Company, including Notes in the aggregate principal amount of $3.5 million to members of the Board of Directors. As of December&#160;31, 2019, all Notes had been converted and were no longer outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;margin-bottom:15pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At issuance, the following amounts were recorded:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.052%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:35.290%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.220%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.408%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.220%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.408%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.220%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.408%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.226%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Note&#160;Issuance&#160;Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Note&lt;br/&gt;Principal&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&#160;Value&#160;of&lt;br/&gt;Embedded Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Debt&lt;br/&gt;Issuance&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Carrying Value upon Issuance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,657,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(35,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,306,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(724,216)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;272,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;November 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,150,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(21,127)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(50,646)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,078,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,857)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(14,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;132,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;450,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(182,882)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(29,358)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;237,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;February 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(302,379)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(55,875)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;641,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,750,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,891,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(189,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,670,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;All Notes accrued interest at a rate of 5% per annum and had scheduled maturity dates on the eighteen month anniversary of the date of the issuance of the Notes (the &#x201c;Maturity Date&#x201d;). If prior to the Maturity Date, there was a consummation of the sale of all or substantially all of the assets of the Company, change in control or event of default, the Notes would become due and payable at an amount equal to 1.5 times the principal amount of the Notes together with all accrued interest (the &#x201c;Change in Control Feature&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;If the Company received equity financing from the issuance of stock of the Company from an investor or group of investors in a transaction or series of related transactions above a certain amount of gross proceeds, the principal amount and all interest accrued but not paid through the closing date of the qualified equity financing was to automatically convert into the same class of equity securities as those issued in the qualified equity financing ("conversion feature"). The price per share varied among the Notes ranging from a 0% to 30% discount to the lowest price per share being paid by investors in the qualified equity financing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company bifurcated the Conversion Feature for the January&#160;2018, June&#160;2018, January&#160;2019, and February&#160;2019 notes and classified it as a derivative liability because the Conversion Feature does not have a fixed conversion price and conversion will be settled in a variable number of shares of common stock. There was no bifurcated Conversion Feature for the November&#160;2018 and December 2018 notes as there is no discount to the lowest equity price triggering conversion. The Company also bifurcated the Change in Control Feature for all of the Notes because it was determined to be a redemption feature not clearly and closely related to the debt host. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of both of the embedded features was accounted for as a derivative liability and was recorded as a discount on the Notes. Inputs used in valuation were unobservable and therefore considered Level 3 in the fair value hierarchy. The debt discount is accreted into interest expense over the expected time until conversion of the Notes. The accretion amounted to $0.6 million and $3.4 million, for the year ended December 31, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;margin-bottom:15pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of the embedded features was classified as a liability in the Company&#x2019;s consolidated balance sheets at issuance, with subsequent changes in fair value during the year ended December 31, 2019 and 2018 recorded on the Company&#x2019;s consolidated statements of operations and comprehensive loss as a change in fair value of derivative liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:82.795%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.621%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Balance at January 1, 2018 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Fair value of embedded derivatives at issuance &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,405,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Change in fair value of embedded derivatives &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,664,689)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Balance at December 31, 2018 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,741,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Fair value of embedded derivatives at issuance &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;567,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Change in fair value of embedded derivatives &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,319,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Conversion and extinguishment of debt &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,628,283)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Balance at December 31, 2019 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company considered several possible outcomes in the likelihood and timing of a qualified equity financing and/or a change in control occurring that would trigger conversion or redemption and believes the amounts disclosed above based on inputs utilized in the valuation were the best estimates at each valuation date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On April 5, 2019, Former Ocugen entered into a Stock Subscription Agreement (&#x201c;Subscription Agreement&#x201d;) with existing investors for the sale of 0.1 million shares of common stock for $1.0 million, or $12.41 per share including the sale of 40,286 shares of common stock for $0.5 million to a member of the Board of Directors. This capital raise triggered the conversion features on the convertible debt described above. The Notes were modified to change the discount percentage from the 0% discount per the terms of the November&#160;2018 and December 2018 Notes and the 15% discount per the terms of the January&#160;2019 and February&#160;2019 Notes to 30% at the time of conversion. The Company issued 1.1 million shares of common stock at $8.69 per share on the date of conversion to extinguish the debt, which resulted in a loss of $0.3 million. This non-cash conversion also resulted in an increase of $13.0 million in additional paid-in capital, which was based on the principal balance outstanding and the unpaid interest upon conversion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Convertible Promissory Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On April 4, 2019, the Company issued the convertible promissory note (the &#x201c;Promissory Note&#x201d;) to an existing stockholder for $0.9 million at an interest rate of 5% per annum. On May&#160;16, 2019, the Promissory Note was converted into equity. Former Ocugen issued 0.1 million shares of common stock at the conversion date to extinguish the debt at $12.41 per share. This non-cash transaction resulted in an increase of $0.9 million in additional paid-in capital, which was based on the principal balance outstanding and the unpaid interest upon conversion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Senior Secured Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On May 21, 2019, the Company issued senior secured convertible notes to certain investors for $2.4 million at an original issue discount of $0.5 million, and on June&#160;28, 2019, the Company entered into an agreement to issue additional senior secured convertible notes to the investors for $2.9 million with an original issue discount of $0.4 million (together &#x201c;Senior Secured Notes&#x201d;). Immediately prior to the Merger completed on September 27, 2019, the investors offset $5.3 million from the amount to be received under the Pre-Merger Financing and the Senior Secured Notes were deemed to have been repaid and cancelled. The accretion of the original issue discount to interest expense amounted to $0.8 million during the year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i41512e91ea66459091142a09d64979ee_I20160930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NTM0OQ_71a74ad7-581f-49ed-b43f-6b0a45242462"
      unitRef="usd">10000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <ocgn:LineOfCreditBorrowingEachDraw
      contextRef="ie26010e163a44d8f8901034a2237a150_D20160901-20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NTM4MA_84983f5a-a014-41ea-b9db-194353e2f4e0"
      unitRef="usd">500000</ocgn:LineOfCreditBorrowingEachDraw>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i41512e91ea66459091142a09d64979ee_I20160930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NTM4Mw_6e93f818-e5f2-436d-a90c-4c8d5750142f"
      unitRef="number">0.040</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCredit
      contextRef="i5f4493de5f9a420f8e7d280ce9393d02_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NTM4Ng_d062af63-b5b6-4c92-8cf9-cc4f87d6e009"
      unitRef="usd">1000000.0</us-gaap:LineOfCredit>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i49703b2d634a40219c09a4116c60351e_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NTM4OQ_2125b798-8ae3-4c38-95ac-9c17839a89fb"
      unitRef="usd">100000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMTcwNDI0MzAyNTIxMjU_943e98cd-64c7-4c5b-b4fc-5d2ae8cd1de5">&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.175%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Principal outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Plus: accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;127,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;87,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(55,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(70,495)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Carrying value of debt&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,072,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,016,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ifa216e92d8ad45f695cf881fb2ec681d_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjc5Mjc3MDdhNjRhMTRkM2FiZWUyODhjZmUzMzg1MDkyL3RhYmxlcmFuZ2U6NzkyNzcwN2E2NGExNGQzYWJlZTI4OGNmZTMzODUwOTJfMS0yLTEtMS01MTM5_e473840a-2395-4269-991a-294f72ae5c36"
      unitRef="usd">1000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i10a74d4f5772493bb775e01c0458d587_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjc5Mjc3MDdhNjRhMTRkM2FiZWUyODhjZmUzMzg1MDkyL3RhYmxlcmFuZ2U6NzkyNzcwN2E2NGExNGQzYWJlZTI4OGNmZTMzODUwOTJfMS00LTEtMS01MTQ2_0ced3bfd-12a3-4c50-b017-f98b502f9250"
      unitRef="usd">1000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="ifa216e92d8ad45f695cf881fb2ec681d_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjc5Mjc3MDdhNjRhMTRkM2FiZWUyODhjZmUzMzg1MDkyL3RhYmxlcmFuZ2U6NzkyNzcwN2E2NGExNGQzYWJlZTI4OGNmZTMzODUwOTJfMi0yLTEtMS01MTM5_2068fa95-1e38-4fd6-bee5-ea0ac1c7a56f"
      unitRef="usd">127777</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i10a74d4f5772493bb775e01c0458d587_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjc5Mjc3MDdhNjRhMTRkM2FiZWUyODhjZmUzMzg1MDkyL3RhYmxlcmFuZ2U6NzkyNzcwN2E2NGExNGQzYWJlZTI4OGNmZTMzODUwOTJfMi00LTEtMS01MTQ2_9c9688a9-49b6-4658-b101-81c1d715103c"
      unitRef="usd">87222</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ifa216e92d8ad45f695cf881fb2ec681d_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjc5Mjc3MDdhNjRhMTRkM2FiZWUyODhjZmUzMzg1MDkyL3RhYmxlcmFuZ2U6NzkyNzcwN2E2NGExNGQzYWJlZTI4OGNmZTMzODUwOTJfMy0yLTEtMS01MTM5_1565def6-0413-4b8c-9a26-74ab7d7c9b15"
      unitRef="usd">55654</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i10a74d4f5772493bb775e01c0458d587_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjc5Mjc3MDdhNjRhMTRkM2FiZWUyODhjZmUzMzg1MDkyL3RhYmxlcmFuZ2U6NzkyNzcwN2E2NGExNGQzYWJlZTI4OGNmZTMzODUwOTJfMy00LTEtMS01MTQ2_a27f19a5-99da-44d8-bd4f-2182420bcd2e"
      unitRef="usd">70495</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="ifa216e92d8ad45f695cf881fb2ec681d_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjc5Mjc3MDdhNjRhMTRkM2FiZWUyODhjZmUzMzg1MDkyL3RhYmxlcmFuZ2U6NzkyNzcwN2E2NGExNGQzYWJlZTI4OGNmZTMzODUwOTJfNC0yLTEtMS01MTMx_4622a595-8336-4fcf-8290-74f73550bdb0"
      unitRef="usd">1072123</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i10a74d4f5772493bb775e01c0458d587_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjc5Mjc3MDdhNjRhMTRkM2FiZWUyODhjZmUzMzg1MDkyL3RhYmxlcmFuZ2U6NzkyNzcwN2E2NGExNGQzYWJlZTI4OGNmZTMzODUwOTJfNC00LTEtMS01MTU1_95b84a82-7a51-491f-b997-479f722af4db"
      unitRef="usd">1016727</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4dd588e3e2fd4d56ba9f7ed7bf627e44_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNzE0NjgyNTYwMTU4OA_1811c294-bab7-4749-90e6-e29bb0d4b97c"
      unitRef="usd">3500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie107e1047f9e4c3fa462f46cf3e5e3e4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNzE0NjgyNTYwMTU4OA_5bd91d46-51b2-4aed-8608-8f659530f1f5"
      unitRef="usd">3500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ConvertibleDebt
      contextRef="i328baa90b6ca4ecf9cdc9e0a79ee26ad_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMTcwNDI0MzAyNTIxMjY_0fa51f98-4f5c-45d6-a944-901a0a1fd374"
      unitRef="usd">0</us-gaap:ConvertibleDebt>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMTE3ODM_aa470aef-f4c5-4da0-8416-8b81c06f7071">&lt;div style="margin-top:12pt;margin-bottom:15pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At issuance, the following amounts were recorded:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.052%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:35.290%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.220%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.408%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.220%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.408%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.220%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.408%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.226%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Note&#160;Issuance&#160;Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Note&lt;br/&gt;Principal&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&#160;Value&#160;of&lt;br/&gt;Embedded Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Debt&lt;br/&gt;Issuance&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Carrying Value upon Issuance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,657,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(35,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,306,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(724,216)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;272,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;November 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,150,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(21,127)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(50,646)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,078,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,857)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(14,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;132,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;450,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(182,882)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(29,358)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;237,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;February 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(302,379)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(55,875)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;641,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,750,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,891,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(189,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,670,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i65b540d692bb45958ed8ced1fb3911da_I20180131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfMS0yLTEtMS0w_00a62779-ded6-4804-afde-5b3562b718d3"
      unitRef="usd">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="i5cc3532217ff4a829773c63ec209eebb_I20180131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfMS00LTEtMS0w_fe5a852c-507c-4c22-b521-ff632ed3b853"
      unitRef="usd">2657711</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i65b540d692bb45958ed8ced1fb3911da_I20180131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfMS04LTEtMS0w_3140f0c5-23ca-4afc-9744-10e45743080f"
      unitRef="usd">35969</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:LongTermDebt
      contextRef="i65b540d692bb45958ed8ced1fb3911da_I20180131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfMS0xMC0xLTEtMA_da44213a-2a8c-449d-abbc-542dd5800323"
      unitRef="usd">2306320</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i161b6716805149329fb75cb8d891a7d3_I20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfMi0yLTEtMS0w_f6891a60-721f-4315-bfb1-b9c4db96b542"
      unitRef="usd">1000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="id0c9d3000afb440eb2ae0e4453fc13cd_I20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfMi00LTEtMS0w_4b7c4b09-0263-41f1-9885-916fa997fe6d"
      unitRef="usd">724216</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i161b6716805149329fb75cb8d891a7d3_I20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfMi04LTEtMS0w_7255e065-8b5c-40b0-a5c1-67ae24defc01"
      unitRef="usd">3000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:LongTermDebt
      contextRef="i161b6716805149329fb75cb8d891a7d3_I20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfMi0xMC0xLTEtMA_af3e8f69-e686-4cb3-b3cd-e2ed2a16b371"
      unitRef="usd">272784</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i514af234321c45249033c2c6004c3681_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfMy0yLTEtMS0w_c9897230-b9de-4f00-a5cf-8de4dd37273d"
      unitRef="usd">1150400</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="i94d7513be73b4b42b644afe0f55eda9e_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfMy00LTEtMS0w_7e5fed21-9103-486d-86ec-75905742735d"
      unitRef="usd">21127</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i514af234321c45249033c2c6004c3681_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfMy04LTEtMS0w_1151e875-c89b-4e79-93d5-cafc69f81785"
      unitRef="usd">50646</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:LongTermDebt
      contextRef="i514af234321c45249033c2c6004c3681_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfMy0xMC0xLTEtMA_5dc525a2-17c5-42de-9030-1f05a356916f"
      unitRef="usd">1078627</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i932ae52afffe48a19dbc8e83e080b098_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNC0yLTEtMS0w_7d474c97-4abb-4e44-8f2c-fc93e515346c"
      unitRef="usd">150000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="ibf9bc486110443f69af07574bf14d5f7_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNC00LTEtMS0w_c9a3211e-cc6f-418f-9f0c-137a9a104910"
      unitRef="usd">2857</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i932ae52afffe48a19dbc8e83e080b098_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNC04LTEtMS0w_375cf1e1-3674-4fe6-8e2c-0614cb0eced7"
      unitRef="usd">14310</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:LongTermDebt
      contextRef="i932ae52afffe48a19dbc8e83e080b098_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNC0xMC0xLTEtMA_05221911-232f-4462-8af9-eff14ea5d590"
      unitRef="usd">132833</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="idf78c78261294ef3881f6cf13befd9a5_I20190131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNS0yLTEtMS01NzI3_74e9f133-09e1-4e33-a940-3f798f01cbf9"
      unitRef="usd">450000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="if379bb8b26134244bc1ef93807f107a8_I20190131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNS00LTEtMS01NzMx_f02e755d-5b0b-4da4-8f2e-cfc8e0492b0e"
      unitRef="usd">182882</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="idf78c78261294ef3881f6cf13befd9a5_I20190131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNS03LTEtMS01NzM1_e3fec30e-b4db-40e9-91dc-7bb049c77c11"
      unitRef="usd">29358</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:LongTermDebt
      contextRef="idf78c78261294ef3881f6cf13befd9a5_I20190131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNS05LTEtMS01NzM5_0cf12626-596e-4386-bf5c-0a2e949b5ea2"
      unitRef="usd">237760</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4183d88399e94dd0af0b9cb7d63d5f7d_I20190228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNi0yLTEtMS01NzI3_7f179e04-de7a-4e1f-a20e-81d067a0d4df"
      unitRef="usd">1000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="i74fd32d2c80748aeb83fa8309f3b484c_I20190228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNi00LTEtMS01NzMx_d8e08b00-dd1d-4097-8511-a2bd2eb15c3c"
      unitRef="usd">302379</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i4183d88399e94dd0af0b9cb7d63d5f7d_I20190228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNi03LTEtMS01NzM1_27a79014-1da3-4a13-a22d-704ddf8a7612"
      unitRef="usd">55875</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:LongTermDebt
      contextRef="i4183d88399e94dd0af0b9cb7d63d5f7d_I20190228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNi05LTEtMS01NzM5_4ea8ed8a-f7bd-46e7-802e-cd7785fa56a4"
      unitRef="usd">641746</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i17e3a21a882c45e6a5d43855f575a703_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNS0yLTEtMS0w_b8318ab0-48d8-458c-8707-add4b67e0de1"
      unitRef="usd">8750400</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="i1432fdaf1af748b9aa5b711d2c461c89_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNS00LTEtMS0w_4fc7a39a-abc7-47a0-bc12-6fdbc618e93d"
      unitRef="usd">3891172</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i17e3a21a882c45e6a5d43855f575a703_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNS04LTEtMS0w_345134e9-3e4d-4624-ac2b-263bb36b7dbc"
      unitRef="usd">189158</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:LongTermDebt
      contextRef="i17e3a21a882c45e6a5d43855f575a703_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjNmYTAwMzc2NWQ5NjQ2NDdhNTEzZmExOWNmMjcwMWFlL3RhYmxlcmFuZ2U6M2ZhMDAzNzY1ZDk2NDY0N2E1MTNmYTE5Y2YyNzAxYWVfNS0xMC0xLTEtMA_a2e3dd3e-39f0-4404-a3c3-5908841af9e1"
      unitRef="usd">4670070</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i328baa90b6ca4ecf9cdc9e0a79ee26ad_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMjUzNw_792d32e4-b27e-4bd3-94e0-4d7f4bea5d16"
      unitRef="number">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentTerm
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMTUzOTMxNjI4MTc5MDI_e9ee6832-8a82-4f59-9f20-539b44f79623">P18M</us-gaap:DebtInstrumentTerm>
    <ocgn:DebtRedemptionMultipleUponDefault
      contextRef="i328baa90b6ca4ecf9cdc9e0a79ee26ad_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMTcwNDI0MzAyNTIxOTk_f56e1682-0f19-4613-b5e5-c8702f7aa0a3"
      unitRef="number">1.5</ocgn:DebtRedemptionMultipleUponDefault>
    <ocgn:ConvertibleDebtEquityFinancingTriggeredDiscount
      contextRef="i30518d590b384689bc953bae8c788989_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMzI5ODUzNDg5NzgyMQ_8c617bd7-3694-43e4-bc8f-0d73d2042d4f"
      unitRef="number">0</ocgn:ConvertibleDebtEquityFinancingTriggeredDiscount>
    <ocgn:ConvertibleDebtEquityFinancingTriggeredDiscount
      contextRef="ie03c47b9f9564d4ea485d3ffdd995bb6_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNTQ5NzU1ODE1OTUzMg_e0eb8606-30e9-45b7-b7fd-e4466b50bbbe"
      unitRef="number">0.30</ocgn:ConvertibleDebtEquityFinancingTriggeredDiscount>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i7ef067fabc2048d49a715adf223a6aaf_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjI5Ng_87f5fdfd-75f6-4af4-bfe9-bb8e0fee7bad"
      unitRef="usd">600000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ie32a5c52109846399c80873ec089ffbb_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjMwMw_a8b2fb8a-14b1-46c1-a31e-55cb930d5a5e"
      unitRef="usd">3400000</us-gaap:AmortizationOfDebtDiscountPremium>
    <ocgn:ChangesInFairValueOfEmbeddedDerivativeTableTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMTE3ODU_2cf71071-8315-4943-822c-e35a39cf90f6">&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:82.795%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.621%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Balance at January 1, 2018 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Fair value of embedded derivatives at issuance &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,405,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Change in fair value of embedded derivatives &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,664,689)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Balance at December 31, 2018 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,741,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Fair value of embedded derivatives at issuance &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;567,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Change in fair value of embedded derivatives &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,319,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Conversion and extinguishment of debt &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,628,283)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Balance at December 31, 2019 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ocgn:ChangesInFairValueOfEmbeddedDerivativeTableTextBlock>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="i3b0b2789ee4e45ff8aa700de563ddc85_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjIyYjg5NDgyOThkMTRkYzI5ZDUyNGE3MTdhNTgwNzAyL3RhYmxlcmFuZ2U6MjJiODk0ODI5OGQxNGRjMjlkNTI0YTcxN2E1ODA3MDJfMS0zLTEtMS0w_d5dcda11-7262-4176-9d7c-e6540cad76b3"
      unitRef="usd">0</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <ocgn:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiabilityAtIssuance
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjIyYjg5NDgyOThkMTRkYzI5ZDUyNGE3MTdhNTgwNzAyL3RhYmxlcmFuZ2U6MjJiODk0ODI5OGQxNGRjMjlkNTI0YTcxN2E1ODA3MDJfMi0zLTEtMS0xMDY2Ng_2755126c-3d8f-4377-9602-c63e885aca7a"
      unitRef="usd">3405911</ocgn:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiabilityAtIssuance>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjIyYjg5NDgyOThkMTRkYzI5ZDUyNGE3MTdhNTgwNzAyL3RhYmxlcmFuZ2U6MjJiODk0ODI5OGQxNGRjMjlkNTI0YTcxN2E1ODA3MDJfMy0zLTEtMS0xMDY2Ng_b122fdab-58e4-4e03-8b5b-ace72e8088df"
      unitRef="usd">-1664689</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjIyYjg5NDgyOThkMTRkYzI5ZDUyNGE3MTdhNTgwNzAyL3RhYmxlcmFuZ2U6MjJiODk0ODI5OGQxNGRjMjlkNTI0YTcxN2E1ODA3MDJfNC0zLTEtMS0xMDY2Ng_a54854a5-5235-4c56-9450-505ec2261cd4"
      unitRef="usd">1741222</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <ocgn:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiabilityAtIssuance
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjIyYjg5NDgyOThkMTRkYzI5ZDUyNGE3MTdhNTgwNzAyL3RhYmxlcmFuZ2U6MjJiODk0ODI5OGQxNGRjMjlkNTI0YTcxN2E1ODA3MDJfMi0zLTEtMS0w_3e711078-4759-48b1-84c8-1bd5356b21c8"
      unitRef="usd">567661</ocgn:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiabilityAtIssuance>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjIyYjg5NDgyOThkMTRkYzI5ZDUyNGE3MTdhNTgwNzAyL3RhYmxlcmFuZ2U6MjJiODk0ODI5OGQxNGRjMjlkNTI0YTcxN2E1ODA3MDJfMy0zLTEtMS0w_57099c74-b122-4e6b-8f76-ff977b44254d"
      unitRef="usd">1319400</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <ocgn:EmbeddedDerivativeConversionAndExtinguishmentOfDebt
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjIyYjg5NDgyOThkMTRkYzI5ZDUyNGE3MTdhNTgwNzAyL3RhYmxlcmFuZ2U6MjJiODk0ODI5OGQxNGRjMjlkNTI0YTcxN2E1ODA3MDJfNC0zLTEtMS0w_03116218-8f08-426a-8bfa-6e5d47f72fd0"
      unitRef="usd">3628283</ocgn:EmbeddedDerivativeConversionAndExtinguishmentOfDebt>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RhYmxlOjIyYjg5NDgyOThkMTRkYzI5ZDUyNGE3MTdhNTgwNzAyL3RhYmxlcmFuZ2U6MjJiODk0ODI5OGQxNGRjMjlkNTI0YTcxN2E1ODA3MDJfNS0zLTEtMS0w_8722accf-dc1a-4660-a367-d1de5f6db2b3"
      unitRef="usd">0</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <ocgn:CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement
      contextRef="ic10bc878b71a4eec829c618f097ab1f3_I20190405"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NjY3MA_43e16e69-d3a3-4801-b96c-9dbe9c96c31d"
      unitRef="shares">100000</ocgn:CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement>
    <us-gaap:CommonStockSharesSubscriptions
      contextRef="ic10bc878b71a4eec829c618f097ab1f3_I20190405"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NjY3NA_50d00e13-b504-4f78-ab83-9f964732a2b0"
      unitRef="usd">1000000.0</us-gaap:CommonStockSharesSubscriptions>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ic10bc878b71a4eec829c618f097ab1f3_I20190405"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NjY4MA_72e90f5d-7210-4dff-afb2-cdaa49d0b801"
      unitRef="usdPerShare">12.41</us-gaap:SaleOfStockPricePerShare>
    <ocgn:CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement
      contextRef="iaf15ac65c13f41efa5b2c278c90ef1ad_I20190405"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNzE0NjgyNTYwMjEzOQ_6762e170-1a8b-4494-a68d-34ed3f7f93c4"
      unitRef="shares">40286</ocgn:CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement>
    <us-gaap:CommonStockSharesSubscriptions
      contextRef="iaf15ac65c13f41efa5b2c278c90ef1ad_I20190405"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNzE0NjgyNTYwMjEwMg_4d51ab13-aca4-478d-a1d7-8d6d7e03fb83"
      unitRef="usd">500000</us-gaap:CommonStockSharesSubscriptions>
    <ocgn:ConvertibleDebtEquityFinancingTriggeredDiscount
      contextRef="i30518d590b384689bc953bae8c788989_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMzI5ODUzNDg5OTUyMQ_8c617bd7-3694-43e4-bc8f-0d73d2042d4f"
      unitRef="number">0</ocgn:ConvertibleDebtEquityFinancingTriggeredDiscount>
    <ocgn:ConvertibleDebtEquityFinancingTriggeredDiscount
      contextRef="i408357dbb20b4db79414a01968187418_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMzI5ODUzNDg5OTUyOA_aaa2fb2d-497a-483e-b744-0f437b017c09"
      unitRef="number">0.15</ocgn:ConvertibleDebtEquityFinancingTriggeredDiscount>
    <ocgn:ConvertibleDebtEquityFinancingTriggeredDiscount
      contextRef="ie03c47b9f9564d4ea485d3ffdd995bb6_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMzI5ODUzNDg5OTUzNA_e0eb8606-30e9-45b7-b7fd-e4466b50bbbe"
      unitRef="number">0.30</ocgn:ConvertibleDebtEquityFinancingTriggeredDiscount>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5d316476da1f4704bd006d963c24c9f3_I20190405"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NTc2Nw_b9540b96-c1e3-4d4d-b8c1-8084838b575b"
      unitRef="shares">1100000</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i5d316476da1f4704bd006d963c24c9f3_I20190405"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NTc3Mw_37584a95-1fb9-4634-b584-129ec9d813ab"
      unitRef="usdPerShare">8.69</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i2c77d97bd72b4690ab70a469f8712825_D20190405-20190405"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NTc3OA_537b9841-8630-4d54-9bfd-1b06c63a089f"
      unitRef="usd">-300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="i016d0b71e20d44c6b6f177338d083e24_D20190405-20190405"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NTc4MQ_2b9037a5-6013-45c8-8929-232da6c1e8fb"
      unitRef="usd">13000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3af9928ff5934a50a728ddecb0030b9f_I20190404"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NTc4NA_404d0365-0e6e-4dbf-96a3-f732d58418d3"
      unitRef="usd">900000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3af9928ff5934a50a728ddecb0030b9f_I20190404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNzE0NjgyNTYwMTgxNw_c928329a-8dfa-4f39-86e6-85f662ae25c2"
      unitRef="number">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ocgn:CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement
      contextRef="ic10bc878b71a4eec829c618f097ab1f3_I20190405"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMzI5ODUzNDkwMDU0Ng_9ef427f5-3f74-40a9-8026-d7914c1b2f73"
      unitRef="shares">100000</ocgn:CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ic10bc878b71a4eec829c618f097ab1f3_I20190405"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMzI5ODUzNDkwMDYyMQ_72e90f5d-7210-4dff-afb2-cdaa49d0b801"
      unitRef="usdPerShare">12.41</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="i9825c374339d495092fda175dbb9ecc6_D20190516-20190516"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMzI5ODUzNDkwMDY4OA_52886914-6a8d-47ed-b49d-4b779d04b730"
      unitRef="usd">900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iff635dcebab24f36911b7b91f40c1759_I20190521"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NTgxNA_8df613e4-00ed-42c4-869a-3ec1207096d7"
      unitRef="usd">2400000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="iff635dcebab24f36911b7b91f40c1759_I20190521"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NTgxNw_74be4947-36fb-4bb8-be00-14b1df557c39"
      unitRef="usd">500000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i58aa2dbee17a4346b99dfe95c91e455d_I20190628"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NTgyMA_1d5f8ce3-d422-4fcd-8799-3c23bc2e150c"
      unitRef="usd">2900000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i58aa2dbee17a4346b99dfe95c91e455d_I20190628"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NTgyMw_4e50c8ec-a1f0-4ddb-b6a9-ff617a6b09b4"
      unitRef="usd">400000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="icc8f3b70120644bcb0ea07e4c4e58532_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfNjA0NzMxMzk2NTgzMA_e95e94d0-8ff5-4adb-8815-ae400aef24a1"
      unitRef="usd">5300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i9169a31e29f845df9d4dcc1d4c8e89af_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83My9mcmFnOjQ0MmU0NzFmNWE2OTQzNjBhY2UzMDk1MTU5OGRhNmUzL3RleHRyZWdpb246NDQyZTQ3MWY1YTY5NDM2MGFjZTMwOTUxNTk4ZGE2ZTNfMzI5ODUzNDkwMjQ4Nw_51661c6c-b46f-439e-9c55-7bbd10b6b93e"
      unitRef="usd">800000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGV4dHJlZ2lvbjo3YTM1NjhhMDc3YmU0ODIwYWM4NzY3ZDQzNTI3MjNhYl8xNTM5MzE2Mjc5OTE2Mw_5f13c459-d190-4262-a5fa-bc6d9d34ed20">Stock-Based Compensation&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Stock-based compensation expense for options granted are reflected in the consolidated statements of operations and comprehensive loss as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.175%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;362,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;515,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;521,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;559,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;884,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,074,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of December&#160;31, 2019, the Company had $0.9 million of unrecognized compensation expense related to options outstanding under its equity plans. This expense is expected to be recognized over a weighted average period of 1.7 years as of December&#160;31, 2019&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Equity Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company maintains two equity compensation plans, the 2014 Ocugen OpCo, Inc. Stock Option Plan (the &#x201c;2014 Plan&#x201d;) and the Ocugen, Inc. 2019 Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;, collectively with the 2014 Plan, the "Plans"), which replaced the Histogenics Corporation 2013 Equity Incentive Plan (the "2013 Plan"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On December 18, 2019, Ocugen&#x2019;s stockholders approved the adoption of the 2019 Plan and the 2013 Plan was frozen. No additional awards have been or will be made under the 2013 Plan and any remaining authorized shares under the 2013 Plan will be recycled into the 2019 Plan. The 2019 Plan provides for the granting of up to 2.1&#160;million equity awards in respect of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Ocugen&#x2019;s common stock, inclusive of equity awards that were previously available for issuance under the 2013 Plan, as of December&#160;31, 2019. Additionally, on the first business day of each fiscal year commencing on January 1, 2020, pursuant to the "Evergreen" provision of the 2019 Plan, the aggregate number of shares that may be issued under the 2019 Plan shall automatically increase by a number equal to the lesser of 4.0% of the total number of shares of Company common stock outstanding on December 31&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;st&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; of the prior year, or a number of shares of Company common stock determined by the Board.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of December&#160;31, 2019, an aggregate of 0.6&#160;million and 0.1&#160;million shares of Company common stock were issuable upon the exercise of outstanding stock options under the 2014 Plan and 2019 Plan, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Options to Purchase Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Weighted average assumptions utilized in the fair value calculation for options to purchase common stock as of December&#160;31, 2019 and 2018 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.175%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average common stock price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$1.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$9.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected option term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;6.0 &#x2013; 10.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;109%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;85%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;1.5% &#x2013; 2.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;2.3% &#x2013; 3.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the stock option activity under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:37.766%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.625%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Remaining Contractual Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options outstanding at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;632,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,801,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;238,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(140,324)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;731,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options exercisable at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;385,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The weighted average grant date fair value of stock options granted during the year ended December 31, 2019 and 2018 was $0.84 and $7.97, respectively&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"&gt;. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The total fair value of stock options vested during the year ended December&#160;31, 2019 was $1.0&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGV4dHJlZ2lvbjo3YTM1NjhhMDc3YmU0ODIwYWM4NzY3ZDQzNTI3MjNhYl8xNTM5MzE2Mjc5OTE2NA_dcd0aab9-9c36-4fc6-9c2d-10d8b9ca6d01">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Stock-based compensation expense for options granted are reflected in the consolidated statements of operations and comprehensive loss as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.175%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;362,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;515,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;521,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;559,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;884,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,074,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1dd31fe358a94242921f371e4a12056c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6YmRhMjE4ZWQwM2U0NGUwOWJkYjEzMDM2NmI4ZjAyMDgvdGFibGVyYW5nZTpiZGEyMThlZDAzZTQ0ZTA5YmRiMTMwMzY2YjhmMDIwOF8yLTEtMS0xLTQ3NzI_c6215217-12a9-45e2-8bb1-04a16708e217"
      unitRef="usd">362833</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iee4f88bad8cb4836b9a7cc7122e34867_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6YmRhMjE4ZWQwM2U0NGUwOWJkYjEzMDM2NmI4ZjAyMDgvdGFibGVyYW5nZTpiZGEyMThlZDAzZTQ0ZTA5YmRiMTMwMzY2YjhmMDIwOF8yLTMtMS0xLTQxMzE_ec42f7b5-84e5-43d9-b551-9ba567ab7133"
      unitRef="usd">515160</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifb06df9a8042478fbcacfde1e1ec008c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6YmRhMjE4ZWQwM2U0NGUwOWJkYjEzMDM2NmI4ZjAyMDgvdGFibGVyYW5nZTpiZGEyMThlZDAzZTQ0ZTA5YmRiMTMwMzY2YjhmMDIwOF8zLTEtMS0xLTQ3NzI_c18f3957-604e-457d-9d3f-92ae5bd46d65"
      unitRef="usd">521256</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i81f536df668b463db04d83beaea9fca4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6YmRhMjE4ZWQwM2U0NGUwOWJkYjEzMDM2NmI4ZjAyMDgvdGFibGVyYW5nZTpiZGEyMThlZDAzZTQ0ZTA5YmRiMTMwMzY2YjhmMDIwOF8zLTMtMS0xLTQxMzE_96f00e8b-983f-4a6e-ad60-549be2d8de3c"
      unitRef="usd">559527</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6YmRhMjE4ZWQwM2U0NGUwOWJkYjEzMDM2NmI4ZjAyMDgvdGFibGVyYW5nZTpiZGEyMThlZDAzZTQ0ZTA5YmRiMTMwMzY2YjhmMDIwOF80LTEtMS0xLTI0OTE_6c9a7aeb-7fdc-4a3c-8cfb-a785eafd0a02"
      unitRef="usd">884089</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6YmRhMjE4ZWQwM2U0NGUwOWJkYjEzMDM2NmI4ZjAyMDgvdGFibGVyYW5nZTpiZGEyMThlZDAzZTQ0ZTA5YmRiMTMwMzY2YjhmMDIwOF80LTMtMS0xLTI0OTQ_b163339d-245f-45bc-a8d5-b470415526e6"
      unitRef="usd">1074687</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGV4dHJlZ2lvbjo3YTM1NjhhMDc3YmU0ODIwYWM4NzY3ZDQzNTI3MjNhYl82MDQ3MzEzOTU0MDgz_2b7b2047-9645-4f4e-871d-0c3249e5a010"
      unitRef="usd">900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i21b036a7018e49f1ba389957307f069f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGV4dHJlZ2lvbjo3YTM1NjhhMDc3YmU0ODIwYWM4NzY3ZDQzNTI3MjNhYl82MDQ3MzEzOTU0MDg2_356a2837-6697-46c3-b9d0-e0ace15b682d">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <ocgn:NumberOfEquityCompensationPlans
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGV4dHJlZ2lvbjo3YTM1NjhhMDc3YmU0ODIwYWM4NzY3ZDQzNTI3MjNhYl8xNTM5MzE2Mjc5OTE4Nw_f3ba72ec-4f07-4c29-bfbb-d86b2acde359"
      unitRef="segment">2</ocgn:NumberOfEquityCompensationPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i9dd0fe8be9d9438c8e720727830deb3e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGV4dHJlZ2lvbjo3YTM1NjhhMDc3YmU0ODIwYWM4NzY3ZDQzNTI3MjNhYl82MDQ3MzEzOTU5NTk3_01177549-80b5-4c0b-844a-9fa44d1bf003"
      unitRef="shares">2100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <ocgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGV4dHJlZ2lvbjo3YTM1NjhhMDc3YmU0ODIwYWM4NzY3ZDQzNTI3MjNhYl82MDQ3MzEzOTU5NjI3_b63bc10b-5ec5-4929-893c-8c9c6aed4b6e"
      unitRef="number">0.040</ocgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i901327021f4f4d8a9e7429629a2fe235_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGV4dHJlZ2lvbjo3YTM1NjhhMDc3YmU0ODIwYWM4NzY3ZDQzNTI3MjNhYl84MjQ2MzM3MjE5MTQz_0e93a90a-7545-4d15-a20b-97a34932ea23"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ie4c25c1678fc46f2a94db1f11c7a25d1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGV4dHJlZ2lvbjo3YTM1NjhhMDc3YmU0ODIwYWM4NzY3ZDQzNTI3MjNhYl84MjQ2MzM3MjE5MTUz_66960988-e2ec-4ada-9aaf-eec6d9d68583"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGV4dHJlZ2lvbjo3YTM1NjhhMDc3YmU0ODIwYWM4NzY3ZDQzNTI3MjNhYl8xNTM5MzE2Mjc5OTE2Ng_0d332500-ec01-4781-b7ae-4e28f3b61f58">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Weighted average assumptions utilized in the fair value calculation for options to purchase common stock as of December&#160;31, 2019 and 2018 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.175%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average common stock price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$1.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$9.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected option term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;6.0 &#x2013; 10.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;109%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;85%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;1.5% &#x2013; 2.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;2.3% &#x2013; 3.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="iaf4d04bf884e47208ec21854eaf3c6fa_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6ZThmNTE1YTRmZDI0NDBmNGI1MjRlNTU4YzY2YmE5YzMvdGFibGVyYW5nZTplOGY1MTVhNGZkMjQ0MGY0YjUyNGU1NThjNjZiYTljM18yLTEtMS0xLTQxNDI_00a99e68-a20f-4e4a-bbac-bb1131059e91"
      unitRef="usdPerShare">1.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i81f1955a085348c7b2651edceb71e43f_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6ZThmNTE1YTRmZDI0NDBmNGI1MjRlNTU4YzY2YmE5YzMvdGFibGVyYW5nZTplOGY1MTVhNGZkMjQ0MGY0YjUyNGU1NThjNjZiYTljM18yLTMtMS0xLTQxNDI_7d4bcd53-8513-4a34-86ed-357aa4040976"
      unitRef="usdPerShare">9.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i6258e5af615841ca8ed08b5fc6e64f13_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6ZThmNTE1YTRmZDI0NDBmNGI1MjRlNTU4YzY2YmE5YzMvdGFibGVyYW5nZTplOGY1MTVhNGZkMjQ0MGY0YjUyNGU1NThjNjZiYTljM18yLTEtMS0xLTI2MTE_99fbea53-5aae-4dab-ae48-93571a145081">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ie8f44ff16f6a48a5b00b8d8fb4955d6f_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6ZThmNTE1YTRmZDI0NDBmNGI1MjRlNTU4YzY2YmE5YzMvdGFibGVyYW5nZTplOGY1MTVhNGZkMjQ0MGY0YjUyNGU1NThjNjZiYTljM18yLTMtMS0xLTI2MDcvdGV4dHJlZ2lvbjo0YmM5ZDQyMmZjZjU0NTA0OGVmNWNhZDY4Mzg1Yjc5NF84MjQ2MzM3MjA4MzM3_865be958-27a5-4262-af4a-b094933c0941">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iac0f32c415484121ac10d938108c47c4_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6ZThmNTE1YTRmZDI0NDBmNGI1MjRlNTU4YzY2YmE5YzMvdGFibGVyYW5nZTplOGY1MTVhNGZkMjQ0MGY0YjUyNGU1NThjNjZiYTljM18yLTMtMS0xLTI2MDcvdGV4dHJlZ2lvbjo0YmM5ZDQyMmZjZjU0NTA0OGVmNWNhZDY4Mzg1Yjc5NF84MjQ2MzM3MjA4MzQz_71a2d3bd-dfa8-46ab-ba58-6b866e432805">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i6258e5af615841ca8ed08b5fc6e64f13_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6ZThmNTE1YTRmZDI0NDBmNGI1MjRlNTU4YzY2YmE5YzMvdGFibGVyYW5nZTplOGY1MTVhNGZkMjQ0MGY0YjUyNGU1NThjNjZiYTljM18zLTEtMS0xLTI2MTE_26492558-6d86-491b-ad67-fb8a5b19b7ae"
      unitRef="number">1.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="iebb192fe177843a59dda713200213ad2_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6ZThmNTE1YTRmZDI0NDBmNGI1MjRlNTU4YzY2YmE5YzMvdGFibGVyYW5nZTplOGY1MTVhNGZkMjQ0MGY0YjUyNGU1NThjNjZiYTljM18zLTMtMS0xLTI2MDc_7a2604aa-4e67-4e06-a01a-eddd78f92e0e"
      unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i8f30ba30167e413fa31d614ef91c6c25_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6ZThmNTE1YTRmZDI0NDBmNGI1MjRlNTU4YzY2YmE5YzMvdGFibGVyYW5nZTplOGY1MTVhNGZkMjQ0MGY0YjUyNGU1NThjNjZiYTljM180LTEtMS0xLTI2MTEvdGV4dHJlZ2lvbjoyNGQ4NDBmNTNmMmY0NmNmOGY3MGNjZWE4MjE3NGYwMF84MjQ2MzM3MjA4MzM5_a7d05f5f-4619-4e25-8696-83e260540fce"
      unitRef="number">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i9d9bff3d3ae843c7b1af7507aeb3bcc2_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6ZThmNTE1YTRmZDI0NDBmNGI1MjRlNTU4YzY2YmE5YzMvdGFibGVyYW5nZTplOGY1MTVhNGZkMjQ0MGY0YjUyNGU1NThjNjZiYTljM180LTEtMS0xLTI2MTEvdGV4dHJlZ2lvbjoyNGQ4NDBmNTNmMmY0NmNmOGY3MGNjZWE4MjE3NGYwMF84MjQ2MzM3MjA4MzQ0_5a554cef-28a7-4f2b-b2fc-dc0937b02f85"
      unitRef="number">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ie8f44ff16f6a48a5b00b8d8fb4955d6f_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6ZThmNTE1YTRmZDI0NDBmNGI1MjRlNTU4YzY2YmE5YzMvdGFibGVyYW5nZTplOGY1MTVhNGZkMjQ0MGY0YjUyNGU1NThjNjZiYTljM180LTMtMS0xLTI2MDcvdGV4dHJlZ2lvbjowMzA0NDY5YzQzZjk0Y2ZhYjE0Y2Q5M2UwYjQwNTY4Y184MjQ2MzM3MjA4MzM5_1fb8830b-5221-4f83-a534-bf184fc8004d"
      unitRef="number">0.023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iac0f32c415484121ac10d938108c47c4_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6ZThmNTE1YTRmZDI0NDBmNGI1MjRlNTU4YzY2YmE5YzMvdGFibGVyYW5nZTplOGY1MTVhNGZkMjQ0MGY0YjUyNGU1NThjNjZiYTljM180LTMtMS0xLTI2MDcvdGV4dHJlZ2lvbjowMzA0NDY5YzQzZjk0Y2ZhYjE0Y2Q5M2UwYjQwNTY4Y184MjQ2MzM3MjA4MzQ1_d66d9c84-2ef4-4b52-97d7-97f22b9405ab"
      unitRef="number">0.030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i6258e5af615841ca8ed08b5fc6e64f13_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6ZThmNTE1YTRmZDI0NDBmNGI1MjRlNTU4YzY2YmE5YzMvdGFibGVyYW5nZTplOGY1MTVhNGZkMjQ0MGY0YjUyNGU1NThjNjZiYTljM181LTEtMS0xLTI2MDQ_876281f9-d8c9-4da8-bd3c-99625a9ed41c"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="iebb192fe177843a59dda713200213ad2_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6ZThmNTE1YTRmZDI0NDBmNGI1MjRlNTU4YzY2YmE5YzMvdGFibGVyYW5nZTplOGY1MTVhNGZkMjQ0MGY0YjUyNGU1NThjNjZiYTljM181LTMtMS0xLTI2MDc_5e2848c7-af49-40fb-b1f3-461b2ded63a5"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGV4dHJlZ2lvbjo3YTM1NjhhMDc3YmU0ODIwYWM4NzY3ZDQzNTI3MjNhYl8xNTM5MzE2Mjc5OTE2NQ_0fc84d4b-bceb-4572-add9-a3bccb762348">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the stock option activity under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:37.766%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.625%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Remaining Contractual Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options outstanding at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;632,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,801,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;238,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(140,324)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;731,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options exercisable at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;385,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i78c531e0c2834d2c9ce23d519b06d67b_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF8xLTEtMS0xLTI2NjI_2cf69880-385b-4052-8996-5c6073d16066"
      unitRef="shares">632752</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i78c531e0c2834d2c9ce23d519b06d67b_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF8xLTMtMS0xLTI2NjI_8800f59e-2736-4a44-80b7-02a59b6a458a"
      unitRef="usdPerShare">5.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i765c6c431bab4e9ca9750ef3e6d5c0a4_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF8xLTUtMS0xLTQxNTk_eec4a89f-7af0-4f4e-8216-07cd915c5dda">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i78c531e0c2834d2c9ce23d519b06d67b_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF8xLTctMS0xLTQxNTk_68564df8-09d4-4e73-97f5-3b709506e76c"
      unitRef="usd">4801696</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i4f2a660290394b9288e546c9be4bde7a_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF8yLTEtMS0xLTI2NjI_e5303511-bf96-414b-bbad-18f365d615ed"
      unitRef="shares">238761</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i4f2a660290394b9288e546c9be4bde7a_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF8yLTMtMS0xLTI2NjI_39337d22-d8ad-4418-bc43-14a41923e485"
      unitRef="usdPerShare">1.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i4f2a660290394b9288e546c9be4bde7a_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF80LTEtMS0xLTI2NjI_659f0ebb-caf0-4256-a600-e6134715b0b0"
      unitRef="shares">140324</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i4f2a660290394b9288e546c9be4bde7a_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF80LTMtMS0xLTI2NjI_8ecb5e64-63e0-4ea4-9946-aaf0a1c02485"
      unitRef="usdPerShare">4.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9dd0fe8be9d9438c8e720727830deb3e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF81LTEtMS0xLTI2NjI_29e61e8a-10b6-42cd-bec9-7765d732224b"
      unitRef="shares">731189</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9dd0fe8be9d9438c8e720727830deb3e_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF81LTMtMS0xLTI2NjI_68fbb015-6eee-4a66-a0a6-e4cf9066d3fd"
      unitRef="usdPerShare">4.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i4f2a660290394b9288e546c9be4bde7a_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF81LTUtMS0xLTQxOTk_71055290-ca9e-45da-b8ea-bd57dd73c918">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i9dd0fe8be9d9438c8e720727830deb3e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF81LTctMS0xLTQxOTY_dc81fba7-e2ab-49a7-a462-9ca3f7728ce6"
      unitRef="usd">24028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i9dd0fe8be9d9438c8e720727830deb3e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF82LTEtMS0xLTI2NjI_d4f83d89-5e76-48a3-8472-cc75b66855a8"
      unitRef="shares">385841</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i9dd0fe8be9d9438c8e720727830deb3e_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF82LTMtMS0xLTI2NjI_fc8d5f3f-4406-4a20-a111-da2763797379"
      unitRef="usdPerShare">5.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i4f2a660290394b9288e546c9be4bde7a_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF82LTUtMS0xLTQxOTk_1bc9a409-9da1-4af2-ba7b-3e4b66b7755c">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i9dd0fe8be9d9438c8e720727830deb3e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGFibGU6MTRiZGY1OWQ1ZDJlNDVkZTg2MzUzY2FhZTEzZGQwMzQvdGFibGVyYW5nZToxNGJkZjU5ZDVkMmU0NWRlODYzNTNjYWFlMTNkZDAzNF82LTctMS0xLTQxOTY_65fc3103-a7e0-493e-83a1-d26057d462ea"
      unitRef="usd">3049</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGV4dHJlZ2lvbjo3YTM1NjhhMDc3YmU0ODIwYWM4NzY3ZDQzNTI3MjNhYl82MDQ3MzEzOTYxMTYy_e30c11cb-6564-4498-9458-c4ac322167ac"
      unitRef="usdPerShare">0.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGV4dHJlZ2lvbjo3YTM1NjhhMDc3YmU0ODIwYWM4NzY3ZDQzNTI3MjNhYl82MDQ3MzEzOTYxMTc0_54c6e936-82cc-485d-b5a2-4ed7a8e7a4a3"
      unitRef="usdPerShare">7.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODQ0L2ZyYWc6N2EzNTY4YTA3N2JlNDgyMGFjODc2N2Q0MzUyNzIzYWIvdGV4dHJlZ2lvbjo3YTM1NjhhMDc3YmU0ODIwYWM4NzY3ZDQzNTI3MjNhYl84MjQ2MzM3MjE4NDE5_27b58b3b-e799-4ac8-8ba0-91394a32ce4a"
      unitRef="usd">1000000.0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RleHRyZWdpb246ZGM3YmMyNzE5ZTYwNGMyNjlkMWNiNjIxY2JhMTE0NDNfMTA5OTUxMTYyODYyNDc_1bdc082e-0f91-4600-822c-c303443f41d3">Commitments&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has commitments under operating leases for certain facilities used in its operations. The Company&#x2019;s leases have initial lease terms ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RleHRyZWdpb246ZGM3YmMyNzE5ZTYwNGMyNjlkMWNiNjIxY2JhMTE0NDNfMTA5OTUxMTYyODYwOTQ_ca47572a-04ad-41bc-8ba1-21a7e15ee217"&gt;one&lt;/span&gt; to five years. Certain lease agreements contain provisions for future rent increases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended&lt;br/&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;250,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;79,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;330,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Right-of-use assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;344,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;172,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-current lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;163,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;335,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Supplemental information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended&lt;br/&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average remaining lease terms&#x2014;operating leases (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average discount rate&#x2014;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Future minimum operating minimum lease payments for all leases, exclusive of taxes and other carrying charges, are approximately as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;191,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;160,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;364,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(28,645)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Present value of minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;335,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company does not have any leases that have not yet commenced which are significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Financing Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2018, the Company leased specialized research equipment under a lease classified as a financing lease. The leased equipment is included in property and equipment, net and is amortized on a straight-line basis over five years. Financing lease liabilities are included in other liabilities on the Company's consolidated balance sheets. The interest rate related to the lease obligation is 7.6% and the maturity date is July 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Future minimum lease payments for all financing leases, exclusive of taxes and other carrying charges, are approximately as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,851)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Present value of minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i67871994f7b24db59223486582b30e7a_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RleHRyZWdpb246ZGM3YmMyNzE5ZTYwNGMyNjlkMWNiNjIxY2JhMTE0NDNfMTA5OTUxMTYyODYwOTU_f880dddf-9bbf-4dbe-a4f0-dc0ba2e62928">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RleHRyZWdpb246ZGM3YmMyNzE5ZTYwNGMyNjlkMWNiNjIxY2JhMTE0NDNfMTA5OTUxMTYyODYwODk_1303189e-b5b9-44f0-9c3f-f98a2db785a5">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended&lt;br/&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;250,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;79,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;330,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Supplemental information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended&lt;br/&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average remaining lease terms&#x2014;operating leases (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average discount rate&#x2014;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOmM2NzAwZDZhNTJmZTRkN2VhYjM0ZTAzYWZjOWMxNDcwL3RhYmxlcmFuZ2U6YzY3MDBkNmE1MmZlNGQ3ZWFiMzRlMDNhZmM5YzE0NzBfMS0zLTEtMS0w_8f5c50bc-310d-4324-b275-f63bba0f1f7e"
      unitRef="usd">250361</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOmM2NzAwZDZhNTJmZTRkN2VhYjM0ZTAzYWZjOWMxNDcwL3RhYmxlcmFuZ2U6YzY3MDBkNmE1MmZlNGQ3ZWFiMzRlMDNhZmM5YzE0NzBfMi0zLTEtMS0w_2413952f-beb8-486c-9a12-7e62ffabde62"
      unitRef="usd">79700</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOmM2NzAwZDZhNTJmZTRkN2VhYjM0ZTAzYWZjOWMxNDcwL3RhYmxlcmFuZ2U6YzY3MDBkNmE1MmZlNGQ3ZWFiMzRlMDNhZmM5YzE0NzBfMy0zLTEtMS0w_f8e97617-8c91-4637-bfd7-f1c4809894be"
      unitRef="usd">330061</us-gaap:LeaseCost>
    <ocgn:SupplementalBalanceSheetInformationLeasesTableTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RleHRyZWdpb246ZGM3YmMyNzE5ZTYwNGMyNjlkMWNiNjIxY2JhMTE0NDNfMTA5OTUxMTYyODYwOTA_27b23922-0181-4d15-98f2-5235772ff2e9">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Right-of-use assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;344,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;172,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-current lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;163,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;335,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ocgn:SupplementalBalanceSheetInformationLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOjI0ZDQyYmFjNzA0NDQ2ODc4MWE0MWZkN2UxMWM3ZWQ1L3RhYmxlcmFuZ2U6MjRkNDJiYWM3MDQ0NDY4NzgxYTQxZmQ3ZTExYzdlZDVfMS0xLTEtMS0w_654657b4-31a2-4b4d-b7c7-446f92927d9f"
      unitRef="usd">344574</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOjI0ZDQyYmFjNzA0NDQ2ODc4MWE0MWZkN2UxMWM3ZWQ1L3RhYmxlcmFuZ2U6MjRkNDJiYWM3MDQ0NDY4NzgxYTQxZmQ3ZTExYzdlZDVfMi0xLTEtMS0w_a6a8e5f9-d872-452a-b78b-c002c95b37c6"
      unitRef="usd">172310</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOjI0ZDQyYmFjNzA0NDQ2ODc4MWE0MWZkN2UxMWM3ZWQ1L3RhYmxlcmFuZ2U6MjRkNDJiYWM3MDQ0NDY4NzgxYTQxZmQ3ZTExYzdlZDVfMy0xLTEtMS0w_afb592dd-c784-4ef2-b691-60c79b2ff803"
      unitRef="usd">163198</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOjI0ZDQyYmFjNzA0NDQ2ODc4MWE0MWZkN2UxMWM3ZWQ1L3RhYmxlcmFuZ2U6MjRkNDJiYWM3MDQ0NDY4NzgxYTQxZmQ3ZTExYzdlZDVfNC0xLTEtMS0w_7aa7f327-95f8-4aa4-9963-35b399448c54"
      unitRef="usd">335508</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOjIyZjU5ZGJmNTBmOTQ3YjI5NWNhY2I2MzQyNzI1ZTlmL3RhYmxlcmFuZ2U6MjJmNTlkYmY1MGY5NDdiMjk1Y2FjYjYzNDI3MjVlOWZfNC0xLTEtMS0w_bddcd83b-2275-49be-9e35-fa120f5b2299">P2Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOjIyZjU5ZGJmNTBmOTQ3YjI5NWNhY2I2MzQyNzI1ZTlmL3RhYmxlcmFuZ2U6MjJmNTlkYmY1MGY5NDdiMjk1Y2FjYjYzNDI3MjVlOWZfNS0xLTEtMS0w_06f66d3a-fd48-4922-89d3-efb1ca919efa"
      unitRef="number">0.076</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RleHRyZWdpb246ZGM3YmMyNzE5ZTYwNGMyNjlkMWNiNjIxY2JhMTE0NDNfMTA5OTUxMTYyODYwOTI_4f112bb5-044a-45cc-825f-387a85f16428">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Future minimum operating minimum lease payments for all leases, exclusive of taxes and other carrying charges, are approximately as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;191,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;160,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;364,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(28,645)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Present value of minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;335,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOjA4MmU1NDQxOTMzZTQxM2Q4MTJjOGM2MDNjODVlZTFhL3RhYmxlcmFuZ2U6MDgyZTU0NDE5MzNlNDEzZDgxMmM4YzYwM2M4NWVlMWFfMi0yLTEtMS0w_06a2cdb6-969f-4ba3-bb62-30403709f98b"
      unitRef="usd">191890</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOjA4MmU1NDQxOTMzZTQxM2Q4MTJjOGM2MDNjODVlZTFhL3RhYmxlcmFuZ2U6MDgyZTU0NDE5MzNlNDEzZDgxMmM4YzYwM2M4NWVlMWFfMy0yLTEtMS0w_526364fc-eae0-4949-aff4-7575bdf054c2"
      unitRef="usd">160909</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOjA4MmU1NDQxOTMzZTQxM2Q4MTJjOGM2MDNjODVlZTFhL3RhYmxlcmFuZ2U6MDgyZTU0NDE5MzNlNDEzZDgxMmM4YzYwM2M4NWVlMWFfNC0yLTEtMS0w_7bcb7e65-aa8c-491a-a212-beee2be70a62"
      unitRef="usd">11354</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOjA4MmU1NDQxOTMzZTQxM2Q4MTJjOGM2MDNjODVlZTFhL3RhYmxlcmFuZ2U6MDgyZTU0NDE5MzNlNDEzZDgxMmM4YzYwM2M4NWVlMWFfNS0yLTEtMS0w_3c985ba2-59b3-4da3-a10a-5f940e1c22ff"
      unitRef="usd">364153</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOjA4MmU1NDQxOTMzZTQxM2Q4MTJjOGM2MDNjODVlZTFhL3RhYmxlcmFuZ2U6MDgyZTU0NDE5MzNlNDEzZDgxMmM4YzYwM2M4NWVlMWFfNi0yLTEtMS0w_cd716466-c562-43a7-b66c-643c50a85d41"
      unitRef="usd">28645</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOjA4MmU1NDQxOTMzZTQxM2Q4MTJjOGM2MDNjODVlZTFhL3RhYmxlcmFuZ2U6MDgyZTU0NDE5MzNlNDEzZDgxMmM4YzYwM2M4NWVlMWFfNy0yLTEtMS0w_c48d5bce-0455-46c4-af6f-2d181ff1b512"
      unitRef="usd">335508</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RleHRyZWdpb246ZGM3YmMyNzE5ZTYwNGMyNjlkMWNiNjIxY2JhMTE0NDNfMzc0Mw_89a4764b-b491-41ce-9d14-3fc912da2404">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeFinanceLeaseDiscountRate
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RleHRyZWdpb246ZGM3YmMyNzE5ZTYwNGMyNjlkMWNiNjIxY2JhMTE0NDNfNDEwMg_8059093a-fb06-4139-8fba-3e3a6c3ee1c9"
      unitRef="number">0.076</us-gaap:LesseeFinanceLeaseDiscountRate>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RleHRyZWdpb246ZGM3YmMyNzE5ZTYwNGMyNjlkMWNiNjIxY2JhMTE0NDNfMTA5OTUxMTYyODYwOTM_060d8971-f5c2-4e43-8a90-2ea15a6a125a">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Future minimum lease payments for all financing leases, exclusive of taxes and other carrying charges, are approximately as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,851)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Present value of minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOmNmODY1NjUyY2I2ZTQ2YWFhNmJjZjJhY2E5MGRmNmJjL3RhYmxlcmFuZ2U6Y2Y4NjU2NTJjYjZlNDZhYWE2YmNmMmFjYTkwZGY2YmNfMi0yLTEtMS0w_6595f2cf-e26a-4b4b-b47c-06110656f9ea"
      unitRef="usd">23856</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOmNmODY1NjUyY2I2ZTQ2YWFhNmJjZjJhY2E5MGRmNmJjL3RhYmxlcmFuZ2U6Y2Y4NjU2NTJjYjZlNDZhYWE2YmNmMmFjYTkwZGY2YmNfMy0yLTEtMS0w_c0cb250d-1eb6-41f3-b030-7d2cb4a46193"
      unitRef="usd">9941</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOmNmODY1NjUyY2I2ZTQ2YWFhNmJjZjJhY2E5MGRmNmJjL3RhYmxlcmFuZ2U6Y2Y4NjU2NTJjYjZlNDZhYWE2YmNmMmFjYTkwZGY2YmNfNC0yLTEtMS0w_5fe49a1c-2c37-4e6a-9952-471dbfea0c9a"
      unitRef="usd">33797</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOmNmODY1NjUyY2I2ZTQ2YWFhNmJjZjJhY2E5MGRmNmJjL3RhYmxlcmFuZ2U6Y2Y4NjU2NTJjYjZlNDZhYWE2YmNmMmFjYTkwZGY2YmNfNS0yLTEtMS0w_4f843815-76b2-4714-a623-132cc9939909"
      unitRef="usd">1851</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV83OS9mcmFnOmRjN2JjMjcxOWU2MDRjMjY5ZDFjYjYyMWNiYTExNDQzL3RhYmxlOmNmODY1NjUyY2I2ZTQ2YWFhNmJjZjJhY2E5MGRmNmJjL3RhYmxlcmFuZ2U6Y2Y4NjU2NTJjYjZlNDZhYWE2YmNmMmFjYTkwZGY2YmNfNi0yLTEtMS0w_a1d1f970-5d78-4b25-85fc-9abe9ddc6353"
      unitRef="usd">31946</us-gaap:FinanceLeaseLiability>
    <ocgn:WarrantsTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTUzOTMxNjI4Mjg3Mjc_eacb5352-3bc6-4882-aad1-9a5db090f94d">Warrants&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Pre-Merger Financing Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On September&#160;27, 2019, Ocugen completed the Merger with Former Ocugen. Immediately prior to the Merger, Ocugen and Former Ocugen completed a previously announced private placement transaction with certain Investors pursuant to the Financing SPA, whereby, among other things, (i)&#160;Former Ocugen issued to the Investors shares of Former Ocugen&#x2019;s common stock, (ii)&#160;Former Ocugen issued and deposited additional shares of Former Ocugen&#x2019;s common stock into escrow, and (iii)&#160;the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Company agreed to issue on the fifth trading day following the consummation of the Merger, Series&#160;A Warrants, Series&#160;B Warrants, and Series&#160;C Warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Pre-Merger Financing Warrants are subject to blocker provisions which restrict the exercise of the Pre-Merger Financing Warrants if, as a result of such exercise, the holder, together with its affiliates would beneficially own in excess of 4.99% or 9.99% of the outstanding common stock, including the common shares issuable upon such exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Merger Financing Warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;If Ocugen fails to issue to a holder of the Pre-Merger Financing Warrants the number of shares of common stock to which such holder is entitled upon such holder&#x2019;s exercise of the such warrants, then Ocugen shall be obligated to pay the holder on each day while such failure is continuing an amount equal to 2.0% of the market value of the undelivered shares determined using any trading price of the common stock selected by the holder as in effect at any time during the period from delivery of the exercise notice until the applicable share delivery date, and if the holder purchases shares of common stock in connection with such failure, then Ocugen must, at the holder&#x2019;s discretion, reimburse the holder for the cost of such shares or deliver the owed shares and reimburse the holder for the difference between the price such holder paid for such shares and the closing market price for shares of common stock on the date of exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On November 5, 2019, the Company entered into an agreement with each Investor that amends the terms of each of the Pre-Merger Financing Warrants held by each such Investor (collectively, the &#x201c;Warrant Amendments&#x201d;). The terms of the Pre-Merger Financing Warrants and the Warrant Amendments are discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Series A Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Series&#160;A Warrants have an initial exercise price per share of $7.13, were exercisable upon issuance and have a term of 60 months from the date of issuance. The Series&#160;A Warrants are exercisable for up to 8.8&#160;million shares of Ocugen common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Series&#160;A Warrants have an anti-dilution adjustment whereby if Ocugen issues or sells, enters into a definitive, binding agreement pursuant to which Ocugen is required to issue or sell or is deemed, pursuant to the provisions of the Series&#160;A Warrants, to have issued or sold, any common stock for a price per share lower than the exercise price then in effect (a &#x201c;Dilutive Issuance&#x201d;), subject to certain limited exceptions, then (i)&#160;the exercise price of the Series&#160;A Warrants shall be reduced to such lower price per share and (ii)&#160;the number of shares issuable upon exercise of the Series&#160;A Warrants shall be increased to the number of shares of common stock determined by multiplying (a)&#160;the exercise price in effect immediately prior to such Dilutive Issuance by (b)&#160;the number of shares of common stock issuable upon exercise of the Series&#160;A Warrants immediately prior to such Dilutive Issuance (without giving effect to any limitation on exercise contained therein), and dividing the product thereof by the exercise price resulting from such Dilutive Issuance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Each Series&#160;A Warrant was amended pursuant to the Warrant Amendments such that an equity financing involving a research or non-profit foundation or organization qualified under Section&#160;501(c)&#160;of the Internal Revenue Code of 1986, as amended, in an amount of gross proceeds not to exceed $10.0&#160;million and closing on or prior to May&#160;31, 2020, will be excluded from the anti-dilution adjustment, as set forth in the Series&#160;A Warrant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Series B Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Series&#160;B Warrants have an exercise price of $0.01, were exercisable after the completion of a 10 trading-day period following the effectiveness of a registration statement covering the resale of common stock into which such warrants were exercisable and will expire on the date on which the Series&#160;B Warrants have been exercised in full (without giving effect to any limitation on exercise contained therein) and no shares remain issuable thereunder. The Series&#160;B Warrants were initially exercisable by a holder for 8.0 million shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Additionally, each Series B Warrant included a Reset Period pursuant to which the number of shares issuable upon exercise of the Series B Warrants shall be increased during certain Reset Periods (as defined in the Series B Warrants) pursuant to a formula based on the greater of (i) 80% of the arithmetic average of the two lowest dollar volume-weighted average prices of a share of Ocugen common stock on Nasdaq during the applicable Reset Period immediately preceding the applicable Reset Date to date and (ii) $1.00 (the &#x201c;Reset Price&#x201d;). Among other things, the Reset Period was triggered by the effectiveness of the registration statement covering the resale of the shares of common stock underlying the warrants (the "Registration Statement') which became effective on November 5, 2019. The Warrant Amendments provided that Series B Warrants would not be exercisable and the effectiveness of the Registration Statement would not trigger the Reset Period until the completion of a 10 trading-day period following the SEC&#x2019;s declaring it effective. The Reset Period commenced on November 20, 2019. As the dollar volume-weighted average prices of Ocugen&#x2019;s common stock on Nasdaq was under $1.00 for the first two trading days of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;the Reset Period, the Investors elected to advance the end of the Reset Period to November 21, 2019 and the number of shares issuable upon exercise of the Series B Warrants was increased based on a Reset Price of $1.00. This reset resulted in an aggregate of 12.6 million additional shares of common stock becoming issuable upon exercise of the Series B Warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Series C Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Series&#160;C Warrants were exercisable upon issuance for up to 50.0 million shares of common stock at an initial exercise price of $7.13 per share. Each of the Series&#160;C Warrants was amended pursuant to the Warrant Amendments to permit the Investors, in lieu of making any cash payment otherwise contemplated to be made to the Company upon the exercise of the Series&#160;C Warrant, to elect instead to receive upon such exercise up to 20.0 million shares of common stock.&#160;Prior to the Warrant Amendments, the Series&#160;C Warrants had permitted the exercise without any cash payment of up to 50.0 million shares of common stock in the event that the volume weighted-average price of the common stock on Nasdaq was less than or equal to $1.20 per share on any &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTUzOTMxNjI4MzE0NTk_881a6831-237f-403e-b78d-48afce88aefa"&gt;five&lt;/span&gt; trading days following the issuance of the Series&#160;C Warrants. The Series C Warrants will expire upon the 45&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;th&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;trading day immediately following the earlier to occur of (i)&#160;the date the holder can sell all shares issuable upon exercise of the Series&#160;C Warrants pursuant to Rule&#160;144 without restriction or limitation and without the requirement to be in compliance with Rule&#160;144(c)(1)&#160;and (ii)&#160;October&#160;4, 2020, provided that if such date falls on a day other than a business day or on which trading does not take place on Nasdaq (a &#x201c;Holiday&#x201d;), the next day that is not a Holiday.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the activity of the Pre-Merger Financing Warrants, including the effect of the Warrant Amendments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:31.479%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.520%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.520%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.520%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.625%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Series A Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Series B Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Series C Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,771,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,614,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,385,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20,613,036)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(19,999,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(40,612,036)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,771,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,773,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$                      0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Accounting for the Pre-Merger Financing Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Although the Pre-Merger Financing Warrants were issued on October&#160;4, 2019, the agreement for issuance of the Pre-Merger Financing Warrants was a firm commitment reached between Ocugen and the Investors as part of the Financing SPA upon the closing of the Merger. Therefore, for accounting purposes the issuance date was determined to be the date of the Merger. As of the date of the Merger, the Series&#160;A Warrants and Series C Warrants were classified as equity and the Series&#160;B Warrants were classified as a liability on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Series B Warrants were classified as a liability as they did not meet the derivative scope exception related to equity indexation because the Reset Date was triggered on the effective date of a Registration Statement and the timing of when a Registration Statement for the underlying shares is available is not an input in an option pricing model. Series&#160;B Warrants were classified as a derivative liability in the consolidated balance sheet measured at fair value on September 27, 2019 and marked to market at September 30, 2019. Upon the completion of the Reset Period, the Series B Warrants were reassessed and determined to meet the derivative scope exception allowing for equity classification. The Series B Warrants were marked to market a final time as a change in the fair value of a derivative liability and the remaining liability balance was reclassified to equity. Subsequent to the Reset Period, almost all of the Series B Warrants were exercised for shares of common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table provides a roll-forward of the Series&#160;B Warrant liability:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value at issuance (September&#160;27, 2019)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,387,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value of embedded derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,867,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount reclassified to equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(11,255,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of the Series&#160;B Warrants upon issuance was calculated using a Monte Carlo simulation while estimating the stock price during the 45-day Reset Period, based on the terms described within the Financing SPA. Key fair value inputs included the starting stock price, expected stock volatility during the 45-day Reset Period, and additional shares issued from escrow. The methodology for measuring fair value was sensitive to the expected stock volatility assumption input mentioned above. The volatility used in the fair value estimate at issuance was 96.0%. Inputs used in the valuation are unobservable and are therefore classified as Level 3 fair value inputs. The fair value of the Series B Warrants upon the end of the Reset Period was based on a Black-Scholes valuation model, which is classified as Level 3 in the fair value hierarchy. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Accounting for the Warrant Amendments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounted for the Warrant Amendments as a modification by assessing whether the modification resulted in an incremental fair value of the warrants. An increase in fair value resulting from the modification may be recognized as expense in the consolidated statements of operations and comprehensive loss, whereas a decrease in fair value is not recognized. The Company determined that the modifications to the Series A Warrants and Series B Warrants were not substantive amendments that would result in an increase in fair value based on a qualitative assessment of the terms of the amendments. The Series C Warrants were determined to substantially modified. The Company estimated the fair value of the Series C Warrants immediately prior to and immediately after the modification and concluded that the fair value of the warrants decreased and therefore there was no incremental fair value to recognize resulting from the modification. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Former Ocugen Warrants&lt;/span&gt;&lt;/div&gt;Prior to 2018, Former Ocugen issued warrants to investors of the Company pursuant to a stockholders' agreement and to two employees of the Company pursuant to their respective employment agreements. As of December 31, 2019 and 2018, 0.9 million warrants to purchase common stock were outstanding and exercisable and had a weighted average exercise price of $5.67 per share. The warrants expire between 2025 and 2027.</ocgn:WarrantsTextBlock>
    <ocgn:PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionLowerPercentageOfCommonStock
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTUzOTMxNjI4Mjg3MzI_88de9d62-945f-4801-a8ad-c551b7558f9f"
      unitRef="number">0.0499</ocgn:PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionLowerPercentageOfCommonStock>
    <ocgn:PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionHigherPercentageOfCommonStock
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTUzOTMxNjI4Mjg3NDE_4bfb0dc5-6442-4df6-a61e-98de3144d24a"
      unitRef="number">0.0999</ocgn:PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionHigherPercentageOfCommonStock>
    <ocgn:PercentageOfAmountOnMarketValueForFailureToIssueCommonStockOnPreMergerFinancingWarrants
      contextRef="if38d3cddf7364a18958c9f6b986c7132_D20190927-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTA5OTUxMTYzMjAzMDg_129fe7f4-1adc-4b3c-9867-ba5d43c03df8"
      unitRef="number">0.020</ocgn:PercentageOfAmountOnMarketValueForFailureToIssueCommonStockOnPreMergerFinancingWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i6745b0e5cb764520ba29b0c6f1b86602_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfNjA0NzMxMzk2MzYzOQ_47c63b9a-b137-4c7c-bb8e-896fb5166cf4"
      unitRef="usdPerShare">7.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i6745b0e5cb764520ba29b0c6f1b86602_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfNjA0NzMxMzk2MzY0NA_b2fefbb8-9bf7-4b36-ae83-7e672950aa83">P60M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i6745b0e5cb764520ba29b0c6f1b86602_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfNjA0NzMxMzk5MTAyMA_56026b49-b0d2-433c-b414-77dba9b16bab"
      unitRef="shares">8800000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ocgn:ProceedsFromWarrantExercisesMaximumAmount
      contextRef="ieef5bdfd701441fea03e6621fed01d9d_D20191105-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTA5OTUxMTYzMjAzMTQ_87f131d6-d467-4587-97c6-a5e9093bd6af"
      unitRef="usd">10000000.0</ocgn:ProceedsFromWarrantExercisesMaximumAmount>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i77f0ebf13e6e4a578b9b6ffd815a024e_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfNjA0NzMxMzk2MzY1NA_8d46bca6-2515-4d2a-9427-242da3745712"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ocgn:ClassOfWarrantOrRightExercisePriceDeterminationNumberOfTradingDaysConsidered
      contextRef="ice482ddff55b45b4a75e3de02537f56b_D20191105-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTA5OTUxMTYzMjk2NjQ_e8127236-b094-4253-a188-8540344abba0">P10D</ocgn:ClassOfWarrantOrRightExercisePriceDeterminationNumberOfTradingDaysConsidered>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i77f0ebf13e6e4a578b9b6ffd815a024e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfNjA0NzMxMzk5MTA0MA_a9437042-4adf-4e45-bbd9-590f3f81ec37"
      unitRef="usd">8000000.0</us-gaap:WarrantsAndRightsOutstanding>
    <ocgn:ConvertedAdditionalSharesThresholdReleaseTrigger
      contextRef="i77f0ebf13e6e4a578b9b6ffd815a024e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTA5OTUxMTYzMjAzMjk_f06a155c-fb29-4aa2-8bd2-2c6edc0eb111"
      unitRef="number">0.80</ocgn:ConvertedAdditionalSharesThresholdReleaseTrigger>
    <ocgn:ConvertedAdditionalSharesThresholdReleaseTriggerPrice
      contextRef="ice482ddff55b45b4a75e3de02537f56b_D20191105-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTA5OTUxMTYzMjAzMzQ_3068da9b-bd6f-43a3-90c0-c095b96b45f6"
      unitRef="usdPerShare">1.00</ocgn:ConvertedAdditionalSharesThresholdReleaseTriggerPrice>
    <ocgn:ConvertedAdditionalSharesThresholdReleaseTriggerPrice
      contextRef="i3cf5412727aa4f75918abdb76b03caf7_D20191120-20191121"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTA5OTUxMTYzMjAzNDI_c9258290-7fb3-480a-8dd5-93003af7597f"
      unitRef="usdPerShare">1.00</ocgn:ConvertedAdditionalSharesThresholdReleaseTriggerPrice>
    <ocgn:ConvertedAdditionalSharesThresholdReleaseTriggerPrice
      contextRef="i9a4dec58cf3a474a90c3320d94bff77c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTA5OTUxMTYzMjAzNDk_6ced5bca-0073-42c0-98f6-6b072b124696"
      unitRef="usdPerShare">1.00</ocgn:ConvertedAdditionalSharesThresholdReleaseTriggerPrice>
    <ocgn:CommonStockAdditionalSharesOfCommonStockIssuableUponExerciseOfWarrantsBasedOnResetPeriodShares
      contextRef="i77f0ebf13e6e4a578b9b6ffd815a024e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfNjA0NzMxMzk5MTA4Mw_51fbf27c-f8fe-4d1a-bee8-c53203e3e8e5"
      unitRef="shares">12600000</ocgn:CommonStockAdditionalSharesOfCommonStockIssuableUponExerciseOfWarrantsBasedOnResetPeriodShares>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i914cfde7eb234db2ac6c9112d30eadfb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfNjA0NzMxMzk2MzY5NA_46af1248-51f5-4b91-afb0-67e4121cb8a3"
      unitRef="shares">50000000.0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ib3301d78826140fb96af8db1fc68d531_I20191104"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfNjA0NzMxMzk2MzY4OQ_9cc403a7-6aea-4035-8ae8-8b6b314e7b7a"
      unitRef="usdPerShare">7.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i1153f084349d4b7ea469d4f40aff5141_I20191105"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfNDk0NzgwMjM0ODYxMQ_dd775a4e-c6b8-47d3-b9f7-7a0d81ef63e8"
      unitRef="shares">20000000.0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ibca9608a3ab44021be1d03353a57553c_I20191104"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfNDk0NzgwMjM0ODc1NA_dbe61b83-a573-473f-9f82-4e3384f06c77"
      unitRef="shares">50000000.0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ocgn:ConvertedAdditionalSharesThresholdReleaseTriggerPrice
      contextRef="i3da044ce503648edbe7ad9e78f55ca78_D20191105-20191105"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfNDk0NzgwMjM0ODg4OA_8dade037-f6ce-44cd-b5cf-f96cc74025d6"
      unitRef="usdPerShare">1.20</ocgn:ConvertedAdditionalSharesThresholdReleaseTriggerPrice>
    <ocgn:ClassOfWarrantOrRightConditionForExpirationTradingDay
      contextRef="if254d19519344254a9f50cfcfe386457_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTUzOTMxNjI4MzE0NjE_140ad7d6-6e05-4c57-a58d-1a1b2b198ee0">P45D</ocgn:ClassOfWarrantOrRightConditionForExpirationTradingDay>
    <ocgn:ScheduleOfPreMergerFinancingWarrantsTableTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTA5OTUxMTYzMjk2MDk_058eef10-525f-465c-814d-d37794be469e">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the activity of the Pre-Merger Financing Warrants, including the effect of the Warrant Amendments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:31.479%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.520%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.520%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.520%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.625%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Series A Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Series B Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Series C Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,771,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,614,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,385,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20,613,036)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(19,999,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(40,612,036)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,771,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,773,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$                      0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ocgn:ScheduleOfPreMergerFinancingWarrantsTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i27857d6d3d5a42bd93969147f2520cad_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfMS0yLTEtMS0xNDcwOA_ad06cc15-9b10-4844-9d08-f4ea70dee04e"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i71ce16f5e5214d2780d7f39624f8b29d_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfMS00LTEtMS0xNDcxMA_63a5c09f-b5cf-4034-b6ff-93131a552775"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i1d0d3793e46440a899ad41a111b2431f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfMS02LTEtMS0xNDcxMg_17644656-c170-4747-b7ed-cdfdcf2824e1"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfMS04LTEtMS0xNDcxNA_ee01fc4e-d649-4da5-a24e-589d05bf9197"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ocgn:ClassOfWarrantOrRightIssued
      contextRef="i1b2b631bda3048ee8c734721295f429a_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfMi0yLTEtMS0xNDcwOA_e1ee5e82-2ca0-4697-b687-fa263a75e86e"
      unitRef="shares">8771928</ocgn:ClassOfWarrantOrRightIssued>
    <ocgn:ClassOfWarrantOrRightIssued
      contextRef="i9a4dec58cf3a474a90c3320d94bff77c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfMi00LTEtMS0xNDcxMA_51072fa5-2540-4344-b440-0bc0f0ab2f3c"
      unitRef="shares">20614036</ocgn:ClassOfWarrantOrRightIssued>
    <ocgn:ClassOfWarrantOrRightIssued
      contextRef="if254d19519344254a9f50cfcfe386457_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfMi02LTEtMS0xNDcxMg_3e2f94dc-b7f7-4dec-9259-701df48705b2"
      unitRef="shares">20000000</ocgn:ClassOfWarrantOrRightIssued>
    <ocgn:ClassOfWarrantOrRightIssued
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfMi04LTEtMS0xNDcxNA_9dffe7ec-299e-46a8-917b-0b28aa814092"
      unitRef="shares">49385964</ocgn:ClassOfWarrantOrRightIssued>
    <ocgn:ClassOfWarrantOrRightExercised
      contextRef="i1b2b631bda3048ee8c734721295f429a_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfMy0yLTEtMS0xNDcwOA_19481ba5-a21d-4962-bb72-36aa41ef2e96"
      unitRef="shares">0</ocgn:ClassOfWarrantOrRightExercised>
    <ocgn:ClassOfWarrantOrRightExercised
      contextRef="i9a4dec58cf3a474a90c3320d94bff77c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfMy00LTEtMS0xNDcxMA_8be05a79-5bea-43f4-94f1-371d3c711fac"
      unitRef="shares">20613036</ocgn:ClassOfWarrantOrRightExercised>
    <ocgn:ClassOfWarrantOrRightExercised
      contextRef="if254d19519344254a9f50cfcfe386457_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfMy02LTEtMS0xNDcxMg_a410daa9-7fdf-439b-adca-f126878be06e"
      unitRef="shares">19999000</ocgn:ClassOfWarrantOrRightExercised>
    <ocgn:ClassOfWarrantOrRightExercised
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfMy04LTEtMS0xNDcxNA_1479a678-98d7-4995-bd96-d6c6cd16dada"
      unitRef="shares">40612036</ocgn:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i6745b0e5cb764520ba29b0c6f1b86602_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfNC0yLTEtMS0xNDcwOA_4cf08e64-8a8a-4513-8193-20b37d3093fa"
      unitRef="shares">8771928</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i77f0ebf13e6e4a578b9b6ffd815a024e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfNC00LTEtMS0xNDcxMA_c3dd10e7-259f-47b4-a3c0-268db7403dbc"
      unitRef="shares">1000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i914cfde7eb234db2ac6c9112d30eadfb_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfNC02LTEtMS0xNDcxMg_29a93a44-e45d-47a4-b816-4218019a7e58"
      unitRef="shares">1000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfNC04LTEtMS0xNDcxNA_438e8da4-374d-477f-a72f-afbad2f4f4e9"
      unitRef="shares">8773928</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i6745b0e5cb764520ba29b0c6f1b86602_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfNS0yLTEtMS0xNDcwOA_2a50829c-f74e-4ba0-95cd-a82c6f89a0f4"
      unitRef="usdPerShare">7.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i77f0ebf13e6e4a578b9b6ffd815a024e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfNS00LTEtMS0xNDcxMA_fcc9e8c3-3a09-4921-ae74-bd040c494622"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i914cfde7eb234db2ac6c9112d30eadfb_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOmY0NjdjNWJkNjllNzRhZjM5MzNjZWQwZWVmZDZmOWY5L3RhYmxlcmFuZ2U6ZjQ2N2M1YmQ2OWU3NGFmMzkzM2NlZDBlZWZkNmY5ZjlfNS02LTEtMS0xNDcxMg_7740431e-7e26-4e2e-9a28-6ed27a8a41c7"
      unitRef="usdPerShare">0.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTUzOTMxNjI4Mjg3Mjg_f9e7fe32-3dde-4a8a-9ce0-dc47f6c49865">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table provides a roll-forward of the Series&#160;B Warrant liability:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value at issuance (September&#160;27, 2019)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,387,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value of embedded derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,867,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount reclassified to equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(11,255,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="i71ce16f5e5214d2780d7f39624f8b29d_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOjcwYzQzNDM0MTdmMDQyNWJiZmI1NjcxYWY3MmY2YTBlL3RhYmxlcmFuZ2U6NzBjNDM0MzQxN2YwNDI1YmJmYjU2NzFhZjcyZjZhMGVfMS0xLTEtMS0w_081bf7fc-e40a-49d1-96b4-227b34d93103"
      unitRef="usd">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
      contextRef="i9a4dec58cf3a474a90c3320d94bff77c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOjcwYzQzNDM0MTdmMDQyNWJiZmI1NjcxYWY3MmY2YTBlL3RhYmxlcmFuZ2U6NzBjNDM0MzQxN2YwNDI1YmJmYjU2NzFhZjcyZjZhMGVfMi0xLTEtMS0w_763e03c9-eebd-4233-829d-229791fc379b"
      unitRef="usd">9387760</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease
      contextRef="i9a4dec58cf3a474a90c3320d94bff77c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOjcwYzQzNDM0MTdmMDQyNWJiZmI1NjcxYWY3MmY2YTBlL3RhYmxlcmFuZ2U6NzBjNDM0MzQxN2YwNDI1YmJmYjU2NzFhZjcyZjZhMGVfMy0xLTEtMS0w_43e69d25-b6e2-4037-8c0b-90509986e303"
      unitRef="usd">1867980</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease>
    <ocgn:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationAmountReclassifiedToEquity
      contextRef="i9a4dec58cf3a474a90c3320d94bff77c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOjcwYzQzNDM0MTdmMDQyNWJiZmI1NjcxYWY3MmY2YTBlL3RhYmxlcmFuZ2U6NzBjNDM0MzQxN2YwNDI1YmJmYjU2NzFhZjcyZjZhMGVfNC0xLTEtMS00MTE3_3aa55b6e-ee9f-4e5e-9121-0d6d0878550b"
      unitRef="usd">11255740</ocgn:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationAmountReclassifiedToEquity>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="i77f0ebf13e6e4a578b9b6ffd815a024e_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RhYmxlOjcwYzQzNDM0MTdmMDQyNWJiZmI1NjcxYWY3MmY2YTBlL3RhYmxlcmFuZ2U6NzBjNDM0MzQxN2YwNDI1YmJmYjU2NzFhZjcyZjZhMGVfNC0xLTEtMS0w_84cbf107-c16b-4478-a07f-6ec0ede377b1"
      unitRef="usd">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <ocgn:ClassOfWarrantOrRightConditionForExpirationTradingDay
      contextRef="ia7980383d2e44bc2b50a1d2faf810a91_D20190927-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTUzOTMxNjI4MzE0Njk_c363e06a-3de4-4375-8a1b-688a824496b3">P45D</ocgn:ClassOfWarrantOrRightConditionForExpirationTradingDay>
    <ocgn:ClassOfWarrantOrRightConditionForExpirationTradingDay
      contextRef="i9a4dec58cf3a474a90c3320d94bff77c_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTUzOTMxNjI4MzE0NjU_28b48fa9-0db5-40f3-aa21-d59bb5ba324e">P45D</ocgn:ClassOfWarrantOrRightConditionForExpirationTradingDay>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i8c7e388caf954f629bf3e170e216d890_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfNDk0NzgwMjM1NjA2OQ_2a23d5c8-280f-41ee-b88c-3cd017574995"
      unitRef="measurementinput">0.960</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <ocgn:NumberOfFormerEmployeesWithWarrants
      contextRef="i3b0b2789ee4e45ff8aa700de563ddc85_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTA5OTUxMTYzMjk3NDU_9cc9a4bf-b31b-4a49-bf59-017342eff74c"
      unitRef="segment">2</ocgn:NumberOfFormerEmployeesWithWarrants>
    <ocgn:ClassOfWarrantOrRightExercisable
      contextRef="ic2c38d1a38a84e6a82c73b5a98cb3e80_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfODc5NjA5MzA2NjQ2NQ_9dfe4d8a-0bca-4e94-85e0-ab4d750506ce"
      unitRef="shares">900000</ocgn:ClassOfWarrantOrRightExercisable>
    <ocgn:ClassOfWarrantOrRightExercisable
      contextRef="i86aee3af2c3f4b798c30aaca8de9b337_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfODc5NjA5MzA2NjQ2NQ_c5b73fd9-2144-494e-b04f-d0ea9d6055ae"
      unitRef="shares">900000</ocgn:ClassOfWarrantOrRightExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i86aee3af2c3f4b798c30aaca8de9b337_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTUzOTMxNjI4MzE0ODM_c9dc0565-35e5-4468-aff1-76ca2c579c36"
      unitRef="usdPerShare">5.67</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF8xNTM5MzE2Mjc5NzE4Mg_11de8e1b-5627-4d6c-9a10-a21321de2aa1">Income TaxesFor the years ended December 31, 2019 and 2018, the Company did not recognize any current or deferred income tax expense or benefit due to the current and historical losses incurred by the Company. Losses before income taxes were $20.2 million and $18.2 million for the years ended December&#160;31, 2019 and 2018, respectively, substantially all of which were incurred in the United States.&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company&#x2019;s deferred tax assets and liabilities are comprised of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;margin-bottom:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.175%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31,575,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,864,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Capital loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,298,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Start-up costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,234,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accruals and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;166,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Intellectual property amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;555,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;121,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,123,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;993,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Convertible debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;498,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,926,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;548,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;96,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,976,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,061,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(53,877,168)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9,061,568)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax assets, net of allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;99,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Lease ROU asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(99,558)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;As of December&#160;31, 2019 and 2018, the Company had U.S. federal net operating loss ("NOL") carryforwards of $113.6 million and $23.7&#160;million, respectively, which may be available to offset future income tax liabilities. The Tax Cut and Jobs Act, which was enacted in December 2017, will generally allow federal losses generated after 2017 to be carried over indefinitely, but will generally limit the NOL deduction to the lesser of the NOL carryover or 80% of a corporation&#x2019;s taxable income. In addition, there will be no carryback for losses generated after 2017. Losses generated prior to 2018 will generally be deductible to the extent of the lesser of a corporation&#x2019;s NOL carryover or 100% of a corporation&#x2019;s taxable income and be available for twenty years from the period the loss was generated. The Company has federal NOLs generated after 2017 of $61.2 million, which do not expire. The federal NOLs generated prior to 2018 of $52.4 million will expire at various dates through 2037. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;As of December&#160;31, 2019 and 2018, the Company also had U.S. state NOL carryforwards of $112.4 million and $23.7&#160;million, respectively, which may be available to offset future income tax liabilities and expire at various dates through 2039. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;As of December&#160;31, 2019 and 2018, the Company has federal tax credit carryforwards of approximately $1.6&#160;million and $0.8 million, respectively, which are available to offset future federal tax liabilities which expire at various dates through 2039. As of December&#160;31, 2019 and 2018, the Company has state tax credit carryforwards of approximately $0.4&#160;million and $0.1&#160;million, respectively, which are available to reduce future tax liabilities which expire at various dates through 2034. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The Company has recorded a full valuation allowance against its net deferred tax assets as of December&#160;31, 2019 and 2018 because the Company has determined that is it more likely than not that these assets will not be fully realized due to the Company's history of operating losses and lack of available evidence supporting future taxable income. The Company experienced a net change in valuation allowance of $44.8 million during the year ended December 31, 2019, primarily related to the increase in NOL carryforwards. The increase in the federal and state NOL carryforwards during the year ended December 31, 2019 was primarily due to the acquired NOL carryforwards as a result of the Merger. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Under the provisions of the IRC, the NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Utilization of U.S. federal and state operating loss and tax credit carryforwards may be subject to a substantial annual limitation under Section 382 and Section 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of NOL and tax credit carryforwards that can be utilized annually to offset future taxable income and tax liabilities, respectively. The Company acquired a significant amount of federal and state NOL carryforwards and federal and state tax credit carryforwards as a result of the Merger. The Company &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;has not yet conducted a comprehensive study to assess whether a change of ownership has occurred, or whether there have been multiple ownership changes since its formation. Any limitation may result in expiration of a portion of the NOL carryforward or tax credit carryforwards before utilization, which would be offset by a change in the Company's valuation allowance. Further, until a study is completed by the Company and any limitation is known, no amounts are being presented as an uncertain tax position. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The reconciliation of federal statutory income tax to the Company's provision for income taxes is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.175%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected provision at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State tax - net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(24.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(29.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross unrecognized tax benefits as of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions for tax positions taken in a prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;303,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions for tax positions taken in the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Reductions for tax positions taken in the prior year due to settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Reductions for tax positions taken in the prior year due to statutes lapsing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross unrecognized tax benefits as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;303,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The uncertain tax positions giving rise to the unrecognized tax benefits of $0.3&#160;million at December&#160;31, 2019 relate to the timing of certain income and deductions for federal income tax purposes taken by Histogenics prior to the Merger. The reversal of unrecognized tax benefits would not have any impact on the effective tax rate in future periods and is not expected to create cash tax liability.&lt;/span&gt;&lt;/div&gt;The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In a normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The Company&#x2019;s tax years are still open under status from 2016 to present.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF83MTQ2ODI1NjI0MzM4_81df8153-8238-4436-aa18-aac2d1b897a7"
      unitRef="usd">-20200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF83MTQ2ODI1NjI0MzU3_c99ae0fd-ea38-4a97-871d-cdd7c6060399"
      unitRef="usd">-18200000</us-gaap:NetIncomeLoss>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF8xNTM5MzE2Mjc5NzE4Mw_42cb9e06-13c3-4217-948c-08cc10e6e60d">The significant components of the Company&#x2019;s deferred tax assets and liabilities are comprised of the following: &lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.175%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31,575,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,864,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Capital loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,298,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Start-up costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,234,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accruals and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;166,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Intellectual property amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;555,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;121,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,123,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;993,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Convertible debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;498,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,926,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;548,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;96,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,976,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,061,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(53,877,168)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9,061,568)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax assets, net of allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;99,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Lease ROU asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(99,558)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV8zLTEtMS0xLTE1MzYx_06710877-ce26-491b-b6e3-93886b820e90"
      unitRef="usd">31575288</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV8zLTMtMS0xLTE1MzY1_e2961160-f1e8-4a89-a3da-ed6f7346fc99"
      unitRef="usd">6864360</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV80LTEtMS0xLTE1MzYx_8612719e-9fcf-4d29-ad70-867f743ce417"
      unitRef="usd">7298052</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV80LTMtMS0xLTE1MzY1_c4c0bab0-08a2-4add-9d61-1b4aceba2e05"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <ocgn:DeferredTaxAssetsStartUpCosts
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV81LTEtMS0xLTE1MzYx_93a50580-6a9e-4ccb-bbf0-228259b65dce"
      unitRef="usd">11234751</ocgn:DeferredTaxAssetsStartUpCosts>
    <ocgn:DeferredTaxAssetsStartUpCosts
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV81LTMtMS0xLTE1MzY1_068ecd49-5db4-4f35-abc8-5c4b5d731491"
      unitRef="usd">0</ocgn:DeferredTaxAssetsStartUpCosts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV82LTEtMS0xLTE1MzYx_b8175461-c84f-4515-ae8f-89b68cd8348b"
      unitRef="usd">166611</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV82LTMtMS0xLTE1MzY1_a7036e05-6d37-4e5e-bd19-c7461e0ed537"
      unitRef="usd">35645</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV83LTEtMS0xLTE1MzYx_d73c1184-c8e9-4b77-9383-a27ca9a55c47"
      unitRef="usd">555352</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV83LTMtMS0xLTE1MzY1_934435d1-b3cc-4593-9632-8f0471354406"
      unitRef="usd">121694</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV84LTEtMS0xLTE1MzYx_2202ce86-4485-40a8-892f-29b3535ce1a2"
      unitRef="usd">1123100</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV84LTMtMS0xLTE1MzY1_a15e6276-0122-499b-8695-fe4f63e99012"
      unitRef="usd">993234</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <ocgn:DeferredTaxAssetsConvertibleDebt
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV8zLTItMS0xLTI5MjE_cc0a00ec-c706-4287-9e7e-d13857ee4cbc"
      unitRef="usd">0</ocgn:DeferredTaxAssetsConvertibleDebt>
    <ocgn:DeferredTaxAssetsConvertibleDebt
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV8zLTQtMS0xLTI5MjQ_25e47d91-9242-4528-88b3-a2372dbe1933"
      unitRef="usd">498236</ocgn:DeferredTaxAssetsConvertibleDebt>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV8xMC0xLTEtMS0xNTM2MQ_14a9771f-ac1b-42e3-8084-20f015792960"
      unitRef="usd">1926677</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV8xMC0zLTEtMS0xNTM2NQ_1ebcb708-20ff-4f65-96fa-05bb19fae417"
      unitRef="usd">548399</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <ocgn:DeferredTaxAssetsLeaseLiability
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV80LTItMS0xLTI5MjE_dabca6e1-89a5-42f9-aab0-f9021e25a6d1"
      unitRef="usd">96895</ocgn:DeferredTaxAssetsLeaseLiability>
    <ocgn:DeferredTaxAssetsLeaseLiability
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV80LTQtMS0xLTI5MjQ_cad37882-a0ae-491c-8fa9-eedff93506af"
      unitRef="usd">0</ocgn:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV85LTItMS0xLTI5MjE_68fb3417-f12b-44b6-9aa8-537fb8b65bed"
      unitRef="usd">53976726</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV85LTQtMS0xLTI5MjQ_0c97d569-e167-498a-81ec-e56d8b5582dc"
      unitRef="usd">9061568</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV8xMC0yLTEtMS0yOTIx_14d012a6-55d7-4dac-8289-ef8527b800aa"
      unitRef="usd">53877168</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV8xMC00LTEtMS0yOTI0_0fc44351-5d21-4c60-9794-e555f98b6c0d"
      unitRef="usd">9061568</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV8xMS0yLTEtMS0yOTIx_5ca4c2e1-7bac-4ae8-bab5-49ca3fe6f38c"
      unitRef="usd">99558</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV8xMS00LTEtMS0yOTI0_3e6f9a37-e4f5-4bdc-9053-f9d2c0d980b6"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV8xNy0xLTEtMS0xNTM5OQ_50ef0f5c-6608-467b-8e99-ac43f3f45327"
      unitRef="usd">99558</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV8xNy0zLTEtMS0xNTQwMg_d37ecd79-f9e5-42de-9611-ef53e0ee9750"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV8xOC0xLTEtMS0xNTM5OQ_c325b337-2b31-40f7-ac69-de376b441172"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MDJhZmE5OGY2MjIwNDFmMzg1Yjc3YWE0ODk5ODVjNWEvdGFibGVyYW5nZTowMmFmYTk4ZjYyMjA0MWYzODViNzdhYTQ4OTk4NWM1YV8xOC0zLTEtMS0xNTQwMg_faaaa777-b9c4-4f7e-be15-698dc2be4ca1"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i3cbe8832ab0843b598d967b9b9032b0d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF81NDk3NTU4MTQzMDY0_0e5c92c5-c24d-4e03-a2cf-ed570af44f4b"
      unitRef="usd">113600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i3d8219b4b2bc4150b6b1c651c7d324a5_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF83MTQ2ODI1NjI1Mzkw_03d9ee64-00ad-4750-8526-af12d8009d6d"
      unitRef="usd">23700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="i3cbe8832ab0843b598d967b9b9032b0d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF83MTQ2ODI1NjI1NDU2_e3cb3b89-0c06-4058-a6eb-a5ca4f28338f"
      unitRef="usd">61200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="i3cbe8832ab0843b598d967b9b9032b0d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF83MTQ2ODI1NjI1NDM2_fc1ae006-29ad-4aeb-8e44-10705007bf81"
      unitRef="usd">52400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i45e1ee8f0a174a99b058fcc427e9def5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF81NDk3NTU4MTQzMTAx_24fb0c61-641a-4ebb-b78e-fde297c32a27"
      unitRef="usd">112400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i10ef3ad5f41f48c39073eca93c89a51d_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF83MTQ2ODI1NjI1NDEz_00c18825-1e19-4b48-9128-64d02ea18dba"
      unitRef="usd">23700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i3cbe8832ab0843b598d967b9b9032b0d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF83MTQ2ODI1NjMwMjEx_3e244846-a429-4016-9c5e-d1794ff8312a"
      unitRef="usd">1600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i3d8219b4b2bc4150b6b1c651c7d324a5_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF83MTQ2ODI1NjMwMjY2_dc0c28f6-ac9f-4d4b-8c42-e1b1a7abe27f"
      unitRef="usd">800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i45e1ee8f0a174a99b058fcc427e9def5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF83MTQ2ODI1NjMwMTcz_a969b1ca-e526-45b2-9446-85877d58f893"
      unitRef="usd">400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i10ef3ad5f41f48c39073eca93c89a51d_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF83MTQ2ODI1NjMwMTg3_f8d30dad-d3df-4ff5-b3d9-e1c650645e19"
      unitRef="usd">100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF81NDk3NTU4MTQzMTgw_9f39e4ec-cba4-474e-aa46-cd92361482e3"
      unitRef="usd">44800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF8xMDk5NTExNjMzMTEyNQ_403b07f1-1882-4913-b828-1cbcc0c63b37">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The reconciliation of federal statutory income tax to the Company's provision for income taxes is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.175%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected provision at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State tax - net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(24.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(29.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6ODI3MTYzZmI0NGRjNDVkMTk2NjAyYWNlMTNlYzIzMDYvdGFibGVyYW5nZTo4MjcxNjNmYjQ0ZGM0NWQxOTY2MDJhY2UxM2VjMjMwNl8yLTItMS0xLTMwNTc_bb2a505a-2223-4ee4-91da-bf1103fe818e"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6ODI3MTYzZmI0NGRjNDVkMTk2NjAyYWNlMTNlYzIzMDYvdGFibGVyYW5nZTo4MjcxNjNmYjQ0ZGM0NWQxOTY2MDJhY2UxM2VjMjMwNl8yLTQtMS0xLTMwNjA_69aecba2-0ee7-4c39-bda8-da76ae403773"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6ODI3MTYzZmI0NGRjNDVkMTk2NjAyYWNlMTNlYzIzMDYvdGFibGVyYW5nZTo4MjcxNjNmYjQ0ZGM0NWQxOTY2MDJhY2UxM2VjMjMwNl8zLTItMS0xLTMwNTc_0ba4c64d-a0a9-439b-ba2c-3670b530db3b"
      unitRef="number">0.053</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6ODI3MTYzZmI0NGRjNDVkMTk2NjAyYWNlMTNlYzIzMDYvdGFibGVyYW5nZTo4MjcxNjNmYjQ0ZGM0NWQxOTY2MDJhY2UxM2VjMjMwNl8zLTQtMS0xLTMwNjA_bd927b7a-1525-4f8a-b3ac-bc18f4cc2f46"
      unitRef="number">0.076</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6ODI3MTYzZmI0NGRjNDVkMTk2NjAyYWNlMTNlYzIzMDYvdGFibGVyYW5nZTo4MjcxNjNmYjQ0ZGM0NWQxOTY2MDJhY2UxM2VjMjMwNl80LTItMS0xLTMwNTc_3b6d7530-1d8c-4f3a-83f2-a4330426a20d"
      unitRef="number">0.032</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6ODI3MTYzZmI0NGRjNDVkMTk2NjAyYWNlMTNlYzIzMDYvdGFibGVyYW5nZTo4MjcxNjNmYjQ0ZGM0NWQxOTY2MDJhY2UxM2VjMjMwNl80LTQtMS0xLTMwNjA_691d1c23-9020-4cc5-a485-93e0b8edda41"
      unitRef="number">0.021</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <ocgn:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6ODI3MTYzZmI0NGRjNDVkMTk2NjAyYWNlMTNlYzIzMDYvdGFibGVyYW5nZTo4MjcxNjNmYjQ0ZGM0NWQxOTY2MDJhY2UxM2VjMjMwNl81LTEtMS0xLTE1NDM0_b7b4b2e2-96a1-4442-bd51-0200845bdedb"
      unitRef="number">0.081</ocgn:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent>
    <ocgn:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6ODI3MTYzZmI0NGRjNDVkMTk2NjAyYWNlMTNlYzIzMDYvdGFibGVyYW5nZTo4MjcxNjNmYjQ0ZGM0NWQxOTY2MDJhY2UxM2VjMjMwNl81LTMtMS0xLTE1NDM0_d7cbd02f-93ff-49d5-b50b-9f8333ae9d74"
      unitRef="number">0.008</ocgn:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6ODI3MTYzZmI0NGRjNDVkMTk2NjAyYWNlMTNlYzIzMDYvdGFibGVyYW5nZTo4MjcxNjNmYjQ0ZGM0NWQxOTY2MDJhY2UxM2VjMjMwNl82LTEtMS0xLTE1NDM0_273d796b-19df-4f0d-b7a4-f5701560b365"
      unitRef="number">0.029</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6ODI3MTYzZmI0NGRjNDVkMTk2NjAyYWNlMTNlYzIzMDYvdGFibGVyYW5nZTo4MjcxNjNmYjQ0ZGM0NWQxOTY2MDJhY2UxM2VjMjMwNl82LTMtMS0xLTE1NDM0_e0381f35-ae93-40e4-aa80-4581d47a94f6"
      unitRef="number">0.0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6ODI3MTYzZmI0NGRjNDVkMTk2NjAyYWNlMTNlYzIzMDYvdGFibGVyYW5nZTo4MjcxNjNmYjQ0ZGM0NWQxOTY2MDJhY2UxM2VjMjMwNl83LTEtMS0xLTE1NDM0_82129676-6104-4391-a696-da83ac080376"
      unitRef="number">0.243</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6ODI3MTYzZmI0NGRjNDVkMTk2NjAyYWNlMTNlYzIzMDYvdGFibGVyYW5nZTo4MjcxNjNmYjQ0ZGM0NWQxOTY2MDJhY2UxM2VjMjMwNl83LTMtMS0xLTE1NDM0_7192528f-48cf-4522-849f-4fb2c60a51e0"
      unitRef="number">0.299</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6ODI3MTYzZmI0NGRjNDVkMTk2NjAyYWNlMTNlYzIzMDYvdGFibGVyYW5nZTo4MjcxNjNmYjQ0ZGM0NWQxOTY2MDJhY2UxM2VjMjMwNl84LTEtMS0xLTE1NDM0_cde20721-62e5-4d0f-ab89-358704c47d76"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i384a6eb6c2f34b8cae96d35f0b39c573_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6ODI3MTYzZmI0NGRjNDVkMTk2NjAyYWNlMTNlYzIzMDYvdGFibGVyYW5nZTo4MjcxNjNmYjQ0ZGM0NWQxOTY2MDJhY2UxM2VjMjMwNl84LTMtMS0xLTE1NDM0_23d394df-46c1-44fc-a4c3-710cbba5d971"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF8xMDk5NTExNjMzMTEyNg_1a6af7b3-dcf7-4807-92b5-979bbd6b2aed">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross unrecognized tax benefits as of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions for tax positions taken in a prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;303,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions for tax positions taken in the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Reductions for tax positions taken in the prior year due to settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Reductions for tax positions taken in the prior year due to statutes lapsing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross unrecognized tax benefits as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;303,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="id9fa7f5e04ae40a392f7022c5d18fbe1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MGMzOTNjODlhMGM1NDZhOWE5Zjg2ODFkNTg0NTU2ZmMvdGFibGVyYW5nZTowYzM5M2M4OWEwYzU0NmE5YTlmODY4MWQ1ODQ1NTZmY18xLTEtMS0xLTE1NDc5_3bfa8071-13e9-48bb-a29e-92fb7a700838"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MGMzOTNjODlhMGM1NDZhOWE5Zjg2ODFkNTg0NTU2ZmMvdGFibGVyYW5nZTowYzM5M2M4OWEwYzU0NmE5YTlmODY4MWQ1ODQ1NTZmY18yLTEtMS0xLTE1NDc5_57d645f8-4996-4f4e-9af5-8309fafe11d5"
      unitRef="usd">303050</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MGMzOTNjODlhMGM1NDZhOWE5Zjg2ODFkNTg0NTU2ZmMvdGFibGVyYW5nZTowYzM5M2M4OWEwYzU0NmE5YTlmODY4MWQ1ODQ1NTZmY18zLTEtMS0xLTE1NDc5_032656a0-f025-4660-ae67-192cb8b0d3ba"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MGMzOTNjODlhMGM1NDZhOWE5Zjg2ODFkNTg0NTU2ZmMvdGFibGVyYW5nZTowYzM5M2M4OWEwYzU0NmE5YTlmODY4MWQ1ODQ1NTZmY180LTEtMS0xLTE1NDc5_9a0ae393-6ddb-49dc-9545-1684403621d3"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MGMzOTNjODlhMGM1NDZhOWE5Zjg2ODFkNTg0NTU2ZmMvdGFibGVyYW5nZTowYzM5M2M4OWEwYzU0NmE5YTlmODY4MWQ1ODQ1NTZmY181LTEtMS0xLTE1NDc5_cee3cd0a-7807-48ff-a1a8-3f18c101b479"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGFibGU6MGMzOTNjODlhMGM1NDZhOWE5Zjg2ODFkNTg0NTU2ZmMvdGFibGVyYW5nZTowYzM5M2M4OWEwYzU0NmE5YTlmODY4MWQ1ODQ1NTZmY182LTEtMS0xLTE1NDc5_8675f73f-2bc3-4a97-9f61-97715192866a"
      unitRef="usd">303050</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia6368cd0825d4ed8bf32f05ae6035107_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV8xODg2L2ZyYWc6OTc2NDcxZjUwNzFmNDBmY2JlYjVmNjlmMWY4YmMxMzQvdGV4dHJlZ2lvbjo5NzY0NzFmNTA3MWY0MGZjYmViNWY2OWYxZjhiYzEzNF83MTQ2ODI1NjMwMDQ2_4ed8090f-b587-4556-b199-b06442664eeb"
      unitRef="usd">300000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ie74d6ac1a95045b28b4bf4a6318836ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV85MS9mcmFnOmMxOGFlZTBiMGE5OTRhNzE5NjUzNjEzOGYxZGYwYWY3L3RleHRyZWdpb246YzE4YWVlMGIwYTk5NGE3MTk2NTM2MTM4ZjFkZjBhZjdfMTA5OTUxMTYzMDI2MDI_7c25f05d-7e14-4ec9-8e20-d8ff40d9018d">Subsequent EventsOn March&#160;26, 2020, the Company borrowed an additional $0.5&#160;million under the terms and conditions of the EB-5 Loan Agreement. Outstanding borrowings pursuant to the EB-5 Program, including accrued interest, become due upon the seventh anniversary of the final disbursement. Following this borrowing, total principal outstanding under the EB-5 Loan Agreement is $1.5&#160;million.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i1e36ccdb3dcd46a4ba0bf2a92174d054_D20200326-20200326"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV85MS9mcmFnOmMxOGFlZTBiMGE5OTRhNzE5NjUzNjEzOGYxZGYwYWY3L3RleHRyZWdpb246YzE4YWVlMGIwYTk5NGE3MTk2NTM2MTM4ZjFkZjBhZjdfNzE0NjgyNTYwNTM2Mg_c22567c8-07d9-445f-9a49-7a80a743fc57"
      unitRef="usd">500000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie83135b281cb4e26b25b62e6bb7f951f_I20200326"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV85MS9mcmFnOmMxOGFlZTBiMGE5OTRhNzE5NjUzNjEzOGYxZGYwYWY3L3RleHRyZWdpb246YzE4YWVlMGIwYTk5NGE3MTk2NTM2MTM4ZjFkZjBhZjdfNzE0NjgyNTYwNTM0NA_84a79b7e-a636-417f-8dd6-3a0f7848e090"
      unitRef="usd">1500000</us-gaap:DebtInstrumentFaceAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6778278848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - EB-5 Loan - Loans payable - Subsequent events<br></strong></div></th>
<th class="th">
<div>Mar. 26, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Note Principal Amount</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ocgn_EB5ProgramBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ocgn_EB5ProgramBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6790421296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 8,085,522<span></span>
</td>
<td class="nump">$ 10,321,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">6,077,097<span></span>
</td>
<td class="nump">5,819,111<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">14,162,619<span></span>
</td>
<td class="nump">16,140,508<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(14,162,619)<span></span>
</td>
<td class="num">(16,140,508)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of derivative liabilities</a></td>
<td class="num">(3,187,380)<span></span>
</td>
<td class="nump">1,664,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_GainsLossesOnConversionOfDebt', window );">Loss on debt conversion</a></td>
<td class="num">(341,136)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">1,214<span></span>
</td>
<td class="nump">19,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,767,836)<span></span>
</td>
<td class="num">(3,750,630)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="num">(784,873)<span></span>
</td>
<td class="num">(12,428)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="num">(6,080,011)<span></span>
</td>
<td class="num">(2,079,156)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,242,630)<span></span>
</td>
<td class="num">(18,219,664)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(451)<span></span>
</td>
<td class="nump">451<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (20,243,081)<span></span>
</td>
<td class="num">$ (18,219,213)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share of common stock - basic and diluted (in USD per share)</a></td>
<td class="num">$ (1.46)<span></span>
</td>
<td class="num">$ (3.67)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares of common stock outstanding - basic and diluted (in shares)</a></td>
<td class="nump">13,893,819<span></span>
</td>
<td class="nump">4,960,552<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_GainsLossesOnConversionOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on conversion of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_GainsLossesOnConversionOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6592005840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
<td class="text">Nature of Business<div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ocugen, Inc. (formerly known as Histogenics Corporation), together with its wholly owned subsidiaries (&#8220;Ocugen&#8221; or the &#8220;Company&#8221;), is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat the whole eye. The Company is located in Malvern, Pennsylvania.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ocugen has a late-stage, Phase 3 program, OCU300, which has received Orphan Drug Designation ("ODD") from the U.S. Food and Drug Administration ("FDA"). OCU300 is a small molecule therapeutic currently in Phase 3 clinical development for patients with ocular redness and discomfort stemming from ocular graft-versus-host disease (&#8220;oGVHD&#8221;). Ocugen is the first and only company to receive ODD for the treatment of symptoms associated with oGVHD and is the only company conducting Phase 3 studies in this patient population. OCU300 is formulated using the Company&#8217;s proprietary nanoemulsion technology, OcuNanoE&#8212;Ocugen&#8217;s ONE Platform&#8482; (&#8220;OcuNanoE&#8482;&#8221;).</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ocugen is developing a modifier gene therapy platform for unmet medical needs in the area of retinal diseases, including inherited retinal diseases (&#8220;IRDs&#8221;). Ocugen&#8217;s modifier gene therapy platform is novel in that it targets nuclear hormone receptors (&#8220;NHRs&#8221;), which have the potential to restore homeostasis to the retina and may target multiple genes that are associated with a range of IRDs. Unlike single-gene replacement therapies, which only target one genetic mutation, the Company believes that its gene therapy platform, through its targeting of NHRs, may impact multiple genes that are associated with a range of genetically diverse diseases. Ocugen&#8217;s first gene therapy candidate, OCU400, has received ODD from the FDA, for the treatment of nuclear receptor subfamily 2 group E member 3 ("</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NR2E3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">")</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">mutation-associated retinal diseases and centrosomal protein 290 ("</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">CEP290</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">") mutation-associated retinal diseases. Ocugen&#8217;s second gene therapy product candidate, OCU410, is targeted for dry age-related macular degeneration (&#8220;AMD&#8221;) and is currently in preclinical development. Currently, there are no FDA-approved therapies to treat this disease.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ocugen is also developing OCU200, a novel fusion protein for the treatment of wet AMD, diabetic retinopathy (&#8220;DR&#8221;) and diabetic macular edema (&#8220;DME&#8221;), which is in preclinical development. Ocugen expects to initiate a Phase 1/2 clinical trial for OCU200 within the next two years. Ocugen plans to expand the therapeutic applications of OCU200 beyond DME, DR and wet AMD to potentially include macular edema following retinal vein occlusion (&#8220;RVO&#8221;) and myopic choroidal neovascularization (&#8220;mCNV&#8221;).</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Merger with Histogenics</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September 27, 2019, the Company completed its reverse merger with Ocugen, OpCo Inc. (formerly known as Ocugen,&#160;Inc. (&#8220;Former Ocugen&#8221;)) in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of April&#160;5, 2019, by and among Histogenics, Former Ocugen and Restore Merger Sub,&#160;Inc., a wholly owned subsidiary of Histogenics (&#8220;Merger Sub&#8221;), as amended (the &#8220;Merger Agreement&#8221;), pursuant to which Merger Sub merged with and into Former Ocugen, with Former Ocugen surviving as a wholly owned subsidiary of Histogenics (the &#8220;Merger&#8221;). Immediately after completion of the Merger, Histogenics changed its name to Ocugen,&#160;Inc. and the business conducted by Ocugen,&#160;Inc. became the business conducted by Former Ocugen. Former Ocugen is deemed to be the accounting acquirer. Accordingly, the historical financial statements of Former Ocugen became the Company&#8217;s historical financial statements, including the comparative prior periods. See Note 3 for additional information.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Reverse Stock Split</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with, and immediately prior to the completion of the Merger, Histogenics effected a reverse stock split of the common stock, at a ratio of 1-for-60 (the &#8216;&#8216;Reverse Stock Split&#8217;&#8217;). Under the terms of the Merger Agreement, the Company issued common stock to Former Ocugen&#8217;s stockholders at an exchange rate of 0.4794 shares of common stock, after taking into account the Reverse Stock Split, for each share of Former Ocugen&#8217;s common stock outstanding immediately prior to the Merger.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The capital structure, including the number of shares of common stock issued appearing in the consolidated balance sheets for the periods presented, reflects that of Ocugen. All references in the consolidated financial statements to the number of shares and per-share amounts of common stock have been retroactively restated to reflect the exchange rate.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Going Concern</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, warrants to purchase common stock, the issuance of convertible notes, and debt. The Company incurred net losses of approximately $20.2 million and $18.2 million for the year ended December 31, 2019 and 2018, respectively, and had an accumulated deficit of $51.5 million as of December&#160;31, 2019. As of December&#160;31, 2019, the Company had cash, cash equivalents and restricted cash totaling $7.6 million.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has a limited operating history and its prospects are subject to risks, expenses and uncertainties frequently encountered by companies in its industry. The Company intends to continue its research and development efforts for its product candidates, which will require significant funding. If the Company is unable to obtain additional financing in the future or research and development efforts require higher than anticipated capital, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital by raising additional capital through public and private placements of equity and/or debt, payments from potential strategic research and development arrangements, sale of assets, and licensing and/or collaboration arrangements with pharmaceutical companies or other institutions. Such financing may not be available at all, or on terms that are favorable to the Company. While management of the Company believes that it has a plan to fund ongoing operations, its plan may not be successfully implemented. Failure to generate sufficient cash flows from operations, raise additional capital through one or more financings, or appropriately manage certain discretionary spending could have a material adverse effect on the Company&#8217;s ability to achieve its intended business objectives.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of these factors, together with the anticipated increase in spending that will be necessary to continue to develop the Company&#8217;s products, there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that these audited consolidated financial statements are issued. The audited consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6775794768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash in the consolidated balance sheets to the total amount shown in the consolidated statements of cash flows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.175%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash reconciliation:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,444,052&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,628,136&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">151,016&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150,477&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash, cash equivalents and restricted cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,595,068&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,778,613&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restricted Cash</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash in the consolidated balance sheets to the total amount shown in the consolidated statements of cash flows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.175%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash reconciliation:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,444,052&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,628,136&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">151,016&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150,477&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash, cash equivalents and restricted cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,595,068&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,778,613&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6779186032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.175%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Principal outstanding</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Plus: accrued interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">127,777&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,222&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: unamortized debt issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(55,654)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(70,495)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying value of debt</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,072,123&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,016,727&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of Principal, Embedded Derivatives and Carrying Value of Debts</a></td>
<td class="text"><div style="margin-top:12pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At issuance, the following amounts were recorded:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.052%;"><tr><td style="width:1.0%;"/><td style="width:35.290%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.220%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.408%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.220%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.408%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.220%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.408%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.226%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Note&#160;Issuance&#160;Date</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Note<br/>Principal<br/>Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair&#160;Value&#160;of<br/>Embedded Derivatives</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Debt<br/>Issuance<br/>Costs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying Value upon Issuance</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,000,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,657,711)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(35,969)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,306,320&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(724,216)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">272,784&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">November 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,150,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21,127)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(50,646)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,078,627&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,857)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14,310)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">132,833&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">450,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(182,882)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(29,358)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">237,760&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(302,379)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(55,875)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">641,746&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,750,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,891,172)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(189,158)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,670,070&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ChangesInFairValueOfEmbeddedDerivativeTableTextBlock', window );">Schedule of Changes of Embedded Derivative of Convertible Notes</a></td>
<td class="text"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:82.795%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.621%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Balance at January 1, 2018 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Fair value of embedded derivatives at issuance </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,405,911&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Change in fair value of embedded derivatives </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,664,689)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Balance at December 31, 2018 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,741,222&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Fair value of embedded derivatives at issuance </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">567,661&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Change in fair value of embedded derivatives </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,319,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Conversion and extinguishment of debt </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,628,283)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Balance at December 31, 2019 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ChangesInFairValueOfEmbeddedDerivativeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of the change of the embedded derivative during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ChangesInFairValueOfEmbeddedDerivativeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6775760240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets</a></td>
<td class="text">The significant components of the Company&#8217;s deferred tax assets and liabilities are comprised of the following: <table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.175%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating loss carryforwards</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,575,288&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,864,360&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capital loss carryforwards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,298,052&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Start-up costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,234,751&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accruals and reserves</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">166,611&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,645&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intellectual property amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">555,352&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">121,694&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,123,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">993,234&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Convertible debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">498,236&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,926,677&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">548,399&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96,895&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,976,726&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,061,568&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(53,877,168)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,061,568)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets, net of allowance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99,558&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liabilities:</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease ROU asset</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(99,558)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The reconciliation of federal statutory income tax to the Company's provision for income taxes is as follows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.175%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected provision at statutory rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State tax - net of federal benefit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Permanent differences</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.0</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(24.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(29.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total provision for income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Summary of Income Tax Contingencies</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.380%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.620%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross unrecognized tax benefits as of December 31, 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions for tax positions taken in a prior year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">303,050&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions for tax positions taken in the current year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reductions for tax positions taken in the prior year due to settlement</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reductions for tax positions taken in the prior year due to statutes lapsing</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross unrecognized tax benefits as of December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">303,050&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6775784000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses<div style="margin-top:12pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued Expenses are as follows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.175%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research&#160;and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271,322&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">705,436&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Clinical</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">421,788&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">469,473&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consulting</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">98,245&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">86,619&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee-related</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">624,420&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">123,372&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Legal</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">819,323&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,947&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,450&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total accrued expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,270,045&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,402,750&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6779268496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_WarrantsTextBlock', window );">Warrants</a></td>
<td class="text">Warrants<div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Pre-Merger Financing Warrants</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September&#160;27, 2019, Ocugen completed the Merger with Former Ocugen. Immediately prior to the Merger, Ocugen and Former Ocugen completed a previously announced private placement transaction with certain Investors pursuant to the Financing SPA, whereby, among other things, (i)&#160;Former Ocugen issued to the Investors shares of Former Ocugen&#8217;s common stock, (ii)&#160;Former Ocugen issued and deposited additional shares of Former Ocugen&#8217;s common stock into escrow, and (iii)&#160;the </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Company agreed to issue on the fifth trading day following the consummation of the Merger, Series&#160;A Warrants, Series&#160;B Warrants, and Series&#160;C Warrants.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Pre-Merger Financing Warrants are subject to blocker provisions which restrict the exercise of the Pre-Merger Financing Warrants if, as a result of such exercise, the holder, together with its affiliates would beneficially own in excess of 4.99% or 9.99% of the outstanding common stock, including the common shares issuable upon such exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Merger Financing Warrants.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If Ocugen fails to issue to a holder of the Pre-Merger Financing Warrants the number of shares of common stock to which such holder is entitled upon such holder&#8217;s exercise of the such warrants, then Ocugen shall be obligated to pay the holder on each day while such failure is continuing an amount equal to 2.0% of the market value of the undelivered shares determined using any trading price of the common stock selected by the holder as in effect at any time during the period from delivery of the exercise notice until the applicable share delivery date, and if the holder purchases shares of common stock in connection with such failure, then Ocugen must, at the holder&#8217;s discretion, reimburse the holder for the cost of such shares or deliver the owed shares and reimburse the holder for the difference between the price such holder paid for such shares and the closing market price for shares of common stock on the date of exercise.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 5, 2019, the Company entered into an agreement with each Investor that amends the terms of each of the Pre-Merger Financing Warrants held by each such Investor (collectively, the &#8220;Warrant Amendments&#8221;). The terms of the Pre-Merger Financing Warrants and the Warrant Amendments are discussed below.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Series A Warrants</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Series&#160;A Warrants have an initial exercise price per share of $7.13, were exercisable upon issuance and have a term of 60 months from the date of issuance. The Series&#160;A Warrants are exercisable for up to 8.8&#160;million shares of Ocugen common stock.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Series&#160;A Warrants have an anti-dilution adjustment whereby if Ocugen issues or sells, enters into a definitive, binding agreement pursuant to which Ocugen is required to issue or sell or is deemed, pursuant to the provisions of the Series&#160;A Warrants, to have issued or sold, any common stock for a price per share lower than the exercise price then in effect (a &#8220;Dilutive Issuance&#8221;), subject to certain limited exceptions, then (i)&#160;the exercise price of the Series&#160;A Warrants shall be reduced to such lower price per share and (ii)&#160;the number of shares issuable upon exercise of the Series&#160;A Warrants shall be increased to the number of shares of common stock determined by multiplying (a)&#160;the exercise price in effect immediately prior to such Dilutive Issuance by (b)&#160;the number of shares of common stock issuable upon exercise of the Series&#160;A Warrants immediately prior to such Dilutive Issuance (without giving effect to any limitation on exercise contained therein), and dividing the product thereof by the exercise price resulting from such Dilutive Issuance.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Each Series&#160;A Warrant was amended pursuant to the Warrant Amendments such that an equity financing involving a research or non-profit foundation or organization qualified under Section&#160;501(c)&#160;of the Internal Revenue Code of 1986, as amended, in an amount of gross proceeds not to exceed $10.0&#160;million and closing on or prior to May&#160;31, 2020, will be excluded from the anti-dilution adjustment, as set forth in the Series&#160;A Warrant.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Series B Warrants</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Series&#160;B Warrants have an exercise price of $0.01, were exercisable after the completion of a 10 trading-day period following the effectiveness of a registration statement covering the resale of common stock into which such warrants were exercisable and will expire on the date on which the Series&#160;B Warrants have been exercised in full (without giving effect to any limitation on exercise contained therein) and no shares remain issuable thereunder. The Series&#160;B Warrants were initially exercisable by a holder for 8.0 million shares of common stock.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, each Series B Warrant included a Reset Period pursuant to which the number of shares issuable upon exercise of the Series B Warrants shall be increased during certain Reset Periods (as defined in the Series B Warrants) pursuant to a formula based on the greater of (i) 80% of the arithmetic average of the two lowest dollar volume-weighted average prices of a share of Ocugen common stock on Nasdaq during the applicable Reset Period immediately preceding the applicable Reset Date to date and (ii) $1.00 (the &#8220;Reset Price&#8221;). Among other things, the Reset Period was triggered by the effectiveness of the registration statement covering the resale of the shares of common stock underlying the warrants (the "Registration Statement') which became effective on November 5, 2019. The Warrant Amendments provided that Series B Warrants would not be exercisable and the effectiveness of the Registration Statement would not trigger the Reset Period until the completion of a 10 trading-day period following the SEC&#8217;s declaring it effective. The Reset Period commenced on November 20, 2019. As the dollar volume-weighted average prices of Ocugen&#8217;s common stock on Nasdaq was under $1.00 for the first two trading days of </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the Reset Period, the Investors elected to advance the end of the Reset Period to November 21, 2019 and the number of shares issuable upon exercise of the Series B Warrants was increased based on a Reset Price of $1.00. This reset resulted in an aggregate of 12.6 million additional shares of common stock becoming issuable upon exercise of the Series B Warrants.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Series C Warrants</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Series&#160;C Warrants were exercisable upon issuance for up to 50.0 million shares of common stock at an initial exercise price of $7.13 per share. Each of the Series&#160;C Warrants was amended pursuant to the Warrant Amendments to permit the Investors, in lieu of making any cash payment otherwise contemplated to be made to the Company upon the exercise of the Series&#160;C Warrant, to elect instead to receive upon such exercise up to 20.0 million shares of common stock.&#160;Prior to the Warrant Amendments, the Series&#160;C Warrants had permitted the exercise without any cash payment of up to 50.0 million shares of common stock in the event that the volume weighted-average price of the common stock on Nasdaq was less than or equal to $1.20 per share on any <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV84NS9mcmFnOjhjZDg5M2FhNTA1NjQ5NjdhNjNjNjY3NzQxYmJhNjIyL3RleHRyZWdpb246OGNkODkzYWE1MDU2NDk2N2E2M2M2Njc3NDFiYmE2MjJfMTUzOTMxNjI4MzE0NTk_881a6831-237f-403e-b78d-48afce88aefa">five</span> trading days following the issuance of the Series&#160;C Warrants. The Series C Warrants will expire upon the 45</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">th</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;trading day immediately following the earlier to occur of (i)&#160;the date the holder can sell all shares issuable upon exercise of the Series&#160;C Warrants pursuant to Rule&#160;144 without restriction or limitation and without the requirement to be in compliance with Rule&#160;144(c)(1)&#160;and (ii)&#160;October&#160;4, 2020, provided that if such date falls on a day other than a business day or on which trading does not take place on Nasdaq (a &#8220;Holiday&#8221;), the next day that is not a Holiday.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the activity of the Pre-Merger Financing Warrants, including the effect of the Warrant Amendments:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:31.479%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.520%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.520%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.520%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.625%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series A Warrants</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series B Warrants</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series C Warrants</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at January 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issued</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,771,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,614,036&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,000,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,385,964&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,613,036)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(19,999,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(40,612,036)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,771,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,773,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.13&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.01&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$                      0.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Accounting for the Pre-Merger Financing Warrants</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although the Pre-Merger Financing Warrants were issued on October&#160;4, 2019, the agreement for issuance of the Pre-Merger Financing Warrants was a firm commitment reached between Ocugen and the Investors as part of the Financing SPA upon the closing of the Merger. Therefore, for accounting purposes the issuance date was determined to be the date of the Merger. As of the date of the Merger, the Series&#160;A Warrants and Series C Warrants were classified as equity and the Series&#160;B Warrants were classified as a liability on the consolidated balance sheet.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Series B Warrants were classified as a liability as they did not meet the derivative scope exception related to equity indexation because the Reset Date was triggered on the effective date of a Registration Statement and the timing of when a Registration Statement for the underlying shares is available is not an input in an option pricing model. Series&#160;B Warrants were classified as a derivative liability in the consolidated balance sheet measured at fair value on September 27, 2019 and marked to market at September 30, 2019. Upon the completion of the Reset Period, the Series B Warrants were reassessed and determined to meet the derivative scope exception allowing for equity classification. The Series B Warrants were marked to market a final time as a change in the fair value of a derivative liability and the remaining liability balance was reclassified to equity. Subsequent to the Reset Period, almost all of the Series B Warrants were exercised for shares of common stock. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a roll-forward of the Series&#160;B Warrant liability:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.380%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.620%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at January 1, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value at issuance (September&#160;27, 2019)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,387,760&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of embedded derivatives</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,867,980&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount reclassified to equity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,255,740)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the Series&#160;B Warrants upon issuance was calculated using a Monte Carlo simulation while estimating the stock price during the 45-day Reset Period, based on the terms described within the Financing SPA. Key fair value inputs included the starting stock price, expected stock volatility during the 45-day Reset Period, and additional shares issued from escrow. The methodology for measuring fair value was sensitive to the expected stock volatility assumption input mentioned above. The volatility used in the fair value estimate at issuance was 96.0%. Inputs used in the valuation are unobservable and are therefore classified as Level 3 fair value inputs. The fair value of the Series B Warrants upon the end of the Reset Period was based on a Black-Scholes valuation model, which is classified as Level 3 in the fair value hierarchy. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Accounting for the Warrant Amendments</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounted for the Warrant Amendments as a modification by assessing whether the modification resulted in an incremental fair value of the warrants. An increase in fair value resulting from the modification may be recognized as expense in the consolidated statements of operations and comprehensive loss, whereas a decrease in fair value is not recognized. The Company determined that the modifications to the Series A Warrants and Series B Warrants were not substantive amendments that would result in an increase in fair value based on a qualitative assessment of the terms of the amendments. The Series C Warrants were determined to substantially modified. The Company estimated the fair value of the Series C Warrants immediately prior to and immediately after the modification and concluded that the fair value of the warrants decreased and therefore there was no incremental fair value to recognize resulting from the modification. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Former Ocugen Warrants</span></div>Prior to 2018, Former Ocugen issued warrants to investors of the Company pursuant to a stockholders' agreement and to two employees of the Company pursuant to their respective employment agreements. As of December 31, 2019 and 2018, 0.9 million warrants to purchase common stock were outstanding and exercisable and had a weighted average exercise price of $5.67 per share. The warrants expire between 2025 and 2027.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_WarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_WarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>62
<FILENAME>0001628280-20-004221-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-20-004221-xbrl.zip
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MB9YBNJI1VT/O^I=?#;SL_*27Z&38M!ZK!B:!7\MTD<LH(@S=WU.&$'UX(1W
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MX$2$B2"\0G- F<:21/?&=--$^D&IO>FFOW(2. X- AA@"3*,Z5"%#D<1I<*
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M;%4C<BAL, I_I#^,PU!*!6$TCG"T\A:+M4DERIJ>E;(!4>C!M]5 20\&1R=
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ML+.S4XH\>-SK@\$(4%ZYL<G;TBW0V %&C7\'EX<VP?NUS8;2'R(Z*%6ZMQJ
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M5RZLDT;QG0[.FZ/:I$L6G.-.WY<%JTJ3XZ!]-@"?OIN<^&(/[X'B,AD$[^S
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MY@VC\$0T'"A0FQ58X>"['/59]W4.E$$R83#3!Y)+(-@("PF4TJ"V$"8HVLU
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M5U=3T).VS.YH5S!4=+E*0E@YT'J2RXY J08JI5D!T  KV;@LMM77T*<VGI9
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MLG&RT+(J9I_HR25Z;TJX(TM=5,P $B*MFDM!HJ?!N0S-CI*%8(XF:JXAMY,
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M':DI^Q(<RK.2R5.XGKC1;,7#5"!OO[I(;<0NEF/D#PA*AFJ>0BJQ;8,="2Q
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M&!B_ H>L[3*;S(*MT"_7Z<](<@">VNZYTA[ZSL E+?%!4W*Z CTJ0[3'<4?
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MSU2#)8E%+TCB26S7+L[UY;0+LK(GM -)-N4I! ,:;C;1%=!Y8BAV^R,C9A9
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MP/#)$1)3A^\>WB/4C/FU.4Z:: 39@G64@V5--=IN6J<IXUIS'@-^A0D 2"H
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MQZ0#+AO73F%U"%3#.?DF.8C)C]Y9M<#V)5T%GXST5+5&J U UBH3,4RG-X6
M=-"<"CX#<$2U9U-Q8L1W8Y3+DF7MJ\SK$%>WZB",\D*,_?IT?)Z_Q&2C__M_
M]_.?_WO!A\LJ!1]A3& )J]Q9&EQ@;&$O"9_67/N.<'26Z0%HZU*QY&%H2VRW
M40C*C<;@\I#IGTIYLE%;Q2>Y<W:"N#$.$(,^=VF%,NLJYSO4AP.7AIWV7I.C
MD!&\,%_J#APN)373O#A$B\D@AR0&I4/&9;@5U476"'GC&%0:IQGDE31N%((_
M[3,<_(M,-Q!QD<'%5>_<>4E>Z&!PB-QD:0JJ1V<EL#W0!" 7I#G1R4X<1\[_
M\ZI;_,;\;%,A21_8]H'^3>[:40G-.799>3]HZM> 9"$%3;YLB%1RP?'S^AQ!
M&_!:L*)72O5&2T]?8B 2,9\6OC(D94B"G(3]3-N>A#E3DPCBC!>V-E4]T\FW
MD3Z2P<*819C/F&,1-[SD!^U:M?#M?"3LIJW_4NF360NF,*T-LE1P(:R%)ADW
MXBQTM;S^3LTSLP;&K8ND-,)?6&;D=YTG<FN4_T!5+:L [7[8AB4*('9"IC#K
M@*(:,$99EV_N3E%PJI9H]!C26,ZT"1HM?\AQ#D:WD(>/IJ-92OLH 5F@HCFX
MVG,/MAV^\<6B;$98\:UXH$W4$HS9MD_+0335\MTXD"BP31D"=PF()_TJ+^2$
M.[;JVE'R^N25XSB/=OB0,+.&"(]=EXRU895*G:AR8-FX, ZH;25'AWU.\NR"
MMQ:;]KQ.W;D[$2N:]T3PW7+T1(,/S9WH@P1[I)V "W2^T]YS/7X$_]8M?(D?
M,-P5/ZH;QW+W65POS3'<29Q.A^P6HN%.L=+)^E"OS*\*U55*,[5:G[/Y&2;V
M/H_S^D5RJM5)YW%41:O7'Y;0[F19:WN\O>^AKT,HFJ+*H8+<*.JMI,F%,WQ6
M&/.):0U2VKV<\?1C8U&RNEY%N5.G39U)\^5<8>M %?;QZ/RWMT?'-[]=G9V_
M6R,%JD23+&8T\C'35'/NB"Q>N?#@]] '=Q ;_P 7=(_1 Z8<!VT801":@?#P
M]*7MI<O/ZY^YHL3RO&@?34]8N=8<L>'ZL?9N59,*"I/M,\X((N<1-6]G6Z\N
MF8H\+BV9&*MUE,%/D M3^FC[.1M(T.,EW<3]JK31#P&TXCA8ZTC,@LB8J=/A
M_G7BI=_(?E<X.1UR,;0T[/_@A.7)RM)ZN+?7Z&<ZIS'5TO"',8VGN%;,VMSY
M%^+G'7;Z>5L:@Y(+FRY-,GQ) Y-K=!ZFV:G&.@*R\S,SJ9)";57+AK4MG>M=
M.,';BX@I9-*6\3>W9XQ2%LJB&3<7KUG<.RI=A!U=4W::IU5#O3%$<CT!R^>#
MRF'=O=V#G4D\@-]*QD7IA;%0/$1&#K\5S@O_S"CX;0=G^S8.$\LD)JTK]4@X
M[*6:/L,*^1<^Y!%.N><+>?9 8^Z[P0<U8R3$2K(3CI0&C-^K%R;*PXI +;:"
M#F+C+/A'0*[=19]V: 2MY/BG$;YY(3U'=%F1]VSZQ!-AV:3_W3 B?"V<S8L-
MSF:#LUDSG,VBK&.M_Z[1;P+T\;DQ=8&:W%#K<N=J++.^&&VX4A'_I)P#]1<E
MHYV&SJ9LN-2\5&&]5%(_=8L2]E&FS43@B]71%RU/6'@#V%L)+$9Y/,G2..)Z
M0?IBSA9!\XK=9FN.LYYL<U9*_%<C6>XUR?@J\R)PWMOY*?5<_;XG&OM"Y:G)
MN0(AZ;XEE8#)QG[A"EX+V@"]8NZ,Q"\4S67L^+O&WK@2A30^D8)9KGUT_J1Q
M+)VMO;K'ZUMR&5YT9&TXLGU@[7E]MC[G]2(-KLVT-!S_.WC9XU8O+$!L65CC
M,*0-WUD< G- ++=26Q!R-"@_V'M]'*;7<9J].;NHEY(_VG^]+8?6^P;_&]AF
MM<KNC[W9%VM^K=DRHFWSVYYLO;F7#,B%#3V242_WW)C)V]@DD1WZ[N-28G\;
M\O_[MJ"0KB47@WI$^I+4J?<%N"J6?-M65?J3%D(+MV&EBV*%W&.I_JUR=HOA
M7+%^]_1O<&F=T*W(D-Z'>T*[>F=9' )>7,D'>!<!X@;DQE3,A>QL=?:)C7:Q
M"N>N"PWK>U<%/T(8.^J95U.::OUO3''_Y6O$^_!VB7/A3;("N\N= 7T*@]$W
ME\G& ;>YM8;@6>&1<E$),75@B!RS[OPG_\QBMCCJGC*TZ0TYCR #OFC_ S\)
MSBY]X=:?]QJR>T\0VO/$M>7CEC[="KQ[>D/0E248\GX\9E*.]TC*_)\,@?V/
MX2"LQ!:X">.[,%VD4&_ ?8S8L7N)EF;R,@-AS4>U7N?%Z<@%JE7Y]A^S+P_M
M*J9@EWQ.!SOUL&B5$'8?)5D?53:9PBBSJN10?MG4>6Y5FHIL4-$%,;]DJW&P
M=7JRL9Q(:;*UA&SO%>I5#,9F$@L(L&N3A9ZS?:_Z$H](Z%RC/ $9V[[L>&.I
MBREL'*U3CLQJEI@.:IEZL+;^(-6B5P2(&^.J#5T5C,Y]]J7^WL5Y^OO:8K.L
M]WY[]:>AWGGT_].*J=1G#)NT=.63F#V-,3W$EKQ&\0@+T@^Y03PHN4N^@GFI
MVB>T:R-ZC9W $.@-36-CP6@2R1K0H':^9#!SN_3E.:C#-<A!?3@[/CV_/@V.
MWEV=GGX\/;]9IUXTC)8*U'W-W"7C10ODOG&=F/0;R.644@XC_]$HH>@)RD0A
MU$V&XDRYI+INOMHI[&F#O)Y-.S#82KL?'#L?(XE'G.SAB\TAB;)^HBU.->45
MVUR7:<R-PQ+<-L->J76YAK<"8@&#7B"W1#-T=_>1]4!9Q,I)PR(YU[VOO1RV
M*WY+T?&A4$C#,4831MG*37K!$3A+R4 $OHR<]6<]E!"3S68U8--O[S+&PN9:
M'?_F>I:A>)H^B"03]0\R![3[ZTM%I86Y0,+Z,R8I8<ZB;.@E5I6IYCR[U9 "
M?KM%SP6V41_=?)1OU_XV'R"0])/_23"*;[E3<6-V8'S*D^B.3@5[BC)9CB_;
M>2.J)N??GEE 0-E+_631(I,0OZ\* "BY+5S/<DAE04&'OZ?_5WE"DJBG%0*P
M&P9&2]^T=]74NZ/86%I0O+5+\FH/LS]3CL-,JJ*4X)TSS=F@"HLLM9TK /M;
MY+MXJV%ZBA:4V)Z1(<V/=_6TPX*#<EGE116F\R&#SI6>AF00T5^Y>4G,15=#
MPY;P?QR\Z.V__$73ID5%:[6WN^^("KEWDX 'M']3F0T^,1 9':SU3. HZ'MF
M^IJ6*40?6*:"ELASZ"8W7&"@A6'R7>%[DIO% Q+1R P-(N7*EQ$]1JD,_F-_
M][D==D^YK.YLRI?M+9]UP(0YPC0R/+;_?2.,X:+N(\LZ2>9;2>8<?[<6/*"1
M0:I3=P-:%Q&;VZH[*9N=QKE1C':0A*HGN>P1'XEEP4 $_7,2%J7TD.%?UF=2
M#!7%=R,7P12%,P[3WT*VT6VCXEW/&F RJQH96HA*[HA-!Z#!< X8>3=W$"0F
M]F*/QC8K-" &2"'0TF18H]EDFD'3[>)G7_ L^34 ?W= 7,:)5<!6H@O+5ZP_
MY"(BT/_IYRY*%S$'&L*Z2!);M+608PPD:#/SK*W:OF(DY2W"!OB&-9%(J0[I
MF,%W9.""1<;=Q87QOW3/RYRUQ<\OO,"TORRK)_I_QO8Z(UV39C%#.([)R@A'
MZV2&O37]W-I(+_Z,)>;'J7X[.UZ4**&/M.UU^ 1S"&%ZBZ"#R? ( TFRC:QZ
MO(:;ZM8\:#*)C<2.DY2(HX4,(OEUU#0):2_$D$RCGYEE=&#K[#AU:OE]:@AR
M2R=Z9I._'E]J- G,WD(2%2Z7J<&T&]QK2C1VK+8E\&<MUP;82VV)_>>@>NNP
M#B3O)L4)I%CYU\Y&V&"/OA+VZ.4&>[3!'JT9]FB!K)-=%D^JB?,5I,!+RSL*
M5C "^'!J,<H&%;Y:&Y[S47-Q3QHJ[\G^2:N"YAYWY=!Y64UOQ4:'$?]#Y)A]
M#L]W:3@MJD.;OHOGG7!SLLHHYK.)EA["<Z_S5VW#7&['U;/I[G%GFEO[E_@S
MW.W5I'Q3JBVNC@']!._GI:_J%'QW:!8XY(&1_,!?Z""Y+";\F5^4WO5A!PGS
MF']8<W4?X0<!K$4CM+X06&IHS%R_UWPCE^7$A:SR3$P1YZW,YIV2UA%N.33L
M<^G/=22'XI$UGEJ[57I(^(]29^N>;7,\"L$0R^;!USU[KJ_C9;G'5Z,!&0XO
M],/T4UY-2V&M+T#"C46 ;-A':,M>EB]M%A+2!M/@4)&6DOKKYXRPEP#Z- D'
MDGU:?/CY^5WRN7I:X6F>'I3%]6!L<"\$IS,37-G"YS,E2#%2=;YRZ[#8XSNA
MX^<BVU_+X[L^O3I;Y/+A,[ERF]_Z\V%P%=\>BHM16CW@&@TY8;9<HDOKPF9(
MJT$"#NHQ_175]+;'-4/PBB4ABW@\T85L[_G5_LG^<@S](7+=Y1CETQ?XX/1P
M.8;^ -IF2S*ZVZNZTE<75T=+,O3[![HE*?.57>CSWRZO5D1G0*,OQTB_0&\<
MK\0B^YG<YG7=LR0!W9'3CB2S9!LYHKK&*=JO$L*5L*VR^C SP7P.WL5R T8C
M9*EPZ>CC9C:%CT>OS>+>&[3ND$^.6O/?02\Q'>89BEXT;GWX2^_%JWWIS*0Q
M)/FNMF"RI>P"M))N3?+:FB'"CQ"TS%FIRG>9=U=,H&_W\NV=UK +/DGA 0+H
M=?#</HSQT"9E_XX>W/F@ORR4]<)###R4>;\_>H5N #]PC(HWS$+;"X=FEAX)
MS&20&Y V2*YW&">6/:<P@\I!^CQ9V V.F#V<P73H)(@EYR0F4GLNSF5_O5B(
M^1"Q:L=GO.SD754EASF8<=!+0L-%+(IJXJ&5I=1.P.Z1/S$6P\43<$&WSHWO
M(?<*]!_ V,(9Y,5SN3_8G;'!&%?[PBI9RH%J?8QCA2F[)'Q6E3O9<&>:#:!9
MW?&W'3%5 3QB#^Z? A/=\"[<2OTBS8B7/C+H7R5YO+BHZQU;ZX5KX?'+];1-
M!&<3]HSC3'[%I1T PZZT$(.#3/3E@4:\UORH=NC7^7BRQ%._+(XL"_:8N.W^
MJ\> 6E2WS,CP AN^=.=J/K4U'XG@<A2:2PG#'#HC;<!M.ZL:%TG?7Q<,MD]F
M:O9938;9!9)!#UPS#,$KIY/Q(KTBW -;&>6DFVFE<,)Z8HQ)K7 &YC,P<,2L
MK&]C9J%"IP>39!*H]Y7%G.DFS.IUR-G!;+P1J;2$3PEG_V(!1KENXGU1Y#]1
M3_!B#>H)SLYO3C]\.#V^^>WH0W!Y=7%Y>G7S/^NBI?Y0?2]UK?6)) $LM5.;
MURBVF^.OQ1;@CH10@ XY+U7EK<2!G".\@S^L&1Y!WPJIDX/H<6&)2PCJ2H7Y
M6T*GAI<D7J-G^+>Z\C9* ;B>@ R>K.2"K2JW'4)J%E774<1J76?QUP1X6A2L
M.-!AQ55DMAZK,3IRZH95PHTL=8&5B,F?/^?SPM*]QCY)X;>V()#LC:@>6*LE
M1M[Y9SM@OK<;PYUC,+3,CNP31,AS2&=WE)Y8M0AP59P.X8$:KT5$$TGE,4S9
MG-&PR8:Q-E?^$<_-UB<<[/5\N8=8#C-R@2S/<A0</@M^V[W>Q6Z!_BT>I7:/
M_14\W.LNV:E9CLLQ65OUY<&9?)0VV&2CY%$N%A:P<DE-(3O3,8#[!$UKUBV>
MBA]!EU1IQ(Z?&!I;Q'_E6(_'Y<NN<P=?J,_<YB2GJ1[LO)G-6EG+EIM8_IZF
MALM/+*]Y@7H/R&F<DW1V'"(O[5<GB+,[AM);O?]KL!5S$U)CNJ1M?]\)'!\.
MK8'FT]$E@9X))1C-U_1\>@&LL,;C]4DXD?K\>YZ#1> ?T+/H80?/[;,6C,FV
M&L:D[CLOS;?<6PVP03<^#=WX:H-NW* ;?PQTHT=]["'779Z%% ;?D]+->Q#G
M@VHBS%Y%CP,/>1B1N6L&N;G/$M\-WF=W((WNM7Y!US7L430M D-\Z3V"36K+
MGNP_MOLVMR:BV/B*F^\[[Z&.'=VA.\$XGOJ1Z':3)K8G>\#5DT$S1&]WA--C
MQYRB7@5"CZ3FQ%6NJX8Y) !8I9E,DVQF\$P81C2_D!?7[P40W:+W65''*H4_
MO6;!K9? T"9K0 W6URBW VH/4AT.,H-"N4P::]Z?N=7@NV4\*X2@PI"/[_V<
M7CB)K;_DOL5!3]A]>9;2^-L_\B$NWN84LZ(TDS_#:?U\'0@%WI]=WUQ<G1V3
M^\__^>[T_.SX.CBZOCZ]N0ZVSD\OCH^N;I;* .V<R8ITU5ZP"]OKXB6^)U<K
M&YF4.S#BOW-L"G"=Z Y6(RY;@8L<N35MO#$PKJ0:B3++NG1U?.,8EUP3<FE6
M6Q.(AT%*$QDD8=',IOG=3"4E[[I=,O7^#NE"@Z $YP"3V P55(]AP>NL4HLO
MS6VS<8!4PYCQTE$X(=.+P<IW64[?8GN:KIAZ->KP- ^I1RN>'9-*7ZJ3M9;]
MZN-"\L]I=CLG8#,%I L#?N&:U(4<T7=$0B1[0 R7S-R)T!OZ!>DNTY/_6>4S
M%W%B>BM</7DY!EL9MXGCWH9#/0H#1(82I(-%;NQ//Z5(7;>PJ*]ZV@*Y3@D,
MC8FXX:JKH /%-3+2>63[VKO.H6%M3:%;7[.!C\OF%U4?206-N(=HLL?(T< A
MA+T>I_9$OOEP5!](_^![&;NHZ[1O1/_;@)96[E)Y *;.-(]S1'8M\/K'TY.S
M\],;^N)N+_A01JNW"H\&J?MGK@%1QYG[<XOF#KE^XC,I,M6H^TG8(@.T#LS]
ME$RVH4BOQJ.+6=XJW&V2,SKGR"-<<7=\*]VX43+?)G*J/=HX;&KIJ^IZ F;O
MA;PHQ[27".[5(@1AC"R\RY=JH:(E"X_FRY$/"UX;A(5CCI#J:YJV@V'5M$=R
M:\[Q'KW:#=Z$GCDJG=8<A&XC.]]&=FQ#Q:8J*ZIB*HQ2F[WX#N?XNNH7YE^5
M >DN>MT#/V)/*OM&[M1LMN:;;0UG$NM6 VT[7IW96J4VSU#+_HZ9J,-_@DUZ
M.0/C<-]2QDM7 ^V#T# 6H%_1F!:I_U3[&IB('Q7:WI5U,;'TJ&.VD(V6_:;B
M$Q:%$0BKPX):O)JTA67$A2([?+K*ED75N*[7BO'HHXG"6^  C[!4X(09C$._
M+G;E)KK8AQB@=9T$L[1WB]'&M9P^^4@6V"M[]A<Z&&$J4A5,[5)U%\ N6L]F
M*:Q;_N,LGZ+CMF/V#!QWD!=WL%^O@P]3KQY";+^&$>G,2RZ_T4XPI8"6%/P%
ME<@S4JGG.$K&?]ZHJ6]J@'@8&&GHD56HDYK$I4*S.V$^O1J3RS48\]3!\^VW
M)1O%$5]2?8H%G/<L7M34BKM!LZ_*"_^2M.V/Y@X*Z%%M]PI\<=&A '5&;OK:
M2"CA[L""F?8)7 &N&)09WO],7L^C:OWMOB$A0Y:A*L<-K%&S+A\>V0]]S__1
MHW=J@;L6\_AI5W.A]* '_<=+SUNK"UP6/MLV-6ZLBIH1BP?$_M]M[&!CK37B
M&=UEM>0P:EBBK4XE2<*VL(3.0NK%NTI'![4#TDJ8&_=VS+S1WD$'?^+I+BU5
M:JTY7<:YA8G=2AT$PM2QD@YZSZ$K'9W3Z5+GCHJ!U$2XN*Z=<6W.:19],,XR
M ;8W0?"+%U-/(CG4&9>(T9;T%%^M9L7CGM3K6J9B##UL1238W_M/5$T%$U(;
MXV#+8D*S7',P)&C9<-O1C[1GZ<3%7REE7VVL71QY2Q=*'X2N9]W5WVU.LC:%
M&J@Q_BV 8QU3'<^=A7V/#6EM3*IEO#77,'$<G/FWX:7>ABLG1$_"''?C?&L(
MLN>V+*,4KJ/MAJM6D-)2 ;3_J@O]6L2?.W&C7=V1Z_J#.V6TYC=V/19@V/G'
MWO_41D^S<!!&9A(/4!7$]$;2K &\H=8T )*)X?S-5N#TOCS['$^DGNSE'BU"
M!5N+"PD\9&YG&0,CA^EN<]AV&K'-<%@ [C^K/"ZB6%H7_PFLTB]K %5Z=_'[
MZ=4YFIX$5Z?O?OMP='-V<1X<G9^@<.GDM^.;X.B2_NOWHP_KHO_>9:07%,Q7
MD?V5-QH8-22[9WMI#PT2,.":*)E$6TK2X?0DB +V%"^H=0@LKSEC#,UGDM%"
M6M1K'3Q^/D'W,ODRJNM&1<]F3#1TW^@\INU$>W(R;C&.1L\"U^D4XR/'?D1_
M@TF91Y^,F?+?;6?4'I"(4(N%K3&>9.(!1NB %?<K^9>P/\@C449?TQ5K-32S
M?@_!AC4=A_DD''#B4(&#C2ZM4DT8%EIT<B<M:72"W-S< Z?J2%$ ^<BG;PF3
M8<G@Q+O48C7.0T5GG.#;QUD$]524%L!A?[\M[MP@GDIX@O;P(^ EX'; N^0?
MN8Q9B0ZB=EDH;48D_ 9BC0K1'B\>HS8J;"*Y<3!PZVH5?9KVJ;F1(FPM7<,8
MQ4G"H'P"!96 !?I=Q= J.D\0PR2SC85YZ#'7=DL78%&@R 0*^Z/M5R"OE=RR
MCM8%GE/:+VU]YL5^I 5\LU</"349&(/[JK8VA0M/*USX95.XL"E<6)?"A87\
M5@LL%N#RKIQJ6A>KY*S3_/!PB&PZ%*W+KX[RO14+)7B;95&/+[V>HI2*B0&D
MYVA0NF#_VY/CHT8/5(3DZ8)/^#;RKAQIN-0J'I%!'1\]^,N:++,>L=RC,IO(
M&_\ETV\&[TV8@,?3Y+>X2?U!7[Z_?LJ@O0NUOK@UDHHE[1O<DET%I0CE<3LX
MF$#B0<S?M*#NS*5^/+T%ZX'0'[GV<K\N%$Q6 '&*.HY?=_9?D7A,L;KI:"<Q
MP_+7Y\_H+Y[POEA^V>5=>?%Z^3GG&@N]_VQ7[ FVAXQEQIB2Y6PS&F2+0DUG
M7(%4,#E02GYI0K.KHMB6'R%%KW)G/V"OLV5FJ> Y-J!W=%*##_4;+FU;-"OP
M[S[4O98]T7Z]D:SE&VJW9'D(<*<WCX1R/3@[/[$5%\P6I7PJ-?V;*JAQ16-K
M)=FLCAHA;5*V-%,K'T?VL=G(S#(.M5MFK(<GW7X<.;@XLU?F-J9WO\G"/')Z
MXNSJC=,3<!R9MJ?N1QTCX@#2!0.\40+\F8H6?U&D1.\\(10D8=H(S!(.=8'
M1&3=V- "N#)VE LO(9W0K3U $48N.UE<A=Q+13@T6F1J4*(;#J0<F-/#H726
M"!NV9VTPL7#) Q@T$I?:V'J:D4_2^:"V65@_C 68#3MF!X*)"%"S \)QHGB
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M_1DTU*MLEMPE)1![N44-;;.(HL]85J;C9JT^FYJ>JM_/3EVG&3E)I>/=M\N
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MX[$D]/K@-$CX7M%YV*6EO6RL+?!\0TY-Q@EG$9NU:2K6+AK:GF \],WK3/H
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M*E'=)V"5VFX09)!'!$U=D6!6\\Y,17B$LAX<;+Z,1*'/$_JH>0W@1/!'^Y4
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M;Z"*S4 6N"% -!=P\ST?4'A8ZU=ADBJ&<-'JV ZD/:(G%U5YJSTSF>B_,G"
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MGS3UF$Y'RB%Q *3]1:E1<G9>2.0H46^<O&714A*8 G :0GFLJZ;;$7A0*D\
MF'H>GB^^?/B#;EYVAL&9G:PL/&):^5Z\"B_&+M8/F<VQ(QB9G<(>3&J:)G@#
M-Y2S!Y]_=O'FU6?&M10V^'1:XTNG]T\F95K)B.]AM2JW4T8$TGGML:]AY4OY
M0".5&%LX!QV./3O\XR7'0QKQZ2-!(;3=?.Z 6V73,:E&]V#!]O%G[2\QO)D
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MVT2UV\'FI]'N&XV[#]3!L7Y[-?-:PTZXE#+.JJ^;;=%I5,'8#8K6LD.%;N"
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M#\+,^QT\3T?'Y@P5.=/9Q&2SG/E3:EE'%)Z2(*:K8H[>Q-]/EU^\KQRJP9?
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MRC\:/LE5 TPOD@NS]M73(KK'BPBPQ%6S*S*7\-$T#U=,NOZV[*4G%0O'&V6
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MC30=/_G<_@N;^ 1I^420EF]/D)83I.7/H13:#1TJ5U()BII$D*WA0GI94V&
M;!A'MJQ$%&GLTY,W9?H,5KS(6]6]&FIN.B?AHI8*4+&LKV$>BMP(E5T=WTL)
MFH)@DH@!NP1A"X"'S0ZY#UK=ODV^G)Y RB%[<8Z\"-3HGE'/X9;;W>YMI'>\
MY=&.R2T9G?S:BQ;+)3'.NDW]$/BC%82P< 07AYU-PH9T6\I;;4-L%7Q4%4^#
M(I9[H##)X)%?. KY5&*L)5Z?4K0'Z"G_]H\?GV;:$L8=<,7L;[%WSA<7L5/M
M(-U8CJW'ZE_\NX[!'W:UD1+#(1]FS/XP]66\@$)>;9NN3]R:T863I7Q06Y(+
M-Q-6''7\N4SN^RH?:E^E;^W5B7 <_3J;X:ZQR30\+;4 A;?]^J&?'*9FH*1;
ML\5>0ZGF\7\^6N!\<+S%BZ+$3 A;Y>?+M@Q&IUQ3"/_P_-&W?UT$A[@IMD-%
MV<$'@ $1('E5+)L,^7*-1-9<U?SNJ[^:?R?*1$5-A4YKZY3(AX1CPEQ#GU?[
MQ^G!MT7!<1#X><A7-5'FR?J<C \LJ#+:^946AVHBI.*=3B*T('H=-M7TF/'U
MN"17#P1P8+[QO#LFQ-[;#PUY[PX;N+WMEEAV7K;$G:+I+4Y]DO<82VNI"BP=
MZ> Q"%>B)09\Z"$Q+]GLXTS>_#([-</<XQ5#O(%[.TGUI)H[;(723ID&>4%%
M#W+HKYKV#BK\TWKX SWJH4[KPW$+\F1@>13*J-8SU8$GJ2O9U(PTMFT]G=;&
M$:R-5!:2F2^=+(8H#EGUO&S79ZSBGGXO_)?B.4_&Y<^R@-JAY%0U1RJD*%R1
MV/@ZQE1L9GZ/)\*QEY"-;BDB:D_KY1ZOE^+]CK7P'+E_CAHY]WT0M:*E<]:+
M#IU&9>=I,F3IN*Q/J<K657$-FB:3)Y<RMQ7CE4GMY/8>W<H*AQ*1%;1A167"
M>+VKFOV(J9!K>VVQ(P+!ND=E2W%TX;<K04/DR2&WF1 >SE]FPNP[;\].*HW'
MM.ZJ?*A75XH1I42.L+.LBRV*XJ9A,\/\*+K1,VO+,XNK>J@DXSPA98_J][9A
MH>%N=LEY#8I(+VD4UZ?5=X]7G^HZRYJ3XIB4S@XLN^7>/#-.G&_!O57!> TU
M)0W';OXNWS?MR4[=YY5B\&/!/U%.D0M10LM#9:U20CPGPZ1+"[U:IQ5PCU>
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M-5SPGFD\0*<A]P1V81L'3YJ_!7R-P6^8.,DG])D*E7FE2Z9Z?6]V.JJS4Z.
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M).UPZ!-0$P1O(-L:CMI+;B:X:=JW@JH+@QD</3CT&P]\$.,&IJK_GA7*Z-$
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MKH%!7/L,LD5S%B;A+DP?"?HUZMM8?!^F!?=[F"\*F$*X1VJG4<I:A[.6[]$
MB*T$%_7Q8!M*4P$)3L_](,<%5_PH)0Z933=8V4>JQ<2,3;=_L6\FZ:=$T.S1
M')A)I,<%)/*8I,RR5)(<]"AT5YSIJ/;+!7"\3[\.K_F$GKK$?S_[6C?64B)O
M.[(B%VI:V-*#XS4_V'UN$I:WI7?@L6Q6(12Y-QQ+ZLP:3=#04ZZK&Y>QV6J0
M4)LF M4KZ>)QIY_"$#E_%OY52XO)";U,YF$T5SI5S(E-A$5MN2<?TKU=$::%
MLY'DU&\%'^HWDNA.Z,;63</7@@R18<GVPG'+6Z5PLD24+2%)P)VM.7 'L;:U
MG+4!>2_W[@)F37\A'/!2T+NNRAO-9PG@%=W$N_&;T-*[B7[.\;%M>SW2#MD%
MF)E]32&JS<4[56@2P2&5E)>GU$B&[GPTY\%OG+UDE%$P1$YLX1S )<@*!$@9
ME@R'FMRO]%U,VD[3O>(Y'4*$AI:HNJB;<C_LD";IR_55'5[O\C@C@,U!.@7"
M<N(OD+_$_<'&.AU#'.*,J';5C;>##A(AK*0/_4!Y&.Y+;D!(''.T$TV7];\_
M'ZM_F\L6TX84&&)VR^MB-P"$DSAVA!]Q=8<G.WR@%^,#\"S\X+$K[?*67&U6
M9OSIQ;,O__>B/):X[KJY&6*XV_2'#^YG,Q+GDC$G&MI.4Q,R&OYA>FZPZ?\,
M_S,[O-L&-C&'SNQ!P-GJY[5^N8#ASZVQ>Q(>[9_@\$OT-#+^E/LT3$W!-Z/#
MO2>N*D-6Z(=2C$D4W7 _>/)LI(-/E0$%*N.SU\8Q7LI(#\U-J0 3$A(4#5)W
MJ*W-G>/<?;</3R;'[[#S[M<I+?L[B=./Y_=.H5-F;QL/\G0I\=;&\\><VIR@
M+M]FD."^8$1I$00/Q6(3#"4XAS7H+.(+MR50X&#I)GP<O8-7S?OVF^=+IO:3
M;@7]=2VV<"5/GLAU!H98K%EK91.>M*8K!^"PR4&B$<)OI281A7 2!_((0G-&
M9'PD1,;G9T3&&9'QQT!DC,Y?C\GPC/"C" WIW#"7Q"^^V!;7#7=>V8-0-U7/
MK6K:;'9F2NKZ@'SKNZ9[?QWI0*?(6G;A*O*-"4  4"SG!=\I?Q;[&E2"V'62
MH!A(71QR,P]HXDZ;8[C>/Z,@))N!=5!G#@ER98\ESQYWY^B4BI(05ZZY6M.2
M6\#-#E1Z9H"J339EB/B9NA-2&'2R5K)22RW^"20$45-2BMQ3VI<\+BR:%4<D
MW/+M=,@1."1K',QR#,AN)XUJA1N>3"*_W03*G;R&C+X;.M*TJ03,HZNP:ZA.
M-Y16"J/PFY-)Y ^Q50N/Y1*:F%0&XI3F3CRUQM6&@!/1+RX7U\%O:MKX"4IH
MMFW3(ML8//_@TJ*1*$S,L2IWFS![HTRHF4L(WJF)HH47+'C7BIST :Q6F-M@
M-*.6/DNZ4!L-&IK#"Z*O]+J2X -N?$UEVMVL'@=G$V*F!B5*CJ7T5W3\.N!-
MR:6U6.04V/'&P9/A.H8%*AD@T9W WSZP+8]"3G&3 \Q+%;:_JMK-$SKSCF(G
MUELTMPR(",/CKK694RV=[A^&37FG&HYTN3@V@R09\[^*G<JZGM(RJI W00I1
MY=(V(TX"Z;H)'RK;/3<&*NK(Q9>@(>\D/.M\\\"M+_$+!1CI_&DX#(M7!#F]
MG[:M(!6Y2I*LR986=$L8)1IL]]6Z;59(L5U7+7.?:#7>?4M_.(2(UPA'!6@C
M>C/2U<%E]<@8*6!']R'$BJ7U)J(4S+$M(7'>B682$[TCA)0T=LQ?E!+/[\O-
MT; ^[L#R$!P&ETWJ.'$'^UW'E8/!>-Y'X*1)VI"J3%8D!TU]"!J6,K=+GF:#
M52A.3S,ZMM@X_]D,1,?=U4XRS229TN48;J0%^];Z")-$NI .:VO[Y-[(_THZ
ML;Z-; [");>!JXYQ=T+TD] "0G/Y:%R<"09Z<EF/:\[!+Z#LA)(S:V;(P4?L
MDK8+D2D2))/IYC.Y]$VM0/U*:<4BA@[W,S,/]U!1J]'0_^;6RQ[K*NX5&N2&
M,'ED^]6A8MB4N$=DT2=?PS#@X6Q'$W5Q69!C05/BFG$>D(G<-7SX+5$H<<P6
M<D6ZWFI9[9PQK0J! ]-7?EH//Q9U\^I>$?3,O'ZX[K_XTV?WA$OHKFN7%D%\
MYA)2R@?-O,I6.J_-O5B;K>+Z$%'%TU#C147O\S\\GNM)& 1BJ,T9:J3%":,B
M%IH!&DI?2N<CYYR3$.$C($D@5&J&ET7+D<F9Y4N+ND?$_F97TD@1N%[7=KW
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M<RMTAD@*L[N^JDK[9Q&!IJCLT=P"3*LE5<U<)G(4(IZ0&^,#?#B,W,[;+-\
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MIN*[>H; \U'=]*&.1 +>O*HZ>1\5@8TB"2/:?WXP8T$W''G0GHTL@HXPQNT
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M*X%G9=IPI#;M5S\:$86_F[:X\3!I[AIM]MKA2Y,#.'HO2B HU__?#IPOC^:
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M>+[;E;3"R\7K>GT1_IN(+8?]XH4S1UC+#V75%M_]^BY\\&^OWKQ^209K7Z)
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MRTT< OP=\/^'"WPA4A=I!(?\J+8T:@LL=S'2?['B!B4T.P1<-/38Z2R('D.
M) -)[A?82GAY+6$HC4:J8D..3O(-ICJ\"7X8_5_TT5%ZE/N=7&(UQ1[T#<@\
M&!)+?P!UESA-4&I\0,[*G14R,KQ"L>X0FU S3<_+I,V<:^,]>\*-DZQ45(^W
M*=]U'IY&"W8B-]"3%^Z1J5X:)PY;5/,BD$/U\A[0\MU:XXAI>J&5XW3:/'F
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M7!ZK8.9,KR*1M&$;_!W@IA[^")6X67,&=Y66(<:8IN3YTZ ]@H3"1#+'382
MZC#(<A# 75=AJN&-2[G #4H'D+06<9NL"+YR=U<10VS_2IUFB4<OIOEA8_NA
M6UR^)7<N987>2:R!%$U,K\2$;I)DLK ^7.&EI;:B2M@HNQ7EYT[FL=SK?% 6
M"REXT?885Y626545O1"',?4C #LMHYG[ZHFG_S(6B /$]]92)"IJ?RI3NWO;
M#58'8HN+@!Y./'?^#<6EGE2_HAK;36DA32HW)"?,&3?RD7 C?SKC1LZXD3\&
M;D1C$SZNM-*BT>&3V-61BUGDV,Q1L AW!?*$0[@?P] 5'YY>FWP!:*VYSOV
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MH9X0:E9>7.SS;I\##AHC9L"=NQII%) ]QP0/!S!76[]%'+"50E\'T U@HP1
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M,/DP2#U2P&5*'J"Y<_5&-^. -Q#-6Z$8P7D#QAMPJ1Q?ZV"I>&L094+&:)W
MNB^^A4X-8VAQN+U3:F^2WK($C8%X.VC1DE2$<LTLWB$+5\V2XWXT%8X,_6$
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M7;NK$!U-(3A\U#0^E&ND>0AZ]S*>$R^P,1HQD!;OKQ#Z1SC4&?R/DRT(R9:
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M%6!P*0"#>W)]8-'*&T^X2&O#JU 'YI4D93176)/:*-29.72R%WM:4[ T(<.
M-)LFSSM)*T"+U,L_?#7)7DC@9LH.D!44P@D@FS38V%]MYV<Z814#S<24TZP(
MWK$1\QZF3O$FJ.XJCE2[:D=>DO>E:_(PPC?\9=Q5?=M0=LU>L%W$TAN[C@5*
M^36B 8L7E64()N1E4Y76Y31ITHY"+PF*VQ#2AJJTWGF*ZI]3#^ [JT#]/8;S
MCN"NUB#]XX8!([YLU D7YMBH,R</0#\5X>;>]X+\=5]N "E=^2C%-C*IH!]
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M=6\6KU8LA0DR 6H0K,W); ^A46^.BY3G/*THXDBX+A]1*J4D2D+*B-B5:L?
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M4JV.I;.X,0'>^^OQSC7$G31!TV$;\YJT$/6K<?^54A1"2JVL8H('D>0#2T7
M!>';N(^O<0X=>#D]%Z]C_&)P#^5J"RC+CW'1E+2S[0< H7((X\?= %(15AE8
M<&IJ]&J.B]5Y9%+,>L8M!3%-LNG:N8]H[CRU$09S&70U4OQ /R3F]'2']C'!
MF>0U M]1&U2GRP#'$D=8:V_H@M:N'SB8[-IC60\ I#_2ZA@F=3MA(L:MDT(_
MQ>A>:@]0T??PC(AN?>Q2C,\]E4(+V]B+5$RQ0QZ"5LE[GF@3M?^T][$Q."(
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MQ"8D\J<K"+BP+T,R%AB<<?#&>XC/9JZQA.,51I\3IG3DWULZ7%/N%TI5IPO
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M7TZ.XT5N+]-SEQ2+$$)7M<9TA()&*&AF6.X+:3FF$DCM?N%HG2%R&+K\<X2
M5<(X4$@GZB(8%')74_$F8:'9(11%4= 1J0BW$?8@]@<4>.C.0VZQQJ"]"&YY
MI8QXAC+ ?V[4;AB>'<$3 ;=?\I(W&(WMN:_2=.7E=CML7]FYIOL)D@1K/2E9
M&TI'@GL-V8#:TC4CH]1.F]5J<QR312#LT2;@.C"MX@_UVLBC5SS57RAT :,S
M9XS3Q.ZPY0PA, A-AB_FQKX 3SEC_?MRIR3=G$R6Q\TDT0<B61>B#EB%D)[_
MZ?W;']_08O%@>+6H"H]K<$L<4+>Z+I)#X_9M>>38 &YO5_-$0R85S- Q02&.
M#1 :R>\ A75NG8N0Z3>?E)1J;R)2HX]"7,PT&8 UE!Y*^#!2/"V6[9KVN5 Z
M0ED.FKBX.1<3Z%(4B$+@55U6NU[3QC@I\'>,<8GMO!'-;Z3X4J:"]<+M_.]6
M6#VX6;P=E^$<0*<*=+0#WU<H<O080,.#X&A#>@=K73XD R?J%EI)*EY9Z9D-
M#Z%5SQVZ,\Y3[(8@X]5QS^^"FQ(&CJVWD'.K%R__2!P/.V]?MSWST9+[4_ Q
M)?98Q&SBAL$:*B8+D=78$6C*WVITQ8IC) (\!R)K'CNFL((< ?6P006PZOJ!
MBKH?F,NAN2-$<4^K1;5DQ)0<^'H7.K3H-F:3E9DRSH00DO$>0P'?@)##TV0)
M-QN%05(/S!)G)WR'K8?9)-Q<PWM[@Z4"N,:YO@VZ M@&3VU12!A&)+?>.S ^
M#_ 8<.G4[]\@[>+_@^TNE;YF)^/_X=WR\9<*O&FX4&1*"1;$K_DQ=P1NRK86
M82*(8?Z?7!P63,,:O-;_E;SV9#+BY8D_UP?Q,;0@X5M,,(9Y^W'/2>@<Q[&I
MCJ%)9N )@!SE?V/A#H]./^ZQ')LUV1*7H9TD&ZO^;>)XZZ^''..D)Z$UWK)_
MRXI.L-@=4(EI4>(K:.4L7#5LN<(>;II>D<1[P'K)9*<?NG<XBA/+W 7XE<P!
MP-]LRJ[C<ZI'U)R1"_2]O_7'!;J!@YVFTE)DJ).+# XRDC32Q!5$GBA[AOX9
M R>4OB ##K>V4":-PB;J#P4T,/IS!<P@F63Y@W(&A9Y^F]76)G B9L<?'@WI
M%=)#YD9FS81!$;Y)LN:BY<''9%5UJW%'-NCDU;<\6@"QR7Z5->,^4O/46FYU
MY/1NF^=5LP&[Q"!DC$\3PU6:X<:R#@WU>9?81>+_7 ,+J&B#LR 4' 4?Y2 8
M A2*V!&F'.@1+T'(*WG[0NN.JSTB'2/"#:E9./P.^&DP,6]6X]_+IOWV?_[W
M/_[NCY]_Y4]>T[K=6/>\_+M1V'+9BR:7)>PR>F\GQ;KH%KN8T_EC>HW(>S*%
MTZIMD"SF#L\CYZ?(QVF1Z;<(I+\3+R$J#>&5$/*LLZ9 -[R".R,NKBC#8J*8
MO)TF/K6;Q7MPS0Q:--;^ )HG["<B8IP['GI(B7!P0&X&F7!(+?EY@#?%U%T+
M9&^@D-A$Q;"L8S$%;R3)TGX 13_C85"K=Z+LD1QKD]3.9\ +54C V5J/7>[B
MBWW:>R6Z;Q9_ :T'<C=0;0&?"2H6RC<G2E\F+P4$&/T@CE]$"7A704_B1CA2
MIW:8MXII_4?OVR;?D?C'_;*OL,T+SS;XUEOOJV#3 [*#)%\BV*[)]*\3K]C>
MU?Y!F[:N6AO61T;>.#(ARL=-MG8G'<A[U2R>D UZ:$'G+=M:DK::BJPJI(EN
M"@XF!G&Q26BO'SM\24,(;AUKLY)QHI8C;XM\QD3O!I72^)MQ*NL)+<69RDZS
M>._V@P,I#U9V_#U*.[ZDB.-OKMP>G[_?P>YF<4'O#=SA641D#9_RZ'/P=Q#(
MA-X[HRE+H*+DDT))VD>*(A$Y&KOV_B&QO0^.NRAF"KVI@8X3#%PD*9T?5RZ\
M8LGG::T 4_+\=?D]DYS]45-N;.90P>PP 7AB76,M]*F$H8T8WH)5GLPD#858
MPCA93!FN.V?GQF354M*7\-@K_.+3')L_O+C"+Z[PBTN!7YP1/HY-4=(1-DV7
M!N-+35@[%ZL(_P"YSNBN^8(,Z=QCC O+7A6FOS0J,=9/_XK8@@TZ:=,1!GX%
M30W0]\ES*(?PD *[WY7<+#S\P,4:>K+^/7_'X;Q!C!U+!SY.W^;74+T_&'$,
M[T$ZX7%1*7,3,MT$B.O"%9OPHZ("!Z0-B=Z75X?]RA\[P<:_VH.H>;_XNBV[
M-7HO;W]\]77![45"P% N6("4 C N"9,^ T64DO/CL'=C,R*:]T?]/"C[TY[J
MN;CK8TDN+Y%R")%9=T-*?@7Y7,A\PLPN5+4$G[%!1D$?JM1 -7N[Y1H_!O"U
M*R&/70[(R><=A\+_)&P;YUUKH^8)+QX1:&%&#=>;,\FZ5K)1PC+C/X\#$LU
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MG6N4^PJ1Q"35&8"!WHLCKO"NO>W*G?0'C;I]#"73QJT1U&A%L*0C$F#LG[\
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M Y646MQV,G;0W)1TXLT8@>SD;%DN0X<NG2O8KZ/"?>DTI8\1VT4B.=*);R:
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M0\WOE10]->Y!>C0E#^$4 M0<MJ#Y>'LU_(]RJ'/VX*CY( 9K$<[&GW2@O4.
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MOFQGE\HV57(E.'98=(;72K;V(YG244G:M?+Y(W7E2QVY['@19<:O6<5/&H2
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M*V5I+]'&S@K-F5,T.9P W^*$I=&(UH+^..WU+</_LE!D,7OI@$X]4[L%R]=
MWI1* 13!?&"&#FL0;A8\JTBVE?%5\-T/==X[ZZV205X".V)YJK2]Z&O''BH
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M:#?PH7;^V-I&(RB<&!T%EF0M,, RP6#A%+,E7A?EE%*DBB=1)<H@7!#ZB8X
M*SPH^ "#T.I#I0/"?LI5!LHDQ/PM7RQA>DGF(9+$*TVEE_A3OB2M'V<(QMB@
M8SZM%=&,DI4#+#Q \%M4G4WBOD1[Q0&%'1'B/&TZJ<8E;\4]*?I2WIZRZ[Y^
MKNC"1A9FV92>-B>-+EW4/V!DNG[-6-YPS39<!<K4/+!X>K)I+:PU*-*E@*J_
MA+"TW$/0I]J%A@%05##')"EVX7?6:MI?QT%P]#;QH\_>'U@M?)DE6(?\D?H+
MTO O*#0)(_V0@$QD2[;8TE[''#$J\I"39QE%UB&UXIE6%X.4%M2G/C8(A8CV
M![8@P)"GT&0*!@F>-=^0(<CG;4D@M_$ ,1D"H\R2G#11&[:ORQ6@;,PS1D^8
M+@2IP(3F,)\$T0=5!+L21^: VW=A[F;1")B/J91991ACMN&ZK*[/M =HC,V5
M3WI)R44'S-9>3 8%,[PC!KJ_TL&@(AU&O\G:($N;*>#%L&Y6[$/8C8@JR'7-
MF1+%0)7%$MZ 4!I<R%F.D11>[4/2DKCO3E$:5$_EMS&DTK;.K1 =KBZI1FN"
MH&;#$$$ ^0?7^1&M<NT@.N#+.092NIS"QE 2!I_!TE$2=#ERU1LX.3'W+=V9
M.@QIP&-FTZP'&:* CP)#CU*IC_L>X'.4_5(U$[3F6:QL!&P.ZY?M*F?&B])%
MQ50CR8\;]QYQJK4(#OEWY=WKD5'3O!&=;G#<62R_I;P9'S41$BH%,:4;R4EO
M]'K:(\T#?V*=F<K#$-<CM9I(:'<F:]CLQK3 BL-(2JYY50H$#-LZ$@5^#9:0
M1F9%6U)T.>*<I?$093CY5^Q_%A:A'5&X&&E&7DVF.O*!4_93N!",@!+/HDU5
M.J:=)U('CI7W(MLJ-"UTP7PMKJ7ZJ92&IXU+7*PG' M4L80.:<Z<[A,J?2;2
M(H=(2/H50WZ#7E%XE0LH<&[,F"D!5TMK',Y[Q#WODG%:N(HY8J*1E;ECD0Z]
M$PM-R3Y2Y!RGUD6FBY&^G$<S_PLHQHS:M'XK)\B7.4TU5D6<M=Q;IQQ*V9_]
MV"S-/JW7H=="+W'. =??H<H?ZTQ+65\^#KS [%&^94_U;O%NY/I E'9$!K3>
M&M7.6"R4#18OPM0Y)T"XGQFF9D6,*5BJ5U@;(LG(*+YU)MP[BT2&O!P.>BYU
MH'IMRZA6$O[2N#E6$A?S*4*(M$$S4/?BJ6P>C1D#98/$$?%AXF7BT3"CQH1'
MNCE%QA;$-]$5#!7?JL>W?BIXP//P,X[4!!7?U7THM3Y%V9UID>N:FU[7&G\-
MA!QZ1(H#+H<ZHG4D91FD1#D+SIQ'$K]EE-OZ '2<5,\TN?SV[4#?@<&B1PJ6
MNR2IN7<!IZ@8)\36C4O6T&E9V:$RF3S1*:FH?\*^%L];-3I33?T:M+93R=XC
ME# +8::F'Z+V"%01-9H#9/CB_=ORS3S\@V7;7[*ESBKDJ#>J\VY5E/DP+6EY
MO*I>;J+G]VIPT_7.C?:&26_AC.$%?9(9A$(T)YLR()\I>E+AJ%]SU)0^Q)*'
MG:0F]URL*<MSC 6+M3Y]M&/2(K9]S]E\*MM\;-(;U#(#KD8B4.?=+Y2&;S-K
MGA'*$0UAE^^3EX/,0/551"Z;+K:G,HBG^8(K]BC[2U):R68#NR=DO8AQ"+EJ
M(.9WKNQ,A;(S?*(8*:,8B?8TU8.5%%[_2/$VY$N2+S+?HGS.(/*"0 9IH1;I
M2\M-:_>^,\O!(MZLI?:/=JS1R:MT*]PIV'1 5ESA>HT+9KVX$G[@[]!FSF8:
M;#!.B'0U70GWRP-NU%Z.L:/I2RET1 2[[2^<14.A[>&'+H2_$S\^Z[D0O@OA
M'TH(?QL<2TI@3LG_C(B).K$I4:6Z3^/WNP&B1_G+-DQ)=FDTT+#HE[8#][1[
M(G"BL@UPKC7?[5_(.FJ*IB099]%U. FS=;QY5GD)H)*4IS)?-L[+3KWG$A>!
M<KMG\_C&X-M^*Z$BHJSP3G=TZ<ENNI8NPE.I@1KVU[>X<8-7.V_O%O)0ZO1A
M-Z827R==*2MI>]57IW?+K1,_J3%C[#IE>+_962DJNBJ:&6C471U ,YWBK""0
MGV?7L935>&\+(B;%C1%;U]=Z]Q7E=(E"WR(M58Z)Y&$8VU"_3>M61LDV2,1V
M--SRJ>I$7EY]KCU Q3]-#="[8)CR'ARRM_-#D7<@NP5*,R:$&+6=E596JU^#
MOG6#C #^3]-?F,(_R,WD4^18RH>IF-=*0<83HN/\7N$0U>XQ'0^$#R9P>JYU
M<X!"K]ZC3;@%Y!ZY-7:WEV8O2([<9T[!*9AQ=CX!L>B,"AUGJGUJLJ*29CP-
MXD;1&TJ;("*C8'GS>MA-JRJ4*N@+<%UN7Q(+,,O<7]DPKZ7\#SG=:QU&2UEN
MG$S/!311*MM<'Y1@\W:Y!8F&1AJI(LC^PO6S;-]0&YK9<I-%CEJM$X)V!"1*
M':V4CS:+?W5%V@ 5DMF9!4RB)'DGIM"XVH>HP-#U%I18DUZ'2RX_HAZY5GWR
M^FA<=]P6#K6>KB)$]E_D["70R3JBF*FY9!'!WEK5-4Q)5">85LD(U$NFC2H]
MT;N*H/84"Y6PJMK12AN'6D\K7&H$<H0R%@CTIYD'=&PHF1J&=875HBEGDO&K
M1+6T*:=3D(Y?$ _6)5(U*0AG("2P'#"D9.61EBIX&[XOM;B(?',5^1K#W\\D
M\KR(0? +]+T\HRE?)'M:IG'*J1&OJYB -$@>8JC2YM0"=P1:.-3F(P#J%GD5
M!$O.HI6@)(Y1B^.X9I 7';(V27%'""T<:C,A6'*O_F"3H<!^ 6E($:88^&-_
M15&$"!QEIJB,M$"ZHTBW.&PJ$#%2P: ! A@G2=?R%DGM_%;TM*2"+,.9N 36
M5E3MIG;J+&%I8]6#'9R?8*8=!X7*9E(0SG-) XMO(EM'A"%E6%&A32-'V2T<
MZGTI&_O6L&MU@]FMR8RS82IE]X;@''VT<*C-]&$\B7K_Z-1C?9B?9AQH/SDY
M&CP?_@?_(6J8<#QJ7C!GAD+E>Y3F'F/S!J(DR?U3^-I;J*NX4U>CE.N$&I_?
MY$IRQ-C"H3:Y12K:6%HI!(FI^Y1&NA:'FA9OLYA:;-4\PQ4GW+V*.EI).2!%
M1Y:*^R(H93=%LZT!1T$M'&H#!46630L$D2\*%B(]SDP?6^1A%[#79/9>7*,B
MEYB^*Y>9\!(3 ]#)366[F;]!74Z%96FL99/[HO"3CHC:.-1;92)GBW&SH1I.
ML1;RH98J!.P;1Z!2BP=C>NV'R<+?X,"0ZK;K4,W6RP^T=Z/NL5L<P75-Z8E/
MFN"4 >8AYKN,4V:+IB[2  !I0X179]U*INPN1^3M&VH#I\2"UZG2+;^+++VZ
M8":W6B]R%$.K8U,4$Q2PLKS NG2^P5$7"Z6I2C,BRKSGS%<^<-88!-Q:'[X2
MX1<A60K9H1U3&] CIQYF@V!/4,JG3 E_-#-G@"">E.7BYHP&?M[@:Q.J]USD
M0V!/C6SY&T3SQ8EA#3'7NTKQ@ D98H'"P01X!=F!<@TJ\ Y8IW9DHN26,B_A
M6ZYF+R5-#WI#S2:-Z)6N!R"MBP#Q+_Y-U_N=PO35YSO<$-;<*@#!A.QTQ:_J
M@-ERA11#F.%6V>1BHG&MI1/>RA-=$@;5/_X/N\Z"BIHE=8)=/9:37)["ZFQJ
M8V&<X0(<B5C7&-M+*2/(!K,H6N=)+S-]B@I2HYIO[I1F,DUO[^7B\DAWRR/M
MNSQ2ET=Z*'FDNV9*O2>PH*_( W=.WI%FTNF=[*PP;32QR@7[B)N!'69RU#@F
M*KM1"@O6#-A4.?1HN\"YFT;U'JUB6*FE(K=]*X/K7Z %DQE0#,L,@D0&E]=5
M,"P-<B467)O.W(>B 3P8K9@P\TV1+H7X%IB)631L2^U4!G3FV"W7<5<Z#TAS
MJ $ =2#2%5X0CQ*EA&G;'KM:Y!0^%P0%=>W/9QV[<SI6&TEMB#?A\BMLLQ6"
M*AIB4XD@SU:-#TSG?KC@ENAI1A2>< >=-5296Q2FSMT\J)J>-[ANN7W]EL/7
MO8RY>JL(])O$67\V X,9RV*G64)%KM1ZJMFSPY6QE :_1".%P#U0/=,[0ZF6
M;/CB* OD!3R^L/;5G(,R>JHVP.T2*SUAUMEXCD@O10] W5H)C1/=%*V8PK_@
M_6G ^+J4^(?9U->Q9#]7)B@9U\2V2G91T1ZW8%J3Q%YW8E\5IL4;D&%.,@*9
M&]YV!V8F*JMF:0UV&>6%()W0IMB4++RZ[NT6&)WAF-ZK%2,'&W: D*YZF3J@
M==\HZC>[CHLN51 !H@Y3L((VY,8G+%A=X"[X+J803^]AI8E3T6%O V (%F"0
MUF%PH-!P8-XDQ&BG[&FTCF8:,$GA)L];BRSK]*;KQQ>MA0D*1Z#>^1P,'S:[
M&./&<E%R4KW Y.I217%^$1&+^$2RD2+S;+740>\B#Y>,>3"C"@ >A.^(S)SG
M7+6N7TK 9)1@H^&;-B]!GFSF5EM\GTY%9)Q;)4"3-;@3X&4QH=P'!A]06I<S
M<)9N:"Z;8Q_LBMZQUAYH*WS!_=$2=M4Q+S2$-\ME$%V<1H9Y%070W8=$'3'"
M)36=I#Y*5OXWD,K1A""'_.!?N6XL4Y",;N6*G:Q#SJ+EGBR<S5-"@"^VGI(A
MA)JJBN(>[<CM>MLE=@D'*>?]H5??;IY4JL!YBKOQ9.V!)\\Z!J(L4=;FU6&P
M_PW.(2'Z5;"ZL9J'WU<TRUH#AG\;)XB(]WZ:7RDN$?AK",_#'^%4!%81A9DB
MQ%&F=#_W6+J'X;&_NL*F95G1=Z(H._II<-SM&6AWGG$= >*DMZ;!,OY?H2$4
M[1XV8,@;>#W*-D+F11Y2]54ETY";:Q(?6M]("4CPD,BS>H.>I-!&-K&0'YGD
MOQ1I350MA3"&;["C1VA%$PSL5FHZ?W2VGU'S1%CUJIL')B 52&)<*3$-DVF^
MP-.+8^62G1T7]RY#J5E20K9EF 'VCM<^?3!\HQ&DLW!\FN6657A5K"&>6_GU
MPOQ:8B'D2M[,1^K.9(>Z:^A-#/A8&*&R=OCM[+U1KWN\14,'C=M70QD^ <#)
MISOU[0G6R$_'E'FN9@VXXQ$A/)MS68@B^'YT5-_VA(&4+$2\M4-0:D4!/S0U
MHX"97F'R/XI:X0\3;-U1=N.74JC-]-/F\Q/.Q-"F._'MXB?78$P1%:B2?P?#
M+ 1(.Y7JT5%W/"8'_!C_09#$=AFM?-3NG%(67^48Y@8^0(2C9P.,OL QK69]
M<N7JUW !:NK:6N_(7-:.3P-;YZ7BJ%11=FO(VH]LXCOKGFU!UYVBT3C9CJ5>
M)_U1=_@?^JDLSBB1JV&-BY6BP>NEJL!I:9ANDN\LW?U2JU4ZYM9*U!-3)K6M
MV#<O87KG-%HRO>)9LTBJ]/<Q0KG,,:PC3=M80"9IE$M=42YE-M3YZHH\"4GI
MV#8?V:YG6D&M-X(JJ$!35'/3IX VT.Z96B@U57*O$41A\%]/MO"'G_1'3_9(
M?C5!<F5JP49[_U67__%[Q&8=B(U+1)[!?K",7WDH0ONWN!9C9MN-'_0.9..]
M@6SY!T)@0Y_.H6PQVG/7R@^DR0%S,)#:/IM!WJ_^'#VN'>^#BJ)T-?_B1Z'?
M$:2&* 7VI#WJ1IK$LXHT..OTAF=>BI] ]YBB1^:,^<NN.P^6:*I$'T=HPKFH
M(W[&S;;8L'BK)@F\9"5A^S-JM#6H](,$GLA/S_T)^G<0FX%?SPU9(]LAMMHP
M1]L HPE*]['RL(!!DH$Z['';K[N?EV'M<7$1^-TB\ ,7@7<1^#M&X$L9AY1?
MN#'CL%7GX5:]92@R[!?RX7\H?/@'HZZ\1?ZNNS_A_YL6(%:.&86XTMI@A@F2
MBLX<(>0A!^-2D[VE?>\VH/$$3&3L ZV-%,)\- ()T9<9=0H;'BDV@:1;P%0'
M?@P."5H),8)(D=>(H>:MX-/]L/BW@[.ZA\9W>B :GZ"QRI'Y%4LP+_V9@GU\
M;1IW',[!^4VBX.P6N<?^]TZ<"G-_%6;H5!BGPMQ'A=D+ZF^"6SO_^,E[]^[N
M/&A8RX/V;!4*&72L95#1ZN$C(3VBP_$_4W(Z@>A_\^\\Q'RPC\ABT2.%WC]Q
ME/\J)1-HM+_#L$'B?9 H)BD"_*R5P+1_@JUA&671WA7HU7LWLPU^FTHX@K"C
MN1,YACI_.[]\??X/[T*J#60I"O#O=+68Q'/=M^W]Q5]^ZTK+MKU;HX;=MWK"
M'8R_CN.HTFF^ISO-$YQKX!T/NB<UH9L2G=AQ&*HRF:PJ[CKTU=D1PAA1U+$Q
M(H?0P6;)3;AAK:(1<S0EF@%&3<39=L6]_"+/I%A+]!&1"2MP2MCM!.VH(KXG
M$",=,'$RO&PP3^@^FDMH>F.FU!U1]R",L+\53'22Q)_+>8)4BD9I@I_*(UV;
M/8>8@QB^)TUM"4^Q.NAB5!+XUP/+$FHNH-,_"0/AD'CMZQ"3LF%A/V"%W&KO
MIM5<JD:&-^XY(@G[A)^;@%4?!F31D^$<R.0-R%>IR*OBH2Y:+!J/@<3O*6@N
M>+O*IS85*6,_8XM23GCD.#)\PK+?J:,D^R*LE_-PJ>X8Q[OB/@-K(]88W#%&
M<SG7T>!Q%XVCV9=2&3E5+"/WP#)GG5Y?8!75AHWU;&C*DLI/7X%/1MRTKI1\
M): B36/<.SIK.#X8330 WB; NZ::T5;_SNXH\>$=C&Q;;W],W:=TBCVPYW/&
MX/A(<-@=#5BON,EO2HM&^6=4+FLOJ)6,+4=.^@IC(@HV*S9(\/RU/.4L^'^8
MWM\?!2<^HI1"K]\[^@<>JPOI&UNY?';T]V;*M-W,_>[P>/^\RG:M@X8W"^BX
MOM.9+EQG*_1[@8W@HI19Q(<Y?/I0:-8R+:PVA8JG/;6GO<1IHWY4I)[#FB$%
MAP118\#:D =^P(Y][]Z]ZW@4?^X/F+%6CX!-CAL(KJUKVD1=J#_A#,5(W;MY
M-=ELD?=^FL6H8([M'N51!&.<4EFV=(JH04'(0?"'"^94IH[;9UT365>1EAQ?
M)?["P X6^!OF%F2.2Z2RGP96XK+.RKTM*4ZG0I0*R:@C674,-#LD>VE2IB^O
MI=*)%A 4Q9_<2K93,388'X>P)Y1@L=?E*DDYA_Y>8'(FK3"0!;B.14>@?6@(
M>:Z=O\K#@+OKFI0IB:&@U5*4B7 <QVZ^90.??,SG2K*&>I.C_ID>;:DJC* 9
M04^+46Z1;3#S!=S]7>3]!AMM)F_R9PWQ%,L:>(.3SG&O1S>.CSM S TV($6!
MEMPC CN\";Z5M,(L\MI[W<$QO0W^-1H4:UY^_AX)#P?BJ/-.Y$Q<4I4I[,1;
M$WI[[6?^H? O#!,9X#\JKEY@<9CNTUOTF+/-VE9,J&'SO+N2[K@VI='%N7:+
M<XU<G,O%N5RJSGK,Y]3$?+228HJV,?T@3U.MK)Q3Q^:01'PA="ZTKD+W?"Q2
M/MX;E]$>&0N-):(-?.6_XQST%)U,$Y0[WI"V9RV@;RU@0P\X#5Y0DS?#E4;_
MRJ-*J5%M^V1= ![%A'>&EA]YN\B/''AJGJH;<FB$T0933ZN38.]YE_'"*,!V
MA]825!:]JF'6MJYJOT 7+2]%6\:58?L5G\;88Z:N5J8Y>JD>.9$(Y*RHL=*^
M<K@?:]^.YG'\F:L:S.(POD#T!?/IO21,/U/_"*DC,HXO[%BX8* K#8!@+S"&
M"SBK6*-JS$,UXT<YDTK[2\E2%T<K_!/4%OV%<K88C43:>]F#L1*VBL[E8JQH
M4D$ ]W &1KU)V<+&VIR#K-VHAK#(14P\E# 4(P22F4L+.BZOQ?H->$&^#-C]
MBI-O7E L#%-D3/B%#Q=I)8)S9VUUQ[B;N:6%C4C7]>J.D@18/L+*>&_94-%A
M%EPGN7PIR)>_(;SS1S"2$B*RMS+@7V3 EV; ^AVITHWX-CD\BE/ 3F*;P#%1
M;X$W4V6P+W#EU0W;>K.D20C=%2@P%<,)'RSL%(CP#P4$R ;ZKAS)+3C2 7/H
M]PC@M\S$E#W5OA ITM8=( /*M\1"0<QR7'#E)G$FN?']\B(&$WG:]9[.J,P;
MMNQSA#6 0/-\3T>N"U66JL&%XIX]\[CX.TZ",I*'U6 !+'63_H^;A#Y,"L3R
MJ%C,QLD5V#[_JWO)T/'VZ07G8%3/O6,]T<E*FM4A@I]5C]ZI*5?_2+$0I;]T
MF4]X3HA8>',=2]4CE:Y.TC @:"#XHEWEKF=?O$)/G0LB!:/GJ76ZY58SZ>*!
M];+TXK6\28'&090J_-*<N.U$99YIGGP)"1Z#F-6VTUH;KQYEUWNWX&[I#)R1
M2;W'7-DQ*GZF4WHGNV68\BAH#.,O4=);Y#9%7U58#40EE4),60E*Q5!Z^WT]
M1DW)"'24<3$F6WV:]7%NAL!-XL"GB.K(32"M3R8@3L/EO*CM^STBT +BI<5N
M_]Z]['I_.3__H%>%=J2\\&%J0'T%%=)NK<[EHDG7.Z?# ;^AMVCM#)%>>HV+
MF(13BZ665:5$@0(QE:]<</'-]D\3D\=X(<6%$+\G%,3A8MEA>IVU&\MUN'K+
M;9Y>R80V[L0)<6M=)F3*KK6Z)FM?G4F=YG=G#]GX$-*IWP/5?PG5S?Z(L^VP
M:SWL*HPD>X2M%D'S#./EM0]JU53E&9&RIIU9/,U%*R6 *U@04HL#8 CS>,EA
M>2*U!58.@Q1EKSU6-XNB1L4%0*1+@1HF_L((., L07M;[6$D?$-J&S6[728Q
MXBX7*-&@(ES\/NSU.LBX?'8_>@N8_S2?ZP6BQ;>2+>"<?J"HP]!LF%YXDN8S
MRHT I9[JY%$VP6XAJA9P1&/3T+8M$*K#PT[*"VJIC<JAW'N5@) Y0O:>IT?8
M^@B?H")$S8WCO_SSKZ\+^62E<6D,XDHN5Z$%$1#R^)CJZ=$(0[:DH@08FVX!
MC,;'VB2S1-#;9-&Z\O^$[96HJ2(4L_?)$M.T7B?YE?>Z:(5GQOW^M1EUH0Z3
M:'D;QXSK1\^>![ HE)6:&10<K72]/K?T#0,7QG9RDK)"19DD:QO.@2,:*FOP
M@37$F4#LT5G02Y&NP#Z,%^L07+0!7?X_U)VX13P(_"2.L%=ZGL7A8H&5G'KK
M.!J'O<E)TG+([*1'^P"$ARJ#@B>O%1S0>!F'"@D/R<.;JOF<CR_N5U9>T;]>
M7GPR2ZHIKX-SM@ \YG@@8(P1:@A?*+.702T(X[]$H!T]%?EY25A&* L198!S
M^CJ>H!Z"P8)]!;!9-!J<V.9\(>:D/C.4$N'/E<!5F+.1YF@>%92/"UFO@0@T
M>RFI\&2( 2E#@R&)=&H[BI X5'5%3H8D!M&N,E3W0)#&"FZA@6=J>AT!![I:
MD9WP&UQ[0T)W\+*BB;S_[0VJYQF^WP0A8/.^,[<[(=#\6]G=%RPG1R'"GGP@
M).X3,#H;8!YNOFPWKR[XA.R)6_%OO.(%*]7H1Z;\T "RH-"2LD#D%P$RZ !N
M^H*(M@N%1DZ8+@H]0C@'F&$SK),'!DBM&M@I52IN=-O\O0Z6 3FVD'G@MTR9
M_E24I%'>.>UB+CI9H)!4$:$9!T@2L"133DRB1%8B =]\0/-D=K"*IEL(:JW0
MPE/H0FM@T%HH@#H,-#-?\(\$P7 P.NH?DG9HJ? HV?J]&GTR@$,'^KG6*_3!
M1146,\K7Y* [8]]I$XG"*;F[4+;]VQ1IV&+.(/51*X2#HY%2+(]FKW\&*OX<
M^UY>B2N1WI$BUK!D.<F[@ I2?\8G]P;41C@!<T6I@1W4DT$-IC15[&'#S4/B
M(U"0%J@?J2@ K5/CU(GBRP$:V US?*/8F\<1.DC(=:==(;8-I%WM:_KW(9U7
MTW#&-KO!>@RP&3.[W<2$7*&91?HC<CKVQV6V <Y6"+//63ZG-M]YM%"X3P'1
M3(1YV09H#80LUY%D(0/%$B.H1-_@[2$'A,IW&17KW<?7:6%!HI5\R^##5/J1
MV^,%U?H*!AKE4["Q$^\:;D3 ';2REA0IT9_[[:\?TZJR08>E+& $40U=U-?Q
M0H'MZV,X5>033P:[[LS#S\I#_C971S1<<0@*HHXLK?X0F8,R5!P>/H'FU2+/
M? / 7-),T'JH70;T]A&D.YV?G/,?<7*=DL($YP3(@JT6Q-JGO6/,<RSD 2E,
M6&D+-*J 5ZQO$UN9D=*GB+>(!6=I8&5WQ@C=&<8<SVYB#TSNM+"UP7KNT&MK
MS5V]C7K[T%W.)\@;>'@ E]X;($K&W/2>/FE'5M:N\:+?/@[>#-LQ],T#??+,
M4.B1Y8!8HQ6MITFZ9]W.8DY7$J?Q0NM]0)"#<6]O]_#BS0<8?CO&_B";: 0L
M^>2DN8#6"(P>T7\^\!M4B1'Z001I1GW-Z.Q3>R_F'*G"#)2-K*//GE#-Y$FL
M,9?/LW"N6\ZO\0A\9>I]//]XI',U8O8"FCO.C11HQX;M2FP?WW\\;\?(MS/F
MZUD &@Z8_:AW:>&SM1<HT4ELM^+YKY9[F6I9"R\J_F$[Q+%>K\87[MK /51F
MZ['+;'69K8?2!NX60 +CGL(P@P8_*SJF-O :2=MBI7L2HH\(U/MU Q3EW( #
M!OKN6:Y;<Y-25#)NR)T9A/Z$K05AF"I0"]]PRM>_OBGL&G,OB?=XZ6?7J^+.
MCZ7<B1M,V]B6'^/-)9[\AT9S:](3&M0$G#W:%@VJPA]%B16\7BN6=BQ4JI5,
M?H.\<Z)6J%_ :G2\UQ_-!&',E&^H#3R2&)R^65[.(K-":T9?<#OB*;6KLE;B
MXS_?EY9QL0+C>XHM>Y(8-AF-Y?B+G]*[)7O*/+NX^.V?9@D/R!DAD *:X*W6
MK-07WF0"4%$SK9H!(=#^"$8?(!S]7+!M]?&A2NC"NQ5A?)#;.<$=LU!2BO1+
MJ8<1H1IP&@RB$\:I-.J@OG-(:FB[3^EF[C1+KS>/@G6N'UJ#__UIT.L.3)DA
MU9/USZQ?M.XS"U,D?NYPRREINMY-$"RE:02] YULE4(TK]QDHOR0":Q3$Z=I
MKGVN :&+D+[UTW'?:NE &7J$E=!AQ 2L?*+ :*83G5,XJ%3O1=<G_EQC_/]T
M6@"Q=#$SKM*#4F+V:PO. 6"D MQ.9!<1[X,L<TUG"WP/.C$($89R%2PF*X68
MTB@*WRG993P[*V9/3M"ZUE5EI(F#.8.?8H_MJ!LY))BB)%W=*L :7"I:271/
MR2=3;&"JKCBJOID&K<VG-,"4PP@6X/9:.)VMP3)&=Q24!KD%9/?=JS1[AX#B
M7M3&%"4PWOYEIC7:P0W3_MC$&(2U[,_,;['WF^8I/"U1>L:4DJOYJ6FB27=9
M>/9%6U&J')$_-#_&NNS*3T9'XN11?@N(83\AIS:#6&4V\)16(NG;=B2 2K2E
M-9@-(,&YK4"]*4H ["^9?!&P8LF<(=E?TK&E,"FE/&\,+U%"\EPSBT2GLY.[
MB I;BCF^J4[;S-'Z1*>BM&+?,C^S5K[H<(DX_%:_3+YN))NN..)MM#/I[44#
M+3@)CAA0&?2>@(KD?PFG.#[L+) R+!-B+4NO&\RA3KE!G95:9 6K2[3!P8QZ
M4I(VPYR\%B@L#J ,X0*SP(J IS7(S96NPUQVDV.9S3DF+-.R'97(8J/@G\&6
M2>8H3 T!;MC>XN4O*?U-]+]QOO* %^1*1W.*&JB5E%!QC(=26DVO9'H0C$)"
MD/I#:?@TGA&IM[I[G/4U1,+^0B38D1Z9Z3IIE8J[,$DMKX!.@;8CNUU.]T<E
M$9M_>IF/]5P<9P?Y[YMO2<C>2JRT2#L-,V[C_,67XX2U/U:]7 %@@9D1!/(&
M(Q0*Q0'#\$)3(%;>VZ[WP5]QD9!HPJFREJ-<U;96EA)&!.2%KZ4>1%=%^5?1
M5)?JFDQ$:4EPH!&C0M@CZ9@*N$3-!,E -!+DC?$\#.S*ODIU(X:/%1T_+I%(
M<JYNVTA=Q)CH V@$,V+>P>B8EFG.?6)O6XVTL(76@,Z8@ULN!*PH"]'T*QTC
ME%=8R<=T5B24FX-":BN&CA.#S[;F=1',.3%).=!117[;:CHW=@=&NUL5VD%I
M*0V)*SITV88O_=PY+:.4X,S.D6J%JN25,C=42Y_[ ],*H+2Q@C',3.I>0*%8
MCJO0B]A1TBGD#Q9%ZHF6/E4VVNW5KEU>X/@99UQPEP*+Q5(> #OJ\VB)_4BG
M;*Z#V,AYRVR/&M4-U+C7C"<NC^AI] [I7%^ISEIY!3/76DMJL BEL;%V)\$P
MD<!3"ZO0]))CB#\FQ@H=S#!E_G",QO-R*6U9)%)B")=RHI2=P-$A48;ZQRR?
MKQW3LH2JR#K4(,RKQ0I=D?NGR!$W+B/M1.I2-9*\DPBM^B%1='V$>L*V2.%5
M1#VQB=XH51#=/<)PUK/QM7A B1).<1AT<(E(B4L0:1C&1#!+GY51EK0VDA:U
M@^MG0WH)I[EXJ.(;;Y'3H!B*B@IU$SFT--SU<9+W!OY[%>,3$TI("2F]?AFC
M2B,5[;J5.KZH:"L(U"2=H[A?985/U'^22\K2*>H0I&B4#J90 >YSPX@M]5P/
M&_T#:6J$J_ 'RS58Y. TOG>?CMZNMNU?FCU9!V;=WCY3;;M2823,#O-_4%(8
M8U%+Y)*A66^>-MF?A<I&C )X2KQ2XB3^2M8',CR[?M28;95!&[.TZVTQ->[L
MJS&B#70B5O;S\5VSH-?-VI+]RY!M9"UJ:XN.O7[QPH++I[MFY9K?8EZXZM+*
MDZSQZ5X=N-LS)FMTO@W^8[UA9:6O C_A1Q*F(MMBEOA%,U8&/R@ZI9+/DU:]
MJH%>PT!I^?665=YDS!HF"$8,1^$Y#Q>A['>QH1VFB(YWG2^X" LF.D6B*?97
M(Y4S,C'3#1<FJPIU%<,/!+N1"8;Z'**(2?.$'" @-Q=AOJ"GRR[W"1C,"TY/
ME;:MDG@/>F,IVDI0R@$B?41V/J1ONUQ82V AX==)GN62 BZ8GXGO=#D@#Y0#
M<N)R0%P.R./( 2DCPUL\G)+-_!6ZU P(4[0N%,),G$=)4=EK*;I%J*OCD2)N
M' AA)B+<Z,<, LX&$^*V4F%IHQV^/\)Z5^WX@O%EL9V 'R8%LB^0,7DQ04S,
M0S: #JB;\6ZS+K1*LJSJGB6SJH W%5AZ>.-3_YEVC&+9OTX8*%Z"5C#0/2@(
MY+A)/8P'!X(<H@U[?CH+R<$39T7] T6%#=8J%U1/PAGH)9+Y$9!;'<QW!%[W
M,VO,K*H\G3RKS(K<BJ55L?!+_C/U+A4: ]XK[P_=S+Y R@^Q:U1M%,*W>Q/H
MKE(66!+);B5(0/2$<6I,I^@Y8">S[O@02C=EC)9SNYG:;6G>4DNCQ^GQI#@*
M;\WLAB$0]/KI A&JB]+E\.OK(9LRG8/"AG4W]!6&>N>Q%M>F!KA-H. )1X"2
M; CA?=/[V?"77;8#33&7@7'UEIE].@7^2.@ E)=CKX!\&V$ROPI$O<[9(AM.
M4.I+8^["P!3#MO6+_/388K&WQP+*(#F,#8[8&61(%>6L5@3EOGLM/LCR8=IB
MFR5T)[>K1!]H3HJWO+ZIRK*Y1(RMGA,-(Z.1:_"O^ER0;K.FW3JFNZOP>4_6
M,?8Y6"COJ0C]9_LSWUOP:6IGU^""H4P"8&Z%]Z3P4U!MX )%2Q$P"-0D(W9K
M!<DK=$ZWD+$\U;CUPLP)IB;'X+O CPDNH98<UJU&&ED"S(@J4M7,#<TBC4**
MFI\;Y*SB%(+&M8"YH!DJTLTLARP?-CDJ0KJ41D=BM)IO1TVT2'R  9V%62XL
M9.)'GZ6-&(;,P%R42H?IRNP0Y]8]TU$6I;'WV8LT1Y^!3HZ-&+5%MV4.%+4'
MTXE5?O%NG8Z NBX&;L6CA4$WN>4>"5>'@(M_@2H!^K[/"\<9-0;34*Z71>P!
M1'YP56#DOI% U<%HI=RK\=8 .H5<% =$:Q I"72I"@ZH@@9H0)U ;0, LI"U
M#:TUT&-K/*)]8K:$B>3H&")OU+_,MI$@];D/N30;X59*P-[RB$'V)-\1'[1$
M98>8%C?4YHP$F@IY<&L?\$1D<Z!G=CO<<MU83( Z*%I.F?M8R6?L$U^@?8N)
MPZI9:(7X(E#CJ%$(0X]F"355,X'XM+F_AU:PBT)FTO--!WAE=>N<ALDT7V#X
M?*K1)BT 0S8:N&+]6DG$"[4MV#6<7[%31=K.%-1.:@E'RLJ&+9+=E899B ,<
M<@\:GQSMC 9%\Q+'*=<Z<'I.=?DJ*,YUH3I.>*W@\]8DLJ0V/?)*\1U"/.8;
M' 35[5OVR.B_Q4-_'<YY>:TX;HD=&'Y+2"46=#%E?P38;G!^1Q6?W<;XE77<
M\D3:LU5+],NPQ[4#Q5-3T J!SV!'S05F5$ZU2)%!UC"R6\?]8G\V?U>E^[(A
M;K<_,[X](,4D8W#G&T.5/L)PITVXSD4RN*6<7&*O*WJ*FF\9.#D#'7U^^<J4
M,=4^=T%H'--*6>[EA7GJ$]4]G6+=2CN*DW>NX;?66,#WB.I*_?W:,;4M8>M@
M>W!#+&!._J'0?K!BPZ:SI4[61%-"!\%MJ^Z*G3FH9<AEZ4H66^+(JAWBBWFD
MX^\+BXSX*U]!WR".J;UJ:<>H"L:Y(6S<8M%E8&,[A31,+ >+M!Z0OFROYK!5
M1Y=31)5-9<B(.(2-''!HBMBO\4K5>!7U-&D=5' PXO9]A>$(CZDTC) \ +D'
MW9K<%LMH'^5>F#H@8IGX\EZ;O 2#5K<")$9VVX>\L.3[0J9(C3MP2D<X/=$2
M2ZG%M&>L6MN;^D644"M0+9^W/.)T X[= C@KS!6\J@>)M',P9"'6JK8BZL^"
MX2:<XKG,N3Z$R0:=AY:Z:O,24T0P#V=%8\8EEX/HWHFX#5]BC,G/"2B6;(,P
M_7PT W91>%P2G<%G7FI:0$MC=TME)KQJR>W<@B48("5INX+^KI+*KSN[^%:'
M=;2)T,JYK=.+L>2LF@9\?K'>'4G;.3JMG,L[K)S:8LF[WCMJ1%WZ$GN&.IN5
MBR+G"KN)3)3=,:0P0'3$Y98NU2ZK8K>LBE.75>&R*AY'5@77)MZ#*_M<-<(F
M]T&8ODTR6$NT3[9FT>:]]5X7)1^6.Q'W5!+U./%/F@\7\%!^8&6TE)H>:RFI
MWX%X[2$EI.OTP2-3!F=]$JO@.J9NCRL6815+]HM68\J%CUQ%9P']I]0."P/C
MNJ/-0F77<="1XC#+ 64E#9#+7\=D0#G&B!%\[3_!]'YR^>;BR3,TL6<SV^9^
ME<^QH &;(W>]?N_4F'.7YZ\XR@H7=(NP4QO$$F2SQ,3*JA7H9UAUP6B=H%XO
M"!-&MT06Q<O67PL(OR2\(O03BHZ)UU*O8*&NL8JUML01'-JZ9:;Q6-ZXTIOW
M2'>^\TG^IU%H]^,\EW:WT,8]V\*R3IVY(V3/.QR=D*!U@,#I-T'\P5,>1D$.
MEMO*3@WBPC9,)<XLQU:9O K)@>>OY/^%<^+91^2 *0K[%!Z]14OHG;:$/MK(
MQJVGJB93KFJ[EZ\N_15K2!$'#C]A5"G'FJ^"\X:Z28".J6&9'U(CNP$8H4L,
M?,;"31L(CTA-!64"/&"B,FSJM3&A]X:>ULQ_;Q5B=@5L;N\_L/: VF-J6!P,
M^15\"WOT^*$4B@<Q796*Y V5RUC1YZ\ZU*53/JD3/BP%9H_(9?,J-P5BB@(9
M8,<_];KC"B96M[\&B56'A>7=#H.5W8:!5?HZ'/@\DCPD=7O]E^VKS"EQLW '
MRF,E?[?E#K0Q,<K>:W(Q8DKXP@\)2Y>76 5'6@?3RE?A<.QW3P4$;W\H9]>@
MWNN#3M=^7YNU6;3*M3*>Z]+4K$1<4G!J4S$UOL3:\\"_X#+Q-X)G\6;AU_*'
MV+4JV0/Z1]T(4A)".2],NS(M[V9Z#>:WY#*LSY&*&F6BI6DV)]L5V=CEG& Z
M2($23:^4PX>3(^SG^4H*DN,4$?DJ2=*44(A=ZTH]P8*&C/&ZS,%;4M]AX)1(
M;_(:.=&G,4^0/<"LDY"TF#4DXK,)R@4GF.MGT/O) 8(X3<N<\I%IIL"!V#%B
M@S45/ F5'S0PY_;,L!)E;6)4T%?."C((-!-=56[FV/P>3@J'*>BT8NG70: T
M!3UOE4]L4"14*+F)2L<JZ>/64&:2/L1$0"N^1RSTUBP!*5:X,64,!"C A0EK
M'I.;]:P"\V!-^@!F 5",F&/Y9_WCHU%O7\/YKRT*P[7XJPJN\#Q):)]<J^AW
MH)5X@Y9IT>?V_0W\1/4#[9C[#O%^WK1J:Q/I2.GGV37HNAD+DJL\Y,V/(SM?
M"2G%$C=%HA$F)R>Y+H((U%<)Z2)4C 6H6Y(=TTH'84PB9(78^V1'VF^N%1?3
M&W]0I7VS]4&R!_$8)*77<L$':8' 0$VZH-4C^28&*E((;L--Z%]X3_O/F-&8
MA#X]$-LUI6592B$U&$8R#1F6@+,Y=787U2RG<<=^"4;-4O1WA;-5^:64Z<?=
M#<JR7D^$*IT&,D"NFRD-CQ>:6\P0:I: 4V.B/OY(9[J^#.: &&*I!NNV@JU;
M:[3J6L#?&*Z;7:.G(N7:)LQ,%6;:*95BG9NBITY3B1;EB%N7+LPE=J76OV[#
M8W6ZDZFGPMQ"C.%NJHOZ?2F>%E2CQ N/?]I-Q9OJS:1RS!3L8?UKC<*Z,G'K
M4N.OT@@WU7>1 F?7IS4/R5C@5L:D1C!.K_&KS8.432]75Y6*$(W*MZ:R(0@8
MC%LQ^;#C*B04&Z,=LA*&EVZ:2^\,%_ H#O#%M%X;VSFFQ)OG%$;A)'8*I^1F
M)TL83%22#)=EI.MD3GFR%0V?]3Q+J^"@YDK'1FK*_$HH$65H/XGOL.6AO0"E
MUU-GY2<?:: ?:*!/GG4]+GPU'<>:RN=J*3&NKV>J0_YKS"[3.%.)NL:>Q4@M
M<7I06N4FLZCAB!4!LE\Q2.U=@"$6HZM?6FQJ*^7O<-ZM%X;::)$B2DGKXU-D
M)?UT"MNE/A7(KFZP"49P'HM"3*%D8>&,/9Y.D_A&F![0@ ;U%YY7?MW-[5;C
M^C$0VZT2R"Y /65QD-=S&)&A5:FJ@7S9I(E9RY::?MDFM%I9(&MIK. (YV,A
M5<-?&KK-V(XZYDX!0#,XAM:+)^CW,FCZTBPU4>@#K6@LOR#ZFS=<WV>>H;2E
M*]*'BD\1K&SX;RK12,K92I2 5 #"U>8AV<7LVES]036^=Z^(.ZFKB'.I4[NE
M3IVYU"F7.G5@J5/-N/>Z-*[ ^]\?961GL!?"T0W30C[_-P6.WFS31&7K99&_
MA57VC]NP4K=FT-G.#:)[$)]8G?^_DHQM%5%66G_L%H/SGI(<C',8<) ^VRG9
M3@96NCY7L^R%GV>Q7O:$)D:_3.($#O\1 94N4_5"_^.E):/P>?X;K<,H>X%+
M%H3I<NZO7H01+19]5YCW>-P].QX2_\X2^%^@QR.\O<N\_7D6K%\\/NT>CS=<
MW_APK]O?=/%X.+CCLQN_VN]U3X>G;LC??LBC;0GC.=$=TQY0-!Z?_WHR?+(C
M;ZD>@4J+>F9>+Y>HH497?,KZ<#+T#WS*^GPN]9A;.IJQ&8V^'YG*8/G5/"^L
M&G_:?<"BY=YGR+9L*+CW68T,WUH(E&7'EK-Z\C/*0Q:'?YXDSW^V^;CAU,V[
MK?EF%+.2^#"WMH&&?OQHVG?LVT.U;1J*/B6W'I9VD?7W9XVBG9&"M\P\<J-X
M>KWWC0)1Q_W>>_[-%K#6;/A!9_C'C&7K0^R.S7V/S9ECE0>G17*4K;2QMZ@O
M=UG3/TVG2LUFWT&G^2%,Z+WIF:I1N%[<Y:A\BU7Z=M]_ .[F%L<MSCT6YQLP
MJ@>35B<<1FH[YVKJ,MMN2=^&#6[?7OY4W;1ON4RT+[>L$^\=^T-;M$YGG=[9
M"4>.VKEB[2.M^M5J!U-HT3*U:BSUAK%CG8YUWGV=^KW.<-!WO/-0>*?C"HXK
MW'^=G@XZ@^'QLW:N5OO(JH8AM,OEMB>V:W.CU=8ZWP8/O:7;G(.&,;:.C9QT
M>J>G#ZY;W''1VDKT=]<F'I9ZVK<RK1K++5%)QP<V+-YQYZP_=GS@._(!)^B^
MZ]X-CL\<>;=!1WY4SLE/<58T'K9"U>WV3#P01[F707F?>&7KF$]_U.F?#-OE
MPMMJ@=MZKMKLWVO1,K5J+-]4/7>\QO":DTX?88D<KWD$O,:=HF_E7N]WQJ>G
MK7&O']H!:I?O?1]$^2]Q*HVRX_5*]$?MB3@POD.FPD,RGF^QG&T])<Y3[TR!
MQ\T^2/MW[*,%[,.)U?9L+&GS/]K_?VA'PP4'[EG!5@N8N2>.!E>T?6!*E_.9
MNSUSA_ P-]3Q^,=+7NURM>Y)FO.%Z;'3!(%>VT?K41N,^V83/AUV^F</&N(Y
M_'PPYTS="Y[O>,#6?J&3D^,?[1=J.[4[K^C^$OC34>?L>."$W*'X-?=$?Z9L
MA3CBEJ!%S\@]L7M_8!+5WO&7X:C?FBRIMI^*-F<2MFB96C66]F8M[QNKD':P
M[<I,;OM9:#/+<(?!R<T#TM$/WZO]CAKXIIGD'#B+?A\YQ\,C@1V^1>_<UH],
ML3YT'N"@.IS/^F"I^VG_S#FLG</ZQZC&DH;K+.[#XRJ=TY,'92R/S>9NS3%H
MT3*U:BS.5_V N6&GQ\Y!=PC,PAV#>Y7-G;4,MFH/CX+S5?_0XCAGT/_HO7QZ
M>O:@2/6';]$[A_4CTZX/G0/T70ZJ<U8?)&6?GOY(M*8]).TV>ZOW02@*IO0^
M@T<XE,H'8CXGG=[9@Z(].93*-AZ@%BU3J\;27H?W8;&90:=W.G9LYM#9C#M
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M7U1ZBTXU;0&LV-XAAPTZP^/3UB"'M9TN';K>@1Z#4W<&VB7N'HO38)G$7\*
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M32=$EV!S,^OK(/HP/F2QPS(W9%+ED@=.CC5E#Z*RZ&R-6Y,5]\^7WD!5KZ3
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M2ACLM9^6:@_%<T <F!PRHBVL0")]5IS_NW9_9[?QW3VK8%1;N7+8606O)*N
M"Q&L H3]._8;_(#K+BHB3>, !![ZZ3I/T@#+E EM?(3,;]#3:"6!(.XB)=+O
MYU&$D#B_*L41,I /"+5]'<]!@J:E8'+-_3JFW/6:3?@]6V;,2:M;&5U*?JU
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M'A?+</:0LX>^ISTT[H].QV>#Y\%X>#8Z'I ]U-?POTL_J0]&:93?P9",C8W
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M]WA?MA9=H!M\,W*+:[8V[/72NS^%Z$"=NV0*_?N"UY4:1:9SNF#)#+PN\+K
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M5< R?>RK-<URO+HY13#R8JQ8UB<\&77T+!(X=7R2D67&V -#D'B9W':1*?[
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MJ9#AP2*NM436>(98H501Q\IZ2I961"-7NA'_K%U$Y%X3K*Z@!:%B0,J9\F1
MRFF1\IP=XW1*6^YLU!LNTA%N#EG/,&)!"2.4L\J[R(Y%(^7YY_DLJGN\;JBL
M461Y'ACR6K?=+@?MZ"/W,]/Q%0K%]H:.B\"0_=;L#D*F_WX/VOQL;MICD?XE
M4P@OSN:9B.@^BO:"(GD>9^%GOWS;*5O_MS3H#<-E2S>AXJL=OS:IX&#YIK%\
MOU8O^ B82B6I1U06.>*T"$@7T4>(OH.*9C .5J[3N%^R=W6.^@*& 88]*89-
M0^,!PV:%8>?L/3>4^X(:Y%,A4DY]CE0H),)QE.)@"6U,?B.&02QVJMFS,^BZ
M;X?=5IS^_6H#:/Y[%OX[+ <GV6\^%*4K!S?SS)<.>KRR]]=(;6K5EFNV!LV#
MO^G+[Y?;,YGZ=$G(]Q3'11G>6_1W#&&K[ 1T./J;X(H416M7]=RV0G;<"T7H
M]4+B(Q%.&MG_W&:-/X3>SJ'IA2<)KFTVWUVVRA].6U-AVP?3V^[M#,P@^+],
M:QC.WPX&>@H#O3G86CO=<+3Y<VM-XZ__.<2N_5?'?-'#[79\[Y]_E5___(RW
M?AV0K5\?Z?;NI\/X7K'W:^]G\VCC1Y2 ^+KN6__YY7XVU_?XUM%GLKV^RII'
MJ_LFMYXIBI$L7+3X*CADM16HT-P&&W_55-T>J;U!J1ZVM@5*M0A*97EA"<,4
MY0Y'5]@'BC07!@E+L=-!*TO9TDI$S:ME[:]\D!V;7O8]#74CNU$-^TD%^D^G
M@?=>-;BHG)4F]E>'@\-N+R*Z!Z6LBU*N1Z231;1Q@2%GF$J[^0-2RBO$C).\
MX$99?1O27:MBC["<H&*+IV*NH-(K$I (#"/N&(O&-"AD<,!"%33B8CI>$C<B
M0TS_W@/]1FJ7F;,!?QD4C&35)37]T>WY?NC<1T<W^_TAZ&>-]-/MTY 76/EH
MB*GD$0*M1)8ZB8C)HY$6-)V8-RT$OIA^;0\'_8'I).\-E*Q&2J9"<"8HCW(N
M*>(\)T@9IY'&H7!6>\Z\6%KIA^^A<P_\2VNP+V&302$70R%WM_;SB$AY5 2$
MI8U6N7 AG;-%4,A](-)[FSOQ,L0/K.HBZ)?FRDH5]2O/C46<88.,C:8UY]P6
MP@A*1&1]OT*O>P^\*ZOQK6"O>XXGC2P._7%PZ43XULE9O-67WU]ZU\X"YQP^
M279V&G9O^H>WS^TJE 63>MI)?9Y\(20QP6J!K!21='@ND=&&(*TI53H(QZ4_
MJ[-:NRTY=5]S@FV*KP+PGB3)&@#O&0%OHD"'IC@.D$>2\$@ZI/,IQ.X1YB00
MZ_-0[4($P*MU'O539[?,^[IVN]WMU&(A>]046'!\.O#:NL,%^^O;UZ-W1WM'
MT?W:]=^V=C_2^&X>>WG8_++WX^N18UOKJWCOR][)91=L:_?;OLAE*(1W$?X*
MA5+1"J0%D8@XH?.<1[!4Q<NN8H-&S9=&R=QC[W.'#"<"<9+V?A:%1\9)$KA5
M.O?\^9>P9[&^.*&9L+A85XW\M;FO):-.:HJ(T3GB!0O(4D*0XYR''"M<),97
MOQ0)T*_YT*^"Y88Y9E&N4^ZW8!C98%VTH4907$3#FOMT*/LTJ]<OO6P]I69"
M<+U66ME<_[A?$$>$MQP)D_O([#Q!2@B#@L6%D]SDCD>M%+21\U1=_>JY82^V
M@@BZ-]>ZM_MYWUHB';8466ZB[HD(BY9;C (K"B8],U2Z='ZYEK@AQ-6M[*?)
M.Z,UG8MK.+_/ Q["BG8-%?/([>=&:DUL'J%05?FUT51+HI''43M<(;TO3 6*
MDHH&G6-0! 6LH0+^.MAWTEG!0D XZD2*/K.TUYFB0)R*6I%CK?+[(.,++7%#
M>?:9%2";F-*PYO.@:7R^R.V$$45><,0848B'(C(3)7&T BP('[@L3*I"1O,&
ME[,X9FCAJ[+7:<<K0%Z-%KD!\IX5\LZ7N9E7.:/*(>%$)!HVY$CGF"/*C?-:
M8V:PCD1#-R2>1:7=A4<\V+W]W*O<N[U@^L/>2;8S6N<V@RCH_J"&X8#3EE8-
M'8/:N"T :%, VL=S5^SH@#=/+KEB1\UR^TO5IQ][=.]'_#[^^F5#Q#;C9GOC
MU]:7KX?;NU%>ZY_))5>,;NUN[6/*)#94(H[30J7Q!EF,\\01K<]UKHA12RN$
MDH:X)F1?U_T5H'OUU[V]?:I(096.R&JB&\)Q_*&5"\@088PSCN6%OR'S?1P!
M@,3VIS+FO]7*[;\P?X$%/VCB[DQ,W!_[*A<26ZE1B"P8<<V+Z/<7.<I941 G
M@F)%"KGE#27YE=EVI9 4I'I";OO\8]XXO1FRF6OAYSTPFWE.SAM<=6[8'K92
MUF;6K8[3=MWV<2\<ADX_DI>L[,2_0SW.4X%Y_%KB-1"AGA,5GT6$^B(%GP"L
MZHSDM4FXVJS0ZGVWWV^&P7:Q:WX"/Y^6GY]'J2TA@G$FD-(A<G.9#M#,@T+<
MFD(XP073(7)S<357'""O%M1EL8]*7HW-2]IF6MFQ*3TJ.YDSQ^7 M.IQ3O("
M8_GS1UK.!_=#'-O-SMIH9 '.IX+SSQ?R+#!VE"N,#*\*>FB.E+,%"IP(K#G)
M63H/6=)&-,,-R69QAM'".Z00<UD\\'O^5 L OR<"OW,NJZ-=(O%?A+%QB!.5
M#G!S!>).%H670EO+EE8B\/$\;PA]-;<8P*\6E/;U1./&AV5 Z&W^EPT_A8$I
M.\%OF%XG"JT_,<SKHU$&:)\*VO<F>2TWV!F?<R1SIA$/W"/M*44BUUXSK%C\
ML;0B2(1VW5#TF9<1%SY0 ;'9!<3 Y^>T@(%/CX'G]%81RPNC<J2E37LH3,1
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MIM]O+4SX6E:+IEN#G3,[59,]?36?)D^:X_1<QZF_",VI45.N/TP=4 !0 %
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M@JEK?L#B%CEYU^W%EW4R-^SU0L>=9(->?&:KJH $^0$+GKL&2;*0*@_^+Z
MH "@ *  H "@ %06  4'!0<S!V9N05%@FABLE(P4W!%EB.$XN/@2Z20M-/5!
MY/JN\IV3]44N1ERW!X>AM]9M'_?"8>CTR^]AL^.Z[?"^V^^/ S)KXWC,;@K'
MC)JZVO&[Y\&957\T[ _:H3-HAL%VL6M^0HQVJACMQT%5E?HL1OMM/Q"#2>$D
M\L&&=.*U1DHK@8+*M=,YS:VA2RM<$*@V O8$[ G8$V"54&< Z@S4)GE@H55E
MMLD#0%SK35P_7R"NNF"4&FN1(#@25X4%LLQPI)D3EEF1&Z>!N-8RLV!Q*P]4
MZ43(FGY(TFH?1[RHYG\6?J;? V07+'BZ&^350G8].,B  H "@ *  H "@ *P
MH7QA%7RFQQ;<>VO'>:REO]M=C?)+;3.M#Z;TFYTU<UP.3*LZ(+!RT]8FO+1/
MX;_#LE\.PD[H?2]=&)60_!1<]Z!3/:7:* *1FZDB-Y\OG'&P_7&?$:YT8 YQ
ME^-T!JY$AAB!C/328<ZT]'1I12G>P$K# ;C J8!3@<D!3@4H "@ *  H -4+
MH'I!G1(0%EM5:EF\ #S<FGFX5W(3J"!<.XL\-]'%+4S*31 8J<",SZ7R(=6>
M!!>WSDD*BUO^H!D&6:O;[T,RPH*GST&>+F3K@[,,*  H "@ *  H "@ I0Y
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MPDTH"448$=!J&4DC+R0^BX,LB$/F\GCGN9^.*+W>BV%(.A@,QI^<(3YA!M;
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MT;UF+S)>:W.1I:17^EJGYS%[]@S/+L9Q2ZDQ3?2+]/E1Y40?%OQC[ZQ4QLQ
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M3AFGB8J(*[*4T"P*2<(#3B(*:Y_2.(M#8%6^N^M?5ZWAR(UK(GX(!7QCL=A
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MDN,2J]!A\1R=YC6<,W8[LDU:L"[5IAHTZ#)V%6WLN5BY<+;F3UH8/YAZ5U5
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MRIWG_JY_)V&O#A2WE-[C\LWN.2M)_!ERWV]COQKC1VFE=&#&FTRS5R_=HX]
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M$J74!FQ=JEW-:\Z87[:K>;\_LMWU<"]?&UA_UX1?+TI1/&&EA5I;/+FV6 B
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M"]VQU+]7NNU[^R*EQ^N+8BA#]!6]^Z4![8J#?%INO'U^C6X<#[)9\E_?MN+
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MMK+)5)W9YF"M=F ()@S=@P%I8<8N+^D-I@.3;U&.S'!Q2F<EE"?TRY'-64Q
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M]=0A*IES3#H%*BKO[S%-LEYA[K5FJC53K9E>KV9:*\54+Y'=7Q<ME.&CD87
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M@HR':3Q%HSL)J,B\V(Y!<5S3RM"'^V4]=VP+-9HZ7V-HS*F.4@R*)\Y^/.^
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M7)9I>OQRD'*!4/;4];/VHCR\%>7A_VMZ_UF?E(EO43MSM#V![?J%2W'#J:^
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M+XGIZ+49B.Z69G,O=>"Y;$0CBMDH".:?2]+XH@=O(MGF6<'U8E8[H!E70#D
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M$/TVZ<Z?>?:U[STV*L'D#FTQP4D-*%YH]C7+Z(&)I\W9QJ:-F;/VK9N&T>R
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MCIK.^<Z[7V:2ITIO76SAQNZ/ RF)SB0CB+(\1%G/(Y-+A[C4P7H)<E\ 62^
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M[\ Y'EAX$]\A#>11;1']:6-$*I)?\94[\97F!%_),^8QLPIY;QSBE#$D06X
MOJ)R18)EN3(KZ[$Z?KZ:9\N7A+?LN%<EBCS")+Z_- U/FX4CXW#.NPGK</^I
M&,?;KLOWZS&.PL;_J6.C:\1O^N)OQ4CNPDC.)Q@)9SY3C@ID,D\1QRQ'TF*#
M%!98*9EY%A44LBJS?%7)Y0LW6G8,K+201S.27N$/K%2.QZWH^B*L(Q5S?4J^
M49#0EPD*VNUN)?JI>,<=>$?C_27O@.=LL0.FM1# .T 1B764O/ ("( @[#*'
M92Z%P*"($)*(+^=/7#&[4D(J)>1JW]"-Y6%?WCMT?8QTY3NZ7UF*6T_JDC+K
MNWB6[I6(5WF67AGS/3N0W,(RXQQ9DAG$>2Z1QGE F;?8.\_RW)!7Z%FZZUY=
M/@2\BFM?GPP1O\>-W.P,D[PZ%4YUTNTWXX_O4A@P;+EQ/-.__RBCO#A=RT4Q
M&8NNU ;F>#CP?Y03BR=O,7W-?*C-*XMT^X HG0Y-F_SWJ#>F\T./3,_K'T@'
M>,]WNG6FS_LK_YF:CIGYG9NVA\Y%"$\W%VDI >:[1;#VNS(V&TZ+@]>O;]"U
MHUYD<__35%Y9;:CCE@>N&8./"GM-/.BF0>7J !32?&4]!;U&F_/[R"13XHU>
M7T0;,]NO8$96$^(P]QYNS[V2QAJJM*2& L+FJLRYA&N\VXBLDQ"+C=/:"^-!
M4<9:<"6<EC!*:N"ZUQ\_.F7'OR9#).7*7+J+8S WL  [+)(8ABE[1M?J<4UJ
M[W6OU:WUF^UX-$[]V5$3ULSW!R"<I/29^)P4BUU4G*JY86_T\W7AV#I7$C/)
M'/6<&U@!@35Q-.@@"=:*E&8+1?,)L\6$& 0S9=_!LYP^O[GG#-"72TC[H=O;
M^GG2+&AWMZ<CK]J,=WB-XLWCQ%M?;.'&\8\#RZ+3,M.(.<\19[E 4A.#,BEA
M;W"N,L-6UKF8Y8T(%F FPM_H_CBE)>9$Q"2JONTU#?Q\!I)FF8XPE<"U5OM_
M_GR2A%/^21_^V-8PNJ,*.M.]1'03!+=:\S]/O(VD6_QZVHVDFO(5;DF+]S*A
M5;3X1+3X[2#F9LB@%<+.",1Q8$AK2I 3RAAA- .\OR4MQFR6*)+&.=:M<<I3
M2G0,O6X[IA#TNF=%HDW;#XZZ#C#[\#PEG13I1RE#9TR8$2_[OA-%MU,_RG&Y
MF@:!!(;M(M^G2*F*Z5CP+68-F>ZI+YX\<<$P[I[YC)T2<J=#?>)8KM0_R^2I
M]+SXY!EE5-K<,RFM#DKPD%%E O,DQYZ2S$F%%RNC;%;M''&5C8XKZ@M,U"*M
MCT?PJ1A!J5 B^HN1.1S#C8O#L_IQ'9ZQ0;=W#JBFS DK$94X($X\B+NP'(A9
MATDN\MC1:V5=96OS9ME_K]4*#7V*6"*=%$P:B!S(8*S.%]N@EY(0BRS8F02]
MO_RI;]78//X6U'F59%&;%2K25NBX1:ETB58O68.N_=D"$0I]M4?=%MQH//:4
M7+@:Y0Q[%-,1%P]T?G\<-7U/]^S1^6Q.V#(+=8^0R3Y*_-F 7>;:_@VEKT?*
M>]]MPPC/1_G:93+@XO<N4AZ!?B[3)VLFX:_O)YGV[,A'^D]73YT%+&'8&A0;
M*66^V@*S@&',4_Y92?!KM8WR5*#IF3":XH9IE2*+F7M@&_B4B:?9[F$'IJ3(
M[@86TNG[A5FQ_5$>;\J [)[X0FHH<L=C"FO/'T66%#,YN_U^W#X^#BPE>2X<
M8IGH.QY"L=-'\SV9S'JD!W.OT!\QOA((%J>SSZ9TQB?VAR:RA\0\]7CMTE/.
MNL.6*V=O<C'FAS\!)/\[A-TS*-)8B\5."<_E<A7R9_EE_+RIQ-K9K/OI3-[+
M >M6Z[R<A-GI&C%GMR#/=K#P0<UVV[LF7 +W!#DV$G4W3=WD@63XF">?8M''
M@G&Y/E?3ZB41N%%Z;\D%TJ>$S)WN570/X[JDDILH^TU@;WZ%X0H$?EB-LCS%
MXEHAUQH*EVX&KH??Q5:7FZTH?X^H.6;)K-:FIZV4O"\)<Q#);E3@HZ3:T:8Z
M&?:BF)ORR'4A6(.PX'RO_W\FRI D@NY>+07W_6$\;T;X908;FDOE/?=<A""U
MAF5W7F3,.2M%$G[SFRKU)\6O,VR?=7L.5((IY0^4$N-[VZ%X_ZWV2:M[[GWR
MM(QHYQ>3@>N[&V)[]]O/^N[>11W&T-C\=J"L!>W;!&08,8AKKI ) C0_DC-.
M/:C?W*ZL#\ZZ<S)PS8^F]#JZ@=\!R "U3LK"&L55!>6,:*@_*MXRYX-.U%70
M\=TZ05AJF71$,ZDE]UDL+9PS([22UC O\>(<,B0>H[5RE/@O-:WL%R.R[4T+
M]]T0]8L-.+9#&SL'R@7/G=0(&ZL1]XHC*3Q&VG"7"RQP9OU=.WW(3'O/=(!E
M#MSDL*P,:VT!![TRC%W1Z:-:WZ=87RM,SH)3B!+.$5<<%&G, W+8:^4R+(3V
ML1Z?FL.0>5 !1MI*9NX)!@5X8H^B"#I9>:20%+N3+8X!*OQXA=+W(PT25ZW@
MLU'X.@7!_7!<VJ0TF0/R_.L>523O1X.TJB'YF/;*[<WZ@57.8I$)Q(07B/-,
M(AT"07EF-;4B5Y9E*^MB+<OG"0Y4N<(J62@4EW3GHVG87Q9%HYB*DAG1?&U>
MSEP@=Z=EN=D3)V6V\AK$]>N%<T+62M?^TY8 ^M0!$/"[^N=FLQ\KS0U[RU*U
MY^?VYB']B^Z?[WVW&=R#QFJE^\??SAH7']J-S3_;>_1S:^_XGW;CN-6N?]_C
M>^WZS_K%SJG[^ ]W__W<VJ>M4W/<%8V+/9RNV=U@<!ZN?]P_WFO_TVQ\WZ/;
MW_?@GD?-O8NMB\8'^;.Q&RNNQIT!J'RQQ>N'!X0X+ST(<R*C.8()MTAI MR6
M$D;A&-6:S+IF,Y# \Y I#B(2;!]E- _>4FT4P5)D?K;03[$*-5B&F)LT&ZSQ
M6A30^ZA?-\_4],QJ10C)F*0X$&Z$-)FC+#<22Y/;//BDUB;I^=QK4,%\)YH4
MKI.#)R7M49&\L7T@_AH#RY(%I@=L)_A>+UG6THH-],]+.Q<<-K[C0W-0<\-+
M1\KHXL0]FU$OC/%)R:KEDS=PF.YGSB<'LE;[JSAN"K/&^&F^-.E<RU]7'@$F
MIH6\?O.P Y_ND);5\(."JN.;+(MT]Q*8PNJ[.W1[,P;G?<+UBSH_D,0%241,
MHF42V"O+$& (\%AMJ2-&JESG*^L4K]&KY;E(3G>A 29AP;W)+ V,&VFU5YEC
M(F##%'!TEFA CFA@H2)7T<!CT< W!B*6TAX'A[R.-*!5CF1. *J=RVV&,\R4
M BE 7D<#X1JD*X2'!7 W-AVTSE=G;,%E#</"5554T!WA4VG$_P84!M]2&<[^
M K'M2F95!17>-:B054&%55#A@X,*;Y279B571T2NI2$N&L.-,<(:1X)B,F?2
M:/:J@PHW1]);(4CIWI3+,L&I;Y_ HO6B*!C@9-^Q20HKE-:(@":F%Z1RLS$1
MH? .CFI41I=8O$LH L%B?,Y4?>,)H7%4I'OMVD"N1U#POL9:Y,.6WPZCMP<M
M(R51Q B7O\8C7Z:*K<NA^YT=<&J-\CA#A%D6^XWG2'%I$9;6$NPSGV$WNX-8
MT$0X&3+N)"?*P5X2)&#X+\=6T&Q6]XM6DBA:)9\C$$KT?G<[(]?XA%*0LBOR
M/_IC)202TA5D&&D[^=%3P>'R1I<%6=_5[JUEEM]+'CS:]0NQY\:9> -U6C.Y
M1G+Q5'5:B;KGQ7B-7'<0M(%[7GMS:5GZ=DK+JJJT[.VK)LPY'&_1O&:T*P&(
M_ W%?1>>^@IHZ"7+$]^M+.R2$]BB%.JG7O-GF\!GR>M=HJ&,UO'&Y:PVS4,W
MC:Q*.CQH"C?GI>UW]\&AQZK9\-(=VU[Z^8\R,TM6%4N^@GW0\(-1H';LH=/M
MQRS+7N^\[.(Q5U/QY0J,+=>\/6J-DH>4''K-A49TQC)I'994..Z=-('1@(7V
M&6:"X"M"@^Y21G+..K8]HO7HO'H_2>G+$BOT "O9AZ;Y^"VK;WX^VF]OB>V/
M>[1^_.FLL1G[QAZ2O6/+]K['6* ?8GOSG^/&]ZWRFG_@6:*SO]L]J[<_M/=V
M?_#]X[WS^O$&AOM?P+G-QH4[VMO=X=MPK/&]3O;^D1>C?K/PE\#;_#S 64ZP
MS'-D4\=914RL",F08E)F1E+L%5Y9!QU2Y$ R4E85A1]>%N2VS/@)BCO^_^U=
M^5-;N;+^5UR\>]]293%:CZ3D%55,(+F\BLTD(9,BOU!:P<387"\AY*]_K7-L
M,+8AF-4XFJH)X+-82^O[NEOJ[DP)F1(>G!*\CD9&$3 WJ=P%TS1*3*D3GJAH
M [E559-,"<]&"8U)2B '@>J" &BA2$(Z$*$T,LP;%'P1)>-%=.E 1%%7!:^S
MG&-^!=,[O@0CZ(TY30%VMS!_<DKYEV\"C&8[H_T]T1[/& "J(%02'9".+B+N
M*:"]EQBI0D;)F0N<R+4-6:=:U;&8/0/WW!D%EQVG[J'_/X4S,&/B$NG U^5?
MS7#X>' XI?PZ[K U%B.L# 7EUWND?4$0L=RX8 T-6"QO>M47"(;9_[_P*'Y*
MN>K0\!3&JS]X-'5WM>M@+(6Z6\9CSX![.;V?3]^DR<V OAB@DQG]5C,CL% 8
M%0:47.Z<1=9&C"B%^=2V$#Z%Z*="%8S7I2#9G;$2#NZ,@B]!P<T ^ @ .*71
MXD(%Y[E&PEN.>&0"&>L4$HY;X24C7#]IP8"51[_LS%W\R+)SO2$ 1AD\T0LI
MN6@N#?J"%=MK'1<IO<7HL^TJ6/_C:+8W.WXL!>7/,!D1E5E@,1:@,VJP540*
M7A#D%(^("P(L$%1$"E1@D '%N$KUVHJB7I"GT(%7WJ^1G;RK!YC/<- A ^93
M >:4VFPD9D7  A6>R:K I?5$(R<!10,.7C"YML%$O;BL%I#Q<KFTYA7W ^\
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M$&@V"EEC!>+:&19#$9E*/B%=%R([A);"9GA$)WIFD<PB+W]KX=95"3.!W(E
MKII3##A"&R91X!%HPWJ'-!8,1>TI6%):85LL;P'"E6*07]A:1U7CB(#6/H\K
M*K=E.=N2C?1[&>GMRSH&KVZQ(_7;!9G-1_=5CP):-N4^2V*6Q.4[=_!R(M$^
M[GZNW+'YT,%*'3J8J$*4)AJ&<+/7,YW#<!(Z.1O[P@9B\_Q*!@:Q^^% X!!Q
M% X5!5:(%](B%;1&QG$66>2"47FMCS%OM^6#!RL(ATOH%,M ^-! .)%VX<-9
MX_# ,QF<EQI%'5*,K@](%X2@$ 4+. 0M!<Y1:OGTP3,.8C,,;A.CM@0[1:,K
MHZ]B<-%WARGE;]Y'NJ/+^W8C^O()]5'2%5^[RS1!JWG#:7$:W7TS8T\X1H5E
M3")J&4$<1PFF1*&1#TP6EG-")'V)6TZ+K+_E@[1\I"$3U1(NE)=,5$]['"(3
MU7V):MK>BP;^DU(BJQU'/,J 8-8$*K3RCMK G2&9J): J$H[\8^!@3YLE/.0
MEF&K4\5>P">^]7WC?^&?<0].3.^PU:F&1LUV\)9-N=K^6W?[%\/7;G4"&I\C
M("+!WV8_'1[?"BZ<V-"K^L](O9;4W)KI^/2+JM<&1Z&6*B:9SGGMR/C:Y_5/
MZ[488*I-NSJ!?@J_PK@<UMK=?K_VWVO-W?=K_U-SD^DYTS?]8P&,8\X&I1@U
M%BO.K("EH0MIM=6848O]?&4<B06<_;OC9K^'5L_/)5J\6)#[F_M__5_[*VU_
MM\==T?RYC\MG]C89W(<;[P"Z3@"PONS3W2_[\,ZCUO[/[9_-MXHTM[ZQYMYG
MWMC[\+.QM8\/<!!. [L@1[E'/."4 =]%%+R0V$3.([=K&X2P]=E\&C60VW89
MFPOBM-#\>T _;;FEUG$BL"TL<84@3GI&N1'S.2[/_[WGG\&\T]VM'=(\WB&-
MG]_.#C#S.H2"(XP-S+\4&"E!"V0BH5YAK'WAUS8H6[\N2?9(!NJU7NB?!KCR
M/;3/Z[6SHY8[JIV8\YH--?/=M-H):&N#+F!%!,VC%H>#82_46AW7/0G31VK6
M:WN 2RG]_9OAH!2O_^O:?FW3#<9O/C/]6NA 2X*'=US@7$(U"?= HVJ'H9-0
MK'U>A=!<H%K",0#:ZG)ZWL3!Z,G4/FAO K<67.@"2<+;?8@M$.:R7Q;:,_7V
M=NND-2B!%* 1Y-4/JP4 [TH?M@-\72]!Y/B6$CO+=W=[-87_64;YP KIG79[
M)?N4VH%\W4_#4@Y;-4KKM1U8:T"T@W+ X74P@&5CH,V=;O7>Q$-IF=S4S?7:
M^^F+I[T6/ --3BMONH<VC+LUFL/4$UC-H3,8]^NRE_-[,M-O@F_?\5("KLA1
MZN#@#+[_O'8>3*]?B[WN2=D06/>MKJ_:E @K"<I%-RNYNN2[_H500/NN$8GE
MX[89+?YZL&MV!Y^&]AC6Y5YW^\=IJQKF#($C"&QN?:8' ::,6:41=JD<%A8*
MF2)89%*<3*2*,177-@JR3J]EP#$J^2ZLPT&JY]SJA4K8KA&PJ^OM1<M8%K";
M!*Q!#Z(C)F"0+:H3QYJ0SD)PC@B66& L;51@$@JZ/EL\\T+%*A&YDJN:&=2^
M&Y"?8;_F09@ +8_ \#@\ EEB@.T75LY-%@Q=20L&Y+Q[:<;T!S ZE\QS5VN%
MBT!"4!$;(KG1V@)"1.<XE4&#:B"RM?(DULK>YH\#RJ/%KB"HX,2 M6(MLE(%
M%'V@6CI Q'2JB) ;E]*BU@K!(3+C1>0D<N68QI(%9S1S*>TV\=E:>1HDW?YY
M@+$C2E&!2" :<<L5@H6G0!P\IL$0Y:UY>FNEE*A;8+/^K;%Y4ML>7!0VFX5F
M<WK:Z_Z 59(,KF53B^:6I]D\@8D9Y)5:KM3&6>-X^\<!"Y1SQ0MD.(65BDF!
MM!.IQJS4/$;%"(652N9XE:XLU&5T+649N(T,[-,#[["C*H(,.!T1]QST7E";
M4""6&&ELH!(,*[P^>P"X=B-.F]Z-(#T),I,H73U\.YR^([Y5&N?CH-L3J*%9
MLF\AV7ONYX'1A09<,2@D7RD7EB+- >R44%)ZF!>E69+L62WT?NCV!*IHEH';
MR, A.XC*,^S!H/?,IWIJ42#+?$JT"WR#B[1<=9(!<A=5= ;B>LG_&L80=V=H
MXZNC@DY[<GO!I2UJ7S,P2NTVC,%,ZMB:.32M3G]0:PWZY>;FG%.O\.,6T ]V
M@C/#?IAA !\&H7<"K4TN:)B)5A^^K';2[:6R9M\2YL/'G=)+6%Z'Y^$MHZ\N
MG3SID@UE'\ZA4Z8-@^)K?GCA>!]]W7_U:T>M_J#;.T_MO;I-.[))VFDO()'.
MA22%[RT?TDCTAZ>GW5[YP*5,7=EKF!Q?D"R8I?1@&MXT<NXH10FDK9=YX[R@
MAR5([@OCB-$")S!5H+]%;@H&QAXK@CG82H./"2;HWAPWFUYQVM7YINS:3B>#
MWI0#YO#L0$>F P\..6LXXI('9 P0G_.:LH)P14.JFLYOT.E E'M)[)(HI[V;
M6NBD57NQ@S=>:_7D(P=,:I7+H%UZS4<K $2T5\9G@OC-N/<JR9V\93#AAD_+
MXCJ_X"T;5FXI7;9M8F4:]^]A*\')[+OA$9.0?MB^V#)KA-YAZ-T R!-G=HZ'
M_4$KGH\Q>>-_;>^/C9D'EQNP/\-P]JH]NE[W>ZL/LM ?C\7.QS?UB_W1-$?7
MZM")&?O5CD/%B]];T+[TR"D 7[E!:7P:KA3!5+/GU>L!;'H=F/Z/X7OHP(1]
M"KWO+1<FQ*%D@.'@J-L;[4!_'@"[_JR0#5IYY6#,Y6-3QV-N;/K(OS31>I/^
M@!=U!JWRK9UAVI].^\EFA)EIR#Z%"D&9HN477/[-+L9ONH-ONKZ$8:)542^E
M[Z04YWKY!F#*I'5T.^G0UM1T5/UJF[/Z6+2[9YW0ZQ^U3D>HWZ^HZ\A\AZ]P
M;E@RZ&F:"= Y8$6DC:UT@^L.V[ZZXV(9EEQ3+E%8F[,O3D-TN9]N2@1.C?JE
M6%1?",(/ SPL9RY153F@B7.G;<0Y^\M3.M55O>PJ'5ZL<Y@_6)VMV()O'DPT
M]S9HDZ[-WG>]W%\/()--NXH)L\?:)N %UDMYDN!5B:[0S==G+3\X>I5VYE^/
MEBZGZU)4NN"\)XWM=]O#07@].A:()U^Q=AV8N9"D]?6+T3=IV9FWB/*IT9WX
M]ZAW>4KS," +Y/,-E:<(7IGVF3GOK_UQ93BFQG=FV.X[%C$^WEB44^F3NET*
MU:L*IM)MJ?'FY36Z=M1+>NA_M'30SECJN>.@?S(&OVH<# G8L:BE/@ M5(+I
M46('K,(W28OMI% YLS%/-J:67Z5 %IX(:90E'O0G;*T5SGH2-5.2*6M8I1S#
M,\%O)HTVBB UE3HP1CB36#%9!.:,AT8Q5Q0/(S"/R_W)-$J&S7DR'8!VAN7!
MK73VYP2(XRAT^H _T/BA+\$ZV4/I[,Y12(><TGV5N9$,G0O.2.\<TT\]D<[X
M]NI@5$E/-H1.[00PLW7:GL<W_58R5Y(Y6!D0,$GKM<W.^20))TX: 2^P6+@X
MY%"=7BJMJ.J/*^>[1L!=DN%UF&Y#3(;A\%+3N#C>5E*G#6/: CW&3-A<5\W
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MV=W:YXTO'\CNU@?2W/MZLD_4CZM.12<.F(T&%$F"" L:=$IKD:$Z@&(9K31
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M&I18*:/[8D/)!E$7(R<Z1W$&*XH6]PTV4S4#B_JKH5N?H"9!D9B W0'!?KX
M$L.S>',?P_8$')B&W#<<@,1"HH>JW'P3+?(V'TBPC?\M6F_I\[RM!Q)D_>$;
MOJ$H;\.!Q %WIHC:,_H9_*Y@\[[1)^!@-Q3V[.MD)'5[N%Q1/F 8L R5\',+
MW%?X5VF&[GA3X50_7>R7W>/B.<@<VY_YY_WV^<1^$0GAGCG(3+<[C@Z2^0^#
M_I/UZOAY,'R>#@?P83I^' VZL^&@UWWL/O>'TR_#X6R:I\O3F4GP4#D>;0!A
M"KV) D "GDJ4J>)S503;,V"1/G[1*31OA5P,%3XI>KN<Y5 R U $2N5/.U+^
M7'=HIS/X^S1\GDW'#^.7X:0[&\&OW6<H]/0R&7X!@M'?AX_CZ=$#-8<D.?2=
M5DO+!GTH4AD_**%0!:0J.V(5)O>L"R%"T]FX_[<OX\?!<#(=_N_7T>S_!L.'
M47\T.Z4:) N1:X &*XTB&A"5]]^*D*C\R9=Y-@529$YJ]O.(DJO"9:MU=3I5
M.,\-22CUN],O#X_C7TXZ#81,Y2!?M5K714!F_!4NH$90/NNN1Q%9]#P'V\AQ
M<@ 6(Y7 TE9;JBJ6-]@Q+.( )7P1+!2R4 (F->[Z"6*;-FCJ$N/;=&-A=X!<
M'5O'0)+(4@:5UH)_,T %#WW^"A>@< DP0PH9=3*(^_W^,\'VLD]L U'[>!0/
M<9,#V-'XTC4=0,Y:\7G7$KJIMU[K])TLIGAIXP5,Y;;;-0SBV2YTS0NQL(%1
M'O0R,I0;2TV- ^@S9@A&6"LA;R5@?H9OK[<_#,9,<+9;E^VX0<T.)WB:_J?S
MP-P'8*;/K0_ U6<K0[73NNH<AZH0<L9TO_.?=4JAHJ\H_]194(!\-KW6>/2P
M,,Y;<7\^S[")F/BE^KJS8O\-?_/PJVY!JQW=-B?(<2DV7&2RWSY*+0I40:XX
M-QJ//196G* LD_@C_ZM$*J5 K92P6OSW>FK8$Z)+1*$[7B@2GQ^PK=L&]&8.
M)9%QD7MKMVK<0 @.'"/@U_2_;CF>T6&]D'OV3N<EG;(!I[A?G8)4'>?I;3=O
M>R'>W_FM<!ZN4L.JJAH/Z2?!&&+73("TSD9RVPWB"<OV_8(=ERR1C0WG%+!*
M&<N1A5GS*B.R_F.>K1R14TMPGY'[2!SG!='I2F>QHSY9KXG-XW)Y(D\R-M(Y
M4 7;&O-U@)W"^"G 4.$<F=LC>(J8X1DBW@VYY\$,S.03H=:)NRSI<-5Q+I1U
M=8'8;@9N<@MYJ?'MK=S(U= J/F(#V0Z"B:-/+$N?$\HKU%U2Q'<&\P"7SDMN
M'Z_4N,OB\^0SVPY7)61[ABOLB_S#+3-+^9B[AK5\$?!J.>JZAD$]9 [?-JQ_
M\J"U3RD?43=JW%7T.2@!B_IV>VZ7XC"]W(NX[<2=OGT(ZN@S[/5E?KN5P$!J
MI=HMK76;CD8-+=( S=T<G<^+2VT/6)^X$\;(:M:IN8U,A$AJ6=KM3MQ=8L1U
MM":LW</>Y2/1"R23'""66Y&.IK8.]GQ3&?::EPKC5%LKLMU(.@J/)"YR8#1-
MC6TW^\!$-I7.&/6)_<I.D8&9>"9ND=E7QD6.T:6FQO87?(PB#!7.L;8 L2L:
M3,]"9/&@8_IWW?+@H[M"P_4<F28R'Q!/52L(7%[N<D"O-#46)PL&G2^(C3HF
M2N&RV#>0I@3BE$!>;>'>'TECZ!XZLA>$KGGM3C,^D[C*X;W6U-@")G&\<A%*
M1$9M(9TB&Q,Z10;TF'D:>YN)I1S,&TT][#/"6.7<%9_]V1:+Q!P6*.[I#NOO
M-5L>\OKD2:LYS$"^=+I5X[$TSJC).2E15K4'(W]ZHXR-=,G5:77B\;0D8.JX
M#./[*+&N#=V-Z%,_W (SQ7C#OCL_4]UVD5D@=>V$4J7FLZ-J:AQ_)OT0_KON
MS\Y/?BT4J(;BUT/Q*U)?,VO&("R@"G)&<G39+L;!T6T>'-YUQ"EEI#'W7NP>
M.8ZW%HI]^O$LDR)'N*.I\8DUV_C="E4B4L]*$(/'-V<N>?&HL8)21^4"'"]+
MKA":IL;V [(H1&"T7:($LL^Y!*P#L)LW:R!*)76+.Y=J?/,F0EW/GL[M_L9I
MY3[O52>^CQ/A44<W-]+\_";M +'<1EUK[=ANPPX ]38UXPUB227VTD)@A1WH
MYPVQV0]DP9\@X6L?!51.&7(\;[1V;),BBF=3V8I3A+P?E5 B\T7X4\47>L9_
M!QO'VVS$A;RZ-=<M=JFJLT+(Q<=$4T\B3JX5MUH[MBV2IA51X8HO7>'B%5SS
M$&PVQ"*]1)'%;O9VB2CU43J2+E&J)EI+:\<V6W*I250Q_!HP+U:4/:O*#G +
MCVU+K4'4VEOS1QO]_?AI/[<4N4JH6CNV09.F$D*FX@OU)Y1 ;-VU0)R@02<P
M! <YR=%D.^1R-'VFYR$;[^(/&K Y9<@![FCM6 Q9!O!YL)X0_U_5WT,#?E7/
M.O#A.O +NS(B7ZAI2R*-,[$DLMB".R"M80?GCC#M$4K#2]IE)[[7'3"H8VPI
M:'O^"6N?4FZ"KK1V+*P7]GL-[4FXO]0U7/R*W7>>$Q<_?U\<H<(BY%!>:^WX
MKE9DZRH0%N3='3SO?\:> S,AE@4+Y.\Z-<EBBBA&3L_OFD>LS[$%_7@,\'GX
MRU&_T=KQK:L(ZDQ2TQ?%K]+APO[K/]6KUO_T KB5K=!:XCZR 2(TT]]RS6]1
M*KDG<:O&\]$%M<+)Z]G5N1V*.*W4I[AL=>(;A=%NKZ-?$9J@ 5H@2I$)7=%U
M''3<1);(3&J\+MGE"C+C%;!E>"F"<=T-5'Z4#A#+46$9;O)Q4T,(0ET?+A:(
MN5)HV[$3W2UR V-&CG*P.EHG?O]M9 AM>4<@5!C[FJ/XU:;(($L;_XM;K1ZR
M0<YQ1C"%I1Q'3>O$K\Z,X!AESC$,V-<31V_NH-\\:,#P-6>B48Q4ZKM=7JKQ
M<VHA"T7PJ''/%[EB]# '^?BXTCH';@C=P^'??2S\=+'[IDWQ?>=MG.Q=G/ZK
MB#E>[$6 OTZ@?3HU5EW;'*!79)$-^SVXZ:#O4?9ZEH:BSQV7ZH9[WUCH%GNC
M('O#Z'TC([6-V=4N[,V"+O78ZPC9&Y_O-K#>)"9KPGU#O-[6#7[R4Q7N&P:X
M>)B]&17P=+'KL;;\3(FWN6^(DMA%ZX;B<B;BR9K8@#1]'\$OC'GX<M)8XZ7G
MI?[JV8B])O$)K>?L/85A%XA&B![(Q2*]'TR/^@>(,K58O K[SB1K'=L9&OSL
ML8J,%WY%D3EBNJ9;/(G=X7?NF#,R<AP/O4"EZ(R(,! \ P+')=1)U(63\#YY
M#XDG#J]#%HU@N;F\CN; H^QV32Y:M,%_4P=?;72-WSSL8%&3A!XIQJSL+OBK
M;GLP?)C>PK!^0',:?.4Z+1\.&8DK,Q!.J?@G5O2M2?P(D!_9]N VM)?8M/UB
MU37D+'39#T+4:2;[8.'2=5(ZE3SI[T=.1GL<2F^N?_?;]J(W?I.[O7Q *%D=
M)21YVK.GFR::?YQJLL/3$V0B<2#HR;-<O %W>,/2/A<Z?$UL;0;*C[$B&U"?
M @ ^B=2#+JB!;DW(NVZY[R\B 2$SHE(>586X"^-*>P%)\M$9*U;Z$$S>5^Q9
MX+J\4/(*;@FQG>$;H@9FK_D6;TJ 9U_P<H4H>#0&6Q\MT7CWNN0$O#]0XJG'
M NO)C1"6H2N'O4NH_)+JZQZAE'R'EJ5,0S**TC5CFZ&!WER.3"*B!TI^5.W=
M0$1FCR"/0U Y?\!?(8CQTHU<#1]&.AZQS2VUD]2T?#P^:NGALL5/%GL4&=LC
M&UQ&\#Y'=G!^$IQI W[@*R8H^41L=Y5L: JP.CWB^4P(+ +=]R_$,@&R\2)R
M'7^?T(U_,6Z*3<G#HG0%[UNZ [7T!]Z83L# NX'A-Q.A32,K>P&][WCWB$[-
M\6* *3+8XD\.85;JTM';T[6QX8&FP5!CXXF;FURJFDQ>>D.#5WV"MS$'\\EX
MBZ".6/ /W\"DV$O$=LX2=387CY+M4$0#^<67'*CMQ#&C> GH()/-(.QU6\GC
M-"^?<CVX;=RR:YH\%!>$+F<K^+,"19V(]&Z_YB*8E];ZW.P^R'H%1!DZHLC$
M4_&9YO V^@09!'31PEPT +#6V0G: 8;2%+&#FKX7D0CRT7Q+'NH\5 3:"37R
M/:-P)9[B,J<2E@[ZX;<5S  .R:!-)BE_8!Z^EZS+W* E+]I[#XOX49,NR^[L
M>BYA)SJ-T!/V;1'I(1&HWKK+R;L9OX_T"CCA?!.3+98\:F-VJB;=DTDD*7\4
M<,?"&=G;FUS'B^!>U0%4XU5G]HNG.Z8O]HLQJT(\X."B0;A@^18: 4W9JXSH
M K>[9@[4V'[2Z3?D<EP>" 6,+-!$?RLJ$BL;V\EAN$P+ZI/**WG Q_)3,VZ-
MI=(5WRO[T&#U,W)?*#$0,IT'2M8[ :+D+4XI457C\GL+D'!O^B;S$CR!KG2K
M/HW<V- 3G3EEUWI$+E;F^NAD-.R%^57"MN_B]4Q>.4RY@3Y$6#K207:!6#Y'
M72^VE92>E9!(]S%[A]AV$1B% MN'+\2%OUBWV,S!@GFZ]80MEB]AH[S;B)EX
M5=5LQ1TJJ;>UG7*ZW#=A%4Q>KYZ ]1'=]K%)("*:O[\<Y6^B)[:#3134*J%S
M,M-757'VS-D &<7LX"'"TNU@;(CG-0E5'_81AWDWDZR'IL0RQ0\@V:!XLQ.>
MD$0S"G,L.3V-#\4OR#)A63'5+?1"+&R\I[LQJ715<%?$<B%22WES=DM6=%71
M-?_I.?Z=H22,>+_HV!S9?7V#P:\4RX6)N%*L3QS)8K,HN^J.;:B>7U6Q/F9"
MQPL^!+_:)FM'OMSB(SA6M9.>B6W 9,O7&?X1@F3O]E#9JC;,S[X(,>#@C6R#
MG8](#C^ED56UN=%E%#\8$GH3&3+(LU*7[I!T#;YMZ8!CP>K1M["-#=U*MFE)
MY:N:5!VL(&'N@374<+VQR#M"SB_87:5&"S/1EKT"E262L'H5RD 1A"7[3[DW
MGUD^U.FVL@6WCPKL<ME98F3!2P 6R>'GK.&Q JRJX&KN+>RBYW%RK0@/$99N
M@ ]OUC(3\]7&S/?![CO+$;:@B$G2VEN$5T6[@.U7^TE&D5.9S'M(6S07YE?^
MYGAT?\(?DD%.H/.DO_%3!6MIOE(.#E5UO5@N+Z@I=PNV6>5#W5@-J/Y=$BJ1
M4E4VX)=POI*',T]T5E/.J[H] _,56Q0-WU%P1'MD"SDIR0Q9*/]P9F_JPC+Y
MI(8OPK$*IJ_XH9I'\OWW/<4C%UAN"JC\_.011R^K,G!V[Q/,="PF5KCT1L0R
M+V P4O?K1AY23*&J:%PU85K:#D ^/^6=U/:I*SN-Q:Z4V%^ GOC&BH+LRTX%
MRW#(:[8?S\AY2&R6-:R1VE+3O5N],Y/LS?DBON!1L<0<G7P+VP-TI=LW=D[X
M-MMQXMM*'2<^&!:##A>#ZH'0X=L&BQK,8!G-%$Q/3K KR*U\=RQ^IKU@%LL?
M)V7E9U 0YY' O.J,;3'$F/\W7K QEMC>%*K*3DL39##=Q ML</%;)>6A@VW2
MS(R(W"O)[5DY^52V1_:MJKCW*F>:Y1Y1-<U9L*+A,>X!<L,58N!-A,;("?*&
MBAYFS2VD?..7=Z_@9)L.I:\= U^;C3=_=SZXE3/=03](5%5KGRU8/K(L;!/L
M]%=@WI8GB;\GL"S=4B2FGT:B1N!73]"270E)Z/OQB:W9.5=7B[;F_P6F.^PX
M4/T,D99TNM+U89M4^XS<,)N6AQVVL_H3V"X6*QK;$Q8T8LN>GNY@YZM-Y@ZB
MKZP!(WOC"9,0'B<56Q"AZ\#6IRE^1EG5J:KF\:PA/M&.%U_]N+[\"KQ8X8J&
MBT)T6=">>CR##NS#%V0N 5'_/2\8.>'*/FMJY2E85V%+/+K+%X]C;S^$[<FT
M7YB14U5'A)].-Z8O.G6#+QO_G:"YADL!3E7ME+3HJ7!'"P=? _*RHX=[R[!P
M'?Z ]/3#SUFI2Y^3Q6Y&-UAA@^4J<&EH!O+2&YKL2O=U6"G:I(>)19;82/6S
M\O(IO>G[*9:P,F:W9MK+S$F9$8JJIF4&MR@,4'"; C>KX[F%E[QSDTU2%M*J
M6N/(-O%^1&!G#YFOIN?BGM0@CA(&UOCE%,S'%1>_;6_CSG*&YD/$EGT/]-[Z
MLL]?8FL%%]= )6!E)<L-S<Z@_-A4; MX;_+*OG<<(ZSH>B!^I#.<H&$*&[XQ
M4^=A9\7(4J+UA7A5U9H\(V* @YIR%&&W4.G3&[C3[#3JR'81C&XWPQF9@\6K
MBDDPRD3X(!H5#<Z\"#]Z9XF!=<O_/@-+Z^B&-,OOE"*JVHV'5F#^A2WAR_C"
MAK#&YUK-I?*J:L?(4CR#B3K]]M&<7"J[91?W!0- )[* =!I95<$7!Y'$+:/9
M5GPRBM]O*N#O<7*,%5KKGW_X?U!+ P04    " !H@'M0.T5#+GDA  !;60$
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MLKY$(1*G,;6@/'%;*I0M:]*\IP$O?0I:>_S^W(UWGAI5];9DUK_RP7+J(6,
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M?_WA_9L7;]X^?W?RX27]]N0U?>BWM^^>_TI_\/(?SU^]>=_?'%KCE0W5N.G
ME]2JI,VE"*1)9+4/WFNR0FV*4N7(I=$#A29Y9RW+R66F95#,@_,L15(L!^<@
MF[9J??_AS=/_]>N;5\^>OWO__/_[_>6'__/L^8N73U]^:*+1N]^V(V5V'.Z2
M'AT8GDE7V7F:;LX$)V7RH8"+!G.* PBD2,R:25L2TY E"P8*2T84VN:T16WF
MMO/5&,_&Z;L7GE7+?7R]EYY!Q+/Y3P<74W8*\&GP?D9.5/6G2"CXDKZ<#FCA
M5NAIL9;%TEMCS"Q*KIE1T297R%FR<:6A,C=2"DSCW%*Y?,,O596_X-EL>O63
MN7(9%Y?&_[_?#66AOLT']W*4R$F<XC-<_/_+T?O9./WKX_@LD\/Y_+\NAK.O
M[\9G9R_&DS]@D@>BD-RYETR )ZLA9V2DEL*R,2A,":!=:C'R-7%^+Y9OO#Z9
M7 GHTN#<T"*M;G2O+)F-=Z>7!3=H?#__-)[0X_[V,]^61N\_THX[?7,QJUYT
M/9@8H/<&?=!,X7SP4C/(FC/0(H5LA).V"5%N(=D]%9KJ;MRGX&\S06S-A%M#
M'?BHT6=-VE* 3"NRHX(F;!%M5+X8(:UKLUHN0SER+FPG^MMDD-N2X0W9X).G
MX_-/$_Q83PH^T_C)9,!7X^F41HS#T]'3BPG9ZNGKAPF,II#FVACE^7=G\R.U
MD_Q_+Z:SNK*^QMF;\@&^#%")X%P!%@36DT;R6D&389YB*D;J))1ILOVV&<YQ
MD_( *'";V&I;8G]#-/TP/LEYKC X>PO#_'+T%#Z1A7PV7YKK46ZNPZ>QS\?R
M#DF\T^$,W^/D\S#A6YP,Q_D=IO'I0NW_@+,+'"AN,R W+"FK:'Q!,%\-")N@
MR.(+6J];4+SUP(Z;[ =%B]NTU]O2GJ;?M]D[,$F28TT^M"#'C"2E HO:%1;0
M!A"(6$)IP='O4!PWH387^&WMFUY,NY?3Z07F9Q<3LC47)%V8H*_QC_FO""4Y
M.=QRQQ(DR30-D8'59'@4EW4F7SY9W\S<>Q#><?.E@8IN$\DV(M)\B?L&,IC@
M9: 5CCOP3$N?6$CT3^;&>1=R*+')\M()W:.DT18*NLTBUW0Y>CH>749,O"F+
MKV?#>$:[:Z*/SH:$WGKN@O' ;*SR<>0Q>R$*DUZ3IUQ24F[WR]2#L!\E[UJH
M]#8A?<ME[6'P6IJ@=<K,V>JJAZQ84!%8AB!3H(EEE=CU<O<G'7>DT-ML#)NR
ML5X.W87\[01_P\DI3A8S:@#"1:D+9]I&@EB$83$*8"I@4$[FVU[F[:NG-=YW
MG&QI)? 5A[,;G]-WPKAP,:6015ATS)E(NSK2HN$51^8X!E$"B</'7CAQQ.<!
MC<2]@A$;G]??!W%!UG=8%S@\F4YQ=I(6QQ.DF8'Q+@NR_5ARY'MJ3)S%8ATK
M@3Q0C,IA$ML0Y-ZW/SZ^]*>,%?39^(3_/L1S8M\%.&874$3'4"M+NR)7S&=!
M7REA$HDL(:UR6[#GOI<_/O+TIHH5W-GX$'T.^!VF,YA.AV6XB)Q^4_X)DPF,
M9M,7),570XC#,Q+.A_'E319:X930P$(,M'T6^LI'6YCGV1I78BA@._%FS1<?
M,6=:JF %7S8^?7Z0X%>PGW_!21I.,0]*SHX'XYBTW!#4Y%B :%C@N=X.R2AR
MWGJ5N?7:(^9*._&O8,K6)]4?JC N)E_GJ.<8Y^O>I-ZY3&>_X>SC. ^\5T&8
MG!E'H$6/5SJKA$S0ENFL] &\;.%P=P%WG$QJIIX5'.KGD/K[: J)AL>4"BN&
M_M$BRGK_XEFP12>$PGV$?02R]!*OI33X HI9#:1/$0H#("@N)YZ\3J3E)K/A
M@7BM+<(U/T \PX%&Z3EYVXQ;XI(V&!B$2%SB1A8#6*0*34,UYS!ZG,\W\KB:
M1R%N(<M5H64_+;)R_IK.QK1+_.WGV>0"O_UP/)KAE]GSL_D+__;S%$_K%[W1
M83%QZIW[>%0OZ$^^#*<#9:R/42#CR9%P!&8R:9QBTELKM2BN6-Z4':M0]4B6
M>Q+L[B'/!MJ^BSA;2[U!B.(2IF?S#;(3J,%2RE^?E%B)JD\[X*Z\Q7N(L+WV
MQJU$OS->>$TV:^' A/'UW-;9>LNI28V84W$J16E^<#Y\EQ>Z?SJL(_$&-" X
MY^.%]?O;W&@>R& 2QN29JHE@6DK%P&M#9B GQ]>5HGT3N^\6DMV[!3UH:-RG
M>!OD+GSGC5Q"*B483VXJXUS2 !V0I2]I W16*!=L#C$VR5Y8@>48=+ZMB!O,
M\CNB,R_!H?8^I%Q85(*\(>XMBR4[Y@J0,81"8&FB_WM1'0,3^A-[@W2%DY0N
MSB_.:LV4N\+6+X$J4#)9%YA!547 /8LI!%:L<I*#1UZ:>)6=$1X%5YJHHT$V
MP#N<T5@Q/X?):#@ZG5ZB"CP%G6A+0V>!::4C"T@V$J=1)^1 &UL3DJR&<PR,
MZ$'0#:+BG]9;E.O+DS>3=[66TMPVYCJ*!+*FI1 ;M2K :OHY#9B+(EQ&4YH<
M+]R)Z B.%OJ1=H/=8R6P2])W@=;R<.$>;/LY8NA)BUVXL84*6GB7]T 4P2;!
MR7<NN4@RB1VRZ)5B*<=LA/(NBGP4['C@P&'WY%A'\@U(<8GI<CN#E%P2*)E1
M%IDF-"Q$\H>-Q1RUCL'Q)B=.WZ'8O;G0FW[&?0GWSL.&__AE22JOZ-O=%HMI
M4[MIG7?NK7!,]^I.VEB=T2O/5:Z+A=<Q"R- 0P$5BAMX[R%Q4"S7\P<M56(
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MEZ.E5IG::<N2Z9 ]BT*356ILR1$\5QT/.'L <]2DVI62^CX=OX7_6[/&M88
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MJ_'H]%4M!'/=D/[;E?2 MBKI)=F=Q7%:U90GTZ5@J=6&K.=)<-.HO=PZ*(^
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M"0F 9&NB#21_K*6>3&1%D;$)RDJ+LIG\MRBLT^6Q[370I82.S$XZ9[A/(>J
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MR(W=,[7?M;\WQC38$58CN]&8H N^EO$?#P'<3\C'P3"B$U.W5.<^:*?JO3-
M8%E&S;0VEA#;P((DC!9!.MNDB-!^Z/9  ,@/R[9UM-C"W*TGN&\^W0CE3%Y9
MF4HD6PF1Z>1=;7D764&, G1" 4U26&\A.12O?U-EW6H]NXVD&US47';&NP13
M> @Z6K*3Z[ZO9?0,=.2UDQ)@EE8 ;W(-\QV*(U/YYA)NTSYTJ1>BSAIX5.1D
M9QJ5-D(S4+5!CK$F..ML+-URRE8]_4A4V8_T^FYQL+JW90K"<:Q]T!1/3',)
MS+M06,!B0LY>:MVMBNV!- 1MK=!MY-?CX?X-1,M-9T.2SF5OF0R+YJ>1@2!8
M"EP$Q846RJVAT;WW[FVMT6WD=^<)>-_QE9?E*&&4GX[/B >7F337Y9,WBC=[
M^*']1)NM"7XYW%*YD)4P21:NN;?5C#;6!\Z+=E#,/(](9;*&'!G7M<FK8;2,
M)F:MY"F5G&U16X7[/8A_BYB_SL_>D2JZ1/]E'TRP0J J63MIR"3UWLL"&0-$
M#0.R4 7)OK BQ7Q15 RL#/2/DS$*$11N&_UW _YG/*D3^'0Q@)-1?CT>I3M^
M_8&^FD*:9RG=./G5!I$'P43-2])H"2\-A7E: 8HNQJ%940ROAQXM/0YBJYUD
M-1D^X.1\$)-,L9#QF>NMBE8:632:O%E004+2(#)TVD[N?L?N]Y2]L>>[_:<G
MJ?==1.)N6)>]W9[5=(3QIWG9_O%T]GX&L_E'!N23&H^:,QMJO30PR+Q&QPS$
M7!3'&F.X)5<>@/ GE5KJK&\/<UW4E_WC!AZ#4L8YAKFF9#F1:ZEV3L::PY2%
MR-9TJW6X(8 _6=9.7WV[O9<6SS7:*TS%TP);2PQF76B%M5ZP6%UQ,F8@2UFT
M=*D3A^YXP6/E2!_R[MM1OH5I3/;L; AG-_A*0GJ'IQ=G]3E??QN>X70V'N$5
M^FBE#!'(L[0A,"U28A&E9;7OK7=6*,QA,[:L"^5/7NU"AWWW_KL3?8V)QTFB
MKV[AU>3>NGD0L@JT5EI56&UNQF)61ED$5WRW[H ;O/Q/EK714X\="5?BO4UZ
MYZ+D5C(KG*DUSQ/S (8E4(667\43/'A&T>E-?S*F!PTT:%5XH^?RN_%7.*N'
MIP/(.OLB%2V X)@.F@8JG&5<@$_"^JQ<DXN[56 >(7%ZTTW?O0^7R?P41@E)
M&G7,;W$R')-\9O29@0#A>-2.)1Z(U,D$&K"2S*%S(6<RYGRW:Z.N;WR$+&FG
MD1[;)5Y)ZQU.L5:_J'DOWPRRYU\^5?0#1RN>BY$,+E/!H:H9^3$SGHWR3@!W
MI4F*];VH'B&E^M=6CTT55_+]_?"T!EV]0*P7<^AH)V6.!L<T#9;%R#F3I#J5
M=2B$;*,UY]L['B$E^I1ZGVT1[S"N1L/SB_.3T>@"SA9;YM=K,QQ3$(4C0U[M
M+,$=BQ(BLS0 GI-U-G1KP+K&2__D2[]Z:=(UL<;0O9Q.+S _NY@0JQ?;YB*Q
MZ37^,?\5F5TVA"R%9<G.LS]JGY\ BDD'%J) -'9%1[N>0A@?A/<(B=90?RMH
MMG7.]K>\BAXDM\BMR"4&90.9=,!K%QQI&#B>6;'692%2=+Q+%? M\L#Z&LJN
M<L$.A[3[9<.AY(1]H,^]*3>&M>C#5[(E$7I&&X!B.F=+)D5 IHRE;X27.6,+
M7J]$L_\\K/TP9-RWIEJDL]P2!JP>_U6_M@YPFR95K8=W/SE6/6AZ.5]E!VHZ
M '9EEYU2D6:6LKX6WB0'N18L,BE'KZ3.HDTEW8-@U0.I5/LGU3K:V4T<RS^'
MLX]/">=P-'XR')^-3X?I"FR,*J)RA97@=$TUE\S+(IBS*;C @XO6;A' <O>;
M]Q"^W5*/#P>G]*2$OF/LZNY?#]N>?\6KL[B7H^EL.+N8X24\X2(*FQ)3)9'Y
M"3ZPF*)G9'5&+-ZD$'TGCCS\KB-F1<^"WMW*\?N(S+W)=#C[^J:\/*,_'@^G
M3S\.$YR.KU)/I(=LB+#>QKJZ$I.#K&D0&9*(4:>BN\4'; 'BB)FS*]7T'?#6
M#3=]BCZ2KP#'I +&Y&OM'%M+)OO:BZ7. 82<"JK0\3YOD[<_>A)MH8R>NY)=
MQP6_3T@R&8[G=IQ/6N@@-8NY#E^1F1I#S"P$[Z+(0:*T'2S?3MVK5B)XY$YZ
M/YKI<:&9 [K$\?MH^@G3L PQ7R;D=0'5=RN[.]'LOJE=#YH:MQ)SSVWN[@;'
M??#2><Y\J M9]K7-N@:&F+-.U@CCNZ14':+N[VE]MRO5KR/=1BI_,9Y@@NGL
M^DR'MD))JZKFY.]KL,@\YAKL;[6AI<W(TJ4"R%KZ_A[";EOD]:2;%=K>0K [
M:_=RDM+D O-EP,A&B:_+C^@GO_5>8$MIK,9'9PJ/P@6M591 HK8BDI:$+2&G
M@7,N*.=3;=Q"\E<AL5#(,912 I(J4TAAJ\3B);2;MVY9_: F(NW0H$59KDW1
M)$^G=7 F)*VU$P@D8C2ND WD-92@&89YQ+0C1RE$SK@QPFEK"YC<IV"WR,^^
MXTE-1-LE]UH42?*2:$HN.MA8R^R5:.@G42J4M?F004]?,55L=3V![$OE!2M*
M!RZ0_A*VD^TSC+--)#G_NW[D=AO"DI2<U#(%;[@ I066X ORC+&Z;YSK.$BZ
MQ!)5)I_* =.Z9J@389D(*;FDT(+A6TMI\_E\XZ_[DUB'F>N]]<5+!>BSQL A
M.TV3$1V7,="_@P@E.Z(:TQ)$K;6@R*@!RXSWR= G/8]I:[D]?V)>C6&TQ:Q=
M\93^Y'@?O&5YDH5GP(-6=;<FJ6K-A0W<Q^)"*&(0K0J&R,@2]YEXF$0M"T_>
M(%<EFQPMYK)EI80*N1YY3BZJ8?KJ.KQ!)%7K,0AF'-*KA>6TN]E""P4JT$[3
MQ,D=++:UK[/NP+/M;5Y]$+GI$\S#V0M(P[/A[.MO\*6&I3T93R;C/X:CTZ?P
MB7XS^SJ()H#V)'$3!6U N5BRT03M\;2S0Z3EP-DF]>K6 ;G[4[$^F+)\C==,
M+7W?R-P$>HWL.:2/SR;PQP 28HB$+,Q% +RF9Y <(@8(,=*V@MTN[.Y]S8^M
M\I[%V.#&__O1OAS-<(+3V3ORV>>.>WZ+$W+"9G"*@\A]LB49)E/MLBD*L%AT
MK :"2I8\/*Z:9"QTA_ACDZ6Q2AHTY;G)[$'QO @!R&ST4)/ZB-*%M!E%#(DF
M/(^\2;3P31#'08"-Q=J@5<Y5/MZ;,A_I='I1LZUJ)8OI(&1;>"!GP2M!EJ_3
MO%[N11:-3S$AYX*G%AJ_!]-Q$* OH3?H1O/]<!?W-X*3C2*$JF7N:ZN1!"P8
M4?N-I*B](<Z*)L&K*[#L*JJZ_;J_OF@/)<+Y^W$L&L:C5B)+S3RWM(@%J(V_
M,V="9%=$*HX&UIXA^[PVW5JY]Y)E;2$WMR1O%"/M@JME"/)=P/83:[RMXN[E
MP992WR4KE"@U5$0S])SP94M(15$,HPJ^* DN-^GHM%LV/! CO"LRK"/LON/Y
MGC\Q;R?CTPE\.]VXBB$B/U=K[Q)S)B6F41,L973MF8/>*P1MNU5.O_L=^S8(
M-U7"N'\)-NA]\&H\.B7W]'Q^EDY_,V=P\8E\3\-93BZ2#60B\[4=DLQ0DJW5
M.Z#)S%X%YEBV^ZT%W<+[7\)T2?,NJ%IN]ZMA[6>SWUYM#_!@"YDWV.SO0(?1
M&"YKQPZHX1^>EL#H0V;9>Y2F7G^[)@>'NV3" QO]KHBPCJB;$ !&T[?PM:YW
M5W'?Z UXZVC#T_6(,B:R;)1D!4!&)1*)H,GAP&THNS<%^E#2+;UO)>&=A4/5
M(;^_.#^'R==QZ>?V^J[']7>-W0GPTGUV05FXY9G' IJC I51<),QT.R.)0P*
M<I4=&N:R)+./\T)ZKWS-N@3PH1KVC>ZS2^&<7J49X3),QR!9Y+3* -@@,$6+
MV*1'Z [NLP=*RU@X66/D+]7B7C61TGC.P"-"=%K:V.2N_C"O&];1]+W7#>N(
MM8%#\?WXGL)D\K4VV%ZTM$9:- /7F<F(M%_2V.H**AC]E'QF*2R/.[B _![4
M<5"@-[$WL"FN+D O-[VG%Y,)SNL:UQR3Q3<#:VBEU;29&EDARE*(M34C208$
M,$9RUR1XI0.VXR!(WTIHX(X^PX($)+\8CJYORU[C;"#!H->8F)*VENYSY'%;
M#\P51;MO5,6F+IE:&ZP:*_$<!Q_Z$':#V^IJ<'^X-+@'/"0TVCBF3&WC$169
MV4IP9HR+7NOBBFURZ703Q'%H>V.Q-K^ ?@$)+[<IYX3AR4:&266BGA0L:-0L
M&,V#T%)*WZ06R5V CD/UO8B[QQ+O]QVPTOJ2HB ?6/!:[Z[P3,R4A?%B5$G)
M&UQNW'FT<0C]J7Q]T1YP'$(1:$QTU1<O)!;''?,&.$.>@1N7:.DR[1ER:!<3
M:RGWX3B$=82\RQOG+K@>=1S"6HKK>O6\B=1WR0KPVD(@.]6;F)CV#AG$ BPG
M5$('E[AJXCH>>AQ"$S*L(^P=QB%PA1@A"N9 U;MSB<Q;22BSC=I%]*B6SA)_
MY#B$M930,0YA'0GN*@Y!%V]1IHJ$[%*=/#'8 K+D"MD_+@'W;3*:#CP.89OM
M?FM![RX.H0NJ1QV'L);:NET_;R+SW<4AE))YF5<K\!"9YK3P!<3"LH2@LE;I
M5H>>'X\)F\0A-"#".J+>31Q"CB$&93BM>AF85DK1_L<)((]USTK!AR;)*@<<
MA["6DAZ.0UA'PCN-0W@Z'GW&R6Q(4%^/9UO5OKCO<?W%(70"O)Q7CZC12E4<
M@E80P,=$:A1)9V53B8/DZ7<%/ ,P-9-8) ;<<B95+O0;8TN4C>(0:$G)BDO/
MBH^!Z6@M&88H:A$@[PA>K:/P \4AW'DF*BP&HZME1>QG6G.H"ZFAA50X#G$>
MIO,XCZ#784#G(^AUQ-W Z;@Q2^<7(\9' +2"<4U[J=:AU!YA@=&\Y#&@)\^J
M243*$H[C4/HVPFU@4#PG"61:;)_A9/AY7M'R!0PG_X"S"WQ3;O_RU1#BO*[#
M0(%R.A#N&HG/M*P7HN1\,Y"!]MJH!2V\+4BQ*>#C8,].U+6C&(:_3\;3Z< H
M,+%V<,J^)++1=6#@52V FT&4&ODI&FVA=R Z#J+T(_#6D0PE%6N!.Y;0%:9+
M"<RC5 Q1&!')B,/8IK3"048R;*/OC<7:/)+AWCH?/EGE@XPL.D6[7ZGE8D(Q
MS":>A1-&VS8$^!%+K_1G:O:FDO;Q#T3I@8L8(OER+),;>)D'4'QARD>4H>8"
MM@F"O WE&,FPMHAO*WWCQO7SVY<*YQUF//]41?G;Q=EL^.D,?_\T'CU;'*@.
ME$Z$2&NFR*5GVM8J4D5FEE3)26EORW+!X3NNL1Y\U8^MX ;BO*WL[;K.+[D_
MS__K@JS3A9$RI!UL,CP]I:4I/QM.TR)&.P60/),K7$.R-!97 [$4 Q&\C9G<
MX=RM,\Z:+SX"(K04]6U:;-U5_N1\3&#_>]X]8U$?Z K9VPF>#R_.!^AT[;\1
MB*@::B9X9%X15*> <VY23*9)D-.#R'YLLK11P&V&;-PL_KX[7UUXA,(ELSQQ
MIETM(ZG(N3'%.LZA))%W4-GT($(C>S0)UA;M 8=&&G"TN^E(PS U&9G3, QD
MYF/RKA3)H_;M&7)HL1)K*??AT,AUA+S+(+@NN!YU:.1:BNL:#;>)U'<:&IF3
M<^3N, N65DI,JO;9D RMX,AS\6;9J/P1V;!^:&03,JPC[ 8D6+*"+Z_TE2LA
MFU(+U41R@8))#%P]$W4@HRG< &\2,;,2S;[-QTV5=?_-U@:2[KO.]W*XP9,Q
M3#*9ML,))OJSJQC/&DR0:GZGEK(6YG>21:D=(Z,6%4:C]+*%\+"/><_[=J_N
M'C1SAV/9EUC[CHE>&O'_A-$%3+Z2QOQ5WT4="N3 &0+6^F(*R5@F<#R+8#%9
MS"FLJ_.5;SHF;6\ORAZO%E>"NQCA#62U*%F.T3*HYQ@ZUO9<FCS7D"1@R<)C
M2ALI^;O7')V&-Q=BC_>%JY"]'G^>8[J!3FB3E:XMD#"46GL06$3DC-,F5B/'
M CDSFZCX]JN.3<U;"K/'>\-5Z)YA6D:7';=9%<-*EI)<5K)2("C)L@)ID*L8
MG-Y$U;=?=6RJWE*8/=[RW;^CA$MPWD@(,3D6LB!PQA,XK/U#3*1%IS;U6NZX
ML.[F'(Y3T=N)LN^+O25P+S!.EM"95#!GH9E*WI*=6/<6:24KL7;0$H[@NDT4
M??M5QZ;I+879X[7>O1D8$6*B\7&6>>U0*'UBE9&L<!3!&6=$7"J$_#A2U;8Y
M?MU:T+M+5>N"ZE&GJJVEMFX92IO(?'>I:@H49/(,F0%5B>]K]"%W3*#)TD8(
MTC4)&S[T5+4&1%A'U#L[>*471U%S[EWDM8^,0>:%B,PFHV1,Y%"V*69T( >O
M?:BJT['K.G+N\=BU-C=_!Z/3!:FM2C+H (S7;D[:1S)#M2-C)RBC5>$NA2ZG
M[)T:Q5^_]4??YC<788^G+]<@+NG4!<8:&WEWC?8_41_>L;?0P+(.MQ!?CTOR
M,AQ0$F,.1$M1/06?#0M@+>T].6K+N2C+94$.6(MW[+;]*W$=J?6LO-](4N<7
MYY= G ?I>=;,9TF# 2-8Y!Y90@E%.U6"[!(TWTE]W[UY=_OE5K(?]R&XGC?%
MRS[(5]UMN!;H76:YV)J#XQ3SRALFA-/>@,%BNA1\[J;!FV_^ 36XL>!ZGH,?
MAK,S?%->CO+P\S!?P-E\81'"EIQM9D4'1X",9-[2.I.1S#DI(FK3FXFS$L$Q
MF#O;B[;'VXB5@/XYG'U\AV?SV-CIQ^&G#^/GH]EP]O72?N\"M6_S:$V,NS>A
M>M#J?1QIH)+6*\8#D$-!S76.C*9+S=&-D?E2(E,.O2Q9V*"Z]!?[<=ASC^FV
M7_*LHXF>27,517-U7R"4R;5-(E:[1:?(63 8F<RTO*8D8^@4JMB)$]^_>K>F
M0E,-C7L1;Y.N(%>9^M^VTG?#Z;\6U:M,+!!H=-+I6!MB)]I-N6>:0RI.HY"=
M3D\VB%*]&]2/;FWT+O@F&;!7V)Z.1[,)I.\*T77 UC:@_6YP^PIJ[TN5=W*D
M)STT"7&_!R.7M9AM(!=).MHMK4 &COPNL"%*3"C0-5Y =L61!T/=]T&1=<3?
M./YU\6V5U0N$V<7DRBD7(" )6UNUNE";8B&+%:(6TL0@LBJZ6WW@;N_;1Z![
M7PJZ)Q:C#^GNM&[@^_01\\49CLMU]:!QF7W$JP)"E\/8MI[@NJ_IL=_A-@-<
M[H-H>902K>&8-(@2$C?*&.%5",(Y',0H:E,*9*4>1^E:<3A$DU@1Z -ZQX,5
M-\?62ZG'-S2:R<M1&4_.YR9RSZ4?[WI\NU*0G0:TI)I4A$\A5C\@:8P\:&$%
M(,G<N>"2&6@P)M//&>><9CBOQ_[% /,N>%Z<5,E@H]*0IM#DYQ@8A$ ."I*=
M&CQ]JPKYK@1*&MFD+&O/I2$OU[OS\_'H_6R<_O7^(]"\.3F=(.8/XR?X?GR6
M%[^XB-,T&<Z+3LQ_75\_D.!\)A4Q[S4M?"&[VL(U,!D52!^=TF [;C ;0MAW
M<M5FC%C:;G8A_B:%))> WT0Y'00E9>'!,[*YYIT8:.L--M 4#<9HDE*(36*!
M[H?U8Q.F@>@;N"WOH1[VS-&]G0P3OL7)'.5 *BN,)ES$6L$T;;QD/&7+R!;G
MAOZ3>6A2SN$N0,=!AE[$W3AUZ\'R- *5=#4AU0@"K T*!CXJ1BM<5":7%/5&
MF3X_3B6@+3:0=J)N4"+RUMKU<CJ]P#PH9,")H@F65>2I:QMI_"D32A]EB@CH
MFQ0+O //CTV,/H7=H(;DWTD>TU?CZ90\@]'S+S/BZ<5P^K&.>U&;:%"L$,'0
MLB5]C9C5Q==.@)DE00Z9$*9&%[1@PX/(CH,7_2J@P3'Y3;9^OZLE*,D[<*SD
M>0=/2\ ,% ;)\6BL=,9B$R/B+D3'P8A^!-YCDMEUX;+\?R^FLSK0Z8?Q2<YS
MV<+96QCFEZ.G\&DX@[.E+;#>+MXZMANDE PW.C$;'.U[F#4-026F>8HAI8((
M3:S/O@9P'#S;BSH;),3=V=X!4_;<9V3D?VNF2SUW3@98<NA]P* *[Q+GL>71
MT"%VT]B&-KV(NT%=RS5*+ULG/92@R0TOCNG @=%.*EE1CGSUHFCTNCTQ?HQJ
MV/U1I3>5[*CD)0_1.Y7):8^EQK)+P[Q*MK; AI*+CCJK]BPYB)*7_9%@?='N
MN^3E/5%R7@<PBC,H$F@41;(8)6<BAMH!+04MNM3)/8Z8Y+54^G!,\AJBW7,T
M:1>H?\8DKZ_5;6*2-U#)GED42S;DO:G:*(:,)QWK])'SVP( V@T]A"Z]%WX<
M]JP?D[PC\JRCB;8QR2)P6DMM8JYFXN@@,PNN5O<KTAM=:K)Q;^F#/U),\EH:
MNCLF>1WQ-KBT7776M\BA!(@EF<*R<#0\09# DQ]E->VG,CLHI4W'MSL _>A6
M1J\";U#3916N&]%S7="UC$2^']Y^8I'[464'?FRIAP97^@^@C!J UUX1)5GR
MHQWA]3$HVB6MU2Z(#+%).-0^6/) -/(^2+*.^'=6"P8%6B6PD.,>;6W3+6BK
M!,&L=$(9 HRZ4?S/0=2"Z5-EG6K"K"/O)LE.MPK.AY+!"T16G E,RQQ9S(DS
M'NK]H10E8I../H?=FV,;8V)+(3>(YKBSUGP77(^Z-\=:BNO:CF$3J>^R-X?'
MXJ( QZPHA,\&R8(U1'Y4:+E+7&&7TA@'SH;U>W,T(<,ZPFZ8HO26!#"<3L>3
MK_-4@*NZ\D&0[PO 8JK!^T9[%I54K$@)13FKG%J[..S*-^W[4FM3A=P1XK>]
M-/ONPW&C+/')*-\L77L380DJA, SF;_&D'E",$.(B@5#.V 6W*34K>ISI]<=
M@]+[EVO?D_QFD7F">+,0^4V(7$7N@I3,!&'K+6MAL;C,C/7&.7**HNVF^F[O
M.P;=-Y#L#NH"+]I,>1MH6)IYX:!&XY"?"_4KZ7/FPB&()EO\H1>%WL;NWUK0
M#6)X[RAVV@75HRX*O9;:NM4"WD3FNRL*72\\7 J)1>L3+5(J,A]D82H7F@#1
MR*";1+0<>E'H!D181]0[.P@TT@HI4JWD4G,-BD$6I%(L*UKQ:HZOT%TNF7_4
M@\ ^5-7I ' =.3<K"FT,!ZVS8!%)*5H4S<"YQ'@1'*WQN2QW;#JRHM";1B1M
M)L(>,R^62WIV@7&D1:'7TL =]80W$5_#HM :A)>U#DXQ/M;J-X8\A1I:F60R
M@=.ZD7JK/G@81:'[4.(Z4FM:%-ICA%H'H]:VP%IB1K):$)?9Q'DB+]DJT5NA
MP ,I"KV6[.\L"KV.X'9;I0='P_'D/::+">;E<BG;EN;I\NP>Z_&L/92E2B\Q
MN^ACBLG;HH$+SW51"DA%PGN5Q2#S(@U&S9SDANGD'0-3FUBKK$U2(*6&1I5>
M) @N4LQD5;F:*2LSBYD(6;MEZTRL,JK)-7;/E5X>S*/QJ@"F%!FY'62W6%^M
M1PXLA)"Y*B[+752T.<2TI748T#EM:1UQ-[^M_WT$YV.:L_]]LTJ (R>$*\\P
MUM:"-&(6DRTL>\N30#)S80>7]RN0'2,QME5 \RO<A6]#J[,2SBO:@Y-C&FHP
M=.UJI5P2N= S=K(6'D1N4G^Z7U^T^\Y-NN<>6SB#H93:$%YZ,K=B8"''R$R*
M7'I4CILF.=:''?*SEG(?#OE91\B[#.[H@NM1A_RLI;BN41Z;2'V7K$"7I,BQ
MWH'29J:5R@R\GE=I5-X)P\,N#(G#"_EI0H9UA-UW-,"];N!O<+.9L>8E2)>!
M98$$TQ;%?*U&Y(1-0B9-8U@ZSK@C(J#[._=M-FZJI'%["?<=$'0_S 6^Q&UT
M,7AF0Q$D Y ,=*;)H# :2WNB3+$'!CP2U:\OTYU._O]Y,<*;W%0V)$&NC%1$
M4%VD95Y%S0)(RZTU2MMNM?[6>.G1<V +&=\9&=3WN>>\GM03F%;TYY]HZYSG
M6FYRRGG'D_HYT^P"<^D$D\M8O"/+WA2A(\=@C(*@G0S9%"7RH&81^U(KJ0DM
M:VL[MZ@6KR)FA:E@#G:K,N*K0<_]CXW.D>]]7DLYKX*\?%X\/R,6"1SGVIH4
M+(0HK0R*2VV\(&F3:R5Y8L[FPG2VKM:&TFP>"QMU;4I8MI-VK:AX"_JWPO0W
M?_K\2_T2RWCR9E&?]^\3('\\;W'(W^?K>])E*X$LJ5XJFX6U4##21 (?>9$Z
ME<RED46D."C&&&YJKRA;0RZ-I#5/U\J64(_0LA,YZ2VO"E;S]F0RJ;=7=;%_
M\O7;1]["U[G)_P=,\K?C(Z>2MZA+K=",A%(H!L$C,]JCBTC$[M3X:VVG:'OH
M6Y?S.YM_!O-J*)?<& @>2%<U@L(:VK\,[901O6#S.Z*@(!ML4BRK&[S=6Q,[
MYMRMJGW]:ZW!K<;5<O.F/"BNZ5WRNHSBB3P"F,B*-&2C:6X9T.;"N$DJ^R3(
MBW)-YF=?(]C5^?B>>;D?C1_* ?S+$>V_BZIV\]N)^@=UT/-T\V*M<)Z<09]H
M/+DH%B+6M#(#"3W*S)N4R;T'T[Z.Y/=$DG$;934XN[T#VE4)B@[@6A[KWXMN
M/V?[O>FR&T>V4,3.V<(-.#!*,-"U:",7G,62:ON)Y,DOEEBP25O"/;#D@3/_
M_9!D'?DW(,??<803.#L9Y9-\3E*>SB;S!GV7%N+5Z90@C,XA4\G2EF^39-'0
MB@JY5M'R,9%$6I"D$[K=&_<]:G2YSG_OZFA@MK_#*=(#/\X3'3_CV?A3E<+W
M$)T(%NO0,Q?U;-O7LVTCF90Y6\Z3=\OW!?TPI@.V8^)+WZJX<X5I<K2<;YEV
MVYRQW?_$'H] .\)>/G)&J<D6338XJVNO1%($MTII:]%;YP>ZD)Z*4DQE6:L"
M*<<"_0T32AJCLY$FB?V?A$4KO FT_W&M:.WQ(I%);14K)@:K,P_>-XDIV_])
MV'-BX?@KXGN<?!XF7 WH=;WFF<XPS]\]_3">MT?X]ONGX^GL]7CV?W#V#M/X
M=%1#".=GL9='JP,O0NUV'UGVJ&OLD6/>!\N$)O>Z%.GE<A/@GDJS[6)T/^0Y
MW#J,OU4([N XTZ)&::M!OL7)<)Q?C">7/ZJ?$X.29=):6&8LU'4RP*)1M%?:
MTTB]++*)Q[+;8?XY50Z'1;W78;FHFGA3%JW_;N)_>P8TGWE1OH"U+'HG:Z/8
MV@K=6Y8 ?'!2T:_-0^90EQ<]&H[U+O4&Q5DV%LW5N"Z[$7\F2[0>?A+AY_>T
M [(A(Q<%&8D-F,XRLJAHB^#2"\TQ)_(=#\IB>V! CX:U!\6,'FM1+H*C-AW4
MR<5L7)O2)_*J)TB_?3E:C*]VX)[WP[O1,*@Z3<5P3JN\H%5^'E,29:(1\J"#
MBT*ITFDEW0G<1\/L V5 @ZI+&P_R9JC-].5H8<3\$X>G'ZOU\QDG-+CY+Y_!
M#%_ </(/.+O 03$YVZCJ074]3%(R7.9/VQBB$THK.*Q E<W&^6AFRH_ HQZ+
MFGPWW/CP<.,=P_W'W$FX&N[UL,0 -42@_8V!X#7.EDOF RC2!M>.8PED_C>;
M'PT&]#@GPKZ9<9OQ6[?-W5BL-QL!7PUK('*0R8!@,M$_NI10"S @<_1C+DP"
MZ9N$X_4ZBL?)[;UPX#:AMVZXVU\4CPS!)RUT[79/(M4(+&CD](_DW" (*7@3
M,C_"X+ZMZ+L7C1]*<-\"_E6Q2.ES2KZ&TA93JT'$3)//<08>'%=9>Z>:W']_
MA^+'#^!;BPC+,= ;*Z1!G,WF@O@VC%&N!Y4W,M.ZC*EEI%^+0>TG0' +KJR[
MA^]*T3\*B4&ZP",*ALX:IK'&,5F5639&.*TLT,[SN,G[0-SB@7-W'?WV?=%V
M4G5?\5R&0DGIR/(%R6H. UDW-<_02U4[,(B2Z2N=NEVL+3WX #V5YJH:]R3G
M%GE%WX(CKJJ[:BQ:T*P(F#33)KJ:7IV80^366QT+-@E@O87D$3.E'^TTV-:N
M(P]N 4M<6J=E8@:XHF$ZRT*JF4^^.,ME %1-CE'N1/0G?7K25H,+_*LQSK=A
M<-HE1QRV0;O:/91VX)@=2S%K4S#K))HD)-X$\;C=OXW5T9 :5_3O@*:EWW8(
M'M?FZKE#SUO(ML&>LHPJZL)]LLP:7XN;<[+*BZN*T5%S1!';.#D'X)XT4_0:
M(FWA5^@;]FY,1D:)EKD4"M-U4P.N:^USY*EXQ!2[U4=;>O#NM_MMA+SL$6PJ
MH;[KFRU[)PJ5]1*(>NAJFDU-M'"QL&"U,;6?2\K=ZEGMW0OL4UN;2FAW*4,/
ME*RI][@+^V(ZO3A?W/8VK-ESW^MV4Z.G\X"7:_+$*#7&(C4GX\HDJ%D"X(R;
M]QV5>E 4*"M!,3+,:_"'+[4[*=%*HA?T50*/^\]$"AAM5&3?!^]<[:(>6)"6
ML^)*M )U4,O3^%@RD39&<!WN<(,QS[^093^<XMO),.$@!26<,<"B+.29>669
MUX*^S8IL< DZAS8')<V&=( N<[_<[BV*H%]VM#C7VS3V9_7(/F&:8?Z DW,Q
MX"B]M"8S85.HG5FQGAU(&J@ S\'0:M@FQJ#9D!XG[_?/CGW<NZTSHY=B/_\Q
M/J.GG0UG7]_!# =9^@*</#(?R%C7!DN].3+,N.(0O3.Y'%9Z[]I#?)SSXO#8
M<T@I5*M&^FXX_=>+">++T0PG.)W-!Z@BEU&3)^0%25\'\F"#Y8J!YJ4$"!YT
MD]S3YB/[<U;LE2L]9E<U,@,7V^&SX>=A)E]R/D A!09;:U;S7..D!5F#A0.3
M$*1Q5FL'36+<FH_LS\FP5ZZT2,/J[4K*N RJ3NAY]V<M?:T$IC2SQ9!):&-R
MO@WI'V$P\E:4WHO&#S,8V0#$4CN61Y7);0_.U!K;CMR78,F?5RA _AF,W"\1
M[@U&7D<A/TH<9Y<Q_1F,O'XP\EI<V45 YR:*_E%(#$YSYP,-)J @!S8#\[)8
M)D()NJ#'$O93*^-@R+M6,/+!<7<=_>XTTC Z9WFL=6=HXC"MN&90FPS;G#/:
M!%H+]6>D86.%=XXT7$=;/=Z#3">SP;LJC45#0N,$US2OBA>9S)%<&$3KF%&E
M).Z$1]ZE S@]] 9=Z+MEJGSWUL=IQ6TN^!Y/.:]!7)*P"XPU#*[N/.A_@7C8
M-MI" \LZW$)\/6X)RW""-C'K /1^9YD&5,Q'-$SYD+72*O+E$+(#UN(=1D+_
M2EQ':CTK[S>2U/G%^240'D(*P@3:77PD2Z=&M/.DF/568':\)-_;8OS=FW>W
M3V\E^W$?@NMY*_T-OMP DF+R7AG.4@3:TSG/S-N<F 4I,PU1H>URL-=-@S??
M_ -J<&/!'4BPX&4MF-GX[<4D?:1/T8?.Z=?UCYJ%#'9YZ2X"!]<>_%+XH)<I
MZ""<"R+KF')P0@G$S(5*43@Y",(G"=PQ%239W%IS%F,4#,GN0AY<,8KO/WQ0
M)(LR9,^\J2A5[;@<2V+..:C\I1$V.13]@<,'+YGSYF(VG<$H#T>G[\9G9R_&
MD_K+ >?2 ,T&EB4@[>>.!)J]928Y:2%D%W6;'FQ-AG. _F^_G.Z[PEP/K&@5
M,MC/J!;55 <T BTM"55R,$P[5VHL&!FPU6B5!:UKT^FR]Y'\0 SOD6+M6+\!
M/PXI5G!EH<B_3\;3Z2!K89#3LJ*DJJ7QR&(D4\\QEY2 8K0KN8MSLW/*KQC+
MGZ0_ (X<4NC?Y9!(K(5,Z8M:)WN4GW_Y-)S,GW ]RH%5-4H%(U/.%+)J4V)0
M+S2L,;3/DOU+/S_$2?#@R/Z<$@?'GT,*!WSS72)(/4*_W.B*52)'@PQ+]?LC
M)W$GYQDO4G@5C2:7\! GQ*V1_#D!]LZ/ ZR\?D/&2T'OW^5$5?F72_GKZ(16
MTI/ :]'LZ"*+P3@&V7*:ZR'+=)#%U]<?Z@\T90[..V[!I@-T)#J.>*!M<%C;
M[CB/KK:3%PP*1"84C=@GP7DZK(RC_[^]*VMN(T?2[_M?$('[>-D('^W=WO"T
M.[H],X^,!)!P<T<F/23E&>^OWP0IV3)%BBQ6H4BQ_6#9IJ2J/#X F8D\NO'W
MC%;*2% ]S\KJA+.+2E<[9H+#]ZR"D1Y4A?QZMIGV0%M>R8P'!4*8&'B;X;LC
M\OAC6?5=5F?"VW/T_9]DWKN8 X^"":XR[2L<F5=%,\^E\EA$X>XBW:!>7/]8
M?HU/M?$P>=FQAJ>/=&^E]4*QI!(G?[?0ON-X8@@B%A0R2H^7N/2.Y._'(FN\
MR%K@[ (C&2]R7N,&;EY/E[4*;;VKQ.5J 6DU\4HZ-,(Q4XQG.DGRBHTBV#N,
M=>"'"^(\_=?[</6,ELYEQ">&PT@K R\>9BYVWI9^PZI<^OS5?+9F]19N:LL7
M.?'1(J_E^EE+.D*C]2SXK)G5"328.@PX-UL6X_+ZC!;+\&@=>+Q<:ZBUBDST
M8'G_*;J/93&QO$#@Q&TP4A/+TI"*?&$)Z+P7WNL0FY0[G8'7'ZOK^4#M H,3
M#S:4GXFSZ6PY37<C6I57/.;,O/>UN%+4VSYK6+!22!#%"GN163E[.?JQ4BX-
M-JUB \-L =\S)B8Z:0UT9)+57.>V8D 6) "3B7,%2I=HVGDR35CZL2(N#C@7
MW9Q(9&Z%B)G%7!OFR,(9."U900GH8P8Z INL@#]A<Z)>WOI9-'Z9S8E2-@:$
MLHQ+4Y.6//$BR$B#@LI&7J1133I.7UESHDY >+(Y41>%7-1%^1-M(([AZ4=S
MHN[-B3IA98P&+Z<H^MF 6"E(UFKFB@Q,6PL,N"&#!2+'7+A*>)Z!!Q<#WD[-
MB2X/NQWTVWQ2*I:4BH_,@HZUG",S"%BG-97L0G*2OGVH'/HR9N2<7U5/3DKM
M(.>]Y9%#%\_7@O#I:BV;4\K@'_[Z, 7M>PG:*DU'2)&;*#EWH'6RD<QP6N8Z
MI!B\%GZBLR1KG78YIX"L)!\C"\I[QFU44G.A"OB'-/<1W=HNZRO NX<,+L9=
MQ&T),V>>O94E>(=:61Z#M9BU$I!M<0DF06>0#DB$%E(=-^593!@8%FMC$E <
M5T,)LT=7AAU/&5R<Q_1-0+#2@Y E:L)F3B!S%%D*&:V3RLN)\5$[0X:[CT@'
MD@K  I>.6<5YJ(#V4?7LF_ 6ETO$MTA;W6M<IL7TTQWG=TZM%"6$&)!!<G7@
M)KD2H))FP6#2(F/BV*3([0!=?<VQS>/?D6-&F__LP_H]]7;@7;F_+I@H%Q7M
M @1F7L.BQ"^+17B60=OHR:/WLDDT_3!IXQ^90Z)DVW(:6!4-6@;LYG[C90=G
M><A)T2%=CVMO"@,PAB4Z5*+V2@K?)-GS"9K&"IFU!T5_D9\[PO5]@S/":\PU
M)(A86T46X"SZXNO%2PI 1P%/QZ0G/H\&C8.I<&?+Q2ZB;-BD[Q@RKK3E8B<-
M[.G6=XKX6FJ38Q1 OE<I@6!IM&0^F%QOHR0JF;V(Q\13+D.+1[5<'$2)':36
MM.4B@,40;"!?N4Z[=9R8L>0_!ZW0A(+1V&,NNYY3R\5.LM_;<K&+X)JV7!0"
MA"D:64 +M4Q!D.OC,Q,N DCAE'37UG+Q9 V>++C16BX^<(>_FO<WU1Y8TH]\
MFL_J-^9E_0G^NP;B<!BGON/+!O?]^S"['2(P1BC:A T@UQE]U*31$%6VNB8D
MP$1(K8.B'3L(E9A&)/B@#,P:,!9LY$G 4"&7+;Z6MY\^;<QDN(EP [.$RS\0
MZ0?*?/%Q'51MHL\.[VVMVE-%L*5E$9)*0"H-(6FL Q)E$H%KEYS).N6)5UPY
MGRV#G 6KJJ\]<2/#!)('I"/;\1&T_("M!=[ "O-JOOFIYHH^_.HQ==U1$%OJ
MML:J@MH$I9W.V8#*&;+FW(IB=8H30:<O6&^83;51BB2GV2=)]IGQUJ,*(J;8
M2-WEMI88?MR8!^N//FTN0-JH^/#K6JNU(\/;JK0AE"2YS"YIIR &+B%PE:)T
MS@N8())R;7",%,U)@:D.%[#D[G+I<]$V.66'4N6;Z:SN0$.NR)V/'%PEAPG?
M[C@<8W;**,UI?^3U)'0I8W#T'U5#3A.N.->TJ[)"'S!M'2>)"\U,@>+(ON)!
MER9B;[U^.KZLK:KZK1WN2^00BQ36:6F%-QB!K!L9A%5:B(GG,090R)P5EA:0
M(RO'6<^<T0:E3N!"[J7$O\-BW=/@%)U\_=UA1+R;E&W89YF!!*6TS]I&54<I
M*?">/(@B!%<3[K4T+AB6UYW7E>3,2V69@40;E3'1^32(Q$Z_RMQZPK#2.^(2
MD^#F?$G"6#I^/1?U^L!$4T1!KT1V$VL%MW0,,T*88KH(PZ)PA<7(#3H,2.P,
M(L,>&\+V(X:5XC&+-UC:06M!=A!<JU)]$>>M(#P&;[3E$VDTSREJ)H6DQ<N!
MSKSB)7.8282ECF&R/>\N7]W <OFNW)'];O%;+0#Z=O^ R9!GK3.+?CV829$B
M.;G7D1<=;)2QE"87>$^3U2LIY]<%_@47'W"QV89K3>&=SE[2S_SCU\7\\W3Y
M(+>=@+E<+:9I#8?YOW#Q*WU<+=@/6*_7OG;YG]#F6NCDS$R0\DA;)K'@>2;E
MT<9AT=)&G ^!LBF%X]]Y#HBN[Q)^+D*' T;Q>C/UWR38_5SYJ!QX8YG5Q3#M
MZ32K+A +)5A?M("\7</3 )E/DO@#FL-J<>A,QH<TO?@XOR6)S?X"BW_@:EWM
M\V:^>$/''1FR[^<_DY?_</K)N]E^D4R*5S('8J>.-V&:CC[FP2I&GH>69$Z8
MO-WW?Q\RVQ!X1;B\  TVJ 3>*:[O&LU\_>;R[KM+,>$ 6IB(M*^;NI2B8! *
M,%NB#ZBE5$&,9M8<HO8J,#B>OAJ4U]X3]&*6-Q0]* 2N:5837\CO5F0G&%_I
M2V0[>!ER+02.M5._T*;)E)Y#A%T5= ;50H.*TZ?HFX@BR<O#&HZN#1.<UK51
MO5V[<CRX:#UOTI#W*:+^-.CH)/W'R# ]S?IY0LS+-R2-.R+O][OEW07TYCR>
M:*%=$.B8,16U*I"[GS5G-090G-7Z4='F7C/]R%=>!0(:2ODQ%FPO++R:SS[C
MHC98^5K1OZZ26;XG?2[_F-_DWS9AX?>+Z8</-;/!.&.B(9L*'6>Z6 *NK_-@
M; Y1.F,CF*,@T?7-UX.,IC)_#! W*D VK12Y-T)*"8SP6W./P+(0N&>&W$5-
M/F*&?# <>OKK_[Q0Z2[]QWCQ/?'RU4O;IOF[X$%UZ6I<_Z^?YK/[??&;H;TN
MTGLW^PV7N-HTPMT\8B)#*-PHQY!CKCT\' -> C,D1^U30....Y':TGE-"+P8
M?3Z&:FCBK&\&V[PKOV.Z71#'N'P%-S>87W[9]@,G1= >;% P+8.GHQN 0<ID
M\X9$<M7<1]VD%U%/NJ\"GN?0X8XH9K\0^^'HPVM<D2LYG:WSDN[9>K^ ZD:\
MAB]+.B*64R(%\X3<2E.XY2Q;K9BV@K,(4K%BN79<:ZU4/&YS')"JJ\#:>76U
M W7]@N<[.2'B-OO[F_GB6R?Z;]1/0K8\2/)4O>>%Z62 14O_$D9BC@I-S/9T
M>!UZ_97C:%#I[P!,[[CV4^&,OY )6G.&<+;Z>?;I=C7Q6CF%-9=5:;) BXXL
MN!HM349P,D'1FB8=RKH0>16 :JZ='5 Z.7J]1O_]MD@X_XB+GSY^NIE_05S^
M?;KZX^L53B@0--80B(LDB1!,/9+KI!G!G7$64,!1.\T1+[L*&#21[ [5GQR2
M/GB KBM(;3(FE40,NWJA[ )G/G.RQUP(20E'-!^7L'+H3=>C]$%END/C)X>:
MGV1\4S L;5%))\FDK<Z?P\ \QMJ].9D4B\QTM(WF/8U:93^V.]1=WN>NL7^2
MG765JXI.\XB:'#5=6R$2Q G1M<NL=BFXG.!;9\[FZ#EG3?Y0&C\&2)TEWZ#K
MWD["[CIV'4-:RPZ03]!VGD:. VGQ&&ST4,'(* E*H(/H&1G!Y$LY*QEH5UC@
M/"@I;=9AO*WCC)T2QP='%\D/G3+X.RZF9 [?F<+W-=:6<U^"8D)GQ33QQ\@L
MXF0:@T$E0&E[W'WFKJ=?B)EYBNSG0PINZ,3D#4$OMRA* 8N1N3"NH 9R:[9-
M2()%,G.++$(DV465+Z]8EWU$UV99OMJBB-LL0B++A:Q=<ENX*@SJV-DD@M-9
MJY"WYX4_J<Q75ZS,/J(;, %V3=$F]O NW7[ V199 2(71D:6L[5,I\19C-XR
MHV0Q(EL ?5QF]?YW7(E:!Q)B@[S3[5#BUR[+0>JH$"U#VBOJR _"G'2>&?(P
M('D@032Y"-U'T)7Y8H/(O4&R^RZZ[M%_!&4M/;']I)W'$1M&A4?@HH?\&[AA
M3U$8K,F1%H0+0,M ",%"(3-20I$I94P8FI1RCHV, T[8Z,#H(/81 +&^./_;
M_ 96TYOIZLO=.8?!DDE*9Z?A-2DC<621J&2U[WKR*2?>9ES,4=2-;V8,I<X#
M*.FOBX$;R7WK:>B-2DZ1*2L5UW<75Z$VY8_&"I=)"?&8EKS/H\OJP%;$Z9(<
MT(3<;I%W#!E7VF2UDP;V].<\17P-FZSZ(ET2AC.?DJZM"J&VUG"L]DM2F8LL
MP[#+\^Q-5@=18@>I#=UD];M.DTHI'PW0%E_H]1J$K!4&@B'9&[2G<%Z.:HO_
MG%IT=I+]WA:=700WVF"7^W%S\_(BK::?Z22?E]4?N+]FND?3FI/?-4QWFV%8
MW6Z#8[*/0A<=/&KA;-!*:>4B6F6=TVKBR.(I9%]58TC5*7R*@4V%*=IO4P C
ME.L[PN,-3!?K.OB7FPZ4O]<.E/^UF-]^(F;NN(*;WU>P6IMOKV S_O3MM\&5
M((+*PK-DI:%=B==,'_KBI"G)6A6];6)!]R7\@B9Q_S:_N7DS7]1O3J+5"!@3
M"QIKA#Q9!L(A0U6P^*1X$+Z%.-NP,[X',RJ>&X[9/A43#2:8[/02'A89^T N
M@26O, 94M0[,DXEB').UX;#-1>HP7G[56<N\+P$ Q]R2GZJ]H>_D=A*W[L*2
M)]F+I#0*)I2!>JU!'J@EPS<8K^C05 GR<<FY3[SD3XV0034P] 7?DT4P1%HI
MV=3&]PBEEIZZR "R9-:CX28@:#RR/O/)]_S QX!Z:'!/>'!S$^0B1T$0]JK4
M>TQ)]&&,+ LI,2@A0ILAM]V.IH$8/]A-R"00$$$R7J]VM9;D13I(M+XY1P]*
M^-#$N'PFW9\N:.V-I^<!N[X\ML&_[++"-P'FB#RCI",%A28[&S+YMAHLJVE_
MH!.F L=,:^GA-^XG;JST_+,Z*X-KZ?)3^2$GX"8&)HI--6,I,>^JN)Q+.>HL
MDFD2J[BX5/[A=7]T4G\7'8R<KGT,:3^2^KMKL4/>]BDJ&!DEF#)P61LDQ1J4
M]5PS7U1F3@ (#^AS&,^DO,BD_E;@Z"+Y49+ZC0T@2DB,*T/>#]3!:8;^E;DV
M*4@G0CK."[W\I/Y.LC^8U-]%<.,D]=M0(QH&:V8Z\9=-9+%V0L<<DK(I<:^.
MZQ3^#)+Z>^JRC^C&2>H'8TJLR,JN-CTI$EE,R3.1,X%+1^U0=E#F12?U]U1F
M']'MC?FUNVBN?G79^-7S\CT<WTXAKM/)!KEE[O*BH:^83V9RZW[9"++<E?/&
M9J]- < 07;':T-]* QE2 I3(.C,P2M(V3 =U4*+07LP%>H4Q.M]VS$HLSD@3
M,RM6U?H_DQ@4%UBH3=2CA8R^20.7-F-6'KE7O^#J->GO,ZRFG_'%<HG?%'B7
M$[GN5I=N%PMRNU["<KK\ZVP>E[CX7%VP=;(D?7L^2_0[ZVC4P\"2L=8%Y3.S
MJ3IHV446?$Y,6I]CUEQ8W>3>;1SV+F2;/0VK>X,MEX.(!C?%?;BL[6,><;J<
M!"X+9E?[%2O!=!+D2R@'Y%6(Y!RJ$$R3$NKA63EC+L0%@6[ =3$ 8AJ$#@85
M^O)[J:_O96DC2A%51&0NDF56^6+D5=/9G8R3M"UY9R]N31S'VH\UTOKLZ(^H
M!N5]+3G<M '^>986M7_U:]S\/?$.0A+UOJ36+>L(Q'&QEIF2M!;6"YZ:#"X9
MG]4?:VKD-34 X@9,E=A4>C=D=S-=@CZKUO.T3#&_G__TSUMZXL0)RT4VFEFN
MD8YBZUA41=;(4"Q"HM/QN/CH>>C_L7*V8T;/ $<-YALU,%(=&,<S".:MY]5(
M+<Q'8C 7^LM+7XK(EW;\'./6#!0@VEQ .V,L\J!8@!I8=JDP4#PQXW0N1IE@
MV]BY%]^WL4\D8B!Y7WZRA\W>95>[EP1'?J"(GN1C/9-&H>/1HQ%-++R+2_88
M2N-'IWATD?S(E_?'D/8CQ:.[%CO<XI^B@I%1XE(0M,,6EI6HEV"U):[WR 2Y
MR1E0@L8F,PN?3XI'*W!TD7R;N^3MVVW0RFHE."N529UJ_T%TG@&@)N8E>'!'
M^3#/(#&@D_0/)P9T$=UH1<ODE\\_XGOX-YYT0_SPUX>Y]]U+T-9MKE,JIN"-
M4Q"U@P"A9"^RCB&##=Q,9'!9D0*9#"J25R<3"R75')L2#<182E8/:>XCNK7Y
MT%> =P\97(R[B-L2IL;$O2R"H[;:&A>ED2**$M!':[2= (AD$BT *=?1FMK<
MT'/'A )P3HE8HNLES&_7_:^QX(+\+:)][8@-4R:_]ZE#9RL<1_XVF,G/3<+&
MVN>7P*R#%K2[!%N2Q!"-FT3!O7"!1$^89IJG0):IU<QALEYF4I:*0X&YA[QW
M/&5P.!\C3V^QY&)UD$5I#<XG1$&N8%129)'#!")MN")JIDA\)-3"29[D05HK
M3!01#"FA9ZK'._))8#6=?7@[7RY?T5'PY2Z)Y4'!0K&T?((V3'E?$_\LLD"+
MBP7/C;(IVA2:.&5'T-;7H/P%5QNEU5=,P.=8(#H65&W8$7(-69'XG3.ER,!1
MV28!GN^H&-^Z&!H#V[;CZ4)ND.ZPG]E)J %]RSVS'#+3QCA&=!:R?V1(Q?K$
M>9/0U7Z2K@\+ XF_@6_YZ$C<3^HO\]7OM_%_,:W>S[_-8YN ="6OV^"5VO5)
M.<)X3)IYX"6&**WC38H,>E-^?3 ;5YD-;M<[,+"3>NY2]A(8>D'FF*SY-!EH
M:3D#8#"$()H4S?4C^T^-P[YJ;%"I7R^=-M=\-S?S?]6*PVU^7OU1RZQ_OKL'
MG#BPTI=4F!!U-A4=\[1HLJ0OQB<-&4R;RY^NA%X?T)JJJL'U+%'UBHB;KA[*
MXHXT[U. 0%NO+*[V?U""05":18B><T#G19,J\R=HNC[ #*6 !JT(_CI;8)I_
MF$W_;XW>ES@C>:^6$XTZ:LX-2T$29"T@JTXS$S9P+0WR[)OT!-]#S_5A8@C!
M/\:#;>>R;2Y$C2U2HLQDF^7:\D@7%F4"QI%LN&!"4:#&]=M&S3LXG\O67?R7
MDH'P-5+WXG;UQWPQ77W9%$'SVO;5J1J1$'74$;&2(V=227".!Q=-DY-G-SGG
MRCT85.'SP07?P/=_3-5]:X,CZ&J9>K"/L//D'0RAO(-XZ"'Y,9$14:>D,+&"
MY)_I; *#7!)1&I56V6NRHY\_(@[D&HP)B"X";P"$=4.G%[/\EG[RYG]N%]-E
MGJ8JX+M[\Y* @^7D0'E5,RQDJ8,P! MU?!X([^E_+?!P@*[QC=1A%+C=I'=
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M6*POO#!?UL-'C&0 5C/#,;MDM%5MKMC&1<.!N/E88.@B[*$K\WYZ:<BT_;"
MCR_GB\7\7]/9A_L:LR"$$=PXVO9(49IGQ3S9LF3?*,WI3Q%QRY784YZW_QWC
MVX3#*&$^O 0;N 9OY[,/*UQ\K#Q_'4F?H\WDJ0.S:RNH5B-ZFP5S*8;HP8>2
MF[0%W47,U9SWO27=(#=YFZ8[G!]#5<OS?C=9YSGM^ZOM  YZR+S!:;^'NN2<
M@-J7&AQM55K4ED4<74T44<&;H$4*SQT)!T[ZL8#01=1-  "SY:_PI>YW=T>4
MELD6!98EC+4N/3D&/ GRD5VQG!A5;2($CTD9WQ880DF/]-Y+P@V,@.VS[A[=
M2M>6! 3LD C3.M8V68%+YE$5;9Q,7C1)T]U#S]68 D/(NT&1R ZR[N!^#&$M
M#8*]E)W')AA$?X<QT4/X(P2/'VZ&Q7B+NHXZK$4&=9P,:%I:M&]99YV(ILE]
MTLBH.& ?C N*+C)O#X;[Y)V@$@3KF+,*R1J2F06H;8F*SCK&Y+5M4C:[DYJS
MWR6=JJVG,7""J+LV][G[N'Z)L,3__(__!U!+ P04    " !H@'M0_!IP+*4;
M 0#LK0$ %    &]C9VXM,C Q.3$R,S%?9S$N:G!G[+P)/%1_WS=^1)$PD25+
MID540F4K9)1L2;9*$5,A6TRRC0R39%^F"*68;$E"]MW8)2%[$;,@"9DIQF&V
MY_3[7<]SWU==]__^W??K^3^OZWZ>^YC#^)XYW^_G\WF_/]N9,\/YP"$!6T\;
MFA@"7%Q<P!7H!^"0 5L#M-MU # S PX  , ';.3F C9"S[B@_30W]Q]_?^Z
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MOTYVLIT%[SV0 [#Y8QD&;H2M.B<\4;2DCO?CX^ZI%NU2GYY_Z+_N=QZNH@?
MPYU^IT1GB#P'Z#*C:;(B5!#+F?,B_^>=..SZ/U%(<, Q=G" YM.-")!(KP'M
MLN;A$CK.+]RT"+&^==KC)D7G.GT$4BT+.EI1$\YR<$?DCM&7[!;D]R .L(D#
M+/A#"RV7'@#6B]G\!5 RX@/)5"AZ;Z8IMH9(@-F4GBUZ TM* [TM(^0+TGX>
MQI?#-YI?N(ZP1NK^KDHFE"-[L6_/-A[D *.L8O8#N]%W:O_E"/Z_7[SB4@Y
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M?/WQB)C5D3M%QK.B7+FT/6R^GJF^2-,I4Q7P;(CD5_8!JF$<QB" 7*!T5K_
M]/E+7DU3:4,QFR*Q1]NJ*F?>:>4M<%%4XCM)9R/)YC"T0JN-KA)5(&/?D/J]
M(2^>([:&4^\(0P)WHM)/6);N;$KT_J)EO@UJ5*PQBD7L<:2$[OY.,D+$*)=I
M2.69A)65!%[1U/!I*+>(SME5^>B'Y%$K.Q[OL6>@(]0IV+QG[R!B%*M2F]<[
M<J$A,L0]P7IK#_J+S"=6$==R\RJ\TW,\2;JJ3[U'[N@$(ZZE:_R8\LL+6PA1
MQ^P:.EA4'CD"BWI&J/%4%C4\<$6A:])EZJ9>GF+O;6ZH;B@M9FX[0B17+3YB
MP\!L9S)!!AU@!_J]0)>=:'A=_7@!U6\1J)K)^A3S]N/:1:'L(@\<ZPG!$Z(E
MOA2+8SK"[]9OHUF;40FQ]8?25.C%](E,FN%C7SE_C]A _T!+1<4#5\]B_:4S
MDB<N0\H[8@[GL]\[P&BYG6%,AQ&V).B#);E=?6(5\_W;YTOXU0 E[?M.:X#R
M.VX)N= 8@,FNO$;_TIEO8:;[A#_0XB4'\+V6KK<Q>!YR>6CO6D)GL]O,]#F
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MET CLZ%ZW4&,+@IFG@FULE6+HB&B$5.J]J^^&WTO,6ZV_JX*?\A5/?H.RTM
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M:O-P.,%UT5"[6+:39M=>VLK.]Y.6KMD=RWK3PH,$^6,HV-^ .2.8O2%F_E?
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M[@ES'P>(],-@.$"6)DT:LE$2-AQ ]X@M$*G?BG'X94/V'BB<H:C9__^*Y5#
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MWRKD=4H)U8,+$*..84G%Q/(P 5S,[0>RV6=+.,"4^I(L%]4PD^'$_B#EE5H
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MR[-B_UC;U!#'6:%QQ1N+3$<>W!W-:S;29YK[(F;^+.EYP/KJZ<52#X"%J_G
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M7V!1%Z2Z4K;4% \$8IBIVF\^RPV,U]JO%-AK!-[Q4>:UCL)KR:P8B0TTG:Z
MN&A[:\XJ$ARA/=/#*V'*G$[IJKG0H+G:M#XA#I9+?5S(+SOJ6,S3)PT[O^9=
MN#O^,L[(S52O^W*=>]XE_!.5%*W\_$FA=]-I3B7IRYX;4S#TIQJ0@.9JI)6
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MZF3B9M$ZO?$XIPC T2D0RSG2<:!E"</N=56T,S/:*IX"TRT(L@AJ]Y6<W#3
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M(HKB/EF>W%]*]7^")3OK1V(F4A"*X.W&U_=__H6NU4OZ_5 "/D< :+U =F5
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M5PTS#BJ:USUU,TU#8G$]9F'*:Y<DW5HC<ET&C);&H7]"(5Y0_"U#?R26W-[
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M7&Y*!AU2,G@I@]&:3UM9XLW9$' ^@38:0V:20A&9_[3U :!M<BC=S91*J4&
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M&_(^ALB_CI<.)-W/R'B9(A=!^!:+5GUOZ5F^*?+LHN^II_?/M;]HOR"X\JB
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M/O[=6D13/JOG=5R$C_=I&WT!H8'%=%Q-VAN>)Q?13:+3<6JYI+GHX<NGA<2
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M$G'AINJI)L1:4]CUOB$-:?VRV/NEZA87ZX8$M$T.3[1KO&DO/!!^Z%8I.;Q
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M:1+WE/Z#2^:-<[$D,M(1RH[Z3:K0WZ6<16G=O<?@JJWEGX9^;Y$*Z#V%C^V
M^)UV.UJ#XHVJA 1C<-\@K-#9!&([%3CHB/2W0L ),L2L";*1O#QR_T)9A#"I
MM/_$CA#+3G$M[<\H>!'(VV_2Q3##2,U_RB%#@+<NPT-Z[3!.EW=GP,(^=@N2
M"*$%6XPDN+2(Y L@?#6F=SHRK R#3RSV7?CA0/G"O9&?I<1-XL;EU]=<,$+
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M=8(_/\+3E3\W/\#N/.EP7'^L^X676OW)_>+?!X59W8HDGH>T!UVY\F*_^]#
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MOMI8X?!'LKK[_^(FVO>?_C8H;FIA^H8(8*(O'H"(HIQHVN[$ X:X62IH^0"
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MMO1+V9QIV ?(<T^H6_>ZP%%<7&>C_X7GRL5,+V0HJ'[]]YAWW@#&7E8Q1F
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M&6)G3R]8.7/J,68X,BF\J!L#2Q^\:9,6_%C3PM^MFK(7C'([X(%F'7"3U*G
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MF9:(/%CUT#ZKO-Z9BKVXKI#LMF?-G =$@DX$7A,S\IG[>([?BY$[<P\10C@
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MGF#*_@,;A3)6$095SX]NODPDIY[@8AF^]X"]YS";Z<JH)/,,1:(-K-,EEEW
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M%01"D%ZN04BR&M5+6P(D7F#"9MI1),((EF$!0ZMG"?)4$(/>$,G$$ZC&& _
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M+U8U+G+0E;W[0Q0&V[1$BX3O96?%/HQ8[+-9LQ@A&Y<6KFJ)>QR[%WTO7!-
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M\1M)\BL30!O?'(?E4&T]3@.^$)/$O0,6/9?#["K6K3:>FP!2U@UPRQR/:-+
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M%-2,3 QT3+1T]'1_&B$B(=Q#2G:%C.P*'>552KK_VP?^&T!SF3B<S)Z$Z!9
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M2IZ1>E;Z\-^XMH9\,DRW?OM-Q=*]>^R^:XT: $].Q'^2U+VJ4M%[AGH)/UR
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MB\"QV!ENI#'XD-YYX:C#](A 4A/)+JIJ=_# 3WX=/##\./^SI@GXMJ@SJ63
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MJQDEOFF FA/.0%NE4L2+Y("YZ)R!:/7.0(55"[BKP%H:]MCL+%CLT_4[[KY
MVOA2@G%C%(*>@-&"GW0#\''6,.QW>^3?FQM.UFGM['[QI,.*C_K2;LHD>*T5
M@(-W*SZ:3&6?BFD)=@NWM J5O;HGDYY2%/':AK4"#J'O)(LMY32U.-%7,)6M
M)5'R>0_&,VAA@Z)NYVNAIXZ(DVQGH,$;4!QO,HHR9[FU-8"X0GH&"LWZ(6V$
M674?%+G;?51 =EO ZCG_?&,3!*VF-<U9-XD#V ;Y[VHY0 ED&C"CWN00./H-
M!!<F_=3YVPI6U5E5:7TZR_NI3)S^Q"02O2DRS4Z$P63/0 %^9Z V78 E0[ !
MYGW1(>^/QOW )^>9:0U@=E@F'N=R\X-\S5=%KZ**.WS:9%;>R5YR.5QAPCY!
MXAD,L:'5_3,BM)>\.9];G('N%; 0*<1/'X3, I2,UN="&="[5U .3*ON:>WY
MY$W-_9Q^Q32"'0K8FOZ:Q$& 3=Y>H+48W!8 !J!'#BAA!?T*,N7+<8S<$@.:
M*BA.E&-</2(*+W+*!*]+BMO^F''G&^>\[8DHGR%2L&-P!R,-,L@C-C!>B91(
MP8DA&))JH7<G3E_",8S%]53)7;BM9;OX"U@2E8G47&SWZ'-9DAT[E!%D,0Y>
MP3CC,;5!R_+-3A'0V>^WF.J^@V#A.:G6\.B3"#KBM: -BK?@RRFYB<%&[Q&C
M=*']@,TU,\,XFA+-KR/D 2.[?MUS'2_CB'U'&BG0^AP@J.^;SD#+ EN0:?9%
M:*0<8!MDY4.-G&;6^[:-@B/"0KK>0DQ7T!D':_$"Y<Y- N<>W\W3/8!<74*Z
MV?_0U;)B$C2.>*7$T-;SB4(O_O"W\VH)PGWPPDMCK(@4PG!<F V."B-AY=B*
M8+88.658_VT07>GZ+NAB/0<NF"TDZ,/*M6PC"_=86-MYF?V)64-U7S*\UHP?
M>J4]8//S[Q>XC LX;>3E,]!&&J[L##3[AXC<WC5AQ;2W5R/R^ S)''HRA@,$
M3>EOQ2YP*KE:+(JT$3/0I7)&P&+)9A"O)< NX#[AH;1_+XC27A45X@[;-+E<
M6+;!>OB%+$9X<==? %!F$ 6&=_\,1+G>W@/?H0 LLPW89914RX90G&&C(*!(
MIHDS$+U&\H]T+?%DNP\LY.XK&S>-]^;**\2(3,/PEA!<&ETO>KL]F[B8#,$K
MR?N2X+4<C_,;!<%'9'6 EF_N9=726J#<9SP%V6>=M(*Q ^0_7@U4NMJCR9>=
MST!]\AAS"/:/FC>@[\Y EPT1K7"FZ@G%/]HZ?W;F^6"W[<1'<AW^/>Q37H7U
MV+AYVEZ.X<.%<T2^KXLP28QN^JJU!Q2O=!MV'I<1I<#I678*?_'[53*C<\C5
M[84RO0?PUXY!?-**ZT\<Q+L(;96S\&9#5KH9<>@AL6?D#'3PQ(+8@KR(=_KL
M"RPDU>ZA" @7K_:M>C0E_WO]<.FU8,D]7K97+T'4L:-'B%*D QV.W[$-.2V"
M#1R3<USZ.'>!AF^M8WR*F;BE^I.&P]N$6UE9?%>I.$Q]J/Q8QDGS%=5XXUXE
ML IR>/-MA:(EP*65^P .?%K_&+(8#6:A==]J9..IVIZ"X\8T\1&'.S"ZM>B6
MY& >IB,->#,G4=)!U@U":4%$_CP#K4C* .O!112_Y4?(7C*;1SHFGX$BG\#"
MCL'D+E$)<ZURJ:=5CCB>@8X^)%_!DOAA8P(<=>O+ EH%&O46@A%%1Q.I^0 Q
M$N.YO ,A*?$V[=?*6-<:%X$F^9V*([KHT#-03<0"_M4'^&(4A),.W]8 A+(
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M@^[GX]0QP\1NKL,,T8$?  1!US5>P^("EA%XSM_UH#@S*'T(-)3K%A"%Y@#
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M-!QUXY)%V@%>X# <*T\!&#$"Y\_+%KWCRSTKWU#=Y_OX%Z<HM!C\E;&$',^
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M*"V+C7LW*2L(C,F5V1FJ2?0(X-*_X]QP,K9ELWNI^052*E'4<*[2.9\\JK8
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MZ2F>$9O9><G$EG[9"2IIC%DV&JIX4.%98==:?*5%O43!F7[OMC%/*EQCLUX
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M->N'T E\PFD5U4O[1>9<+,\A-VY\DP3"RSBVL"J20,'P)1'\&4"-+D$QSNN
M&#=R3Y,N@H#HHJ5&CU4VW?=-:LG.P8DW/(G(BEXE@8(JF"KD.:"EMIHURE_S
M'V69!W,N'*XE["^]0OH=-<OC-(]:M+HM3/IB8YB6N5\A-6&+O68T@%#@2Q \
M^2D='8PS,B@*^H'(10(UR7HK("CW)4IHR#6>K,?I^@WTSBJW)=XME*C*,M$L
M-5=UD*LP"R![&ZXK,7_%Q)IH-\40YL'JN_.E]O*B^N8GKW;_KZ?E,O#L)) *
MI V&H7 \S4PH@)&IQ>N@P42RZ5'<33L6/R.Y^H1G$%$'O&6!K?XU7;.Y;L^Q
MQ^^_T*7-&5U^J[3P$M&*ICU6_VQB/7V0IE3E5?M.K&KJ)O4(XP#Y!!DT&XI:
MU3G/@:3#JY-  0D'TOBK^LWV))"D-$#PXCF=;Q^'IJZ@7&=C-3I7LZ:RJAAI
M9QZNV:S*IAM>%#384^=I,![V-<S;E'XR,V4FQQ@CP&7"1U@6H&*8'3_KCAA>
M ^;+B^&KQ6NC>8AGE  2EW50JL[^-S'O2:#I[ ;H=QU56Q0Z9C7F)[XV!5J3
MXN5% GEQ.5HQ4>F,%^O>C38(8T:Z&WL]F:';.D2,BF"<0P/O FO7@Z8 V!^"
MM<;) ;9%1:"-G#A3O%E@;1MH#([7M>TR_!#'^Z(G?YD>AZ#5].\:GNUU_E7W
MM*O]/4?J^*]$O RD&7+PI!Z09H#4 1AS(RHP"C\R<"7J^'5Q.^15V)%HPT#/
MM5$NA^P/6/TMBNV/TFDDT-FOF+"%*]2A[[U)H'&>G-,"&7*, &W9-BBP,%!-
M/(00M>//X-^CP(L1S? ,\3D8+9:\\')4DE=1M&%(;#7^;C!/E:2ME&0XO>G
M>E@808@$"N7$]!+#W(,!*9T@,060Q2X%P 9_3<N +30Z$OGS1O!#7T]U[#\?
M1V&<:<*1&[G64(Q("@D4]D78W^8Q-!N)6@$SPP:U?R)1IW?@&-3P,A0=T /=
M<A$\(_"6MS]BA$CD(8;F_]([D\@6M"R"Y9MB)%("R[641PE/?JJ_Z?B7WJ<5
M1)30B03Z'<!(GMN'H9^>&^CC%SBH^FOWOW%U9GTMG@%K_+?^L-9/OI:G KP'
M^"??>;P>F<N^1F,OH0"VT@88)< U'8\A#[(%)I!_X;^!]>@M(;1\UFX!UCP?
M;%35X7@>8VZ,$FK8G8+JI;V4%G#A=;6(2!5[6QZ>7GX!'_ZU$7 ]H<\WH ?.
M<&H2",4'.4T=O\U.28S47402S_&<YD[W4+CRCW8OK"%_:4?Q[^V$?:^K^,T#
MS#3_A&VL*K"20 M/8.@IR.+$748"6VXK#'])ARBK:()1+'50[_[:B *&A&Y8
MY>[PH!8 E>\Y3>P.Q;@= >&>VDW4.@ET1I\$BARJ+HD*RM>\AJ@# K()%F D
M^#]'>@!;^.Q]Z9"0K< :A?,&'CS\8Z:_@6%?6H,/G)'42)30/R:J14Z,U%^L
M(I[+/9THS3MK1!UR<:*6@L!6U>J(I]0YS3$ORPA8Q<P$#/"&O[4YS59/O@Z;
MZ"1J]P(.)_R/<U]3R(5BY)X7=OT?I=KIS(I1TD<74)TM.N%F5.CL\1T&U"_B
MM-*H_2&ST,N&"#.]B%:&L[T!VK+CM<0)"$J[&F(K$C[LJU*%*<SR].[5'=YY
M,C=EK*1P\ #%;7BV@-DX\ +]!;Q-NXQY-V((AG'1@ VZ "IK L$01/ RQ9"-
MF@TH1AB,]W\+3BZJEOB,&$+^1R,>O$SV?S4*@$AB!SN]"?R /"00=S"K@(Y4
MP]!8'8R+$>"__NP$\K?=@6I(A1'X@':2:H#6#0 O?_,;$FCY -::O QHU^87
M8"E/NX+P8TV941K_:-H)-!W^'YI.F)AG"SP?WX3@94H@6.%DX"T NH"S_M7W
M5+D]3_N2G92N(HI9]8>0@!5<[+/Y\\\_!XXE?DP_?646@579.$4#@>* ?Q[>
M@AP)S@!^"R, !&L?MAF78!^UQ2"5PAC(X>36D?@1.R'@)2&>>-L44X37&JHW
M&#<RJ76>,)IZ#Q=$-^)/BE,O###MFDDO(3!<SIX?VUDZ"OS%-RO7L$=V".Y-
MSKAY+JD90F:J%3T5?F ([U%L3609E8/8> YNWHW6=7$,4+[B?.%@@S\AR,W+
MO-!H9C.\-^\^;MFR\ZP' U87> N>11$_ODHYO9MR6C"*!G.CWJX+,YT#>-KG
MT< 3!K9"8Z$?#?&2?;T,NX[KPV;K:SD-^= MH^+VW]FRIF8_IK/B^S797N93
MZ-R,RS&)#AG0,2+< 80G<+I&55JGE<)/:QU!%GN T';P]3 ,]0AR<B/?4.#&
M,@/]UX3W^)DJ= C";C$%0:,"$[,>?U*T;YA_PCZ>"1[>*Y"J+9X-EQ8UGNFE
M\N!;[2^M.:/2_V8N4Q)K_K>9PUKC,X&5G03L^L(7V)Z*L$'AQDWM2T?&6_N0
MVQN(X0&,<Q'LP%AB'D]/0WP V,Q",.%:'V!FSY&?UJR*H/DAKJ$$XNC,]D\[
M==GF_SX6&+5J *Q@I0T2PPO&1RN"/T=P29&]O!=.E1X7CP4<WF6]O\[E/_J#
M_%\,0G/AJ%7K?QL%L.[/(%BA9$?BI=,*38\H^KVU88L3WFN0C=S3\W3D^CTI
MT]4$@:-G8,PM_DWX]_C=EAI_WHDL?7_^CVT")0IIE:*5,ZTKV^+..J;3=>8,
M@&*CUJ9% !V&$"D!QQ;#RXWO?0:9[<(^_>CT;57Y^N%YY$/(8E\"],!4 H9G
M0/RSK)3]]],W A#>0C'LY,9;<%*?QZW9=(L4\4]UD>);82Q[KQ1#U/AE**N7
MD)H#^*LE@&WO<QT$B#U#XJ-/ P*;TC\'* 4&2'AKOG]/MCN#LU,@\_*O-A;G
M>>WZ#R:PIL*#,B+;P M *\8!I-/\D@0Z%>R:#Q@K7*OVSPG_%(SJIX32VX[=
M+K]BRWA5<46\K<1=E/TB.[5!;$?MR-@F^2^QSUQGN:$M25MOIR6Q@ >^;'5*
M?2L+]@?Q*(R+?!2!T10,K.O'4_65*]VVVLZO\F X!J?RM$TE3K8CIRWWR&97
M+;8'2NZ^2LKW#'TRZOZQ<#)7C^GIJQ/]C;N7"-<!]16? +35_91+@W]R^0>=
MG3^YA/-OZY<%[YKO/YS3_G$Q?B*OJ;M?0-7QFIWTM4)[X4*OF[4!7Z^EA8'N
M4M>T^T?"6I.V81MUP/)C!*%_:-\ H" JTVI_"D*6I_J.ZC/[U_YV,)N9';W]
ME2F9#L]<K<(YK:L1Z^XZO]?#"+?^-JO36/*?3_:!U[7]]#T3#%LUC1JE":G'
MRZ 0_[ACJ*]NR'%U>'E(CB_30-DUL73*L-6A2G3Y==T5X<5 SSN'Q=[F_UX%
M74&-4 .QA%S!6X2L=Z1?P;Q+/S_VVE?&+=,L^U?!Y.Q$W8<DB\_[H'/.)N1-
M[*)FHCAA_,-17S>T>6LZVS )]-H:_QSK6EH.8%5*H:^VM]L@7E32EPOK7^C\
M0$J==X+:^@_-4XD0)7S/H0<")>K:OXU4%(MI&MNL<'/&!A:T.3.\G_+[/-[=
MR(:!H1V7:<(;KV[<76]J "\*QZ-P^I6C(KY:CGYG<YP<WE'Z2(8[7.3K6%!G
MZM!A"_##G5Y3 H10I;]#OBP"P"3:1K"G3HN_,!*E%7\$S[--[BC,];3"N3\-
MDP^\OF+/+>S[HU*1/'9"?PA*YJLXQX^17]0RQ+^@B)K[W6VIP%U9;GP?R0V'
M=[.IPMXA'CT-ZG.:9R=>P6N@$S^4-\ 6.]NR4<%MS^@V$VN?Y5LXNN+>KZSW
M7PTU+;N^,1,40,,\8(R#X%D!D5CM!A%94)>3/*0R[#*;!E.ZF_33U=QCU#C]
M9NI*R;\UK07(7SK-0Y1^:B[^<O00.LB#IZ<D/AQ80A(":8CA&D3W#?+-W?^+
M/01\Z/]Y.T+BS^V(+S1?)?^:I1/WSRR=ZJ=9.L<;;.%[5$!04R)" GU)1D$Q
M/,?XI/E6$2PJ%H#@-[_09/P+-:[M.!*?L"XZXFX=SV.=0AJC$2D5R),'CL'(
M[91YV&8'R^D^@ /A$VS%C? 5N9T)4-T4JOCC(%\79.\N<1!Z]+@$0+<)4P$*
MT7]>'D2D(.T0)V"DE0B.UQT(*57<H _&^^8KQO%1\V6)A#A9&.%&[1_;%W\[
MY2>PR7]2=5J1)S:&\!D0*:0 (%BI <)J_&MOQ.LT$S<@HU2\)@F$N ,Y*&#!
MLOQW3T''L])$I3'D83?L$R(=LO %N?<:&T4(E8 0[AKK_SRM/5L,VP)H78?*
MP9J58"N3AV#<96L8UK7R"TWFI@V?];^*3*S33!P35:%3E,2>9QF 31':&FN4
MAG4SHH%@[2,VE!BK;J:)XR"!NGIQ2K!)C1'8@4J#]WC'[LD-H@()5 I[1 (-
MV?"2)YX*<I1("YLHSH5MWM4O&8\^%:,M"701LOUL&'F0)C!N_7^N:@'[2ZJ=
MH0"(-\P*<G+7$+D=X^E( JD.0*'C7> R.#Y-</Y(70YPE9E6",0&^=KN.\!D
M^8+!D&WJQ0$"@],?"W(1L#X8!078!&LK',N_U!C]/Q?[K*<XPM2F=Q[)8O+E
MRX>,!SAB--3I&"P57CI?6-%'Z@_\Y5HLP 21!'HWW08]N&V+Q+"+_ &/;LT!
M&#TC2 \ ZILP3$'7U62/>"5I2=BB%!I,H&)!$"DT_P%\+E8!:'7C^2@,=1=*
MY/]>7Z:^2K"F3)Y'I7A&$4.H@0">//L?T <@ ?LO$H:L%S)[)<[UP3!:]8"M
M5CX/Z-7;(0 !/(6UV"]!L$R24/SE1 "#%<6R2SOP4J: _]<1P2(/7317<3\9
M)9'_VS3ED-YRM6?6D'_E$_*?'9\IM"9#!7_*)O<M.U[=@: ?V39 UK'  $A_
MR;I>8,2%]'%&.R?^69J0QN=I)A^ >.=54)V'R7KJ^/[\#7S$ 6)#P(P$BG,S
MA4T"*&W&DEQMH0"OB%8'Z(6E&/9#-KA.T2A BI*\'7(@;J=,7!*'H?7Z,U@I
M2OA<E'A4@)D#36$;K\9@*/-_(%=!&GK GO05 =0[ ,17L[JENML?<)<&8\ !
MA.49*8: YPL'(",8]4T."$.53Q-7!#$#8'.]F;[ \PN WDY;+A/Y[0$3=AX@
M]Q2)@F,RB2%__M8;L-JZE_J30OD?Q"'_1?R!/Z<GT-#4[I\-W];1IT2 7"$
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MB[@,$.YJ0N7P*OJ0J_7/? 'T^:EA'0T^^7UX((VG,]7!2WD$B&_Z  X_9GP
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MV^E>O')[=D+6I%#^#O)#<$)I8,VF67LY<;VZ8)E_$CH@(?Q;Q^$D]T4BI57
M&[[IMZ_)GSH;*F91]::*GD_D+;+MR,N\^=T&;DT6Q7EIP!!>N02[JQ==T[5
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M)]9Z>>@2]#&V&2>#!6M.>8D@J,SQX(;&\3<G"^[;5U<Q,@M2+KO779/>K%,
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M)8?IHDZV3&C9G*F%KJT[AI(C7KC[PHC*?!"!2GAS,D@.-#W45L]+0TB!7G2
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M]FZ8\88@ DZM2 #.XR_P"2G0N3.+0,;><_[\C-@V7V/GGU6;0;<UVHO;!NA
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M-4?.)MCCHU>+0O@&Y[RAY*OO6JGP&XB 6E4(D69?B$>O0_\?,#94T+F2<QO
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MEU?XBP9N1U?TA#J:)J5Q?AJ=?>Q*6U,UV[KSLFVK();KW2 X46NV*'0_)S[
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M!O7"HT6.*RB<%@>WU]#N/@L%MADY\&C*'%V15F[BRP-E7G4&KWZ034W,]V?
MSY:7"6Q>6CTT3(SXX!']+7LN/:YU<P3OO,QQ@F GSF2RH4)#;,=@-QR_N@9D
MT_$((Y,"[^X%K-6E/+._>FF=]?OF=4JG4T?R*)5BV9?-LJXN8@?)^/!.X4_O
M.A5N"P?F;1@ORN(@TD%L[B$T,=.OT-:I$R9+D=!'75)AW2H#!N:C07NQ=BM
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M(N_S:W]8S>X@Y!J6; 1_=2N@OCX<GU>Y<S&!32^JKG0:%5C88=1]:^N9RPL
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M&13W1=(JVI(?Y1ZF8+U\O.S.AG:3-RNK$!69O&!VK7S:*E906I;TP]C\M4;
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M8[Y?;9>7GT'GQ3MG5^^O<SL"UIP"]\\?#G8<8(K'1=EWCSLUD&>P91 -9((
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M)  )3TE7]/O"=XW51H4R-&*K%>5-]NVQ_#G3-/@ K#QQ\$1BL#H.[?B*>TL
M-F&=<"P(A%=4EO1"B<F&;OHJ>.@+H?1"\R)=3F&S! !M!*X"84_1O@0@[)@
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MQZ#RB_8HO-[1UXWJ=&V,^JO20BD!$"F$5$,[C2$_H"?:^U!D8@+6$8PH [^
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MF_1MS5PZO. 5?GM,DA)B]K4"Y4OLHI.TPP5Z\$\7N'<7/ZV>5HXG5>3/]EE
M''&]'8OW1X/N%DEHYNWJ[^QI#/7,]^3B)?MP611!^0GFL29;,*S0$IHGA$F)
MSE/QY+LR =@;_X&RP9/-5R0B[I'B?P1$$@!Z(Q:QZ/J#-WH_AC[)FL^W+F&O
M)(1AI8EJP7&>7[[@*9&2Q2H#)A:K(E?\Q#N_23!*6?+J6.)UX8[N3+B97L]
MDVFB.?N+CXH' ;A>MCJ&$2%66OD*1S;"E[-OK_GI_0T1]5V5 $27KT=F%N1(
MQINF!3LE&TZ8J;W1AJ8AI2/W[TS 4A8Z>EG9W.:O@<4M?&,4_G)!*K.>Q%T#
M2RNQ]95X"=[L[A"%J1D=E#L1%EP0'P^BR(EH3>W^1AUL(<X$)+L";WN@XS\B
M/7GF+Y4C&6DB4J9?;E<FT_W& F*?^?=;]C=+E)H873^MHSE#Z+Y1*.95ONL=
M^,@\1^9)'RRJ[:Y6V(I&C-@O G G9DB< .@LPBT)P"MX5$[U<)22E$.*%9G$
MM6K4?*(Y*U]<W)J*X<,>JW35NE?2WI7N76#D4_<95BW4M:^OH,A135A%96'$
MBBY:33#C3?2:N&W;DT<\][[QC;TV=MO,B^CL?V?^2EJ@97?L)S9\'KYDA=G2
M9[X!92$ 2P_@?[7DRE+U$HZ6#(S\6$/$<HL 1,9 >J$GC[F)VD6+.,"8"A?O
MHYR/V2_?+,+__"X\IBTZ)0!MX9!Z:&<WW 9^<8]HE>\2S70W43/1,.#BB0KL
MLR91$243;26C6M@G[*=C6LSN>;0>IWVD.4[M?UNO[[_72]50GEF$9VEO\ECL
MGD_M@K *9F=$NO+%A@=_R]@*:P%"HMRG#_'O8W/0FL^AJ#?/S(O75G[&$0 A
M.HC$Z4?)7<ZD4]@D".W7N$?D80][=+'<Y7#T-]W_M<"8VN#HO:TZ>)?QF*[E
M _27&G;WU!?/(8KA@(Z(_C7X B)XX02T7^^>/[%6O]6_:@EV_X3HD3X9%=G@
M6WSSJ("9$:QG509%HA*FC_'O/\'_-22BJ 3 9H@ 4+[Z#YJ%+]:4W-#'_# L
MK<B9GUL9KJ7D#0$(V&D3,SMY*;LE.@@9P[Y&5V# ?BUGLLCAK@5G1,$B%]J+
MXPNC]N\O(8(%H28ICYYW.7+FKH$A7MGUJ&&L1/&>!0%0GRJ%+NL3@",UJML>
M&IU@%Y+:I!Q]!^GKGD!?;T4PL6\J 0Q1X8W4[^2@Z>#8Q+\<A@_#*(*=LRP!
M[V]#SSEC[GA6;G8X2_S\\2&Y5PLZ6[C+Q4P-CII:($ZSG&JH+MINT(  7")B
M\I$/BB@ OR0N-ZF94GM\VQ2QB/>W8$*XTD*R3(=T"5U9<-WEWE/8-S@B'_X2
M#T<.!A3CK\(( +<^:%;U3 1T[/J? CV'2$'=\+;99ZBC"I&,H>O@K. AJ"-H
MNA4Z^)^1*N,*_]/7OT5D4.EOR:'\)778JLT2=O=[V>%57 '<YAH!R'"= ".%
MB+(DH(EM=!9CQ>V^$H 0HJQ]= X,&AULUWYNZU-$D%][0JJ%*<.S:)^)$(!\
MEW]7^@ 9!54'0@<;G/[5L7K(JWFTM1NE@^;CZJWQZH5/YF+OR4[I_VA@)7SW
MK(F8SY3:_$MX/C 1#QN:"ZE_$/JGQ$'8:!['@PNG/B2J+81L#WA%C0:4%?C=
M'[ZW5.;G;(F^N>RJ\6-6 .W;\2? 7-QQUC"NN<+:.OF!IZ=ZL$Z FH,+G9X:
M\)]'U7\3%P^MV9-6,O.WM%]82DA5FND.8D;1(C1Z JD@P]W%/^" #4JHYYTM
MBA[_G2Z7,=Z?0_.&-,=3XZ@T)K<^69GNX&.K;'AC:OLAN]^OE=.)P?"*=+19
M#XMZ!J(9JQM<WFW/$.;*OJKK%\<6VX)=K@:E<N]Q?0>")3&W%]$P/;3Q'TM>
MXOH$RAMKI+*)<V?.Y_,9QB3S9 D.\=@2F!?86)J.1+@5(J<ZVN12W&E^(*@H
MS%"2W?A(!,;Y?[#VWG%-/=O:^*8H*@(6$) 2%!05I?<6%.D"T@1I01!I @+2
M2^A(;P(*TJ2#$! 0J:$C(+UW @C2$TH(I/V"Y]SS?N\YYW[NO>_[^V,',MDS
M>\V:F;6>9V;/FJ0,*:,;K&]R U)^L=N\ZPW HR J3ZD>H.2[AGSXD.R52^%5
MZ3HF)I(@?INZ!R7&<[,5-_0XHURYX@?D!#7)&X24\?4-,HX(OO#4V*@&[C(/
M3F,,E*%J&A:V>U'_:MUL %KK:F<'<RX7[_!#ROU-TR%49+L?+S*V+=W" "D6
MFHV"AM\?LJP9>E6+!4_[OVC40_J9U;]C^]'EA=NOPV=(^Z)8FN$@EA9V ,48
M+,U71C+%=I+N80VF/74QV24S_8DF#%9N;Z**>[)G;&ZY+<<!LK,8:JRR/"K'
M "46YLIWP7;^#"HVS&_@%CKDB[2V,L=W=>236!8&2S-:[T!^NRF>7YI3D0HH
MI6BH-22<9-Y<,\_9R5(-'::+J0U5;8NU7WK'9VGWUD(XFHG;-O2&;D9.ZDG9
M_S[F]W]W[>].LQ"40>TP[+5J/ORMA,:S#5AT**FKGD'Q$#I*26-$Y646W:IY
MTQP)-,F21LPBR7J94>^N,?@H_+?$'W8!$X:JAR!AVR^0!8CJ3Z(/LCQRU$=W
M=O.21<4NH']?%V Y"UP\_ $.<7D&KB[ <8*OP:VI02S==@4>($2[H>Z0J>%T
M[ZW.F<(:B;B[)"0K\52TL#F++K\0EEE*!!P<0Z[WIRW5OI4QW7\&'Q2VFJ#-
M$.XMS&VH-J7\AOW,;GN-PU&NV4J&3*0')T,2/\Q'9ESVJ@=WAQ^_V/SU49SF
M6H=COGS>O+%C!L>7H=;'S]/".<G>O_@0)T$)T!7_AM&.$P%[OF _%M2MIK B
M3(PWSX21A?/P>LU--IDR@+_+G2_EZ]0D__&M>XJ>Y+F8).PKG]L8M65J&(U'
M2KN.X8;H(PKHK:8T%R='L]M=2>CPG.B$!U-,LTJ& 'J:9XWN/&':E!T%VF9;
MAH>F7--93W4,%<;L$(&:@L 7%W,5]S3V).3B'Q?FV%6::Z@FFD#:8-/["/T.
MGNU'$_(H 9776Q ];IVO&1U67S7AKM1/(FX%N[_]P69-,74'%E<&=E2GZP*Q
M-M%AU! =!Y)ED4N1V$U?;7OY)[4U\=D1Y"BUU\.4M%$;;1X79;7%86;X= */
M'83I <ZS9$'!ACW,8BEMFT7>SGI2>/Q;A[F-<?*-2-6O>_S\9RADW"+N9#TT
MO8NU(_6&7!R)7E7\>1<F%5V'TIR!$-2YER;PD2F9)_<'J?;?TYN]N>M3?4#/
M9VM(>7OL@-X>\O!8>TBN\]@\Q?J ONHIN3U[8'3.("GI?)77!?4<[.?D"$"4
M+TO8'K(3VT/Z7SUG4*O*R^]]U5.J)D)S,1CQU>\JB@@())&\EB.D#ES-C4O3
M[]#$,ASRX6\GP$F<QPQR+!T;3 30S!#\M4-L)E8;VEV%TR7)"2'YB6&;.Q3'
M%;&?8VT]99-8/:>IJB7]&6^G2&RJ=^4] "1CI COYV>U!\D3?]^%=PRGS,>J
M I*'>4R=4L-:<F=MQ*X+]$GZ7_;,Z^!>5ZN9]K_:9+=!-_U0WJ\/^G4'^MMX
M#'RP.+9_=@3RS&_P4NY"I=56$R@6DW_X!(1])_(D/?Z*F[ZL&5:<Q/@-(95"
MJ.%JKIKI8VELA.Q/4[TNSJ(OQU$2/UM>:P#=,D6R/_4JC9(W;K"4G^,$\:\;
M78])S,?'J=CQJ$A;N%CMB VZ,O#FI4?-F3Y+%.^HLI$URPU85T%#/ZR-U_&H
MY!A81B>>(:R) V.W*P1^:-61NT3X_+I;O_&*J:DJX^E HQT^!LS'?*M>U\XV
MHI;YP:[F!Y]5Q_?4SE++XB60J3(+0;*]F :]ZIK)J>7YJKR&Z%+M.Q.!LBX;
MML:9CXSGDR4.*UE1 \/OC4+8A PW6F4FCP.8F+>?'MO^9#KL8_TI\5&^>P]C
MV=5H-'* KJL]7WXPH*&NZN=@\'+L(]^J5720O4!T=DJ0]LQOM<3?WA-;8@6E
M*=MAR,Q?]_J**NT=<HZN3)1 6ZR@*RLX;B)@7@4YT7,R5<!2K6K.7$78"=R"
M5[,D0->#JS<7D,\'CB7 %Z"3I8R$).-G5>C1^:1C5UF*SRGT]J7JCS^GV+-8
MD]W)F]E5G 94[[JEBJ:>_AGZYG\EPMC[SQ^3JGH;LD-WW)4)@J9%"^1P\\_2
MX3YWQ]FN=C@C&1%X&'EZ,M3!&N[*)+3SM0</H=&5#L^5T&2!R>YJ'V"$3OXY
MWU-&,+YW.*@FX^#M9A^;Y*" +W;$QA?[U+>0]'22G56]DT5EY2BO7F#/,YXX
MNR]WAB)5!JLUBI*C'MWON"'LN]S!Z]$!^*5@$"0&W\+D<\F+"+3/@_%\&7")
MY"<!\3$>A.H3H>5\$CFGA" U\2'+I*Y\O+D?Q/W);5U;_KYG\1P9EQ?MP5B<
M _-!GY";(#T14-77,_:?ZH(:/DXH.>L@4:05ZGN]J(AZ,G0[PAG^,;J+Q7O(
MK,*IJ:I?0VK,=\V.5V.YR_"]1*A,WSZZ)??&DJ#GAI"Z)46"T^:VNLU'9-2;
MVM\-.L]K7$VE(H#XCSHLY2REU/RO*,!YBO9S[YM&-F3?=T1C^82M*>>]0EH#
MU?FFKPZ7%">]9FO-Z&'^MDRF>*?\:G7K]@_*V#RA[3.9E.12%Z+UG/;?Y!0T
M*GQ/%M]4"(4^SJQ@Q*6*M4*PC*70@POH$R01F PCJ#,BN/&1W^ G9[Q#K&W_
M"H 8CK%8*QO"A1&X+8V0">80D0YM)X%S*(+5R/?B^N" 2'1&WII YH"R 7]\
M7/[(+%D7,\C;CK'KR;"C(_FN*%(Z6].W6 .LBNO&**$VE_(SO9&0I8)P/_X9
M3) *)G;IV;"K(^4 ZUW[O)D?>^_F)'I>[^U_HBU)<'8F.X#CKL*4FH;]KF+2
M2ZOFK!XC:2;"><NDV?(V$2%S3<F/["D%[A<:*^M>\9#H[M<<<U52F1">\YHK
M&!&A-E$\8Q]]*[?W7NAFH&Z&)X/7__]^_;_U[U3_SK]#_S?N_3@%_1D#1K'H
M8JJ1 TL#K5@3;B,47? 5=/_RPW%>]2IWMZ,[#!%J43R\=!"M"299I6*_'BBC
MM#LR%ATS[J-6\'L\\[+?'6JF+1RX8#ZLIC)B]//GJNV0^[I7O'V:,.PPU%5T
M#XHJM$D4DXFH"?:CW5RX5 VBFYZ>FS=>=T<^+D[L9)/59]Y1TADN(3'4FK70
MZH$P CE*H2;451R,X$)Y841W6M&ZH2;W]A.V;ZP(%@*H&#KS<UF6-"YH>U1,
M*6JD31(GFNQVP@9KK8\]-_#&@5$ (ONHK&6?'L O"AA3M<*G8I<:D]:V&D'O
M< (%-J212;WCRF.O:N!JO4,YV'"A?)8#8*U<>;T2G97Q'>1H/<\_Z*.4VUML
M(SF?7FP3?^TYW^N=Y51ZGJ, 5ZZ+[FL1CF$X&P01N&;0YYV]6>=0:47-D+RL
MV1#CL<R9P!P71S?N+TN#B<;28<JPRXSMX2M(+YP<,C9&Y-WA0P%4XW@D0^HW
MZ<DR>PM*S:JH'$"Y^>0<V!8ZI;F\T%&JLW0MJ$!@7/J&M_VKC.L**(F*RJH(
M!I/!6<-W^RYW[[DUP*JL9-LVIN VNS2S/FY(:)LORQ:!@X3=(S4;FTSLU.$1
M=MXN]D>?S6I[03"&=4/W&&F)+W8IAB*A\+SYS6N9*%3!S+S2K7;P;B?+Z1%+
MLC+C8$OXNU22F8)$C \4/'^.@2PI!;P6EA )*"Q*4:G_5BGPVEKNMIX-[7F=
MZ(:5@S)YA..6T)*]FGS3D+3)8@NB40-T;M[#;:;#?KFD4>_)R*,7#\ZD15<\
M:KOX-+ZF?#VV=EOVM@?XZ6CIP2:$X7>*9$A[++UHW 9_U=<Z5LGBL]WW'E*2
M=4H4[33X(M) EQ6RC#&Q*C43K[I2\GI]K\S)>IG?G(GQ#0%\9')P%S!XER4^
M?Y<-/RKD?+H],K]GK]W88%.%<X,/S7E1L/@]Y %S@D!5@O-/#0!6 K9<"&5<
MH)(EPPBU>GUK*YUZ[IF:J-C29JJZ?7_M#7:A(?YXU] 0VM$+Q:@U6.7;O5DG
M@(9]),>+1;S3;<>2H1(N^^TLODTL%Z1G'?KU149_^Y'ZA;J3IV/.II=#J4SB
ML;N6P5R7D-S"W)O<)&EV&N"UE@+].9X.L+WCL7!F).1/%(=*TPE3'JPMM#OO
MS^:POT$L@.#2SDU!(7QN?Q,S^NF!^%$;A7)DW+%I^MV+/LNIZ8!$=\NVHLM1
MG5L6K_PO7VL!B_%\Q\;XYFWEG]Y[UM1QQW[OSWVLUZT//\S[<9C%^R/YK&R5
MIY(XZV@M&UF'Q)NVLN5M.>.@[K7$(*7$ >.1H\(?TMJ5%%%.<K:*0V=L[7BE
M=&OI&R7CY8R/8B>9G; O?4C.N;R'"/RN@<WN3B<2U&%+!?B(DQ1"H@HD-+-<
M$Y<!;G5P(0)7_P;6:C.K&7%ICAU@[#614[#V49G@D%W]T];;HE3"_M(!5VH"
M+R?DR=L"W7BG<'.6^.$"$QE=2_^6_%!..+V#U!L5X>IK.;CO2BR>AX53]&+4
M >L16C'G-U6W6$^>4IJ+_S)C"< 502O'".M+T=E>.C6L%MSL[SN5T)<B$P>6
MU;&"@AFT]UY['V9[Q3C)F<0]2*U@);R%6YE,4MS.R[I2P!DD9QPC'B?&2;_%
ML:G6DM>\+ S,E<1\FA@%5='ATMRW6DA 9+6 "!2<A7UXQVJVVI2.SX*OS$!?
MT6$91<!X<9$GWVY"J&6]E^(K)Y=2W+R>3G51B(3WD]5KU9?9I-6=O,W#=E%%
MG&7J)KS?7>KWS+=:+>!S&1VD*,3=%=->DST(OS[:6)B+';UH.JJC+UP/O2I'
M-9^WJ4S6S59D$[ ++K>S0K=A#*CP9XS^Q,(BV>DSGXA 8B*2I/(AZ+I>A\?1
MUO4< @LUXD77?P3,@I-N2O]S4^;?;[*GB8F 4LM2??ZHR@13K6=\,:KC?K4[
MQY7G3)B6^JSUG$)@6V'^3HXK(!5QM[YP3B'D](;K8M?O2]%^3OL^E*C18K$)
MPMR"XS*Z N&;$T])*$2%9Q44 =K3QIG\[11-UL.#W7]!4^V'#U!"'9.@_;\=
MH?FDRAEOS?Z^.*_N ET6VQVF]SKU]EW"F>X<AUEGA]2BM)-X A4 T0CON]C)
MI40;A_= NG41Y:LG9QBXQA&<3)MR#!UL&[I1@I>\T$771CVM9)SD&&+9[N1A
M:RFU/_3L*=&3G1@MET$7(PGGNL HL5@BH+8&Z[<,:2AO?GG$<**U1"WN"%^,
M-J6.>=Z0("+R<OG&!XC&(ZS5.%Q"H5ZX!UB3"7GUJS0J[Y8W@T+3\,5@V@\4
MXQ\J0A??<K-4Z!/ZU:Q*058O6W# MMJ'M(_;3,^8F3=QZRS2 DQG2_$?%54H
M,_M3S8]K8GOGT[N<L[#-:W$NVJA?:RRU2U\\;[S'P754RZ,L6+7>U.KW>K(P
M;?;;;LQTL= T2]%.+>5%Z[U1F?8]+M3+V'!,\K3XP1;FHN.=Z!V38/'=#*&+
MGP]*3>>[^O-9:\HSRIV'L>U>VK,&GSLA7/Z32R6BU_6=SVH:'Q4-1:K<E/H!
MZN=ZN]XA_ROS?2$S1:+AZU(NNT\[7>S55Z;C$\<41&[LTR=35%DV!7[ZAHT/
MNLB*M-WK;"#WRP_E,%.L'^!,]6EQ.:'&OTMQW(I&OO?R\)H@ G(P1]A5?'@S
MZ"ND]0WXMVDU$1CDF>'1JZ@C88T/K7_?;''.8=N\J3IUVG+AXH^ANC5F;7ZE
M7Q#^&MQ53K3]*RZ<>*P,=(7;DPATE6RHXA;PWUUWR=JPSPUM%ABEC9:]P51\
M(=EIZN7((,WK,R8?5VA'7NM\KPL(K 7STHK_H)H%G96E\&!!^R)_S0<M/J!Y
MRW9OX_>\ND/-E;XZ[>*\2DX!;&$.<Q?#;X9]QRUN<!M+;,A)K\^],6FM$FO(
M=#_O;92.Z@2UTR^E)(C PZD:*PU!==];<JQ*G? +\QXS",=W549\C+.8"VHE
MYEPHAHP%T7X.>>4> _]:N38WQ4&5 08D)*1JEU$%68!^UX21<5]*UT?D$9(<
M<S'JA^FJSV_#1\_OE>W:<Z6WW3=X)54#M%MZF?DNH^H1M!]1,XA\V**OE=9H
M51^WGF[,ALEMRPCW:&,!]9]?1+\!G*Q1$7M\YPDM[%3(HR!I%02;3CM!&!46
M*M(H*2-R +MLI[A$_3BZK1.]P>!3H%T2*&EVT=Q?&HN^6E&!@:)X.F7)Q]^"
M&#VLEAB^Q5OZNMLLT5VEL9U>'0LG]S"1,YCQOM0[P_%R<6*&805""7VE>=&'
M9LPU^E67SD2#^I*ZX1W[LNJ!J[9GT<B9=@'Z"Y-D%EJ3M-YKY(UN_P"3_-(V
M19@@U6%M1YK?Y7;3 4EZI0Y\9XJ#6WH=[WE2L5HT>NZV+43*2J#Z2^_;+]KQ
MR @.:">JP^NO]]3+H3Y)Z.YU(L^ST8FLB8*KQ#H70!Y=7<FR ,8*X:LOCX2_
MXQ6F\"SQB%%[GI]P*22M]Q(_$,:VF8F!+/--G^T$78FE]1%%AN8G;-8X+U2O
MA;\,^M%P7WHR\1+;[P(FO_,']&1H&885:"5WIZ_1<E@;7MY@HDK*D<Y.TJ':
M][/)U/,YE@^/OXTP3<7W%''$KYO6_K_O9?(\VJ8A ES42_KX2,,40D*W:9"I
M+U8>VDV.(;D[\_&\TU=+GU+M"_P+CFZZ":N!+L;"]SP$H)/DV.,..5#MV[^P
M&C\/G"X^R4<--8.NPVP[%6SZW4?>ZL)Q3C\?K.[C]2R]7[;SF(/IER7PQ+_L
MW+.>E52$.<;199EN:FU1,_ V1KW$FC&5KGW3#GK-YHK!;"\]YLIYF*$29??%
MK*A:\YRD?F!@0X'^(JX;M=L,9JK.W'Z.&*# 2!)ZVR;8N08=MP\>B$Y]61Q[
MK2TS$3?MS\#BSGQ^@L6W&,SD<P/%V)&NN=19@11"K%8C)UK=,^DF%-+4&T9H
MHUQ]%1RN:/+RN-3<+Z>*ZHZZ,DEB/>MC]&<&?D(I,*R81'0 QA.*;$-HOI-E
MBH2&G93%.A5#?FL6/$XMF&+FG)W\E33I=]AT+'VMXR$2BGB5)]*U=8R T^!N
MHZ@"F^YX2)DR9@BA+-'O[3][ZRV@LR;2>3LZ]6U#'37.^&4.R8&BY^F1QK+2
M&,UE/AJ,/B(4!D49:6/2G&2CE]74^:M$X]L\\N9@2B<!U\,%@Z-V*2E&O>@Z
M8:&2.P'8AQY?L6T0NNH%IDVOL/ 'KI<_>^2T+.WT$YX^94E3?\5(8W\EA(NS
MG )@V. Y"$-DML9>] $-.1[ +MBLJ5<TC7*/<4?U<=67W38;EC4)9^;,6G1C
MF!AD! O ;>A"_?@FP(A*]8+@P\C\\5_(EI&.ZN"OOI6]EX^;5*BQ?1\D>#Y9
M?-*O]KF!D0&U@6:JU!"P<^ P:4ZQ-C5KJ]3.CJROR2@'W1>30*GHH%#FAT,1
MM.^?_6DDO BU-\Z<XEL:9"/QW5.O^JJQN &"'EQ#:V)@_>"EC/HUPA0),KY-
M'59X:D"@7ZCH73>BJ?E\6,B<='*7K2*C.E.(?]52H2J%<XT:,RSRI5&,7";:
M9-IEQ'H]5E6'66<O01-&[T(ED(E6J6WN9C\(''<9<C%T8$ZQH7 Z$+XC'30P
M>$'B@XN0V%8EWX/F M^D-&:PZM TL^C:7O[7@!JG'P-YIU-!&:\U%L6TJR.+
M<;F9K\UAL/G[ C6@)"[+/2,)B)/"I(M@[*2?<<K)2%-SPXM>/P8G7;:IY50/
M!=/0F!<N0C('^U$E5AMW,U_X"<J!#4<^7OQP7)XSJ$/-BBNI89_J8_UI^P0]
M,,D[T8VO:+J:L)BYG;0(G1"#S69.1Q+4:Y8R\9'7_^#1,-+@BW^&KY"]FLEW
M423I.!;OD@!_ [;E.Q8=B("B[]M"3M1O&8I$UH$_W6G>&SWJ>" @'BTT>\%5
MA1PUG1+;F>CN\-YLD)SPGF(\#EF+NS.@"NAU.:7R-U6]#^+F+L^B8C6S0.44
M&(IFW*7V&B13,E35Z:H&^.@ICG7>V+A]LF*UH@?T1S*K6,[@T^"6.)+GK"TB
M NLM):OJ\+L2:\P=OB)8>5'PJ]TIG\NDL9Z: 46:C>:5YR$KUQ#;&M//-<[:
MPE,9FK2^9:X*5K2], JTN_I!C-Q7*>^"ALL3O0?^_)XYOV8^X:;R!35;TX><
MSTC2_PQ6"\QZZ?+(^(Q)A :9^'+I#6/')HDBCNID:\MD\:F<=Y:3M(PR0EH-
M.+,H*[C7-<2HL%/%!1P_59":EM0[8PKEA@RI(=Q]T,UW^T=!2,F7.DSXTD"W
M939;A1H;>E;_@B9;D0;+N&3R)U&L@QVQ5#L9[T.*.$(%)_=CO'RGW>/JOQW[
M[T>-LA@L6Q\GIS+M<#(?9CU8]=[=XHB"?^-K'6RCP.I5[&+#[4C 8K$RC$"2
M&XKF42 ">?H,RYGEQFGPUYHAM1)$(#R'C CXW8*1S&=@/Q'H[L9H$CJLX0?%
M2S6A7>K@8 QC!/_=.R7";"H1JG?(9JQGU#_[LU5I5>E89U'9T]O33]\AFZ0W
MT['1G! &S+R&4:2?92M(91DN$UC^ E&5VG=3EO0C@=_3':?;[$^,".?MB !W
MQ6+FR>$H^"!!];AFZ1D8\=*C"G1RD430CO*%G;>9PG;VU&F8HLZRIB;I.QK2
MVUNDGE6HLE_ Z?8UF2=XB)@5/MC6^DKB)UI=:P+=>:N*TQ[DF0&3VMO+\P%1
MTS/?K'X5;._-6.\JWNW=E0OA4 B4'*K_:49S#U<[IS@7G$K)HTBEZOAAP9U^
MQROCO6"R5$H>P"E7[ZR@$"OP+0,H4A'TG1=0[JT/&/<'J_I8W@@BG!M8#-4A
M @(>703- 4B&Z$DP6L@WFRT^\7V\\SDPQ!!/@RH (14=*6@S4>)_P\4#0$>*
M#3;"&;[\7,U%(O?HMEA(:3--W/?[/3(V-[[?<MY-HL@Z+ Z\RJ[[3=XU_YYD
MXGZ2::X;KOCUNU^*,:.NXF8VE)P.#X^E] Q4GNRVELGJQ#15'?H.[2ARQ$2<
MX3D3WO C]_C15[+Q!)OW$I<OHBF/"O5Z1!=GPMP&;J?=9.:<%V33\-C5:#%+
MO$?-[I?4F(OQVEOJG[8N?6GARF-TO]EOZQM]"-7$*NC#%Q[IV9_%#/X4GR8&
M050X1D_:#-<0086+;W[&'2]^,?\=5PS(M.*FT P#[TJV<EP&NI;&:5.J7N]'
MEAC)W()Q*OMC)3]PJ@!6O)KWE9NY83(ASHQQQ;."V=I*MH>Q3!Z/I'QO/QU6
M?EFAS?X,Y*6(S3IQWUPW!=_\6J$H\?I3JJ[ES[(/Y7HYIJPH=P*\8/_6[,^\
M ,!J/%G1F8R;8M+\LZ 0I?@O12KZ(+R!],'V85G04/DON9),R'"RV(66@,Z1
MKO%4]U_AS#2S1$"569XBAA%4R@_.!DW&[> 39*^"('2&)";-L#UVC$*ZHT,P
M(7;(B47'%EC0"6UDD4?_<LNUZ=6\8H\$E6MM&E7]'3U=^U)"M%U1,;0:DO8Z
MZ$E,["*4'&<[*&V'**53P50CL2IA!C7>UQ)\>72JDX:>66JW-)]IOF?T?3V0
MQR47&QJ!\5; -QW&,OOP8=B6:-C;U&O&&S27>1S/>Q1HU(5W5[PO$CRV\+AG
M8._Z((/)M<,[;&L-56F*J5R&1$TK5IR)$IVG0QG7W<X8C_]:V5S(Q'S>(KE[
M@U^FD&+6^N\3A*%[$OF5&5*>/N'3H@:_>.HM+K=9--'X:*+<GV :%[]7]=JK
MH8N01""DFH:[#5:XL>F)*/%\^3U&8E)FM;\XLR&4/\NYMU-%!'WHYTJ"4(]D
M&9[WH<QI]$U01T$-MQ @YN<VT\^J;S>^62]JL;-Z.U(W]3G0A&LV+8S"F5?C
M#L4Z=+*F?3HSBG!5L]06S+ ERY?7G\T]=5@*5KO^)H \BU^:@YQ)U&@50'2]
MUF^:Z(=4B 7KJR'#HAJ>LY<@YE1G.DUO?A\KM4#F?E:CMG-]',@T&KL\=:'R
M1.B2)\.!/4"O?PMEM!0;1J#&@<=]K)8B4ZJ'A N#$ZNT/G*9&]S[? ?[\V=/
MEE=&6^H>'QUACAUH0NY&'_)=LFGB1(HL!&UEC[H^X&Q/=8_WL,]?.G]3X14M
MEWDQ(-$+.*4")_<B]J !T*JP,(*4.LS@N8WD6JCTP^PJ\/1UNO#[':4K C_3
M$"EFK\ZP.3^DJA&'&?QA7G09LC(>A&7YB@G76!J<27E%0T6TEK08W>2JRQVS
M,MG7W1DJG*SF]7RA!+[AJJG<;V.RO.NR O6-'L/CUS+Z&:-K6?3,7U>8*['/
MZB^!HJH:A=3Q)=*N2S+R[:D:Z0PUD:XF:/<KXIGL/L6TY,M4LM5]/A3(/CC)
ML]H,!/LIUN;;F4/I;5:(@%6]6$KD!U2]<TSM\KH<J )<Z1BZZZ.[P+ZU)8(E
M C3]</IJ"9K53YR"EVX&OSX>"Z7UE;IPJ$F).]^(E"WCW6Z +E&G>?*9$C8Z
M+6OVRO+\C)LX!_H6*-^6<:-)#B%NH&L!>[<.1H@,;(K-HDN#O@ ?<Q.!2]"M
M;(](DDDS;4J _;O$?QL:X']U_>O:..PA3!:?#5\)P*D2@0J[TP7&YW<HCC_\
M$\*'7-:?@2.5%HZEF>!;9+ZXI2RZV;K_R?P]"CHC3U '+\&AF((R(G#P'&8-
MNX:OZ@9]=>Q(D"0"K5+N1.!S'SDX(]FBDNL%7.!I7^8#SUE"8_%E9]&++\7&
MXU0Z73+P L\-UBJDI'R^FU/YN&C8,-0%^O9IVX4Y;%ACY;>;7Z2Z@>YZ0J@3
M.T32+]<D=T+O?;E]['DCMO'>3P-V75\;@_LJJV?C/CG-9KS_M9ETK#\1$="_
MF.-!! )TR^L07Q6WS#_0Z=E(S((I5"^AS7QM:U.L.4Y6KD<76 %OC_+,*MXH
M7TJL/QG<\YGBG9*=U1.00M4SG;Q*?26U_RG")[O'F._[I?,=]VIZ  >_) ,3
MLD]WSN:%OC5.K/(EZ[M&S8["GOO!@F[#:.U#?]J0'OK-67^'<9L$%&[/H$A(
M(/JT'7)A;;#)1X\62,#"[RQM50$1N-$-^0[_S_.-12SR%L=PR'?_MQU\;-Y#
MH)/J$^V0[>G A\[.7MI[/8).*C'OW0=L 1>!U]IO[KH=Y= 'B\714, WU2($
M)M_FDW4AE/9R5U/H 3CO/)7PM=FI7/:J>F]T+KE8>9_8KM-PAF\AJP[9%]^O
M/.L#TRS@TP-(OV[2G?QM=M"G9PJ63P2L%0:V%K!\)]!6B3_PK]BT-:5U(,--
MB'=)7.:>]4LNL[T(@52S3J]/WCKR@K#>A?$*B2"'ES?$)0[S$4GE;;!2'HY9
M[ZL_"G;NDR]:-0I$<3O*:/ +:3PUW_#3Z<ZQWFF4*'"XF.Z%[C)\=-66GZ5.
MH*OQ=@O["%Q\X_N*B^)\E*(B_UU=UWYEF=_ 1V/Q >F7E^<_ S%2NFWG<A*_
MNV^K=&Y/3DN-D&F/Y2,D''=.1LS-2I.Y(KP%M.K%C^B_M,5CALE\NJ:=WS0%
M?MCH$8JZEN/^B,[K6:+$ ,>>K_7E75"YZ0#F-5^(V470MB*)DUR9*">9[G]:
MR97"GNTI0'=@GM$'TA:V$0$.-=->(G F-:H;JX+1 1W\'056B4H6X;B;A76^
M:96/)8M&F.1'%PQ_.*_ .Z)6-4AA76 O[/G*GT5!ZD7.BZRS0QI[ Z7L)APL
M"N#>H[P][%-&V2^G(.\TYNK_6;-UP+S/PBFC;, '3'_F(2&JT)8'(X[;%8N)
M1$"C+HR0H (1]2$-Y83XI07L'YB7Y4OK"#/4;-2<FT[X$(S.7Q[.5&?:E6MO
M-E3/*96B7S%=RP,4:H)4&_QM^MJ\M9=E))^2\W)M:O2[9+R/WO>=-MXQE1PD
MMZJQU;-OH'WO[T:XI[5WN"D7PE,3KSC7$%.5Z5[*.PP7D'Y*M<X='0->C)JG
M$E_#FO]9^I7$=9K ^>:9Q"5@0U!FI35HRW4?VEH*PFW4(1& '6_N#]HX"[?$
MY]PPVA'H]/B2.W9X4YV[Z)F*[$AM+.OR9*PJ@T^K4<" 7UNUP?>17&- 5A'D
M@7K:5M6)^$H.F]?JMR'YO&>#,4]VQ+E_L=@\#RR<?D-E#BU5'!9[PK]^6"3[
MDPC(4O!K12T%A%^EI?_$1Y$IKWG_FF++=J!,G^(+1Z&+Y]<HK-$EER=[.1E9
M>3WG.N\,&C(*\^@\&*M?*7PUS5][PZ6[PS<\=][0T.".K$KTPTCG6@5/560S
M^P>VQLTUS3/K!0HCJQ,[\=H=>J7Q,Q(7VY@[)<V;@@:A7Z55$*7F\KZO+&J"
M&\N?PSU7!:,D79)>9]BU=_;)H)6:G2@;&[)26LO2]D?VI(V6K-Z)3LU9HS\+
M.:10JKUEQ#L9AYAIBJ],1'];B_OUK>R-!L\,3F%QZG#@_"-T[*JGH#)77'I'
MB[G<@UFD9J/';#(-:X"!/]GN^D$93BCV0?Q!K7'1/5[Z^:+-S855W0=[.U3B
M1YL:<Y\<^B4!GF<CFBJ@7F5#9^4;#'8C#7Q8<8_*CFM+*U-=^7)E%C1OE>U;
MG'.L*1=77(:KBDS3;WG6LXVAWK_I3?V28&KUONV5VZI%M9-_H_* 5X8:A;2/
M44^VTOTL%.2YAQ+Z5=7(_1M!NM2R)5P9ML=A5LDY9;Y*M6R;.8F&2*N G.IA
MF'TI^UA^FV.P,K59@N:;6AQ/3[+EV6T%%S#GZCT4@ZR?*OWL'!Z\F/D(QX81
M0LFW^3%@;J%J$ QEB4L/GF!H)]JF!T)=2W)L:T07C^.[Z2=;R\V%,G>.NAE@
M2^ IL66J#KYS.#=45]3V6V]HN*S$8/;@V]B+Z^XO2K_8FR>(3>\WT=?34TET
M466\D87A/[ZL3$-#D=3K2P(OIQ_37 I^(9JT[%CM9>]+"1+6D9U_C\\3[Q^O
M4UJ;:.>;U.\L004MUD3Y<++5V8P?>3TXBCI(KHN^S'??PH PP>Z'99I6D/*\
M]7!-^FW&921\FQG)MY39R;)PSN?^H(]1-J:^X^JF6TW*/%?$4/MK\L*I0$\*
MZ<5]R)NA9[9/D?C.;/=LFY&-\?A)VP0CQ2.W>)55+B&&,T,0C/_KJ*,.R.<(
MRC]O#" +M@6R,6&M\.I9=M&O&$;N3M_;NZW(]33'_)I+4S\K?TS57 EE>2?N
M5/.]924"Z]+..++N19OG:4<W[6"_G9MZ![J64WR%$<5Q ;>'_P!]J1FZ4+W;
M\MN/Q^<I"74Q8]9,4I?LL-5CO_QM!.^7?3ZW_*S=F_YN&[D$$U,'X HM)^2A
MI!!=D=4#M+8+E0388B-%1]/-^G'+AACTK9$J7>O0'Q;!%Y>/;,]36F;Z QV^
MRY [T!8IG^<E=B!:'Q=$_<"E60^X A(:R?>6C:Z=47-5Q=.229X=@D'O<+KG
M XL73IK\I=?0P9A/<"K")4Q8!P09:X(I6^WA>%!EQ..6H58[%=B9IF<0,OOP
M51=P%9+>G6,+KV)LSHPR_/R[B7]"5M3N\GIJ?W%=<A!OIA7:R.C[BHEHLT1O
M\-,Y/RL.]N\,)S %P"<>^Z /BI)"?\!4H,P7Y,;?@LYOD+Q SB2;<Z?:W;+\
M0%$A_O!F^T(#WIW@-8;#QK]'L]V7QZI#NSM/3X2N2#O%2A_O=6V5D%BV +*$
MT!DM1F)&%L5$H&H"]\FJ@P[+7,V'OYOPQ:]G8<\%= &^93T"/<B7!/!=^!CH
MBA#JB-#C0,K\>1&6L[E&-[E&D >#H%OY&_ 3W@LGLOZR]OA@(K"2B7M(\L,A
M2WSX!UXGJDW_+O'_^O4*SHPE'KT%X:(K:RRY9CF'A9]'2[GCN/2?_EC[_,4_
M$?.JEH\-VDJVU&N1XU&\^[@A8O[%C<JF^FA593(@Z?XY<>Y]&#L^\RTX-)5F
M'/Y%8O"UJQW?)=M+D[/=;R-0,P[3 8(+[C8<(%7@Q#3BI78N*C>^KIO%OV?#
MF8D]F'TI\Q]ST'3_,@=-\?\Z!_U?70PKX.KMB W(5R+00:V?V/V\BCI7T$+*
MA7F-87.,]!N" @W!9!@%X -<3W'IDR9&<TL_?0ODC2:&J@0RAHT/7<\%NG[I
ME350GZFG.]A>'Q2(VC^0X2GZ"%Y2LG.Z=O2<[F?+.\[#=6V;RI)'S]89M[8F
MV=U?;-!X^HT7N#3K;4SC)BI^MB%7SW/:G.D\@#3HA=&O8,PKH\<G/BMN5I61
MG5R?:8JAUMLS<T;]Z!0YKOB.YY%PX/VB92K15QME$4XVD[&0IUVDM=6K=Z_;
M5)#3,1C;/%5X\X?DEW?/"N=]A.I"OGZ)2J?FM *%O"6X_BRB:8,6O^Q?01B?
MH)XJEA5)8U/%0EPX?F + OIN/2MPYC3\ZC6 E)CR8VNL5(J<_#4K^(9?KF@%
MR9:Q'*U]NWGEIDNFZCK'B.&\5:AY2[K\'8H81241U3EF5WD*SYLB&UW4)X?"
M^"\+VHT-OZJB[&!D1FW7RQMM!(7VBOKT8UM%;>=?U)H7B^\([<:;Q!2.HS?R
M[^8\:BO@WAP<T_S&-_7+Y?4U;O5"O)%[Z:UG]@[BXX7CJY09YP(WK@S-?^C^
MW:157+2H75&1UJ?SZ:S!9%%9S FH8J:9TW>C62CAX8O,SH\%'>ZTN9FOTK@E
M>JY6[2]4:Q?Q.&B7ZB1O*!J#Z>RY9A7VV7)NN>FPM'K9-C-;9=HB=TJ2V \G
M;2?H&-K?U9#:T:+/&;@WGW$866C;ZLAK9;!\P>U+A3]SP):3SO6D6Z/OGI5(
M21$!B-,FF(0"0U[?P']I8I@WLKVIPUY>\$);S&_[Y!7<"F[+#GVU$&%!R/L[
ME.\"38[+DVBB)3([=_+KM_*2"ATJO/&G3^Y=I7Y=A%'0GCV<'KYE, H_2%7=
MSN&^52+S1#CO3@VWRW%;M%.553E!MYZ63N8NY\-?0=\MR-]W\BN_,$P[.UNF
MJ>JLM"IZ]HP8Q@]YN/FHW__B)[)U.5J][0R7/AHF-M03[&,3=Q=YX\>]$_2V
M FX'7;<_]30U2@XKN5QAZUFY'KYCL>4L)!=.'FI^UDE#KS5C-=ONPP23!/V#
MT=>YK!$6%:)C_2K-VZKZ1R\J]D[T7.NBZP(%AN-A*9\>7*,6[-Z;=(ISZA-[
M\^-'<X>>W>K:A;,V,"^#&(G/+:],X_7TY"2610YJML_'8EX1@2G_:RU$(-A1
M5_H3].?#DE]C3693G"('N]O7*OJP8H3>D)7+L1@E$0TX^I*MNO5=/M=,V8]C
M!K@V]JK0#8Z'KZCQ]S[$C"N!UPUFAIS&0RHK[U-&WXQ:XWKFIGC-A*1C6_]B
M1 O-B;;,\)T;,0+]&T5<;O'B).XM];9H.:%'N>='-)QM_?F%'W:VEZ.@;VFK
M)JOOJ%EP_UKQ'GN>*KU"4_)[3-A9R*([A),GD"G"36'*H +]V^?S%(<KNE #
M=G8V?7)=R_>KKM65]H2+!YWW+K_ALH=;*LH\.BCHN7 [ B+/6<:"S)?]7/J>
M\Q>H0^_,V!=;IAE^Z$Y&TJL%W6\&4TT#W\E&AB,]J5-^6*%3]RZ[5)E=B$]=
M?W\F-I155%*'<VSI@I!#U/R'XN$YZ3TK[WL9<CK^=VKBME<,B, 3FW,OIT"U
M1<O5B3_P*RWG)2Y*FG\U>9E87]-D:[U].T$N:JOBJ'M=H\WZA =-61D"?JT9
MDG _+Q9=XK9(6#(\XL/<SSF#SY6^)Y5)W?&'A"R!R]D:^ F3(&JJ- [+,1;;
MRRVRCZNWB #R^;>94[KR][GH3ZX*70:5B\M7(C3OZ[+$EO)JEC[M]LGNN//.
M?35;4&!7;;6:X]9>F+36KXC(?D?#ZXJ+:_1D?,E5^?PJ R(0I\,.4AY^[KV)
MD<.\O8GADAW9*@?9*O],<YAX7@]6SWG^8&ZTN;+VKD_'165PGB[O&;'^@\\M
M%IN9F%LK 7![1TI_":SHWZ++DD#[%>A*KD<Y=/1T@XQ2H^\-(D!9E>A.8CG9
M_V Y8CA5>_AEG"%X0^#/,0\??6E=FXR?SKHH%]ASV!?<_A!F\:M/K)1U9VXZ
MC?NG\QVFAFKN5/TH';%KZ^HV5!H'M!TA)K.I4=_&NS1L.=^X;9,G_F11EK$F
MMW+DR^ZW?JU8']!=R!G7]2EJF(?!OOV--7D_HL;/,^_9%1<]:K:9^J<_G]=<
M(.^H=A0JE3!RFO;2>Q7WX^R\P/BG84>3DJ-"BL,)1%DD8MN=<%YGT0A"KW+1
M$#SS/#?!1O1>S8S5!9?-!)ZU@<M^/S,NC#U*XTDK%5<L#&?[4B*E_,7#F:[)
M:>"AR434B@=T,:J)ZJ5]C(@'$KI-\,+L(R"91?.&DV+AYH,B=]$#]D7&&C[?
M<V+=NUN.C20ZWYR5V6SM>K%1B_70<U*QK]UG+KO6D'<8H??I];?Q>?BP#(L!
M_GVU1ZZ1/>AIC/?A,ZMOM3<%JBZ'4L4GG#O6O%F+ET>;HDJCAKC<T"[=-QU?
MQ>A-%M2MU7:#PK]T-\EB9N2:4L<=K\@75UWUS^OI80L]Z^[.Q%X]"&TS\>AZ
M4IN\H%,S?$CFB"W_0:8GFQV'6R@L<S#N%*V,BCG#NO3)=TK1A$19.:^!IW*Z
M^CB2U1ENOFA9N'>1-B]6'* SK:K)!'R,\FT$!UPI[>Y5O6"P?$8IT<SJSDV1
MNOX27RFM8.&0C+))]6-37+XQ%Q]UT0)4JEN'_^JC.G'Y<NYZ<RO41\5Q_N6!
MN$.Z0,R';#5!1P/%^9S5?DNK;M#FJO-X)H6TG70+1%VT]I:8K"!+.8>S4,SW
MKIMUF>=QY DRMD.N1\]OD+WR?NPC=4<;LKK^"14P7E"#+X5QCMY,IJ-[3I\
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M ]_QR&#T5&L=\^ YH++U(0QKLE@II;XCJ7^GN</(NB94.=)/\=$CER=%+-4
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M+V#[P94C82T/ SJR&)"^AW<4S90UO)URXQ?F<^-4$6FTK,HZB:Y9-V7[?JM
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MA%0<CCT@C65&Z(B",3?H+I1:G*YR1M<>'*YB!ZR@EX#L3I#*?ZF_2\PXP%'
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M\<;T1%OW1GO;R(K]Y^]C+/5-F:4=O:2I?:4)5>^11\0>U*UD,O1YD*7?TP9
M?JTOM[,9HHH6,F,[([H35FH^TWH&=R:7/V<C2=VJ1=474.F8/$W7[CI6?9R@
MAET R1Y@_$].4AWR3;H;72H+A^H5.A]Q!!]L97';2].4\2VN"N;.A>/LNM</
M-Z&Z$;N?WP_?05;"]]&?"1QIF,4D)D+#Z1G6EE\WJ/D_4:VI^*Z6ZJ 7R&Y+
M]82:Y9/JWB_7;=MGVI&53XJ,<T5=//U%QC5W-EQJT]43; 5-BYRKY!1J9ZH
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MM;\H7.52%&?4JA?MLOLU-^A#IT!$7%[?,Y[I@]+G3&L?=K,=\GAP?U]&?[[
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M'Y@\Y^S#$OF(1*<C-EBU!T/'MRP,UDO3B'I)#"Y4B<#>J^RJI.J]U(:96=4
MJGDR^Z-HLNM/]7E]R?--#V:6Y*^M_ Y81%>Z$(BQ"7-"FEZQ%U^^T=:_G >M
M_%UU'^[]X0\*_KZPPM^%-JH98!5R>+U%\T?0U\:1T<F<>?7@SQ<8+=^0W7D@
M$WBWPKUCZ>BYFDL93#T':8[_"LT\^W"W>,-4292/S_U"B"IZ-$(J^#3V2/"U
M:)V\2(8Y$W"Z!YWMHR,[M^4@Q&V:O/<Q\)G)>]KS4_:HC_MUO7;L'<=.1VEI
MWK,QF7ET[^7&OH: K(>I Q<Z2&_0B[=P2!<0MZ;=ND,KH0KV9<=HJ@SQC<<^
MH\ME!P]DRH?_T!,,.T:XL \J1XWMM?SLPU]]6L7&9+]\@%3 4\:@Q*4CA4I?
M@O)/;JF?SD(0Z]IB?%SB&<J<H*ISL$3RE(#YAA9T5;$&?O8;9LL;4D.[B2*F
MMEJ=0'>%2T-7>X4/?%%@69?$V T)8S_[EV]48_GZL#^>:;M[W_U<(5DA/.HN
M5KV?IZ!MV:!0;>G\5(?@L_F=JLP3/X"^T> ^1]4,52;@5DB-W7J +7I&UH,6
M]C#T-CEIC[D9@:Q;UMF8 ,<O B+0<$<<E#<?<(7'?,W%DB1]U6O?\/58#0BN
M(NG\),:M]&_HE7%6_&U?N1'N(Y5=C+JF9&ZD9'E#-CO:Y;]._ H\N^,/?B<U
MXO@K+%!3!LW(P_,$HK^2O]HW4?_ZA!R#(())WH"LU-+T6GE\1,,")K%!!52<
MA$;H:,[#CNOPC/E#F]5>ZAFS-Z<I1BEJ)5=8.WPTM+20_-'48&,=#VC-AO"L
M# GK451PC4L&#A18S 9:S!0SOT:"V[:]#KU)PS7EM"F[+E\LQ(AH>R<>Q.0M
M?&,)G12N,8LG[0=1S1)ROWSBK%HDU <_4J6SQB4\B3[&<J>+GZA1"^YR/GMJ
M*O-I\SL@_[L;E$V-\$4*!G<X7JCJ+9X=<*U*^;X-UW16E!JDC.E)9<DNO+)\
M].(L)G<NBR^>";C CKDS 6&HQTHLDC]0JF_<7W3-H->G1@5Z:C)Z?E[V;?LG
M[+[6"]<RU64$:6<NJB<*CHC**6[>O7=GCEW'6(,\_5#T53M7NUE1Z%)?TH[J
M+"/L#A,@R3,$<_:>'TWR@3+(;PA!.#&^LLA?B+AY=^"Q5%WMUX"HQA2K!UW-
M7("(5.9^Q0B6;Y$)VZ<E.<FC9M^GQ>/I5/BG6FF,:)_7/)/][OA%]0/7N#C8
MVR6CM_4_U&+#OE_8/-:V[UA(7XTY^E8:L#;&23['.(PCS%*Z\EQS#4KF+WH0
M"A\Y6J7-7_DP\_ 26U*%#^#55P4E2U 1NSRJ:/ <@J'M8%RR4;E:5E43/:'(
MT4PNVVC17#+;S6E?<UJC+:]6\PQMM-F;<8I0-LD.J?@,B>4VHW>/6I9V6_-]
M:3>^YU9?^OK<&5_^QB;>5'U]7RUB\0=ZF\N4"01B0,MD ;:,W7?>3.#J62:P
MDLP$#D'+%9!S9Z"[JSBRK;(99W2@&]CB3L&9_A*""/U9F>2V=DHYS[_XP$;M
M@K@N[P7#/\1:$@#BC:G35J8Y8!?!075':^6S'&/ZLSI/XHL)AL70F%MMT&*K
M70RW^XSD_IEP&]Q%N9O:JOVF))J=M6?U[HKTA7?;$V:<:!!)%F-PU1/R**UY
MKCGX$H^+\X2"1XZ6+&2T.D1BOSDOB0-B/B5HT"#0C@GH&N<S#HTP 925I<('
M>$2(482O0ZLV_HE$S7K^N=X.R=;2DM-.3\.X[-?;EZZ(6>%)X2E(7I^ .AXY
MEW*['PMQ1@N+"<F&CV6>KG9$NIXL%TMX_X+- 4ISZ=[ER&<"#59T>?UHH(O1
M^77O_",FL/F="81#AE.AZ_QHQA:,4B(JR][,4 YT*@=A^?,Q?#$^F]3]Q4H=
M0E$^2N?2W_)FQ?\-S0H XHRIBVHL:+[O0<-!NF>QVW'OQO\+-*/G/>]7\6QB
MWS:Y+H1>D4"2F< K;W_I-<>DINWD3!1OY:>;18X?RI[;PC]=63OS7UI3NN"X
MG\KYN@*^*W.;RI,\GH%D^<<_Z_Z4<B1H)/M*F? >2E377L!FAUS&<(/2$$X0
M8=134?3NW/I/U4%-3;C_7X_BU0?D"L:20@"QQ*"?'LB']DR@QPBY,X-L*M$-
M0GAK-U\8U3LWN"CDUMOHUL$6<D^#_Z 6[71^UN&5_Z%4YO^L4+VE,BVP$PWB
MH+!5D'QSL"9E_.6G[*+*S+S"1L3%HL.?9)</<OA,AJBCXR#'EW2$ASSVT-S2
MN@H7>*J7[7#XIO1O\X$+4^[G^RM]&6Q4O_2I]L<D VIR:1W-,PRQN $;$^)D
M^ZK]!"E77>#?3Z9GBE=1C9>KR6T]RV.G7EIGSK,C+BD17Y<?JXS2 OALYQ^M
MCQAKJ0V?OU_%]P^ Q0Z\I*1--3ZK76\0&5A<?^U;8N1@N\$3\[W?P4BX,_EM
MYP&3WAZV-J/*4G^^9@GI7A4>R3LL?'^G%]AUN/L^WG8*3Y&Y79H;U=AXVX"S
MWN]%0PD\ZX]:;<;Z#X23*_NHZ26?&[TW+T&R. B1((SVF\7$2VK6N"]4YS=V
M[I;<A?;BNK?J*EVK%,JB3MN<OB.K,)<E/7FS8%F6_1=6<>)M((1<KWBM;]FY
MO-]GQ'KI?,FD^1?UWFN%<</J &\NVML6_=]JB3D[@'L$"1<U?>G#! 0<_%-N
M5-2-Q,3<A2TN)'D+L.(@ZNJ9$(/?UT^+??5EN\J1D&!7V[8DPG) =/OI\"!?
MC.P7BF]]95>YESCVBQ27U_%$\;R[6^$)?Y$O!M]?N"+>_3_L0_:?;<.^NN9F
MD7\^2L<^6OS9/MZ#[1/KG]S^-A'G"A#F5'A.YWS_-,M$O#HD8O9,Y)W^TX,,
M?KM\CT6M_9-C:FUOQCIR_+\3'(5:.#XV6AT5X@@9EBGEFW$(&HS)'^]TJ?E<
ME7FG\?E]2T1G=,2?"C37'RMB["?/C]9VUPAJE\[=%Y34.]<Y) YP]' *[EE+
MM<0A+,&9TIKOFJM;/'][GO#Z;R:Q?YYX2212QFT.F,JS)6#W8\!TW0'E(--F
M5:NTQQ\09_)^L:Q%R#KWOZ6I XD/WI=.MD?RFT8MWJ=HO3GQUV IMQZW/I=]
MR(225!C0:CC'(Q/7H.G/26X+76<"Q_W1+4(:,I&^''&+*PK#J4O[]'C#E%MI
M9TS\PKLTS0ZT100*\[T*O)PW]\)A("7M<3I</*,2:Z3:)N8A>-=5!@ N2^VD
M]?\SN.84&116DZK95*4C12DM@Y?.67VW'=_^N:D/2AV=/W@RC.]DK"CIGZW0
M0MR[2<D_56] .<YD'EZO9E:=.#@_%K+/.L.H-A&0E+LQL5FR+<L^0P+]4(NL
M,/;Z*BNFW/<8"L[XLEQ+Z /2*Q('_:Z6X03JL"YY]\D56M.J2)[?*NE$*N_B
MY6]+Q/JNQ! M$I[$)4/1ZZH9%QXH7@\(<KJ=;EF'6E24O^FKL$?:^)1O>U#;
M_0-JGW] [?DWU/%[4,>_^@^HM7XA(/0@2BH>(>'OW;C=7!UI3RA15"PY55'I
M'A(Q*"G5-1W46R'V(G/_<[5PY$0V^A#V_A2*#]3_WMWR>2%MZ?N(=>/S+..#
M"5&-CZHI&,O'(?N,@8"5"+J(\"NZ9MY<F@L+;C\6W'F56(]_AKOOG^%VZ_T_
MGK/Z=W'V;QJ$KW#!_09[*ZJ/67>+F6,LG4X G -IA.P0Z#X<.1[G3H@^@XS(
M/"FM%#+R80QU+;#+8+#$AM'.!"J6XO"FPGAQ?Z/A#IVK74$QA!4'P=0OD4[O
MR 4=3VN*7D!>E0=WHBN5WVRY4_"V(8)RO\^$"',2-C-GUXI;=A.@[AM$ SSR
MZ(K)D95(%#T*5E]QFW;!X?!4&+[1]L+-Z>"#:HN1.V8J_?;5K*NP2YOO<E_-
M5D.QA4A*"[JB_-89Z&&L[F_V&B7_<C1L(WEG4\^J/-+)(C)//!O5& >EW=[]
MI$Q2-J!T._K/['>.1YSZ%3I_P7D[^-J'AKW.EPPW32F$9KVA(YTEAV;S.?D#
MK%8\!>K_4@PX\ODO@:]_">[R?4O9^T///:,82K8%7T?N;"4J(%?/*"&=($1W
MIZ.HB'&I@[S7MLJ<=&K6Y#=_1P=W:<=IAT-GH/L^[L8AW;\.B\(B&)+)_>$/
M_:,DT*M]!0X,/++"=P,_:DRI<WP^K9EV[7Z'#FY!?ILC.^V59;M7C@GT4!E]
M![,HOZ.',0VWG9CG^\D'W>)GA8(1/+O9=B*@12EUA8\)B&'F5*,#"QJN!Q^D
M:^Y&!$/_((]H*08\I]39AO6-6%1DNK]O>3UED_ .M:()& <3Z;Z4CSE3N+ &
MUIJ5('JS<)XH/A.7^U1=S]TYO)?-Z9N(9-JRV\?;ED/T<R@&E^:.OGX1BF]N
M&+(A&I$' \\H+ATO"B4O"4-HHA$X[X*L<Z@F#.A#6!*L@PZ)*C&!F@&5AP0&
ME\'.]:9.T\@*\Z]^TW SPK*+@+7H+;HZJP'8THD30@[<-[HN'!PD<P2K<#&!
M, M&WQE5Y+VYNDL9N!&SC8T%V->*VS/79@S(+*>H40;G-@R,9<W-2M0.0*=,
M8* 488D/E8[?OJR#&WE"6$X6U"T#DS[LO??,BE5*5"'E.B^S=]^E>R.;YQ5P
MX>X>3(!R<P45:100X,"GEV;S[F92X;5]&-\.[: %6F)T2U_,LPL^DF>](>&)
M>[U!W3XF1(-(/6 =,F+&!.(,F #ONUT6[G-L.<B)>0@5,_9"WBD $@ZC_,$0
MY1GAN\),@'/ORE.LJ=QB]!I J:9S)% CD@[?M(T&]OY[W7N8A5P'>B-W6UGC
M%%V$PA'#T,DN% 5%"Z;DX4(W/ .L*+3( CL/7=VJ@*&LA)7#T7E3',Z?.-<P
M1 ]9$3H)B9>ALR:2;3JE2.?O9@+-?4P +TOW@*P9TIV1R]Q0)G ,UK=?X%#;
M6C#2!1*'7#>DN[#&8\,$P#3.1305@VM"B2 G4I ,:5SN(5ENR,]-^L7(UC(F
MH(QN-6!,E.^=08ZF=+"&UTWO0_[7I7+_>2FB%;<MQ6!)N/$<$Z ;0R@=.%'<
M7!+8QHH ]^Y5V3W9>\6:@4"2DQ@J3*!7AIK*X')E I-N+(TU!0DL,D:WLN2/
M9@)1F#^'HO>UK04P@<.L@3&BH+$XRLV]&1C0+R+_[N?B/_I!WKAK)@1-)X'.
M+(#_:5)0<E*P"I+5#^H_^H%O7\L.*0/O[_ RNJ""@9([-G3E0=_N2!W9/N5T
M;</<FH;ZOH_1QU,[WKB\+04ZV-&V:Q!0UI6>F=J"V.'",%Y'XSX0J; H7%ED
M(RS6\70ZC(K +UVZ.YA_\F?@QQMGWH8 "DXNHT^ CFXC@/%DWKDB>>"R_HVH
MMK??IM8P<R<8XI@=-62O$@N,;PLXAJ;M,62C-M*U+D:@/(E<GV1WLJF-]N,]
M'SW&D)25]S/_+'WU1F&I7P:^[$..+Y!\3_L&9NXR<B(=6?YB';SO1- :'X/L
M%ME9H3_#OLDO''-7PQN?SSIYEEOJ^Q.-P,8U0]*'B][&3W,92(H(?=X<UO.,
MK@FC/69IB!,+C% "DNZ' OUPBV,LW%M9^L)>RL)LR;RD>[8U!9=%^O>?()0E
MY' =(RH.S>!T^#M! R.P #.G]J_3,OBW?D*^TL$^POH)EIT0=M-Q<V^'6=&D
M+^GOM ;_<O,5>T:@.WR;AV41<,9/TOJM1RS;U%CYCXP)_WIWED)P,+)1@ E,
M3V*=F,"#3O3VG?W^5DOF!8V(G5N!EOPL)6GO+6#O9P14!A,#(;N)C&-T=NK^
M\>H)1<X1,.!N;95JDKV>MU;XY+EB*WY-WL+\C_ZEJ+L@-Z7?=D !L\$7.2[<
MT%";\#'S]ZQ!=:*ALU/*PP?OI#)S!XRT6BU.+0FB9N_-"ZD=G32+S>"#EIAA
M*3.Q<XZ#+IRE:E;K+&8Z/$O)9T3EOT)2##Q9%GDG<G&%4J+/B4=PL3&!>S<1
MC-/E-,]'G1;"D B#M?N^>3\>F4S6;+07VBMZ;1'6JTCEU4W5QQ$1X_SW5[+M
MD%2![KT\O:^8P/HM[!Z5:+(:J+*:]Y':1O]4G6%0Z'_\(<TUV]&,%"@YG7$,
MV7N1@F0<+$&"T?_ZW0F:YOECEZQ/WLLWLLX"_S")DLZ(2GW)0EL/SAJJ^;]7
MF5W:RAN%8J$::GPK?%VX/,S?@V&)" MAC44>QCB- A^N[%4$_J,B!)KF)6OV
M9*B[7IHZ%CD+Z^NF7T(V(;:E'5GK4J,@A@D<-?BWFBO%2.7Q!]NHKC@R[G6P
M[R[+RO%J=&F60KGLY4PZ:LO2/0'DOU?M1[7@>!ST6$K'T3TX;IV= 26[VLTX
M=\! BA85IC@&<U\[U9(+/Z6E_.@*)!QIF,H$ !U1CV!A!,\HR(E'D6FUPC_S
MXBX*5JNQ&47=NG]%02"A3J3%&TEI@[$C643&XOG]%_:(3*MVU.1L';KKI<'C
M+_KF2].CP?-?C],NE_PTCH]G L.;-*.DD(.KTKP')>.OMB"OL1J [C7@_X\&
ME)%X,3K/'E>3(70!_%X>C)K12.[*3_0Y>[OB6YV#_:<_;26'?J,'W/WB,7A,
M5]3P7M%GI\"GGC(++4B]/SNGZ +Q:G$Z0J"%4["(\,W7![9CO<V1>/' O3:-
M]]K4W=MP^W13/F4'W16(R'=^;,.GA;I4/6,I%7,#'M0;TRBOQBYW!3*(RT:!
M3NA0W+HA=B^EUUOD'FO&-QQ@T;,T!<4X='^/GF?6>&&7MKIVSN3(MOPF0/&G
MG38.Y"0V*^RF7OA1C4HN0W^$;ZNR.%P3%-_C\"8H>#:2Q>$YC.,K$\],P;N,
MHRS1WH+2C47CN[_22=6<!3]O"A;WZSM(GOO:JH<T@%':D.RX_P3XR![ [R8Q
MPS(3'Y/)<8ZT$;+I*_Y)8I=[CE/NM2LNUZZVCC\7V)#(7RLY=_%*B[-^;/R'
M"#EM_(#5XBS]&(J,"X&ZK0S3D(+@++DZ;$/<W;<H_92RZ/X*[IG3U^]Z7F>_
M[/>[(9<U6@UP;S]S.FNTLG^/UIQE1 R#6[TU7B\W,'_8&<=G)Q"[_(B#>[DK
M( QI;"KMRRXZ6"!09O=]('*2"?#0%2B>I74Y?TJ\W95KQ;&%\2+Z1E\F-K3=
M0[T97 @F(&T\8;JY@EPOM=UNPAZC'?EUH&[G#/WR+YX(],<?00\V^4?^^'D1
M1R(O&2:6G3STM=6$TYY0W_./MX;VRGYQ7T7GG@V.?IL[YO#G^\O5KBKT?T:#
M0O)K>)HFV$\Y1H8M[NTX.Q!H1GA F8W?X"X:HOM^!-]V*F >VXR)9?+.N+6S
MN^I@UV Y:L)'B78_M+HD(\XH+(\)7NF0H6!2L*8[-X+;=91_Y0S0=2=AD2]^
MYTGL&_=0_=PMVW:U?DHF&F %!F$/AV_"*2];^OYX>0BQ2+@4:Q6D]O+4P.;S
MHKS$ND/+L_>?3+N.;F(P1;&@%=7N&Q,0PFI+?Y@0#S AK,,O![?V_8E[F^UK
MH0.[&BNO*/'*RI453U@E,'Z1!!6#>1A=#3K4")26UX*&8]J2<V>,](_(T^I1
MNF^>+.=S^&7QV6<WW-J-U%'P3YWT)40=:V8"PI[8@ *;$=N*M&.@385FB=)[
M(06+7[9W'X4</QS8L+&1\?>6,4$JC"YXC;#$!+@8HL0,67B1U]22@F2><O:I
M%R(/):YZ-T7N?-4Z_+MA "._RW*Y7#.$:2A* RI[P;8!\R%.QB+2IJ*^U^5&
MJ63-ZPOZA^?P85M_!@X!(&Z"\1K-R00>FQYH5,2?;6 ;6LB4:*BN["G>L!@H
MP>KYO O4O-XBJ51ZW-GY#><+*BXL^%1#RE0C5(R.)!LN3PTP3NF@H7'%6KK*
M+[Z82L667?>,?OLS,?1S\T$9N \GY[KD-W19PTLR,EK4H)GOB']_*_2HEF$V
M_IS&W7'Y :>:^&\W#B;D7(\#'G")7%Y85$IWV6&G7_Y,7=18?S9^2D-,E$"7
M>@*J5(K-E7DX!/=]]NRZ.JVP]'4I7I;]CZCM?YRBRR>P^Z5!U0-:/KNX-(D6
MF2OB2-LH"".9Q$]>.JW=7"[E<2B,^TGSE'81?EGG<G"O%TAJ1!Y>YGRIO/):
M1ZG*T\V09OB[LL>G/8>M.>?%N]GG:H?/'JIIN]R^;3J5^JV>;VHS<MU!N%DM
ME4;T>U=LNZ!C$9.]FWV#ZZQ8>G*YB,R;"_YB@\*MR.%G>)P(UIV,$?Y1"J*:
M',_V/$@DDJPH/\&*F@!W'3JO4?7WIR\ ?5-EMM7\Q6Y7JL$4M)F/J-9FOK -
M":<'I@XZ\J <JBOA1?+7RR>7K4][KPFQV5C$LSU^8<5R'#FJ>Q&E#2P::!.M
M*@^8--9M<3Q;E^ ;IQ=C^@R!>.WD=UE[T(2375WLT";T);1<.*)A/_W,()V=
M_-/ $BYN"_\1$Z>_ZI.XUEGC4$RFA=CH7[BA?<#; =H(>26J^ T63N0+U=(^
MTTPT01W3$R#$EBB'9V2\^UX8UO(V$\CB_;UW6''"6[E$$V ZZ:9-IG3?+$%+
MK?!/%<'5]"NV(F5<OM+X]P$?.3$%?;^D]\ZN FQ;/'!J4A.#M3Z$?YA<$;M)
M93GSUE1(-*(8*PP)7T&4K/^>KZ(8G&XO$R;]>G*#NV<=<X]J\+I!Q3U89#=1
MY\0"SR</]+'2#>XXA$7_] !QT+!D*<K-"9OQU.\58MQ92?,@7B4( EE4S,(L
M!GA2SE1VE#T*[N=\W3=TKM>1^Z5ZC?4FY>J#FK&>3'A1'_+AR  X0R9%;1-B
MI@<KXXXUZ>*?7!L\K7Q):.P\6;.[<Q8J@[,%J)["C$,\&"B>>R2&">RS':<;
M($_\F#"6U^O##!=7<C<?NI7M:E]\LRX)9?)NJI#2O72&BG*DXF*"!;LG, >'
MZ%:]CY9\ X*(]?@_PI87/ULYG8SI-#R2?,)H8GJ][=SGO6-5_J0A&M&'P=LC
MK;7AZ!BLYN19K'D^V$3L4Y(C&9YZZ!H:965<=_>3UJ(8#6,(\NVHY#?!!/V+
M6AM.4HTW4<&G_-$_C U@#6&:]S[K*XD=P4-^"#BQAY@\T99E_PN4=Z&:#*K3
M]>!9;@DR,5ASY"?_M_ []G9C1&)Q%.+1^9S5+B8P>B67Z] &S';;-EH6P'2,
MP2>%JMVI3K2W(%FX29M]$A>N//9 &QB#)[4BRQ-[K^M-A68__=/YJ.7&2;Y2
MJ'713RWN'0WP&)F$KT=^V]9GQ9"4^(5^!]-/=F/V6DNL5;KJ05=SM60\ED5W
M73<Q80PI"LOE@0YODE4B7RO;Q<$G^>(?4MLU'GGJI#K!!<[*G7/S6XFRJ/:<
M.-96_\('4CG; HF <#5H.3HL4/QIK'O'E2.;=$0)*MS'2]Z8GAJ1-TH \B35
M)4<GWGO![/TAM#O@<\J:+<6Q*-=]$_>(XI>ADYQ=^8O>'V/W_%V:'EZI8^LU
MQW1HB/J^C_U(%UC$"R3>]"BXGZY>S3A.Y:$3,_/A05I)RIL7/S],?:Z9_*7P
M*H<3NP#;JFMSAL'41]34PDI('/70R&1\T12)?=QDR??^@4P?]XY5HIY_Y';*
MG9-LC5)3U(V?NK0[@SI<@9J_%(,%#)%3J*AR]S=NMD$L7[\258'/&RXZ<)K#
M=Z@@3U?.*84[\X \08>'T0GETV$G>8BB7JT_3[(:D+1^[&ML1(./5$=Y52FJ
M/GQX\(*.V96)%X<V; $PIAE=;M6\='/B,8HRJ]?CLZM*L+9Q)52R'/,CV-J_
M-%ZE7IVMK4F0''Y^F+I, BPZY'*7!),F,4-0&+5R&8>9EW;S70IHHVVFJE81
M!\K<_V1=/7>?W>[LZG32]U= +K]:+"2E82T[Y,AAX*Q;=HB.)+42%P]U4QQ)
M;\D\T,.0\H]LE#A(04<\ZK>$\3D\?_K36W.KL,#$4DWNRL5[G^_**=5)_NZ.
M@0AJF5+9:5Y@$55G<_+WUYR%Q(4UT. ZY4S&:E#28D#*6%;:6*B[M/^[T>_!
M]RLD-K;?D5G1D8X(!1,5>'527$:O\O,@_0JUHQ!V[6W*4L[M OM-(M>^FC@[
MVBU0K=0_<:U9F,2#U?0J<;3/F][\Z9QM*&TY*B7U;*QC0]O["D2 ,0(M5PC/
MI?.!I\A?2S?L4$?&[.>"#_>MXRJ_#!&KI7]/7[D@:CDM_(BBKV0+J_R86K0
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MU8:3"H[\SP3S=N;Q-A4[N>&2B0^CDOGO__7PY(1:U0O"[]DX+3[J2_)0.4(
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M:I!RF-\<]T/GC-O]*'YNE[AJ=XO4G&D-G+ZE5'U</ H35%T=/7AP(DPYXOC
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MF(PWANROD8YA[3B)='( ^A;4G;IESGW^Z;] L:BWWS4[O7 KTM?HC731H\U
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MR;%7)ZH;-N/R)&I<CFQ):V\H^Z?=<^I?ZUG3ZS19-&[T?"VP(=T'$M;&>,$
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M"TTN.QL*:]]\8V7'H;L(K1.@B_MWH>OQZP*% /LDT\04'5V*7EF5][Y&77!
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M3+Y)>^36JM%]RH,.F4C2E=$/Z;.?$A_U)BNAM2+_WO5:W60*]4Y#!B>@>,W
M+XTI+AP1\0VC:ZB<,"W)O^(2@Q\<^OK(V,?KVJF;;[>?W6IBALYCNE"]05\6
M>1*KI+NTK3EVZ?$L>%UL;-^+&S+[?H'GV6)@BAD(B5[_MV3@&TM]P+SD)4H;
MT$A#6OGS^^:[-5$\Y^8HJ7=&JX+ABPTCF;B+G0XHX"R$<+//\)96'A+V;X<"
M&?0'[8-/GI>8"'*1H75"!:X/_+'VSG)'^)"D5?;GL2[-G^-G3Z9P-/O&4=VR
MYR<>8X42:*H]F%H)K*;,Y07OW=2CWH[I]!MY$TO=O4A]O1J%<J/,(56O\_%N
MB6YL""7.SL4/6!H?73:J2T;JIP1Q,P930Y>3*1!/]4'49IJ@>7_.E__ZE1BW
M<=I!7P3S7?[7]B6P[ J,[)1KVHUI0&,/P%WSDL.31,WX*G72Y\E@J,Z@0GMO
M0;G#991B?)+XP\&#UYX-)N-YN_>Z0CU#O=9#F)-!&(W@1TZNPP36=@1.T,^U
M .B CX[(=#G5[OE3+9E4:0ESQ$=,2TO6[=:DW,]-Q\A8PX,0+QHGZL0HW8&
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M(,D.0?JY.G)FI6>E9C)$13'QW5AU<>88[AA)(O#8-Y7;^HC.>0./O"$&]_E
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M*_ E<.5)7PQB7OI6O6WFX)&^T >CUTMZ%9.K)'6;0^!GOGD<" #)- ^Z.N!
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M#2AV7=73OM>'43 XNGCES+R/B",\!/=BK*K>ETOS?OJ/'TXO-A20")S2 $?
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M.E/Y"T(5NZ4<U=A]K/<$TG/'^7!0!!C_V^.BXG]A5(H7+; 4>$)]@/<CKWE
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M.@><SG@^=3Y2.\Q4U#;'JCK[AS:^^4OL%S;ZQ\I$:,WM_L.:J_40J X) X*
MKMW(*U8ZWL\D&_P<BNG#GNZ(QDR96N5]^'1PD#,!8[I&7X&6I@[?;JC5>DO%
MF.X 64PDJ/IK<-Y$I'Y[GI[T1,$FU=A_5H;9P]9CIM!JU86LTUU-9:B!PPCV
M>U8)\]2OS46/#%4PXTBN_AT85T9;67-4Z>GR[MZG_'U[V?<+SGQ+UD^!^&Z$
M%V3+9EASQD&P'<&#$P?RZ%=9Y:HM9TAA>Z35+F=94;DSQ[Z?G5)_?['@R;<;
M&:*IC#O@/'@,XEA*N*_;]!C&<7!<C([G;I/M)L^ZH[%[74/\AGM^S\0:/?F=
MCOUU/^T-6].JT4%.ILRS'9@"GH1@''"%$-K5B;].J-9YZG44,;T[CWI=;4JQ
MG9>*I >Q7FOS'J@SQLN4!"_(T7F+*9H=X/4J<P6R_&?:8*G V-8E)"D)7Q>*
MV-+%)\P#%V?Q-!$V%F1F[4?QWV60W#NP%9?:W3U)E/'$#^2*&608YR;P$"*'
MX!_G!-(=3ESR1W4^N":F:^5+0FB(W3.QOI+X(?5QX&.E,<+_):]?[,;TG[N$
MK@G7.;\Q#\6-;??XMN'*3WE$,Y"'EYP"^?P&JY5YFJ8EZ\D.S/?H.OS1'4SJ
M1G$15<+B&<>KHH):F0MQY[%Z:5-*X1_[PZ#!P6MRP"1-.O2H3@P28,%VSVB?
MA3 _F@X!HFH6V8JE6%WYO0'D9=^!'=,"(-FY\N5M[[%;XUP)@J9BT\A*,,#3
MK,QHA)5YQB6'I?E:SNZDX&[#_=56'.&!Q4Y]ONQ;QY-.J.C)"^F_#B"V_"S'
M(<&Y/.HE*Z(3_07K7=LAK!&D2RL+M.8)$YKMV\WQ0!3&=D%5D*>8;<P8AC'8
MX\4^BB0-([<N/,?3U:#W%XAML)SM_NRB:376BS8#?+L6WM\= M+S4WGT\-%:
M[>%O57_645R6@;>E"^+:B0R.$S&$ZW:_.9*@\;[.L1]77AE8*6*@B*P*#.EO
M$8 5.QI\POGW')Y',RT4YL6^^O;HZX?'@(3.>ADU*HN>_G:*N*3G411 ;[B?
MI1YWN"EJM+1G">/N+K\?<V@\N!,9;2@#:)).ZW: (D.0H.% J%G"Q^J1E9O[
MV_V>R4==63*7WY!/NV,9,/3/EK0(UI*<I-GN@F@9JWMAVFL^O [L'E!NX$:C
M_2)+#9+/ODVQ-JI42' !Q"EY4B8T(EP4(V[=1O7(N+O027Z/%S(YDISE':BL
MT;^W6KGM[.^THY=0/_;"N+["3T/S\P(TR2@B N2NHN6URP@,NTU@KY#1?#.3
MB]G8.V92SE\FB>'Y[D:7D+'ARZBLYA2FT#*E-XFYCZ)R"1[=IC*R[FW@OP#?
M/[.8]0#_J'9>"(CFUQNX7-\</]<QE6>BQ'Y]NE^PR6BX,6PZWNPA?.:TYM7Z
M\=KIT#[]6-65WQ2'E[D2>U._)&J4E9UT/[1;Q'-U(O&?OALRF,X%M973U/>=
MALCA=6EXCQXB9K5LPQ)I$GW4S^^[R8=DK4=<63ZK?+(R+JO3AM?M:OY52/-\
M$5GMV;D*IR>.XI2)P/T#+6%OIUC1/ZT9Y[H=>+H2.X3 "Y^'VO=HO0V?.IQD
M(7I9::AXM]U090XA@# UT8N )-*=$M&&& Y""7DA^=9W-X'L:;,0!^8<6@LX
M'-]A7[;2T+6L::;=M857>]TY9G[52":'A.)@ZK)R#)Q"WOSZ:4:=:Z*ANL1!
MN5#%5J07C:-P\,WL@,@==8^;(D>_5"6]+7TNX%M&17;Q\Y(#(EDE"_V>%A.U
M X:^J+K%S6-WV3(E)(]=UA,J2#OG=C-7XKQ!).HIHJ:(*6Q'L4O"*?GDR@(+
M"RG"ONF+2'[FF?PO:/!PSD>L'9G_+,N^+M[DI)Y_J8.3<8#.EGRO:B]"23.L
M<[>C">MI ,'5:I)]0;?3\L+<^(@]E1!33AY[5>_N=8OP6.+W& _UVG6+HWN%
MN&"#G.]WJV6%PZ\CHI$^^&A#'>>;M>C8.?:QF)C5N;\V.HZL@EZZ&_?F]SRW
MF,\FOP<>ZF=7,IQG@>I>NBV0JOBP]GV2;R^"FN3#O< X<.2\6S/!-]@I2&#E
M+:'U6-]^6.4G%3C(Y4XS7N",Q)XA:5>WT*SH:YT# AC.,S0.B-G]HF\KO"A>
MNO^FBSH7>T6AI3&:%ZUSZKN&>+(I*MO( H;[P-0!U$@[L)@V)1HZ'JM=Z.2X
MA!>LO#&VT3?I$<)1:G!_R*E;3?G:+:XW5][!SD9^DA]?H!6F&7BT28.#=>",
MKUQQ@O0.K(UQ(E B"[T9_+AIH[+/2AKL)]1SI)-R^I4NO ?:B[VR[%RT9/97
MCV#]T;XE&/SE4. F=898,)/.F6.9/'RLXN*%X84?D[037)&_D8^0[_H)CUJN
M>I+7A##O>QQ_)KFE6#6.!EQ%M203+8KWKFG(HCE7K/L#Y5BI-3RKEL7J1C);
MNQJ;RPQAE>/$P+XKBRDT);)B!'-/\U"J'SQ6.R=,?[7P=)MGUH_JW].M=Q,I
MMS<J(CN1X@9*%&<\0\V,IA!3ZH.:RMP>K*]I2P[A3VH/W#<NDC?SV?6Q'&M\
M<E*1HXT7\L[Y_QB4+FXRKY80U^)-<KY#Z:C"(!;\LA4C#9[5;J*$EH(;4E3?
M>!YM2K[JEX+V]Q;ZND<TA)WC>&)1 M6,*51#[NVL3&FVBL/)3"^C!,K6P]!&
M@UHFZ=VX>Y*H1[4HWB^/.T/V6F>T>&^$QB2-=3Z._[TG>L;(< 7("*5FT34F
M("(0VH7RI'XMH'S2:E5R'+/5SRFI\U;I>CS9\<Y4^MD3BT-[M#[-F'_5T"#O
MMKMC\C<.?VM+(>LD'7D>.&7Y,_]JK;_HI )W1L3-U_I.]Q*>))8(7(M0^H:<
MW(&!W$$T.?)<Z\T=&#^?@3>:Q!(V'U:M0\"70/VPD!84^9=KJ].LE_G!)+J^
MK?AYN8:HU[/?7GD-'K+=YMF]^]2"L^G?;I\Y#=HC1[N$(,OCY#"] RO64BJ:
M%SOM?]7WKGQ_^2Y\S"U)[O@28SK$^\!C^#T@D'$!$"=OQIJF+^0)>V]_?>GW
M8W2O#B..86"7[F#0)"=E\D78[/D?5S\WOHE %T[&04@"IPREP<ZY(Q-U*?O:
M,<U9<;7O^76OY9)Z7#96W9HS*IZ_K?#,=OKD8OKK_,5]['G8EWLB;A^7-OV^
M4KOU(UE"U2U:)RB*B_\8^V%3S*?%@7*<.;!&O\ZJ,CC-T,)X+#E?I60EM-RD
MJ'%A$FPG[JTB>FW'JP%\=WJ&O\S0EQI9U6?^!R<.4Z+R'=S/,[N#!!^R;=LL
MH 68ZHU 'Z(K26:Y<T+F!(V>))" ?NNT=,MV?$5YSGOXY+53YF(*N9XJDFGL
MSY^S);__,"^$U:<A+^9N=NJ!"60E?:>8VNPPC6VEQE?/#)D7AZK8)N2.ATAW
MX]R W:7EIJ!Y,5GV$ &P',LL7T!-I>%CVB3'5>OJQ8JZQ-7-?+\[] R+UDSQ
MO]&_$!N>3U#^TG4P;+?!]BW64X,K#%4F&TWG&1G%A^!UFO=-W8'=</(1:W;3
M^[MX?SNLH$S1VO^424LZ9_2-1V*!7(_T-=D?PM\5_W.$]E_7#^85:F@'3H?6
M&\.T+,.@C<<,3!9L,VK]+RQ]/A506W-\]7&GW)ZAWRX"PYK.1_Y=B,E)1CQ"
MP$%%K!\U+ZFR[%ZK4R]"X!4AQKA5_.+(XK$'<:*37)4-FPF2QV:*I$Q/^#;6
MMT2OGXJV_R'8E!1_PK_LY/' F6!1X"K$!'I0$LQ3C%MA[SOQ?"UF+S$UH-!
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M .>+$M<MWN]KE%1(Q6.':W9@[G/3T\5_WL3A0^2OU)][G_6.E8N3P8W-5^W
M/OC"]TW.8IW0^^S;20/ ^=]E6%WOL')OC27>8A]#V723A(\JNED&X[9?W1QF
M)7X\WG,-,NB-T+?$Q>KIWL"[Z(#-M"VQ9?GPBW_\/28?LGX0RVZ?ZD@?E*Q"
M"8.?YZN+>N I>=Q83@HB$278)H=!=V?>]C'E5_)XP4]_FG:ZN^W% _))R:-U
M:BM;@;=Y/N:ZE8FZ'K]++V]Q,6D)S K1.>J\MIDC/=#TDG.WROFRJ0GN#.3@
MW'<;CEHR'+"F[P!7LI4T)K@=P<D\]G+QP=?2UYC":9.1%ETR?\!O5/627IJ%
MKT&6[65CNL<S61YK7?G' J8-T;M?]$%"9,4S+X&P?Z-ROUDA\QHUF,B\XNU9
MY%C[&!5%C8[TRT[Z_OKUTS<-36,-)7S2X8U[;QRR9MO.H%(6\F) .$:UKS-7
M=&A]'NXEZ17H733I5"9&7YC-]X]M9%?]TBMM(>R4L17B3D%#T)YJ;UZ!Y70E
M#^P%[$R X++.H K,V@?)BE<ZJ<52_2(MMK;ETET:ED&>VA^#;ZH_,K@LGG+D
MM;3)SY5TAKF/9&%3F"\BKI;1EW*PO=3[&+)+-W-NN-/JLEC([:Y/@27''E\(
M%SN #)+LKM7*9U\/B-\*A2 VX]1N!9,KV01HIZ@!%RMS+ ?O)<DNR-^(D'(^
M;=E9ZSZ_V1\2>*=<7;_0_LTM&)%S5 MVQ02' Z>:=V"K)J$T-*4ASA#AXX(<
MPBJ2I)"098L,W2/ B2X[L YCE1'V,I]WRD// AR_$K]M77ZS+V35Z'#]R@UX
M0\M5$IP'Z.U^H-I0YOU ]549H." UGK?]S3-?-TS4R'>7,[UBPE9.3_1W5Q:
M"8LZ&P ._#2A)^6BLUK04\\#>J][)DY0-B#6)4XSHT<!@I7SF'BK9'')E.[*
M%*)_W3?'Y\<*47. 87_9JFS3^,OHH^U1*LH5#I>Y!EM'_9:^F)[6I)]D/3=4
M=<"W>[<=PBSWM,%'-_@-G=%=Z46Q=?[*T\:O%TWUE?P%YB\2S)'#E.R92^YU
M;EZD>YZ'C^@_9U]?^J<I!G/C/80.=F"+S0<E)^*TT0\)8F5MPD!P3SI&[BKM
M&[IHH)#HW%N,]WS&IX0D\N%"SJ1*($^0<I76C__GYJ)*R"Z<\C!3^E:68UM!
MT>+]X0OO\ANRN/?ZRX6-\G7MZ7VWY+O;HE1Q-R[8Y+E4U8VKK&^IJ;B.JE)"
M;M1[9W@\$Y::NGKJQOLL>3[^SM->XW5]:OS>=U$^NIG-84G-OS/)/VSBC\9<
MK%&'P4M>\EZS#8YBWLP'YBT8]Q/>>A.[X^X>:*QNLHA-$'AS1TCCM*:CUK]:
MU-B7TA"= ^3YE7T3M;83[ZSH7JT)JUA5"J-\&EP[K7?7Z=J__F?J!:U(- CR
M'^_Q+2UY55_?8)KI4' [M2M>P^$I%<8NG[M/;_BW$L/^9\3Y']%N0F;R?A)N
MUAI<<A%</V4?RO^WI9VOL[>E0M).*<2?DC]IXLF6\TM_9-C]\3M;VZ.W/QQ<
M-8Q^*/U/58C6C&E-F?OH^0_O+C*[!(H0L:^]A^<40B1<39:^W.:D& F\?H:^
M*SUS]GR^N5Q 8E(CHB?O7X>L1?<3PBM:4K5,;WY*P<P@!>I4_D^UQU6WU%NF
M'NXV5]+,/^QY7B9]YF#D1[G6_U 1<KF16I\5(KW=7SAYH?GEGO73S2=:.E9E
M/,P&HF#8*=*MM(&.![8OM.XX01Q6Z*R\/5'_GNT9.8['>SBE)O=,+ADI:K^"
M?/X@5K\(L+MH(:W:,V!9DYB627]7IGY849'G)5N:N>&/BO^B% 7'@WD#<KVB
M@7^=:=WU,52> 4L:O8IF"%'&-DF@4K>[OUY/Q-JG\/=<\* IX.Z6(L<7%>>7
MFAK/^C[R.IO?<$X_+I.\(&>3>3EG;S*G,J=?;B"Q\#\WOD7J0ZZP%57]NXYA
MW$OMO#QLB,",](Q@[!CV'[8O114 I1>C0V-OG>%X\WK>?'_VJ0P)ZR4)6XM;
M9:8&_9V<I.ZL58N%RC@]_\S6A8%8G.AH&5,\?QHC9T1M&;=#":R71@T6..6$
MW7*8_6V55;+O>EF2:CLLZ06V!UDP>IGSFP;V&*L8IX2Q:]<$"A%$@;5.4(16
M%!XTZW/Z0JA46"C#5K?%.:QL>#1<-4.&H7ONE'/[EYL9EF[8VT [XR93$ IC
M\D!.5_9 MQI\SF$Q 1Y7&3!AZ205%H 6F9Q>7%R(8/L"+^J[G?3C^XE!M*SU
M!N.P3= +H8$NQ[M32V+W&\;31#TCR$<R=8ZW/\FX<:839O8*1G\)_WS:UXA5
MJUK;;VQ-+<RAE,:5W4-)MY/>KXD0O?O)YU5<**;@@$63>AU:PLY&YW,7Q[7(
MKWO#79H83DP%&J%W#9!%=:]Q>>G!>^$BF!3;NV*I1=BS]55975E#*AMEC8(=
M-B[[2Q6ZG\=)7(LFE50.OCW*_F<3Y'9EZ#,Q@!%.LQ^BFVP8_(=M="+6XO6,
M"3+!0*.-VR+GW#N,&J[WS>*= =':H>H.VSN= ]X'&[?8RA 1^W'SMO,2M0R$
M.%S<!3"S:GI?FXM1K(DF@VH"Q$OU?]:"CDJYY(;><8@>8V@*[:&ARG8[@8AW
MI B"<]F<'PABF+<#9D!&,2:E$W=HI&"P18T<]S+-^5:O]=#<,,TMYY8$?W+^
MX&QDO?8>B;.56;+AJQ!V9@HS[#"\((_)FU^&BK2BQ+J\:$.9AG=5"9>SSB>O
M7: 9YF8?5_FR>57I94-;V$4+!7(!55#D0([<NEX\C-F-H)Z?%P$'$=1KB 2$
MB/; "H(#P)L!.1!Z/3MJ%74KO<L1>#>L;);A7[KU:K7,!4,\]DI0AYK&ES15
MH4CJC<('6!WT<C3,H:!%L=;#Z*!*F5]B;2I._!IS0^NAIKD[,(9UF"&UYHW#
M =R7QN33);'/!'X\AD_P["XV^1BKHLQ F_9V_BPZ:1A[*>5*:\R%L.SKN?PR
M,LZ.DT[FA<)QTU?U[)Z:Z2?.!3^+_E,*[P:%6;7:\*@KL]Z&*L#[P!),\$);
M0]FO'GZ-Z4MY-A.W)FZ"7ZK:(O#J!8&WW*^F17N-:JYB([=;(5O6QV( /,,.
M*TK-ZF8A%G!1M"6T(":=C(YCFMTL<_3)_#/9*Y)YQ;R :V@HUU[^<?,3_H-7
M:MG<9GA*(KOQ]5:K@GB&7SMI5KQ71B&='%U*]G?LZ.OT#BQLB")7I[0/S]IW
MGV[L[])5*KE9J $+C^6[?Z"&<=CA-B!UKH%V;^Y0BMDP9:+BD-CPDH7W@9:T
MPXFFPY20*^%_TI/WP7"AX, \'.^%BD-1+R")NIT$X0 #7W*E&":G0R\S;X$E
MAQK*'+!Q:JHU30YU2_]R,_!@EM^<TTT;"[T*5R[?),"52J%_ (+)_!S+G5DN
M)VMC+,;+6S0+@;M7Q7H[[V?K 8(2BIDG<F]P5[PV=?NKD:\17OL<++IBA'@&
MJ5"+(L.8>6ZPC=NK@=B[>N8EJ[3[,;)KU;CKCO?]X7/"9YK2R/K'#EDOW]A.
M,\J)W\">._L\&;Y +V?<]D;M;3ML03D*'O?-E1_5EM;X^O?B<'GY^I96G-.U
MG%6[;/>?:]CEPUZRMA%S)Z9Y-/1.92'*GT!*O]O*#$V?K@,B&?KSF-<3Y/JJ
MPR/*909V^?W\N3DW]Y86H\Q.?U_]'%*BSE";<CF?>W(VXG#$V=\;:PBJ&8;@
M'5F&^8PF\MK2SDU8.T['U:[:F25+.3E?'6ADG,L.&SY_+K,<D2:F=44RZJS
MC]N&O_[KCN-(+3RI%$*&EBF[I;EG\6B6N.7P/0*?/>#&5"",N-/LXNY)E5^:
M/M.2=2W&+SO4V&"/]!4Y%?F E0_'&S[[<K;G<>_ O-%3*?04VEP)=1D4?G%K
MQ 7("RJ0UG0<>9U^?J+L-55KS[1]8Z/ZUB?"M=J&V"_593<32JSMLUD7H??+
MOD;4P;M7>3_8R<BWL%YY4">BF6A2F*]C<U[G.^\'WQPC$]HKG4S\T3"&:7K
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MHMJKQN:VQE#OPVZ3F=7G7SN9&;$]LOAQ,(P3"C*^M(;5(Y0PX>X&1"W_^-N
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MSW!\7N*>-*]NQ]/OQW6_:^9Z.':$^'GOM;JM]5ZI](O\;J@TT-?%D@D) #5
M.D@&5M3R*4EB>>+3LU^Y$+ZQ[V6-4\@GJ3>'A7,R%GMN/QI3K?/BF,Y""LPX
M'S%O,LY'O;*;5^-E/@#9\0+VVW$,=*N#+O2WURH)..;'N0"E/^8TNGVRY@B
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M5+"PFP+EO]+#!$< D*V4^4';6A%/Y#QU:"L%=<2JK3^,N7.,"YEMS88N5S%
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MKW:)*)9CD!A25RH]NH2!G(G=D6C>@L4;:5P]?SL[!O#O$\U'TVHV%8 SFI
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M,00:+BI$.->J\>%34@7*\WF[FOJ]CX+.J2M=\2?N=P "3"V^D3S)10V,1)5
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M0OFVIOV,(ZF)8C3]CP(R'ZL$')<TBCRE$X"=K*Z))U36:2^",PQ+K2LE#IW
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M@*\:2>30"WQXHK0T&A^N0N]5.-60U-7#17>5C\TH,%0PK=59&QNG>7AP\(,
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MLGEA8180V/1IG\8M ;M9@IW2 Y4GAV#2=4\*O6$PD176H@F]&V0UWJ"=LR5
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M11A;!(<(B..-OZB(^\U--00O2G 1RMI>XNU*%K%^5ERNSM.CC[6U(4MWW/!
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M&\B1E9.5E:2<-FM.%C1R=\EJ:CEX1/H-6C!<5]UO&3A4T>9#=_]=3 FYO>*
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MAXS63DC1T-X5^(P2.[7\: .< </I\P>[0D4<TAQI!NT:44*2G*8&&E%? _^
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MKS,NC,**5_E>VHA.*8+\-ILU+XX0>CI2?UY>4(SUY1/$R8+>CB"."CC^@7/
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MJY4*P)DV2ACAG +0/W,(+BUOF:9#PX_S$XAZT[J&R]%5)J$*V*]ZW @HD*
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MO!3A[)(.L0TJ,G174F*3R@C2*0C6#E*\D)S,0=-W^EM9!RJ@YSM3&U)RGWF
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M/)6G,CL>;ZJ9?7ML]IA+?7MN4>K=J;;X<;=DS[;6%<#D$TGG2;??&8'#&U*
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M"4U+PW%"13W#%"\PQ*33^J;G7$'#3F('Y<8<#G-FK7XODZICN@"\#WF]X/-
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M=J0<[:3<:EQ(?7P<0N9/@.%,JG*K4^(*S0")("65T>;^*O<Y/.P*\-^ME$+
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M./4E] 6U^E0V6BY5Z\9YV2_)S]E%Z>>#)KC.PD[^1"O'5#?-H?L)=XUH.:X
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MR>7"[-<@+5YDU%K0"AO95K)X:6Y<U.JRC*%'[DEVBY/!F1B:]0;#R<3TY*\
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M[XXMO2QZ/WI?I-1;;ZE8'!8N-L@TF,[(^1G9[#T^G!FXV($A7.:E+G9P/#^
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ME[E-]EBHZ8Q8T+VM+6RU!3#*<UBR*]%B"V%R6P?ZQ$J@WE@MQZN2=HU36!/
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MN3QG[3WKF7D^L\ZLO<=\U][)GC6,C/@Q _M=.=.$F'YXTGLS?Q@7#W2Y,_M
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MH47V+V$W^YZVB<PB=C&1[]I<WSH\>"=B::2$]#:U'V4<B?4+95:VT?OV3*Q
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M%;V)XPY^O8;)6[VG4H&N:O#R;:G$O:7;T:F+W.^O#:T3:HQO$%N9XD*F]$K
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MZ=)S!'Z)N@)T0ZX ]\(@KA=\5G_/WYFYN.V=%N,T9V,TN9XS2<LTT>4S(%(
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MT""*4"5L)2ADF.(6W?^3ZS,(<M*AZ]EZMR.M8&EH)(JPVUE1B!@YO+08)3Q
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M8K3G"Q)J3[9 BK]IH&HJ!#O\:90JT+'F[[E\@9=O1;5NZ8 3N^^#Q5H!B4^
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M0.;H]X"J=0P4@:KMG]YEE_+I*$J]X<YYX\.\T%=?2WTK)M<Q<X/LGQ:=J*8
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MKM_1A2.$(B%$(VO\/ ^7'UQH>>'=V]]RI(81#'_1#F./YC-7&MOT&T9S+6]
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MZ<>M<D'-CK_F:C<I4!M.ISPDJB19NCR&I1,[A#PO5GWP\5K02-&:+LO?"
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M,J\[]*Q5[=DI47+9\EO];N5?@^EG= 8JTLORM'R;#0O2FC??V-9X](EEK\%
M.Z;&E"WJ(9HFB7>=^A%QZTF+G*OJQ(?KUFX7N1)*]W,O>SZWNO?Z/OOM+G8.
MM!",D+P>6(*P(ZZ'/]43BZ YU1 1W+A$Z6NJ%5?/=A_N)@<$BJD(RSRR1Q8E
MF:S-Y[7#IO@U>$TP\0C?^;J4\MDEKG[E@0N!4+C+X9EZ32<9V_&D4U0Q+\RZ
M/XFW.U=FM!8F"2^]T$2RS[:^CP#CZ/I.;M8?^QAU[98%L[IZ<D$GSQN<,@GK
M6-HM+/M$XYYL;);JNU7:8VWM4ELU-%"D*K]K4XO>_47 S&>Q8 AZ;@JD9'>
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MEVSJ^0JGIE;Y6O?V#!._6>FHE)TKB2NPP4]:W\E4>/!F\,J!)!/@\<CC\ZV
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MC<.?[CVL#RH;N9IE=%G6]HB9?./S4->3Z$LOF8#GH/_8-?L :&K$!."L_9F
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MR(^X0>5D%:<SQDY4 ^0(JZT)MB@A[L(2Q%AUDB8_>Y@8/TUQQYY/N#+"W3Z
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M4TAY\R"LZK%>Z+SC[C!NTAG%^[-73JMQNOM'YT*E\CD;E "J$K8^2)*[1*]
MBLVZ(TQ(_>7EF#A5=Z?"H8!T6=MSBZ]?$P&;X"N,B2:]4N<>W(R)\^J,D_\'
M-E%VB^^GV:&V]IA_2?/POZ;XB?#_V6 !?[!2RK)09T2(6_2$%=;/<6P'$:W
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M!>C2V$$,2JN+1CW9/79"+U%'YU?JSV#DR2MCY[NSE?UC[&.^=,E?=([,,A@
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M+T=K$R]/YWDJN8#',1'(&E.-H>(AUX6).WXZ\5KY)G.JQ_L#QT$6[\P<:HM
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M# X-CXR.C1-FB7/S"XN_EY;)FUO;?W9V*7O[?^5B 5A9_N/XEW+Q@7(= ->
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M_+)^:\?O!@GN>5)-4,UC, #EV#LNW('G^8-GI=UK'&[@*IGZ;3TP.GI'O7+
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MTF,"C4N<8;R@ B QL1^7GZ^*:F07].0L7UI2=,^N?1F,9XM/JS>6O'S8FL]
MK[COFYBG.>:7ZRG633#]S=3B!"9:ZL2,2\"P5TFWO<?XB8H4%CV(90*<DXZ5
M7%7:9\)PXVP+R\,+:M5)M)Z(G_>*O0[&-9KMJ('#5P;>INQ2?2@P BZ&)D+
M<R_I*Y%B2ZOH2>Z. 4I5.?>:DMBW2Y";JI$GCC:\R?NM5[TG<,,1?X3:V0[E
M;M EPH]1G-I$J]%.025(C=F DJ.;EC_JGE1<V-EL<"I#/GJF_\/MPP?(/([!
MNV!&F8CI9.1,*>SUPM_I6SVW7A:F2;0R@=,>:?.]-/,Z^%8F3L7A7LAF&5%N
MO.%Y_^[8S*R,:\(?A;W;_M+<&=?*^6MR3S*!0^YL0<]G*Q8>Z_T(;;F8%^D'
M_86Y5E;/\7%Q^H4A+&)R(>ZQ_N,+#R9&1_I@I*O(,M#QS>@92":0B@8SPE*@
M^M9@BN>G^1&8S3Z4P<7O"SHFAJK#L[05:/CKPB)V/U ]1[LT]O26MR(W$R!9
M"RN '5RC9^%6LU?P^T]3FWR<IN!74,WWWN,(2_!*:[.]TZ*[C'19;(:9S;9.
M)M8\-PWF&U.EIQ00I1(R>%.4L]CH@=%[-$$@)R#J1L9OEI8+J'#<1=C,"&S/
M-+\%M?]GF EL]_G#,;JW=VE%VV(,'N^;('1&<>TA*/]^[X9NJ)\>BL&]LXFF
MR/NM05Z 8",LK(2(W@]*;O*Q3OD5;+D-HPENKB7^%>4*T-W9=AX!RHT9<UNT
MK/.FF>R)MIC<XK(G=E\-N*WJ4:"W(%5R60J5WG_)P%_SUE6'&_&XGRX?%BDX
MFXHK@ 9L?VC?!XS&"0>A)&LW*%6@RF.ZSWI!)\]HFNZV363PR)CB2-:VT#08
MV=BUD9Y5&#=O-&NT8!9W!RKBBF]EI&E"2>?N,CRL/8*7BJ8U3]!<BC5\F4!>
M#Q/XF/I#X6LQ;X!D$?4TI;>5 27/3Z?,1B,?]P6:.LB^Z^^6_;::_^28TT.6
M$Y9?V6($>>JK%1K((VT@"T/6$ YFYZX\-XU=SW\@[F0Z.%L>\9-Z.,H]_^;7
M0,(/SZ;Y[U96QV/2:3,1D$X+?\%IBE&':%A3HD31I)K&U?H?+XW6HS2[TQ<5
M$HQOL 8+;HGDF=RX$Q83=<,Z+F[?MCA 6]G7Q$4Z41^N_MVE^TA9F7$7N0]_
MP[YL=:YQ3+DRX?J,!]?=H-.Y[UX%[:>NZ:M0E! 09/]<>5&[?W1.@O0$?_)\
M=<QA8.S8VL"G4O/>I,?6'JHW("5!!Z'\HH/9%A)/P#.^OV=BN@*.B4_<]ZVW
M.4 =7SB,O+SS9K>>M,%X66"]1=<3NZN]EJ"PSPH&R^.]- M8900]& G2T0N#
M177)RYT?#2>[.C? P&5G=-_<0 #XGPK+#YHEI?XC39@TJ9.'\U9L+&D?U##G
M_."?DW#WF/R+**ZO\^^V+:WD -&B')HWB5%%[*48/4A=64LP]71GZWVRXNZC
MWJ1'R7X36TR>FT.54WX.=RBO\5"U\SO=V)S_K-E>'E1<RQSF4OR!X"[JYO_B
M/&7VX\K%RP<XV>)"0VZU0"O:=R,8QY=&1G0&-6WT0PJ7GW=D -4*7@-X_\S[
M[W?='<UT@NIO\S=Z[P;?AUC^#]L^_^>%=>\^J*TF46_03_W>W_+%4RX_*V7I
M]%_97)(D.$R$TU9V_!B\;^FO@U4# \"(EVV"I4 )1FWH8[^=6IX[U@ZJF?':
MP\?W(A]/9CXR+U\7$1'Y]@W[\P'(#;[0<R.).\&4/@I%V1R$ENJM%O9;O[9<
MC;?4'19Q2EXJ%9MJ\U0KK6-$$=DF$*5$V#+Z6[&K3("<#0;?1B,F$#. (HQ@
M*O-0<_@F=11!L !%3HU[O"^R5?-KCZZ8%_JJI'[P8#MO#>_B/'4JVDEPFPN<
MH7UP?RCJ.R[0E0FTR%F XZIA2"N]XS<U:6F['=C69IL4)B"2_7Z'U\57/]!6
M&]=0E%FUC:*!$,KL$=B\*/CGF4=+9*F+6DR@AN(:#U;!@_M#&.Z[1&L&G\[?
MQMB_BK@#PBI=F#,$0#5?TS_@EKKXE0E$I^K'YH"Q\DI#$ZZ)E$1OK'K+%71(
MK_PJF?V*)5OR0P!(K>VR5HO)?X8<H0DV@RU>Y3+Z[M70W@:!7=[@M_[9_A.)
M+<'-%,$/-K@4@R.8@DE-MQO&@JS>_$F<E:V7UCRR)*PLOHQ8:"UB:STM_DI+
M*AZN7_,5!55A @E^Q!-,X*DMAG&R>I@J(>0W.LL%(J =-2]===_L&2@:]3N3
MT@VNS B,9J 7R$9>0,UE4 ; BETXS4!TAR= 7(-(QP]GI#,!R(I=)^T4 HKJ
MTR/G,[C6490I38: ,OHU.(P_$4'COP>N4YWZJNB.5@RQ'W<1-3/"CZ$H_EM,
MIJ(&)3>;5&! 8"!J(1,)4DBV&G#(H#70:7\$2I/]0G$S%1AN;!7B("7;N"QN
MXB[$QR_7[+ *?XX]RY>Q2S'I+(G?C_N<C)PFQJX'@JW8 Q-4_LE$6>>D0L D
M!K$E>OY;A+ZHYL"P@=&WA_[4T 33") 8'RSE].(:BX_3#%0(;C,9>&$X4R'R
M671$G(]F.6'HU?V"9<Z9.(/ '?V#E!7&Z\X8',D$M/V.%1&YH!@9X: XK1\A
ME(DM=8%$]#V&;+TW2;,3OGTCT %<*ELL0]/<A*3<"9J7+CF"P>6!HTR)8S^_
MA3M$),P,Z/\:8P*K;A6),]9HW.],9.M?J4&]J@5RDQFHN4S*?U18*ZRZ=%'%
MGW=UXAC:\'PXR>4<F&Y>U=W9ZJ2=M,&2'"HM]];UV6D7_I)S(H3&;X<B"^Z#
M'G0PEZ9*M@9U5^RK:=,9VG Y&QRQY72AW+BRVMA,I K??0\?5CG)*O/HIM88
MN.HO6@$YJ2"MXWFS77O3A J1OE/<5OF8^/$GE_IZ,(S^5L](HFNJ/0=9Y]9X
M:=FZ-AS&:X\I"]HY$9',I3T:(G[TSK9(L1:#=>7SF$N19BOB=0V/>,)WWX)<
M4\F;Q.Y8L2Z8)EM%?-Q3#A']A^W:"BV*R\,][L$[:W0[R7N>-ZZ1HI]75=C"
M&^M*].WZYLLF@JD+>^^>L::/5 ?W9(K^>N168MO^9BF_];ECVNOAA>6KXV[]
MMM_#? ^_%PF?P?EQ&FO-?M[08R=+3A@G=%ZC6,_:R=CL(?H7%'G733YUM4GQ
MO;[K7;&AK[*;=CY<.PWS L^_?O_.Q%>&MO-0"!NCO6XBW4%K;$3<J<3;X:PZ
MN5)"=DKWC]ETC:VMT]C4V/*_J)SP'FFX^,")>@59;Q'$V\K@H^K:*BO?Z)^L
M6'ODN;"Z#7__/EK\H,/ <>L$5WU@4\VPM@%76555DV[X-:-?2H6Q<6LSAHRY
M'!64T@R+2O6Z6LTX3-X.]O)'5!C5VZUDM$$3WUSE6&:_A=GQI23Y2/EGLI$K
MA-:?F6 9)\N_SE5]QM>'F7G:=(VX3BQ/UZRO;_@-=K,F#+<&KPN>;W=3L"M"
M%'GL@M6^&][OO6I>^LH7GNX@[J*'<<$@AOWVSD:9D]$W@5O<:AUE DWJ\K1K
M)#!Z*(O<=7DXO4%PBLY+[#&D6ORN"7:^F+'R*LUKC%7:,XK^&PS]VH$R<J%Z
M,N1-+CWH+/S0N=X/%?IE;&551 >+;^CGG^1??")F>GF^41C)MG MCY"JKEMR
MKYEFV,+G"U8?+)M:WYSS';%3K*;BN]UHZ/%"A2TFT XCF<.BJO5ER2GHDBKE
MB&$<)/ 0^?D$X4H3.\8TJ>%BT9F4G6I%?XG%<< VWPU;:?!$L:N![Q7\S)U
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MI^]HD+6F+>^^2N#B[CS&-N+M@$P->ZO)MY=Y[W>YTO:I42DI^:]'@B+9K+?
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M!%E#UV!X_I>/E%OZMV=B6G-O,;/Q"6?M:G^:>DZ?S5PV$UM^B?*K8]SDVKM
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M,Y>GAVM86AQ<*UF8*Z\F? -B)"&"W?)Q?Q\ KGK^K%CPRU<<'WLW,7.&*\%
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MG4'7I57I%A1VN4W^^R6^^]:^>%;3_1'83$'PL;ZF4ZZISRERG2G!K"0F$/V
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MC;KA+RXYTZ:*^(0G_?Y6QY<_WODVAJA/.L8A]T&;<8#2'30+B]89B?"Q#9"
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MXG\I_MJ-.3C)$CJZ0MB(QLWD8B2K3"_O)%,N$U;6+G?6M;?MV^VDS&I^&<C
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M$A7T+D41Z.TCX%8J:/X,A'  QETNB(7]G839HDG7U*D@WISI;?& NJ-9? ,
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M^KY.N3\]^O&')*:^$5"^Y"F2S#$P LR^X2/@_5NA#,!@6 &SDO07&/1ZB!-
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M8ZR(.87IU",/@C#I]P780MQP<)B[\.[05UOP';OC&+([X+BK-U_4G6Q6Z*S
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M9LY%M8*K4I>%Z_?::G]N[#K[$0198NJE;C-7E/U9S-Z!HA%8VUQ1I@B8XQ?
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M,.QQM@;M5>2B?+L1MU56.(^^_+LZL]U*)RL]MYLN),)!A(Y5POE]3VX=+..
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MCW<N(FO.MHXXRZ#7_*6M939EUIW#@X/SP)=O;.B?>]7$5A*J %-QQVVEP]D
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M,VS9_^D][RV#>Q&+Q=-YCFQ,S5O0</A6!M8=04,!\_^_"0!02P,$%     @
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MH,PC9!1JZ19\$DF,5&L@ 1\RR!?:Y22;%/OK_"KREP'^)GNW\E\2X $*G^?
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M/@81IJ831+;(9<,0O3IK&OT0Z[IW[AW'[WP[7XT/?TL2YNQYYE[2\H1F)9G
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M;D_F%@GLD]$\Q\3VTR_13C$"[<Z"E]77+H?(W)F=L4ZD,!6A*2]+U2>[6]+
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ML3TMR%SV[ ZB3,MH-#XU"<$TGTK4PV-4^(8F6[9_^3 $ 8H>W7>Z!S("4\Y
M:-R[LH6_UY!+R"G%^Z'*RJ!;EMQ2%SM%$*]SZ%;[!3->=KUB>L1ZIW? ?V\G
M_HR1X(*OP22YQE$3*/$OGO-+ZU\JBZ?.*ZU5XZ/2B<_0X/6K2=(>O%A%'"Y
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M>;S1X DYL.C"QES++-,=T9 H>8?Z&DL#F5XCP5"65JWIVEX>CTU5O4"M5A*
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M-%<N"L19$!+(X2D4[,Y\JL3,"5\H-B#*0F#DV(@![;\B 13P;>M1$G"8QT6
MX T7X?C'\CLCDEO*5G*(G8Q^HMHHF^VNP4<$QF)OYFEG3W)*V [ELI,[]]<<
MLU)*O5VX%SEINGLTQT!DH#XSU8]:(WAC4VL@#60.Z7)=1=#\?:_T=,4PFI%B
MN.G*0TR[LN38-O-P9:&A!+,K]=NUL6+$PRFR))9PESO?C(/<L(E7)L3<R5N+
MELFSIF2"?)B\AA]9!E"[,W!LT3Z(&:\R*^H *2S[N=QZ*="108OF96[XEI5'
M67Z3@5A47%OS<K4!_M;ZCH[8#Q+P<6P9 (@[9*?C*II 84R8I^-ON 5Y8-_Z
M\":1C3S&5$#JG04#/$5AMBF\M63G:>O,E5=/=)DNBH'==IW/$[F#Q'8E_5%$
M^JDS2VY.ZIIN%(\E"E,OD4>6Z_K$(/$.V:[WB#/-%\:YQO>6CZ._60K??*C0
M8 \Q/,MHSJE^HQBN(IIX$GG5XW!;K!.F%,05UFG!B-LMJ@S&VW5+@VT/MX.+
MZV/T[8)V7R0K!0YIH/#AMK@_)"#G+3;Y_+2*!"S+G]\E7X,""7#CK([#"TVT
MH'B#]+#WF[%242HBU[(""R%LYE)K#/6:[IF79F/?HZ+U=/53M4>%JVO5><9W
M;7U4PY=0I<R3H+9F5JPC@2459Q#2:9%+C"U&1\$K!]P9O>CNQQW'WU6Z7LSX
M^@Y'6;UT=-[GGRK;0AS&I1SZN. :M8@Q<NS,A]%$CNN4[D)54G7-]R0%N;PK
M1;5K;]5V67Z"91P9H-<)5T$6^)"EOX<3&"^GG_69WZHL&^K>)C]AT:RX$_A:
MO8U>ID+6'O*)5H"-''<9FB\NS%2Q^R6Z7//2P&E6U5UBO-0SJQT'"HQ^_X;^
M$,D>1(EACJWZV? '/>Q6':0%=2V>:I',K0+>%K\-B&;Y0\@1;ECY@1WY<EHY
M46I ^<BJ+"UA=X*@^"L5S;X3@49%$=F(?X9W+0)N)&_OM\LWF/^RXWEAFYC&
MUZTR<;\,-FS#AAE\>R3%LGEW+<8U[V\F"7#JF\!^W0[G?]3 1'GQNOM68B1V
M9A OC'PK/T<_H0-GPT\+_6QVW6IU+*NHGEM^S5&YYT,_\\W6I&V]R6&6K)];
M06QY>-,."TAHX[,E]XL3G8:=?%G<@[PKLCT)=(*I=B'GWB4HY9"MMV**C&*!
MU?M$E$"L,4;2XI$.I.;HA'>O#8X776A;B$Z>P)W:U,@7;S0P#A18IAI/;M4)
MF@1=?* <3>1D0R%AD_/,F'DD--_*A07N;#TM0;@6=>-;;HW;SB>FKTJJ9PZ-
M&2.XFW\.HP9LM;"*'1*N'5S@R(2'/T/5&2%33#?HHQ.0 [7//]'.Q \W[G6"
M,3I[H7?7$E]DDC6'B% ;R]3Z.;SB(JWQ"A?]ZV\BZ^U.ZZ^%5B_\N]^@;#\V
M[>[\]197L)G;$WL#_CUW_.?L2AN8ZQ#"[1P_9S8KAZETDV"-^,)C>ZM3AH*3
MA\>8*VR' MVDV#GM$7KZP;W 9;!B6K6G5(#1COHEQ[* $@TG7_6!-XJJF5Q2
MH9DC&^71D*OXXO:)#)FFT&!-,OV.]C;)JG]DY7?+%K 59^<N[C%=O!CGB.G6
M'ZZ&<_A'66#E9$I,U81KG#I7?]&?A25Q!)4LTQ-"SGYH.N6'Y(LUH!JP8LR?
M1XIO0KY))FO-+V!JMX4:1B70)[DC=I?UA;[P3_&OOV!\S42K>F?':CT"Y<K,
MC+=I.]7-3YC759J^7\>1L[/I9\M];]WWC6DGBA/&A#=8DLQ?BMJCVSI-?K=;
M[<ANZI<XZ.GI5S3K82*^#6&HX7YF_)SQ=$("T[VX:;4U(-)A$#XOC[5/<[/@
MO3N^.#756_DU@A/LG=07'](P:6OVW-GR&RH9LJ]\T^[J2<#JP/#F]/F9[!3*
M'8&_F5%*)D"J]_A.; -:/S/%($+E6C8#0VH4=8:2@V6QW4O6)T;/I'^]FISV
MZGY$D TC,L6?5TU9@EE5E/^"ESZ-U)* 'I]3+ F@5OQ#N(,FUU&*6[B/59CF
M5&CN1KE%ETIMLE,\<<H^^;IGPFVE0^3:)79;A\8@^YQG7=P@L91.HXY'E^MU
MMF$?X_!W37&_,W[_^]_QC^C:U;@][6;6'VI.QQ=5* \+<DE 2#8)<-<[@43P
M\3[;9OX@MT=4A"""'$_^O#R@&4E967-,*=+Q =_C)C+%G%>'$4:13.1,GS\?
MCJT'+XFB9B#@?:-&91+P(32=3/A;B]JEC6B!2PVVUAU)E'%0BZCW_B3@:&0]
MN'U&M^X4 "]N,,^8W3'!QY,AM;>>D@L&[L)=U.*&U,P#DP,!?!SZZWW/,Q3^
MH?=^0W!$G/S)]LO9A5+YS!ZBMY?TF=;LV:X!_JX(#NUV F=M5/BET\9,Y]PD
M2P*L7#XO8+P7=OHO)4^#T2_\@]K7."I41/+L%&1'>@>7(1>K["W]C@.RELVM
M]N[-A-[6<"J2?6:A-<=  F@LB#._)T$L<GS!00)Y) ";<N9*I$.0;[[^/ _E
M"IEBQW6,!WDN]]^IC@N%,PI-$.1]7OP?Q+UW7%-1MR8<1$0$1*37*$500*1)
M)RK21$#I/2H@38CTG@#2I H(* BH]"Z]$^G207HG@" @D%#"@;0OOO?>]YN9
M^WYW9KX_9O[8P"_LL\[>>ZWUK&?MG'7VE]F9@7SKW<:NG(%8:OX!?<I0N2UH
ME+_BO.-97DNU6:_;^5?:'1;GK"_+8^4@X? H1/OE$$AE-IZ9UF<H^XT^XK=L
MRM,BGQ=K9OW&E2LYQ,M"A-I*$D@0UPT%J&S^UJ>20WTTQ 5Z)KYTBP3Z+@(F
M2D %OMY[%G,B<A#2P-""X'0VGW\WV*^N1]O[J/P%X<OQ=[(FWR)=R!?+_ LI
MQ']*N;XP:U%QEM?_;4]QXF9>CU'5S-,1ZYH]$TF5CO_<6P/_\"G.B00:@V-,
MB!2F?POY@-VC&XRN)KH-E_2&QN5["UK5I1TYKZZ]DQCU^OI;/A'[STL0_[P$
MLLJ7,&]"C"&!HI'H2[TD4*Q)+Z-#!9^47V+1DXO&<J(,><*C0AX'<<MY;/<'
M$RJ1_ZF_OBR>FRPU!8)!X(U(H&!C"/Y%V]T@B<2Z(_E>_E8-L60-)EEVYEY/
MA 8$[?;W496UBC]!.#"\C\@'.&.X3-%9M6NMG!9Q\.TI6A\7W?LV!3\XNA*_
M40=6@=]3'&8[X=^#T6[BNZ6(#:1O"0D$*D4 W4''9.-XD0!\1\[$$+\SD4!;
MS8\K.DT_?@E,Z G)=D!T/5RNJR>P[;,@5EC(/).='(/:R?RRCDQ9T@FK%?AS
M9(VNL6 \JEFE/RP(4^Z* U$9V"D2Z.L__\F,Q#"*[Y:10&K_5)G(VL4O(TM;
M^A?'++*G@E4&R3IYBR#K1([A/VZ30^03)-0B?J\H_7,E9(0+:M7'"E]5/Z&>
M_3>1":?_K^'HZ0%RD=@I#[)]D4#_O,_J0MRR=]JP$PBG1^3C)=0RX!>HH\FI
MV*7.O_K9G\9S;N)L G4)]8B5;!4^#*P;QK;-*XUA*8BK\)R!5?!'R_/7:5O(
MFGZ/8WG-J:$L=1@D<BKAJ.(J*7(60C9%B6'$2JHU>0A5;PL16RSA('C#F!HS
MZ.E_V0(CR5Y73<CQ0H0@*FW3&<+V6E1A:R,QYHL)(7B5)7#XYB3*N5'*1[G4
M+7-7].[31<WFUZK%[E+IH+.#:#R4G%B$!@/-.N1?[D[0:GQ300\8L'##6^B%
M3XUK.9(7@!;D^](146M@>!?7<N@N?9_OPK!/H?R^Y>6_-Q8!BG#\>&DTF5**
MBQ,%?2.MQU[AM=&4!J,M]S?+4!AFVV5 5;^QQMWLMFM9GFE>2N-K&L$Z- 6N
M50T.UEA#1I$G6X]GGD9%=K9JKXXDR/2U4)?X,G1RIF;[K&84R20PMF(S/<_>
MU_G;2+QY,OZKT2MI8^_5@.L+N]@0SND_T.^(V.I -[173X7LFT"7%?O0 VW(
M-]^O/2**?0^H5-QSW7_0Z31?FJ_RSJ("P2G^%?&O!VZBC,9:Q)U*D:T?_ [<
M)NKE\!>HX(6(]EWO91<RFMG/(#;KP@L+-GTN5@PSG#<K?,B.:P ]\42AAA1Y
M1L)+5?F.>(^WK.G&ZEE.>$8>K07*YHO\*"&J^4=VSLM$0#-2MG5%0FLRRQ.J
M!@H7<WVR&91N50^\O8+O3%(P0<!R5?/,@C(?E"_</5"<%LS?V;%S&N+R8;?>
MJ.7J<>4S^E"W20EB2&W(X=#)MMH5[DBO[S)/'ZM5[!.86VZV*@RSX6N$,/T&
ML=*MW*61^RU2/1ZHQRVY]Z[0V"I??=,!"YZJ4GJ,A1$K-L0R@]UU@W:*30.<
M/&Z-N=7NC4A-2#_H*BYGI]N4V5R2&CT1#57;Y% RJ=BAO80<N#QU_IS'J GU
M&LM5#J5:18OX%$\#?27N(('50##.Q%?"4YR]L[ CPV:"N30K8QJO#KE%V)]&
M.HHQ85^2+4D8WGDV7/'%RME Y\O[ZKLGYV[4O3-W?^W[JHB?.AIO2JB6IE*A
MD7+I-%_(27CU2^^P8@86*XF7@0'73_[(PS!\.^;?JAM&E__(<@8&]#\2DVQO
M$+#SO\+ 7QO@%VC0I0;940]L@_K[A<F;F[=B9[-\ LB6^/XGETY#71UZJ=61
M_^9#-VF+KS_D WDE6Y[Q-ORMJ.[%L[QIOP/ >SA:5%<O[K,*3VWXU!V8MDDD
M,=:M9S7[5GRX_9+P\17LZ'0#P>Y<)[D@UKI0)I3V[8ZBK7?/:_FM88U'HQA$
M!V1V>O5"XR\ UMN$"/<$1K]J"*>:<:0)+N;"<V"ZG][$3H\W,4/5$Y#8E(SJ
MUVF)V/P,\MB$T#R$M5T@#@93+A)[(]7=V*LOMY[PU%")C"I4HNCNO8]<#B00
M\ZNCG00Y.-$HW7?VOLJSF3M^H.#>V$^'T,O6\)XV2F3]QQIHS!)]QD!BW=O;
M#\+C@B]I;5NX]5!3RACO8]E_NHAWMR"8E=BDA[\7MZXL5H?\6/>B5IHH%>/:
M(X$JWI% _B30KPGX45"9.)Y%'.5;D[Y&O.J\Q:).^$H#?W%!\^D.?LA^YF]Q
MB@KG;Q/_V''?3L.)-/W,#=."L,H:J)A>ZB=[QUY0<J@>7]LC#/B/%"H&3"\S
M!I2A: UJDJHJ'?I.]8P$XMF]B;>68X@TE05 IT:D8360@N**$:5H$A)0D;WY
M7:Q](=>CO;W@V)]UD02"7C]\P50O -LAL[X3%U7BI4QT&U;S1A*,W0)AI\D[
MQ6YSJ][>=4$KXO2]?0[OY*,3(NUUE.GMQZS^K&7N&8GZ9CP&\M1"/%'7?/:M
ME=&;1)K)%1*(U?'04@NCW>ECL"7+I%JH=BF1VPX$]NO S[J:L'.[.PLB[?3"
MO.=BW:T"]<=%UPX_6DN\/:Q)X3*3PVW/CK K<>:I1V:O:J@(ELQ!I@>/,P.(
MM(KYI]==\")NLA_"^KCK[]\7X@>% !N-]!9$6K;5BV)BEY-15BI+[ B?:TE^
M-Y;TN)G>O-/3]3!M(H'^A*-C.FESEZP"]2HM>'3]!*N3 DQFW4"W'A2=!RUD
M?R1:WF1?_8*ACD2^A-&8!47L]YC7E4F[B&<08CAF12-@[Y,Z*=*^)O90'%\H
MERXLCR.L]_O&5\7"UW9@O,2Q]()="1+H0C?Q9QO?9-FN2_EG9,"UU)4PX30%
M#\H^)?SF0<7F\,^7C='&A+G3H(^-D$?$4"6+U01*WP$B?3JA(!] Y%LZ*G K
MY,RW>&2GFTT%W5'*U)4-S$=FOY7NM9I/U/6CGVJ3DJSJTA*3@=P>$0RTW=O;
M;]A7#O(MM&]Y(0%>HLY^KL?I_2!BP= C6"&]TB[WY;I2,<I,]T$\ 6F^,N;D
MQQ8]D8-]>^/Q+G[H&A,[1^.K['R1IT?C5Q;Y^2ZO9[W'::+"3K-L)5_?HQ_=
MC+8<^!R@-CIBT7>-MB%HWRG0/,PICL-($5=%6/Y2XEC P4:P=;]P+,.Y%=#Y
M7&6K=RK>]K9#HE3/?%WF@&8S-(7(*QPD7WU0$K$G\52LM'!9)&COC=+XJ/_5
M]VLL9S?)-@9) %=6X)DIP4?JN230*$SD\).:1,>NLIS\!E(-N1)UZ3DAEISU
M?S9[@5@=_.%O \!N;>TY:ZQ"I%Y$,A;!FH,E (/H/;DY$,_]XJV .KGHO<5J
M;NR78VHO7$N0B(64A61O:L-BO<^7PCG!2Y!9Y2+>/T5]UK-X!YSY+F'UTPE?
MC,1L#/>SS"Z<?2/SRA =4D2RWD G[0E3Y<OA/X?)4UE"5SUA'U[?.\IY2O^^
M9K!TL8G;ZXMV\DE&N<=CG%.$G!/XJ26^>%E<7OGWA'_T;ZN$H:=6H6("ZX3Q
MA/Y<6<"5F6@D\RMK]ZIVMN2U9DW&U-,SKVXN5[:ZS5T?/,];$N@&!XZ1!)JY
M@"#(.J8 ,.0O2A?X^M^:1<@W^S\:)- SCG^O6?QPWB@C0<AMZ)J<]-A!O?)-
MFHU@04>SHMR-= HQW1X'BOF1H_S4[P473>/?S_(IWO]\@77HQK;;V_?ZN8*%
M%!^'_D7MXB^R+S3@>I"%XH#4=6\RRHBVD*F8'=,3$NBGR"40X?77:&'0?]7*
M5=>RX_'B:!@JHG&-!&+3<&V2#?;<*?-?W=T-^SFK=O[V08LJQ_*O")"XD-R^
M59"O#YX9@77%@'=#<%Q ,RHM_)A'5JL5\[%ZG&S#F5-R-8=^E-8AE:9ISD8?
MF6VH/MF&)/]]60H"$&;[KA?7)@8@2G[[I+]*C^R"7=1>BQ,W;1Q?J\?=S6 >
MG65M; CTD_2;%@&IRXOR!# :!9+S5BHZ@!JU/Z>G!B!\XXJ<>6].>@[83KLH
M*0IN1#25_7CO.*I=6,P.G[P6>I^5(_I]^ZW7(NM!SD3Z/0Q5;P\X"OL$B.FH
MAUYH<5PEG+-@N+P@O7,[#N7@Y5@[!'T4*QI@,C)A?ITS8HZ?/M4@Q#H#XT&D
M*<$DKS'LAM[X2&0!$"L:8=+:K5RH\I2<Q26S1>#<MC/-,^)\=(^(5UT6P3:-
M$?9.L"4@UF;PQ1'%,:)[?TX;Y=,)ON@,OE+A*KU_56]E:UPC!0]Y*=-J35OT
MRU2_1VZW<_!&DAFC4IO\J[H+FG.$#Q!'Y"7B-(*Z-!"V,ENQ_M-U[_:KW CB
ML+;B %>)X]+2ZI*O+45.JGR.IYWR=*@Z?2 UCI.L:;XV67AW]N5:+;RB&SH"
MQ@QU:-)[X\6CH(W[[;G,Y%"7:%EZH.7FXG*^;OJG]FM;+7SS6Q8??LWU2&@U
M9"5CN0K^!<< [UJB "Q*G%G]L04H"WG^IK::X,[S2=I*R2SWEA5O^650_G@<
M?T4J:="!$B-.9#!_G5UK\N?/T*A#_2F9T3>('*:U._X*/]ZCAY-9:_N^@32X
MQOZ[/%N$'H/38Y6OVYSX#<"Y6*-TQMPR7ZDY*O4>/$>:Q]3$D;<5I>CM4B5R
M*W[!-OUHGZ9CV=YH09972[ED,/#V3NUK/93U6]1\:_%7Y4$"H23+<__+L:F2
M'K_BR+E<6;AX=76KG84C-PU'Y"+OY Q\E+,MS0XE6%\9+;?'$IK3D^%=@41-
M+S4H*Z^%=I/Q*'5G&(.'/!J8<G7U*E!K:'!4UN8F@9)U,[F<F7YFR;@_NCJ)
M_.X3*5-T^UJ<;=HO:,NBOW%/D>_/ST:)/KSN#.;=5I(RCSORO$]XMI*JS1*6
M[+W=0DSZ/.16KT81]%'/]''UXOI2TW.-8,8%J51!N/%FUF1UB;4$8;E OE3,
M=R_,WZ;5\VDGU&"PUT:!?Q,\SQL8*-NVN.3P/@"_BM1 KGP9I,9?T</2[C3C
M)!]<)',*B=XUZ =$/3A*?UIM_&@2MF1MR?'!9^8-> CYB) 'O,&)9<_%$"\^
MQS'/Q!2)DIF^I\1K6\W.RD7GFLN:/18P5&*/\VB'>=9MMBVBQMO@ B5UR3OQ
MN\B^['<AO^;Y8DO=P9\%Z.(1O%G'_/-_WMI\-%?,4C'6_V+R3"0Q_O0\>6WB
M@HJ"R+#^:2+WYWHDSF977^WCFKU.OKH$U=RB=^&SRWZ"OBO3X I$NV2@F\M-
M3=?GR/?RI@:P_HL@N]FHN3MWJ(=.-!Z==4?EGV5;B::QUOY"#H%%<^D.JCI\
MI%_;KL6_$9M>'B^_);^>/&*_H++U-%B=FI;HL0.]#R03:7;6LAGFB7M#KF9G
MMVYHCL"\SU,=K:^LI0]F8-DQ'327MMQE8LE6O<:P$4Z'"::06[C,5<#CB--4
M_A@S(*'M*]7E^B)IUK_ZZAO_K.:H\T3N-R30=@F?=\ #_H9$[RN_*&W /O+\
MHUE+Q-H_[O .)"._;P;NTJ^<AB<_,*#?]Y1X=?THY?B;T"(V>F3&[1>H[L*U
MZ_QUKEE;CO=A6E35JV>=XK]9ZG!H10.OYXOGW1=,-"$-:+^\)K]REG(!]W$F
M_GV7YLK8Y/U>H2PGN:/9O$QLF[8+0S#"IYG;<XUC'GK/(1NMNQSED^#ER!/>
MXG%Q\+$J<5N=N\15;F208DW)*(>\\'M HNATY8?'H0NJ$N[>N55]2=V:?8JF
M($W>HP!3'Q&<%,L4W>G4:L^]YK!\E-%]6(8BPZ"DU%Y^+BO<*C>-(B63\TX[
MW/*N) *JN]H6G4&D&<'PZZC'U5C<)8$T#N?[6U13?SSGM0#B+[VC6#\S"B-/
MU!XX(X'$E(P=JLMMQ%\;@EJ$G[]IM][\M+:4X*SCI4H<Z(9\&\EON[ @LXSG
M?(-[^FB^7FN58V9O)_EN2CI>L;XM?0*?))GPB!@RCT5,$B^1T> ;M*8^<C]R
M3KS\V,QU[+G5K''#^+T>J:PKZ?ASV9UL[[I&L'Z!M<_RL)G%>O?T=(,((B@/
M^>Y5^^U 7A>P_=N46QD%E313K@(0Z3A /ZCJ!6(*LJDY%YC8DUMRF=K),:0=
M%V<=E*8Z-.HA_RYPT&+;L;FN;HX_/!A7D.UT_E578-DA+W5%*R6WBO4GSK3=
M<1YD"RQMZ?/#9YK=\NI_UHX_2]^VV)F^\NV7!:RP: W#K^$L+4('U^E9OD-Y
M4O<IWC^AHVJ=2UUQ_,G+@I2K6]WI>J61 ^R&=;ZB'M"O"/3#(%T=/:PL>>5"
MM62A@('>I\M(L5]PEV1H3C9:-9D$8K<BAZ[S9.>4$2*^\3/1%4G?>/^BL1SN
M\/W5H/8AX\$)\XZS@Q LU<MH1)W]^TGI3,-;>,HU*+&QS$^G48>V1-L3@D''
MME+TRM!YBUQ?-1U>6I^TN[2H)5] P#2JG\NB8GW^,B;MB;D&[Z\&T8%@]>7A
MG  '[;OSX;WWLZ1VAHR4$"V+CI7YA$6'VC?O:[&^*:&G)5O=FG7._34Q#6[M
M^X9TT [JH:64I_<$JX*4?].R9<U!I-7';^UR9QU;[_])[)0L2HE2K?TF+[?_
M.(+22Z@?*>X?O:'T$#B2-G4$-T#1WJ"1/V <HS_BV0@)E+\HB;S\T+F!&W&\
M<\)%O(R4(Y#][@492T;_G16Y-9_<.S$X,^*,$:&S 7OGO,@[,\A-- WRS2^V
M*SRGV?O^%%_\3)8W6^Q!\0]BX_Z6/N7I*,6G:)H![\_ICI<8N-H*6D%WU0<P
M]2I9[P<Y!-H+!FKB%@E%Q9P:O9]WEX*Y2W[Q+/KUB)PA2* WDCV0E=2L6R=
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MU!TH?IJ8JZV'OLV^?6.^Y QR* M3H7.N8XMSG1+]J2YUP+U1DAT^5Z53C5.
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M!833*;"P[ = ]$$L81Z:?9>,-IX^?[1];LP0Q:RD;,@T-@QJ]/<]AD<X)*#
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M3=E#A,UV>E#7M@__5B*K-R4_1'B%P;P6E3T[T)VEU/!NFU[FDUOCW(G!5>T
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MPUDHGX.V4^UM\2#T<1<X,O$)UL<=+1]/Y=@%#W@SO8&6]W$XHZ[NX7FPP_"
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M2F_XU?K_ @'^]\=B-TJ)@>#3;5;C%Y:=;]Y;]*2):8][R +;+?V%Y]XJ;%J
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M2I8H]*TVMB1/),D:6JDN](@4PY/&_^=A&78K+G>_X@-1@JS90GP<_)2":$<
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MILV78&%!G 0!'3EP: #/JQ2VP*:G(XTY*RD^KTSG/U=+W$RQ$VAY^^E_.F[
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MT:UWTDNG+2V&G;Q! R#LJQW1QGU;[T21Y-IB]&G@- =M@QFW\A]"< G9UQB
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M4KM2:(W8<(!D26^&VYW6IT6$-R;%L :U,:=JEXYN@F9,_P]02P,$%     @
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MZ0#,DISA"F<F:+E?(2BV\W5D?,_5Y==?M;H^6S3O+UDX^,Q.($2N(W"\*_0
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MBK?R?LUJ5^P^.)/'R-NY%9=KD1OD!?J <,U;1;N+LQJ.&U\ O=6W?&^$]'N
M?F)#!?"7+'_BJ,"[P_H9O0U5U:<5\7\EI+%VZ#P5RDX Z!.MAO349JQI>1HS
M46EB,X5HRY C<B!Z;H]3@:V;5.!47&H< W:4T5_0:,R'^J]V\H6-1_U1+ATY
MJ&5XT\*S6*[Z.6;:(TW6Z#C&#MX>*T*P+"IE"!O/5F-!'MXVD\/M8-JAE><J
M%U@AYGBWG,Q7/$\B7HQX?X&5L.D,N0$;+1]%#SJ\38Y_)%B*G8@P!=Y'*YZ4
M72>I!A#E2<ZX#U^_NRABX *8Y6?VI?6?%&<]^.T KOC&9[> 0Y#UT-3QO$:,
M1+B/K. 7=W#5X^GI"%+'GL(N<WJ]5QK(8D%#!'9K!'Z9Y$APM?^Q<9J<+];Y
MG:'\9JYGHMJSC%LU3(5O S8Q0N/;T$H,Z1/9C-(D@SYPGK@S$6V/^4)Q(0UD
MY9@)I17N.; W8R?;6D_=D//L?!U>!8+FQ5<;]Z:\]V!=4:*N%])@7=$3[NWG
MW FOXQBBTX(_!A$A-CTX9\V4>=G0R2NW*#U5O$*9\HR'W(M0#O#2'HR;"MCH
MDW)+OCC9W+:\#N[Y^Z'%I41L"BD2+:@V%(:NN/Q>S8_7[N>8PK3-S_6]>1#X
M:.!SG#?*CY"UR(!3;!OPLIZEG[8H#<\H4^RC":FFB)*'1]]H[%8<>?X0(@6^
ML_]7Y_=SYR ]Z8L4@LP)$P[%"].L(93C4//(T**<.\Y3.;W3L^]ZA'0Y\]U+
M_&BDQB5Y\+%W\O'H"'0YORD^->^H"GVT>Y)53I#VAK/"!RV&8E B<M"-FYB(
MA$1BJTXL1W#4Q:[)?"0;Y4QU)XJU99$]PF(G/\]F(R!U:N+">X\63M&;= PL
MB\(L 'O@-L()PLR,F-PA&HR*7,/JQ_XN<J$":EGVC'L"%.YFDC YG22#IY^?
MC2F6C533%1A]6.7O*KOX;"')WX[)5I1N#?) VEKL>D55F4VRW,3MF-F2[=,C
M68+XIAGA$KZSK_F2,\8"'>;S-ZR/O:IJM=JV_A7CMY-/^?3 D@#3Z<L&QS90
M&3J,)+M0K-C.N<E')N\@A9.YF^IB'W4/RD6\ZU*/0#ED;64?DU68MQ6J*"5<
M1II7_WE14P 9!U[<;\$>W3:G @HH*$H8OTJ"^ZM2.J7!*^.;A^;:Q EIRA]2
M6 R%%40,VF>2S&S*WOOOWQ']G\ :JMM!>Y:)E(YA*I CWJCW7\^;O-0HW*#3
M$]#8X1TJ$(N8=R!S&5FMO-/D>GP.&EEQ>P'!XGRJ_'5K\7%%\EC_9=^!-3/?
M.W+1!P->B'.4*W'OFY@- &?H5+UC@I?'4H#R3*S"CMO?AR4+D3PQE6-"^1*_
M]MWI2/Q"%PCQ"RCN&*M9A%NYXJ3&0'EWWRZ1.+AK&%))N0E3 7&KL?O-C^8A
M'((S=9:(D,25[=_SI=6>JTJ');V15H5)VIF"4XDIIIX>_BR:N I_Q>WL=]E4
MP)Y<W4L%?MA OY2#8^4(X^ZA5("UJS6.89K@[PR>RC ITS]"2O0,K@S2S@II
ML?VJH'[%<^.8U%-=ES4LY()GGON%7VUGOT#X>V.EBWCNOL0D?& E@/"&,-/@
MNA[[X0=A!O<>9H>;2?[L\R0[.'7-Z@3KN%_]PMQWT7-QUV?(^4#ONJ6A30JZ
MO[#)S:VJM)\PVF+;,0N,J=T^&BICKH>4D0M[L>7O]EV[APR_H,0ADW<$12"C
MT#:X[!A,'G4?"-DT_JFE6<\+EM,291!*YQ?P'I+?/7A\Z&:-0.U?')8L3CD\
M%=+'51_YC<*%-D?]HXS&W4A&"^:>X KW#PIVSY.,G^V(Q'3$"=X><(*Y$)0T
M;CN=:N:/#R:2D3Y'Z5B'_8;!V]7\&)"-RXAD[G2W OJ+*14PJ!Z_VQ>CL7-;
MOKA=AJ&T6DO+.ALNC'G_"EJ6OAOF<Z=.L=W Q? 7W[QC\$UNZ97GL;P3]W*%
MZ=+3I=?XKLN(]5>SE_?]VAN*!--M4X0W)V:OCE:2M5LI(M41]ZJ/;NA(7A#F
M/FL8H'XE:.4G29IXN\ME(4@]J&/VQEB#:]#+EFU3PIW.]P(A#U430P?OG L,
MM<%J<AY;_]*?'0[S!/%H@.(BA<ZA<>MHR@#QB1;6:0\V4V^E./.G=O#V1-WI
M];O919U?H^INJW'.Q\]AS[\ZY:@A/AO=3L .39;W3]VN=S.46T^TBB+QL^)K
M-:Y2 9=/IM-;5& 2ZT"+$WO%@*_D_9C*];M/%99O.J)/$A+TDUY[8"\U<:U!
M>>[*CU;F99\3EW7W<6NQ?Q=GG!UR*RCD%H+.QM*=>(=0U2M664EH0TVOKRET
MN7V4_-WXF5.)'L=](,BMH%-8GDAPQ!V!/C0)NMZ4T3LV#7!T^5*"6IH1J0?8
M?\&R,)M6VEVRDX/3BQKY/S9$S%5DQK-EZ*LG:2Q!7M'-Z!AS1:PQ$%,Z;&BS
M;W!PGEA=&O6#8#ID@ M&AP-86]9/I6JVG@R_#=6[]E$R!&GBG2D8"*\Y6^%3
M->&0<*XZC&^T9^_^<]W!HS]O@#553)61X>Z7H4+QV8WP1]QF3TLI8R.[-XY/
M$*_"YK'1VW^R'05/QPND+(Q-[<5'ZS0"1Q&V1$'^^^4&X([+4XX?B^U\XZQ_
M1K3V1\,7M4!I7MW/ PX6JDC,M*.^TK@1U3XKCA<\CCXL]&1MP/0^%1'9*679
MT15L>LVN=U0@E5A>)[91] ;-"Z>UIM8_.*=?B IT6;D'30B]VE/;K<]0V+&I
M/2SYJO/KZFB#K'TFI.IH=G;@!K;_?M53D_.>#;A[Z[L6GXW+RJV[QC6ZAHZA
M94&O3BL'L"$PKT*""G/H%YGG,]>(@.DC)<%J.R)&'X<]\AJ!L2_0+\@\,6G$
MFWT$AS\>,_05L/7,%]WIXKWA,<V]Z6T$\GL./UI57QRB6Z,"%]54-:**I[]L
MBUX=_[3MG^;MK?ZW'<5.(-3FMCM1:G/*NM[I%-IA[=GV<$DF1&3N^D:M>5+
M$;2U*2(S*7FQ7BDN#'W^+OO[0).J.C5/?8\W#ZVP5I]&_]+^ZQ, V,W186M7
M2BFRI+,C&C<,'//X>PZL _O/AAI7\KZF_W3%SI'QTWT&Q^+ 8*[E7>?VQIDX
MYA&T_7A=#1$2#7M1X#_A;^M=8?#0+Y[^5N=>C,B.\-RBL( GJ]]_JK4L_[G6
M(BH"A""S7?Q^BG\%8KPTY7.VV*U;:]!16)9BN(S_S>!S"VN_ZW42'WI?VV<Q
MS"WY$[W$(ZAML2V9[Z1K'J.0/KP*98"S3L-X<8>S2,&3<;>2';43%(N0X1S
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M3M4,+>K^E_0OWQ3;I3!C&K+'JTPE^YM-^K>CYI13K>1EY@-,6MEY$+D_!%U
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MS1$F_?+'*P=Z"#7O%SA[+N;8_1>&@;B]@ W3R'V7K'5#&&"_B&BZ8H3SF[9
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M?S0?LP)U/X.>X6$7[LIIW:] 'T?MT0GQQ3^G^$>YH!>WC69N*Z=;#@R\K^;
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M@(11EGYY8[] :;Q4M<,HNV'=/10VPHCQ(')T1:6Z3+KK25;:@Q-.IZQ<SI(
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MT#E[:,UJ "C1^^RRX>'MRV"2N*V1^D)L@.?@'^S4P?ENRZ;<"A/ZCQGT8G!
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MIX9#__@^Z7(1V#+4R14)^7$$B/J";DB?5C@"(!,V04$4&&'#9>\B>2EJ!R9
M"3#'DC)SKP5[Z'=?TWTN7_ZSG*.S^,F[KQ=#*1.44(*]SQZ!7!NQDW *'FPV
M3!/(N^O4,*9(/'EBG=U9QBB,_\E])<FD(%]J7[0752%H<@=/[V3@%-+H ;6.
M1!3^Z8 <UMTTS)]TY=<3Z*.A$ '/K^P+%BV7EFU04>#9SR#1D5T/S<F'(WDC
MN('JYE#G*+*'DDAB*#LKR[=5MI <O1LM%B)K+LRB*I3O,A+J!L]=<23(VPR
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M=]4'4B[':^&6F_FWMO0A_; .,M"0F4 LP'0)BGB76;5FGNYSVOXM7&D$R_!
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MI^ .=;&SV$_SP(F >S:/?BJ=M/4N9 W]*"" &S)23%7049C)W9=*@TFFE=:
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MN35>'N,=U_40"51G@1J=^.G==\W4"V(V=+\J*0VV#=V]NL:IVU!^0*7>9/Q
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M/H5?<(?*:UMS6Z?<@L30\M-9!0-0#O5AF;R 2WWV 4\L;DM)R<F6T'- 0FM
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M3D\P)1W\'\\T">(P6K0J*>37!)7T9<BKR//>-_K$WZ\-D#\@.\KN,Y3+=4<
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M8<S]W!M$GJ''A!\!C)YB?JU69AK]:&/&KCO_W;9,_]J_E^Q"XX=U34N32HX
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M V?M*VOXS5>,4\VW3V(5H7:=PV\>= ;2K$N^+F%:P_WXZ+=S5=)K=:A"1JH
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MC$1'^ A\@$4C83?X.;D:MCN0RT6)W3#&:M.3MKNGESK@+IG86^>,A^O-_(-
MDVW36H>Z#RP(A9S3"2^6O/Q5STD&VF\#G@Y>ZO)ZF]#?]?F%R".Y>=T$OLQ
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MR0$K-@L^;_Y)6WLCE7M+4X;T.[ZC4/-LK10:VRV=IKP!7B95R$X(&>O;U@_
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MSEPH$9G7DYJ4I5G=RAF&;[^_8S?8@\IJ)5EGWU, B.68.8#@1F//_/#N\1O
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MKH_\T:)/^U?.-=<J;*W%).2HS<BF'01\.EPZ/^8LXS!1A>\*)G.MY0]M+T2
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MXC)EF[DZJN;V[TRYZ_O8D==!5Q!V/_[UAQ"4:FM 1)C-X62 6Y2KS*^JPM5
M)W5ZP@'"=/FO+F']PM:%#$W5/:R0GZ#[V#XYZ<.TR.IX:LP+>-4B2SN-@<+6
M?D_'92ZJ._$)1YI@K&+JSDV/$B,ECH^"%B)!/FC-G" >5&VG.LGKZ>R'<7[
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M[_N!I4) (O]4QY">]S8?5'_?BB$:,3T*#N;9@:!?@9W=+NF#^'& ('K@W_7
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M%3LN('=Z:->UC&8M30G_U<*&9EHO?=4VM]A(Y[+GK;R8$WOHOK'X^G8YZ;+
MER-_Y'.6/#W#C3P8\L.5":BS5GL;!Z##/.:/Q? P1E,XUGYG+%.X'?#I42&O
M9&?_R(CSNY8F-!'>287P(]9K8J0*!;>3K=&]A\R"V&UJ#3SGI&,N-)-:"5+B
M% >&.6_M7'+]VGU2S$-H0$=<\"C>V/O_S#^CMEBJ"2-_^26=>:"_Y3F(Z>X8
M9QU$0$N1)4@K(561V/L$K[7[WBD![IU<<MZZ:,"[M21Z%P=X#>Y>1C^IQQ-7
M+O!J' @/H\984+78.V5@=!0V@3/O77W\U@&6%K$.O<:[-0-X)0J! WS.^:<:
MZ#9%%*^<U07>R\,E_JMASG]NB^?R]<]H(D',(F1F_9\LK_]O+#/V'/OB ,2>
M*#CV,WX]P [E/7& 3NU_KC(\B91_2/JW?DC^<S\D_D4_<( .QB!O/$P'KKMA
MR$WQ2XR*[!^[]A\=67>+A-E91(D##]4U"?T4^"-:GB9U/5R2S#YSH?.JCUUX
M3VM[TR#:=>53PK$58]2%&K;'@@GO_VRAW;#_V:C<SY2H6 W]<LQ*_ QBO>":
M@@P?)O[6R'<0_NO /U_\\$'FMB$0(P]6G-3NMZ@)CD?<QO8 F?!!DBWB/Z=L
MX(H9XQ-;R]'.S\#CP_JRGN7J*5@Q6;N?>?8,F-EUG=@B6R..84>5]Y2%X3E(
MIQX.<-B/ [ D<T/;->D!3<3V-"SX%N23#5R3S?_LQ%F: XDA2R,()I@U, [Y
M?Y'WGF%-=6N[Z$34J(B1W@D*BE)51*0&19J( 95>HM)!B@+20H(@O0D(* H!
M05!:I",M=$2D-P$I"2 =$DH,D++C^ZVU]K?6>L_9:WWG?.=<^]H_9G[,.3+F
M*,^XG_L>XQEC7DAH.$D>?J/8V??;&(;KJ:D-*EWNQST0IXAUFDI5)*YVU/8Q
M6L3BNWLV9]]8G,AX8!WCP*OLZ8:ZJDU2(C.&T(WP]CS:S.]*,),4R8S:W?A/
M;:#Z#O-RCC2EO?4<:H..\Z,#B==FX7]I>H553V)O5?/_;!7,(BE*46/"#]+#
M@>R "I(@Y')A>7%:X^^\ SL9(U&"BJ:=0=SJHQW2QD&971I.!8JWN+HB:P*3
MOKJ^GW#?U %V+>;=P%F8X32)Q!+V#W/K*$7I?2Y*@"A-%QR-)1B)D^\P;(!Q
MHX.2".%AO#<?1L LCD09:Y!*H6\3?B?=((0S $4RB?+;D"3)O]"[8FH,#M%D
MB<;!^RLXGV0%Z$)Z[B+;4,*]E(&_YL&PY[+9*>C<"S*#-!QZ@@I%:94;?@U?
MLT4IZNUS4P+@NSE_9'(/C=-E6+,9<>LIK%GV]Y^+?Q=@/$K1(, ,TF-(C4:J
M+HCBP-&,+C01)QM,E[AWE#*D3:@&@[90N'1I7%3^?FT)L(OH;A>$\>R;#8WK
M;XFQC!L5="#M/])V_DYKJ"T!J4R@S$.^,XJW2@>:LX@^M&,Y=.#8BAH[K0,K
M6(Z.%CZ*;2#?Q==:2%H]:?=;2+V5<.?J"([O==Q5X( N";-XEE&X^L*T$G+2
MOA>R$\J'%$&.P-D0&CALV!ZMXAW<^CII="3E_;O7FN4W;[[=^B)*P#!0,XR'
MF@E=3/1EZ!:@ESRZ;:5YB3,-FBZZST+K@VSKJL#H0!"*Z@]>E=U71_6+$:$T
M)CJPL[(G_2X:G([N2:5<P*XQ[MQ(:F5X8T9^HXPFAI."&&-7%X^B,$-GX?VN
MG*:JV=!T6?(#U#@S=/-/\T03,8N545+"_>B>5]0P-2@#^,2(VG^\:Q'^W6:6
MS&BO/S*D RNCVV::,H;[6B@E%*$%4G[X=WOE_*5@B^[?'6892HL=QL'H-#X&
M':!%G\M^B1Q&]WRDAB&ALS1=\4A&/X 91%,'^PG;0<!NZB+^4B!:U&)V,GC\
MZR^H-&HF"56&;>T-P?*IV'STG6A2PH9)R93+EC4]_C"QZR2&=HRM#%D)@N'@
M'^\9WGLX.=G,D#/7_B_8+?.9R?F&7FQ(E5I]P2Q&$-F%YE:[XIM(6VE'L_\D
M;(0C?G+7N$7=LM7.4%#PA-N:?$43#* "S@TL!(7G/\L;4O4&YD=F^&.W;\1+
MG+PFEC >I-*\03LZ.#/-LIQ@84&Q)IY(+IY$]$7*'U>)78G9LE[95Z7(DLL(
M>:UR2];B1(3U!4)J,BU6I2OZU<0G\7HD"G$C;7K6[E<;/+H;SS)=2G8.<)%E
M_7%-6>S)EXM]/MW(?(K0T ZK \X]%..M>?X#+*]YZ_!*=6:/(W/)GT[NQD!=
M,+M*[L^@.U3Q34QIL>%<5;*H:^*E%T6+CYLPW=@H-29RZ,SOCYCB]#MB*%:0
MB%6WG?/\[9.GO[N.]NT1&0Z?L_QE^;_%WO_=RUB;,?[FC(89!C0"HQX<J;?U
MQ=(TK>"T>EL&\=0'$ P@/,AXFJB,8="IIPS'I"&_,XR(_K.[_QX5V.Q8.T4X
M,(QPE6W%L%#<&\CBL]%#<3S5-0VAV^D:7PWRSY:_3A8,!9@307=R1H=VB*@U
MGOTSY);V:4@%.*)!F/"K!15IG#IN59DJ$TEDD^%=<CUJ?WBHO;#64L<L!+BF
MXJ$/^&ZTR[(CM/U49/&PF S!T1'I8XK9@[1+".9AE6$+/V!+<[A6$CFWZ_RM
MPSGX0D@BN ]5@@YO..F2]K. R-*$Y9:/CQ&^5#^8=+MZ&*&??W2'1> D_IJ;
M-$FK3PM^7$-<.BE#WPM;@E[=P%"8^A VXA':X5Y=O1S.OV-K6AI.ZJ;J#@S=
M2#@4WMW"?3_H<R,?<.*0?U@D0:%1C8^<[#-+A337N"7@][O.7]XONMTL>ZKX
M0:+.W .)7*X)KXOIJRRLU:"#P4R3AOIQ-UXS9TMF+7Y]<G[H/U3:5RSA'FKW
M(C02^^LX'1A\_S[0Z,^DRDNF96RI#R6MMPF[SW'9G7HJK-ZXKH!TFZ%<S,@*
M=."A?2P=R+DPFO^'D 7%TA@N?=.M09H.5,&HDF%8>9?M A+#*R1Y$]VI-:@E
M2_G= O@;HOC^#U0S]DI@BCYM0Q;>SY T\',!37\9V*#EA2;4KFC#(3KPB36<
MEO3^J5$[A>>WM<S ]X'OJ"4E$SMXY0,Z$ +6W(6D&='$ZDT--;D^O_@'XV3B
M&BY4&!F8^*$AU%;WQ2:1[]XEI83@'.$CHC'\NQRS& K[Z$QXNV;:UJW^:1RI
M9JYJ J$0D6FS2,K[9;KRZP!'AGE#X[L@J-A9ZEOH(_1W-R<W) \Y<18O'CPS
M[S4!C#J5]2T-S"<P@ _]I(-WMQ9L0)9D^+\7A,F=Q3[:)=^;6XWC=;)SO1^=
M2G0?.\>=$/A6)=H3#9D4=IJMNDF%8&3(W?L7*;+4S,N[TA3OF4D%\_149V<U
MD^0 'EX!&0[V<TN;ZTV-7ZYFGLC&;;3)'D&8]XV:$APBO; <3GE\:/T:W>>V
M,:$>)PRQ8_>/=-Q<=MF<QBM0V+7;X2P4#3IPU&=UBWAVZ]90YH]^I[WD+G,K
MD9ZGVCXGF9IF'GD9=DAYMLN&HV;>8<NU5_,*+<CNI#"RCV?A]X(CJ?=\C0>6
M&GF_^;"%N#X![O[RT.VQ#H*:?L!D-!Q"3DT?@CK*ED[XHMH(3OYK[0<6E6A2
M&!_TC$&';=$:!]9_C_O_NT]@[+HT8RN'&+91"8MN +FDG79Z6@EF;4@JSHGI
M]/8BK5RM2A5U5A9/NXM^T_E@I.$]IC<6/%.4UX$9ER/U$ 8GA21-XWXUC^Z=
M+>-5<WO]H<7!@_3KG+9(P;.W)V^F\/T,4BLF+Q%S-W#"]80J6,7@J2&.=F&)
M*L)V[^50UE)=P3A;RQ,ZF\20#OFEM.**O,4K^-D[V(K!HBY7]LE;)3*!EUJ/
MCS8A+Y#[_8A1O20/.-MX<3*1N07+Y7H9SKET[2DU@R;IUZ($WIT_UQJA=<VD
M4?QP]32[-3AFN@+4S@IKAS)3=(DMMPD]'QH$^Z6E97 6K,+G9N_*G/+CN?1U
M3L<RI!T0Y<T$#_+.F;%9\2I=^&*G>- _ZKTK9BDU[>5>8$.VDRI%L-M%<'F@
M@[89DD".H@RA6^&<:@=I7U'"7EW@X[[A#&\$-QQ8HW WG&I@_['D ?_VR;J-
M\\.JT6E%QYY5S%L!L1#T#>I[[$-L&(/+0.V[M=OIP FI/$)JJRS3Q-FB/-_2
M$5SWZI96UT^_N?32H]<\[L6P?F=VNQ<4..'ZT=S:TK+)W?OXUL0%W=DX]6X.
MMA>\S)MO_0<T\\UZ U5?^GCH!APHT',K/9]X8=JK=$%$> R3L&WE2[E K511
MQECQEE-!LR8A WK/$D7Y>]#L7_A>4?)9"Y+YFL[XD]1,<),NNB-TP!X2CQ6B
MP/"L[LTC6(Z=S13S^+"9R0+=G(EOE<97/HG2@2ZSZYW"MP^/L2 R;0%DL!GY
MC?:0]]%'TO(6 @6+93_-6SSB)6R*[PE&(0LP2VDGGR^;Q^9FG'4M>?-Q1'IM
ML3:B<\]D+KX=<ZB+L-&,!!/#@QDO5<8$/]T3KLA] ^-;%A8QS&<?E/"#.1=:
M1<?Q?H49[RR,T0%'3+A/!ALUM\YG%AT%/2 ?'X<%R[]QX?72U]-\.:6?I2FH
M;!]D=N!BC7Z/[=>XYQ=E9@!D5 '(X*O&>;Z#7O):'?!!>;W:: M5K8'UG].1
M6<'>/M'4>9 H$1.L8D$4;7J";)F"$*8;I]E6S&%A.[T\IF09)TRQ'6V@;^#G
MC$ THBLE)E\HTS:HU,/?I-H)36!0LM"&(T10,.(:87-@ ?<K0N6BCV#VG0%[
MAZ0[5<SL$U9'C[+GA/ ]5#C1:@#J3U$J2LD=97'P<W\ZLOGJ[,F;Q0]?>&LU
MX<*S?M;YD%Y2WX&;9 \N*I&B76SPW$,JAC:XL6P%J)1:0&FMG>=6,>@KBG\+
M3!;_18F!ET]3D[L9XE7#?/=-:PR$Y#1LIF/G/BYSY\@<9+M%'?)1*1=C\\[\
M39$6::KY^\E<EX_&EP]N"[QZIJ_O DO2HPU:[!L//N53^UYV/MQQ>6(K)N!G
M P\U%T= Q4&=]=:NP,/5SE*S$(;O%BL9JNS(<[D.]RRRM]V9UB2=54[+6SD7
M?AR5X.FS:5,3'%NFL1#@:VTSM9BCLBVQ2KW-(S4QR*-5PW%YKN_U'^=]W9CO
M?LL^DWUE^J7@.1QW$/1>X4ZW@D&-BXO5]9&?\S9F:;SV)H\% *,O(&4=45!6
MMV7BC; KB5KW8J_9VU\%3N2D[>:1^,B@&7>&#B'[S<9*:D3X]K8*<Y94#^WL
M3L[7UNS?NO!#)V95=Z+N+$_FD4RO0LS$\E:S29IX"QU@]<V5Y2"_<A[O#X"'
MTSCI !QO'*G ^_/4RVC?*LG//4S?8>KJH,$::$0YYJ2VZ))_>D9.P@NAPG5V
M@YSM@Q^O?J #N'/]=4T04GW\*S?^;[+C=]7\9[U,>Z?Y^*RS526WM!NG($,T
M >0/^ '9\HW@\P1F&%&<U(Y632ZN2XTMNL;U#KLQ$['[^,CD4 SEFX[XNK0_
M9-6&P,PP,K6+R#[K2T2M2.':PD4LM_>#G#<=3^.:==9O3#W237^GY2[K:2-V
M(R2S#0C$?7 9MT]Z['YH/=O)0;5IXK@)1_[EO/YKBN(9PT]UN2\[/#T2=<DL
M#A#.Q9ZA@;5M]F_XZEF2(V>GQZK:IOGD,3S64Q>(G$HOK[-8&*7=B!KIOO7U
MOFF0Y MFM\Y.7HS>R)EAACZQ11U@L#YC].S2AD5;J5,-/+C06M$;S67::J[G
MXO*9+6@SY<H!K3O0X?,K40#UQ !",V>%YDZRSW/XL*O-'IB(._,]\,3 8W/Y
M7?=,LH,AV7/_/N+0B%=\T!+A<(OID/OECRKIWC*Y(_>O[+\^6Q6Q&GOOA=9J
MB3*,$(-\32XP08')<--AT6M2*5<\+?,O-CZ,,&7>-0"!9N"QAKYTH -]4EKJ
M='E\4\.)=*\WZ?YZ00?W$C\D+I^!>-\YY#C\ZFVJ/2_3I8 =XMD7HY4DFWNE
M"C[GS@3_L!1_+<'VXNOGK@/*4>3PQAH-)RQ!AXI<=GDMZ\UJT[377A;@<_%;
MT@_+US^?VOR8)Z(UN1:$+U-?T 2_,^B;HM=&9,JX]Q"<'4>H?(/_0K%TSU4*
MGN)]D'I GR)R=SY_]MB!A#"F#\S;[>N;+"Q.,C+V<5-3%S_/OVY^%W\'!MSS
M=_OH4&A^9CCT!\\()KW,0J=4U*:85]"$(439+IM"G67',3B?%HB0GOQ&L-=T
M^,?9KFYAQ7%>>8M=&>,Q;F]+-YU=#[FA3XLZ2@T"9)=WM"X&$P2%J"@3UA4O
M0T"4ZWT5Y[UAK!J2 N?65T<4XGZ*/7RJ:/S]\;.8/M!(/QE[/>VJL*K+[03Q
MV/G(E/5+8C?$E,_WGO)XHGU+<(BAP7727*[>-2KUPW!T5\:ZG2Q?HL[Q[897
M8[KCO_O,@)X50^_7Z^'MUB.%LV=M!U34I>5=JOS$2F-M:L*_/N>H.!F6$,&<
MDAQOWD(47ZV=20?3CB;D40P21Y9G\5:5H;DK3Y$2+F/(,<=F4\2K=Z[?XZ[B
M)7DU =;:AE_=#(2"3)C[#9]X);MV.X?CVQ7DD]T)5'V98D?#>7E7S]M]KJU[
MZ=3B=";E&ZF>4C=AN:9Q+EO[L[VK*S/3H5A0 S?"H*^H.)/\!A)9+M"%Y9$?
MBD5]T/>^)-V9WGDJF=*N#!R[:G!@_A8=$))"2!)92.^(=<8,$E<'V]?US=8N
M*R^C==74A'6TT/@G3Z).*^:XYIKY)HPE1X@?\[4#(.;( 0B_&%F< &J#LY6_
MT;/RWH[66<^L<HH(\QAX%[C3RXN8\S?JYNEH.#-29X=3]AK<OD>8*L@L?N\M
MM\R+C9H/DDAHBL^0$H:K\%-&^G'#%/G]T[0Q8=:&/NV01U[ZU]O6$.(G<L:?
M\VO<ZB]/T+XH[G'FWMO';_$-KP>P<_L-A^G F$0J'= Z!NP-TKA-GJ,6G?NA
M!!LP'>"RN+ \8L+O,72ZKBJQ,>^53*+115<::756>(? TR$[AI[9B%<[W490
MQL%;4&!3WWR=[%HB+$JZ\'DT+E;UDWJG6&"Q'5Y,)<B'<&$8LF:19>X(X51C
M01P90( POM.XE.A,6 %LIO[$]HV]A- 1 52Y<LUK]K.'OJ[OOM[T_,Z\#;HU
M7.A=H%DSB)'>6#-]<;8BV?:Z]D&W.YIB>SUHEP_7'LCOE"L,!O>;=UXJ+&4:
MRD]*5$LF.#2ZLY)3<71@3?[=,NTP&8Q'/Y\&5UA=(DVWF0?N_)#-JRMIMBNK
MCA)+J.RJ/WXCB(D=;-R%LI,=@S5!RG^M$B%MT(CS5SX3Y3IX%/QS,B2JL*^L
MG.Z>&?KH)O7CPN8--?,'(.#CW60# /2!HD MWX%ST;J0G.3) M^'([W7T28!
ML),3X[<VKZ3;D%(K]RT=(%=C*7G>(@_E3H'FF_8J%=D=!W3&;&,;[1B<3_@Y
M/QE%.[J!>P/E1S7)9Q)HF<%Z0G<&+4O331WF$@.>0[,PCZC/*7<#9F7'6'#6
M>1^^#%K1 1MMYP%E-X>39=<+84^,+^BJ+C)/+O[#L0K_=Y?M@-^%+S-N$N\K
MX\A<!'![_(2U^TG]8E\%*_*I(M\0;=VTP]),MB^98UNBJ$R8P]0BVD5] @Q'
MX>$_^\;5#^_Z<$GJ\N+/:U4]GD&P@2 UZ5)J#@+J,!/M#KJVK^3BX8N4?%G#
M_9&)*>?NB^X.^3TCPB]S.O \NDE)YCT)--#6G7^U[,6#K(.! ZH%,Y#C"%]R
M/0X:"N64AY_LS5M6$R54ECP2-V3?U75KY#&:[1N=G@8C#'EB5=BR5C[)?-EA
MT5D_\"S&S>"QNA#KGYW8^G_L^NUT.735!(^"( S1^/#FZ6C_Z1:8P ^-XPH>
MN7:#&]QBWY_-WJF^VNYSE">^!BR_$\O)1%#-"\?.9-+XJBS.$F5;T%S)G;2^
M-'DME6V1:V#:,_( 9C5^_Q[ET=GI6= :L_ S',E]RDGM4/A7O^SV8Y>C!7E[
M]ZT=2:MJO]X%*6+#: <&D=P4*&$C9-NG.NEF7^&IP2+KI9:O_:W/.&L!IH<@
M,4#NNXGN7\O[?\!,QM\N(R'/ZX,(_9Q))_]VM$N!4ZKN_ \SN'J9QB4ZX-W_
MS%BXU6CY'#-.-AY.T$$]QW(<:L^:>;W>(+#B9M9L%E^^M-ZQ/[+^Y&V<2I7!
M)>3==K4 *Q;2#VJ()<I!7[P-PF1.F;IU7=]\V*87)A7ZN:I19;7Y $PZ9G3E
M=Q^+-TZ3I12:-X1X+V]$F-O]:HFUK4K9JG:95*F"[42\N]&YVK]FN;EP</0'
MDHL8%CI;Q,UJT^+?@\8LW445- RZW<'SS @+'14Z0EGY@E1!MJ) *,?W&;-M
M&6Q5\1:IZ+4U,6HB6>%7V@W\;<I-P0 O3!B%T84'.\G3^U=6/'W1I*?D5._
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MVH='$6=P*]48;!E%.3OVTH)IBNP.ZM%KRQ>O^1P'YUT[5$)%E_W/,<^;H>S
MD<+'R 6S@>XX][8 U&&R20?_LV'O6)D5C3A2@%X';UJ B?TQH1Y83PYS3'AC
ML5L'Z=#0-OK94SIP8JW.BJ&^[<AA#9>B#>KC=&T#O%]<"-/J,;\#DNU[^]9D
M;(AA8%,JU->TTT[30BIZ1%F<>&L ^(B5;\U(ST2KN5M%=NSUHSD5\5^#\:+U
M-TO;GZ[.L.N*+<1I:%-#*-?>=1 ;841N&(<UQ8 P[E154XQQY,:Y-^OD/DG
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M:-.44%EU-6&AN9?%'+X2X_I5RB2EO_V7N -15/]0J1LD\#W%91E*%M>?F^9
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MI -'M$-H2K1^% ?R_*WG33A54$?T*Z4'&V['A:UR$#'E;S<OY'C"=6AM= !
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MV6<>!IG \LG^^L\>9?/_>,R-""-#3=HN?G_U\<[T!8%K5'^]3R9CG;HVG)3
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MVV534[%7_3KLKKF$O=-^V;2=A395BCZ=5.VS[?-?2MQ4J*.D.UK4F0FY+OF
ML%V'YESW?I<$'PMZOE]^UFT&)Z2FB' <Y_.U)2L$IMGE''YS@\CO>7_=6*1P
MU]I*L\&@"'$R+21G@U.VR:/\_#M/H8N.YDBT^V8K:)_:U,%M7%VU<!$)$R W
M*M#HCC>K>:\%'3(*HN:AQ[.LCGP(B!J'<Y=?W#*S>*:=XQTSCCNF230X..<U
M=5C'B9/.H51_H3[]8>R1!77!%W\3Z?^5*;*[6IR1)1_,>8>23A6(]'A_O]*C
MF]TLY9!I*'4.YCARK>2PSE';IT%WB3]"3&>@3>"AS7K8/IQCYYORT !I>I1
M=:I8U.[EB51# ^AIU=-LZ\[_K8F^4FS-A%71!<(&48'IXXCZJ@+ \BFU*A;(
M2A8]N\\'&MO^![^GB1M\B\LA?F-+@>GO4(1.14H#?WX.S/ *8(9A0K'T>UX
M),(,'UPVV'!:Q^+15/%->G1D(*#=CJ)GC:EY?\N F.;D9BH"?(]II/J]8(F.
MR4E/"@)^K_GCQ'!4RKVDWGDS&N3V9P"]*K]1R%EL\389OES@X^!%MV,4T2TG
M]>+QX4V\%ZGAQOD%A4?>/B@JL^M[KKKWH57AA?71>XNA3V^=.FY^JTC_ TV0
MD6'# D&?H0F-@,;?LF >E)ZL<JS'L2T5&7 @/EMR;W/>&A70.Z-NJ_4L!>)
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M-;GZ218A XX8$F]=2 RH??1L'>=1(FVN\#''$3=6'<<3R32932(-ND_%#+0
MQ&*3 3##3O;LW_>IPA$WZW&@A7"[L1-DY[A4A_>9E9$%96.O?&R^L87X@HD6
M(GNHB1,&@?TE'B*\ T[RI4Z6UG$Y9O'2;[^QBY:RK\H'Y>C>H3CHQ11MJ)[]
M]$0M8F]0QC6'F(*?+@Y*2SDYV%LS +\P:8[^U9ZQM*UI(8GYX64&0?=$?H'?
M3+0&_71"&/KD?<D:;$@Q3D!%RC5#>_>0%7ZD\BB>?<3H^4VG!=_2F3Z+[K+4
MP-2#7?6M5O1P>R]GET[^:Y]/';^GVQ/F='[.',"YF<$9G WM;393:&&M\U3]
M'O/EA-4;,P<SCW/K+()R8*]8(.%%-5F%MZ*^1^POQ[BW'7L<V^;0L/7\L-?%
MVCU<L5X#NT@EM=M1F.H]"&S]]I/,<KD2_,;B[5$Y+8UIS]=>/OMI]9A$><E:
MW)"I*56#F&6)&FY\/U*73AHU#[Y4C;RIMNQ!]C]8/ZJ)C.0N5I-B%U)5[BZI
M7"[?KIC#?2(?%]*RW>OCSQLESP7S'E-]85%!J]A:](9H'C,=AB3^B_^B)?E2
MW:QPTKD4]IO.]S?Y]SS!R<O#!9&>/<PKT/K3=)>LMLPX=7/-\^HF@=4VL3Y<
M?&TG.Q.P*2WY]VS/9_J9U7]P57-<ZIO]/.IMX"'5FAJM%"0O*J+I\1*X5NZV
M =5+S\0[94<JN>44EERR:CND)SC2_F[U*XCO*>B25RSH2I;\&D;[,0+^+"GH
MS/[_5UF.4Q#J&?G$\(DGKSSA"03$:Z.\/M&RDL+"-ZW9=Z<"V/)X-C80F"5[
M<C7:%\*I2?ED(Y(\*:SEEM<CG<)O\JEC%U07M"6IQZC$/BPH\H<-=1IQ9V9>
MM#@20E+<<EP_.L$L1>J/5T'N.JD6)GL\#8N1O'_\N=J<2!_))'D2CD>/"\?A
M&J""HW;; (@)W" 8=D\$:@Q?G_(>4WY2S0*1XM]*(^]-Q,F:Y9_ $RQ2R,0N
M'[E=.9K:+BX\V=+GNL\98<5'QL%-$1(ZHMQ265I:&FQ-JG:[UHTY5%_J]SJ+
M^?8SQR81'2**J28VVSX.^AHF^=T/U^"Y$X4818+<*_8%==[9])SE1^5^-OYW
MHR7X3;7V0)HRF['V^03Y,-BPZN3&*YO;1%*'W6X&CQ6%.:Q?8K^\+%KLY]4B
MM=>(&GW.C</RUJAM86G03]XYL?/\!I.G=S?R7'-ZJ5]2;7$&OI1< :]@TTWL
MG(CMVP9)$<'X!>:MF'$#!EJ'GK6X3:VGE .$]<O.ABJP;O19$$WI_WK9F@MN
M@@FH*(QGY9SGR"HJ#6-2[>>E!Q6BSO#7>YFZ>PG0!Q@9U?NIG6;4"/N,N<N=
M$\I2#+NK AJR.I2!YNU^2.WG3PG@KC;A)VUWB\(F6W]*E2:+R5Z;\!%-)U8A
MP30SU*")J94H*=4_W&G2Z4QACAMJL,N\7/R[PS.C6VI/!_H(!:9O5E3X2'C.
M\RS0-0&>J=M?(WEBOXM#UWI<-A:LI&DO[UF=SR$%T"[Q6(Y)!K3C7W]841<A
MDPR(3Z+(6==+<3UR2WJW]&R/7'(P//Y;K!MH(,7XI3)B:>F'F#W_6=D\]1F>
M1W],!*(;,PJ@4TLJGBS04UP$JL]T$KOTB062M"=VTFSH6=_:<2,SJ_2N"5OT
M,H\:+%K%'^#;'9VMUW8&/Q\W_A&]:J(&D.&!0OEM;]AO4)(N=$L*<AB]@!=@
MJ&%[OL*6>QE':"(PYHP>76KUX#<RFAY4CF-X =8E(7H@&P-(DV]9@'8:R([?
M/I#;\^._+^-I2X/RBJI ,Z"V33I1,DC-Q,OAXYW[=0Y)P5-&A\[E:\W[W&A\
M5\'XV4(;79C?I@_LE(8R1Z \U8+484.J!:E'L[RKP?UKF\=DC)W(RX U0V@4
M>UOQ.39?>C%JN>Z2NDHR)9&*H]U@MI*"]=&4A!\;\<?4F@RX[ 6>7K)\(X9<
M?=)[3N_UATK?P:VK2QMI]*-1AHQD%:,)%N@((IP8MT2<\WKC3ACD+8^KY-T\
M ;[0=B9(L2_"3.X!?&I)[-!SE! C B6#Y&+$8T^186^9O/0;5#_R>6W'P"+&
MG9M^1%_;DY\2 M,4G[) ;:;?WX1=-6QT7"^A6##R"J'XI+4&DVWHFTJ]"?\N
M:U\=P0;>KCJ)-3T?4?Q2F$I!+#$] 9SP^R$W4M,PZEDH_;?X!@+-'SW7W?W+
MI?OGS75!&[ A9::^[3B!$1BMP'Q?;Y5E9?Q7;6OW*\6O">!;?Y:MV\8T&#"@
MY=02YBAT/5> WH=MIX8SE@$6'*/6)L$">41A9W?$W4?5\=]3!3=<_Q+*(*+^
M%.[ #E\ )%5 $AW3?I8%XK;*!IYIY)O4'\(9VQU_C'9(R0%4.+YM39M XJ-_
M1,!H@.[6_[9U"6B]LW-A_!].SGYS>C3PLIT=S+2BX^Z0(#RXGQS,2?22;Y<F
MSX;M^"]Z/2-#/P9GZKD'L$"/%B';=UQA4J9]4)(1;DL:#V$$?T7/Z;<C<V!#
M(R<!/!.2I**_;]&UR8\!RN/MV?%+,X_L5/F&#9-HS"9A0 OJ6N>*_$7:UOZ&
M+@/H]R&<Q'TU,50CT#[]E/?IG=*,:0) [P-YXS>8\=MGS;?J@:7S_BD4Z*#]
M UV VOCW/AL?><@"B<;3W% !:S(BZ&\L$',$EN@.=,%[M<._0WA'/ZX7D)V6
M45L"V[CQ3GJXMRAS&#T[@_THC]VX@!ZP86I58ZFR+) 8X09 M G;5Q:6%469
M6A&XVNT&!J0^?DMXQU6%IKVXU0]\\PAX=OP_ZV'.E21Z:4K6HB$I,]J'%0(V
M=ITD'WAOGXAJET#U6F_10[P9\9='!V=XADW?,'OC\[$!.+O.0_-:-.,^.7TG
MN9=9',IM^K=>OC3L>)>7^U"+XY*44(1SPM=9.[;&:BX$'Z63"B<1KI*6W^70
M#P^\$.103.B1Z(TQ\10M-&ZXZ!\J-Y(ETG>[IOC8X_ P[P***YG0P (=1B0W
MHP2I:5ET^<J!2B@%3(VB[EH)*48AG^LP(\^7PZ\>U2Y)!W_N(]M29A;U)Q0G
MNS9D0M4NEO:>>W1#,NIFOWS+4ER?NO71>D$M4]7+8<JFO9"O_:DT%8(&$4,U
M,A^=>8LU=]2A:V0X.*(&;LN>RWHJHE=XNV9/S"[74-=-?W6U+SNKXCO4C@4*
MX<.Q,7E'$!B='ST-Y5,E%"6KF.06-\I##Q=7-Z']GY_T#V,NE!A,- MKF=;B
M1)"V9.W Y1S4*;I4-QV<)!ZCQY5H/7EC@R]L7&GOVZ:\#%#&AQ+;=SX>F; B
M:#TG'Y$W;AS*Z4 X+$':VTJ-)-SN^9)G%[FZ^G-_ZAF>"IWW^9Q-ZK5FKP7>
M*V+/D)K]Z1HT-53/MG:]$U_SY]/D9C^Z_42.GE&4/MDDE4*+.SM/:#N@XEK,
M;_VQ3#_MW= 5:!W($C4V)A9SLY=Y8I; CMV(?R7@1"]VI>(YK2"%;8=N'T^M
M\F^SMWUE::"<?Y=7L7XO;7?3-J=NZ]AJOW%I4>D[FR"[#N,NG[,UVX>O8M\R
MA1RC=0$8.%7$SVOG-!$P0<EY>/JI1%LB9X.T(%?'$\7:J? 5J\9$>\+Q=?20
MZ81F0+WKQ%%BL"6?SNL[:@HTV)!*:A['94+!*\F8GV_)I;M*4)Z-H.>$OPCG
M<<X[3#XT7<%V$< CCB@F#PM$;X<,P4B^C KF*^N.-68?8%>+%UD@N&K6"D#"
M)@B#',Q;=RBE $@6H=<+[F!+L_YZ#?<--Z41"UB@*&;\JQ93:B$3_6&3!]DU
M2=BZ ?5!+VKC 'B-P*;,A+?XZUR6BSE6_*WIWE>E70LP?[5SC+*=$\8@B=1$
M>+I&VKS)KJ5S+S8"1<8$+WLW#?HFE']>1#WRW// >G"<B[^)S'G?NDXQ5>!V
M<$5)U>U+1N:20Z/K><<SNU*2VPFKT!? S5&E!N@Q,'_<HE,QT*HR'J#*$R7!
MD&8"5Z7TI*<T5[Q$4:KYO+Y=>VG-$[_'IV_]*DN!G4#76N&F\'1Y%LC:J83Y
M86S@4TWAC';PA;M?LHFW._ON5]ZI.B _2 O:X1,=.W$WMM48RBK0MQ-?Z+KN
MQ8=X$41F7#(6@&+?1U(R_BH(W0_,3XZ]Z#QQ)(/FB6[I0,0P2^\!8"CGMLY.
M/PIF:L:+H >FL<Q7XB@/7T"\CN :H;W,;Y/PK<O'H O]D+57E%& ,29!FG;B
MQ^QQ=#>J9S;]-DF*ZJ'=]Z!;LV%VX+:!X(4P\9;!BST_]Z,/KA&&6" *G"Q9
M"^<=<>!&A+9NWJSPJ7>U/7:+XT/KA9::$YOKYY0'?O2:?C"5JC=I;!:48Z2X
M>Z CFP,LQ&LG+W[]?E9RR=I1N4IZ^J6;QS)B8!$+0#Y7$= C>S>9_E)#CDTX
M&_3683<L[;@,;OVB59O6'>:$]H]+T"W>'RS008"V5+F._"(OTY)4ZXD%3.#E
M,>6P-H^W2XN"!J%$Z.F08E?,2DC^\D+1V_5F4TW'6SFZII3G#G-ISAG+59PG
M;[]8^;;D9CN[O?>8T3W^?P2^>?9.;U3'.=M6E ;A]Y[@EW@6=.#$KO#Y&Y!W
M!GJ?K 9ZW=UQZH"N>_M/:[F9E6'!"<Z9)@/_9RQ0G>I+.#A0SJ*P5XX2J7ZX
M-4!99Q.+BH8J\8NR.T]+?1@^56U 'EB$H[,1LK>[4ZGQ67/HIWT6AA:=RO;J
M(_M?K2> P633$+0=!J^@\7HBM&B\0N:0?7B+D/GG_+5W.0(?2K&J9%C"&#MI
M%/>:#DF>C4R1X[V<5Y-=Q=7')K^UA$4U4D1XR,+^?EG,+O/&R"S$5=\.QZ_"
M#,5VU!L$7WW.!)1]3D!YK"6]**[\FO/T%?MG:F2U]5VKN*46F49IO3JO[3F/
M"U2/6J_GC>>B7,H4^-*>?;>F)96OO&,JX4CHQ8(D08[F EQ?8F%/]YQ!A[]^
MPGMOE^@YG).F+2.6?IOG7LQCY.D6VF3I"@;%74Z67$Q.N&^.;_&X_$'X<_*4
MU@'W(TN2; /'=M73=:E2*<SO3 @)TP#FF%<*$2A4H.3-&\BW*8VEO&$?.[ A
M7Y:.,*^G)#&2D-K)B%#*O $G]7D=6$:_Y%.R=O35L*77+3P8<C+1U@]G9["7
MJE SQOW9TL*\%[XD,MEWZH'3[4L<GQ2W7((&"\BW FF7F3TB9\K(]S&I<R*B
M/>-A!*/'$D?%K/<>$.8$/9Q%*550V9+I3TGO<M-<7&TGVFS*N\?FKZWL;KWL
MU[+(:4M]3?'Z2I*I488&F2@U 6SD0%]1H7GV=KCEQ;7 DY_X7=^5*J:9(XRK
MH??H"/(3C+U<N56>0Z37T["3=URGZ$.&+[G/PGF872@^<M1BB^VXJOQ,3)-'
M__LY2<U5,WVAUP>'_179A.W8/!H]=&BZ='.2C.^&Y;5)"%@8Y&C:[Y[_D:;Q
M55#C"#Z%E*5-DZ4_)L/>R&4-!Y"^E[/-4R*C;G]2ZSS%]CZ%(F]ZQT)FJ)YH
MZZ,"Z.*4HBY)TN3L)M^\7]B!NX?8FZ_>GEL=9'9#1%0LL-07JBL!3^E7)")$
M$@RS7?5/7#EH<-^077F<!1H"!$,<Z?SF9&1JUOQM*IYR9D/*2?.\F7>\O3B/
MJ6+37F]5FB("3YSDJX5S.'J$>9:$F_O%L4"5\[KAVZ;M4# +9 ?G0"HQ8E8J
M]V96]J,N])R(OZDOG B_;"OF-WCQVQ6A@2Y" ?CU,I*#)%L7;;PHP=%0Q*TO
MZ&;RR()]+0%\HT_>0I^WSG&8]G9)^J1EM[[47F.1E(%Z7&$4!JE,A.'#QSU_
M%,6HFK96H2^8?\>6A%+E*?$A*J)?$"OU'GC>/';\B^'![W<T8YWOX'%0IC2J
MHWH?]2CM-AT@XV^@NLP.Q[:!HY +Q8M<2C_89]NEQ:5!/%1@6/>&L4#A0=VX
M1=[X[P-+-G_*W)/;11+^/04$D(Y_E/QTP/;ZJ@"\O'$>0N&"S\"*_W7W*1-V
M#&Y*>P"WT 1G@/H9#Q TYG7OE\S*)RS0#TX0^DKT'S+SLN<)JT)]T(55..-0
M'R  =:D6S.MFD.T-,$,<(@RCYF_LU.LFU#R-GQ^>@Q6R0"2]E2UYZ:/,ZIU$
MORSRH[]U#M"+B!@22:2 GO3RD^WP%L3""*#/22]?_>XE-U[.EL::R[KL<3T^
M_)S/T#W>R.1TPNXR A^"79-</X?-PDOWV _LGA^67+ZA)##4B]T7ES8R>LQ^
MS\5"/].,FHZ]GNR+,S1]>VCA(T1@8<ZE%0-+WL6A5N>H78/<7-"S((I+\['"
M/X4S4&>90_&K[I^!;BN&M>(<LLBFE._ "!229QCY3..I)X1? 3=2 6[S8+Q,
MNXC&3EVT[?3)'5,&\(T_R.[O$*HXA!Z!>0O=6.)$Q9O.#<IL.J#>,C R '-)
M9?)L_0=[<@_8S_YW)?K!:3#F $J%9-H$/H#DIDHGF"T0N(NH:D/R3:G?>2_8
MO-UZGA"7U[KX_5EF\J[@$.\/L%B<B,I5>]IYH&W]2@6R:9/1R#TJ6V,TF'+'
ML?H>0OK\]2>7<@J/-D=Q0"@VYV0+?7918$O\V<B;72A.1U/"@?5@:8OFKOU6
MW:T;O0UW;WQYZ&]S"/EU0DM+!Z*[MC*(II3#\+@)9I9:1@J8"T&HC[I6;]G5
M-)[W[>K062ED:^[MJT75-G8CKCX&+EA4/VPO77ZB9 !;?8:J1[MH?>E<Y';#
MT<J$0Y.*Q">>@ICRA'B'+3WF 5@*@=K62(!4RP9SQ,G6HY3(Y\+F#H]*#+S@
MXY.]LOX 9W=C\XSH\QNRJ]$@QMY_37_^/_,0F_\/MZ""Q.+^(K7O_EVZ(=KV
M60#][;/X"19(=H8,:7P/8,#&C.*O_(:_1(V]_F8K@'T/F3,6]$OT3\^H'VA\
MP!V0 M<3=U9C%*H+LBIFCA[81L]F.,YP\C&O IU3@UL7A6DS_]V/7KL$T$/1
M2WW;D.^5 *"*LD T%Y0?'A@"=:KZ[PX097,6Z X[PQTVY3C/ KV&KNJO8VA.
M+%#RYVK#?T^:EXYCM@2 OF)?.+J.YD)/N0&KG@5:ZE(V!WKX&33Y'SW\'_V4
M@O%<4A88'S1W4G5?Z*O'3/[>?N][1B-#6DZ/.17-:EV_VGQ-R!NN:??8Z*!K
MDE.Q]>B ,4FRT[J!:N3KU%&'@F;(&&(\,/6!ZC<-=0@GJ@48*>S0 #  BYOC
MZ(,+5@"\O-$V[9+[)D=KD^]RGM))>[=;YUG.GG,INC4MD?5(%N@"N_Q&5 T.
M'SX1L'2&40)P9&(#@?2!!7JT!8&S0.KE1:O(%=F=LA-NY\X(R=&.RVLA(52L
M#Y.;[D$=&F?(-*-$J6L9"(E-J\+@._FD&;\7,; \>Q?=5\3 ,?7.9S4\(V8;
M([M$]U5Q4!Y1WQ&]-1K0AYG\R!N]YS98(#XJ[V2;VLFO1;QY\Y&FSPHCUU34
M/PB5A1J[W3]]PEHT;-=*H9$FZ%D\/^H 0H-(>,,>H&+SI8@1XG' TTGNJ H?
M;]2!N/#ZLX>_+81_4_&]^DW,] KI#L6"9%"38WUWX(5[OSSNF,,SZ1S"6Z1.
M1ELZ3&=W\?2;&S,'?<8GU#OZ.MQ#O#:.[5KSW]EW?6?[U$D9 8+C@!<J^YP\
MYW5'/B9?P-T(.;VV[[ZVD3^$0QK2Q;Q[0@YK:7H+@0Q!QX\5_N<#OZ;UN*]\
M]-BT)1=@M@-&=^Y)&LSE[RZB/Z"_!5P!J((, \H6AB7;TX&)N\Q=>U5LG.L+
MCE]-'.E,W97%' R<_,84;L]$<%V)=3@E]5I@GL_J"0K_58CS$V0^T) 8>5#G
M#DU6[HS+T<93 >]ZLZ2X]JL<@7T0 :2C+[S=GF9JC^-<Q_)H\+[*'M+/J?5T
M/:K:6)2D5Y1D(Z3R^@1;F8:U)%R7!N'(X[\E4GWEI_&T/DW!V?1TKH6"PO)"
M.X\M)$;WY_$^H_15*<!P'4(5(=!F/73-A+GRW' 5#R7CC4)3D_#K%\*NS?(?
M!U]+@33MU&CZ5J%;BJB.S*9A.$.T"IM//SGQ$L)&-;A.^AF9&_T$8[TOWB'_
M\L\CF@)-/I]G'$(=B09_ULE;M_91T M/.(9@47A[[Z4<[$^G(-S7"!K$92=)
MIFN0IPVI177]@C0D;<]N%S4E.CD4Y-1X7Y[+21U)\%' *FYA(+KS=AD?K15+
M6RQEO7CF)QR:B@XHMBI]*;E)[V1D9:L)TB_VR>,.V"U,SI!3,RWDO/Q^IO>8
M^WF'';[JU+SY5/O6ERHXQ8-J3<(0FV)R[E.?(0C:P?K1BC_UXNQ[/-W$CN1A
M-@W,M]8H%(SMDORD;)F%6]6GNL^F#)&+KU>:T$>L=H[FV5-_$V':#"_SK"H2
M=/W6 .]<V!:@'I)Z=[/_KOC>-O?BI9?H6FBN[#?3NF><A_"1$DDY;;=,9[S*
M8X-,5V$V3W.7RBCN'[YH)LU=-G_!*5IKO]NBJ>>*Q]F@8[S6O>//7_:5KT(%
M4?V0@]7"U.C-^K$39--!^9>GLE1+>Y93!^]I@#^=LE&Y,.N(I3J2876XXW)7
M-M#[YW'X[1=\^_IUJCO/*3\^F&WZ-"@M^4S'Q7;OAHO'Q&5L#J2)=\]O>T+:
MS&*3Y9*O6N<I.GQ(DU+SO*8K$W-W*[H I^^FA%_#X$4;\26O4%S4U_=_+#/K
M,\T9\2VEJ]WZ%;FGM+;N\UPQ>?AMQ0IC=95F@6ZI1F#_Q5$]W2YY%G%P[76!
M8;C^BZYXX=B[<>=*CMZ.*?PHT6,NUVN5ONJ8HT'<P-3?)3=V-JCN(VAYJZE>
M/Q?9=<!=:=_UYB'W%>4(E]C'&RMFN/V5GN0VXG6EX%F46K=T:I[-40O"4%W8
MPP)_0:??CM0*(YI+L4Y%5 M[LBO%FR02@,ZPFNMW3+5?:Z%(&-H,/TV0>BP4
M$DOL/:AVC/G=7*8.PH-VME?JSY#+X1AN@5_!M$4(LG/Z=>YAJQ5Z!1/)_XXD
M'[.YE:JMF=I.&[):<BZ:11Y[CNSX(@56<G-0XI+Z1+/?N3IDGV9I<(AJ8TT.
MZZSQ6LY+1 QH=,DI"PZ75/*9S%JT8SX]ALQVUC8+,7<G4+7)>D3;)OW;M%M=
ME2]3\5;FUR4O.EQ^=O(#QX-\I^*GXQ$=+IL!$_/Q[$@V6[+L.#90137=RFK(
M;!3A3VJE< 6*[HTP.W_/S/J$;6C?#Z0J(YPN1>ILC+0ZV;7Q#C&&7]ZM'/S6
M_ S/QPR3W8=OU&X(9T6!(ZTSS\G-WHW/MW=%K>JA6K<MT+(8CO"?QB;<"(<"
MBO1Y]%@+G)ZY?<]Q)J\#>81<T@"G6C%/DJ"A*E>=LEF@)_8P^U/=8V+!WY^4
MV#QHX[Y8=U-K?Y/.^K[J4&PL$A!LDK5D#F:-"WJ65W[=S=M9=V;1X=KSY],9
M<C%.%9(V66K$@%@FUOQH3)2T[H=;^B4V4M([1=;K[+U"RQ7DHW5,_M+(X;MD
MWHB'G@)P1XN8V>2HX]^V[KV:*4(RT>-)\1Q];R^KB74 ."IBA";/4UB@HTA^
MDLP[>=L^^94#]@+5R:<RY?NFDW1.&A\'A2D?W)(T8T167H(Z62IH^'?LIY]Q
M^<("U6E(?,QZV]1O]_T$^L6WS(87^$;'Y><JE[4#WVF^F_D9(E28;[4\!W^Y
M7H7):;6SD2?*!\U4/IKNDE;0&TCM_*IRD0RMJ[Y@<:Q[@W%Y<G7YY%DSZ2G]
MYY<J@@H=&OS9K@A_=<S(E:I'[U79.\YXQ&FA0?+'I#H\VW?$$F\N]EQB^NS@
M \5O8BAY_,"WR6KL$G3(LPQ=Y<CD4X,?600,PM!*VXPC$]!2IB>_[X0TD#2:
M@9W(F5ZU>K>G2QX3LZW8(:<?RZ&/GO$WDVT5V8M=?&Y9]%0?L4>=Z*(?L7&:
M5'XE/Q_2%! 5I,*9WCZ"Z4ES6#J-C:Z?>D':2KW?=3?<5>=Y21(+!!7OL?#T
MWHN<_")Z/C5*R467:[,8NSV_/;>V4TU^9Z;N/TMM_E'6HP<@?Y!C-"8 )8(P
M9Y[)E2Z\(9\NWB=1TG'[L&MX:-]&*J)SR9*LK4ZU)'U97K#LZFG0VFA,S0V;
M%URZ5'*P5&[75AZ1PQM"?!).MB6*+T:Y:MMZ.*51S:>#SYS?7VO.,*<JG$]6
MJ,,=;,GR%PBW__%ITVWTJVG=V"%&0EH1%3*YA=0CX6[FYY.*2QPP";7'.?8X
MO?ZID,&/_6&PWS'RLP2I.B)ST(G7P[VK_;#5*UW?O2#+WO4*?8<./;T%Q').
M"JU+M^(C0U-/./:(>4[^==]1TP<8R'G"S;N]AOOV8<8A7 BT831@Z+O./85+
M7 E#G#!VIZMGB9PBA09/#C^$9\^YE\>>?<[]\\0XR@VK";K;\R)+5:1564_0
MS$G:^KC90_5,]A\F^KAZ J?Y CQ;(]%,.U/!(O75]0!RXPLYPWVHD@F&0D.D
MC&VF62W:8?1A:8@24RLF$>&J1VH,&IJ[S+OMG;D>-'8A>.M@=Y+/E87.@&J!
M7OGTC9=Q7'5.MZ 5+TAGWJ,4<WU ": +9^R  ;G R,5-S54#A&=@/;ZUNA,;
M G7$;BG!7T$W&)*K">""#/LS=J _;R^"<Y0B&S YQ(&US).*'I2&?DH ^\S^
M3S<EK9.Y?PWXA"\=/7@%%X?"#TR:_NE(K'^=$7_*4BA9^+=)#'9L6]_[<%-7
M,M$#4X1M_LP^VS]N0&*Z;5I'6#U5 ]Q\.GKN-!7@[(U1Z3M"8Q\;(+Q-"+J,
M-&#"P= M&7;Q&V0%IA\LF!N=!4]%]0"2108WU5MHL+V33WP-.XT50@?X;,1/
M'QUI4R-\V\8'G<8"O_\>W5:S9."JE:@%XP9U#*G;I#<_AAT\\$'FG]+T:^_2
M3!O8*..,!.CLXQXTB;<Z 6@R%]URDH1E^$]B?;*F9"N;C_AF[>^*"+?$S'8>
M4E26G+S/>ZK85K_5,$RWVU$/EJSJ#!MV)=*[*ITF5>6R=J<QCGGD0B9@S=A@
M KM3D9V**M:L(3IN>&S$,W+\I]85@-AJ(@F49>4M@#[L/,OA-#_HK# +-/X<
M4%L#Z(E2J!UXFU^.0-^;$\^&&B$(8AK A^[-;_?'>Z81'(Y8Z'-;+(F;C:]9
M'351V<D %JR%4/@!NO_#S^.!:XC-4WTEU\AW%.TVLK8_72'R\6^53P1>&Y_<
MU_,SO _9.2KE>>BKUDS6:<G5C+."4.K::T8CTU@>%83F_[_,V^+Z68WJ,8$)
M^LQ?1EH)7I>"'+&+VB,7:?[FU/5S:@N'&/W"OST(;2I7FD3)P1!$/2ILD@/G
MCW<+Q1+?GN"V=Q<(WUM2^EXI+%0O 90[T895G#+\'^R]9UQ3:[<O&D1%$8@B
M16I44!1$1*H*1$5%0$1!>HF*="E*"Q 21 'I B(J2E14E!:I05J 4 2$T#N$
M$*27A!(":7>R]MYO66N]Y^SWMG-^]ZX/DP\D<\YGC&>4_W@R"D^X*XIB2!S(
M-N@A=\O0 Z8.])^U&7%;+SR_2\M1_.Z!8/4+BPHS(_MUNRK4,@9FSEX.+TG]
M-'#IF_6 56V^[G:W4U^>OMMQ8R>(>UL5I!V0A\Q6RI)E))X#*H+4HO<QY7M>
ME9S\Q,<?<$<'=*1[3'T4]0N=MC:O4T*'4?'5$''?KI QE.B,SM'P6ZHQ=Q[F
MGK":V'V8044[W7#A+LU!':"7ZU/ X6HH0?>^_)E-]63W([]&NM_*1 D50GP>
M54LFAY[)C?XMV3P>@:3D%5/3:J#;*ES'Y2B1^/MX#+SQ)D.QCA LF.\>?.P)
M;YO&@2:GH=!K'NAG$:!50C^$-DZ%+(23O:)Z-U_$?)IF2[>_'K63\KB;Z/E3
M15]S&^FUN;EW_F=_^=@7"]'+1*&MWG+*=(P9E1"-W(N0[T084X)K- 0O9[EC
M5[#H!Y*W4U\?+CQH)J]!<GB>)>S4X*TUQ]X]1$TCL= +^HP+,^)7OKSHH"^9
ME>H(%)?DOQ59%'J]Z;AK^^V+VZ\]V:T>Y" CW+$E(4NY'KBQ-U"IN+H./4F-
MUQ/)@;&GHEB)'BL:[S9LEE6Y-O=0Y,@B"50&22ZB(N2][+.9S1[L:\5?!RL$
M%81>')7YJB_<ITU-7QN'_:[MC3>*8O2UPNPC\)*S]4OA\X=ZM*Y'Y=JZB&CD
M;1?54)"MNG3?\-TMUU37C=2O9Z3<IW!#*N.PA>1Q\$!A@PA$N&H_'8K7X4J;
M1PU:?TX-D!B^$/-#7#'433"Y[(X@>@3+%^0'@GSXJX7._X8M=+A;</^RL"&#
M _J7G]64XMEZ4-HL"SQI#UC61 Z(58J[N  PX2#BX'^U#GV;B_KZF%VNM*RV
MAJI!;QS=U&,!\7(' 7;L7U8/#'OK,>,44(_7HC:AD=#ELUO]L0"C./TV%WAT
M*:2CYL\Z5/]IUVKVH:[5$9OSW?-^+TEI5[^7O)#XL2APV$5LU[,S\Y_T"<4N
M%D>H 37KT'TZ^^E=M24!L#OE?:J&(Z<E<A(G*MJUW)A!(CR4=^#HJMU#B%MI
M)/M*'\HY,O]D+J403]!.CQ*-KA!Q[A8?W&66HKJAD3E(GF@4\X.]4K]];#O#
M>5[1F71N:1L\N=Y:+]9/29J.M^O1ISH5YUF%1+"\2'$.C!,O2CD@/<OGH/R'
M0LHU,@=(.L+L$31?U6ZF"B7SD<ZQ(7<8GY8KB7667SID&^-">:+CBU&UI\4Y
MSRY1F_:G[#B@OLMOH34 6F!KG1F'/(RX2_^N%+D&Y:7[-/25^5J?3,LY[[&8
M&=$\\-Z][\ERN@]4XEO]71-XS4'(M7\<.[N,6=@'P*,!A@QJ>(0#^ER:O579
M_L<6,"!ABM>\GE^P [6+UO*]2_'%RLW(NH0CQ86^+V[Z90GIKMWF(<,"+6IP
M^=*?3L9L?:G[8''P3*[6U95/.<[\*HJ]7VIXOLM XI!1^*\5R1KZL)&,3%;C
MHR:;W_(=-EH"&;J(&\7T7+FX3*I_/CCV\/>3?8*VIX[IWJMS@!Z+]5VF8B4=
M)"VFNU%%1#S+BU9"=R;S&S8@I8I*8%R$G9E:06$2P88#LGHN>Z;$>/QW!O$R
M1_O89]S9<O16/^I^BRY?15/+[Q4:^_OM76C+ P8J"8IC]^3QDIYGD RL#ZS$
M7I"5SMY'CZDM4\]]0'&OL?:K9SW7,+%J(K6<;E=IR'& ELU^)%,PT^!][HX;
M9B<DJ?WV%F?]CK-G&J^[?"1G6=RL'%_P6+5#Y!Q^JW=$S,_8=$I)$E5C7<%#
M2HCB?S]C?Z"**A>1^VO94TO7PS]QL0:ONO>YSMU-P1ETIAH/4]BT[K57+.H>
MFGNN3+MS=,8Z->I$WH*GT%[9J'DO,1N>Q&=ZV^\%8$Y0UYF"<O6BZ/TGT;7I
M<AT>B'U^#QUCB6+A(V^.%#@L]_#^N"5Y?%3#X6W*-(QB"MW6CU!FQ51)P8VO
M!<I^ZZBXX. HE+ROZOP+C<?!#K'Y39KDHU5Z.\))DCJ!22V1;F=N^:PO#G4.
M-6\>AWV\C^UR"#3<.W.+UJ*[*@Y T,GD 1T!5J6.)GV%A*UOE3"@-$9A?.UT
MC 04,L.ZO_ KV-H>=TA\0Q)""B<RCK(']/1ZMJ89[7%NM$BR:N*#W6&8%6$/
M/%/Q;$R1V#KP4)-;P)+*86+(?BB_ZAY:XGT_&\73#?[A8:7Q=A=][WX,X\)+
M>KM/+T4 5@Q62XQ8%RT\&JUEX)EBZAQU.&SM;HV<\N.]@]<#=6JKY(6HQ86\
M*<<((S&S(R7SJ.OC#X:54RE(\.Y7I*%L^]=NM\@[M.6RIUP'-C/]WF^L,&S@
M'- %^EMJGRT5' &8F**BX)>Y+Q301Z]BA1[MJ[(2MKSS2#*^9Q[R+;61P,44
M:Z^P\2)+!3"DW>?2 A7[YGT(E6:VRC]OEIRZ.A<]A_/0#A[K>\)4&(=N<ZG:
MWZF*ELH<D(T/@5Z, "M>2_Q1?2UKU\_ -NT']B,4?V@H4>J$GP*&EPFE3'2X
M+LN:LK+Q_AU[+05+FWW:^]0A>TS./,_D_>:GYM_;%U!6O)3Y=7YR8U(0NZ,=
M?_?;@:<D\=C Y.BD6.VT)V_>V'JHSZ-/EOA#M7"N!'$7XMXJ37A&G32D@MW>
MJ>08]ZYT.5U[[%(TTN(&_EE0-,.+O;O8\8$'1=?BM7O@W6BRS8NK]Q)Y<[(.
M11D>A\)WFMO&S^JYK2K%H;>SI6:@.Q'!(0YC2GQ6HT,NHBL7'GAEV,@F7BWI
M%/:[_<I\^[9=$_O,.* [Z TU-!"R#:VS4VTM_,%<6NKWIDSTOQ\W-+Z%,YW4
M3(TY];UONQXX+.-8;8K!K<K)M((G'].C%!@E08H$..8@*Q<W0=2R^,_?JX)8
M@3P+'AS0T8UQW'_^7#74BINP PS2=MSJ"Y3\%'I9OA[5]YT#FCDQQQ9 -1VF
M0%FA\ZC5MPK?\J!C4\PD)6X.J%^@<2MEM 1A-QZLM(/N;-JG)KH\/W_0=6)B
M6[_D,<)#;Y[OPAV1SUU)=\Z<.R*\(06W:DCG?3,Y_]P4^4*KD08L)Y''&I"[
M, 8'I"L\7[RB,6],%236B8.?%AUO;LS20QW]O'>O1OU)C=M^&[8^[,V^+K6:
MQ-[P^V6Q8XNY&](P@;[,I\U?KJ>5%5>Y7T&0QU ;.N"G,!HWX$'/YV,RLJ<@
MP#*;*(B+ #21A&WNB N1LIH@[D!M,DPY( ,G!)2I9<Q"9G- G[Y]B-YXW(C&
M9@)Q^%SZ84KEXJOQHLIOWTN[CG[/QV(/)(IE.,?%CJUM#SNOK8DIK/Y56M'L
M><# T\/+,W*(=$KSC>\;;\I#]V"(<5^8&WH9(:[$>KH,L,_!8FH54J17!UYX
MVNOUE'U"W"*=NU5J[A7S[?"S"*/R$MI([/J2/4MC 3WFSWKOBY,ZF38NUY&K
MI3JHT"B[5^+SR[9[X(1SKK;2U^>GBI&QI><@+[XO(U?2W_25I<<WM]CG,,+Q
M!W[N257"M>Y6%&D;]!IF;$8SP_M0+@2(>CG2-^&IO>+9"Z6H@K36"[THN0<#
M%0HI_+'WMEUQGR,( #A4MTIR&@GI\IV+@8BY^0S:Z&U/Q9J7--A$F(%^3"U
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M[ /;%-9D2!Q0.(EB$59DQSO"_.'+L%SH>=3F_T4,\S25O3MQ7,U1CJSQ-%X
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MWY]D*P&:@[=D[N6 /FRUA>6 >&,@[',P278=3*I*G&Y,>\3ZXB?E,PX)]_6
M6E(O#KMB@R*P'MLM\D,P-SPHY:6")V5U4V3O=*\+KP=*7=63:3MT7';XN%4
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MCUO4&8O!GTW#]JD9+_#KXK&B(DV0@=N1S4Z.@K?K8DHABJ>NPR7]\O -N**
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M%)7*I!C ;11]!RBL&#97V1>7E'[8TTA!@39*C-%\<""K_^MQBU05 Z(,($0
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MI=!]#*,'3KG]K?05^5B7P<=U5!^R<O.-\,H)>QDPGZ)U7*V$TASV^@CX&&Q
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MW@4<'7N?SO,MD[2\-"C#OA1CO,D!&;.$%1&D#X"PJT, !CUQG^: _O6'%$\
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M,F8PZY^!4* 8EO&&#>"=$TNLVLR6%;UG'9>%-P8VKFYM$\WBGP^55GC8N_4
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M"ZF>9&MQ&)4!U(:C)(.\E2.SR,TRZ_'>CBW%H18?TZR+M+HB1L=U9TK"DFM
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MY_B]1[3*" ,ZA*YVF)#S*4@0R;OZO.5C0)99D"R;MC#EG6INZ5X/T9C.WI)
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M>VR,. N$.I4%8/!I+9KW#18W;'2">>X.*5TVUD$Q=+;RU/@]W(='OZN5H4]
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MP1-%4D_INV-O73P# D.JF*X X8M.HR:0DVX:$A1>50\GP,$S!G_.J_%BBM[
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M\R?GOFJQZ&&# H5MP>1Y)G)NS/02()3M"UEYOGT!C5M*?PIVQ3SN\:/-F;W
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M>M25RJ=W']"1<ICW/VZ9_?U,1DU2'F./3^N0%@X6TXC>\MVQTQNGSC[+E>-
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MF!_^_+R#O?G'!$CQ(12*EQ">6YL"(QK._,;0!YO_)%?5-!GG#ML]+(7D--?
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MYP+QFYN?^7INPM?_+P31_;\)FJOI_P%02P,$%     @ :(![4*EGZH,<8@
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M!?'_NO8?GOVO.?;A?\NS_\.Q__0+ V*@I+C8/$H6$ 1$)&1&W 7]=Z4\(,&
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M$Z5-0TQ']U"[0OA;J<]^3^ZO'9MRJGVR/'79X3>--N_(U.OV26K*"#AWNNA
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MNMI=*OOG4YO):7Q 3T/]S7F;W\.^'"^_T(."WXW 0,,74&T E-D6 2.E)#Y
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MC3=XRQ0+);"^)4'[EZJ)84@R2$W#ZH8Y@181>>BP.FM'VF+"!T<=+P#\U0M
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MM%AC6%V#7A5M$9MLN)P%V'\&2)8+%,%"SJF$#DI-.Y(SC),AGB8+'?4H()O
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MU^;V5\.#3=X^,5_-V'L:!)NPHFF3JX@-F'@)9&'DK) S,5Z;D';^N;!#L"T
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M66"L+#+  7X65GX61B< 8?:5C>7?RG]TF>4 ZT$V=F:7N+B9%]0=87:?E?4
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M ,/H_.$"L*-3XNQ!%ONZ)SRC;?:ZW3][Q, E(*<0[!41 VBR3=F0(%*>TI-
M5UT50\7>(;=4>1?A'%:/# 4\#)/_IJRBH7*GQES/GY6+(P(X.,PQ]=P^:AK5
M9F8@,8N0M9GP%^G<=<%)U7CG^SRZFE]H[OO>>U+']$CH!P.N@I]&=Z)9MKI\
MD!?V/[= :&?&]4/=WUN65RQT3&_ON5X\%OC[Y69QR_6)X9G89?M[_%')4N\B
MS[]-I, $(^;H?.3B6'V=<+4,4FZ%9Y<)W@'A,=G1</I'S_JZW0-J5,C;;M,O
M/:DFARIG6AF I"8T"<(&)9PEUPU_J_U4OOPILC?E*$?2?42A49RIO8F=3:_T
M,(>W,=*03*)SB5+@5T%>_%"R@39YH6,/'1=QLBEQ=%7SG!IA//!N%GZF\*N"
M1ZJM $OF=3[9G+EAJ#]: K% _40QC5S?V8J.D!RCZ1 1VV:U^P^(JUJ#;K(?
M:IS?]_*_BCN)5=.YR;_&0A42HKBF;8Q3RFS(Q9V8)\(&(F!(*8*#@$[0DI39
MLW2LW-AI2O+59C=/O^C$VZ[-6XO1<Y8LPV&]^7#U5G'H#_122D@[-:LQ;E!X
MQF$,W\*[U)OQHC[A@(:^RJM(4]D*(,Q6B++?0!-,ZQ2(Z+)!-%KQKEI03"#\
M$(Z4@_KH.WY67TA@\Y!R[_[6_%<]4LX":,\ V%1&MK">D'@I!<K5[#(W1$?/
MQ)GY#@(#X%JU6;.WE#BMVW>RL^BE^[4WZ8/?7GER )!K(VY'RU%M)A&BTZ!R
MV^Y\;E E(ATJJ?+3.]A)+5-K@Y*ZD)2=SB8^<DLZOK=7FGS?-VH_%XI_^\$U
MHG_^,,4TU?D&A2.QV;O4QZ[1+ILP*&"1NW%5SS?!/C!X)'K&/>%&DX0[5E&0
M9:=(Z)?($Y3?M#Z<DHOGB6#_)IO1CN*ODW0;L$]<Z^P)D<C*VFO.LN\PDGL0
M+1J [L",U0+6QH+_[7I#-[;)=<J*"Z]957W@T0&3DSY*K/A@YK0Q1,38@J;D
M[([?+7(C?INT$P]1[L1WM:&/G>93@DKV:W&87FX-:1X-ZRQ%?1YJGA:SR4-$
MF3.6,H\I^C$O636Q97!\"MQKG[_WH,_W**[SMH/:<Z7CC@[)/4T2_*NPV]87
M("(@B7YHA+25E'<43"'R\2/2VK49P%%]^'LO7&:SW9%928&^P)H7QSUNK6B3
MG<,V>DD ?KDCHATKT'QI040K31#RF"XW$:&D_4QYU5YC02U#9%K@4OKY'PG/
MGI\^MF*$?9!N^Q!V.6($*EZ[,-V!3TO0#R@SEN_*CK^'6VP3]PO+[G4@7D?P
M;/:_R=MP"R>A02732/H1-^]&6/+7JK=@*NEB?*<(+NA=]L-2!G#7N:]#L[I-
M]%I)V_.J5I+^G6L<46 #_9 52?5A*Y37HXG"%X]T)::QX>:G7*=]G>)*X<5#
M?@&GLI3>-C8$!.NG"EFL(%B/7SC0\G+_%0/PU :/[VGR'2P7$T8':=I[F&WG
MW[^7GQX<W"XZMW13!W#,54W&>[(.TT1)*8I$R./M_1"C;ZIUJA#;*#4_M?Q[
M/?K^I\OY/OMP7-\+X>VH#WW#]Z1%#-5VGJ[J V%!BI##>J2DP7 X>;(]Y.G<
MG'9<PT.?'%S'?7\!CC,G306R954^G65-7&\6VE-%.H 6>^8@J;-1$MW.Z]Y!
MUZ*<]O4S^ !GQQ1WU?&GRSQ]SB-D#LL5;TJF;(=T+CRQ@W)%2/Z85_AF1_2%
M')ZR+)GM\<]_YT6\N"XHP'*/-=),=,L%U:Z.*S8!AXCG%3HL1I V\,,UA#"X
MT,R:2/ !/8C,@_R;9]B5J5$?!6+.BBX2(PU"Q["WX"E.GH];Y&G0:HIZ1X5.
M*^RHOFFIS^_&MSTA 17.,VX: A>?"3GH'/NF1ISUE_-,I&)P-E3;#*+]NO%[
MFBSY=5<>>MF+BC-YK;K7D"EX7],Y)-,.W@2Y5ISA]I*B1SP(X6Z!^!K(?*P:
MUW((=+9O3!^ZTK!GO$@P">Z1,ED^'V?L0DY+(%)0C[<KG/3"FI1V?,TJ20W-
M:7T?'YM%M9NAVTEGE:>BE5B7JAC 0=(W!D#X\ Z,#*HXUZRC\&Q%[5DC+-MU
M3V2J9;+!?S#/[NKZYFS$EFBY51R*;+65L%"SF43&N) ]/N$M,!((\0[[/*%O
M%3M1@8%-,]Z5.4MNYV2M3S:>$NT'YD[K[>=_#MGHG4LFZ4\.#:/:C)IU2K]'
MB$V4;[NZT_GW'W:/@L)KU.\]A\;@@M5RR8FP0"N9#8X'SYZ:;5R0\L-C0$5X
M6@N+&TV/(A*E;TVPV!)!!"_<J)UT=JU[?0]NDG_N8[J9L$3UBT7HR5?L7*<'
M,EPJ_YKT@F(\V8:)JW_@,W]T4M^*3-]R../LYN(CK.M6P;;?EZO@?#W[2"_Z
M!,N#PD6)5*OYVFL<?2A>%#YO=RBRV8IL<ZT>SN&M03L_H94"<Z@><]MYFXGQ
MZS3[<+[#7"ZYR60E,SOX3-1H2^W;1$#I?U#_H.C<K()H<B?N^9)C>?G.H QQ
M3_(@=_AAXL)Z] UTT7VH6 07HH840A-L<JDA#R76J;.N.A6W@WYPK;!P4?6"
MEH:P4:EQJ2MR_K8Q[-<=6,:$J!Q=D+A&:+=5O--D+-+0CSHH JM-[_\IW25:
M$! 3)U%V^$VJ(9":^; M3ZB!K/Y8\[/PJ$5I16"263DA[.65FM,F48)->8X?
MV,W7O%A)?+ST;C?),2A\@Z]]L& MFRX(HL@3_9;B&W[JTW+8N/TOU_L''J?;
MJ@S5DKD]X:Q2(GO2M/.4#OHHG;]I$B,_$J'H39?/0_%_('^MW:TO]?]*O-3T
MV5.;UVLD\\0'7FR3=,#06H4@RY\B<DB'KCZ$W>"D,UC03C^;2XW_.*I_16OP
MHC/W[U0O5_E3)UZDR9@YZN>+J9$^\KZY[YM+L8II-EDX3#/F<;KZ.7O_E::S
M68%P!M_VLP#A[ZT]N\.ZF'D 8@1[KWF-8QG5B8T^@Y2)(;)G$"0AG7;U!DH@
M5Q"O,4OC1_KP>">EY-GT@,>*KT9WB+N^NU:5.V%#3!T',423('$TOPIO*/DQ
MXH$ZP*TLOA=;U^P@NW?-2OJV^#/M0]Y<!%/%8T*[IXR!"!<P[I?3!!:?WR(Q
M7DX3#R+XW1XBWK-S>EPUY2LB5M?]ZJ??KTKUURGHJ27>GVW'_K"?XYZ@UN0O
M>#$ \M4Y9\N/-8U5$UI6*4V!O2L)^<\6PZU%15EY7I7<X]^"%0OUT"Q!42:=
M)\W+D[-**SL>!JE'[ZAOA&OSGW)@&[Z8(%MLJG0L<^BB)1 L:&T,_,\K[%C$
M.+J.8X,3BB_8A;;!HJMH\A;G#,3Z2+Y_FN_"D58O&M].^Z5LH,^+7IVPLFEZ
M\X:OYCLFE8:>(='#(OH8P.\M5P8@Y@O"J7^P!IXT>5AU7FY3FK27[M+$0O@R
MX4S>QYF>ST"X'_&'<]G6H;6G4R^%=WW-K\_VG&T(.'Y11$#H?OS9/XG:NAMG
MV\ 0ZJ']URAO3'P.1W=)BQPBQ_+ZGDO.'Z0^=3?'>TE=[.R%CX?][O(V<0G_
M\"DY!=T5VZS$T(]LS?R@QZ.G;1C H7 X TC_S@ >ZU%W&4#^"O4& VB'.3.
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MNAQYOH" HA6'$'_O/\-PHU9G'#%5RN0MP@)-HFU/=15+OI$FAG1H&F_V]B5
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MY?I")$M%(O2Q)O:(EUAF5E7^#[NJ!0>88[]"0W.T\>%T60Q/>>$1TVN^BPP
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MY253TTK:A6&D2B"A],<CD]?[54IQ'1OVSSJHTX<UGOG+ADDDL_6=$V3!& =
M:N$]ECK4>^"I"L30C;I&;,/H=:W$_DDX3GU3(?-X]/SY3K4_"NF:HM)W/U6R
M$GMH@I V%#O2NGQUMSZ7F)L+X<R5HWC4%4^I=F<3=!IQMYT_Z<037"6_G%#,
M2BW?,QP$PNJ$>I%PD$1@ -._",$%1 ; ;XX,?'U><'ULO:BEL3'XN'OBL=MV
MH9)3D6\.%Z>SF^'%J;_)?I.MV#BZ[ICF@N /<XK?30/AX?5UFSW8=6;VLXAY
M_O.DB7OT.;D'/T^6&/6=/<@Z4X+)W8+B2V&\Z\A316M6[B3>R3,+'66.S!11
M'=>L4B_RS-&M+R+NBHQ1@*99M^QQO>K\YP)Z*''ZI*Y!%'XK\5%]0J&O 7..
MQ5K Y7+>.YJ4"GVC&*T,>L.5GU9;"2+4"F(];B@&7P!V<I2'D*@]:U"'@&V=
M@Q*%\TOZU..#2LH7+N_)\3X,*NL+^>#4!N<Z,#IXQBRQI*#L#OZ B7V[%>Z'
M"9A+T84?7#.0I(1$(6\VAHYOU*(%'+L.-J;D-';_FNGCJ>Z0*:@N*\EX)'*]
MG_6$M!3&^)875%#_#+'L;JX%13BVU$A^^H.C*ISXT@E_PIWS9&=HE*&>+MY3
M:/GOZP._R"2JT6>ROMNI;Y4%\3UY<C!NQ]EI0VI9F'CU(=7 -=1#@9OL#W];
M\$2>OL!1:^T61EC H=H-I"F83DO>K5R+7$+X>-&[IJ"2C;J:V$V_@D]/RLMG
M+O]Y\$:.Q!/@JO5W YMWU4TRWJ&1<CC>KW#6B/H"<Q>;H+J4M+1/['7VAKV,
MN!GPB\_Z@OAS.\4$ WD0WM:H6EE4CHBY-%K[@WJCOK&Y)9'37S1NB7.]S2'S
M8.2A7E&,-IB_Y[&*Y3/05^P(A[;EZ5.*$Z$?2!1!RG?M+ QOQ:N,SXUZ?0$!
MG'WIVN+V :W,@)(7^H5*80#X$@-6$$;AN$%F (F!4'%$0""<?QKTV++Y_"%^
MSX [J<RD.=4N4^%V_0__%O?^_@/LHCUG=V#3&&K\,,H''=,(3]77.EP&+UA+
MG^W@>9196O?)+IIH$3(G*H<9.LH_)!TS'ZG7^(_/G/TIHW.),H"#G\E6-,$8
M!] ^C,0+[\K11Q^B64 2 G=&,)>X0V6>*YPP4KY_Q3O>19<VX^"OM5VA;9ZE
MVO32/@!W.B!C]<+AOQNJ1'1\HV>GU;0] =K)C+M@%+>^-7'?N5/J.(6]F)#B
MT^V,6@\W475:\WV20PUY?K[FTJ_JRSSW@CM%=38/O-W/I7,@FNB'&DAUCOH0
M(E^"E,2D/AL!?ICIJ+CC<;Z?H==&*N[6(1;C'&7=X:=[Y4P/QMY<:[US='W^
M&)-)$IA2VZHK#;Q4 #^*&U1,\$=*PM_/?;?7\!9YU/7QH7QRR)469XLGA:U?
MQ=UO9K@5D(:>%+=]6%T>,AZGF6MM%OBZJXA=2S2_5Y!C&;=V;?-%M(%C[\!-
M"64I)=8E++]WA %X9N\"THLB >/1MR4FP5)P[.F!1:,*M=E[RM?JJ])'+?1&
M1TMB'U T7H;DLUMM K.P;NATT@WRUKHR?BCZ47S'0J*4!L4TOIG5N]#[47'L
M3@!['.Y]>XGPILZG5)'$<Z2$OL:&K#.B4&5D'^R1>9E3YT]E5^<R8]&7;4\/
M/-&MVG;C.W_V[0_;NNI:YX1*/T)45;WITY/:CV[FG7O#%X.T)=>01#I\^5)U
M>7]'!?%)(I)("X\URY1=89<0LJ,J=0%O*S,?9;NY%S@[%[ZO*3NIX377RI+M
MO;P#GU8FVK<O3 ^0K-9_%8-0)\H9I%W62"!4I$,..BT\/%CL,.UZGJ09[> T
MB[M,.*#SHN*(F_G,[JD@%%NB?Y[7+9>H[/L%BI'G=LHM=7HRW, ]EQ&/X: *
M@R'CNOI&5X\E&5?HM5_(P9'VMH&LI 'QWV^CEA6X'T;RR>T78>_"A9"N+>0]
M1$AGO:YE2]I-E241G=W]FBNMY*FQ(#U-?52XZ^=CAY6_H/RW(L6H%<417PU"
MXI%W298ZK5)RZ2N=GNUBL;-BR0&H.V[.Y57]OY.";PS*W437ZC\^->O@:;#Z
M)F+""9YL</Q'GN0P38>8XD/J,%"L(W\M?NC-P^OGX3DV^@<NFOPFU]9<]F*K
MR#S^H.PRYEHB_="FV+'EV&5CGMY*;J7SAZ3B(J'Z*,^T*8O.!7(- _!D .!E
M X@^FH_&3>23\-$UCJOUVU)KUGFWH&)ZQ6*]Z4_#E<%SLU?*B[+#LEW'U3OX
MICR[1)C)RF2,EI40\GS<K_9'\"Z^)RW2GWR_,Y7(V_IOQV/OJ?'<3;U4Y*#>
M?YGTM-G^NVT=3:="ID/31E/-_:ELW%1'R=GOX2D6%R Y:"XF6N1%Z)+5V_AB
MQ#QC:7+(H\SDFAO\93)>=U8^431P&DY\[CV/?+)4:*73=X<5D7:;Y \436+O
M0H5IAJ!]D#M^*$87T^'8K$>V@9$]/OEJ!@?W=#46C9?SXW#MMY\G9:9Z>61O
MG,X4?7%S:0$2AO0'_Q 6IAE !U4'1YM,MRQS4WM=M$H53G>#K4U>*6_G1LBR
M+8:7K-_7>)_<&7FH#,+;<FH5)D 3W:^3;*G*OUA35SN!VT2KO0SR8W(2=X^&
M3:]T]&E.V8/#'&W8.I%U(>)C\N\GV]AX!G"XH&$L*"UV7FA4H6XL"S>O/'BY
M!Y;H:>JZ)N90$5)/_6J?THFWQ0C2!Z34F\$V3_< <L:UB69+3PI]IF>0E$&%
MUKR+AK,6J&Q(OZC57E(=_. F+--QDAUE5%G''28_ISG<7L@,V>8\#IB3PU9^
M9J%MCH*7\[W(LP:.VP;Q/RY T.@:Q77)2F@G-DX L4<8K%A.(7PWD!-_L7.V
MHK)BX\ZW';"X1N'\EV-#]^[<:FN5TQ[K"KV'_@#KW#=EBH+(0/0Q+P.-<*DM
M@F5QU&!]YMM5IZ7?\1C9IL8SO)/IMT=R3JB*JMU6C:MS[3PV!GUO7NYDWN W
MWN3_O/WCTX?2:S'HSSU7:Y>Q47#AV4'.CW?G9=1T,G=Z7,*&.088 /GZ>1DX
M6T1WA-"XVE++YS&Z%**LO7&^3G4@M$' T7$M."5 LTCCV-L8Y6<]O3U%H? >
M=#2*/W^8 7AOQ3U2C]I)XS?>,X(E+1Q&I,][.9M_2/UUM;[JXYYO37S\^H)G
M*' #=<KQ &V:=;/"Q%+'KKJQILE7/#?X\?Z[0XF-FI>.A)22O$4Y]*5\9?BD
M-L 8WS?.WQ_5YK@T6JPI5[9722K(I)??_M:R3P_@<6$R@"RR%7_D,(<KF%"&
M<,9/)FO6DSE2,5""2(JF.*LW6UTG7=:D/L5XKEJ%=DFTOR''.BKE*V<;5,QJ
M#XKX132E'6V@^I$5GQA((J^.U&+C:QS;2$K;)@U5E-3,AY[N]*2@HJLUM"=J
M3\SEXPR//_G(ZGL^?(Z21GTV;,"%C:(O2"Z_R3.@G&^(U?RC<N#RL[FK&;K-
MCS]TWKR(SYPUE(WY>IIN$#'5PK?_NJZW]O,M?:/W/H/%%A56[OG??ZUE"^LB
M3>]E9\B=O'(_[D^(E,.BTNW#@($YZ+UW!)%[;3\#J4?PLVAMB.^\!N9>'T,>
M+UL;[3F<3\ >GG51[6V>&)VXD4A=?/$X3O1@F2:1_;GPKV.^M%,CS? ]>2^4
M2/E?<BV/.(J =D3(?/SHYS6M_?+!P0TUM%9R%3%4,6^Z4HH\E#XIP'/SE?VT
M#DJ49H#F&.L)MK?Q=1/_.%8PKJHXZE?8DDX_)*CIP4FT"^6.<\TW5+R/4?VT
M_SE"!,02)I^\^U9.NS#V/:<+$Q^DSK7F)OG*5V%WZ;JS;\#MU18CE7O5QZ_=
M*%%%/\>S]N#W7] "_CX20]A_<:MJ9'%2WY'L]A<H6X:1.W'AQJI^8LI)7B][
MK<[+OL9I+-UH/GGZ4V_QW@T:!'RY%PJFV5-$8I&*1+YX+#F1IDN!Q->>0)JJ
M/ JG8LI\$NXU\<NF&_$V&L-C](Y8#/Q,/NZ^P]?! '#85@8@N /EG/82*\1E
M+J1HAFKM&RA5W%$52C]2H<D U#<Y7LP["/BI$)X?L*WZ?AK6QCL;O*&I'*"A
M<'8@<I/#Y7"QU#<69L))/S:'R&B#<="L\=C("#FR"Y1+/ZC(UZD[5BJW&+>F
M^[]Z^=)H*..P_9&D0F0-,;:HD!(I:4;)GJ@L,9@DZS0FV4:&0=F7B4)&D22R
MC64L22;,F$3&+D.&F:Q99JCI*8Q7[_M^>-]S_A_^Y__A_^$YY_GPG/.<<YW[
MOJ_KNG_W[WZZK\1M[-,(AWIFK+4WP/-/;DR(T]A[E%%\S,9!= ?+-JE%4S =
M(L]8X$ES9"A0101$J?I=<T/&$O&%DTUS,MUYQW*A0K-.U06ILLZ.X[=$AHVL
M?8I=&!:#YFIXC$B@WJDFW;*RE8UW*X8^(^]P8^.L$=R&-4:83<#]M"!H_<1)
M+]Q;'*F&'S</$M:MVG$TSD_!KJ<4?_+]66673(DN2['SVL#2TQRG6!8G^VTX
MA]]DD-3H-;A4GU+I>;%F4+P_Y#WBV.N;W]^KG)5BY0@XS]ZKL.<?Y'61JE=3
MJ,D0 0)N<]=O.9U'F(N</;Q9$1<ZM6M0:<C'L5J=+N/K*6ZVADQ6ZE*T:)]R
M&H?H;!4905]. .^M!UQ0,NCW;<W!+B]6X_5\DFU<[)]9>-QD9?1;6\Y8-@;%
MK*V9AF;3>W2WLL_)(JNJBL2/$*M>>71:C.<7/6>I/C0&/]\&"4"]H5*8 X,0
M!3C&&-"OQ%BP1U*FD+#VABCYQEC:]2?&+4AOIB_NB=XK_?0(L(KR\4S/FP[R
M?&DF[&ZN,R?GHVWJ-DAXE:<"&# )J;=WE&_[A?,=M7"TIG/3140IY>U$+U+#
M]\14^,!11;4]QO/C09,DB[1-H>#JW,+UU[LK(CIG^:L$W8_[@U@AVZ 8=T$@
M#14>6(76Z: _0:3G.'65^CWN^:T;6; TU7-(H5=)_430H\\_F<TZ0H"U-=OL
ML=Z6O$W-0(6CL[HT]['6*<$,NJ6\?[1N;P_YMY;M@[[_PQV-/RF\_:?_G9(/
M8J=>N3#:8=],J/DZ;!CF&.>*NWK\!6FW\K=/CV,:N^1=[_)YR1Z5_2@8!K[:
M_Y_-&_ SJ"C)!ROK$M7W); $\&$V ]VVP%8I.G]2P9'^'7U"^P BZ7H$9U:T
M5M:EU[GE36HNN2K.N-OI(IO U1EI.;BACCF?.3J]4N+#2J&E_QL'2_1"N"[:
MO*$R4Y)&_)YG,KRM;V<>G[M=?N=H%XU^DC=&VK_"4UJ,DFC@S"7H8&R*+I"=
MFAV*^YK>-V1.GLGTI>MUAR<FD]\8" =7,3[FGQF,.H+6M.1(IQGEN%Q]YR.U
M]92V^[%>]>>8_M3[QYO%7RM4%"9<XGLIVHN*@;-MLS-M8UT2$ENEOV']+3DF
MG4[N)_ KPZDYAO9KBS3?QC'4Y-C[R+1,F9[+?WR\+=_R#FWR#T,.TS$&.^Z@
MDDV@Y)\#X--Y.C(+CA Y-X%?C"4$=50M$N)=P]=]F>Y[LDWY>O5;H:<'1**>
M[F"7!Q<B>:"DT$V^<EB*+3\#G7Q!9RJ^LAA&?0MN[/ (/U&NENUHVBB)^'2W
MY^AAKZ=%4E&69TVXX4!Q^*M)?W=E-CQ5/^T,2GCS.$IZ8?GNJ(R[*K%&!EDQ
MMK?;FVFO(V\MJFZ\WZ,1"2UUZ-VT 0@[5/X0+]#PENEF=>%$^[H=<: PBQ7.
M_\WM:C:7,\UW+OR.:=<A^5H+63V^/^OL4>Z]463KR?'%5@G B8G; YR9X\8-
M&MEZ>4&>WR7+70>\EK]_6#/PGIR8F,$T[+6KOB$'?FK"MN:>XC Z<(\*=NFT
M:$Q]LVTGB9?TM?B5  \=T3T&CNMN+FX7HEN?9G:>"F[X(A;9+;M?\BB39%WZ
M4C1N1P(^W0;5O:EA#U*AX_BX_ _3[[M1>^CS<K-/)W>C1,8F&=2304$7.KY=
M"=&DH(PBRTXZC'AK*VN]^F#-#%L:Y=B2&401:J)>@=@14OSWUMC@AFW0(Q:,
MJ**VKR4R6YD;^*)R#9=51[L!M]Z!WS!J#"(Z&JQ#EYDJH+A!._Z6)!.A"4XN
M'ZKJ/8IA>956= 6S?B7KKTJ"P9,W.J4&3@Z$![USN'N2<&[KU0E/H(/S^R/$
MD(-K+U!$=T]M9<>5+_QXZ8Z^;KVPK!^?S2_RDWY-Y)A3H_6SHDR+.ED-Y=V%
M./J_[0N"L5@/'5ET@[40/)''-U0__Y,6_7<E[XUI:4P4WNLGO:5V843^MV[]
MTAG4?LU=SOO%*R?F-N]NI1@ABZ)Z#2=SIFWY@,(044E>[XBA=Z/4JT\!^E@Q
M:OA=2H!\Z!\4&168>SCW3+9\]1ZH=90RYN:_ E2P! 4L](_^9 "6(6@];8/@
M@&V0_X>"L*R]] -"=P-@^T]U26ETV";A=2C;($'8#QZX&;]NU9SMZYEM[8S,
MQ<NZR^[I<G"];?'U3M5>6=G=XGQ_?FV8;X/:(*-7AW9TF#5.8/-4<X,WNR1^
MI>7@5D[ IYH?8O5M^4PR_Z,61;?&7-T830'CG@[]$N3&28 !WR+II\'(701G
M_Q2.XB"Y69KD,17Z(=M-^NAM^SK>N(&F5"7A::/8%]_^/1#/VM=I*C5;8F7-
MDW6HZ6]RZW8MH>D#G3)-+X9E/[\ZYJUL+WT6Q.;3J-Y)8>B.C*2/1F-O(>7\
M('+^.7+UORG'?A$2'UQR"6^F)6X:-?_Z_F:BL'O"9$:_Y=60 D&NMNS%#"R,
M28T)^:;)S/[7^8K#\H<D&6DBV DW!X.W02*+<B9^H3D&]Q'9F7KJ?;J&JTG>
M+Y <^<^E]@(G-%=M^=&C-L"3J0\:9$.C =<%PYGG3MP;1N+& QW'!<U.?2J;
MMWH<6ANOL%<PF;2G!!42$8A2(.NZNBROOW(29J_(NG64?OKN4PF*\MA4VWK!
M4R:08>>0&)E*.G =G!YUB*/PR'%2#"5\$_:5^HHF,O/=!6&CW)!Z5=+"\GIO
MF*1 ;=1C@ )-)/DPQK&=^>>QNP%J9[X"9[3CA[:\#4IT@5;ZH;7(,P@].V!O
M?$73<%)5BY!8BWN7PP]UWDF 8[P>E]])4 _"5^QE]HE*]F^JNR;'O)T!&F/8
M2L?=:G2D?QD/3PX>/Q;&XTXKW.OP=3 SZQ+DI_%$,=IU0,'&!8P%)X%LNV_S
MZG#K4>"A Y&378(JF6_.C@GSPJ(.X:Y6#QS)4@F%W>PSG>-?ESV2P:Y%@D-W
M?EQ  K7NW73=RMP&^>*$YO^ZYT1R40=%9.NQU7[[P@JW4B.KW5TLHQ:]&V%[
M6W!UA&?QX5[99LYR/N-#F C C> '95];EJ!,RK#S"<R-+=CU?J3^42.3Z1N!
M;^9'Q)*,EDVL1C*BJ]']7[ON;K3VS3O=6C<!U^O4:T:>\D3D)2)'_*0/]51)
M1-2TE](<-:(%U4;W,.IMHUF<+4+<]]$KAK]6/NC$(Y>]:M[AEN4>.<(#,B6]
M4U7YD.NKNTL$3 ($?/FG&0_!=:/)6E6MAQ:J-\]QSF1P\CJBU(?K=QRPP;N!
MU-"_O'P.7*LTA'^-H=V/IWV.<=ZL3,G"=;'2V#)MMDE0@1W+/5+7#/AP^.V'
MC1 ;IUW0!SYWV Q>&7!&.,[9,1#!X[$P\<:,D^'[R^_>VW=+DE>^ US.-N@P
MZ8X;S*8/<JZ8T.YFM;&3L&*0??/TJ)BR!9ZB\VRD&;UW37[<I]GTFT@'*B;T
M_;&G J"&"1%:*K9N-5D?M@U*=G%EB&S:E&/N< P2?^;1$MS/I%CITH&(J^GR
M.FHB)BM?CY13T%Z/:O6*QV>>],[]S$P&;7*'L'?<0AGD*'5.<6.,OBUP58:;
M1AS16[YI;+/F:P8[6Y*MT>OXI=" ;_A>JD'V]7!"'UY3@YI_OI]W"*UCSY%)
M#-%T YOT(_/7_G)GN";(_2(]2Y$@2;Y*TWO8W5 _W!Y>O^!-7#M]!_]\Q>Q#
M]><53*S?#ZQ67.G?YZ$+^V9^N*S6S$1UF=YQ5D-0808DZ2A(AB?1==K3%$?M
M1JO>$.M;A[2)3>[GG:N$7%VMJMN+;SLJG:Z-)0O8W2>#;%!]?*:!W&V0_,_S
M-)P3_(#'QIU)E9J^(HY(OT40$HG46MU]\3M-_+SY,0>JIH3B!/=_#//W[ 0;
M:2R(A5M6K<*H%DPQ.C6 &XAIL)1I&?J-E#.4&7FK.$CTDVAN].%PW=L&Z[ID
MI-3/7_]U:XM-6,J1(2.%3+9*0X1$K"_6L%^0R%!96P42UVO@1Q0Z43);/N9D
MHDXN,?725;XVFNJLT"I=II-Q4!MS[!7P9.>%&(B:0B7DS%%2F$A;F\%-PT%R
MCES=XJ7!W/R%/0S=J5BA7TGVGQ@E?W'+#]DT2R M</H\3L:O!C&"+WZ3I%TC
MCK3>>"DLG>_-T*'=^XRI'H]6>GSZYHY-@=Y:C2<=POA5(![,YI8;Y:MO&'!_
MQ54UAON] 1*6IK3@2&*R0_S<WK*$'K.)Y+(Q.P$0)K>"-PA18V/3C"Y.P59E
MT;D8+X-EA6+SDH64H$#] ;1[N):"H4] /B?WHK>*2L^GJZR'+R*8.DEX\%($
MIXY*1R7O<#8Z$YM,+TB8PV^X?K P,I@N_<41[AP^J":](%6:T3KPV%++M\=^
MV53HKU5BC4I9J<.U:-#'7=G1$.>M^%^V!ZW9.X /4\DB,L[L/T,!WFP*]TD5
M ]W!.PB(//>VX'T+V7T?'AZF>#?YI271(*LIBPXQS^ELIE+ 8RDPMOXLJ1Q=
M=*U_TW-*(HQ%.@ TK,,'?B7-C;P4_X+DUOL,KMHK92+L&9(7F5ZJ9PG#*T_M
M!.?@Z1@DTS9.T8B#C4$9>;&^G)\^D,)!6=6,A)2_\%^#+<N8-?=ESW\,T? ,
ME"I:A-@C#?*:]9^]^268^LV$F\S):</NAY*7Y<GY>AR-]H)]FV9#+:=>6@9&
M!&+P*UFE"S44A%:FA?-*8>,(UT2J.P<"(_5\UL5>@JAB[/ZQM\U^$5LROK@*
M5_(-#O.KL;UGX?2N*<LC5CDZRB=CV/S]_LD=ZB/%16D"&>76+ +('RS9XO:2
M$45K%1H.?@&G&,:ZND>6V ^]%O>CQ[6S9"[1!S0PJ<NZ 9^JZKA8X$?%#W"U
MT[+ 5MZ9RJV:*1MIWGGHP87\DRT<LR?E;E6XN<@2*]*[77-"QSHN4UK>7MS?
MV3K_*AJJRV034IUL<J'3WA@OS<"-<U165QB0S:X#TOCOMH@\_L3Z0/2ZA1'A
MG!%PX,ATDE(*Q'FZ[8V39P<W90E=Q>CS=NQ@?$E2O;:*MJEW?4/!-71P'L)2
M>?C*J&C0[B356:524")H^6^D*2CJ%M#=B>2(LA*B:4DM#JQ]K<?]2$3#\4G@
MYN0W2\\W\WVT^]FZ\EKA)\>W\I;6CGQRT.TZ[6VN5OH=HL0;A6@V;"7]3+E@
MXLHA0B [>M"'0N=E$?PAND-$BYEW#2,$I?I8^GE?KR<W6DUO)M,_&Q7N=4T]
M8_X#^6\1%P='98BUV$X7T 6I8#8>8U(] @&C;=OHJPG:>LMFS(%V^E^8#M'-
M8*RH_<H1CUJ+UP?R+/^8* QS5]-Y9_T4-8$PCI,U>Z5N%EWR\8%]C7^&2X(S
ML?S=7<CP_I6/?WI0\FFO6??F$4.:+X (=LE%P(4^[AL*]<HAXU_3>TLTK=:Z
MPL-.] V</J>Q4G:\*K3L55GT3M7\0W@#/&&*D@NB(2<X!PHY_,SBJLHIPMAX
M>[[6@$!^?8A_B5N$S26_@!F'MJ9<^MX1BYG)]'T3CY954(GX'7U-8B8LFS-I
M^]S1R=W,N:06Y>DTU&6B'&5=?X:8_>J"V0J]CYC1Q?5:3WX:;\+G>EQX&35D
M=91_7?PW.>KL"$1^@=NJ -2$&3PT<N# V_XZ/&T5Y726,*V_'*='=KTUIM</
MMUS7O5(N<:@-J_;^>:'7+BQPU)PB3X@M84WFE6(L@*2IR!L?)R4&X--7I"'*
M).=Z-=^;WVQC>U'?-XQ]9S-1^H5I4G72F,];>E5A3%K[!R$6KL,&U:ZH7FN(
M2]@T]>4:QE7G3J]/!\:[S9N<, ]1ZA/\2"+BEDV8J'@YPO+!Z?<X62#/E@,I
M86+WN **[4(I"<V\GEP]XOO,?COQAL[+'R0,IR7_Y'V:.(UPW2H+24/P]EM.
M*T [PO*5!JY@Q0D8#:;(:3N.VZ]ARG*LWZCP$:1\UX9"\1.KQQ\^C#X[\@2T
M.>G)]U?!#Z&057&O\[UGW"ZE']%[!"R-P5E8=L4X=1O$OJ+SD"3&4T67,]T;
M2UTQ5OV_4 <7FW.20\XZ6=7BW#(EU+_.F#8F'PH5U3OJ]?'^1OPT@0"P*/AM
MT+)IR82?#)Z:3)J6 3HJ.Z9^?6C"<R5C,/RS=.KA]*L>X8QSW^+##ZUT2\!+
MB':";05L*[@L,$[-OS#X2_L&%1]:APJ:(D.T^XHY <4$?\>_OPOD96<;WQ'C
M+QPWU0Z1H)NU71W:_^BR2W-W)/PFN&%T^1S3S=,%R"WSQ0JU0(LFT=@./*3H
M7D.[I=[[W "7R6&+=";S4K+4G0,Q[8\+TQ%+#X[RKYF!Z3BJHBJ X-3QQ!@R
MZ!2;_I46U6D%3^L<2TYV(3,O3?'OZLV3;N%AHW8:.8'?)9TKF>LJ:3DO)SY'
M"G++@$J6Z!BA$RS> B[ZL0T2U\?M'P=8;9I2T:,G9H>KM'5>-D6:]0[\R:WR
M%)=WB*PY8U]7]FRX6V<!&5@@'\6']N'&]NEMB(K#)FOZ5UG#>N/=0@L5.L3N
MUXZF>*%$9[4TKE&B5?7G3Y_O[]M)F?IBC!7',87-FOZ21L7IF[&OOF/J2'4S
MK4EB&(N1G^%&4+2B^@ 1M@SORES<=ZLAZU-JQ;4>=N$$2]&G#T[,?LO<L 54
M59V!YD@H\T!CY7RHRPE2U45DB':%=)C!P7%:A5Z$2OY%9,#L3#I9Z[9VG"MK
M$1Y+XML\O0%%>Z];L[^\()]:#!M8Q,=]^3;1V(A_,=&T?N+$"77O3.>]#FZ]
MY#C3:]$O#W1&0_6P4_B"P_4Z"8R&8(9PU:8)BO6PDAI9BH!+>X?K(*..V1Z^
MIYZ+0-P#Q4ZN# S9S-$O6QTU_F09UDE;9I2CZ=L@YN]E&VPQP&(ZQC*$>8?G
MY>8>+?]$NC/IG[NOAP[)69+WK;F>6U-Q3#?FU++[,R^"7[V\O:/RYH V)D,!
M(PT4,DDBOE&Z0%S@ZY*DJ$,,\F]\\9>)>7I\I98A7JO'>J]&NN2ZTG65*PU#
MIK>/_^[0#NO$FR>U"+'"C;PX$G;#(03<3A0_TKF[&H)("J8M08G^&10DUV0C
MXS#6)X[UE/!L+_6971RXT,&$XBY?S\F)U]=6!*Z,&-97-(3M.I8O*WQ?V8P^
M;Z)ZZ[GNXXO?Q7SYU\O)]'02BQ%_$'.S/X0F@8[ZP9JCN@E:P;;$%ZT1-,"T
M<O7 "Y18B."=^Y3#@Q*IV&*)YU/#)%%"*D\!7?O;KH8S1_Y! \RPOA'@/7[9
MS=GU(1$(Q9C@AM;(UTG*4+_4O-R]^""UC"7CVJ.N3HQMT($HL.\V:%\4>#Y*
MFOTK]4' P^GNO<'?#(</U8Z/M\>>'=2R/.O KY;Y(-,&:2<X\R5A.6SG<^RR
M/#=ITX:%$D!+P/HP")E4SQVF(?SZHG#WGE(3GM9U4R_BM>]W7]6&Q^^+HAV:
M1UNP;2I11S$7@8<(5@HV=8<299CQ>#TR$FSGV-B08(JP"]Z8+Q3N__,;WAJ1
M?>-=@!13V5%-<&GQ?PV8\:_E=&!%/=C8Q!!KRJB139E>08-4&BZKS+_6K>.0
MK?;#LD8A90:Q^GM9Z;Q &$, B\3*POT*0$:G-=*\1UO5;9BHPS!T7L>::^=H
M#M0CQ0EQ'C%T[9GQ'>)>>8];DE733^"%W<@W'Y:RNQ527#N[T1P!MT7RX]J,
M4;6W?*0Q(\ZUA6;O='K6S/"+5CQ*^*-;M[#?K*P#>OU04)-FV/<]/_7X_G2S
MJ=P"CL:F*EPT!">*<1G=#&02Y $)^$B4BM^-2>J]?/'FA"L13[.06>9<A DV
MQ2$Q;N)0K&R1EBP3FK0-.M@*COJ\#:H[W%@@9N1< =MT&W1RX>"2]*'2IM.#
M7-)2J49C?3K0WN]LKH53W=MO_^D67?Y$&\GB;HO.&[\<IR?C?@UGUOW-0R8R
MQE_I]\_E[I4-**EZ@ \MFOX&O3EPH"#,TR>DY'$9\DV<N[B,@%G[J<X]9UF[
MHJ%G,6X;YIL6@/6;3=71EG".2C?E3(.AZ8O6HM=H#4JU2:7[M^YRHIC_J8]L
MK0=#U\?#+=4LQ 23O=-@/8<6E[9!?B@QPB/>.70;!EOAB@E@5Q4Q*\\; P$H
M>]B?,]>ZN:#F@$&UPL)T^8RSLH^[TR@65ANMV'T+80;93N)^>$R.G.^XGR:L
M,.+:X,'G7H8'GBU<UTD(_CDJ?P,FKS^4#SU211::J\4&MQH@IP*?VPG.ZL23
M?$G)BN =,=%9P-'5OG%Q6']U5WNM1EKEIDV9:5!8I:D =S9]4K^AX5UCR V^
M+G-1HM)9@C';@&(+]IO48]/2JB"JZ+KKR!O<V)$HL/6K"1L9KD5_ZV!IAU13
MG%W4FNKN@#J)V4!B9A/_*NS?S*:].!51O##23S.@W[&HS)"V1$,\0/<G1)^M
M4YSE'$H=P-Z-[9]]^+L/6]RWW@9]Z)HCZ/%Q<)N2YUFS[]@&W,?LSFJ>SON\
M-CHR*]D5;=O1JIQ@PU&9I)56(,(5GI=VEQOW/X[_*M8] ^G[HBZH7Q(UX*X4
M*<K*2<%.W_)?PR#8^6^9:08=)!'Z'^GAEW7)-V[MP3MAVJ8MJBZS<H6;1(AQ
MA/>$38,2_^:LRIF1 J^@\-N6#?DWI;XW:E1UJFH6W+U.^"](I<]X7O?=?!*J
M!#<J^1W&"F7<9>X49(CZCO%1 L+8*9U/-D\"@TS;Q).V;'-'CGM]A:O_*7^=
MZ4A_9;[:IK38Y?I,3^V^C6-\QHV[E>A!@[Q!GCX0P\9=!YRF0CB_DR4N<C3B
M='YMT"3]\PT>=@0MRC'^ZKZ&([/WJ=BG'<%[U:5=@\EVJ'DA?HIWM!M>S4*%
MB%3EE(R;8B@KUS7OF#9Y#C7QSVH,S194HE%7.4>2Z8N&D5E;92=#XF<%LO4]
M^N)NF9E7@NXSZKS+F39!7 S;9BX5I1=I30ES.?(:_V$RDU(14)5Z_$ZFN(-E
M6IX6Q&'JIX)FP__CQE[-F57@F P%3/><;FADQT/'6!];%3A9^03F)Z31W;_/
M"V%7!_>Y];[\E&?_4-EO#_=2TB-D9VOA?^_*O,;6V)2@DB?%_W.KPT/6;L;!
M$R@];6=K2F%&4(-N^S(F4WA\E_E<^=L_3^LL$U^=#6*M\;Y Q?ZUB;%UH]2"
M%.D"L66,1X7V\]%FT]9*A:'LP-,7JL9\1,]UGM$]F',O,:'WXU>H23D-Z[\Z
MMD;C5FR]:'%FK]H-J0\LM3A[<8^MO(I3]WWRH.8/>.;N<IM@JH0Q^"RZCOL1
MZ&?+4/XM+%?'2^&H"M@.GD+_YK4W9U+N!*_6FD<&AJ#TKE/DK=:IHF,MWP\>
MPU_V=CT-&IZ![^>=LMSPQ3@ T&F&/,:IKU4;[=-)GTN<X^Q)*O83!["V SK$
MC:/X45/\P UNW<QJ_E3E."IC2I2H$@=^@#F\E8\YN %Q]I?F";%[LZ:__O*C
M4.;&5.BC!\KKPTYU'2]?*YOS3Y?DN[9Y<^NYT3X.S0S?0<F7ZJ\O#Z]BDH+T
MFYRC^L67TCU4ILG)N<9M,?NMYG8G@_X0N)< 7"6:GZL#+* *)UW]+=D,,D]G
MH$7XA _BK6(O-0)FG$XF=@F_GX9_B$O4.8^@\4  ["H0R''BFH\8R9;Y:S@"
MP]/:5EAY.+7TPE"KZHW7E(BMHL"66F+_I.'R4US.\A'(#P&P/QK+1;)%X]39
M&#SJ4;"\+ 0\[NJ"#BRL=S T<MHK'I( #NMQX*,Y+MX/KZ#%;8-J5CM$8_&S
M-6]W/)7<@9A(PF7N[R?.;3-UEU<&C"Q[5=)>I$CB_)\\3(V)%OT7)S! MO40
M,+A3,)8>E"3II]BH,A%4D<EW;[^43EZ!6PQZA?IYJ6725,\)Q<D#H%M.(\,S
MVR!^DN>_PX4Z>%*]C<_'5M%!C$$9PKK1[EU#N/7D%@-OTQ-VYN >5G9[S'-A
MI]+_^PNQ_Y\?P>VQ_P!02P,$%     @ :(![4/M27>?^6@  "F$  !0   !O
M8V=N+3(P,3DQ,C,Q7V<T+FIP9[R[!UQ349<O>A 5I/<.4:E*4VD*2&PT$1&0
M(BTJTH6(2).0HU3I(@(* @("(B4B)0I(I*N D2)($$("BC1) ,/!M!>_F7GW
M>S-S[YVY[_W>3E9^&\AAK[57^?]7L@_[*WL6$#EK86T!<'%Q ?<Y#X!- HS-
MHP)\ <#6%C@(   OP&TO G!Q9EQ_7^Q%@9U_Y\#?N=C_F/\=["G@-+"#B^OO
M\U\']R[NOV/WSIW<NWAV\_#\%=X]_'MX>?EX>7CX!/GX^ 4X@V>/D+"@@-#?
M^=]_\O?ROU=QG@*\/+P"_^W!?@>(\G))<*&XN?8#.T2YN$6YV#T C*/K+JY_
MC']3F6L']\Y=NSDJ\?%SWM LPE&?FWL'1]E=.SFF<<5R_@[L%-TEMN_PR=WB
M]E=X]H=*'+F;7<JK?*JA4])AF**B=_5FW!X^*6D963E5-76- P?U#0R-CAXS
M/GW&W,+2ROJLXT4G9Q?72V[>UWQ\_?P# L-NA4=$1D7?CD](3$J^EY+Z(.=A
M;E[^H\<%9>7/*BJKGE>_>-78U-R"??VFM:N[I[>O__V'CR.C8U_&)[Y.$DCD
MN?GO/Q9^+BY1US<V?].VH.T_?^WB KBY_FW\IW:)<NS:P?'!3IZ_=G'MB/S[
M!M&=N_8=WBUVTI[G2JCX_B-W>25.99<V=.Y1UG.@2%Z].<PGI:)/4J7^->T?
MEOW7#(O[/[+L_S;L?]A%  2XN3C.XQ8%X "349:J ?S_)-QS<$@C\A[K  2C
MM3 ?(YO6E,"K*-.)C@.N4,1<-\&I_;['LEE(=LVW<UL39GYK^YR;$RQ#[E47
MK>V[OWU55Y6*Z;.34W0GN_3]9 20Z;'N[^!-2EF4A?.4+=J7030LYV2^P_!F
M6J'?Z)?>]D8;VG)::9A*\!'KQJ $V^1?NEF(1HMX^IEEHN!OQ< UY^9"$IAV
MA5K\L.5(7UIHM&31]X)^L\VKGQ^M^:A>* ^Y:')GIQ$/!NP\9BI/AF5BE8X4
M>E)3 XQ8:DW4.C80[[#T%8J\,%%W-<DDUGK.7[#K8]+,C)W.L1&I/(GL,K]=
M]W@^&H-]6;((*.L"-&L:/*?Q.TB7$( 6%Q8V?!O*!GA7BF&LF:SNI*\!DW2C
MPHW"M:9HT%]<AVCT4>E2(V6 O)#^N\ZO&Z900<6FPYN;UPCB3A RDC3Y>R"'
MM$7YLX0EF$IE+_:R!G-Z:5$Z'2/9*80S]_63C Y/C-FQ@9VSE%LE,!S)$"D"
M33:!T%F>3#B)SZAEH1NDW.=%95=OHRT)*/QVT/?8\A46N-9>8K10,8R;?6(F
M.&QVW!T:.1[3YQ @9:;61FW.CYMO;3%3;*3N&KOY[$^9^GV=<_B%;];?F[M/
MO,*KU(C<3P9DX&)L8+81UNC7R0:FU*9H:*IT3];*6AJVH+ZPS/PI&^B"O[#M
MV+C@JO1)MZG_^GCWH/LCH3F=+\0-R6[O)3Z(F\7OQP94TVCV;"#G#AMX4$,B
M;DO@YL^P@>R2;C:PK@^N9C%-D1C<S_^/P[*47'=UKGM&>JR9WU:'[M':T)Q'
M5C3^4.9>N'5&ZV6/;Q19:'Z7HW+9CNXPC0^ ]$_,HW $09><N+HY@TQC [YX
MKF]N9ZDV98'&7_J:;Z776GP(D;(Q3SI_Z..^^\IB7+%OD$[,)RRMJ!HRNN@Y
MV&5+(@HOL@'O]:'*!A)1I+_.OW6DX3Y,[53V^0>6W[,.JR0<W'XN9GWC^XGC
M:JD:3W=P1!C/!B!=Z1136<K'[EG=3-,K5'XR-J&<DMQ3(HPX6>Y_B#A$*A'K
MA]V[Y9Y66JOZMJEA0+6YKFE"*MM:Y:9^]L!WK<':\A$S*3;0&0[ZX#/@(IM(
M/LB/K%-=O4Q@U>Q.\4%R M*WC>_M_(B6?<^Z];6&/IO6N&L^3I]<[PZ=9 .[
M;K"!Q&IF/@7!$H5#+FR 4HLC!4*Z+''\*MC,!I#@>^)3T _TV4:\9@-9&2R0
M /]>;(B:K& #<59LX/UI6B4;>,4D(YCB5Q">#Z_<3'WLI2R:5N'L%'!SLJ_6
M6WIPY>V$!=*6^!:3C7=PDAA)<T8C*':8YV6IV^)/-<I2@7\OFKG0)#7-@EG"
MDESV.D(%QC+3GG;IZ"0F)F G3&P.,N[WU"D_>4FZ^.0:K?Y%ZDCZTQ?F7VS[
MEA9-#%N?K:P0EOU"!A572ZD&6(:"(/W83%"^VS4C4.S[6&VY=8BV.(GV:O1=
M5E'Z3^TMC>L*8H=NA"+\?A:TF^T=KEU;9> ;B:?R1:/O><?6ER9=7*_B*9UW
MZ<<UEC JMVAY;*!!N@OVB=4QB'E.'E2[E%AS-@]Q/O1'U?G@3X%@3Y7LI)L(
M5IO0@5W)1)E6J7PC3->UF41>,9=P^5#$92YQX;\B/#]<4ME $$BHL:3Z]6A+
MW@+3!*D[Z%TL,/&6NVY2W$)7BY=RLN-K_]I\9[K1Y%!&[\.( ?TMHVVG8HOT
MSD.NHYO)[N-K*/ALX9 -76W-=>SZ=:\%NIZM?SM]TN'(S!DUO\SCO[H#'RM*
MJX3XR"K/VA$0G3.ZXRPYJ Q/PB5PEAZ"DR5G\Z:Z\SG!(*:<;"67\B%Y5;XY
MSGDT0J!&;KM,A.4JW(([N?G(%SM2Y_UZ:J%?K+;0\YG\'=EN(VU\V(>GPH.7
MS.0A)44D.3\AY+=N7#&L%1HFQSHZA%&K2'7CA?6JGTH?NWU1>9TG'QNP5V"
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M,AP<&M)N5H<D*<;^S9;)EEE>8R/+MB)QV+#F=C79@86#5YV*(NXFT4^JRUN
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M9MV_:L;4.MR=*'[(1?/\OF(<_F1"6JP?B0Q)LO;)CGL6N-OFL"G HU*<NSW
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M^=3-4],6.ZDA*E)==S<0*S5TO2@MALUK*&86+HWR8B:Q 7]! [?UN7=Y<FR
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MLV>="&DB&.++),O51?K!H&'&6<J@6^]:7-/ JO>)L=+<NK6FPH2[3QY5>$7
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M\,L@9-$N3L(TLH& 0 2E;3,&WQB])>IN3J^)N:0:/&HKQW@>VJ8.B/VG^B#
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M!>G#P, 14KC!DOXF\&F 2DUDISBMQL7,)&-Z??#2#I=_95[N5LB"^D&IB!O
MN=T+ ?"30??V)Z(F7 DO_2#=^BW3JZ^-BR=Y$ V^#0WUB2<O:9XP</F>7YM
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MZS8:L-DR-O_ .V?Z.8,IM] ^@2ZYP.S[G9#;#_Y8L9L5_X7V6=7E"777N[Y
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ML%R\:O#*7K=O<)<X"%QW:'FS<XFWJ:VFO6^_...6VEN#Y,+_IM=CBDL8 9=
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M49V]E>R^K[[PZCQMIUTR4^G,:A.J&HS-/P$0K%  1LG3P7AL 4^1189<[#E
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M*C/1X[L>JD/B!""]L71U# [D:<^].PX:DGVXX$5J=X(Z]0?4F):GIKG*2F9
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MG)D6\@S8(\^HG@+;?;*HZ15KG]@O]BNF_C<Q^J>)'"! ^0^2])-6R"@8,R<
MDB7Y%?'F78C&]/<YGJG*7\B1KK2>VS:1+I;QX*4J*Y(W+9N!:MKDR15U:4\0
M&V$I8Z7Z+-X9"D'7,UM/!*.#6DKDE!23[@<490>R'+@P1#8;'YR7G$EA"+]V
MI99G6*L8D/2$@0T>)>"\\24/-&RZDN[DN2>3X_I.S)[IL9C8^E)K0J@0[@=<
M6IWW]_V0=X1IJH0HY8JW7G7[B#1B/%\WW?DN7K27QV^[]_,"SQ@M07?P-C;?
M)"]T33"%LQWH3;,0QF,(=]2CLI?K4K=Y",COQ\7Y<W>J<1BN!_.;=CXWM1MF
MK31P#J7GOF0NRPEHNDRZJ$;H6M;]X6Z+*HA+$O6--&]:0GO@*L4/;"?\*K>U
M:""V;TU->1U&_@*G?FQ;&0$$+!&, &NW9M1/+%(<UKM"2G4E0+J7KI"AV$AU
MJR91T:RPJ6E-Z#Z'\6 T5]?:V8[HYW<"9J\:V"\O$P)2NX;NXHZH@CO;(;,7
M8O^)HA&3"6D01\.\RO;+8_T;"28!IGN0ET]]CU["S:# )- \\M=,1H&%@#'?
MB.SGSO/K&2G!2>(TKA<!$7(K%]_5MGPKZ)L+>OD8A1DZ^_6;LS841!O^T1D=
M_'Z9I>R7\$9W5;BBN;> MQ+(<\"L\--RZR]?$M@(_!A)5E'OJIYS(ME-PA56
M4(DYU9W+ IZB]BXR2.F;N"WH#N0!8;'>V+@._9Q)8%/ENT_8;3TW8R#+W]0N
M=;(NW\KBWK:]5^'O+V3$=/?/>>W&CRLEUMHZ7(&-N@*C]GT)OPKF:CV"8A>N
ML23!N?"_X6!LGOG6S;H6XNU+GD<CRB.LW]S&48!,8V;62\&Q;,*CWL?A+_X@
MF4KBUB:T"Z 1/NB,A?GO?@:%:9T<19%?K8<6IL?_([1(Z34L>@>9C=;[*U?[
MI4\ZW1<9MWOJY"RU@Y]D2.8$&JJN).%#B7%8Z=,:NVC?H,5F767]ADG'8RU$
M*:R:SE5 U"2]&J<SR )'_2A=(C*QVT6\EGAO?U%BQP*2LF>3,F=:\2+)1%+_
MCIL';7T/<$=C\M CV<"(&$R:IK6 +L%U"9 >GKO8U"@Z>W>10WV.=)I79!GT
M.(_V[:N Z='Y3-4"R\_\ +79]7%")ZXD%:[_D3ZQS+M34DL,J_3'+8MX'AW9
M>#Z%NCC?J5DPTBB\^.%ORD#+.3&_Z"F,%1);EP^BH1JLQ#=S"O,5R=-8< +H
M*F$J\W0K6ZRO7,.7YL:O_CH6Z&GXS)+^LYB+/0:/G^P/K 9 \>2!6.LZ+Y4$
M@>33M$E5QS#[S<5O&;5^FVNPBI)+ UXJ(*B+\,5N-829BXYM>F KVF4S8R^T
ML60>3+AM-0?N9@ GY#OPC,D*)5G'EEC2B3J[26>=TK;4FW%RW J:,>?W%SAG
MFM27TOPFX.R5RS\CQ?7LUZVVS2BJB,GE+]7;M"*R1\<(%B7P6ST45)SC7OY+
MOHC96>?]&CYTQCW[F=3P#Z</X+#6$%@G:63<H;Y-D.S\.?%%IL/N?=#@]G*+
M& VZZCUVQV7+V:"AL7I/N\/U J?9O9?5&TC+IQM%1Z!O\@E_3Q_A]W8B"3T<
MVI;^N/47<.?BCF*SRI!GR6C%@HQZY5T%J2CTS^G/B#XDVB,6[*/;H&\(M)C6
M2G:Z61^[;M/8%L_R*N\=MR>6VFTJ=0/U-G#Z[$"B.>58ZDW-Q+J:F3PJY\L>
M61&U'5%(7P+7E*2TB7F_[IH6G\H_\!+\NM9K&R_:\,[*Q_04ZEZX% ]#%A!\
M[F"(0<MTCH_%,,T5MFCJ USD71R]X$K:QZ&J!]IUWGKV?&S97T^[O4IZ'65\
MJO<LR_2X1YI++B'*#-AI&Y'O,7AYSNGK=^W)%V5[?; %HYC$J"JTH[0'0[YH
MT1I"3@!DA>IM;:(@?O)/P,)#&,12X79#9F/E#K7B?$/\4>?MC6;)&.YG]FM
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M73=GNL;P8G(M%>)6CV$[KH>Z;-F1_8BKD8HH%F?B!N0V:9PXZJ.OMOM2ZX.
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M#Q"'IU/P=/GW&*H8C<-)EHJ(X_J!O$(;C]*_]'H!$;HK*2LR)7K9\TB%N&I
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M)+ZM>)HBT4?9/YLG8H[P6H-4O5 7SPO>Z]^T0GLQ!<%WJ!>A[2A&*A3_5VF
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MC<5![=?"8;F.WYXN13!F%@Y(EYOT2SZV*D=-NIN$T6?3 GP+Q#H.<0!\ANY
M.N(!B:?TL\#U?]F*+[8 ]YL<7<UH8OQ;QP4TJW/0M8Q[-0V:><HWOI>UZ'ZX
M? +Z[;JW01"O]*7X4VU)!1U_!>P!=V+J-$6^_8<VGW%CX 6-]LD=OJ$G&HD;
MU@6;W93;UE2G,;.G#>D21#+:![Y#4+FEXRFQ?<B6H5-DXZ4^66O)$-KFL2+]
MWEMJ.TM(T?&ZA0I<6V- UK3$*37-\?>2&IN,&U<SW*:B@+GY6?YTA:&!Z=;?
M$&'*7=H(FIBCM'7*?M3,9/3@U<>A9?T:IX<\((S=&-'SH'2UY01TP><$]%[@
MD;^I[>X\BNWL<N5T?R1_JRD#U"C1QJ2$U@-CI4+L:".WS .G=FF3/QJ#29."
MGX+(I1GDMX#1=X05$9F<[Q3T+LAZH#2'9PB7KFT:SBED[T?MK!<Z#:FF3KT[
MTO,8#,QZ-<6N%5Y\B5 @^11C(9>NK\-_3\K$I.:[1;&Y>[!P=>&R=X%VG(1D
M4V#!-?OFA!0UFSX# <UKLB_UYIY%\Z3?8?A5R% G4A*+[LH;L O@;O=OODBL
M+HFCE0=BK-IN3-9*%HEE_S&:GI<82^\%#DE#[:A*E=8$;L0=4LAF$"J"*EK0
M4P1[V'TVA:E/(*A'%/[ )C]+)^AX+L^X<)&I'_-J_(!R /$JN*:\N9UR\)=Z
MA+R-5@+ --:B11UZ+.R9T_I$A(CS$;[R3-UX4I'K46/HR\*U4IGLM= 4E+S;
M2LVC6XZW1(+,_LP3G^PDV(@?IZ%LY:.PG(U@/$6>)R"L->@BKE'@V6*#EJ^0
MJG/MQ7_-S^_'@M:?GH]=P<J?@!8F#-_21(_S(<H(_^-J#5_;B:/(3EGC$' [
M\L6,Z?0@U^REG@V!CS6UQM#5N;LXK*.&5@XN(.->XZC[UF)#V=CE8-=/8H))
M3ED/&SAG>,3 )4'[^+ZSW'LSS_Q-*XM63T#G$=QT4O/MN"Z#QBI*80\P)(3,
M-F?8E;IP6?W9,#4]]8[7[,.C7B,MA1LF_%%=>OC.D(OLKB0LC>4$1#B' :XP
M47D*NN<K, EN;C(T;JKI&+<ID;<RJ!4^H<>B;^:H@23I3+W2_/:6@]4;EH^M
MGMQ"T[G^E+Q>96U]=?TDU;I$)2T/0/XZ >7-EJMKJ9S)"ZX;9+%K.;,J8A#$
M]4S-;M)NRXO:Q7.C-U_G^_ 1/;]ED#/8BHC/%%=D?[8H$%)D2.:O%K/,4CYT
M6'P9S#E_OFY;!?%#O;@,LZ).F-^,(BF0K8@2D;#.9K;)QFLG(!;Q+\;K;#8#
MF[31)>O*D@[;.PKA"X>X7L]0-M3=N8MTEWX.B&BW&M>06#0,QT5&(J]8=@L/
MI&;*H8:OO>U"3+UZ8:%D%.IQJ<8#I/;?:I&)_*DY5*MA\VGGYE.D:V0TWE)0
M$%_4U!F1GE;9U%;T]&;/S5G6-_V"#N?"0N\0FMLC AQ5NQ^,M8VLA ;7)&$M
ME0]&M1,^$SCX >\(^X/7O;58R;[4Z_KI&H,JJ8EILF.!%BZ#LH?U_W[2ZPYP
M%=J=@)/&1W9QO!?P2RAU,OKK7;*=B*=0 N$%I!\.DG,/JHR_?'@I6W-'U^\4
MDUCBX@D(K"%*2 C=^ +(=XF<)G6_]=FRTX]>T97W<9;=D7_QR\C]4IIS"U2Z
M5DSD!@MF=B<26RU21%%%#F'/-PL#)NVUV5)C&FJYTTYI H.UP<LMB;BVQ*B\
MJ30'#\@ST*G85Y/OZ"XQ13*@VB<T1/&S'#83HL2(#/SG=/(?\[4/<U9-?=>U
M[;S%Q9Y')WY*=K+]WJ_'(-+%]"X@WE?*Y'FPV(B_,WQ8?1V=^LZV.;E1)>W[
MG^^7"OLV_).C8Y>WZ]54:U((&<G&%FJRLO5$B<UV"D= )3U\MNX6 QB"Q%N4
MZP[C&OFZ(PK_$Q.!9 W.6/2Z*BBF\##_ZNYD+.AY:G=?&,R6_GZVD&L(G>/"
M9CDJ-_!@83X<HEHW89^F2TJ(W/:]*7@7T_SG<T2]>SA%?9IYE4OL1Z"C=/0Q
MUW$61!GP;P=7+L?%D8M#W,'M:([IZ765H(]SKRI;X:>[W,Q/0%$9#H8A_4R>
M,&G@LBM,&-XL2AM.[T;GEU8KVH@0WYWM]])RJ)3Z6?1+#??3ZW;RS368BDPM
MWW&Q$.\MH>25AT/V_?L'%ON.OQ>\7ZOPCA=$]Q5?U^)1<13^FJ^\G#MN85!L
M#EG]&Q7O#''F.XSK>\WD%KPX#<T/3.M"X>YU+_C'[F>IFXUNYY6/7W:.ZV?R
MOJ,%7^:8$R*KD3&?D(((&2"1Y'HG1%\+VUQ7%>]0ZY!F[I01 $H,G7OG_1QV
M"2D$%.._Y3MRQ(CYUS5$Y;UI.L25O5G82Z[-'A]/7@@P+KC0%_E]I<J%D-N?
M?^]6]=,QM^/I6=427TMPA7VC8.CSH>+)CBZXM6K)M>"@_1E*;:L-9!AY=4T_
M)&?=%!>.-7Z)2E?XVS=N.&::I_P!5UGUI)WCD[]:O)+QZMB"5\@ 0I[(MS ?
MC[ K[2X,L"]5-&(_YR)__>VS$,_#/)$_ER>G;3A'#X2EVVMJCFJ^-M3D"!!<
M\VLOL!A2<A-(I1#)7QZ?X6Y6<E>>&G[U3SIP->SY!U;H,)<3E"\M^OWC>V!(
MX=&T82?TZD%7CGN^15]@H*(?V<^SZI"KOJU3X'1_]Q])<:P:'6 GH3%(U>-2
MK#,4]Y- +B&X7W01.376J%TC(C@J=\"_,EIROG+&"IM\KOS^JW>XL*KS+)K,
M1= % @R0?'H"JIS<W'(GZK? /8L0+X"%7.WRLC)&_6)-B..%7HI9HMARX_M(
MDP9ML%_S.AU:%.C!",VA/SC_UR>!RDF<>!;>J%N6!>L8U=9BJ=:/U5C@;)<)
MT'UZ^/SI(4:4P:!PK[E@>>9NM$EZKDA&#)WU&0''%$U:'YII'R: _,U+NT01
M_O9-%J'I_SW FV)+$)P0<;9\<37QJU?9MHSR">C[1DMII/[XRTG%GY8;YJF$
MB:.+]1'/U+BZUOF?@WTOTY3:4*V^V!>4!$ 21>6&$IC>^F0\:R YH+D"PMIU
M=?J/PK]9V\'(^;%]S">@TO'=2*I@'R7 DO8'7:8<@Y\U7L/B-0$=(:3 I*PC
M:C\R](;IX%+8WLNO,)EDJ@>VL+!?<C;XOFM[737_;:Z-[Y!=I25P#4=[B7]W
M\[G1I=^+J>L&M_U3@W6'AJ120+?BEST"-D(]G\.J#;<&'(D2G>FH4.K-'"M@
M@Z!=IC-5I:]RV5+:"Z,.>KCD==$[7L]H(!".IO*X/A^3F6RK.0&Q'OQ,B(TI
MA&3)1PP/3>5(3YB(J]B56WG&IDZ'6=TLB#+RRI%@41PG;(ZX#!0T#&^'G"']
MX3&]V=FF9,>;$9L[P*]:->+J^/UQ-],)B-FOH;;9D/RX?-5MNG(S:7NHX.%F
M-?8-[3;QL/V3KWJ6\L;F[B,;RZ=] Z_K"#JQ/K]^#1G%>]I,4:XBIXC(X2/H
M^Q^^ S<;!1?!9WN'77$/^D] LM]C$]3,RRGE56'H!AUC9HE>1##=HP9C&*59
MOPT\NCU+JQO)1GPY6[I!\[[+? =IQWZ1R*CKT".:E1-8*H1F^K0\6.7QIR%J
M+";F,+UZJW3'6C&X-/)GI]7=#ZN>;6/]M]:YXOB+.E7%I^,FY7H*-W8>S#IA
MRI<]9)<.]86NKCM_6KB:J\"]R:2&*3\!O=IAWLCF "R776.N-::9L6DV_8A<
MK8U].X9BL4N.GSK$H)4P@-1<?FG^?P>Z1:@2XU2=A02V3B'<=J47<I!,>2-3
M>)$SI6<I.?/5F\;)!L2=XRJ$Z,+\E"[5(G3-73&X[Z9<UCGABME9Y7N6G%/M
MH>#?HB+CWRPC^SVJ5N_57/4550^N\-<K\#EP&\J?U*9D3I'A'QQ2BFS+/@D\
ME3+Z:?+NZ2O"Z&,5HVB/#4??_F13IUWAEY'='(#T2L;KFY#/Q(3V"#SEA[]7
M;"PEXK,FS=#EB.B#23X!O1@Z-TUE .P*$7I ?JESD$0LY(8+PY.4 _6/-=<%
M[7/"_1/WA)=[Z2Y^Q90?8L\DG5A=&<OY.\$%. %QUQ$2F)>>*?1693T?74Z0
M0M1Z)<7'%;C:4$0>PXAJ?8'JTWT%"XKGTW=W1&AC%M!VCFCO ,<.WDI+7'6C
MMTX(WX[=E=8SNEEWSHAHNPY3;Q*"H7Q.I/D_E=6- U>OOY+JR*U0 >]<QR2@
MW%:ZN[M.0&7PNN-7F$2B3L?KZ5@-[1.0J4)L\W,-]?;'!3([6VJ+DOG7I*_U
M[E3&3'MOJ<*D<A.Z->2N*];;X!3'$TJILB5K0;08X<$83SOO A5)<CBB.23M
M34B"$J3VQS3@K=4\AA&[,+5&'ID=7 5$X\Z54T^G_V,@>P-\) &XL;"E3D,]
M,2OF@\7*JI0<'XZ!5A9<QC!7YPZH.I*73D 1>L=OY!$\!3#!H2CPI:_NY]<\
M+.6FP]PHIKO+=L:Z9P5[K5!"B\)LJ/N>C%J1+;;CYY5\GZF4U-K4C-#07AIS
MXBWXW8)K#RO2];^MD4/D_])T#Q, %0R-U7MQ")"2WR0M8G@#?K;11(CD-#R:
M2YA/.^.A7O+6QC)+WBT689H]5\>M J%LZ7'H0A&TRFQS@R(5X-_:+ .L<81O
M':A5*U41:W(*Z:AG3#[WYM>F[!*G^MVJ3:_I9$'O;%5W*B<3^5(&C6693F['
M 6_BX=,:2]C%'A?<_/LQH90QMZ$,F=?!GSYVLZ/6WI=RT-B5CM]N8]WG 7&^
M6,4LQE^P@+Z6$?D8'^84?SU/V0HH^K2_[+7*_N_JS:U/U@I$'D<NEG?HF9*'
MS(*S__X0]F<\_^/6):$(D2H1U\4$X IL:\V9$DQK$>%KJFLTI[HN/+]*G(SZ
MXJQBL*IUZ;G;<]]IC8<E/[\=?$"QE*(7):@7=^X3T^(QC2H+4)8-]$5?8381
MN(VU$&&DE7N'1I1VEPY+ CW1ON7:0E98\=2WV]==_/O]9K%$KBH*^*\5LM0B
MC96-HCGM(L(=S0-D+=BGPB_>9#DN=EN\-<6KP2C&%)O-$*K*KDMSIII_TR).
MFM2-*)5P/!E%/,@=)!JX%DXKJG ."IX74KDG6*@I?>0UCETHQ8'?PU^?@/ P
M*I04&8\Y^P$[?C54E'6-);;AY]F0_D9JR]E]B5H).AG[TT<.H5>T-]3G))4M
M61*KIGQ7NA(YP3E_ZB]N1M_5=0'_.J,TKC4N;?#STN4H,0G.#XQW+QUWAVJ\
MZJ^0J5![+)?I8E+07_30(TY'[['1QWH[\91_21^%1XWGUGL02/<DO">0  _/
MRML:&%;WQ28%31.AUU$+2;!R:.=0S/QY#5^2-_XXUQKUHBO]#)M+BS6L1TYD
M8[-^?;A+=)!9->-<<J?=+-5M0M8=4\V\A12%3:VE&3@'EYH['Z;QFE86;[X*
M#O\U4[*;Z<@47WTT16?9T\5XPQ9A]0X!5!LXM"$BC=@X&QBT^EY#O4 .;2?4
M'\I1)2.5H7^6]91M;*L9KIGG-Q0.CIL'H5ZPJ2S,M\$XJ%8COO+O#G&QSG3Z
MS3*%,\ W(:5CBL2J4P^VO]JQ(UH&(6:S\YEFJQ!QQT]SRH-S[O&9"Q]?,M\U
MF)+\.WMPF+VU/;T!1STC[G5TMZH]JIBI98DL4NOI]774>^QE.L*V%N!< #=V
M6:U"R %KBQP1\OE4!5)D6+-,0!^!*1%>8F!']PI[<_%Q7(%U4FHEK$>0MJZ]
MNZ1J_ROVNECFVS%G6'5"A-(03A/)-_4'^+YA!;>G*BHQ[YMGZ-QNT%E1SB W
MOJ8\>?S0+L%J$HUJU?)1-PBV22;0#1'9#256(A[PA6,:KY.Z=4EB27\]E!K:
MY'"$*V*NKF(O'6.GWR\IO$JL%3/[A#@-)!.&WH)KY3XOBHU Y "S]F9)8!A%
MZ";Y+N_W+1P;MDU>R5X?^P.R<^VV+0C:1H3SG[H+-FRG75FI]SN=RH;[&I$Y
M^C.YN@JN%"*R8WT;W8>\$J#3/J.#MJWLYHM(\;_>X&,<IZKF4F\[NJQ7<A4M
MW?R7K@_)9O1@;*6J / %RL;.!4!_T2%Y@;)S ?4*&R.'X)>GB@J$M#V"6_8W
MZ=@_<?C' EIXPZ$)U6YIH7'/7/#BJ,.L6K:G^T=3N8F1K<BK)+Y(B$I !EYF
MGM/] ,P)G#,:WX93U0CGE,?RZL(WMXR>R PO2T@.;DB?]F!T/30AIQUC$+*4
M6X@;Y23>O%JST8WHL <C+PSE]HS]G_3F<,R ;FV+(>H9SGR0QN_U6[]NYY:!
MNP8_3+!TJK&&8C0-QP-43H7W> '+SQV.XWB<]M2;+.'S)4=(@><'%M+=V%=@
MW GH\7%Q%=L+E-T<8-?1+-! D<-\G8.LE; ,3@Y>3%%]V1O*KZM9N:GY(.!6
M3$Q5+60DQ>EI@H;P<!C)L-L4>ZZ9#\CHY"M-G +<]7Z..SA2<BZ'+]-Y<+-K
M'VIAWAV0Q'1P ->QFV9%B#NDU7"J&AY=!L2'<#\24/ULUQ0AF>.?\JYTB5/L
M1Z80(K+9E5XG #43\JA[&*Q\J[85<TXQ[03$25.WTOF*<R9C-7O75IYQWS :
MVD';-R00]L2Z9Y6.Z"K\3-9Q##>-Y9#^] ^P(]8\>.>"8_]8Z6K()RV7[]$5
M_)7#XUKB1_#VU\F2M-'EF(QU!(K3MGY=ZOK?V@-Z98)$?XV6_@UY_;^M6*D"
MI'\GH$AC.K,>;JAJR(S+IZH<?__1^*=4B# #LZ[(+!]DD,OE9LB.\>$ 3=+9
M>#1"G2\:H5*XIF)L;=E>9*GG+#W]\&6ZDJ_40]7EYPRMPFR!W51>1QKSP?_?
M %#0YL[LK")R);D5(D74KA;)S0<BSL&J#.!NRP_&3OE?_S=N]'%;\%6TPNCE
M([<$_+FAR",1=,ZZ0!RM,C /]\!9+C>D=NMVS-6S"CU59^7%56X^8=1;,/L<
M'YZ>#JF,]!3ZG<(2A!G;E3^%;$>> ^ 415?P>47LECI<OH-W5ZMHW>B1Z)C[
M9^QR[B]&=L:+<LI;O[HEH*H(]L:1$]!+^1B:)@!>W#*W!?P)LIH'6PQF/Y]I
MQ:%5)2[=NO )A.K3C8  F";I(1H$V8<\>_QML^J/ANN7[N(X<1/9O%"S4*?*
MN)XF9GC<VY2_'AP6W1S1*6I[L)*=J9+/:W:[#;Y%7MK2#C_(GBX#4/&$(3IW
M0HY"N$G6^9LCUH:Y)2F5<V^+OKPM?<%1I6&5* K>EK.,:%%5F@_ W".=Q6X6
M^9+L[HY./AF!1UO+EK0UJO"96I+[/&)BPQD2LXM3_ZH=51(<-W6(E01*@#\E
MN/4HI /)$PZO^H-WJ(U7Y4MYF\(\?TECZ_6N8=%0 2395?P#+MABNCKL+MG.
M=9E#K+/6/:WVVVRCW:5NGB,#=SZ%ST9/OQ#0YEX;0 V6@9@)'JZ,N$[(?U\R
M)+GAI!9<BXQZV/=UQ7&E%$.Y&Z"B73FZ @^:V*!H&1@\R<_SLE+*@W?UA%[?
M73)I-5UKW580*<+W8%UVHH[,VE L+KPJJ4=-5;>S?Y98J.!D]V.@J8_\V.1G
MSGK=Z.<K]22?@-KE_X3A86UL*AVF0>"P?0!.?<8][>+L,>2YVC+[XFS/=7!(
M<?R=_4N3  M%'A DVP_OR#3RY>CDE>9>3EUW2%G-7DAH$-"Y5E/ZF._+QF1Z
M^RV2OE+7B^5W:5+&IG!I%6 *D3C\X5C$ZWSMK8@7F<N]_S[:2W?)PEW%Y@>.
M5SM1Y^V(<RD49<2+XVRDC,&WO_XP]OZCTHPBYA2199;YBW]O]USV>W0J]56&
MNPN]/+TTC)[C#9WL!/,W2V\,$.2Y$/*C/S8UU/)MZF0*+_Q@XT(W4M[<N:-^
M:]#+0V<&7*6RR4^<)Z-)@\D$>9XU_V07"PL9&7*:]@SL?H'TQ1:.SW<ESKPL
MTQV42N@P!"1TVF!1\SQ50WSK-D+7@[\]N BSJT[K*?OY_,WS=V5O(W Y9J W
M+2#O:. 2X8I#]>01U?!/?NJD\6-E1(.\T@@M[3>@0D^]S;3%H:EB?'8RQ>3Y
MK"'O3Y'2HZ:Y-R_;2E.\EOC\-B)F>Q/;;M<:P>[0)L'"5?3Z7=L!9J=Q456M
M52Q@%PQ="=8.NX19MYQA^*+@.R_ITRJ%#G,%Z 9TE^M6ELG]RHG]F#C([L3<
M>MLN8TTV3K?]@<RCGP]YUJHPE_9+^194-G/^Z]+G8*U/NX#ET,KK*[ZA8E*%
MT1B15'O>7B^FK2ZYB)5(WRO[@Y!E=4NY[2P^7;,!LT2_S/9D#\FP*UHDU14]
MS+.[5+3&?XVMWNHIO)F2!6U/B( ( W?QNC[0<TY'R+#<EATI"_/[5\.M!ZU#
MX\,3Q)M%3D!A'Y'* 6%X-)5;W8(X%+X/]W\VCA1W49X32;6&].J_WRPY%^5P
MJR*4NQ_WH=2SKO?.7]?M$Q 7@#8@FH;Y%[L*Q,4GY_^1^.P=&.R12B;W?%#1
MB+]7V,,@=J"T#F6EBE\>M3G"FQK6?.$L:K^>4 B)U.#<BEYO'3X<B1X.^454
MF/')XA\K45Z%E,S6',*;8!F.:?]MPX>^0@$O48!$6EM"^)Z6T.V"2!])M.DS
M85^6GKJ?J\T2J7<XOO#L)5"%>.C8[EM/+\;Q5+Z11E_B^H,1B 9"!NI&'-\T
M#N1R*<L-_-;Q"[*Q(_)*[C'7H]C"Q$_(* D+3\'PX,C5C-=(,?IH\BBW^<@3
M$/$96!@P;$<)[U/BSI$_ 7=7S:V<!!)=+:%<&CIL'C5#X91'KW_FA;&V?OS
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M;MQ8 ^3&LO9H7]375<%N[:!Z!\TGA2D/ FAFFX'E1$?J;1CY_6]?3>6-)PV
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MZH)(I.82']LG:FBNBMNRL,_VE#2RNA"JPDO.@&9<% K<RK9>I9E*$P?TB<#
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M>7E+,EJ\'!0X8;V6&$T1:B+R/8C_7D=$]\A$"G'S13]*]=C3\#'AJ-6@BMD
MG'D'/-1K2)P*#30D_GF/]V CC^A?W/9>T!/0(V@H_F*,RI<X :UT:]-D/J,2
MY=37=WI^.&Q\^B[GFY1?YTF5(O6J%T<8Y\$BB)N *=D%L"R%S?4*-(=R1.Z9
M\[>TIEQ*?L2E7REER?ONYX(>Z&_Y#@/09$HZ ;U^WA)F4&\_*&-7'47M?U9T
MEV@808"?.]O_5>VBB-?N)2HS#9_IRP'HD2NB4TL-\,9!6> 6U=,4_?02#_F2
M#W(MI>\J<.\QC?TK\,JZJ\79UL6(82SQV5([-!)Y"LZ)"S?JP/(53L!5/]AX
M!!LS1CO#,FWD"+']W&J2P=+M%UV<(VZ!BQ]8K^51[J*)XM1(A80EP)@&9WT\
ML?_UYQMX*R_0\T--$J[.U+X-(1!J:>X>A>8B25S8-M0A3^O_[)MUR)$2LCVP
ME9TZ"15NAA#W;X]0)=9#IV,+TP6E:\.Y-+SND+IVT]QLW[VTNM[;'[+W@:/F
MOX>FH[P+E$'FCNHT43B_R'@<H<6I35 0KOL\&SY)"?4NK\CQJ798N(?+\A2_
M05?+^>-G%*^I8]IN,YCHCVG+RO)31G # [)RWY(U55E$#Z_6=X,0D?\UL/>?
M@?^O8^_G_SO-V$H_I&]Z%N[N=","]RX)LNOT G*G;%A+$S&).'7\'MTLXTU
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M\70G W65+R51Q>8FR@3> 5X7RRMFQ?0FF>9&^590?\B_._FMD$H42DN4(M$
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M& RMP5:ZKST_DAQP!"S$E;PO,K$^[6NJ&-,S).\D,D)J?;<LJ</=<FJGUD]
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M*28C)R"W O^ZWR&DO'O8^@RP0O+-[%.%9AH(X@W"!"<T417"H^E,0(+U2I>
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MW_9DO G!KV=2L]XM4U4H;1O_M CD,V*4;]_:O @;J?+YTB0Y9]=C \N=T.W
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M[D'V[T$>?_Q7=*3UP@J)#QL^@!,%8;3O38 3W70KU@N(F'Y>M" ^?M_Q7IK
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MV+7S5T+!K<UFX& QW1PP*S;HAA[Q'IR:]-&W=KX^LBQT6A<PJX:=#F?_(KZ
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M7(UM)*8T"^G*'TN]Z6=:VP.KGQQW49_(J]/FA8I&?1,H^GWK_IL!$,W1R.%
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M<V?1]Z=71B4NHW<WU!4?_BDYG;7PS_5]Q J3P=,%X-=1!T",ONBJ2FC-"#]
MCEF=!63'A[AW\Q'L7GO2@&K\Q= #)TN_G%$RMH2RA+DZTECWB( E9O2RM]\>
MQ#L[-9G@):X3H__0A^PN+C65>@:6_8W9L.P X%OE6<%4@G3/S!Z$%V2VU>]!
MA'3A2=.*(($V4SQ_>M)'V[-LO-LGH,CE[=5J":%"FN[]DRW8!M7T>;SV+N?L
MUZ154OE$WQ[$GS@+:RYGJG*BU)%ERKP,SK573:-P_/VUA"-8;P 9N='CQ5C)
MW^P-O3IX@MV/GJW?K2?>\7R'BN:[].)0N>L$TYC3]"Z.FSTH?Y*1DDPC'$%5
M?9E9E%E<A;KZDN1(@T&[[DM'DY=.3O8*=ZQ?>-^K?+>ZA'?958/!\:F#,_@8
MCN[DH>./8$T9*Q^+,5[T/4@"Z=C"3<=YX7%-<"1HW5=SQD3IT+B!6T?Z1>?#
MS?^!-ASU[#I"DF4I[KY@&91CVJ\-E^U!O-X;V8G7GKCOF6*%TW3[NO!3\\,)
M+#')>>[W]RLSHI\>:9.^[D'B'0V*"+^70?M-RA,RPX[R^']1QB$.4*/]'#%^
M10\=U_N>&%VAU:S]WF&>??1)J]2*EI]_8;1;!D3LR><R$Z''0UX+^P;(,GN0
M.X@8\I'@O@F[33/&<"F8WR'/O9L=1!"=?^[B2Q#40QR:],YX^+,\YQDY@_'2
M7UOYJ#NOMX-^FX?:[Y;=9W+JOUX\1XX4AE-6^(Z]+7A3V8<$-;,,.BK'338O
M@4[:'58H&OOYC#;,V7>G8"1S).-!W^$7J,W/6^<[[I<?:Q!?E/52[YPX]9&?
MN*%>Q;+C(.M%8*R&/=D?E'-GOH8_VR3"2ZY[S%-..15C:(_'W!D([7^S!E?%
M"C(QK)N$38?8&6*JL2%FU)Q!Z8;*+N2*@4C:*A0,-(&-;58O"&N^Z^SD9&/F
M?H.QI5G>$RM*R?>F;>T4!%(YU^#C!U8W,QF9;>1]X"-Z1G'A(ER(9(AJO)Y,
M-YRP4KLU3*8=_K'T=+0MA!CG,'DJIP.EZRT:8Y(.A5>$<J*U6;L$HP,[[ RB
MVK?D8?5CO^8?SC,^_>=TV.:^2HA@4=KCUOGK_3@QT*N=6+\E+B_SX[[_B:Q0
M8@8%D:#VN$CAFW7)D\)+^QX:;QX,O*Z/Z$&T47ZM+D!OSU7.X+\N3,?^TNQC
MB2)G3-A?;>%C<.G:GOF_>$X\)9HVC=2YR+3CU !DE&Y3E*]Q)S[8-Z@JA*B^
MA/T\G*NP?X9[],<>A(\#0?EXH;J^GTYM6;\?4]%)KD8#6!OJ>1-7#CKDESO^
M&;?Q%E:<#L/[U28/76%L"Q%?<:N>O3$3S!.X;\NLA@%O#>=X4+\-.9-6M@3I
MQ_U?IR\6.?M86_IPI=M77_YZP^E$MX*7\L[(^KQ^C8^5VV;]LAL0\7JB]D);
M_XQ_6T/79$"2NZSM0ZO6KIT]2 N1)305B-SA@#,#VL7Q];A)O#Q)EOV%4BU?
M5(*]!624[D$$Q0HF,5&=.#6#7-D?'@/O8J_%//+3_[JP,W5?\Z:95]HWVFSV
MY^#DS)#^P'^6X@8\$2;!\F3JS\.%X=Z6L"?G$!WX:&.%4;U/CZXD6EJZV*X-
M6J\M5="S5G@2Q#.F+I=!#K5_N\P5?G+7"[!K7^5Q9AGZP9Q_L'390H-O#H\8
M;%K+Z8\<BZ%>\S>JN\5UMH7O(*83.SN#C$)RL_]A@RE.'I.^Z)KJ"N@1VV5F
M!XST=>L^_="+X*.O36:W'X]^H^(AQ'U1]>JSUBM2)9F?-,R;MC6N4D((P6/\
M5[8+2.&<+B*UBKX@JY#+Q<#BYAC(9)Z;-U8 HRI!L]$.Y,%@J-SB>$ALX9CC
M%WIVHF;0N.-WXW[N9+3<Y'Z#N_*4C$LB_B:'>39E.;!<B?M!D<(&%U(6IC4'
MW!H!NVB6>S&8:#ZB%=33@S[H//]%^^>[^D%=,/M67<+T[12I&9+6>JRFY(E3
MR.HTC*5%K!-Q6&F@%ORK@4)^: ^I?Z^60#G:_ +K;[^V[^=AG7V=[A0'C!)-
MJTF_*1!-PPLNY*I_(@[.#LD?.[&BEU@LXW&D]J6@;E*W[U&5^#_'_S+_-\&H
M-Z(3W\(2WH-HL'8(R>2:;I88<J9C#\)C?-JGL;(S^0S8-DB+)B8%(81]3_L8
MJS"^$QZ@E8A9:X;+Z@<>G7GG$""7\[?42,"@Z3_S'C)M!BF*O<L49R$'FBWI
MEKTV'%@"MB)GGD1X&IVGESH9NEC>)%JXI]ZJ2ETR&!M?*9@PT=V7>?:.)*X>
M"P'4VBBRQ)1E-LPGZP3\Y[1BXP\CZXPLH<&.QM='L1O/@ZYHG52&-;O\F4B1
M7'<Q>\YP:FV$/OW^V)T&$QC[@_>6P(]]\+$V]YD[**"R]N(26J"DM>IUY*/;
M@<JK_I2</8@F;WICP%]6&<X%PV3SF0+NU\&B&4$<A9X4\N_SF@$P#HO9,6_I
MO^MF9_]#>D72M-4$-I'EXU>0#J"%;_"5^(U?T+.TVVU@G_WCN)5DK& "/+)I
M&,#"F [XMOQZ1EF6[>MQEY'8\T-'FD]?.<J\F*&7?:KQZSO]A[+UYHL<M*)M
ML]"P>.4?M3& \DD9[[^VU4D4<]Y%R6Q_1A$\2-9&&72B%2MDB3-6GOZ8].6R
M?2'XU,GC$[?0PW;T:0^NW[!LA<#.8WHR2">G/8@?1Y.OO2M?WD6S42O&MSC1
M58@;R#T&P@%+JMJ3)=9#RJ%F7L"PPV 'G]",31O?;E2?&#/:K$_K#4IW<OH2
M>NRGR@L9F4,WGB-56/J[#<9G<0/X(^1[E'TF0*CMCPVT+-8<V'I*Z&K4RKPK
M-YH:I"D_YED]]-;A3?J!M,]!ZW<1F@DUT0J/D>4<)O5_/E,)G?1Q_)U9A')T
M^<E_/N=OM;/3]WV?!5+XB KRII=)D!\#?HJF_;II:K']^0,_'<UDK&RMDA3.
M[/XXMO_9R\^2\U?/&9(7T2#:#(H*PQ.V*QOZ!Y>RNKY*.OKX2XO>TOEZ,>S!
MJ8\?()/AKR&GYVV/B=I WOYO^=;_^U'@ZV@F);IO^S8PLQD)UC&XV'S)3'=,
M$^U;+B^I%L0SFMI=U89J5\6L0OJ=+_H)+E5?]/WPN50@_2W)R^]K4O%_=SHJ
MX)T(4+VPF)'=#9?#Z6!@M#U([$2',/8\>+?"L;"R&$F>4!Q9^8:\EWO*($TH
M6LVOVD3XE#_R&^08LV8FDR5,H<*7U0"X/9"93(*-+^8J V+EY2G%F/$72[!Q
MV_JQM?+"E.,99Q7F?L?_5_#296'"3IH@#*?FP [@M%S!ZID.^7V#:$+72)9I
M2JTXG7YH56&@4&0>6$HQM1_AA7@*17^'^+4G]*H%_]J#\#?MSE<VJ*,>H8NH
M^6S$JK$9R!&]!S#@)X;(+7"0"A?&.-%(58!,J[P6 QW=;/#>ISP,]6;2(#XT
M3-BU(&5=?4(T8BG%B)*YWPA8)W9I)QJ?9,"ZD>,+B/@08TD@A.@.\-#DLS5S
M7[U?"''4J?V>0#RI'*IA)+A^(D9$X^C=V'5K*KL0>W$WD@3%VI'!Y  Z8O]\
M^#>*.&UPF67O[_$JIJR>S_9S&EG(Z.Q7(R?9(S*&D7H]X",V[WFF,8B\,+HQ
M 8_E9*PG8)O_SG>G'5%"F;0JGO9)ESKAKYIE,6Z>KG9VTDF;]6B^\]'7F^PZ
MY"RXS5=8%8 <9)/+$9FK<&HE3%J7++?H^&U:"G0W:,<?9O=K,L[]'CNP@,JT
M_A(H*H0LB#'A,\(]]+^4I+P=M_;!P!;09HGM069N=?5UC6O'D,0[&>1;X!9/
M:R)*9C"<K9"@0M:WH32=2(2^7$JZ*1?5XU+6JZ80D1G&$8M;H"'^[8)CT#1O
M+4K3O1L%Z*QIUSNGPCLN7?[/ESM>!X;U#A$P7]O]=H]T#7S':> "2'0A)K0H
M7=*1()RVRN>$O5H-)FKETYB"MA37(8_:N\H/+%$J[3^5US[<SMU4<5"Y+75M
MHQ$O&E;?2"YJPG]%AHM9UJG!#/&_1C:8\("=,Z\U-?7U)U\IR0\M\'$$7^3_
M]3CT^6T"Y&XJ9HY0;OS_3Y)],BNC=+NE7N9UEAN 9(GQM(1'9Q0#IQ'/.UV/
M M-I=+@@)F75OM'R^-':CQ'R%&L+Q<2KM3;*IV0P2X-AJ:]4TUZ.+M<(]EB-
M_67-1Y1NZVW%_I]YRW?OYUBXX^]"^V1]Z8KXB(_V;QT?Y???4_[A^RCBG^J/
MN+];]=]XQV:9E+>J":TZGFXX@V/MP@VIG@_OK.MKF1S\K? #,.'99<1S[Q/[
MH_WQ^%%]OA=5T]^LK/[F/7%-UK6+F78&VZ_J&L2<.;!D8XSRX<T-&_)[&7H>
M[<\Z<?)OU863>XKG+Y4V^[VZ*E-W_P?]@VS7_NTZ_I]AXI_('^=S?P?^*?AQ
M\C?/GZ2_BVP"E]=$?MASS^#*'M,'O,:'?Y4M+EU>?T@W/>7"\359FW0"SJH(
M^%:K7CIMNT?M@:-42ZJ]P<>]3O=C?NS_;9!I'B_TM;\SZGGS/^&ZJ[^RHU]I
MEC[2N.WV8<FWB3MW=3XK7F&Z:7>:],S(I0Y/%JM]TO[^P?U/S(73[:_N5%\]
M5C;=='<=K_W1Y=\W1GO71YL"@TR^KZK_Z/S.R:Z/+C_*%ZZ)V?Q#6OZM_2-9
M^V.[]LTL7MGK[?/A5.8%L]DBP:ZS9]<:KNOJ5-FN)6)^+_;LS#W\:VIB?BPO
M_L!_>'N=]H^K^1^.'Y&7_>.^M*(\='+ %9._V5$?O%X6;5U^._UG'H^OP<2D
M:46JAAVW"W+7QF\XL:1OV91E_'7U4>>S]:[]L:S_*7^T+^K5EOL?]__\Q_'C
M]S^.A8_DQ;/D-]OWF=2+O]JG=4W^X'[A&M^'9\6>'PD^6[Q"5NO6EZ6+]GRN
M^U2@;"%DF71XY]':3E^7P^FS2D._Q'5_^NN\N@[CS,0A@-G_WP0 4$L#!!0
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M.FIJ&EI"4%#1 ^EHZ?_K__<C_Z7_ET4X:"DI*&G_/\=-#X"1DDB<^ L)$1^
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MSOBBK$@0Z(L45!J/MXW=8;4=UFE:J\TCD%(V_GBW85'^30N30?(5Y(E!#']
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M8U&(M)<XU"#<.SGBQTIJM'.(@+)&6&."4":7.9^B_5N-74!O"&5OT-VT_AO
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MS4AZ&KNQDJ!CD2L'[T+:"-Z#7/>WW4ZMZH*>>U9= I . T1G\])F1$^[LMU
M-J8ABD-[+C_J_M:[S8N<?D>L0LO6VPV^N$$P1Q.0.V*V0''H<E&=SSO B_7G
M<.:=>@M;R/:YCF7/MMQY\. )#8[ANC."W,N!!6/6189-V?)Q^^D9T.?WN3WZ
MV 6:P!V_G+KC2T9]/]V%A3_:D1'KB(*E=6]%=M^2A9'C'BTUP>-A=9L)<.<Y
MJ,RVCW;*4!6Z.83^QPLY)<#U\1M%J_W;(>&*@#N :R#6_@H, 6Y%?.3)B<*Q
M(,&4RWU%ICQ<>BUU*1KGC'R)AP=<--A 6W;?&K?8O<5=5BNWA/YAT?MC]=^V
M*DD9=$G-YHGR4'Z4GNIR<P[CUK/GUS93&EJ:(2]R&+^I:5J2@L:Z3*X_P[:B
M;P#UTX0=%N:MCVXQ1!LG;,.4-P=XJ3)P2I4VXS< -?-C WYPQQ?+'\Q/*/;5
M-GL<5RWQ5-^Z?;'NVX/7-5T<5KA9+'CXJ6!.<LTS'NVRKU]<Q[=>M_*.O<W]
MQW5!0U@VI;C[U]U99K.O.9H<J7 ZZ-%3G.X6^-8JC\J ,G,TT=OLX_$A*I*)
MY/I3F<9/3>?OH0V$94-/2+2 @"_V\),8MYR*3:@,=AW);8PD>$"*WX'V$N93
M/_96=%=\TNX4I6][WS?M2-50+RONND=("R"PC#;4=AN<I-QR='SU\%<H["W8
M8YK"YKJ2=VEG-N*VYY<[@?:RZ40CI*.4@"):C2>U&>'E!)(QT6"&:LH7^97J
MK=AWUJS_%*L7^[A"^</%7:)BYYE+6DXF8%N)NR4185SEB6=H2#-M16_$P1WU
MBIG#$B1JLLW#ESD851.9B=<DE':(LE:72##[!M\#K_F&A@<<*&"<5NL&,P&>
MWJHV09C=C]Q3AW4&'<3C62G+EX#=)M@M2#W!,%F$^A:AP'$!GJ(DZSJR?YU;
M[<=;G@-?'G0]D_9QLW-Y_2*@'^*LB_;KO0&DM3LD?<:"!G.9<\4;/()LYIO/
M]$L0T@]:'B6)*=E_+A/(?W]G4?9O*\GG>;8'&(H$R<8B]-ZE[GS$=Y^C/ZMP
MRJ;!3_T?%I)GR4SBAU#)]M^E+'I[R;\:N=="N 9SPUN2\$(0;S,?*SOQ]^]_
MI_)=V2V/R!^T&+@LXU/S'N^1BHPUOOU.MFX!YH(^1--WEOY\Y1E!M^0+_WU\
M?C6L60D0V-AP*F/8BJ.W;FC,)K.-^D_*@FX E$M],7'#2SD.\M]+VM-&^1][
MK$RPB19OCSG9.R&AB]RB4?UR,U!I=$1YR60%5XKIMMFBZHZ?W+;9E:CTG15J
ME#1[<I?R-[6H-U7H;CL,>5RYW0]L*4*%MUAB7QXU]6M1J7AJ[QD/$2FKDF.>
MA]@9]UZDQ(]1BK>J*D6CI1"SR?(J;>H\SSLZ<^)C^1,; 7=6DGK-[V%51?9:
M8<M]/LXHPOZ9\M0&T?4>KJK]U=%+^6$._>]FDX]6MA6]I#HLEJ(EKM9Q >9@
M@K!/41=#+_4#V6NZ8TPW#<,<CZYX7 XJ\S[Z\EM]'R:?Q!G>G=+[U>IBZ8,.
MZ"O@PX9]AL T;=7(P72_0EWD\4[V!DL%3L/1IR'/I3JX?T_; +ZC2]@<Z1!B
M-5Y=PHA9YU6!G*5;U@/HU7[JVT-:#=PQ3_,9%+G=!?ZF]0&3>86OX1&4!^H"
MZ+>YL&B_NPNU1T=[G8UAK;7'_&OQ1V_F7N0E?NK)N*J_K^6/@J$M"K'"[F_P
M9-[*QOWVWD^Z)6' B[(ZGW+;OV>R8EE^OFN150*)'/4!=<H\"[\+T4:%[!#'
M8<>ZN*A $.7!DX/0%]G5#0;QSB[M]!M0WW(R:Y<U2K!)NF:M#>1(]5!5]6[^
M=GM7U4XH-CE:NNA-K+O-V^T'7QK=4/.V2]KB!5/K1\<-4MT>A7&%Z&].Z):W
MQSA_4 S4_.51PZBTGN\?8+K(BE.N(&-&MQ<R/2NRC=1R&L38O?5.^3)V)Y8'
M-+A"7UE9G_<V%E(P,'(8"2"V\'VUYJMTKLARL30,9,<J((WC)!#F**MSEO:9
MXX*]A1-:J34]3-18ALI9:PL)#Q4\&4I@(+*[7=@8C,/4MA76$4GGAD)&_4 P
MONUN?IX%^O>P*'9A=+1O6R!-ZP^')=UV [<<U()%B%KT%)$Y._DS;^GA#4!\
MZBCG;0/W$E7\T!8J__YA;G"FD9A"L>_)?^?.%8T('D6H[SB4#CC 9A,7'4B'
M4@G9-$=$&W^*]4]8-!:GNNT<*BD0"+>=5W7';"-Y/_C!_Q@SZ)85_[XR:\E6
M6-P-W7^-N:N+HZ_!SQ)L2P<*1+QNB.IT[MG@GMOA$YAMC*:OJ9[NB"PJ4;%<
M1WRC@!N@C>-R-H#94QOV,J88^IKPXOS>SY LXRS3YM;D3./L9P*ZTU 1#E!H
M6\4.Y%^KR)[L+P4=B2G[6W/["Z]G]P5YN2<.7><F*TVRBB@\C8M#H?^J&JOA
ME7,0FHLCO]C*&GM(L!$:WQ1>X1#>\.2MQUF_X.[0]XZ)RE=.4]_)-88 /=LL
MI>C^B['98YS85^U*J/R,^/GJ:$EK9[V1@VSNKOW'9)-!/I;3GF>M=E(D)]Q9
M#D5(.%88V ^G\_P7E!."[C:=#3QLV!6OZB6VR?Y)O&9@%O#C/L6AO4YW  J8
MD)W" ^\QXE4L<Q"8#U2EY;URBD_#A6'@PIA'!+T3L=S.W$4_>W(':UGC:#U(
M?8_*W=E3]LD7%FM.M=I'SX0%RI16(XGXU4JGC]W1_2BV-W#98X)W414)J>*G
M$FR;^WW/]X@[64Q;8NBA"_M*;]JC2[XNP[;K-((<[D=QA_I6YX+B7JAZ5M;-
M-=%E3O)^%+L>-P\_&"M!E];+I'[<7RPA;##A.'MT>:Q?:0.V,J3"B/O1C+7>
M1TOPNFFP\Z'!X[&]P*^*3]_-OJKW'0_>@;L&SQ[S?A3J2XL"L_F\ON"5GOV3
MXC0TJ_)P@;Z!^N#I5UHQO9\F26&18GLW@"0PVO@&D'"(X3PTGY$3D1M7W&=:
M.9CU>K'$.B,I"AUR6M:@T%III;C.[+J';7E2.(6.;:@QHD$]#'%:T]_Z)JW/
MB5DZ 1;]LC_IW>2VAY+.!_H13%5,C6<-Q&G"=K.:LVIY.H"E[Z^AZ-!7C(R,
M_%K5RVNI=.\%9*KHA/2H,6.TPY3I8\E<D5]?#KIK6^31XP/Y^W0&9<XQ_=,T
M2@[T<L]9UUX'Z]? =YJ,K&OP^5A'C#?*[VTU01JR;4",!SC5/C5P"#2T9&^:
MM;Z[:RH;GZ]WI*MMU^)G4%>)<VG'[B(?+JA*RD: SN#:R6Q?^$Y_S>Z/9K!+
M.[$/+=T K&C2U5&!%5 :I"&(?@W$X%7 O]#D?0-@>ISRG+Q%<D7B7K9B-K\K
M+V _5&]WQJQ!Y;=;SW0!3A^;)A37)0_QUF[ [.44>[,M,3:J,RVP&C<>F!RW
M)]_YZ'*'-]AQ'1%70DO<Q>$]OO9I?7R3%R\'V>^U"8Y:TFM%WTM?V]!U#N,M
MA?KLM&6\>ICYZ'/9B+U INM#-V'NJ&BE3A0HB79H?%!9/L\'9<RH)1!D7/'+
MRX8K3,[RN:@,R2G/5.O:8$(__?8T7L$C)W<Z4;9##$XY7.-Y?_*Z 0Y)M/[H
MUN"2^EP<(85+H=5S;I:6D#?B>OV2P]MV>R//W1]),7N$,P+&^<JI/=B853PN
M;I7>R-R=\-T4>\@3_,@U630E1E-4[S/0 ^T7[Z<JY5RZZ>#)]@0;]^2=G0-W
M0DF;]!WZS[Y3"Z[;_B1$_M,DU7&Z?@P0_))#5YZ=Y:Q9+[?\M^/F#_E9W8"<
MU8(!VOWHY$*AZXJ3<R[)R W1-%/OOPAP]6I-*7KF-]6"YOM%247UXPIDVD;/
MB&E0\_V-O^B&/HL($JQ_\<\+&DAS>WB^O^Y%B[0=M_!H1E[FSD[^=F;HZ\^4
M@MBFTG[453A=#4Y#LK:NKOL;W*AB1,"WE3%$K <<,@3DT6.9F]$&L(Q "K?3
M8A$@C&._.F57EPM&(2D392\_\RSXC(ER19\CG[B"N'((I<"@,46O_.^T,"5[
M [B$%\?R;5I@Z$N+L%6&896R,AZ%HN/!WG)E^VX)*+JF$JFJC+:Y+Y$6N5\<
M:C] VN2J]!6*L06?WO]9YLVVC(GE:RA7'#/,]ELW:IRW-5H&!QJLK4 5%CAA
MMV">,'K</<Q>(;)C1.[8T**KQ7"Y:/9U)7RJT&N.DG4/)JZO-U'NH2AP')!2
M,?@"?JR WIF8(4B9D*T;@+3*WAP'?9U?J[WPVO?MB."84;%Y@+'!-EX$=Q^=
MVH9)G'[2@=F,1PBA4L!:+4E/LX>?I(X<K#C9<_#K[WB,:.Y7=\N*,W_(-)]:
M' R9BKD!D%X1]K-C6ZL%/ZAKE3<(G:%=:6TO7UJSJOC>UZ>LJ563K[C-)5;7
M?C"I5DF(_%L!2.HQIOSUQ<QQ]_2_G^'D7*)CKG')&/IJU_%PODV9TW9],:]<
MWX/)Y;4_?C01:R :Z//K.KF<9%FWV?-;PH@%E_94-35HPPOVZMUFQ<EY4>I,
M&GF9C,0#WVX/(+&U1TVEX3:8>KC\LYL"A7GT>-\P=W6P[S#CY*T;0(<H;W(;
M^E@%3[6//GG<X>.#"$0EI80=TU1JUHS#G/=MUZJLC;D/BM<T#)(4[]=PW=%]
M4;E&F:5/8,XP*+^47&TTBLYIZ- &O5Z6YG>WL'I@%L':,"BV/D3]S?/N_5[N
MZ:@T;KT\#?9J9]K^[-^Y.!C\,,!FV0^X@:XT%Y?\[=BT?M1HTW@<E'5I<;+L
M?%V*YYGFV<G 'O9)\A:6E]6\'J_2L-B8Z7OW*?6(<N3UG32*T!L Q V>"/,J
MC.MB0G-O"&0-YHI?O"?U%@ZC:41DFKOHDP\D9\/61])B2(^>K2O!<_$\^,%"
M8I\_>9U"NICR9'%?V4ZA(^HYEKHWX/K?Q]VS RE>&?:&/FJ-@!SIXE?RD0.6
MSK7X'A@MPK!VW;@">S60DSGIUA*<KE]E[?-QISGQ^V8K0RR=@,E &ZGV\%BT
MZJ$M3>[LI=>3W0A/>$'%KYITEWDQ88M/+BT-97/>1EGV]@O_/-M^RV\V^O5?
M35I9]6_[4>M#5])GLM<#K6AKPFX ZKW!+N-+.R3!%*ET04UG,((C^/$%6=@'
M2[' *S9@@N#5D"B488K7VH%R4U-/MA)?P=UT1O;@%.?6E]QUBC39JOL;XHB0
MH@U#KV^'RH_@%6RL7W/\Z]I.3T%NP,D6"L4IJ4GON"^)_KZ-XK_"NTOPVWMG
M+\@Y/^E5=Q?X-ZV^\ZEMT;=UR5I:\N9B-E?CMV[ D'_BV8U9:/I3LBPU[2<Z
MRK6UA7R7_O(5F+K-4KCQ6'R:U<0?6F_A(5R<^#"&8+3(H'$$7>9^C5#5OY+"
M2O9UT^&9EFT.-QN%AL87OT.!96.::<:*DU-5+Y4&.ZO=0P08;'TUGV#_H5 H
M%=L0P>R'J>SS'1W-"]K<F?H_I1P_=:/U4D1N '[@E2K4_G$1O+)]+O#P%XX,
M7::DLSN'4W"6$6CQ)U:WZ&BC'TC5&>;A8B8Z3\/="L93_4)V8X5@/67?[_F6
M8X125+5?!L(X(<V7DA78*O,L<?&)J66?HH]O/?0IRSMD&L)I_M>K']!A H+P
MZX9 X _O"R#&/4E5A<8!<F;C 97:6I5],FM_:#F]8Q/S-&601K8C+#[^,S 5
MO%7F((:YQ+&"4?L#\.4; ))GX1Q&@:>V1FPR_*%A&MN0PQ#77OG1]?-E7)6\
MY-RJ'!'5)7L*J\%N7QA@3]#!_1>A%&\"#0\=Z;#!FHC6V?,4&NOYKFGDN?41
M?^SLZ ID\GC@I7;@/1.'V)A<8^$8X]Q.K8MGUZE-T]B[2SBF3@3=%G.6)3:C
M[&<.9W-I1-WUUT/KI7)'^=,CBNE/(NDMV?!/?8KI.Y8TVVD)^+O-V<(XP6W8
M"NM9?YUG[D2[>I'DVYW<;9-%4S79%9OT177GU9,P.!:KEQ7R7N%]\@O & 8<
M@U>%#!O.OT"PA6.BM3%D>Y45=-Y/%G[?-62?06B3>,)=LJ3,S>N!>S7MU3#W
M,Y;>5Y&FV.,K3L@^GEH%'6R&WA^B$QH*4N?&Y*3)=CI?W9J,GD2O1__RRG/*
M\985][[/))40^RM78W4FL2 /M3D,6NE;-<*6-8/H<;KN%9*QYW]EGY;!7.TU
MR_2BGUR9793N3RX,3#*S)PPY6?/_98>?=.W-^KITSM:XY6X86I<E\.JYB#JP
MWF8JJ>2_C>GE3Z7Z#(P#;[WK;DI+1=S!J S"ZH.'.[4E\5)0X2;#2>  ?5!:
M? 27V[)/I42(S/#I\/W1.]_TW9@8+^VA!&HD^X$%5T/XD6EOP5Y^<8LEN$?7
M'_Z L'H&@Z==3<C+/J]VZ-M7SAXT^M/KC%WWK7*OC)$4@T9LVX5]:;38N?X<
MPW#D#8#5,VAEZ-/+[M/%#4BVU>IA4QQ/"N#UZ__QGPI4C7 ;B^LHJ!%*DM$3
MU CO8=^>[?8$QKSDN)UZIQD$\C0\,R[>$![^V*EY^N$4'DF]:TU(N:"Y;L2)
M$U))KK,1,ABM/B=O;[57MW@N/KV$S3;:_IP:SU.*\^1+9_FI0%>M^-QAT#&_
M&]BX0.!L%UBOKQ]4R*W[.5;WRGG%[G EL+UVU4=H2-Z \_AILG!'"Y_6B/C=
M[^2LD6"=JC,8GIH-?M"--KL!K/K.72BALTO#GZ/'>R\N-@2PV]6_SOZ^TG^Q
MHU88-ZN]Z]+:D_GH%?_PI;WQZF93SC&P!#\*:Y!,Z[KK_4'9_<UKL4XWJ]'>
MUOL#$QG BT]]GR^?.RK< 'JIP&XUMEM+1TKNVW!.WS9L*>;@GV/\QGW$>^/<
M2X7]R2B2_/=6/BN"5/EB;$,R&B '"%M/.[@?2/;+@0=]D>=>_%.9IR1(.3PF
M_X%8F"+_DTI.X2W1"@#UXO]X:UE,9BA":A;/"]$RPY"WA/N5_FSGR6^YO,RA
M:Q;3XWMPJK=?_[52X!_U'#P2MM41(;*@+N=!L";=KF"Z#2/W*OPL7L1>Q;9@
M_6+2'5D%: DM24K5=&$L5Z3E6.H2)NG'TT1,;MPFC.R((P1^T8[9'>R./8_)
M%0.]L;&H\Q?_U!TGFV2+=<VQRLC9B_U].>)J;>:;8LO_\G3LNLD/_=@H%!0G
MX[UQ%QUZP/K/M[-TI72J5**QO;<[A85:_Z6I87IBH;*+Z^/O&GL=CBO\%P&.
MS!%CANC+WG;UR.Q0S=E;1K.2^;WE<C4QQ]5]"_&I1A5.+5)I&9$C(_QR6TP1
M/;RJC9BAG%K/%>/(QK;:P#8Y?G>_X/U?>(XW\,]M\I6DB\DY4H4"4[PLC>\E
M7%^!GI-IR*NSXD?Z]6>0+1B*1%5R7P01:I++/FI13?./%K*BAL^JQ+AI#;4'
M5B*YYS]A.ZI59S^?^R\+!2>0/BX$ZUR#U1W,-4J+1TBBO$7N!7+1E)S=1D1I
M]XN 4C79;T=JDI(X<K8<"6)D]+[G&,_@%-!QYO;\!C[<=@=[8C%+^PH8X^NJ
MV_*2HNO"^H(>Y=F0W)VB'NJ)&X 3]!;Z'HP&3X^U[/=?S5/$@4ML?HT3(11B
M&9D-WD!1\2Y#:WX_.MJ/'2))D(Y8P9,TA#9!A>&OJ^2F?^2A[E:%5'M<L#)!
MLK:&XR6M&MN[X_I!"H89TW3^+J\ !TZF&F9F+/\$':D)"S)<G?;P%GXL%#P,
M(^DGN"&5"^=%)\Q%DFBRVN0[ 3J#R7C2O](K)^Z.J%.-W]Y'D@0O* M+NP&0
M(X2VX< )"5DP^R_6]H6WD='M-/$69E,JQ_Z%6KF @__Y&OU?2SQU$Z&VLZR+
M#2RX[-"!KNL&\-:20!M7<*R>.@^D@/6T;.X/)7K3+>,&D+BX[9'Z\ 5<=("G
M5643;5BXVK>)IZ:[$O'$BW?,$38=$*8Y+E@A3M4;>8FR)[%MNB-1LVQ\Q_#Y
MG.I11L"(W+EK1.#FCQM ?V?W5F>[W45( S;XRO5GEE8(@-1V%=)BD#9AW=U>
MAEI(/"?;<=)79";Z)Z+-_(3(*%NP0%[7W.69E@@'K1J=<B)@&ZI 4,I,V "3
M18$V#*ER=C8R-><Y74Z&7,7:1,69:BIH5S0RYC&;D)#<P/@6G 8_NY1I7 MQ
M6[5VI++3E8M9A)>.4MDVB8B<XDX^%-=_'NE9^WC[O9;#C-T-("5""!N&[&VT
M][.::QR5HW!I3D4A^<.BOMHW1^F\_*H_K"%,4H#U_/(S0@+#C9?_#G6L/F15
MCI1J*O;J.S1*6'C 4!7=6$FZ)4_"JKBS]/'0L;&EKYME;<V+EZ^I*>/<WL$:
MIQ(@"WJ1N??PH6ZF7#0T(P+-(B+\0,-4<V3X>WOX<7/E<^[%>BU_;^E=@81H
M_K0GNN1=?M?%$<1:R+1$3M_.+14>B^FAW&\9:<LO+ Z-VJW&7!RJ[C\IA_0[
M!],U[CR+A$P/=J_^.T0QXUEF$$9;QP8J]F#;:(N.'(-$:_)2;JZ/%HIN9OY7
MD\FO] #A8M\P0CA6,:T&]$512!GDP5%S :7\O^S/V<&/PHC(AYS_T0:S]$(E
MZQ:[/4$KF2=:V"\H071LQY>5IO==.67?ZE,/PWP]G"!H*Y8?J]8M^9?$'87T
M^,%N(%X.%[ @F\?#J:3*LC4OKW"6?2\P1?.;RP-CL_CGQE794_X:(#K\K"-%
M('SE]YGV0J!DG'))P5V,6U6]>.A3\>K+S$>&\0]8A]_%MW(\;;*,G@POO)*+
M&.SFCF#%L<P1A!PD2XLP3QU\4^+G'^)6./)_!WGJ2;,*9-J^%%CJP (ON+ZK
M<^,T9P)]%,P6P0VO.1S"U$1MRS-GJ:RI_1XZ/4@O2<OA\5X3RV579OB*88QZ
M&JID;?^O<]JT.?C#8F^_1)7#JR(*2.]HJ_;AUY2C KCKPJ7[:*@DCJG?J&.>
M\VH@0F))KN:!WY^&41D.KJ4]H>!#>Z$8V%8VB!(G61'>< 4\SK%_E-66!;Z<
MD3N/89D-<4\[+/P&[^<)Z#?UK$%6*3I!&=#P'#[0$VU;[)TK'@AHBWE)QN.?
MTVC :WG$$@@1_N7;9&@-RPRW&Y^L Z],9G2P?\>N7X=E@[N9U(\/SS=8Y00J
M1]<']4^;VULW)O\V!A0H8 V1F_&YJLW*S5G.P7[2QW>*' K?1WC">DVZG=)6
M:#27SFT=HR,$,&\W@<_C(#/5<FTU-D/[_N.TBFLQ0<C@YWJ*)IG>?QXDG@9P
M=[&O ($FC856'6#$GU;W^#H.WN>TXS24C_T[WVU/\I@WMP<?S1GO!B +?W0,
MYCC(7Z>?$YCC!M!(WE QB"&Y_*[K7TO"G2/L(NZWNWZKV=HD*#E30(">7CK<
MNP_4*#E@'/M/%.MN@X750JIL9JQ6/MEP??@<;9H 6Q@S=&UY/W22P_6&OY:B
M :J'U41N)BG+-BO_SO$.I_U"$4K<AXC'"6#3KI1 "CWMW3A!7NZX0JSNGX^<
MQB*ZZ%ZPM.X1_0YHG64FKKCR:8KP>D5)4W!H<+CU[A[[KVTI<ZE )M-*H;O%
M[YSR@CT%B^US'BQC#S'1=M,7?GW'$CT*6N'5JG$8*DI\X)GNL78IS@Q[C)%P
M=P1BU9H*X]"ZP:'BM)5<)_TUC9DRN_DQ%D0O=32WMM+*),!^A32_'.@6RA;O
M-4G28\L?-8?<>C#_]$5+?2K+[71HEJ\3Q5@PX)694^,-P/5D&;74&RK8G8C0
M=/8+W+[V, RN]*+M[K3XU(+0N &\=A$^)VY6G+YWG0KE^NK)R]*&:<$)M-NG
M10?JE74N%GG;&=S5OH,;RMC0V[A+&HZ6_K++SS(>,>)PN^VZ09T@AVP6JU\?
M&^O6O?_\/="P0P\_1R(P6R_20]=I<LK-8!E -K0G!+RHQ;# ^XV3>05GSX,6
M)-2YI@/(]I./CV_)-U^.56.*;M^*Y9.4,PLX=2]B.=A$/TZ1ZV*+& PNX+-E
M;6WKRCRS8)W!U;S4.:Y0DVD!I0"-]//GG78N=(S[@<M!JQ=P=&TAZH3YX%\.
M3B"49V&QT-O?]?7%IIO'W=Q[HI+CG/FG#,1CUL:TR^>'\&6G0W/T<6=JZ=V8
M2F7KU>51I2@]*AH^?8GU:FLM6>==6J)[ W]Z_\(ON*^;5)_> &A"@93-T<[^
MQ=@LZ[:.5CU33?_24179Y& F36W?HDC%DP*QWWX\T(<S$9R>WS:\@V=^V*X]
MNIVR=JMM+'NU1^U=85_;M]:OD/BSN<[F!:N_4VRH"0J&YZ5)XW_;G(78)MG8
M MV7PI=VCB9LC6/$O<G.](/P/D=)8HVT(Y5G$EMU:5GOB$(#4I?YBM&ZJ7^
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M3V$1F\M=")F.:#.!7GZ57=H*Q =1L[;ZG*NT/5KV'ZW6#Y<O:BQJENR-SWE
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M"YMBZ_"[1?MXI0J%TIICBTA[FO87\]7N:FI =>>*V*#K5\JZQC0>JBJ]!,M
M"2DRM'^$*Z@6HO19"E;%>W/>)RHM+I[%*C?GR--V:[Q&BPPY+'G*+X(6Y?!-
M5_0X$86@'\'6:SG+\#RWT%_VARL4:SG^P9H]_6 ZG+Q/TFUJO-@?MOU:.N@H
MO!S,^)M6]&_"6@2FAVC;H<I)L#,C2,$-5<OR7("+JO>;QR5J/D8?[:XH.+!T
MC;*Q?2B3,7-TI6 V+)0JTM-]2,C%(R]^J0J=L\R6'6<#ZC[\E(N0"=3S,6OA
M*3('Z01<_^HBY>+[V_"QK7=K0_JRVY(>:\>'+/E(XT^,$P]$T:L?$'4B&#IT
M^X(<*B&BY2VVUTH$V28T<= 7-5(84>&%PCR]#_V<NS+ 7P=VN&GQX%G& D)9
M/HI-BP:?\G_39?_O0WL7<*\@ZO/&@25YZ)BFKI/!IE_Y)H>@\@<UQA_I$P_L
MO,@:UNQ/<F$\?98OR(O^=]A-MW]!])-8_^V4#O!A95[I1@T.<##5S=Z)Z ]D
MS"GVH[V:\*RDL<WA[/W?B<SF]/\UB'^O^Z^-AJEY0W/MA$3>K[KHHW_R7\LP
MFQD#>GGDFR:!934L'YI=>KU")ZI]$)&<;A'H(0;FM94K%?'NJ3EE_*"+(+^3
M0N*K'^O<&['V3AP<2]_I5VG GH0()/[4E&W'"8:$C%0-;<6XZ##R[C/,V6B[
M/YYM]6@B?45)AI!DH"QZ'M?3 LNI0GS2-_'+<21PU?V[\([G,'+!>/D2TQ4R
MG#T?4\&,]"6 78<WYK'HT _5M)O,GS(0Z^MI1C"%A: _K+>RZ)JP!F'+?V&A
MH/2%OPSPM-.0#?-R]+ M%VS4%V));Q.OPW\[G;TW@6QY[MV*V,1))ON+#=7*
MNY%O\F!RD7;,KI11"9M\<LMGG7WR&\=CW# [%-L'-'5%BZE7B0OI06.ZN*QH
MR8!P4J\ A?63YP?#=E3TH"#RIXR##8L[67>(3TA\+6V_)U;P^XOZ=QM>)\VL
M'!B4OK;J< #4D;DR*ZRML_YUZC;0[&V2W-^WKR8@[(H,2G5GJG;P"[&.*PN]
M!ONS;G:4ZRM+TA[%("FU[INW@QD-"0Y%*S!)O.^O"1+G[MXZN,CH5CSQU;36
MGZA3;2?FIV$A/W,0*=IV\F2WWX)G6U2^R^;GN52#$^Q^[G[JXQ[&E>_!"A:'
MN@H+A5 )(Z&+\A4<[.;XYG6(T@N(DR5V48S_W?M;G-Y^)6!^8\G#K2.K]9>9
MH?89EM>&DO2-@^C@3PE.%>>ZLQN3YX$_WZ6]SY^/R\TPRN(2]-2@L:W3%JV1
MF(MZ\31DF\^_B/P/@]J(QUOW.F.+/K_*5)'4QT(>;?)B.9\_R0M=IXA?+_/@
MI1V'VZ&LV$V@K.\X@]HHI^I-<C6K N[#DW+.ZTT3AY/\,[I2'"B?7J.AS+!
M;7]LN;LFTC!Y+G<CV>'NN)P7$B)0D[09;^^FS]28(-*H6EN-SI0X-,=NGN3'
MYT@D!WK0";$G=E?55B<>M<V<65!Q\^8V[ )4+7"2";D$?#(LHTN5DO1[YC@C
M2GI9&AS\IBQ^6MU+N:AO^/.M+^6OS40[C-T56+UZ%E0KT?/>(*9WG'7YV(F_
MR#(J?%F1OFB##.#PQDN-QCN#AU%/,D+$,D+8(-/3Y^:_9_&!A =5NPO;D2?
M8X=)KA>3WJ<9K^3N6@REP%LGZ!/KZ;*>G@IEZ;68%G2"G7) SM8/<>(3;2:[
MA\A_*=U2@^2ZCOX%L56;Z[=?,W '3+J=NY/UP:T)H6N-BYV*M=V<A<F!L+(
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MM(CXIN4N&$?!),HP<;Z21E0]-R:DX5C0?,B],69SD/-[Q_RUD:? FW\\=S2
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M'317CGM2UM-2F96M\ 9?']=TW' )N2B>/HD#G85BHZI'7-.5.&J/G=+Y6.K
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M?Z?(&>"]YTA9OAR]<]\(H!@B_K44B55$"NN25[U&=T6@&II:6)+Z,F$JO%\
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M&%**]<7,]]@Q%29ST5K7M79$7'G'?@XY6Y]1H"=-0C QS9L)8Q@V:L+@PII
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MRO<6K\>9DZ]6[A:8R2)X:YX6XSN0RT;ZY8P L(M-PKH/_S-R$S::T:CS]D:
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MS;/'5\EX81PU?!1.BS7;:$,(JJ##0I8*8[_J!C[F_]V2P?4FW=2?]63DRRN
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M,YF"[6M?8!Z[7MHQH80T^&OJ/CA_YYS5EZH .9[+-3_9;=DM]'<L*!X?CR3
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M=:WS6DR<-]*6R3FA.BU-"KA,4ZF"S>K_)"ANWH/4X_SNLT<.=%F"#H@JWU<
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M?A_^M6&M>)+EZY%5 3!,RSX53@K%*5W'*H2(G4GH%;]^7-V- H=?12K[33+
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M9!"2,\%Q/O>98.02EL>(X/^%]A^1_?<">_-_%-G_".Q_QH4&,%-341:/F@T
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M>I*$>9VF]JWGMRY_$?2P\=0)^O/\M/=J]L9\1J1'V >B;Z^U2[S\=-ND/Y^
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M_*&_]#O_HOK&J6 :L0;3[$]]LL*N4537E(2!&RX$;DJ'0)(0Y>I-DLCJ C+
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MWVZN79M_$%[;ZO@9P% 9^E.[1GO(O#*F#RN@ES!6N%P!W4@AI=B_F\EO,\(
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MTV]_9Q"\FP!XS;[CG$8;?4>;R^56!B*K@AA4G*%K#=+8K..K"<>.I/;;2CD
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MW>1640 9(]N%/S99K49ZY6VE%6UJ7VHH+)/1A\D@S_:S91"SN\@9XDHYZRQ
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MSYGSW0/5%Q8O;/$,YF1 9W8<R<L!?][_M[=/_P?-Q365;8D^2VMN,;VY6G<
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MC.^^X3:"5#$.AHD&>V#J8K&;-AN5QBL_AG5.?!/3N8&3,DR G+%VX1=^-%&
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MIZ7[V>M#^3X-:;<_LW) 3N5:.G<\ MBB\O0HMG$4W;6-18R?5B  X3.P Y[
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M9I9F  <'!_",_0.PR, I4Z2W!P!86P-'  #@!3BO" ,<["N./V]71 "N/]?
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MW5,EC>2<&=:7]&JVLMYUV-6S_(JK#@O@1TQ#=R6+H R%8B*X ?W['3'7\U@
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M@S#"IZ![1KS[3"G8?5[5F=#1#:MG*RJ9OB4%Z98I)YY\K.'@^';TTCDZKMR
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MKPI;"$I7^LOMUR"6KT<.EWPHB.]=6M[_=4DS<L>E[[A"6&S;V9GPWYA&>92
M;P[*< ?ZE'#8 <22<3$_J>D9E.L-_3.#6KIV 0']RT9C!M4IAQ.]9VJB[KA\
M6N/3L$(?Q31*&TLR/&CT2KPK,H)R*9V@FGJN=KBBV\#9X8->Y_C^=KK V'.O
ME]GN#LFR@B)-[]RUWL]S;+2*7SD#/<1LA:W>QVURTE29>9L;&S.HF!UQ%M#1
MAOD!:<%M9TP.#Z<M>4ZNV&S/]V21X9O<JVRF<_L^ID*U=9HJ.T6OIO0L$I>P
MBU[G\T<K#:V/'Q?@UE3N_I'<*(AXU;4\S;^/\X :N&G&CJ$M$-HR(0B&AQ0@
MM6VS'&B_XBNQO G>]2:Y8][IP9E.9EH2@>8UDO9[;3/UJQQR5:;\QI+R"?F[
M>!;@CA=@CD&YEHT$*'.5")?C3@NGK\J^.AX0/]\WWT?6TIRQ.2:O/Z;D$_3E
M:5*BA$(]]"I[/"64WB!S#P(JN&R$H-G9\(!XYX% %B!V0\ZN"Q_G24B1UI*<
MWA7CK7O#+?/#1.G6#\7"@Q#Q[;.UU0Q)/)D%1#%L:'.!Q9R.?0S#G=/%7:%+
MB]55JE=KLR6C]C3G;4TB5CU#!F_6N M_/;OU_&:FU)_GDZ<-FNQ)PY&,*]2L
M=E<YL-6MZ+>CULLI^[J/-37#*D/I'A^]_*9?C&D@JVO6,LWAJE_N+F\]'&)<
M8(MKR% #)Z?QH@NNA@-&WM,6E2Q@'QR\.GQI4&\_H?NU]W"*J5*OH]'E7(;1
ML?U=JUVW1_1]I27,%IB\'=1AI]Z-A"3_5IRXD>ET@[U][\871D@AXKY!G&[G
M*V47W6E_A3,?%9K*ONF_V&_YZZO[FH#'HZ.^F*DWH9N1!$.&*W.BM_Z&=\@4
MEAL9[%A+-<87_I9!9[WN#+D?)O9%S^[E]0AZ>)]NV7->L<ZK778UIZ%,@4"*
M?Q*&S?T\!3#1, &WH?K3-/\65P7J9*SDFG/9CFG24*IXOGM%S5,W_^.J&;^V
MOKJH) C(RT6?#J,8,$2(Y)[6=QM%+$ $641Q+:9H!FE#0K9GOA7Y*L\[_\X(
ME@HRN*GW*2IWS<]] BM[[OJ1V.>'WQF)L$%((.A+G32G"H:JQADKS&VW-^/V
MSV?K]U56#"Q]>[V9^2*0&.\\]B*;;W#TQOE;CV#J:K./C-BSF$B]%].($4'Y
M$JD_>EU&0?1)O84P(:1/D)2HJ]7;1J/-?&MC-=(J2>4I::I9H_=(]\S]I+E:
M_Y%4)K_R]"1IC<E_H-9Z,XIAR@:3Y*%2JJ<-K2WI#0)V,QLQ6S<P?FO@_-#B
M8MU2O.*99<&[!>K9-H4H [93;1@&H/T',%M3^QH-PSB$U@AW=.KAM@Z\2Y*I
MRB]+Z(X\HT4_F>TA4MELEG3H2%%4*WY4C,GW> HW,DGQ)294P,51IC3]4K>I
M'0S':'6<7NQ*3EGO4L%:<7&.;9Q^+/8KY"J?EDN<#[!]H3Z53F(!*=*0W23C
M RR@?R8I=/SOBV>+G<2).4P<VFMM#;,I,SF5\;-U-Q+VLYLIPP)&]K)3]1F\
M(U[Y;TTY1UE :!%3#7WW!FPG"D(U9X-I\U;F<;"!9D)_RU;T!>H,>(P,C<V8
MY&.H4K%-IRY5!H?D>4L:D-*)A?,V)V-U7$UU$=Z"]X2_Q)8L_]J,!R3.:8,:
M7"3SUI& 3P3HN ],Z -3K95Z8:V-2*(UAS*5CA3V"1T]C_G._'[>[*PQM259
MY&QM0_OT+X;8"GEEB8_FT],^W$-9$01)PY>8K1G.U((X[0#9<1.;-<$GWV:6
M<FU."?_\"$G)3<E[\# J#].HCA;Z33RPQ CSSUEXLCKFC&WUSNG 3W2\D;M_
M4'*AJ#+!XA:"O)^SYXZ&S;<'+$#O?G;<6L\CXE3#J@]L'YM^2H$Y4]^*WX#!
M+=E[:39)1D8D3*S"H+8>##3/6UWQS1811%]B%)V?R;KW;>:BK0 &U%[[C>.K
MMZ9@11@GJ<5I#;C$ /\]8"@+N$!;G<_<]ZG01Q+N%QQN>C?M4'5E-0MP_9UZ
M_ MV_[G/?ALV6"+5U#]&WGCWN2]3#JDUSV88V]@8E"H%RH]TLZW-=+FB^T7O
MDYW3BK[T ;[-LD<"<KT1SX^<T>MA=L&H9FG4ZF:L!#*8$A/W<Z#"VLJ^;Z-'
MX+>QU&!@& (>LTE7.RBU[3LS.#!<ZG*Q3^J!TO7])/'HNX_<P(=, >Q[U*5>
M(Q[_*6Q$,45;'-D%5DE59K6JN^6/=9)I?JN=W-.DU(?>#^6:ZG4T+ERZ?ER[
MZUHK"_#&@QJ>25)D[1;_!!S/TL87_Y^@^11.UL$;K3)X*^-\[YO!0,.$$!E#
MW>J)83?/]$4__E-I-Z4\H"O=ADR^32ISK,558 B?3XN)U>OAF-MNR\J?#QV.
MT]:3[5 8O'IXQ6A..3DQ*GU_TZ]8VBIW1\FY?B;O)E5EC(PNG1JB3N3=)^\^
M_$SR;^XL5!Y<OO$TM:!;@^Z#KS_>?:"L/.[L^+-ZVID#!G^6UK@#:W=3F$=1
MIZC!2?6J4X&#1C<P;^<<&Z(SIG_6#>F^VU"/JKYQLVQ'H8+>:[%0:^DZ_BI8
MW(R$*&-'N27#A6;?!G\,%]:N=RF!([:CTVCVK=N:%9L7I5^75PPN'ZQ^?(^G
MXX#7>Y[7!<BB/Q+ZMT.%BXVN%4'D)A?NO]KG>RX$Y8+!"KMX]?'TEVQPK>F/
M.YLD\BEQ/;OTL%%^< ?&_.8JL?O2Z-@'+Z9(Y:?RTN'*7?.6X02]SF\]89A[
MFP9: J*VCN:WQ>^]GKK,$_CWE<D=?L+I/YL+5+MP]..@#@LXCQA<<L?(P:FP
MW2.JW31MZF\6,,QV6.Z7'?Z<VJS%H3X+D=S5@:K6MMG/OX^?Z=A4R'UOK$J=
M*4A$Z15ZRT3Z:CY]YZO\ZJOZB]'IY M'!7,EE"U_"IO^X:^"/A@J',(%7KL
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M!7B[;;_U/;6)C2HO/'N$_&J=?CN6),@HXI/.I$74T<N5%'-L8P-'O61V@.M
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MRIE31^4^'S34*<QM<Z!BZ)]H5=F,;:.(<U\*>T]2T4I*DQ*,&D^G. S@X*@
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M \5:%5Y6TP&),^R8+G8R;K?&N%/-]RD9N_>F=%!J1WHT<L\3PD3&2T< F>B
M-T[@5MKU"D2S_.>50XO/22FM35-45"9G]^78B;$#&V&1SNES]]LJ2+T$2=+C
M/8<_3IX8P0!;DC""#\U+T:\:?AO^=C[LZ,Z29J)NEF2IEDTBCZWNPK?U9^VB
M7, ;P.J=EW%!8I0+Y-@CM4;BXUG;(B(""^1$Y0:="[A$_(9[3[GOFRUA"N7-
MGD0H&1+$M1W*QK7>O/;@9U;?%(*[!ITP*:>6T50>'EVIG?#!S7H5_5B;.G^E
MOX+]DOU9+^D*LEKB5B\T=_7B,E3FT7ZJ4DYEJ:U4VT36,7>8?>YW]E^;870
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M<^P\L)6 <!FN1X(;:/UE!WP+<>#;W(R))+^1LS;(.SD@DBPM9)IK<E_HQ)6
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MCW'9U;KIS2MKQBEP1N[\^L\T._,9PR'/(F;15\A;RD+:_N'%2HM*PM8SWQI
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M3P!=5MXH^I-? 98,I$F-@,@DD_B.N=Z_9\*3(E\NO1IUX132E:=_-^Z=8@2
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M:V,^0RL7ZKGR"+&)+)NC8!236&>'F$62"6F5G&E8YP@@H:2+4X]'9!:VHNM
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MQ6<[:&Z/+THL2:-].'$ =80U@BCWQ\0U:(6A[:5QBT<IAO'_?0PC !^SOB:
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MI)+_!H8P7M3;88D)$6R$ZZY99MN#4)+#,)Z?8DSR.@:S[G+*_)+^ <:2,;)
MKN3ZP="2HUFK?9Z7(L^$SE[1JG@$8NZ+!-X$Q@!9BJAO3/5-)'7P$.O.\6,1
M4L\SR-)F4NO+G>.3;JP_T5C)IC0?:LJ6!HB>$%G&_\V:K=LZ:6"<6ZWT+B\3
M%D3S>G^5FL%[(,_#&CN]_<7ZY"STV@UHQ16C\^!HZW$+\B0Y\V?A;>I58'?A
MGX&?GI(#H/?MGS7ZN7:2BW@<KS1+8Y9D/2Z]1EE?XKM&Y).0CWGIZSXI2> !
M_*<5,S+FK\[5)YF]JAT=I8CP.3+>UFTS@/7G1\,>+[;**T]?D[4XB2?/9/"I
M<&?S4H,:.GG736"Q3\YY<!%0-DB_7R_E^@V+ CM2 8H@9W0U^R"1[HS6AEW?
M*JQ=GW3$V]EQ9.N_U"<0=#>%)S@RV3L[K'>[ _$1D!LZ92V,O =B4')0D<)D
M'-;(9 [&5\-N=X+$_8(1E1K5EIMOJJGGS%:5G..%<O56L]YQLN.SKY\I[F3=
M ?#=>[1W0K7%0([+V,?$I,3:\W7U;9.=;H(VLQPNOL5^[LT$I]HMW<T,ABD6
M!W*V,T,0#)?U@&)"(>N2[ZVYVI(B/!2>MTUO9;GVV]B_(QD2[.SFCIYB3OA-
MTFZ_+O;R@S!+)_-C<N65,#KP5"][B"CR+(ZC+6;X<E-D71<(;F3O2<'EU^(:
MSA6QRU0]QG]E&#ZVD[!9H\" W(+N;).Y7"ED.'E4'@9IM_K[^W_A&JLO3G[%
MX8JO8@C 62'Z]C(R@:?HP?]%R5,407< #"_MUVO^&UN43NP?<MQ?8=RS(0]A
M]>SF*,%Z")SM>'A>4#Q44UM6IX-]W(_ DF1NXKB6FN#L@J4((S1(OG: .#L)
M1@GU>V(@\+:.#^YR?B@FZ^:F^1[I"I>NI0^%U#]9B4'*NEJ3B1X*-N)K8KI2
M*\36Q4_BXAKG9;>)#W/3MXF3)49V7-/B//"R?FT#7Q(0<ZE-%U$"W%)TZB4U
MD8691;?08QE'J!/:))= +M$W=3SYL^BS$US7+,!'*0['B-S[SO2 B*<D_/^N
M"B:HV!-1^ GQ"&-;:U#*9+#Y>*DNJ(0WK?2CK#T24 <21=>C4LJ=#I0;!D7>
M1, <.F*!4?ELW9CE_)MW* (V*CGUFO'S(V-3Z5U;?3+%F:"I^3:51&=2:K?9
M]"/"2682N\9*UOSEK\S\@1X@G=[*[-E=G32W+O85WYDUNY$YC>L3+S.YG<SV
M:!-?Q.E%;GM?ZW;2DUZ+(U2[Q@.)%NU*UAY<K HX%Y.UZ$XM5C7GQ(2_E2H]
M2'%V4Z,1$EBY8CD(Y#P6GF1_W*PE2 [(V&Z?TPDA69C$#RB#X%H?7[&-]>X&
MNQ=<JX([5R7S&OACB4+Z71@_<#?]"V2F^&T65'F"#]>6XO>H"_3N?="Q6N)@
M):(A=?"%S<!:Q H[IT#U<[\WY7J(\8V^R7?!+0IP74B=\ 7@M/Q=!^Y'$1G#
M/(\UR(!0*)JP;4K,0EMH5<_*AO;0NU-%<5OV.R#TU"N?L3)ST?V(_/3ICF<'
MQNXO^R_,'<!YF^JMS?DEC1N7 ^L[FQ09:/?A-&\@Q+GOL?E6F9.1J<"_S2<=
MJ3[D%;)$2!8M.#;*H?IAGMF<6V8#8K[9Z=WY@</#]S8+FK ,(J^"089J@5XI
MC-/0"$/=)8@-J(%67SYQN?AJ$#>C"&XP(2LC@3=E6<O_LTS S@QN30A?I_WA
M[!CIH[:*.[%99 2V)753X)E"F6]*/2I=:VM#0"B_5DK0(@=3[[MG]-\\-?Z!
M1W];4=2!:]50(U'BJ3<<5.:!*(YX!6C8TZXU)D@.<T( ;WKGV$ZXFOC<'< =
M/@<_^^&"6!,IEGQQF!%Q-HWO.GCDG;A\SBL-8KJAZ"A1B,-0H,@M4+'Q9:F&
M"Z\GT4Y^[2:( =YFWFZ1I%.WK%$ ;I)C]^\3LR-2)81YW("[U"/%+OEIX. =
MP)[42L!XU)A26>ASALLQ@G=BD/+)[@N\L&??NBY?]F;OL8FR;@*SRBP<'$,:
M7%2I46\I-)>4(>U"+.WUPWU?":>DQ;5^(9C*3)EN/V,J  F2-EXG2]FVXZG?
M?H]C,PNF64W0S+D;,]'7FG4YN_3#VC2W8_A_!W1 )<7II+,G8XIZ<R42$\<B
M-::AJ)?>0^U7=;\@RT+S3F9TYGG,'8<6VT,N<BH5&%S3[/XK_[0J<#&( R2X
M_>XK,%C:W1_*_^:(&&\SZ82AXN9)%\JJ%%D[> $^&E6;OW$0_Z!=;W9H(+;T
MPI+B>BAZ?=\>OUC<HO=,_ XP<TK'_[:X+9"(I9GG*N(-R-5>,=!43?_A*^1K
MS0S*C%,9 X0Z^J8HE!<W2SZVO4T1V0%KAKK43(E-U$W^#7]"U(!J\<7]Y<*>
M;'7^8+*@@8"][<%><KN8'\-^#"2MU[+/OQB8%Z]P_*-T5:GZDO[OY$RE9KS.
MU/AHD?POZ5'.W2+2J>7BR^J2@H) C_I7:0U;,D[B(BH127[4N,S3WV_WL9\8
M. Y<*@G"%6.$E<+)+:YUGY"M_-9V8=H?Q!8\AXL/"T=&G\VT 4CY>"ZQK8.R
M,6XMP?JGAJ!O\@]%C VO-Z]TA='S8Z?=M;O;"8JMHRD]B@AY[ZU!JW9S619-
M$PJ[!'SADK%W[(\LOZ.2SN6G0NT>2.96XK-IPN1\KI^'*&*B:RPVMS%!6_*J
MQSF<76T!'9DKE[:ZX1I_\<47HZO?4MX>=?WY>NCPN4Z>*!G^] <T'9)S(7S[
M10["4=LQQ&3L<49W_"*#X51I/46>7"P*W8=)BI,$ZHU1[\JL#F8Q/+$'G4K#
MOS&-0)!O/S^<M #;#1F8M;P/S=-+G$Z*6 \">?Q@O%"DQ XK4HE]O0/XV%4>
M4:B^':RT&J8]]1E+>X=8A[[-_/W*1./$([?I\I.7J:'V)[H:K0OKJM^-Z^QP
M$F%A[(;A^<9SCZ;OV\$<7AW(FGGL*H2B_EGBC^4%0IJ5KRU1X96-FZ/_+NMD
M[P"K?7"N'+8KIT@_1^F-*3>[',)1.3ZV/1.J&T$43=]IHYPBG)@YN9P,RAM.
M>"#0&EZ4,4T>QN>G1H;NV FB/MP[<U:Z*9F>.$ O8Q+Q:IHPR1R;'W&^Q%:Q
MC%D O/$7WDFRM?<-#4-M,0F<PDDO@/321U]AH9Y>RXUM@7> N%8JX N)*Z%X
M&R.]5 7\][7Y:6F4?^1';7XN<0X=O"7E^+EM/L7^<0O4&F<L/SY"SWP13H:O
MV195AIVX3HF#>6I#B!0Q1/+F>K>="MS*0":51N4N%<^O31].V>^!-RJE!"54
MW0$Z*H=V9OO0"PIOQC1M)RC2B7?.OWUG"05.G)V6O."//)*V>DQCA^]^'-[C
MU.@.9I KO"2Y*B/T:O<B>;-BK)(!3O(:QSY68MA!L_@87S)")GKAO951D/.C
M>]-W /8EP3Z/L[A#)DWQ#&;7K_^.=P"%D)7#CX$UM7> AP\P6>5_@?,@YR5#
MFTISV#O$;>&H]ZU*8%O+H0]A,79KKEZYEDW0>_B *6+E1=E3NT@";OJ381OK
M[<-J]L  H[2;854M2GSX6]F+PAY_6-U#2;3Q!IMA_];6R/]N_-?V>BFB,?&>
M!F<H4("CWJ)HV\J/<B\'Y3>G/IS87T01O]AB?V(7[C4OS[=[/;.F!?<MT3"&
M<Z<PV#$EDIHYN#GA[I'> 8X:V[#/PB9SLT_,KQEON%I_MM5S*V''4D^"&XK2
MX=(TI?9$W0271V!T(T/W'2!2!8S,,5*D!\O/QCRF=S?&[;.[;/C12!59KI9>
MJZGQ;1E:?"[F]=G5XF=F9KE@H<<8\BO$E3Q^BMIMFR+$OM)Q7W&MY?UY*)-T
M34O8/)3ZM3,$9@>&*XIFKM?^\):?/BW\3F6M9'9_'GLBY\#>HH. $(^.CN^M
M;0A;-[R< KIL(]4$7H7V>6#B@8\V=LQ<WF!FY#R\MM>Z^UI%AM&E=X#POG/)
MP I2_^N^';87,]=O;_1?EH6HHTI!#/_\ K&0RJF/"GWEQE!T*:;DHZSDD >S
M6FORL%\UUN(/5@%:$!H%NR=D[,:QH$IN(TP$7%N3]LEGV/S)"5(UD"2 8AEJ
M=G32M_,1BI]^!SB1)(;7KKXHBO<3)QR]YJ/'E4<MM61Y9:F<0-3O  5)Y?DV
M1K-]XV&5W\_#EB!4V>.;*+Y1J;PX5+U./%VATDR'=;V$T%HMO*(X !WL$7<'
M>,R=UFFRLRA8D>'UJ]LPG@/!TD=T*X5<OJ$ZV^F+%D"D;,-.8Z4^V)@AQ[VW
M,=<45\;E&"T8.F*'6.E1=/&O*SE>;]J)::G RXEP8%8EQ?MEY*_MI<F;:;.<
M*<4F[9#C,'NP[.O;VC".(3J-#/B :B>ICU^UC@O30?&F:*/2\H-OI=\5O_P]
M>0Z/-[*F#'%=DN-V'Z*B:>_PJ[+ P8@4R?=>AOX\%XO==_2HKEC.-H_CU=+T
MA;%E;B,J=P(O17G35SG/Y: PMN/F/A*[%)#!Z#9ECTM5 [%V+3AR1RGM=H7]
M?2<:M/BK\!F*<SNREQ6<H=M&9WSAPBB^N?M8[,>4Z"B33)6\M_IW^=I70;5A
M6.-8\57%[O(-9E:HYW*&?NO19&Y%W_*.YX7TY):"9.M]*,;=J%_XK@?/Q&!E
MM"9_R\OLJK@$DE20*ZB:DGQ'3+Q\M&,NS5H -'AS^R6,$]/7W[=&E^N1TL-7
MY1S46NWGX<)2<'Y?6\NC>)NSG.T9=*D.2%. ^0OW/.H,_U#2P'P3G#CH?^ZR
M<@&71/$W24XH^$WOJ.Y(8Y%U?![K:H.2 8]737YOX>?"I4MC]8@;5*MM.6V+
MJFVNE_@?G !8@VU[8X^:LKX496]?_0K%1X=">Y8W^F SJDN0G2KL4^1N5V1C
MY(U+56C"VL0OPC\V9)=?D\?VS*5,'Y<EO:0X-8@D]<!(8HE:@'5JL#R007\O
MQYS?#"53M"47?,FYH=B9\(*<5[=BME/B^ 4^;L+ K +WZK;+^;KR;:9D-E\@
MG#+) E&PXY/_WJE1QZQ;H>.]H_'YVQW<]SC+T(,+8PXDQKBTO#'C_,]9%<2A
MKS5[$_OF+UOT':#]#C"8FBC23Y8-GY(\":#][?M1?J+C-">![U3_W2.']R)J
MRE9E0JSP->FG:>4I2I]\0R<0"Q3]-WP[\A"86N1^^Q)[K$K3_*GXI%[EIN7A
M[&WZ\7<F<)(&/4D1%32L@&^&OQ?OJ)>J':J#A RELH+-M0K]NX&R\GJY\C_*
M381#;C[ VM^_3XJ:\IE\7BSO,C6Z:(VRWK6[392L@S1.7B@JASA<O\*HP5:[
ML&LHHSS;-<A-2.VT9='AX$.\J+&=BRDG#!^Z!^.!8AJ4"6LJQ5P,_I6QJAGF
M/[7OOI8+(*&O-A0!C6\0C%HDW%S,0][/D!ZM*92S?H,+4;J:532G"6P5N7\
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MC+1XH(_1$D;5N T4^P9FRVC')U8QKWMBW)DW7O6E\EAU>PKI>1C)^0AO09.
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M#0F/?_9!U5T#W-&_1LVOBM>F*_:[GL#ZNO^IQ Z?M8O<KP N>O9#W)Q(=3\
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M"7_UVEM8?T1F&'A9(C,-V^X/X'ST$V*NPS2<JA7(%\9S/\=B4]7FR2LF<+-
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M\7/#?Q=^(6L6/Q)UWP;HOBCP6D^O7NFK%<W4FC16.UY+LSC,1F\IHM[H"S(
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M\/">85)#AOW;>_0U1?2([<1M%#/#NRVYG/"@8 SU/UXKA?AM^T;K?C'1I/\
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M=+=?V#IVIW9M]6U&2WU74;&:#R),%I8ELE9Q'NP6;^'!/7?\$E?$?ASX@_\
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MW>:+:M;1/H4U\1 CVTL$#'?(Y9\':246)\#<*\M\*V6D^,O#H\,>$]3U>/\
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M\NC67 [_ .-?I7\(/@+X=UO]E;3)+6QTV\DL?$=X7N+1%\IKB2V@5BQY"L%
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M(DDLC#-J=EHS2:D)F*9:%W($,8"!=F&/7YO7N-3_ ."*_BC6YO['O/&VD_\
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M&.@Y6E@=[NH6=JE":2@3H_@EQKMF>IX93!L,%S80+P#+YU_D(0\X@O\0_TR
MEG+,T;7H,#]^8#><J\V\$!PX:4O^E3-_SOP(Q^;C*G>S_T1 ZQ[TTX_^UC!W
M[4YEFDS"/+Z$E MW'WL+9/=#1J>3)9L)TP6GHIVYUPH4T[9"["W&K9_<Q1B4
M<$I<UVPSWT_(W4W #AN&XLDTV%W6H+!7\OYYKYFS]ZYIOO3]&U3>@*YU>E<A
M[2&:U)-^4[^4/"UQ [.A3SI,W['29[^OZ6RC>0;__/<"X#*)5,@,G4DZ!%&#
M',")R+J,7IO@L]656XF7PJQH=%0^H@@GTSV<X#BQF=LRXM:503-EW\B^F\-&
M0A!M\J /7>97F7=W<$JZU3EJ?I,9IEG+^S$B'WWH=3U+=7ZEI76FA,EBN0/,
M=[]L=B)IT0.R(U]=#D*_VCTP7;\ \&U4^5T ?N\L@^-N'AR# 01K4X-6^D4+
MX:6DT,Y-7"'?&[-&>.YV@JUO46K&Z$\"? E!9#-:,HIJ8RAU1EY7#T) ^6?K
M,55_-.L+%1*B4^1:N/;-1VIRQ9;8+:T%KVA MI,B@90P5JC9902]E^'<6BOE
MUFQ]B7E%$*^%[Y9JB3W<XJHY&EQGL]W@&L[("X!#>\"J$49A&1S? *> WNR@
M(12&7%)(YK\G)^DP@82ZD@IWJYLSBVYZFL)!NMF#/Q\)-G+Q%P_ PW*QANA(
M-"71>P5X98$\<@:.E_]R];)<Z:8]PME\\"6UJ+E877T8N^8)OR-]E<XC>Y-]
M[!G;?)LUV'ODF7SI;14= QMT<?%QZ1D(B^Y,1S(2V>WSYH;E9V;HGPN8*/%5
MV_^BF,JA]C ?@V/UQCA=@=>12YF@*T3M[R_T KX'QG4%.Y:7&*ZEYVR$O$DW
MQ__9':!\EPVX2AU*]R(US6/W8%OOAZ'!0M6WV-O7V<S B5#/ J(<U@RQH@%_
MVCA1IW%UU%WK:7N3>[65=6_$6LK8Z^<F>D?LJZ#: "([*SZ(A&B#+;(37' A
M79IW<#?GVW]/2GJ^:TD5[C]Y^)(A8O"6AY>*,AO%OJFQ-H#M?S&P(M']$O +
MB!H$7ERM#99Z(VYUQ+-7 !@J/0'?#>5Z,3\"+TW#,VFJ,,;R;+]D>*],'VLS
M9^KQE;F@!!$%=QHC2(!C0<Z>\4#:(R;0LG1^L3.(HQ[-6E'4"@^L*DQ/R6__
M>7_QVFNE5'W&D+0K8KU;YP/VL>>Q;^G%OOT7AAA#SAN1&816$',G^'W/\!QZ
MK&+4*D/<K5^2(]DUKA*E.XVH#ZEMZ?Z>3'7I*1KM'^RV$J:JPR*B!TWNT?P5
M8<=N=LD0I&7"B*&%8.T*@E&_V>+-MFE;(/U6L-DG#W0_AYQK(YX'.O/D9]F(
MN,OASPTMGIOY58[:?T+EEHJ); IPER16 O@I5NE=FV_HDI3=2$&N:=.$"4>0
M[8;$&S$K+PZU( Z<!R6EH+.Y7<N77@:@_K@V&\#X_Y]1X)CC04O)X&MD 131
M&W<$8H(!B:Z$!!RP]Y#0T@_D"70=/;)4+Z=R[+[-Y7']'6]-Z@_*1WJK*@<:
M6GCQ"2A\*2N7=AM<Q=P=*F,Y[;XG6>_N^;AJW.WKA-UGRQOZ*CRW7*2%=,P8
M[V3-JKS @"?+Q/A'&?!6I-PC])PNW@,KTZ,A<'9N,@&ER4,YFV4$%!J,])KA
M)!\?N%,$7/^:#9!#M:+$OM[_]]B6V$NMIO>]: JYE /DK\!@-EJ:F@CPR@&V
M.WDNHO;%HU=*N(73.BES(+@L,IWO"L9Z -Z0M&O;D",^U2%G$TBCW3SIQT2G
MR?HG4 /&/2"=G*SGJUF\7N8J8#LF=/(^AFL?J$8)_L7/QBCV+9;*-Y<3)D7P
M75+JX0_HMY69KG@CPTAP'=4GZ3]M$M:&7&&LS78@ VY 5J-!2ZO,<SG;M.N)
MARL?4@;SQC.6.YJ>OUN[#AL>5/ASZ;,?<ITYMTZ7%!. '#3_!:H=YB!0+-D%
MW>K!4Z6A23RJ@%,@^>9M4B9R<V>EF,SK'G !2'&^ $3'PAT1IV>$T@M Y+S-
M!6#-ZIQAU:@73# %TJA;KJ"K.@K_/4HV(:B<E  <AB!J.P].7U7YI\_%+ZUJ
M,$%;_^W26T@(\EQ1^>XG!;1(G<1PX/I*_];.;_MKODAO,8W4$[[V:=Z[7,NS
MGBK*AT--YQY@\P*P<C-WKIP,ZQ"'+S?,PD\YD@C1Q7C7"T N(C:7X%Z/)FM7
M5)B3&;*P2?<G%2!Q"Y0KVJW.P;9?RM$/WP1^0EDO#KC+NPM][Y>G8UIO2_S9
M]?P%L3<_8JL>3I"DZ0ZEGX ,EQ"U!;+P.\.\^EWLY;HE[>5U/I^FC#8H-H3*
M8M@9LP+$7O\3+3?VGYZT^:[D$MGU\;2X](25'02[,YQ%<VSEB\=8G]4"L>,J
M3J2@^&EMI)@[@KJ[%^$QKLWH7*1XCXV%:) ;$DYF@&/'^F9Y%!#OCV0X($JH
M@6BWHQ>V]SFR&.\8E?S^'5H+37P2UT*^6:U3(4.E^E"VI^ 2I-:JP01A3@Q[
M(F@E:HJ&K/65.9M\ ]YE>0%XA0R'+,4ET?X%LM0UD8%_ U1I(C.!41TW4^3G
M&4K_20]<7:"\>LA#:]'JX5N[_S+[+(KX\-FY GQLML^(J(C:OP#<G)T!UDIX
MD+(Z!-*&-'DF:^"8&=4],18L\C^^.7X!8&$CCX /CW'/+@!,#:T7@,'ZO\!&
M,)$M9P<O2\!AT5W^9,JL/N_ '29?F(*0DT!J18FE19[O6AND>9\M,O.1O<@5
MFL5M9I5_SV)\0Z9S;>!QQS7B^HK2RC2_56USJBIEN!E\J6H1\H;6#K-2\KDR
MOH]D+#-]R]C]7Z4AZ'^/3"N0!][E1+X!59G,,? ?ZPL.W?4??]$>'3:QX;TQ
MX//W:X_7W[ESN=*7?>Q?*&6)??X7 "<$05SF/=P5B!+2Q<J\/^(/V46EAP=\
MUR]SM;7)"WO$:I \SQ Z<ML],UO[2UB1Z7L7%4&6'@(K^1H%*1,:LDJBZ4G9
M690?WU?7*]$JM!BK")0PFY1$;3C.L[FKS^SP<+J)_>D1?F<;<QX [])7!YW3
M$>:7]R/VVBAQ:BOFL1VB_%KGG-I8G12!PM";OP?X&J^-MU43RU+#^P/-;G$A
M)"ZC?WZIVQFKL>VZQ#K"R%*]T"Q9M'H2[B$ 6FI 5J%)08$G%P #Q2-&T/)Q
MY@")NQ'S;\,V1A#QHRY1L];B I"O2*H#8=]%70!2R_=<3WOP7RX'C?^;6W,!
MZ&M%T&^CG@3<F)__:QZM4\AGKI2\S9G1<"A_1W8O;7?(P>%E,=4CBML)O90_
M_F^&=]TD,R1@<X:[E3)_+O(3$MAXW-OD;'O?#-M+91FI>\T_7'J1TF$O+HL1
M>9#6_(%8W[Z\3Y T[QYC)\S K_W>ZI!U=Y4R01OJZY>+23IDJK@7M'"^?&$@
M(-5K_"A D?O'1VU_*H 3\R7K^3X#^CN"=&<F"EZBRUK9 8*%/$>FQGD45Z)=
M@55&F 2-"T",NK[]*M.#W4"QPEY4_0=C+8A_C136&266EP!X4%YW_3[CW(EU
M$D':LW/>':Q?ZX1[DU!Z+^,)U@7D;*UL15N$%DR8J_D6^#%%2S55S^9K%=[H
M=RV^LY94I\ZP8G3=Y8Q][YU+'B',_8:8Q][7ILQED\5%O\]MZ8&_:OXP)ZMA
M!FZI "@/H_1)=7"G7.X=U<V>4!D\-ZG\UBR4L]B9HR7Q8W'@J^5I=16("__0
M!&W@,85"PXV0FL3X"L%TF[X:"+J#&]YECB$S$C7'B;>7P;_A^.Y?ZDK+YP^K
M)^MV9**2=:D+Q.Z4E$DC;0O6LE,-/&#]NF2EW',(_#=R"4@2;$<TE[!@Q_XC
M2"47@*@9"/#($=T01;Y^YP)P\#S$G,AFCC^8A"_E@*CJT#RN.< .G$A'_G?1
M5,&&;"T\%/7G3]UHGS5M-:KCT;/X,"\*H;3:RR0:A#)?F\E,K/[NHCI=_OM^
MB4OMEJ]\YNN^/Z[D)Q."=R4>6@@G(%T; )*/!FDH_S-J_Y%1M@.WB.R42Z1Z
M!*I2H<)LTBA93ZI^]TQCRK]Q!K<X;U'_4Y:M-YGT;4]XL1D8>&0"R<(BB!R4
MR\Q]_$Y=#9JT+3-M-J"X^E8;_H2&7$F6+0:? TDE3N:;965ZZ]7Q5RP'[G=U
MRKW]+^;OM$MQ6:0HL/M$MEN=MI(S=4!ZPFI7@"T=3F0@0N$+L"\8ZJ^:\/&(
M15LX>KP@E>*=;**A#S/[_G/L+)'%Z%;?!:!!/Y@\#A/A/KMO)\9R(L5F?"\L
M5N(PH!?) 7)&$,3&,+.XPTX0+4S.DDA[J>J/\#SR-[26LVSL#GO/1D9:#<=\
M/"A84#KFCH.=CGR;ORB/8F.7X*_S<4)D[I/N<EP(F<6?D,8?6]1&Y@L"/LE<
MNJ$^".TSHYB28.]G__QV$# ;>H_Z\J;_OPQXZU^^H -?2D+^#\)P1EN&I %Y
MA#X87N9\]X;$VVWEB! G^$R+1,)O=!7_*>SNNO[HQNUD[LQ[>L^X!3%""'9/
M,D/^!4 ,1OH&WWW<<0'XI0W]B'7<[$'RP&@#;4%'4@:\VG5Z=I]ILMS03MKB
M?U=][HA[#QCW!<_9\K '%9HH/5XX:C]7.,UI, \KCMEX7_"ASI44T)%A4(EW
MR3]BP$-)U77,*-XG;9&\*O+M/KTMMBZ</LPJBM5FG8(<%.]HQ&F%4G[-:A5=
MR@G-\/SY+3R,&EN?D^LQMF9]OW!^@%%DS=+:E8HBX%'9)F7Z4R-!'H)2'P\T
ME5!KA%.?712^3,DT_09%/,_'^EX('UV-((\#JF;P M B_MTF\K7(Q[==>#0U
M>:&XV_Q,.FEUO;8US;1!UGH;!M3S;&M(8!O!EWP$^=4&GC:-_?1_>WNEIEDF
MA+EL<;Z>[#@7::3IX29;E_M[[P+0A.Y%MJ!5YXJ;CT3SEIBI(7?_2,V&J<OY
MX:,%&SXZ3K[TEK\#_-,_9VBFSA0;^,([-LGD4FN&6@45MV%E(O8<6UH-= *R
M#!I3"IJU46G-8KXW2U%\Q$ZO:^)&3(&U!KB&3S)U-H:3IE5N\ +KQS5BRG^]
M?YWS 5V;A6%![F4_83N41%MD1!!/Q=BG4O&JM/>5F7]G"M62* CLA8U9Y.M(
MAA'O5R6:A2P\[LTAD 'Q,9]B1S,S\8)!33M3/IPM]>6JJ<5Q3<.7DN%U3P\L
MY99"#E1&=3KE)A<[WG'L%J][9O E7@M5P2,^7P"6ZAB?D>ENGVN+;0I0(3>3
M]BJH'K3]J=>,)&43+?&@N=7E(PF/ Y;EA#N;_A0CWY_/70"ZW?(^*70H8N&!
MJA> G.,-<"UAH-,H:K\9!F;<>I>A#G!;Z2)> #[Z\?17>.9;#@FGZK:(H8QN
M;SQ"N5V[-\:WDM@ K"M92#%:E8FO8Y+H#LCL1RQ+&%W_Y![/S)=>JL;U)':=
MJX9/MYTE>NTUV^I;W8@==,-8-S/@#P&.R6' 5D0B0S<7K;L%PSF8O2R% [[8
M]8HZ4EAF>9!6,U38UV&BI/("0L[BK?;9XXIGW2A0I%%:P&OA&JM[=AX43D]2
MN9P8?615^N\A.*?;Y"[%N@#A7&O<S8_D,_L$=S6[)35N:*4Y2C_7^XYU:N""
MF-GG%]]JWG&#GQW-.>ISMZZDK9NWVF9@YL%39VW^UD;4$:;B0^K/7 HKFFUQ
MP85^[>=;L*1MYLC<!IH>L(!SPTDZG(JHX/2:D9-'H[R^_:M.P]H0FT44R E^
M]Z#IJ2'6=/-6V232S8B&8-1[RV*R@V/+7[7 '^(@X]XQQC0VEPRHBN&06K2@
M_2KJI?@N46)3)M*6-ZEGD3E1A4&J5^Z',1\C9I3A'SZ,FP?#I*]*IZ2O_@HX
MUNBMIL .3WO[FMDLA]F8_ VD"]MK[RY 6N=JI0K[^#.I[C&6W;\#.KOU3C#.
M6_GZU)B[CP]BW5L[,H]<W'Q V.>Y!+'U#(P$]G I*N(EMNY,/;.X#TV[H-%[
M%H9,Q6U[I=$FO;1;4AKE=7F@S$CK>F:$Q[99 PE22KMR0DZ><VW!Q92S>HV(
M061,:E$N#KZT>V=+I.)8)E;@AJ8;[C3UMZ&?Q?IGJO=IZ0&"-WRK #[!L,I_
MQ=OQ/)SI\O,5_-5\><7BX[[5#VK>V0T9;C0F$DDQ!R@+2:O\*"N?XO:]A0O
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M24UUN5>E,TH":4RG!,>AK(5!F0V(I7DTQJ621XTBJ"3H=H-:5HFM-=:ML?^
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M'V;35_+!0K.WXLU$9&CLO#WC/(-W4[R#O4(_]"$N*EK>1G.U5T L[2G!?<E
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M!(R[M[!S"0X*:I2YLOMDHL:U]A98:URLIJ&QL3%9+ AW.U0L_F74!?U'SNG
M8934GB)L E2K@N5:C(^:5_1TZ!%AFM!@P'TC[/3JC4%90]P\H-J!\$NRGR\U
M7KFEL\.ON&+:<._YAUI6 =.(F0.C-RS+AQ'PA1([3IQYM%RKF'L6!PX>>3!T
M33V\$171$W0)ATO<-V])_CB-$<PTTT5*8@F?$D_-L>E4" G'CVU*?@O]/SP2
M>I<.$KF4-)@$;(+*BP-%PD0VS,U3L$7WC\M_V,F\O>]^[P1_,&\J5S.?^8-2
M2?W+1T^-Q3Q"?H&\S;OA.-M2]W[P<^\S-JX?.RGECLOJK&6RS#4SVG-Y/5*?
M.+QO-M48B[&X#!_]/+7R<3'-5._4\?BB\@??140X3&#<:[DY8LMHK-RS(&YG
MPZN":^R\&?>#J%*QL#.V3YA510%?N\OTNH$I;V7!"]\@U>79H9Y04\YWCC53
M]I,PM/(7[]Q/T@I:?<:.']K95?VE1)ER3?V#ID=;X O<;L90-IS5%CO;YD:.
M1?E>YRMT9=G2'&.HLU/ 9Z]A<=GNQA3QE778**9F_2W*48[!BOBV)SU\,CF6
M0K:R_1*0HH"QM;/I$TB1S D7T?7\(/:QQ*>R$GL;!'*'5S-"3H 7JD'5U))6
M-6+"4H.&T2)*H(\ NXB^</APK+F^!I72@W$Q>.*Y+IDMRP/0P262GO"((T=7
M(-6%E' E#(7''I*/J7DY&$AOGC,EV3D^,%DEO-EGX'YRWPU7EIP5_S_!B"$0
M45.!JI^ZO4$#[ WI_]2V>,2RW_N?  KI\X3;0:HQY!P0P9X&5!K<H0'C_D\"
MK^F*00)A?: ]+SLZH%>8T( _&U*+%TA-A-LT(.D%;H3R(I4&Z.J;/WYF=/];
ME)0HVQ+<A3-JIK#=.^*P]=(X5"ID:65L.7%M;V:,,#^E)[,<NQ)\(BW9^H1O
MC5!BYWR3&S&>D$YL7_J@*4X<[(RT::5VUB=:\U4SW7-BB9$J?+ 0(5817,CC
MHUE&%,:+F1(K<<=HV\EFN>!%"12[4DOF)+;E=^+MOHI$K_ TG4 'KQ?*%*GO
MB"BP4W8,5:J!6+PHS&SXBFHH[&APQZ4;BKIZZ>+C I^3<4=+K>A"R5]TJ5@,
ME-3-S&7NY/LZ<\R5H5/L'^#$2\;NU#L&2JK:Q*5MF94.PT2H_=031$L\IB?[
MG.(M9BG0!:B60=!?[+W[V^C2D]CWGN(E3_U_,2_W]P,_67+_JZ,J]F6RL8/X
M2^M+IR\H4.G*F/MB948O=Y!IK8*_A^?R^*2\4NXP;."'5BBZ& LQ--8&>,@M
M=(3[ ]G[%,]" Z;5*FG &$4+572?:D?W@P.YH_NZ;VG =J8%#=B Y=P&)64Q
MT2DU1I<&(/Z #YZA"9YTMZ 7?42_ V_U>%/8U*CR4'8:(-8:3P,@/^%_NA';
MLU0V>LE%Q"DX.@9S?-[_T>]BD-IO>&]S]DXZ18Q(=Q=Q>HZ@9_ 0%#7:BOR[
MG@;$!X/GE(YU<;M4?6HX#7A*@E-X:TU9E>E@]N-_:.]3_E('8P=;T<4,_-AE
M5PO)E7#&+S!3G%RG'/$F@RYQ>L%0O=ON-"45[C["0W2PT$DUFJQ!G>CV=7X5
MFL:N>VG./F+5/N'W!1*JFP;L777+_KLA1WWCOHP@JFC3G;:=1Q.@ ;^X%^ K
ME"'@\;^MN9N@ V=472%5L(@&'%V+)X9XY=  G=<D-_AB8_R_3>;FR[OD\[M=
M$$:P"^A\D#*F_3LQ:KE3+:8J4VU&ZC/"ZZ5?GI41TY]/I?=*9F([9_G:^6,J
MYMK2!U#T7#@ V5!65DD%,4)=+Y?/HQP7D<I(+==+3>FJSU/9GCUR,)(L\["$
M3CV]_ND\"'<\=Y<:<TB8H &=_B :<-F8!G"63X#_C, ]C<@JQO]V#NM_I;?!
MB>6]XE$Z^!U5K*ZE)L3Q2FU#RR_GUTRQ*>SF9S\UUG^Z'[O:U76)1?U7L56N
M']V0[95)=NZVZHN<<;7NO)6MK=&/D?:$JR;S2RZ,H0/PHA^7\S\QK$KES"PD
M O*[=/\H.=8LYR$'0KZ/8-W]14J#>7-?59&OU?DW-\8[IVJ\^0W=DT@507M4
M';F'*<?X4MGH[>PA2Q'W%[ O1CHQE1 L:&F7<V:.\XP;@0!GE_;"BM6/SSZM
MS-3\:>Y?S?U-&=0D_H8II)+$!7TU!79%36??P=<U%6P</\POLW'C:JF-[B-L
M"?$=\N+E%=\HE/9R:Y*!621P H#2J0$CMRI1#+]%'5R/11TL2)ZU@+<[>RF6
MGO+TA#O 9]5FIF:4HOB?$;VY=;DE.TJ*&ML  ! "KGG_IUEWKDERX7;)FLA'
M-"#W%J46C)NC^W__$WCGEC_GL0)F]M^9$Q-P<K)=,,Z!ROX8K_ZP.M'[0S;S
M[DJ2Q=3+61GNV=M5Z3-.-4TJD5COM?YK_;PRR5S(>T,J&8*ZO)-.!R$,5'99
MC;O.RB-T2]6VU*1:QKE;9\Q%!'RWF'Y:Z\MJ4/KA7M&\S0.MKWXM4<E?2^DT
M]7]^M.Y_5,_4;)W*_M;A2@/!\[\;E.\[ZK\;5-5D/CB'F^4JM?!Z2LIMSD\5
MD>YA>L?FA$O$PU+J.+Q:Y^VRIY_A^$&F@7G#A)B[.U^B@7\<.RDZ*$VXS=D\
M3CR$> +I!9P$&*$->'K-YQQPV>UJA1^@QJ1KU%]V(KB=2*_#]+C"HB!F?AD/
M>^.41%WWLFNA_1+Y(5=)>K#?L+,4.I8_L[5>[GWO^;>X62S?)65FNK8&:2E7
M:!U_]6GX8Q_(C2P7= H;:_]-1G06W8]]C,AN@H1H>L+@HZ>&49UF,)5=D 9<
MPP1E4[M0I^G89)=Q6_@5O-V)['A)2F[;B 0YVRE&O5K*27U )^21/X)&J#'9
MA%8Z5W;KI"<4*2R6G7H[!?ZW'7S 92=(TJ/.'X.W9_'WC=@W+V@@4]D+_\R\
M\T*.=J'9B]R--[0=8B/6KJ<Q#L6LPNQ8F=]H&%%!-Y;!Q_+P&1(-8/WWE-S_
M**EHHH+L<:90,=G:2\0I08/7YR><+!55+"]&/"Z,?M:&)"/5\C_&!.ZW>H9:
MQ!J=_K?ILY6#B+96LXL%1]7*F.A4\088?.OGZ/F6:C9F*_VS5[;')9'?T?GC
MF]S!:_D9;+<U#O_?U&+=C!YT8V3FG[6WSDSMVDSE)-FE2Y;WC3GY1.V*PQRP
MC"52NA$+"2T/3_6+9)- L%_'8&S:MZ!<TY\O8ZT-QLC@DL["V?XB)GU__H)Q
MK%QN/5?8 [?1^2L\<=NG/[+. )J/\:EDOLVMQ?5HLMPBQ8^@32E5+'?O09I,
MNRB;BX#&ISRM@KXIZ N)8;,5I-V&=0^?I&^ %_=%Z&(I5X*"0.'2O]. E8$D
M*MM+^+)#]G<X)3Y]E_JY0FKG/D"$_+]H(J)1:@'%#&]_33[5*H9?T53%Q;_7
M$,PC@LTN&)8?\Z'42C.&M.;N=Z_J^#PV;,AXZ61!R)6E 8K!ST^NDS4=>N '
MSVE [2'UG!F(G*;['R5VJ8N[1*G(#A#O5F"C5X9$E&PMAS)U9W@'31)>KJ^-
M^G7/L3E1Y=J&-XFH50V,K)TL><)]PQ]!E.EM YW9K L(3"<TG$:FR!6%*0;G
M6>3P/IHO?O%U^:7?I="1X5/JOHDG>N&=:QK.=,BA>RU\48E.B_J3&W!(NH=[
M+QE%:_+B1KHXWV"$J*P609TFAN<>X%GB:DH-A&67C9,M9J=9Q>H38L9YKD7Q
M)6U [L &X#7)2*PQ;GB_:ZI1-G^1B%6:,[JG'+@=L6@UL&/MY'Q*SZ1'?O:.
MNE],5NT^B,PGMS8*=S2E'F(%%G9NP5Z7 *3TUG\NTP45Q1_V[/XB+.OBSB3D
MNQ^>W60/*=U(_X0@V&IU"+Z.#!)_9V.=/]#T_E.G=);E;W8I)D2)^Q*<*"W1
M%<](/(-IOTX<;&\5Q[^T>A>XP>UJ=PN%:^SXJB6D)_/\SDW/-HZCV;?QS2[<
MM]!45M)")D,[J+*P,V&Q'&3P\^6<MU8-VJKSP5V>\.;#C_D_.N:EDR/.B5>8
MB7>(WGS$=)?D3^W,XJ.TMG)9$'6[^=(C,GA32ZX@'(.=SY_3][X>X1YP)!&G
ME_%2Y9RD]+M<^<:/?_("X8"G8A-GJ";KV[OC?-JC]C\]',8/\#<^6UA'!W7Y
M'$6F_LHP]UU95HHF65$G85R4:$V&+0B7AJ?2RBN1*#&SB '.&CL[ [%W<?R7
M^C!B-S8^ J>[PDUNL_2KK6\'X^@"V8G>:?VPD5>HMP<96S+6W5D"^(PMOD"K
MEM5]3(VQZQW^LKW&BT>_LV7,+S<,,VO2]>W;9?!*&FPXFW >#3\P#8?%D/V)
MH5^)351V5I*BI>NKJ:1BB*N=(+[+?*H.F3!T*_KSP1?IHC(KA<[3UX6*#Y2.
MZ 2/I0?>+T_)!&]?K:!SYE(VAN+_+T<S4& :X.I])#<O3>=_^S3@:SGLC?DZ
M#<#*T$D(J3O[+Q5^P%-:6'^&\ID>TPL:$G0.B"(9;NUN$ED(#G3@?8/+IL#H
M_U=!H(HGZ!I=ZOK_>1/K#9BH;5#$2$>@29!9K^Z$?_<LX76(&<% W?PH KO7
M>[ZLWB;AG:KH&86$=50EJH<&",!^T@!V4;QSE(;*(HK#<O--729S6ME0\?UV
M\415#8S\S-DO7Z60 7>%EH6(V=CBI3EK'>*^+T=6>8EE1YWRMEC8CMY/(96;
M)LSN ]0+[JE4H2E%&16C"25V837!7R;JUJ^+Q<(9'K #;Y89$_5Z596@;V!Q
MQMH\__VD/C.GTF5;D%:CBURMI_RPXZ,UU9U$9;970MQG;FWI7#4+2AY-'FUS
M=%0]S:G% :C]%^,FYG]9(8,8L@B=X5[5P\$I2:4@BMR$),.>W__];!>DQ^C_
M?KBE1#!9;-WZ?S&'!<E(_5^,LI3D7.D^;VSYQE@;BB*YS<)^(D$U*IVWK!=O
MQ02*,.$>=)KB;3],YM1F=+LJ#GH1;NALWE54[@GN_8S+^=@9^2S?A6&336J_
M=!'3X3T; #EG-4O,M=CS@)HN"8A/RI9IW&'LI\>WL4M%OH5I@B!6[?6TOCO_
M[<W'3YCL[G#9[T!P#PW9">]Q\>'>9:WRVNY!2+66U9%9)0Y'+R6IH!]F'9(Y
M<>>#TAFN-ZJG/Q'EF>46NR;*,F8G1]<C1D_H_J@//V" I&!P=VD 43+@+4Z.
MRLJ%,[_;A/..4_IPD'DE:"75L!:9J*H"L16JV/B4,%XD#*L]3EY:S&;['^0?
M+TAEO;JH.X%:R  SS:C_*=OQ>CF8X%5_M&[_6E,K*Z.^AU/<6?CF9L>>*A5O
M"Z4!=S>(YI*=3C?3QKJ5$V,GTZWF9(L/P;>QJ(7:[#,(_X#*R XPU_-Z,W\&
MDB: 0(HN-F,+U\SL.(V)Z!"<.I7-%S>R[!WM^1*D;H(;+B_ZFM@A['1ST7K!
M'"R6VQ@A?+W[X2NG5B5\:CL)Q+T)P6N,!Y:Y#,1[4^-&$_,?*B^K,L:%Z%<P
MCQ.LX]!F)-FD,GW[ZU$7W0/E%*:/O&S.WC0S&V;[?K%'8<ONM\^1O][?M\@,
M\NO \9;XTO*V&C'#$O.DW1^IWM7>D)I6W>T(%\3@(&1689EO.V.IGUL]#U_X
M3LPI,\?9O6"WX8F#\NA7@5/"W]6\^ADVLB- .#,0$_1>E=,%NYPU:U32#60]
MTE$.Z?-+_*63&>AEZ/[9V\-2/TJ3IV)X+*R,0\RW9H\WH79RD;XOG?MYAE:K
M:4";;;9N+3JK=](4AR2?U:7J1?8B2')9RG0!BK>C_K>WK99:;%MM;EE4&^#R
M+]@JVWY?-8#]_<0EHOQ=O:_=A /Z[^43CRBYY!NX]06)7E9$A<3'>6@0_M/'
M/#WY#FN<0_^S\UZ'-ROX[KO.S'X!3P=UC;W,KYC1C-Q04M;GE9Q.2S;5T9<
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M.4X@O0[(6MRON_DMH5,_J6=U6:D3>IM23F4B6AM/RI"M<2G#&"H7\4.]_)\
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M1.7"7'#U^W,<_VM]3_;TN8NZOXCJUJX:2XU#RNV*Y6KS4_(]ZBY3XM*!-]@
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MS-,$BX!) 6.9Z=BI2!DM"=<!5"&/,4]Y*+"+H!F:X*E)J\]KM<C0, /8'C=
M?-<_.T9@#;[<=L)P2HLX]$7NQ[<O9\ PTZQB>U5SIQTK]T+_/ -OEZS4V]NH
MO-HW"_9X\B=SQP+>I^ >G.91I?]8*W!\A(PV;[]SZ,VJ%,7]\N6F+,52'6]J
M:U2$Z=&KNR4WORX,-2?J5QHK739+ BA2K X8&F)(0G74B!A3EB=QDI#0Y8#I
M3<G43HZ&$=!R O9H!V3)P3YK;L=(_]6R.Q]&68.!!?]Y^!LN=O@W?(!&TQY4
MX[X95I]BO3\QH\KKFS$[%L2W#]A3PA9+?>]KC(AW!:'%HEC_:.^&7VW$?PE2
M?OFVFO,L0[$,!<0DSB&*<0)SEJD5S!'6R7DDRYT<DI;S3DUZZKQ&1Z%H";"E
M"/0/V] "KZ:X]AW,P);H6:OQ5C.@" >:<J!(]RC7W+#R*L4LIQY79KGA<2*A
M'+_>]QJX'KD052T+U_,P2#.$0P1EK-,?&,U@GLH YAE)<DSCG*;!?+W-&[.X
MO3N>PDG*7,B#\QKCK^< K"8.+';TNMYLGF!I>[]Y"T)#.R-WQ,T:-<KK#><E
MUOW><Y[,,O)MYR4N3^\\+S[9;X/_NBQK&_'O)HGJA5@*6:RKN8RR7 0\AI%$
M$40\2"')90)%0#,29RD*\M1%P;@PS]04BGTRP9I\![0AU&VK7T*5A$0B3C(H
M@S169C 3,(^S #)&)<)Q@!))YD]'^?AC8'L\YT@(ZU3+EMR9^NF^6"Z+Y3UX
M01;NB:N70(^DR%F$U*Z/DQ"BB&I=F4902(E3S%-&:=B WB:2CP?Y^2SYD0!7
MDWM'V^Y(\X#?P.?:1=C\'6Y70/!YPEV::M1C[@J_QV?=M<=[WJ7M'/K:E'^_
M6I+=)_MV_B_BD8IRGH<DQ2EB,.>80I0I$9*'@8 Q#4F$41#BR,ESZ3C_U [(
MEZN%XF95DG7Q5>S?CAAGV?[O']8/H@3K![($AU_Z[=7JD11+QQ!KUW6SO.,:
M;C4&ED]C+(3[S54_.+U>1#F2,.Z]4C]\3JZ)>@[3.SA2Z2KK'Q_5^[=6T[W^
MVZ9XTC.]^/%%C6@2^8,X39,H#2#'6:;,A91 2G$$.<]X)A,NHL2J)H+#G%.3
MC"W),V"(-MMP2_8,:+*=JB:XP&\G[#R#.K" \X!GGPA)6X0\1TE>G7;L2$E;
M',Y$2UI_M9\\.BWQ<EP%YN6#%H9OEW4NQSS-J1 B%Y %@5+A9)A"G*<"9I)0
M%"=IR&CLEHCA2H++MAHG6>.]6 -F: 3%$GR]M6B4\YK82:PA<1Y8?)VI'#4#
MIS6F]H**?GHEZI_^, ,U._X$6U\@?4HY9QI&%7E]$3J6?[W'Z2<,WXMO=XSI
M@8KEO9*]2_4CJS7#^F;Z.+:#1BSD:91"%#"L[%F.E&4;*F&("2:,I G.G&+*
M70F8FMJFP_B7Z\4/<,=73SIU9<<-^+Q62@<I>?4OH'YL_X^'O+J)2^=5LQ.7
M0Z[%P.)2D7X9W-DH@3=]T?,I(YUI&%5&]D7H6$;V'J=G!01E":L!N1'+.DK_
MBY+ ?WE8+18_/GQ;"OYY0ZN"%Z3\\9'H*S7]85D]%$]OETH"B6K]6DK!=&V&
M6G17NKIOL11OU^*QF@M*,,(H@RP/(XAT=9L\$0D,:1S3@.) <N941&%(:J<F
M?=^3]:8TN;$O-I4BLG(4I,,NK9W4G<R"#>YQW.-39Q]55>U5K'D%AEFPXU:'
M%)F(B2W#H.5X!AJ>359TS?4,:)OD-\TY,*S[+"<QQA)YK4@Q*,'C%K48 _N3
MNABC3.IV''%1S)N@C3=%Q<A"AVB]7O)79"WF*-;E((B$/,HB72PBAI1R!L,X
M2&1&.<[L'*A=DTQ-^#=T@IK0.N10D0HTK7;'0">DW=+;%U!#"]T^&%G+1QL0
M=F*M:N5:)=@?[U=??U9?KT6:^N%8DG4./8H LF&NE1M6S]Y>6Z*MZZ7$RNKQ
M<;4T>8-S&7"<YFD,1<P(1%$B(.8RA$RF24@8)QCSOM4ESLXX-4%P6 6ATB2"
M2DEH5A9/G:EU/0&WOB[Q!^/PER5["&[K^6GMRM +#,'#E)+HQ&:H8A+G)WVV
M<A*=&'05E.C^8L\0%\;*C>"GL:)WM%J7A*WG":59EDL&!=.%_[@@D!)"881Y
MFM(P()Q*IZ"6:S-.3>(T!(-ST<O@MY9JUQ"5J[A;!J7X1'-@P7,KD.XA)K;@
M> TJN3KIN&$DMAB<!(Y8?[&?Y/DDGK9U3#^+9;$J=373.8YR+GDF(,$Z922*
M&<RSD,-8I@1APM,\<7*1G9]F:C)F2Z4^ABM#IOH/V^C[O^5J[9H^<@%;.Y%R
M.V(#RY$=@1JMFD13G-B?Y.C&P*>XN##3J#*BF]MCP7#E:7='Q^OENEC_N.-<
MO235QU6U)HO_KWAZN>)BGI,DRSB)8)2'$J( (XCS3-<I%R@*<8I(%MNZ.BY/
M,S5I4%,*&E+UC98F%BAJ@2;7WM_1@>QUCX<?O :6!7VA<G)[7$?B!L='Q^"C
MN3ZN,[CO_+!X>L#:5=KHT9:0X$?](G35X8!'4.:I4AQX1B$)X@2*.,CC))<H
MY5:BP@<QDQ,H?]OH77+80P(\*5;JOL#"_'V RE.7%LO2N!EI"8:V>W9LZ&*G
M.T: YD3'U#6\S&K7"ZC9F0W6:\$'KJ,7A+I$S_2*/5U!KE<AIVMC]A.XIC[4
MB^/Z4'LI R]^[!YI"@;<?2,E_V!\K=6'S5JWS-:9@>\W)I6&QQFE(D%0I$FF
M(QP85*I: I.<T  E<4HP<I'"WBF<FFANZ 2K':'@)R42*LU5]0<WF>Q_/>T$
M];.NTL#2>[_2WSYW!WE3],?YBH":QQEHN%0_[/B<@9I3?U)]L$7P*>K]$SFJ
M_!\,X^-#8;B)>IX4NP/HU:;4H7@F)=U4"GPOOIF_5'.$:1 B&4$>B$29ZQ&!
M>9A+&*2Y# 3EL?H_)^EO,^O4)/K^C1JK;]3J:TK3(G/OJA+<W9?"+*:CE+=:
M"TO)[1OAH:7QGH(,:HI!37+=@%OHT+!O]0,>-68GF+S*2ZN)QY6!+EB<R#6G
M+]_>C^@-8:;:U2_D>_&X>7QA6O6H:95>K?ZR_C'/TDCRF"4PIH) E)$4$LP3
M&&!$LB2E298Z9:.Z3#XUR=70V30T4H3V;\=S%7<[\304F@-+J7<'37Q 2_D,
MM AOB0<M]<-T^K'%;*A.0%?G?[9.0;;(='42LA[#8X'/7Y5.5YE\",%??V>B
MJMK,U2A (M&EHD(ES5 F0ICG,H-YS(.0Q%DB<^+6+]=I?JO=-VH'71W*^R?0
MM(DV::L"D*VOQ4,IT(M+82?;_,/[W&5!]XD'-?7>LU-[H39X@="+!#Q_F=!K
MV%@5"[TZB.=R(>_%>AXG-)4XIC#(=!UXGB!(S9(@GH5IED5A[N1*[)IL:II8
M2ZNI9"%VE2R6PE%P=2)L)Z=\X3:P6+I2 ^1]!W+^:G_L03)*T0\]WS2J?>QQ
M;EWF8_\[;@)DQ>Z7.G'GJQJWH NA(U#>K[Z:$D8*0]P4]I(9SQ,1!S"*$P91
M3&*((X0@HI$(*):"I%;!9';334V([!$,WJ_6 D#0$@TTU7:2Q!+J;EGB'\"!
MI<D^=J;O_3ZUX+>:7LN87TL$^8IM]*XPGMX1D3R8=SA$=R;OMX>"/0!&EH *
M(+[7I67JWJ $5$^"%;+0<8_&;ZW-:+)<F;IT)B)2!S*0-5 ?@%7M1E5/Z-]T
M=(-^OC2_/:P62HS,S*CB.WE\6BA=E6[6.IP2+(K'HFX].C,/"Q/1\OOJP%\[
MJT<T%_0'^^:/MQ\D;JM8'R7Z.^: "*/F>+ <990#PHVC]HAP_%;O'(?-XV:A
M34Y3WU#?J)3B02RKXJMXNU1K+IHMB)B(I4ZE9%FN2]/%$<0B36'&4818F)!
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M\Y#S,(@$%"A39T7* H@E5JH[T_W2F QC:M6 Y_SP4U/1F]Q70R)H:'3-#3Z
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M% FDDB80!;&$).8YY'&6<Q)&D1(=+J*A'QE3DQPM%X#4;&Q#B8XZ8.^'%D%
M-5/&U. U6_W#C7JN9IPG$:7*:@^D6D.4"PYUAW*8I"A/=<G12*1S-21=36<]
M]\D9;D6;\*5-90IY*:M\P3:+.D)U*6I=4SO&MLMKBGA/84GMCI[AEVG@DVF[
MXQH.0,V"WG&GD6<S\&*[+@TK_DZOVZ#T>;CUI&34L^\VM(Z/QAM'ZWG[M"!5
M]4'^A>B@W_6'\I.FX?5W4;*B$A_+@HGM'ZOFKU4XEX0$+$HI)"'*=8=P#$G
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MJ=K9)!:0TC2! <YH'LD@4CO>K0#AP?A3V]9-(3U#(VB)=*TV>(A@]Z;V@,O
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M%**<,DCSF$"N4\L$B6@HK:JL79I@:N=62R.HB6PZJ-N?6&=!O'Y<W0K-P%+
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M_4Z]4ZF1JF:,,A$+G7J5)#H.6V*( Q9!PGE.$<\8$U9'C1YEFAHS=&]_&KT
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M'$8TR6@82RSC=+9:KLC<CO?6+3L1VKK] 0_D=1\-=^G;,=<HL!8P.]+I!</
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MUK6L=F&JM,BZJD>Q=+R+<QT'RZNZ =$=^B:O(_IOH!;>++]7C6N?4> *;%0
M7T_B[G[=UQ,\K[>!KC*,>UG8$Z&]N\2^[?2)QBV73 A>?5#:-/69VMJ;U6?R
MJWA\?FPBS;,(H2@.,ABPE$)$!=%9J7(8YWF29)+P'%E%,+AU.S6":P4'6G+0
MB+ZNMUOIG!I&>E"+[Q(":CT2%IOC0? =_(+Q]:%U":H= N*Q8FD]0>T8VNJ*
MV.F(5NO61@QD==5P.W[5^>T+*X=\$:M-ED/C![C)$E/7X^.WBZ_:;"J5Y?66
M5$7UQV))*U'^T,EC3*$^]6<%C'K'?+([B990)!.<9P)F<2P@2F(*J9!"+QR"
M$4%E%CN5$1U-\JDM.]WL6>66W":X0T$A*O!V/9/;G*LOX+%!0QN]G?JESU5]
M)_%#?1XQJ(K[A;*:F7[UN0.3LET53HXWU.-]77:;_DE^,P,OI9OZ+"8E..@D
MF*V#?MZL5?^]K:?*@;896O6!T?\*=!&HJZV";0P&S1TV^M@-4CUF<.%?IP#-
M6&-RM(;-: +T](,2JQM2/:A5_4?!!7_[\D<E^,?%^BKQFBFY31;$==!SB#"-
MD*0P3=, HC"+(,540"D$"0.&U2^<BG6YBS"UA4^+#^1\^;,"^E/L^$^1M>R.
M'E3NPV*WT P+]L KAEXE#-:M^+IBZQNM@=H$_-YQQ-IH,4AP>W\0O;IKN4LQ
MKA]7;Y3V'+SZM]23%77Z2;'V*%LNJIDD.9)!0B$F@D$D)8)YPG*H_B5I2,.<
MADY.[/M=3(W5:@GUUOVMWHF+$UD.;4&TY*B+H!F:@]:H;,13V\LA-I;'<?!*
M(_N]C$L31[7<HX'C3U[HX/G^EZZL+*H92T46\XCK##AJE@N6JKU-G$#)U/2G
M64RXS%T\F?9ZF*9'TV;#(AHY>WI=KH&TF^D7P3/P1-_L)MZ?PZ2_3^2NWH,X
M/:X[>1VOQET=C[HM[CW8<_%>+M;?\\<%6SZ*IN'U5CF(\C @NB YX1%$1*_E
M.0IAFK$\BJ) QK&3G_;9'J>VM-\:7Y/"B K>-'/>T=/Z/,R6J[U/\(9>_#NR
M@H\-?(VXOP]C:MBBXW5+<+;3<7<(MACL;1BL7^QQ*?VI8*:I-MOJW7*E?:S(
M_&;Y^*@O1,C\<S'7Y506XHZ\Z$=F/ _C**84ABG.(6)!!DD4YC! N=1QL2EA
M5B4W^@HP-1Y:BVR\TFJ9P6,K-'BJI7:X1.TS*!8WU0-#/3!K-=)OBO_H@I$M
M\!L-P%H%<#<*\ [WV ,/P$@WVOX'PNUN^P(43]YR]VEWO/ON"[3>NOF^I!VW
M]86+8O;>^.O^3<SG_W>Q_+GX)DBEVN4?C0?P+,\R&8:!A&DN$$2)(! SB2$F
M,LMU5:= 6F5N/MO3U%:,6EB@I85_U^*"5EY0"VS'6><1/KTJ>,5M8/KO#YDU
MNUC#L=FE5NTVM1+L+_?+'_^FVJAWJ.J'W8WI^?9'H1-K-5O>L'^AGZG[_I?>
MVCX7U8-FFUNI?<V_JZ;>+76PWTQD'$6,QY"'7+%$3!FD)$\A89RPE#,48NYB
MYY[N;G)4L26M/K&M"_9HB<&?M<R682V6>-L9O/Y0')HX+@+0V=2UP\6GG7NF
MQU&-7#OM=RU<R[<&*"KYQX(7%=..?H*__\74HXUW:I+1'-.8:_> %"*4<4AR
MQ3P!R6*&422"4,X6XEYG=+&CG5YR6,TC7,^CKC0#[OZ5;/\'-,5;&Q<WPO_G
MN5K9VUJ7#8T=/PT']W2*2G;5 +4>WMR(O> X6E7)HX),IZ[D.:R<*DN>;:P?
M5WX5S6%559/P3/(X"R1)]1V#/NJ+!,11BF$B0FT\TX!(XD:#NUU,C^$V$K:;
M!3=6VP/1CK!Z 3,.%SD@XLPOQ]3V21U[?8S*"L<TW)WP1Y_K:5614B=*J=I4
M<]HIDUTO^+MB_JPFT8QE'$N14RB"1$UM$6%(I8PA02S(4Q3AB%G5U+#L;VIV
ME?;"FR^K:I.BLBX6L DK!Q!0K8.I'\5K+2Y.;'EN5"R-+W]8#VU]-9)NTE5>
M&7_W&M5&7H_6EQTP7LVO,UV.:W_9Z;]G@%F^UH^)FE"92C7X56=SZN;NU2F<
M9CA"N<0X5,860HJ*U'Z#I%PG8A(BR7*.J'0ZX3G7X=2XJ)6W6[CZRJ25<R.7
MLT#;L8M/^ :FES5RFDUJ8;L9N*\\9X&S1<8GOYSM<U2"L45@EV&LW[NPS'5M
M!MTN/I/R[V)E8E<^+,L/1!%9*>HB,>+&+/(FR/]V<5>*SZ*\%^6'8D$63(G3
MBCI#">*(*1YB 5:T1 2"-.<!S$C(H@3%21S95QT;2,BI4=E.Z>"F"M,"/!I5
MF_,BG>I'UMJV!9G$]M9+_?!4"OAHE :RU1K\;.>[WH<]K?NRW(0-^K6<YM:I
M? ,#\_%V">]:1W"[ )^[PZ_T!(VBX'M=.TV 6M<FPXIZ0ZD+:WW!6N$VZ-;2
MKW?0X>Y9$_R5AGTDUY"/QH)Z(HL7,[^KS>Q6/Y FU5>;!NSD")LG-HG%ZC(C
M>Q:::K7.458]J_]IFB^J.DW87)EKST_ZV<T??U-_:^+\6S',7UM>,5G&%FLE
M5+?SN4Y^MJ3SXKXM(*?,]$[F,LU5@J@VN/JUDF;>--D27*&3E2EY%L\FE&[1
MDJ+XQS.9F^:V*%,WO$66S>]TC;IY\4.8<@LU&ES4-=&UGE7=N!*L)*9(2UV*
MO7FY"]H0U=,'^*JM2ZS[[/MUZK /@-[18NU#]-4S-89I3VR?:S<>1]6[9S&3
M$1>1(!C&.>7:*DQ@'J>)+I\7\8 %*<N12Q3+N0Z=ME)C!;4X)H0XAZF= >@3
MJ8$W'(VH!R['&GFO@!+88YH$2VB\9C<XU^>X20DL$=C+)6#[7M^BG'3UKJC8
M?*FS$:RC-]*,QDB2"(82I1!E80YSE">0DRS%.$KC(,G<:G >ZF9J5IA)?KL1
MTR:FPP54.Q:Y'*J!N:,'2CV*:9X"P6_MS(,]C5PJ\Y2V^Y4Q3S[=/Y&XX-><
MFTJ_9%Y7B_NND*[T?OVK,'GOOY?%O=K3S$@:)RG# A*N]QAY',&<\1RRC(5)
MCM1?L%69I%Z]3XTUML]N?BSGRF2$/]LZ&VWUDST#@QRY/EL]Z.S/M:KJ_;+6
MO7ZL 0J0-5*M4=/_8,=Y\"U.;(8<TH'9;2TZV,@.VBJ5:_%!(S]H%!@2;_><
MZ8/@/F(5^GW3_N)912KPC^?EJLXAIEO\0BI._@%NR%.A@^";DS;99%>715GI
M'.REV/3!R4L%BL='P0NR$O,7]?!\7F=\-X<%BH_KQU;BY%D-J4S#]7>T6JYG
M^(GI[3DKN_/W89.HW;[1T7.W.^M[*)V[>R-]=^1MPK"/"[6TFSGWM:C^?OVK
MJ&:)B"*9!,JD#W1-ZI1*B'G&8!2%*$ZEMO:=O$].=3:U=;:3(G CK-I]*E&=
M]^<G(+;=I?L!;O"]>@_,>NS6SX/A=\]^HK^1=^[G-=_?OUN\T[,Z1).$]5;J
ME%G7"Z[_HQ.T_R!S?5ZPDYXTIWD6!A&'/-&ENZ*,0!Q%&)(<2\23C KLQ"9N
MW4^-7[H9;$VB.>T<87[HJ.!8)<)M/.RH9SB4!R8C*X 'S=;:#SJO]2'<)!BW
M.D0O=/9J0_1KI1_A?5RP4F^]WHGZOQ\7^Z4IOJIM^H=E^9.4?(8CSFB22<B0
MKD8O"55D)U)].2)D+BAEW.E<T['_J5%>*SYXTRKPNZX&=:B4BQOQN8Z+'?,-
MB/; U.< -/A3JP :'3R27T_T?+*?JPBCTE]/?';YKV\S?:U%*<I2\._DE\DO
M76TBGY95=4/*\D76'55?EJMOS_1_!%M]7[[_]534:11GDDME3(8QI"A4E(B3
M&!),,A@S%D8DCAAUJUM]L413(\E-**$)?&!=#:Y,N;VJ5D(?YHBU&JXFZ:7C
M:&NWCC@Z@QNWM2Y *5-7#:BV C_U:-ULCY;2"7S;C-;[\Z/5PQCVA+!?B_E2
MH48VJSUAN&][^VJX]WYU^2B^K<C*9!'ZI+\FU6J30D(F>4QE%D 1YA(B?>%.
M<2!A0JB,8I)QFC@%=)SL;6HTVV147$L+6G%[INLX#;7UAM,/@,-O+_MBUV<;
M>1X3SYO&$QV.O44\K_N!#:'%2VY\4I6KV5==5M@<62L+%@=9A""/=&;)@%*(
M0T4>&$=,"$9C(JVV<%NM3HT?-(!%M2J8OJVKBZ<X7P!LPW:: WJ#,?0I6C\<
MK.?Y0;U/S&?U?&<NJW_MSN/M!D>9KP=U:.?EX3]>DB6GZZ/WKDDP\55-]QG*
MU-RC,=+EY*A:T%,!L2 $,HES3B,9IVGDLJ"?[FYJ,_;C0O4B*E-?68 WI *D
MO=IW#/\^ [/=8NX/O(%G>)O#9L=)MY56ETWVZ)IK!XO_E#1'>WR%W#/GM#^<
M9.;L6Q<6IC -_ZUQ>;FN/5ZZ_32.9[,DS=(@I@A&/(\4RS .21CE4** Q$F(
M.:-.)SBN DR-=UJ)8>LEU";],43TK_^21V'T[YM4[L9WHV_-"]LQLJ.H(9$?
MF+3V$FZUTH-&_&W^N@*-"@/4U7 $;Y"R&[8RO$Y5#D>$CA;M<&VGIU=#DUM#
M\)OEHT[A;^RG:QU.=6_VOF]?-H\TH1'7^@SG]LD4"NK$S*LM25DLJH*9$"Z=
M29ER&@20Q;JNEP@$)%&L3*@X#PFE*&7(Z3IP,$FG1K&-O-N9-XI6Y#H$T]%5
M8K!!MO2JF,+0#6TZ:@4@U1J KI:@HZ:NJMA]KE$5&%WU\;K1]FH[7<A:X[JD
MKT>'C:%'Q:MOQV#"CNL&,C3F>QXC@W?8(R:FMU#7SZOEHWJ8M1?!'Q>-N_#R
MK3"!PIN D1G*XUCB4$(BL53+CD@A#?($YA@EC* <!Y%5*O_Q1)[:2K2675>T
MJGTLBD4;%;-:ZBP$=2J%_A$RXWP*IY>I:0[P]->KS>>Q=L'YN&CB>706E;>B
M3J2RMD<4 I/[-!PB@";WB8P4-C2U3\4M+F?443L9S#..).-% (V*[%;8T+@]
MO[IEW?7F3&,IU;XF@RE3NV24\@B21&"8YVD0!"2/0IG-?HB2+E_!L.[I(-H5
M=S@:^[).W50/^:O9T-WA1!A+&L0,"LE2B!@A,&<BA%D:",[B4"8B?Z53D@G[
M5I_.T]54K7=TJQYH@$<_(9FFD_9 QR.#.70/.R 3/1EY-??P8=$>\$S$G[.Y
MSF]=W<IK9@[X5=-WRWG!7NK_[805Q@++C(50+1<8HIAD$.>80IFG*(@2E'.&
M7=8+NVZGQO]&:KV2W]5%?WHXA5OB;4??_E$<F([7 &Y$UB53M;C@S^:_@T0)
MNB'EDR<M>QZ5]]S0V.4QQ[=[FC&M;^6M;+9:9'ZWK$RRAG7VK01E7 9<PC /
M HBR $.:RA"2."+*+D$L%$Z^6#:=3HV3-@[":EJMI0:MV+T3GED-@.4NTS.L
M0^\9+T?4?=_G )'779Q-O^/NR1R0V-MAN;SK([GB9L%FE$:QY!1&(E$&-55H
MYVDH(:4DB;C,$$IH_^R*D]T1N=<$.P:@'95X@&5@]MA+I3C(?N8,#L-E4WRE
M'<L9?4_G4_2U)_DO4A8ZTX%QD;I95KHV:ARDDB,8R8#HW ,<XIA)2$@:*TLI
MSQW=-/=ZF-I\;P4$;7ZSRG'Z[V-H-_$O0F;@*;\&I7&3O#F%BO-4/ZJYSTF^
MW\FHT_NHCKL3^_B#_:9T)\%[?3I__;QZ6);%_PH^"V(2LY@FD(<1A2B)0D@%
MYS!@& N:\1Q1IS/R$WU-;9K?=/(L7K6>%V0MKG&\J'_K&/5Q"F\[(O"$XL"4
MT*WA<M5>.&\D]<<.%G#XY(E3W8W*&!9Z[W*'S2L]O,J^+'\(?<.G$,MUH4#!
MUO_\LER)ZK/YYXP(JMY%(60\$<I X!E4ID$ A6!9&N6"X]C>+<RNSZFQ2BOU
MO_Y+F ;_KH6M2U\VT@/SFX66W\%=QQ+^T^0R$*@#D\P!/*_W\#2B@S]KX2W/
M@%R =7!D\@_P2)Y(]D![<AYR0^JD]X]E4^.Y[[CIMN5_X_AJ'S(WSAJWLED@
M[DLA>%,+Z*XLEN7W97W_KWZW^"'4_JBL9@'/TB 5"<24,HCB((<XC!E,XBC/
M$HY#;A>JWU> R='\;JTR8K385$#K)MQ^TDKI/YEJ7[5OA?/NLO?0V:P*PP[(
MT$O$CO,1N%Z/15UL\*[%O_%KT7]H]1@8?)>58]A!&&L9.3<Q#DT&_<=6)U\Y
MXR^ \_1:TZ/=$1>>_EIOKT(7M'/Q9:C.O/IAOOQ9K>_@ I&E1*0)9'&20Q3&
M.L,4CJ#Z&B..41*(V"G#U*G.IK;4;%W5F;3#1EP?EY[[0#M?=EX$WYB7G&[(
M77*Y>122@2XU]_M[K<O,HYJ?N,0\_HX;CW!1S-[K0K O-ZK=DLP_+KCX]7_%
MRTQ0'.:$!3!-4@Y1EE)(:9S!3,0DD[GZ+;.ZMCS:P]08HQ82-%("(R90<MKQ
MQ'$@3Y.#%W@&9@1G9*QYX*SVF\E?M;._$NPO]\L?_Z;>K2>^^F%WOA]O=Y1)
M?E:M=F:??[#?MJ M&?EA67Y=OI#YJA#5C 9<*"UR2*6R01'G$A+!8AC0'*>I
M%%2XI4,_U,G4)G4MV(LN1VUD=5OT#\)HM]A?"L[ 4[H5S]3 6@OH;V$_I;[/
M!?U@/Z,NY*<TW5W 3S[;=^%^K\W!8G'_'^7RY^KAIJ[*/HMHD@2$<!C$4NW]
M(Q%"3'D" Q8&ZO\Y3@,KM^PS_4QMOC=+52LKJ(4%C;2N2_EA:&T7](L!&V=9
M=\6JQ^)^$HF+E_C#K8^\T)]4<7^Y/_WX!<?3BEI4T^\?G^;+%R&JOQ6KAS8,
M;29$*K(DQC ),P(1C3#$29Q"GJ(D26*.&+.J &7;X=3(87/*)HW00+12@Y]*
M;/"SD;O'Z>8IV!V.DCV!.<[1\:T$M;Q@+3#0$J_C'CWCV.-4V!.>XYX"]\>U
MWUFO!4A69[NGVAG_+-="JX-GMS;O]3/*_EB4@BWO%]JMY#OY]58LA"Q651OX
M7WT5U?-<1\U\4!K=/)>E^N+N1%DL]=.MLWHUBX7Z>B1BNEI  %&0!Q"S(()I
M$"1!F%"!(R?/4C]B38WKV_*MM86S(K_ 4RNJ^M??Q4(G#C*5?&N-P(L@EH6=
M/8^GG3TY_B@-O(AT%3(U75J5KC896=9* 3W)0:,6J/4R+ZTU\V>Z^D7:I['K
M2;)1S6._:.X:U)Y;[WD'1W3]0^,]^$5]\+?RNUHM*L(Z!4@"$;$XPR'D(F 0
MA8J]%6?G4(8R3!DG,@L#IYNXLUU.C8^UQ,;9P!1H[U?DQ0)HRYLXK_ -?1_G
MAIS['9PU&%YOXL[W.NY]G#4*>[=R]F_Z2!'_J2"TF.L;@YK.%+<$RHB/$A@D
M7!_KAP',69;"($MQC%&,(N)TRW^ZNZGQ2J=>G]DR+.F\N.^1?>$,R"F+$QQ@
M"A6H""*, UT\F\&$B2SG@4@XBMV27/F#>9QD5>WF:Q?FBW+I[^%LQ]_^L!N8
MN_?RY*]EO6IWLT.EQ#^&RG )\/=Z?,5T]\>T/YW<_NA;/6]ARR43@E=Z\_FI
M6(CJ5MZ40MFE,Q$*Q1LQAS34="+#$%(N)1113##!&&6)DPU_M*>IT74K:&W0
MS;6H>F_#C+".E[-'T;6\H?6!V=#7M%MP?6KANCD-E_MM[3DHO%[9'NULW'O;
M<SKO7=Z>?:&G^<@>!'_6>\CWI%PH*JJ4A=JF^RJ8CF8HYL\K;>#2>2<M0AHP
MS"7/H5 [/8AR02'.L@2*D"<B"$.4$N)D4_:38VH,TZJAYPG5@IM(,EZ+#D2C
MFDX.7OM:&_KI!+4ZFJ0]!\_23AU^2(8V7CNCT>J@S^_JH(,K\'8]0HTFX$^C
MRS"YOB[$TZO]VU.4<8WBR_#:LY0O;*YGU<;EXOZ[*!]UYH\O2N_&TA T0R0)
M)$Q3I&/X<0[S)(H@B5*:\CBG*7(ZDCO<S=3844L)5$>/@"LYK\!"..ZZCJ!I
MQV>78S0P76D!H8'GG8'G_2\V?S9I75OS]S-9/9>%7V>YT[!X+<9XN*=QBS">
MU':O^.+IIR^(FE%THZLSS_]3C6?%"W->UT0NQX(GN60!Q"*+($J3#&(>JDU6
M2%(>4(X)<ZL4=KJ_J9&$$=<LROK;G?<(E#F!K>7.QQ]B0^]PUF 964%7V//!
M]?TB9LX#XSUHYD27X\?-G-?_8.B,Q6N7N=LWUP ZX$_7BM59B*H9(3P)1$1@
M+)G::$2A@#166XXXS@*9IIA%$>KC=G^HLZDQR?M_/&L7TZ*1T60%4[87*;AV
MOV"D>NCGD'\0:,MC'T_P#7WRTSKHKV_^6DE-$K$!7/5/ 3*$R_[!_E[%=?^4
MYL=<^$^^TX]%/B[8\E$8QX3ME-^")+F@DD$>"[4=H43 G%(,$\$R%' 1D-SI
MI.=81U-CCUI.[>?C6AOE*)1V'.$#H('Y88/-.&G2ST'BDR&.]C4J.YS3>)<9
MSC[?CQ5:3]2O8JZV,+R]HE(&:'MGRE/$28RDOIM.U 8CPI"@(($B"5,6ICR.
M[")UK7N<&D^T L.REMB-*\X#;$<:7F$;F#UV$0,=:0>XF;:&QB>+G.]T5#JQ
MQF"75^Q?[$<P'TA1F@*Z'Q=/SZOJD_@AYE%CK".:29%F 8RBE$&$X@CJ&K:0
MQ&&*!,:8QDX'(2?ZFAJI&-E Y,8EI["T8Q%/" W,'UK*NOJW]M;6@EZ!!K !
MSCPL,/%)'*>Z&Y4R+/3>)0N;5_K4Q]ZS=;ZN_:YG(<X#0?(8)A$+($KB'.(8
M$2ACBA%)<Y$%L7U9ZQ,]38TB#IUNN)03/@7J:;;P"M7@!Z3[IQ=@(ZDOP%S*
M)GL";J2PP.\/ I!'75'))(@S<.Z<J'5":?ASJ>^K=&C3DXET\)4:S@:UT]6&
M3S4P8I%@"SVV:_O:O-#3N)-2Z-J@8FT\?E5[/-W\@JE-GOFPU"]K/R,=S2)4
M%P\SM2E+1*QV9%+&F;+XDAA29>M!(L(P%())(H23Q==+C*G1<2M7[?"C5[[E
MD\EC5GL7FN2A3^MBRH[IZ7N.E*7I.#C^0]N3K0)@<RX%M Y@6XDK\X=:CRO0
M*K*NL>[1XKP(4:]F:#])QK5-+T)KSV"]K+4+#\\/59"*6)SFDC(8<"QT3>L,
MYB)2MBP)8HQ#)M30]3I _R>HP^7A$+U_42Y?0(UVF#Y\?2X;2 8Y3'_U2ETV
MFA\]5/=?L^N3J"HAM@- M*?1K;Q9+NJ\KFD4*W8( QCAD$,4YA32B.0P3CG-
M\RA-<>*TSSK?Y=38PXA87=4N@\93NI;3;*9TR@37,C\6J-M1BU\L!R:86EA=
M,7XG'NQ[@VLKLT>G0FM\O#H8GN]U7&=#:Q3V' _MW^P9UJM,]%*[-)+JX?TO
M7?5=S' DXS@-(B@08<JP0PB2)(\@H0IO9=1E2>#D*W2@CZDQC!$1+)8+Z.X.
M= A"._:X$)B!Z:+&I!$/-/)Y#!0]KKS7Z- #W8P;$GI<S[TXT!./]C@O5\;.
MG%15(0MFS)U;V>:0JJ/'FC#3[\OZ"'F&LR"15/L(TBR#B.08YAFG$.?J+S+/
M!$?VA6(<.Y\:(>R*;SS@1%F("KQ=IT!KXT<;770M#&&T<3A.=ATDBR/Y :$?
MF'+V4+^5&[ _U-&G+=C?E^#]T& ['.</"/I()_Q^P7<[UN^)WLF3?M<VQSO\
M[ZGMUGU WS9ZK",WR[GZ>5F:?DP]&?TUZIR$?RR*'XJ,5?MZ0SI7C_!EXV@0
MY"DC89[#D 98!P9G$ =)"G-,64J$S)F=/UAO"::VHFSI4)=6,O<")NGK1HW:
M#JL5<6"V7F-DL98,C?S "\HVZ&OYZTRF'=!O-Z#WJ479"WV'Q67H41AIA>DQ
M&I[6ETL /+G(]&IXO)7F$KVWEIN+&NIW-'%=56)5_57,^8=EJ?.;?5FN[DBY
MNI7OBNII69'Y?Y3+YZ>U W(<\R2E$HK8."#G%))<*&,FBGB,LX2S+'0YM7#K
M?FJKC9$>/"CI3>I9)>UQT]T'^G8''L-A.O Z4@L.M.10X0DUGE>ZI"[0XNLU
MNU4 & T&<%_NAYW/HQ1'"48]9>F'SNX!3,]6>KH\%POMR[.=\ZN)['_9R=0B
MB&HB##,H<L85N9$ DB0+(0TR]7\RB]+,S07:ON^I,5LWF<OC.@^"J:=0*U4G
M!W2\9G89##NN&PCB@8FND?I IL!6]$%SX_0 S:O3M4/WXSIAN^.RYY3=HXF>
M&[?%JC"IKM3&\)M@S0RMLY@(;I)@+Q^?GE?-N<5>&IZ7PPU<_RJJ681HA% @
M($^((D(18(BS6, L)3'/<(@12YUV></).C7B[$H*-J*"/[6PCDFPAQQBRZWD
M- 9NZ'UGOS%SWUP.CZ;7G>B XHZ[;1T>][T][@A=>CMDUKX.:MTR6<PWOM3:
M_;U)@3"+4\2R *=09#J#6AKJN)],0)31B(1QD&;,_M*RIQ!38_JF-(D^62X6
MX.=#P1[TW60IBD?ZK+H'-V11%8NEWC1ON:B?S.GA;\QZGSM['8G7.7JNO:T:
M):Y 1PT3E 0:1488A8O/G[V.QDA'T >GQH, HBY#653;$X6 )V7^FYM]=N3^
MYM < D2J>:[>KKIE[*MGU9GJX:E<_B@4UX+G)]72:H.B?D@+0S8?RY5.4?3;
MW>*_%Y\7[[XO_JK^\^TW4SF0J+_JHSWQBSP^Z=.HW^["_TX^A_&[WY0"3PHT
MD[E'MZ?^N2QU@+W43I.JD^5"&+])U8+>6#PN%ZN'ZLJ$K"A<U*-B 3AYJ7Q%
M;5WX_?0X@3_?]FL?PEMK;W$.;]]6/XONLUHLM)GX<:&^5E&M;G\NU#+V4#S=
MK2.9WK[<$7,2C!.2!C23$ LF(8J# %*:I3!B+(]QE 1)AMV*5#CT[L(XXU2L
M6 L+WI!*\TDMLZ/#LLL V-E/ X$Z\**JG>.TXZN:!=I_N17^"FQ@WL@/Z NH
M-?!G*/6 S:?AX]+]J(9,#UQV#9,^3?3RBM37E>*S*.]%>;W@];F8^IHZP1WZ
M-&R6I9@@B2*8I F&",D<YK$^@D<L"I.,2T*MSMR=>IV:*='(#6K!@9(<K$7?
M#E/2TKOX3%B/@X6U, 2Z S/9!(!U\F[T#_!(._X.EFKG6RSJO;/9P]/E\TIM
MCNN!>*P'0N^!9:N=K_VO*WQG_!HM&QO3H=%-OQU/1L>7+\PP]5D0W:;^].HD
M>;OI&:,P#CG) BC2)%8[6$EA+C"#..%4)]X6.;*J4._<\]3(?Y-@"71$=[U9
MM<;=\EYU"#2'OE4]".0X.3.=\1HDB]79SE\GIY4M)D<S7%DWT(^T&I_NQF,T
ME%A9SSR#S)QUZT(AF.4IE'F2A#03&0F<,@ALM3XU\FG=V=W89ALP.T;I#</
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MKOJ:2\@B%,6<A3(E3AY4XX@]-7[;%O10=/ F+KBGO33L9^!H;$UF<$>SU*Z
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M481IMS[#\#G:ZPQ\S#"RO#/1IYU>+FK_5+&R,('_U2(,<Z1V*!$,1$1TB*"
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MB".24$XD3"C.())I"*DD(90I3GF6\8C+ZTI%]0P^-X[4_L[E4K"-=@RU!?$
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MK3?JF@5.4)R&F$)* [7+8[D.!! 49IF0(LMPG-K%D#N-.C>F[<JI^\PH06_
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M*E-%ED$:0HPB >,41U*@, D86?P0)5U;14;[D\SE/>[*-Z;'Y(=F:T!TVVA
M.J\M4_I5X)=/:[5KCETRZ#Q.9#^;ON+DC$RRN^[LM5:@50MHO4"K&*@U XTJ
MX+X$C7*[CSKJO<X,.H2(O\Y,3A12_NV[>L<>=6:P7CAY.[^BGM^BG5_]TH'-
M=[(!/X7:M13M3/-ZI@E8-1.[+O5YCIGK]J/-'H _>XI5]S\EO;'M'H>;+A;>
M/T8'L?,C/'Y(?;6#AB:+-(X(9SB%09(+B)*80<IB!$64(2ZES FWSX,\?/;<
M-AI&.K!LQ7,IX'6(F<5:-AR)D=>CE_V)AJ/@4JQL,!I3E22S1<6QZMA)O?MK
MBQW>,F$%L9.R'M8).WW)\ ATMBZ?UG5#:W.0>Z=7U?+Y;LW%(E=F?I8E!&9Q
MG$"$$84X57L 1J*<DSB08>@<B-XSWMS(:A=@W9'YIHY0T!9#(SG0HKO'IO?A
MWD]N(Z Y,N'Y ')0U+H%/!Z"U_M&F3R&W4+E4Z'L-K<-*;3S,FK-%#CDW]9O
MQ-?UDM=_V-)=O\E=_<,%"U!.:$!A%!)E%(7*,B*AT%TA:91F 4IP[M!Z;:@8
M<Z.DD_'PQ"BCHRZH )72YZ:^ %0=E>JKM$Y#2_D,GDH+6VV2"1J9Y4X&S=9Z
M@&]K\$: KV9NS 6@J\V^#.LD\^%2,VB*>9FJF-"8\^-8:NA:6/MK$ U^^H3%
MB:Y%X+!JT=5/&[*V?5??+E%]6+TG16G"'^_ENT<J.!?\K2B+'Z:UA?'D[XLN
MHCP508H(C!+"(4J548%E%,!,!BGCC 8XL=_K#Y%@;BM:]P2LT<<$'31J@+T>
MYHKUZH<H-X4.0M.^=)<Z)8/FRV;M&GD6QEZV&M _K(!6H F]OC\]!?7I([ I
MH>EI EP6JY$G8D+G]H;0[5)'TQ856ZZK;6F^_3K4EADEV]]$.T=\/T>-=]O$
MY9K*X;[\U]?@V[]@#7GPA&O5%7H?+E/7/&A8:$RG:L%NT%O^7]MJ4YN"0<;R
M4!>YBB6!*--U2((DA5DB(Q'&28Y3J^7(;KBYK3WU?.@@=JF9KT[G,0=*NY=I
MN5?(+=;E O TCWF2,P8E%@@BB4(%O P@DS0F089)(#*W3DH>H)^THY(#^)8>
M<DOH^Y=T_]_DL4\3NA5B.BOX7EA_L4)VH/B,#+HPXJ1Q0';:OXSZL;QK&+V_
MC*CLE-CGB<@#$D&.0PJ1B!3!)'&H<,YX3"F) [>276='FANI?Q(;\'%==<.5
MS<9AO_EW8Y/S$-L1B1?@QG;0GPCQ'J5,_D4P?'+'^<$FI8V+.K]DC,LW# R3
MU@][0RK!=52V6%5F(W.K*P@^&&_(F^?])9_)L_[H]B<I^:>MKBYX+QO?R@]2
M++6-^GY=_D57'UQ@3%&6T0!F F&(PH!!&J)8L8Y,N&""1\BIV?=8@LZ.JHRX
MFIY:3WXKL4FX?# ESP>7N1EMNNUX;PZ3.#)M&@DAU0J KI*@HZ6.W^Y>UV@*
MC*HW8/\5:!W2!U\!H[''6.^1Y\1K3/A8LDX;.SXRXD<QYF./-[BT[/9QN]3;
MRK?BJ12L,'*IGY?""+CBMX_K<E/\O>YX5ZZ?1+EYUC6_-^IO.ESOJ3X6SG76
MOHQAFNG.4;%,8!Z+ /(DC3E%,B&Q584CWX+-;6GIZ*5VU'O%ZJ[R'8V<2Z_Z
MF4>[->0U9F?D-:,[,5V=;L!.J[J#?4>O&]!J=F,:!6QNS"4[];P6A/4*N.?Z
ML7YDF[K<K%=$3U2G]?O\D?86U;F%Q_SS38VJI-%2?5(OS]OU(RE6BS!.XCP-
M(BAIJ ]+@QCFB"/UW<@22;(T37(G'\880LZ.^+6D0(L*_E9+Z)JD.<9,>MHR
MC#P_8U._P]3X-^VOP&Y2LWZ(G/,RZ:] VMF<OV:L0?&<2_5S$RBZBZ+Y)LK'
M12PRFH1A#A.!*411G$$:9!G,TA@SS$2:NK1,/#O.W/A6RV1\-+KZE6- Y5DL
M^^G2(T(C,]Z!D)T(5#4QCWZ0<HIE]('81$$@7[0M5^D7W 1R:,"TDV@/X;H$
MC\525)OU2G@+\+B(T(6XP[.W3QE8>$F'%Y&#%R\?9A!_6+%2Y^J\%?7_/ZSN
MU426]\KZ)KK*U:U.$:\6H>[QD"<YI&D6010S O,\U[GVA),T"'B>8+<X +N!
MYQ</8*2L,^<=0RTLH;:S03W"-PW'M@*#7UJ1_Z2#*FHX=V*#VWY@G>U--YQ\
M6I"6(T]J$[JA\=+*<[Q[>)7GPL0<5,HDO%N;KMIBI7MJO]U%&>X/M\-()%$H
M&20(Y1!1JB@J80SRB&4AS],XEMRUX+/]\'.S\CK2NQ=W=D#=CJ/&PW)T>W G
MN/%@'H@.]K*/%'TP##??=: =))B\)+0[.J>J0P]XRL01#?M(K*K:/IJ<D*KI
M<BT^EP43"RXPQU*H_2L*4HAP'$#UJX"$A(G:UR9)RMQ*Q(TFZMRX\J]"]PP7
M') ?:OUZT&58]DF+NE0TN[YF_H@3[\E5.<ETCDS7'N(;N@&I>X5O0*LR,#K/
M(,+!>EYF$>-P6=IYN42O1MU;G(/]B,.6I/?%2I<4>E&H)29!%"0(0<K2#"*6
M*6LZR@@D61P000B/,ZML]MY1YK80?*X]6/O0_L=B53QN'\'2[%>?ZEEQ-*A/
MXVM'VE>C-C+?-O(!_Z5PK!#PR6RG!YJ4E'IU?<DG_1=/?29^7_.2B;RJ/JP^
MFS2^UJZZK<VJ0ZL%15&:9X1#0G,"4<(2F(=I#%.)0X$QP8(Y$<R$LL^-MHSD
M37_)46U4C],_]OGZJ),Z RNVNF#&WK=V:XV =K#6&-R W7:G@>'U3%O_LS>/
M@W]W\>=E_/J?%W]A L-%&! ]\'_):DO*9_T%N5WQ]X*6[:^FEL.O.IN]7)!<
MXCR+(HA3HI8RR4-(4OTK5U8R(111C*P#":R&G-L*U C]+_\4IL&_:5F-L[05
MOO/QRK$$AMT$6$0?>(=UY#7@&-';TX@:\<'?:@5<BEO80>L0KN =XHDB%]R@
M]A2YX 16;Q"#W9.FBV=PTNP@M,'MSH%;'.W3K3M;UX63ZP6D3B+Y)'Z:/U6+
M( \S$6<<QIGD$&$:0Q)%":0\S5,1QDPDW*Z%@-O +J_'-!T"=K7GU_+0+SX\
MS<]N"E 0X3C#'.*<YA"I1192$:HIH#'+$0\203.G#:+W"9BDVE2=9%<8N4?'
MW')7YAW)L3=4Y@M;2]QV36AW0[74-T#)75_A,>3$#2BO>Q>[D:?==CBA<;1C
M<+M[8-;?KLQ%]6U]R[EIA4*6GTG!/ZSNR%.Q(<M.1;>W@F[^6FR^UQ]5ZMKW
M@FRVI5@HXL("RP"F*5/KATP0),J.4+]BRC )0AE:;0E\"S8W>MO%@BEB(SNU
MP)/2"ZJ/6*U9W>6/[91Q3 'T-:EV[/@:4S4R?W94TD5[]TH!K96>NT:OFX-Z
MAUHU\%/I!O;*@48[CQF GO'VF@'H2[9I,P ](WJ4 >C[^8-3O'7-<+64?-V0
M%2<EKWY[XF0CU&2F0=1L@!DB,N9,P"Q$4NT$\ASF+ IAE*92)H+G/' R0ZU&
MG1M-[X4&.ZE!+3;0<L,@<D[+ML#>DG!](SHVFUX&\[(_9TBBM#U*GK.@+0:>
M.L79'HL3^<L.-P]P.C<#5)_)LRYHH6BOZ3.^D!1E@>2I,BAIHK;$RJ#,L=H7
M1TDD,:<DS.VXJ'^8N9'/7C('[^9Y$"V<Q5Z@F89%*AV58JKO>(;)P?'K!:Z)
MG+VWNR9\:[HL'LQHU;[1'EN2JBIDH8-!JPZDOA+6+D+5Z^H]?_=T[MV+&ARX
M="]?[4:05;E9W/]<*=;Y7CPUJ?JQ#*. J;4G2@B#* \C2,,@5S]APB.F()38
MAA5//'MN5+@3S[%4PBG8^GGP2C!&)C\''*S?SQZ->\PA=5?'%%*_O32#3CUV
MDK>U1Y_V%>V[9$B7R(*)525V2:F_UM&3MZO5EBR_K)_)<O/<'.4O:(8QE:':
M3 E]P$)0IEY:%JN?2$Z#1'O^[<_,'0:>VQO=B J(D164M;!MJ*E+HT4'\"U,
MH)$@'9D7&JGW[6]N0 MP+3EH1&_#I48"V*7-Y3A 3]4#TQO@CDTRW5'K[Z#I
M\+P)VVNZ:WG8>W/ _0-X_ZLH"U'=_964)BBK<=[$<4))D$60LYCIQD$AI(0&
M, FS+!0Q0\INLV;XDT/,C<MK(<$=:,5T8)?3&%H0]=7(C'WV^A*4(;%*I]%Q
M8-FK49JLE4Y1@4<C':BT>ZDR576/0/2U'^W%I9<Q3]\Y'3?V2G[ @OU7#N"[
M3T*!6FZ:;V$21&D6,0HI3B.(,%&6K @"&""6AT'($IE8Y=T>/WIN_-8(Y_#>
M'B)EP6:#]1^9Q1JYAG#7(08.G#48BXFX2LEWU_=U<&.BD]KV,M#A'=,QSTE)
M#QCG]!7#3BF_B$JHF[[?KOA;\4,LUZ;XZ;O?=="\: /0:4!$S#GD(B%J"\US
MM9FF&*8YH7DD,FV)N9Q16HPY-VYJ13:!YWPOM-NQI W8=H>2GB$<F=X.T.O(
M"QJ!1SB/= #(YVFDS;"3GD4ZX/#R)-+EUH'1TDVOTWNI@S ^K*I-N:WC-G8%
M@**$TBB.(YC'!$,DU(8/2\0@P9API+=YR,K[;C_DW*BGVQ!6R^P8F7L98CO&
M\0O<V+O"#F8?UZL':.I%FH"QCN0NW5O=@W.M\?(:F'MYU&F#<JU1. K(M;]S
MB$_I=+BO*83Q1>@X,&&*S-VR_]D6E8D@6R2(!S'/)<QYB"#*)(68Q4CMQ-*8
M88&SA%I57Q\JP-R(J9NZ4>=L:%]"60M?%ZX$9"_^#5@)<S+^S]&?TSKMZ;%8
M+G70ILG]J-P<6@,FT,;=->ZTC$U[/8D(1H4;T"A1E[\$'35&QM[%F3;N'$RT
M?=6-)#;/H'A4?]^T[:EWE5_J]Z5)NSEJ4 V>MJ5^MS8Z'/KL"^7-23<<[WX7
MWH#G3NC@&Z[UH?OOBN<,['$JI6"Z'_"'%5L_BF_D]R]D(^K*@ELE0%,F=;VJ
M%HB'(4UTE3Z44HAD&D!,&(8X85DBF$CSB"\VZPU9VEG/]D,[+58[ 4;T?.LQ
MP%.Y_E&8/ &]5!5&"; AO[LVLW:8 COK>AQ@1UYN=D*#6FJ@Q 9:;K7*Z%>P
M6+:MG-0[P;R<S@['RVLC5?O1I^VLZHS*4:M5]R<,L+Y_%>6#*#N,>*>MOP]-
ME.1";?ASFK,,!H)FNA>\XB\>8!CQ0/)(1B255NU3+<::FTW=D=.8Q+O040?S
M[ *Z%E:P/\Q&9J!:T*X9"XRHX(-WV!P,6'_P378L+'0/Q"9RF;SX#G;BEX\M
MU5+4K?N4H?IHU/9EE=J!V&N 7GC$=+:FG2X'9J7E+0/(][BXOBGR=[^/5U_$
M.*.)C#B,LE J E;_X"B-H: X"C.!!(Z9-0%?'F]N)&SDZP;P.["(!;H6!.P7
MLY%)^%3#C0^KNF@GN!\+10<^]HOF1)Q\-:IN=&N/42_E6CQF.MJUU^F >AUN
M&T"_[]XDG\OU0TD>WZS+<OU3K:=MP)F,1"QU5:"4,;5;STD"<Q8G,,!1%B>)
M@CJWI]WSX\R-;M^]@0GXN"8N+L@>%"WHU0\V8^^NP9L$-&*"O9Q#8H1ZT'*@
M43^H3=\OCNZQ,X4^M/7ZVY^__AD\K'^(<J6%^:/:,3P^%@\Z@D^Q[ _=1JYL
MP;]I"E,MG\%_K]8_5SIU3S_CW1N0:(^2F:!?]"=_,!\UM_WA3[Y,X<O ]W)R
MS^W3<?%E'0XXV.+R8<Y3?9BXK_1P7Q8/Q8HL]:=UZF:X")',(X$3R)#,% LS
M#&G,& P))D&<I"Q@5GT[K4><&Q]WJJF8@[E]Q1537A/\HLOE@<RQ1-AEX.T\
MI5[A')G"3<#!7M@;T(IK0A%N0"VQ/Z^H-38^G:&7!YW4!VJ-P4O7I_V-PYBG
MK:)?"+7!#F,2Y() G',,42!2B&F>0F7@Q0CC#%/*7,YE.L^>Y\'+<B^@&VUT
M4;,CB(%8C$P%'RT <'[?3ZCJ\\WN/G[2=_B$7B_?UE.77!N$>/KPX_ LRT2,
M[6/G I83HCO58HHX1"E+(0UDH@MTLSC.DU2F;FTFKA!F;G9$-PC/]JAP:'#C
M@*FS8Y.I)F1D^ADR%Q.%1P['=9S R0'RO%)(Y7#DS@=;7O',X6UXURL316-B
M9A2E8A)'*(!YF.<0"4H5F\8(HA")D(@ XS1U;;3;'6!N-'G7J7I] _XY^',0
M@B=2UK%B-T )<Q/4_P&RW7Q?E\7?!;\!2723H?0FBW*358%N<!K<)$G4%'!N
M8LMN@/KYJ9[1Y?._Z;O2*+F)SMVUWFY,7JC:;Q_>ZM[E]V!2[<CVFJD:F4";
M6?I:SU(33%F'??GMQWM*?]\==P_&F+RG[BD-3W7-/7G=0)(AU7?]GP[*5.^5
M=@M^$=6F+-A&</V'VQ4__*!SY2U5?R!LLY IHV$:Q#"(E8F'6(XAT2"G:9*3
M/ \PB:SB4KQ*-3LZ4V+> *;^!6(OK6&;<J=+_??R8%7Y5T>*\3*EEKPT]42-
M369FCO2_H".H#@[?39#YHYZTEY]U;@!_:W7SV9/<)]9>B=.+8-.RK4\LCRC:
MZ\.OJK'<UO]3(ZI/2K4F=]P#)[JL+V(I$B(E@:'$RL8,,8/J5PJI#%FB.YVG
M,1]0==E5CKEQ=R-TFY;KZ*H;.AEV'#P!Q".S[JZD:J."H=<6\HX68*^&VH*/
ML?F^$LL1RC<[B_(:!9V'XG6FQ//@QXU0Z6&!:4@C&5*(0Y9"E,4"$L83J+;B
M:2 CB2BV*J=E-=K<>&^"Z@X^ZCK,B,LN5728J)##&(S4/^!\BC><8Q>[FT;J
MX'VAK>K[=2E%H9MK5$H\)5/19)-8-75.,A9$%&<P8"B$B- 08B8%Y$@&A(5!
M2KC?GMYC:C,W#KS3J=S+Y11]OD?]DE@>Z_RC3/W8YT(6O<!M6X%W,#'+0@>5
M>?8'GV*.)^T8/JI"\^HA/L7<.7<5GT2H82MWG4]4=1**M QJE_&T;G[=[SBZ
MY9=2E(L(,XAQG$,4D0CFC#,822QTN]0T#9V"(8>),;>ULDD[U"3W6=%B\^O[
M8J764.L&*5?.C-TZ-S[>(R]0C0(WW1S/>GGI*M%QF50C^4RN0]+G,C!0DDGY
M^SJT7A+OE4\;VLJ;; RKW\LZ%D(-J7F_%-\5]>\B)'9'22),&1=I!O-$*JJD
M2$+*<P$Q8GF4,1YB'KLUE'8:?VX<N1-?AQP=R-V&'5F<'GF9&,L=P7APCVW#
M^T!Z0//I07CY[4+M)L+$[:@'X7/<EWK88X;'2>@!+ASKO?C[Y_6R8,\+1!*6
M!+& *8XQ1!D)8!X)!..(D3PG-%4_N(9'#!5F;FQX^L3]U &[>Q3$X FS#WZ8
M8AHFB'DP>-N%/1Q?56L$_M;\?Q0CTP?6OF,>!LLS>:C#M<B=BG"X^ID3.]K?
MDZ(T$7.W5;5]K/T.+]P*_[%>JJ<MB\VS#NU=2!&$5&($$\FIVN+'&:0)BV"4
MA#(/TTRDH5N%Y<E$GQO)[SR;I/%LBM]U_*SZH"[W^*3]..#'3@?C:7^J2Z.I
MRZ=RL[M_14;VJ8\Z\?-WH&OUZXABT '@A*-\#X))UYB!IWSPS,W"+>XN_3^&
M#WSPK'AS> ^7P.>^Y79S1\KRN5@]-)DE1(9ICAE,9:I;@<8YQ'G*8!+C$ M,
M.'/K)6 UZMP6J9V%^S)$V\?&XR7BU^PPKL#Q];829 -:J6M*'WMO< :E\3<!
M+P>>@;5_!@L[L_[<S4/+C$BA"_5]([^;ZL^5^J']K G%.:#4%7\C5D(6F^HT
MY^KJ?PL2RRA2_\$PRH3B+Z9;7@8)C%"(8R3CT-'!,H:0<Z,[DT+4V%VL:Y^)
M"X%JTTVK'4F^]F2-S*FM*B89N5;PQOR\^T.CY,VAF:UIN%7T!IRUQK6V/NNL
MC#<7?DNSC"#GQ-5<QD/ZN #,B&,-38Y>JE_7.DSDA^C8W:?2*+)$A%&"*,0T
MP6IUT$5;>19 ]>J1*..$B]RJ/<V L>=&^FW;<&.C[=70N_*V5[6KN>LP$99&
M[SCPCFWZ=J4^\'&,GK0R #"_>=/VPT^<4NV,RW&VM?LCAA%:TS]@]6!*JG[1
M'H%[^5O3(F5!>9PF.%8K>$13B+#,($W3'$HNLI2+@ 3"JM>QU6AS(RTC'EQ+
MN&V;_52F998;4?4#;$=-WF ;F8QV<M95D6_ #L+?V@Y7_NC'"A2?A-,_X*04
M8Z7[2U*QN^EU\E!N.3=Q8V39"1S;!0S% <6<)Q*FE*I]=H922 @6,$PC021/
M2!1/<R)F(^W<:&PO+.![::?-(.F?WI%/LWQ/VOP/L'89()VY/PC('2/\;(KI
MF<4IE97 _Q@'4R[8^TZ^L!MT2"M941;J27\E6I2-#DRN/[EK/VDJK0<!PGD0
M4Q@D60@1"F.($QG!+$IR3' 2$&ZUJK@,.K?%H182W)J=>?/+'?C9R.S2@M02
M]'ZN'PO*L2F[1;&5$-QVX=Q].J!3@"VN+NU<_>,[60L6N2X?Z]50&;,;4JQ,
M]ZLUJ+K?X_T7V%M'5C?(^KNP6CYKPLZK;MH==EMUO/?*U(^ZB:]><-8K<TCX
M>U$M0J2^.+HS88KB%*(<QY#F.8><"!%$*(ZRU"DGKG>TN3%XT]9X+Z2R[I28
M0U,X3@)L::#[@FUDMG9&;'@J1A\2HR1>G!SP==(L^G0_FU31>], 6_!NWRQ#
M-PYX*YBA(P5CWBR<<1X*1&0(HQPE$$F60?5; "4C>12A@"?<ZI3&;KBYL4='
M8&"ZB$#0"@VTU Z6RF6H+6P_KP".?O2RQ\XT%NE*.\36NXR@@Y7G%<F)[+M=
M:R'P\WO!O@-&5H#JJ&WV76\JN6D23H N@ES(0OV^VIIOJNZ1NEIOONOZ*()M
M2TWO9&-Z0JW-9E-?H7\S-9C5]:7Y[?MZJ6CDQCQ5_$X>GY;B!M#M1K?5 <OB
ML:C[J-Z8BY7VZK%_K)K>4VUYZ+JJLRZG<?#>^#(\K6>QU^2\_)3IC$UKC0[,
M3/N[AAF8G\3/I@B<^O9]+M<K]2.KSZ7ORSOS[?NPZEY1K%BAOB\?BY7XH):N
M:J$LSIQ%C,",R@@JBQ3K*ND")F&41&&21FGBE&U\M41S6VJ^O+M[]^D;N+V[
MN__MT[</G_X"/G^Y_Z1^OGOWJ_K#5S>#]?H)LS-J)YV&D1<LI0O8BPH.M=&D
M6.NCR>S@LD8E\#>M%#!:>326O2'LTZ"^7JA)C6YO&+XTS/T]V%/8;J<BYR<=
MH!"JKWJNF[-RAA3K"@DIQ0PBPI.$LC@38>;2M^O">$Z<.D$O+R42X&T\YH;\
MWH0I7!E#^P)C.Z+TB-S(-'@RLO63S] $2RQ&C2Q],>3K!HF>UO]BO.>9VP;X
M 3Z7HJY9LZL)U?HG31"58K8?A>XR6+4EOMJD8O79Q_5/47[>987>RTXOC$6(
M(D(R'D N4@)1Q#*89[I#3D BCED>BL3^$&DL*>=F"NH:78]UC2[9:KKSV:LM
MV+).SFVUO5&[LZ8B8;E7N).H6[=%W6_+AN7QCOM%L7!^S&'Z1^;>SLSOE-R=
MC]W4(:K@<V?F=[4H.[H"HRS8:PON39V=73^@.<RW@ZMF#O,^D8?GE>??S?DR
M]KST^FQ&&WPZ5\_8^!UXB$8?;-@&YLVV4ENAJE)/I$HP$R*SKYKW12R)KENR
MKC;5(D&<I$ABF L6ZY.($.8YC: 0 D=YE(LD3%P\2/9#S\T^Z(BIUO5J ]2N
M<JLM0[>-C0/V=GN<<1 =><EMA08=J0^J=X)&<).3Y[$9LCM:/C=$#J-/NC=R
M1^7E-FG $ZYMQ'R0B6UJ)5>;XE&/LRLL4=U+[9G_L%*L:BR)ZD5[WR@)6"3B
M'-(44XC"D$!"X@RR0 0D3&08Q&A89V8/TLV- ;OM@1NG&EDJ:^B1"LZ%[O!1
M%C],=E#5%#[HUCC0=VEU7:.\O<ZW9=#(:\WBR*S;G<##R6EJ\;?*=:H-5>V\
M@8Z&$S5]]HC^.%V@?0CX2FVA/6)[OD^TST&&!NFI9]1GZE4=Q[-(TER2C*:0
M1;$^%$T$S(.<JME.9<XE2GF*7-SSQT/,S2/_38]1>Z$:.?_EG_(HS/[-5/;1
M)>:XD 4K-J[%Y8[!%4P0G$H$<4:#!ERL-@U,)$@D/,V#5"R>3!^#KQM2;J:
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MAIG4SNC1\Z4)T7?I $]IW8'AW^MV#/?RGFT?Q.K#BGT69=UXLW68"H8C]66
M,B,8(A2H[92D".(X2Q).B$RQ5;TMET'G1CV*SA]%"6IQV\X_32<+!Z^?+>06
MOM,1@!Q[-U2CUHBLRW8T<"JIS1%Z+?<0;ZHMK@Y.U1'PG<BW^N[@VZDWF;7P
M-QKH/X/B\5'P@FS4B@:HD,I.,5[/NHFS+W>F(WJ]7DW;9TWGW'34[L#'Z7KO
MP%#-TA0=?]ZO%*:C:%GW$?U5*$.(+RB.49XE$M(TC75T-X<X2 .89BB*XT#R
M+(K=W)HVP\[/A?E%[ *F].E!HT-M6#K&9]K ;F<%>H-R&G)OQ7UA%;8R-R'A
MM=@> S0=0/(:KVDS[K3AFPY('$5SNMSKQD=<%(OF7/_Y77.X]TE]C18H9TCM
M4774..$0441A+L-8<0\-9":IPB"S,2K/#3 W [*5$;1" BVE';N<!;&?27Q
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MI__SO]I/U#\Z:?/__*__!U!+ P04    " !H@'M0*(<VJG^7  !YX@8 %0
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ML1MB.C[U'$[$76#E6<ZD@]7Y?]Y,Y\@G11JOC8F *AB*O[@"3V(A5TIQGU3
MS(8[ZKJ'@-TPTO$!Z#"B[0D?S^G;D^7'Q1_SB8P^L42>D]"9S*$)"(&CAH!1
M)%'0>3'<[G/G];MAH_L#T</$VA,R-MOER?+=<O%U.D]('XA8$GKP@B.H(@+X
M'#G$)"42_(VP0]R=/$;#;ACI_J!T  'W!)1WB]4ZS/[?Z9>-4Q6<#2Q2.*:-
M)=&PPB!H#*3EK)F37.>BAX;)#0IV TGW9Z<'"W?L ]3*PQ+#AFZF0RE!)3""
M2U".67"6\.W0D*\M)"?A#'%H>NV=N\&@YY/2?04XLN)K/M_LW:?%_.)BT*!*
M/"8$EIT')7P%K5' H]+"Z!1E&>)8]/9[=P- QP>B!PER9!!\P'2V) !S$3].
MUS.R7,P*F[6%$ F[2A/_P4IRE[5D@8Q9B7:($/7V>W=+SNKXW/,@08X,@H_+
M4+.G/WS['!>S"3HNL @$FZI[0ZX.!/H?6;3 '=/&>9T'0,"-E^ZF_HZ/._<7
M82<&X.6?Z5.8G^(F):!(BR%X#<(YPJZS!5P0&J)!CLID5=R01N#ZNW=#0L<'
MF@<+M(N0X>\XF_WGG,+B#QA6M+/EUZO5&6UMJ+)S1GLH99-O6CAM;9FDHK--
MA@O%XA!W(8\2L1M$NC_!'$+$76#EOQ:S,U+ <I-DMEQ-HM.HJM.K!+<U1[U
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M<+#H.\#/M9+(W[ ZCA/A=<*8',@0%"@A) 2G-!3-C*8@IRC7I #K#B7CXF8
M[3Y<?;J'J#O RHWNA><LE.*U$Y$#8X($8H. *,@:6\.E]2;[&)M< MY#R[A9
M=\/CY5!Q=X"8!X;HG3.#RCF?<H$H.0?%*/B,)5NP)="NCIQC:8*=1ZD:-]5N
M>!0-IX(>\/3]>9_GC,D@13+6@\9ZS6"8@YB\AV*D%8PB#5;&FLKZ!)PU2UQH
M@+,FJND <[?G-9YSX5GR*M&VC=:$FIT:P2/YD(RDE)"%TFB.T_WDC)L&,#R:
M!A!Z!]!Y/@NKU4GY>U@NPWQ]LGQ?#VHW<0=3D:= 6WB*OHYM*0$B$YH$Q'CA
M-J,N32+\!RGJI&KO\.A^&)GW"I[SI<6]29Q1G%IR$>0&6H3HI(248]9<.AMY
MDZ2,1V@:-UH;2.N[8&D/%72 IG,>SNUHJ,W^.(I-B3,HHAY\I,!3&\Q1J>@M
M:W(^=(.*#A&SCVYOW\;M+>@.4')IA]_0YON:OEU->$*)C@<0Q=1VMS%3Q,EJ
M<7PTR1;KG6G2INPN*9T4_ YX +V?E#O R>V$L]?SN[<\[Q>SV:O%\H^PS!->
M-&;F!/!0Q_%09 G>Z@)9:^2Z^*!LDTC_B71V<E*])RSN%$>UTU$'$+S;P ^=
MT^B\ HD;80D%(=?,0L63)[MMA6D"LCV'([6"45.]W[9D!REA;Q1]V62]TGI9
MK@?:]NZ..X\*75:D;QFPNHT4O"KB***)TA7-A6G2[W7/<?/-(K.CHNDP-70#
MIT:9TRBYMY;B%\^Q=BEUOO:$KX%-*EJHQ*5NXHF-F(G?S)L[)JP[@$,'^_45
M!ZN/BP<N)3;;221U;'(E258;WM\CJ6,U7>,'7'Z=)MS6/+S'M#B=;YZR:5<R
MD>2)!V0:DC22Y.$YN.HPF12*J--LC6M2\=6:L7$O"HZY4+J"2 =+YF;%IT["
M.64,<*M];7SM(2I;P*/Q@2-B\4T&RSZ]W+;9/<,QP;B_\#M SD8LVY[Y+\Z6
MY)=O%\3677^+?VS^1%Q1,,D,LY!"$J!J2Z=@%+E8Q6:54>=DFA0P[4;>N+5,
M1W=\AU57%_V5'N!K8XROV/+:.^')%C,;'"CA4KTG3)"9ML[Z[$ML8MAVHF[<
M(J<.0'B LGHWA-<;F&V_7T_CC'R(1!^MO? FQC'KM0M@XF:,N%?@."\@G%(\
ME92D/;Z!_"[9XY8^=8#9%NKMWJ!^GUTEM%<J9;"F'J;X+.ODP@ Y>)$\+6,C
MFS0)/HCJG<#L_XG!W$"Y8_?H?(#3=TO\#9>GYT6VJTG@-@I5:NY0));*IBB2
M!Y >:UNW?#>B?Z!9YV[OV^W8GOW(4&LE_=X!M0W_!1>%&[1@=23?!<E8.<D0
M+$//BR?IN3@(GG8_M^$_]#50(]EWBJ;MNGB/U1#CL]4*U\_2]MB)=#K1SF9.
MWC%L&@$H3+6<VE@H'NE_45I,_!!P/?KVW;#V0U\2'4<SG4)OLX8>XB]FZY%'
M"ZBDH9V?27"9TW>2ZT023LC9(<A[[.6[ >^'OL8YBE[&QMU[3#4?;EJF::.]
MR\2XU2L2^D5[^&\?%^?WLFBXE5P%\-&3AU#H.Q=- <>RT;9$7X+9"7-/?/%N
M>/NA;T.:ZV-LK#VVEBZX?/DG+M-T57OKY&R9UQ:$89HX2Q9\J+UU6*ZWG"+R
MV_WG]K!N=UZ[&\Y^Z(N.QKKHX/#O1@'E=J9%-<_+>G>X6O^&ZT^+/'%.>JYS
M!H:!;#.K*T<F!$Y>@37"^>":]-C>A;C=4/A/<04RN*ZZZ.]^3T:30,UB2@6*
MIB^*1U%O$AUX4U3"4)B+3<KK]TPLX_\\=QO[Z^' S+*7\X'0=#?;4JK@2I!@
M5""9<%\@!-*]S8DEIQ))JHGQVC/E]9_CSN$@+0P*I2ZZJ;W;:.@3KLE5G=UD
MLUE/M9OO'+&SVB/,'[6_&GG\A2=51W*I!,H$1I% ;6:C,UIO#).N3>Y[R_YJ
M&P^U;O^K][@I+/^XJ*YJF"<\?]WO).#E0_&W#3:J@@7XII,BA=L0@R865!8)
M76#>BYTBA[U)Z*2>9##DW @=CJ.8'[GSY/-G'WY]]>;D[Q^:6,6KIQ_-_CW
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M.NL)D*_G7\[6JXW$Q$5P0#L%3]: #!1HJ,0UQ$1H23PD9R(/.33I7OD(39V
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M4Q#Z<)KY*.KO(';Z2)\[*=<XVHX1+]DH61P(9!)4S@9B[44@-<6AF3N1,[;
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M76S\7)<45UXHB+F*:]/UQ<<,WCL;>?8"Q2Z'\SL-)+Z7@E[RAT>-4H?1S]@
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M7B3E;O]/OY&49.M$B456LI*>F8AQ2Z)4E0"^1 )('!*$6OFOO> N15+5>C_
M['C!Q*7Q[2 R!D-[ \5RL;Z\V,P7'V<A&YN3YF3GFVV,@D[LXC)HQ8L2*;!2
M]AM@M/,5$U>OGPX8AS&U@]CD:S(LEM^03):+L'F,5S,?51+&&9"E3GHJ6$<S
M&:P\TJ$V2,RZ26>V9U<V<65Z$W"U$4L'.+MFU_O5LN!Z33(*%V_P!S4F"\\5
M"L @6&VX)"$J1YA0W"2339;W9ZF-:L[M6-;$3=&;(FQ$@70 KW>;3[C:R; 9
MLU)'E!Q,[5.C@@[@32'/4<B8=5$RWZ\#&0=>3R]KVCS4MO :42 =P&LW(;R6
M[F?C(9>B06DGP$M!NIBV#])24O1-+NV. U6S=-.3Z*PCQ7 XGI:;<-$T%O0+
MQLTAD9_MWXT5YWFXB)&B.O7!/^X;OB."\1BQ6C+UR*E== QXRVI/,5ZX]BB9
M:9)/]OARCE45=Y]Z*UJ9<RPQ26!1U*9ILM1R-@TAJ!*8BM&X)HIBQWJFC>J,
M@(3[NF$,OG<<):[D'7Z#=>NOQ]02#>^J=B!$B"A#L Z$U+5]I26[015#5BI7
MCCGMP_WF!CWKBA^7'?7YM<WBZG*;U/(#OH7,(BUCK;2)GNQPH\%[F<$Z6S '
M7ZQOHAR?7UJ7&F0(/G9?/8TBC0[,UEO=6L)J]6V^^/C/<'&)-6?J]7HS_UQ#
M"V_"?'7UTX=TW[UO$SF95#,"3*A94X%4M$.G0,04C;'>B#:!H%&IF#94W12U
MIY;QU('M5Y]JEM_ZU\5W\MZ5UY\C9CI]?L'5_.LV&? >@<DR4:348&WM7<L8
MF1CD>4#6:"-SSLNP7T7^(6^?-AP^(OA.P__.S;'7+_7;95@<<6'_R%/&-,^>
M6F!C,RWH:)@E)]QA=<<E8<K7%%@7!$O9&I/=^9AI=U7F5=<RSGQ0G$L(R=71
M=XDHU+S.OTM1.:U*XDUF?3RRECX-L0$(>,R5.X;?'5A>=TG8=OSTJ"3/0H%C
M)H#R(4' S(#S; M/Q1)-[1$S_6B8HZ7[)%H&L[H[L/P6/N-UZT_)2VU<K0 =
M"]7=((IXD8!1>E>D"#8WN;;8M:">@#-<T$_BYD"N3VT#TQ'_?K7\N J?7RY7
MJ^6?=4CK=:-7-$PI9Q-8G1(H5$3&UL)#C<Y)#,J(O2S=W>_H"0^'"G Y/C<[
M4"EOEXN/]+3/VR@=_<UVMQ27DO&:04XV@N(Z@O,60>10DJF-$$(3=?+88J;W
MP\<\@XYF=X>0N=Y,&+5FPF1PH;:?=K2MHO,9LG,H-&I;;), Y./+F5;C'"_F
M9W!S ,^[0$Y8W&3"W<QD0:>#JPEP6=$_/"8ZHJ6 $H*(DB=B61/WZ.%2^D+,
M(0)^@)FCN-T!7NYJW[??RW)YDL%8P4%;S$2&8>"+*77*LPS**JGNY[6W,'??
M]M%IO:V;=!C3.\!.7?B[\HI>/-^\":FF@7S[>_BKM@KX;K.]"E_HD\VW6=3$
M+U>3;R.O26REWB=S!"5$"%$I84V3XMPAB^S)ACX0%?<55"L13>ULW2;L.R6O
M0_KTRRK\.0L)T4>BQ&]9%EAM,$9\B^B#CU$:A_N-NGSR-3W9S<?!9626=J";
M[G+GUP4]&=>;#V&#VZ[K^3VN4I761YQ%YI(I28-(N9[8)4 L*@+W29(UZ023
MS7*>]EMB3Z??.'JID7@Z -[M743^""N<!P037:BM-&G[%$)"Y-$G4C0LLB:)
M9K<7,6UI1NM#;1"+.X#'31?,Z\O_]?JR]BFLO?;7,Y]-8=X&<))S(":P.D8S
M0M0NQ82,<99:H.6)-4U;==$"/&,)H/,+\=\O/W\.JV_+,L[-^*['C7E%OM>2
MV]Z5%\.--J6 #G6ZA54.HHI8QUX$GYU'U&=^5^XC^:=<6>"L]L(J+$.4H@ K
M6I:4G,8V'37.Y:Y\" +VN2L?PN\.CJ='[O4*1ZVCU6!S+>>PS(+3@0&R')BV
MJ9C0I _-.=R5#Y+N\W?E0UC='5AN7?H%ITSP-M/J8P+E+$*(9+?GA)(K;Q.3
M36(]9W-7/DC0^]Z5#^'ZU.&;)VYWF42,(7*P0=8[78%DA FB*INH;$2'<K\&
M&6=W5SY(@'O>E0_A9@<JY=%;/56<09'JRI%H2(YVBR&/+]D2#=H46)N^CN=Q
M5W[,&70TNSN$S/5F*B6S4J(#X4($Q6@SD?%6((O@958R/1C"\&]V5SY(S/O=
ME0_A>1?(>7![FZ./7FI&FRD'4%)*4L:,"&*Q*M#DG6\2@CF3N_)! G[^KGP(
MMSO RZYP5"F,!<85,)1DS44O(#(=(03C.2;:37@"G_IMOW?EX[E)AS&] ^S<
MB5E+)6)A-:J@ZMI3-C7$R" XQ!"M$B8V2:X8?"UP\KON05)]ZEI@"(L/AL=7
M7,5E$^5R4S_XXG-M;39#)HQG*H.(2'J7N%&SE3C03Y7D@AL63W!%>7=1/5G"
MXP!H-!%TH&]NKE1OFN)==WZY&M!PTU=*Q^+)\ ,M*DFB%-HC/$$4'D/06C#;
MQ*_:8VT]G6'C@&ML@72 L5^N7_MFOOA^A_8;;NO-T"E,((6IDZUL!F]< %MD
M<&0+%)-,&VWUZ'KZO  _3E$=S_CA^/%7^%G@QVT;Q+%\]S^NW8P9\PFUTA:D
M3I4C4I&56%N5:QN=4L46TZ0H[_8B^KSO/LHJ.I3%H[7F&LLF>A,27A_&UG+-
MDHF 2>8:U>3@%2KP6C'/E1#"-6E1N6M!TW8/;&\+'<CZ$0WK-ED2KY8+>M5F
M3@?R;\O-40W_GWK<F%D2>RVY;9:$RLERE :PE)IRA0:"-AE,DLQK[U1(S6H#
M3I,EH<AU#(4),"S5+(":"2U3!%V,I3U5$L\GJ'[H-TMB" +VR9(8PN\N#-\'
M-[HZV%B$BD2!KI5GM9>*#AE<3,Z6(EA4S3*'>L^2&"3=Y[,DAK"Z.[#<ONZE
M361C+F#H/*:3-$EPF 6@X0Q9+DZW:\QR%ED2@P2]=Y;$ *YW@)Y;QWTEZ?KB
M1-KBLRZUY"S6P1<Z0;"TH[(-(NK"-)E]+:#SZ&IZPLVA@EZ.S?6I$VSNFXDO
MEV&5WY5?YBM,]&<WZ2&^5J36B!,9[F3-*TLN@E!U1ACY#!BU5/>/K5TMV/9Z
MW[10&4&JR[8L[@@UE4/_%1:78?6-I.VNB8G*EY ] PQ86V](!%?KG%GFWF R
MF),?BI='WS3M[4([I!S/UMXP<KG 6Y34DN@<8_4'E 05G0.O%+$LB8 E<X=I
MSYZ.3[UFVNN!QN@XG*&=0>.WY=<M#;>HX4IG64>92/2EM@,*$!$9,#JH':+R
MY \< H^'KYHVZM\6(D<RMC.8_(+I/C79,I-ET5"'4)#'2%9<\%) ED%H9#)Z
MJPZ!R<-731OP;PN3(QG;&4Q^G)K^FABG1? Q6?"9BSIHA(C!6I>N(RE'QM2#
MZMJAQH@? ))FX?U3&2.'L+4SC+S!N+I'C4X%<^8*9'*&;/!Z?@HCH$2E W)+
MY.TW6/'95TT[[:<M2HYD; >!E$=SH&.HXX\2@\R,K#0DJ.B'PI![JZWF\5Y?
MQG^GRH)CXK9'L[M#R-RTM PR9/+,0 =9V>(\!,<L<-19F!B\L$W26\ZFLF"0
MF/>K+!C"\PZ0\[@RIH5&7FO];&2U;8$F+Y_S""9I*6(B;ZY-UD*'4=LQQ+Q7
MS'8(SR<$SGJUF7VH(QRV&\C()+SR 5AM0:'J2#ZO+)W:7FHE"[/)[Q/>IX?>
M @E]=Q\@=][:4\KEX>?/X8SL0?K7H U28,R>".?5M')9@P_&D#[-41G&>+E?
M GND_*=4"4=([+[,#V#?Q%+_^WQ1>_%=+]RZ(!S+"ERN@WZ#YA"90T@H0E%6
M%B_V:1>UE]SOO'EBR1\BM^483)Q:^E>=&&_:FC/%T=D,N9@$*ED)3CH-G%OE
M=-!8]#Y%'OM)__:;I_$\1I/^P4R<6/I_S#=U5-BOBSS_.L^7X6*K #DW)6>3
MH2AOB0 MP!G2AQG)+A(\HM*CG?V/KJ"G=/GC[(#C&=P;0OY[OOGT 2^VTEA_
MFG_Y8_EZL9EOOEV;S[Z@8BI'(,8(<KQB!%=*!&G1B9*Y\7*?H0*'8>?IM4UW
MPHR @J<P-:)()D;;3>+"3>B02YWK !>LAZE*D8'7&$%DVH$IB>CW2D_;"TQW
M7]T15L:4[G(45G<0W?@Q4/"'IOXP7__KJJV$CB5XXH:P*M8&:HF4-7.@6$C%
M*N1B+]_U@*S&W8OJJ:IGC)38D=C?%91>+1?;W/);T2 F:B,L3Q:<L*2C#4<(
MELS"8'P4F)"C;0REAXN:.MEQ+-'OQ-21<NCL0O#JVS6)YPV&S>7JQMG@@8?$
M31W78'UM#X 0*TF*"QT]S[*H_9J,[?>^7E!SK'"?N"$<@]-=**3':^E4<EDR
MX:"X.FT\DF/J,G+PY%;:+(U'VZ23]S$]7DY4<#AVD<=A3.\..[=J)KE!KU7M
M?Z.D!$4*N;;:TI LMRS$[<"@]N 96*YZ\MXO@Z2];[GJ$-9W *%[2G6F70P!
M#0>F$M+R?0$?B3NHD$6/SMLVI9;WUM%3;L(X@#F&T1W@Y.%L]R<'O[^=A[B=
M_5-O6*WR1&<=DDD>:VT1048C!.$]8E3<ZB:JZ- %]W0K.0[R3B*Z+KI[/-:F
MY&^KY7H]T[*.)*]Y:*[4*+VJ]_S2 >H<>*F3\W@C:VK'BGH*>H]U(H[!_"YP
M=*>%22%WQ01F(:$MH$KQX%!(0.2:1V88QC8C=;KO$G,,6@YF<7==8IZ<)>62
MD<Z+2"ZHI%.^U'%FOF@PB65NN5:F#7CV7V)/CET+TWPT\71@A-US@VG[S&Q$
M'W.1D UMF*OIK\45D"ZB\'4T>9N6>@^7,FTV>GL@#6;WU)')NOP/F/'SERJ$
MOU]>;.9?+O ?7Y8+.JH#?3N3*A$%2H&4N8Z4K=,5B\B09,E)*F=*N0>>'4')
M9U^U%SC<.8"C 6NG!LH]U_3U_UZ2]7]EQLWIE%[-/WXD%9IK6YZKSJ3)!\&R
M!5[;<BDLMC;CDA"X=R9FR\+]B]K]8MG/O7@O$/FS 5%+MG=P6+WXO"3B_N]6
M/E>S[VXH>;_"S_/+SS.T2@J5/6T*%8@@'<%)(LW*P!C3*2;=9-#3LRO;+US)
MS@%I;:31?9^]W],GS)<7N"S?8QW+LOF$-^&.ZRNC8_OO#7W-J-,+CR&Q;;\^
MK7UDG"O"#B>'WUNRDH3#.L0A,"V2"NUZDXW?K^_@^%FP,6#Q"C"GVF3#"7 6
M$8RWP9%+FP-KPH:FH<]3=_X;@J71(I]#)#>U]78HD2^^SZ*=91<*YX6#1:6)
MQ\:"XRX!SU%+S9)V8;\F.\>O9?J+GY$P.(5L.K#Z'A+UMS!?O%VNU^\6#S^K
M/<01O?;"&Q YDTMM+ .?3"&SMDBOM"2K]D071,^L=/J;H>;J<4Q9]:<7?V0,
MO5CDUW]MR,NZG*\_52/[RB2>">LEN?4(R#B2WF<9?)U@Z .Q&*-(P8@#%>&S
M+Y_^1JBMYAN7^R/>$YVFT_<[,LU7OR[*<O5Y^XJ1.W_O>GS+3N![D=36T_!*
M, P\0A2!\&D(,LY[ :S$$*..3(0F(QQ.UQF<^>BLS YR++4^56ARRY.I/?5#
MR45%E64K"L^A,_@0!.S3&7P(OWNKUKHJ-'+*!RT9A"("$5 $Q"@8\.CKU,3D
M%=\GJM:XGN^D_< 'R?3Y>KX!#.X-(<^4%\62M38H:Y*& J5B911Q*W@3@F>!
M?(U];A/_+>KYAJ#@B'J^(2+IJYZ/>T;;S22PM3Q:>4'FG*W-B(MP6I7:&F6T
MIA+G6L\W2+J[Z_F&L+J'(,$CUO]5,XX08DFZ0.:6V,&)A.!T *-(78ML0REM
M8@$[%C1]-&J,HVQ4MG<*GUL%1E&1;UIOKDHR%I0ENESTDC2S,<IZGD-L,E+[
MZ65-:Q6-(_H]\'2@'#I U>/MO)"CD1P+*(RF#B#GI)L#!R,LEYH(1-5$(W78
M0FU,<>_52FT([SL T",#97S)P7%$*%9[4"*3FYH3 ^8YUU[P$K%)AL.!0YI.
MVFSMF)/L2%9W!Y9;4V0<%AMYL&!X(3J,%^"-)K:@1,-L8A)/,'F[XR%-@P2]
M[Y"F(5R?^F+CEK)\3PR;K]?+U;=M0/9FN(?GY &$ #$QTL1:.8A22"A"A"*M
MD58.[D#]Z)MZPL:APMR1D7<\9Z>&R:T^ZR\6^78_[=L4%2^]]RR3_:<UG;%$
MEO=1@M>DD#-G.J7]6MKO];J>_*DQ #,^CZ=&S>U)'T32[8D.MTEB,C+KA0#M
M.9EFGA6(Q6;0QFEKR:.(9C_8[/>^GJR7,7#3@,L=V#2/]N;6SGAB@P+';2#P
M)W(P0_U*N)P9MQAX$WOFX([W)^TT>(P1?#2[.X3,39LS1CA//D$TKJ8=R C.
MBP(R%V)/U,*K)I>>9]/Q?I"8]^MX/X3G'2#G\9"!%H8+GFI3&%J_*AK!"RDA
M2]I(A;O$59-RN [#-6.(>:\PS1">]]#S_&H#:1:4RAPBDD 5+PJ"M0E8X0R-
M=KG<GPMWJH[W)VT+>.C-^&&,[$'Z-U,. W>B]JXKVL7:L4Z3:84>0A))>T9X
M3J-UKNVLX_T@B>WH>#^$?5/W/+_3K-UA#"K7LEWKL?:$$U"[=->*;Y;(-S&2
MC]9DML..]X/DMK/C_1 F=F J[*JGTX6'Q"KU-6%,(2/WS=&WLA3E=8Y"BR87
MA6?38F^\$/UA3)\Z&/)J^?GS<O'[9IG^]?LGXN+ZQ<<58OYC^1)_7U[DJP\N
MXSJMYMM"\.W'E=R9"-;EY,FV<MNJC6S!,>E!1!F$BU:J<._:<&<(]L E]!2;
M/5#ZRY.+H@-E]8#0VU2M9UX*49AW8%4B:BS;Y@IY\,5KK8BK/C:ZCWYJ63W%
M=8\#6P,Q= "JWT/-2MM2\WXU3_@>5UNJ9D(:KA7103N$@XITDGN9#3!BG*;_
M9>:;M'O<M:"> KWC &D4UD]_$ YK5<%1"HM)@N9$H-+((;@H@31QE#J7%-5!
M4]='Z1!R\JYZ1QQZ[=C>@59ZH&-KT2OF65$LDE=*9)@:4%(F$K]2)JI<%"EB
M0->D:=J.]?04M6ETN!W ^ [P4ZM5U[5<%6O!ZF,5A<5P[C6I5^'J8%A5'$2F
M,R0>(Z_I(L$TL9:>75E/OMXXF!I7&%VT ;V]-^Z>W2F4Y&RP4++,Q"A#I.A0
M("3+HC;":H--S*9=*^JS^=Y1=M,HS.] 2[W(_W.YWE3&K/]8OLAY7J42+MZ'
M>?YU\2I\F6_"Q;V#OA:-/!AO,4LI::95JEU(Z'3'K(ADF>KM7_0I%<30Q%8?
MBX ^>P >@]%)1-L!I'<./\"4'7,9P<I:SE3J;)>D R2+SGGTLK!];E6.C*@.
MG#MQ\HZ!QT!N%-9W!Z$GF_0:*URHS9A\*;9F004@>T% D99Y5V1M0]$>5$?W
M4#Y]O\#Q<#::?$9#7J.V@;B8+U>_8R*EG.^WNSBV5^ ^SQZU0>!@8MKVZF#)
M)9X4@5!X6=M7>G"9%):40O,4M4;;K)/%:7IU&/*=N762-&^BG1!J3;A-#*1-
M/!=ZAI8G&+O4;Z^.(0C8IU?'$'YW=^9==1&P&DEMDANCA*O]Q#WX'"/H%)EP
M2!I4-['I#RP0.VG7CD'2?;Y ; BKNP/+K:1SM$GP'&O2N20Z)/G P:E0<S&D
MLUPS'TY04]AQ@=@@0>];(#:$ZU/?UCQY\/\];.M3;O*!6/'"Y@"9(Y%EB@17
M \"6F\3);B.:]VOEOO\[>\++H0)>MN=VWR"ZHB<Q$VWT#HPOG'@6! 25:>-)
MC-J0BA9IO_D1>[RLIQ2#]K 9SM^N\?)?EPN\O0^D\8F; D+29E!%&' RD@,9
MA&'&:*G,?M?# U[:4V9!<_P<P>_N3)\?\0P1.",W(8-AMEY/B@PQNP@L*J<R
M<>PD[M7;0?F:)VT.-)[%?!C3N\/.K?BHDR5@2A&0"**SU]4J%1; >Y^9+#:+
M4R3[]CX2>9"T]PU-#V%]=Q#ZQR)<C4ZYG6=C4]2L3K",7( B#D&L;;"S,RQQ
M9#Z>P@5[9&4]J:06H#I6&%UWC=[>;K\,ZWJ<?_Z"B_7VH8>$FW<\::S@\CX+
M'2N4_#V(^*[<?MFVI6)]_WJSWBXGUN6\#]^VE['? XZQ*)V"X1!E+6#0WA(V
M!"-C*XABM&9"MKDZ.FK91RNP?=_^\O;;_R"1O:3'_&LFT4K%M(9$)BCM5\?(
M[2"#0I Q(2P3QO!IN?;XNB<^44^'U <Z\H3R[O@"[W&UM+6,#[JT>_)Y;77I
M8XON0Z/:[$,2WI,K&0S9<JG4LYP 8^I!B]:61@WW)]6H-[/6ZM">+Q?+;XB_
MX^KK/.'CXGMQL7WD=M3>!TS+CXMJL;S'U7QYM=(?>R]R)U,FB]CJ6HR+C&QC
M63CP$'6=A6&4;:)KFU%TUEIX"+H?)"QV@9$._*<?C'APZ+SX,ZRN:O7>7152
MU5%85^Q8KR^OINFNM\KO!_48G(IDXI/W*.EDY+Z +YR#MEDG'S$JQMOND#'(
MF-@SZV%;G!P-G>Z%VP*X3?V+M)E_G6^^W:-8.X79^5#;J]1)TBR BU9 TB9P
M&313HDG4\_BE3QQR[POS#:7>LTU>*7U(__?1M;=_^OJO^B66Y>J:-7];A<6F
MCA [..]NS->/9O&W8DD?#@(O2FW3NY)*@8 K+2EH0PI&QE P<1]3F]AH)P["
M#FMOM:I=6+;O?/GM\9/PNN=&9#$$':$([<@99P;HI!/ =)+9)<Y-LE.H^[TI
M.&L'8 AZAVK]-ACHP,CY=4'*[2HO?!OXO_9KKN9+%&.X=0Z,2T1*+A*JE49G
MJ0X)'8K,FE3*/;&F:0$Z$4J6;436+_JN\RN8#C9HR2&H6@/!.(-84NVWD!Q#
M+VC-3;S')U<U+0)'D_U^F#I $!V@ZF^XP%6X>+'(+_+G^6)>SX<ZQ?;:(KM)
MK.%$D[4(,AFL3H* J&DSAEP'=[F8B(,MT+77ZKI$V2%HN%]I/KIH.L#;!Y(.
M+>#3MAOX5[Q8?JE<NTN2Y=Y@955FO*8#NIH.J 4(D;-A+#E[/]UR'+3ML;9I
MPUOML#:V6#I VK-FQRZKXT="AY7)&52E=K^BO:6YA. =@E8.;<1@V?VL\1';
M'QRU]&EQVH?M=V( = #YZ[L6S(^3?KV=9YSY;'F]?C>:G#\M'41T'$A/F.)E
MR!J;W,7MM[R)W983@^9^IX7Q)=ASU+02F1]0>4P@].DGCIK-L.?"^PA7)I.D
MY=7A0:Y "6'!6W)]O'*1H;(FMAE/\K.$*X7W+BEBG>:TE97"0*Q#1O_0AM$8
MN.!->K7])UPY%+WMPI5#,-"#-;!=^<TD%>%R2JZ>$477].&8@?Q&!L'1@22S
M<E8V<:KNK.)G"4D.0L+](_Y@L72 J<,9]X/L17Y_$1:W:L."L)Y%Y(#6:%!8
MHQ=&9LA:<ZND(?N_R=G4@IAI$7X$MH8Z3ZT%/76=YXL*FKK^Z^@'G3F,ZR"@
MFO>@G+'$1R'KA$->,GVE[M_W[JCEO/?@SMV=YF)>CL3S'I3CCW27FY%1"HOB
MM ,])K);=+2U(#6!163&&14+-HF;/UC)Q/&@7E VCJ0Z@-KWU-L'A"0FC%4B
M@0Y,$ENL 9]J,,(5:YCP =N4 NU<T;39<=U!;QS)=0#!&YYL38U@E4TVUL:>
MRH+BU<J(V4**6>F"627>))OG]B)^EICW,<[%P4+I"% WFRRJPEPR8+2KX]L8
M6:_%5@2HJ!@BCVV\@I[L^</%N0,7!_"V!T-<W3(*8](B"C1@DR^@J@8.3-71
M;LA2<8@I[M?*Z=Z#^Y#T(0*Z;T(?RJT>)'W;_)<HC1.!8(ZV7F/7)$4;"WBC
MM*YS7%/>KWW.(2Y7LX-B3$D?RJT.M/T(%VW1<*=]D<"4I(/2\01!&@F%S"^C
M,O/.M:D8.<WU?#N;N M3Y<0 Z #R>]5+_E9;7*TW>.5_K/]8;GOK__B\7I7\
MMMS\']S\J*:\76<S<]QG94N$[%#5YDCDR3IO@"OEL!3AA&K2:O4DU'4>+1L9
MLKM<QV[P\S-OJJL2Y3?+U?6/ZN_Q6<DB*<4-:!/(GD(?(-A<Y\4J1YQQHH@F
M>=:G);/S<.&9;K/C$36UA?[;934UWY6K"7VWZ:V&Z'K&BG0E& /165%GT"+1
MX@RD$)RW0M+'^UV2//.BSF.*;? YN@0ZT-X'L_*&#]=#DK^&^46U2&ES;4M'
M9RA49+P@$)L#J"QB[3AD@0G'R:W*M0M_5[[!,P1-._%S8HW<!4JFUKT',^'%
MY6;YF7XY_;I(*Z1/?UU<\:,.%=\.GKLUY$8+G8IFC$XC3J=1D@IJ^V7B"//*
MV\BE+'MI\),L=]J1I5.> _VAX9Q/D]M=!]:_+JX,M?_&^<=/U<+[BBMBQO;#
M7\(&WX3YJG9PP5G1.9LH:Q5AK;B1PI,B"1J,B3Y:+I4,?=6''$;GM$-<S_7L
M.0&F>MER\7GVQ!WL^>?6B;IASW<V\!FJ$ .=PQ XJ[W<F0#G@R3I,649%D_N
M4;.]U8"@:2?7]K")ID9)+[OE$#%<'=%74X)OV##CV8ND P>1Z!]5BH>@-8*E
M'S.N4Q"N34_%,:F8=EIN#_MB$CST7!7V3..HQ[KG->R=]=3K3M4K:V^2^R@V
MB['$X+*&Q#0!T28#P2H.GJ>L.;,8V4_=//?8:U5M<Y#<,#K+!+E=PM7N).1[
MF:)]4B8FZYK4ZORGV&PH>ML5FPW!0 >6S=W*$QU")-NK1M.(C\I;#;YV6H_"
M&VZU1!Y$"P#_E,5F@Y#P9+'9$+%T@*DVN=M6,>OJV &/M+MU#N!$,<!]\:J@
M(Y]AFHN!,R\V&X2MDQ2;#1!T!V#?71<0K36L]L156,C'E4Q!J+.E3,X930I*
M\2;SQ(^KZ#BSDK4A8-F[HF.(Y":$X'JUF7VHW+L:*ZPM9XKV<'$\TW&3"X1H
M+&A92F*6.V3[#)"CA]Z"&GUW'V9WWOJSU&X<<E8?SOX>,',-=:]TS,H'6J<U
MH )*<!$U2.>SDDI&=C\K_TC43*F*CI#8?9D?P+Z)I?[W^6+^^?+S]<*9]\ES
M[4E=NDC'?BV%8TF"<89CMJPD-YJVN//FB25_B-R68S!Q:NF'OVXM/,7DG-0,
M4@QTP#&6P9F<P 0A,K%$HMDG4+&?]&^_>9KS8C3I'\S$#@S5$4+F'J.A4[&
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M<'W]Z9K/6 B*ZXAT_NBZ;2,G[Z\$,"4ZCTH(Z?G)K-WG5MNA$7P<?D\GNPX
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M\"X(\)9%PX@4M.DP]73W17M!QI\-9$;G;8_*Z6^KY7H]TS%B-)R3-U1JZ\Z
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M@CTO)#]*+?GCV9'-BXX74*(V1L^!MK'5(6CTWO,FON9QRYXV%Z(C#!\KT@X
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MO_B^_J#^$\,:_]__Y_\'4$L#!!0    ( &B >U";Q-@C4Q   (%K   :
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M*7#&=A!_4D(^PAQYQ%(!*DP2M:#NL+Y(G8TAHV' X1B$-' -  T:(LL_TOQ
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MMUS=>()T9<0P!0Y.3.'+D1EQC"X4G#7Y8!4O1X^V4A/*)U41)!RO()5+[1<
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M? D4_H DGK0'"H?NCU/1G\EZ_3]02P,$%     @ :(![4+$?]SAM#@  7UT
M !L   !O8V=N+3(P,3DQ,C,Q>#$P:WAE>#$P,2YH=&WM7&USVS82_GZ_ G7N
M4GM&LB2_);9<SZ2VVGBND3VV>IE^ZH D**&F"!8 K:B_OKL+\$42Y::]=D[2
M5=.ZE0CB9;'[[+.+)2^_N+F['OUP/V 3.TW8_?=??W=[S?;:G<['X^M.YV9T
MP]Z//GS'3@Z[/3;2/#722I7RI-,9#/?8WL3:[*+3F<UFA[/C0Z7'G=%#![LZ
MZ21*&7$8V6COZA)_@;^"1U?_N/RBW68W*LRG(K4LU();$;'<R'3,/D;"/+%V
MV[>Z5ME<R_'$LJ/N49=]5/I)/G-WW4J;B*NBG\N.^W[9H4$N Q7-KRXC^<QD
M]-6>/#\[.XW>Q"(2W;.3XU[,3^/SZ.W9T6GW)#B-S][\>'0.L^Q >W>3L?-$
M?+4W$3CXQ9NCS/9G,K*3BUZW^Z_^'C6ZNHQ5:F$H#7>Z_W4=K'1CQ2?;YHD<
MIQ>TFOZ4Z[%,VU9E%SWL>\_U5;0/>/@TUBI/HW:H$J4O]#C8/SH];17_LNYA
M]Z#OKKWJTJ>/';1C/I7)_.++D9P*PX9BQA[4E*=?M@SL7-L(+6/7T,A?!"P&
MQJ:O,[]0Z">1J6C[A?>.:+6#3Q,92,MZW</C[N):FU<9PHX(O6W+O+O^_MO!
ML,5NA]>'?VR59YN_R,?1W?6_V=W]Z/9NR-Y]^S 8?!@,1VN7NV5;^/I5[ZS;
M__R_Q;HW8DTGS6L:O;]]9,W;QO9?OWI[=-3MOQMK(1 'Z7NO?\"D85,>"<;3
MB)&> L;*U"K&#5,Q^['^8?MV(ICOZEL ><MN )2+OEHLF%,_@; S(5)V%^9C
MD8*AI.%ABW%V(Q(^XUJP4.E,:8X>8J'/:S7->#JO.L3>?ESZX*\P15 ^&>4\
M6>C@+L,^13FE/VB?VZ#"']DM&[$A&S#8=?@[8N]?OSI]VW]YQ2 W6.W%,2+0
MMBWX_>!A\.ZQM0VVR+)<FQP-!"P)];-N"D!2>N=L\',N[1Q_@ V1SX+=)WS1
M&O"'RA3P@K</!NQ':I@N=#[6?I1"]9W1%-_J37D8BLR2^2BZC#_"1,,)-X*9
M"<=V8/,X4JBF4VA@K J?BM_\Z"V6<<V>>9(+]D^D>YG0[NYE6\8>'K&':A5Y
MAL-"*["XJ:&IA@IL&:=CF!&6Q4K;"=@WM )L*@&+FN*-*)7?,.NZDF<\BH Q
MMA,1;Z?:#^\^MM@(=?^;NX?!=F@_[A,HB970Z01<"BH?;B0ZE5@EB9J9'<&J
M-1+H'6X@;VA4,))T)$+OCB\8S$MH; ;+N!&Q3)UM;OY*]JX.&=NH::Y1CG=)
MPD*>20OTXQ>@6PX*4V69 L/1,VD0MD'R< VM![ 0X!5NFG!P$VA;4\%3 #7
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M/C]PVC3XA+$I6I7)1"AC&8(5SBL3JYB19T1*U[E.JV[(,TD&#"&L* R6!XG
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M9^%HX$4P@$M ^"@9'\-FX14W)^YV!467 ]5;,Z.#)H;CU8&H#,@SY&9"67H
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MD%-I?(] %ZL31M>/6TS#JA?GX-D??Q).Z=P1IN.+,Y4GJ#EX[9G+I'X66FX
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M$OPOM?V_T?P& K+Y-WU.AW]3W!=>EK.>XG;<J\?I)>A7OP)02P,$%     @
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M*TA!DQ!ZX6VH=X/,-"%4/#64\ZS.*=M#IRSSO@/E(T=U!E(AOD0?ZU0" 2R
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M-Z']5- ",_)H%?;D$MKI:%Y-^1>[V)V4_@_\SK1>&BSH3C$_*Z-O].&(:\U
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M%^16Z;GD;,J;P?4F^)QIL$%IJ*DP!!6*4+4@I7*FY#!3J+*^X (.*,GAR0B
M2TH3:#)$Y\(1IX/<AH#B";>6F@6*Y/26P[AK.BVT,3 &AI2^6L,8*) ( ]49
MQ!1T!TL8-V2>B20CML2/5?\Y-[Q2@A/(A950QI$1S(7+8(*VX(DW$/468)IF
M,,T9=&,D7JPOPZO#=/^OAVE.4J$ -0C %4J: &@0A]=F[;U0*20ZBJP4OB>R
M9* 3D+@&B2:@6!BY( 4 "6, 8T/*%<@K?-D'0T,<,4]WFRA12A  9&N GQ_.
M>GL2:C.22CVW->P-GPKK@"L[0K$QV U6-M?0:VMC-JQ]=0 ^VEL 3^YY^^V;
MDUYW.+851"MRA4E,IZF QP-[&&HOXN&:4,,]\@!)(I8<$4(XP#V6PF;8#<5R
M2.28S/&9"9M(;4OHARG>:!D@6!B=< ;-EAP XA@'" =87=TE&5533MY#]KPI
M);<5(^C35G=PP-?LZ0Y8:#KT.@5R=Q6" $<BF&S78B-@%:UZVI#IYI I#(ES
M?Q@[(($\YUG$M'^\?_% ]RX>NNUHZ-<5MN^P\P,@^ +_;;PVD7LDM+2[=T$2
M$'.R'"G0"ET:4 "I=2:L3]@@Q977@YN;5:I?+Q>&2^HA7/&*%?B RP12X^N2
M0H'2(M'PH6T]*_%96UL.XSBH$CB9@D)()*6D6&S 6J][15B@1Z _ZZP-OL4<
M!:$>0'_.GI7_]Q'O\=[AO<[_]^&^<\K<0/WNR79G\$/ S 1#3%.K%<7Z0BW$
M W)Q!#HUK$8GA(&@L9#"+9#";!L60] #V6,T1,\]T34N[\O8736AHC0%Q(CU
ME"M)M&'> ,_J82\*3$I"J, ;7B 30A'8L81P #8G"E\_7EE )'L7$,L"P&=4
MEOY %^'"TQ1HM9B!H^T6>KPD3#MD_?"XG3'[ (".0/YMX.6Q+MWC%NQ2E^A2
MFN.F(_WVQI/$]7;&QW2U$F"/QR\.\)HPS/8.P\ND'M"QB3(\3JFXK7^S%<I/
M2.7(2W22E :QM,86MFC-M770CB?JH,LFH.BW$L@&J#YXI$L*00%)]H%T93AL
M6KD_"<)#(G]N&.PZ#%9EU"X9$Z9G'T2<^;KEUZ.J*0LBQ2V7U;'0 _GFLY?H
MV8&SC[OAP=X&SO-VP_Y(>QE[S54VQ>2^CO]58D4$/X%T;;#\I8FT9,)I8Y<\
MQS> RCP7SG'^E=(5:V!2^)X)L,\K.8 H@4IAL1+!_[C?J$.;_U8*,-^'<:D2
M?XIT^/<&]P5:^0B_P6-#Y-X"((R'%'CPD0@.6*LXRG*C.>?T%DE'X+Z>=GC6
M[D_;ZR/$)R&XVCR&8Z,M&9@RZ&CY,@$_BO:*ZT,7@"Q0\F9@/A9HCRUS !,L
MDY],5?BV'K:^2E:SOUM5)"^I@;S6!!AQGY(!B/['E@JQS5#[A9II.>-( !2=
M5K\9F2J+\[R0>L'A[3S3(673>_$ ^/U=V%%[YU_>J^=8.Z?ST7' D/,;WOL]
M_'K0TNFZB[^)$5IBB )NT'N2%I:/ZB_CM>L,V'^\CFGT!A2L0M+%2"CO!S]N
M=5'D]+0]C(;^KH@S\,=J>ZI[).UPCZ3CV.;+_J!]?-)__/U7.W_UY7'4[G>'
M.W;N>,.#\; DMJ#J7:/?J'O42$-?](J[)?(J7V#3CJ&Q<3]FAG0!B&O5&#0^
M@/9:0@FN[&XFD&\$S\Y!>#]V=YQ5X_P28LN7=_(S-9"[>\.FO\JT1'?E@C]J
M<3V&_R)K^_;-$:04_[GE<LN]%?X&CE_W.KXH6VJOO;CPJ"J$+SL%+)>6@I%Z
M?K^KSX=_P#KO7;R\("3L9O#R>NB?3A(?N^>8"9Z2#TOJ]2GLRA]<9/T;#:\#
M#0>?P\\M (0-2/BMX/O5+S-5\^%C4.EX%KS[I=DM%ZC7.A4Z7#D?A5]K9WS]
M'O:#&]J-[3UI#.FZ='Q<@2!Z\E7NZC/<*O?WV\__#U!+ P04    " !H@'M0
M[$W?HC,&  "-(0  &P   &]C9VXM,C Q.3$R,S%X,3!K>&5X,S(Q+FAT;>U:
M;6_;-A#^OE]Q=;#6 62]^/TE#9 Z*5:L:8+&1;%/ R51%A>9U$@JCO?K=Z2D
M)(Z3-MF SNT<((9)'H]WSQU/YSL=O#@^F\Y^.S^!5"\R./_TYOV[*31:GO>Y
M,_6\X]DQ_#([?0]=UP]@)@E73#/!2>9Y)Q\:T$BUSL>>MUPNW67'%7+NS3YZ
MAE77RX10U(UUW#@\,#/X24E\^-/!BU8+CD54+"C7$$E*-(VA4(S/X7-,U26T
M6A755.0KR>:IAK;?]N&SD)?LBI3KFNF,'M9\#KQR?.#90PY"$:\.#V)V!2Q^
MW6#MT9#24=_O#7M^MQ\&83_L#(?#'NV%_6Y_$/\>H) >DI=[E%YE]'4CI>;L
M<;?M#GJYGBQ9K--QX/L_3QJ6[O @$5SC81(WEU]+'AN<-+W6+9*Q.1];?28+
M(N>,M[3(QT$;>3=*7C5]2*++N10%CUN1R(0<RWG8;/=Z3OT/ONOO3\JU/=_^
M30R#5D(6+%N-7\W8@BKX0)?P42P(?^4HM%U+4<F2DE"QOR@J@V?;X;+4=8!\
M,L9IJ](]:%MM3ZY3%C+]<B_H^Y-.VPW6]7U8TPCM0N7WINJ42LT2%A'CYW!>
M2%40E%8+N*"1F2M!&/E]$ GHE,(%D2'A5+7.KC.Z@J-(FY6V[[?_&4K][0>I
M>5&$JH1#09/LEY@0'D,SK 8(P1I@0:?G.S!-28[J0K]C,)J9.PO!T(%/G)DH
M<*$Q&"B\]S'=?Q2\;76H[L-8_3L7@J9Z"M05!90H1VLHZR^A[  E45K+@:!1
MJ= MD4HD> MP9-;.HF).N5,>]XY'+C0-^50L<L)7R"06R#"EDH8KB.P-6CE&
M84,54F75484]R')]N3=L!X.)@DLNEAF-YQ3)4X(1IC><_"B6GZ'R1YP7)(./
M-!<24>#P5LA%=2/\UJ^0"&E!6E$B@2+\,1S3B"Y"-%\G<- '@E$)]OK&_=ID
ME0T@*;(,L<=1QE"')=.I79?TSX)):AZ2UI3W+N6-1Z$<0:\9W[J4]4L:%1*?
M^,CPY!J]BL]I[9S!J--UP/BA(60<%5F4,3-"9 @S+L0X;$H."6$21<TE548H
MQY"1+ /<CD C6+B0HY3*L;L3Q@F/S#PRCFWZ88]%JB(K=1(YE:2\(>NHN,]Q
M)4U"O"?KZQE-])@46M0!VCZ^RYE02+PMQM4RDBLZKK],[D1WL[\<,[0MUV/C
M.C%3>4968\:MT]ASJ^QB-'*'O8Y-,#1F%3JNY:F2#[=,/CP=;RYVAVX[&#V^
M_L7-7^8\< ?#X(F;/2MX*3Q"HM .KQN=1KTC)W&,J9Y%OIU?3^IQ*+06"SOU
MQ'M\'^8K$W<BDE5S)<,;_M:2 :)?3Y26##;#R%<N^I,#QGJ<>:)2C<-CO 8V
M#)X2B0&S/7!L]GOCR94!=M ^']J7>UU\YMA/N,!H=HDQ][10!<<@Y\!YZAZ[
M#IR^.5K#^BO^_!\@ND4N4,5 &T9S-+/(6 RU7;X[_]CYQ-:%A<$W,/LT933!
M! >3'<VN*)R5.2J\W.L,)^8G"\/4AN\<X(=U@.:Y9)ABYIAC;GC!_G/L7N7_
M(]1ANUQ@"P3;Y86[O'!+H5W+"PG_@ZS@H@@E0?9L%_C_M]G@SA.V(P1\NQSP
M[4VMJ7KZ[RS^PUK\3M*W879;8#R*(F2C35_R\5S0L]6[QUH\5=$O&.:/MOP>
M:!]^OQ7O(ZB;!VAU!#4KZ[%,P5(RK2E'P3&-L9W?JC =0[C:[(ND1$%(D3Z7
MXHJ9JGC53*C+W<9 2Y9E2(6<JGHS<KI/DQ22,Y7>,KA3TC;K-V5MW+1@2IGJ
MLI# M#*B)@D4.<X86:G2+LR,+M%:B]"T,MK^A$21/189VYE@\E#M&X58I@S3
M-V8 R$P?Q@%DR86&F"(P*#'+:'Q;O[\XF5I!*R)D$)IR>R1D+J1MG:/6DB94
M4AZ9%:2P_0"6&<^]UR6P#9[[.-Q6]#L.(/!D81L1#H@-TD>Z #=[H+E,*>Z1
ML""Q:?TD0E+#AR2Z.CA&H6NQ[O4T$ I9%?_-+S D,C+/*:<27>E6:0-[AF(4
M!"59:S?8'E.I^N.U_UR4;S&,K07PI+NM_7M-_\;#.TF(R4VAZ:0*I_ZSWPZH
M/LL7%>PK$X=_ U!+ P04    " !H@'M0';1JKNX7  #0=P  &@   &]C9VXM
M,C Q.3$R,S%X,3!K>&5X-#$N:'1M[5UM<]PVDOY^OX+KW&:=*H[>'2>2UU6*
MI$U\YY5]DA+??;K"D)@96"0Q2X SGOOUUV\@P7F3?%?9DL=)56QKAL1+H]']
M]-,-Z-6?+M]=W/W7^ZMDXLLB>?_K3V_?7"3/!OO['XXO]O<O[RZ37^[^_C8Y
MV3LX3.YJ53GCC:U4L;]_=?TL>3;Q?GJZOS^?S_?FQWNV'N_?W>QC4R?[A;5.
M[^4^?_;Z%7X"?VJ5O_Z75W\:#))+FS6EKGR2U5IYG2>-,]4X^9!K=Y\,!O+4
MA9TN:C.>^.3HX.@@^6#K>S-3_+TWOM"O0SNO]OGG5_O4R:NAS1>O7^5FEIC\
MK\_,CR\S]</P1:[RHX.3%R^5&AYEAX?')R^/3T[T\?<'_WUT"*/<A^?Y)><7
MA?[KLXG&SD]?'DW]V=SD?G)Z>'#PY[-G]-#K5R-;>>BJAC?YG]S 2C->?_(#
M59AQ=4JS.2M5/3;5P-OIZ2&V_8S;"L\/578_KFU3Y8/,%K8^K<?#YT<O7J3A
M_^1@[^"[,_[NFP/Z[PP;&(Q4:8K%Z5_N3*E=<JWGR8TM5?67U,'*#9RNS8@?
M=.9_-$P&^J8?YS)1:*<PE1[(Q ^/:+97GR9F:#PHP6%_INOGF,%ZZ/I+F^3E
MU>W%S9OW=V_>72?O_I;<7/W\YO;NYOSZ[MMO?C@Z?'EVF]Q>7?QZ\^;NS=6M
M?'MU<W4)6^;F]E=X++E[AT_0^X='T,3_353?/WU)W?UR%<OBZC\O?CF__ODJ
M.;^X0\D=_GA\LGWNILIAWJ<G+_:.7T"7D3P^-LZ;T>+)ZL[)>HF\RYJQKM+D
M397M)<_]1">H-$<'9Q>VG*IJ03\=GGV73)1+;*63K% ._C5*G,Z:&DPJ#*;6
M8^- &] 8@H#JY%9G:&M1F^!);/6V>_KJ4S91U5@GYYG'KU'J:0+-*S"'N<Z_
M_>;%#V>);>HDLV4)K3AOL_LTF:HZF:FBT<F_'J!-GT)';J)JO9<DYP[,,'1O
M*NC-N,0U)2S$(J6^862E"_.2"<N\PJ?XF,QX^:NY7OX$AA8^454>/FU<^+#6
M(QB:MTDLW*],K^Y H"-;%':.SA%61"7@(+/:3$DQ1"M*<*"U484L$4IS6MN9
M<? ,JE6A/+X.HEQ6!UCS?A=QZ]2=J #THSQ^4EF/+4P+[37U1&HR_ BJBAW@
M)_]H0.8CPWIDO$M@34RM_2(9+GA5=97I,)Q;\\E/DG-66GK_1CM/D.!"U[!H
M)H,?<*JP_K:>VEK1Z'J[;,N#[=;#IK%#%755AZZ&BT+-7:_1G^BC\'I*S\.8
M(\F*^"]!P'/80,G/NM(U+,-%-,RW:MYK]?+GB[>A39 ^ !S<S- 2#FWKA,/X
M>5QIHE4VP:?F$P/_*!6(5[>3&]6V3#SH(@X9_X;QPPA-E14-31Y6A9VZHR=@
M@.=5!0L'TH<>P:)4R=]L72:'!X-_QR>X%[(*RSI2A:8V[\ZGNNTV.#A9R$<9
MFV-TV$]U?IO<%6Z#QD]L#6_E2::FQL/2DTF W0T8WWE2RJ/#@Q3&@O^SDP"]
M.SKH/FO5#Y4+] ),+6TG4*_8S"1S WM<1;X'7EQR/Z3?AX]J>DI&!/WD ZWO
MC$)>L#!O<;H[JY6WI&#!%O;T9Z)FFHQ4YZDHD )UG+8>)7@^,S.%'FM'".C+
MT0#J^!0WHLD>(Z[?+'GU&Y+#SBK%%7JYB2T0#X-F]+3",+2 L)\\,^+JF077
MV=D4=)M%@0 )H!$!E=)XSX\K?A@Q.+;&?3CPR1\TZQM"'?+VY% MJ&13-HBE
M9M0/(;**M%(7@M2AL1R@3N8MM72>@0//X<%",+1T@L\I&-5',,  BP1'N,WZ
M'T^31FT0#RS6=PSVO.)O:/+2>O<U0)X*!T5S"BW :"&BT%./!M;""_7<. T
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M0SRPIWEZJS?/[2Y$N&JQW+\UM7$Y%]*0ST$HCL4:Y[)0.XL7/H_'38,#G>M
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M+3(P,3DQ,C,Q7V1E9BYX;6Q02P$"% ,4    " !H@'M0_!IP+*4; 0#LK0$
M%               @ % Q00 ;V-G;BTR,#$Y,3(S,5]G,2YJ<&=02P$"% ,4
M    " !H@'M0?A)AC8+^ 0!Q*P( %0              @ $7X04 ;V-G;BTR
M,#$Y,3(S,5]G,3 N:G!G4$L! A0#%     @ :(![4&C+(YX6N   3<,  !4
M             ( !S-\' &]C9VXM,C Q.3$R,S%?9S$Q+FIP9U!+ 0(4 Q0
M   ( &B >U"5,WUISI\! !^N 0 5              "  168" !O8V=N+3(P
M,3DQ,C,Q7V<Q,BYJ<&=02P$"% ,4    " !H@'M05+X,].S(  #2TP  %0
M            @ $6. H ;V-G;BTR,#$Y,3(S,5]G,3,N:G!G4$L! A0#%
M  @ :(![4'+\O'!2U   Q]X  !4              ( !-0$+ &]C9VXM,C Q
M.3$R,S%?9S$T+FIP9U!+ 0(4 Q0    ( &B >U 92"%(/H\" %\4 P 5
M          "  ;K5"P!O8V=N+3(P,3DQ,C,Q7V<Q-2YJ<&=02P$"% ,4
M" !H@'M0J6?J@QQB   V9@  %               @ $K90X ;V-G;BTR,#$Y
M,3(S,5]G,BYJ<&=02P$"% ,4    " !H@'M0B +?9Z9>  #+90  %
M        @ %YQPX ;V-G;BTR,#$Y,3(S,5]G,RYJ<&=02P$"% ,4    " !H
M@'M0^U)=Y_Y:   *80  %               @ %1)@\ ;V-G;BTR,#$Y,3(S
M,5]G-"YJ<&=02P$"% ,4    " !H@'M0/3$_I#8& 0"X"@$ %
M    @ &!@0\ ;V-G;BTR,#$Y,3(S,5]G-2YJ<&=02P$"% ,4    " !H@'M0
M8B2M=CP9 0#S'0$ %               @ 'IAQ  ;V-G;BTR,#$Y,3(S,5]G
M-BYJ<&=02P$"% ,4    " !H@'M0Y%/6<;6"  !4B   %
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M &]C9VXM,C Q.3$R,S%?<')E+GAM;%!+ 0(4 Q0    ( &B >U";Q-@C4Q
M (%K   :              "  2C1%0!O8V=N+3(P,3DQ,C,Q>#$P:WAE>#$P
M+FAT;5!+ 0(4 Q0    ( &B >U"Q'_<X;0X  %]=   ;              "
M ;/A%0!O8V=N+3(P,3DQ,C,Q>#$P:WAE>#$P,2YH=&U02P$"% ,4    " !H
M@'M0AY W"U,#  #8$P  &P              @ %9\!4 ;V-G;BTR,#$Y,3(S
M,7@Q,&MX97@R,3$N:'1M4$L! A0#%     @ :(![4-PR]['F @  H@@  !L
M             ( !Y?,5 &]C9VXM,C Q.3$R,S%X,3!K>&5X,C,Q+FAT;5!+
M 0(4 Q0    ( &B >U"W1& X(0@   PO   ;              "  03W%0!O
M8V=N+3(P,3DQ,C,Q>#$P:WAE>#,Q,2YH=&U02P$"% ,4    " !H@'M0R7AL
M.1\(   Z+P  &P              @ %>_Q4 ;V-G;BTR,#$Y,3(S,7@Q,&MX
M97@S,3(N:'1M4$L! A0#%     @ :(![4.Q-WZ(S!@  C2$  !L
M     ( !M@<6 &]C9VXM,C Q.3$R,S%X,3!K>&5X,S(Q+FAT;5!+ 0(4 Q0
M   ( &B >U =M&JN[A<  -!W   :              "  2(.%@!O8V=N+3(P
I,3DQ,C,Q>#$P:WAE>#0Q+FAT;5!+!08     '0 = +0'  !()A8    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6776652880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ResearchAndDevelopmentExpensesCurrent', window );">Research&#160;and development</a></td>
<td class="nump">$ 271,322<span></span>
</td>
<td class="nump">$ 705,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_AccountsPayableClinical', window );">Clinical</a></td>
<td class="nump">421,788<span></span>
</td>
<td class="nump">469,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_AccountsPayableConsulting', window );">Consulting</a></td>
<td class="nump">98,245<span></span>
</td>
<td class="nump">86,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee-related</a></td>
<td class="nump">624,420<span></span>
</td>
<td class="nump">123,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Legal</a></td>
<td class="nump">819,323<span></span>
</td>
<td class="nump">15,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">34,947<span></span>
</td>
<td class="nump">2,450<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 2,270,045<span></span>
</td>
<td class="nump">$ 1,402,750<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_AccountsPayableClinical">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as Clinical.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_AccountsPayableClinical</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_AccountsPayableConsulting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as Consulting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_AccountsPayableConsulting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6789678912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger and Financing - Pre-Merger Financing (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 04, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ReverseMergerAndFinancingDisclosureLineItems', window );"><strong>Reverse Merger and Financing</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger', window );">Percentage of volume-weighted average trading price of a share of common stock that triggered release of converted additional shares (in percentage)</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPeriod', window );">Period over which trading price of common stock as quoted on the Nasdaq Capital Market was considered for the release of converted additional shares</a></td>
<td class="text">3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ocgn_SeniorSecuredConvertibleNotesMember', window );">Senior Secured Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ReverseMergerAndFinancingDisclosureLineItems', window );"><strong>Reverse Merger and Financing</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayment of senior secured notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ocgn_SeriesAWarrantsAndSeriesCWarrantsMember', window );">Series A and Series C warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ReverseMergerAndFinancingDisclosureLineItems', window );"><strong>Reverse Merger and Financing</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_StockIssuanceCostsRecognized', window );">Equity issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ocgn_SeriesBWarrantsMember', window );">Series B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ReverseMergerAndFinancingDisclosureLineItems', window );"><strong>Reverse Merger and Financing</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_StockIssuanceCostsRecognized', window );">Equity issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ocgn_SecuritiesPurchaseAgreementMember', window );">Financing SPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ReverseMergerAndFinancingDisclosureLineItems', window );"><strong>Reverse Merger and Financing</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_NumberOfSharesAgreedToIssuePriorToMergerToInvestors', window );">Number of shares agreed to issue immediately prior to the merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_NumberOfConvertedInitialSharesAgreedToIssuePriorToMergerToInvestors', window );">Number of converted initial shares, agreed to be issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_NumberOfConvertedAdditionalSharesAgreedToIssuePriorToMergerToInvestors', window );">Number of converted additional shares in the form of escrow agreed to issue immediately prior to the merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_MergerAcquisitionCostsIncurred', window );">Acquisition cost incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_StockIssuanceCostsRecognized', window );">Equity issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Equity issuance costs paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Equity issuance costs paid with equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_NetProceedsFromReverseMerger', window );">Net proceeds from pre-merger financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of the volume-weighted average trading price of a share of common stock as quoted on the Nasdaq Capital Market for the first three trading days immediately following the closing date of the Pre-Merger Financing as threshold to release converted additional shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period over which the percentage of the volume-weighted average trading price of a share of common stock as quoted on the Nasdaq Capital Market to release converted additional shares is determined, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_MergerAcquisitionCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of acquisition costs incurred during the period related to merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_MergerAcquisitionCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_NetProceedsFromReverseMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net proceeds received from reverse merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_NetProceedsFromReverseMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_NumberOfConvertedAdditionalSharesAgreedToIssuePriorToMergerToInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of converted common shares, which the investors have right to receive pursuant to the exchange rate in the Merger, as agreed to be deposited in escrow by the accounting acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_NumberOfConvertedAdditionalSharesAgreedToIssuePriorToMergerToInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_NumberOfConvertedInitialSharesAgreedToIssuePriorToMergerToInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of converted common shares, which the investors have right to receive pursuant to the exchange rate in the Merger, as agreed to be issued by the accounting acquirer to the investors immediately prior to the Merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_NumberOfConvertedInitialSharesAgreedToIssuePriorToMergerToInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_NumberOfSharesAgreedToIssuePriorToMergerToInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares agreed to issue prior to the merger to investors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_NumberOfSharesAgreedToIssuePriorToMergerToInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ReverseMergerAndFinancingDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ReverseMergerAndFinancingDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_StockIssuanceCostsRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of stock issuance costs recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_StockIssuanceCostsRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ocgn_SeniorSecuredConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ocgn_SeniorSecuredConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ocgn_SeriesAWarrantsAndSeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ocgn_SeriesAWarrantsAndSeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ocgn_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ocgn_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ocgn_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ocgn_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6774124880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of Business - Reverse Stock Split (Details) - Histogenics<br></strong></div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="nump">0.0167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_BusinessCombinationIssuedSharesExchangeRate', window );">Shares issued exchange rate to former Ocugen's stockholders (exchange rate)</a></td>
<td class="nump">47.94%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_BusinessCombinationIssuedSharesExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exchange rate of share issued to shares surrendered by stockholder of the acquired entity in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_BusinessCombinationIssuedSharesExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ocgn_HistogenicsCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ocgn_HistogenicsCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6789232592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments - Operating leases, supplemental balance sheet information (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="nump">$ 344,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current lease obligations</a></td>
<td class="nump">172,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current lease obligations</a></td>
<td class="nump">163,198<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 335,508<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6956085472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments - Finance leases, future minimum lease payments (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2020</a></td>
<td class="nump">$ 23,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2021</a></td>
<td class="nump">9,941<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">33,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: present value adjustment</a></td>
<td class="num">(1,851)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of minimum lease payments</a></td>
<td class="nump">$ 31,946<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6778424112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Deferred Tax Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 31,575,288<span></span>
</td>
<td class="nump">$ 6,864,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Capital loss carryforwards</a></td>
<td class="nump">7,298,052<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_DeferredTaxAssetsStartUpCosts', window );">Start-up costs</a></td>
<td class="nump">11,234,751<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accruals and reserves</a></td>
<td class="nump">166,611<span></span>
</td>
<td class="nump">35,645<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intellectual property amortization</a></td>
<td class="nump">555,352<span></span>
</td>
<td class="nump">121,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation expense</a></td>
<td class="nump">1,123,100<span></span>
</td>
<td class="nump">993,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_DeferredTaxAssetsConvertibleDebt', window );">Convertible debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">498,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">1,926,677<span></span>
</td>
<td class="nump">548,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">96,895<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">53,976,726<span></span>
</td>
<td class="nump">9,061,568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(53,877,168)<span></span>
</td>
<td class="num">(9,061,568)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of allowance</a></td>
<td class="nump">99,558<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Lease ROU asset</a></td>
<td class="nump">99,558<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_DeferredTaxAssetsConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Convertible Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_DeferredTaxAssetsConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_DeferredTaxAssetsStartUpCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Start-up Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_DeferredTaxAssetsStartUpCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6781020448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax benefit at statutory rate (in percentage)</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local tax, net of federal benefit (in percentage)</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="nump">7.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credit (in percentage)</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent', window );">Effective Income Tax Rate Reconciliation, Permanent Differences, Percent</a></td>
<td class="num">(8.10%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other (in percentage)</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</a></td>
<td class="num">(24.30%)<span></span>
</td>
<td class="num">(29.90%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total provision for income taxes</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Permanent Differences, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6777769280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shared-Based Compensation (Details)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>segment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense | $</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_NumberOfEquityCompensationPlans', window );">Number of equity compensation plans | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage', window );">Automatic increase in shares to be issue (in percentage)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in USD per share) | $ / shares</a></td>
<td class="nump">$ 0.84<span></span>
</td>
<td class="nump">$ 7.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Options vested in period, fair value | $</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ocgn_A2019PlanMember', window );">2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense related to options outstanding, weighted average period for expense to be recognized</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued in period (in shares)</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued in period (in shares)</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_NumberOfEquityCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Equity Compensation Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_NumberOfEquityCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Automatic Increase In Shares To Be Issue, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ocgn_A2019PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ocgn_A2019PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ocgn_A2014PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ocgn_A2014PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ocgn_A2019PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ocgn_A2019PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6661839584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Schedule of Fair Value of the Embedded Features (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair value of embedded derivative</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,741,222<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiabilityAtIssuance', window );">Fair value of embedded derivatives at issuance</a></td>
<td class="nump">567,661<span></span>
</td>
<td class="nump">3,405,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of embedded derivatives</a></td>
<td class="nump">1,319,400<span></span>
</td>
<td class="num">$ (1,664,689)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_EmbeddedDerivativeConversionAndExtinguishmentOfDebt', window );">Conversion and extinguishment of debt</a></td>
<td class="num">$ (3,628,283)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_EmbeddedDerivativeConversionAndExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Embedded Derivative, Conversion And Extinguishment Of Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_EmbeddedDerivativeConversionAndExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiabilityAtIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Embedded Derivative, Fair Value of Embedded Derivative Liability At Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiabilityAtIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229187<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6774122608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share of Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted earnings per share of common stock</a></td>
<td class="text"><div style="margin-top:12pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the computation of basic and diluted earnings per share for the years ended December 31, 2019 and 2018:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.175%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss&#8212;basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,242,630)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,219,664)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used in calculating net loss per common share&#8212;basic and diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,893,819&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,960,552&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per common share&#8212;basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.46)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.67)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive securities excluded from computation of diluted weighted average shares</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as their inclusion would have been antidilutive:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.175%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options to purchase common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">731,189&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">632,752&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">870,020&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">870,020&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series&#160;A Warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,771,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series B Warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series&#160;C Warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,375,137&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,502,772&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6776446624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of components of lease expense</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of lease expense were as follows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.380%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.620%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended<br/>December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">250,361&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Variable lease cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79,700&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">330,061&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Supplemental information related to leases was as follows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.380%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.620%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended<br/>December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average remaining lease terms&#8212;operating leases (years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average discount rate&#8212;operating leases</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_SupplementalBalanceSheetInformationLeasesTableTextBlock', window );">Schedule of supplemental balance sheet information related to leases</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Supplemental balance sheet information related to leases was as follows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.380%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.620%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use assets, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">344,574&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current lease obligations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">172,310&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current lease obligations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">163,198&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">335,508&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of operating leases</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future minimum operating minimum lease payments for all leases, exclusive of taxes and other carrying charges, are approximately as follows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.380%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.620%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Years Ending December 31,</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">191,890&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">160,909&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,354&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">364,153&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: present value adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(28,645)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of minimum lease payments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">335,508&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of finance leases</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future minimum lease payments for all financing leases, exclusive of taxes and other carrying charges, are approximately as follows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.380%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.620%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Years Ending December 31,</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,856&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,941&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,797&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: present value adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,851)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of minimum lease payments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,946&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_SupplementalBalanceSheetInformationLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of balance sheet information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_SupplementalBalanceSheetInformationLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6779331824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_CostsRelatedToIssuanceOfStockUnderReverseAssetAcquisition', window );">Issuance costs under reverse asset acquisition</a></td>
<td class="nump">$ 2.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_CostsRelatedToIssuanceOfStockUnderReverseAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs related to issuance of stock under reverse asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_CostsRelatedToIssuanceOfStockUnderReverseAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6789597200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 7,444,052<span></span>
</td>
<td class="nump">$ 1,628,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,322,167<span></span>
</td>
<td class="nump">313,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Asset held for sale</a></td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">15,766,219<span></span>
</td>
<td class="nump">1,941,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">222,464<span></span>
</td>
<td class="nump">245,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">151,016<span></span>
</td>
<td class="nump">150,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">667,747<span></span>
</td>
<td class="nump">116,333<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">16,807,446<span></span>
</td>
<td class="nump">2,454,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,895,613<span></span>
</td>
<td class="nump">3,277,525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">2,270,045<span></span>
</td>
<td class="nump">1,402,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,483,847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,741,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease obligation</a></td>
<td class="nump">172,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">205,991<span></span>
</td>
<td class="nump">204,242<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,543,959<span></span>
</td>
<td class="nump">14,109,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease obligation, less current portion</a></td>
<td class="nump">163,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long term debt, net</a></td>
<td class="nump">1,072,123<span></span>
</td>
<td class="nump">1,016,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">9,755<span></span>
</td>
<td class="nump">37,459<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">1,245,076<span></span>
</td>
<td class="nump">1,054,186<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">5,789,035<span></span>
</td>
<td class="nump">15,163,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock, $0.01 par value, 10,000,000 shares authorized, seven and zero issued and outstanding, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value, 200,000,000 authorized, 52,746,728 and 4,960,552 shares issued, respectively; 52,625,228 and 4,960,552 shares outstanding, respectively</a></td>
<td class="nump">527,467<span></span>
</td>
<td class="nump">49,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury Stock, at cost 121,500 and zero shares, respectively</a></td>
<td class="num">(47,864)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">62,018,632<span></span>
</td>
<td class="nump">18,477,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(51,479,824)<span></span>
</td>
<td class="num">(31,237,194)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">11,018,411<span></span>
</td>
<td class="num">(12,709,539)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">$ 16,807,446<span></span>
</td>
<td class="nump">$ 2,454,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">52,746,728<span></span>
</td>
<td class="nump">4,960,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">52,625,228<span></span>
</td>
<td class="nump">4,960,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, common, shares (in shares)</a></td>
<td class="nump">121,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77912953&amp;loc=d3e400-110220<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=116631420&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6781200960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share of Common Stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net Loss-diluted</a></td>
<td class="num">$ (20,242,630)<span></span>
</td>
<td class="num">$ (18,219,664)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss- basic</a></td>
<td class="num">$ (20,242,630)<span></span>
</td>
<td class="num">$ (18,219,664)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used in calculation net loss per common share - basic and diluted (in shares)</a></td>
<td class="nump">13,893,819<span></span>
</td>
<td class="nump">4,960,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share of common stock - basic and diluted (in USD per share)</a></td>
<td class="num">$ (1.46)<span></span>
</td>
<td class="num">$ (3.67)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities outstanding excluded from the computation of diluted weighted average shares outstanding</a></td>
<td class="nump">10,375,137<span></span>
</td>
<td class="nump">1,502,772<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities outstanding excluded from the computation of diluted weighted average shares outstanding</a></td>
<td class="nump">731,189<span></span>
</td>
<td class="nump">632,752<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities outstanding excluded from the computation of diluted weighted average shares outstanding</a></td>
<td class="nump">870,020<span></span>
</td>
<td class="nump">870,020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ocgn_SeriesWarrantsMember', window );">Series A Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities outstanding excluded from the computation of diluted weighted average shares outstanding</a></td>
<td class="nump">8,771,928<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ocgn_SeriesBWarrantsMember', window );">Series B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities outstanding excluded from the computation of diluted weighted average shares outstanding</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ocgn_SeriesCWarrantsMember', window );">Series C Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities outstanding excluded from the computation of diluted weighted average shares outstanding</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ocgn_SeriesWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ocgn_SeriesWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ocgn_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ocgn_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ocgn_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ocgn_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6789132096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>RECENT ACCOUNTING PRONOUNCEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Asset held for sale</a></td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>RECENT ACCOUNTING PRONOUNCEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>RECENT ACCOUNTING PRONOUNCEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>RECENT ACCOUNTING PRONOUNCEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>RECENT ACCOUNTING PRONOUNCEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ocgn_EquipmentAndFurnitureMember', window );">Equipment and Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>RECENT ACCOUNTING PRONOUNCEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>RECENT ACCOUNTING PRONOUNCEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_LeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_LeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_LeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_LeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77912953&amp;loc=d3e400-110220<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ocgn_EquipmentAndFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ocgn_EquipmentAndFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>80
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M.%*"IFZ ]<O$<)J'#JZ !4887?HNH%F)I?HGMG2 G9-SLFMJFJ9Z:DLN[]#
MV]/C2UFWLF,B-6K,OY*5= JX99?)K^W=_>Z!]8(+7O&V$K>[9B.YD$W[OKC^
M\+L*.V_LWOYCXXM@W\&ON^B_ %!+ P04    " !H@'M0F5R<(Q &  "<)P
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MOC?T_JMZ4;F1MW=B//8ZK[M?;W^M&UT,K9A;*=+7?IN5W?;67XD60QDNH*&
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M3!+E%#ZI;Z-4;71<4'*6>IJJ.>][2;^0K!WZ)!B;=?$/4$L#!!0    ( &B
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M2!+J-N/K@# *+$MQH@0E2A"BV"'J-7Q4B9,T):-"/9&O2P1DX_L\ >(H$$>
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M)'^XZ9O]\>>&V>DWC_G_4$L#!!0    ( &B >U &</[\L@$  -(#   8
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M,BYX;6Q]4V&/G" 0_2N$'W H:WN7C9K<7M.T29MLKFGO,ZNCD@.Q@.OUWW=
MS]K6]@LPP[PW;X8AGXQ]=AV )R]:]:Z@G??#D3%7=:"%NS$#]'C3&*N%1].V
MS T61!U!6C&>)&^9%K*G91Y]9UOF9O1*]G"VQ(U:"_OC!,I,!4WIJ^-1MIT/
M#E;F@VCA"_BOP]FBQ5:66FKHG30]L= 4]#X]GK(0'P.^29C<YDQ")1=CGH/Q
ML2YH$@2!@LH'!H';%1Y J4"$,KXOG'1-&8#;\RO[^U@[UG(1#AZ,>I*U[PIZ
M1TD-C1B5?S33!UCJ>4/)4OPGN(+"\* $<U1&N;B2:G3>Z(4%I6CQ,N^RC_LT
MWV2W"VP?P!< 7P%W,0^;$T7E[X0796[-1.S<^T&$)TZ/''M3!6=L1;Q#\0Z]
MUY*G2<ZN@6B).<TQ?!.3KA$,V=<4?"_%B?\%Y_OPPZ["0X0??E/XC_S9+D$6
M";+_EK@7\Z=*MNFI!MO&:7*D,F,?)WGC70?VGL<W^14^3_MG85O9.W(Q'E\V
M]K\QQ@-*26YPA#K\8*NAH/'A>(MG.X_9;'@S+#^(K=^X_ E02P,$%     @
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M?K#54-#X<'R/9SN/V6QX,RP_B*W?N/P#4$L#!!0    ( &B >U ]VXF5M $
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M-#X>WX>SG<9L,CSV\P]BRS<N?P-02P,$%     @ :(![4"!:D1>U 0  T@,
M !D   !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL?5-A;]L@$/TKB!]0$N(V
M561;:EI5G;1)4:MMGXE]ME'!N(#C[M_WP*[G;=:^ '?<>_?N.-+!V%?7 'CR
MKE7K,MIXWQT8<T4#6K@KTT&+-Y6Q6G@T;<U<9T&4$:05XYO-#=-"MC1/H^]D
M\]3T7LD63I:X7FMA?QU!F2&C6_KI>)9UXX.#Y6DG:G@!_[T[6;38S%)*#:V3
MIB46JHS>;0_'),3'@!\2!K<XDU#)V9C78'PI,[H)@D!!X0.#P.T"]Z!4($(9
M;Q,GG5,&X/+\R?X8:\=:SL+!O5$_9>F;C-Y24D(E>N6?S? $4SW7E$S%?X4+
M* P/2C!'892+*REZYXV>6%"*%N_C+MNX#^--LI]@ZP ^ ?@,N(UYV)@H*G\0
M7N2I-0.Q8^\[$9YX>^#8FR(X8ROB'8IWZ+WDG%^G[!*(IICC&,,7,=LY@B'[
MG(*OI3CR?^!\';Y;5;B+\-T?"F_6"9)5@B02)/\M<2UF_U<2MNBI!EO':7*D
M,'T;)WGAG0?VCL<W^1T^3OLW86O9.G(V'E\V]K\RQ@-*V5SA"#7XP69#0>7#
M<8]G.X[9:'C333^(S=\X_P!02P,$%     @ :(![4 V/J1&U 0  T@,  !D
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MF_DMSPNGAZ5-R?JOJ'X#4$L#!!0    ( &B >U#=7SM3LP$  -(#   9
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M:%S8/OB]F=[R%#C=SV-*EO^*\@]02P,$%     @ :(![4)F9-@^V 0  T@,
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M:&5E=#(V+GAM;&U4;6_;(!#^*X@?4!R2N&ED6VHZ39O42E&G=9^)?7Y1P7B
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M CLOL/NGQ?VJQ1 F#IOL@R;[@,#]RB2$.81-XJ!)'!!X6)D$, _KXR*+VR%
M57XN-,IEW_J97&3GT7ND_G9]PL>Y?6&J:EJ-+M+8.^IO4BFE 5M*=&<;KNU3
M,0<<2N.V]W:OQH$9 R.[Z2T@\X.4_0502P,$%     @ :(![4)U)XIC> 0
M 04  !D   !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL=53;CML@$/T5Q <L
M"4GL)+(M;;:J6JF5HJW:/A-[?-&"<0''V[\O8*_7=>F+889SF<% ,DCUHFL
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M;.=JO)5C8&0W/3AD?O6R/U!+ P04    " !H@'M04$6@U,$!   W!   &0
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M.@&][F2/%-0Y?M@=3ZG#>\!S!Y/>S)'KY"+EBPN^5#F.7$' H31.@=GA"H_
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MTK?6WJTSYPJT3>]!M[C0XWD\5'!69AOIO>B'5']0O!WF+QK_!+)_4$L#!!0
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M@$,@X&+<-K5[U<V!+C"RZ4<<&N9L_A=02P,$%     @ :(![4#M]RAVV @
M6PL  !D   !X;"]W;W)K<VAE971S+W-H965T,S0N>&ULE59AKYHP%/TKA!\
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M'NP.9(:A5!0ACY#'A@@0*CP4L$'0$PY!L$40=/Y'Y:;C<I/()P3;!$$>\%'
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M-D)(KC+Z-PJ5'4_7YXN<;Z0^C=5YU6Z&VPLI]F:C[YU_;9C_!5!+ P04
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M$4E\#5D_8+2Q8,+(7DUHG=10"8272?W$+A!9!2(E$%TE,"I9#9A485J%R;+
M,Z=DBO*], MB>YK8FB:VI+E13F(52!Z?C]0JD%H2I,:JI99*AS^[T\SJ-+,X
MS8S],)LXQ7=\,JM/9O')C(HLF.B&B>_9=[=GD?#-[>W=FCEC[SP O YUX\CQ
M__]UKS5HZF58@8N#KD'TH*XIYI3DV'*YAR]&QZOP.9 'I3&^\N?KX4([RPSW
MZW=(#W7+G"WAXAA6A^6>$(Y$3.])[(U*7.EC!Z,]E\U4M.EPKPT=3CI]9X/Q
MAT/Q#U!+ P04    " !H@'M0MK7Q+AT"  !$!@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970T,"YX;6R-55V/FS 0_"N(]Y[!&'R- *E)5+52*T577?OL))N
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ME\/%-@RTZ,8[&TT_CO(O4$L#!!0    ( &B >U! \>C ?04  %(>   9
M>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;)6976_J.!"&_PKBODW\-4XJBM1"
M6RKM2M4YVMWK%-R"3B!LDK9G__WFPX=#G-<HZ46!\,Z,)Y[']I#95Y;_*+;&
ME).?^_10W$ZW97F\"8)BO37[I+C.CN90??.6Y?NDK#[F[T%QS$VR:8SV:<##
MD()]LCM,Y[/FVDL^GV4?9;H[F)=\4GSL]TG^W[U)LZ_;*9O^NO!M][XMZPO!
M?'9,WLUW4_YU?,FK3\')RV:W-X=BEQTFN7F[G=ZQFV<M:H-&\??.?!5G[R=U
M*J]9]J/^\+RYG8;UB$QJUF7M(JE>/LW"I&GMJ1K'O];I]!2S-CQ__\O[8Y-\
ME<QK4IA%EOZSVY3;VVDTG6S,6_*1EM^RKY6Q":GIQ&;_A_DT:26O1U+%6&=I
MT?R?K#^*,MM;+]50]LG/]G5W:%Z_VF^TLF;8@%L#?C)@=-% 6 /QVT!>-)#6
M0 XU4-9 #34@:T!##;0UT$,-(FL0#36(K4'L& 3M_#4%L4S*9#[+LZ])WM;T
M,:G183=Q57+K^F)38<UW54T4U=7/N931+/BL'5G-?:OA9QIV4@25]U,(CD+<
M\YXY[P98]!6DNI)E7R)EW-4\ (T*NYI'I&%=S1/2.$->]36"G/$\ PV+\)T3
M<')$XT"<WSE&V(&$#F3C0'8R$<[LMAK=: Z-QKEGB[[BBFG).'=NRO,E5YW1
M*CA:!48KG=$BC<)!" 8AX,!S3S5TH(=/2@0=1& $VDD3:3RE$\,@,7 08P<L
MQ"M#.#Q1YEE<6'\4%+JK"^M53:15*$-/[3"XRMPQ#F(Q-U8KHDXI1S'SW5N&
MN62B'TNZ4VA%Y[$DZ3#4OKPPP@PP3-R-)7NQ**S_')*!3LBNL#LF#"H#%)+P
MN, 8,AI171A$I@>L;E;4F7%1S3C3W!,,0\L D20]+C"2+!Z>,L=,\A",PMDJ
M[ZUHP#+,,;8<8"MB-PIBVY<-1I8C9%V,K*A>C4[IL&O/DL\QKQSP2A[D.<:0
MRQ&3AZGAB!IW-;2B\\D3"J%LA71!V!T4YI"#_9 \&P7''/(1.R+'='%$EY/Q
MRHK.;TV;L"]CC"$'6Z.[4:RLJ+MLJ-AW9P3&50!<W7UB947GH;@(27!/6@)#
M*P"/OJU&8!X%'SZ1PG-B!:2Y:_+*BCH'2DY*:^;I*P1F4H"M4?M<8":%&I$R
M)D@@@IS:?;*B\Y39I=H5&#4!MCRW=I\$VO+\D3"1 A#IENZ3%75*5W,=>?9%
M@8$4 $C?[BPQ:'+$655B?B3@QZW<)]D_JUYI+OVQ,&@2;'S:<WZ2&#0YIC?T
M-(?H9.GVR[+?TS%VX70N,6<2[7W,C=7?TJY42-*7%N91 A[=RGVT(NKPJ"/B
MVA,+\R@!C]I3_1*#)J,1$XD!DJC9$V[&,5AT&?,EK#!H"NQHVG,84Q@TQ88G
MK# _"AT<W0.2ZO=Z3/E77(4Y4^CHR-Q0_5;OBDG!?*$PCPKPZ!;N0O4[."9X
M)#RKA_+\T@)PU+XYP)BI$0V<PO2H 0W<PHJZ=1LI7]EBR!38S;3/!89,C>C>
M",-#J'MSRO:!^MV;O%"VA"$CU)TQ-Q3KERV/A>_'$,(P$H#1+=L'ZL/(A=;D
MRPK#2 !&[1LMAHQ&]'&$X2'T&Z1P$^[W<5<LXE'D.=B0Y]=*L)EI3Q-"F#(:
MT9X1QH<&M&=+ZK=G%X^XA#FC >W9DD![IE3DVXDTYE$/:,^6NM^>D63:=RC1
MF$<->(P\-T9CSO2([DQC?O2 [FRI07<FPHI6M^R"LV=,>Y._-P\MB\DZ^SB4
M]6./LZNG!Z-WO'Y&Y5R_9S>+]O'F;S?MT]8_D_Q]=R@FKUE99OOF.=5;EI6F
M&F=X71&V-<GF]"$U;V7]5E?O\_8I9_NAS([V"6YP>HP\_Q]02P,$%     @
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M _/)GAB31/D,G]0956KJCPM*3E*_JBGE<3O[[$*R;ACKP?C?DO\#4$L#!!0
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M=7??[@9*5O9;(KA^T"S_ 5!+ P04    " !H@'M0DF@DZ3P"  "C!P  &0
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M"WOAR4O34/%["XSW&Q_[M\!+?:Z4": B[^@9OH'ZWNV%7J%)Y5@WT,J:MYZ
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M,-B(!A-:3&4Q:+: 14)0) 1$PH%(@XEZ(@26B$")")"(!A)C3!!,;%8,BL2
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M'HNFB6@FBM=M@^1U75KR#U!+ P04    " !H@'M0@<O'[7P"  #;"   &0
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MYB;)>&;VYV*ZK7Y2\I.VP\R,9=MRM!,MFJZ=BOJ>;OT/4$L#!!0    ( &B
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M7(Y7=S2TZ*=7"<]/8_$.4$L#!!0    ( &B >U (\T=0Y $  *8$   9
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M?$M+H*#U8?N(>SO=J"GP9I@?"UM>;/4?4$L#!!0    ( &B >U#%^&UB_@$
M &0%   9    >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;'64;6^;,!#'OPKB
M_6HP&$A$D)I6TR9M4M2IVVLGN014@YGMA.[;SP\4,?#>8-_Y[O^[L['+@8LW
M60.HX+UEG=R%M5+]%B%YJJ&E\H'WT.F5"Q<M5=H45R1[ ?1LDUJ&<!1EJ*5-
M%U:E]1U$5?*;8DT'!Q'(6]M2\6</C ^[, X_'"_-M5;&@:JRIU?X >JU/PAM
MH4GEW+30R89W@8#++GR,M_O"Q-N GPT,<C8/3"='SM^,\?6\"R-3$# X*:-
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M8XP'U-L\X&UI\2W-@8+&A^T.]W:\46/@33\]%C:_V/(_4$L#!!0    ( &B
M>U# 'S5FZ@$  /<$   9    >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;'64
MVXZ;,!"&7P5QWS5G2 1(S595*[52M-6VUPX, :W!U';"]NWK T$(O#?88\_\
MW\S8.)\H>^,M@'#>>S+PPFV%&(\(\:J%'O,G.L(@=QK*>BRDR:Z(CPQPK8-Z
M@@+/2U"/N\$M<[UV9F5.;X)T YR9PV]]C]F_$Q Z%:[O/A9>NFLKU (J\Q%?
MX1>(U_',I(46E;KK8> ='1P&3>%^]H^G5/EKA]\=3'PU=U0E%TK?E/&]+EQ/
M)00$*J$4L!SN\ R$*"&9QM]9TUV0*G ]?ZA_U;7+6BZ8PS,E?[I:M(6;N4X-
M#;X1\4*G;S#7$[O.7/P/N .1[BH3R:@HX?KK5#<N:#^KR%1Z_&[&;M#C9';2
M1Y@]()@#@B4@,+48D,[\"Q:XS!F='&9Z/V)UQ/XQD+VIU*)NA=Z3R7.Y>B_C
MS,O170G-/B?C$ZQ\_#A=?)#47R"!%1)H@7 E$ 2A72"T"H1:(%IGF<:;+(U/
MJGT& PFS.+%C(BLFLF"2#<;X)"O,X1#Y=DILI<0[BA]N6Q[O*&&8'CYH>F+%
M))9BL@TFV6$^^5G\036I%9/N,9F_P:2[HPG]0[0]&K2ZL^I)^(G9M1NX<Z%"
M7G]]21M*!4A%[TDVJ)6OT&(0:(2:IG+.S+]H#$''^9E!RUM7_@=02P,$%
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M/&LE>O\[_^!9BW=*VC8.95;W_U>'][HI<Y&EE9(G/X?/M.@_KR+_9Q@<0$4
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M4F8LP'@.W$H MQ( .I7:>1X8OV>*GD'&*X3;"($V?#A#!&>(S.NA<T#0V!Q
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M:Z:J+?JS?=^1_&#N+<%P>5K^!U!+ P04    " !H@'M0[F_M1 ,"  !Q!0
M&0   'AL+W=O<FMS:&5E=',O<VAE970U."YX;6R%E-N.FS 0AE\%\0!K,,>-
M"-)FJZJ56BG:JMMKAPP'K8VI[83MV]<VA+*)H][$!_[YOQD[GF+DXDVV ,I[
M9[276[]5:M@@)*L6&)$/?(!>?ZFY8$3II6B0' 20HPUB%.$@2!$C7>^7A=W;
MB[+@)T6['O;"DR?&B/BS \K'K1_ZEXV7KFF5V4!E,9 &?H#Z.>R%7J'%Y=@Q
MZ&7'>T] O?6?PLTN-WHK>.U@E*NY9RHY</YF%E^/6S\P"0&%2AD'HH<S/ .E
MQDBG\7OV]!>D"5S/+^Z?;>VZE@.1\,SIK^ZHVJV?^]X1:G*BZH6/7V"N)_&]
MN?AO< :JY283S:@XE?;7JTY2<3:[Z%08>9_&KK?C./M?PMP!> [ 2P">:IE
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M__A,HIN-8+F@/E$HF_E?(=A"$086B/HP.*R;",ZX[_D%H!0I0Y3E,U2P+R/
MF$GP?2'!7!\HR3E'S+=F2'J?"W9G!-@SX3Y7Z+M"4!HP_;<](]B?$0T_?V2N
M'MA6$>2K_N<&A8X)UA/*YNJ!714!MAKXV"3B=XSCKF0$2:[N.>[B^5UV^[+I
MHQ=M[)5IN-CLM#;*IDL?[#(?[%WWTJG4SK@FM^UNO/"-':/;Z3*;7&[4JW]0
M2P,$%     @ :(![4'YNIE.L @  F D  !D   !X;"]W;W)K<VAE971S+W-H
M965T-C N>&ULC5;;CMHP$/V5*._=Q)<86 $24%6MU$JKK;9]]H*!:),XM0UL
M_[ZVDPTA'B@\$%_.S#DSML>>GJ1ZTWLA3/1>%I6>Q7MCZL<DT>N]*+E^D+6H
M[,Q6JI(;VU6[1-=*\(TW*HL$IRE+2IY7\7SJQY[4?"H/IL@K\:0B?2A+KOXN
M12%/LQC%'P//^6YOW$ RG]9\)WX*\U(_*=M+.B^;O!25SF45*;&=Q0OTN$+,
M&7C$KUR<=*\=N5!>I7QSG6^;69PZ1:(0:^-<</LYBI4H"N?)ZOC3.HT[3F?8
M;W]X_^*#M\&\<BU6LOB=;\Q^%H_C:".V_%"89WGZ*MJ LCAJH_\NCJ*P<*?$
M<JQEH?U_M#YH(\O6BY52\O?FFU?^>VIF,M::P0:X-<"= ;IM0%H#<C:@/OA&
MF0_U,S=\/E7R%*EFM6KN-@5Z)#:9:S?H<^?G;+3:CA[GC*)I<G2.6LRRP> >
MYHQ(K/>. D,42QR8XTN"58A@&<Q P""(MR<706#8 04=4.^ ]B/$9)"%!C/R
MF,IC/N$44\Q(.@@'0*(Q1A/&*"PJ T5E@2A&AZ(:#.M143I.W0]F8B 3 YCH
M@(D%3"0E:3:,/81=43("E8P )5>VPAAT,+Y_*TQ !Q-  1OD8A($B1"FEVEO
MTA$B,1G=6!^4PJ<T!52-AL<T#3<#I G H5N2KA0.!$@:7W$!%H8%PO<O%H)/
M/B)W+%<+NEPOPL#<A-#_+!A<4%!841B=#'71@(PA?(L,+A0(J!3#@[E$8:G(
MAGOVD@RN%0@J%L%69$$)1'"^0R!8OI+>?58*M?-7OX[6\E 9=W/T1KOGQ0*[
M^W POG3/#G]/GMTT;Y8?7.WR2D>OTMC;UM^)6RF-L#+3!YN\O7TF=9U";(UK
MCFQ;-6^%IF-DW;Z#DNXQ-O\'4$L#!!0    ( &B >U# )L]$10(  )T'   9
M    >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;(55[8Z;,!!\%<0#'-^0G C2
M)5752JT47=7VMT,V 9W!U';"]>UK&T*(L[G^B>UE9G:6F-V\9_Q-5 #2>6]H
M*U9N)67W['FBK* AXHEUT*HG!\8;(M61'SW1<2![0VJH%_I^ZC6D;MTB-[$M
M+W)VDK1N8<L=<6H:PO^N@;)^Y0;N)?!:'RNI UZ1=^0(/T#^[+9<G;Q)95\W
MT(J:M0Z'P\I]"9XW@:\)!O&KAE[,]HXN9<?8FSY\W:]<7SL""J74$D0M9]@
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MFI73@<)!ZFVF]GP8&,-!LFX<AMXTD8M_4$L#!!0    ( &B >U 1-H.N!0(
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MPU5(2N9C9>/B*9\19L'LD18*5-&\IW]+NT:XSG<IRHWL6XHL)M$A#W!5N*=
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MTV)_G\*WP ;L12<8!T[+]5/$&0I)%?V< <^!)[)%!?-QB3FG<81_)CGZF.V
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M5D/9A@$$Y*\#.MC@"09XB,31#?,QF7U88UW'.!S:E5(M%G;K<:!C>DBD.EO
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M1?_BAC(3>.P;R)0:@-&PFX8M2_@*FMFV.BG7.M%@L9],'=.=7WB=L"W5!;J
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M!1J?P(V!N_2K1O_-K[/S>-;7"H'@K=&H'_?AK1N$1>*&R^L:Z&F8;1HV'I7
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M5$.TW1;LXO/'$ B-P,[]COR1TZD2VC3O.V_;8F0.X_'+T25CZ1&<-5M"6(=
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MG<@MRDB"<'"AB**'-F;V;"C[K,LP]=%AS[O=QSA?N9>)D57+_=0J!H.&-T6
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M6K[\]_WRWC6KH=O$-B/GEF$HQ1T&=:8D?=-\B3T.\:'+UPIELM"H-ZZX9+>
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M*[=P)E4JAD20[F6K[.G2Y86DY>"9)5O*^L&N7<N2F_2D5&<'3.BI&0'^ KM
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M!079"/6ITMOAC6\:'M])G)*Z\>NT%Z#945'0[4=*,LZPW<R+!;T]"T8!ZNJ
M7$CRJ/E,J\0Z@"4$&RP5B<>1'Q(5*URKKIWJ=%_-BR/4_-KW.<,<2T3'HG7O
M'_)=_L^*S?OJKS4W?RM3Q:\H<GE^^!K-._H(1/K'(/(HCOOB\$4N+P]?HYGE
M_JU(IQTR1I/,SAS31\&Z(E01WLK-29)@J\<,DB'\:J94NC--#..,IE=HK3]7
M=O@U-L$IJJBZ,UMLDB$<["]&N.?WJU8]10@'^Q8GI&)VYAV^B:*?4$L#!!0
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M C)Y0\A6)%,",GU+R!A!C@G(\5M")@CR/0'YGA=R(7UE09BU.*V<TN <XOI
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MYIUI^M^2/%F[_IS/QG]=+=X 4$L! A0#%     @ :(![4!\CSP/     $P(
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M4$L! A0#%     @ :(![4(QW%*I& @  N <  !@              ( !W!$
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( &B >U I!$6/
M6@,   ,-   8              "  5@4  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " !H@'M08SPQJUP$  "M$P  &
M@ 'H%P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ :(![
M4)@\A.R[ 0  U ,  !@              ( !>AP  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( &B >U!*/0;H'04  /\8   8
M      "  6L>  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" !H@'M0!G#^_+(!  #2 P  &               @ &^(P  >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ :(![4""F)+JS 0  T@,  !@
M             ( !IB4  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( &B >U#%MUZ:M $  -(#   9              "  8\G  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ :(![4)<9VKZU 0
MT@,  !D              ( !>BD  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " !H@'M0,?:!8[,!  #2 P  &0              @ %F
M*P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( &B >U!,
M^>;BM $  -(#   9              "  5 M  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ :(![4.#RW^"U 0  T@,  !D
M     ( !.R\  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &B >U!0S)W2LP$  -(#   9              "
M =4X  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ :(![
M4'GRDG-G @  # D  !D              ( !OSH  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " !H@'M0Y9O)A<,!   W!   &0
M        @ %=/0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( &B >U#=7SM3LP$  -(#   9              "  5<_  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ :(![4)R47K#" 0  -P0
M !D              ( !04$  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " !H@'M0F9DV#[8!  #2 P  &0              @ $Z0P
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( &B >U!7,)FU
MTP$  )P$   9              "  2=%  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ :(![4,JU0C[/ 0  G 0  !D
M ( !,4<  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !H
M@'M0G4GBF-X!   !!0  &0              @ $W20  >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( &B >U!01:#4P0$  #<$   9
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M970S,BYX;6Q02P$"% ,4    " !H@'M0D%/JU <"  !S!0  &0
M    @ &>5@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M &B >U [?<H=M@(  %L+   9              "  =Q8  !X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ :(![4+YEM55A P  < \  !D
M             ( !R5L  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    " !H@'M0/:4<K P#  !A#   &0              @ %A7P  >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( &B >U#C;R2%:P,
M 'D0   9              "  :1B  !X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ :(![4*.1F+%- @  + <  !D              ( !
M1F8  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " !H@'M0
M0T3>YFH"  !$"   &0              @ '*:   >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    ( &B >U"VM?$N'0(  $0&   9
M      "  6MK  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%
M  @ :(![4$#QZ,!]!0  4AX  !D              ( !OVT  'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " !H@'M03,=H$$,"  !G!@
M&0              @ %S<P  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+
M 0(4 Q0    ( &B >U!YH&?V"0,  -P,   9              "  >UU  !X
M;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ :(![4))H).D\
M @  HP<  !D              ( !+7D  'AL+W=O<FMS:&5E=',O<VAE970T
M-"YX;6Q02P$"% ,4    " !H@'M0337SUCD"  "0!@  &0
M@ &@>P  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( &B
M>U"I@=/XH@(  +$)   9              "  1!^  !X;"]W;W)K<VAE971S
M+W-H965T-#8N>&UL4$L! A0#%     @ :(![4('+Q^U\ @  VP@  !D
M         ( !Z8   'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
M    " !H@'M05[1@8L<"  #?"0  &0              @ &<@P  >&PO=V]R
M:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( &B >U I_HKRTP$  "8%
M   9              "  9J&  !X;"]W;W)K<VAE971S+W-H965T-#DN>&UL
M4$L! A0#%     @ :(![4 CS1U#D 0  I@0  !D              ( !I(@
M 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " !H@'M0XQM-
M;]8!  "5!   &0              @ &_B@  >&PO=V]R:W-H965T<R]S:&5E
M=#4Q+GAM;%!+ 0(4 Q0    ( &B >U!)G_C'I $  +T#   9
M  "  <R,  !X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @
M:(![4,7X;6+^ 0  9 4  !D              ( !IXX  'AL+W=O<FMS:&5E
M=',O<VAE970U,RYX;6Q02P$"% ,4    " !H@'M031)]!J@!  "] P  &0
M            @ '<D   >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4
M Q0    ( &B >U# 'S5FZ@$  /<$   9              "  ;N2  !X;"]W
M;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ :(![4#-Y_>]3!
M$Q@  !D              ( !W)0  'AL+W=O<FMS:&5E=',O<VAE970U-BYX
M;6Q02P$"% ,4    " !H@'M0?Q=N,!4#  !(#0  &0              @ %F
MF0  >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( &B >U#N
M;^U$ P(  '$%   9              "  ;*<  !X;"]W;W)K<VAE971S+W-H
M965T-3@N>&UL4$L! A0#%     @ :(![4/?I-_'N @  70L  !D
M     ( ![)X  'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &B >U 9":C=?H8  'T# @ 4              "
M 9.K  !X;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0    ( &B >U#!9G87
M90(  " -   -              "  4,R 0!X;"]S='EL97,N>&UL4$L! A0#
M%     @ :(![4)\&814;!0  D2D   \              ( !TS0! 'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( &B >U"X]0,.(P(  !(F   :
M      "  1LZ 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( &B >U!U'BN_[P$  'TE   3              "  78\ 0!;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@    !( $@ JA,  )8^ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6771981568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsOn March&#160;26, 2020, the Company borrowed an additional $0.5&#160;million under the terms and conditions of the EB-5 Loan Agreement. Outstanding borrowings pursuant to the EB-5 Program, including accrued interest, become due upon the seventh anniversary of the final disbursement. Following this borrowing, total principal outstanding under the EB-5 Loan Agreement is $1.5&#160;million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6775796448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share of Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share of Common Stock</a></td>
<td class="text">Net Loss Per Share of Common Stock<div style="margin-top:12pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the computation of basic and diluted earnings per share for the years ended December 31, 2019 and 2018:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.175%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss&#8212;basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,242,630)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,219,664)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used in calculating net loss per common share&#8212;basic and diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,893,819&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,960,552&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per common share&#8212;basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.46)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.67)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as their inclusion would have been antidilutive:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.175%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options to purchase common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">731,189&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">632,752&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">870,020&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">870,020&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series&#160;A Warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,771,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series B Warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series&#160;C Warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,375,137&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,502,772&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6779176672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock-based compensation expense for options granted are reflected in the consolidated statements of operations and comprehensive loss as follows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.175%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended<br/>December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">362,833&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">515,160&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">521,256&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">559,527&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">884,089&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,074,687&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, the Company had $0.9 million of unrecognized compensation expense related to options outstanding under its equity plans. This expense is expected to be recognized over a weighted average period of 1.7 years as of December&#160;31, 2019</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Equity Plans</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company maintains two equity compensation plans, the 2014 Ocugen OpCo, Inc. Stock Option Plan (the &#8220;2014 Plan&#8221;) and the Ocugen, Inc. 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;, collectively with the 2014 Plan, the "Plans"), which replaced the Histogenics Corporation 2013 Equity Incentive Plan (the "2013 Plan"). </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 18, 2019, Ocugen&#8217;s stockholders approved the adoption of the 2019 Plan and the 2013 Plan was frozen. No additional awards have been or will be made under the 2013 Plan and any remaining authorized shares under the 2013 Plan will be recycled into the 2019 Plan. The 2019 Plan provides for the granting of up to 2.1&#160;million equity awards in respect of </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ocugen&#8217;s common stock, inclusive of equity awards that were previously available for issuance under the 2013 Plan, as of December&#160;31, 2019. Additionally, on the first business day of each fiscal year commencing on January 1, 2020, pursuant to the "Evergreen" provision of the 2019 Plan, the aggregate number of shares that may be issued under the 2019 Plan shall automatically increase by a number equal to the lesser of 4.0% of the total number of shares of Company common stock outstanding on December 31</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">st</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of the prior year, or a number of shares of Company common stock determined by the Board.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, an aggregate of 0.6&#160;million and 0.1&#160;million shares of Company common stock were issuable upon the exercise of outstanding stock options under the 2014 Plan and 2019 Plan, respectively.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Options to Purchase Common Stock</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average assumptions utilized in the fair value calculation for options to purchase common stock as of December&#160;31, 2019 and 2018 are as follows: </span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.175%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended<br/>December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average common stock price</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$1.04&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$9.72&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected option term (years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.0</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">6.0 &#8211; 10.0</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average expected stock price volatility</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">109%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">85%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1.5% &#8211; 2.4%</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">2.3% &#8211; 3.0%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the stock option activity under the Plans:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:37.766%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.625%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Exercise Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Remaining Contractual Life (Years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options outstanding at December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">632,752&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.93&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.9</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,801,696&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">238,761&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.04&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancelled</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(140,324)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.58&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options outstanding at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">731,189&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.59&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.0</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,028&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercisable at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">385,841&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.15&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.8</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,049&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The weighted average grant date fair value of stock options granted during the year ended December 31, 2019 and 2018 was $0.84 and $7.97, respectively</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The total fair value of stock options vested during the year ended December&#160;31, 2019 was $1.0&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>162</ContextCount>
  <ElementCount>416</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>67</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/NatureofBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2109103 - Disclosure - Merger and Pre-Merger Financing</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/MergerandPreMergerFinancing</Role>
      <ShortName>Merger and Pre-Merger Financing</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2113104 - Disclosure - Net Loss Per Share of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/NetLossPerShareofCommonStock</Role>
      <ShortName>Net Loss Per Share of Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2116105 - Disclosure - License and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/LicenseandCollaborationAgreements</Role>
      <ShortName>License and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2118106 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2121107 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2129108 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2135109 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2144110 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2149111 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2155112 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2205201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - Merger and Pre-Merger Financing (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/MergerandPreMergerFinancingTables</Role>
      <ShortName>Merger and Pre-Merger Financing (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/MergerandPreMergerFinancing</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2314303 - Disclosure - Net Loss Per Share of Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockTables</Role>
      <ShortName>Net Loss Per Share of Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/NetLossPerShareofCommonStock</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2319304 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/AccruedExpenses</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2322305 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/Debt</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2330306 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/ShareBasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2336307 - Disclosure - Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/CommitmentsTables</Role>
      <ShortName>Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/Commitments</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2345308 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/Warrants</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2350309 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/IncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Nature of Business - Reverse Stock Split (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/NatureofBusinessReverseStockSplitDetails</Role>
      <ShortName>Nature of Business - Reverse Stock Split (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Nature of Business - Going Concern (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/NatureofBusinessGoingConcernDetails</Role>
      <ShortName>Nature of Business - Going Concern (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Summary of Significant Accounting Policies (Summary Cash, Cash Equivalents and Restricted Cash) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesSummaryCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Summary Cash, Cash Equivalents and Restricted Cash) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Merger and Financing - Pre-Merger Financing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/MergerandFinancingPreMergerFinancingDetails</Role>
      <ShortName>Merger and Financing - Pre-Merger Financing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Merger and Financing - Merger with Histogenics (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/MergerandFinancingMergerwithHistogenicsDetails</Role>
      <ShortName>Merger and Financing - Merger with Histogenics (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Net Loss Per Share of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockDetails</Role>
      <ShortName>Net Loss Per Share of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - License and Collaboration Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/LicenseandCollaborationAgreementsDetails</Role>
      <ShortName>License and Collaboration Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/LicenseandCollaborationAgreements</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2420409 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/AccruedExpensesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2423410 - Disclosure - Debt - EB-5 Loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/DebtEB5LoanDetails</Role>
      <ShortName>Debt - EB-5 Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - Debt - Summary of EB-5 Loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/DebtSummaryofEB5LoanDetails</Role>
      <ShortName>Debt - Summary of EB-5 Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Debt - Convertible Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.deitaxonomy.com/role/DebtConvertibleNotesDetails</Role>
      <ShortName>Debt - Convertible Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Debt - Schedule of Fair Value of the Embedded Features (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/DebtScheduleofFairValueoftheEmbeddedFeaturesDetails</Role>
      <ShortName>Debt - Schedule of Fair Value of the Embedded Features (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - Debt - Convertible Notes Other Information (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.deitaxonomy.com/role/DebtConvertibleNotesOtherInformationDetails</Role>
      <ShortName>Debt - Convertible Notes Other Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Debt - Senior Secured Convertible Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.deitaxonomy.com/role/DebtSeniorSecuredConvertibleNotesDetails</Role>
      <ShortName>Debt - Senior Secured Convertible Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Stock-Based Compensation - Schedule of Compensation Expense for Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Compensation Expense for Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Shared-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/SharedBasedCompensationDetails</Role>
      <ShortName>Shared-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Stock-Based Compensation - Schedule of Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/StockBasedCompensationScheduleofValuationAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Stock-Based Compensation - Schedule Options to Purchase Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/StockBasedCompensationScheduleOptionstoPurchaseCommonStockDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule Options to Purchase Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/CommitmentsDetails</Role>
      <ShortName>Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/CommitmentsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - Commitments - Operating leases, components of lease expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/CommitmentsOperatingleasescomponentsofleaseexpenseDetails</Role>
      <ShortName>Commitments - Operating leases, components of lease expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2439422 - Disclosure - Commitments - Operating leases, supplemental balance sheet information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/CommitmentsOperatingleasessupplementalbalancesheetinformationDetails</Role>
      <ShortName>Commitments - Operating leases, supplemental balance sheet information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2440423 - Disclosure - Commitments - Operating leases, supplemental information related to leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/CommitmentsOperatingleasessupplementalinformationrelatedtoleasesDetails</Role>
      <ShortName>Commitments - Operating leases, supplemental information related to leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2441424 - Disclosure - Commitments - Operating leases, future minimum lease payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/CommitmentsOperatingleasesfutureminimumleasepaymentsDetails</Role>
      <ShortName>Commitments - Operating leases, future minimum lease payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2442425 - Disclosure - Commitments - Finance leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/CommitmentsFinanceleasesDetails</Role>
      <ShortName>Commitments - Finance leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2443426 - Disclosure - Commitments - Finance leases, future minimum lease payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/CommitmentsFinanceleasesfutureminimumleasepaymentsDetails</Role>
      <ShortName>Commitments - Finance leases, future minimum lease payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2446427 - Disclosure - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/WarrantsDetails</Role>
      <ShortName>Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/WarrantsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2447428 - Disclosure - Schedule of Activity of the Pre-Merger Financing Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/ScheduleofActivityofthePreMergerFinancingWarrantsDetails</Role>
      <ShortName>Schedule of Activity of the Pre-Merger Financing Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2448429 - Disclosure - Schedule of Roll-forward of Series??B Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/ScheduleofRollforwardofSeriesBWarrantLiabilityDetails</Role>
      <ShortName>Schedule of Roll-forward of Series??B Warrant Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2451430 - Disclosure - Schedule of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/ScheduleofDeferredTaxAssetsDetails</Role>
      <ShortName>Schedule of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2452431 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/IncomeTaxesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2453432 - Disclosure - Schedule of Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/ScheduleofEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Schedule of Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2454433 - Disclosure - Schedule of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/ScheduleofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Schedule of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ocgn-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2456434 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/SubsequentEvents</ParentRole>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="ocgn-20191231.htm">ocgn-20191231.htm</File>
    <File>ocgn-20191231.xsd</File>
    <File>ocgn-20191231_cal.xml</File>
    <File>ocgn-20191231_def.xml</File>
    <File>ocgn-20191231_lab.xml</File>
    <File>ocgn-20191231_pre.xml</File>
    <File>ocgn-20191231x10kxex10.htm</File>
    <File>ocgn-20191231x10kxex101.htm</File>
    <File>ocgn-20191231x10kxex211.htm</File>
    <File>ocgn-20191231x10kxex231.htm</File>
    <File>ocgn-20191231x10kxex311.htm</File>
    <File>ocgn-20191231x10kxex312.htm</File>
    <File>ocgn-20191231x10kxex321.htm</File>
    <File>ocgn-20191231x10kxex41.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ocgn-20191231_g1.jpg</File>
    <File>ocgn-20191231_g10.jpg</File>
    <File>ocgn-20191231_g11.jpg</File>
    <File>ocgn-20191231_g12.jpg</File>
    <File>ocgn-20191231_g13.jpg</File>
    <File>ocgn-20191231_g14.jpg</File>
    <File>ocgn-20191231_g15.jpg</File>
    <File>ocgn-20191231_g2.jpg</File>
    <File>ocgn-20191231_g3.jpg</File>
    <File>ocgn-20191231_g4.jpg</File>
    <File>ocgn-20191231_g5.jpg</File>
    <File>ocgn-20191231_g6.jpg</File>
    <File>ocgn-20191231_g7.jpg</File>
    <File>ocgn-20191231_g8.jpg</File>
    <File>ocgn-20191231_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6775809888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments - Operating leases, future minimum lease payments (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2020</a></td>
<td class="nump">$ 191,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">160,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">11,354<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">364,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: present value adjustment</a></td>
<td class="num">(28,645)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 335,508<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6790046144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Activity of the Pre-Merger Financing Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 04, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Pre-Merger Financing Warrants Activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding at beginning of the period (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ClassOfWarrantOrRightIssued', window );">Issued (in shares)</a></td>
<td class="nump">49,385,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ClassOfWarrantOrRightExercised', window );">Class of Warrant or Right, Exercised</a></td>
<td class="num">(40,612,036)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">8,773,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocgn_SeriesWarrantsMember', window );">Series A Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Pre-Merger Financing Warrants Activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding at beginning of the period (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ClassOfWarrantOrRightIssued', window );">Issued (in shares)</a></td>
<td class="nump">8,771,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ClassOfWarrantOrRightExercised', window );">Class of Warrant or Right, Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">8,771,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Initial exercise price (in USD per share)</a></td>
<td class="nump">$ 7.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocgn_SeriesBWarrantsMember', window );">Series B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Pre-Merger Financing Warrants Activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding at beginning of the period (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ClassOfWarrantOrRightIssued', window );">Issued (in shares)</a></td>
<td class="nump">20,614,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ClassOfWarrantOrRightExercised', window );">Class of Warrant or Right, Exercised</a></td>
<td class="num">(20,613,036)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Initial exercise price (in USD per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocgn_SeriesCWarrantsMember', window );">Series C Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Pre-Merger Financing Warrants Activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding at beginning of the period (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ClassOfWarrantOrRightIssued', window );">Issued (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ClassOfWarrantOrRightExercised', window );">Class of Warrant or Right, Exercised</a></td>
<td class="num">(19,999,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Initial exercise price (in USD per share)</a></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 7.13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ocgn_SeriesWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ocgn_SeriesWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ocgn_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ocgn_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ocgn_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ocgn_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6789780240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements (Details) - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License agreements:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,085,522<span></span>
</td>
<td class="nump">$ 10,321,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ocgn_CollaborationAgreementWithCansinoBiologicsMember', window );">Collaboration Agreement with CanSino Biologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License agreements:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_CollaborationAgreementTerm', window );">Term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_CollaborationAgreementTerminationDevelopmentCostStatement', window );">Period within with Cansino to provide development cost statement</a></td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_CollaborationAgreementTerminationDevelopmentCostPayment', window );">Period within which to reimburse Cansino of development costs</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ocgn_SchepensEyeResearchInstituteMember', window );">Schepens Eye Research Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License agreements:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_LicenseAgreementPayment', window );">License fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment', window );">Potential development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_LicenseAgreementPotentialCommercialMilestonePayment', window );">Potential commercial milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_LicenseAgreementMilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_LicenseAgreementCancellationPeriodNotice', window );">Cancellation period, written notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ocgn_CollaborationAgreementWithUniversityOfIllinoisChicagoMember', window );">Collaboration agreement with University of Illinois, Chicago</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License agreements:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment', window );">Potential development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_LicenseAgreementMilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_LicenseAgreementCancellationPeriodNotice', window );">Cancellation period, written notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_LicenseAgreementSigningFee', window );">Signing fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_LicenseAgreementMinimumAnnualRoyaltyPayment', window );">Minimum annual royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ocgn_CollaborationAgreementWithUniversityOfIllinoisChicagoMember', window );">Collaboration agreement with University of Illinois, Chicago | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License agreements:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_LicenseAgreementMinimumAnnualRoyaltyPayment', window );">Minimum annual royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ocgn_CollaborationAgreementWithUniversityOfColoradoMember', window );">Collaboration agreement with University of Colorado</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License agreements:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment', window );">Potential development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_LicenseAgreementCancellationPeriodNotice', window );">Cancellation period, written notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_LicenseAgreementMinimumAnnualRoyaltyPayment', window );">Minimum annual royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_CollaborationAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the term of agreement or milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_CollaborationAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_CollaborationAgreementTerminationDevelopmentCostPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period within which the entity is to reimburse a party to collaboration agreement of development costs after a statement of such is provided upon termination of the agreement, , in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_CollaborationAgreementTerminationDevelopmentCostPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_CollaborationAgreementTerminationDevelopmentCostStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period within which a party to collaboration agreement is to provide the entity statement of development costs after termination of agreement, , in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_CollaborationAgreementTerminationDevelopmentCostStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_LicenseAgreementCancellationPeriodNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Cancellation Period Notice</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_LicenseAgreementCancellationPeriodNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_LicenseAgreementMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_LicenseAgreementMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_LicenseAgreementMinimumAnnualRoyaltyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Minimum Annual Royalty Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_LicenseAgreementMinimumAnnualRoyaltyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_LicenseAgreementPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_LicenseAgreementPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_LicenseAgreementPotentialCommercialMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Potential Commercial Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_LicenseAgreementPotentialCommercialMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Potential Development And Regulatory Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_LicenseAgreementPotentialDevelopmentAndRegulatoryMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_LicenseAgreementSigningFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Signing Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_LicenseAgreementSigningFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ocgn_CollaborationAgreementWithCansinoBiologicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ocgn_CollaborationAgreementWithCansinoBiologicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ocgn_SchepensEyeResearchInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ocgn_SchepensEyeResearchInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ocgn_CollaborationAgreementWithUniversityOfIllinoisChicagoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ocgn_CollaborationAgreementWithUniversityOfIllinoisChicagoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ocgn_CollaborationAgreementWithUniversityOfColoradoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ocgn_CollaborationAgreementWithUniversityOfColoradoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6662045808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Summary Cash, Cash Equivalents and Restricted Cash) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, cash equivalents and restricted cash reconciliation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 7,444,052<span></span>
</td>
<td class="nump">$ 1,628,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">151,016<span></span>
</td>
<td class="nump">150,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 7,595,068<span></span>
</td>
<td class="nump">$ 1,778,613<span></span>
</td>
<td class="nump">$ 6,301,572<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=116631420&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6779235104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger and Pre-Merger Financing<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Merger and Pre-Merger Financing</a></td>
<td class="text">Merger and Pre-Merger Financing<div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Pre-Merger Financing</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June&#160;2019, Former Ocugen and Histogenics entered into a Securities Purchase Agreement (as amended, the &#8220;Financing SPA&#8221;) with certain accredited investors (the &#8220;Investors&#8221;). Pursuant to the Financing SPA, among other things, (i)&#160;immediately prior to the Merger, Former Ocugen issued 4.6 million shares of common stock to the Investors (the &#8220;Initial Shares&#8221; and, as converted pursuant to the exchange rate in the Merger into the right to receive approximately 2.2 million shares the Company&#8217;s common stock, the &#8220;Converted Initial Shares&#8221;), (ii)&#160;immediately prior to the Merger, Former Ocugen issued and deposited 4.6&#160;million shares of common stock into escrow on behalf of the Investors (the &#8220;Additional Shares&#8221; and, as converted pursuant to the exchange rate in the Merger, into the right to receive approximately 2.2 million shares of the Company&#8217;s common stock, the &#8220;Converted Additional Shares&#8221;) and (iii)&#160;the Company agreed to issue, on the fifth trading day following the consummation of the Merger, three series of warrants to purchase shares of the Company&#8217;s common stock (the &#8220;Series&#160;A Warrants,&#8221; the &#8220;Series&#160;B Warrants&#8221; and the &#8220;Series&#160;C Warrants&#8221; and collectively, the &#8220;Pre-Merger Financing Warrants&#8221;) in exchange for an aggregate purchase price of $25.0 million (&#8220;Pre-Merger Financing&#8221;). See Note 10 for additional information on the Pre-Merger Financing Warrants.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On October 4, 2019, the Converted Additional Shares were released from escrow to the investors because, as determined at the close of business on October 2, 2019, 80% of the volume-weighted average trading price of a share of Ocugen&#8217;s common stock as quoted on Nasdaq for the first <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjllOWNhYjJkNGM0ZjRhMzNiMmQ5MGVhMWUwYzNmOTc5L3NlYzo5ZTljYWIyZDRjNGY0YTMzYjJkOTBlYTFlMGMzZjk3OV81Mi9mcmFnOjVkZmJjNThhMWY3ZjQwZGZiOWRiM2ZkNzBmYThhYjY5L3RleHRyZWdpb246NWRmYmM1OGExZjdmNDBkZmI5ZGIzZmQ3MGZhOGFiNjlfMTcwNDI0MzAyNDIzMTA_2a410e8c-05ba-4258-a80a-5a97f417ce2a">three</span> trading days immediately following the closing date of the Pre-Merger Financing was lower than the price paid by the Investors for the Initial Shares.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Approximately $2.5 million of the $25.0 million Pre-Merger Financing was utilized to pay transaction costs related to the Merger and the Pre-Merger Financing in the form of equity. In addition, the Company utilized $5.3&#160;million of the Pre-Merger </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financing for the repayment of the Senior Secured Notes, as defined in Note 7. As a result, the Company received total net proceeds of $17.2 million from the Pre-Merger Financing. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company incurred $1.9 million in equity issuance costs related to the Pre-Merger Financing, of which $0.7 million was paid in cash and $1.2 million was paid with equity as of December&#160;31, 2019. Approximately $1.1 million of equity issuance costs was allocated to the Series&#160;A Warrants and Series&#160;C Warrants and is included in additional paid-in capital. Approximately $0.8 million of issuance costs allocated to the Series&#160;B Warrant liability was expensed and is reflected in other income (expense) on the consolidated statements of operations and comprehensive loss for the year ended December 31, 2019.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Merger with Histogenics</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September&#160;27, 2019, the Company completed the Merger in accordance with the terms of the Merger Agreement. The Merger was structured as a stock-for-stock transaction whereby all of Former Ocugen&#8217;s outstanding shares of common stock and securities convertible into or exercisable for Former Ocugen&#8217;s common stock were converted into the right to receive Histogenics&#8217; common stock and securities convertible into or exercisable for Histogenics&#8217; common stock. Immediately following the Merger, the former equity holders of Former Ocugen owned 84.25% of the outstanding capital stock of the Company, and the equity holders of the Company immediately before the Merger owned 15.75% of the outstanding capital stock of the Company, including the Initial Shares but excluding the Additional Shares and the Pre-Merger Financing Warrants pursuant to the Financing SPA.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In accordance with ASC Topic 805, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Business Combinations</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC 805&#8221;)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the Company concluded that, while Histogenics is the legal acquirer, Former Ocugen is the accounting acquirer due to the fact that (i)&#160;Former Ocugen&#8217;s shareholders have the majority of the voting rights in Ocugen, (ii)&#160;Former Ocugen holds all of the board seats of the combined company and (iii)&#160;Former Ocugen management holds all key positions in the management of the combined company. The Company has further concluded that Histogenics does not meet the definition of a business under ASC 805 due to the fact that substantially all of the fair value of the gross assets disposed of is concentrated in a single identifiable asset or a group of similar identifiable assets. Therefore, the Merger was accounted for as a reverse asset acquisition. The Company incurred $4.9 million in transaction costs related to the Merger, of which $2.6 million was paid in cash and $2.3 million was paid with equity.</span></div><div style="margin-top:12pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Assets and liabilities of Histogenics on September&#160;27, 2019 were as follows (in thousands):</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.380%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.620%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">September 27,</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">2019</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">302&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset held for sale</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,106)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,196&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Asset Held for Sale</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the Merger, on May&#160;8, 2019, Histogenics entered into an asset purchase agreement (the &#8220;Asset Purchase Agreement&#8221;) with Medavate Corp., a Colorado corporation (&#8220;Medavate&#8221;), pursuant to which Histogenics agreed to sell substantially all of its assets relating to its NeoCart</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> program, including, without limitation, intellectual property, business and license agreements and clinical trial data (the &#8220;Assets&#8221;) in return for a cash payment of $6.5 million. On September&#160;26, 2019, the parties entered into an amendment to the Asset Purchase Agreement whereby the closing date was amended to October&#160;4, 2019. On October&#160;4, 2019, the parties entered into a second amendment (the &#8220;Second Amendment&#8221;) to the Asset Purchase Agreement whereby the purchase price was increased to $7.0&#160;million under the Asset Purchase Agreement and the closing date of the Asset Purchase Agreement was revised from October&#160;4, 2019 to two business days after Medavate obtains financing in an amount no less than the purchase price (the &#8220;Closing Date&#8221;). The Second Amendment further provides that if the Closing Date does not occur on or prior to October&#160;31, 2019, Ocugen may choose to terminate the Asset Purchase Agreement without recourse and, if Ocugen does not terminate the Asset Purchase Agreement, the purchase price shall increase 10% per month (or any portion thereof) between October&#160;31, 2019 and the Closing Date. The Closing Date did not occur as of December&#160;31, 2019, Ocugen has not terminated the Asset Purchase Agreement and as of December&#160;31, 2019, the purchase price has increased to $8.5 million.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The NeoCart</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> asset qualified as held for sale as of the date of the reverse asset acquisition and is carried at its original fair value less cost to sell on the consolidated balance sheet as of December&#160;31, 2019. The NeoCart</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> asset held for sale was valued at the </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">acquisition date based on a quoted price of $7.0 million, which is an observable Level 2 fair value input. Subsequent increases in fair value are not recognized beyond the initial value at the time the asset was classified as held for sale. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">MEDINET Agreement</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December&#160;2017, Histogenics entered into the License and Commercialization Agreement (the &#8220;License Agreement&#8221;) with MEDINET Co.,&#160;Ltd. (&#8220;MEDINET&#8221;) to grant MEDINET a license under certain patents, patent applications, know-how, and technology to develop and commercialize certain therapeutic products related to the NeoCart</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> program. As consideration for the granting of the license, MEDINET agreed to pay Histogenics a non-refundable upfront cash payment of $10.0 million which was received in January&#160;2018. Based on the results of the NeoCart</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> research, Histogenics suspended the NeoCart</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> program. Subsequently, since MEDINET relied on the NeoCart</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> product to supply clinical trial patients, MEDINET suspended the development of its clinical trial. As of December&#160;31, 2019, the contract with MEDINET was wholly unperformed. As a result of the expected sale of the NeoCart</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> asset, the Company does not expect to retain any future obligations related to the MEDINET agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures.  This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6775740320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">EB-5 Loan</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In September&#160;2016, pursuant to the U.S. government&#8217;s Immigrant Investor Program, commonly known as the EB-5 program (the &#8220;EB-5 Program&#8221;), the Company entered into an arrangement (the &#8220;EB-5 Loan Agreement&#8221;) to borrow up to $10.0 million from EB5 Life Sciences,&#160;L.P. (the &#8220;Lender&#8221;) in $0.5 million increments. Borrowing may be limited by the amount of funds raised by the Lender and are subject to certain job creation requirements by the Company. Borrowings are at a fixed interest rate of 4.0% per annum and are to be utilized in the clinical development, manufacturing, and commercialization of the Company&#8217;s products and for the general working capital needs of the Company. Outstanding borrowings pursuant to the EB-5 Program, including accrued interest, become due upon the seventh anniversary of the final disbursement. Amounts repaid cannot be re-borrowed. The EB-5 note is secured by substantially all assets of the Company, except for any patents, patent applications, pending patents, patent license, patent sublicense, trademarks, and other intellectual property rights.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In 2016, $1.0 million was borrowed by the Company. Issuance costs for these borrowings totaled $0.1 million, which was recognized as a reduction to the loan balance and is amortized to interest expense over the term of the loan. See Note 12 for information regarding events subsequent to December 31, 2019.</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.175%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Principal outstanding</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Plus: accrued interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">127,777&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,222&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: unamortized debt issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(55,654)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(70,495)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying value of debt</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,072,123&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,016,727&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Convertible Notes</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the years ended December&#160;31, 2019 and 2018, the Company issued convertible notes (the &#8220;Notes&#8221;) to new and existing stockholders in the Company, including Notes in the aggregate principal amount of $3.5 million to members of the Board of Directors. As of December&#160;31, 2019, all Notes had been converted and were no longer outstanding.</span></div><div style="margin-top:12pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At issuance, the following amounts were recorded:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.052%;"><tr><td style="width:1.0%;"/><td style="width:35.290%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.220%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.408%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.220%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.408%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.220%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.408%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.226%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Note&#160;Issuance&#160;Date</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Note<br/>Principal<br/>Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair&#160;Value&#160;of<br/>Embedded Derivatives</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Debt<br/>Issuance<br/>Costs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying Value upon Issuance</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,000,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,657,711)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(35,969)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,306,320&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(724,216)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">272,784&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">November 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,150,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21,127)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(50,646)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,078,627&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,857)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14,310)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">132,833&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">450,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(182,882)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(29,358)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">237,760&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(302,379)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(55,875)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">641,746&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,750,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,891,172)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(189,158)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,670,070&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:12pt;"><span><br/></span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All Notes accrued interest at a rate of 5% per annum and had scheduled maturity dates on the eighteen month anniversary of the date of the issuance of the Notes (the &#8220;Maturity Date&#8221;). If prior to the Maturity Date, there was a consummation of the sale of all or substantially all of the assets of the Company, change in control or event of default, the Notes would become due and payable at an amount equal to 1.5 times the principal amount of the Notes together with all accrued interest (the &#8220;Change in Control Feature&#8221;).</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If the Company received equity financing from the issuance of stock of the Company from an investor or group of investors in a transaction or series of related transactions above a certain amount of gross proceeds, the principal amount and all interest accrued but not paid through the closing date of the qualified equity financing was to automatically convert into the same class of equity securities as those issued in the qualified equity financing ("conversion feature"). The price per share varied among the Notes ranging from a 0% to 30% discount to the lowest price per share being paid by investors in the qualified equity financing.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company bifurcated the Conversion Feature for the January&#160;2018, June&#160;2018, January&#160;2019, and February&#160;2019 notes and classified it as a derivative liability because the Conversion Feature does not have a fixed conversion price and conversion will be settled in a variable number of shares of common stock. There was no bifurcated Conversion Feature for the November&#160;2018 and December 2018 notes as there is no discount to the lowest equity price triggering conversion. The Company also bifurcated the Change in Control Feature for all of the Notes because it was determined to be a redemption feature not clearly and closely related to the debt host. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of both of the embedded features was accounted for as a derivative liability and was recorded as a discount on the Notes. Inputs used in valuation were unobservable and therefore considered Level 3 in the fair value hierarchy. The debt discount is accreted into interest expense over the expected time until conversion of the Notes. The accretion amounted to $0.6 million and $3.4 million, for the year ended December 31, 2019 and 2018, respectively.</span></div><div style="margin-top:12pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the embedded features was classified as a liability in the Company&#8217;s consolidated balance sheets at issuance, with subsequent changes in fair value during the year ended December 31, 2019 and 2018 recorded on the Company&#8217;s consolidated statements of operations and comprehensive loss as a change in fair value of derivative liabilities.</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:82.795%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.621%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Balance at January 1, 2018 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Fair value of embedded derivatives at issuance </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,405,911&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Change in fair value of embedded derivatives </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,664,689)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Balance at December 31, 2018 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,741,222&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Fair value of embedded derivatives at issuance </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">567,661&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Change in fair value of embedded derivatives </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,319,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Conversion and extinguishment of debt </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,628,283)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Balance at December 31, 2019 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company considered several possible outcomes in the likelihood and timing of a qualified equity financing and/or a change in control occurring that would trigger conversion or redemption and believes the amounts disclosed above based on inputs utilized in the valuation were the best estimates at each valuation date.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 5, 2019, Former Ocugen entered into a Stock Subscription Agreement (&#8220;Subscription Agreement&#8221;) with existing investors for the sale of 0.1 million shares of common stock for $1.0 million, or $12.41 per share including the sale of 40,286 shares of common stock for $0.5 million to a member of the Board of Directors. This capital raise triggered the conversion features on the convertible debt described above. The Notes were modified to change the discount percentage from the 0% discount per the terms of the November&#160;2018 and December 2018 Notes and the 15% discount per the terms of the January&#160;2019 and February&#160;2019 Notes to 30% at the time of conversion. The Company issued 1.1 million shares of common stock at $8.69 per share on the date of conversion to extinguish the debt, which resulted in a loss of $0.3 million. This non-cash conversion also resulted in an increase of $13.0 million in additional paid-in capital, which was based on the principal balance outstanding and the unpaid interest upon conversion.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Convertible Promissory Notes</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 4, 2019, the Company issued the convertible promissory note (the &#8220;Promissory Note&#8221;) to an existing stockholder for $0.9 million at an interest rate of 5% per annum. On May&#160;16, 2019, the Promissory Note was converted into equity. Former Ocugen issued 0.1 million shares of common stock at the conversion date to extinguish the debt at $12.41 per share. This non-cash transaction resulted in an increase of $0.9 million in additional paid-in capital, which was based on the principal balance outstanding and the unpaid interest upon conversion.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Senior Secured Convertible Notes</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May 21, 2019, the Company issued senior secured convertible notes to certain investors for $2.4 million at an original issue discount of $0.5 million, and on June&#160;28, 2019, the Company entered into an agreement to issue additional senior secured convertible notes to the investors for $2.9 million with an original issue discount of $0.4 million (together &#8220;Senior Secured Notes&#8221;). Immediately prior to the Merger completed on September 27, 2019, the investors offset $5.3 million from the amount to be received under the Pre-Merger Financing and the Senior Secured Notes were deemed to have been repaid and cancelled. The accretion of the original issue discount to interest expense amounted to $0.8 million during the year ended December 31, 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6775855376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income TaxesFor the years ended December 31, 2019 and 2018, the Company did not recognize any current or deferred income tax expense or benefit due to the current and historical losses incurred by the Company. Losses before income taxes were $20.2 million and $18.2 million for the years ended December&#160;31, 2019 and 2018, respectively, substantially all of which were incurred in the United States.<div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company&#8217;s deferred tax assets and liabilities are comprised of the following: </span></div><div style="margin-top:12pt;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.175%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating loss carryforwards</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,575,288&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,864,360&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capital loss carryforwards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,298,052&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Start-up costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,234,751&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accruals and reserves</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">166,611&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,645&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intellectual property amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">555,352&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">121,694&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,123,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">993,234&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Convertible debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">498,236&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,926,677&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">548,399&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96,895&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,976,726&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,061,568&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(53,877,168)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,061,568)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets, net of allowance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99,558&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liabilities:</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease ROU asset</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(99,558)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As of December&#160;31, 2019 and 2018, the Company had U.S. federal net operating loss ("NOL") carryforwards of $113.6 million and $23.7&#160;million, respectively, which may be available to offset future income tax liabilities. The Tax Cut and Jobs Act, which was enacted in December 2017, will generally allow federal losses generated after 2017 to be carried over indefinitely, but will generally limit the NOL deduction to the lesser of the NOL carryover or 80% of a corporation&#8217;s taxable income. In addition, there will be no carryback for losses generated after 2017. Losses generated prior to 2018 will generally be deductible to the extent of the lesser of a corporation&#8217;s NOL carryover or 100% of a corporation&#8217;s taxable income and be available for twenty years from the period the loss was generated. The Company has federal NOLs generated after 2017 of $61.2 million, which do not expire. The federal NOLs generated prior to 2018 of $52.4 million will expire at various dates through 2037. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As of December&#160;31, 2019 and 2018, the Company also had U.S. state NOL carryforwards of $112.4 million and $23.7&#160;million, respectively, which may be available to offset future income tax liabilities and expire at various dates through 2039. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As of December&#160;31, 2019 and 2018, the Company has federal tax credit carryforwards of approximately $1.6&#160;million and $0.8 million, respectively, which are available to offset future federal tax liabilities which expire at various dates through 2039. As of December&#160;31, 2019 and 2018, the Company has state tax credit carryforwards of approximately $0.4&#160;million and $0.1&#160;million, respectively, which are available to reduce future tax liabilities which expire at various dates through 2034. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company has recorded a full valuation allowance against its net deferred tax assets as of December&#160;31, 2019 and 2018 because the Company has determined that is it more likely than not that these assets will not be fully realized due to the Company's history of operating losses and lack of available evidence supporting future taxable income. The Company experienced a net change in valuation allowance of $44.8 million during the year ended December 31, 2019, primarily related to the increase in NOL carryforwards. The increase in the federal and state NOL carryforwards during the year ended December 31, 2019 was primarily due to the acquired NOL carryforwards as a result of the Merger. </span></div><div style="text-align:justify;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Under the provisions of the IRC, the NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Utilization of U.S. federal and state operating loss and tax credit carryforwards may be subject to a substantial annual limitation under Section 382 and Section 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of NOL and tax credit carryforwards that can be utilized annually to offset future taxable income and tax liabilities, respectively. The Company acquired a significant amount of federal and state NOL carryforwards and federal and state tax credit carryforwards as a result of the Merger. The Company </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">has not yet conducted a comprehensive study to assess whether a change of ownership has occurred, or whether there have been multiple ownership changes since its formation. Any limitation may result in expiration of a portion of the NOL carryforward or tax credit carryforwards before utilization, which would be offset by a change in the Company's valuation allowance. Further, until a study is completed by the Company and any limitation is known, no amounts are being presented as an uncertain tax position. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The reconciliation of federal statutory income tax to the Company's provision for income taxes is as follows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.175%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected provision at statutory rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State tax - net of federal benefit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Permanent differences</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.0</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(24.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(29.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total provision for income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.380%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.620%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross unrecognized tax benefits as of December 31, 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions for tax positions taken in a prior year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">303,050&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions for tax positions taken in the current year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reductions for tax positions taken in the prior year due to settlement</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reductions for tax positions taken in the prior year due to statutes lapsing</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross unrecognized tax benefits as of December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">303,050&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The uncertain tax positions giving rise to the unrecognized tax benefits of $0.3&#160;million at December&#160;31, 2019 relate to the timing of certain income and deductions for federal income tax purposes taken by Histogenics prior to the Merger. The reversal of unrecognized tax benefits would not have any impact on the effective tax rate in future periods and is not expected to create cash tax liability.</span></div>The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In a normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The Company&#8217;s tax years are still open under status from 2016 to present.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6667839136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments - Operating leases, supplemental information related to leases (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease terms&#8212;operating leases (years)</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate&#8212;operating leases</a></td>
<td class="nump">7.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791997776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 21, 2019 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 05, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>measurementInput </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>measurementInput </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>measurementInput </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 04, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Oct. 04, 2019</div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>segment</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionLowerPercentageOfCommonStock', window );">Pre-merger financing warrants, block provisions, exercise restriction percentage of common stock (in percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionHigherPercentageOfCommonStock', window );">Pre-merger financing warrants, block provisions, exercise restriction percentage of common stock (in percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_PercentageOfAmountOnMarketValueForFailureToIssueCommonStockOnPreMergerFinancingWarrants', window );">Percentage of amount on market value for failure to issue common stock on pre-merger financing warrants (in percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger', window );">Percentage of volume-weighted average trading price of a share of common stock that triggered release of converted additional shares (in percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_NumberOfFormerEmployeesWithWarrants', window );">Number of former employees with warrants | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Price Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants fair value estimate volatility (in percentage) | measurementInput</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.960<span></span>
</td>
<td class="nump">0.960<span></span>
</td>
<td class="nump">0.960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocgn_SeriesWarrantsMember', window );">Series A Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Initial exercise price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.13<span></span>
</td>
<td class="nump">$ 7.13<span></span>
</td>
<td class="nump">$ 7.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants outstanding, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ProceedsFromWarrantExercisesMaximumAmount', window );">Proceeds From Warrant Exercises, Maximum Amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common shares in to which the warrants are exercisable (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.8<span></span>
</td>
<td class="nump">8.8<span></span>
</td>
<td class="nump">8.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocgn_SeriesBWarrantsMember', window );">Series B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Initial exercise price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants outstanding (in shares) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger', window );">Percentage of volume-weighted average trading price of a share of common stock that triggered release of converted additional shares (in percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPrice', window );">Price over which trading price of common stock as quoted on the Nasdaq Capital Market was considered for the release of converted additional shares (in USD per share)</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_CommonStockAdditionalSharesOfCommonStockIssuableUponExerciseOfWarrantsBasedOnResetPeriodShares', window );">Common stock, issuable upon exercise of warrant (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.6<span></span>
</td>
<td class="nump">12.6<span></span>
</td>
<td class="nump">12.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ClassOfWarrantOrRightExercisePriceDeterminationNumberOfTradingDaysConsidered', window );">Warrants, exercise price determination, number of trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ClassOfWarrantOrRightConditionForExpirationTradingDay', window );">Warrants expiration, trading day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 days<span></span>
</td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocgn_SeriesCWarrantsMember', window );">Series C Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Initial exercise price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 7.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPrice', window );">Price over which trading price of common stock as quoted on the Nasdaq Capital Market was considered for the release of converted additional shares (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common shares in to which the warrants are exercisable (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ClassOfWarrantOrRightExercisePriceDeterminationNumberOfTradingDaysConsidered', window );">Warrants, exercise price determination, number of trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ClassOfWarrantOrRightConditionForExpirationTradingDay', window );">Warrants expiration, trading day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocgn_SeriesCWarrantsMember', window );">Series C Warrants | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common shares in to which the warrants are exercisable (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocgn_FormerOcugenWarrantsMember', window );">Former Ocugen warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Initial exercise price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.67<span></span>
</td>
<td class="nump">$ 5.67<span></span>
</td>
<td class="nump">$ 5.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ClassOfWarrantOrRightExercisable', window );">Warrants exercisable (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ClassOfWarrantOrRightConditionForExpirationTradingDay">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The trading day after which the warrants will expire.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ClassOfWarrantOrRightConditionForExpirationTradingDay</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ClassOfWarrantOrRightExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ClassOfWarrantOrRightExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ClassOfWarrantOrRightExercisePriceDeterminationNumberOfTradingDaysConsidered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of trading days considered for determination of exercise price of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ClassOfWarrantOrRightExercisePriceDeterminationNumberOfTradingDaysConsidered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_CommonStockAdditionalSharesOfCommonStockIssuableUponExerciseOfWarrantsBasedOnResetPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Additional Shares Of Common Stock Issuable Upon Exercise Of Warrants Based on Reset Period, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_CommonStockAdditionalSharesOfCommonStockIssuableUponExerciseOfWarrantsBasedOnResetPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of the volume-weighted average trading price of a share of common stock as quoted on the Nasdaq Capital Market for the first three trading days immediately following the closing date of the Pre-Merger Financing as threshold to release converted additional shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ConvertedAdditionalSharesThresholdReleaseTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price over which the volume-weighted average trading price of a share of common stock as quoted on the Nasdaq Capital Market to release converted additional shares is determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ConvertedAdditionalSharesThresholdReleaseTriggerPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_NumberOfFormerEmployeesWithWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Former Employees With Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_NumberOfFormerEmployeesWithWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_PercentageOfAmountOnMarketValueForFailureToIssueCommonStockOnPreMergerFinancingWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If company fails to issue to a holder of the Pre-Merger Financing Warrants the number of shares of common stock to which such holder is entitled upon such holder's exercise of the such warrants, then company shall be obligated to pay the holder on each day while such failure is continuing an amount equal to percentage of the market value of the undelivered shares determined using any trading price of the common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_PercentageOfAmountOnMarketValueForFailureToIssueCommonStockOnPreMergerFinancingWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionHigherPercentageOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre-merger Financing Warrants, Block Provisions, Exercise Restriction Higher Percentage Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionHigherPercentageOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionLowerPercentageOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre-merger Financing Warrants, Block Provisions, Exercise Restriction Lower Percentage Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionLowerPercentageOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ProceedsFromWarrantExercisesMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Warrant Exercises, Maximum Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ProceedsFromWarrantExercisesMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ocgn_SeriesWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ocgn_SeriesWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ocgn_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ocgn_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ocgn_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ocgn_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ocgn_FormerOcugenWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ocgn_FormerOcugenWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6778450128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (20,242,630)<span></span>
</td>
<td class="num">$ (18,219,664)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Net change in valuation allowance</a></td>
<td class="nump">44,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">303,050<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and local</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">112,400,000<span></span>
</td>
<td class="nump">23,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">113,600,000<span></span>
</td>
<td class="nump">23,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Operating loss carryforwards, not subject to expiration</a></td>
<td class="nump">61,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating loss carryforwards, subject to expiration</a></td>
<td class="nump">52,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6776593584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Valuation Assumptions (Details) - Stock options - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Weighted average common stock price (in USD per share)</a></td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="nump">$ 9.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option term (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Weighted average expected stock price volatility (in percentage)</a></td>
<td class="nump">109.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate (in percentage)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (in percentage)</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (in percentage)</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6789811408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Convertible Notes Other Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>May 16, 2019</div></th>
<th class="th"><div>Apr. 05, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Apr. 04, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement', window );">Common stock, shares agreed to be sold, stock subscription agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Common stock, value, subscriptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,746,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,960,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Increase in additional paid-in capital from conversion</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ocgn_ConvertiblePromissoryNotesMember', window );">Convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Note Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ocgn_January2019AndFebruary2019NotesMember', window );">January&#160;2019 and February&#160;2019 notes | Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount', window );">Conversion price discount per original agreement (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ocgn_November2018AndDecember2018NotesMember', window );">November&#160;2018 and December 2018 notes | Convertible notes | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount', window );">Conversion price discount per original agreement (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAxis=us-gaap_ConvertibleDebtMember', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment of debt loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Board members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement', window );">Common stock, shares agreed to be sold, stock subscription agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Common stock, value, subscriptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Shares Agreed To Be Sold, Stock Subscription Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of discount of the convertible debt that automatically convert the same class of equity as those issued to the lowest price per share being paid by investors in the equity financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ConvertibleDebtEquityFinancingTriggeredDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 51<br> -URI http://asc.fasb.org/extlink&amp;oid=117331294&amp;loc=d3e34017-109320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ocgn_ConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ocgn_ConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ocgn_January2019AndFebruary2019NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ocgn_January2019AndFebruary2019NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ocgn_November2018AndDecember2018NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ocgn_November2018AndDecember2018NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6779354160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger and Pre-Merger Financing (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock', window );">Summary of assets and liabilities to be sold pursuant to Asset Purchase Agreement</a></td>
<td class="text"><div style="margin-top:12pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Assets and liabilities of Histogenics on September&#160;27, 2019 were as follows (in thousands):</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.380%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.620%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">September 27,</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">2019</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">302&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset held for sale</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,106)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,196&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6779277872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense for Options Granted Reflected in the Consolidated Statement of Operations and Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock-based compensation expense for options granted are reflected in the consolidated statements of operations and comprehensive loss as follows:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.175%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended<br/>December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">362,833&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">515,160&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">521,256&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">559,527&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">884,089&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,074,687&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted Average Assumptions Utilized in Fair Value Calculation</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average assumptions utilized in the fair value calculation for options to purchase common stock as of December&#160;31, 2019 and 2018 are as follows: </span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.175%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended<br/>December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average common stock price</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$1.04&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$9.72&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected option term (years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.0</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">6.0 &#8211; 10.0</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average expected stock price volatility</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">109%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">85%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1.5% &#8211; 2.4%</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">2.3% &#8211; 3.0%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the stock option activity under the Plans:</span></div><div style="margin-top:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:37.766%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.625%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Exercise Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Remaining Contractual Life (Years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options outstanding at December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">632,752&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.93&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.9</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,801,696&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">238,761&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.04&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancelled</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(140,324)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.58&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options outstanding at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">731,189&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.59&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.0</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,028&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercisable at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">385,841&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.15&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.8</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,049&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6789304528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (20,242,630)<span></span>
</td>
<td class="num">$ (18,219,664)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">60,608<span></span>
</td>
<td class="nump">49,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_NonCashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">1,733,521<span></span>
</td>
<td class="nump">3,750,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">250,361<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of derivative liability</a></td>
<td class="nump">3,187,380<span></span>
</td>
<td class="num">(1,664,689)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">884,089<span></span>
</td>
<td class="nump">1,074,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_GainsLossesOnConversionOfDebt', window );">Conversion of convertible notes</a></td>
<td class="nump">341,136<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Other non-cash</a></td>
<td class="nump">4,803<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,007,367)<span></span>
</td>
<td class="num">(201,861)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(1,628,621)<span></span>
</td>
<td class="nump">3,633,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_IncreaseDecreaseInDeferredRent', window );">Deferred rent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(227,172)<span></span>
</td>
<td class="num">(54,203)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_IncreaseDecreaseInLeaseObligations', window );">Lease obligations</a></td>
<td class="num">(249,389)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(16,893,281)<span></span>
</td>
<td class="num">(11,630,543)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, plant and equipment</a></td>
<td class="num">(29,446)<span></span>
</td>
<td class="num">(77,414)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Payment of asset acquisition costs</a></td>
<td class="num">(2,327,273)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(2,356,719)<span></span>
</td>
<td class="num">(77,414)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ProceedsFromPreMergerFinancingFinancingActivities', window );">Proceeds from sale of common stock for pre-merger financing</a></td>
<td class="nump">22,546,353<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from stock subscription</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="num">(47,864)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Issuance of common stock for warrant exercises</a></td>
<td class="nump">183,034<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of Debt</a></td>
<td class="num">(5,290,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">6,800,000<span></span>
</td>
<td class="nump">7,300,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="num">(99,202)<span></span>
</td>
<td class="num">(103,925)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on financing leases</a></td>
<td class="num">(25,866)<span></span>
</td>
<td class="num">(11,928)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">25,066,455<span></span>
</td>
<td class="nump">7,184,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of changes in exchange rate on cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">451<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">5,816,455<span></span>
</td>
<td class="num">(4,522,959)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">1,778,613<span></span>
</td>
<td class="nump">6,301,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">7,595,068<span></span>
</td>
<td class="nump">1,778,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Purchase of fixed assets by entering into capital lease (Note 9)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">63,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of convertible notes (Note 7)</a></td>
<td class="nump">13,979,788<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost', window );">Equity issuance costs (Note 3)</a></td>
<td class="nump">1,150,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset', window );">Right-of-use asset related to operating leases</a></td>
<td class="nump">470,356<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction', window );">Reverse asset acquisition costs (Note 3)</a></td>
<td class="nump">$ 2,252,795<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred equity issuance cost that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_GainsLossesOnConversionOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on conversion of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_GainsLossesOnConversionOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_IncreaseDecreaseInDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change during the period in carrying value for all deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_IncreaseDecreaseInDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_IncreaseDecreaseInLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Lease Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_IncreaseDecreaseInLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_NonCashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of non-cash interest expense during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_NonCashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash or part noncash amount of deferred transaction cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash lessee's right-to-use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ProceedsFromPreMergerFinancingFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the pre-merger financing during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ProceedsFromPreMergerFinancingFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6956097088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">52,746,728<span></span>
</td>
<td class="nump">4,960,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">52,625,228<span></span>
</td>
<td class="nump">4,960,552<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
